<SEC-DOCUMENT>0001628280-24-011648.txt : 20240318
<SEC-HEADER>0001628280-24-011648.hdr.sgml : 20240318
<ACCEPTANCE-DATETIME>20240318161009
ACCESSION NUMBER:		0001628280-24-011648
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240318
DATE AS OF CHANGE:		20240318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		24759108

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>advm-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0eb1737c-384e-4b48-8e56-f7ff90dff097,g:c0462913-63e1-4ed5-8ab4-52645bec5fa8,d:ee15d89dd75f4b25b706a37b8daeb24a-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:advm="http://www.adverum.com/20231231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-32">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-33">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-34">0001501756</ix:nonNumeric><ix:nonNumeric contextRef="c-28" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-260">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-118" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-663">0.10</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>advm:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>advm:security</xbrli:measure></xbrli:unit><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>advm:lease</xbrli:measure></xbrli:unit><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>advm:milestone</xbrli:measure></xbrli:unit><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">advm:PazyukV.MachadoEtAl.C.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandSeventeenInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:IncentiveStockOptionsAndNonQualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>advm:employee</xbrli:measure></xbrli:unit><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">advm:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:TwoDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="director"><xbrli:measure>advm:director</xbrli:measure></xbrli:unit><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:TwoDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-07</xbrli:startDate><xbrli:endDate>2024-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-09</xbrli:startDate><xbrli:endDate>2024-03-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-36579</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Adverum Biotechnologies, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">20-5258327</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">100 Cardinal Way</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">94063</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">656-9323</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.967%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.301%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.0001&#160;per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">ADVM</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq</ix:nonNumeric> Stock Market LLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Nasdaq Capital Market)</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:19.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.354%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-26">&#168;</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-29">151.8</ix:nonFraction> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Capital Market on June 30, 2023 of $1.59 per share.&#160;Shares of the registrant&#8217;s common stock held by each officer and director and each person known to the registrant to be affiliated with an officer or director have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is not a determination for other purposes.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;8, 2024, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">207,549,152</ix:nonFraction>&#160;shares of common stock, par value $0.0001&#160;par value, outstanding.</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_19">Item 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_22">Item 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_22">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_52">Item 1B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_52">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_52">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_52">Item 1</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_52">C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_1878">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="i2dec62e6412e4e1f9cdb1d4215160abb_6-2-1-1-63926"></span><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_1878">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_55">Item 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_55">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_55">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_58">Item 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_58">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_58">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_61">Item 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_61">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_61">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_1934">Information about our Executive Officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_1934">83</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_64">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_64">85</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_67">Item 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_67">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_67">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_79">Item 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_76">Reserved</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">]</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_76">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_82">Item 7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_82">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_112">Item 7A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_112">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_112">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_115">Item 8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_115">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_115">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_193">Item 9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_193">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_193">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_196">Item 9A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_196">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_196">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_199">Item 9B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_199">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_199">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_202">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_202">115</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_205">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_205">116</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_208">Item 10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_1839">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_1839">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_211">Item 11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_4947802326840">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_4947802326840">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_214">Item 12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_4947802326854">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_4947802326854">126</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_217">Item 13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_549755815773">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_549755815773">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_220">Item 14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_549755815788">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_549755815788">132</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_223">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_223">133</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_226">Item 15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_226">Exhibit and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_226">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_229">Item 16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_229">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_229">136</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_232">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_232">137</a></span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this report, unless otherwise stated or the context otherwise indicates, references to &#8220;Adverum,&#8221; &#8220;Adverum Biotechnologies,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Adverum Biotechnologies, Inc., a Delaware corporation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum, the Adverum logo and other trademarks or service marks of Adverum that may appear in this Annual Report on Form 10-K are the property of Adverum. This Annual Report on Form 10-K contains additional trade names, trademarks, and service marks of other companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum does not intend its use or display of other companies&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of Adverum by, these other companies, and all such third-party trade names, trademarks, and service marks are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, progress, timing, costs and results of nonclinical studies and any clinical trials for our product candidates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to advance our viral vector manufacturing and delivery capabilities;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our research and development expenses could fluctuate and may increase;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing or likelihood of regulatory submissions, designations and approvals;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to explore potential applications of our gene therapy platform in other indications in highly prevalent diseases;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding the clinical effectiveness of our product candidates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the pricing and reimbursement of our product candidates, if approved;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding the potential market sizes for our product candidates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intellectual property position;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential benefits of our strategic collaborations and our ability to enter into strategic arrangements;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments and projections relating to our competitors and our industry;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our estimates regarding expenses, future revenue, our financial position, capital requirements, uses of cash and needs for additional financing and the period for which our cash resources will be sufficient to meet our operating requirements; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety, efficacy and projected development timeline and commercial potential of any product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in &#8220;Risk Factors Summary&#8221; below and under the heading &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statement in this Annual Report on Form 10-K reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report on Form 10-K may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in common stock involves numerous risks, including the risks described in &#8220;Item 1A. Risk Factors&#8221; of this Annual Report on Form 10-K. Below are some of these risks, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our planned operations into late 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, whether in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in methods of manufacturing or formulation of our product candidates may result in additional costs or delays.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to produce sufficient quantities of our product candidates at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have relied, and expect to continue to rely, on third parties under contracts and partnerships to conduct some or all aspects of our research and development, including vector production, process development, assay development, product candidates and product manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies, research and related activities, and these third parties may not perform satisfactorily.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare and other reform legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and, if approved, may affect the prices we may obtain.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our information technology systems or those third parties upon which we rely, or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; material disruption of our product development programs; and other adverse consequences.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure or perceived failure to comply with existing or future laws, regulations, contracts, self-regulatory schemes, standards, and other obligations related to data privacy and security (including security incidents) could harm our business. Compliance or the actual or perceived failure to comply with such obligations could increase the costs of our services, limit their use or adoption, and otherwise negatively affect our operating results and business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to licensing, collaboration or other arrangements, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART 1.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_19"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Business</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. We discover and develop gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our lead product candidate, ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, is a single, in-office intravitreal (&#8220;IVT&#8221;) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (&#8220;VEGF&#8221;) IVT injections. Ixo-vec is currently being developed for the treatment of patients with wet age-related macular degeneration (&#8220;wet AMD&#8221;), also known as neovascular AMD, and is being evaluated in the ongoing LUNA Phase 2 clinical trial. We are also developing an early-stage pipeline of gene therapy programs targeting the treatment of other highly prevalent ocular diseases. Our core capabilities include novel vector evaluation, cassette engineering, ocular IND-enabling nonclinical and clinical development, scalable process development, assay development, and current Good Manufacturing Practices (&#8220;GMP&#8221;) quality control.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ixo-vec (formerly known as ADVM-022)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ixo-vec utilizes an engineered, proprietary capsid, AAV.7m8, which along with a proprietary expression cassette is capable of transducing retinal cells and expressing aflibercept after a single in-office IVT injection. This product candidate is intended to improve both real-world vision outcomes and quality of life for patients. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with wet AMD. Age-related macular degeneration (&#8220;AMD&#8221;) is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases. Up to 42% of patients with wet AMD experience neovascularization in the second eye in the first two to three years following diagnosis in the first eye.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we initiated the OPTIC trial, designed as an open-label, dose-ranging trial evaluating the safety and efficacy of Ixo-vec in subjects with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Subjects in OPTIC are treatment experienced and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision. OPTIC was a two-year trial, which the last subject completed in June 2022, and we continue to follow subjects in the OPTIC extension trial for an additional three years, for a total of five years. Through the most recent data cutoff date of August 23, 2023, we have seen strong signals of therapeutic efficacy in OPTIC in both the 6 x 10&#x5E;11 vg/eye (&#8220;6E11&#8221;) and 2 x 10&#x5E;11 vg/eye (&#8220;2E11&#8221;) doses, including maintenance to improvement in best-corrected visual acuity (&#8220;BCVA&#8221;) and maintenance to improvement of central subfield thickness (&#8220;CST&#8221;), currently out to three years, and stable aflibercept protein levels through latest reported follow-up, which is currently up to 4.5 years. Ixo-vec has been generally well tolerated, with the most common adverse events being</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dose-dependent adeno-associated virus (&#8220;AAV&#8221;) associated ocular inflammation that has been responsive to topical corticosteroid therapy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we dosed the first subject in our LUNA Phase 2 trial of Ixo-vec. The LUNA trial is a multicenter, double-masked, randomized, parallel-group trial evaluating two doses of Ixo-vec - 2E11, the lower dose used in the OPTIC trial, and a new, lower 6 x 10&#x5E;10 vg/eye dose (&#8220;6E10&#8221;) dose. In addition, LUNA will assess enhanced prophylactic corticosteroid regimens, including local corticosteroids and combinations of local and systemic corticosteroids to test the relative contribution of local versus systemic AAV exposure on ocular inflammation. The endpoints are similar to the OPTIC trial and focus on mean change in BCVA and CST from baseline to one year, and incidence and severity of adverse events. In August 2023, we announced that LUNA was fully enrolled, with a total of 60 subjects randomized equally between the 2E11 and 6E10 doses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we announced LUNA preliminary safety and efficacy data suggesting that both the 2E11 and 6E10 doses demonstrated maintenance of visual and anatomic outcomes. Notably, both doses resulted in favorable reductions in annualized anti- VEGF injections and the percentage of subjects remaining free of injections, consistent with results observed in the OPTIC trial. In those subjects who had completed 26 weeks of follow-up, at the 6E10 (n=19) and 2E11 (n=20) doses, Ixo-vec demonstrated reduction in annualized anti-VEGF injection rates of 90% and 94%, respectively, and injection free rates of 68% and 85%, respectively. In addition, Ixo-vec was well-tolerated, and when present intraocular inflammation was responsive to per-protocol local corticosteroids. Preliminary data suggest that Ozurdex plus difluprednate eye drops may be a promising prophylactic regimen for future pivotal studies. In this potential &#8220;go-forward&#8221; regimen, the vast majority of patients had no inflammation, with over 90% of these patients having no or minimal inflammation. We plan to initiate a Phase 3 clinical trial of Ixo-vec in wet AMD in the first half of 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Designations for Ixo-vec</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we announced that the FDA had granted Ixo-vec Fast Track designation. Fast Track is a process designed to facilitate the development and expedite the review of drugs and biologics to treat serious conditions and fill unmet medical needs. In June 2022, we announced that the European Medicines Agency (&#8220;EMA&#8221;) had granted Ixo-vec Priority Medicines (&#8220;PRIME&#8221;) designation. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. In April 2023, we announced that the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) had granted Ixo-vec an Innovation Passport under the Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;). The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies to partner with Adverum to charter a roadmap for regulatory and development milestones with the goal of early patient access in the United Kingdom (&#8220;UK&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ixo-vec Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance Ixo-vec for wet AMD, we are continuing to develop our manufacturing expertise for ongoing supply and implementing strategies for large-scale manufacturing and supply. We collaborate with external vendors to manufacture our viral banks, drug supply and drug product, while maintaining control of key aspects of the manufacturing process including development of scalable processes, assay development, and GMP quality controls. This approach to large-scale production is essential for addressing the needs of highly prevalent diseases like wet AMD and sets us apart from many existing gene therapies, which are approved or in development for conditions affecting smaller patient populations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strengths</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have the capabilities, resources, and expertise to enable Adverum to become a leading ocular gene therapy company. These strengths include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Ixo-vec, which is being evaluated in the ongoing LUNA Phase 2 trial and for which we have seen in our OPTIC clinical trial strong signals of therapeutic efficacy out to three years and stable aflibercept protein levels through the latest reported follow-up, which is currently up to 4.5 years;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">industry-leading development capabilities in AAV ocular gene therapy and AAV product optimization, including cassette engineering and vectorizing therapeutic biologics;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">deep understanding of how immunogenicity impacts ocular gene therapy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a pipeline of early stage gene therapy programs targeting the treatment of other highly prevalent ocular diseases;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">deep expertise developing and administering clinical trials with a focus on regulatory compliance in the U.S and Europe;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">gene therapy manufacturing expertise, specifically in scalable process development, assay development, and cGMP quality control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">maturing a portfolio of proprietary vectors with specific ocular cell tropism;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a robust patent portfolio; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">an experienced leadership team with expertise in ophthalmology, gene therapy, manufacturing, drug development, regulatory approval, and commercialization.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to discover, develop, and commercialize novel gene therapies with the potential to treat patients living with highly prevalent ocular diseases. The key elements of our strategy to achieve this goal are to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Target large patient populations, such as those impacted by wet AMD.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There are approximately 20 million individuals worldwide living with wet AMD, and the incidence of new cases is expected to continue to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases and a large percentage of wet AMD patients experiencing neovascularization in the second eye.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">With Ixo-vec, target a well characterized and proven mechanism of action, leveraging anti-VEGF within a gene therapy for wet AMD, a retinal condition that is known to respond to anti-VEGF therapy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike with many gene therapies designed to replace a defective or missing gene, with Ixo-vec we are leveraging gene therapy to deliver an already approved drug. For wet AMD, Ixo-vec is designed for continuous delivery of aflibercept anti-VEGF therapy by a single IVT injection. This innovative method allows us to harness the benefits of gene therapy while providing a well-understood and established therapeutic agent. We estimate that the standard-of-care anti-VEGF therapies used to treat wet AMD and other chronic retinal conditions that respond to anti-VEGF therapy generated in excess of $13 billion worldwide in sales in 2022, underscoring the demand for this class of therapy.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Develop single-intravitreal-injection gene therapy treatments, which in wet AMD have the potential to relieve the burden of frequent, chronic injections and improve real-world vision outcomes and quality of life. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are designed as a single, in-office IVT injection therapy to address the unmet needs of patients with highly prevalent ocular diseases. The current standard of care for wet AMD requires frequent injections for the duration of the disease. A significant proportion of patients, estimated between 22% and 57%, discontinue anti-VEGF treatment within five years. In addition, even well-treated wet AMD patients can experience a loss of vision over time, which is thought to arise from fluctuations in macular fluid that can be pronounced with standard-of-care bolus anti-VEFG therapy. We believe that a durable treatment option has the potential to reduce injection frequency and thereby mitigate challenges with treatment compliance and to control fluid fluctuations and to improve long-term visual outcomes.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pursue indications with well-defined clinical and regulatory paths where possible, to mitigate the development risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In wet AMD, we have selected an indication that has prior clinical validation, including established endpoints, standard-of-care administration methods, and established regulatory paths. In wet AMD, aflibercept is an approved standard-of-care IVT injection treatment both as Eylea</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Eylea HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Ixo-vec utilizes our proprietary vector capsid, AAV.7m8, which is designed to provide a codon optimized cassette of aflibercept enabling patients to generate their own aflibercept through a single IVT injection. In February 2023, the FDA published a draft guidance document (for comment purposes only) for drugs being developed for the treatment of wet AMD, which offered the FDA&#8217;s recommendations for clinical trials including eligibility criteria, clinical trial designs, and efficacy endpoints. Currently, the effect of this draft guidance document is still being ascertained. We will continue to seek guidance from the FDA with the goal of mitigating development risk.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand our process capabilities to support late-stage clinical trials and commercialization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing process is based on the Baculovirus/Sf9 production system, which has been used for a number of vaccines and recombinant protein therapies approved by the FDA and European Commission and is capable of producing large quantities of AAVs. Our strategy is to develop scalable processes to transfer to our global GMP contract manufacturers, providing a flexible manufacturing strategy to support a potential global supply.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Build a U.S.-based commercial organization and form partnerships for global distribution.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We plan to build a specialty sales force for our ocular gene therapies to target the approximately 2,000 retina specialists in the U.S. Internationally, we aim to leverage partnerships to extend our reach, ensuring global access to our therapies. We are open to partnering with one or more pharmaceutical companies to develop Ixo-vec and our other programs outside of the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advance our pipeline by leveraging our industry-leading capabilities in AAV vector and cassette optimization and moving our early-stage research assets into our development pipeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Integrating our AAV engineering, cassette optimization, and innovation together with our manufacturing expertise, we have the capability to generate high-quality recombinant AAV product candidates for ocular gene therapy. By expanding our understanding of AAV-induced inflammation and ocular inflammatory responses, we are better able to generate optimal prophylaxis strategies to support IVT product candidates with favorable attributes. We plan to use this expertise to expand our pipeline and manage the life cycle of our novel gene therapies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Collaborate with partners to leverage our industry-leading AAV vector expertise and ocular vector development and product delivery capabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We explore opportunities to work collaboratively with potential new partners that may benefit from our capabilities and expertise in AAV vector development or may be interested in licensing our programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gene Therapy Background</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy is a powerful treatment modality to address disease biology in a targeted, efficient and sustained way. Instead of dosing patients with proteins or other therapies repeatedly over a long period, gene therapy offers the possibility of dosing once to achieve long-term, durable benefits. In many gene therapies, patients receive viral vectors containing a new gene, called a transgene, that encodes for the desired therapeutic protein or functional version of a mutated protein, and a promoter to control expression of the transgene. Once a patient&#8217;s cells are transduced with the transgene, the cells have the potential to continue to produce the therapeutic protein encoded by that transgene for years. We are currently advancing this field by focusing on localized ocular gene therapies. We believe this approach is particularly promising due to the ocular environment's privileged immune status and presents several advantages over systemic gene therapies. For instance, our product candidates require smaller doses than systemic gene therapies, which reduces the manufacturing burden and would result in lower cost of goods sold.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy takes a 'biofactory' approach.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike many gene therapies designed to replace a defective or missing gene, with Ixo-vec we are leveraging gene therapy to deliver an already approved drug. For wet AMD, Ixo-vec is designed for continuous delivery of aflibercept anti-VEGF therapy by a single IVT injection. This innovative method allows us to harness the benefits of gene therapy while providing a well-understood and established therapeutic agent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to existing classes of protein or biologic therapies such as monoclonal antibodies and antibody-drug conjugates, gene therapy has taken a number of years to evolve from a research tool into a viable and compelling treatment modality.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Novel AAV Vector Platform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ocular gene therapy platform relies on vectors derived from AAV, a small, non-pathogenic virus carrying DNA encoding a therapeutic gene instead of viral genes. These AAV vectors are utilized to deliver the transgene into a targeted cell population, ensuring sustained protein production upon expression. We believe AAV vectors offer distinct advantages in ocular gene therapy, including enhancing safety, applicability across various indications, and potential long-term efficacy. Noteworthy features include high efficiency in transferring the gene of interest, non-pathogenic nature, non-replicating behavior, provision of long-term expression, and low integrating potential. These characteristics collectively contribute to the potential success and safety of AAV-based vectors in ocular gene therapy, making them a promising choice for sustained therapeutic benefits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, natural capsid-based vectors exhibit inherent limitations, stemming either from their limited tropism or constrained permeation through biological barriers. Directed evolution, a multi-step process, addresses these limitations by utilizing a library of engineered AAV capsid genes with properties distinct from natural AAVs. Millions of AAV variants are created and screened </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for novel properties, such as specific cell type transduction. The identified capsids undergo further optimization, resulting in a select number of engineered AAVs with desired characteristics.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum utilizes the AAV2.7m8 capsid as a key platform for IVT delivery. This engineered variant, derived from natural AAV2, was developed through directed evolution for its ability to transduce neural retinal cells upon IVT administration. AAV2.7m8 capsid has a 10-amino acid insertion that has been reported to reduce the binding of AAV2 to heparan sulfate proteoglycan (HSPG). The altered HSPG binding is believed to facilitate spread of the vector in the retina. More specifically, AAV2.7m8 has exhibited the capability to cross the inner limiting membrane in the retina, a hurdle for naturally occurring AAV serotypes, including its parental AAV2, which displays limited penetration from vitreous. The AAV2.7m8 vector has demonstrated widespread transduction of the retina and robust transgene expression in animal models post IVT delivery. As shown in non-human primates (&#8220;NHPs&#8221;), retinal transduction is primarily located in the macula, or central retina, and retinal periphery. AAV2.7m8-based vectors have also been demonstrated to transduce retinal ganglion cells, cells in the inner nuclear layer, and photoreceptors, particularly foveal cones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key advantages of the AAV2.7m8 capsid over standard AAV2 include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Enables Intravitreal Delivery: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AAV2.7m8 capsid has been engineered to achieve retinal transduction through IVT injection, the standard in-office procedure for wet AMD standard of care. The IVT route of administration is a routine and less invasive alternative to both the sub-retinal and suprachoroidal routes. The former can pose risks to the structure and function of the retina, particularly in cases where the patient's retina is already compromised or undergoing degeneration, while the latter relies on a novel specialized medical device and can be associated with complications related to the device or the procedure.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Enhanced Retinal Transduction:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AAV2.7m8 has been engineered to achieve widespread retinal transduction through IVT administration, facilitating the delivery of the gene of interest to cells in the deeper retinal layers. This capability is crucial for therapies targeting retinal diseases.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Potential for Lower Dosing, Increased Efficacy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AAV2.7m8's efficient IVT dosing overcomes therapy barriers, enabling high gene expression in the retina. This allows for lower doses, potentially enhancing efficacy and reducing the immune response and inflammation associated with higher doses of vectors with limited permeability from the vitreous to the retina.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Efficacy and Inflammation Balance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> With its highly efficient retinal transduction profile, AAV2.7m8-based vectors, when coupled with appropriate corticosteroid prophylaxis, may provide an optimal therapeutic window and a favorable benefit/risk profile.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Retina as a Biofactory:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AAV2.7m8-based vectors, administered intravitreally, leverage ocular cells as a biofactory to release secretable therapeutic proteins. This approach can eliminate the necessity for repetitive IVT dosing, as a single injection may sustain the continuous delivery of therapeutic proteins throughout an individual's lifetime.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Benchmark for IVT Delivery:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AAV2.7m8 has set the standard for IVT delivery of therapeutic vectors, given its optimal retinal transduction profile. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Well Studied: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several gene therapy product candidates using AAV2.7m8 have shown positive results in clinical and/or non-clinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ixo-vec, Our Single Intravitreal Injection Gene Therapy Candidate for Treating Wet AMD</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ixo-vec, formerly referred to as ADVM-022, is our lead gene therapy product candidate being developed for the treatment of patients with wet AMD. Ixo-vec is designed to deliver long-term, durable therapeutic levels of aflibercept associated with a robust, sustained treatment response and reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-VEGF IVT injections. Ixo-vec utilizes an engineered, proprietary capsid, AAV.7m8, carrying a codon-optimized aflibercept coding sequence under the control of a proprietary expression cassette capable of transducing retinal cells after a single in-office IVT injection. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ixo-vec is designed to provide long-term efficacy, which would address one of the major challenges in managing wet AMD &#8211; the frequent need for anti-VEGF injections. By potentially reducing or eliminating the need for these regular injections, if approved, Ixo-vec would offer a more convenient and less burdensome treatment regimen. This product is intended to improve both real-world vision outcomes and quality of life for patients. This approach could optimize patient compliance and lead to better overall vision outcomes, making it a significant advancement in the treatment of wet AMD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Market for Wet AMD and Unmet Medical Needs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Age-related macular degeneration is a progressive disease affecting the retinal cells in the macula, the region of the retina at the back of the eye responsible for central vision. Disease progression results in the death of retinal cells and the gradual loss of vision. Wet AMD, also known as neovascular AMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD. In patients with wet AMD, the abnormal blood vessels invade the space between layers of cells in the retina. These new blood vessels are often leaky, which results in fluid and blood in the retina and causes vision loss.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide. The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases. Up to 42% of wet AMD patients experience neovascularization in the second eye in the first two to three years following diagnosis in the primary eye.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current standard of care for wet AMD requires frequent anti-VEGF injections for the duration of the disease. Most patients with wet AMD are commonly treated with bevacizumab, often used off-label, or with specific wet AMD therapies. Bevacizumab, while not originally developed for wet AMD, has found widespread use due to its efficacy and cost-effectiveness. In contrast, Lucentis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranibizumab), Eylea (aflibercept), Vabysmo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (faricimab), and the high-dose formulation Eylea HD are FDA-approved treatments specifically designed for wet AMD. While effective for many patients, these options typically require eye injections every 4-16 weeks in order to maintain vision. Real world evidence shows that this regimen can be difficult to adhere to for patients, caregivers, and healthcare systems, leading to undertreatment associated with persistent macular fluid and resulting in loss of vision over time. A significant proportion of patients, estimated between 22% and 57%, discontinue anti-VEGF treatment within 5 years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even well-treated wet AMD patients can experience a loss of vision over time. This is thought to arise from fluctuations in macular fluid. These fluctuations can be pronounced with standard-of-care bolus anti-VEFG therapy, in which patients see fluid levels fall after receiving an injection only to rise before their next injection. A growing scientific consensus views controlling fluid fluctuations as crucial for maintaining visual acuity in patients undergoing anti-VEGF therapy for wet AMD.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that the standard-of-care anti-VEGF therapies used to treat wet AMD and other chronic retinal conditions that respond to anti-VEGF therapy generated in excess of $13 billion worldwide in sales in 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Ixo-Vec Addresses Unmet Medical Needs for Wet AMD</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gene therapies are designed as a single, in-office IVT injection therapy to address the unmet needs of patients with highly prevalent ocular diseases. We believe that durable treatment to reduce injection frequency, reduce fluctuations of macular fluid, and improve long term visual outcomes is the largest unmet need for wet AMD patients and their caregivers. Lifetime need for frequent injections burdens patients, caregivers, healthcare providers and healthcare systems. Real world evidence shows reduction in patients&#8217; vision over time associated with insufficient treatment, and the persistence of macular fluid between anti-VEGF injections, including as a result of poor adherence to the frequent injection regimen. Furthermore, bolus anti-VEGF injections may result in fluctuations in macular fluid that have been shown to have negative impacts on visual outcomes over time. Ixo-vec has the potential to revolutionize this paradigm, shifting from the traditional &#8220;treat-and-extend&#8221; approach to a model focused on sustained anti-VEGF delivery, potentially effective for the patient&#8217;s lifetime. A gene therapy administered as a single, in-office IVT injection has the potential to deliver long-term efficacy, reduce the burden of frequent anti-VEGF injections, minimize macular fluid and macular fluid fluctuation and improve vision outcomes for patients. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advantages over Other Biofactory Approaches</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe IVT injection of ocular gene therapy for the treatment of wet AMD, as with Ixo-vec, offers substantial advantages compared to subretinal and suprachoroidal administration. The earliest ophthalmic gene therapies have been delivered subretinally. Subretinal administration requires that a victrectomy be performed via intraocular surgery, which carries inherent risks such as retinal detachment or infection and involves a recovery period that can be uncomfortable for the patient. In addition, subretinal gene therapy may be administered only to pseudophakic patients, that is, those patients who have had an artificial lens implanted, typically during cataract surgery.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The more recently developed suprachoroidal approach, while less invasive than subretinal surgery, still relies on specialized medical devices and can be associated with complications related to the device or the procedure itself. In animal models it has been observed that suprachoroidal delivery may result in higher potential for development of the immune response against the transgenic protein, potentially linked to the vector's exposure to inflammatory cells outside the blood-retinal barrier within scleral and uveal tissue. Furthermore, suprachoroidal administration in NHPs revealed a diffuse, peripheral, and circumferential pattern of transduction, with the retinal pigment epithelium, or RPE, and scleral tissues identified as primary targets. Thus, when suprachoroidal delivery is utilized as a biofactory method for delivering therapeutic proteins to the retina, these proteins must overcome barriers by diffusing effectively to reach the targeted disease site in the retina, to provide optimal effectiveness. Suprachoroidal gene therapy appears to require higher doses than subretinal IVT gene therapy, which may have additional implications for potential inflammation and for manufacturing costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contrast, Ixo-vec is administered via a straightforward, one-time IVT injection. This simple procedure is performed during an office visit and is the mode of administration for current standard-of-care therapies for wet AMD. The IVT method significantly reduces the procedural risks and potential complications associated with the more invasive surgical techniques. It simplifies the treatment process and fits into existing retina practice workflows, making it more patient-friendly and accessible.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OPTIC Clinical Trial in Wet AMD</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we initiated the Ixo-vec clinical trial entitled &#8220;An Open Label Phase 1 Study of Ixo-vec (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration" (&#8220;OPTIC&#8221;). The last subject completed the two-year OPTIC trial in June 2022. We will continue to follow subjects enrolled in the OPTIC three-year extension out to a total of five years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OPTIC Trial Design. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OPTIC trial was designed as a multi-center, open-label, Phase 1, dose-ranging safety trial of Ixo-vec in subjects with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Subjects in OPTIC are treatment-experienced and previously required frequent anti&#8209;VEGF injections to manage their wet AMD and to maintain functional vision.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In OPTIC, subjects were dosed with a single IVT injection of Ixo-vec. Subjects in cohort 1 (n=6) were treated with a 6E11 dose of Ixo-vec. Subjects in cohort 2 (n=6) were treated with a three-fold lower 2E11 dose of Ixo-vec. Subjects in cohorts 1 and 2 received a 13-day tapering course of prophylactic oral corticosteroids following Ixo-vec administration. Subjects in cohort 3 (n=9) were treated with a 2E11 dose of Ixo-vec, and subjects in cohort 4 (n=9) were treated with a 6E11 dose of Ixo-vec. Subjects in cohorts 3 and 4 received a 6&#8209;week tapering course of prophylactic topical corticosteroids in place of the oral corticosteroids.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint of the trial was the safety and tolerability of Ixo-vec after a single IVT administration. Secondary endpoints included changes in BCVA, measurement of CST (a measure of retinal thickness), as well as mean number of anti-VEGF supplemental injections and percentage of subjects needing anti-VEGF supplemental injections. Each subject enrolled was followed for a total of two years in OPTIC. Most of the subjects have enrolled in a three-year extension study to continue to monitor safety and efficacy out to a total of five years. Below is a schematic of the OPTIC and OPTIC extension trial. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="advm-20231231_g1.jpg" alt="OPTIC EXT Study Slide.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OPTIC Two-Year Data. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last subject completed the OPTIC study in June 2022. On average, subjects had significant disease, having received an average of approximately 10 annualized injections of anti-VEGF therapy in the year prior to receiving Ixo-vec. In OPTIC, Ixo-vec showed a robust treatment response from both doses through 104 weeks. Subjects who received 6E11 of Ixo-vec, Cohorts 1 and 4, experienced a 98% reduction in annualized anti-VEGF injections and 80% remained supplemental anti-VEGF injection free. Subjects who received 2E11 of Ixo-vec, Cohorts 2 and 3, experienced an 80% reduction in annualized anti-VEGF injections and 53% remained supplemental anti-VEGF injection free. Subjects also experienced maintenance of BCVA and a reduction of CST, followed by maintenance of those lower CST levels. Subjects experienced sustained stable aflibercept protein levels from 10 weeks through the end of the study. Despite the short duration of prophylactic corticosteroid therapy, Ixo-vec was generally well tolerated, with the most common adverse event (&#8220;AE&#8221;) of dose-dependent, mild to moderate inflammation that was responsive to topical corticosteroids. At study completion, inflammation in the 2E11 dose group resolved in all participants, and no participants required corticosteroid therapy at the 2E11 dose. In some participants, asymptomatic pigmentary changes were observed, including iris hyperpigmentation and iris transillumination defects. In December 2023, the OPTIC two-year results were published in the Lancet&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">eClinical Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OPTIC Three-Year Data. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we presented three-year results from the OPTIC parent and extension trials. Subjects who received 6E11 of Ixo-vec, Cohorts 1 and 4, experienced a 98% reduction in annualized anti-VEGF injections and 73% remained supplemental anti-VEGF injection free. Subjects who received 2E11 of Ixo-vec, Cohorts 2 and 3, experienced an 84% reduction in annualized anti-VEGF injections and 53% remained supplemental anti-VEGF injection free. Subjects continued to experience maintenance of BCVA and CST levels. Subjects also demonstrated sustained aflibercept protein levels, measured through the latest reported follow-up, which is currently up to 4.5 years in the earliest subjects enrolled. Ixo-vec at the 2E11 dose continues to be generally well tolerated in the extension study. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below, we also present two case studies showing that in subjects who had experienced high or fluctuating fluid and CST despite having received nine anti-VEGF injections in the twelve months prior to receiving Ixo-vec, a single 2E11 Ixo-vec IVT injection reduced absolute levels and fluctuations in fluid and CST through 3.5 years post injection. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="advm-20231231_g2.jpg" alt="Case Study Ixo-vec 90 Yr Old Female.jpg" style="height:387px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><img src="advm-20231231_g3.jpg" alt="Item1_Image3.jpg" style="height:385px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LUNA Phase 2 Clinical Trial in Wet AMD</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we dosed the first subject in our LUNA Phase 2 trial of Ixo-vec. LUNA is a multicenter, double-masked, randomized, parallel-group Phase 2 trial evaluating two doses of Ixo-vec - 2E11, the lower dose used in the OPTIC trial, and a new, lower 6E10 dose. LUNA is assessing four new enhanced prophylactic corticosteroid regimens, including difluprednate drops alone or in combination with IVT Ozurdex, a bioerodable implant of dexamethasone, and both local regimens with or without oral prednisone. Participants were randomized approximately 2:1 to receive local versus local plus oral prophylaxis. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints are similar to the OPTIC trial and focus on mean change in BCVA and CST from baseline to one year, and incidence and severity of adverse events. Other endpoints include aflibercept protein levels starting at 14 weeks, an interim efficacy and safety analysis at 26 weeks and reductions in fluctuations in CST and in treatment burden. The study is also evaluating the effectiveness and tolerability of the prophylactic corticosteroid regimens. In August 2023, we announced that the Phase 2 LUNA trial was fully enrolled, with a total of 60 subjects randomized equally between the 2E11 and 6E10 doses across 34 sites in the U.S. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we announced LUNA preliminary safety and efficacy data suggesting that both the 2E11 and 6E10 doses demonstrated maintenance of visual and anatomic outcomes. Notably, both doses resulted in a favorable reduction in annualized anti-vascular endothelial growth factor (VEGF) injections and the percentage of patients remaining free of annualized injections, with data trending similar to or better than the OPTIC study. Patients were hard to treat, requiring an average of nearly 10 anti-VEGF injections in the year prior to receiving Ixo-vec. The data cut-off for these data is November 15, 2023, except for treatment burden reduction, which is of January 2, 2024. As of the data cut-off dates, only subsets of patients had completed 26 weeks of follow-up or completed the period of steroid prophylaxis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment Burden Reduction. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In those patients who had completed 26 weeks of follow-up, at the 6E10 (n=19) and 2E11 (n=20) doses, Ixo-vec demonstrated annualized reduction in anti-VEGF injection rates of 90% and 94%, respectively, and injection free rates of 68% and 85%, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Visual and Anatomic Outcomes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Visual acuity (BCVA) and anatomic endpoints (CST) were maintained at both dose levels. In a sub-group analysis of patients with higher baseline CST, a greater reduction in CST was demonstrated, indicating the efficacy potential of Ixo-vec gene therapy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aflibercept Levels.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Aqueous humor aflibercept protein levels at 14 weeks suggest that both doses deliver aflibercept levels that are within the therapeutic range observed in OPTIC. Importantly, early aflibercept levels are associated sustained long-term protein expression in OPTIC through the latest reported follow-up, which is currently up to 3.5 years at the 2E11 dose. No minimum aqueous humor aflibercept threshold for clinical benefit was observed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safety Profile and Potential &#8220;Go-Forward&#8221; Corticosteroid Prophylaxis Regimen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ixo-vec was well-tolerated, and when present intraocular inflammation was responsive to per-protocol local corticosteroids. No Ixo-vec related serious adverse events were reported. No episcleritis, vasculitis, retinitis, choroiditis, vascular occlusion or hypotony were reported. Consistent with OPTIC 2E11, the most common Ixo-vec related AEs observed in LUNA were dose-related anterior inflammation (primarily AC cells) and asymptomatic pigmentary changes including iris transillumination defects and anterior chamber pigmentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary data suggest corticosteroid prophylaxis optimization at both the 2E11 and 6E10 doses appears to result in improved inflammatory profiles in LUNA as compared to OPTIC trial results. Preliminary data indicate that Ozuredex alone or with oral corticosteroids do not provide adequate prophylaxis. Accordingly, early on in the trial, we implemented a protocol amendment to augment the Ozurdex containing regimens with a course of difluprednate eye drops. Preliminary data suggest that the amended Ozurdex-plus-difluprednate regimen may be a favorable prophylactic regimen for future pivotal studies. In this potential &#8220;go-forward&#8221; regimen, the vast majority of patients had no inflammation, with over 90% of these patients having no or minimal inflammation. Oral corticosteroids showed no incremental benefit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graphics below show a schematic of the LUNA trial design and selected data from the February 2024 LUNA data announcement including treatment burden reduction; BCVA and CST maintenance; aflibercept levels overlaid onto aflibercept levels observed at the 2E11 dose in OPTIC through the latest reported follow-up, which is currently up to 3.5 years at the 2E11 dose; a summary of some of the prophylaxis for Ixo-vec IVT gene therapy key learnings; and selected safety data. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="advm-20231231_g4.jpg" alt="LUNA Phase 2 Multicenter Slide.jpg" style="height:385px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><img src="advm-20231231_g5.jpg" alt="Compelling Injection Slide.jpg" style="height:374px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="advm-20231231_g6.jpg" alt="Visual and Anatomic.jpg" style="height:397px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><img src="advm-20231231_g7.jpg" alt="Aqueous Aflibercept.jpg" style="height:384px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="advm-20231231_g8.jpg" alt="PreliminarySafetyAnalysis.jpg" style="height:395px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><img src="advm-20231231_g9.jpg" alt="Ozurdex Difluprednate.jpg" style="height:383px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INFINITY Phase 2 Clinical Trial in DME</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we initiated the INFINITY trial, a multi-center, Phase 2, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of Ixo-vec in subjects with diabetic macular edema (&#8220;DME&#8221;). A dose limiting toxicity at the 6E11 dose in this population with poorly controlled diabetes and microvascular complications was identified in April of 2021. Consequently, we are no longer pursuing Ixo-vec for DME, nor are we evaluating the 6E11 dose in wet AMD. We have not seen similar subject safety concerns in any of our subjects at either the 2E11 dose in the INFINITY, OPTIC, or LUNA trials or the 6E11 dose in the OPTIC trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunogenicity to AAV therapy has been broadly reported to be associated both with systemic and ocular gene therapies, regardless of route of administration, and is generally understood to be dose related. Based on an extensive evaluation of data from all of our subjects treated with Ixo-vec in OPTIC and INFINITY and all of our nonclinical data by internal and external experts, we believe that utilizing the 2E11 and 6E10 doses in our ongoing LUNA trial, along with the new enhanced prophylactic corticosteroid regimens, which include local corticosteroids and a combination of local and systemic corticosteroids, may allow us to minimize post-prophylaxis inflammation in our wet AMD trial subjects going forward.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ixo-vec Regulatory Designations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we announced that the FDA had granted Ixo-vec Fast Track designation. Fast Track is a process designed to facilitate the development and expedite the review of drugs and biologics to treat serious conditions and fill unmet medical needs. The designation enables more frequent meetings and communication with the FDA throughout a product candidate&#8217;s development and review process, often leading to earlier drug approval and access by patients. The designation also provides eligibility for Priority Review, Accelerated Approval, and Rolling Review, which may potentially result in a shorter FDA review process. The purpose of the Fast Track process is to get important new drugs and biologics to patients earlier.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we announced that the European Medicines Agency EMA granted Ixo-vec Priority Medicines PRIME designation. PRIME voluntary scheme intended to enhance the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (i.e. there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if such a method exists, the new medicinal product will bring a major therapeutic advantage) and they must be demonstrated to have the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we announced that the MHRA granted Ixo-vec an Innovation Passport under the ILAP. The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the All Wales Therapeutics and Toxicology Centre, the National Institute for Health and Care Excellence, and the Scottish Medicines Consortium to partner with Adverum to charter a roadmap for regulatory and development milestones with the goal of early patient access in the U.K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dry AMD / Geographic Atrophy Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we presented nonclinical data on an IVT gene therapy for the treatment of geographic atrophy secondary to dry age-related macular degeneration (&#8220;dry AMD&#8221;) via expression of Complement Factor I at the American Society of Gene &amp; Cell Therapy&#8217;s (&#8220;ASGCT&#8221;) 2023 Annual Meeting. Dry AMD is a highly prevalent disease in which patients experience a chronic progressive deterioration of the macula, leading to central blind spots and permanent vision loss. Geographic atrophy can be seen as part of late-stage AMD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Optogenetics Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we presented data on an optogenetic approach to vision restoration at ASGCT&#8217;s 2023 Annual Meeting. Melanopsin, through its ability to regenerate chromophore, has the potential to be an effective light sensor candidate by generating pseudo-photoreceptors. Our engineered melanopsin demonstrated favorable kinetics </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and may have utility as a therapeutic transgene for optogenetic vision restoration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADVM-062</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADVM-062 (AAV.7m8-L-opsin), is a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (&#8220;BCM&#8221;) via a single IVT injection. ADVM-062 utilizes Adverum&#8217;s propriety vector capsid, AAV.7m8. In January 2022, we announced that the FDA granted Orphan Drug Designation to ADVM-062. In September 2023, we granted an exclusive license for the rights to ADVM-062 to Blue Gen Therapeutics Foundation, a non-profit organization dedicated to advancing gene therapy treatments for rare inherited retinal diseases, that will now lead all research and development activities for the program. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCM affects approximately 1 in 100,000 males, worldwide. This X-linked recessive hereditary condition is caused by the absence of function in the L and the M opsin gene(s) and can manifest in loss of visual acuity, photosensitivity, myopia and infantile nystagmus that can persist into adulthood. Consequently, individuals with BCM have visual impairments to important aspects of daily living such as facial recognition, learning, reading, and daylight vision. Currently, there is no cure for BCM and to our knowledge, no other therapies to treat BCM are in development. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Partnered Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed to GenSight rights to use AAV.7m8 for GS030, GenSight&#8217;s gene therapy encoding for channelrhodopsin protein. In October 2018, GenSight began its PIONEER Phase 1/2 clinical trial in retinitis pigmentosa in the U.S., France, and U.K. and in February 2023 announced one-year safety data and efficacy signals from the trial. In October 2021, GenSight announced it had been granted Fast Track Designation by the FDA for GS030. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed to Ray Therapeutics rights to use AAV.7m8 in conjunction with Ray&#8217;s RTx-015 optogenetics payload for ocular diseases. Ray Therapeutics is developing RTx-015 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed to LEXEO Therapeutics rights to the intellectual property and pre-clinical data package for LX2006, an investigational gene therapy for Friedreich&#8217;s ataxia.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance Ixo-vec for wet AMD, we are continuing to develop our manufacturing expertise for ongoing supply. We currently have no operational clinical or commercial manufacturing facilities, and all of our clinical manufacturing activities are currently contracted out to third parties. We maintain control of key aspects of the manufacturing process, specifically in development of scalable processes, assay development, and GMP quality controls. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AAV vector manufacturing process is based on the Baculovirus Expression Vector System (&#8220;BEVS&#8221;), which has been used in a number of FDA- and European-approved products. This approach is well suited for the production of large quantities of AAVs, as it takes advantage of the efficiency of viral infection coupled with the high density and scalability of insect cells grown in serum-free suspension cultures. Compared to the mammalian cell-based approaches commonly used in the field, our manufacturing process is designed to produce higher yields of vectors per manufacturing campaign in a cost-effective manner.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AAV manufacturing method is industrialized, highly scalable and ready for adaptation for commercial stage. We believe our process provides the following advantages over competing systems:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Industrial-scale biologics production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our BEVS system can produce quantities of product required at commercial stage by incorporating scalable, well-established process steps used throughout the industry for biologic products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Safety advantages.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our BEVS system does not use mammalian cell cultures or tumorigenic cell lines, and the DNA sequences used to allow AAV vector production are inactive in mammalian cells, which lowers the risk of off-target expression from our products and infection by adventitious agents in humans.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">High yield and cost effectiveness.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Because of its scalability, our BEVS system may allow the production of large quantities of AAV vectors, up to the 2000-liter scale, providing further economies of scale.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">High purity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our BEVS system coupled with our proprietary downstream purification process produces a highly pure drug substance.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Precedent regulatory framework.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Several other vaccines and recombinant protein therapies have been approved using a manufacturing process similar to our BEVS technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are manufactured using cell banks and a scalable process developed internally and externally that are transferred to approved Contract Manufacturing Organizations (&#8220;CMOs&#8221;). These CMOs produce investigational drugs under GMP conditions to support our clinical trials. High quality raw materials are purchased from various suppliers and are used throughout the manufacturing process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate new raw material suppliers, as well as additional CMOs, in order to provide manufacturing flexibility. As we prepare for larger, late-stage clinical trials and potential commercialization, we have in-house process development capabilities, allowing us to develop larger-scale processes together with our global GMP contract manufacturers. We leverage GMP contract manufacturer partnerships for flexible clinical and future commercial supply. This strategy capitalizes on our internal AAV manufacturing expertise while providing both security, expandability and flexibility as we prepare to potentially deliver one of the first gene therapies for large indications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by intense and dynamic competition to develop new proprietary technologies and therapies and a strong emphasis on intellectual property. We believe that our single-administration IVT approach for the treatment of wet AMD, our AAV-based platform, our nonclinical and clinical development experience, our gene therapy manufacturing experience and our expertise in the field of gene therapy provide us with competitive advantages. However, we face actual or potential competition from various sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as from academic institutions, governmental agencies, and public and private research institutions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ixo-vec gene therapy product candidate for wet AMD utilizes a proprietary vector, is administered through a single IVT injection, and will compete with a variety of therapies currently marketed and in development, including biologics, small molecules, long-acting delivery devices and gene therapy. The key factors that contribute to success of any approved product include safety profile, efficacy, durability, mode of administration and cost of goods. Existing anti-VEGF therapies are well-established therapies and are widely accepted by physicians, patients and third-party payers as the standard-of-care treatment of patients with wet AMD. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, most patients receive off-label bevacizumab, including as a first-line treatment. Many patients go on to receive Eylea, Eylea HD and Vabysmo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (faricimab). We know of a significant number of product candidates in development or recently approved for chronic retinal conditions that respond to anti-VEGF therapy, including wet AMD:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">biosimilar anti-VEGFs (e.g., FYB201);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">bispecific / combination / add-on therapy for efficacy or durability improvement (e.g., Vabysmo and OPT-302);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">next-generation anti-VEGF for durability improvement (e.g., Eylea HD);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">long-acting delivery device / gene therapy to lower treatment frequency (e.g., 4D-150, RGX-314 and Susvimo, which is Roche&#8217;s Port Delivery System with ranibizumab); and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other molecules that inhibit neovascularization in wet AMD (e.g., tyrosine kinase inhibitors such as OKT-TKI and EYP-1901).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several other companies in the U.S. or Europe with marketed products or products in development for the treatment of chronic retinal conditions that respond to anti-VEGF therapy, including wet AMD. These companies include 4D Molecular Therapeutics, AbbVie, Bayer, Clearside Biomedical, EyePoint Pharmaceuticals, Kodiak Sciences, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Regeneron, REGENXBIO and Roche. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These companies, as well as any other competitors we may face, either alone or with their partners, for our other product candidates, may have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments, and commercializing those treatments. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance. Our competitors&#8217; treatments may be more effective, have fewer side effects, or be more effectively marketed and sold, than any treatment we may commercialize and may render our treatments obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our treatments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. We expect any treatments that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price, the level of generic competition and the availability of reimbursement from government and other third-party payers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AAV.7m8 License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In June 2013, we entered into an exclusive worldwide sublicensable license agreement with the Regents of University of California (&#8220;Regents&#8221;) to certain intellectual property related to improved AAV vectors, including the AAV.7m8 capsid. Under this license agreement, we are obligated to make certain de minimis license payments, certain milestone payments totaling up to $1.0 million upon reaching certain stages of development of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the licensed products for a first indication, and totaling up to $0.5 million for each subsequent indication for which licensed products are developed, for up to a maximum of two additional indications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are obligated to pay Regents royalties on sales of licensed products in the low single-digits, subject to adjustments and minimum thresholds.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, this agreement will be in effect on a country-by-country, licensed product-by-licensed product basis until the expiration of the last claim of the licensed intellectual property covering the manufacture, use, or sale of such product in such country. We may terminate this agreement in whole or in party by giving Regents 30 days&#8217; prior written notice. Regents may terminate this agreement for breach by us that remains uncured for 60 days, if we become insolvent, if we directly or through a third-party file a claim that a licensed patent right is invalid or unenforceable, or if we fail to meet or extend the date for meeting certain diligence milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GenSight Biologics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, we entered into an agreement with GenSight Biologics (&#8220;GenSight&#8221;), in which we granted GenSight a non-exclusive license to our proprietary AAV.7m8 vector to develop gene therapy products to deliver certain therapeutic transgenes. Under the agreement, we are eligible to receive development, regulatory and commercial milestones. Also, we are eligible to receive low to mid-single digit royalties on sales of GenSight&#8217;s licensed products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GenSight is currently developing GS030, a gene therapy encoding channelrhodopsin protein which incorporates the AAV.7m8 capsid. GenSight is conducting a phase I/II trial with GS030 to treat retinitis pigmentosa in the U.S., France, and the U.K., which began in October 2018. In October 2021, GenSight announced it had been granted Fast Track Designation by the FDA for GS030 and in February 2023, announced one-year safety data and efficacy signals from its PIONEER Phase I/II clinical trial for retinitis pigmentosa. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo Therapeutics </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into an agreement with Lexeo Therapeutics (&#8220;Lexeo&#8221;), pursuant to which we granted Lexeo an exclusive license to the intellectual property rights, pre-clinical data and know how associated with our Friedrich&#8217;s Ataxia program. Under the agreement, we are eligible to receive development and commercial milestones and royalties related to sales of a product containing our licensed rights. Lexeo is currently developing LX2006, an adeno-associated virus mediated treatment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Virovek</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2011, we entered into an agreement with Virovek, Inc. (&#8220;Virovek&#8221;), in which we received a non-exclusive license to certain Virovek technology and know-how related to methods and materials for manufacturing AAV. Under the agreement, Virovek is entitled to certain license payments and low-single digit royalty payments. This license with Virovek continues in effect until expiration of the last-to-expire patent.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of gene therapy that may be important for the development of our business. Additionally, we may rely on regulatory protection afforded through orphan drug designations, data exclusivity, market exclusivity, and patent term extensions where available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; obtain regulatory exclusivity and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents or trade secrets that cover these activities. In some cases, these rights may need to be enforced by third party licensors. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2024, we own or license more than 370 issued patents that are still in force, including more than 35 issued U.S. patents and 11 European patents validated cumulatively in more than 245 countries, as well as more than 210 patent applications pending in the U.S. and foreign jurisdictions, 12 of which have been allowed. These numbers include more than 44 patents and 8 pending applications filed by or on behalf of universities which have granted us exclusive license rights to the technology. Our policy is to file patent applications to protect technology, inventions and improvements to inventions that are commercially important to the development of our business. We seek patent protection in the U.S. and abroad for a variety of technologies, including research tools and methods, AAV-based biological products, methods for treating diseases of interest and methods for manufacturing our AAV-based products. We also intend to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets and that may be used to identify and develop novel biological products. We seek protection, in part, through confidentiality and proprietary information agreements. We are a party to various other license agreements that give us rights to use specific technologies in our research and development.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company-owned Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own at least five patent families that are directed to AAV-based compositions and methods for treating or preventing eye diseases associated with neovascularization. Patents and applications in the first of these families relate to compositions and methods for the AAV-based delivery of anti-VEGF proteins, for use in treating neovascular diseases of the eye, including wet AMD and diabetic retinopathy, in patients who respond to anti-VEGF protein therapy. Twenty patents in this family have issued in the U.S., elsewhere in North America, Europe and the Asia/Pacific region, and seven corresponding applications are pending in the U.S., elsewhere in North America, Europe, and the Asia/Pacific region. Patents in this family are generally expected to expire in 2033, subject to possible patent term adjustments and patent term extensions. Patents and applications in the second of these families relate to AAV gene therapy for the treatment of neovascular diseases of the eye, including wet AMD and diabetic retinopathy, using the AAV.7m8 vector to deliver aflibercept. One issued European patent is validated in thirty-seven countries, eight patents are issued in North America, the Asia/Pacific region, Israel and South Africa, and at least sixteen corresponding applications are pending in the U.S., elsewhere in North America, Europe, and Asia/Pacific region. Patents in this family are generally expected to expire in 2037, subject to possible patent term adjustment and patent term extensions. The third of these families contains granted applications in Australia, Europe (validated in 37 countries), Hong Kong, and Japan, and pending U.S. and corresponding foreign applications directed to AAV gene therapy for the treatment of neovascular diseases of the eye, including wet AMD and diabetic retinopathy, using the AAV.7m8 vector to deliver ranibizumab. Patents that may eventually issue from this patent family, if any, are generally expected to expire in 2037, subject to possible patent term adjustments and patent term extensions. The fourth family contains 28 pending applications, and is directed to methods of treating neovascular diseases of the eye, including wet AMD and diabetic retinopathy, with AAV.7m8-aflibercept. Patents that may eventually issue from this family, if any, are generally expected to expire in 2039 to 2040 subject to possible patent term adjustments and patent term extensions. The fifth family is an international application (i.e., Patent Cooperation Treaty (&#8220;PCT&#8221;) application) directed to methods of treating neovascular diseases of the eye, including wet AMD and diabetic retinopathy, with low dose AAV.7m8-aflibercept. Patents that may eventually issue from this family, if any, are generally expected to expire in 2043.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own sixteen patent families that are directed to various aspects of our proprietary technology platform. Fourteen patents in these families have issued patents in the U.S., Europe, and the Asia/Pacific region, including one issued European patent validated in six countries, as well as at least forty-nine pending applications, including PCT applications or national phase applications in the U.S., elsewhere in North America, Europe, and the Asia/Pacific region. Patents that may eventually issue from these families, if any, are generally expected to expire between 2035 and 2043, subject to possible patent term extensions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensed Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained both exclusive and non-exclusive licenses to patents directed to both compositions of matter and methods of use, and to other intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we have exclusively licensed several families of patents and patent applications that relate to variant rAAV virions having desirable characteristics, such as increased infectivity, as well as novel methods to screen for such variants. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One patent family directed to improved rAAV virions that we have exclusively licensed in the ocular field includes ten granted patents in the U.S., elsewhere in North America and Europe, including one European patent validated in three countries, as well as one pending patent applications in the U.S. The patents in this family are projected to expire between 2024 and 2029 in the U.S. and in 2024 elsewhere, subject to possible patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another patent family directed to improved rAAV virions that we have exclusively licensed includes three granted U.S. patents that are expected to expire in 2031, subject to possible patent term extensions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third patent family that we have exclusively licensed includes claims directed to the novel AAV.7m8 vector, which allows delivery of transgenes to the retina via IVT injection, and which we utilize in our product candidate ADVM&#8209;022. This family includes at least thirty-four issued patents in the U.S., elsewhere in North America, Europe, Asia, and the Pacific, including three European patents each validated in thirty-seven countries. Seven corresponding applications are pending in the U.S. and elsewhere in North America, Europe, Asia and the Pacific. Patents that issue from this patent family are generally expected to expire in 2032, subject to possible patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also non-exclusively licensed rights to a patent family related to the Baculovirus/SF9 production system that includes eight issued patents in the U.S., Europe, and Asia, including a European patent validated in three countries. These patents are expected to expire in 2027 and 2030.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusively licensed a family of patents and applications related to the treatment of cardiomyopathy associated with Friedreich&#8217;s Ataxia. This family includes two patents granted in the U.S., one in India, one in Mexico, one in New Zealand and eleven pending applications in the U.S. and elsewhere in North America, Europe, Asia, and the Pacific. Patents that grant from this patent family are generally expected to expire in 2033, subject to possible patent term extensions and adjustments. In January 2021, we granted an exclusive (even as to us) sublicense to this patent family, which does not relate to ADVM-022, to Lexeo Therapeutics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secret Protection</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some circumstances we may rely on trade secrets to protect aspects of our technology and product candidates, including aspects for which we do not obtain patent protection. We seek to protect our trade secrets and confidential information, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our confidential information and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. However, trade secrets can be difficult to protect. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Relating to Our Intellectual Property.&#8221; of this Annual Report on Form 10-K. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., biological products, including gene therapy products, are primarily regulated under the Federal Food, Drug, and Cosmetic Act (&#8220;FD&amp;C Act&#8221;) and the Public Health Service Act (&#8220;PHS Act&#8221;), as well as corresponding implementing regulations promulgated by the FDA. These laws and regulations govern, among other things, the testing, manufacturing, safety, efficacy, purity, potency, labeling, packaging, storage, record keeping, reporting, advertising and promotion, distribution, post-approval monitoring and reporting, sampling, and export and import of biological products. Prior to conducting human clinical testing of our gene therapy products, we must submit an investigational new drug application (&#8220;IND&#8221;) to the FDA, and the IND must be cleared by the FDA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the FDA, the Center for Biologics Evaluation and Research (&#8220;CBER&#8221;) regulates gene therapy products. Within CBER, the review of gene therapy and related products is consolidated in the Office of Therapeutic Products (&#8220;OTP&#8221;). The FDA has also established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before our product candidates may be marketed in the U.S. generally involves the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completion of nonclinical laboratory tests, including evaluations of product chemistry, formulations, and toxicity and animal studies in accordance with current Good Laboratory Practice (&#8220;GLP&#8221;), regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission of an IND to the FDA, which must go into effect before human clinical trials may begin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approval by the independent institutional review board (&#8220;IRB&#8221;) of each clinical protocol and each clinical trial site before the trial may be initiated at that site;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approval by the institutional biosafety committee (&#8220;IBC&#8221;) of each clinical trial site, which assesses the safety of research involving, among other things, recombinant DNA, and identifies any potential risks to public health or the environment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Generation of substantial evidence from human clinical trials, conducted in accordance with Good Clinical Practice (&#8220;GCP&#8221;) regulations, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and potency of the biological product for its proposed indication;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission to the FDA of a Biologics License Application (&#8220;BLA&#8221;) for marketing approval that demonstrates adequate efficacy and acceptable safety profile of the biological product based on results of nonclinical testing and clinical trials, as well as providing information on the chemistry, manufacturing and controls to ensure product identity, purity, potency and quality, as well as proposed labeling;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Satisfactory completion of an FDA inspection of each manufacturing facility at which the biologic product is produced, to assure that the product is produced in compliance with GMP, regulations, and any additional requirements made by the agency to assure that the facilities, methods and controls used during manufacturing are adequate to preserve the biological product&#8217;s safety, identity, strength, quality, purity, and potency;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successful completion of FDA inspection(s) of the nonclinical and clinical trial sites and the clinical study sponsor that generated the data in support of the BLA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successful completion of an advisory committee review, if the FDA convenes an advisory committee; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Payment of user fees and the FDA review and licensure of the BLA prior to any commercial marketing, sale or shipment of the biological product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any biological product candidate, including a gene therapy product, in humans, the product candidate enters the nonclinical testing stage. Nonclinical tests include animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the nonclinical tests must comply with federal regulations and requirements, including GLPs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of nonclinical tests, together with manufacturing information, such as laboratory evaluation of product chemistry, formulation, and stability, as well as any available clinical data or literature and a proposed clinical protocol, are submitted as part of an IND to the FDA. Some nonclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions relating to the content of the IND during the review period or places the clinical study on a clinical hold. In that case, the IND sponsor and the FDA must resolve any outstanding concerns before the IND goes into effect and the clinical trial begins. The FDA can impose clinical holds on a biologic product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold on an IND, clinical trials may not commence or proceed without FDA authorization, and then only under terms authorized by the FDA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve administering of the investigational biological product candidate to human subjects under the supervision of qualified investigators, who are generally physicians not employed by or under the study sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, the parameters to be used in monitoring subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur, and the effectiveness criteria to be used. Each protocol (and its amendments) must be submitted to the FDA as part of the IND. An independent IRB, and IBC, at each institution where the clinical trial will be conducted must also review and approve the plan for any clinical trial before it can begin at that institution, and the IRB must monitor the clinical trial until it is completed. For gene therapy products, the IBC will also assess the safety of the research and identify any potential risk to public health or the environment, until the research is completed. Clinical testing also must satisfy GCP requirements, including the requirements for informed consent from all subjects. Some studies employ a Data Monitoring Committee (DMC), independent from the study sponsor, to monitor clinical trial conduct and safety, assess risks and benefits, and make recommendations to protect the study participants of clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical research performed in the U.S. in support of a BLA must be authorized in advance by the FDA as described above. However, a sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the FDA will accept a well-designed, well-conducted, non-IND foreign clinical trial as support for a BLA if (i) the clinical trial was conducted in accordance with GCP as further detailed in the regulation, including review and approval by an independent ethics committee, and (ii) if the FDA is able to validate the data from the clinical trial through an onsite inspection, if necessary. In addition, when an applicant submits data from a foreign clinical trial not conducted under an IND to support a BLA, the FDA requires a description of the actions the applicant took to ensure that the research conformed to GCP. Further, additional requirements apply when a sponsor intends to base marketing approval of a new drug solely on foreign clinical data.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are typically conducted in three sequential phases, which may overlap or be combined.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1 includes the initial introduction of an investigational new drug into human subjects and tested for safety. In the case of some product candidates for severe or life-threatening diseases, the initial human testing is often conducted in patients. Phase 1 clinical trials of gene therapies are typically conducted in patients rather than healthy volunteers.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2 clinical trials are typically conducted in a larger subject population than Phase 1 trials to evaluate dosage tolerance and appropriate dosage, identify possible adverse effects and safety risks, and to preliminarily evaluate the efficacy of the product candidate for specific targeted indications. For Phase 2 clinical trials in gene therapy, although the subject population may be larger than the Phase 1 trials, the subject population may still remain relatively limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 clinical trials are typically conducted when Phase 2 clinical trials demonstrate that a dose range of the biological product candidate is effective and has an acceptable safety profile. Phase 3 clinical trials are generally undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical study sites. These clinical studies are intended to establish the overall risk/benefit ratio of the product and to provide an adequate basis for product approval and labeling. Phase 3 clinical trials are commonly referred to as &#8220;pivotal&#8221; studies, which typically denotes a study which presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a product candidate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial approval. These clinical trials are used to gain additional data from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. Phase 4 clinical trials may be required by the FDA as a condition of approval. Additionally, FDA recommends that sponsors observe study participants for potential gene therapy-related delayed adverse events for as long as 15 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for any serious and unexpected adverse event that occurs during the study, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the clinical protocol or Investigator&#8217;s Brochure, as well as any findings from other studies using the proprietary 7m8 capsid, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects from the product candidate. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for expedited reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor's initial receipt of the information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its DMC may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB's requirements or if the biological product has been associated with unexpected serious harm to patients. Similar rules govern the conduct of clinical trials in the European Economic Area (&#8220;EEA&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the U.S., the&#160;various phases of nonclinical and clinical research in the European Union (&#8220;EU&#8221;) are subject to significant regulatory controls. In the EU, clinical trials are governed by the EU Clinical Trial Regulation 536/2014 (CTR), which entered into application on January 31, 2022 repealing and replacing the former Clinical Trials Directive 2001/20, or CTD. The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increase transparency. Specifically, the Regulation, which is directly applicable in all EU Member States, introduces a streamlined application procedure through a single-entry point, the "EU portal", the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I assessment is led by the competent authorities of a reference Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which on-going clinical trials will be governed by the CTR will depend on the duration of the individual clinical trial. For clinical trials in relation to which an application for approval was made on the basis of the CTD before January 31, 2023, the CTD will continue to apply on a transitional basis until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all cases, clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Medicines used in clinical trials, including ATMPs, must be manufactured in accordance with the guidelines on cGMP and in a GMP licensed facility, which can be subject to GMP inspections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and the National Institutes of Health (&#8220;NIH&#8221;) developed a publicly accessible database, the Genetic Modification Clinical Research Information System, designed to facilitate safety reporting, assist researchers and others involved in human gene therapy clinical studies, and manages information about science and safety of gene therapy clinical trials.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving the use of gene therapy. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors that the FDA will consider at each of the above stages of clinical development and the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for up to five years for nonintegrating vectors such as AAV vectors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The responsible party for an applicable clinical trial must register the clinical trial of FDA-regulated products on the ClinicalTrials.gov website, including the registry of new, on-going, and completed clinical trials of drugs, biologics, and device products, including the publication of the study results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics License Applications and Marketing Authorization Applications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of nonclinical studies and clinical trials, together with detailed information on the quality of the product, are submitted to the FDA in the form of a BLA requesting approval to market the product for one or more specified indications. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the submission of a BLA must be accompanied by a substantial user fee unless a waiver applies and is subject to a sixty-day filing review period to determine if the application is sufficiently complete to permit substantive review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under PDUFA, the FDA has a performance goal to review applications within six months from successful filing of the application for priority reviews or ten months for standard reviews. The review timeline begins upon the FDA&#8217;s acceptance of the original application submission for filing, no later than 60 calendar days from the date the FDA receives the application. In some instances, the review process and the PDUFA goal date may be extended depending on the information required for the FDA reviewers to complete their review of the BLA. As with new BLAs, the review process could also be extended by FDA requests for additional information or clarification.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. The FDA may deny licensure of a BLA by issuing a complete response letter if the applicable statutory and regulatory criteria are not satisfied and may require additional clinical data or an additional Phase 3 clinical trial. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary to assure the safe use of the biological product upon marketing. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the FDA licenses a BLA, or supplement thereto, the FDA may withdraw the licensure if ongoing regulatory requirements are not met or if safety problems are identified after the product reaches the market. Even where a withdrawal is not required, the FDA still may seize existing inventory of such product or require a recall of product already on the market. In addition, the FDA may require testing, including Phase 4 clinical trials and surveillance programs to monitor the effect of licensed biologics that have been commercialized. The FDA has the authority to prevent or limit further marketing of a biologic based on the results of these post-marketing programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics may be marketed only for the FDA-approved indications and in accordance with the provisions of the approved labeling. Further, if there are any modifications to the product, including changes in indications, labeling, or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require the sponsor to develop additional data or conduct additional nonclinical studies and clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will inspect the facilities at which the biologic is manufactured and will not license the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with cGMPs. Additionally, before approving a BLA, the FDA may also inspect one or more clinical sites to assure that the clinical studies were conducted in compliance with IND study requirements and GCP requirements. The FDA may also inspect the facilities of the sponsor to ensure that processes and procedures are in compliance with GMP/GCP requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. After approval, certain changes to the approved product, such as adding new indications, manufacturing changes, or additional labeling claims are subject to further FDA review and approval. Depending on the nature of the change proposed, a BLA supplement must be filed and approved before the change may be implemented. For many proposed post-approval changes to a BLA that include new efficacy data, the FDA intends to review and act on the supplemental application within 10 months of receipt. FDA intends to review and act on the manufacturing supplement within six months of receipt.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biological product approved under section 351(a) of the PHS Act (a &#8220;reference product&#8221;) can receive 12 years of marketing exclusivity, four years of which constitute data exclusivity. In other words, no biosimilar application that cites the reference product can be submitted to the FDA until four years after approval of the reference product, and no biosimilar application that cites the reference product can be approved during the full 12-year period. These exclusivity provisions only apply to biosimilars&#8212;companies that rely on their own data and file a full BLA may be approved earlier than 12 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EEA (which is comprised of the 27 Member States of the EU plus Norway, Iceland, and Liechtenstein), medicinal products can only be commercialized after a related Marketing Authorization, or MA, has been granted. To obtain an MA for a product in the EU, an applicant must submit a Marketing Authorization Application, or MAA, either a centralized procedure administered by the European Medicines Agency, or EMA, or one of the procedures administered by the competent authorities of EU Member States (mutual recognition procedure, decentralized procedure, or national procedure. An MA may be granted only to an applicant established in the EEA. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure allows a company to submit a single application to the EMA. If a related positive opinion is provided by the EMA, the European Commission will grant a single centralized MA that is valid throughout the EEA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, advanced therapy medicinal products (ATMPs, such as gene therapy products), orphan medicinal products, and medicinal products containing a new active substance to treat some diseases like HIV/AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, authorization through the centralized procedure is optional on related approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, conducts the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. The maximum timeframe for the evaluation of an MAA under the centralized procedure is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike the centralized authorization procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the Heads of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures &#8211; Human, or CMDh, for review. The subsequent decision of the European Commission is binding on all EU Member States. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States. Like the decentralized procedure, the mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the MA of a medicinal product by the competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent authority of an EU Member State requesting that this authority recognize the MA delivered by the competent authority of another EU Member State. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An MA has, in principle, an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was granted. To support the application, the MA holder must provide the EMA or the competent authority with a consolidated version of the Common Technical Document providing up-to-date data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide on justified grounds relating to pharmacovigilance, to proceed with one further five-year renewal period for the MA. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for a centralized MA) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The European Commission may grant a conditional MA for a medicinal product if it is demonstrated that all of the following criteria are met: (i) the benefit-risk balance of the medicinal product is positive; (ii) it is likely that the applicant will be able to provide comprehensive data post-authorization; (iii) the medicinal product fulfills an unmet medical need; and (iv) the benefit of the immediate availability to patients of the medicinal product is greater than the risk inherent in the fact that additional data are still required. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the EMA and approved by the European Commission, the MA will cease to be renewed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An MA may also be granted &#8220;under exceptional circumstances&#8221; where the applicant can show that it is unable to provide comprehensive data on efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved for medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for authorization in exceptional circumstances is not subsequently required to provide the missing data. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the MA will be withdrawn if the risk-benefit ratio is no longer favorable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU provides opportunities for data and market exclusivity related to MAs. Upon receiving an MA, innovative medicinal products are generally entitled to receive eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall ten-year period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for MA. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advanced Therapy Medicinal Products in the EU</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advanced Therapy Medicinal Products, or ATMPs, include gene therapy products as well as somatic cell therapy products and tissue engineered products. The grant of marketing authorization in the EU for products containing viable human tissues or cells such as gene therapy medicinal products is governed by Regulation (EC) No. 1394/2007 on ATMPs, read in combination with Directive (EC) No. 2001/83 of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation (EC) No. 1394/2007 establishes specific rules concerning the authorization, supervision and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety and efficacy of their products to the EMA which is required to provide an opinion regarding the application for marketing authorization. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell-based products must also comply with Directive (EC) No. 2004/23 of the European Parliament and of the Council of March&#160;31, 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells, or the Tissues and Cells Directive, as well as its technical implementing directives. This Directive describes the conditions and quality requirements which must be applied when sourcing the cells intended for manufacturing of the cell-based medicinal product. The EU Member States have transposed the Tissues and Cells Directive into their national laws. However, various interpretations of the Tissue and Cells Directive have occurred and are reflected in individual EU Member States national implementing legislation which have led to diverging approaches.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Development in the EU</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, Regulation (EC) No 1901/2006 provides that all MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for a six-month extension to the Supplementary Protection Certificate, or SPC, if any is in effect at the time of authorization or, in the case of orphan medicinal products, a two-year extension of orphan market exclusivity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has created programs intended to facilitate and expedite the development and review of new drugs to address the unmet medical need in the treatment of a serious or life-threatening condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track designation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify for fast track designation, a product candidate must be intended to treat a serious condition and address an unmet medical need. Advantages of fast track designation include the possibility for a rolling review, eligibility for priority review (under which FDA sets a target date for FDA action of the BLA at six months after FDA accepts that application for filing), and the ability to have greater interactions with the FDA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product submitted to the FDA for marketing approval, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation, priority review designation, and accelerated approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough therapy designation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review, if preliminary clinical data indicate that the product provides a substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program; intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross&#8209;disciplinary review; and rolling review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A designation given to a product candidate that is a regenerative medicine therapy intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the candidate has the potential to address the unmet medical needs for the disease or condition. The FDA has indicated that gene therapies may qualify as regenerative medicine therapies. Advantages of RMAT designation include all the benefits of breakthrough therapy designation, early and frequent interactions with the FDA to discuss any potential surrogate or intermediate endpoints and address potential ways to support accelerated approval and satisfy post-approval requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority review. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product, including those that receive fast track, breakthrough therapy, or RMAT designations, may be eligible for priority review, if the product meets the criteria for priority review at the time the BLA is submitted. If priority review is granted, the FDA has a six-month goal for reviewing the marketing application or efficacy supplement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accelerated approval. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Accelerated Approval Program is a drug development pathway that offers an approval based on a &#8220;surrogate&#8221; marker in a clinical trial. A surrogate marker is a biomarker or clinical marker that can be measured at an earlier point in a trial than the type of endpoints that may be used in a traditional approval. Drug or biologic products with evidence showing that they provide meaningful therapeutic benefit over existing treatments for serious or life&#8209;threatening illnesses may receive accelerated approval. As a condition of approval, the FDA may require that a sponsor conduct post&#8209;marketing clinical trials.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (excluding clock stops). The CHMP can, however, revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation (&#8220;ODD&#8221;)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biological product intended to treat a rare disease or condition&#8212;generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or if there is no reasonable expectation that the cost of developing and making the product available in the U.S. will be recovered from sales of the product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ODD must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. ODD does not affect the regulatory review and approval process. However, if a product that has orphan designation subsequently receives the first BLA applicant to receive FDA approval for that product for the disease or condition for which it has such designation, that product is entitled to a seven-year exclusive marketing period in the U.S. for that product in the approved indication. During the seven-year marketing exclusivity period, the FDA may not approve any other applications to market the same drug or biological product for the same indication, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Among the other benefits of ODD are tax credits for certain research and a waiver of the user fee. In September 2021, the FDA finalized Guidance For Industry on determining &#8220;sameness&#8221; for gene therapy products for purposes of orphan drug exclusivity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug products are also eligible for Rare Pediatric Disease Designation if greater than 50% of patients living with the disease are under age 18. A priority review voucher will be given to the sponsor of a product with a Rare Pediatric Disease Designation at the time of product approval that is transferable to another company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, Regulation (EC) No. 141/2000, as implemented by Regulation (EC) No. 847/2000 provides that a medicinal product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that: (i)&#160;the product is intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (ii)&#160;either (a)&#160;such conditions affect not more than 5 in 10,000 persons in the EU when the application is made, or (b)&#160;the product without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in developing the medicinal product; and (iii)&#160;there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation (EC) No 847/2000 sets out further provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product. An application for the designation of a medicinal product as an orphan medicinal product must be submitted at any stage of development of the medicinal product but before filing of an MAA. An MA for an orphan medicinal product may only include indications designated as orphan. For non-orphan indications treated with the same active pharmaceutical ingredient, a separate marketing authorization has to be sought.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan medicinal product designation entitles an applicant to incentives such fee reductions or fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Upon grant of a marketing authorization, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept another marketing authorization application or accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of market exclusivity may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria on the basis of which it received orphan medicinal product destination, including where it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, an MA may be granted to a similar medicinal product with the same orphan indication during the 10-year period if: (i) if the applicant consents to a second original orphan medicinal product application, (ii) if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities; or (iii) if the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior to the original orphan medicinal product. A company may voluntarily remove a product from the register of orphan products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any biologics manufactured or distributed by us or our collaborators pursuant to FDA or European Commission and other regulatory authorities&#8217; approvals would be subject to continuing regulation by the FDA, the EMA, the European Commission, the national competent authorities of EU Member States and other regulatory authorities, including in relation to regulatory requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and comparable foreign regulatory authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to an MA, various other requirements apply to the manufacturing and placing on the EU market of medicinal products. The manufacturing of medicinal products in the EU requires a manufacturing authorization and import of medicinal products into the EU requires a manufacturing authorization allowing for import. The manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including EU cGMP standards. Similarly, the distribution of medicinal products within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of EU Member States. Marketing authorization holders and/or manufacturing and import authorization, or MA holders and/or distribution authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in case of non-compliance with the EU or EU Member States&#8217; requirements applicable to the manufacturing of medicinal products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or our third-party manufacturers may be subject to periodic unannounced inspections by the FDA, certain state agencies, national competent authorities of EU Member States and comparable foreign regulatory authorities for compliance with ongoing regulatory requirements, including GMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the GMP regulations and other ongoing FDA, EU or other comparable foreign regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA, national competent authorities of EU Member State or other regulatory authorities may impose sanctions on us, including shutdown of the third-party vendor or invalidation of drug product lots or processes, fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products, if approved, and significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. For example, under the FDA&#8217;s current interpretation of the relevant laws, in proactively promoting a biologic, a company generally can make only those substantiated claims relating to safety and efficacy that are for indications approved by the FDA and that are otherwise consistent with the FDA-approved label for the biologic. Claims must be truthful and non-misleading. Failure to comply with these requirements can result in fines, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians may prescribe legally available biologics for uses that are not described in the product&#8217;s labeling and that differ from those tested by the sponsor and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers&#8217; communications regarding off-label use. If the FDA finds that we have promoted off-label use of any product that is eventually approved, sanctions could include refusal to approve pending applications, withdrawal of an approval, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where an MA is granted in relation to a medicinal product in the EU, the holder of the MA is required to comply with a range of regulatory requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the individual EU Member States. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk- minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the advertising and promotion of pharmaceutical products are subject to EU and EU Member States' laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities in connection with a marketing authorization approval. The SmPC is the document that provides information to physicians and other healthcare professionals concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU. Other relevant laws at EU level and in the individual EU Member States also apply to the advertising and promotion of medicinal products, including laws that prohibit the direct-to-consumer advertising of prescription-only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care professionals. Violations of the rules governing the promotion of medicinal products in the EU could result in reputational risk, public reprimands, administrative measures, fines and imprisonment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and Security Laws</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may process confidential, sensitive, and proprietary information, including personal information. Accordingly, we are, or may become, subject to numerous data privacy and security obligations, including federal, state, local, and foreign laws, regulations, guidance, and industry standards related to data privacy, security, and protection. Such obligations may include, without limitation, the Federal Trade Commission Act, the Telephone Consumer Protection Act of 1991, the Controlling the Assault of Non-Solicited Pornography And Marketing Act of 2003, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), the European Union&#8217;s General Data Protection Regulation 2016/679 (&#8220;EU GDPR&#8221;), the EU GDPR as it forms part of UK law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (&#8220;UK GDPR&#8221;), the ePrivacy Directive, and the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their implementing regulations (collectively, &#8220;HIPAA&#8221;). Several states within the United States have enacted or proposed data privacy laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act. Additionally, we are, or may become, subject to various U.S. federal and state consumer protection laws which require us to publish statements that accurately and fairly describe how we handle personal data and choices individuals may have about the way we handle their personal data. The EU GDPR and CCPA are examples of the increasingly stringent and evolving regulatory frameworks related to personal information processing that may increase our compliance obligations and exposure for any actual or perceived noncompliance. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CCPA and EU GDPR are examples of the increasingly stringent and evolving regulatory frameworks related to personal data processing that may increase our compliance obligations and exposure for any noncompliance.  For example, the CCPA imposes obligations on covered businesses to provide specific disclosures related to a business&#8217;s collecting, using, and disclosing personal data and to respond to certain requests from California residents related to their personal data (for example, requests to know of the business&#8217;s personal data processing activities, to delete the individual&#8217;s personal data, and to opt out of certain personal data disclosures). Also, the CCPA provides for civil penalties and a private right of action for data breaches which may include an award of statutory damages. In addition, the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), effective January 1, 2023, expands the CCPA. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal data, establish restrictions on personal data retention, expand the types of data breaches that are subject to the CCPA&#8217;s private right of action, and establish a new California Privacy Protection Agency to implement and enforce the new law.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CCPA and EU GDPR are examples of the increasingly stringent and evolving regulatory frameworks related to personal data processing that may increase our compliance obligations and exposure for any noncompliance.  For example, the CCPA imposes obligations on covered businesses to provide specific disclosures related to a business&#8217;s collecting, using, and disclosing personal data and to respond to certain requests from California residents related to their personal data (for example, requests to know of the business&#8217;s personal data processing activities, to delete the individual&#8217;s personal data, and to opt out of certain personal data disclosures). Also, the CCPA provides for civil penalties and a private right of action for data breaches which may include an award of statutory damages. In addition, the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), effective January 1, 2023, expands the CCPA. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal data, establish restrictions on personal data retention, expand the types of data breaches that are subject to the CCPA&#8217;s private right of action, and establish a new California Privacy Protection Agency to implement and enforce the new law.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign data privacy and security laws (including but not limited to the EU GDPR and UK GDPR) impose significant and complex compliance obligations on entities that are subject to those laws. As one example, the EU GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. These obligations may include limiting personal data processing to only what is necessary for specified, explicit, and legitimate purposes; requiring a legal basis for personal information processing; requiring the appointment of a data protection officer in certain circumstances; increasing transparency obligations to data subjects; requiring data protection impact assessments in certain circumstances; limiting the collection and retention of personal information; increasing rights for data subjects; formalizing a heightened and codified standard of data subject consents; requiring the implementation and maintenance of technical and organizational safeguards for personal information; mandating notice of certain personal information breaches to the relevant supervisory authority(ies) and affected individuals; and mandating the appointment of representatives in the UK and/or the EU in certain circumstances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA imposes requirements on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; that create, receive, maintain and transmit individually identifiable health information for or on behalf of a covered entity relating to the privacy, security and transmission of individually identifiable health information and their covered subcontractors. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to penalties if we, our affiliates, or our agents obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information regarding the risks to our business related to laws and regulations to which we are or may become subject, see &#8220;Risk Factors&#8212;Risks Related to Our Business Operations.&#8221; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval for any of our product candidates, we may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we conduct our business. These laws may impact, among other things, our research activities, as well as our proposed sales, marketing, and education programs. The laws that may affect our ability to operate include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any health care item or service for which payment may be made, in whole or in part, by federal healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical companies on one hand and prescribers, purchasers and formulary managers on the other. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Law constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exemption or safe harbor, or for which no exception or safe harbor is available, may be subject to scrutiny;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the U.S. Attorney General or as a qui tam action by a private individual (a whistleblower) in the name of the government and the individual, and the whistleblower may share in any monetary recovery. Many pharmaceutical and other healthcare companies have been investigated and have reached substantial financial settlements with the federal government under the civil False Claims Act for a variety of alleged improper marketing activities, including: providing free product to customers with the expectation that the customers would bill federal programs for the product; providing sham consulting fees, grants, free travel and other benefits to physicians to induce them to prescribe the company&#8217;s products; and inflating prices reported to private price publication services, which are used to set drug payment rates under government healthcare programs. In addition, the government has pursued civil False Claims Act cases against a number of pharmaceutical companies for causing false claims to be submitted as a result of the marketing of their products for unapproved, and thus non-reimbursable, uses. Because of the threat of treble damages and mandatory penalties per false or fraudulent claim or statement, healthcare and pharmaceutical companies often resolve allegations without admissions of liability for significant and material amounts. Pharmaceutical and other healthcare companies also are subject to other federal false claim laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health benefit programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which also, prohibits, among other things, executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false, fictitious, or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to direct and indirect payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Outside the U.S., interactions between pharmaceutical companies and physicians and other healthcare professionals are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Certain EU member states, or industry codes of conduct, require that payments made to physicians be publicly disclosed. Moreover, agreements with healthcare professionals may require prior notification and approval by the healthcare professional&#8217;s employer, his/her competent professional organization, and/or the competent authorities of the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare professionals and other potential referral sources; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs (such as Medicare and Medicaid), imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, and fraud laws may prove costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the pharmaceutical and biotechnology industry have received increased public and governmental scrutiny for the cost of drugs. In particular, U.S. federal prosecutors have issued subpoenas to pharmaceutical companies seeking information about drug pricing practices and the U.S. Senate is investigating several pharmaceutical companies relating to drug price increases and pricing practices. If we obtain regulatory approval of any of our product candidates, our revenue and future profitability could be negatively affected if these inquiries were to result in legislative or regulatory proposals that limit our ability to increase the prices of our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement and Healthcare Reform Legislation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of gene therapy products. In the U.S. and other countries, sales of any products for which we receive marketing approval will depend in part on the availability of coverage and adequate reimbursement from third-party payers. Third-party payers include government authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payer will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payer will pay for the drug product. Third-party payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. A number of gene or cell therapy products have been approved over the past several years by the FDA. For example, although CMS has approved coverage for Chimeric Antigen Receptor T-cell therapies, such as Yescarta and Kymriah, and has established reimbursement methods for these therapies, these policies could be changed in the future. CMS&#8217;s decision as to coverage and reimbursement for one product does not mean that all similar products will be eligible for analogous coverage and reimbursement. As there is no uniform policy for coverage and reimbursement amongst third-party payers in the U.S., even if CMS approves coverage and reimbursement for any of our product candidates, it is unclear what affect, if any, such a decision will have on our ability to obtain and maintain coverage and adequate reimbursement from other private payers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, contains provisions that may reduce the profitability of drug products, including, for example, by increasing the minimum rebates owed by manufacturers under the Medicaid Drug Rebate Program, extending the rebate program to individuals enrolled in Medicaid managed care plans, addressing a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and imposing annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Adoption of government controls and other measures, and tightening of restrictive policies in jurisdictions with existing controls and other measures, could limit coverage of or payments for pharmaceuticals, or affect rebates or other price concessions owed on such products. Certain provisions of the Affordable Care Act have been subject to judicial challenges as well as efforts to repeal, replace, or otherwise modify them or to alter their interpretation and implementation. For example, the TCJA eliminated the tax-based payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, commonly referred to as the individual mandate, effective January 1, 2019. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argue the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, policies that undermine protections for people with pre-existing conditions, demonstrations and waivers under Medicaid and the Affordable Care Act that may reduce coverage or undermine the programs thereunder, including work requirements, and policies that make it more difficult to access health benefits through Medicaid or the Affordable Care Act. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 &#8220;Inflation Reduction Act&#8221; into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. Any such changes could affect the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, it is unclear whether such legislative changes, regulatory changes, or judicial challenges related to the Affordable Care Act, or other health care reform measures will also have an impact on biologic product exclusivity, or the biosimilar product licensure pathway established under the Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), which was enacted as part of the Affordable Care Act.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have also been proposed and adopted in the U.S. since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013, and due to subsequent legislative changes to the statute, will stay in effect through 2032 unless additional congressional action is taken. Further, Congress is considering additional health reform measures. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been increasing legislative, regulatory, and enforcement interest in the U.S. with respect to drug pricing practices. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. The Inflation Reduction Act also, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is unclear how the Inflation Reduction Act will be implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. It is possible that the Affordable Care Act, as currently enacted or may be amended in the future, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare financing, more rigorous coverage criteria, and new payment methodologies and in additional downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from commercial payers. Coverage policies and reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement schemes vary widely from country to country. Some EU Member States may approve a specific price for a product, or they may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular medicinal product candidate to currently available therapies. This Health Technology Assessment, or HTA, process is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. In December 2021, Regulation No. 2021/2282 on Health Technology Assessment, or HTA Regulation, was adopted. The HTA Regulation is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. When it enters into application in 2025, the HTA Regulation will be intended to harmonize the clinical benefit assessment of HTA across the EU. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to what is occurring in the U.S., political, economic and regulatory developments outside of the U.S. are also subjecting the healthcare industry to fundamental changes and challenges. Pressure by governments and other stakeholders on prices and reimbursement levels continue to exist. In various EU member states, we expect to be subject to continuous cost-cutting measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The making available or placing on the EU market of unauthorized medicinal products is generally prohibited. However, the competent authorities of the EU Member States may, in specific circumstances, exceptionally and temporarily allow and reimburse the supply of such unauthorized products, either on a named patient basis or through a compassionate use process, to individual patients or a group of patients with a chronically or seriously debilitating disease or whose disease is considered to be life-threatening, and who cannot be treated satisfactorily by an authorized medicinal product. Such reimbursement may no longer be available if authorization for named patient or compassionate use programs expire or is terminated or if marketing authorization is granted for the product. In some EU Member States, authorization and reimbursement policies may also delay commercialization of our products or may adversely affect our ability to sell our products on a profitable basis. After initial price and reimbursement approvals, reductions in prices and changes in reimbursement levels can be triggered by multiple factors, including reference pricing systems and publication of discounts by third party payers or authorities in other countries. In the EU, prices can be reduced further by parallel distribution and parallel trade, or arbitrage between low-priced and high-priced EU Member States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of adequate government reimbursement for our products may also be subject to regulatory changes and controls.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we or our collaborators will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our future drugs. Whether or not we obtain FDA approval for a drug, we or our collaborators must obtain approval from the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing of the drug in those countries. Many countries outside of the U.S. have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. To obtain regulatory approval of a biological medicinal product under EU regulatory systems, we must submit a marketing authorization application. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the EU and the U.S., we or our collaborators will be subject to a variety of foreign regulations governing clinical trials and commercial distribution of our future products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brexit. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom&#8217;s, or UK, withdrawal from the EU on January 31, 2020, commonly referred to as Brexit, has changed the regulatory relationship between the UK and the EU. The Medicines and Healthcare products Regulatory Agency, or MHRA, is now the UK&#8217;s standalone regulator for medicinal products and medical devices.  Great Britain (England, Scotland and Wales) is now a third country to the EU. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules for now. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK regulatory framework in relation to clinical trials is governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is derived from the CTD, as implemented into UK national law through secondary legislation. On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials, and which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The UK Government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations will align with the CTR. In October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and risk-proportionate approach to initial clinical trial applications for Phase 4 and low-risk Phase 3 clinical trial applications.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing authorizations in the UK are governed by the Human Medicines Regulations (SI 2012/1916), as amended. Since January 1, 2021, an applicant for the EU centralized procedure marketing authorization can no longer be established in the UK. As a result, since this date, companies established in the UK cannot use the EU centralized procedure and instead must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain a marketing authorization to market products in the UK. All existing EU marketing authorizations for centrally authorized products were automatically converted or grandfathered into UK marketing authorization, effective in Great Britain only, free of charge on January 1, 2021, unless the marketing authorization holder opted-out of this possibility. Northern Ireland currently remains within the scope of EU authorizations in relation to centrally authorized medicinal products. Accordingly, until the Windsor Framework is implemented in Northern Ireland on January 1, 2025, products falling within the scope of the EU centralized procedure can only be authorized through UK national authorization procedures in Great Britain.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MHRA has also introduced changes to national marketing authorization procedures. This includes introduction of procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment route, a rolling review procedure and the International Recognition Procedure. Since January 1, 2024, the MHRA may rely on the International Recognition Procedure, or IRP, when reviewing certain types of marketing authorization applications. This procedure is available for applicants for marketing authorization who have already received an authorization for the same product from a reference regulator. These include the FDA, the EMA, and national competent authorities of individual EEA countries. A positive opinion from the EMA and CHMP, or a positive end of procedure outcome from the mutual recognition or decentralized procedures are considered to be authorizations for the purposes of the IRP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pre-marketing authorization orphan designation for medicinal products in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding marketing authorization application. The criteria are essentially the same as those in the EU, but have been tailored for the market. This includes the criterion that prevalence of the condition in Great Britain, rather than the EU, must not be more than five in 10,000. Upon the grant of a marketing authorization with orphan status, the medicinal product will benefit from up to 10 years of market exclusivity from similar products in the approved orphan indication. The start of this market exclusivity period will be set from the date of first approval of the product in Great Britain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental, Health and Safety Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous foreign, federal, state and local environmental, health and safety (&#8220;EHS&#8221;) laws and regulations relating to, among other matters, safe working conditions, product stewardship, environmental protection, and handling or disposition of products, including those governing the generation, storage, handling, use, transportation, release, and disposal of hazardous or potentially hazardous materials, medical waste, and infectious materials. Some of these laws and regulations also require us to obtain licenses or permits to conduct our operations. If we fail to comply with such laws or obtain and comply with the applicable permits, we could face substantial fines or possible revocation of our permits or limitations on our ability to conduct our operations. Certain of our development and manufacturing activities involve use of hazardous materials, and we believe we are in compliance with the applicable environmental laws, regulations, permits, and licenses. However, we cannot ensure that EHS liabilities will not develop in the future. EHS laws and regulations are complex, change frequently and have tended to become more stringent over time. Although the costs to comply with applicable laws and regulations, including requirements in the EU relating to the restriction of use of hazardous substances in products, have not been material, we cannot predict the impact on our business of new or amended laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced, nor can we ensure we will be able to obtain or maintain any required licenses or permits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2023, we had approximately 121 full-time employees. Of these employees, 21 hold Ph.D. or M.D. degrees, 83 are engaged in research and development, and 38 are engaged in business development, finance, legal, human resources, facilities, information technology, and general management and administration. We also engage temporary employees and consultants. Our employees are not represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. Our employee engagement is highly favorable, which we attribute to our shared mission of transforming the lives of those affected by highly prevalent ocular diseases and has led to our being named a Top Workplace in 2021, 2022 and 2023 by Bay Area News Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our employees are one of our most valuable assets and are essential to our success. We have been purposeful in our efforts to hire, develop and retain diverse talent as well as create an inclusive culture. We are investing in the creation of a work environment that values the health, safety and wellness of our team, and where our employees are inspired to deliver their best every day. All employees are responsible for upholding the Adverum Code of Business Conduct and Ethics, as well as complying with our Employee Handbook, which together form the foundation of our policies and practices. We continue to expand our systems to track key human capital metrics such as demographics, diversity, compensation and benefits, and engagement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity and Inclusion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are committed to diversity, equity and inclusion (&#8220;DEI&#8221;) across all aspects of our company, including hiring, promotion and development practices. As of December 31, 2023, racial and ethnic minorities represented 62% of our employee base. 57% of our workforce were women and 51% of our positions at director-level and above were held by women. Our employees bring diversity to our workplace across many critical categories, and we believe our company is stronger as a result of our diverse experiences and backgrounds. We are committed to creating and maintaining a diverse, inclusive and safe work environment where our employees can bring their best selves to work each day. We continue to implement employee-led resource groups (&#8220;ERGs&#8221;) and to assemble DEI-related resources for our employees. We currently have one ERG that represents and supports women in our workforce: SOAR (Supporting Women of All Ranks ERG), providing support and mentorship for our female workforce, including guidance on career advancement. Overall, the goal of ERG programs at Adverum are to mentor, foster, encourage and inspire employees in all stages of their careers by providing access to senior leadership, peer groups, mentoring and other valuable resources to help them pursue their career ambitions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to our employees starts with benefit and compensation programs that value their contributions and offer physical, financial and personal health programs to them and their families. We strive to provide pay, benefits and services that are competitive to market and create incentives to attract and retain employees. Our compensation package includes market-competitive pay, broad-based stock grants and bonuses, healthcare and retirement benefits, and paid time off. We also offer an Employee Stock Purchase Program through which employees can purchase company stock at a discounted price and offer stipends to cover expenses associated with working from home and the use of personal devices for work purposes. Additionally, we continue to advance transparency in our pay and representation data by complying with all applicable statutory filing requirements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Communication and Engagement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly believe that Adverum&#8217;s success depends on our employees understanding how their work contributes to the company&#8217;s overall strategy. We strive to foster open and direct communication and seek to empower our employees to be our greatest ambassadors. We use a variety of channels to facilitate this exchange of information, including quarterly business updates from the senior management team; regular all hands meetings, open forums and company-wide written communications; postings on our company intranet; and employee engagement surveys.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and Available Information </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in 2006 under the name &#8220;Avalanche Biotechnologies, Inc.&#8221; We completed the initial public offering of our common stock in August 2014. On May 11, 2016, upon the completion of our acquisition of Annapurna Therapeutics SAS, we changed our name to &#8220;Adverum Biotechnologies, Inc.&#8221; Our common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;ADVM.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 100 Cardinal Way, Redwood City, CA 94063, and our telephone number is (650)&#160;656&#8209;9323. Our website address is www.adverum.com. We make available on our website, free of charge, our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov. The information found on our website is not incorporated by reference into this Annual Report on Form 10-K or any other report we file with or furnish to the SEC.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_25"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Capital</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since we were founded in 2006 and expect to incur significant losses for the foreseeable future as we continue development of our product candidates. Losses have resulted principally from costs incurred in our research and development programs and from our general and administrative expenses. In the future, we intend to continue to conduct research and development, regulatory compliance activities and, if any of our product candidates is approved, sales, marketing and other activities that, together with anticipated general and administrative expenses, will likely result in us incurring significant losses for the next several years or longer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently generate no revenue from sales, and we may never be able to commercialize any of our product candidates. We do not currently have the required approvals to market any of our product candidates, and we may never receive such approvals. We may not be profitable even if we or any development partners succeed in commercializing any of our product candidates. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our planned operations into late 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect our cash, cash equivalents and short-term investments to fund our planned operations into late 2025. However, this estimate is based on a number of assumptions that may prove to be wrong, including our expectations about the timing of planned clinical trials, investments into our manufacturing capabilities, the scope of our research and development activities, continued compliance with and receipt of rental income under our sublease, and changing circumstances beyond our control, that may cause capital to be consumed more rapidly than currently anticipated. As a result, our operating plan may change, and we may need to seek additional funds sooner than planned through collaboration agreements and public or private financings. If we run low on capital and are unable to successfully raise additional funds on terms acceptable to us, we may need to significantly curtail some or all of our development activities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require substantial future capital in order to complete the nonclinical and clinical development for our product candidates and potentially to commercialize these product candidates. Any future clinical trials or ongoing clinical trials of our product candidates could cause an increase in our spending levels, as would other corporate activities, such as expenses related to manufacturing supply of our product candidates. The amount and timing of any expenditure needed to implement our development and commercialization programs will depend on numerous factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the type, number, scope, progress, costs, results of and timing of any future nonclinical studies and clinical trials of any of our product candidates that we are pursuing or may choose to pursue in the future;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need for, and the progress, costs and results of, any additional clinical trials or nonclinical studies of our product candidates we may initiate based on the results of any clinical trials that we may plan or discussions with the United States Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory authorities outside the United States (&#8220;U.S.&#8221;), including any additional clinical trials or nonclinical studies the FDA or other regulatory authorities outside the U.S. may require evaluating the safety of our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of obtaining or maintaining manufacturing for our product candidates, including internal and external commercial manufacturing;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability and cost of acquiring and shipping of supplies necessary for manufacturing and clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing sales, marketing, distribution and other commercial capabilities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of establishing collaborations, license agreements and other partnerships;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with any new product candidates that we may develop, in-license or acquire;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain partnering arrangements for development and/or commercialization; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing enhanced internal controls over financial reporting; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these factors are outside of our control. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of our clinical trials and remaining development programs through commercial introduction. We expect that we will need to raise additional funds in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no product candidate approved by any regulatory authority, have not sold any products, and we do not expect to sell or derive revenue from any product sales for the foreseeable future. We may seek additional funding through, among other methods, collaboration agreements and public or private financings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funding may not be available to us on acceptable terms or at all and the terms of any financing may adversely affect the holdings or the rights of our stockholders. General market conditions resulting from high interest rates, inflation, bank failures, domestic politics, global supply chain issues, and ongoing military conflicts, as well as other market conditions, may make it difficult for us to obtain adequate additional financing when needed or on attractive terms, or at all. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to obtain funding on a timely basis, we may be unable to complete any current or future clinical trials for our product candidates and we may be required to significantly curtail some or all of our activities. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to our product candidates or some of our technologies or otherwise agree to terms unfavorable to us.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have one product candidate in clinical trials, and if that product candidate is not successful our business could be materially impacted. Our other product candidates are in the early stages of development and will require substantial nonclinical and/or clinical development and testing, manufacturing process improvement and validation, clinical studies and regulatory approval prior to commercialization. It is critical to our business to successfully develop and ultimately obtain regulatory approval for one or more of these product candidates. Our ability to commercialize our product candidates effectively will depend on several factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of nonclinical studies and clinical trials, including the ability to demonstrate safety and efficacy of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals for any future products for which we complete clinical trials, including securing regulatory exclusivity to the extent available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities, for example, by engaging third-party manufacturers, partnering with a pharmaceutical licensee with manufacturing capabilities, or developing our own manufacturing capabilities that can provide products and services to support clinical development and the market demand for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful launch and commercial sales of the product, whether alone or in collaboration with potential partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of the product as a viable treatment option by patients, the medical community and third-party payers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing market share while competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile of our products following regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining compliance with post-approval regulations and other requirements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to commercialize our product candidates, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of gene therapies, biologics and drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a biologics license application (&#8220;BLA&#8221;) to the FDA or marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (&#8220;EMA&#8221;), and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market any of our product candidates, any such approval may be subject to limitations on the indicated uses for which we may market the product, or limitations related to its distribution, or be conditional on future development activities and clinical results. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, there can be no assurance that any of our product candidates will be successfully developed or commercialized. If we or any of our future development partners are unable to develop, or obtain regulatory approval, or, if approved, successfully commercialize, any of our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development has inherent risk. Our lead product candidate, ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, for the treatment of wet age-related macular degeneration (&#8220;wet AMD&#8221;), uses a proprietary vector, AAV.7m8, which has undergone limited human testing, and may generate unexpected results in clinical trials in the future, such as the dose-limiting toxicity at the 6 x 10&#x5E;11 vg/eye (&#8220;6E11&#8221;) dose tested in the INFINITY trial in diabetic macular edema (&#8220;DME&#8221;) subjects. Although we will be bound by the generally applicable laws governing approval, the fact that Ixo-vec is a gene therapy and the broad patient population that it is intended to treat means that the safety and efficacy of our product and the related clinical data will be under increased scrutiny by competent authorities. There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or any licensee or development partner, will be required to demonstrate through adequate and well-controlled clinical trials that our product candidate or another party&#8217;s product candidate containing one of our proprietary viral vectors is safe and effective for use in its target indications before seeking regulatory approvals for commercial sale. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors. Any such delay or failure could significantly harm our business prospects, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, whether in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of nonclinical studies and clinical trials, animal models and human subjects may experience changes in their health, including illnesses, injuries and discomforts. It is not always possible to accurately determine whether or not the product candidate being studied caused these conditions. In addition, subjects may not comply with the requirements of the study, such as missing physician visits or not taking eye drops as prescribed, which may result in changes to their health or vision that could then be attributed to the product candidate. Various illnesses, injuries, and discomfort may be reported from time-to-time in clinical trials of our product candidates. For example, a dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial in DME subjects resulted in our announcement on July 22, 2021 that we were discontinuing development of Ixo-vec for the DME indication. It is possible that as we test Ixo-vec and other product candidates, in current and future clinical programs, or if use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomfort and other adverse events that were observed in earlier trials, including the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. In some cases, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or later stage clinical trials, or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that one or more of our product candidates causes serious or life-threatening side effects, or side effects that outweigh the therapeutic benefit of the product candidate, the development of one or more of our product candidates may fail or be delayed, or, if one or more of our product candidates has received regulatory approval, such approval may be revoked, varied or suspended which would severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to understand the safety of our product candidates, when a subject experiences a negative health event during a clinical trial, we must determine if it is related to our product candidate. The subjects we enroll in our clinical trials for our current product candidates are generally less healthy than the general population, which increases the likelihood that a negative health event, unrelated to our product candidate, may occur. These health events may be misattributed to our product candidate, either by us, our investigators, or by regulators. Such misattribution could cause regulatory approval of our product candidates to be denied or delayed. For example, the subjects enrolled in our wet AMD trials are often geriatric and have other health conditions unrelated to wet AMD. We cannot assure you that we will be able to accurately determine whether or not a negative health event experienced by a subject in any of these or subsequent trials was related to Ixo-vec, nor can we assure you that the FDA or other regulatory authorities outside the U.S. responsible for reviewing the safety of Ixo-vec will agree with our determination. If a subject in one of our clinical trials experiences a negative health event, and that event is attributed to Ixo-vec, the trial and any other trials of Ixo-vec may be placed on clinical hold, and regulatory approval of Ixo-vec may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a subject enrolled in one of our clinical trials experiences a negative health event, the subject may be forced to withdraw from our trial, or may become temporarily unavailable for follow-up visits, which may impact the amount or quality of data we obtain from our trial, which in turn may delay or prevent regulatory approval of our product candidate. Because subjects we enroll in our clinical trials for any of our product candidates are likely to be less healthy than the general population, and particularly in trials like OPTIC and LUNA that enroll a small number of subjects, this risk is increased.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates built on adeno-associated viral vector (&#8220;AAV&#8221;) vectors have similar risks to other gene therapy vectors, including inflammation, cytotoxic T-cell responses, anti-AAV antibodies and immune response to the transgene product, such as T-cell responses and/or antibodies against the expressed protein. For example, based on our current clinical experience, dose-related intraocular inflammation is a known side effect of Ixo-vec administration, but the duration of inflammation caused by Ixo-vec, our ability to prevent or manage that inflammation using corticosteroids or other anti-inflammatory or immunomodulatory treatments, and any potential clinical sequelae of that inflammation and treatments used to manage inflammation are not fully understood. Our LUNA trial is evaluating prophylactic corticosteroid regimens, including local corticosteroids and combinations of local and systemic corticosteroids to test the relative contribution of local versus systemic AAV exposure on ocular inflammation. In February 2024, we announced LUNA preliminary safety and efficacy data. Ixo-vec was well-tolerated, and when present intraocular inflammation was responsive to per protocol local corticosteroids. Preliminary data suggest that Ozurdex plus difluprednate eye drops may be a promising prophylactic regimen for future pivotal studies. The use of an Ozurdex plus difluprednate eye drop prophylactic regimen may not be as successful in managing or mitigating inflammation in future, larger clinical trials or commercial use, and our reliance on the availability of these corticosteroids makes us vulnerable to drug shortage or other supply problems.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we achieve marketing approval, doctors may not prescribe, and patients may not use, Ixo-vec or our other product candidates if they deem the levels or risk of inflammation to be unacceptable or if they are unwilling or unable to use the required prophylactic corticosteroid regimen. Further, patients treated with Ixo-vec could develop antibodies against AAV.7m8 capsid and/or aflibercept protein. These antibodies could preclude these patients from receiving other AAV-based gene therapies in the future. In addition, patients previously treated with or exposed to other AAV-based gene therapies could develop antibodies against AAV.7m8 and/or the aflibercept protein, which could reduce or eliminate the effectiveness of Ixo-vec or could cause unanticipated adverse reactions to Ixo-vec. Studies have also found that intravenous delivery of certain AAV vectors at high doses may result in adverse events and have prompted the recommendation that studies involving high doses of AAV vectors should be monitored carefully for such adverse events. In addition, patients given infusions of any therapeutic protein or injection of gene therapies that express a therapeutic protein may develop severe hypersensitivity reactions, infusion reactions, or serious side effects including transaminitis. With respect to our product candidates that are being or may be studied in diseases of the eye, there are additional potential serious complications related to IVT injection and taking aqueous fluid samples from the eye (&#8220;aqueous tap&#8221;), such as retinal detachment, endophthalmitis, ocular inflammation, cataract formation, glaucoma, damage to the retina or cornea, and bleeding in the eye. Serious complications or serious, unexpected side effects in connection with the use of our product candidates could materially harm our business prospects, financial condition and results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our lead product candidate, Ixo-vec, is designed for long-term, sustained expression of an exogenous protein, aflibercept. Even though Eylea</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (aflibercept) has been approved by several regulatory authorities, including the FDA, for the treatment of wet AMD, there may be side effects associated with aflibercept being expressed via a gene therapy treatment modality. If such side effects are serious or life threatening, the development of our product candidate and future product candidates may fail or be delayed, or, if such product candidate(s) have received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are not shown to be safe and effective, we may not realize the value of our investment in our technology or product candidates. Promising nonclinical results generated with a product candidate in animal models do not guarantee similar results when the candidate is tested in humans. For example, the levels of protein expression achieved from a vector in a nonclinical model, including non-human primate models, may be significantly higher than the level of protein expression achieved in humans. Similarly, human subjects administered our product candidates may develop side effects that were not observed in animal models and/or are more severe than those observed in animal models. In addition, even industry-accepted animal models may not accurately replicate human disease. Success in nonclinical studies or in early clinical trials does not mean that later clinical trials will be successful, because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through nonclinical and initial clinical testing. Further, safety and/or efficacy issues with a product candidate may become apparent only when the product candidate is tested in human subjects suffering from the relevant disease. Furthermore, the initiation of future trials for a product candidate will be dependent upon demonstrating sufficient safety and efficacy to the relevant regulatory authorities in preceding or other ongoing trials using the same product candidate. We will still need to conduct Phase 3 pivotal trials in which we anticipate Ixo-vec will be compared to available therapies and utilize longer term endpoints in order to support submission and approval of a BLA or equivalent outside of the U.S. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition, only a small percentage of products under development result in the submission of a marketing application and even fewer are approved for commercialization. Even if our clinical trials successfully meet their endpoints for safety and efficacy, the FDA and/or other regulatory authorities outside the U.S. may still conclude that the product candidate has not demonstrated a beneficial benefit-risk profile or otherwise does not meet the relevant standard for approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that results from any clinical trials that we plan will be successful, and any safety or efficacy concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our gene therapy platform is based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and the time, cost and probability of subsequently obtaining regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our research and development efforts on our gene therapy platform and in product candidates based on this platform, and our future success depends on the successful development of such product candidates. There can be no assurance that any development problems we have experienced or may experience in the future related to our platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to external commercial manufacturing sites, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the clinical trial requirements of the FDA, EU competent authorities and other regulatory authorities outside the U.S. and the criteria these regulators may use to determine the quality, safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel gene therapy products such as ours can be more expensive and take longer than for other treatment modalities, which are better known or more extensively studied to date. To date, approvals for gene therapy products by the FDA have been generally for rare diseases with limited treatment options. Because we are targeting a broad population of patients with wet AMD, for which there is an approved and widely adopted standard of care, the benefit-risk profile of Ixo-vec may be subject to greater scrutiny by regulatory authorities. Regulatory approaches and requirements for gene therapy products continue to evolve, and any changes could create significant delay and unpredictability for product development and approval as compared to technologies with which regulatory authorities have more substantial experience, including, for example, reevaluating whether to require a companion diagnostic for gene therapy products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a clinical trial can begin to enroll at a clinical site, the site&#8217;s Institutional Review Board (&#8220;IRB&#8221;) and its Institutional Biosafety Committee, or Ethics Committee must review the proposed clinical trial to assess the appropriateness to conduct the clinical trial at that site. In addition, adverse events in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory authorities outside the U.S. to change the requirements for human research on or for approval of any of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory authorities, review committees and advisory groups, and the guidelines they promulgate, may lengthen our regulatory review process, require us to perform additional studies, increase our development costs, increase or otherwise change chemistry, manufacturing, and controls requirements, lead to changes in our regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will usually be required to consult with these, and potentially other, regulatory and advisory groups and comply with applicable guidelines or recommendations. If we fail to do so or the consultations take longer than we expect, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs incurred in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trials will be critical to our success. The timing of current and future clinical trials will depend on the speed at which we can recruit patients to participate in future testing of these product candidates. We have in the past and may in the future experience difficulties or delays enrolling patients in our clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating and patient&#8217;s safety concerns over participating in a clinical trial. We will be required to identify and enroll a sufficient number of patients for any clinical trial for our product candidates. Potential patients may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for our trials. Additionally, some patients may have neutralizing antibodies at titer levels that would prevent them from being enrolled in a clinical trial for any of our product candidates, or may meet other exclusion criteria. As a consequence, enrollment in our clinical trials may be limited or slowed. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for such future clinical trials. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek initial marketing approval of our product candidates in the U.S. and/or the EU and we may not be able to successfully conduct clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA, the EU or other regulatory authorities outside the U.S. In addition, the process of finding and diagnosing patients may prove costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if patients and investigators are unwilling to participate in our gene therapy studies because of the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, because of negative publicity from other adverse events in the biotechnology or gene therapy sector, inadequate results in our nonclinical studies or clinical trials, or for other reasons, including competitive clinical trials for similar patient populations or available approved therapies, our recruitment of patients, or conduct of clinical trials and ability to obtain regulatory approval of our product candidates may be hindered.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Our product candidates use an AAV delivery system, with which host integration has been less of a concern. Nonetheless, if patients negatively associate our product candidates with the adverse events caused by previous gene therapy products, they may choose not to enroll in our clinical trials, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have difficulty enrolling a sufficient number of patients to conduct clinical trials on our product candidates as planned, we may need to delay, limit or terminate future clinical trials, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nonclinical and clinical development, manufacturing, analytical testing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA and by comparable regulatory authorities outside the U.S. In the U.S., we are not permitted to market our product candidates until we receive regulatory approval from the FDA. Similar approvals are required to market our product candidates outside of the U.S. The process of obtaining regulatory approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved, as well as the target indications and patient population. Approval policies or regulations may change, and the regulatory authorities have discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable regulatory authorities outside the U.S. can delay, limit or deny approval of a product candidate for many reasons, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with the design or implementation of our or any of our future development partners&#8217; clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities outside the U.S. that a product candidate is safe and effective for any indication;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. may not accept clinical data from trials which are conducted at multinational clinical facilities or in countries where the standard of care is potentially different from that of the U.S. or the other regulatory authorities outside the U.S.;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may find deficiencies in our manufacturing processes, analytical testing, or facilities or in the manufacturing processes, analytical testing or facilities of third-party manufacturers or testing laboratories with which we or any of our future development partners contract for clinical and commercial supplies; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners&#8217; clinical data insufficient for approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of related products, including those already on the market, may result in increased cautiousness by the FDA and comparable regulatory authorities outside the U.S. in reviewing our product candidates based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our future development partners from commercializing our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical trials that we may announce or publish from time to time may change as each clinical trial progresses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may announce or publish preliminary or interim data from our clinical trials. Preliminary and interim results of a clinical trial are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues or further subject follow up occurs and more subject data become available. In addition, in certain clinical trials, such as our OPTIC trial, individual cohorts of subjects were enrolled with different dosages and other treatment conditions under our protocol. These different doses, populations, and other treatment conditions may affect clinical outcomes, including safety profiles or efficacy, such as the number of supplemental injections required, in each of the cohorts. As a result, preliminary and interim data should be viewed with caution and not relied upon until the final data from a locked database for the entire clinical trial are available. Material changes in the final data compared to preliminary or interim data could significantly harm our business prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track designation by the FDA, PRIME designation by the EMA and the Innovation Passport by the MHRA for Ixo-vec may not lead to a faster development, regulatory review or approval, and they do not increase the likelihood that Ixo-vec will receive marketing approval in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received Fast Track designation for Ixo-vec in September 2018 for the treatment of wet AMD. The FDA may grant Fast Track designation to a drug that is intended to treat a serious condition and nonclinical or clinical data demonstrate the potential to address an unmet medical need. The FDA provides opportunities for frequent interactions with the review team for a Fast Track product, including pre-investigational new drug application (&#8220;IND&#8221;) meetings, end-of-phase 1 meetings, and end-of-phase 2 meetings to discuss study design, extent of safety data required to support approval, dose-response concerns, and use of biomarkers. A Fast Track product may also be eligible for rolling review, where the FDA reviews portions of a marketing application before the sponsor submits the complete application.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA granted Ixo-vec Priority Medicines (&#8220;PRIME&#8221;) designation in June 2022 for the treatment of wet AMD. PRIME is a program launched by the EMA to enhance support for research on and development of medicines that have demonstrated the potential to target a significant unmet medical need on the basis of data showing a meaningful improvement of clinical outcomes. This regulatory program offers developers of medicines enhanced interaction and early dialogue with the EMA and is designed to optimize development plans and speed evaluation ensuring these medicines reach patients as early as possible.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom&#8217;s MHRA granted Ixo-vec an Innovation Passport under the Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;) in April 2023. ILAP is a new pathway supporting innovative approaches to the safe, timely, and efficient development of medicines aiming to accelerate the time to market, facilitating patient access to medicines. The ILAP Is comprised of an Innovation Passport designation, a Target Development Profile and provides applicants with access to a toolkit to support the design, development and approvals process. The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the All Wales Therapeutics and Toxicology Centre, the National Institute for Health and Care Excellence, and the Scottish Medicines Consortium to partner with Adverum to charter a roadmap for regulatory and development milestones with the goal of early patient access in the United Kingdom (&#8220;UK&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, Fast Track, PRIME and ILAP designations for Ixo-vec may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA, the European Commission, or MHRA. In addition, the FDA and MHRA can rescind or revoke the designations for Ixo-vec if the regulatory agencies later determine that Ixo-vec no longer meets the qualifying criteria for each designation. The EMA can remove Ixo-vec from the PRIME eligibility list if Ixo-vec no longer meets the eligibility criteria.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our platform technology. Our research programs may fail to identify other potential product candidates for clinical development for a number of reasons. For example, our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to lack efficacy, have harmful side effects, or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that may ultimately prove to be unsuccessful.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of commercially viable manufacturing processes typically is very difficult to achieve, is often very expensive and may require extended periods of time. As we develop, seek to optimize, and operate the Ixo-vec manufacturing process, internally or through third parties, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical manufacturing campaigns or process validation campaigns. For example, all Good Manufacturing Practices (&#8220;GMP&#8221;) activities at our Redwood City facility, and external manufacturing, testing, and distribution partners are subject to significant health authority regulation with respect to manufacturing and testing our product candidates. If we are unable to satisfy these regulatory requirements, or if we are unable to solve the technical, scientific, and other challenges described above, we may be unable to manufacture a sufficient supply of our product candidates for our clinical trials and may be forced to delay or terminate our development programs. Additionally, changes in manufacturing processes (including cell lines and viral banks), equipment or facilities (including moving manufacturing or testing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to conduct additional studies to demonstrate comparability in order to receive regulatory approval of any manufacturing modifications. As a result, we could experience manufacturing delays that prevent us from commencing or completing our clinical studies on the timelines we anticipate, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may revise the process that we use to manufacture Ixo-vec for clinical trials. Before we use a revised process in clinical trials, we must submit analytical comparability data to the FDA and comparable regulatory authorities outside the U.S. to demonstrate that the process changes have not altered Ixo-vec in a manner that undermines the applicability of the clinical data from our clinical trials. If the FDA and comparable regulatory authorities outside the U.S. do not find our analytical comparability data sufficient, the FDA and comparable regulatory authorities outside the U.S. could place our IND or equivalent on clinical hold until we conduct additional nonclinical or clinical comparability studies demonstrating that the Ixo-vec manufactured by our revised process and our previous process are materially equivalent, which could substantially delay the development process. If we make further changes to the manufacturing process, equipment or facilities of Ixo-vec in the future, the FDA and comparable regulatory authorities outside the U.S. may require us to demonstrate comparability between Ixo-vec manufactured before and after the change. For example, the FDA and comparable regulatory authorities outside the U.S. could require comparability studies to demonstrate that Ixo-vec manufactured in its current facilities is comparable to Ixo-vec manufactured at future commercial supply sites, which could delay our commencement or completion of clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether any required comparability studies will begin as planned, will need to be restructured or will be completed on schedule, or at all. If the results of these comparability studies are not positive or are only modestly positive or if there are safety concerns, we may be delayed in obtaining marketing approval for Ixo-vec or not obtain marketing approval at all. Our product development costs also will increase if we experience delays in testing or regulatory approvals.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to produce sufficient quantities of our products and product candidates at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the complexity of manufacturing our products, we may not be able to manufacture sufficient quantities to meet clinical or potential commercial demand. Our inability to produce enough of a product meeting all release acceptance criteria at acceptable costs may cause us to be unable to meet clinical or potential commercial demand, to lose potential revenue, to have reduced margins, or to be forced to discontinue such product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop, seek to optimize and operate the Ixo-vec manufacturing process internally or through third parties, we will likely face technical and scientific challenges, considerable costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. We have in the past and may in the future experience unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from commencing or completing clinical studies or commercializing Ixo-vec, if approved, on a profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing processes will subject us to a variety of U.S. federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use, as well as comparable legislation and regulations outside of the U.S. We will incur significant costs in complying with these laws and regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy products are novel and complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. If we are unable to secure adequate manufacturing capacity from our contract manufacturing partners, or if our contracted slots are canceled or delayed in order to prioritize other projects, we may be unable to produce sufficient quantities of our product candidates for our development programs and for commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of manufacturing or formulation of our product candidates may result in additional costs or delays.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our product candidates progress through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, and manufacturing sites are altered along the way in an effort to optimize yield and manufacturing batch size, reduce costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have relationships with a limited number of suppliers for the manufacturing and testing of our vector product candidates. Our suppliers may require licenses to manufacture or test such components if such processes are not owned by the suppliers or in the public domain, and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities, and may be unable to acquire such rights, to the extent that we do not already have them.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract vendors for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product used in clinical trials or approved for commercial sale must be manufactured and tested in accordance with GMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s GMP regulations enforced by the FDA through its facilities inspection program as well as other comparable regulations enforced by other regulatory authorities outside the U.S. Our contract manufacturers have not produced a commercially-approved AAV product and therefore have not yet demonstrated compliance with GMP regulations to the satisfaction of the FDA or other regulatory authorities outside the U.S. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. If the facility does not pass a pre-approval plant inspection, the FDA or other regulatory approval of the products will not be granted. In addition, the regulatory authorities may, at any time, audit or inspect any manufacturing facility we may have or those of our third-party contractors involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Should the FDA or other regulatory authorities outside the U.S. determine that the facility is not in compliance with applicable regulations, the manufacture and release of our product candidates may not be possible, and our business could be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time, inspect any manufacturing facility we may have or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if we become aware of a violation of our product specifications or applicable regulations, independent of an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and which may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Such violations could also result in civil and/or criminal penalties. Any such remedial measures or other civil and/or criminal penalties imposed upon us or third parties with whom we contract could materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our third-party contractors fail to maintain regulatory compliance, the FDA or other regulatory authorities outside the U.S. can impose regulatory sanctions including, shutdown of the third-party vendor or invalidation of drug product lots or processes, fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products, if approved, and significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the service provided by an approved manufacturing or testing contractor is interrupted, there could be a significant disruption in commercial supply. Alternative contractors could need to be qualified through a BLA supplement which could result in further delay. The regulatory authorities may also require additional studies showing comparability between approved product or testing, and product or testing provided after a contractor change, if a new manufacturing or testing contractor is relied upon for commercial production. Changing contractors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, causing us to incur higher costs, and preventing us from commercializing our product candidates successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face difficulties from changes to current regulations and future legislation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. The policies of the FDA, the competent authorities of the EU Member States, the EMA, the European Commission and other comparable regulatory authorities responsible for clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each EU Member State, leading to a single decision for each EU Member State. The assessment procedure for the authorization of clinical trials has been harmonized as well, including a joint assessment by all EU Member States concerned, and a separate assessment by each EU Member State with respect to specific requirements related to its own territory, including ethics rules. Each EU Member State&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the clinical trial approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials in relation to which application for approval was made on the basis of the Clinical Trials Directive before January 31, 2023, the Clinical Trials Directive will continue to apply on a transitional basis until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on April 26, 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the existing pharmaceutical legislation. If adopted in the form proposed, the recent European Commission proposals to revise the existing EU laws governing authorization of medicinal products may result in a decrease in data and market exclusivity opportunities for our product candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2020, the UK withdrew from the European Union (&#8220;EU&#8221;), commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the UK and the EU, the UK was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. The UK-EU Trade and Cooperation Agreement, which has applied since the end of the Transition Period, provides for tariff-free trade of goods, but not services, between the UK and the EU, but there may however be additional non-tariff costs which did not exist prior to the end of the Transition Period. Further, should the UK further diverge from the EU from a regulatory perspective in relation to medical products, tariffs could be put into place in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the body of the UK-EU Trade and Cooperation Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. The Annex provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extend to procedures such as batch release certification, and Great Britain (England, Scotland and Wales) is treated as a third country. Northern Ireland, has continued to follow EU regulatory rules, but pursuant to the Windsor Framework, a post-Brexit legal agreement entered into between the EU and UK Northern Ireland will no longer be subject to EU Regulations as of January 1, 2025. As part of the UK-EU Trade and Cooperation Agreement, the EU and the UK will recognize GMP inspections carried out by the other Party and the acceptance of official GMP documents issued by the other Party. The UK-EU Trade and Cooperation Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK continues to accept EU batch testing and batch release, but has recently conducted a consultation as to the future strategy for batch testing policy; two years notice will be provided of any change to such a policy. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. As regards marketing authorizations, Great Britain has a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland has continued to be covered by centralized marketing authorizations granted by the European Commission (&#8220;EC&#8221;). but the Windsor Framework provides that the UK MHRA will be the sole regulatory body responsible for granting marketing authorizations for Northern Ireland as of January 1, 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently delays on cross-border trade between the UK and the EU as businesses and governmental bodies adapt to the arrangements. We and our contract vendors currently rely on other contractors based in the UK. The implementation of new governmental policies associated with Brexit may affect our UK-based contractors&#8217; ability to comply with applicable regulations, including existing EU regulations. If they are unable to return to compliance, or if an acceptable substitute vendor cannot be identified, it may negatively impact our business. Further, to the extent that our UK-based contractors have supply relationships with vendors in the EU, these contractors may experience difficulties, delay or increased costs in receiving materials from their vendors in the EU, which could have a material adverse effect on our UK-based contractors&#8217; ability to provide the services or materials to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant proportion of the regulatory framework in the UK applicable to medicinal products is currently derived from EU Directives and Regulations. The potential for UK legislation to diverge from EU legislation following Brexit could materially impact the regulatory regime with respect to the development, manufacture, import, approval, and commercialization of our product candidates in the UK or the EU. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of these changes could increase our costs and otherwise adversely affect our business. Any delay in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the UK or the EU and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the EU. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the UK or the EU for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the UK. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Due to the complexity of manufacturing our product candidates, we may not be able to manufacture sufficient quantities to support our clinical trials. Delays in manufacture and supply by our contract manufacturing partners may also cause delays in their ability to supply the amount of our product that we have ordered and on which we have based our expected development timelines. Our inability to produce enough of a product candidate at acceptable costs may result in the delay or termination of development programs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing and distribution of biologics is extremely susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, or transportation or storage conditions of the product. Even minor deviations from prescribed manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facility in which our product candidates are made, such manufacturing facility may need to be closed for an extended period of time to investigate and remedy the contamination.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, contaminants, raw materials shortages, natural disasters, power failures, and numerous other factors.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contract manufacturers must comply with the FDA&#8217;s and comparable foreign regulatory authorities&#8217; GMP regulations and guidelines. We and our contract manufacturers may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We and our contract manufacturers are subject to inspections by the FDA and comparable regulatory authorities in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow GMP or other regulatory requirements or any delay, interruption, or other issues that arise in the manufacture, fill-finish, packaging, storage, or distribution of our product candidates as a result of a failure of our facilities, or the facilities or operations of third parties, to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates. This may lead to significant delays in the availability of sufficient supply of the product candidate substance for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions, and criminal prosecutions, any of which could be costly and damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates, if approved, and/or may be subject to product recalls, seizures, injunctions or criminal prosecution.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are biologics and require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our product candidates generally cannot be adequately characterized prior to manufacturing the final product. As a result, an assay of the finished product is not sufficient to ensure that the product will perform in the intended manner. Accordingly, we expect to employ multiple steps to attempt to control our manufacturing process and assure that the product or product candidate is made strictly and consistently in compliance with the process.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to develop the manufacturing process for late-stage clinical product, and our current process has not been fully characterized and therefore is open to potential variations that could lead to defective product substance that does not meet specification.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Problems with the manufacturing, storage or distribution of our product candidates, including even minor deviations from our established parameters, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims and insufficient inventory.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some of the raw materials required in our manufacturing process are derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates, which could affect the timing of our commencement and completion of clinical studies. We may also have to take inventory write-offs and incur other charges and expenses for product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. We may encounter problems manufacturing sufficient research-, clinical-, or commercial-grade materials that meet FDA, EU or other applicable standards or specifications with consistent and acceptable production yields and costs.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied, and expect to continue to rely, on third parties under contracts and partnerships to conduct some or all aspects of our research and development, including vector production, process development, assay development, product candidates and product manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies, research and related activities, and these third parties may not perform satisfactorily.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to independently conduct all aspects of our vector production, product and product candidate manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies, research and related activities. We currently rely, and expect to continue to rely, on third parties with respect to these items. We may not be able to enter into agreements or partnerships with these third parties and if we do enter into agreements with these third parties, we cannot be assured these agreements will be on favorable economic terms or that any of these third parties will be successful at fulfilling their contractual obligations, and it is possible they may choose to terminate their engagements with us. If we need to enter into alternative arrangements, it could delay or jeopardize our product development activities or be more costly. Our reliance on these third parties for vector production, process development, assay development, product and product candidate manufacturing and testing, protocol development, clinical trials, product distribution, commercialization, nonclinical studies, research and related activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations. If any of these third parties on which we rely do not perform satisfactorily, we will remain responsible for ensuring that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our nonclinical studies and clinical trials are conducted in accordance with the study plan and protocols and applicable regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vector production, product and product candidate manufacturing and testing are conducted in accordance with applicable GMP requirements and other applicable regulatory requirements; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other research, process development, and assay development are conducted in accordance with applicable industry and regulatory standards and norms;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of which we may not be able to do.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to rely on third-party manufacturers and suppliers, and may enter into partnerships and other business development arrangements, which entails risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to negotiate manufacturing, supplier agreements, partnerships or other agreements with third parties under commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced control as a result of using third-party manufacturers or partners for some or all aspects of manufacturing activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements, partnerships, or supplier agreements with third parties in a manner or at a time that is costly or damaging to us; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the acquisition, change in control, or bankruptcy of the manufacturer, supplier or partner, or their commitments to other vaccine and therapeutics production projects that may reduce available manufacturing capacity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could lead to clinical trial delays, failure to obtain regulatory approval, or impact our ability to successfully commercialize future products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct all aspects of our nonclinical testing, clinical testing, or clinical trials ourselves. We are dependent on third parties to conduct nonclinical studies and clinical trials for our product candidates, and, therefore, the timing of the initiation and completion of these studies or trials is controlled in part by these third parties and may occur at times substantially different from our estimates. Specifically, we use and rely on medical institutions, clinical investigators, contract research organizations (&#8220;CROs&#8221;) and consultants to conduct our trials in accordance with our clinical protocols and regulatory requirements. Our CROs, investigators and other third parties play a significant role in the conduct of these trials and subsequent collection and analysis of data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that any CROs, investigators or other third parties on which we rely for administration and conduct of our clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, fails to meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in our ongoing clinical trials unless we are able to transfer those subjects to another qualified clinical trial site.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the utility of certain data from the clinical trial may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any IND or BLA we submit to the FDA, or equivalent submissions to other regulatory authorities outside the U.S. Any such delay or rejection could prevent us from commercializing our product candidates.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies, and their uses as well as our ability to operate without infringing upon the proprietary rights of others. There can be no assurance that any of our product candidates will have patent protection, that our patent applications or those of our licensors will result in patents being issued or that issued patents, if any, will afford sufficient protection against competitors with similar technology, nor is there any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Issued patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain composition-of-matter patents and applications covering components of our product candidates. Composition-of-matter patents on the biological or chemical active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our patent applications covering composition-of-matter of any of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) and courts in the U.S. or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found invalid or unenforceable if challenged.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain method-of-use patents and applications covering methods of treating certain diseases with our product candidates. Method-of-use patents protect the use of a product for the specified method or for treatment of a particular indication. However, methods of treating human diseases are considered unpatentable in many jurisdictions, and even where available this type of patent does not prevent a competitor from making and marketing a product that is identical to our product candidate for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications may not result in any patents being issued;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents may expire before or soon after the product they cover is commercialized;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use, and sell our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by the U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on the protection of our trade secrets and know-how. Although we have taken steps to protect our trade secrets and know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets do not provide any protection against the independent development of the trade secret by a competitor or other third party. If a competitor independently obtains or develops our trade secret, either by reverse engineering our product or other legal means, we would be unable to prevent them from using the trade secret, and our competitive position would be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets and other confidential information, which increases the possibility that a competitor will discover them or that our confidential information, including trade secrets, will be misappropriated or disclosed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to conduct research and to develop and manufacture our product candidates, we must, at times, share confidential information, including trade secrets, with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements containing confidentiality provisions with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that they become known by our competitors, are purposefully or inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Public disclosure of our confidential information also prevents us from seeking patent protection for that or related discoveries. Given that our proprietary position is based, in part, on our know-how and trade secrets, the unauthorized use or disclosure of our trade secrets would impair our competitive position and may have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our confidential information and trade secrets, although our agreements may contain certain limited publication rights. For example, academic institutions that we collaborate with often require rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential information or trade secrets from any such publication. However, we may fail to recognize or identify to our collaborator such confidential information or trade secrets during the appropriate timeframe prior to publication, and they may be publicly disclosed without us filing for patent or other protection. In the future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, including through breach of our agreements with third parties, failure of our security measures or publication of information by any of our third-party collaborators, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology industry expands, especially in the field of gene therapy, and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming to defend against and could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in costly litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divert the time and attention of our technical personnel and management;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cause development delays;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidate or processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market our product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign our product candidate or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes collaborate with U.S. and foreign academic institutions to accelerate our research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are heavily reliant upon licenses of certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product candidates. These and other licenses may not provide adequate rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future, or may contain other limitations on our ability to use such intellectual property or technology. As a result, our ability to develop or commercialize our processes and product candidates may be limited by the terms of such agreements. Further, the third parties from whom we license certain patent rights and proprietary technology may attempt to terminate their agreements with us. For example, in 2019 we received from Virovek a notice of intent to terminate our non-exclusive license to certain Virovek technology and know-how related to methods and materials for manufacturing adeno-associated virus. Although no further action has been taken in that matter, it illustrates that if one of our licenses were to be terminated, we may be unable to obtain a new license to that technology on commercially reasonable terms, if at all.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to develop or acquire alternative manufacturing technology, our product development activities may be significantly delayed, and if we were unable to develop or acquire alternative manufacturing technology, it could have a material adverse effect on our business. In addition, we may not be able to prevent competitors from developing and commercializing competitive products to the extent our licenses to patents are non-exclusive or limited with respect to fields of use or territories.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that licenses to additional third-party technology will be required to advance our current development programs, as well as additional development programs we may initiate in the future. If these licenses are not available on commercially reasonable terms or at all, we may not be able to commercialize our current and future development programs, which will have a material adverse effect on our business and financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we normally seek to obtain the right to control the prosecution and maintenance of the patents relating to our product candidates, there may be times when the filing and prosecution activities for platform technology patents that relate to our product candidates are controlled by our licensors. For example, we do not have the right to prosecute and maintain the patent rights licensed to us under agreements with Regents of the University of California and Virovek, and our ability to have input into such filing and prosecution activities is limited. If these licensors or any of our future licensors fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We require all employees to sign proprietary information and invention assignment agreements, but they may fail to do so, or our agreements may be found invalid or unenforceable. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patent rights held by third parties that could be construed to cover certain aspects of our product candidates. In addition, changes to our product candidates or their uses or manufacture may cause them to infringe patents held by third parties. A patent holder has the right to prevent others from making, using, importing or selling a drug that incorporates the patented compositions while the patent remains in force. While we believe that third party patent rights will not affect our planned development, regulatory clearance, and eventual marketing, commercial production, and sale of our product candidates, there can be no assurance that this will be the case. In addition, the Drug Price Competition and Patent Term Restoration Act of 1984 (&#8220;Hatch-Waxman Act&#8221;) exemption provided by U.S. patent law permits uses of compounds and biologics in clinical trials and for other purposes reasonably related to obtaining FDA approval of drugs and biologics that will be sold only after patent expiration, so our use of our product candidates in those FDA-related activities does not infringe any patent holder&#8217;s rights. However, were a patent holder to assert its rights against us before expiration of such patent holder&#8217;s patent for activities unrelated to seeking FDA approval, the development and ultimate sale of our product candidates could be significantly delayed, and we could incur the expense of defending a patent infringement suit and potential liability for damages for periods prior to the patent&#8217;s expiration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, obtaining and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Further, following Russia&#8217;s invasion of Ukraine in February 2022, the U.S. government has levied sanctions against Russia and Belarus, Russia has issued a decree that removes protections for some patent holders who are registered in unfriendly countries, including the U.S., and the USPTO has terminated its engagement with officials from intellectual property agencies in Russia, Belarus and Eurasia, so we are not currently maintaining certain intellectual property filings in these jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system was introduced in 2023. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates. Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. As a result, our owned and in-licensed patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. For example, given the large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensions of patent term may be available, but there is no guarantee that we would have patents eligible for extension, or that we would succeed in obtaining any particular extension&#8212;and no guarantee any such extension would confer a patent term for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. If we are able to secure FDA marketing approval for one of our product candidates that is covered by an issued U.S. patent, that patent may be eligible for limited patent term restoration under the Hatch-Waxman Act. Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, the Hatch-Waxman Act permits a patent restoration term of up to five years beyond the normal expiration of the patent, which is limited to the approved product or approved indication. In the U.S., patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval; only one patent may be extended; and extension is available for only those claims covering the approved drug, a method for using it, or a method for manufacturing it. Similar extensions of patent term are available in Europe and other jurisdictions. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial conditions and results of operations may be materially and adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interpretation by the regulatory authorities in the EU of applicable EU regulations governing data and market exclusivity may impact our entitlement to data and market exclusivity. The revisions to the orphan drug legislation in the EU and the EU rules governing Supplementary Protection Certificates that are currently being discussed may also impact our entitlement to this exclusivity. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged administratively or in court.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our future development partners were to initiate or threaten legal proceedings against a third party to enforce a patent directed at one of our product candidates, or one of our future product candidates, the accused infringer could claim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, as are claims seeking declaratory judgment of invalidity. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a false or misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our defense of litigation or patent office proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research and development programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal or patent office proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some intellectual property that we have in-licensed or may in-license may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property rights we have licensed, including certain rights related to our proprietary AAV.7m8 capsid, were generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980 (&#8220;Bayh-Dole Act&#8221;) and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability, or that of our sublicensees, to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to comply with any of our obligations under existing agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement, what activities satisfy those diligence obligations, and to what extent those obligations are relieved or delayed by external factors beyond our control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of our payment obligations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our rights upon termination of such agreement; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of exclusivity obligations of each party to the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make gene therapies that are similar to our product candidates but that are not covered by the claims of any patents that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patent applications that we have filed or may file in the future may not lead to issued patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we have filed or may file in the future may expire before or shortly after commercialization of the covered product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where, or for products for which, we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of our employees and consultants were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that our company, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could materially and adversely impact our business, financial condition, results of operations, or prospects.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have one product candidate in clinical trials. Before we can initiate clinical trials for other product candidates in the U.S., we need to submit the results of nonclinical testing to the FDA, along with other information about the product candidate&#8217;s chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND. Similar requirements may apply to conduct clinical trials outside the U.S. We may rely in part on nonclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. If these third parties do not provide timely data for our product candidates, it will delay our plans for our IND submissions or comparable foreign applications and clinical trials. If those third parties do not make this data available to us, we will likely have to develop all necessary nonclinical and clinical data on our own, which will lead to significant delays and increase development costs of the product candidate. In addition, the FDA or other regulatory authorities may require us to conduct additional nonclinical testing for any of our product candidates before they allow us to initiate clinical trials under any IND or equivalent, or at any stage of clinical development of Ixo-vec or other new product candidates based on concerns that arise as the clinical program progresses or if significant manufacturing process changes are made to the program, which may lead to additional delays and increase the costs of our nonclinical development. Delays with any regulatory authority or agency may significantly affect our product development timeline. Delays in the commencement or completion of any clinical trials that we plan for our product candidates could significantly affect our product development costs. We do not know whether any clinical trials that we plan will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed or terminated for a number of reasons, including delays or terminations related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. failing to grant permission to proceed or placing the clinical trial on hold;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients failing to enroll or remain in our trial at the rate we expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients experiencing severe or unexpected drug-related adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or other government or regulatory authorities outside the U.S., to temporarily or permanently shut down due to violations of GMP or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process, or in the manufacturing facilities in which our product candidates are made;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of non-investigational materials or supplies required for the clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of non-investigational materials or supplies required for manufacturing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party clinical investigators losing the licenses, permits or resources necessary to perform our clinical trials, lacking the ability or resources to appropriately handle our product candidates, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, Good Clinical Practice or regulatory requirements, or other third parties not performing data collection, sample testing or analysis in a timely and accurate manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspections of clinical trial sites by the FDA or other regulatory authorities outside the U.S., or the finding of regulatory violations by the FDA or other regulatory authorities outside the U.S., or an IRB or Ethics Committee that requires us to undertake corrective action resulting in suspension or termination of one or more clinical sites or the imposition of a clinical hold on the IND or foreign equivalent or that prohibits us from using some or all of the data in support of our marketing applications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities outside the U.S. for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one or more IRBs or Ethics Committees refusing to approve, suspending or terminating the trial at a clinical site, precluding enrollment of additional patients, or withdrawing its approval of the trial.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development costs will increase if we have delays in testing or approval of any of our product candidates, or if we need to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to competent authorities, IRBs or Ethics Committees for review and approval, which may impact the costs, timing or successful completion of a clinical trial. If we experience delays in the completion of our clinical trials, or if we, the FDA or other regulatory authorities outside the U.S., the IRB or Ethics Committee, other reviewing entities, or any of our clinical trial sites, suspend or terminate any of our clinical trials, the commercial prospects for our product candidate may be harmed and our ability to generate product revenue may be delayed. In addition, many of the factors that cause, or lead to, the termination or suspension of, or a delay in the commencement or completion of, clinical trials, may also ultimately lead to the denial of regulatory approval of a product candidate. If we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Further, if one or more clinical trials are delayed or terminated, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have amended our clinical trial protocols and from time to time may further amend our clinical trial protocols based on a variety of factors, and these changes may have unanticipated consequences on our clinical trial outcomes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully complete our clinical trials and submit a BLA, and/or an MAA, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, and we cannot, therefore, predict the timing of any future revenue. We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the applicable applications. We cannot assure you that the regulatory authorities will complete their review processes in a timely manner or that we will obtain regulatory approval for our product candidates. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in policies from the FDA or other regulatory authorities outside the U.S. during the period of product development, clinical trials and FDA&#8217;s or comparable foreign regulatory authorities&#8217; regulatory review. If marketing approval for any product candidate is delayed, limited or denied, our ability to market the product candidate, and our ability to generate product sales, would be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from product sales, if any, could be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payers or the medical community. Coverage and reimbursement of our product candidates by third-party payers, including government payers, is also generally necessary for commercial success. The degree of market acceptance of our product candidates will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of clinical efficacy, including duration of efficacy, and safety compared to competitive products, some of which are more established than our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of our targeted patient population and other limitations or warnings contained in any labeling approved for our product candidates by the FDA or other applicable regulatory authorities outside the U.S., including the possible inclusion of a &#8220;black box warning&#8221; from the FDA or other applicable regulatory authorities outside the U.S., alerting healthcare providers to potential serious side effects associated with using a product or the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) or comparable foreign strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of new therapeutic options by healthcare providers and their patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new procedures or methods of treatment that may be more effective in treating or may reduce the incidence of wet AMD, or other conditions that our product candidates are intended to treat;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost-effectiveness;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators&#8217; sales and marketing strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain sufficient third-party coverage and reimbursement from government health care programs, including Medicare and Medicaid or foreign equivalents, private health insurers and other third-party payers; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of third-party coverage and reimbursement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payers or patients, we may not generate sufficient revenue from that product candidate and may not become or remain profitable. Our efforts to educate the medical community and third-party payers on the benefits of such a product candidate may require significant resources and may never be successful. In addition, our ability to successfully commercialize any of our product candidates will depend on our ability to manufacture our products, differentiate our products from competing products, and defend and enforce our intellectual property rights relating to our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in highly competitive segments of the biopharmaceutical markets. We face competition from many different sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, biotechnology, and gene therapy companies, as well as from academic institutions, government agencies and private and public research institutions. Our product candidates, if successfully developed and approved, will compete with established therapies as well as with new treatments that may be introduced by our competitors. There are a variety of drug candidates and gene therapies in development or being commercialized by our competitors for the indications that we intend to test. Many of our competitors have significantly greater financial, product candidate development, manufacturing, and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. In addition, universities and private and public research institutes may be active in our target disease areas, and some could be in direct competition with us. We also may compete with these organizations to recruit management, scientists, and clinical development personnel. We will also face competition from these third parties in establishing clinical trial sites, registering patients for clinical trials, and in identifying and in-licensing new product candidates. For example, REGENXBIO is developing RGX-314, an AAV-based gene therapy delivering a gene encoding a therapeutic antibody fragment similar to ranibizumab (LUCENTIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of wet AMD and diabetic retinopathy, which competes for the same patients, study site resources, and personnel as Ixo-vec. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New developments, including the development of other biotechnology and gene therapy technologies and methods of treating disease, occur in the pharmaceutical, biotechnology and gene therapy industries at a rapid pace. Developments by competitors may render our product candidates obsolete or noncompetitive. Competition in drug development is intense. In addition, we believe that duration of efficacy is an important consideration by physicians and patients when choosing a therapy. However, we do not know and may not know prior to any potential approval the duration of efficacy of our product candidates. We anticipate that we will face intense and increasing competition as new treatments enter the market and advanced technologies become available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors&#8217; products could limit the demand, and the price we are able to charge, for our product candidates. For example, LUCENTIS (and biosimilars thereto), EYLEA and VABYSMO are currently available in the U.S. and the EU for treatment of wet AMD. We will not achieve our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug products or choose to reserve our product candidates for use in limited circumstances. Our inability to compete with existing or subsequently introduced drug products or other therapies would have a material adverse impact on our business, prospects, financial condition and results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential competitors in these diseases may be developing novel therapies that may be safer or more effective or easier to administer than our product candidates. For example, if we continue clinical development of, and seek to commercialize, Ixo-vec for the treatment of wet AMD, it will compete with a variety of therapies currently marketed and in development for wet AMD, using therapeutic modalities such as biologics, small molecules, long-acting delivery devices and gene therapy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, most patients receive off-label bevacizumab, including as a first-line treatment. Many patients go on to receive Eylea, Eylea HD and Vabysmo&#174; (faricimab). We know of a significant number of product candidates in development or recently approved for chronic retinal conditions that respond to anti-VEGF therapy, including wet AMD:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">biosimilar anti-VEGFs (e.g., FYB201);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">bispecific / combination / add-on therapy for efficacy or durability improvement (e.g., Vabysmo and OPT-302);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">next-generation anti-VEGF for durability improvement (e.g., Eylea HD);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">long-acting delivery device / gene therapy to lower treatment frequency (e.g., 4D-150, RGX-314 and Susvimo, which is Roche&#8217;s Port Delivery System with ranibizumab); and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other molecules that inhibit neovascularization in wet AMD (e.g., tyrosine kinase inhibitors such as OKT-TKI and EYP-1901).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several other companies in the U.S. or Europe with marketed products or products in development for the treatment of chronic retinal conditions that respond to anti-VEGF therapy, including wet AMD. These companies include 4D Molecular Therapeutics, AbbVie, Bayer, Clearside Biomedical, EyePoint Pharmaceuticals, Kodiak Sciences, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Regeneron, REGENXBIO and Roche.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if regulatory approval is obtained, the FDA or comparable foreign regulatory authorities may still impose significant restrictions on a product&#8217;s indicated uses, marketing or distribution or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials. Following approval, if at all, of any of our product candidates, such candidate will also be subject to ongoing FDA and comparable foreign requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of safety and other post-market information. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities outside the U.S. for compliance with GMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents. If we or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requesting recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or the manufacturing facilities for any product candidate that may receive regulatory approval fail to comply with applicable regulatory requirements, a regulatory authority may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters or untitled letters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend, vary or withdraw regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements or applications filed by us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">institute import holds;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products, refuse to permit the import or export of product or request us to initiate a product recall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. The FDA has the authority to require a REMS plan as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. Similar restrictions may be imposed by foreign regulatory authorities outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if any of our product candidates is approved, our product labeling, advertising and promotion would be subject to regulatory requirements and ongoing regulatory review. The FDA and other regulatory authorities outside the U.S. strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the competent regulatory authority as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and regulatory and enforcement authorities outside the U.S. actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or be subject to permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payers for any of our product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement by a third-party payer may depend upon a number of factors including the third-party payer&#8217;s determination that use of a product candidate is:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement approval for a product candidate from a government or other third-party payer is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of the applicable product candidate to the payer. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. While there is no uniform coverage and reimbursement policy among payers in the U.S., private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Further, reimbursement amounts may reduce the demand for, or the price of, our product candidates. If reimbursement is not available or is available only in limited levels, we may not be able to commercialize certain of our product candidates profitably, or at all, even if approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of cell and gene therapy products recently have been approved by the FDA. Although the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) approved its first method of coverage and reimbursement for gene therapy products, the methodology has been subject to challenge by members of Congress. CMS&#8217;s decision as to coverage and reimbursement for one product does not mean that all similar products will be eligible for analogous coverage and reimbursement. As there is no uniform policy for coverage and reimbursement amongst third-party payers in the U.S., even if CMS approves coverage and reimbursement for any of our product candidates, it is unclear what affect, if any, such a decision will have on our ability to obtain and maintain coverage and adequate reimbursement from other private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans. or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;Affordable Care Act&#8221;), was enacted with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The Affordable Care Act, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations and established annual fees and taxes on manufacturers of certain prescription drugs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the Affordable Care Act have been subject to executive, Congressional, and judicial challenges as well as efforts to repeal, replace, or otherwise modify them or alter their interpretation and implementation. For example, the TCJA included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, policies that undermine protections for people with pre-existing conditions, demonstrations and waivers under Medicaid and the Affordable Care Act that may reduce coverage or undermine the programs thereunder, including work requirements, and policies that make it more difficult to access health benefits through Medicaid or the Affordable Care Act. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;Inflation Reduction Act&#8221;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. Any such changes could affect the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. The EU provides options for EU Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product, it may refuse to reimburse a product at the price set by the manufacturer or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Many EU Member States also periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in order to obtain reimbursement for our products in some European countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. This Health Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislators, policymakers and healthcare insurance funds in the EU and the United Kingdom may continue to propose and implement cost-containing measures to keep healthcare costs down. These measures could include limitations on the prices we would be able to charge for product candidates that we may successfully develop and for which we may obtain regulatory approval or the level of reimbursement available for these products from governmental authorities or third-party payors. Further, an increasing number of EU and other foreign countries use prices for medicinal products established in other countries as &#8220;reference prices&#8221; to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare and other reform legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and, if approved, may affect the prices we may obtain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative changes have also been proposed and adopted in the U.S. since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year, which went into effect on April 1, 2013 and due to subsequent legislative changes to the statute, will stay in effect until 2032 unless additional congressional action is taken. Further, Congress is considering additional health reform measures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cost reduction initiatives could decrease the coverage and reimbursement that we receive for any approved products and could seriously harm our business. The Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. Further, the Inflation Reduction Act, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect beginning fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. The Inflation Reduction Act permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. It is unclear how the Inflation Reduction Act will be implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal, state and foreign governments will pay for healthcare products and services, which could result in reduced demand for our product candidates, if approved, or additional pricing pressures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of health care may adversely affect:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for any product candidates for which we may obtain regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Regulation No 2021/2282 on HTA amending Directive 2011/24/EU, was adopted in the EU. This Regulation, which entered into force in January 2022 and will apply as of January 2025, is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation foresees a three-year transitional period and will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected. In light of the fact that the United Kingdom has left the EU, Regulation No 2021/2282 on HTA will not apply in the United Kingdom. However, the UK MHRA is working with UK HTA bodies and other national organizations, such as the Scottish Medicines Consortium (&#8220;SMC&#8221;), the National Institute for Health and Care Excellence (&#8220;NICE&#8221;), and the All-Wales Medicines Strategy Group, to introduce new pathways supporting innovative approaches to the safe, timely and efficient development of medicinal products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market for Ixo-vec, if approved, in the treatment of wet AMD or any other indication we seek to treat is smaller than we believe it is, or if our product candidate is approved with limitations that reduce the market size, or if this occurs for any of our other product candidates, our future revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing the development of Ixo-vec for the treatment of wet AMD, which is a leading cause of blindness in patients over 65 years of age. If the size of the market for wet AMD or any other indication we seek to treat is smaller than we anticipate, we may not be able to achieve profitability and growth. Our projections of the number of people who have wet AMD and other indications, as well as the subset of people with the disease who have the potential to benefit from treatment with Ixo-vec or other future product candidates, are based on estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations and market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effort to identify patients with diseases we seek to treat is in early stages. We cannot accurately predict the number of patients for whom treatment for wet AMD using Ixo-vec or any of our other product candidates might be possible or whether the FDA or other regulatory authorities may approve indications for Ixo-vec or any of our other product candidates that are more limited than we expect due to efficacy or safety concerns. For example, some patients have neutralizing antibodies at titer levels that may prevent them from benefiting from Ixo-vec. If this patient population is larger than we estimate, the market for Ixo-vec may be smaller than we anticipate, and our future revenue may be adversely affected. In addition, we expect prophylactic corticosteroid treatment will be required to manage inflammation associated with treatment with Ixo-vec, and certain patients cannot be treated with prophylactic corticosteroids. If this proportion of the patient population is larger than we estimate, the market for Ixo-vec may be smaller than we anticipate. Additionally, the potentially addressable patient population may be limited or may not be amenable to treatment with our product candidates for other reasons, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates, if approved, may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of, or the availability of data from, scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones will be based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the novel nature of our technology and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are designed to provide potential therapeutic benefit after a single administration and, therefore, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in establishing and maintaining development or other strategic collaborations, which could adversely affect our ability to develop and commercialize product candidates and receive milestone and/or royalty payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into development or other strategic collaborations with biotechnology and pharmaceutical companies in the past and may do so again in the future. Research activities under our collaboration agreements may be subject to mutually agreed-on research plans and budgets, and if we and our strategic partners are unable to agree on the research plan or research budget in a timely fashion or at all, performance of research activities will be delayed. In addition, some of our strategic partners may terminate any agreements they enter into with us or allow such agreements to expire by their terms. If we fail to maintain our current or future strategic collaborations, we may not realize milestone and royalty payments or other revenues under the collaboration agreements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments may impose price controls, which may adversely affect our future profitability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the U.S. and in foreign jurisdictions. If we obtain approval in one or more jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to our product candidates. In some countries, including Member States of the European Economic Area (&#8220;EEA&#8221;), the pricing of prescription pharmaceuticals is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. There can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. Publication of discounts by third-party payers or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form strategic alliances in the future, and we may not realize the benefits of such alliances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our existing business, including for the continued development or commercialization of our product candidates. These relationships or those like them may require us to incur non-recurring and other charges, increase our near-and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because third parties may view the risk of failure in future clinical trials as too significant, or the commercial opportunity for our product candidate as too limited. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Even if we are successful in our efforts to establish development partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such development partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in entering into development partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no sales, marketing, distribution, or market access and reimbursement capabilities, and we would have to invest significant resources to develop these capabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no internal sales, marketing, distribution, or market access and reimbursement capabilities. If any of our product candidates ultimately receives regulatory approval, we may not be able to effectively market and distribute the product candidate. We would have to invest significant amounts of financial and management resources to develop internal sales, marketing, distribution, or market access and reimbursement capabilities, some of which will be committed prior to any confirmation that any of our product candidates will be approved, if at all. We may not be able to hire consultants or external service providers to assist us in sales, marketing, distribution, or market access and reimbursement functions on acceptable financial terms or at all. Even if we determine to perform sales, marketing, distribution, or market access and reimbursement functions ourselves, we could face a number of additional related risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to attract and build an effective marketing department, sales force, or distribution capabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing a marketing department or sales force may exceed our available financial resources and the revenue generated by any product candidates that we may develop, in-license or acquire; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our direct sales and marketing efforts may not be successful.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing symptomatic treatments they are already familiar with and for which greater clinical data may be available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Although none of our current product candidates utilize retroviruses and we believe AAVs used in our product candidates have low-integrating potential and are not known to cause disease in humans, our product candidates do use a viral vector delivery system. The risk of serious adverse events, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial, remains a concern for gene therapy and we cannot assure that it will not occur in any of our current or future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events in trials or studies conducted by us or other parties, in particular involving the same or similar AAV serotypes to the ones we are using, even if not ultimately attributable to our product candidates or to an AAV serotype that we employ, and resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Similarly, our lead product candidate, Ixo-vec, expresses the aflibercept protein, which is also the active component in EYLEA. If safety or efficacy issues occur relating to EYLEA, even if not ultimately attributable to aflibercept, this may negatively impact our product candidate. If any such adverse events or issues occur, development and commercialization of our product candidates or advancement of any potential clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on the principal members of our management, clinical and scientific staff. The loss of service of any of our management or clinical or scientific staff could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. Although we have executed employment agreements with each member of our current executive management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We have had significant changes in our executive management team, and from time to time, may experience additional changes in our executive management team resulting from the hiring or departure of executives. While we seek to manage these transitions carefully, these and any other such changes may result in a loss of institutional knowledge and cause disruptions to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract or retain qualified management, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in the San Francisco Bay Area. Our industry has experienced a high rate of turnover of management and scientific personnel in recent years. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we will need to grow our organization, or certain functions within our organization, substantially to continue development and pursue the potential commercialization of our product candidates, as well as function as a public company. As we seek to advance our product candidates, we may need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management and require us to retain or otherwise manage additional internal capabilities. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate any additional management, clinical and regulatory, financial, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish them could prevent us from successfully growing our company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or those third parties upon which we rely, or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; material disruption of our product development programs; and other adverse consequences. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and the third parties upon which we rely, process, collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share (collectively, process) proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property and trade secrets (collectively, sensitive information).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by AI, and other similar threats. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, disruptions of clinical trials, ability to provide our services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, CROs, CMOs, collaborators, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and confidential, sensitive, or proprietary information. For example, the loss of clinical trial information from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders, such as governmental authorities, partners, and affected individuals, of security incidents. Such disclosures may involve inconsistent requirements and are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security incidents and attendant consequences may prevent or cause customers to stop using our platform/products/services, deter new customers from using our services, and negatively impact our ability to grow and operate our business. A security incident could also disrupt our operations, including our ability to conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business, delay or impede the development of our products, and damage our reputation, any of which could adversely affect our business. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. In addition, there can be no assurance that we will promptly detect any such disruption or security incident, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our data privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer confidential, sensitive, or proprietary information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with applicable state and federal healthcare laws and regulations, we may be subject to civil or criminal penalties and/or exclusion from federal and/or state healthcare programs, or foreign equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on the marketing of pharmaceutical products, several other types of state and federal healthcare fraud and abuse laws restrict certain practices, including research and marketing, in the pharmaceutical industry, and foreign equivalents. These laws include anti-kickback, false claims, and healthcare professional payment transparency laws and regulations. Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering, arranging for, or recommending the purchase, lease or order of any healthcare item or service for which payment may be made, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced-price items and services. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formula managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices may be subject to scrutiny if they do not qualify for an exception or safe harbor. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Many states have similar laws that apply to their state health care programs as well as private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully obstructing a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in significant monetary penalties and treble damages. Pharmaceutical and other healthcare companies have faced enforcement actions under the federal civil False Claims Act for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for allegedly causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. In addition, a claim can be deemed to be false due to failure to comply with legal or regulatory requirements material to the government&#8217;s payment decision. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false claim or statement. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Affordable Care Act, among other things, imposed new reporting requirements on drug manufacturers, under the federal Physician Payments Sunshine Act, for payments and other transfers of value made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other healthcare professionals (such as a physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties, for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Certain states and localities also mandate implementation of commercial compliance programs, restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs, impose restrictions on drug manufacturer marketing practices, require the tracking and reporting of gifts, compensation and other remuneration to physicians and/or require the registration of pharmaceutical sales representatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, interactions between pharmaceutical companies and health care professionals are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to build and maintain a robust compliance program with different compliance and/or reporting requirements. We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our employees, vendors, or other third parties that may violate such laws. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly caused or cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability, and a breach of warranties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims could also be asserted under state consumer protection acts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our products or product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decline in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold $10 million in product liability insurance, which may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing U.S. and foreign laws, regulations, rules, contractual obligations, policies, and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, interruption of our clinical trials, and other adverse business consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we process sensitive information, including personal data, business data, trade secrets, intellectual property, and data we collect about trial participants in connection with clinical trials. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security, including information that we collect or will collect about clinical trial subjects and healthcare providers in connection with clinical trials. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable protected health information. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to penalties if we, our affiliates, or our agents obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), (collectively, &#8220;CCPA&#8221;) applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. While these states, like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation 2016/679 (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal data. For example, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized by law to represent their interests. EU member states are also able to legislate separately on health and genetic information, and we must comply with these local laws where we operate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the U.S. or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the EEA and the UK have significantly restricted the transfer of personal data to the U.S. and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the U.S., are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we are contractually subject to industry standards adopted by industry groups and, we are, or may become subject to such obligations in the future. We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. We may also be bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We publish privacy policies, marketing materials and other statements regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, &#8220;Trade Laws&#8221;). We can face serious consequences for violations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, Trade Laws prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, provide, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else or anything of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax assessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We engage third parties for clinical trials and/or obtain necessary permits, licenses, registrations, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our development partners, third-party manufacturers and suppliers use biological materials and use or may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our development partners, third-party manufacturers and suppliers use or may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and any of our future development partners are successful in commercializing our products, the FDA and foreign regulatory authorities will require that we and any of our future development partners report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our future development partners may fail to report adverse events we become aware of within the prescribed timeframe. We and any of our future development partners may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our product candidates. If we and any of our future development partners fail to comply with our or their reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of the product and delay in approval or clearance of other products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, CMOs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with our code of conduct or regulatory standards and requirements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, CMOs, consultants and vendors may engage in misconduct including code of conduct violations, fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, or disclosure of unauthorized activities to us that violates: (1) FDA or comparable foreign regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory authorities, (2) manufacturing standards, (3) federal, state and foreign health care fraud and abuse laws and regulations or (4) laws that require the reporting of financial information or data accurately. Specifically, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs or comparable foreign programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and other tax attributes may be limited by the Code. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, except as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;), federal net operating losses (&#8220;NOL&#8221;) incurred in taxable years beginning after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs for taxable years beginning after 2020 is limited. In addition, under Section 382 of the Code, our ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if we experience an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. We may have experienced an ownership change as a result of the August 2020 underwritten public offering of our common stock and/or the February 2024 private placement of shares of common stock and pre-funded warrants, and may in the future experience ownership changes from future offerings or other changes in the ownership of our stock. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the amount of the NOLs and research credit carryforwards presented in our financial statements could be limited and may expire unutilized. In addition, state suspensions of the ability to use NOLs, and research credits, may limit our ability to use our NOLs and research credits to offset state taxable income and taxes.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including those discussed above and others such as:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll and dose subjects in any clinical trials that are on-going, or that we plan to conduct in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approvals for our product candidates and delays or failure to obtain such approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to conduct nonclinical studies to determine the best gene therapy candidates to advance in development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of any clinical trials of our product candidates and the results of trials of competing product candidates or of other companies in our market sector;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investor perception and analysis of the results of our clinical trials, which may be different than our own;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial results, variations in our financial results and the adequacy of our cash runway to achieve key milestones, or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license and collaboration agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in manufacturing adequate supply of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to gene therapy and to biotechnology generally, including with respect to other products and potential products in such markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our stock by insiders and stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions other events or factors, many of which are beyond our control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property, product liability or other litigation against us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock, and similar litigation has been instituted against us. Such litigation could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to licensing, collaboration or other arrangements, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, licensing, collaboration or similar arrangements, grants, debt and other financings. We do not have any committed external source of funds. As a result, we may from time to time issue additional shares of common stock or securities convertible into or exercisable for shares of our common stock. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect such holders' rights as a holder of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends or other distributions. Furthermore, we may issue common stock as consideration in acquisitions. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through licensing, collaboration or similar arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authorization of the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of the removal of directors by the stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a staggered board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition of stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of the ability of stockholders to call a special meeting of stockholders;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to accelerate the vesting of outstanding option grants, restricted stock units or other equity awards upon certain transactions that result in a change of control; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are obligated to develop and maintain proper and effective internal control over financial reporting. In the future, we may not complete our execution of our internal control over financial reporting in a timely manner, or these internal controls may not be determined to be effective, which may result in material misstatements in our consolidated financial statements and may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complying with Section 404 requires a rigorous compliance program as well as adequate time and resources. We may not be able to complete our internal control evaluation, testing and any required remediation in a timely fashion. Additionally, if we identify one or more material weaknesses in our internal control over financial reporting, we will not be able to assert that our internal controls are effective. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. As of December 31, 2022, we identified a deficiency in the operating effectiveness of controls in our financial statement close process that we considered to be a material weakness. An immaterial non-cash lease accounting error was identified in previously issued financial statements. While the identified error was not material, we considered the magnitude of the potential errors that could arise from the operating deficiency as potentially material. This material weakness did not result in the restatement of prior quarterly or annually filed financial statements. During 2023, management conducted a remediation plan to address its material weakness, which included increasing the rigor with which management evaluates the accounting of material non-routine transactions by engaging additional outside financial reporting and technical accounting expertise. As of December 31, 2023, we have remediated the material weakness related to our internal controls over financial reporting that were determined to be ineffective as of December 31, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though we remediated this material weakness as of December 31, 2023, we cannot be certain that other material weaknesses and control deficiencies will not be discovered in the future. If our efforts are not successful or other material weaknesses are identified in the future or we are not able to comply with the requirements of Section 404 in a timely manner, our reported financial results could be materially misstated, and we could be subject to investigations or sanctions by regulatory authorities, which would require additional financial and management resources, and the value of our common stock could decline. To the extent we identify future weaknesses or deficiencies, there could be material misstatements in our consolidated financial statements and we could fail to meet our financial reporting obligations. As a result, our ability to obtain additional financing, or obtain additional financing on favorable terms, could be materially and adversely affected which, in turn, could materially and adversely affect our business, our financial condition and the value of our common stock. If we are unable to assert that our internal control over financial reporting is effective in the future, investor confidence in the accuracy and completeness of our financial reports could be further eroded, which would have a material adverse effect on the price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, which may include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our clinical trial and development programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition, termination or modification of clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit or other litigation in which we may become involved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements and the timing of payments we may make or receive under these arrangements;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the nature and terms of stock-based compensation grants; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">derivative instruments recorded at fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America. will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising under the Delaware General Corporation Law; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws provide</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our certificate of incorporation and bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our certificate of incorporation or bylaws to be inapplicable or unenforceable in an action, we may incur </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further significant </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional costs associated with resolving the dispute in other jurisdictions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all of </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could seriously harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_1878"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data (&#8220;Information Systems and Data&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information security function, which includes our Executive Director of Information Technology (&#8220;IT&#8221;) and third-party service providers, helps identify, assess, and manage the Company&#8217;s cybersecurity threats and risks. Our information security function identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example conducting audits, evaluating threats, and performing vulnerability assessments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the environment, systems, and data at issue, we implement and maintain various technical, physical, and organizational measures, processes, and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: incident detection and response, access controls, employee training, penetration testing, and systems monitoring.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management processes. For example, our Executive Director of IT, works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example managed cybersecurity service providers, penetration testing firms, and cybersecurity consultants. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third-party service providers to perform a variety of functions throughout our business, such as contract research organizations, contract manufacturing organizations, and supply chain resources. We have a vendor management process to manage cybersecurity risks associated with our use of these providers. The process includes risk assessments for certain vendors and reviewing security assessments and reports. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including the risk factor entitled: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or those third parties upon which we rely, or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; material disruption of our product development programs; and other adverse consequences.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The Board of Directors is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Executive Director of IT, who holds a Bachelor of Science in Computer Methods from California State University-Long Beach and has previously served as the Associate Director of IT for a large pharmaceutical company. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Operating Officer and Executive Director of IT, is responsible for hiring appropriate information security personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and helping prepare for cybersecurity incidents. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our Executive Director of IT and General Counsel, who works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s incident response process includes reporting to the Audit Committee of the Board of Directors for certain cybersecurity incidents. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors receives periodic reports from the management concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The Board of Directors also has access to various reports, summaries or presentations related to cybersecurity threats, risk, and mitigation. </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Redwood City, California, consisting of approximately 79,675 square feet of office and laboratory space under a lease that will expire in December 2031. </span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we lease a manufacturing facility in North Carolina, consisting of approximately 173,820 square feet, which is subleased through October 2037.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our properties are adequate and suitable for our current needs; however, we are continuing to evaluate our real estate strategy in response to the changing needs of our in-office, hybrid and remote workforce.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, Lyudmila Pazyuk (&#8220;Plaintiff&#8221;) filed a derivative complaint (Pazyuk v. Machado et al. C.A. No.&#160;2022-1062-MTZ) (the &#8220;Action&#8221;) in the Delaware Court of Chancery (the &#8220;Court&#8221;) on behalf of Adverum against Adverum&#8217;s nine current directors and four former directors (the &#8220;Individual Defendants&#8221;). The Action asserts claims against the Individual Defendants for allegedly awarding the Directors excessive compensation. The Individual Defendants have denied, and continue to deny, any and all allegations of wrongdoing or liability asserted in the Action. Nonetheless, solely to eliminate the uncertainty, distraction, disruption, burden, risk and expense of further litigation, the Individual Defendants entered into a Stipulation and Agreement of Settlement, Compromise and Release (the &#8220;Stipulation&#8221;) on January 24, 2024. Pursuant to the terms of the Stipulation, the Defendants have agreed to implement and maintain certain changes to Adverum&#8217;s director compensation policies and practices. If approved by the Court, Adverum will also be responsible for the payment of the plaintiff&#8217;s attorneys&#8217; fees. The proposed settlement, as set forth in the Stipulation, is subject to final approval by the Court. If approved, the proposed settlement will (i) fully resolve the Action by dismissing all asserted claims with prejudice and (ii) release all claims related to the allegations in the Action. On January 31, 2024, the Court entered a Scheduling Order With Respect to Notice and Settlement Hearing, which, among other things, set a date of April 9, 2024 to consider the settlement on the terms set forth in the Stipulation.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_1934"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4A. Information about our Executive Officers</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers are appointed by and serve at the discretion of our board of directors. There are no family relationships among our directors and executive officers. The following table provides information regarding our executive officers, including their ages and positions, as of February 29, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:58.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Executive Officers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Class II Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Setareh Seyedkazemi, PharmD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Development Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kishor Peter Soparkar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laurent Fischer, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Fischer has served as our chief executive officer since June 2020 and our president since June 2021, and served as our interim chief medical officer from October 2021 to February 2022. Prior to that, Dr. Fischer served as senior vice president, head of the liver therapeutic area at Allergan PLC, a global pharmaceutical company, from November 2016 to June 2020, in which role he was responsible for the Liver Therapeutic R&amp;D pipeline. Dr. Fischer served as chief executive officer of Tobira Therapeutics, a clinical-stage biopharmaceutical company from 2013 until Allergan acquired Tobira Therapeutics in November 2016, in which role he was responsible for taking the company public, completing the first study in NASH demonstrating an anti-fibrotic effect and selling the company to Allergan. Prior to Tobira, he served as chairman and chief executive officer of Jennerex, Inc., until its acquisition by SillaJen Biotherapeutics, Inc. Prior to Jennerex, he was co-founder, president and chief executive officer of Ocera Therapeutics and president and chief executive officer of Auxeris Therapeutics, Inc. Dr. Fischer serves on the board of directors at Mirum Pharmaceuticals, Inc. Dr. Fischer also serves as the chairman of the board of directors of Teal Omics and on the board of directors of Lycia Therapeutics, privately held companies. Dr. Fischer previously served as chairman of the board of directors of CTI Biopharma. Over the span of his career, Dr. Fischer has held roles of increasing responsibility at several companies, including, RXCentric, Inc. (now part of Allscripts Healthcare Solutions, Inc.), MedVantx Inc., Dupont Pharmaceuticals, Dupont-Merck and F. Hoffmann-La Roche. Dr. Fischer received a undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland. Dr. Fischer&#8217;s experience as an executive in the pharmaceutical industry, knowledge of biopharmaceuticals, and his service as our Chief Executive Officer were the primary qualifications that led the Board to conclude that he should serve on our Board.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Linda Rubinstein</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ms. Rubinstein has served as our chief financial officer since December 2022. Since September 2010, Ms. Rubinstein has served as partner at FLG Partners, LLC, a chief financial officer and board advisory services firm, where she assists clients with strategic planning, executes financing transactions, creates business plans and develops corporate and investor positioning. During the previous five years, Ms. Rubinstein has served as consulting chief financial officer or financial advisor to multiple biotechnology companies, including Alector, Apexigen, ArmaGen, Five Prime Therapeutics, Kezar Life Sciences, Medikine, RenovoRx and Sublimity Therapeutics. Ms. Rubinstein received a B.A. and a M.A. from University of California, Los Angeles.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Setareh Seyedkazemi, PharmD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Seyedkazemi has served as our chief development officer since January 2022. Prior to that, Dr. Seyedkazemi served as vice president, portfolio management for research and development at Pliant Therapeutics from October 2020 to December 2021. From May 2018 to October 2020, Dr. Seyedkazemi served as associate vice president clinical development and from November 2016 to April 2018 as executive director clinical development at Allergan (acquired by AbbVie in May 2020). While at Allergan, Dr. Seyedkazemi served in roles of increasing responsible for clinical and global program leadership for the development of cenicriviroc for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Dr. Seyedkazemi has more than 18 years of pharmaceutical industry experience in corporate leadership, global drug development program leadership, clinical development and operations, global and U.S. medical affairs, and program management across multiple therapeutics areas, including fibrosis, NASH, hepatitis C and HIV at Pliant Therapeutics, Allergan (acquired by AbbVie in May 2020), Tobira Therapeutics (acquired by Allergan in November 2016), Gilead Sciences, Johnson &amp; Johnson and Abbott Laboratories, preceded by seven years in HIV clinical care and research. Dr.&#160;Seyedkazemi received a B.S. in Biology from Florida Atlantic University and a Doctor of Pharmacy from Nova Southeastern University, where she also completed a HIV/Infectious Disease residency.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kishor Peter Soparkar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mr. Soparkar has served as our chief operating officer since June 2021 and our chief legal officer from October 2019 to December 2022. Mr. Soparkar was previously chief legal officer, corporate secretary, head of human resources and head of compliance at Counsyl, Inc. from July 2016 to September 2018, where he led support for the company&#8217;s legal and human resources needs, debt and equity financings, investor interactions, IPO preparations and acquisition by Myriad Genetics, Inc. From November 2006 to July 2016, Mr. Soparkar served in several roles, most recently as Vice President, Associate General Counsel, at Jazz Pharmaceuticals plc, where he led the legal team&#8217;s support of company operations and other business matters, including delivering on numerous debt and equity financings and four landmark transactions. Prior to Jazz Pharmaceuticals, Mr. Soparkar worked at Latham &amp; Watkins in London and San Francisco, with a practice spanning international and domestic markets, as well as private and public transactions. He received a J.D. from New York University School of Law and a B.A. in economics and politics from Oberlin College.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ADVM&#8221;.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;8, 2024, we had approximately 37 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. [Reserved]</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with the financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report on Form 10-K, particularly in &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors.&#8221;</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and, as of December&#160;31, 2023, we had an accumulated deficit of $919.8 million. We expect to incur substantial expenses and continuing losses from operations in the foreseeable future as we conduct our research and development efforts, advance our product candidates through nonclinical and clinical development, manufacture clinical study materials, seek regulatory approval, and prepare for and, if approved, proceed to commercialization. We are at an early stage of development and may never be successful in developing or commercializing our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may in the future generate revenue from a variety of sources, including license fees, milestone, research and development and royalty payments in connection with strategic partnerships, and potentially revenue from product sales if any of our product candidates are approved and commercialized, to date we have not generated any revenue from product sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no operational clinical or commercial manufacturing facilities, and all of our clinical manufacturing activities are currently contracted out to third parties. Additionally, we use third-party contract research organizations (&#8220;CROs&#8221;) to carry out our clinical development and certain nonclinical development, and we do not have a sales organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need substantial additional funding in the future to support our operating activities as we advance our product candidates through nonclinical and clinical development, seek regulatory approval and prepare for and, if approved, proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital, or to do so on acceptable terms, when needed, or to form additional collaboration partnerships to support our efforts, we could be forced to delay, reduce or eliminate our research and development programs or potential commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $96.5 million in cash, cash equivalents and short-term investments. On February 7, 2024, we completed a private placement of 105,730,057 shares of our common stock and, in lieu of common stock, pre-funded warrants to purchase an aggregate of 750,000 shares of common stock to certain institutional and accredited investors and directors for total gross proceeds of $127.8&#160;million, before deducting placement agent fees and offering expenses. We believe that our cash, cash equivalents and short-term investments are sufficient to fund our planned operations into late 2025. However, we may need to raise additional funds sooner as a result of a number of risks and uncertainties, including those set forth in Part I, Item 1A. Risk Factors &#8211; &#8220;We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our planned operations into late 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have not generated any revenue from the sale of our products. We have generated revenue through research, collaboration and license arrangements with strategic partners. Our ability to generate product revenue and become profitable depends upon our ability to successfully develop and commercialize our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the amount or timing of product revenue. Even if we are able to generate revenue from the sale of our products, our sales may not be sufficient to generate cash from operations, in which case we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting a significant amount of research and development is central to our business model. Research and development expenses primarily include personnel-related costs, stock-based compensation expenses, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical study materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We defer and expense advance payments for goods or services for future research and development activities as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate nonclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and CROs that conduct and manage nonclinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. We estimate the amounts incurred through communications with third party service providers and our estimates of accrued expenses as of each balance sheet date are based on information available at the time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will need to adjust the accrual accordingly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate the nature, timing or aggregate costs of the efforts that will be necessary to complete the development of any of our product candidates. The successful development and commercialization of a product candidate is highly uncertain, and clinical development timelines, the probability of success, and development and commercialization costs can differ materially from expectations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses primarily include personnel-related costs, stock-based compensation, professional fees for legal, consulting, audit and tax services, overhead expenses, such as rent, equipment depreciation, insurance and utilities, and other general operating expenses not otherwise included in research and development expenses. Our general and administrative expenses may increase in future periods if and to the extent we elect to increase our investment in infrastructure to support continued research and development activities and potential commercialization of our product candidates. We will continue to evaluate the need for such investment in conjunction with our ongoing consideration of our pipeline of product candidates. We may require increased expenses related to audit, legal and regulatory functions, as well as director and officer insurance premiums and investor relations costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Restructuring</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize our clinical development of Ixo-vec and focus our pipeline strategy on certain highly prevalent ocular diseases, which included a reduction in our workforce by approximately 37%. The restructuring was completed in the fourth quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net primarily comprises interest income on our cash equivalents and investments in marketable securities.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. We base our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Prepaid Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our accrued and prepaid research and development expenses as of each balance sheet date. This process involves reviewing contracts and purchase orders, reviewing the terms of our license agreements, communicating with our applicable personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. Expenses that are paid in advance of performance are deferred as a prepaid expense and expensed as the services are provided.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Examples of estimated accrued research and development expenses include fees to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">contract manufacturers in connection with the production of clinical trial materials;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">vendors in connection with nonclinical development activities; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">services providers for professional service fees such as consulting and related services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our understanding of the status and timing of services performed relative to the actual status and timing may vary and may result in our reporting changes in estimates in any particular period. Due to the nature of these estimates, we cannot assure you that we will not materially adjust our estimates in the future as we become aware of additional information about the status or conduct of our clinical studies or other research activities. For the years ended December&#160;31, 2023 and 2022, there were no material changes from our estimates of accrued research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our long-term operating leases, we recognize a right-of-use asset and a lease liability on our consolidated balance sheets. We determine if an arrangement contains a lease and the classification of the lease at inception. An arrangement contains a lease if there is an identified asset and if we control the use of the identified asset throughout the period of use. The evaluation of whether the lease is an operating or a finance lease requires judgments in determining the fair value of the leased asset. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that we would pay to borrow equivalent funds on a collateralized basis at the lease commencement date or modification date, as applicable. In order to determine the incremental borrowing rate, we determine our credit rating, adjust the credit rating for the nature of the collateral, and benchmark the borrowing rate against observable yields on comparable securities with a similar term. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. We base the right-of-use lease asset on the lease liability adjusted for any prepaid or deferred rent. We elected to combine lease and non-lease components for all underlying assets groups. We determine the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For short term leases, we do not recognize a right-of-use asset and lease liability and recognize the lease expense over the term of the lease on a straight-line basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December 31, 2022, management reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. Management assessed the collectability to be less than probable and we recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December 31, 2022. Deferred rent receivable was zero as of December&#160;31, 2023 and 2022.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Results of Operations for the Years Ended December&#160;31, 2023 and 2022</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,544)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,243)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,219&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (provision)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,165)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,536)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $3.6 million of license revenue for the year ended December&#160;31, 2023 was primarily related to a milestone payment received from Lexeo Therapeutics, Inc.(&#8220;Lexeo&#8221;) pursuant to a license agreement we had entered into with Lexeo in January 2021, pursuant to which we granted Lexeo an exclusive license to the intellectual property rights, pre-clinical data and knowhow associated with our Friedreich&#8217;s Ataxia program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased by $21.6&#160;million to $77.7 million for the year ended December&#160;31, 2023 from $99.3&#160;million for the year ended December&#160;31, 2022. This overall decrease was primarily related to a decrease of $13.0 million in personnel-associated costs due to a lower headcount following the restructuring in the prior year, a decrease of $6.5&#160;million in other programs due to prioritization of lead product candidate Ixo-vec, and a decrease of $3.8&#160;million in Ixo-vec due to completion of two of the trials. The decreases were partially offset by a $1.8 million increase in facilities expenses driven by lease modifications. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ixo-vec</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,845)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel related (including stock-based compensation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,978)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other unallocated research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,601)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, our research and development activities were attributable to Ixo-vec and our earlier-stage research programs. We expect that research and development expenses will increase in future periods as we focus on advancing Ixo-vec for the treatment of wet AMD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense decreased by $7.9 million to $49.9 million for the year ended December&#160;31, 2023 from $57.9&#160;million for the year ended December&#160;31, 2022, primarily related to a decrease of $3.2 million in personnel-associated costs driven by lower headcount following the restructuring in the prior year, a $3.2 million decrease in facilities expenses due to adjustment to the sublease income in the prior year, a $1.1 million decrease in insurance costs due to a decrease in premiums in the current year, a $0.7 million decrease in expenses related to consultants and contractors, and a $0.7 million decrease in depreciation expense as we leased fewer buildings in 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that general and administrative expenses will increase in future periods as we focus on advancing Ixo-vec for the treatment of wet AMD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $3.1 million in other income, net for the year ended December&#160;31, 2023 as compared to 2022 was primarily due to higher average yields in investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit (Provision)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derecognized the liability of $1.1&#160;million for the year ended December&#160;31, 2023 arising from an uncertain tax position related to foreign operations while an income tax provision of $0.1&#160;million was recorded during the year ended December&#160;31, 2022. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity, Capital Resources and Plan of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and as of December&#160;31, 2023, we had an accumulated deficit of $919.8 million. As of December&#160;31, 2023, we had $96.5 million in cash, cash equivalents and short-term investments. compared to $185.6 million as of December&#160;31, 2022. On February 7, 2024, we completed a private placement of 105,730,057 shares of our common stock and, in lieu of common stock, pre-funded warrants to purchase an aggregate of 750,000 shares of common stock to certain institutional and accredited investors and directors for total gross proceeds of $127.8&#160;million, before deducting placement agent fees and offering expenses. Additionally, we are party to a sales agreement (the &#8220;Sales Agreement&#8221;) with Cowen &amp; Company, LLC (&#8220;Cowen&#8221;) pursuant to which we may, from time to time, sell up to an aggregate amount of $100.0 million of our common stock through Cowen in an &#8220;at-the-market&#8221; offering. We are not required to sell shares under the Sales Agreement. We will pay Cowen a commission of up to 3.0% of the aggregate gross proceeds of any shares of common stock sold pursuant to the Sales Agreement. As of March 18, 2024, no sales have been made pursuant to the Sales Agreement. We believe that our existing cash and cash equivalents and short-term investments as of December&#160;31, 2023, as supplemented by the proceeds from the private placement, will be sufficient to fund our operations and meet our existing contractual obligations and other cash requirements into late 2025. However, we may need to raise additional funds sooner as a result of a number of risks and uncertainties, including those set forth in Part I, Item 1A. Risk Factors &#8211; &#8220;We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our planned operations into late 2025. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete our planned nonclinical trials and current and future clinical trials, and to complete the process of obtaining regulatory approval for our product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when we seek additional funding, we will do so through equity or debt financings, collaborative or other arrangements with corporate sources or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital in the future could have a negative impact on our financial condition and our ability to pursue our business strategies. To complete development and commercialization of any of our product candidates, we anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of nonclinical studies and any clinical trials for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing of and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities, including the potential for the FDA and other regulatory authorities to require that we perform more studies than those that we currently expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our product candidates to progress through clinical development activities successfully;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to expand our research and development activities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress and cost of commercialization of our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preparing to manufacture our products on a larger scale;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities including product sales, marketing, manufacturing and distribution;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and rate of market acceptance of any products launched by us or future partners;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional infrastructure and internal systems;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire additional personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies or other adverse market developments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license other technologies or clinical product candidates or programs that we would prefer to develop and commercialize ourselves.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash for each of the periods presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,720&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,042&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,236&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, net cash used in operating activities was $90.9&#160;million, primarily as a result of net loss of $117.2&#160;million due to the continued activities developing our product candidates, partially offset by $34.6&#160;million of non-cash charges mainly related to $17.6&#160;million of stock-based compensation expense, $13.0&#160;million of non-cash lease expense, $5.6&#160;million of depreciation and amortization expenses, and $8.3&#160;million of net decrease in cash from changes in operating assets and liabilities, which fluctuate due to timing of expenses and payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, net cash used in operating activities was $108.1 million, primarily as a result of net loss of $154.5 million due to the continued activities developing our product candidates, partially offset by $30.6&#160;million of non-cash charges mainly related to $20.1 million of stock-based compensation expense, $6.5 million of depreciation and amortization expenses, and $4.0&#160;million of non-cash lease expense, and $15.8&#160;million of net increase in cash from changes in operating assets and liabilities, resulting primarily from $13.6&#160;million in changes of lease liabilities and $2.2 million due to timing of expenses and payments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by Investing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December&#160;31, 2023 consisted of $97.7&#160;million of net maturities of marketable securities, partially offset by $0.8&#160;million of purchases of property and equipment primarily related to facilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December 31, 2022 consisted of $153.5 million of net maturities of marketable securities, partially offset by $11.8 million of purchases of property and equipment primarily related to the new facilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December&#160;31, 2023 consisted of $0.5&#160;million in proceeds from employee stock purchase plan, almost entirely offset by $0.4&#160;million in payments for deferred offering costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2022 consisted of $0.6 million in proceeds from employee stock purchase plan.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. Financial Statements and Supplementary Data.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_118"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:91.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_121">Report of Independent Registered Public Accounting Firm (PCAOB ID No. </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-35">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_121">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_121">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_124">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_124">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_127">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_127">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_130">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_130">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_133">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_133">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_136">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee15d89dd75f4b25b706a37b8daeb24a_136">99</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Stockholders and Board of Directors of Adverum Biotechnologies, Inc. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Opinion on the Financial Statements </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Adverum Biotechnologies, Inc. (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.655%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Accrued research and development expenses &#8211; clinical and manufacturing costs</span></td></tr><tr style="height:63pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recorded research and development expenses of $77.7 million for the year ended December 31, 2023. As described in Note 2, research and development costs are expensed as incurred. Research and development costs include fees paid to contract research organizations that conduct certain research and development activities on the Company&#8217;s behalf and contract manufacturing organizations in connection with the production of materials for clinical trials.</span></div></td></tr><tr style="height:71pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing the Company&#8217;s research and development expenses for contract research organizations and contract manufacturing organizations and related accruals was challenging due to the complex nature of evaluating the completeness and accuracy of the expenses and accruals.  Research and development expenses are recognized as the services are being performed by the vendors, which requires management to accurately monitor the activity at the vendors to determine the extent of unbilled services performed during the reporting period.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.655%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To test the completeness and accuracy of the contract research organization and contract manufacturing organization expenses and related accruals, our audit procedures included, among others, confirming with a sample of vendors the progress of activities under research and development contracts at period end, testing a sample of cash disbursements after period end to assess the completeness of the expense recognition, and testing a sample of research and development expenses recorded during the period and evaluating the timing and amount of the expense recognition.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Accounting for operating lease modification</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note 5 to the consolidated financial statements, the Company&#8217;s operating lease right of use assets and operating lease liabilities as of December 31, 2023 totaled $52.3 million and $75.0&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We identified the accounting assessment of the Company&#8217;s operating lease modifications as a critical audit matter. A higher degree of auditor judgment was required to assess the accounting for these lease modifications due to the complexity of the transactions.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To test the accounting for operating lease modifications, we tested and evaluated, among other things, the lease components in the modified lease contracts, the contract consideration for the lease components and the allocation of contract consideration between lease components. We compared the relevant terms in the underlying modified lease contract to the information in the Company&#8217;s lease amortization schedules and recalculated the Company's operating lease right-of-use assets and operating lease liabilities for the modified leases based on the modified lease contracts.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-36">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-37">San Francisco, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;18, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-38">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-39">68,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-40">21,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-41">117,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">6,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">5,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">102,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">190,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">52,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-47">78,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-48">14,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-49">34,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposit and other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-54">173,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-55">308,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">1,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">2,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-58">12,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-59">16,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">10,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">13,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">24,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">32,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">64,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">93,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-68">89,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-69">126,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-70"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-71"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-72"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-73">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-75">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-76"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-78"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-79">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-82"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-83">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-85">300,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2023: <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-87">101,433</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-88"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-89">100,117</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2023 and 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-90">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-91">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-92">1,003,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-93">985,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-94">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-95">1,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-96">919,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-97">802,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-98">83,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-99">181,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-100">173,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-101">308,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-102">3,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">77,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-105">99,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-106">49,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-107">57,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-108">127,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-109">157,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-110">123,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-111">157,135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-112">5,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-113">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-114">118,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-115">154,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit (provision)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-116">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-117">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-118">117,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">154,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-121">788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-122">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-123">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-124">116,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-125">155,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-126"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-127">1.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-128"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-129">1.56</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-130"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-131">100,824</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-132"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-133">99,251</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.428%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-134">98,381</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-135">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-136">964,965</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-137">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-138">648,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-139">316,185</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-140">20,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-141">20,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-142">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-143">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-144">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-145">886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-146">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-147">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-148">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-149">788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="f-150">788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-151">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-152">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">154,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">154,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-155">100,117</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-156">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-157">985,651</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-158">1,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-159">802,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-160">181,518</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-161">17,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-162">17,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-163">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-164">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-165">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-166">824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-167">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-168">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-169">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-171">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-172">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-173">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">117,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">117,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-176">101,433</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-177">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-178">1,003,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-179">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">919,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">83,469</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-182">117,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">154,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-184">5,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-185">6,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-186">17,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-187">20,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net accretion of discount on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-188">1,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-189">880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-190">13,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-191">4,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-192">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-193">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="f-194">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-195">2,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-196">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-197">1,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-198">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-199">1,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposit and other long-term assets and deferred rent receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" scale="3" id="f-200">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" scale="3" id="f-201">394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-202">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-203">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-204">5,206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-205">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-206">3,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-207">13,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-208">90,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-209">108,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-210">36,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-211">104,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-212">134,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-213">257,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-214">808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-215">11,816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-216">96,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-217">141,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-218">420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock pursuant to option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-220">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-221">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="f-222">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="f-223">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-224">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-225">607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-226">6,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-227">34,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-228">70,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-229">36,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-230">76,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-231">70,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-232">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-233">68,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-234">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-235">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-236">76,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-237">70,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of noncash investing information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash settlement of operating lease liability</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" format="ixt:num-dot-decimal" scale="3" id="f-238">14,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" format="ixt:fixed-zero" scale="3" id="f-239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of operating lease right-of-use assets and liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="advm:ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-240">13,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="advm:ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-241">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets in accounts payable and current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-242">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-243">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-244" continuedAt="f-244-1" escape="true">Description of the Business </ix:nonNumeric></span></div><ix:continuation id="f-244-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of the Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-245">919.8</ix:nonFraction> million as of December&#160;31, 2023. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of December&#160;31, 2023, the Company had cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-246">96.5</ix:nonFraction> million, which the Company believes will be sufficient to fund its operations into late 2025.</span></div></ix:continuation><div id="iee15d89dd75f4b25b706a37b8daeb24a_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-247" continuedAt="f-247-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-247-1" continuedAt="f-247-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="f-248" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-top:6pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-249" continuedAt="f-249-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-249-1">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-250" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-251" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-252" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement. See Note 5, Leases for additional information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-253" continuedAt="f-253-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All short-term investments in debt securities have been classified as &#8220;available for sale&#8221; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#8217; equity until realized. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#8217;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#8217;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-247-2" continuedAt="f-247-3"><ix:continuation id="f-253-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses available-for-sale debt securities on a quarterly basis to see whether any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flow model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were no credit-related losses recognized for the periods presented.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="advm:AccruedInterestReceivablePolicyTextBlock" id="f-254" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Interest Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Accrued interest receivable related to the Company&#8217;s available-for-sale debt securities is presented within prepaid expenses and other current assets on the Company&#8217;s consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its available-for-sale debt securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-255" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company operates and manages its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-256"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-257">one</ix:nonFraction></ix:nonFraction> reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-258" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to securities having specified credit ratings. Management believes that the Company is not exposed to significant credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support growth.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-259" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:f-260">three</span> to <ix:nonNumeric contextRef="c-29" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-261">five years</ix:nonNumeric>. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="f-262" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. If there is an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss The Company recorded within research and development expense in the consolidated statements of operations and comprehensive loss impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-263">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-264">2.1</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. See Note&#160;3, Balance Sheet Components for additional information.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-247-3" continuedAt="f-247-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-265" continuedAt="f-265-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on the Company's consolidated balance sheets. The Company determines if an arrangement contains a lease and the classification of the lease at inception. An arrangement contains a lease if there is an identified asset and if the Company controls the use of the identified asset throughout the period of use. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that it would pay to borrow equivalent funds on a collateralized basis at the lease commencement date or modification date, as applicable. In order to determine the incremental borrowing rate, the Company determines its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. It bases the ROU asset on the lease liability adjusted for any prepaid or deferred rent. The Company elected to combine lease and non-lease components for all underlying assets groups. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For short term leases, the Company does not recognize a right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. The variable lease payments primarily consist of common area maintenance and other operating costs.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-265-1">Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-266" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-267" continuedAt="f-267-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;), the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-267-1">The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-268" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents approximate their fair values due to their short-term maturities. See Note 3, Fair Value Measurements for the methodologies and assumptions used in valuing financial instruments.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-247-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-269" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and employee stock purchase and using intrinsic value, which is the closing price of its common stock on the date of the grant, for restricted stock units (&#8220;RSUs&#8221;) and performance stock units (&#8220;PSUs&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term assumption represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Expected volatility is based on the Company&#8217;s historical stock price volatility. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-270" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability method. The Company records deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2023 and 2022, the Company has recorded a full valuation allowance on its deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-271" continuedAt="f-271-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-271-1">&#8212;Comprehensive loss comprises net loss and other comprehensive loss. Other comprehensive loss consists of foreign currency translation adjustments and unrealized gain or loss on marketable securities.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-272" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, and employee stock purchase plan (&#8220;ESPP&#8221;) are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-273" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#8220;Topic 326&#8221;) and also issued subsequent amendments to the initial guidance. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted ASU 2016-13 on January 1, 2023, using the modified retrospective approach. The adoption of ASU 2016-13 had no significant impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-274" continuedAt="f-274-1" escape="true">Fair Value Measurements and Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="f-274-1" continuedAt="f-274-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-275" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-276">10,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-279">10,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-280">64,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-282">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-283">64,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-284">17,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-285">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-286">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-287">17,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-288">92,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-289">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-290">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-291">92,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-292">70,972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="f-294">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-295">70,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-296">21,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-297">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-298">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-299">21,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-300">10,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-303">10,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-304">59,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-306">824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-307">58,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-308">102,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-310">246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-311">102,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-312">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-314">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-315">2,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-316">174,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-318">1,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-319">173,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-320">56,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="f-322">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-323">56,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-324">118,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-326">1,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-327">117,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-274-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2023, all marketable securities had a remaining maturity of less than one year. The Company held <ix:nonFraction unitRef="security" contextRef="c-4" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-328">19</ix:nonFraction> debt securities in an unrealized loss position with an aggregate fair value at December&#160;31, 2023 of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-329">71.3</ix:nonFraction>&#160;million. These are highly liquid funds with high credit ratings with final maturity of less than one year from the balance sheet date. There were no individual securities that were in a significant unrealized loss position as of December&#160;31, 2023 and 2022. The Company has not recorded an allowance for credit losses as of December&#160;31, 2023 and 2022 related to these securities. The accrued interest receivable on available-for-sale marketable securities was immaterial at December&#160;31, 2023 or 2022. The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. The Company has not recorded any impairment charges on available-for-sale securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis was based on a market price in a secondary market place for similar laboratory equipment. The fair value of the assets was lower than the carrying value and as such impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-330">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-331">2.1</ix:nonFraction> million were recognized for the years ended December&#160;31, 2023 and 2022, respectively. The assets indicated as impaired were written down to their estimated fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets was <ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-332">nil</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-333">0.2</ix:nonFraction>&#160;million at December&#160;31, 2023 and 2022.</span></div></ix:continuation><div id="iee15d89dd75f4b25b706a37b8daeb24a_148"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-334" continuedAt="f-334-1" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="f-334-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. Upon execution of the agreement, Lexeo paid the Company a one-time, non-creditable and non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:ProceedsFromLicenseFeesReceived" format="ixt:num-dot-decimal" scale="6" id="f-335">7.5</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, Lexeo notified the Company that it had achieved the first development milestone; accordingly, the Company received and recognized $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-336">3.5</ix:nonFraction>&#160;million of license revenue during the year ended December&#160;31, 2023.</span></div></ix:continuation><div id="iee15d89dd75f4b25b706a37b8daeb24a_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-337" continuedAt="f-337-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-337-1" continuedAt="f-337-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redwood City</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease for a facility in Redwood City, which provided a total of tenant improvement allowances of $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="advm:LesseeOperatingLeaseLeaseholdImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="f-338">6.8</ix:nonFraction>&#160;million. Related to this lease, the Company provided the landlord with a letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-339">2.7</ix:nonFraction>&#160;million. The Redwood City lease expires in December 2031, with an option to extend for a period of <ix:nonNumeric contextRef="c-45" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-340">eight years</ix:nonNumeric>. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to September 30, 2023, the Company had <ix:nonFraction unitRef="lease" contextRef="c-47" decimals="INF" name="advm:LesseeOperatingLeaseNumberOfLeasedFacilities" format="ixt-sec:numwordsen" scale="0" id="f-341">two</ix:nonFraction> facility leases in Redwood City with the same landlord (the &#8220;Redwood City Premises&#8221;). In March 2023, the Company entered into an amendment to accelerate the lease expiration of <ix:nonFraction unitRef="lease" contextRef="c-48" decimals="INF" name="advm:LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated" format="ixt-sec:numwordsen" scale="0" id="f-342">one</ix:nonFraction> of its Redwood City Premises from December 31, 2031 to September 30, 2023. Concurrently, the Company entered into an agreement to increase the tenant improvement allowance towards the second of its Redwood City Premises. The Company accounted for this amendment as a lease modification in accordance with ASC 842-10-25-11(d). As a result of the modification the Company revalued the lease liability based on the new and remaining lease terms, which resulted in a reduction to the lease liability with a corresponding reduction of the right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-343">8.3</ix:nonFraction>&#160;million. The estimated value of non-cash consideration, composed primarily of leasehold improvements and furniture and fixtures, was $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" format="ixt:num-dot-decimal" scale="6" id="f-344">14.9</ix:nonFraction>&#160;million, which was fully amortized as of September 30, 2023. There was no charge recognized in the consolidated statement of operations. In October 2023, the Company entered into an amendment to the letter of credit which reduced the amount to $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-345">1.9</ix:nonFraction>&#160;million, which is classified as restricted cash under long-term assets on the Company's consolidated balance sheets. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-337-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">North Carolina</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company entered into an operating lease agreement for a building in North Carolina (&#8220;NC Premises&#8221;). The lease commenced in April 2021, when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with <ix:nonFraction unitRef="segment" contextRef="c-51" decimals="INF" name="advm:LesseeOperatingLeaseNumberOfRenewalContracts" format="ixt-sec:numwordsen" scale="0" id="f-346">two</ix:nonFraction> options to extend the lease term for a period of <ix:nonNumeric contextRef="c-52" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-347">five years</ix:nonNumeric> each.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the NC Premises through October 2037, the remainder of the lease term, and concurrently changed the lease payment terms of the head lease. In addition, the remainder of the tenant improvement allowance under the original lease of approximately $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="advm:LesseeOperatingLeaseLeaseholdImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="f-348">22.7</ix:nonFraction>&#160;million was transferred to the subtenant. This change in the Company&#8217;s payment terms with the landlord at the time of the sublease was considered to be a lease modification and the Company remeasured the lease liability and right-of-use asset on the modification date, with no amounts recognized in the consolidated statement of operations. The base annual rental rates, payment schedules and amounts under the sublease agreement are substantially the same as the original payment terms by Adverum to the landlord. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2023, the Company entered into an amendment of the lease of its NC Premises with the landlord and subtenant. Under this amendment, the parties agreed to substantially reduce the total tenant improvement allowance in exchange for lower monthly rent. The Company accounted for this amendment as a lease modification in accordance with ASC 842-10-25-11(d). The Company remeasured the lease liability, resulting in a reduction to the lease liability with a corresponding reduction of the right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="advm:ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-349">5.7</ix:nonFraction>&#160;million in the quarter ended June 30, 2023. There was no charge recognized in the consolidated statement of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, management reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. Management assessed the collectability to be less than probable and the Company recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December 31, 2022. The deferred rent receivable was <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredRentReceivablesNet" format="ixt:fixed-zero" scale="0" id="f-350"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredRentReceivablesNet" format="ixt:fixed-zero" scale="0" id="f-351">zero</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2023 and 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the weighted-average remaining lease term was <ix:nonNumeric contextRef="c-55" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-352">11.6</ix:nonNumeric> years for the Company's leases and the weighted-average Incremental Borrowing Rate (&#8220;IBR&#8221;) was <ix:nonFraction unitRef="number" contextRef="c-55" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-353">11.7</ix:nonFraction>%. As of December 31, 2022, the weighted-average remaining lease term was <ix:nonNumeric contextRef="c-56" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-354">10.2</ix:nonNumeric> years for the Company's leases and the weighted-average IBR was <ix:nonFraction unitRef="number" contextRef="c-56" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-355">9.9</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-356" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the undiscounted future non-cancellable lease payments under the lease agreements as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payment Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-357">11,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-358">5,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-359">11,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="3" id="f-360">5,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-361">11,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" format="ixt:num-dot-decimal" scale="3" id="f-362">5,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-363">12,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" format="ixt:num-dot-decimal" scale="3" id="f-364">5,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-365">12,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears" format="ixt:num-dot-decimal" scale="3" id="f-366">5,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-367">82,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter" format="ixt:num-dot-decimal" scale="3" id="f-368">60,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-369">141,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="f-370">88,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed Interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-371">66,179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-372">75,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rent expense for the years ended December&#160;31, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-373">25.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-374">17.2</ix:nonFraction>&#160;million, respectively. Included in rent expense for the years ended December&#160;31, 2023, and 2022 were variable lease costs for utilities, parking, maintenance, and real estate taxes of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-375">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-376">2.3</ix:nonFraction> million, respectively. Cash paid for amounts included in the measurement of lease liabilities for the twelve months ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-377">12.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-378">6.0</ix:nonFraction>&#160;million, respectively. Sublease income was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="advm:SubleaseIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-379">5.3</ix:nonFraction>&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="advm:SubleaseIncomeNet" scale="6" id="f-380">0.3</ix:nonFraction>)&#160;million for the years ended December&#160;31, 2023 and 2022, respectively, which was classified in general and administrative expense.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-381" continuedAt="f-381-1" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="f-381-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-382" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-383">14,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-384">14,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-385">13,586</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-386">34,336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-387">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-388">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-389">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-390">868</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-391">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-392">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-393">29,276</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-394">51,921</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-395">14,512</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-396">16,994</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-397">14,764</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-398">34,927</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-399" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-400">8,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-401">8,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="advm:AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-402">3,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="advm:AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-403">6,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-404">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-405">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="f-406">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="f-407">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-408">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-409">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-410">12,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-411">16,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="iee15d89dd75f4b25b706a37b8daeb24a_157"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-412" continuedAt="f-412-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-412-1" continuedAt="f-412-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various agreements, principally relating to licensed technology that requires future payments relating to milestones or royalties on future sales of specified products. During the year ended December&#160;31, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-413">3.5</ix:nonFraction>&#160;million of license revenue during the year ended December&#160;31, 2023 for the first development milestone in the Lexeo License Agreement. See Note 4, Revenue, for additional information. <ix:nonFraction unitRef="milestone" contextRef="c-65" decimals="INF" name="advm:LicenseAgreementsMilestonesAchieved" format="ixt:fixed-zero" scale="0" id="f-414">No</ix:nonFraction> milestones were achieved during the year ended December 31, 2022 related to any of the Company's agreements. Because achievement of these milestones is not fixed and determinable, such amounts have not been included on the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, Lyudmila Pazyuk (&#8220;Plaintiff&#8221;) filed a derivative complaint (Pazyuk v. Machado et al. C.A. No.&#160;2022-1062-MTZ) (the &#8220;Action&#8221;) in the Delaware Court of Chancery (the &#8220;Court&#8221;) on behalf of Adverum against Adverum&#8217;s nine current directors and four former directors (the &#8220;Individual Defendants&#8221;). The Action asserts claims against the Individual Defendants for allegedly awarding the Directors excessive compensation. The Individual Defendants have denied, and continue to deny, any and all allegations of wrongdoing or liability asserted in the Action. Nonetheless, solely to eliminate the uncertainty, distraction, disruption, burden, risk and expense of further litigation, the Individual Defendants entered into a Stipulation and Agreement of Settlement, Compromise and Release (the &#8220;Stipulation&#8221;) on January 24, 2024. Pursuant to the terms of the Stipulation, the Defendants have agreed to implement and maintain certain changes to Adverum&#8217;s director compensation policies and practices. If approved by the Court, Adverum will also be responsible for the payment of the plaintiff&#8217;s attorneys&#8217; fees of up to $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="f-415">0.6</ix:nonFraction>&#160;million. The proposed settlement, as set forth in the Stipulation, is subject to final approval by the Court. If approved, the proposed settlement will (i) fully resolve the Action by dismissing all asserted claims with prejudice and (ii) release all claims related to the allegations in the Action. On January 31, 2024, the Court entered a </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-412-2">Scheduling Order With Respect to Notice and Settlement Hearing, which, among other things, set a date of April 9, 2024 to consider the settlement on the terms set forth in the Stipulation.</ix:continuation> </span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_160"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="f-416" continuedAt="f-416-1" escape="true">Stock Plans</ix:nonNumeric></span></div><ix:continuation id="f-416-1" continuedAt="f-416-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2006, the Company adopted the 2006 Equity Incentive Plan, which was amended by the board of directors on November&#160;15, 2012 (the &#8220;2006 Plan&#8221;). The 2006 Plan allowed for the granting of incentive stock options (&#8220;ISOs&#8221;) and non-qualified stock options (&#8220;NSOs&#8221;) to the employees, members of the board of directors and consultants of the Company. ISOs were granted only to the Company&#8217;s employees, including officers and directors who are also employees. NSOs were granted to employees and consultants. In July 2014, the Company&#8217;s board of directors and its stockholders approved the establishment of the 2014 Equity Incentive Award Plan (the &#8220;2014 Plan&#8221;). Options may no longer be issued under the 2006 Plan after July&#160;30, 2014. In addition, the 2014 Plan provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with the year ended December 31, 2015, equal to four percent (<ix:nonFraction unitRef="number" contextRef="c-67" decimals="INF" name="advm:ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" scale="-2" id="f-417">4</ix:nonFraction>%) of the number of shares of the Company&#8217;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company adopted the 2017 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Company reserved <ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-418">600,000</ix:nonFraction> shares for issuance pursuant to stock options and RSUs under the Inducement Plan. The only persons eligible to receive grants of stock options and RSUs under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance, that is, generally, a person not previously an employee or director of Adverum, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Adverum.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2006 Plan, 2014 Plan and Inducement Plan are referred to collectively as the Plans. As of December&#160;31, 2023, a total of <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-419">41,905,487</ix:nonFraction> shares of common stock were reserved for issuance and <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-420">3,158,755</ix:nonFraction> shares were available for future grants under the Plans.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options under the 2014 Plan and the Inducement Plan may be granted for periods of up to <ix:nonNumeric contextRef="c-70" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-421">10</ix:nonNumeric> years and at prices no less than <ix:nonFraction unitRef="number" contextRef="c-71" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" scale="-2" id="f-422">100</ix:nonFraction>% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a <ix:nonFraction unitRef="number" contextRef="c-72" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" scale="-2" id="f-423">10</ix:nonFraction>% stockholder may not be less than <ix:nonFraction unitRef="number" contextRef="c-72" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" scale="-2" id="f-424">110</ix:nonFraction>% of the estimated fair value of the shares on the date of grant. Stock options granted to employees and non-employees generally vest ratably over <ix:nonNumeric contextRef="c-73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-425">four years</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-426" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except exercise prices and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining Contract<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-427">19,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-428">3.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-429">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-430">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-431">6,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-432">1.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-433">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-434">1.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-435">2,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-436">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-437">23,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-438">4.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-439">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-440">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-441">23,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-442">4.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-443">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-444">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-445">10,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-446">8.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-447">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-448">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#8217;s common stock as quoted on a national exchange.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2023 and 2022 was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="0" id="f-449"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="0" id="f-450">not</ix:nonFraction></ix:nonFraction> material.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-416-2" continuedAt="f-416-3"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the year ended December 31, 2022 included <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="f-451">2.5</ix:nonFraction>&#160;million shares of performance-based stock options with both performance and service vesting conditions. <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-452">No</ix:nonFraction> performance-based stock options were granted in the year ended December&#160;31, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-453" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-454">90</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-455">89</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-456">78</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-457">77</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-71" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-458">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-76" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-459">6.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-77" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-460">1.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-78" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-461">1.2</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-462">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-466">4.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-467">2.6</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-468">5.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-469">3.0</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of options granted during the years ended December&#160;31, 2023 and 2022 were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-470">0.80</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-471">0.93</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-472">16.1</ix:nonFraction> million of unrecognized stock-based compensation expense related to stock options that was expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-473">2.3</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#8217;s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company&#8217;s common stock on the grant date. RSUs granted to employees generally vest over a <ix:nonNumeric contextRef="c-79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-474">2</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c-80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-475">4</ix:nonNumeric> year period.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-476" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except grant date fair value and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-477">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-478">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-479">1.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-480">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-481">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-83" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" id="f-482">491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="f-483">3.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-83" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-484">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-485">2.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-486">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-487">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-83" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-488">1.4</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted during the year ended December 31, 2022 include <ix:nonFraction unitRef="shares" contextRef="c-85" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="f-489">0.4</ix:nonFraction>&#160;million shares of PSUs with both performance and service vesting conditions. No PSUs were granted in the year ended December&#160;31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, total fair value of RSUs vested was $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-490">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-491">2.8</ix:nonFraction>&#160;million, respectively. The number of RSUs vested includes shares of common stock that the Company withheld on behalf of employees or sold to cover to satisfy the minimum statutory tax withholding requirements. As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-492">1.0</ix:nonFraction>&#160;million of unrecognized compensation cost related to unvested RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-83" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-493">1.4</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, the Company approved the establishment of the 2014 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The Company reserved <ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-494">208,833</ix:nonFraction>&#160;shares of its common stock for issuance and provided for annual increases in the number of shares available for issuance on the first business day of each fiscal year, beginning in 2015, equal to the lesser of one percent (<ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" scale="-2" id="f-495">1</ix:nonFraction>%)&#160;of the number of the Company&#8217;s common stock shares outstanding as of such date or a number of shares as determined by the Company&#8217;s board of directors. During the year ended December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-496">824,223</ix:nonFraction> shares were issued under the ESPP. As of December&#160;31, 2023, a total of <ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-497">6,219,258</ix:nonFraction> shares of common stock were available for future issuance under the ESPP. As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-498">0.1</ix:nonFraction>&#160;million of unrecognized compensation cost related to the ESPP.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-416-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Recognized in the Consolidated Statements of Operations and Comprehensive Loss</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-499" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-500">4,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-501">7,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-502">12,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-503">12,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-504">17,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-505">20,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="iee15d89dd75f4b25b706a37b8daeb24a_163"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="f-506" continuedAt="f-506-1" escape="true">401(k) Savings Plan</ix:nonNumeric></span></div><ix:continuation id="f-506-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company established a defined-contribution savings plan under Section 401(k) of the Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. The amount of contributions that the Company made to the 401(k) Plan during the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-507">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-508">1.1</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="iee15d89dd75f4b25b706a37b8daeb24a_166"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-509" escape="true"><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Restructuring</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the restructuring plan, the Company reduced its workforce by <ix:nonFraction unitRef="employee" contextRef="c-92" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" scale="0" id="f-510">75</ix:nonFraction> employees (approximately <ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" scale="-2" id="f-511">37</ix:nonFraction>%) as of July 6, 2022. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-512" continuedAt="f-512-1" escape="true">Below is a summary of restructuring costs during the year ended December 31, 2022:</ix:nonNumeric></span></div><ix:continuation id="f-512-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Benefits Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-513">4,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-514">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-515">4,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-516">4,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="3" id="f-517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-518">4,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="3" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="3" id="f-520">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="3" id="f-521">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the year ended December 31, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-525">4.7</ix:nonFraction>&#160;million of restructuring costs, of which $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-526">3.7</ix:nonFraction>&#160;million was classified as research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-527">1.0</ix:nonFraction>&#160;million was classified as general and administrative expenses. The Company completed the restructuring in the fourth quarter of 2022.</span></div></ix:nonNumeric><div id="iee15d89dd75f4b25b706a37b8daeb24a_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-528" continuedAt="f-528-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-529" escape="true"><ix:continuation id="f-528-1" continuedAt="f-528-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents domestic and foreign components of loss before provision for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-530">118,089</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-531">154,002</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-532">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-533">460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-534">118,243</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-535">154,462</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-528-2" continuedAt="f-528-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-536" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income tax (benefit) provision were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-537">1,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-538">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax (benefit) provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-539">1,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-540">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (benefit) provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-545">1,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-546">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-547" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision for the years ended December&#160;31, 2023 and 2022 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax benefit at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-548">24,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-549">32,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-550">6,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-551">3,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="f-552">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="f-553">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-554">1,810</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-555">2,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-556">18,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-557">31,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-558">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-559">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of internal reorganization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-560">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="3" id="f-561">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="advm:EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition" format="ixt:num-dot-decimal" scale="3" id="f-562">1,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="advm:EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition" format="ixt:fixed-zero" scale="3" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-564">831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-565">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax (benefit) provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-566">1,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-567">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-528-3" continuedAt="f-528-4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-568" continuedAt="f-568-1" escape="true">The following table presents significant components of the Company&#8217;s deferred tax assets and liabilities:</ix:nonNumeric></span><ix:continuation id="f-568-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-569">127,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-570">111,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserve and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-571">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-572">2,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-573">24,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-574">21,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-575">7,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-576">10,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="f-578">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-579">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-580">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="advm:DeferredTaxAssetsLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="f-581">17,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="advm:DeferredTaxAssetsLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="f-582">26,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-583">9,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-584">9,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 R&amp;D capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="advm:DeferredTaxAssetsCapitalizedCosts" format="ixt:num-dot-decimal" scale="3" id="f-585">29,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="advm:DeferredTaxAssetsCapitalizedCosts" format="ixt:num-dot-decimal" scale="3" id="f-586">23,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-587">218,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-588">207,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-589">205,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-590">188,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-591">13,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-592">19,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-593">12,335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-594">19,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-595">1,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-596">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-597">13,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-598">19,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2023 and 2022. The valuation allowance increased approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-601">17.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-602">39.7</ix:nonFraction>&#160;million during the years ended December&#160;31, 2023 and 2022, respectively mainly driven by net operating losses (&#8220;NOLs&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had U.S. federal NOLs carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-603">493.0</ix:nonFraction>&#160;million to offset any future federal income. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="advm:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-604">57.3</ix:nonFraction>&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2023, the Company also had U.S. state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-605">300.8</ix:nonFraction>&#160;million to offset any future state income. U.S. state NOLs expire at various years beginning with 2037. At December&#160;31, 2023, the Company also had approximately $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-606">49.3</ix:nonFraction>&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had federal research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-607">20.3</ix:nonFraction>&#160;million available to reduce future tax liabilities which expire at various years beginning with 2036. As of December&#160;31, 2023, the Company had state credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-608">17.6</ix:nonFraction>&#160;million available to reduce future tax liabilities which do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code Section&#160;174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses. As a result of this provision of the TCJA, deferred tax assets related to capitalized research expenses increased to $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="advm:DeferredTaxAssetsCapitalizedCosts" format="ixt:num-dot-decimal" scale="6" id="f-609">29.5</ix:nonFraction>&#160;million, net of amortization on research expenses capitalized as of December&#160;31, 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-528-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 and 383 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to the ability of the utilization before expiration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal, state, and foreign jurisdictions. The federal, state and foreign income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December&#160;31, 2017 through December&#160;31, 2022. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has total unrecognized tax benefits as of December&#160;31, 2023 and 2022 of approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-610">24.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-611">24.7</ix:nonFraction>&#160;million, respectively. If the unrecognized tax benefits for uncertain tax positions as of December 31, 2023, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-612" continuedAt="f-612-1" escape="true">A&#160;reconciliation of the unrecognized tax benefits is as follows:</ix:nonNumeric></span><ix:continuation id="f-612-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the beginning of the year</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-613">24,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-614">21,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to tax positions taken during the prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-615">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-616">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to tax position take during the current year</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-617">3,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-618">2,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease related to tax position taken during the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-619">3,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-621">24,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-622">24,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the Company accrued interest and penalties related to uncertain tax positions of <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="6" id="f-623">nil</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-624">0.3</ix:nonFraction> million, respectively. There are no ongoing examinations by taxing authorities at this time.</span></div></ix:continuation><div id="iee15d89dd75f4b25b706a37b8daeb24a_172"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-625" continuedAt="f-625-1" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-626" escape="true"><ix:continuation id="f-625-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-627">23,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-103" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-628">19,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-104" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-629">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-105" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-630">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-631">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-632">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-633">24,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-634">21,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="iee15d89dd75f4b25b706a37b8daeb24a_175"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-635" continuedAt="f-635-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-635-1" continuedAt="f-635-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2024, the Company entered into a securities purchase agreement, pursuant to which the Company sold <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-636">105,500,057</ix:nonFraction> shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-637">750,000</ix:nonFraction> shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) to certain institutional and accredited investors in a private placement (the &#8220;Private Placement&#8221;). The purchase price per share is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-110" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-638">1.20</ix:nonFraction>, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-109" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-639">1.1999</ix:nonFraction> per Pre-Funded Warrant, which represents the purchase price per share minus the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-109" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-640">0.0001</ix:nonFraction> per share exercise price of each Pre-Funded Warrant. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the Private Placement, the Company also entered into a securities purchase agreement with <ix:nonFraction unitRef="director" contextRef="c-111" decimals="INF" name="advm:SecuritiesPurchaseAgreementNumberOfDirectors" format="ixt-sec:numwordsen" scale="0" id="f-641">two</ix:nonFraction> directors of the Company. The Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-642">230,000</ix:nonFraction> shares at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-643">1.35</ix:nonFraction>, on otherwise substantially the same terms as those set forth in the Securities Purchase Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the close of the Private Placement on February 7, 2024, the Company received total gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-644">127.8</ix:nonFraction>&#160;million, before deducting placement agent fees and offering expenses.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><ix:continuation id="f-635-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2023 and March 8, 2024, the Company&#8217;s stockholders and Board of Directors, respectively, approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse split of all outstanding shares of the Company's common stock (the &#8220;Reverse Stock Split&#8221;). Such amendment will not change the par value per share or the number of authorized shares of common stock. No fractional shares shall be issued as a result of the Reverse Stock Split, and holders of such fractional shares shall be paid a sum in cash equal to such fraction multiplied by the closing sales price of the Company&#8217;s common stock as reported on the Nasdaq Capital Market on the last business day before the date the certificate of amendment is filed with the Secretary of State of the State of Delaware, such amount rounded to the nearest whole cent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Reverse Stock Split will decrease the number of issued and outstanding shares at the time, in thousands, from approximately <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-645"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-646">207,549</ix:nonFraction></ix:nonFraction> to approximately <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-647"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-648">20,755</ix:nonFraction></ix:nonFraction>; it will decrease the number of outstanding warrants from <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-649">750,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-650">75,000</ix:nonFraction>, and will change the exercise price on these warrants from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-651">0.0001</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-652">0.001</ix:nonFraction>. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading is expected to begin on a split-adjusted basis on March 21, 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shares and per share information presented in these consolidated financial statements does not reflect the upcoming stock split. Adjusting for the Reverse Stock Split, the number of issued and outstanding shares as of December 31, 2023, in thousands, will decrease from approximately <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-653"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-654">101,433</ix:nonFraction></ix:nonFraction> to approximately <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-655"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-656">10,143</ix:nonFraction></ix:nonFraction>. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-657" continuedAt="f-657-1" escape="true">The following unaudited pro forma financial information presents the Company's basic and diluted net loss per share upon effectiveness of the Reverse Stock Split for the periods indicated (in thousands except per share data):</ix:nonNumeric></span></div><ix:continuation id="f-657-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-658">117,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-659"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-660">11.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-661"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-662">10,082</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_196"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including Laurent Fisher, our Chief Executive Officer, and Linda Rubinstein, our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of December 31, 2023. The evaluation of our disclosure controls and procedures included a review of our processes and implementation and the effect on the information generated for use in this Annual Report on Form 10-K. We conduct this type of evaluation quarterly so that our conclusions concerning the effectiveness of these controls can be reported in our periodic reports filed with the SEC. The overall goals of these evaluation activities are to monitor our disclosure controls and procedures and to make modifications as necessary. We intend to maintain these disclosure controls and procedures, modifying them as circumstances warrant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of December&#160;31, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we assessed our internal control over financial reporting as of December 31, 2023, the end of our fiscal year, based on the framework in &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management's assessment included evaluation of such elements as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment. This assessment is supported by testing and monitoring performed by our internal accounting and finance organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2023. The results of management's assessment were reviewed with the Audit Committee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remediation of Prior Material Weakness</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed in Item 9A &#8220;Controls and Procedures&#8221; of our Annual Report for the period ended December 31, 2022 and Item 4 &#8220;Controls and Procedures&#8221; of our 2023 Form 10-Q&#8217;s, management identified a material weakness related to the accounting evaluation of material non-routine transactions. The material weakness was related to an immaterial non-cash lease accounting error that was identified in previously issued financial statements. While the identified error was not material, we considered the potential magnitude of the error(s) that could arise from the operating deficiency as potentially material. This material weakness did not result in the restatement of prior quarterly or annually filed financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, management conducted a remediation plan to address its material weakness, which included increasing the rigor with which management evaluates the accounting of material non-routine transactions by engaging additional outside financial reporting and technical accounting expertise. The material weakness was remediated at December 31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as noted above with respect to the remediation procedures for the previously identified material weakness, there were no other changes in our internal controls over financial reporting identified in connection with the evaluation required by Rules 13a&#8209;15(d) and 15d&#8209;15(d) of the Exchange Act that occurred during the fiscal quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">None</span></div><div><span><br/></span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_202"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not applicable</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_1839"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board of Directors</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The names of directors and their ages as of February 29, 2024. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:58.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Board Position</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Class II Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patrick Machado</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board, Class II Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soo Hong</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class I Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Lupher, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class III Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C. David Nicholson, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class III Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rabia Gurses Ozden, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class III Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Scopa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class II Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dawn Svoronos</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class I Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reed Tuckson, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class I Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Whitcup, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class III Director</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A brief biography of each of our directors appears below, except for Dr. Fischer, whose biographical information appears above under &#8220;Information about our Executive Officers.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patrick Machado</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mr. Machado was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its chief business officer from 2009 to 2014 and as its chief financial officer from 2004 until his retirement in 2014. From 1998 to 2001, Mr. Machado worked with ProDuct Health, Inc., a medical device company, as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Health&#8217;s acquisition by Cytyc Corporation, a diagnostic and medical device company, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison &amp; Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado currently serves on the boards of directors of Acelyrin, Inc., Arcus Biosciences, Inc., Chimerix, Inc., Turnstone Biologics Corp. and Xenon Pharmaceuticals Inc., and previously served on the boards of directors of Axovant Sciences, Inc., Endocyte, Inc., Inotek Pharmaceuticals Corporation (now Rocket Pharmaceuticals, Inc.), Medivation, Inc., Principia Biopharma Inc., Roivant Sciences Ltd., SCYNEXIS, Inc. and Turning Point Therapeutics, Inc. Mr. Machado has informed the Company that he will be serving on a maximum of five public company boards by no later than June 30, 2024. Mr. Machado received a B.A. in German and a B.S. in Economics from Santa Clara University and a J.D. from Harvard Law School. Mr. Machado has been chosen to serve on our Board due to his extensive experience dealing with the operational and financial issues of biopharmaceutical companies. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Soo Hong</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ms. Hong has served as the chief people officer at Sunbit, a financial technology company, since January 2022. At Sunbit, Ms. Hong is responsible for all talent and human resources functions including people services, recruiting, total rewards and compensation, and organizational development. Prior to joining Sunbit, Ms. Hong served as the chief people officer at National Veterinary Associates, an owner and operator of freestanding veterinary hospitals, from May 2019 to December 2021, where she was responsible for the oversight of people services, talent and learning, recruiting, and workplace support. From September 2017 to May 2019, Ms. Hong served as the chief human resources officer at Discovery Land Company, where she was responsible for oversight of a full portfolio of HR capabilities including talent acquisition and development, organizational development, learning, total rewards and HR operation. Prior to that, Ms. Hong served in leadership roles at Tinder, WeWork, Spencer Stuart and Russell Reynolds Associates. As a consultant, Ms. Hong has advised Capital One, Global Hyatt, and Pfizer on organizational, executive recruitment and engagement strategies. Ms. Hong received B.A. in American Studies from Wellesley College and an M.B.A. from The University of Chicago Booth School of Business. Ms. Hong has been chosen to serve on our Board due to her deep expertise in human capital management and executive and leadership development, as well as executive and board compensation design and governance serving rapidly growing organizations during periods of transformation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mark Lupher, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Dr. Lupher served as vice president of translational pharmacology and preclinical development at Sutro Biopharma, Inc., a publicly traded drug discovery, development and manufacturing company, from February 2016 to March 2020. In June 2013, Dr. Lupher founded VeritasRx Consulting, a consulting firm, and he has served as its president since that time, consulting for venture capital firms and biopharmaceutical companies, including Sutro Biopharma, Inc. from May 2014 to March 2016. Prior to VeritasRx, Dr. Lupher held various roles with Promedior, Inc., where he served as chief scientific officer from June 2010 to June 2013, as senior vice president, discovery research from June 2009 to June 2010 and as vice president, drug discovery from February 2007 to June 2009. Prior to Promedior, Dr. Lupher held various roles with ICOS Corporation from October 1998 to February 2007. Dr. Lupher received a Ph.D. in immunology from Harvard University and a B.S. in microbiology from the University of Washington. Dr. Lupher has been chosen to serve on our Board due to his drug development experience.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">C. David Nicholson, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Nicholson served as the executive vice president and chief research and development officer of Allergan plc, a pharmaceutical company, which was acquired by AbbVie Inc. in May 2020, from March 2015 to August 2020. He initially joined Allergan (previously known as Actavis plc and Forest Laboratories, Inc.) as senior vice president, Actavis Global Brands R&amp;D, in August 2014. Prior to Allergan, from March 2012 to July 2014, Dr. Nicholson served on the executive committee of Bayer Crop Science, a pharmaceutical and biotechnology company, as chief technology officer and executive vice president of research and development. Prior to that, from 1988 to 2011, Dr. Nicholson held multiple executive management roles, including senior vice president of licensing and knowledge management at Merck &amp; Co., Inc., senior vice president of global project management and drug safety at Schering-Plough Corporation, and executive vice president of research and development at Organon &amp; Co. Dr. Nicholson currently serves as the non-executive chair of the board of directors Wild Bioscience, a member of the board of directors of Volastra, the lead independent director of Actinium Pharmaceuticals, and an operational partner at Gilde Healthcare. Dr. Nicholson previously served as the non-executive chair of the board of directors of Exscientia plc. Dr. Nicholson received a B.Sc. in Pharmacology from the University of Manchester and a Ph.D. from the University of Wales. Dr. Nicholson has been chosen to serve on our Board due to his extensive pharmaceutical experience and a proven track record in drug development and deep experience in ophthalmology.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rabia Gurses Ozden, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Ozden has served as the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chief medical officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, since July 2022 and prior to that was Ocular&#8217;s senior vice president, clinical development, since January 2021. Dr. Ozden is responsible for leading the clinical development of its current and growing pipeline of indications focusing on the front and back of the eye. Prior to joining Ocular, Dr. Ozden served as the chief development officer at Akouos, Inc., a genetic medicine company, from September 2019 to January 2021, where she was responsible for leading the clinical development of its programs for sensorineural hearing loss. From January 2019 to August 2019, Dr. Ozden served as the chief medical officer of Nightstar Therapeutics plc., a gene therapy company, which was acquired by Biogen in 2019, where she was responsible for leading the clinical development of its programs for the inherited retinal diseases. Prior to Nightstar, from March 2018 to May 2019, Dr. Ozden consulted at Clementia Pharmaceuticals Inc., a biopharmaceutical company, where she was responsible for leading the clinical research and development in its dry eye program. From July 2015 to March 2018, she was the vice president, clinical research and development at Applied Genetic Technologies Corporation, a biotechnology company, responsible for leading the clinical development of its programs for the inherited retinal diseases. Prior to that Dr. Ozden held leadership roles at GlaxoSmithKline, Quark Pharmaceuticals, Bausch &amp; Lomb Pharmaceuticals and Carl Zeiss Meditec AG. Dr.&#160;Ozden received her M.D. from Hacettepe University School of Medicine. She completed her ophthalmology residency at Ankara University School of Medicine, and her clinical fellowship in Glaucoma at the New York Eye and Ear Infirmary. Dr.&#160;Ozden has been chosen to serve on our Board due to her extensive experience in ophthalmology, clinical development and operations, pharmacovigilance, regulatory affairs and gene therapy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">James Scopa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mr. Scopa served on the investment committee of MPM Capital, a life sciences venture capital firm, and was a managing director in MPM Capital's San Francisco office from 2005 to 2017. Previously, Mr. Scopa spent 18 years advising growth companies in biopharmaceuticals and medical devices at Deutsche Banc/Alex. Brown &amp; Sons and Thomas Weisel Partners. At Deutsche Banc Alex. Brown he served as managing director and Global Co-Head of Healthcare Investment Banking. Mr. Scopa has been a member of the advisory board and the investment advisory committee of OneVentures, an Australian venture capital firm, since July 2017. From January 2017 to June 2018, he was a fellow at Stanford University in the Distinguished Careers Institute. Mr. Scopa currently serves on the boards of directors of Aligos Therapeutics, Inc. and privately held Neuron23, Inc. Mr. Scopa has previously served on the boards of directors of DICE Therapeutics, Inc. (sold to Eli Lilly and Company), Semma Therapeutics, Inc. (sold to Vertex Pharmaceuticals, Inc.), True North Therapeutics, Inc. (sold to Bioverativ Inc.),and iPierian Inc (sold to Bristol Myers Squibb). Mr. Scopa received an A.B. from Harvard College, an M.B.A. from Harvard Business School and a J.D. from Harvard Law School. Mr. Scopa has been chosen to serve on our Board due to his extensive experience as a venture capital investor in the biotechnology and biopharmaceuticals industries, prior experience as an investment banker in those industries, and his service as a director for numerous companies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dawn Svoronos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ms. Svoronos has more than 30 years of experience in the biopharmaceutical industry, including extensive commercial work with the multinational pharmaceutical company Merck &amp; Co. Inc., where she held roles of increasing seniority over more than 20 years of service. Prior to her retirement from Merck in 2011, Ms. Svoronos most recently served as president of Merck in Europe/Canada from 2009 to 2011, president of Merck in Canada from 2006 to 2009 and vice president of Merck for Asia Pacific from 2005 to 2006. Ms. Svoronos currently serves as the chair of the board of directors of Theratechnologies Inc. and on the boards of directors of Acelyrin, Inc. and Xenon Pharmaceuticals, Inc. Previously, Ms. Svoronos served on the boards of directors of Endocyte, Inc., Global Blood Therapeutics, Inc., Medivation Inc. and PTC Therapeutics, Inc. Ms. Svoronos also serves on the board of directors of Agnovos Healthcare Company, a privately-held biotechnology company. She received a B.A. in English and French literature from Carleton University in Ottawa, Canada. Ms. Svoronos has been chosen to serve on our Board due to her extensive global biopharmaceutical and commercial leadership experience.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reed Tuckson, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Tuckson has served as the managing director of Tuckson Health Connections, a private consulting company since 2013. Previously, he served as the executive vice president and chief of medical affairs of UnitedHealth Group, a managed care company. Dr.&#160;Tuckson also served as senior vice president for professional standards of the American Medical Association; president of the Charles R. Drew University of Medicine and Science in Los Angeles, California; senior vice president for programs of the March of Dimes Birth Defects Foundation; and Commissioner of Public Health for the District of Columbia. Dr. Tuckson is the co-founder of the Black Coalition Against COVID and currently serves on the board of directors of Henry Schein, Inc. and is a cofounder of the Coalition For Trust In Health &amp; Science. Dr. Tuckson previously served on the boards of directors of Acasti Pharma, Inc., CTI BioPharma Corp., LifePoint Health, Inc. and Howard University, and was Chair of the Board of Alliance for Health Policy. Dr. Tuckson received a B.S. from Howard University and his M.D. from the Georgetown University School of Medicine. He completed the Hospital of the University of Pennsylvania&#8217;s General Internal Medicine Residency and Fellowship programs. Dr. Tuckson has been chosen to serve on our Board due to his experience in multiple facets of the healthcare industry, including extensive healthcare policy expertise, from clinical services administration and medical policies to consumer health engagement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Scott Whitcup, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Whitcup is the founder and chief executive officer of two companies focused on developing new therapies in ophthalmology and dermatology, Akrivista LLC and Whitecap Biosciences LLC, positions he has held since October 2015 and November 2015, respectively. He has also served on the clinical faculty at the UCLA Stein Eye Institute since July 2003. Previously, Dr. Whitcup served in a number of positions at Allergan, Inc., most recently as the executive vice president of research and development and chief scientific officer, from April 2009 to March 2015. Earlier in his career, Dr. Whitcup was the clinical director at the National Eye Institute at the National Institutes of Health. He previously served on a number of boards of directors, most recently, Menlo Therapeutics Inc., a biopharmaceutical company, and Nightstar Therapeutics plc, a gene therapy company, and currently serves on the board of directors of Anivive Lifesciences, a private company. Dr. Whitcup received a B.A. from Cornell University and an M.D. from Cornell University Medical College. He completed an internal medicine residency at UCLA and an ophthalmology residency at Harvard University at the Massachusetts Eye and Ear Infirmary. Dr. Whitcup has been chosen to serve on our Board due to his extensive experience in the discovery, development, and commercialization of drug products, his ophthalmologic expertise and his experience serving as a director for public companies.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee Members and Financial Expert</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current members of our Audit Committee are Mr. Machado (Chair), Mr. Scopa and Ms. Svoronos. Mr. Machado serves as the chair of the Audit Committee. All members of our Audit Committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq Listing Rules. Our Board has determined that Mr. Machado is an Audit Committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the Nasdaq Listing Rules.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. The code of business conduct and ethics is available on our website at http://investors.adverum.com. We intend to satisfy the disclosure requirements under Item 5.05 of the SEC Form 8-K regarding an amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics by posting such information on our website at the website address and location specified above. The reference to our website does not constitute incorporation by reference of the information contained at or available through our website.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delinquent Section 16(a) Reports</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10% of a registered class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Officers, directors and greater than 10% stockholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To our knowledge, based solely on a review of the copies of such reports furnished to us and written representations that no other reports were required, during the year ended December 31, 2023, all Section 16(a) filing requirements applicable to our officers, directors and greater than 10% beneficial owners were complied with, except that Linda Rubinstein filed one Form 4 reporting a grant of a stock option on August 3, 2023 late (on September 5, 2023) as a result of administrative oversight. In addition, on March 12, 2024, each of Laurent Fischer, Peter Soparkar and Setareh Seyedkazemi filed a Form 4 reporting a performance-based stock option late (achievement of performance conditions certified October 3, 2023) as a result of an administrative oversight.</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_4947802326840"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, our Named Executive Officers, or NEOs, were as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Laurent Fischer, M.D., President and Chief Executive Officer</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Linda Rubinstein, Chief Financial Officer</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Setareh Seyedkazemi, PharmD, Chief Development Officer</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Kishor Peter Soparkar, Chief Operating Officer</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total compensation earned by our NEOs for the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Principal Position</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary<br/>($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards<br/>($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Equity Incentive Plan Compensation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other Compensation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>($)</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,193</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,531</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546,477</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929,411</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,358</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,639</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,134</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513,275</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,080</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,996,489</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,409</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360,340</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,721</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674,863</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301,333</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,888</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,888</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Setareh Seyedkazemi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Development Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,969</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,525</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,209</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,659</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,362</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,188</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,668</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628,516</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,821</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,563</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520,756</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kishor Peter Soparkar</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Operating Officer</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,494</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,040</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,128</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,362</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,024</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,200</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,824</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,718</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,041</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346,783</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435,772</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,868</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667,712</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,175</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,600</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472,127</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.719%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Amounts represent a discretionary sign-on bonus approved by the Compensation Committee pursuant to an employment offer letter.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) &#160;&#160;&#160;&#160;These amounts do not correspond to the actual value that the NEOs will recognize. Amounts reflect the aggregate grant date fair value of options to purchase shares of our common stock, as calculated in accordance with ASC Topic 718. See Note 8 to the financial statements included herein, for information regarding assumptions underlying the value of equity awards. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) &#160;&#160;&#160;&#160;Amounts represent the annual cash performance-based bonuses earned by our NEOs pursuant to the achievement of certain corporate and individual performance objectives during 2023. Please see the descriptions of the annual performance bonuses in the section below titled &#8220;Narrative to Summary Compensation Table and Outstanding Equity Awards at Fiscal Year End&#8212;Annual Cash Incentives.&#8221;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4) &#160;&#160;&#160;&#160;Except as noted in Footnote 5, amounts for 2023 represent matching contributions under our 401(k) plan.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5) &#160;&#160;&#160;&#160;Consists of consulting fees paid to FLG Partners, LLC, of which Ms. Rubinstein was a partner, pursuant to a consulting agreement. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6) &#160;&#160;&#160;&#160;Ms. Rubinstein was appointed our Chief Financial Officer in December 2022, pursuant to a consulting agreement with FLG Partners, LLC. On August 3, 2023, we entered into an employment offer letter with Ms. Rubinstein for this role and mutually terminated the prior consulting agreement with FLG Partners, LLC.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7) &#160;&#160;&#160;&#160;Dr. Seyedkazemi joined us in January 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year End</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows all outstanding equity awards held by our NEOs as of December 31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities Underlying Unexercised Options (#) Exercisable</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities Underlying Unexercised Options (#) Unexercisable</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities Underlying Unexercised Unearned Options (#)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Exercise Price ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Expiration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares or Units of Stock that Have Not Vested (#)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market Value of Shares or Units of Stock that Have Not Vested <br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Incentive Plan Awards: Number of Unearned Shares, Units, or Other Rights that Have Not Vested (#)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested ($)</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,259</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,763</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/13/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/13/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,750</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,888</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/5/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(13)</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,786</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,454</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/14/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Setareh Seyedkazemi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,166</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,834</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,666</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(13)</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,645</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/5/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="10" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kishor Peter Soparkar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,269</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/13/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,924</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/13/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,666</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,875</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,125</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,444</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,556</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/5/2031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,666</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,440</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(13)</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,166</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,834</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/15/2031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,052</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.75</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/19/2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.88</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/29/2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.719%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;This stock option shall vest with respect to 25% of the underlying shares of our common stock on March 1, 2024, and 1/48 vesting monthly thereafter for three years, subject to continuous service through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2)&#160;&#160;&#160;&#160;This stock option vests monthly over a period of 3 years, subject to continuous service through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(3)&#160;&#160;&#160;&#160;This stock option vests 100% upon certification by the Compensation Committee of the Board of Directors that one full Nasdaq trading session has elapsed since our public disclosure of final topline results from the LUNA Phase 2 clinical trial of Ixo-vec in wet age-related macular degeneration.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(4)&#160;&#160;&#160;&#160;On October 3, 2023, the Compensation Committee certified that the performance condition of these performance options had been satisfied on August 16, 2023. Under the terms of the performance options, 1/24 of the total number of shares subject to such options vest and become exercisable each month following the date upon which the first cohort of patients in the LUNA trial were fully dosed, such that all of the shares shall be vested and exercisable as of the second anniversary of the vesting commencement date, subject to continuous service through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(5)&#160;&#160;&#160;&#160;This stock option vested with respect to 25% of the underlying shares of our common stock on February 18, 2023, and 1/48 vesting monthly thereafter for three years, subject to continuous service through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(6)&#160;&#160;&#160;&#160;This stock option vested with respect to 25% of the underlying shares of our common stock on February 16, 2022, and 1/48 vesting monthly thereafter for three years, subject to continuous service through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(7)&#160;&#160;&#160;&#160;This stock option vested with respect to 25% of the underlying shares of our common stock on June 15, 2021, and 1/48 vesting monthly thereafter for three years, subject to continuous service through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(8)&#160;&#160;&#160;&#160;This stock option vests with respect to 25% of the underlying shares of our common stock on February 3, 2024, and with respect to 17,708.33 underlying shares of our common stock monthly thereafter for three years, 36 months, subject to continuous service through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(9)&#160;&#160;&#160;&#160;This stock option vested with respect to 25% of the underlying shares of our common stock on January 6, 2023, and 1/48 vesting monthly thereafter for three years, subject to continuous service through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(10)&#160;&#160;&#160;&#160;This stock option vested with respect to 25% of the underlying shares of our common stock on February 20, 2021, and 1/48 vesting monthly thereafter for three years, subject to continuous service through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(11)&#160;&#160;&#160;&#160;This stock option vested with respect to 25% of the underlying shares of our common stock on October 30, 2020, and 1/48 vesting monthly thereafter for three years, subject to continuous service through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(12)&#160;&#160;&#160;&#160;Reflects performance stock units, pursuant to which (a) 1/3 of the shares vested upon dosing of the first subject in the Phase 2 clinical trial of Ixo-vec in wet age-related macular degeneration, (b) 1/3 of the shares will vest upon dosing of the first subject in a potentially registrational clinical trial of Ixo-vec or another product candidate owned or being developed by Adverum in wet age-related macular degeneration or another indication determined by the Compensation Committee to represent a significant unmet medical need and (c) 1/3 of the shares will vest upon consummation of a strategic corporate transaction, not constituting a change in control, that is determined by the Compensation Committee to be transformative for Adverum, in each case contingent upon certification by the Compensation Committee of the achievement of such milestone and subject to continuous service through each such vesting date. Non-exclusive examples of a strategic corporate transaction are (i) a collaboration with another company for the development and commercialization of a major asset, (ii) a substantial royalty-based or other structured financing, and (iii) the acquisition or in-license of a significant asset for development and commercialization.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(13)&#160;&#160;&#160;&#160;Represents the product of the number of unvested PSUs and $0.7530, the closing price of our common stock on the Nasdaq Capital Market as of December 29, 2023.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Narrative to Summary Compensation Table and Outstanding Equity Awards at Fiscal Year End</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have formal employment agreements with any of our NEOs. The initial compensation of each NEO was set forth in an employment offer or promotion letter that we executed with such executive officer at the time his or her employment with us commenced (or at the time of his or her promotion, as the case may be). Each employment offer letter provides that the NEO&#8217;s employment is &#8220;at will.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Base salaries are set to attract and retain executive talent. The determination of any particular executive&#8217;s base salary considers individual performance and contribution, experience in the role, market rates of pay for comparable roles and internal equity. Each year, our Chief Executive Officer proposes base salary adjustments, if any, for all NEOs, excluding himself, based on performance, changes in responsibilities, market data and other relevant factors. His proposal is subject to review by the Compensation Committee, which may accept the recommendations or make modifications to the proposal as it deems appropriate. Adjustments to the Chief Executive Officer&#8217;s salary are initiated and approved by the Compensation Committee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salary increases are discretionary, and during 2023 the Chief Executive Officer recommended salary adjustments designed to align our pay program with the market pay levels for comparable executive roles. The actual base salary earned by the NEOs in 2023 is reported in the Salary column of the Summary Compensation Table.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.224%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Name of Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022 Base Salary</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023 Base Salary</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Percentage Increase<br/>Over 2022 Base Salary</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Laurent Fischer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$645,800</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$671,600</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">4.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Linda Rubinstein</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:106%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$485,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Setareh Seyedkazemi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$465,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$483,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">3.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Kishor Peter Soparkar</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$473,200</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$494,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">4.5%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.719%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Ms. Rubinstein provided services as Chief Financial Officer as an outside consultant pursuant to a consulting agreement between Adverum and FLG Partners, LLC, as further described under &#8220;Certain Relationships and Related Party Transactions&#8212;Consulting Agreement with FLG Partners.&#8221; </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annual Cash Incentives</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our annual cash incentive program, our NEOs are eligible to receive performance-based cash incentives based on the achievement of certain pre-established performance objectives that include corporate and individual performance goals. The annual incentive for our Chief Executive Officer and our NEOs is based exclusively on the corporate metrics, without an individual performance component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each NEO&#8217;s target bonus opportunity for 2023 was expressed as a percentage of base salary as presented below.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Name of Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023 Target Cash Incentive<br/>(As a Percentage of Base Salary)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023 Target Cash Incentive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(Assuming 100% Achievement of Target)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Laurent Fischer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">60%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$402,960</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Linda Rubinstein</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">40%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$194,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Setareh Seyedkazemi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$193,200</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Kishor Peter Soparkar</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">40%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$197,800</span></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.719%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;Ms. Rubinstein received a pro-rated bonus that reflected her employment start date in August 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2023 annual incentive program was designed to incentivize progress on our strategic priorities, including an emphasis on site activation and progress towards data readout goals. The table below outlines the weighting of 2023 performance goals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Goals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Weightings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Achieve clinical and regulatory milestones for Ixo-vec</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Advance CMC to support Ixo-vec</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Advance scientific understanding of 7m8 platform and advance pipeline assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Improve the organization&#8217;s ability to execute on its strategy and achieve its goals by aligning people, structures, metrics and processes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maintain financial strength to achieve corporate objectives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the year, the Compensation Committee assessed the achievement of our corporate performance goals during the performance period against corresponding performance goals. These assessments balanced our progress with LUNA, regulatory interactions, CMC developments, scientific achievements, employee retention and financial metrics, against targeted clinical and regulatory milestones for Ixo-vec. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined annual incentive payouts for 2023 are reflected below. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Name of Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023 Goal Achievement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total 2023 Bonus Payout (as a % of Base Salary)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total 2023 Bonus Payout ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Laurent Fischer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">85%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">51%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$342,531</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Linda Rubinstein</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">85%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">34%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$67,721</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Setareh Seyedkazemi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">34%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$164,209</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Kishor Peter Soparkar</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">85%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">34%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">$168,128</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Incentives</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee uses long-term incentives to create alignment of the NEOs&#8217; interests with those of our stockholders and to foster a culture of ownership that incentivizes our executives to deliver sustained long-term value growth.  The long-term incentive awards for the NEOs are recommended by the Chief Executive Officer and approved by the Compensation Committee. The long-term incentive award for the Chief Executive Officer is initiated and approved directly by the Compensation Committee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer stock options to purchase shares of our common stock as a long-term component of our compensation program.  We typically grant stock options to employees when they commence employment with us and may subsequently grant additional stock options or stock unit awards at the discretion of our Compensation Committee or our Board. Our stock options allow employees to purchase shares of our common stock at a price equal to the fair market value of our common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, our stock options vest over a four-year period, with 25% vesting on the first anniversary of the grant date and 1/48th of the total shares per month thereafter. From time to time, equity awards may be awarded using alternate vesting schedules as set by the Compensation Committee or our Board. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Annual Refresh Long-Term Equity Incentives</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2023, we granted the NEOs long-term equity awards that were delivered in the form of stock options, as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Name of Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023 Stock Options (#)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Laurent Fischer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #4472c4;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">930,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Linda Rubinstein</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:106%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Setareh Seyedkazemi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">250,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Kishor Peter Soparkar</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">400,000</span></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.719%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Twenty-five percent of the total number of shares subject to each such option shall vest and become exercisable on first anniversary of the vesting commencement date and 1/48 of the total number of shares subject to each of the options shall vest and become exercisable each month thereafter, such that all of the shares shall become vested and exercisable as of the fourth anniversary of the vesting commencement date, subject to the NEO&#8217;s continuation of service from the option grant date through each such vesting date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2)&#160;&#160;&#160;&#160;In the first quarter of 2023, Ms. Rubinstein was an outside consultant and was not eligible to participate in the 2023 Long-Term Incentive program. Ms. Rubinstein received a stock option to purchase 850,000 shares on her employment start date in August 2023, which vests with respect to 25% of the underlying shares of our common stock on February 3, 2024, and with respect to 17,708.33 underlying shares of our common stock monthly thereafter for three years, 36 months, subject to continuous service through each such vesting date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2023, the Compensation Committee certified that the performance condition of certain performance options held by Drs. Fischer and Seyedkazemi and Mr. Soparkar had been satisfied on August 16, 2023. Under the terms of the performance options, 1/24 of the total number of shares subject to such options vest and become exercisable each month following the date upon which the first cohort of patients in the LUNA trial were fully dosed, such that all of the shares shall be vested and exercisable as of the second anniversary of the Vesting Commencement Date, subject to continuous service through each such vesting date. See &#8220;Outstanding Equity Awards at December 31, 2023&#8221; above for additional information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Severance Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our NEOs are eligible to receive severance payments and benefits pursuant to change in control and severance agreements each entered into with us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the change in control and severance agreements, &#8220;Cause&#8221; is determined in the sole discretion of the Board and means misconduct, including: (i) the executive&#8217;s commission or the attempted commission of or participation in any crime involving fraud, dishonesty or moral turpitude that results in (or might have reasonably resulted in) material harm to our business; (ii) intentional and material damage to our property and/or misappropriation of our funds; (iii) conduct that constitutes gross insubordination, incompetence or habitual neglect of duties that results in (or might have reasonably resulted in) material harm to our business that has not been cured within 30 days after written notice from the executive&#8217;s immediate supervisor or in the case of the chief executive officer, from the Board; or (iv) material breach of the Proprietary Information Agreement executed by the executive.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the change in control and severance agreements, &#8220;Constructive Termination&#8221; means any of the following actions taken without Cause by us or a successor corporation or entity without the executive&#8217;s consent: (i) substantial reduction of the executive&#8217;s rate of compensation; (ii) material reduction in the executive&#8217;s duties, provided, however, that a change in job position (including a change in title) shall not be deemed a &#8220;material reduction&#8221; unless the executive&#8217;s new duties are substantially reduced from the prior duties; (iii) failure or refusal of a successor to Adverum to assume our obligations under the agreement in the event of a change in control; and (iv) relocation of the executive&#8217;s principal place of employment or service to a place greater than 50 miles (or 35 miles for Dr. Fischer) from the executive&#8217;s then current principal place of employment or service.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Laurent Fischer</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to his change in control and severance agreement, in the event of a termination of employment by us without Cause or a Constructive Termination, Dr. Fischer will be entitled to (i) 12 months of base salary and (ii) up to 12 months of continued healthcare coverage. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a termination without Cause or a Constructive Termination, in each case, within the period commencing three months prior to a change in control and ending twelve months following a change in control, he will be entitled to (i) an amount equal to the sum of 24 months of base salary and two times Dr. Fischer&#8217;s target annual bonus for the year in which the termination occurs, payable in a lump sum, (ii) up to 24 months of continued healthcare coverage and (iii) the accelerated vesting of all of his outstanding equity awards. The payments and benefits described above are conditioned upon such executive executing and not revoking a release of claims against us and are subject to reduction in the event that such a reduction would result in a better after-tax outcome for Dr. Fischer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Linda Rubinstein, Setareh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seyedkazemi and Kishor Peter Soparkar</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to their respective change in control and severance agreements, in the event of a termination of employment by us without Cause or Constructive Termination, Ms. Rubinstein (after she has been employed by the Company for a year), Dr. Seyedkazemi and Mr. Soparkar will be entitled to (i) nine months of base salary and (i) up to nine months of continued healthcare coverage. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event Ms. Rubinstein, Dr. Seyedkazemi or Mr. Soparkar are terminated by us without Cause or experiences a Constructive Termination, in each case, within the period commencing three months prior to a change in control and ending on the first anniversary of the change in control, then he or she will be entitled to (i) an amount equal to the sum of 12 months of base salary, payable in a lump sum, (ii) up to 12 months of continued healthcare coverage, and (iii) the accelerated vesting of all outstanding equity awards. The payments and benefits described above are conditioned upon such NEO executing and not revoking a release of claims against us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The general employment benefits provided to the NEOs are generally the same as those provided to other nonunion, salaried employees and include medical, dental, basic life insurance, short and long-term disability insurance, and a tax-qualified 401(k) plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee 401(k) Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. full-time employees qualify for participation in our 401(k) plan, which is intended to qualify as a tax-qualified defined contribution plan under the Internal Revenue Code. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than with respect to our 401(k) plan, our U.S. employees, including our NEOs, do not participate in any plan that provides for retirement payments and benefits, or payments and benefits that will be provided primarily following retirement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonqualified Deferred Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, our U.S. employees, including our NEOs, did not contribute to, or earn any amounts with respect to, any defined contribution or other plan sponsored by us that provides for the deferral of compensation on a basis that is not tax-qualified.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Director Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee reviews pay levels for non-employee directors periodically with assistance from its compensation consultant, Radford, which prepares a comprehensive assessment of our non-employee director compensation program. That assessment includes benchmarking of director compensation against the same peer group used for executive compensation purposes, an update on recent trends in director compensation and a review of related corporate governance best practices. Following that review, either the Compensation Committee or the Board, consistent with the recommendation of the Compensation Committee, has determined the non-employee director compensation program that will be in effect until the next such determination.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Director Compensation Policy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our non-employee director compensation policy, each non-employee director receives the following cash compensation for Board and standing committee service, as applicable:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$40,000 per year for service as a Board member;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$35,000 per year for service as a non-employee Chair of our Board;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$20,000 per year for service as chair of the Audit Committee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$15,000 per year for service as chair of the Compensation Committee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$10,000 per year for service as chair of the Nominating and Corporate Governance Committee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$15,000 per year for service as chair of the Research and Development Committee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$10,000 per year for service as non-chair member of the Audit Committee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$7,500 per year for service as non-chair member of the Compensation Committee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$5,000 per year for service as non-chair member of the Nominating and Corporate Governance Committee; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$7,500 per year for service as non-chair member of the Research and Development Committee.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual cash retainers for service as a non-employee Chair of our Board, chair of a committee or non-chair member of the committee are in addition to the annual cash retainer for service as a Board member. Cash retainers are prorated for any partial years of service. We also reimburse our non-employee directors for their reasonable out-of-pocket expenses incurred in attending Board and committee meetings.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option Awards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our non-employee director compensation policy, the non-employee directors receive grants of non-statutory stock options under our 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;). For purposes of these awards, a non-employee director is a director who is not employed by us. Pursuant to our non-employee director compensation policy, each non-employee director who joins the Board is automatically granted an option to purchase a number of shares of our common stock resulting in the option having a grant-date fair value (determined as provided in the plan) of $520,000, but in no event more than 80,000 shares (an &#8220;Initial Grant&#8221;). Initial Grants vest ratably in annual installments over three years of service following the date of grant. In addition, pursuant to our non-employee director compensation policy, on the date of our annual meeting of stockholders, (i)&#160;each non-employee director receives an annual equity award under our 2014 Plan of an option to purchase a number of shares of our common stock resulting in the option having a grant-date fair value of $260,000, but in no event more than 40,000 shares (a &#8220;Board Annual Award&#8221;) and (ii) the Chair of the Board receives an additional option to purchase a number of shares of our common stock resulting in the option having a grant-date fair value of $90,000, but in no event more than 12,500 shares (a &#8220;Chair Additional Annual Award&#8221;). The Board Annual Awards and Chair Additional Annual Awards vest in full on the earlier to occur of the first anniversary of the grant date or the next annual meeting. All such options have a maximum term of ten years. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Non-Employee Director Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total compensation for each person who served as a non-employee member of our Board during the year ended December 31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fees<br/>Earned<br/>Or Paid<br/>In Cash<br/>($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Option</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Soo Hong</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">47,500</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">46,704</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">94,204</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mark Lupher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">52,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">46,704</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99,204</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patrick Machado</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">102,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">61,299</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">163,799</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C. David Nicholson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7,164</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58,296</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">65,460</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rabia Gurses Ozden</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">47,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">46,704</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">94,204</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">James Scopa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">65,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">46,704</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">111,704</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dawn Svoronos</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">46,704</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">106,704</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Reed Tuckson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">52,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">46,704</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99,204</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Scott Whitcup</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">46,704</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">106,704</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The reported dollar value of the option awards is equal to the aggregate grant date fair value, or incremental fair value, as applicable, as calculated in accordance with ASC Topic 718, of the options awards granted during 2023. See Note 8 to the financial statements included herein for the assumptions used in calculating these amounts.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;As of December 31, 2023, the number of shares underlying option awards outstanding held by each non-employee directors listed above was as follows: Ms.&#160;Hong, 120,000; Dr.&#160;Lupher, 265,000 shares; Mr.&#160;Machado, 390,369 shares; Dr.&#160;Nicholson, 80,000 shares; Dr.&#160;Ozden, 120,000 shares; Mr.&#160;Scopa, 241,666 shares; Ms.&#160;Svoronos, 165,000 shares; Dr.&#160;Tuckson, 125,000 shares; and Dr.&#160;Whitcup, 210,000 shares. No non-employee directors held RSUs on December&#160;31, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Dr. Nicholson joined our Board in November 2023. Upon joining our Board Dr. Nicholson received a stock option to acquire 80,000 shares of our common stock.</span></div><div><span><br/></span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_4947802326854"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount and percentage of the outstanding shares of our common stock that, according to the information supplied to us, are beneficially owned by (i) each person who is the beneficial owner of more than 5% of our outstanding common stock, (ii) each person who is currently a director, (iii) each named executive officer and (iv) all current directors and executive officers as a group. Unless otherwise indicated, the address for each of the stockholders in the table below is c/o Adverum Biotechnologies, Inc., 100 Cardinal Way, Redwood City, California 94063. Except for information based on Schedules 13G and 13D and information collected in connection with our filing of the Registration Statement on Form S-3 (Registration No. 333- 277634) on March 4, 2024, as indicated in the footnotes, beneficial ownership is stated as of February 29, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days of February 29, 2024 through the exercise of any stock option, warrants or other rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock held by that person.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of shares beneficially owned is based on 207,384,653 shares of our common stock outstanding as of February&#160;29, 2024. Shares of our common stock subject to options that are currently vested or exercisable or that will become vested or exercisable within 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0 days after February 29, 2024, as well as RSUs that will vest within 60 days after February 29, 2024, are deemed to be beneficially owned by the person holding such options for the purpose of computing the percentage of ownership of such person but are not treated as outstanding for the purpose of computing the percentage of any other person.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Beneficial Owner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Beneficial Ownership</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage of Stock Beneficially Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5% and Greater Stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TCG Crossover Fund II, L.P.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,763,572</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Franklin Advisers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,173,338</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Venrock Healthcare Capital Partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,564,213</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Logos Global</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vivo Opportunity Fund Holdings, L.P. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FMR LLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,650,406</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodore Capital Master LP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,139,625</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Frazier Life Sciences</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,416,666</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Named Executive Officers and Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143,793</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,916</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Setareh Seyedkazemi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,777</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kishor Peter Soparkar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463,123</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soo Hong</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Lupher</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patrick Machado</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(15)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,551</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C. David Nicholson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rabia Gurses Ozden</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(16)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Scopa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(17)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,334</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dawn Svoronos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(18)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reed Tuckson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(19)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Whitcup</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(20)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All current directors and executive officers as a group (13 persons)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(21)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,990,462</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.719%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160; Indicates beneficial ownership of less than 1% of the total outstanding common stock.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;Based on a Schedule 13G filed with the SEC on February 15, 2024 reporting beneficial ownership as of February 8, 2024. Consists of (a)&#160;20,083,395 shares of common stock held by TCG Crossover Fund II, L.P. and (b) 680,177 shares of common stock issuable upon exercise of pre-funded warrants held by TCG Crossover Fund II, L.P. This total excludes 69,823 shares of common stock issuable upon exercise of certain pre-funded warrants because the pre-funded warrants may not be exercised to the extent that doing so would result in the holder of the pre-funded warrants (together with the holder&#8217;s affiliates and any other persons acting as a group together with the holder or any of the holder&#8217;s affiliates) beneficially owning more than 9.99% of the shares of common stock then outstanding immediately after giving effect to such exercise. TCG Crossover GP II, LLC is the general partner of TCG Crossover Fund II, L.P. and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II, LLC and may be deemed to share voting, investment and dispositive power with respect to these securities. The principal business address of these persons and entities is 705 High Street, Palo Alto, CA 94301.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2)&#160;&#160;&#160;&#160;This information was obtained from the stockholder in connection with our filing of the Registration Statement on Form S-3 (Registration No. 333- 277634) on March 4, 2024, and reflects beneficial ownership as of February 7, 2024. Consists of (a) 5,820,371 shares of common stock held by Franklin Strategic Series &#8211; Franklin Biotechnology Discovery Fund (&#8220;FSS&#8221;), (b) 11,352,495 shares of common stock held by Franklin Templeton Investment Funds &#8211; Franklin Biotechnology Discovery Fund (&#8220;FTIF&#8221;) and (c) 472 shares of common stock held by Franklin Biotechnology Discovery SMA (&#8220;SMA&#8221;). Evan McCulloch has voting and/or dispositive power over the holdings of FSS, FTIF and SMA. Mr. McCulloch disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Franklin Advisers, Inc. is the investment adviser for each of FSS, FTIF and SMA. The principal business address of these persons and entities is One Franklin Parkway, San Mateo, CA 94403.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on a Schedule 13G/A filed with the SEC on February 14, 2024 reporting beneficial ownership as of December 31, 2023. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Consists of (a) 11,063,043 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCP EG&#8221;), (b) 4,091,832 shares of common stock held by Venrock Healthcare Capital Partners III, L.P. (&#8220;VHCP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">III&#8221;) and (c) 409,338 shares of common stock held by VHCP Co-Investment Holdings III, LLC (&#8220;VHCP Co III&#8221;). VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCP EG. VHCP Management III, LLC (&#8220;VHCPM&#8221;) is the sole general partner of VHCP III and the sole manager of VHCP Co III. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM EG and VHCPM. The address of the above referenced entities and persons is 7 Bryant Park, 23rd Floor, New York, New York 10018.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on a Schedule 13G filed with the SEC on February 22, 2024 reporting beneficial ownership as of February 6, 2024. Consists of (a) 4,166,666 shares of common stock held by Logos Opportunities Fund IV LP (&#8220;Logos Opportunities&#8221;) and (b) 10,833,334 shares of common stock held by Logos Global Master Fund LP (&#8220;Global Fund&#8221;). Logos Opportunities IV GP LLC (&#8220;Logos Opportunities GP&#8221;) is the general partner of Logos Opportunities. Logos Global Management LP (&#8220;Logos Global&#8221;) is the investment advisor to Global Fund. Logos Global Management GP LLC (&#8220;Logos Global GP&#8221;) is the general partner of Logos Global. Arsani William and Graham Walmsley are the members of Logos Opportunities GP and Mr. William is a control person of Logos Global and Logos Global GP. Mr. William and Mr. Walmsley each disclaim beneficial ownership of these shares, except to the extent of each&#8217;s pecuniary interest in such shares, if any. The principal address of Logos Opportunities and Global Fund is 1 Letterman Drive, Building C, Suite C3-350, San Francisco, CA 94129.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on a Schedule 13G/A filed with the SEC on February 14, 2024 reporting beneficial ownership as of February 7, 2024. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Consists of 15,000,000 shares of common stock held by Vivo Opportunity Fund Holdings, L.P., or Vivo Fund Holdings. Vivo Opportunity, LLC, or Vivo Opportunity, is the general partner of Vivo Fund Holdings. The voting members of Vivo Opportunity are Kevin Dai, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares. The address of the above referenced entities and persons is c/o Vivo Capital LLC, 192 Lytton Avenue, Palo Alto, CA 94301.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(6)&#160;&#160;&#160;&#160;This information was obtained from the stockholder in connection with our filing of the Registration Statement on Form S-3 (Registration No. 333- 277634) on March 4, 2024, and reflects beneficial ownership as of February 7, 2024. These funds and accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of these funds and accounts is 245 Summer Street, Boston, MA 02210.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(7)&#160;&#160;&#160;&#160;This information was obtained from the stockholder in connection with our filing of the Registration Statement on Form S-3 (Registration No. 333- 277634) on March 4, 2024, and reflects beneficial ownership as of February 7, 2024. Consists of 12,139,625 shares of common stock held by Commodore Capital Master LP. Commodore Capital LP is the investment manager to Commodore Capital Master LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion with respect to these shares. Commodore Capital LP and Commodore Capital Master LP have shared voting and dispositive power with respect to these shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(8)&#160;&#160;&#160;&#160;Based on a Schedule 13G filed with the SEC on February 9, 2024 reporting beneficial ownership as of February 8, 2024. Consists of (a) 5,003,125 shares of common stock held by Frazier Life Sciences Public Fund, L.P. (&#8220;FLS Public Fund&#8221;), (b) 2,395,833 shares of common stock held by Frazier Life Sciences Public Overage Fund, L.P. (&#8220;FLS Overage Fund&#8221;), (c) 2,000,000 shares of common stock held by Frazier Life Sciences XI, L.P. (&#8220;FLS XI&#8221;) and (d) 1,017,708 shares of common stock held by Frazier Life Sciences X, L.P. (&#8220;FLS X&#8221;). FHMLSP, L.P. is the general partner of FLS Public Fund and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Albert Cha, James N. Topper, Patrick J. Heron and James Brush are the managing directors of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by FLS Public Fund. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim beneficial ownership of the shares held by FLS Public Fund except to the extent of their pecuniary interests in such shares, if any. FHMLSP Overage, L.P., is the general partner of FLS Overage Fund and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by FLS Overage Fund. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim beneficial ownership of the shares held by FLS Overage Fund except to the extent of their pecuniary interests in such shares, if any. FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Mr. Heron and Dr. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of the shares held by FLS X except to the extent of their pecuniary interests in such shares, if any. FHMLS XI, L.P. is the general partner of FLS XI, and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Mr. Heron, Dr. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by FLS XI. Dr. Topper, Mr. Heron and Mr. Estes disclaim beneficial ownership of the shares held by FLS XI except to the extent of their pecuniary interests in such shares, if any. The principal business address of the above referenced entities and persons is 1001 Page Mill Rd., Building 4, Ste. B, Palo Alto, CA 94304.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(9)&#160;&#160;&#160;&#160;Includes 3,439,652 shares subject to options that are exercisable, and/or RSUs that may settle, within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(10)&#160;&#160;&#160;&#160;Includes 247,916 shares subject to options that are exercisable, and/or RSUs that may settle, within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(11)&#160;&#160;&#160;&#160;Includes 335,103 shares subject to options that are exercisable, and/or RSUs that may settle, within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(12)&#160;&#160;&#160;&#160;Includes 1,185,532 shares subject to options that are exercisable within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(13)&#160;&#160;&#160;&#160;Includes 53,334 shares subject to options that are exercisable within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(14)&#160;&#160;&#160;&#160;Includes 225,000 shares subject to options that are exercisable within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(15)&#160;&#160;&#160;&#160;Includes 338,369 shares subject to options that are exercisable within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(16)&#160;&#160;&#160;&#160;Includes 53,334 shares subject to options that are exercisable within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(17)&#160;&#160;&#160;&#160;Includes 225,000 shares subject to options that are exercisable within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(18)&#160;&#160;&#160;&#160;Includes 125,000 shares subject to options that are exercisable within 60 days of February 29, 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(19)&#160;&#160;&#160;&#160;Includes 85,000 shares subject to options that are exercisable within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(20)&#160;&#160;&#160;&#160;Includes 170,000 shares subject to options that are exercisable within 60 days of February 29, 2024.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(21)&#160;&#160;&#160;&#160;Consists of the shares held by our current directors and current executive officers, including one executive officer not included above, including 6,483,240 shares subject to options that are exercisable, and/or RSUs that may settle, within 60 days of February 29, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information as of December 31, 2023, with respect to all of our equity compensation plans in effect on that date.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>of<br/>Outstanding<br/>Options,<br/>Warrants<br/>and Rights<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities<br/>Remaining<br/>Available for<br/>Future Issuance<br/>Under Equity<br/>Compensation<br/>Plans<br/>(Excluding<br/>Securities<br/>Reflected in<br/>Column (a))<br/>(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity Compensation Plans Approved by Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,536,654</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.77</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543,237</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,079,891</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.77</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,510,336</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity Compensation Plans Not Approved by Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,491,249</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.42</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,491,249</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.42</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867,677</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,571,140</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,378,013</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.719%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes the Amended and Restated 2006 Equity Incentive Plan, 2014 Plan and the 2014 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The 2014 Plan contains an &#8220;evergreen&#8221; provision, pursuant to which the number of shares of common stock reserved for issuance or transfer pursuant to awards under the 2014 Plan shall be increased on the first day of each year beginning in 2015 and ending in 2024, equal to the lesser of (A) 4.0% of the shares of stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (B) such smaller number of shares of stock as determined by our Board; provided, however, that no more than 10,441,663 shares of stock may be issued upon the exercise of incentive stock options.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Excludes shares subject to rights outstanding under the ESPP as the number of shares issuable pursuant to these rights cannot be determined as of December 31, 2023, as it depends on amounts contributed by the holder of the rights and the price of a share of our common stock on the last day of the purchase period.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Includes options pursuant to the inducement grant exception under Nasdaq Listing Rule 5635(c)(4) as an inducement that was material to their employment with us. Also includes the 2017 Inducement Plan adopted by the Board in October 2017. The 2017 Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to persons not previously our employees or directors, or following a bona fide period of non-employment, as an inducement material to the individuals&#8217; entering into employment with us within the meaning of Nasdaq Listing Rule 5635(c)(4). The 2017 Inducement Plan has a share reserve covering 6,100,000 shares of our common stock. If a stock award granted under the 2017 Inducement Plan expires or otherwise terminates without all of the shares covered by the stock award having been issued, or is settled in cash, or shares are withheld to satisfy tax withholding obligations, then the shares of our common stock not acquired or withheld pursuant to the stock award again will become available for subsequent issuance under the 2017 Inducement Plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_549755815773"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Relationships and Related Transactions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below, we had no transactions that have occurred since January 1, 2022 and to which we were a party, in which the amount involved exceeded the lesser of $120,000 and 1% of the average of our total assets at year-end for the last two completed fiscal years and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or an affiliate or immediate family member thereof, at any time from January 1, 2022 to the date of this report, had or will have a direct or indirect material interest, other than those already described in this proxy statement under the headings &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Employee Director Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consulting Agreement with FLG Partners</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into a consulting agreement with FLG Partners pursuant to which FLG Partners provided us with consulting services. Pursuant to the consulting agreement, Linda Rubinstein has served as our Chief Financial Officer since December 2022. In 2023, we paid FLG Partners $674,863 for consulting services under the consulting agreement, including for the services of Ms. Rubinstein. Concurrent with Ms. Rubinstein acceptance of and conversion to full time employment with the company in August 2023, the Consulting Agreement with FLG Partners was mutually terminated by the company and FLG Partners. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consulting Agreement with Richard Beckman, M.D.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we entered into a consulting agreement with Dr. Beckman effective June 1, 2023. Pursuant to the consulting agreement, for an initial term of twelve months (the &#8220;Initial Term), Dr. Beckman will provide up to 40 hours per month of consulting services to Adverum for consideration of $42,083 per month, with any additional services in excess of 40 hours per month compensated at a rate of $600 per hour. In 2023, we paid an aggregate of $339,383 to Dr. Beckman pursuant to the consulting agreement. Adverum will also pay COBRA premiums for Dr. Beckman and his covered dependents during the Initial Term. Following the Initial Term, the Consulting Agreement may be renewed on a monthly basis, during which time Dr. Beckman will provide consulting services on an hourly basis for compensation of $600 per hour. Dr. Beckman&#8217;s equity awards with Adverum shall continue to vest during the term of the Consulting Agreement, provided, however, that pursuant to the terms of the Consulting Agreement, Dr. Beckman may not exercise any equity awards that vest during the Initial Term until the final day of the Initial Term, and if Dr. Beckman terminates the Consulting Agreement prior to June 1, 2024 or defaults under the Consulting Agreement, any equity awards that vested during the Initial Term shall be forfeited as of the date of such termination. The Consulting Agreement also provides that, so long as Dr. Beckman does not default under the Consulting Agreement or terminate the Consulting Agreement prior to June 1, 2024, the post-termination exercise period of Dr. Beckman&#8217;s vested stock options as of that date shall be extended to the date that is twelve months from the last day of the term of the Consulting Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Private Placements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2024, we issued and sold to certain institutional and accredited investors (the &#8220;Investors&#8221;) in a private placement (the &#8220;Private Placement&#8221;) an aggregate of 105,500,057 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share, and to certain investors, in lieu of Shares, pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase an aggregate of 750,000 shares of common stock. The purchase price per Share was $1.20 (or $1.1999 per Pre-Funded Warrant, which represents the purchase price per Share to be sold in the Private Placement, minus the $0.0001 per share exercise price of each such Pre-Funded Warrant). Existing investors that previously held five percent or more of the Company&#8217;s outstanding common stock, including Commodore Capital LP, FMR LLC and Venrock Healthcare Capital Partners III, L.P., and/or their affiliates, purchased approximately $7.0 million, $10.0 million and $12.5 million, respectively, in Shares in the Private Placement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the Private Placement, Mark Lupher, Ph.D., and James Scopa, directors of the Company, also purchased approximately $175,500 and $135,000, respectively, of shares of common stock in a private placement at a price per share of $1.35, on otherwise substantially the same terms as the Private Placement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policies and Procedures for Related Party Transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has adopted a written related person transaction policy to set forth the policies and procedures for the review and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 and a related person had, has or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness and guarantees of indebtedness.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As provided by our related party transaction policy, our Audit Committee will be responsible for reviewing and approving in advance the related person transaction and in doing so will consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s-length transaction and the extent of the related person&#8217;s interest in the transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on The Nasdaq Capital Market. Rule 5605 of the Marketplace Rules of the Nasdaq Stock Market LLC (the &#8220;Nasdaq Listing Rules&#8221;) requires that independent directors compose a majority of a listed company&#8217;s board of directors within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit and compensation committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act. Under Nasdaq Listing Rule 5605(a)(2), a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of the board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Nasdaq Listing Rule 5605(a)(2) also specifies certain categories of persons who will not be considered independent, including employees, family members of executive officers and recipients of compensation from the company in excess of $120,000 during any period of twelve consecutive months within the past three years, subject to certain exceptions. To be considered independent for purposes of Rule 10A-3 under the Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (1) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries. In addition to satisfying general independence requirements under the Nasdaq Listing Rules, members of the compensation committee must also satisfy additional independence requirements set forth in Nasdaq Listing Rule 5605(d)(2). To be considered independent for purposes of Nasdaq Listing Rule 5605(d)(2), our Board must consider all factors specifically relevant to determining whether a director has a relationship with us which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by us to such director; and whether such director is affiliated with us, a subsidiary of our company or an affiliate of a subsidiary of our company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our Board undertook a review of the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our Board has determined that each of Ms. Hong, Dr. Lupher, Mr. Machado, Dr. Nicholson, Dr. Ozden, Mr. Scopa, Ms. Svoronos, Dr. Tuckson, and Dr. Whitcup is independent within the meaning of Rule 5605 of the Nasdaq Listing Rules. Our Board also determined that Mr. Machado, Mr. Scopa, and Ms. Svoronos, who compose our Audit Committee, and Ms. Hong, Mr. Machado, Mr. Scopa, and Dr. Tuckson, who compose our Compensation Committee, satisfy the independence standards for those committees established by applicable SEC rules and Nasdaq Listing Rules. In making these determinations, our Board considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence. For example, the Board considered (i) with respect to Mr. Machado and Ms. Svoronos, the fact that both Mr. Machado and Ms. Svoronos serve on the board of directors of Xenon Pharmaceuticals, Inc. and (ii) with respect to Dr. Tuckson, the fact that both Dr. Tuckson and Dr. Fischer previously served on the board of directors of CTI Biopharma Corp.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_549755815788"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Auditor Fees</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023 and 2022, Ernst &amp; Young LLP billed the approximate fees set forth below. All fees described in the table below were preapproved by the Audit Committee:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit-Related Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total All Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221,719&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929,621&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.719%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;This category consists of fees for professional services rendered for the audit of our financial statements, review of interim financial statements, assistance with registration statements filed with the SEC and services that are normally provided by Ernst &amp; Young LLP in connection with statutory and regulatory filings or engagements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preapproval Policies and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee is responsible for reviewing the terms of the proposed engagement of the independent registered public accounting firm for audit or permissible non-audit services and for preapproving all such engagements. The Audit Committee has adopted a policy for the preapproval of all audit and non-audit services to be performed for us by the independent registered public accounting firm. In providing any preapproval, the Audit Committee considers whether the services to be approved are consistent with the SEC&#8217;s rules on auditor independence. The Audit Committee has considered the role of Ernst &amp; Young LLP in providing audit and audit-related services to us and has concluded that such services are compatible with Ernst &amp; Young LLP&#8217;s role as our independent registered public accounting firm.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_226"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibit and Financial Statement Schedules.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The financial statements schedules and exhibits filed as part of this Annual Report on Form 10-K are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Consolidated Financial Statements in Item 8 of this Annual Report on Form 10-K. No financial statement schedules are provided because the information called for is not required or is shown in the consolidated financial statements or related notes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The following exhibits are included herein or incorporated by reference:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312520182655/d917807dex31.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> through </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312516588027/d130217dex32.htm">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312524024156/d739306dex41.htm">Form of Pre-Funded Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 5, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312524024156/d739306dex102.htm">Form of Registration Rights Agreement, dated February 5, 2024, by and among Adverum Biotechnologies, Inc. and the investors party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 5, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021003623/advm-20201231xexx42.htm">Description of Common Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1A&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459016023738/advm-ex109_293.htm">License Agreement between AAVLife and Inserm Transfert, dated as of July 4, 2014.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1B&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459016023738/advm-ex1010_292.htm">Amendment No. 1 to License Agreement between AAVLife and Inserm Transfert, dated as of October&#160;5,&#160;2015.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm">Exclusive License Agreement between Avalanche Biotechnologies, Inc. and the Regents of the University of California, dated as of June 17, 2013.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 6, 2019</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm">License Agreement between Avalanche Biotechnologies, Inc. and Virovek, Inc., dated as of October 12, 2011.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 6, 2019</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">Lease Agreement between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">dated as of June 28, 2018</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021015877/ex101firstamendment-health.htm">First Lease Amendment between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of April 19, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4C</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xex104c.htm">Second Amendment to Lease (Partial Lease Termination) between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of November 1, 2021. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4C</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828023009899/advm-20221231xexx104d.htm">Third Amendment to Lease (Partial Lease Termination) between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of March 24, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4E</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828023009899/advm-20221231xexx104e.htm">Fourth Amendment to Lease between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of March 24, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4E</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex105leasenor.htm">Lease Agreement between Adverum NC, LLC (a wholly owned subsidiary of the Company) and ARE-NC REGION NO. 21, LLC, dated as of January 8, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xexx105b.htm">Sublease Agreement between Adverum NC, LLC and Jaguar Gene Therapy, LLC, dated as of October 26, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5C</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828023017564/advm-20230331ex103.htm">Third Amendment to Lease and First Amendment to Consent to Sublease between Adverum NC, LLC (a wholly owned subsidiary of the Company), ARE-NC REGION NO. 21, LLC and Jaguar Gene Therapy, LLC, dated as of April 3, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6A(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312521063725/d61904dex993.htm">2017 Inducement Plan, as amended and restated</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">333-253727</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6B(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312517307248/d463313dex992.htm">Form of Stock Option Grant Notice and Option Agreement under the 2017 Inducement Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-220894</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6C(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312517307248/d463313dex993.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2017 Inducement Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-220894</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022022469/ex1042014esppplanamended.htm">Adverum Biotechnologies, Inc. 2014 Employee Stock Purchase Plan, as amended and restated.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8A(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit1082014eip.htm">Adverum Biotechnologies, Inc. 2014 Equity Incentive Award Plan, as amended and restated.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8B(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018004560/advm-ex1014_1087.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2014 Equity Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8C(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018004560/advm-ex1016_1089.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2014 Equity Incentive </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8D(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312514280644/d729335dex1018.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2014 Equity Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-197133</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 25, 2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8E(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xexx108e.htm">Form of Performance Stock Unit Award Grant Notice and Performance Stock Unit Award Agreement under the 2014 Equity Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8E</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828023028851/advm-20230630ex106.htm">Form of Change in Control and Severance Agreement for executive officers other than the chief executive officer.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020008534/advm-20200331xex101.htm">Form of Indemnification Agreement for directors and executive officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 28, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex107nonxempl.htm">Non-Employee Director Compensation Policy.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.12A(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">Offer Letter between Adverum Biotechnologies, Inc. and Laurent Fischer, dated as of June 11, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.12B(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">Change</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm"> in Control and Severance Agreement between Adverum Biotechnologies, Inc. and Laure</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">n</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">t Fischer, dated </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">as</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm"> of June 11, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.13(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm">Offer Letter between Adverum Biotechnologies, Inc. and Peter Soparkar, dated as of October 11, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 7, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.14(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828022007698/advm-20211231xexx1021.htm">Offer Letter between Adverum Biotechnologies, Inc. and Setareh Seyedkazemi, dated as of December 3, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.15A(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828023028851/advm-20230630ex105.htm">Offer Letter between Adverum Biotechnologies, Inc. and Linda Rubinstein, dated as of August 3, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.15B(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828023009899/advm-20221231xexx10lgxadve.htm">Confidential Consulting Agreement between Adverum Biotechnologies, Inc. and FLG Partners, LLC, dated as of November 22, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.16(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828023028851/advm-20230630ex103.htm">Separation Agreement and General Release of Claims between Adverum Biotechnologies, Inc. and Richard Beckman, M.D., dated as of May 24, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312523142114/d494076dex11.htm">Sales </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312523142114/d494076dex11.htm">Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312523142114/d494076dex11.htm">, dated May 11, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312523142114/d494076dex11.htm">, by and between Ad</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312523142114/d494076dex11.htm">verum Biotechnologies, Inc. and Cowen and Company, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20231231xexx211.htm">List of subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20231231xexx231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_232">Power of Attorney (included on signature page hereto)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20231231xexx311.htm">Certification of Principal Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20231231xexx312.htm">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20231231xexx321.htm">Certification of Principal Executive Officer pursuant to 18&#160;U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20231231xexx322.htm">Certification of Principal Financial and Accounting Officer pursuant to 18&#160;U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20231231xexx971.htm">Incentive Compensation Recoupment Policy.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page of the Company's Annual Report on Form 10-K has been formatted in Inline XBRL.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification attached to this Annual Report on Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Adverum Biotechnologies, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.</span></div><div style="padding-left:54pt"><span><br/></span></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_229"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><div id="iee15d89dd75f4b25b706a37b8daeb24a_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee15d89dd75f4b25b706a37b8daeb24a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date: March&#160;18, 2024 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.152%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADVERUM BIOTECHNOLOGIES, INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Laurent Fischer, M.D.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Linda Rubinstein</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Linda Rubinstein</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power of Attorney</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each person whose individual signature appears below hereby authorizes and appoints Laurent Fischer and Linda Rubinstein, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form&#160;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this annual report on Form&#160;10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Linda Rubinstein</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Linda Rubinstein</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Patrick Machado</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patrick Machado</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Soo Hong</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soo Hong</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Mark Lupher</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mark Lupher, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ C. David Nicholson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">C. David Nicholson, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Rabia Gurses Ozden</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rabia Gurses Ozden, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ James Scopa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">James Scopa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Dawn Svoronos</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dawn Svoronos</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Reed Tuckson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reed Tuckson, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Scott Whitcup</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scott Whitcup, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>advm-20231231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i002c7cf2980047eea50d9c8952aa843c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBSIDIARIES OF ADVERUM BIOTECHNOLOGIES, INC.</font></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Country of Incorporation</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avalanche Australia PTY LTD</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annapurna Therapeutics, LTD</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adverum NC, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina, USA</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>advm-20231231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5f91f772aa154b53a9ba747a8f994a5e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit  23.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statements (Form S-3 Nos. 333-271431 and 333-277634) of Adverum Biotechnologies, Inc.</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-199296) pertaining to the Amended and Restated 2016 Equity Incentive Plan, as amended, the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-203398) pertaining to the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-211439) pertaining to the 2014 Equity Incentive Award Plan, the 2014 Employee Stock Purchase Plan, and the Inducement Stock Option Awards,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-218465) pertaining to the 2014 Equity Incentive Award Plan, the 2014 Employee Stock Purchase Plan, and the Inducement Restricted Stock Unit and Stock Option Awards,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-220894) pertaining to the 2017 Inducement Plan and Inducement Stock Option Awards,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-223894) pertaining to the 2014 Equity Incentive Award Plan, the 2014 Employee Stock Purchase Plan, and the Inducement Restricted Stock Unit Awards,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-230138) pertaining to the 2014 Equity Incentive Award Plan, as amended and restated, the 2014 Employee Stock Purchase Plan, as amended and restated, and the 2017 Inducement Plan, as amended and restated,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">Registration Statement (Form S-8 No. 333-233135) pertaining to the 2017 Inducement Plan, as amended and restated,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.22pt">Registration Statement (Form S-8 No. 333-237136) pertaining to the 2014 Equity Incentive Award Plan, as amended and restated, and the 2014 Employee Stock Purchase Plan, as amended and restated,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.22pt">Registration Statement (Form S-8 No. 333-243761) pertaining to the 2017 Inducement Plan, as amended and restated,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.22pt">Registration Statement (Form S-8 No. 333-253727) pertaining to the 2014 Equity Incentive Award Plan, as amended and restated, the 2014 Employee Stock Purchase Plan, as amended and restated, and the 2017 Inducement Plan, as amended and restated,</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.22pt">Registration Statement (Form S-8 Nos. 333-263954 and 333271001) pertaining to the 2014 Equity Incentive Award Plan, as amended and restated, and</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.22pt">Registration Statement (Form S-8 No. 333-266794) pertaining to the Amended and Restated 2014 Employee Stock Purchase Plan&#59;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our report dated March 18, 2024, with respect to the consolidated financial statements of Adverum Biotechnologies Inc. included in this Annual Report (Form 10-K) of Adverum Biotechnologies Inc. for the year ended December 31, 2023.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">San Francisco, California </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 18, 2024</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>advm-20231231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id94d18e040854890a7dfd3e01cb6b9ae_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Laurent Fischer, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this Form 10-K of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;18, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>advm-20231231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibee8e20e6cab4d9b9bf73341297ae8a2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Linda Rubinstein, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this Form 10-K of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;18, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Linda Rubinstein</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>advm-20231231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if6b53dda902f4f3b81fc3d909db505c9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Adverum Biotechnologies, Inc. for the year ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Laurent Fischer, as President and Chief Executive Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;18, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>advm-20231231xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibbc52330d06c49e8864a2b788569c3a0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Adverum Biotechnologies, Inc. for the year ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Linda Rubinstein, as Chief Financial Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:4.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;18, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Linda Rubinstein</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Rubinstein<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>advm-20231231xexx971.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4b52893935a644e0b8c067363becea80_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 97.1</font></div></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADVERUM BIOTECHNOLOGIES, INC.</font></div><div style="margin-bottom:18pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INCENTIVE COMPENSATION RECOUPMENT POLICY</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">INTRODUCTION</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Compensation Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of the Board of Directors (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Adverum Biotechnologies, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) providing for the Company&#8217;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Rule 10D-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Nasdaq Listing Rule 5608 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Listing Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">EFFECTIVE DATE</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Incentive Compensation is deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; in the Company&#8217;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">DEFINITIONS</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Accounting Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Compensation Committee or, in the absence of such committee, the Board.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Covered Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each current and former Executive Officer.</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Nasdaq Stock Market.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#8217;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). A measure need not be presented in the Company&#8217;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. </font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Lookback Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date. </font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recoverable Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, on a gross basis without regarding to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This documentation must be affirmatively provided to the Exchange.</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">RECOUPMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.18pt">Applicability of Policy. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period.     </font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.57pt">Recoupment Generally.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#8217;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.  </font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.8pt">Impracticability of Recovery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Recoupment may be determined to be impracticable if, and only if&#58;</font></div><div style="margin-bottom:11pt;margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation&#59; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or</font></div><div style="margin-bottom:11pt;margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.57pt">Sources of Recoupment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date&#58; (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer&#59; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid)&#59; (iii) cancelling or offsetting against any planned future cash or equity-based awards&#59; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A&#59; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Policy includes as an attachment a form of acknowledgment that executive officers can sign to facilitate recoupment. The acknowledgment is not required by Rule 10D-1 or the Listing Standards, but is recommended in all (and may be required by some) jurisdictions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This documentation must be affirmatively provided to the Exchange.</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.8pt">No Indemnification of Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#8217;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:25.02pt">Indemnification of Administrator.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.18pt">No &#8220;Good Reason&#8221; for Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#8220;good reason&#8221; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">ADMINISTRATION</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy.  Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#8217;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">SEVERABILITY</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">NO IMPAIRMENT OF OTHER REMEDIES</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#8217;s obligations to the Company, including, without limitation, termination of employment and&#47;or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SOX 304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that are applicable to the Company&#8217;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and&#47;or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time&#59; provided, however, that compensation recouped pursuant to this policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and&#47;or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">AMENDMENT&#59; TERMINATION</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">SUCCESSORS</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and&#47;or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;REQUIRED FILINGS</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><div id="i4b52893935a644e0b8c067363becea80_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADVERUM BIOTECHNOLOGIES, INC.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INCENTIVE COMPENSATION RECOUPMENT POLICY</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FORM OF EXECUTIVE ACKNOWLEDGMENT</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I, the undersigned, agree and acknowledge that I am bound by, and subject to, the Adverum Biotechnologies, Inc. Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with Adverum Biotechnologies, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and&#47;or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreed and Acknowledged&#58;</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>advm-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0eb1737c-384e-4b48-8e56-f7ff90dff097,g:c0462913-63e1-4ed5-8ab4-52645bec5fa8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.adverum.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.adverum.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.adverum.com/role/DescriptionoftheBusiness">
        <link:definition>0000008 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstruments" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments">
        <link:definition>0000010 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.adverum.com/role/Revenue">
        <link:definition>0000011 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.adverum.com/role/Leases">
        <link:definition>0000012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.adverum.com/role/BalanceSheetComponents">
        <link:definition>0000013 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.adverum.com/role/CommitmentsandContingencies">
        <link:definition>0000014 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlans" roleURI="http://www.adverum.com/role/StockPlans">
        <link:definition>0000015 - Disclosure - Stock Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kSavingsPlan" roleURI="http://www.adverum.com/role/A401kSavingsPlan">
        <link:definition>0000016 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.adverum.com/role/Restructuring">
        <link:definition>0000017 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.adverum.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.adverum.com/role/NetLossperShare">
        <link:definition>0000019 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.adverum.com/role/SubsequentEvents">
        <link:definition>0000020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsTables" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables">
        <link:definition>9954472 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.adverum.com/role/LeasesTables">
        <link:definition>9954473 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables">
        <link:definition>9954474 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansTables" roleURI="http://www.adverum.com/role/StockPlansTables">
        <link:definition>9954475 - Disclosure - Stock Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.adverum.com/role/RestructuringTables">
        <link:definition>9954476 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.adverum.com/role/IncomeTaxesTables">
        <link:definition>9954477 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.adverum.com/role/NetLossperShareTables">
        <link:definition>9954478 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsTables" roleURI="http://www.adverum.com/role/SubsequentEventsTables">
        <link:definition>9954479 - Disclosure - Subsequent Events (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofthebusinessAdditionalInformationDetails" roleURI="http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails">
        <link:definition>9954480 - Disclosure - Description of the business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954481 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails">
        <link:definition>9954482 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>9954483 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDetails" roleURI="http://www.adverum.com/role/RevenueDetails">
        <link:definition>9954484 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9954485 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails" roleURI="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails">
        <link:definition>9954486 - Disclosure - Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
        <link:definition>9954487 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9954488 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.adverum.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954489 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansAdditionalInformationDetails" roleURI="http://www.adverum.com/role/StockPlansAdditionalInformationDetails">
        <link:definition>9954490 - Disclosure - Stock Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansScheduleofStockOptionsActivityDetails" roleURI="http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails">
        <link:definition>9954491 - Disclosure - Stock Plans - Schedule of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails" roleURI="http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails">
        <link:definition>9954492 - Disclosure - Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansScheduleofRestrictedStockUnitsActivityDetails" roleURI="http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails">
        <link:definition>9954493 - Disclosure - Stock Plans - Schedule of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9954494 - Disclosure - Stock Plans - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kSavingsPlanDetails" roleURI="http://www.adverum.com/role/A401kSavingsPlanDetails">
        <link:definition>9954495 - Disclosure - 401(k) Savings Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringAdditionalinformationDetails" roleURI="http://www.adverum.com/role/RestructuringAdditionalinformationDetails">
        <link:definition>9954496 - Disclosure - Restructuring - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringCostsDetails" roleURI="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails">
        <link:definition>9954497 - Disclosure - Restructuring - Schedule of Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails">
        <link:definition>9954498 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails">
        <link:definition>9954499 - Disclosure - Income Taxes- Schedule of Components of Income Tax (Benefit) Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails">
        <link:definition>9954500 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails">
        <link:definition>9954501 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9954502 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>9954503 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareDetails" roleURI="http://www.adverum.com/role/NetLossperShareDetails">
        <link:definition>9954504 - Disclosure - Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetails" roleURI="http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails">
        <link:definition>9954505 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails" roleURI="http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails">
        <link:definition>9954506 - Disclosure - Subsequent Events - Schedule of Unaudited Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="advm_CashAndCashEquivalentAmortizedCost" abstract="false" name="CashAndCashEquivalentAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseNumberOfLeasedFacilities" abstract="false" name="LesseeOperatingLeaseNumberOfLeasedFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="advm_LicenseAgreementsMilestonesAchieved" abstract="false" name="LicenseAgreementsMilestonesAchieved" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="advm_TwoDirectorsMember" abstract="true" name="TwoDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" abstract="true" name="IncentiveStockOptionsAndNonQualifiedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="advm_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="advm_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" abstract="false" name="LesseeOperatingLeaseLeaseholdImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseNumberOfRenewalContracts" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="advm_TwoThousandSeventeenInducementPlanMember" abstract="true" name="TwoThousandSeventeenInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedLoss" abstract="false" name="CashAndCashEquivalentGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedInterestReceivablePolicyTextBlock" abstract="false" name="AccruedInterestReceivablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="advm_PazyukV.MachadoEtAl.C.A.Member" abstract="true" name="PazyukV.MachadoEtAl.C.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_DeferredTaxAssetsCapitalizedCosts" abstract="false" name="DeferredTaxAssetsCapitalizedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_LexeoTherapeuticsIncMember" abstract="true" name="LexeoTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="advm_SecuritiesPurchaseAgreementNumberOfDirectors" abstract="false" name="SecuritiesPurchaseAgreementNumberOfDirectors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="advm_TwoThousandFourteenPlanAndInducementPlanMember" abstract="true" name="TwoThousandFourteenPlanAndInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="advm_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="advm_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="advm_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" abstract="false" name="IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" abstract="false" name="ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated" abstract="false" name="LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedGain" abstract="false" name="CashAndCashEquivalentGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashEquivalentsAndShortTermInvestmentsMember" abstract="true" name="CashEquivalentsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="advm_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" abstract="false" name="OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="advm_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" abstract="false" name="ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="advm_DeferredTaxAssetsLeaseObligation" abstract="false" name="DeferredTaxAssetsLeaseObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_TwoThousandAndFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="advm_SubleaseIncomeNet" abstract="false" name="SubleaseIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent" abstract="false" name="AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>advm-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0eb1737c-384e-4b48-8e56-f7ff90dff097,g:c0462913-63e1-4ed5-8ab4-52645bec5fa8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="advm-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_74137949-6902-4248-950d-8ffde0b11a71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_029d0634-8243-4082-aec6-9b4318f475ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_74137949-6902-4248-950d-8ffde0b11a71" xlink:to="loc_us-gaap_LiabilitiesCurrent_029d0634-8243-4082-aec6-9b4318f475ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_18df58b3-3eb9-4d8b-96fd-aa64a9abb8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_74137949-6902-4248-950d-8ffde0b11a71" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_18df58b3-3eb9-4d8b-96fd-aa64a9abb8a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bc97162b-7ca4-4456-9e1e-b9f4472dc5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_74137949-6902-4248-950d-8ffde0b11a71" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bc97162b-7ca4-4456-9e1e-b9f4472dc5b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_99c819f9-a268-445f-8dab-5d39e8e4f25d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f737f8c5-4cfd-43d4-aeba-90d341971198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_99c819f9-a268-445f-8dab-5d39e8e4f25d" xlink:to="loc_us-gaap_AccountsPayableCurrent_f737f8c5-4cfd-43d4-aeba-90d341971198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_7b409ea7-f39f-4ae3-ad62-73254ea78374" xlink:href="advm-20231231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_99c819f9-a268-445f-8dab-5d39e8e4f25d" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_7b409ea7-f39f-4ae3-ad62-73254ea78374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f431e49a-b42a-4c40-9c0b-ba2e9e5db737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_99c819f9-a268-445f-8dab-5d39e8e4f25d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f431e49a-b42a-4c40-9c0b-ba2e9e5db737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8b053418-8472-4e2d-b9d2-5b33d8cc0a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b35aff1c-f575-4e2f-bd42-ba825b19c8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8b053418-8472-4e2d-b9d2-5b33d8cc0a87" xlink:to="loc_us-gaap_AssetsCurrent_b35aff1c-f575-4e2f-bd42-ba825b19c8c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_17ef2f87-f1b2-4387-ad18-28f23f07360c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8b053418-8472-4e2d-b9d2-5b33d8cc0a87" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_17ef2f87-f1b2-4387-ad18-28f23f07360c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1b981a3c-b638-40f7-b8da-cd0692cd4b22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8b053418-8472-4e2d-b9d2-5b33d8cc0a87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1b981a3c-b638-40f7-b8da-cd0692cd4b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5f109351-87e2-46e2-9e35-a1f22be1c523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8b053418-8472-4e2d-b9d2-5b33d8cc0a87" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5f109351-87e2-46e2-9e35-a1f22be1c523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ad09e48c-a068-4211-b496-9b7206bb353a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8b053418-8472-4e2d-b9d2-5b33d8cc0a87" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ad09e48c-a068-4211-b496-9b7206bb353a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f114bb58-0888-4404-9e69-f122548147a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84c2338c-3cc1-4487-a143-9098a340fda7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f114bb58-0888-4404-9e69-f122548147a0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84c2338c-3cc1-4487-a143-9098a340fda7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_1dbcd666-66a0-4df6-9629-962100478b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f114bb58-0888-4404-9e69-f122548147a0" xlink:to="loc_us-gaap_ShortTermInvestments_1dbcd666-66a0-4df6-9629-962100478b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a263fe7a-5dcc-4f10-a10d-4e30cd0b7f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f114bb58-0888-4404-9e69-f122548147a0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a263fe7a-5dcc-4f10-a10d-4e30cd0b7f77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a725e69-33e0-4aeb-ae3f-d084fa161d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fdb3843c-d25d-48a8-b4d5-66ebbd91304b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a725e69-33e0-4aeb-ae3f-d084fa161d32" xlink:to="loc_us-gaap_Liabilities_fdb3843c-d25d-48a8-b4d5-66ebbd91304b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4c72ea1-a88b-4f51-a54c-428ca5c0442a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a725e69-33e0-4aeb-ae3f-d084fa161d32" xlink:to="loc_us-gaap_StockholdersEquity_b4c72ea1-a88b-4f51-a54c-428ca5c0442a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_dc5b2b14-a286-47b7-87bc-783d26b9399f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a725e69-33e0-4aeb-ae3f-d084fa161d32" xlink:to="loc_us-gaap_CommitmentsAndContingencies_dc5b2b14-a286-47b7-87bc-783d26b9399f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1b25243c-f3a0-4607-91e5-3276fed5701b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ee5e7a1e-47f3-4545-a13e-a9defbff2428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1b25243c-f3a0-4607-91e5-3276fed5701b" xlink:to="loc_us-gaap_PreferredStockValue_ee5e7a1e-47f3-4545-a13e-a9defbff2428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6a8f43c9-d451-44a6-a9c1-df3e705e784e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1b25243c-f3a0-4607-91e5-3276fed5701b" xlink:to="loc_us-gaap_CommonStockValue_6a8f43c9-d451-44a6-a9c1-df3e705e784e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8dde9d62-7491-407d-91a0-fcc9b3c071d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1b25243c-f3a0-4607-91e5-3276fed5701b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8dde9d62-7491-407d-91a0-fcc9b3c071d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1c236d57-76f9-4757-ad09-0fe678faf3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1b25243c-f3a0-4607-91e5-3276fed5701b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1c236d57-76f9-4757-ad09-0fe678faf3ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2e99d9a2-86f5-4093-a229-ad5a1bd6ed50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1b25243c-f3a0-4607-91e5-3276fed5701b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2e99d9a2-86f5-4093-a229-ad5a1bd6ed50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="advm-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ce348905-1eb9-4cf3-956c-f2cbc84bc7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_21ea0458-bc9f-4ba5-9d74-098f018db1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ce348905-1eb9-4cf3-956c-f2cbc84bc7d2" xlink:to="loc_us-gaap_OperatingIncomeLoss_21ea0458-bc9f-4ba5-9d74-098f018db1e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bd13d075-7be1-4aaa-948e-000279592328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ce348905-1eb9-4cf3-956c-f2cbc84bc7d2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bd13d075-7be1-4aaa-948e-000279592328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1116dec6-1edd-4c74-aa28-69e96a6f0b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ecf7396c-5f05-47ec-bcf4-c9f581be9743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1116dec6-1edd-4c74-aa28-69e96a6f0b23" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ecf7396c-5f05-47ec-bcf4-c9f581be9743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5d0295fc-d0e2-4bd2-945b-a653f72f808c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1116dec6-1edd-4c74-aa28-69e96a6f0b23" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5d0295fc-d0e2-4bd2-945b-a653f72f808c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a6b0ff90-235d-490a-a387-89c7d8908c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1739ce06-a474-49e9-b592-231c58b88150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a6b0ff90-235d-490a-a387-89c7d8908c39" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1739ce06-a474-49e9-b592-231c58b88150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5d6dd650-0353-466b-9534-ae417e7150a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a6b0ff90-235d-490a-a387-89c7d8908c39" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5d6dd650-0353-466b-9534-ae417e7150a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b0d1ab56-ff29-4a06-8008-f10fe55844ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_103eadcc-32af-46a7-8b7b-4eccc5a7c7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b0d1ab56-ff29-4a06-8008-f10fe55844ff" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_103eadcc-32af-46a7-8b7b-4eccc5a7c7ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dfba40aa-4acb-4bb4-adaf-85955f6b42f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b0d1ab56-ff29-4a06-8008-f10fe55844ff" xlink:to="loc_us-gaap_OperatingExpenses_dfba40aa-4acb-4bb4-adaf-85955f6b42f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2c332b05-6d0a-4633-bc10-8fc1e46bfc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e5f4bc26-c725-4ad2-a99b-af9d9424b900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2c332b05-6d0a-4633-bc10-8fc1e46bfc1a" xlink:to="loc_us-gaap_NetIncomeLoss_e5f4bc26-c725-4ad2-a99b-af9d9424b900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9bbdd630-4441-4c14-b5a5-503affb94bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2c332b05-6d0a-4633-bc10-8fc1e46bfc1a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9bbdd630-4441-4c14-b5a5-503affb94bc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_d6ce7097-efb0-426e-af46-c90fec0f8f99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2c332b05-6d0a-4633-bc10-8fc1e46bfc1a" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_d6ce7097-efb0-426e-af46-c90fec0f8f99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="advm-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6e99e178-1bc9-4d06-8937-440e2152eedc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64e81d4a-4b7c-4f22-86a8-d60f730c0dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6e99e178-1bc9-4d06-8937-440e2152eedc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64e81d4a-4b7c-4f22-86a8-d60f730c0dcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_feb1999f-fafc-4885-a2bf-7aec2abbd848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6e99e178-1bc9-4d06-8937-440e2152eedc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_feb1999f-fafc-4885-a2bf-7aec2abbd848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_595c0906-60b0-4e10-97c1-d4afc279a459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6e99e178-1bc9-4d06-8937-440e2152eedc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_595c0906-60b0-4e10-97c1-d4afc279a459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2cc7414b-bbdb-47f9-9d17-0a8b5100843b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c112e392-13ce-41b1-952d-0569d11887e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2cc7414b-bbdb-47f9-9d17-0a8b5100843b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c112e392-13ce-41b1-952d-0569d11887e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c311cc3b-0430-4ae5-adb2-458fa7a88696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2cc7414b-bbdb-47f9-9d17-0a8b5100843b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c311cc3b-0430-4ae5-adb2-458fa7a88696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4d4e24d0-35e0-4e77-8fff-19e88c8df3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2cc7414b-bbdb-47f9-9d17-0a8b5100843b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4d4e24d0-35e0-4e77-8fff-19e88c8df3d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89655a8d-e705-4443-9a20-c80e2463367e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9f0dd38e-1864-48e0-a215-9871bcc2e842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89655a8d-e705-4443-9a20-c80e2463367e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9f0dd38e-1864-48e0-a215-9871bcc2e842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f2672ae-32b3-46d1-9d8a-ce37bfdf567a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89655a8d-e705-4443-9a20-c80e2463367e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f2672ae-32b3-46d1-9d8a-ce37bfdf567a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_c334d914-6a2c-4bb9-98cb-19309d20fe06" xlink:href="advm-20231231.xsd#advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_c334d914-6a2c-4bb9-98cb-19309d20fe06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_dd5eec7b-0068-41ae-b763-449422109c41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_AssetImpairmentCharges_dd5eec7b-0068-41ae-b763-449422109c41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3e98c2a9-1595-436e-be73-a6a335ce080f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3e98c2a9-1595-436e-be73-a6a335ce080f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3b1f38f0-356c-4474-a2a2-c2a260531156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3b1f38f0-356c-4474-a2a2-c2a260531156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_37877c74-9fa5-4ed4-b9f2-9b35b9597edd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_DepreciationAndAmortization_37877c74-9fa5-4ed4-b9f2-9b35b9597edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a4626a29-4636-4617-bf22-4e8179f5f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a4626a29-4636-4617-bf22-4e8179f5f1df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_664901f8-c6dd-4644-b580-017e994e55b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_664901f8-c6dd-4644-b580-017e994e55b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_35cc1397-c8b4-4a86-b581-8883f10716be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_35cc1397-c8b4-4a86-b581-8883f10716be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e364578c-4125-4d3f-a8cc-2a220667a46e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_ShareBasedCompensation_e364578c-4125-4d3f-a8cc-2a220667a46e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_494cffa5-2ecf-49dd-a85c-24087cae221b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_494cffa5-2ecf-49dd-a85c-24087cae221b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a2a28910-a86c-41db-a3a6-7a3bcc11440b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_NetIncomeLoss_a2a28910-a86c-41db-a3a6-7a3bcc11440b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_788683bd-258d-420b-91bf-374204e15946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_788683bd-258d-420b-91bf-374204e15946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_af205e00-665e-4682-a218-4eb2f93e3111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41ea2e86-574a-4601-bf73-8c75588ea88b" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_af205e00-665e-4682-a218-4eb2f93e3111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7a2913b-040e-4824-a95c-9a429d1180df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_18811224-04ba-4248-9245-8c1a086f7a92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7a2913b-040e-4824-a95c-9a429d1180df" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_18811224-04ba-4248-9245-8c1a086f7a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_7448e4f7-9523-4a9a-9fc0-a2492086d339" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7a2913b-040e-4824-a95c-9a429d1180df" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_7448e4f7-9523-4a9a-9fc0-a2492086d339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_00ff52ab-e0a6-40d1-a037-df9786779347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7a2913b-040e-4824-a95c-9a429d1180df" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_00ff52ab-e0a6-40d1-a037-df9786779347" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_30f494e8-71d5-4b7a-b692-2404c46b9e72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_630c1b86-baf0-42e4-b6bb-76df816499c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_30f494e8-71d5-4b7a-b692-2404c46b9e72" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_630c1b86-baf0-42e4-b6bb-76df816499c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9b9c1cff-d237-40ad-b99d-6788c52c4ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_30f494e8-71d5-4b7a-b692-2404c46b9e72" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9b9c1cff-d237-40ad-b99d-6788c52c4ce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_379605ff-2266-47b1-b78a-0027b1fd5254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_30f494e8-71d5-4b7a-b692-2404c46b9e72" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_379605ff-2266-47b1-b78a-0027b1fd5254" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f19c79-be01-4f6d-99a4-dbecade3cd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f4d2148d-d197-484b-bd09-0110b2163e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f19c79-be01-4f6d-99a4-dbecade3cd0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f4d2148d-d197-484b-bd09-0110b2163e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bc813af4-3b29-415d-9dd8-42c095f44bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f19c79-be01-4f6d-99a4-dbecade3cd0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bc813af4-3b29-415d-9dd8-42c095f44bb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ad5dd6ab-99db-41e6-bcfd-a5c5952250d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f19c79-be01-4f6d-99a4-dbecade3cd0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ad5dd6ab-99db-41e6-bcfd-a5c5952250d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0fb92cc5-f6c9-4f45-9171-8581bd135408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f19c79-be01-4f6d-99a4-dbecade3cd0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0fb92cc5-f6c9-4f45-9171-8581bd135408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f0a40374-8108-4e48-a5aa-dada197a730e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f19c79-be01-4f6d-99a4-dbecade3cd0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f0a40374-8108-4e48-a5aa-dada197a730e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dacc3c60-89db-4193-a103-beb5d580cf39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_20f19c79-be01-4f6d-99a4-dbecade3cd0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dacc3c60-89db-4193-a103-beb5d580cf39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_f62594d8-36cf-4c73-8985-73d69d51080f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_6ec22a96-0e3b-4232-9395-89eeebf94a55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_f62594d8-36cf-4c73-8985-73d69d51080f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_6ec22a96-0e3b-4232-9395-89eeebf94a55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_763fa227-dce4-462f-9726-7e0ca10ba3de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_f62594d8-36cf-4c73-8985-73d69d51080f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_763fa227-dce4-462f-9726-7e0ca10ba3de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_1e6b79f9-794d-4405-8954-96f6c3331980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_f62594d8-36cf-4c73-8985-73d69d51080f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_1e6b79f9-794d-4405-8954-96f6c3331980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_02a39200-ed71-495c-a701-b0ec28fcb062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_f62594d8-36cf-4c73-8985-73d69d51080f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_02a39200-ed71-495c-a701-b0ec28fcb062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_96c13fc6-3cca-4501-b989-cd47e3c26c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_f62594d8-36cf-4c73-8985-73d69d51080f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_96c13fc6-3cca-4501-b989-cd47e3c26c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_f93c1525-d6ad-4edc-9a51-b2c0998eb449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_f62594d8-36cf-4c73-8985-73d69d51080f" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_f93c1525-d6ad-4edc-9a51-b2c0998eb449" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_33503c49-a9fb-40da-a55a-3670a87a4e54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_15444d7f-8468-4264-9ff1-035f3fdc5cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_33503c49-a9fb-40da-a55a-3670a87a4e54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_15444d7f-8468-4264-9ff1-035f3fdc5cf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f626cf1-f339-4152-b6b0-064857db9d65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_33503c49-a9fb-40da-a55a-3670a87a4e54" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f626cf1-f339-4152-b6b0-064857db9d65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_72d77a12-e047-4afe-9dd5-549bad29f12c" xlink:href="advm-20231231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c1dc8ee3-8a0b-404e-9fea-2bd4d46477f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_72d77a12-e047-4afe-9dd5-549bad29f12c" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c1dc8ee3-8a0b-404e-9fea-2bd4d46477f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_a0163e0e-5dda-479c-86e8-5c78c74cd43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_72d77a12-e047-4afe-9dd5-549bad29f12c" xlink:to="loc_us-gaap_TaxesPayableCurrent_a0163e0e-5dda-479c-86e8-5c78c74cd43c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_14e81f47-ae07-43c0-b796-d3dd58909575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_72d77a12-e047-4afe-9dd5-549bad29f12c" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_14e81f47-ae07-43c0-b796-d3dd58909575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent_dd994651-df63-4e0d-948e-895f450e017c" xlink:href="advm-20231231.xsd#advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_72d77a12-e047-4afe-9dd5-549bad29f12c" xlink:to="loc_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent_dd994651-df63-4e0d-948e-895f450e017c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ccdc3ee6-a5a0-4cdb-ba49-9c416dae2998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_72d77a12-e047-4afe-9dd5-549bad29f12c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ccdc3ee6-a5a0-4cdb-ba49-9c416dae2998" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0cbc024f-5128-4114-b1c2-9987574482a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ed27104b-ee8e-4d88-9d4b-d15924888fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0cbc024f-5128-4114-b1c2-9987574482a3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ed27104b-ee8e-4d88-9d4b-d15924888fec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_663b477d-7f57-4c56-be17-502beb263250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0cbc024f-5128-4114-b1c2-9987574482a3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_663b477d-7f57-4c56-be17-502beb263250" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6f936330-6e55-42ea-b602-c91a1b063a52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_99ae0bdd-a778-4016-803e-630aede3f190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6f936330-6e55-42ea-b602-c91a1b063a52" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_99ae0bdd-a778-4016-803e-630aede3f190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b4a0d848-642f-4acd-ae4e-793bd811dedc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_daf18e5c-ef1a-4860-bc17-ae0c895d746b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b4a0d848-642f-4acd-ae4e-793bd811dedc" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_daf18e5c-ef1a-4860-bc17-ae0c895d746b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e84e39d9-2f6c-4f8f-9dc8-19ce80ba5ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c3f5710d-0c4e-43b7-b28f-acd1be9c3d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e84e39d9-2f6c-4f8f-9dc8-19ce80ba5ba5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c3f5710d-0c4e-43b7-b28f-acd1be9c3d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ffbd8c5e-3d05-4487-96fd-3e1b8f9e9bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e84e39d9-2f6c-4f8f-9dc8-19ce80ba5ba5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ffbd8c5e-3d05-4487-96fd-3e1b8f9e9bf1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7b52e637-8f8c-47c6-a283-e46fc5f67266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2f189407-78d9-4ff0-b11d-64291da2ec48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7b52e637-8f8c-47c6-a283-e46fc5f67266" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2f189407-78d9-4ff0-b11d-64291da2ec48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_613d3dd4-441e-4b65-8a3b-ee0e33edaaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7b52e637-8f8c-47c6-a283-e46fc5f67266" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_613d3dd4-441e-4b65-8a3b-ee0e33edaaa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_249f9ff4-6e1a-498d-ba73-5961f53933c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7b52e637-8f8c-47c6-a283-e46fc5f67266" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_249f9ff4-6e1a-498d-ba73-5961f53933c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_50ce6297-495c-4fdf-b6a6-d764f7ce194c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7b52e637-8f8c-47c6-a283-e46fc5f67266" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_50ce6297-495c-4fdf-b6a6-d764f7ce194c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6ebda56a-daf7-400e-9af9-acf314b25b65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7b52e637-8f8c-47c6-a283-e46fc5f67266" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6ebda56a-daf7-400e-9af9-acf314b25b65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3706263b-c4ec-45ff-a274-277b7a4b0293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7b52e637-8f8c-47c6-a283-e46fc5f67266" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3706263b-c4ec-45ff-a274-277b7a4b0293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b59b4b0f-4e19-4bac-96ee-5654f877c08c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7b52e637-8f8c-47c6-a283-e46fc5f67266" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b59b4b0f-4e19-4bac-96ee-5654f877c08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_09bf3f47-68ab-466e-8504-3dbb4784c6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7b52e637-8f8c-47c6-a283-e46fc5f67266" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_09bf3f47-68ab-466e-8504-3dbb4784c6ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition_13efe523-e5bf-4e8b-93c1-f6ef13811556" xlink:href="advm-20231231.xsd#advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7b52e637-8f8c-47c6-a283-e46fc5f67266" xlink:to="loc_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition_13efe523-e5bf-4e8b-93c1-f6ef13811556" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5476748d-ab1c-4de2-8270-3c49052a2a71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_661566bb-5905-4702-b2aa-e4e8608a5494" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_5476748d-ab1c-4de2-8270-3c49052a2a71" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_661566bb-5905-4702-b2aa-e4e8608a5494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f52b219b-302a-4590-804b-cb27bb5bb0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_5476748d-ab1c-4de2-8270-3c49052a2a71" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f52b219b-302a-4590-804b-cb27bb5bb0f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_288bafe2-6299-4a6d-93a3-8c1bbabaa5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4364dec0-9732-49b6-a25f-7e35dd2e5f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_288bafe2-6299-4a6d-93a3-8c1bbabaa5c3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4364dec0-9732-49b6-a25f-7e35dd2e5f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_807fcbe8-839e-499a-9c75-a7b4a3224710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_288bafe2-6299-4a6d-93a3-8c1bbabaa5c3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_807fcbe8-839e-499a-9c75-a7b4a3224710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a1ef0253-38c9-4af4-a07e-c5f18cd89da5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_288bafe2-6299-4a6d-93a3-8c1bbabaa5c3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a1ef0253-38c9-4af4-a07e-c5f18cd89da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f24ff0d7-5340-4629-b6a9-3753cf9c3348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_288bafe2-6299-4a6d-93a3-8c1bbabaa5c3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f24ff0d7-5340-4629-b6a9-3753cf9c3348" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_61f88fef-a047-4593-8cc2-c77a50802bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_288bafe2-6299-4a6d-93a3-8c1bbabaa5c3" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_61f88fef-a047-4593-8cc2-c77a50802bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_97190aa0-73f2-4272-b117-20714f5aa78e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_288bafe2-6299-4a6d-93a3-8c1bbabaa5c3" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_97190aa0-73f2-4272-b117-20714f5aa78e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsLeaseObligation_8608ca75-7a91-4f3d-8016-108a4151b5bb" xlink:href="advm-20231231.xsd#advm_DeferredTaxAssetsLeaseObligation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_288bafe2-6299-4a6d-93a3-8c1bbabaa5c3" xlink:to="loc_advm_DeferredTaxAssetsLeaseObligation_8608ca75-7a91-4f3d-8016-108a4151b5bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_d46fa6c8-eccc-43aa-94d7-8866a81e12c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_288bafe2-6299-4a6d-93a3-8c1bbabaa5c3" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_d46fa6c8-eccc-43aa-94d7-8866a81e12c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsCapitalizedCosts_a4a4f26d-3d7d-4d3a-9ab1-a8bf74833c65" xlink:href="advm-20231231.xsd#advm_DeferredTaxAssetsCapitalizedCosts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_288bafe2-6299-4a6d-93a3-8c1bbabaa5c3" xlink:to="loc_advm_DeferredTaxAssetsCapitalizedCosts_a4a4f26d-3d7d-4d3a-9ab1-a8bf74833c65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5c4108a3-37f8-45c2-88ec-ec2c7098bd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_79824da6-8f39-42db-ada1-3fdc4452a0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5c4108a3-37f8-45c2-88ec-ec2c7098bd2a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_79824da6-8f39-42db-ada1-3fdc4452a0fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4fb440f4-b0ad-446c-bb99-c5bfedd45ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5c4108a3-37f8-45c2-88ec-ec2c7098bd2a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4fb440f4-b0ad-446c-bb99-c5bfedd45ad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fce79bdb-26b7-4e28-9859-7f48c2201d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a88e9144-62fa-48e2-a576-d3e52d4edf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fce79bdb-26b7-4e28-9859-7f48c2201d9f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_a88e9144-62fa-48e2-a576-d3e52d4edf5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2c01e346-fdeb-4eb3-9784-86d5a88b73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fce79bdb-26b7-4e28-9859-7f48c2201d9f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2c01e346-fdeb-4eb3-9784-86d5a88b73d5" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>advm-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0eb1737c-384e-4b48-8e56-f7ff90dff097,g:c0462913-63e1-4ed5-8ab4-52645bec5fa8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="advm-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_62da25cf-fa76-4d75-9300-31fb0d4b0726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6d34f68a-62e1-4bec-907e-a5835d5e927b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_62da25cf-fa76-4d75-9300-31fb0d4b0726" xlink:to="loc_us-gaap_StatementTable_6d34f68a-62e1-4bec-907e-a5835d5e927b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d455b7ef-2867-4205-9ccb-e4b1f87890e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6d34f68a-62e1-4bec-907e-a5835d5e927b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d455b7ef-2867-4205-9ccb-e4b1f87890e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d455b7ef-2867-4205-9ccb-e4b1f87890e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d455b7ef-2867-4205-9ccb-e4b1f87890e1" xlink:to="loc_us-gaap_EquityComponentDomain_d455b7ef-2867-4205-9ccb-e4b1f87890e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d455b7ef-2867-4205-9ccb-e4b1f87890e1" xlink:to="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_301b395b-188a-407f-84ba-40d160610d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:to="loc_us-gaap_CommonStockMember_301b395b-188a-407f-84ba-40d160610d6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_68b0da6b-795b-4671-aa31-824d148885e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_68b0da6b-795b-4671-aa31-824d148885e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e41f46b9-1c79-40c6-b794-cdfc8f46cc74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e41f46b9-1c79-40c6-b794-cdfc8f46cc74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_826d9ac8-1298-4940-9036-18627dff9f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:to="loc_us-gaap_RetainedEarningsMember_826d9ac8-1298-4940-9036-18627dff9f87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_62da25cf-fa76-4d75-9300-31fb0d4b0726" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bf5c6796-e45e-4729-a726-0b2e32e90b19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bf5c6796-e45e-4729-a726-0b2e32e90b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a82307c-df84-4e3a-b7af-74c63fdcfb29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockholdersEquity_1a82307c-df84-4e3a-b7af-74c63fdcfb29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f8e0bd5-a051-4a95-bd2d-ca00b198c7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f8e0bd5-a051-4a95-bd2d-ca00b198c7e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49d43730-dfc3-4a87-a50b-8c0fbca40866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49d43730-dfc3-4a87-a50b-8c0fbca40866" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_33361e6a-3164-4a09-8799-30dbc2fd00e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_33361e6a-3164-4a09-8799-30dbc2fd00e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_838eb7cd-9166-4fef-96fd-cc25ac3d2825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_838eb7cd-9166-4fef-96fd-cc25ac3d2825" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_dc9d917f-ea3d-496a-996e-6b8c57f9fe53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_dc9d917f-ea3d-496a-996e-6b8c57f9fe53" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3a499549-81b5-4112-befa-307fab116d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3a499549-81b5-4112-befa-307fab116d4f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b57692bb-9556-4e51-b608-023faa3cb022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b57692bb-9556-4e51-b608-023faa3cb022" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e11d22af-c145-47f2-a852-5b6eaa2ac6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e11d22af-c145-47f2-a852-5b6eaa2ac6a2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23d98c87-3f29-4672-aff3-57a3e9c1b254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_NetIncomeLoss_23d98c87-3f29-4672-aff3-57a3e9c1b254" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9d1f9ac6-5ff6-4eac-a939-bf4270341a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc09d888-fe19-4a77-8f78-5f78751041ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:href="advm-20231231.xsd#advm_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesTable_b3b28414-0afe-4e0a-b128-87cb32506e1c" xlink:href="advm-20231231.xsd#advm_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_advm_SummaryOfSignificantAccountingPoliciesTable_b3b28414-0afe-4e0a-b128-87cb32506e1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a826882d-8ec9-403e-9c1a-2577c13cafc7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_b3b28414-0afe-4e0a-b128-87cb32506e1c" xlink:to="loc_srt_RangeAxis_a826882d-8ec9-403e-9c1a-2577c13cafc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a826882d-8ec9-403e-9c1a-2577c13cafc7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a826882d-8ec9-403e-9c1a-2577c13cafc7" xlink:to="loc_srt_RangeMember_a826882d-8ec9-403e-9c1a-2577c13cafc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_241f5b91-6827-4d50-9e3c-aa33df1ddf0a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a826882d-8ec9-403e-9c1a-2577c13cafc7" xlink:to="loc_srt_RangeMember_241f5b91-6827-4d50-9e3c-aa33df1ddf0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_75a50ed1-f046-479d-a2c9-08c46e493f62" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_241f5b91-6827-4d50-9e3c-aa33df1ddf0a" xlink:to="loc_srt_MinimumMember_75a50ed1-f046-479d-a2c9-08c46e493f62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f61ccb67-8c63-4d4f-8cc4-47f875dda688" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_241f5b91-6827-4d50-9e3c-aa33df1ddf0a" xlink:to="loc_srt_MaximumMember_f61ccb67-8c63-4d4f-8cc4-47f875dda688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_dee97f13-25d8-4859-ab90-bbb6719fb97f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_us-gaap_NumberOfReportableSegments_dee97f13-25d8-4859-ab90-bbb6719fb97f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_89fc1b59-5ffd-4166-beeb-9c4fe56fab73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_89fc1b59-5ffd-4166-beeb-9c4fe56fab73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2cad97a1-9005-48ed-8252-f9ca984aaf29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2cad97a1-9005-48ed-8252-f9ca984aaf29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_76543ca2-958e-4c6c-9013-ee725a6c0853" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_us-gaap_AssetImpairmentCharges_76543ca2-958e-4c6c-9013-ee725a6c0853" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SubleaseIncomeNet_c5f24a23-ed9c-4fd6-98c2-e4c228440551" xlink:href="advm-20231231.xsd#advm_SubleaseIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_advm_SubleaseIncomeNet_c5f24a23-ed9c-4fd6-98c2-e4c228440551" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_60795819-05a2-4c03-96ae-51a5d3c141fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_60795819-05a2-4c03-96ae-51a5d3c141fc" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_751bd618-ea5d-401c-b708-c074387b504a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_751bd618-ea5d-401c-b708-c074387b504a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_886eca1e-f361-4382-935e-37b88a723a38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_751bd618-ea5d-401c-b708-c074387b504a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_886eca1e-f361-4382-935e-37b88a723a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_886eca1e-f361-4382-935e-37b88a723a38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_886eca1e-f361-4382-935e-37b88a723a38" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_886eca1e-f361-4382-935e-37b88a723a38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3893d520-6cf0-4238-9c80-8038cc32c25d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_886eca1e-f361-4382-935e-37b88a723a38" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3893d520-6cf0-4238-9c80-8038cc32c25d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bc84a43b-a288-45dc-a982-056e2fb589f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3893d520-6cf0-4238-9c80-8038cc32c25d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bc84a43b-a288-45dc-a982-056e2fb589f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8aa4acac-65b9-423d-bc05-30bcd873d623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3893d520-6cf0-4238-9c80-8038cc32c25d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8aa4acac-65b9-423d-bc05-30bcd873d623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6a222c0c-7e78-46c1-81d6-761b6bcc1a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_751bd618-ea5d-401c-b708-c074387b504a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6a222c0c-7e78-46c1-81d6-761b6bcc1a2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a222c0c-7e78-46c1-81d6-761b6bcc1a2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a222c0c-7e78-46c1-81d6-761b6bcc1a2c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a222c0c-7e78-46c1-81d6-761b6bcc1a2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a222c0c-7e78-46c1-81d6-761b6bcc1a2c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c02cadb4-6860-46b7-a068-d61986d6d958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c02cadb4-6860-46b7-a068-d61986d6d958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_086c172d-f295-4d43-995d-1ab8e6fe5e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:to="loc_us-gaap_CommercialPaperMember_086c172d-f295-4d43-995d-1ab8e6fe5e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_86a75c8f-6d31-49f1-a105-caf15bdc11a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_86a75c8f-6d31-49f1-a105-caf15bdc11a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_fc859c66-2195-45f3-ab10-034a86134aac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_fc859c66-2195-45f3-ab10-034a86134aac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_0c779a6e-e822-4c0c-bd78-339749e77467" xlink:href="advm-20231231.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_0c779a6e-e822-4c0c-bd78-339749e77467" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b12bad2c-5d38-4714-814c-376736f7f6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b12bad2c-5d38-4714-814c-376736f7f6f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7e337b63-5a72-49a0-8d73-a7a99a64c5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7e337b63-5a72-49a0-8d73-a7a99a64c5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed1a4e8f-9638-4ed2-b344-2a25256d967c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed1a4e8f-9638-4ed2-b344-2a25256d967c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_51e4d1e0-75f8-4bab-9571-2bbdfac142d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_51e4d1e0-75f8-4bab-9571-2bbdfac142d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_23e572fb-46c4-4b77-b723-8261ca2d26b2" xlink:href="advm-20231231.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_23e572fb-46c4-4b77-b723-8261ca2d26b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_385d2418-020b-4978-8569-a5b53de35c1e" xlink:href="advm-20231231.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_385d2418-020b-4978-8569-a5b53de35c1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_b11234bd-c084-4f29-8d17-b06d4ef98882" xlink:href="advm-20231231.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_b11234bd-c084-4f29-8d17-b06d4ef98882" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b361ec58-9109-4e90-abb0-5ed14a45dd59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b361ec58-9109-4e90-abb0-5ed14a45dd59" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_78b20d28-3fc1-4c14-ad8c-9e523337edaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_78b20d28-3fc1-4c14-ad8c-9e523337edaa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d88a3011-4732-4c97-bd32-68106cc29335" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_78b20d28-3fc1-4c14-ad8c-9e523337edaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d88a3011-4732-4c97-bd32-68106cc29335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d88a3011-4732-4c97-bd32-68106cc29335_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d88a3011-4732-4c97-bd32-68106cc29335" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d88a3011-4732-4c97-bd32-68106cc29335_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dddc276c-23aa-487d-82b8-1b824bb68375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d88a3011-4732-4c97-bd32-68106cc29335" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dddc276c-23aa-487d-82b8-1b824bb68375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_57ce91ea-52bb-45e6-ac13-d2faf42ff990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dddc276c-23aa-487d-82b8-1b824bb68375" xlink:to="loc_us-gaap_EquipmentMember_57ce91ea-52bb-45e6-ac13-d2faf42ff990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_76d86266-9224-401b-95de-68ac84eff7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_76d86266-9224-401b-95de-68ac84eff7f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_4ac4df27-4c89-4671-b8b7-3ba19b1fae8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_4ac4df27-4c89-4671-b8b7-3ba19b1fae8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e011dda6-f622-424b-937a-706f21af9005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:to="loc_us-gaap_AssetImpairmentCharges_e011dda6-f622-424b-937a-706f21af9005" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_0a889508-a64a-4f67-965a-be933feb3dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_0a889508-a64a-4f67-965a-be933feb3dab" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RevenueDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#RevenueDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_40bf3bfe-4902-456e-af02-7ccb48fe5528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a3951d2c-e31a-4694-9b52-5942ef8ed55f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_40bf3bfe-4902-456e-af02-7ccb48fe5528" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a3951d2c-e31a-4694-9b52-5942ef8ed55f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bdf7ff8a-5a9a-4b34-9cae-6c754696a9f5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a3951d2c-e31a-4694-9b52-5942ef8ed55f" xlink:to="loc_srt_CounterpartyNameAxis_bdf7ff8a-5a9a-4b34-9cae-6c754696a9f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdf7ff8a-5a9a-4b34-9cae-6c754696a9f5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bdf7ff8a-5a9a-4b34-9cae-6c754696a9f5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdf7ff8a-5a9a-4b34-9cae-6c754696a9f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_badec8a3-375f-4579-adf1-60f65254f081" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bdf7ff8a-5a9a-4b34-9cae-6c754696a9f5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_badec8a3-375f-4579-adf1-60f65254f081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember_ea41d66a-f06d-4adc-b89b-11f824197a86" xlink:href="advm-20231231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_badec8a3-375f-4579-adf1-60f65254f081" xlink:to="loc_advm_LexeoTherapeuticsIncMember_ea41d66a-f06d-4adc-b89b-11f824197a86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_f7b52258-d737-4505-9dcb-046a639cb55a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_40bf3bfe-4902-456e-af02-7ccb48fe5528" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_f7b52258-d737-4505-9dcb-046a639cb55a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b1bf6e7-b88c-4af1-8425-7df66aa0f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_40bf3bfe-4902-456e-af02-7ccb48fe5528" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b1bf6e7-b88c-4af1-8425-7df66aa0f2a5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5f616824-8fa5-4dc8-8cd6-4d6db80fe57b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5f616824-8fa5-4dc8-8cd6-4d6db80fe57b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4185788-eb7d-4eaf-bfa1-cdf154d8d184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5f616824-8fa5-4dc8-8cd6-4d6db80fe57b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4185788-eb7d-4eaf-bfa1-cdf154d8d184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4185788-eb7d-4eaf-bfa1-cdf154d8d184_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4185788-eb7d-4eaf-bfa1-cdf154d8d184" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f4185788-eb7d-4eaf-bfa1-cdf154d8d184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28001a69-18b7-48cc-855a-080f87064d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4185788-eb7d-4eaf-bfa1-cdf154d8d184" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28001a69-18b7-48cc-855a-080f87064d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_cba85044-0da7-4da4-acc3-e3f0537c6ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28001a69-18b7-48cc-855a-080f87064d9e" xlink:to="loc_us-gaap_BuildingMember_cba85044-0da7-4da4-acc3-e3f0537c6ad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_4cfa2b81-1f88-4d5f-9626-12c1bfec49ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28001a69-18b7-48cc-855a-080f87064d9e" xlink:to="loc_us-gaap_ManufacturingFacilityMember_4cfa2b81-1f88-4d5f-9626-12c1bfec49ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_e68ae26a-3009-4648-8421-56b2704df31d" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseLeaseholdImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_e68ae26a-3009-4648-8421-56b2704df31d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_fb683779-c48a-4c16-8b34-3461166b84e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_fb683779-c48a-4c16-8b34-3461166b84e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_10d56a6f-1a1f-4c68-8309-b4fac70ba062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_10d56a6f-1a1f-4c68-8309-b4fac70ba062" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfLeasedFacilities_a9f0a8ad-c000-48cd-9bf2-a4d44856cb40" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseNumberOfLeasedFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfLeasedFacilities_a9f0a8ad-c000-48cd-9bf2-a4d44856cb40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated_ffc6d62b-8b56-4cdc-a51d-0176b2e1ec64" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated_ffc6d62b-8b56-4cdc-a51d-0176b2e1ec64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_53141933-30db-4f6a-a457-09ef0398d249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_53141933-30db-4f6a-a457-09ef0398d249" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_1d25a461-b230-42bd-9855-081927efd003" xlink:href="advm-20231231.xsd#advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_1d25a461-b230-42bd-9855-081927efd003" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_1ac395f4-75c7-4065-90db-f2aa09d8d709" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_1ac395f4-75c7-4065-90db-f2aa09d8d709" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities_6a9f7107-6429-4605-8424-d8eb10ca5c43" xlink:href="advm-20231231.xsd#advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities_6a9f7107-6429-4605-8424-d8eb10ca5c43" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_9a12be49-4a01-4ae4-ab08-d5aa34e6aa75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_9a12be49-4a01-4ae4-ab08-d5aa34e6aa75" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ee99ac94-5062-4854-a649-9a8ee5ca2753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ee99ac94-5062-4854-a649-9a8ee5ca2753" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8f7f16d5-a31a-4203-bc1b-eb16b47ec2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8f7f16d5-a31a-4203-bc1b-eb16b47ec2c8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a79d0bd3-6201-4f70-be9c-843dee43db3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_OperatingLeaseCost_a79d0bd3-6201-4f70-be9c-843dee43db3a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ede425eb-b708-4bf5-b3b9-83150950a4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_VariableLeaseCost_ede425eb-b708-4bf5-b3b9-83150950a4e1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_7d51fa99-f31c-4c3b-869f-82b33e281359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_OperatingLeasePayments_7d51fa99-f31c-4c3b-869f-82b33e281359" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SubleaseIncomeNet_0b0c1e51-420b-44fe-ba54-37ae3056b87d" xlink:href="advm-20231231.xsd#advm_SubleaseIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_SubleaseIncomeNet_0b0c1e51-420b-44fe-ba54-37ae3056b87d" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d512b07-f4ff-429e-a283-4ddfd3184a28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e21e51f6-d18d-4337-8709-d301c4ade380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d512b07-f4ff-429e-a283-4ddfd3184a28" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e21e51f6-d18d-4337-8709-d301c4ade380" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79f74087-6997-410f-9395-965ef1e81eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e21e51f6-d18d-4337-8709-d301c4ade380" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79f74087-6997-410f-9395-965ef1e81eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79f74087-6997-410f-9395-965ef1e81eab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79f74087-6997-410f-9395-965ef1e81eab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79f74087-6997-410f-9395-965ef1e81eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79f74087-6997-410f-9395-965ef1e81eab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d111da62-8144-41c9-a402-6b40fb440e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:to="loc_us-gaap_EquipmentMember_d111da62-8144-41c9-a402-6b40fb440e23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_881adcbf-77a0-4827-9392-811f3211be7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_881adcbf-77a0-4827-9392-811f3211be7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2aa260e1-0be1-4a0c-851a-0de044d613df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:to="loc_us-gaap_ComputerEquipmentMember_2aa260e1-0be1-4a0c-851a-0de044d613df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6ddf32a3-31f6-416f-bdaa-1248a815cd25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6ddf32a3-31f6-416f-bdaa-1248a815cd25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b26499d8-71a4-4375-a664-ef7e9b21d423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:to="loc_us-gaap_ConstructionInProgressMember_b26499d8-71a4-4375-a664-ef7e9b21d423" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d230d92b-2246-401f-acf3-973bbafad429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d512b07-f4ff-429e-a283-4ddfd3184a28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d230d92b-2246-401f-acf3-973bbafad429" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02f031ce-ea7c-4570-b0df-7e947cfa1cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d512b07-f4ff-429e-a283-4ddfd3184a28" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02f031ce-ea7c-4570-b0df-7e947cfa1cfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_378320b2-f86a-44b2-b292-a36b4431a3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d512b07-f4ff-429e-a283-4ddfd3184a28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_378320b2-f86a-44b2-b292-a36b4431a3f4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_911df08a-02ee-4919-a9ef-ac1da28ec7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_911df08a-02ee-4919-a9ef-ac1da28ec7aa" xlink:to="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3fdf7614-8590-4c4e-83d5-ba937e1b2856" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:to="loc_srt_CounterpartyNameAxis_3fdf7614-8590-4c4e-83d5-ba937e1b2856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fdf7614-8590-4c4e-83d5-ba937e1b2856_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3fdf7614-8590-4c4e-83d5-ba937e1b2856" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fdf7614-8590-4c4e-83d5-ba937e1b2856_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7549057-fd2e-4499-8454-1e675b039334" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3fdf7614-8590-4c4e-83d5-ba937e1b2856" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7549057-fd2e-4499-8454-1e675b039334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember_eba66454-4d56-425a-8839-f4efa51476ff" xlink:href="advm-20231231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7549057-fd2e-4499-8454-1e675b039334" xlink:to="loc_advm_LexeoTherapeuticsIncMember_eba66454-4d56-425a-8839-f4efa51476ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c366126d-83aa-4b94-bcfb-c1d7d9705343" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:to="loc_srt_LitigationCaseAxis_c366126d-83aa-4b94-bcfb-c1d7d9705343" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c366126d-83aa-4b94-bcfb-c1d7d9705343_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c366126d-83aa-4b94-bcfb-c1d7d9705343" xlink:to="loc_srt_LitigationCaseTypeDomain_c366126d-83aa-4b94-bcfb-c1d7d9705343_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7b1ba95e-f642-4810-8019-c003d8e5cab7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c366126d-83aa-4b94-bcfb-c1d7d9705343" xlink:to="loc_srt_LitigationCaseTypeDomain_7b1ba95e-f642-4810-8019-c003d8e5cab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_PazyukV.MachadoEtAl.C.A.Member_530313eb-9b4a-4426-9989-ffb51496cf74" xlink:href="advm-20231231.xsd#advm_PazyukV.MachadoEtAl.C.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7b1ba95e-f642-4810-8019-c003d8e5cab7" xlink:to="loc_advm_PazyukV.MachadoEtAl.C.A.Member_530313eb-9b4a-4426-9989-ffb51496cf74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_97765bad-05cf-4f80-ad45-eed37b344a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:to="loc_us-gaap_LitigationStatusAxis_97765bad-05cf-4f80-ad45-eed37b344a2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_97765bad-05cf-4f80-ad45-eed37b344a2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_97765bad-05cf-4f80-ad45-eed37b344a2c" xlink:to="loc_us-gaap_LitigationStatusDomain_97765bad-05cf-4f80-ad45-eed37b344a2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_0129b350-6b30-4cc2-bd94-3abfdc91ba52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_97765bad-05cf-4f80-ad45-eed37b344a2c" xlink:to="loc_us-gaap_LitigationStatusDomain_0129b350-6b30-4cc2-bd94-3abfdc91ba52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_608e4299-ad25-4765-86ee-1c0f6fba6e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_0129b350-6b30-4cc2-bd94-3abfdc91ba52" xlink:to="loc_us-gaap_PendingLitigationMember_608e4299-ad25-4765-86ee-1c0f6fba6e01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_979b90ca-a3d3-4cc0-a432-1af12d5e430d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_911df08a-02ee-4919-a9ef-ac1da28ec7aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_979b90ca-a3d3-4cc0-a432-1af12d5e430d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LicenseAgreementsMilestonesAchieved_8703a97e-a9d7-4b54-a8bf-a0149601cef5" xlink:href="advm-20231231.xsd#advm_LicenseAgreementsMilestonesAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_911df08a-02ee-4919-a9ef-ac1da28ec7aa" xlink:to="loc_advm_LicenseAgreementsMilestonesAchieved_8703a97e-a9d7-4b54-a8bf-a0149601cef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_f5a3a451-2918-4ea9-b137-621310941a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_911df08a-02ee-4919-a9ef-ac1da28ec7aa" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_f5a3a451-2918-4ea9-b137-621310941a4e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_28994b06-ff1c-499c-b173-ec41c6741eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:to="loc_us-gaap_PlanNameAxis_28994b06-ff1c-499c-b173-ec41c6741eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_28994b06-ff1c-499c-b173-ec41c6741eab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_28994b06-ff1c-499c-b173-ec41c6741eab" xlink:to="loc_us-gaap_PlanNameDomain_28994b06-ff1c-499c-b173-ec41c6741eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_28994b06-ff1c-499c-b173-ec41c6741eab" xlink:to="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_3fc161d9-2271-4a59-8b17-d4be9d3adc7d" xlink:href="advm-20231231.xsd#advm_TwoThousandAndFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:to="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_3fc161d9-2271-4a59-8b17-d4be9d3adc7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandSeventeenInducementPlanMember_bcfaf547-387c-4d5a-a9bd-bf2a307118a8" xlink:href="advm-20231231.xsd#advm_TwoThousandSeventeenInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:to="loc_advm_TwoThousandSeventeenInducementPlanMember_bcfaf547-387c-4d5a-a9bd-bf2a307118a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_0722b255-077a-4493-8c3f-81cbbe1bcc60" xlink:href="advm-20231231.xsd#advm_TwoThousandFourteenPlanAndInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:to="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_0722b255-077a-4493-8c3f-81cbbe1bcc60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_9114e7f5-8b13-4c8c-a299-55d1367bf47d" xlink:href="advm-20231231.xsd#advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:to="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_9114e7f5-8b13-4c8c-a299-55d1367bf47d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_98401617-2d86-46d8-9a13-da44a1c62cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:to="loc_us-gaap_AwardTypeAxis_98401617-2d86-46d8-9a13-da44a1c62cce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98401617-2d86-46d8-9a13-da44a1c62cce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_98401617-2d86-46d8-9a13-da44a1c62cce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_98401617-2d86-46d8-9a13-da44a1c62cce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_98401617-2d86-46d8-9a13-da44a1c62cce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockOptionsAndRestrictedStockUnitsMember_206ca901-599c-4c41-b637-99544cd8dba5" xlink:href="advm-20231231.xsd#advm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_advm_StockOptionsAndRestrictedStockUnitsMember_206ca901-599c-4c41-b637-99544cd8dba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_8ec4eb3a-3b71-4a9f-b69f-49dcf815cc39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_us-gaap_StockCompensationPlanMember_8ec4eb3a-3b71-4a9f-b69f-49dcf815cc39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c4f7cf64-ea76-400c-a3c0-066849504b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c4f7cf64-ea76-400c-a3c0-066849504b5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_19705c31-4882-4e1f-9ad3-d433aa455929" xlink:href="advm-20231231.xsd#advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_19705c31-4882-4e1f-9ad3-d433aa455929" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_dbe42413-0a6e-46db-9a22-436710baa526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_us-gaap_PerformanceSharesMember_dbe42413-0a6e-46db-9a22-436710baa526" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8881cf9e-2bf5-4a4c-98fc-40ad19dd6653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8881cf9e-2bf5-4a4c-98fc-40ad19dd6653" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d4f0c67-fe9c-4201-a76b-20063c3f4161" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:to="loc_srt_RangeAxis_8d4f0c67-fe9c-4201-a76b-20063c3f4161" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d4f0c67-fe9c-4201-a76b-20063c3f4161_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8d4f0c67-fe9c-4201-a76b-20063c3f4161" xlink:to="loc_srt_RangeMember_8d4f0c67-fe9c-4201-a76b-20063c3f4161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7174865f-0f29-4c55-a714-0d2e6427afaa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8d4f0c67-fe9c-4201-a76b-20063c3f4161" xlink:to="loc_srt_RangeMember_7174865f-0f29-4c55-a714-0d2e6427afaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b02ce210-5439-48eb-979f-b698644a2071" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7174865f-0f29-4c55-a714-0d2e6427afaa" xlink:to="loc_srt_MinimumMember_b02ce210-5439-48eb-979f-b698644a2071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d19196cb-2a0a-41b9-b1ca-bbaaf0473c63" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7174865f-0f29-4c55-a714-0d2e6427afaa" xlink:to="loc_srt_MaximumMember_d19196cb-2a0a-41b9-b1ca-bbaaf0473c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_a0e278c3-f868-4d4a-a90e-5c9505115efa" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_a0e278c3-f868-4d4a-a90e-5c9505115efa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_183f840e-80e9-4079-ab41-5d045f6d3289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_183f840e-80e9-4079-ab41-5d045f6d3289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_645ad348-7998-4c20-8b4c-0b9ac7306e85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_645ad348-7998-4c20-8b4c-0b9ac7306e85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f5ba25d9-1c48-4b95-96e5-513dac55c6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f5ba25d9-1c48-4b95-96e5-513dac55c6bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6aa96e43-45ab-4073-a725-09f019fa2d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6aa96e43-45ab-4073-a725-09f019fa2d83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_4005d3ff-bdd3-4755-9de6-50cf535307b0" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_4005d3ff-bdd3-4755-9de6-50cf535307b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_c5041b87-8a36-4dfb-85a2-13b354863b0e" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_c5041b87-8a36-4dfb-85a2-13b354863b0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_433e97fe-e56e-4d6c-9c7f-c3edbacc1701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_433e97fe-e56e-4d6c-9c7f-c3edbacc1701" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_01de5c9e-86d1-40f2-b9ed-880924a77879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_01de5c9e-86d1-40f2-b9ed-880924a77879" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_13244b73-93ae-4eaf-81db-4eacfd6d3d87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_13244b73-93ae-4eaf-81db-4eacfd6d3d87" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0fb711be-49ec-4c17-afa9-5ed095e6faad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0fb711be-49ec-4c17-afa9-5ed095e6faad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3a177f7e-d331-417f-b551-4e4bff2974e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3a177f7e-d331-417f-b551-4e4bff2974e3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0348f54f-02c0-4ff5-97ee-47a4fa22bb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0348f54f-02c0-4ff5-97ee-47a4fa22bb0d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_39e6bc8b-ad04-4d7b-b777-8a600aad818f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_39e6bc8b-ad04-4d7b-b777-8a600aad818f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1bce0619-d1f6-4d4a-b445-40df555d1a54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1bce0619-d1f6-4d4a-b445-40df555d1a54" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_80b131dc-8e5f-4be0-a898-a5862343610b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_80b131dc-8e5f-4be0-a898-a5862343610b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_c125cfb6-31c6-4495-a342-a0a0cc40fa6d" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_c125cfb6-31c6-4495-a342-a0a0cc40fa6d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e40b2960-5915-4024-ae95-614ed65b9fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e40b2960-5915-4024-ae95-614ed65b9fc5" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee96068-f6b8-45be-9f6b-c32ed8c6a2df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee96068-f6b8-45be-9f6b-c32ed8c6a2df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aaffa020-9938-4c7b-8a52-8cc2022bfb62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee96068-f6b8-45be-9f6b-c32ed8c6a2df" xlink:to="loc_us-gaap_AwardTypeAxis_aaffa020-9938-4c7b-8a52-8cc2022bfb62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aaffa020-9938-4c7b-8a52-8cc2022bfb62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_aaffa020-9938-4c7b-8a52-8cc2022bfb62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aaffa020-9938-4c7b-8a52-8cc2022bfb62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ada2d249-3adb-439d-adbd-89e9bd911368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_aaffa020-9938-4c7b-8a52-8cc2022bfb62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ada2d249-3adb-439d-adbd-89e9bd911368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ec662fe2-5a7f-4a8f-9ac7-a4465fb53289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ada2d249-3adb-439d-adbd-89e9bd911368" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ec662fe2-5a7f-4a8f-9ac7-a4465fb53289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b7a487df-4be9-4044-99ef-22db32a2f592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ada2d249-3adb-439d-adbd-89e9bd911368" xlink:to="loc_us-gaap_EmployeeStockMember_b7a487df-4be9-4044-99ef-22db32a2f592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_48ea91a7-22c6-4812-9ca7-7e1f29036c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_48ea91a7-22c6-4812-9ca7-7e1f29036c85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_994067ff-91aa-478a-ab2d-f248db51cdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_994067ff-91aa-478a-ab2d-f248db51cdc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b8a64a7a-09d0-4daf-b52f-d277889954f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b8a64a7a-09d0-4daf-b52f-d277889954f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dd022c26-9218-40d6-9582-3355b2014cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dd022c26-9218-40d6-9582-3355b2014cc4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlansScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33871ea-b160-4ce2-86ba-f798cb2fc979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8dfcc2ef-364d-45fe-8bdb-2223a2246dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33871ea-b160-4ce2-86ba-f798cb2fc979" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8dfcc2ef-364d-45fe-8bdb-2223a2246dbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac1ad6a5-f634-44e2-9445-fd69557911ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8dfcc2ef-364d-45fe-8bdb-2223a2246dbf" xlink:to="loc_us-gaap_AwardTypeAxis_ac1ad6a5-f634-44e2-9445-fd69557911ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac1ad6a5-f634-44e2-9445-fd69557911ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac1ad6a5-f634-44e2-9445-fd69557911ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac1ad6a5-f634-44e2-9445-fd69557911ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e77b52b1-077f-48f7-b92c-43ff67923e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac1ad6a5-f634-44e2-9445-fd69557911ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e77b52b1-077f-48f7-b92c-43ff67923e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5e2aad2c-ab9a-49b0-9a7d-50afc2e25ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e77b52b1-077f-48f7-b92c-43ff67923e0f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5e2aad2c-ab9a-49b0-9a7d-50afc2e25ba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33871ea-b160-4ce2-86ba-f798cb2fc979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_587dcf6f-2421-4209-aa3d-4449b9bb910f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_587dcf6f-2421-4209-aa3d-4449b9bb910f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_32c8beca-6bb3-475a-82e9-88260304217b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_32c8beca-6bb3-475a-82e9-88260304217b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_410d9e5e-9958-4fe4-a2ec-f18623e84581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_410d9e5e-9958-4fe4-a2ec-f18623e84581" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7ff8735f-95c1-47ab-b0e8-a061c01545d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7ff8735f-95c1-47ab-b0e8-a061c01545d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ca8bb936-aec3-4e53-ab89-47dd7ae8a013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33871ea-b160-4ce2-86ba-f798cb2fc979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0fc4fd5b-2012-40ad-9e98-76d98f1d5274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0fc4fd5b-2012-40ad-9e98-76d98f1d5274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e84c1e8-a41b-4431-9d81-b48e7d1a9848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e84c1e8-a41b-4431-9d81-b48e7d1a9848" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6655ef2a-5414-454e-963b-18ddc5d7384a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6655ef2a-5414-454e-963b-18ddc5d7384a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c7688821-8e20-4e3a-98d3-2cebcf2a985e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c7688821-8e20-4e3a-98d3-2cebcf2a985e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c61c30d0-78a2-4584-b052-0cd4a0ad726a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_88f0b414-6ab1-4734-93d8-e3240ee79024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33871ea-b160-4ce2-86ba-f798cb2fc979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_88f0b414-6ab1-4734-93d8-e3240ee79024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_364ff526-4f54-4b12-ab29-38ebc236974c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_88f0b414-6ab1-4734-93d8-e3240ee79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_364ff526-4f54-4b12-ab29-38ebc236974c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlansScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0bab9086-6606-4f9b-8100-289bde6a4aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0d863aa8-778c-4f51-b21c-806c937e5009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0bab9086-6606-4f9b-8100-289bde6a4aed" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0d863aa8-778c-4f51-b21c-806c937e5009" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_764805a4-7c59-4b47-b9c2-9af96b77b123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0d863aa8-778c-4f51-b21c-806c937e5009" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_764805a4-7c59-4b47-b9c2-9af96b77b123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_764805a4-7c59-4b47-b9c2-9af96b77b123_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_764805a4-7c59-4b47-b9c2-9af96b77b123" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_764805a4-7c59-4b47-b9c2-9af96b77b123_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_083fb8c8-488b-4176-bb55-c16f55eaf0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_764805a4-7c59-4b47-b9c2-9af96b77b123" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_083fb8c8-488b-4176-bb55-c16f55eaf0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8dd8ca11-55b9-48aa-a1e5-701e0f7d202a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_083fb8c8-488b-4176-bb55-c16f55eaf0d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8dd8ca11-55b9-48aa-a1e5-701e0f7d202a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_be1964ec-03f3-4528-9146-ce5b7af21b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_083fb8c8-488b-4176-bb55-c16f55eaf0d0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_be1964ec-03f3-4528-9146-ce5b7af21b76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_01fd6b49-ea8c-4b42-9e57-35f3ae1acf27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0bab9086-6606-4f9b-8100-289bde6a4aed" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_01fd6b49-ea8c-4b42-9e57-35f3ae1acf27" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringAdditionalinformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#RestructuringAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RestructuringAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_950b0c3b-cc1a-485b-b03b-62ecadb3d8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0ccea05f-452f-4eb6-b384-d190101d5965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_950b0c3b-cc1a-485b-b03b-62ecadb3d8ab" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0ccea05f-452f-4eb6-b384-d190101d5965" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3d92a657-6321-43d0-9b80-e8c9997203e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0ccea05f-452f-4eb6-b384-d190101d5965" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3d92a657-6321-43d0-9b80-e8c9997203e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3d92a657-6321-43d0-9b80-e8c9997203e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3d92a657-6321-43d0-9b80-e8c9997203e8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3d92a657-6321-43d0-9b80-e8c9997203e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c8af71a3-a797-49f7-b5cc-a9979ad2554d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3d92a657-6321-43d0-9b80-e8c9997203e8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c8af71a3-a797-49f7-b5cc-a9979ad2554d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_00f1356c-0347-490f-b595-4f20fef0d80b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c8af71a3-a797-49f7-b5cc-a9979ad2554d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_00f1356c-0347-490f-b595-4f20fef0d80b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_34014efc-0742-4ad5-91dc-c2cb73c345dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c8af71a3-a797-49f7-b5cc-a9979ad2554d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_34014efc-0742-4ad5-91dc-c2cb73c345dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_89faf80f-bb87-412c-9537-fe15843d9a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_950b0c3b-cc1a-485b-b03b-62ecadb3d8ab" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_89faf80f-bb87-412c-9537-fe15843d9a67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_6afbd889-2a25-4497-8488-fe5b220a1e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_950b0c3b-cc1a-485b-b03b-62ecadb3d8ab" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_6afbd889-2a25-4497-8488-fe5b220a1e7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b4785355-2b37-4da0-a7c5-e4e0b2cb3708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_950b0c3b-cc1a-485b-b03b-62ecadb3d8ab" xlink:to="loc_us-gaap_RestructuringCharges_b4785355-2b37-4da0-a7c5-e4e0b2cb3708" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#RestructuringScheduleofRestructuringCostsDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_602b418c-7cae-46fb-bd0b-99b857c720f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_602b418c-7cae-46fb-bd0b-99b857c720f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_02e49569-4fc4-493a-a3b5-996f2ba2fff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_602b418c-7cae-46fb-bd0b-99b857c720f7" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_02e49569-4fc4-493a-a3b5-996f2ba2fff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_02e49569-4fc4-493a-a3b5-996f2ba2fff3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_02e49569-4fc4-493a-a3b5-996f2ba2fff3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_02e49569-4fc4-493a-a3b5-996f2ba2fff3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3ece593a-53c2-494c-97c1-a3c670a6b5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_02e49569-4fc4-493a-a3b5-996f2ba2fff3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3ece593a-53c2-494c-97c1-a3c670a6b5b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_ca09da90-9bb0-4f6b-a315-24e454b192bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3ece593a-53c2-494c-97c1-a3c670a6b5b9" xlink:to="loc_us-gaap_EmployeeSeveranceMember_ca09da90-9bb0-4f6b-a315-24e454b192bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_da7d0bfd-5844-421e-8251-8ed85bb75934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3ece593a-53c2-494c-97c1-a3c670a6b5b9" xlink:to="loc_us-gaap_StockCompensationPlanMember_da7d0bfd-5844-421e-8251-8ed85bb75934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_6d158bc5-1c35-41bb-8431-0f00e009845a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:to="loc_us-gaap_RestructuringCharges_6d158bc5-1c35-41bb-8431-0f00e009845a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_b8fb028d-99f7-4750-bd7b-0d56f07bc1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:to="loc_us-gaap_PaymentsForRestructuring_b8fb028d-99f7-4750-bd7b-0d56f07bc1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_4bb4c6ff-3b1c-476e-9a13-7693ab3067ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_4bb4c6ff-3b1c-476e-9a13-7693ab3067ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_1bb02142-5d9c-4e4b-aaf3-cecfd68a92f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:to="loc_us-gaap_RestructuringReserve_1bb02142-5d9c-4e4b-aaf3-cecfd68a92f5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:href="advm-20231231.xsd#advm_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesTable_ee02164f-d142-40b8-ba2e-d7d636dfa50e" xlink:href="advm-20231231.xsd#advm_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_advm_IncomeTaxesTable_ee02164f-d142-40b8-ba2e-d7d636dfa50e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f6a1fdbc-680b-4084-ad20-6d8771c6fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_IncomeTaxesTable_ee02164f-d142-40b8-ba2e-d7d636dfa50e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f6a1fdbc-680b-4084-ad20-6d8771c6fe36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f6a1fdbc-680b-4084-ad20-6d8771c6fe36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f6a1fdbc-680b-4084-ad20-6d8771c6fe36" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f6a1fdbc-680b-4084-ad20-6d8771c6fe36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4efc748e-3ed1-415b-b803-fd80cb8a5008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f6a1fdbc-680b-4084-ad20-6d8771c6fe36" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4efc748e-3ed1-415b-b803-fd80cb8a5008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_341c5ae3-66ac-4e98-a114-e903f92eb7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4efc748e-3ed1-415b-b803-fd80cb8a5008" xlink:to="loc_us-gaap_DomesticCountryMember_341c5ae3-66ac-4e98-a114-e903f92eb7fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5320a4d2-3fc1-4ce1-a6f0-cdb33f387337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4efc748e-3ed1-415b-b803-fd80cb8a5008" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5320a4d2-3fc1-4ce1-a6f0-cdb33f387337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_a41c537e-7923-4b05-8aec-71b24198aeff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4efc748e-3ed1-415b-b803-fd80cb8a5008" xlink:to="loc_us-gaap_ForeignCountryMember_a41c537e-7923-4b05-8aec-71b24198aeff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_51e2adfb-2d69-4106-8823-3bc56fe373df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_IncomeTaxesTable_ee02164f-d142-40b8-ba2e-d7d636dfa50e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_51e2adfb-2d69-4106-8823-3bc56fe373df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_51e2adfb-2d69-4106-8823-3bc56fe373df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_51e2adfb-2d69-4106-8823-3bc56fe373df" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_51e2adfb-2d69-4106-8823-3bc56fe373df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_58d8175c-f423-4901-9edf-1fb5c931576d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_51e2adfb-2d69-4106-8823-3bc56fe373df" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_58d8175c-f423-4901-9edf-1fb5c931576d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_eb6fd84b-10be-4380-a797-a4e0f41e6e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_58d8175c-f423-4901-9edf-1fb5c931576d" xlink:to="loc_us-gaap_ResearchMember_eb6fd84b-10be-4380-a797-a4e0f41e6e83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_921becc7-9200-46a8-8be9-ad8a63751fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_921becc7-9200-46a8-8be9-ad8a63751fdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_30ff9645-65df-40e9-9eac-6e20b02c371d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_us-gaap_OperatingLossCarryforwards_30ff9645-65df-40e9-9eac-6e20b02c371d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_2af8e3fe-8eb3-4d9f-b4c9-8024c073bd12" xlink:href="advm-20231231.xsd#advm_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_2af8e3fe-8eb3-4d9f-b4c9-8024c073bd12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_50999f9a-4541-4491-b322-24d3d45c4137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_50999f9a-4541-4491-b322-24d3d45c4137" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsCapitalizedCosts_9b441ac0-8c6e-4b6b-9635-0a7d50a58d9b" xlink:href="advm-20231231.xsd#advm_DeferredTaxAssetsCapitalizedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_advm_DeferredTaxAssetsCapitalizedCosts_9b441ac0-8c6e-4b6b-9635-0a7d50a58d9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_663894e7-194b-4cc6-b96a-b05d3a330bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_663894e7-194b-4cc6-b96a-b05d3a330bd3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_426a1710-8ae2-40d0-af0a-888cf05cc01f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_426a1710-8ae2-40d0-af0a-888cf05cc01f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#NetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/NetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_853c658f-ae91-4ce5-a699-e1c17a1cdeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f3628bd-41a1-46b7-8437-8b11b8bc9bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_853c658f-ae91-4ce5-a699-e1c17a1cdeb3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f3628bd-41a1-46b7-8437-8b11b8bc9bf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5936a92d-e20b-43d2-9f24-1784623e5791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f3628bd-41a1-46b7-8437-8b11b8bc9bf4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5936a92d-e20b-43d2-9f24-1784623e5791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5936a92d-e20b-43d2-9f24-1784623e5791_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5936a92d-e20b-43d2-9f24-1784623e5791" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5936a92d-e20b-43d2-9f24-1784623e5791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea421a37-9607-4f6d-b804-0ff82b352179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5936a92d-e20b-43d2-9f24-1784623e5791" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea421a37-9607-4f6d-b804-0ff82b352179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_01148a04-7f9f-4a4b-9d4e-c11f227c48c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea421a37-9607-4f6d-b804-0ff82b352179" xlink:to="loc_us-gaap_EmployeeStockOptionMember_01148a04-7f9f-4a4b-9d4e-c11f227c48c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_79de28e3-1725-4d7e-9c5c-501ce4ea1312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea421a37-9607-4f6d-b804-0ff82b352179" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_79de28e3-1725-4d7e-9c5c-501ce4ea1312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_44caa4f1-2afe-461a-b623-10912ffd7992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea421a37-9607-4f6d-b804-0ff82b352179" xlink:to="loc_us-gaap_EmployeeStockMember_44caa4f1-2afe-461a-b623-10912ffd7992" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_08a3dd6b-35e9-4261-8464-9e527741f48b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_853c658f-ae91-4ce5-a699-e1c17a1cdeb3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_08a3dd6b-35e9-4261-8464-9e527741f48b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3363cb98-d30c-4d93-96cd-ece84373dc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3363cb98-d30c-4d93-96cd-ece84373dc8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3363cb98-d30c-4d93-96cd-ece84373dc8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3363cb98-d30c-4d93-96cd-ece84373dc8d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3363cb98-d30c-4d93-96cd-ece84373dc8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b7ebc4f8-5226-49dc-812a-8c6d78c7f7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3363cb98-d30c-4d93-96cd-ece84373dc8d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b7ebc4f8-5226-49dc-812a-8c6d78c7f7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a4b90aef-6eb0-4665-887f-e3dcf73c8bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b7ebc4f8-5226-49dc-812a-8c6d78c7f7c4" xlink:to="loc_us-gaap_SubsequentEventMember_a4b90aef-6eb0-4665-887f-e3dcf73c8bc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c21ec4fe-8eb0-4269-a07d-5020d34ffca0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_srt_StatementScenarioAxis_c21ec4fe-8eb0-4269-a07d-5020d34ffca0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c21ec4fe-8eb0-4269-a07d-5020d34ffca0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c21ec4fe-8eb0-4269-a07d-5020d34ffca0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c21ec4fe-8eb0-4269-a07d-5020d34ffca0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b58a5fda-f80c-4b10-a104-ad0d2ba3e91d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c21ec4fe-8eb0-4269-a07d-5020d34ffca0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b58a5fda-f80c-4b10-a104-ad0d2ba3e91d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember_6ec09f30-46e3-4571-a5f4-ad5dea9debae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b58a5fda-f80c-4b10-a104-ad0d2ba3e91d" xlink:to="loc_srt_ProFormaMember_6ec09f30-46e3-4571-a5f4-ad5dea9debae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_74bfdd72-4fd7-4777-9668-c661aa02cfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_74bfdd72-4fd7-4777-9668-c661aa02cfa8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_74bfdd72-4fd7-4777-9668-c661aa02cfa8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_74bfdd72-4fd7-4777-9668-c661aa02cfa8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_74bfdd72-4fd7-4777-9668-c661aa02cfa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6675bd3a-08a9-4e80-b076-d03719bc62f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_74bfdd72-4fd7-4777-9668-c661aa02cfa8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6675bd3a-08a9-4e80-b076-d03719bc62f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f4715769-0be7-4e7c-8162-afac21aba887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6675bd3a-08a9-4e80-b076-d03719bc62f0" xlink:to="loc_us-gaap_PrivatePlacementMember_f4715769-0be7-4e7c-8162-afac21aba887" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c265a9f3-b4a7-4105-ad0f-fb5296c647bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_srt_CounterpartyNameAxis_c265a9f3-b4a7-4105-ad0f-fb5296c647bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c265a9f3-b4a7-4105-ad0f-fb5296c647bb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c265a9f3-b4a7-4105-ad0f-fb5296c647bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c265a9f3-b4a7-4105-ad0f-fb5296c647bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_758fc3c6-d0ca-4ccf-b344-ba4349f0c4da" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c265a9f3-b4a7-4105-ad0f-fb5296c647bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_758fc3c6-d0ca-4ccf-b344-ba4349f0c4da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoDirectorsMember_ee146b62-b4ce-40e4-a6c7-033e40e2b8e8" xlink:href="advm-20231231.xsd#advm_TwoDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_758fc3c6-d0ca-4ccf-b344-ba4349f0c4da" xlink:to="loc_advm_TwoDirectorsMember_ee146b62-b4ce-40e4-a6c7-033e40e2b8e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8f73a6c5-f7a0-4c67-ab16-d57d1ba73cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8f73a6c5-f7a0-4c67-ab16-d57d1ba73cd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8f73a6c5-f7a0-4c67-ab16-d57d1ba73cd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8f73a6c5-f7a0-4c67-ab16-d57d1ba73cd4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8f73a6c5-f7a0-4c67-ab16-d57d1ba73cd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3abbcc05-f2d3-45c8-abc3-45a5d51de29f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8f73a6c5-f7a0-4c67-ab16-d57d1ba73cd4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3abbcc05-f2d3-45c8-abc3-45a5d51de29f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_PreFundedWarrantsMember_0b9f913b-3c8b-42e8-b354-337e2f599f3b" xlink:href="advm-20231231.xsd#advm_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3abbcc05-f2d3-45c8-abc3-45a5d51de29f" xlink:to="loc_advm_PreFundedWarrantsMember_0b9f913b-3c8b-42e8-b354-337e2f599f3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9e4c16ea-53d1-4a83-83b0-0d18b847997f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9e4c16ea-53d1-4a83-83b0-0d18b847997f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7167d426-b51a-4d70-a02c-d0bf07daeb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7167d426-b51a-4d70-a02c-d0bf07daeb3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8c2feb3b-6e4c-4b13-b821-015c1e783f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8c2feb3b-6e4c-4b13-b821-015c1e783f5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0bc6a29e-c34d-456a-b5c8-60411b60ccbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0bc6a29e-c34d-456a-b5c8-60411b60ccbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SecuritiesPurchaseAgreementNumberOfDirectors_200b6b1e-8551-4c6d-87bc-244454b635f8" xlink:href="advm-20231231.xsd#advm_SecuritiesPurchaseAgreementNumberOfDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_advm_SecuritiesPurchaseAgreementNumberOfDirectors_200b6b1e-8551-4c6d-87bc-244454b635f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_63e2940a-2fe4-40f4-b7b0-9021f5e505c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_63e2940a-2fe4-40f4-b7b0-9021f5e505c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b05adc5b-b2cf-4aa6-a411-f5328d629813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_CommonStockSharesIssued_b05adc5b-b2cf-4aa6-a411-f5328d629813" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_363d5d4a-97fe-4076-8455-14639beb97d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_363d5d4a-97fe-4076-8455-14639beb97d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_31e25d9f-d9cd-4480-acc2-6ee8b012bf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_31e25d9f-d9cd-4480-acc2-6ee8b012bf2c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_925b625e-18a2-4014-8dac-bddcc097b64d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_925b625e-18a2-4014-8dac-bddcc097b64d" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c5db979f-3753-4cbd-acba-b75b94140e32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_SubsequentEventTable_c5db979f-3753-4cbd-acba-b75b94140e32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5eb32bc5-30ee-46c3-b807-92e29ec8954b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c5db979f-3753-4cbd-acba-b75b94140e32" xlink:to="loc_srt_StatementScenarioAxis_5eb32bc5-30ee-46c3-b807-92e29ec8954b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5eb32bc5-30ee-46c3-b807-92e29ec8954b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_5eb32bc5-30ee-46c3-b807-92e29ec8954b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5eb32bc5-30ee-46c3-b807-92e29ec8954b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_416887ce-230b-4151-bc71-c751e7b9fd58" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_5eb32bc5-30ee-46c3-b807-92e29ec8954b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_416887ce-230b-4151-bc71-c751e7b9fd58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember_274bccdb-8fbd-4099-94ea-906f44f99817" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_416887ce-230b-4151-bc71-c751e7b9fd58" xlink:to="loc_srt_ProFormaMember_274bccdb-8fbd-4099-94ea-906f44f99817" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0fef3b23-b4de-4698-bbe6-694402f68df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_NetIncomeLoss_0fef3b23-b4de-4698-bbe6-694402f68df8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cf1290ee-3d46-496b-8e55-a6c72e7b8870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_EarningsPerShareBasic_cf1290ee-3d46-496b-8e55-a6c72e7b8870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a000adc2-15df-4384-98d9-f51c75d99b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a000adc2-15df-4384-98d9-f51c75d99b45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d67e0ad-119d-4ace-ac8b-9678862405d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d67e0ad-119d-4ace-ac8b-9678862405d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_31dc6b74-c16f-447c-8c96-9be0b5d11b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_31dc6b74-c16f-447c-8c96-9be0b5d11b9e" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>advm-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0eb1737c-384e-4b48-8e56-f7ff90dff097,g:c0462913-63e1-4ed5-8ab4-52645bec5fa8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_ef613686-c714-48e3-97ae-892a7a940db4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of internal reorganization</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_43149e52-fab3-4a24-a3fd-85d9a869148d_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing Facility</link:label>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_label_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturingFacilityMember" xlink:to="lab_us-gaap_ManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_DeferredTaxAssetsCapitalizedCosts_c7dc22e5-16af-4e78-8098-d808c919a0aa_terseLabel_en-US" xlink:label="lab_advm_DeferredTaxAssetsCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 174 R&amp;D capitalization</link:label>
    <link:label id="lab_advm_DeferredTaxAssetsCapitalizedCosts_label_en-US" xlink:label="lab_advm_DeferredTaxAssetsCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Costs</link:label>
    <link:label id="lab_advm_DeferredTaxAssetsCapitalizedCosts_documentation_en-US" xlink:label="lab_advm_DeferredTaxAssetsCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsCapitalizedCosts" xlink:href="advm-20231231.xsd#advm_DeferredTaxAssetsCapitalizedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DeferredTaxAssetsCapitalizedCosts" xlink:to="lab_advm_DeferredTaxAssetsCapitalizedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_f0432135-956b-4b90-abbe-bf6d74d5a6ce_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_41b8b979-6930-4112-8859-b390ee06aacb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9dfca237-7551-4dcc-adcf-39057f3e6347_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_d3b3aa1c-979b-42f1-ba36-b47556cb0159_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of fee</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6b0a626f-d9cd-457a-ad99-103ae9a9bbf2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_91d10a2e-d31e-4a45-ac1a-0f887e481d23_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d5618768-e091-4e6a-99d0-d72280f0e5b8_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b54cdb1-89f9-4c9c-8dfe-a460e4c13e85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d50ad3b4-d1be-4bbb-9dfe-f089a1e9fb05_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_298f2571-2e28-4f66-b2fb-a4ad3a333fb2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ff001ee1-e991-4905-bb99-31c96f53743e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2c17db82-7f60-4d59-80f4-cb3403d08d2b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_e28c309b-2174-4b6b-b916-2d2a569a8f4d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contribution by company</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_e4ff2a86-5c70-4029-bec8-3762bda57525_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_f9c43f14-57af-48f2-bc9b-ddbead33ded6_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a31f712c-1240-4fd4-ba7b-31bce2c423ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4bb9fd58-314e-472d-99e0-a6d8e056663a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_576594b2-8a0f-4c4e-adac-676c2682cb92_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_acf05d7d-59e4-4330-8a3c-94edc98e492f_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a959069d-ffcf-48c9-a47d-1171c9409924_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bda6339a-7726-4bc0-9987-71b124c0117f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_920e5186-9307-4785-9458-53314c8a2c0d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_a8c63d2a-1600-41f7-aa58-5f8534d5fe9b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_de5bda5c-acbe-4c99-92db-2947eab8f10c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2caec454-f8e4-4b90-8519-b87dd7bd7273_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_f30f9482-7ef2-412d-9807-e20ab36acd73_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total gross proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_24b5a22c-fc33-4ef3-8b41-36487bddf411_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_134b58ab-9db4-4f6e-83de-7eca00fed320_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ef59b724-6ca0-4273-89d3-d0b22393c94e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a2db4b5c-36af-4a6a-802d-323851a537fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued upon release of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandSeventeenInducementPlanMember_87895fbe-c280-4724-bd89-3f4de0e6c55d_terseLabel_en-US" xlink:label="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Inducement Plan</link:label>
    <link:label id="lab_advm_TwoThousandSeventeenInducementPlanMember_label_en-US" xlink:label="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Inducement Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandSeventeenInducementPlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand seventeen inducement plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandSeventeenInducementPlanMember" xlink:href="advm-20231231.xsd#advm_TwoThousandSeventeenInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandSeventeenInducementPlanMember" xlink:to="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_46cce7df-7add-4213-a9f2-14a08fe0187a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_PazyukV.MachadoEtAl.C.A.Member_c96bd585-50d5-4cdd-b1a6-ce719da5ad49_terseLabel_en-US" xlink:label="lab_advm_PazyukV.MachadoEtAl.C.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pazyuk v. Machado et al. C.A.</link:label>
    <link:label id="lab_advm_PazyukV.MachadoEtAl.C.A.Member_label_en-US" xlink:label="lab_advm_PazyukV.MachadoEtAl.C.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pazyuk v. Machado et al. C.A. [Member]</link:label>
    <link:label id="lab_advm_PazyukV.MachadoEtAl.C.A.Member_documentation_en-US" xlink:label="lab_advm_PazyukV.MachadoEtAl.C.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pazyuk v. Machado et al. C.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_PazyukV.MachadoEtAl.C.A.Member" xlink:href="advm-20231231.xsd#advm_PazyukV.MachadoEtAl.C.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_PazyukV.MachadoEtAl.C.A.Member" xlink:to="lab_advm_PazyukV.MachadoEtAl.C.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_1d202cab-85db-423b-8a0f-db670f114bfd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent receivable</link:label>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_label_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Receivables, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentReceivablesNet" xlink:to="lab_us-gaap_DeferredRentReceivablesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_97b41e42-9132-4c38-a3a2-9efaf43236d2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a870386c-7a01-48c7-b8ef-4c8e3bd04a19_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4c3b8d9b-73fe-4756-b2bd-b35bd30341ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_dcc4a46b-1a2b-4c72-b9ea-9d2226f1e015_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4526ec38-64a8-48a0-af1d-3d2f270465d5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_87a8bc06-66e4-4e22-821a-e48d39657e8e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b7a026b9-e696-45a2-b85c-48a82fa324f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated_fe347d1e-ad64-4a21-bd31-998153d86d8a_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases with accelerated expiration</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Leases Expirations Accelerated</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Leases Expirations Accelerated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated" xlink:to="lab_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_abe2b8a9-b63f-4f7c-b308-689cfcba9b4a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7829c7b4-1810-4281-8fff-b5b4b150583b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_28af9180-bb4a-48ae-82f2-71aedb8e436f_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease Payment Receivable</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc6a3943-3b20-452f-a643-de1bac3583a8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_de751d73-d974-4ad3-8867-e290f0b4ca7f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_283a7877-4e5e-4be6-9c55-25785ff54498_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_b9659fd2-2bc6-4327-8ae5-4a59bd29ac23_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e2d39188-ba84-418a-a02b-c2409bcd3444_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c5551d89-e61e-4c92-a177-be5e39bfdc58_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d95be568-3030-4980-a017-ff96e0cc7306_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6a1b825b-e338-45b0-826f-d7b29df36852_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair values of options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9903e519-0cc6-4c5f-8637-f7169a5e3c00_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b6e544b6-467a-4828-b829-3d8fd8dc3bd0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_2cc9ef72-83c7-47a5-a62b-3f6017419c34_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a94a88f1-9064-4de2-860c-350b9c3f7103_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ed8d9893-e722-4f51-8f48-c1b1088ae78d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_98f7d2df-96e0-43e8-a757-f4f3f5b9e5ab_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3790beb5-a562-47f4-a5c6-b7493911341e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_a0304add-96b3-47b9-9aa2-ba0a821105a1_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bbadfb-b60c-4fa9-ae40-84cdc2cdce31_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1fbc1db6-64b2-4f09-a8e3-3ffe24048150_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_71d79184-37de-44e7-8d19-22bdca76bb09_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_43d19701-00a2-458a-bf53-82e38a6659d8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1678d123-f11f-45f9-9c0b-01b6d1409f96_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_623f4a06-98a2-49cf-bc29-09f20dcbc71b_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_774db36a-7eeb-43da-92d4-71d68022f6d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7c83433e-1b42-4a19-9345-ee02a497c1d6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued upon exercise of stock options, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ba0c24dc-2a94-47b4-b720-435a267e9bba_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_02790e5e-25e6-4664-b909-2ee5e6312d53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_231cccd4-6e9c-4c9f-96a9-86bc5ae39081_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unaudited Pro Forma Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b23c6ea6-dd5a-46cf-b61f-2cd6300a5bad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted to employees and non-employees vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_b2263176-ddb7-4f96-8c0f-7d5afb4f9ed8_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_f9fe1d55-9761-425e-8e7f-55c6ae3246e5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_3ef58d75-932f-4648-b794-3d8750640bdc_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b2a363a8-a8a6-4b3a-af8d-f4dfd867c59d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_90488d2b-1ebd-4b5b-b61e-0029d8e893a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_f12164fa-0149-4d43-8ca1-cb7d145531e4_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3fa4f141-33c2-4397-b7d8-0cb6278cf1cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_19b5bf1c-f422-4a4d-918a-467b6e8308da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_d6f8d68b-203f-4041-a69b-87354d9e8948_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_991e0051-c349-4ef8-b727-680d20ce50d0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase related to tax positions taken during the prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f4dad645-9b2a-4320-9a2f-851e6bf1b95d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_86dbe961-0ea4-4210-854c-738f941b9177_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eb6039bd-91b6-4071-a3b3-301617db08e8_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_60089b6e-00a1-4d66-9a97-d29e90485d69_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_20c4338f-b2d6-4d5e-8f0f-79b5e42ec561_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_c97c06df-5dd1-4a4a-bff6-58f35f63578f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_aa8314cc-f9ea-4fc3-9457-deda0c49ad2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_9f60961e-6e4f-4ad3-bbfc-585e843e2550_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_eeb45c4c-7375-4d55-b048-e9f660f638de_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of renewal contracts</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Contracts</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:to="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_457b4946-f03e-464c-9a16-a6b751f49469_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_05ec0924-8e23-4a54-933e-6c1f21e22ba1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bd627db0-c022-47e2-bdff-a4cd87bcff54_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7fb19809-bfe5-4854-a3a0-a4df35c99594_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_85857545-aa80-4fcf-a862-7baced5d1c1a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_f4403023-c86b-453d-b6a1-ad0655d8561f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1d9c214f-2de0-4d53-8f73-b93c1ca102de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_ff115c53-e640-48b5-86d6-8c5185335018_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_90ad6440-8265-45bb-81b4-6df8dddfd2fe_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3ee979af-c695-4516-a14b-98de3dda7042_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d8d14bb9-1477-4920-b5f7-171c82927a80_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_857c027e-eb1d-4a3c-acec-356c622c9eab_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Undiscounted Future Lease Payments under Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_StockOptionsAndRestrictedStockUnitsMember_5171cd6d-c7c3-4403-b928-8fd1564062a9_terseLabel_en-US" xlink:label="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options and Restricted Stock Units</link:label>
    <link:label id="lab_advm_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_advm_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:href="advm-20231231.xsd#advm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5b29a5b7-a247-4162-bda7-260f7a030544_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3d13ea3c-6b6b-43f9-bcb8-0b20e576b700_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b93c61e7-9ad5-40fa-80b7-9ba405f15a72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_38bda62a-747c-4992-96bc-56abb04d8d6b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals, reserve and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_e83d9128-17b3-42f2-a8de-e003ded283f7_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvement allowance</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Leasehold Improvement Allowance</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Leasehold Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseLeaseholdImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:to="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_68751951-3f22-4a6d-99e1-f069c120b091_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a143cb8c-64b5-467b-941e-f1b725b238f7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_86b0da3c-f6eb-4f92-a126-297c4cdf7384_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2022</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_c1aa65a6-04ad-47a2-9f0e-a1e99e0bdb1f_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e9dc4d82-b491-487f-a3b1-a445e959ad1c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d7b8b170-24e5-4f20-ad54-54c09c9fa1f0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d2d2352-e848-4d36-99c0-c9d2341a4e0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of performance units both performance and service vesting conditions (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f78a2382-8fb0-4741-99a4-72b326ef2891_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1c6ddbc9-ce6d-4fb2-83fe-ccb9240b4031_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4e5e4b2d-8262-4add-aad4-8383b8c28095_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a890094b-65ec-489b-bf01-b805f08d3ece_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9f3b0b2d-32b4-4d25-a4b5-4f9dbd361d24_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets in accounts payable and current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_440e0327-1046-415f-baf9-c6e6019ad7e7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_2be00770-b427-4ed3-89d2-03db62e03ab4_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_681bbb00-2bdc-425b-bf00-43a718a05f51_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_18de4d9c-b69e-436f-bda9-3a7fa427c33b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_867b3366-6d5e-430e-9fd2-435738c230d0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_81bf2a61-ac4d-4d7e-b7c0-514c6a6b921d_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contract Life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8583d657-3687-46a2-8e8f-57f52dca4dc8_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_0dd65bde-8a9c-454f-ab78-094da6e2e96a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_3426f1c1-0f7b-4d5d-888e-7fd97cc11a96_terseLabel_en-US" xlink:label="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NSOs)</link:label>
    <link:label id="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_label_en-US" xlink:label="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options [Member]</link:label>
    <link:label id="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_documentation_en-US" xlink:label="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:href="advm-20231231.xsd#advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:to="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_dc1de96a-2217-4ce6-b1ee-afe9f4033d65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax (Benefit) Provision</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_032b2c83-5f53-4b09-b88f-44897dd8ffc9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition_236f4a57-c6ad-46d8-883b-0ff29280aa8e_terseLabel_en-US" xlink:label="lab_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition_label_en-US" xlink:label="lab_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Change In State Uncertain Tax Position</link:label>
    <link:label id="lab_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition_documentation_en-US" xlink:label="lab_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income tax reconciliation change in state uncertain tax position.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition" xlink:href="advm-20231231.xsd#advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition" xlink:to="lab_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a809bd87-8265-4388-84b9-43b547e73511_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_40df4696-c9f1-492e-9e5f-d6a704d713f9_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage increase in shares issued</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Increase Decrease In Number Of Shares Issued Percentage</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award increase decrease in number of shares issued percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:to="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d09f8263-ae1f-4459-aa51-14803081c4a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_12b0e870-ba4c-47ca-b444-1f7b8df62654_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_12a92023-babe-40c6-8eee-d32a677fe5e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b10c6848-b229-469d-a402-32d09d41f132_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2057eb68-03f7-40f0-9900-1e62a437f950_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1e81fd93-425c-432f-93ec-291a91fd84e3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_f4864d18-c388-45e6-96d6-9ee676e61897_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_979bb051-0b66-41ad-bed7-66aacce04466_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ce9550c6-5cec-4a09-971a-81db1d226ae3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e3f3d784-e038-4c6e-b165-c06b66452458_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b54acf0c-cc63-42ff-b98e-65106db02b0f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_8f8b47f7-763d-4daf-b8b4-ae23d6cd84ed_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c0f74123-884a-4eec-8f8e-6a6bd263fd90_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase related to tax position take during the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_136db109-398e-4149-adb7-ca7a11340461_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e62ef467-dd88-4209-bf6f-bb855608ccc2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fe2a221-6db6-4bda-90c7-acd4e4e9ff96_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37b4e544-66fd-47e9-b008-abae1f1420ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_951fcd85-46fa-4fc1-a4c4-fa3509639aef_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a02a8ffb-881d-43cb-a512-33e4cb6d5e0e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_87739209-fc63-461d-a994-94e837d6b17e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_0709c2bd-9448-4bb1-917b-67048c4e8bf6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_f4d6a9d8-260a-4f0c-825f-352b2b110dec_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bd4a163d-5c6a-4e92-aaa9-dad43ffcb2c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_06b9e085-4f70-478a-8b43-0391752dfa9b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_0164f835-32dc-4b7d-b0c6-c2cf8ec293ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d6191538-ed16-4628-a6aa-3bf700456881_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_681d0360-2bc7-4f67-aeec-05d0e562b105_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_2ac98792-efdc-4497-ac26-329eb2afdb76_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d5dca670-5a65-4f9c-9756-0b75290890cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Option Issued Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_af00202e-0024-4a63-b531-9d291c323e02_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_512b3405-a407-4517-bce6-b6c716bcab12_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_03045bf2-84fa-4265-a332-66a8c25fdae1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember_6d466c3d-d4f4-4f94-bc11-c4dc9c18a294_terseLabel_en-US" xlink:label="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Plan And Inducement Plan</link:label>
    <link:label id="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember_label_en-US" xlink:label="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Plan And Inducement Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand fourteen plan and inducement plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:href="advm-20231231.xsd#advm_TwoThousandFourteenPlanAndInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:to="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a3f9a1b8-41d8-4a20-b0c1-3a5983810c16_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_09f13d2f-218e-447e-bb1a-22cee651bead_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e989772c-4a7e-4a47-8aca-a812ac9fc945_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_860e326c-f64d-438c-b9ba-93e5e1295a03_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_0df23ca1-1a3e-4fb5-8931-38f7898a5527_terseLabel_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lexeo Therapeutics, Inc</link:label>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_label_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lexeo Therapeutics, Inc [Member]</link:label>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_documentation_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lexeo Therapeutics, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember" xlink:href="advm-20231231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LexeoTherapeuticsIncMember" xlink:to="lab_advm_LexeoTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a4f6dd6f-3040-44d7-9a1f-087894a3470e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized stock-based compensation, weighted-average period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_16d59375-49f3-4c39-9bab-e2edcc78ef2c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_fc05394a-2487-42a5-9020-7e8d7480b3b2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_48823e6c-b21f-4d40-b106-990e6a579e9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d0f72609-b849-4db8-a6d5-8648bbe62a78_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_4a94c36d-146f-40fa-bde7-af3ddbf5752b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_ea16a883-eeb9-41db-91bb-4f7ba74aa363_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic tax authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_bbff651d-8393-4f8c-ab9f-d36bf8201c9e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_90644043-3372-476e-8c2d-08cc60c63034_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_60675f33-6f3d-462e-9005-26d880e45557_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_bc9a761c-bf2f-435b-a196-d08d37e39b5c_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_64389b5c-2d13-42b1-a6a0-236263e2567d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df847339-8683-4992-b540-37ca064c4dc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_750828cc-9e5b-4d06-a693-60517d92295e_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income tax payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_32b1a1c9-fe45-4607-a7c8-98cc6a4491cc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4c065e66-b872-4f88-b1ee-c8ae65924698_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest or penalties related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_8085d683-839c-4a4f-a5a3-d45fc6c7090f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_0cb62b53-74e5-4386-8836-e77b67cbe4b7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5465feb8-eb59-4410-8ba3-9caf733fa277_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_cbe7c82d-d4ca-4985-a816-2f4b8a36c6a0_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b933951e-cae1-4bab-9210-eb4f50e9aa70_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7c8f0f05-2cd4-4725-980e-31a8812dd9e1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_4f5dc7dc-4386-4654-af71-b6142af173d6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1e288a18-5778-4b04-948b-607956720b61_negatedLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_463f5fc7-3ae1-430f-bf70-efbdc9953469_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b3416389-20c2-498f-941e-885de3efd8e5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_0881ac6b-fa65-47c6-9dba-a75b26c9d506_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_53047125-a29f-4d3d-bcd7-be44487400b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal income tax benefit at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1ffd7e9-640a-41b8-87b1-1dce3789fe65_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7ab0aa88-ed79-4663-95fc-8be20082adb4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_0f1a0b8d-314f-4886-a2b1-e6623402db46_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d55283ce-6877-42d3-b631-269f09b24eef_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e64bd6bd-09f8-4296-8b52-220bf4c9c6ff_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_ee6ae850-b8f7-4ff3-a85b-a8fd8b9315f2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_81e32f5d-b350-4792-a24a-860b6a1c61de_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_d1d36cc5-428e-4adf-930c-cad477746ccd_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_49683e44-9da1-416c-a938-2d6e1f8c4a76_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProFormaMember_ed801a97-8c34-410e-9d1b-b0879a610680_terseLabel_en-US" xlink:label="lab_srt_ProFormaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro Forma</link:label>
    <link:label id="lab_srt_ProFormaMember_label_en-US" xlink:label="lab_srt_ProFormaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pro Forma [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProFormaMember" xlink:to="lab_srt_ProFormaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_1766eb92-32c9-4143-81a8-5aeff2e99cf0_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_af730cee-67b1-41b4-be49-12890bdeec80_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember_c3d6cb20-06b0-4367-a67d-918ce2cc7e40_terseLabel_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Equity Incentive Award Plan</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and fourteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:href="advm-20231231.xsd#advm_TwoThousandAndFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:to="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems_5e4d29d7-98bb-4163-84fb-70d6b0f685ee_terseLabel_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="advm-20231231.xsd#advm_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e36689eb-9fe6-4be2-956d-d2d560d3707d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental schedule of noncash investing information</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7759fb9-7f0d-47ae-9b1f-6fcd1386a1aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_42a3d5c2-f691-4da3-99db-f1763a9d7e3f_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6fd67c54-6bdd-4999-b558-32c6c37bc4e3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2e8fb755-d533-4eef-9d4a-662e60cb1236_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_70f0082d-2148-4a21-a903-d10c804b98fe_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e40fec8c-a0a4-4412-950b-f5acbd46c581_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e10f11ec-65e7-4110-9fab-a9ec663ad635_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e177241b-109a-4c47-8a49-943de278a3a2_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_6085ac9b-d8c6-4941-b754-dff250629b03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a6d17e40-a11a-4403-b728-2b0893492393_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_769a575a-a8c0-4830-bca1-fbf4d4403794_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c6616201-6abd-4e75-927d-7c474730af8a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d8eadee0-8941-453d-8d9f-57a7f8871fce_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6aff4248-662e-4094-bd12-b47aaa14fa8c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_a62e7def-a5b0-42c6-8f3c-c26d7eac806d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_4261a783-2400-4bc2-987e-9bb247f603fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f0474160-d566-492c-bbce-11b8ccdd6aeb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ab716ae4-1d4a-4773-80cd-d98e46c03e4f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_647de670-37dd-4c03-abd7-6efe2ab762cb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_ffb2720e-f47b-430f-b407-b480ac4d6f1e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_edab74c8-e494-4e50-bbb1-3175cf67ab4a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk and Other Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_0e8520dd-c257-4731-ae03-c6b5e42a48a5_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_d1c4c600-2aad-427b-8f53-790c1a9e3262_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fees received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_80cf1bf5-e01c-441f-bb6c-6d2605255858_terseLabel_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and short-term investments</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments [Member]</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:href="advm-20231231.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:to="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c665e2b0-ec00-45d9-b98a-9a3cf20bcdc6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_6d236c48-3b27-4e7e-8ede-9bc0016aad53_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ea23b76a-5e84-4e10-af99-64c210677aa1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_PreFundedWarrantsMember_3ce7c7df-a648-4707-87d9-4773a84b01dc_terseLabel_en-US" xlink:label="lab_advm_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_advm_PreFundedWarrantsMember_label_en-US" xlink:label="lab_advm_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_advm_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_advm_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_PreFundedWarrantsMember" xlink:href="advm-20231231.xsd#advm_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_PreFundedWarrantsMember" xlink:to="lab_advm_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_34f0a147-9c01-4723-ae76-591d300473cb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2b6a1ab0-91e8-460c-ad08-0fda5fb62632_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_5a6eb466-0171-4e6a-9118-65a8833f1403_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities, unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_e2de655d-08cc-4f2a-b0ca-fb98176fdbb3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_25aa5c0b-11da-4c17-b8e5-0202fbe1b6c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_SecuritiesPurchaseAgreementNumberOfDirectors_5d4fe81c-d18f-40bb-a98a-786f27c8b7ee_terseLabel_en-US" xlink:label="lab_advm_SecuritiesPurchaseAgreementNumberOfDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of directors</link:label>
    <link:label id="lab_advm_SecuritiesPurchaseAgreementNumberOfDirectors_label_en-US" xlink:label="lab_advm_SecuritiesPurchaseAgreementNumberOfDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement, Number of Directors</link:label>
    <link:label id="lab_advm_SecuritiesPurchaseAgreementNumberOfDirectors_documentation_en-US" xlink:label="lab_advm_SecuritiesPurchaseAgreementNumberOfDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement, Number of Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SecuritiesPurchaseAgreementNumberOfDirectors" xlink:href="advm-20231231.xsd#advm_SecuritiesPurchaseAgreementNumberOfDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_SecuritiesPurchaseAgreementNumberOfDirectors" xlink:to="lab_advm_SecuritiesPurchaseAgreementNumberOfDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2522c5e7-8fde-4ab4-a46d-e35eb71d03e2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_19a9b137-fbe8-4b02-a4e6-15ed3b0bde5d_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax (benefit) provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3fce07dc-80cd-4560-9dde-968268f6c725_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f0e5daaa-c6c6-4867-8969-7ce419f356a7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_92c5d113-df19-4931-a933-dde00ee0a167_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_53bdbfab-2472-44f6-9b0b-4059c05e8e2b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Plans</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_e8e78fef-2921-4d67-927f-8a760ba282ce_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d5d0b59e-aace-4916-bc3e-8b2216a08704_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bc2914f3-9dfa-4b41-b365-6dd67d815cad_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e7c810da-0570-4ea9-9442-57b0b3b01233_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b069fd30-c902-47ee-a8cb-c4d9d2e9b317_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities in an unrealized loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_6d11e2de-c775-4da5-b45a-7728a205ce7b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15380690-4d03-426c-a90d-83e0e6759309_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_c2bdb151-2b23-45af-aaa9-1eda3d4d1faf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_b2387da2-73a8-4174-a7fd-56aef895acd2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_802d8900-a7d6-464b-85e6-43c822215e36_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b01f8394-2e0e-46e9-b0e1-d9d5b0fdfbb0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5c1f065-5501-43a3-a296-3e692e53dd08_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_2b3896de-b801-451c-a5c7-cabf6b571e01_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0c00190d-6c07-48f6-96d2-9c5c32c8bc8b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_03c2aed0-cb66-4594-b265-21a40527fa32_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7ad35c01-c245-41bd-a32e-7e607608e58c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2023: 101,433 and 100,117 shares issued and outstanding at December 31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_1328a277-0f92-42a4-8999-e85fa550c5c9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4c9f3d9-198c-431a-bdcf-b35cbf8b5136_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_bb17bd9f-e941-435f-844f-7735b226ff77_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ed3f5e30-2d8a-4ea4-90d2-cedb7f7fd46c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f5d8e7e5-22c4-4b0c-9365-8e67a923715a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_173f83fb-c7e2-497e-84da-ec6e1c32f200_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f6cbc5f0-e7ac-4a34-aa5f-6065fc563974_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_b5310c18-c924-4838-b5e3-a115b5bab710_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_17e44a06-6faa-4478-b5e4-41c44a79aacb_negatedLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deposit and other long-term assets and deferred rent receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_label_en-US" xlink:label="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Deposit And Other Noncurrent Assets And Deferred Rent Receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) in deposits and other noncurrent assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:href="advm-20231231.xsd#advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:to="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_f7c7008c-034d-45dc-b1ae-d2c9d15480af_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_5e9f265b-4aca-44e4-a230-d458dfd97530_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_b86ab3e4-ea08-4d37-b8aa-70f2d29808af_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8cabd985-b3e8-4f38-84de-cad6aaa7063f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_ccd54e68-6293-4223-9dcc-419d8d265b77_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_c2ec8c86-9b0e-44c0-ba89-a5ed9faedbc7_terseLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Cash equivalents, unrealized losses</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Loss</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:href="advm-20231231.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4d765d39-b280-4afd-8405-07ea112286f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_dac94ab9-7256-45f9-b93e-aa0430e7d866_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_bcc2d580-6ca0-48e3-a056-529c6f69b1b7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7e7d33d7-4889-4f12-99f3-6ff55ad16081_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6ba311ed-ae62-46a2-a3d6-f910c176a965_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b164d9f2-d0ca-4956-acf0-bc38825fbc24_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits as of the beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_09b4e886-20e7-478e-a1f2-800f4cff1cd2_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits as of the end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_7ceddae4-20d1-4322-b361-53948a09296b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_015bde6e-8e59-4a55-a96b-590b7d567148_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant stockholder threshold ownership percentage</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:to="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_815c66da-1325-491e-af0a-e5a41fd81cc8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrant shares outstanding and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0289ff79-576e-4e0c-9e6b-bc10bdc9761c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_92d647ec-511c-4442-8f06-9bc424a445ac_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5acfad20-cbd2-43fd-b3af-0e6fea2d0fa4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_c62f2533-a938-4924-a46f-ac08a88fec9b_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2c616be3-746d-422b-b1cb-223f53af1533_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6e086802-e397-41c7-845f-703b1dee50d4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6b712314-0147-4500-92cc-fc4abb2aefa7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_6bdaefbf-2b51-405b-a5f4-60a44987cf6a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_242ef92a-b208-46b4-91d1-5a56e6214f50_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a405d9d5-a6e0-4faf-b721-46eaf3b34c57_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_41a0ce36-fe96-4fb7-918d-793be822d455_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_db75802c-f06c-4008-9417-d4d345480bb7_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_244b7d5a-3451-4a8c-8af3-f42f5ee5f739_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bffef41f-53f4-4202-b68a-039c504e4ecd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2d827a4c-f37e-467c-830a-e84beb5e4651_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_827b2808-424a-48e0-81ad-b96f6af23ee1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_c340beb5-f5c9-4ef2-a43d-e490992f5eb2_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ffdbe10b-e954-4926-ab85-54386cff791a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae85c978-ebc4-4e6d-9eaf-dd207e38429b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_4bda429c-fd30-4277-96ae-14de61baafe8_terseLabel_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and fourteen employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:href="advm-20231231.xsd#advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e84bf044-92f2-4990-b430-780e6aece0df_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_217efa0b-b071-40c1-aa1f-b2ba6958d8a1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a40908c3-d8f4-4577-819b-5863e0b77f8d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6ac69c6a-cea7-4346-973e-08fdf0c0e9f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_953995c5-cc33-4d21-8b8b-edb82606c569_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d29bbab-aa06-4f8f-b35c-c2aae28598d2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_a14a96f7-cc24-4500-adf6-47672d151032_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f02a526c-1cf2-4da3-b3c4-93a4b947302c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_26a2cfce-2177-4f6b-99c5-6d9825721d86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OperatingLossCarryforwardsSubjectToExpiration_1dd1ed2d-2907-49d5-980e-ba2f945630d9_terseLabel_en-US" xlink:label="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards subject to expiration</link:label>
    <link:label id="lab_advm_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:label id="lab_advm_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards subject to expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="advm-20231231.xsd#advm_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_18524f3c-8114-4cb8-a0fb-d13adaccf6e0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_b290e468-3a20-4404-95c4-21dcf6678404_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncomeTaxesTable_f37a6ead-28a3-45a4-bf5c-090c1c43ed7e_terseLabel_en-US" xlink:label="lab_advm_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_advm_IncomeTaxesTable_label_en-US" xlink:label="lab_advm_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_advm_IncomeTaxesTable_documentation_en-US" xlink:label="lab_advm_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesTable" xlink:href="advm-20231231.xsd#advm_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncomeTaxesTable" xlink:to="lab_advm_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c47e66a-f0b1-41ad-96d5-bcbba37f1c6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ceebd0c1-692c-490e-9b9e-00f4a7fa4a8a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2dc81a66-8e5e-4d46-bfa4-ffb9c0494d13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities_bcd9f93f-605b-43ea-8f9b-117446f8b997_terseLabel_en-US" xlink:label="lab_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement of operating lease right-of-use assets and liabilities</link:label>
    <link:label id="lab_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities_label_en-US" xlink:label="lab_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Re-Measurement Of Operating Lease Liability And Right Of Use Assets and Liabilities</link:label>
    <link:label id="lab_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities_documentation_en-US" xlink:label="lab_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Re-Measurement Of Operating Lease Liability And Right Of Use Assets and Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" xlink:href="advm-20231231.xsd#advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" xlink:to="lab_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0a4cbbb6-b897-4a62-9010-7f58c34ce5b7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_c6eea6af-8afc-42fd-880f-27d75f9160af_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aa8a3543-4add-47b9-af33-b7c8e80e3112_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_a9b918e4-5119-45d8-8a95-646e64bd5563_terseLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_50f44e98-7ccb-4b3c-8df4-7e333b044978_totalLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="advm-20231231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a15f3ada-0e94-4716-b22a-cbb6f1d905dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6aa6b178-e7f7-4347-b0fd-91bb3df7d65d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_44c9dbce-a13f-4e06-9ca7-85a155aa69c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_41ac22c7-4039-4bf8-b56e-06a396487a71_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_776c3414-f207-4b77-954a-2782cd1800d5_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a2c49edb-4aa8-48b9-845f-652bcbfd23b8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2dccd1b3-45ff-47f8-a68a-e59d4dc4bf9a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b589913d-b790-4d49-918a-4c1bafbc9167_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_74aea917-af9b-47b1-bf3a-e87fe60e450a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_aa4501ce-80d1-453d-bd71-2ddb96738d07_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_f7547adb-492a-4b83-b0c7-2f4f50887fe8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_069d15b0-4489-471c-9d7f-04e5c48d5be6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5d04e757-5dfb-4b41-ae35-59ea9d4a1336_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8d632a7d-b104-4a7b-9da9-72b0ec59f469_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a388c20f-dcc2-4ac7-b5d4-0cf1f26af7d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_74f60996-86d2-4384-a552-60ca66768cf6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bbc60be9-7a64-469c-9df0-14cd439566a8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5a7a1274-2d9c-41cd-8e74-9dd77be57c69_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_4bf8cfbc-54f3-4fd5-8d50-5c26febb765e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease related to tax position taken during the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_7ceecf1a-a433-48fd-af1d-6e4a0a50c939_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2189dd6a-d711-448e-a60f-1f749b954801_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_90aff629-bede-4f08-9134-a5bfa8018268_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_447aad66-3574-4fc8-9677-21e2d4574170_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_2a9a9bd0-baef-4e53-bc07-a1996b661114_negatedLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Cash equivalents, amortized cost basis</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalent Amortized Cost</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalent Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:href="advm-20231231.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:to="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_16f9e184-7b43-4884-ab97-523abec68ae3_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_eeebb382-f317-4552-812e-ec5cf42a49b0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_05d62e3b-00bf-4cfe-8f0f-8eebaeb95732_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b41355d9-2f96-4f3c-a0c1-99a4d07e70f8_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net accretion of discount on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_92e9ba9a-1f81-4edc-9abf-fd7fee48b6f3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_53b9d814-aa29-42fd-994e-f4102eaeb8ca_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_992fd15a-1550-4d28-a39f-b8fb0bbaab39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposit and other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesTable_5205bab3-7a91-4bf8-8d81-e26df62c9dbf_terseLabel_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:href="advm-20231231.xsd#advm_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_76d51765-d219-461b-9958-de3d721dde8b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) Savings Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d6232afc-b342-4744-98ab-ea08b1b32891_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f85d8ae3-911e-4c4d-8ab2-901c765ed4a6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7a52b40f-6b39-4365-b258-3ba647e317f0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_df0cd5f0-6042-485c-8f60-f6afe206e436_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a3ead597-5265-4d1a-ba53-c995a3cc222a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized stock-based compensation expense related to awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9e089f8a-aa8c-4506-84bb-0fa7bb08a92d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d48f2930-58d7-4d5d-ae25-b8a9b0109f69_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_668bee9f-8c48-4f93-9ed8-080ee9d57ea3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncomeTaxesLineItems_3705bbb8-a1ef-45d7-b932-6aed7bb5bd54_terseLabel_en-US" xlink:label="lab_advm_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_advm_IncomeTaxesLineItems_label_en-US" xlink:label="lab_advm_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_advm_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_advm_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesLineItems" xlink:href="advm-20231231.xsd#advm_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncomeTaxesLineItems" xlink:to="lab_advm_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_3b888ccc-59c7-4788-9bd2-3257a8b19895_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7261fc21-4ddc-4648-b60d-bfd1cf1aa22c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35933ec4-36eb-4c5a-b938-d61ebc48cf25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ec92497c-d0ea-488b-8592-d6c509df2566_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7e555191-ac0a-4c8f-958f-0a10611acbfb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_cec549ac-6b7a-4365-847c-783447d9d7da_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b76d5fc4-acdd-4563-85c2-f8da73ca9158_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_64c77e04-2c57-4764-af8b-8c09e7e51769_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9bc6f9c2-4ae9-4842-a2b7-cc12ff563943_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_461d8a0b-c722-4105-b461-a5d4b46a8d0d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_0173d9d2-067c-45d4-88dd-5e96071f20da_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_199b1d6d-5d6b-41c4-8567-9234752a099c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_07d05da4-ab9c-4bf6-96f4-c41ba8ac713d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6164739b-67f4-4070-be3e-d191538ca56d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_14875c3d-feb5-4a98-b17f-77d69a1e5318_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_78973800-5a37-4c87-8572-f5be82efa4b5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2ff798bb-74a5-4d2a-bb67-dc0e1dd98012_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5c8f6a8b-5685-418f-bb1a-3592a58d8497_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in valuation allowance due to net operating loss</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e14fa64e-2715-43ec-97b1-ee6d7766b81c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4ab9a33a-8e64-469a-851e-1d257c443286_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_30b401c6-38b7-4876-a31d-d33b691dbfb6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e87e43a3-9a87-4b88-893c-1271b56bfc57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair values of RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bad234df-2f1e-4092-bc12-070238773191_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a163f53e-f654-4afb-8759-7989b1318b83_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c686d20f-070d-437d-8e84-25e2a7f633eb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_43077cef-1e15-473e-8a1a-9d7f90425084_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2ddea2ae-7545-49a5-94cd-7f0ae8ae02f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock pursuant to option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b1899629-7152-4790-b6df-4ff0df6548cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_eb3dd2ac-bb28-4b8f-aa6c-e15898c8a301_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_c835292f-969b-4701-98f6-c9ad0a29335e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_172dcf35-70cb-4e3a-8a8e-3d4864ac0cf1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_57acbd87-56ba-46dc-8e8d-cd7a53ce2aaf_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d3251389-6876-41c7-83ad-3c213d5ade9c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_66abd9a1-292e-42dd-baeb-71cf4389cfdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_549451f3-4128-4161-8db6-be81ebd053f1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_b1df7ce5-1f5a-4f7c-8112-921566091632_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award price as a percentage of grant date fair value, minimum</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:to="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_56eaae23-3918-4e22-bdd9-6cd0c5a762fa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance and Benefits Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoDirectorsMember_39f4ad10-c58e-44d7-9645-c1d391529f66_terseLabel_en-US" xlink:label="lab_advm_TwoDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Directors</link:label>
    <link:label id="lab_advm_TwoDirectorsMember_label_en-US" xlink:label="lab_advm_TwoDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Directors [Member]</link:label>
    <link:label id="lab_advm_TwoDirectorsMember_documentation_en-US" xlink:label="lab_advm_TwoDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoDirectorsMember" xlink:href="advm-20231231.xsd#advm_TwoDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoDirectorsMember" xlink:to="lab_advm_TwoDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_0d9f9db3-f518-49ca-9499-b0309d90cca9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments made</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_f2389faa-24f4-4c08-bf38-bd1726080997_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_973956b0-e8e5-4b03-a58a-c432a7f9884a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d276cddc-5a02-426c-bd7b-3b59ce30b68f_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_078dcf82-969d-4f39-800a-c9a5401df1e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_DeferredTaxAssetsLeaseObligation_a7596ae7-71b6-4407-bd6a-333a5467062e_terseLabel_en-US" xlink:label="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease obligation</link:label>
    <link:label id="lab_advm_DeferredTaxAssetsLeaseObligation_label_en-US" xlink:label="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Lease Obligation</link:label>
    <link:label id="lab_advm_DeferredTaxAssetsLeaseObligation_documentation_en-US" xlink:label="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets lease obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsLeaseObligation" xlink:href="advm-20231231.xsd#advm_DeferredTaxAssetsLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DeferredTaxAssetsLeaseObligation" xlink:to="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_56d92e84-bd76-4333-9b5b-21573ea2d735_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_f0b66996-7c57-42ee-8775-4fbda6b1fa29_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_dbab088d-65b0-4eba-818b-fcaa5b8a0203_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2bc80b71-aa44-4661-a480-12289d9dbe97_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_14686aa9-5174-4e82-b289-a573fcc4ebcd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (provision)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0c5d32f6-3f9a-474a-b60d-b2688f218770_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax (benefit) provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfLeasedFacilities_f630d6e4-c7ea-4ded-bc4e-11f4b41dddfe_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfLeasedFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of leased facilities</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfLeasedFacilities_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfLeasedFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Leased Facilities</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfLeasedFacilities_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfLeasedFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Leased Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfLeasedFacilities" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseNumberOfLeasedFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseNumberOfLeasedFacilities" xlink:to="lab_advm_LesseeOperatingLeaseNumberOfLeasedFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1d7284ce-7247-498d-ba5a-ea1dfca00cec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_6327605b-5b90-4098-86d2-7362b036ebf6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_SubleaseIncomeNet_e722ec9a-ef55-48b3-911e-8beba2bfcff4_terseLabel_en-US" xlink:label="lab_advm_SubleaseIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_advm_SubleaseIncomeNet_label_en-US" xlink:label="lab_advm_SubleaseIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income, Net</link:label>
    <link:label id="lab_advm_SubleaseIncomeNet_documentation_en-US" xlink:label="lab_advm_SubleaseIncomeNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublease Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SubleaseIncomeNet" xlink:href="advm-20231231.xsd#advm_SubleaseIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_SubleaseIncomeNet" xlink:to="lab_advm_SubleaseIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d05d7a47-55f4-43a3-ad7a-782ca6605d54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements and Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f9a2c7b9-9bba-4d66-a2dd-b88e94bf60d2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_78cc004e-ffdc-47d9-8927-ca805f8d35b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_72ef1e8a-7568-4b04-ae70-2076fbf0450a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_d90c6329-5e67-461e-a9b4-aa16cdf80a21_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_42630765-b85a-49ab-8028-99c31d2065c0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e71b1d11-d47f-4b29-97aa-d2d47637ef2f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_20a33b01-53dd-4439-b85e-965a16e3dfc3_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f9befdeb-6e3b-4186-8bdc-fdb25f2c21fd_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_f864b4bd-08d8-4154-962e-99c06c1c47d4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_0f0e38cc-b762-46d4-ba42-099280fc33bb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_71b2da15-a1a9-4083-b6f6-b8f42d45a576_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_28ab594d-c08a-4296-b4b9-86ed598584ea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average IBR (as percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_81099548-0835-4288-ac8f-bd7652c124ac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of laboratory equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AuditInformationAbstract_label_en-US" xlink:label="lab_advm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_advm_AuditInformationAbstract_documentation_en-US" xlink:label="lab_advm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AuditInformationAbstract" xlink:href="advm-20231231.xsd#advm_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AuditInformationAbstract" xlink:to="lab_advm_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_7366d387-981e-48f3-b3b5-03b60a3e9055_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life of assets (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_4eb694ea-f20c-475e-8b33-ce4f239cea76_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b5a23a4-29aa-484f-b608-bf7432fdc448_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_87f99007-9d1b-499d-8c8a-09240f7daaf7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent_8fc7e48c-3c01-461f-8be2-b64166463d1b_terseLabel_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued nonclinical, clinical and process development costs</link:label>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent_label_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Nonclinical, Clinical and Process Development Costs, Current</link:label>
    <link:label id="lab_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued preclinical costs current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent" xlink:href="advm-20231231.xsd#advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent" xlink:to="lab_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_61cdf617-1614-41c1-8e2b-c1d9312460d0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5e8f658-93e4-4a9f-8a01-fe22903e9dbb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c6e9aa12-1fea-4cd8-986b-329181c1d3a4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6fdbee52-7278-4ee5-9b2e-b07ed8d12c5d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_cb02eb36-2d7f-4c96-bc6f-fa828cc4d2fb_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c417a8b3-eeb9-43fc-b1f1-3b8343971c37_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_96a431f7-80cd-49a2-8183-14fb031e1c88_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b4fdadd4-1c2b-4af1-bc46-05f3ca22d4c9_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_02a7e4cf-aaf6-4e71-97a3-bdde93beeadd_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_9a25a6b9-249e-4e16-9678-24fd65e266ae_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d862beb2-6bfe-43ca-a0db-194a6770bee4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_3d26822d-ae25-4131-bd9d-a3d3a56e61a3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_712a1cfd-24d4-4877-85ad-14642eecff41_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73695dc0-041d-4f25-ad4d-f6e0fff4d9ee_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_63db64a8-1198-4cc0-8383-205ffab63bd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_4ebd5963-2ab6-4b26-a210-45fdb30d764a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees (as percent)</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_fa59a9f6-694b-4b7d-afaa-01b187902045_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_878c73c5-43ed-4c9e-8fae-71b1dba78ff4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LicenseAgreementsMilestonesAchieved_d464d429-3b6c-427f-a0eb-3815c13d6d77_terseLabel_en-US" xlink:label="lab_advm_LicenseAgreementsMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreements, milestones achieved</link:label>
    <link:label id="lab_advm_LicenseAgreementsMilestonesAchieved_label_en-US" xlink:label="lab_advm_LicenseAgreementsMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements, Milestones Achieved</link:label>
    <link:label id="lab_advm_LicenseAgreementsMilestonesAchieved_documentation_en-US" xlink:label="lab_advm_LicenseAgreementsMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreements, Milestones Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LicenseAgreementsMilestonesAchieved" xlink:href="advm-20231231.xsd#advm_LicenseAgreementsMilestonesAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LicenseAgreementsMilestonesAchieved" xlink:to="lab_advm_LicenseAgreementsMilestonesAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72175146-d1fa-4815-8687-e2d4f71f6812_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e5a5b85b-fb76-41b5-9e51-d4e6af5938fd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_47330c2a-017c-4dbc-8ff4-348b0f79b816_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8980ebcc-b5d4-45b0-a997-85d4b717ee9b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_71d506f8-1121-48a2-a25c-d56f4f7ca14d_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State credit carryforwards</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_88d82dca-fe9e-437d-b304-1cd8c45b65b9_terseLabel_en-US" xlink:label="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash settlement of operating lease liability</link:label>
    <link:label id="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_label_en-US" xlink:label="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Non-cash Consideration, Leasehold Improvements, Value</link:label>
    <link:label id="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_documentation_en-US" xlink:label="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Non-cash Consideration, Leasehold Improvements, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:href="advm-20231231.xsd#advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:to="lab_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_ff8ddfdf-c535-43fe-bfb5-b23f9dcd818d_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1ce6aaff-1ed1-4446-989f-51b731fa84b3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a686933-3bf7-425e-b8ab-c8d51b7c756e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0f9ec807-e02b-4b57-8fda-51e5150e0b14_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares used to compute net loss per share - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_5c29d074-c5e4-4ee6-851e-c07b08aaef79_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_837c7d57-2b32-4edd-a9bf-5fa49f228f9e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_bbe6864f-a240-4cca-bb4d-1c1b2a2857bf_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_09826388-8cb2-4bf3-bae7-8b37985892d7_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized loss (gain) on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Security, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9c04dffb-16ac-40e7-ab86-66abd5603090_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c32c719d-77b2-4a45-9230-d02718c4c3ee_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_7489d96b-dc4f-4a1f-968d-d9dcb48877f7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_dedee5c1-348c-4a0c-bc3c-8b45c420104d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6c2373a9-ace2-49c5-a55e-b4a68f2a4f06_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_74ad7954-abc6-48e3-90e2-718f4c5f6fb9_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_65b532d1-08d7-40ad-896d-ec9a497ff36f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contract Life (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedInterestReceivablePolicyTextBlock_7d83b915-c041-4b12-a67a-29b74cbd5bb4_terseLabel_en-US" xlink:label="lab_advm_AccruedInterestReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Interest Receivable</link:label>
    <link:label id="lab_advm_AccruedInterestReceivablePolicyTextBlock_label_en-US" xlink:label="lab_advm_AccruedInterestReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest Receivable [Policy Text Block]</link:label>
    <link:label id="lab_advm_AccruedInterestReceivablePolicyTextBlock_documentation_en-US" xlink:label="lab_advm_AccruedInterestReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedInterestReceivablePolicyTextBlock" xlink:href="advm-20231231.xsd#advm_AccruedInterestReceivablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedInterestReceivablePolicyTextBlock" xlink:to="lab_advm_AccruedInterestReceivablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_df895fc6-f175-44df-b45a-f4ec6afc3d42_verboseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for future issuance (as percent)</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement Increase In Number Of Shares Reserved For Issuance Percentage Under Plan</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement increase in number of shares reserved for issuance percentage under plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:to="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_7c2f657f-97f2-4bdb-9a96-05aa3fe3a0b6_negatedLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Cash equivalents</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Gain</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:href="advm-20231231.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_4074d37e-b37d-4bc4-b095-047697920e4e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_9e6da67e-adc5-4afa-8d52-b9e6f0ed2c4f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>advm-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0eb1737c-384e-4b48-8e56-f7ff90dff097,g:c0462913-63e1-4ed5-8ab4-52645bec5fa8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CoverPage" xlink:type="simple" xlink:href="advm-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1c7f94aa-01fe-4a87-acac-c6ced97f3b9e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_DocumentType_1c7f94aa-01fe-4a87-acac-c6ced97f3b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_5c6c92db-7ec9-4638-be76-3a02393fa644" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_DocumentAnnualReport_5c6c92db-7ec9-4638-be76-3a02393fa644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5674e3a3-d117-4e03-b863-e36c07f6a4b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_DocumentPeriodEndDate_5674e3a3-d117-4e03-b863-e36c07f6a4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_50a242c2-375f-44ad-a380-1e9f15d7cca8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_CurrentFiscalYearEndDate_50a242c2-375f-44ad-a380-1e9f15d7cca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7c94545c-9c14-4b32-a389-d463dc373ef0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_DocumentTransitionReport_7c94545c-9c14-4b32-a389-d463dc373ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4baa6dea-c784-4338-abdd-d3d60155ae43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityFileNumber_4baa6dea-c784-4338-abdd-d3d60155ae43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4aa84315-243a-422f-aa90-552bd22e1699" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityRegistrantName_4aa84315-243a-422f-aa90-552bd22e1699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_70da2c6a-9484-4dcb-9a94-11f3033f49d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityIncorporationStateCountryCode_70da2c6a-9484-4dcb-9a94-11f3033f49d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_bfca9be2-6e1f-470a-90f6-d1a29e93a073" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityTaxIdentificationNumber_bfca9be2-6e1f-470a-90f6-d1a29e93a073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_82ced1f9-f68b-4705-8081-dc7c3183364e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityAddressAddressLine1_82ced1f9-f68b-4705-8081-dc7c3183364e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b5778b35-3665-4695-ac2c-771efb3892ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityAddressCityOrTown_b5778b35-3665-4695-ac2c-771efb3892ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_24c9fec8-2f23-4016-9b10-60d28a908931" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityAddressStateOrProvince_24c9fec8-2f23-4016-9b10-60d28a908931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_cb398cc6-1122-414f-95b8-b29c26672d85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityAddressPostalZipCode_cb398cc6-1122-414f-95b8-b29c26672d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4147ac9b-e6a0-4164-984c-d0286fa5cdeb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_CityAreaCode_4147ac9b-e6a0-4164-984c-d0286fa5cdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f3c5e369-8abc-4cdb-8c8b-32ca877edcfe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_LocalPhoneNumber_f3c5e369-8abc-4cdb-8c8b-32ca877edcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5a515647-5aa0-4c3e-a445-7a142fbbe8b0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_Security12bTitle_5a515647-5aa0-4c3e-a445-7a142fbbe8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b35d79cc-b4bb-43ee-8b0e-429283c30c35" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_TradingSymbol_b35d79cc-b4bb-43ee-8b0e-429283c30c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_61229d23-c8f4-4c91-ab80-694075489ea5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_SecurityExchangeName_61229d23-c8f4-4c91-ab80-694075489ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6844a43d-6c44-4639-a2f8-ea9989df6b70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6844a43d-6c44-4639-a2f8-ea9989df6b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d3430021-70dc-4e34-9f07-4f48ee1ea6e0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityVoluntaryFilers_d3430021-70dc-4e34-9f07-4f48ee1ea6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_146990a6-4abb-4ca8-b13e-ed8b7a6e1174" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityCurrentReportingStatus_146990a6-4abb-4ca8-b13e-ed8b7a6e1174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a7ab55de-d74c-414e-aa2f-c037fa702225" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityInteractiveDataCurrent_a7ab55de-d74c-414e-aa2f-c037fa702225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6ec19fac-caef-4e38-9aa3-f29fa6a94537" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityFilerCategory_6ec19fac-caef-4e38-9aa3-f29fa6a94537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dd9814f4-cc7d-4dcf-8183-55cba4443d95" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntitySmallBusiness_dd9814f4-cc7d-4dcf-8183-55cba4443d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1424883e-b667-4bf9-b515-ea870de803a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityEmergingGrowthCompany_1424883e-b667-4bf9-b515-ea870de803a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_eb5fb7ef-1e0d-460c-92c7-4ab7fef1fe10" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_eb5fb7ef-1e0d-460c-92c7-4ab7fef1fe10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_63775148-2938-4700-af18-14bd76c35644" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_IcfrAuditorAttestationFlag_63775148-2938-4700-af18-14bd76c35644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_24247c69-9e08-42a4-9872-56d6de89b746" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityShellCompany_24247c69-9e08-42a4-9872-56d6de89b746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_c1f012d2-0653-45e8-a34b-e34aee2965cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityPublicFloat_c1f012d2-0653-45e8-a34b-e34aee2965cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7f3c8196-0bbf-472e-bc85-8dae6a76584e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7f3c8196-0bbf-472e-bc85-8dae6a76584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c6b76dbc-4f5a-471d-b0f5-c90f248d6a81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_AmendmentFlag_c6b76dbc-4f5a-471d-b0f5-c90f248d6a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_108e9f93-4fe0-4df4-ac38-df822a9340d9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_DocumentFiscalYearFocus_108e9f93-4fe0-4df4-ac38-df822a9340d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_45337c9d-b0f7-48c7-a025-3c1ebda6bbbb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_DocumentFiscalPeriodFocus_45337c9d-b0f7-48c7-a025-3c1ebda6bbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b4452270-dbba-428e-a928-dd9e25d2abe8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a308590-a485-4434-a612-d260302747ae" xlink:to="loc_dei_EntityCentralIndexKey_b4452270-dbba-428e-a928-dd9e25d2abe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/AuditInformation" xlink:type="simple" xlink:href="advm-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_AuditInformationAbstract_3d0da357-cd40-4411-9d78-ae9476f46b5d" xlink:href="advm-20231231.xsd#advm_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_9fe3019b-dbb2-4d04-8265-bd52de0e844c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_AuditInformationAbstract_3d0da357-cd40-4411-9d78-ae9476f46b5d" xlink:to="loc_dei_AuditorName_9fe3019b-dbb2-4d04-8265-bd52de0e844c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_50710871-6e9e-4c9e-8eb9-22593c8a4d00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_AuditInformationAbstract_3d0da357-cd40-4411-9d78-ae9476f46b5d" xlink:to="loc_dei_AuditorFirmId_50710871-6e9e-4c9e-8eb9-22593c8a4d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_ae1b1f8d-f2c8-46a0-8132-ff1c6996ec83" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_AuditInformationAbstract_3d0da357-cd40-4411-9d78-ae9476f46b5d" xlink:to="loc_dei_AuditorLocation_ae1b1f8d-f2c8-46a0-8132-ff1c6996ec83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="advm-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3f496bee-1376-4735-95c7-094be40712e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5517d3f6-69f1-4b1c-8666-a89b608a1642" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f496bee-1376-4735-95c7-094be40712e6" xlink:to="loc_us-gaap_AssetsAbstract_5517d3f6-69f1-4b1c-8666-a89b608a1642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_cb92de83-2198-433f-8a32-a2ee56d2fe73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5517d3f6-69f1-4b1c-8666-a89b608a1642" xlink:to="loc_us-gaap_AssetsCurrentAbstract_cb92de83-2198-433f-8a32-a2ee56d2fe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a07e0f1b-d4ef-4891-91df-373078f68390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb92de83-2198-433f-8a32-a2ee56d2fe73" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a07e0f1b-d4ef-4891-91df-373078f68390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_720bea32-3020-473c-adc3-4c8898b4dc29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb92de83-2198-433f-8a32-a2ee56d2fe73" xlink:to="loc_us-gaap_ShortTermInvestments_720bea32-3020-473c-adc3-4c8898b4dc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b0b6264-5332-4d48-81b9-42be66bf17e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb92de83-2198-433f-8a32-a2ee56d2fe73" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b0b6264-5332-4d48-81b9-42be66bf17e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3c249333-baf2-40c6-9e2d-48681f42dc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cb92de83-2198-433f-8a32-a2ee56d2fe73" xlink:to="loc_us-gaap_AssetsCurrent_3c249333-baf2-40c6-9e2d-48681f42dc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9d239145-ee12-4271-a58b-06cd36d60968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5517d3f6-69f1-4b1c-8666-a89b608a1642" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9d239145-ee12-4271-a58b-06cd36d60968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_101e8277-37f5-414a-bd68-5302123e7cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5517d3f6-69f1-4b1c-8666-a89b608a1642" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_101e8277-37f5-414a-bd68-5302123e7cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a1359c71-f8cf-46f0-b237-a0d1f151fff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5517d3f6-69f1-4b1c-8666-a89b608a1642" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a1359c71-f8cf-46f0-b237-a0d1f151fff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cdd9f8e6-5442-47e0-95a5-c29178b8d602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5517d3f6-69f1-4b1c-8666-a89b608a1642" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cdd9f8e6-5442-47e0-95a5-c29178b8d602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a5bedc38-a8f0-470e-8e0c-5d9fb91a496f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5517d3f6-69f1-4b1c-8666-a89b608a1642" xlink:to="loc_us-gaap_Assets_a5bedc38-a8f0-470e-8e0c-5d9fb91a496f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f25c002b-3755-44c1-a9bb-875b6e26b8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f496bee-1376-4735-95c7-094be40712e6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f25c002b-3755-44c1-a9bb-875b6e26b8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_30803d5c-51fd-4cba-b4c1-d0b3bfc07396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f25c002b-3755-44c1-a9bb-875b6e26b8c4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_30803d5c-51fd-4cba-b4c1-d0b3bfc07396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c10d1bdb-8e39-45f6-82f8-e717604c11ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30803d5c-51fd-4cba-b4c1-d0b3bfc07396" xlink:to="loc_us-gaap_AccountsPayableCurrent_c10d1bdb-8e39-45f6-82f8-e717604c11ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_a487983e-d0c0-45ee-b1fc-4aa892c018c3" xlink:href="advm-20231231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30803d5c-51fd-4cba-b4c1-d0b3bfc07396" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_a487983e-d0c0-45ee-b1fc-4aa892c018c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a3849013-b7cf-4d08-989d-d67de6f12385" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30803d5c-51fd-4cba-b4c1-d0b3bfc07396" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a3849013-b7cf-4d08-989d-d67de6f12385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b2f83a26-5c3a-4c56-8f71-55eba1cdbd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30803d5c-51fd-4cba-b4c1-d0b3bfc07396" xlink:to="loc_us-gaap_LiabilitiesCurrent_b2f83a26-5c3a-4c56-8f71-55eba1cdbd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_dcd6298c-804b-46df-a376-87113ea51131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f25c002b-3755-44c1-a9bb-875b6e26b8c4" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_dcd6298c-804b-46df-a376-87113ea51131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_01d17339-3889-40b5-9e4e-951d4af0b38b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_dcd6298c-804b-46df-a376-87113ea51131" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_01d17339-3889-40b5-9e4e-951d4af0b38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cd2cac36-3562-4540-8cc5-5d5fba743e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_dcd6298c-804b-46df-a376-87113ea51131" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_cd2cac36-3562-4540-8cc5-5d5fba743e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4d55202e-0954-4b18-b631-6442bda69ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_dcd6298c-804b-46df-a376-87113ea51131" xlink:to="loc_us-gaap_Liabilities_4d55202e-0954-4b18-b631-6442bda69ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c4213ab7-fe62-42bf-8a40-c197a97a7dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f25c002b-3755-44c1-a9bb-875b6e26b8c4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c4213ab7-fe62-42bf-8a40-c197a97a7dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f88b472e-c238-4567-9927-ead0e6c7bc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f25c002b-3755-44c1-a9bb-875b6e26b8c4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f88b472e-c238-4567-9927-ead0e6c7bc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3add1447-c5e4-47a3-873a-7c261dbd1de2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f88b472e-c238-4567-9927-ead0e6c7bc4e" xlink:to="loc_us-gaap_PreferredStockValue_3add1447-c5e4-47a3-873a-7c261dbd1de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_411fdf30-f341-4dae-a9fe-edcdbdedb80f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f88b472e-c238-4567-9927-ead0e6c7bc4e" xlink:to="loc_us-gaap_CommonStockValue_411fdf30-f341-4dae-a9fe-edcdbdedb80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_82312846-7511-4530-b6e0-45ab5d402ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f88b472e-c238-4567-9927-ead0e6c7bc4e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_82312846-7511-4530-b6e0-45ab5d402ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b24609b6-1f6b-4458-a8e3-536eec985400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f88b472e-c238-4567-9927-ead0e6c7bc4e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b24609b6-1f6b-4458-a8e3-536eec985400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20019bec-0482-4c52-a82c-55f44d93ee1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f88b472e-c238-4567-9927-ead0e6c7bc4e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20019bec-0482-4c52-a82c-55f44d93ee1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1d649612-41b4-427e-ae5d-9c3944ed51db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f88b472e-c238-4567-9927-ead0e6c7bc4e" xlink:to="loc_us-gaap_StockholdersEquity_1d649612-41b4-427e-ae5d-9c3944ed51db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d98a9172-c8de-4bc0-9f41-70be5be25263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f25c002b-3755-44c1-a9bb-875b6e26b8c4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d98a9172-c8de-4bc0-9f41-70be5be25263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="advm-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4758c60a-12ee-4651-a8c6-2153d5350658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c9a61987-a5a6-4d3f-8b00-a3fab444f877" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4758c60a-12ee-4651-a8c6-2153d5350658" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c9a61987-a5a6-4d3f-8b00-a3fab444f877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6ceefcb5-1adb-4603-974e-eade241e44b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4758c60a-12ee-4651-a8c6-2153d5350658" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6ceefcb5-1adb-4603-974e-eade241e44b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5db4b10a-9752-4aff-9f7f-92c0dd93ba96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4758c60a-12ee-4651-a8c6-2153d5350658" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5db4b10a-9752-4aff-9f7f-92c0dd93ba96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c2857ec0-bb61-4f69-a5ee-19097d271e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4758c60a-12ee-4651-a8c6-2153d5350658" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c2857ec0-bb61-4f69-a5ee-19097d271e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_81d089bc-2974-487c-a4f8-0f82ac8ce2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4758c60a-12ee-4651-a8c6-2153d5350658" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_81d089bc-2974-487c-a4f8-0f82ac8ce2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_28530c4d-bb71-4087-9ea6-a91192005414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4758c60a-12ee-4651-a8c6-2153d5350658" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_28530c4d-bb71-4087-9ea6-a91192005414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3fab8fd1-cbb3-47fa-8fd5-5091327f0209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4758c60a-12ee-4651-a8c6-2153d5350658" xlink:to="loc_us-gaap_CommonStockSharesIssued_3fab8fd1-cbb3-47fa-8fd5-5091327f0209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6408fbbe-61f4-4006-8370-d184f6be58af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4758c60a-12ee-4651-a8c6-2153d5350658" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6408fbbe-61f4-4006-8370-d184f6be58af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="advm-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bf9b4d13-174a-4a19-84c6-b3bcd4fcefa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bf9b4d13-174a-4a19-84c6-b3bcd4fcefa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a538c907-68e2-4494-9b06-198a2d774b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a538c907-68e2-4494-9b06-198a2d774b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a1178e0a-d0be-43b4-88d8-0aa7cf51da3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a538c907-68e2-4494-9b06-198a2d774b17" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a1178e0a-d0be-43b4-88d8-0aa7cf51da3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3b4f2faf-2a14-409c-943b-ba858abeabc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a538c907-68e2-4494-9b06-198a2d774b17" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3b4f2faf-2a14-409c-943b-ba858abeabc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_45956f77-7c9f-461f-a8ec-de077fdb1f52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a538c907-68e2-4494-9b06-198a2d774b17" xlink:to="loc_us-gaap_OperatingExpenses_45956f77-7c9f-461f-a8ec-de077fdb1f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a476dbca-d1f8-4b79-a08b-cfdd8cb5ed62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_OperatingIncomeLoss_a476dbca-d1f8-4b79-a08b-cfdd8cb5ed62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_78023fd6-a7cc-46d3-8972-eadbaf10be66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_78023fd6-a7cc-46d3-8972-eadbaf10be66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6e3771ca-64a0-40f8-9628-a9cee37e31b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6e3771ca-64a0-40f8-9628-a9cee37e31b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bfd07e2d-9fe4-4e6e-948a-fede1bc43cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bfd07e2d-9fe4-4e6e-948a-fede1bc43cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d8dd7d5-f85a-4c3c-93c7-4562a00de9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_NetIncomeLoss_9d8dd7d5-f85a-4c3c-93c7-4562a00de9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_5c7c9685-a7e5-4b4d-98b2-c29ff5f1b151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_5c7c9685-a7e5-4b4d-98b2-c29ff5f1b151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b5207984-98de-4b42-9b10-7f434c3851a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_5c7c9685-a7e5-4b4d-98b2-c29ff5f1b151" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b5207984-98de-4b42-9b10-7f434c3851a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_432c75a5-0731-49f9-afc0-a9a77e14a105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_5c7c9685-a7e5-4b4d-98b2-c29ff5f1b151" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_432c75a5-0731-49f9-afc0-a9a77e14a105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ef622b9c-25d1-4cfa-b2d5-cc86afad6cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_5c7c9685-a7e5-4b4d-98b2-c29ff5f1b151" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ef622b9c-25d1-4cfa-b2d5-cc86afad6cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_30d6e92c-e1ea-4d44-aec2-461c85cd6704" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_EarningsPerShareBasic_30d6e92c-e1ea-4d44-aec2-461c85cd6704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_29807a52-282d-49eb-8a72-e29b9360dd69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_29807a52-282d-49eb-8a72-e29b9360dd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cd4ad7d3-b0ab-42af-94c1-71f5b3e3e926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cd4ad7d3-b0ab-42af-94c1-71f5b3e3e926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b619138a-90d1-4c48-8583-0f8b95c05192" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4a349fa7-54bc-41f5-8324-cc333eb7d8e1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b619138a-90d1-4c48-8583-0f8b95c05192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="advm-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9c5338b3-f8de-414c-a5b0-8f9163d20af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6d34f68a-62e1-4bec-907e-a5835d5e927b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9c5338b3-f8de-414c-a5b0-8f9163d20af9" xlink:to="loc_us-gaap_StatementTable_6d34f68a-62e1-4bec-907e-a5835d5e927b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d455b7ef-2867-4205-9ccb-e4b1f87890e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6d34f68a-62e1-4bec-907e-a5835d5e927b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d455b7ef-2867-4205-9ccb-e4b1f87890e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d455b7ef-2867-4205-9ccb-e4b1f87890e1" xlink:to="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_301b395b-188a-407f-84ba-40d160610d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:to="loc_us-gaap_CommonStockMember_301b395b-188a-407f-84ba-40d160610d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_68b0da6b-795b-4671-aa31-824d148885e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_68b0da6b-795b-4671-aa31-824d148885e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e41f46b9-1c79-40c6-b794-cdfc8f46cc74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e41f46b9-1c79-40c6-b794-cdfc8f46cc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_826d9ac8-1298-4940-9036-18627dff9f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98e53b5d-ce8b-4b31-aef3-e40928cb7293" xlink:to="loc_us-gaap_RetainedEarningsMember_826d9ac8-1298-4940-9036-18627dff9f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_62da25cf-fa76-4d75-9300-31fb0d4b0726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6d34f68a-62e1-4bec-907e-a5835d5e927b" xlink:to="loc_us-gaap_StatementLineItems_62da25cf-fa76-4d75-9300-31fb0d4b0726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_62da25cf-fa76-4d75-9300-31fb0d4b0726" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bf5c6796-e45e-4729-a726-0b2e32e90b19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bf5c6796-e45e-4729-a726-0b2e32e90b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a82307c-df84-4e3a-b7af-74c63fdcfb29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockholdersEquity_1a82307c-df84-4e3a-b7af-74c63fdcfb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f8e0bd5-a051-4a95-bd2d-ca00b198c7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f8e0bd5-a051-4a95-bd2d-ca00b198c7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49d43730-dfc3-4a87-a50b-8c0fbca40866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49d43730-dfc3-4a87-a50b-8c0fbca40866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_33361e6a-3164-4a09-8799-30dbc2fd00e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_33361e6a-3164-4a09-8799-30dbc2fd00e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_838eb7cd-9166-4fef-96fd-cc25ac3d2825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_838eb7cd-9166-4fef-96fd-cc25ac3d2825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_dc9d917f-ea3d-496a-996e-6b8c57f9fe53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_dc9d917f-ea3d-496a-996e-6b8c57f9fe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3a499549-81b5-4112-befa-307fab116d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3a499549-81b5-4112-befa-307fab116d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b57692bb-9556-4e51-b608-023faa3cb022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b57692bb-9556-4e51-b608-023faa3cb022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e11d22af-c145-47f2-a852-5b6eaa2ac6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e11d22af-c145-47f2-a852-5b6eaa2ac6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23d98c87-3f29-4672-aff3-57a3e9c1b254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_NetIncomeLoss_23d98c87-3f29-4672-aff3-57a3e9c1b254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9d1f9ac6-5ff6-4eac-a939-bf4270341a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9d1f9ac6-5ff6-4eac-a939-bf4270341a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc09d888-fe19-4a77-8f78-5f78751041ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_26c632df-f34c-4b9c-b781-69ddd85b473d" xlink:to="loc_us-gaap_StockholdersEquity_cc09d888-fe19-4a77-8f78-5f78751041ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="advm-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_860b883d-f556-421e-96a7-9d786d5b2a64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_860b883d-f556-421e-96a7-9d786d5b2a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a790774-ba2d-44af-b9dd-dd4589a99e82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_860b883d-f556-421e-96a7-9d786d5b2a64" xlink:to="loc_us-gaap_NetIncomeLoss_1a790774-ba2d-44af-b9dd-dd4589a99e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92d63876-9878-4111-95d0-a95e4910b751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_860b883d-f556-421e-96a7-9d786d5b2a64" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92d63876-9878-4111-95d0-a95e4910b751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_f616691d-40cf-4b25-bb52-f19580a6ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92d63876-9878-4111-95d0-a95e4910b751" xlink:to="loc_us-gaap_DepreciationAndAmortization_f616691d-40cf-4b25-bb52-f19580a6ecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_798c674b-62f4-4a95-a620-fffb963d9dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92d63876-9878-4111-95d0-a95e4910b751" xlink:to="loc_us-gaap_ShareBasedCompensation_798c674b-62f4-4a95-a620-fffb963d9dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_30798d17-135f-4c90-9573-e2e7f62a9cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92d63876-9878-4111-95d0-a95e4910b751" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_30798d17-135f-4c90-9573-e2e7f62a9cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_55f910b9-7449-455b-87a6-4fe06ca7711d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92d63876-9878-4111-95d0-a95e4910b751" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_55f910b9-7449-455b-87a6-4fe06ca7711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_868c4a3d-a166-4ecf-ac14-7f350c012559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92d63876-9878-4111-95d0-a95e4910b751" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_868c4a3d-a166-4ecf-ac14-7f350c012559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_04997551-3de5-4d48-b8e8-440f34565ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92d63876-9878-4111-95d0-a95e4910b751" xlink:to="loc_us-gaap_AssetImpairmentCharges_04997551-3de5-4d48-b8e8-440f34565ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d273488d-5267-4b35-a338-74389e10045a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92d63876-9878-4111-95d0-a95e4910b751" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d273488d-5267-4b35-a338-74389e10045a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df3a8561-6fc2-4634-964a-b3e77430c41f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_860b883d-f556-421e-96a7-9d786d5b2a64" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df3a8561-6fc2-4634-964a-b3e77430c41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_69c23b81-dc25-42bc-a202-3480a5bb20ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df3a8561-6fc2-4634-964a-b3e77430c41f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_69c23b81-dc25-42bc-a202-3480a5bb20ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_dd64a55b-0ad2-49f2-a7a9-f207451a40bc" xlink:href="advm-20231231.xsd#advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df3a8561-6fc2-4634-964a-b3e77430c41f" xlink:to="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_dd64a55b-0ad2-49f2-a7a9-f207451a40bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1d742639-cf8b-4213-a7ef-b1998eaef292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df3a8561-6fc2-4634-964a-b3e77430c41f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1d742639-cf8b-4213-a7ef-b1998eaef292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_68581992-b8f8-4bef-aefe-eab26cd2acf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df3a8561-6fc2-4634-964a-b3e77430c41f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_68581992-b8f8-4bef-aefe-eab26cd2acf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_80899212-1330-434d-9372-cf2516f9c2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df3a8561-6fc2-4634-964a-b3e77430c41f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_80899212-1330-434d-9372-cf2516f9c2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_92e96f1e-b537-4d14-917a-0f47f2c85ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_860b883d-f556-421e-96a7-9d786d5b2a64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_92e96f1e-b537-4d14-917a-0f47f2c85ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a72ad179-b08f-403f-bc6a-ff6a3eb59f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a72ad179-b08f-403f-bc6a-ff6a3eb59f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fb651848-a373-4fe4-bfb8-d167572b28b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a72ad179-b08f-403f-bc6a-ff6a3eb59f7e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fb651848-a373-4fe4-bfb8-d167572b28b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3c33fb52-4a6a-4736-ac3b-0c4c89d2bf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a72ad179-b08f-403f-bc6a-ff6a3eb59f7e" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3c33fb52-4a6a-4736-ac3b-0c4c89d2bf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c55a34e-f180-4369-9f0d-c29ebf6d83ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a72ad179-b08f-403f-bc6a-ff6a3eb59f7e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c55a34e-f180-4369-9f0d-c29ebf6d83ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31ce2d81-96e8-42df-9d2a-7ad7eccbe3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a72ad179-b08f-403f-bc6a-ff6a3eb59f7e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31ce2d81-96e8-42df-9d2a-7ad7eccbe3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a73a8146-e78b-4f01-9341-c478352ca86f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a73a8146-e78b-4f01-9341-c478352ca86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4cb86388-14ce-453a-81a2-7cc6b297eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a73a8146-e78b-4f01-9341-c478352ca86f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4cb86388-14ce-453a-81a2-7cc6b297eaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2fe6863f-29dd-47f0-a164-f950a7c165b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a73a8146-e78b-4f01-9341-c478352ca86f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2fe6863f-29dd-47f0-a164-f950a7c165b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_0b6e830e-7a28-4e56-a808-ee74927ed4af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a73a8146-e78b-4f01-9341-c478352ca86f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_0b6e830e-7a28-4e56-a808-ee74927ed4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42869b35-169c-4af8-9ecf-f33a5abb494a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a73a8146-e78b-4f01-9341-c478352ca86f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42869b35-169c-4af8-9ecf-f33a5abb494a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_daaed29b-f3bb-47e6-89eb-91bb78d83a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_daaed29b-f3bb-47e6-89eb-91bb78d83a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d86048ba-17c5-4364-81e6-48ecf83c2ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d86048ba-17c5-4364-81e6-48ecf83c2ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca1ce00e-af04-4a87-ad21-5442af85d794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca1ce00e-af04-4a87-ad21-5442af85d794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_479ddc54-e576-4704-82fe-e3a876f1c361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_479ddc54-e576-4704-82fe-e3a876f1c361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a5891398-7d06-413d-b93a-eb0767059855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a5891398-7d06-413d-b93a-eb0767059855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a0d04b97-d349-4879-88cf-abdf5b308bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a0d04b97-d349-4879-88cf-abdf5b308bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4655bd1a-d8cf-4e8f-bc10-147b132968e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c892d71d-3b72-4433-859c-97507024021e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4655bd1a-d8cf-4e8f-bc10-147b132968e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_d345a5f5-e99d-470d-ac9b-a889cfa1a7de" xlink:href="advm-20231231.xsd#advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4655bd1a-d8cf-4e8f-bc10-147b132968e8" xlink:to="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_d345a5f5-e99d-470d-ac9b-a889cfa1a7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities_1641aba1-d169-47a4-b62a-bb7781296a74" xlink:href="advm-20231231.xsd#advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4655bd1a-d8cf-4e8f-bc10-147b132968e8" xlink:to="loc_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities_1641aba1-d169-47a4-b62a-bb7781296a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2553a708-7705-4b2a-8375-a2e364061cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4655bd1a-d8cf-4e8f-bc10-147b132968e8" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2553a708-7705-4b2a-8375-a2e364061cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="advm-20231231.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7eca3749-21e2-4999-a3a6-d2aa1c9179cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fc7865f8-1509-4029-a69c-34096f792615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7eca3749-21e2-4999-a3a6-d2aa1c9179cb" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fc7865f8-1509-4029-a69c-34096f792615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="advm-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f60bee97-adf0-433e-84db-3a4727e96beb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b44a193f-0b12-4220-9722-2bf353640556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f60bee97-adf0-433e-84db-3a4727e96beb" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b44a193f-0b12-4220-9722-2bf353640556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="simple" xlink:href="advm-20231231.xsd#FairValueMeasurementsandFairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2d09b9c9-4baa-4c86-ac46-56645d4a2e48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a41091d3-6c2c-4609-bc9a-342605bbf038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2d09b9c9-4baa-4c86-ac46-56645d4a2e48" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a41091d3-6c2c-4609-bc9a-342605bbf038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Revenue" xlink:type="simple" xlink:href="advm-20231231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_26656e51-d3b5-49eb-8251-624d85e07320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_cee9eb24-2534-4177-997a-f2e3c69fdac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_26656e51-d3b5-49eb-8251-624d85e07320" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_cee9eb24-2534-4177-997a-f2e3c69fdac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Leases" xlink:type="simple" xlink:href="advm-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2eee69c0-be30-45a3-92b8-4f7521443168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7c6efc8f-3387-4a0f-b8f2-745eb5aeb3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2eee69c0-be30-45a3-92b8-4f7521443168" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7c6efc8f-3387-4a0f-b8f2-745eb5aeb3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="advm-20231231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ce6c95be-0aa4-4c34-bc96-df1e06135e91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_64d2103f-aa06-4a56-b14f-5fba774491eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ce6c95be-0aa4-4c34-bc96-df1e06135e91" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_64d2103f-aa06-4a56-b14f-5fba774491eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="advm-20231231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d7c7d87e-9d4b-4e15-b881-cb275217894d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ae251f58-bc28-47c7-ac38-7ff24707bd07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d7c7d87e-9d4b-4e15-b881-cb275217894d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ae251f58-bc28-47c7-ac38-7ff24707bd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlans" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlans"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93b59a2d-0445-4f13-bd29-7374e74cb868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_73155dc9-b443-4bd3-afe0-0ca88e1fa2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93b59a2d-0445-4f13-bd29-7374e74cb868" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_73155dc9-b443-4bd3-afe0-0ca88e1fa2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/A401kSavingsPlan" xlink:type="simple" xlink:href="advm-20231231.xsd#A401kSavingsPlan"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/A401kSavingsPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_33540420-9fc8-497f-a7c9-1af7756018ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_58a6caeb-6476-41a7-bd2d-4d46ac42c5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_33540420-9fc8-497f-a7c9-1af7756018ad" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_58a6caeb-6476-41a7-bd2d-4d46ac42c5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Restructuring" xlink:type="simple" xlink:href="advm-20231231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_45febde7-ba53-42e8-a100-828669c6fe24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0c9d8028-e71a-410d-bab8-b03f141affdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_45febde7-ba53-42e8-a100-828669c6fe24" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0c9d8028-e71a-410d-bab8-b03f141affdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxes" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3c146418-3204-4f6a-a493-3c0c44e54e60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0afdc4d7-2ba4-4d35-b102-ce521e2f1dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c146418-3204-4f6a-a493-3c0c44e54e60" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0afdc4d7-2ba4-4d35-b102-ce521e2f1dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShare" xlink:type="simple" xlink:href="advm-20231231.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9ee5ed24-0c64-4105-ab28-96920ecbd2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_bf798e0f-c5fa-457d-95d6-ee08dbca2a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9ee5ed24-0c64-4105-ab28-96920ecbd2ad" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_bf798e0f-c5fa-457d-95d6-ee08dbca2a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SubsequentEvents" xlink:type="simple" xlink:href="advm-20231231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_33ecdd9b-1c79-49d9-a262-551a68b33562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_7bf38db1-562d-4c63-8fd2-0bcfae33cdce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_33ecdd9b-1c79-49d9-a262-551a68b33562" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_7bf38db1-562d-4c63-8fd2-0bcfae33cdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="advm-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_c3977631-0057-4fe5-bae8-e1c52b436b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_c3977631-0057-4fe5-bae8-e1c52b436b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_2957b8f4-2cfe-4797-9077-3bd0ee262fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_UseOfEstimates_2957b8f4-2cfe-4797-9077-3bd0ee262fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ba5282be-68f2-4ca2-9caa-2ed9956418ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ba5282be-68f2-4ca2-9caa-2ed9956418ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_55ead91c-c295-4a40-8c45-74e1789629c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_55ead91c-c295-4a40-8c45-74e1789629c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4123bd57-a63c-41d2-b69d-659658bc4d77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4123bd57-a63c-41d2-b69d-659658bc4d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_3013e6d8-2507-414c-ba6a-9a09a01c612e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_3013e6d8-2507-414c-ba6a-9a09a01c612e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedInterestReceivablePolicyTextBlock_01ddd955-027d-42da-abb4-1d9e7c136493" xlink:href="advm-20231231.xsd#advm_AccruedInterestReceivablePolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_advm_AccruedInterestReceivablePolicyTextBlock_01ddd955-027d-42da-abb4-1d9e7c136493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0c178224-c4de-45f8-989c-64aba742cb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0c178224-c4de-45f8-989c-64aba742cb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4756c1d1-701f-4a00-b898-ec003a29bc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4756c1d1-701f-4a00-b898-ec003a29bc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_010e4eef-dc4b-4503-b5b1-18b41a79a1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_010e4eef-dc4b-4503-b5b1-18b41a79a1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_9139967e-f18e-49e2-9b88-40630477f22f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_9139967e-f18e-49e2-9b88-40630477f22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_7ee3a3a2-635e-451a-9271-e251565c0716" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_7ee3a3a2-635e-451a-9271-e251565c0716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3583aee0-da4f-4dd4-8531-50d5c68ff50c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3583aee0-da4f-4dd4-8531-50d5c68ff50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_23127c59-b3b8-43f9-8562-fb17694b863f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_23127c59-b3b8-43f9-8562-fb17694b863f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1684c6a6-6972-4c62-baa0-b29b964918f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1684c6a6-6972-4c62-baa0-b29b964918f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5bbbc930-29c1-4288-82ed-d6872725083c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5bbbc930-29c1-4288-82ed-d6872725083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_66ea44bc-5cda-453a-9111-5b5245c2994e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_66ea44bc-5cda-453a-9111-5b5245c2994e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_233ac392-5302-4b24-ac1a-08ae952ff816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_233ac392-5302-4b24-ac1a-08ae952ff816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_064bbf08-2da6-4f7c-8a41-71fa6ba4dcae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_064bbf08-2da6-4f7c-8a41-71fa6ba4dcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4da75908-c514-47dc-b503-72be4e0f99ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_865fdd72-7a43-4f2a-9fbf-0f2a3a4fd25e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4da75908-c514-47dc-b503-72be4e0f99ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="advm-20231231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3aaa64f3-fa8c-49f6-a1b7-8d491f132537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3ec6413b-4195-4e53-be82-6a982a40bdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3aaa64f3-fa8c-49f6-a1b7-8d491f132537" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3ec6413b-4195-4e53-be82-6a982a40bdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesTables" xlink:type="simple" xlink:href="advm-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4f9fde9f-fd51-4d28-b4f8-ff781f17abbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0d6cb2fd-e47b-43ae-999c-1d1fc44e0222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4f9fde9f-fd51-4d28-b4f8-ff781f17abbb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0d6cb2fd-e47b-43ae-999c-1d1fc44e0222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="advm-20231231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5dedda50-ee73-4af5-bc88-cae29afef238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_392346ce-11fc-4326-9403-ceed758a4168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5dedda50-ee73-4af5-bc88-cae29afef238" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_392346ce-11fc-4326-9403-ceed758a4168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_14b28972-7b2b-49d1-ae2a-05ce3502defb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_5dedda50-ee73-4af5-bc88-cae29afef238" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_14b28972-7b2b-49d1-ae2a-05ce3502defb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansTables" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlansTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_394714e5-7d3a-483d-8f51-1d30eb3941fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c7df1eec-0b12-484a-aebf-4d1fc4a87a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_394714e5-7d3a-483d-8f51-1d30eb3941fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c7df1eec-0b12-484a-aebf-4d1fc4a87a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c910a3c8-64e8-43a6-b71e-d36553cb0d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_394714e5-7d3a-483d-8f51-1d30eb3941fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c910a3c8-64e8-43a6-b71e-d36553cb0d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_cd248376-7bd2-40de-8473-190eb1158bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_394714e5-7d3a-483d-8f51-1d30eb3941fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_cd248376-7bd2-40de-8473-190eb1158bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ba045f40-56fb-4b6e-b4da-9e4486fd23ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_394714e5-7d3a-483d-8f51-1d30eb3941fe" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ba045f40-56fb-4b6e-b4da-9e4486fd23ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringTables" xlink:type="simple" xlink:href="advm-20231231.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_97233235-b883-4d37-97f0-b8cb25f6d7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_178b62a1-d1dd-473c-b2eb-877050389248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_97233235-b883-4d37-97f0-b8cb25f6d7c2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_178b62a1-d1dd-473c-b2eb-877050389248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_57763ba5-7fde-4967-9535-9f45945ed042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_97bda962-53ee-4639-9388-15f9ee1abe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_57763ba5-7fde-4967-9535-9f45945ed042" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_97bda962-53ee-4639-9388-15f9ee1abe5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_66dc55f0-cd38-48f3-8603-301f9946717e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_57763ba5-7fde-4967-9535-9f45945ed042" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_66dc55f0-cd38-48f3-8603-301f9946717e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_891f59ac-9cb1-4602-93a2-d07b8d5e074d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_57763ba5-7fde-4967-9535-9f45945ed042" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_891f59ac-9cb1-4602-93a2-d07b8d5e074d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bd1f54a9-2ec3-4516-b541-3ccaa60e8abc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_57763ba5-7fde-4967-9535-9f45945ed042" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bd1f54a9-2ec3-4516-b541-3ccaa60e8abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_f921e5fc-060d-4865-b3c1-f9bda5975793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_57763ba5-7fde-4967-9535-9f45945ed042" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_f921e5fc-060d-4865-b3c1-f9bda5975793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="advm-20231231.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7cff8ac0-cc16-46d0-9a31-6933f0e52382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e04b1f82-f110-49f5-a616-f1493ef2ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7cff8ac0-cc16-46d0-9a31-6933f0e52382" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e04b1f82-f110-49f5-a616-f1493ef2ce98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SubsequentEventsTables" xlink:type="simple" xlink:href="advm-20231231.xsd#SubsequentEventsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SubsequentEventsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_013ebe5b-b847-4bf2-b312-75810ce9769d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f81ee0e2-d8fa-40dc-9cef-4105a6fa884a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_013ebe5b-b847-4bf2-b312-75810ce9769d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f81ee0e2-d8fa-40dc-9cef-4105a6fa884a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#DescriptionofthebusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d3df47b-d541-4460-80c8-29f7539e5e55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ba70d7c9-9bcc-4913-924a-70d39173e9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d3df47b-d541-4460-80c8-29f7539e5e55" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ba70d7c9-9bcc-4913-924a-70d39173e9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d88bc342-bb1d-40a6-8ef6-efd6bd1d3740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d3df47b-d541-4460-80c8-29f7539e5e55" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d88bc342-bb1d-40a6-8ef6-efd6bd1d3740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0248d48f-6a19-4d6c-a08d-bf202242779d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesTable_b3b28414-0afe-4e0a-b128-87cb32506e1c" xlink:href="advm-20231231.xsd#advm_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0248d48f-6a19-4d6c-a08d-bf202242779d" xlink:to="loc_advm_SummaryOfSignificantAccountingPoliciesTable_b3b28414-0afe-4e0a-b128-87cb32506e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a826882d-8ec9-403e-9c1a-2577c13cafc7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_b3b28414-0afe-4e0a-b128-87cb32506e1c" xlink:to="loc_srt_RangeAxis_a826882d-8ec9-403e-9c1a-2577c13cafc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_241f5b91-6827-4d50-9e3c-aa33df1ddf0a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a826882d-8ec9-403e-9c1a-2577c13cafc7" xlink:to="loc_srt_RangeMember_241f5b91-6827-4d50-9e3c-aa33df1ddf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_75a50ed1-f046-479d-a2c9-08c46e493f62" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_241f5b91-6827-4d50-9e3c-aa33df1ddf0a" xlink:to="loc_srt_MinimumMember_75a50ed1-f046-479d-a2c9-08c46e493f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f61ccb67-8c63-4d4f-8cc4-47f875dda688" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_241f5b91-6827-4d50-9e3c-aa33df1ddf0a" xlink:to="loc_srt_MaximumMember_f61ccb67-8c63-4d4f-8cc4-47f875dda688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:href="advm-20231231.xsd#advm_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_b3b28414-0afe-4e0a-b128-87cb32506e1c" xlink:to="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_dee97f13-25d8-4859-ab90-bbb6719fb97f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_us-gaap_NumberOfReportableSegments_dee97f13-25d8-4859-ab90-bbb6719fb97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_89fc1b59-5ffd-4166-beeb-9c4fe56fab73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_89fc1b59-5ffd-4166-beeb-9c4fe56fab73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2cad97a1-9005-48ed-8252-f9ca984aaf29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2cad97a1-9005-48ed-8252-f9ca984aaf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_76543ca2-958e-4c6c-9013-ee725a6c0853" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_us-gaap_AssetImpairmentCharges_76543ca2-958e-4c6c-9013-ee725a6c0853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SubleaseIncomeNet_c5f24a23-ed9c-4fd6-98c2-e4c228440551" xlink:href="advm-20231231.xsd#advm_SubleaseIncomeNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_advm_SubleaseIncomeNet_c5f24a23-ed9c-4fd6-98c2-e4c228440551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_60795819-05a2-4c03-96ae-51a5d3c141fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_459c195f-26fa-473d-be0a-4efbdf03e4a3" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_60795819-05a2-4c03-96ae-51a5d3c141fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d82cc803-2ab6-4770-b3c6-bda1c14f746f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_751bd618-ea5d-401c-b708-c074387b504a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d82cc803-2ab6-4770-b3c6-bda1c14f746f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_751bd618-ea5d-401c-b708-c074387b504a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_886eca1e-f361-4382-935e-37b88a723a38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_751bd618-ea5d-401c-b708-c074387b504a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_886eca1e-f361-4382-935e-37b88a723a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3893d520-6cf0-4238-9c80-8038cc32c25d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_886eca1e-f361-4382-935e-37b88a723a38" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3893d520-6cf0-4238-9c80-8038cc32c25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bc84a43b-a288-45dc-a982-056e2fb589f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3893d520-6cf0-4238-9c80-8038cc32c25d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bc84a43b-a288-45dc-a982-056e2fb589f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8aa4acac-65b9-423d-bc05-30bcd873d623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3893d520-6cf0-4238-9c80-8038cc32c25d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8aa4acac-65b9-423d-bc05-30bcd873d623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6a222c0c-7e78-46c1-81d6-761b6bcc1a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_751bd618-ea5d-401c-b708-c074387b504a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6a222c0c-7e78-46c1-81d6-761b6bcc1a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a222c0c-7e78-46c1-81d6-761b6bcc1a2c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c02cadb4-6860-46b7-a068-d61986d6d958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c02cadb4-6860-46b7-a068-d61986d6d958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_086c172d-f295-4d43-995d-1ab8e6fe5e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:to="loc_us-gaap_CommercialPaperMember_086c172d-f295-4d43-995d-1ab8e6fe5e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_86a75c8f-6d31-49f1-a105-caf15bdc11a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_86a75c8f-6d31-49f1-a105-caf15bdc11a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_fc859c66-2195-45f3-ab10-034a86134aac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_fc859c66-2195-45f3-ab10-034a86134aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_0c779a6e-e822-4c0c-bd78-339749e77467" xlink:href="advm-20231231.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0aa2605-388c-4af2-87c3-a91d41eb9351" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_0c779a6e-e822-4c0c-bd78-339749e77467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_751bd618-ea5d-401c-b708-c074387b504a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b12bad2c-5d38-4714-814c-376736f7f6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b12bad2c-5d38-4714-814c-376736f7f6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7e337b63-5a72-49a0-8d73-a7a99a64c5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7e337b63-5a72-49a0-8d73-a7a99a64c5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed1a4e8f-9638-4ed2-b344-2a25256d967c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed1a4e8f-9638-4ed2-b344-2a25256d967c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_51e4d1e0-75f8-4bab-9571-2bbdfac142d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_51e4d1e0-75f8-4bab-9571-2bbdfac142d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_23e572fb-46c4-4b77-b723-8261ca2d26b2" xlink:href="advm-20231231.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_23e572fb-46c4-4b77-b723-8261ca2d26b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_385d2418-020b-4978-8569-a5b53de35c1e" xlink:href="advm-20231231.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_385d2418-020b-4978-8569-a5b53de35c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_b11234bd-c084-4f29-8d17-b06d4ef98882" xlink:href="advm-20231231.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_b11234bd-c084-4f29-8d17-b06d4ef98882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b361ec58-9109-4e90-abb0-5ed14a45dd59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72cd2f06-6e2c-426b-9bb1-9e6125c1f180" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b361ec58-9109-4e90-abb0-5ed14a45dd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0d3990ef-829c-44d4-bd10-845ce85468b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_78b20d28-3fc1-4c14-ad8c-9e523337edaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0d3990ef-829c-44d4-bd10-845ce85468b9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_78b20d28-3fc1-4c14-ad8c-9e523337edaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d88a3011-4732-4c97-bd32-68106cc29335" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_78b20d28-3fc1-4c14-ad8c-9e523337edaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d88a3011-4732-4c97-bd32-68106cc29335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dddc276c-23aa-487d-82b8-1b824bb68375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d88a3011-4732-4c97-bd32-68106cc29335" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dddc276c-23aa-487d-82b8-1b824bb68375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_57ce91ea-52bb-45e6-ac13-d2faf42ff990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dddc276c-23aa-487d-82b8-1b824bb68375" xlink:to="loc_us-gaap_EquipmentMember_57ce91ea-52bb-45e6-ac13-d2faf42ff990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_78b20d28-3fc1-4c14-ad8c-9e523337edaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_76d86266-9224-401b-95de-68ac84eff7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_76d86266-9224-401b-95de-68ac84eff7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_4ac4df27-4c89-4671-b8b7-3ba19b1fae8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_4ac4df27-4c89-4671-b8b7-3ba19b1fae8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e011dda6-f622-424b-937a-706f21af9005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:to="loc_us-gaap_AssetImpairmentCharges_e011dda6-f622-424b-937a-706f21af9005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_0a889508-a64a-4f67-965a-be933feb3dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6376c5ed-f621-4013-af93-3ec532d0f0bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_0a889508-a64a-4f67-965a-be933feb3dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RevenueDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#RevenueDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4d1f6b45-5dd0-4a60-b15e-7eb0b14a13c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a3951d2c-e31a-4694-9b52-5942ef8ed55f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4d1f6b45-5dd0-4a60-b15e-7eb0b14a13c4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a3951d2c-e31a-4694-9b52-5942ef8ed55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bdf7ff8a-5a9a-4b34-9cae-6c754696a9f5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a3951d2c-e31a-4694-9b52-5942ef8ed55f" xlink:to="loc_srt_CounterpartyNameAxis_bdf7ff8a-5a9a-4b34-9cae-6c754696a9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_badec8a3-375f-4579-adf1-60f65254f081" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bdf7ff8a-5a9a-4b34-9cae-6c754696a9f5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_badec8a3-375f-4579-adf1-60f65254f081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember_ea41d66a-f06d-4adc-b89b-11f824197a86" xlink:href="advm-20231231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_badec8a3-375f-4579-adf1-60f65254f081" xlink:to="loc_advm_LexeoTherapeuticsIncMember_ea41d66a-f06d-4adc-b89b-11f824197a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_40bf3bfe-4902-456e-af02-7ccb48fe5528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a3951d2c-e31a-4694-9b52-5942ef8ed55f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_40bf3bfe-4902-456e-af02-7ccb48fe5528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_f7b52258-d737-4505-9dcb-046a639cb55a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_40bf3bfe-4902-456e-af02-7ccb48fe5528" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_f7b52258-d737-4505-9dcb-046a639cb55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b1bf6e7-b88c-4af1-8425-7df66aa0f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_40bf3bfe-4902-456e-af02-7ccb48fe5528" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b1bf6e7-b88c-4af1-8425-7df66aa0f2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_52f785ed-8c61-4316-8ba8-fde2cd86b1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5f616824-8fa5-4dc8-8cd6-4d6db80fe57b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_52f785ed-8c61-4316-8ba8-fde2cd86b1b4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5f616824-8fa5-4dc8-8cd6-4d6db80fe57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4185788-eb7d-4eaf-bfa1-cdf154d8d184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5f616824-8fa5-4dc8-8cd6-4d6db80fe57b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4185788-eb7d-4eaf-bfa1-cdf154d8d184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28001a69-18b7-48cc-855a-080f87064d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f4185788-eb7d-4eaf-bfa1-cdf154d8d184" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28001a69-18b7-48cc-855a-080f87064d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_cba85044-0da7-4da4-acc3-e3f0537c6ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28001a69-18b7-48cc-855a-080f87064d9e" xlink:to="loc_us-gaap_BuildingMember_cba85044-0da7-4da4-acc3-e3f0537c6ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_4cfa2b81-1f88-4d5f-9626-12c1bfec49ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28001a69-18b7-48cc-855a-080f87064d9e" xlink:to="loc_us-gaap_ManufacturingFacilityMember_4cfa2b81-1f88-4d5f-9626-12c1bfec49ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5f616824-8fa5-4dc8-8cd6-4d6db80fe57b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_e68ae26a-3009-4648-8421-56b2704df31d" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseLeaseholdImprovementAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_e68ae26a-3009-4648-8421-56b2704df31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_fb683779-c48a-4c16-8b34-3461166b84e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_fb683779-c48a-4c16-8b34-3461166b84e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_10d56a6f-1a1f-4c68-8309-b4fac70ba062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_10d56a6f-1a1f-4c68-8309-b4fac70ba062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfLeasedFacilities_a9f0a8ad-c000-48cd-9bf2-a4d44856cb40" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseNumberOfLeasedFacilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfLeasedFacilities_a9f0a8ad-c000-48cd-9bf2-a4d44856cb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated_ffc6d62b-8b56-4cdc-a51d-0176b2e1ec64" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated_ffc6d62b-8b56-4cdc-a51d-0176b2e1ec64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_53141933-30db-4f6a-a457-09ef0398d249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_53141933-30db-4f6a-a457-09ef0398d249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_1d25a461-b230-42bd-9855-081927efd003" xlink:href="advm-20231231.xsd#advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue_1d25a461-b230-42bd-9855-081927efd003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_1ac395f4-75c7-4065-90db-f2aa09d8d709" xlink:href="advm-20231231.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_1ac395f4-75c7-4065-90db-f2aa09d8d709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities_6a9f7107-6429-4605-8424-d8eb10ca5c43" xlink:href="advm-20231231.xsd#advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities_6a9f7107-6429-4605-8424-d8eb10ca5c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_9a12be49-4a01-4ae4-ab08-d5aa34e6aa75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_9a12be49-4a01-4ae4-ab08-d5aa34e6aa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ee99ac94-5062-4854-a649-9a8ee5ca2753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ee99ac94-5062-4854-a649-9a8ee5ca2753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8f7f16d5-a31a-4203-bc1b-eb16b47ec2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8f7f16d5-a31a-4203-bc1b-eb16b47ec2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a79d0bd3-6201-4f70-be9c-843dee43db3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_OperatingLeaseCost_a79d0bd3-6201-4f70-be9c-843dee43db3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ede425eb-b708-4bf5-b3b9-83150950a4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_VariableLeaseCost_ede425eb-b708-4bf5-b3b9-83150950a4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_7d51fa99-f31c-4c3b-869f-82b33e281359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_us-gaap_OperatingLeasePayments_7d51fa99-f31c-4c3b-869f-82b33e281359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SubleaseIncomeNet_0b0c1e51-420b-44fe-ba54-37ae3056b87d" xlink:href="advm-20231231.xsd#advm_SubleaseIncomeNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_59845582-88fd-4634-817c-4e0db6bbbf24" xlink:to="loc_advm_SubleaseIncomeNet_0b0c1e51-420b-44fe-ba54-37ae3056b87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_47458663-6ad2-461a-a0c9-138852a40491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_47458663-6ad2-461a-a0c9-138852a40491" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9fead4f3-35dc-43c7-98c2-75b4fd7d8e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9fead4f3-35dc-43c7-98c2-75b4fd7d8e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d3700bc9-2c74-4c26-9ff7-201e5e8ce37e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d3700bc9-2c74-4c26-9ff7-201e5e8ce37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c77be549-e7c5-480b-8c58-c9186f095f99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c77be549-e7c5-480b-8c58-c9186f095f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4ee009a0-6d41-4e68-8672-4baa5af57e65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4ee009a0-6d41-4e68-8672-4baa5af57e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c321c130-d4be-409c-970c-81e8b625382d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c321c130-d4be-409c-970c-81e8b625382d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0c95f332-cd09-4d73-a7cc-f92d0a04acba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0c95f332-cd09-4d73-a7cc-f92d0a04acba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2b5612f-dc05-4f26-b654-26879dfe18b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a2b5612f-dc05-4f26-b654-26879dfe18b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf935c98-84d7-48d1-ad58-74e6a2fae238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf935c98-84d7-48d1-ad58-74e6a2fae238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1843b1cd-596f-49c9-8b43-da3c828aa9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_17c47d0e-f1c1-47e5-828c-c4e263f44619" xlink:to="loc_us-gaap_OperatingLeaseLiability_1843b1cd-596f-49c9-8b43-da3c828aa9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_c401f8fe-eae8-4b66-86d8-5aab764f86ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_47458663-6ad2-461a-a0c9-138852a40491" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_c401f8fe-eae8-4b66-86d8-5aab764f86ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_3f4da170-f21c-470e-9f46-777a80d314b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_c401f8fe-eae8-4b66-86d8-5aab764f86ef" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_3f4da170-f21c-470e-9f46-777a80d314b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_749f26d7-3721-450d-8cd7-c42b66d1c002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_c401f8fe-eae8-4b66-86d8-5aab764f86ef" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_749f26d7-3721-450d-8cd7-c42b66d1c002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_7c8b3753-bb46-4613-9a10-05383007b46c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_c401f8fe-eae8-4b66-86d8-5aab764f86ef" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_7c8b3753-bb46-4613-9a10-05383007b46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_a60c9e42-f368-456d-b063-1928b806be77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_c401f8fe-eae8-4b66-86d8-5aab764f86ef" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_a60c9e42-f368-456d-b063-1928b806be77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_f15003a8-6588-41c4-9d46-1184c169dd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_c401f8fe-eae8-4b66-86d8-5aab764f86ef" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_f15003a8-6588-41c4-9d46-1184c169dd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_b8f7612c-18ea-42d8-a974-6bf194f7a261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_c401f8fe-eae8-4b66-86d8-5aab764f86ef" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_b8f7612c-18ea-42d8-a974-6bf194f7a261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4ddbd534-86f8-466c-9b77-a8604380975e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_c401f8fe-eae8-4b66-86d8-5aab764f86ef" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4ddbd534-86f8-466c-9b77-a8604380975e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_225df2f1-945b-4627-a27b-863b50518d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e21e51f6-d18d-4337-8709-d301c4ade380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_225df2f1-945b-4627-a27b-863b50518d03" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e21e51f6-d18d-4337-8709-d301c4ade380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79f74087-6997-410f-9395-965ef1e81eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e21e51f6-d18d-4337-8709-d301c4ade380" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79f74087-6997-410f-9395-965ef1e81eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79f74087-6997-410f-9395-965ef1e81eab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d111da62-8144-41c9-a402-6b40fb440e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:to="loc_us-gaap_EquipmentMember_d111da62-8144-41c9-a402-6b40fb440e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_881adcbf-77a0-4827-9392-811f3211be7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_881adcbf-77a0-4827-9392-811f3211be7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2aa260e1-0be1-4a0c-851a-0de044d613df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:to="loc_us-gaap_ComputerEquipmentMember_2aa260e1-0be1-4a0c-851a-0de044d613df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6ddf32a3-31f6-416f-bdaa-1248a815cd25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6ddf32a3-31f6-416f-bdaa-1248a815cd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b26499d8-71a4-4375-a664-ef7e9b21d423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ab816b7-601f-497b-812d-b71696a1ca52" xlink:to="loc_us-gaap_ConstructionInProgressMember_b26499d8-71a4-4375-a664-ef7e9b21d423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d512b07-f4ff-429e-a283-4ddfd3184a28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e21e51f6-d18d-4337-8709-d301c4ade380" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d512b07-f4ff-429e-a283-4ddfd3184a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d230d92b-2246-401f-acf3-973bbafad429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d512b07-f4ff-429e-a283-4ddfd3184a28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d230d92b-2246-401f-acf3-973bbafad429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02f031ce-ea7c-4570-b0df-7e947cfa1cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d512b07-f4ff-429e-a283-4ddfd3184a28" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02f031ce-ea7c-4570-b0df-7e947cfa1cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_378320b2-f86a-44b2-b292-a36b4431a3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d512b07-f4ff-429e-a283-4ddfd3184a28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_378320b2-f86a-44b2-b292-a36b4431a3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9083a0b4-4d56-4864-bfd4-b564e99906ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_a05e4655-5876-4a37-b2a9-6d9de238a684" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9083a0b4-4d56-4864-bfd4-b564e99906ee" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_a05e4655-5876-4a37-b2a9-6d9de238a684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent_d15a099d-4dc9-4d1f-a24d-5b0384761472" xlink:href="advm-20231231.xsd#advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9083a0b4-4d56-4864-bfd4-b564e99906ee" xlink:to="loc_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent_d15a099d-4dc9-4d1f-a24d-5b0384761472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_581410ee-c06d-4463-961a-5051e22d6871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9083a0b4-4d56-4864-bfd4-b564e99906ee" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_581410ee-c06d-4463-961a-5051e22d6871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_bb9d2afb-fd79-4a75-9d82-dceb5837423f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9083a0b4-4d56-4864-bfd4-b564e99906ee" xlink:to="loc_us-gaap_TaxesPayableCurrent_bb9d2afb-fd79-4a75-9d82-dceb5837423f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_964fbc46-3630-42f1-8d66-cc4b5848dde8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9083a0b4-4d56-4864-bfd4-b564e99906ee" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_964fbc46-3630-42f1-8d66-cc4b5848dde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6e7cc380-57f5-4c6a-b1b8-e62efefa0dea" xlink:href="advm-20231231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9083a0b4-4d56-4864-bfd4-b564e99906ee" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6e7cc380-57f5-4c6a-b1b8-e62efefa0dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b5c208c-2eec-45b9-86e7-73c602f5289c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b5c208c-2eec-45b9-86e7-73c602f5289c" xlink:to="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3fdf7614-8590-4c4e-83d5-ba937e1b2856" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:to="loc_srt_CounterpartyNameAxis_3fdf7614-8590-4c4e-83d5-ba937e1b2856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7549057-fd2e-4499-8454-1e675b039334" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3fdf7614-8590-4c4e-83d5-ba937e1b2856" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7549057-fd2e-4499-8454-1e675b039334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember_eba66454-4d56-425a-8839-f4efa51476ff" xlink:href="advm-20231231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7549057-fd2e-4499-8454-1e675b039334" xlink:to="loc_advm_LexeoTherapeuticsIncMember_eba66454-4d56-425a-8839-f4efa51476ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c366126d-83aa-4b94-bcfb-c1d7d9705343" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:to="loc_srt_LitigationCaseAxis_c366126d-83aa-4b94-bcfb-c1d7d9705343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7b1ba95e-f642-4810-8019-c003d8e5cab7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c366126d-83aa-4b94-bcfb-c1d7d9705343" xlink:to="loc_srt_LitigationCaseTypeDomain_7b1ba95e-f642-4810-8019-c003d8e5cab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_PazyukV.MachadoEtAl.C.A.Member_530313eb-9b4a-4426-9989-ffb51496cf74" xlink:href="advm-20231231.xsd#advm_PazyukV.MachadoEtAl.C.A.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7b1ba95e-f642-4810-8019-c003d8e5cab7" xlink:to="loc_advm_PazyukV.MachadoEtAl.C.A.Member_530313eb-9b4a-4426-9989-ffb51496cf74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_97765bad-05cf-4f80-ad45-eed37b344a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:to="loc_us-gaap_LitigationStatusAxis_97765bad-05cf-4f80-ad45-eed37b344a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_0129b350-6b30-4cc2-bd94-3abfdc91ba52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_97765bad-05cf-4f80-ad45-eed37b344a2c" xlink:to="loc_us-gaap_LitigationStatusDomain_0129b350-6b30-4cc2-bd94-3abfdc91ba52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_608e4299-ad25-4765-86ee-1c0f6fba6e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_0129b350-6b30-4cc2-bd94-3abfdc91ba52" xlink:to="loc_us-gaap_PendingLitigationMember_608e4299-ad25-4765-86ee-1c0f6fba6e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_911df08a-02ee-4919-a9ef-ac1da28ec7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_93af5ccb-ae15-43de-9e25-c676756030a0" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_911df08a-02ee-4919-a9ef-ac1da28ec7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_979b90ca-a3d3-4cc0-a432-1af12d5e430d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_911df08a-02ee-4919-a9ef-ac1da28ec7aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_979b90ca-a3d3-4cc0-a432-1af12d5e430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LicenseAgreementsMilestonesAchieved_8703a97e-a9d7-4b54-a8bf-a0149601cef5" xlink:href="advm-20231231.xsd#advm_LicenseAgreementsMilestonesAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_911df08a-02ee-4919-a9ef-ac1da28ec7aa" xlink:to="loc_advm_LicenseAgreementsMilestonesAchieved_8703a97e-a9d7-4b54-a8bf-a0149601cef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_f5a3a451-2918-4ea9-b137-621310941a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_911df08a-02ee-4919-a9ef-ac1da28ec7aa" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_f5a3a451-2918-4ea9-b137-621310941a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8d4edce-769e-4ec2-9116-6d565d657d52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d8d4edce-769e-4ec2-9116-6d565d657d52" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_28994b06-ff1c-499c-b173-ec41c6741eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:to="loc_us-gaap_PlanNameAxis_28994b06-ff1c-499c-b173-ec41c6741eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_28994b06-ff1c-499c-b173-ec41c6741eab" xlink:to="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_3fc161d9-2271-4a59-8b17-d4be9d3adc7d" xlink:href="advm-20231231.xsd#advm_TwoThousandAndFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:to="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_3fc161d9-2271-4a59-8b17-d4be9d3adc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandSeventeenInducementPlanMember_bcfaf547-387c-4d5a-a9bd-bf2a307118a8" xlink:href="advm-20231231.xsd#advm_TwoThousandSeventeenInducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:to="loc_advm_TwoThousandSeventeenInducementPlanMember_bcfaf547-387c-4d5a-a9bd-bf2a307118a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_0722b255-077a-4493-8c3f-81cbbe1bcc60" xlink:href="advm-20231231.xsd#advm_TwoThousandFourteenPlanAndInducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:to="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_0722b255-077a-4493-8c3f-81cbbe1bcc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_9114e7f5-8b13-4c8c-a299-55d1367bf47d" xlink:href="advm-20231231.xsd#advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a0678d09-200d-407a-9623-69dc00f33973" xlink:to="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_9114e7f5-8b13-4c8c-a299-55d1367bf47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_98401617-2d86-46d8-9a13-da44a1c62cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:to="loc_us-gaap_AwardTypeAxis_98401617-2d86-46d8-9a13-da44a1c62cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_98401617-2d86-46d8-9a13-da44a1c62cce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockOptionsAndRestrictedStockUnitsMember_206ca901-599c-4c41-b637-99544cd8dba5" xlink:href="advm-20231231.xsd#advm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_advm_StockOptionsAndRestrictedStockUnitsMember_206ca901-599c-4c41-b637-99544cd8dba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_8ec4eb3a-3b71-4a9f-b69f-49dcf815cc39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_us-gaap_StockCompensationPlanMember_8ec4eb3a-3b71-4a9f-b69f-49dcf815cc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c4f7cf64-ea76-400c-a3c0-066849504b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c4f7cf64-ea76-400c-a3c0-066849504b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_19705c31-4882-4e1f-9ad3-d433aa455929" xlink:href="advm-20231231.xsd#advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_19705c31-4882-4e1f-9ad3-d433aa455929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_dbe42413-0a6e-46db-9a22-436710baa526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_us-gaap_PerformanceSharesMember_dbe42413-0a6e-46db-9a22-436710baa526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8881cf9e-2bf5-4a4c-98fc-40ad19dd6653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7e92580-3dbf-43d1-a65a-94d47b38e4a3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8881cf9e-2bf5-4a4c-98fc-40ad19dd6653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d4f0c67-fe9c-4201-a76b-20063c3f4161" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:to="loc_srt_RangeAxis_8d4f0c67-fe9c-4201-a76b-20063c3f4161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7174865f-0f29-4c55-a714-0d2e6427afaa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8d4f0c67-fe9c-4201-a76b-20063c3f4161" xlink:to="loc_srt_RangeMember_7174865f-0f29-4c55-a714-0d2e6427afaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b02ce210-5439-48eb-979f-b698644a2071" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7174865f-0f29-4c55-a714-0d2e6427afaa" xlink:to="loc_srt_MinimumMember_b02ce210-5439-48eb-979f-b698644a2071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d19196cb-2a0a-41b9-b1ca-bbaaf0473c63" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7174865f-0f29-4c55-a714-0d2e6427afaa" xlink:to="loc_srt_MaximumMember_d19196cb-2a0a-41b9-b1ca-bbaaf0473c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7446d89-6749-4645-8d82-129abc91e225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_a0e278c3-f868-4d4a-a90e-5c9505115efa" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_a0e278c3-f868-4d4a-a90e-5c9505115efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_183f840e-80e9-4079-ab41-5d045f6d3289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_183f840e-80e9-4079-ab41-5d045f6d3289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_645ad348-7998-4c20-8b4c-0b9ac7306e85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_645ad348-7998-4c20-8b4c-0b9ac7306e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f5ba25d9-1c48-4b95-96e5-513dac55c6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f5ba25d9-1c48-4b95-96e5-513dac55c6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6aa96e43-45ab-4073-a725-09f019fa2d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6aa96e43-45ab-4073-a725-09f019fa2d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_4005d3ff-bdd3-4755-9de6-50cf535307b0" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_4005d3ff-bdd3-4755-9de6-50cf535307b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_c5041b87-8a36-4dfb-85a2-13b354863b0e" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_c5041b87-8a36-4dfb-85a2-13b354863b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_433e97fe-e56e-4d6c-9c7f-c3edbacc1701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_433e97fe-e56e-4d6c-9c7f-c3edbacc1701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_01de5c9e-86d1-40f2-b9ed-880924a77879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_01de5c9e-86d1-40f2-b9ed-880924a77879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_13244b73-93ae-4eaf-81db-4eacfd6d3d87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_13244b73-93ae-4eaf-81db-4eacfd6d3d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0fb711be-49ec-4c17-afa9-5ed095e6faad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0fb711be-49ec-4c17-afa9-5ed095e6faad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3a177f7e-d331-417f-b551-4e4bff2974e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3a177f7e-d331-417f-b551-4e4bff2974e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0348f54f-02c0-4ff5-97ee-47a4fa22bb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0348f54f-02c0-4ff5-97ee-47a4fa22bb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_39e6bc8b-ad04-4d7b-b777-8a600aad818f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_39e6bc8b-ad04-4d7b-b777-8a600aad818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1bce0619-d1f6-4d4a-b445-40df555d1a54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1bce0619-d1f6-4d4a-b445-40df555d1a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_80b131dc-8e5f-4be0-a898-a5862343610b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_80b131dc-8e5f-4be0-a898-a5862343610b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_c125cfb6-31c6-4495-a342-a0a0cc40fa6d" xlink:href="advm-20231231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_c125cfb6-31c6-4495-a342-a0a0cc40fa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e40b2960-5915-4024-ae95-614ed65b9fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6e57a62-a69a-43e4-ad3e-2a263278b3dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e40b2960-5915-4024-ae95-614ed65b9fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlansScheduleofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c54b2f87-dab2-4da1-91b5-9d90516fefda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c54b2f87-dab2-4da1-91b5-9d90516fefda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee6aa9d8-07bf-45b1-9296-2816f4039e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c54b2f87-dab2-4da1-91b5-9d90516fefda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee6aa9d8-07bf-45b1-9296-2816f4039e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d45bcea6-a2c7-4eef-a867-d6f069c391be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c54b2f87-dab2-4da1-91b5-9d90516fefda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d45bcea6-a2c7-4eef-a867-d6f069c391be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_88989af3-8b7d-43b7-b858-1c9b644afc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c54b2f87-dab2-4da1-91b5-9d90516fefda" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_88989af3-8b7d-43b7-b858-1c9b644afc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8617352a-c68d-410b-bc24-b839600dd5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c54b2f87-dab2-4da1-91b5-9d90516fefda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8617352a-c68d-410b-bc24-b839600dd5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6d952f5b-dd65-4289-9986-c9865f6f9a15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c54b2f87-dab2-4da1-91b5-9d90516fefda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6d952f5b-dd65-4289-9986-c9865f6f9a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2d9a55d1-8511-47ff-8db1-9a8c1f98f96b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2d9a55d1-8511-47ff-8db1-9a8c1f98f96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_37e89383-d41a-4976-b51b-eca7f31759f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_37e89383-d41a-4976-b51b-eca7f31759f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_05d3a02f-ebac-4bfd-88c9-4303935e4fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_05d3a02f-ebac-4bfd-88c9-4303935e4fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46b296c4-6e7c-4308-9bce-6063bccebdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_05d3a02f-ebac-4bfd-88c9-4303935e4fb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46b296c4-6e7c-4308-9bce-6063bccebdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cd8b40b7-ddde-48ac-b42a-c59087cdec54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_05d3a02f-ebac-4bfd-88c9-4303935e4fb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cd8b40b7-ddde-48ac-b42a-c59087cdec54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ceaf2e8b-e9aa-47d1-97ca-47df13b7b4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_05d3a02f-ebac-4bfd-88c9-4303935e4fb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ceaf2e8b-e9aa-47d1-97ca-47df13b7b4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_696bd5ea-470f-4bd9-bb3d-791c6dc9f8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_05d3a02f-ebac-4bfd-88c9-4303935e4fb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_696bd5ea-470f-4bd9-bb3d-791c6dc9f8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0ab2b623-d89a-4aba-905a-e4fb225d09ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_05d3a02f-ebac-4bfd-88c9-4303935e4fb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0ab2b623-d89a-4aba-905a-e4fb225d09ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_66df802c-a226-480d-aed7-095241ff773a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_66df802c-a226-480d-aed7-095241ff773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fe75e76e-2e82-4e84-88bd-920ac7a1767d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fe75e76e-2e82-4e84-88bd-920ac7a1767d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7fab480e-c3be-49a4-9e32-107ab7b91a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7fab480e-c3be-49a4-9e32-107ab7b91a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1a04c8ba-7319-4e78-9a5c-af9a8b75a833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7fab480e-c3be-49a4-9e32-107ab7b91a6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1a04c8ba-7319-4e78-9a5c-af9a8b75a833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ee9cc721-82a9-4eaf-a58c-6e6c5bb20d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7fab480e-c3be-49a4-9e32-107ab7b91a6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ee9cc721-82a9-4eaf-a58c-6e6c5bb20d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_23f98ab1-ddf6-46dc-bb86-78b8094d3cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7fab480e-c3be-49a4-9e32-107ab7b91a6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_23f98ab1-ddf6-46dc-bb86-78b8094d3cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e4391a50-390d-4e98-9bb3-d3b6288c9b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e4391a50-390d-4e98-9bb3-d3b6288c9b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_17115a71-9f7b-4e5c-885f-ca3ab80d0715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_17115a71-9f7b-4e5c-885f-ca3ab80d0715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_89df6c99-a4c3-4c32-9916-55e79eae3623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_499b0b42-98b5-45e4-8867-e05eec0102f4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_89df6c99-a4c3-4c32-9916-55e79eae3623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2cb52842-ac82-4f57-8dfa-b184583b6c33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee96068-f6b8-45be-9f6b-c32ed8c6a2df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2cb52842-ac82-4f57-8dfa-b184583b6c33" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee96068-f6b8-45be-9f6b-c32ed8c6a2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aaffa020-9938-4c7b-8a52-8cc2022bfb62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee96068-f6b8-45be-9f6b-c32ed8c6a2df" xlink:to="loc_us-gaap_AwardTypeAxis_aaffa020-9938-4c7b-8a52-8cc2022bfb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ada2d249-3adb-439d-adbd-89e9bd911368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_aaffa020-9938-4c7b-8a52-8cc2022bfb62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ada2d249-3adb-439d-adbd-89e9bd911368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ec662fe2-5a7f-4a8f-9ac7-a4465fb53289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ada2d249-3adb-439d-adbd-89e9bd911368" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ec662fe2-5a7f-4a8f-9ac7-a4465fb53289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b7a487df-4be9-4044-99ef-22db32a2f592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ada2d249-3adb-439d-adbd-89e9bd911368" xlink:to="loc_us-gaap_EmployeeStockMember_b7a487df-4be9-4044-99ef-22db32a2f592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee96068-f6b8-45be-9f6b-c32ed8c6a2df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_48ea91a7-22c6-4812-9ca7-7e1f29036c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_48ea91a7-22c6-4812-9ca7-7e1f29036c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_994067ff-91aa-478a-ab2d-f248db51cdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_994067ff-91aa-478a-ab2d-f248db51cdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b8a64a7a-09d0-4daf-b52f-d277889954f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b8a64a7a-09d0-4daf-b52f-d277889954f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dd022c26-9218-40d6-9582-3355b2014cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24437798-0152-40f6-a12a-b116778a9b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dd022c26-9218-40d6-9582-3355b2014cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlansScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd28141e-f7af-4954-9c95-df6087916421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8dfcc2ef-364d-45fe-8bdb-2223a2246dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd28141e-f7af-4954-9c95-df6087916421" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8dfcc2ef-364d-45fe-8bdb-2223a2246dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac1ad6a5-f634-44e2-9445-fd69557911ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8dfcc2ef-364d-45fe-8bdb-2223a2246dbf" xlink:to="loc_us-gaap_AwardTypeAxis_ac1ad6a5-f634-44e2-9445-fd69557911ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e77b52b1-077f-48f7-b92c-43ff67923e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac1ad6a5-f634-44e2-9445-fd69557911ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e77b52b1-077f-48f7-b92c-43ff67923e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5e2aad2c-ab9a-49b0-9a7d-50afc2e25ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e77b52b1-077f-48f7-b92c-43ff67923e0f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5e2aad2c-ab9a-49b0-9a7d-50afc2e25ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33871ea-b160-4ce2-86ba-f798cb2fc979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8dfcc2ef-364d-45fe-8bdb-2223a2246dbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33871ea-b160-4ce2-86ba-f798cb2fc979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33871ea-b160-4ce2-86ba-f798cb2fc979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_587dcf6f-2421-4209-aa3d-4449b9bb910f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_587dcf6f-2421-4209-aa3d-4449b9bb910f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_32c8beca-6bb3-475a-82e9-88260304217b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_32c8beca-6bb3-475a-82e9-88260304217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_410d9e5e-9958-4fe4-a2ec-f18623e84581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_410d9e5e-9958-4fe4-a2ec-f18623e84581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7ff8735f-95c1-47ab-b0e8-a061c01545d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7ff8735f-95c1-47ab-b0e8-a061c01545d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ca8bb936-aec3-4e53-ab89-47dd7ae8a013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa0eef2-2a2e-472d-9f1a-9501dbf21f15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ca8bb936-aec3-4e53-ab89-47dd7ae8a013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33871ea-b160-4ce2-86ba-f798cb2fc979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0fc4fd5b-2012-40ad-9e98-76d98f1d5274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0fc4fd5b-2012-40ad-9e98-76d98f1d5274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e84c1e8-a41b-4431-9d81-b48e7d1a9848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9e84c1e8-a41b-4431-9d81-b48e7d1a9848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6655ef2a-5414-454e-963b-18ddc5d7384a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6655ef2a-5414-454e-963b-18ddc5d7384a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c7688821-8e20-4e3a-98d3-2cebcf2a985e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c7688821-8e20-4e3a-98d3-2cebcf2a985e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c61c30d0-78a2-4584-b052-0cd4a0ad726a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e4722d8e-2d11-4835-845c-41f79b13470b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c61c30d0-78a2-4584-b052-0cd4a0ad726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_88f0b414-6ab1-4734-93d8-e3240ee79024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f33871ea-b160-4ce2-86ba-f798cb2fc979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_88f0b414-6ab1-4734-93d8-e3240ee79024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_364ff526-4f54-4b12-ab29-38ebc236974c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_88f0b414-6ab1-4734-93d8-e3240ee79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_364ff526-4f54-4b12-ab29-38ebc236974c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#StockPlansScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_edc8ab64-7ddb-4907-9350-9762d87faa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0d863aa8-778c-4f51-b21c-806c937e5009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_edc8ab64-7ddb-4907-9350-9762d87faa9a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0d863aa8-778c-4f51-b21c-806c937e5009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_764805a4-7c59-4b47-b9c2-9af96b77b123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0d863aa8-778c-4f51-b21c-806c937e5009" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_764805a4-7c59-4b47-b9c2-9af96b77b123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_083fb8c8-488b-4176-bb55-c16f55eaf0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_764805a4-7c59-4b47-b9c2-9af96b77b123" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_083fb8c8-488b-4176-bb55-c16f55eaf0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8dd8ca11-55b9-48aa-a1e5-701e0f7d202a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_083fb8c8-488b-4176-bb55-c16f55eaf0d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8dd8ca11-55b9-48aa-a1e5-701e0f7d202a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_be1964ec-03f3-4528-9146-ce5b7af21b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_083fb8c8-488b-4176-bb55-c16f55eaf0d0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_be1964ec-03f3-4528-9146-ce5b7af21b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0bab9086-6606-4f9b-8100-289bde6a4aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0d863aa8-778c-4f51-b21c-806c937e5009" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0bab9086-6606-4f9b-8100-289bde6a4aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_01fd6b49-ea8c-4b42-9e57-35f3ae1acf27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0bab9086-6606-4f9b-8100-289bde6a4aed" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_01fd6b49-ea8c-4b42-9e57-35f3ae1acf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/A401kSavingsPlanDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#A401kSavingsPlanDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/A401kSavingsPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_93989ca6-1e93-4c96-a911-32a2a423be44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_95dd1ebe-b5ca-4533-beaf-a80b92849119" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_93989ca6-1e93-4c96-a911-32a2a423be44" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_95dd1ebe-b5ca-4533-beaf-a80b92849119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringAdditionalinformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#RestructuringAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RestructuringAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3ba9664f-f4f2-458a-a126-539bbadca060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0ccea05f-452f-4eb6-b384-d190101d5965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3ba9664f-f4f2-458a-a126-539bbadca060" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0ccea05f-452f-4eb6-b384-d190101d5965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3d92a657-6321-43d0-9b80-e8c9997203e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0ccea05f-452f-4eb6-b384-d190101d5965" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3d92a657-6321-43d0-9b80-e8c9997203e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c8af71a3-a797-49f7-b5cc-a9979ad2554d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3d92a657-6321-43d0-9b80-e8c9997203e8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c8af71a3-a797-49f7-b5cc-a9979ad2554d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_00f1356c-0347-490f-b595-4f20fef0d80b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c8af71a3-a797-49f7-b5cc-a9979ad2554d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_00f1356c-0347-490f-b595-4f20fef0d80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_34014efc-0742-4ad5-91dc-c2cb73c345dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c8af71a3-a797-49f7-b5cc-a9979ad2554d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_34014efc-0742-4ad5-91dc-c2cb73c345dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_950b0c3b-cc1a-485b-b03b-62ecadb3d8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0ccea05f-452f-4eb6-b384-d190101d5965" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_950b0c3b-cc1a-485b-b03b-62ecadb3d8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_89faf80f-bb87-412c-9537-fe15843d9a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_950b0c3b-cc1a-485b-b03b-62ecadb3d8ab" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate_89faf80f-bb87-412c-9537-fe15843d9a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_6afbd889-2a25-4497-8488-fe5b220a1e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_950b0c3b-cc1a-485b-b03b-62ecadb3d8ab" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_6afbd889-2a25-4497-8488-fe5b220a1e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b4785355-2b37-4da0-a7c5-e4e0b2cb3708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_950b0c3b-cc1a-485b-b03b-62ecadb3d8ab" xlink:to="loc_us-gaap_RestructuringCharges_b4785355-2b37-4da0-a7c5-e4e0b2cb3708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#RestructuringScheduleofRestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_639ab190-c45c-47d9-b56b-b1cb252e01ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_602b418c-7cae-46fb-bd0b-99b857c720f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_639ab190-c45c-47d9-b56b-b1cb252e01ec" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_602b418c-7cae-46fb-bd0b-99b857c720f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_02e49569-4fc4-493a-a3b5-996f2ba2fff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_602b418c-7cae-46fb-bd0b-99b857c720f7" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_02e49569-4fc4-493a-a3b5-996f2ba2fff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3ece593a-53c2-494c-97c1-a3c670a6b5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_02e49569-4fc4-493a-a3b5-996f2ba2fff3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3ece593a-53c2-494c-97c1-a3c670a6b5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_ca09da90-9bb0-4f6b-a315-24e454b192bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3ece593a-53c2-494c-97c1-a3c670a6b5b9" xlink:to="loc_us-gaap_EmployeeSeveranceMember_ca09da90-9bb0-4f6b-a315-24e454b192bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_da7d0bfd-5844-421e-8251-8ed85bb75934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3ece593a-53c2-494c-97c1-a3c670a6b5b9" xlink:to="loc_us-gaap_StockCompensationPlanMember_da7d0bfd-5844-421e-8251-8ed85bb75934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_602b418c-7cae-46fb-bd0b-99b857c720f7" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_6d158bc5-1c35-41bb-8431-0f00e009845a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:to="loc_us-gaap_RestructuringCharges_6d158bc5-1c35-41bb-8431-0f00e009845a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_b8fb028d-99f7-4750-bd7b-0d56f07bc1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:to="loc_us-gaap_PaymentsForRestructuring_b8fb028d-99f7-4750-bd7b-0d56f07bc1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_4bb4c6ff-3b1c-476e-9a13-7693ab3067ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_4bb4c6ff-3b1c-476e-9a13-7693ab3067ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_1bb02142-5d9c-4e4b-aaf3-cecfd68a92f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9ef9423c-454b-4226-b53f-89a9020cfc4c" xlink:to="loc_us-gaap_RestructuringReserve_1bb02142-5d9c-4e4b-aaf3-cecfd68a92f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_410f86ff-d858-4aa5-9c6c-e98d73be0f11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e80445e7-6c18-4d97-b8f3-fa5ff67d6730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_410f86ff-d858-4aa5-9c6c-e98d73be0f11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e80445e7-6c18-4d97-b8f3-fa5ff67d6730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_45363456-fc7c-4ce6-9ea5-3de76057a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_410f86ff-d858-4aa5-9c6c-e98d73be0f11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_45363456-fc7c-4ce6-9ea5-3de76057a3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc915a1d-f812-47aa-9e4b-e0a28f97043e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_410f86ff-d858-4aa5-9c6c-e98d73be0f11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc915a1d-f812-47aa-9e4b-e0a28f97043e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8a527339-b404-4880-8ae7-4efe2dc996b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3589d5d4-171a-464a-95bb-98e3abcbdecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a527339-b404-4880-8ae7-4efe2dc996b5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3589d5d4-171a-464a-95bb-98e3abcbdecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c772361b-4fa9-4640-a4d2-c22ea263d53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3589d5d4-171a-464a-95bb-98e3abcbdecb" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c772361b-4fa9-4640-a4d2-c22ea263d53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0815056f-1c83-47be-abce-79fa97d334ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3589d5d4-171a-464a-95bb-98e3abcbdecb" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0815056f-1c83-47be-abce-79fa97d334ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0beb7e9-6a73-4c25-8a83-73be5a8ca392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a527339-b404-4880-8ae7-4efe2dc996b5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0beb7e9-6a73-4c25-8a83-73be5a8ca392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5c5f9b5b-0a1d-4887-a9cb-b93f910237cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0beb7e9-6a73-4c25-8a83-73be5a8ca392" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5c5f9b5b-0a1d-4887-a9cb-b93f910237cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6f52b198-a45e-47db-b2ac-9b828c9c9b80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0beb7e9-6a73-4c25-8a83-73be5a8ca392" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6f52b198-a45e-47db-b2ac-9b828c9c9b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_020244cb-d39d-4a48-b539-e3dce3a636bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a527339-b404-4880-8ae7-4efe2dc996b5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_020244cb-d39d-4a48-b539-e3dce3a636bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_69613a40-8768-41b5-8cb9-62a3de541453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_69613a40-8768-41b5-8cb9-62a3de541453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_68793ca8-79c7-4504-9e90-fd5d2b4d0d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_68793ca8-79c7-4504-9e90-fd5d2b4d0d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_c368a139-9cbe-45ab-9e0d-ddc8e885928a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_c368a139-9cbe-45ab-9e0d-ddc8e885928a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_4f2d3c2e-c41b-4400-b4a8-751b33a3fff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_4f2d3c2e-c41b-4400-b4a8-751b33a3fff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_bbd524ea-a841-45eb-9113-bf6b9f951ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_bbd524ea-a841-45eb-9113-bf6b9f951ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4f9e1c3d-1f1d-460a-b59f-7fe8b2d1921a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4f9e1c3d-1f1d-460a-b59f-7fe8b2d1921a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_c95280c5-38ef-419f-8541-fbdef0d9bf55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_c95280c5-38ef-419f-8541-fbdef0d9bf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition_8b0d204f-c258-4b41-b99f-a432ff7593df" xlink:href="advm-20231231.xsd#advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:to="loc_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition_8b0d204f-c258-4b41-b99f-a432ff7593df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1feac999-41fc-46cf-b436-062a0935164b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1feac999-41fc-46cf-b436-062a0935164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f2f235c0-ce04-4262-aef6-d8ddf892e727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_105cb0a3-b1a5-4966-a8fe-8d2f2d2030da" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f2f235c0-ce04-4262-aef6-d8ddf892e727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_50cd3b16-94d7-4a01-bc5e-9763fd7925aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50cd3b16-94d7-4a01-bc5e-9763fd7925aa" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f78c2155-4782-412c-8648-a250890fc58a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f78c2155-4782-412c-8648-a250890fc58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_9cc759b9-89b4-417f-9de1-31c58cda3c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_9cc759b9-89b4-417f-9de1-31c58cda3c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c90a3078-1463-46d3-afe5-8f6e54b8fe28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c90a3078-1463-46d3-afe5-8f6e54b8fe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e159f097-46ee-462b-8c13-496fbd8bfc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e159f097-46ee-462b-8c13-496fbd8bfc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_024210c0-fbd0-4cf5-af7b-15ce1fcbba49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_024210c0-fbd0-4cf5-af7b-15ce1fcbba49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_fd6b341b-0d4b-42f0-b700-ec8d6674f7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_fd6b341b-0d4b-42f0-b700-ec8d6674f7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsLeaseObligation_a67b161a-6e6d-4ec4-a8b4-968cc5ac23cc" xlink:href="advm-20231231.xsd#advm_DeferredTaxAssetsLeaseObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_advm_DeferredTaxAssetsLeaseObligation_a67b161a-6e6d-4ec4-a8b4-968cc5ac23cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_d619f531-7167-44b5-a6fb-1f73926aca62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_d619f531-7167-44b5-a6fb-1f73926aca62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsCapitalizedCosts_3bd8c51d-41e1-4c6a-89ac-58411fc72585" xlink:href="advm-20231231.xsd#advm_DeferredTaxAssetsCapitalizedCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_advm_DeferredTaxAssetsCapitalizedCosts_3bd8c51d-41e1-4c6a-89ac-58411fc72585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4fdfdb98-affb-45bc-9ba7-e9ca94f54b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4fdfdb98-affb-45bc-9ba7-e9ca94f54b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a97bdba2-50f0-4ff1-a9fd-a0159b1b61eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a97bdba2-50f0-4ff1-a9fd-a0159b1b61eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1304a6c2-1e3a-4d66-9c8e-5da8766a2380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1583bfe3-580b-4870-ae90-dda45b9c4c37" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1304a6c2-1e3a-4d66-9c8e-5da8766a2380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_be49fe40-f7a5-4dd1-a0ab-69478564ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50cd3b16-94d7-4a01-bc5e-9763fd7925aa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_be49fe40-f7a5-4dd1-a0ab-69478564ceca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_bcb5171f-b372-4763-8d89-69bb57598e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_be49fe40-f7a5-4dd1-a0ab-69478564ceca" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_bcb5171f-b372-4763-8d89-69bb57598e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8351c576-3f37-4b8e-a08a-4a8c09d4a962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_be49fe40-f7a5-4dd1-a0ab-69478564ceca" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8351c576-3f37-4b8e-a08a-4a8c09d4a962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_260ec86b-4b73-412d-b069-393e7a4bd92f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_be49fe40-f7a5-4dd1-a0ab-69478564ceca" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_260ec86b-4b73-412d-b069-393e7a4bd92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_874fed0e-f7bd-4b4a-a31f-92cd4361bc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50cd3b16-94d7-4a01-bc5e-9763fd7925aa" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_874fed0e-f7bd-4b4a-a31f-92cd4361bc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7134796a-0d1b-4da5-8df6-ca80ab6f2dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesTable_ee02164f-d142-40b8-ba2e-d7d636dfa50e" xlink:href="advm-20231231.xsd#advm_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7134796a-0d1b-4da5-8df6-ca80ab6f2dcd" xlink:to="loc_advm_IncomeTaxesTable_ee02164f-d142-40b8-ba2e-d7d636dfa50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f6a1fdbc-680b-4084-ad20-6d8771c6fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesTable_ee02164f-d142-40b8-ba2e-d7d636dfa50e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f6a1fdbc-680b-4084-ad20-6d8771c6fe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4efc748e-3ed1-415b-b803-fd80cb8a5008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f6a1fdbc-680b-4084-ad20-6d8771c6fe36" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4efc748e-3ed1-415b-b803-fd80cb8a5008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_341c5ae3-66ac-4e98-a114-e903f92eb7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4efc748e-3ed1-415b-b803-fd80cb8a5008" xlink:to="loc_us-gaap_DomesticCountryMember_341c5ae3-66ac-4e98-a114-e903f92eb7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5320a4d2-3fc1-4ce1-a6f0-cdb33f387337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4efc748e-3ed1-415b-b803-fd80cb8a5008" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5320a4d2-3fc1-4ce1-a6f0-cdb33f387337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_a41c537e-7923-4b05-8aec-71b24198aeff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4efc748e-3ed1-415b-b803-fd80cb8a5008" xlink:to="loc_us-gaap_ForeignCountryMember_a41c537e-7923-4b05-8aec-71b24198aeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_51e2adfb-2d69-4106-8823-3bc56fe373df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesTable_ee02164f-d142-40b8-ba2e-d7d636dfa50e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_51e2adfb-2d69-4106-8823-3bc56fe373df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_58d8175c-f423-4901-9edf-1fb5c931576d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_51e2adfb-2d69-4106-8823-3bc56fe373df" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_58d8175c-f423-4901-9edf-1fb5c931576d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_eb6fd84b-10be-4380-a797-a4e0f41e6e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_58d8175c-f423-4901-9edf-1fb5c931576d" xlink:to="loc_us-gaap_ResearchMember_eb6fd84b-10be-4380-a797-a4e0f41e6e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:href="advm-20231231.xsd#advm_IncomeTaxesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesTable_ee02164f-d142-40b8-ba2e-d7d636dfa50e" xlink:to="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_921becc7-9200-46a8-8be9-ad8a63751fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_921becc7-9200-46a8-8be9-ad8a63751fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_30ff9645-65df-40e9-9eac-6e20b02c371d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_us-gaap_OperatingLossCarryforwards_30ff9645-65df-40e9-9eac-6e20b02c371d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_2af8e3fe-8eb3-4d9f-b4c9-8024c073bd12" xlink:href="advm-20231231.xsd#advm_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_2af8e3fe-8eb3-4d9f-b4c9-8024c073bd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_50999f9a-4541-4491-b322-24d3d45c4137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_50999f9a-4541-4491-b322-24d3d45c4137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsCapitalizedCosts_9b441ac0-8c6e-4b6b-9635-0a7d50a58d9b" xlink:href="advm-20231231.xsd#advm_DeferredTaxAssetsCapitalizedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_advm_DeferredTaxAssetsCapitalizedCosts_9b441ac0-8c6e-4b6b-9635-0a7d50a58d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_663894e7-194b-4cc6-b96a-b05d3a330bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_663894e7-194b-4cc6-b96a-b05d3a330bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_426a1710-8ae2-40d0-af0a-888cf05cc01f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_df882933-5422-49fc-b8e6-85fa8b857375" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_426a1710-8ae2-40d0-af0a-888cf05cc01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f70bebf4-f062-4d60-a0b5-0b30f8faefa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b58c3568-3938-450c-963a-dca752d4cd36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f70bebf4-f062-4d60-a0b5-0b30f8faefa3" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b58c3568-3938-450c-963a-dca752d4cd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ce661e95-9e89-448a-8af4-c397f8b660e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b58c3568-3938-450c-963a-dca752d4cd36" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ce661e95-9e89-448a-8af4-c397f8b660e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2fb362b0-d5fe-4429-a4fc-55e57e82a82f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b58c3568-3938-450c-963a-dca752d4cd36" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2fb362b0-d5fe-4429-a4fc-55e57e82a82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1b4d9fd1-fac0-45ff-b0ab-f00478c1787a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b58c3568-3938-450c-963a-dca752d4cd36" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1b4d9fd1-fac0-45ff-b0ab-f00478c1787a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_ab5d85f8-6c7d-4b46-a3c0-2bfdf66b5a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b58c3568-3938-450c-963a-dca752d4cd36" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_ab5d85f8-6c7d-4b46-a3c0-2bfdf66b5a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7728fccf-d64e-4585-9590-eec22e6b6fba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b58c3568-3938-450c-963a-dca752d4cd36" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7728fccf-d64e-4585-9590-eec22e6b6fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#NetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5f82fed2-415b-4937-b3ec-78665684d50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f3628bd-41a1-46b7-8437-8b11b8bc9bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f82fed2-415b-4937-b3ec-78665684d50d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f3628bd-41a1-46b7-8437-8b11b8bc9bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5936a92d-e20b-43d2-9f24-1784623e5791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f3628bd-41a1-46b7-8437-8b11b8bc9bf4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5936a92d-e20b-43d2-9f24-1784623e5791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea421a37-9607-4f6d-b804-0ff82b352179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5936a92d-e20b-43d2-9f24-1784623e5791" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea421a37-9607-4f6d-b804-0ff82b352179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_01148a04-7f9f-4a4b-9d4e-c11f227c48c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea421a37-9607-4f6d-b804-0ff82b352179" xlink:to="loc_us-gaap_EmployeeStockOptionMember_01148a04-7f9f-4a4b-9d4e-c11f227c48c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_79de28e3-1725-4d7e-9c5c-501ce4ea1312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea421a37-9607-4f6d-b804-0ff82b352179" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_79de28e3-1725-4d7e-9c5c-501ce4ea1312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_44caa4f1-2afe-461a-b623-10912ffd7992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea421a37-9607-4f6d-b804-0ff82b352179" xlink:to="loc_us-gaap_EmployeeStockMember_44caa4f1-2afe-461a-b623-10912ffd7992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_853c658f-ae91-4ce5-a699-e1c17a1cdeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f3628bd-41a1-46b7-8437-8b11b8bc9bf4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_853c658f-ae91-4ce5-a699-e1c17a1cdeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_08a3dd6b-35e9-4261-8464-9e527741f48b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_853c658f-ae91-4ce5-a699-e1c17a1cdeb3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_08a3dd6b-35e9-4261-8464-9e527741f48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c3aaabee-f66d-42d1-8ad2-fc8f49d580af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c3aaabee-f66d-42d1-8ad2-fc8f49d580af" xlink:to="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3363cb98-d30c-4d93-96cd-ece84373dc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3363cb98-d30c-4d93-96cd-ece84373dc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b7ebc4f8-5226-49dc-812a-8c6d78c7f7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3363cb98-d30c-4d93-96cd-ece84373dc8d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b7ebc4f8-5226-49dc-812a-8c6d78c7f7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a4b90aef-6eb0-4665-887f-e3dcf73c8bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b7ebc4f8-5226-49dc-812a-8c6d78c7f7c4" xlink:to="loc_us-gaap_SubsequentEventMember_a4b90aef-6eb0-4665-887f-e3dcf73c8bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c21ec4fe-8eb0-4269-a07d-5020d34ffca0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_srt_StatementScenarioAxis_c21ec4fe-8eb0-4269-a07d-5020d34ffca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b58a5fda-f80c-4b10-a104-ad0d2ba3e91d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c21ec4fe-8eb0-4269-a07d-5020d34ffca0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b58a5fda-f80c-4b10-a104-ad0d2ba3e91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember_6ec09f30-46e3-4571-a5f4-ad5dea9debae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b58a5fda-f80c-4b10-a104-ad0d2ba3e91d" xlink:to="loc_srt_ProFormaMember_6ec09f30-46e3-4571-a5f4-ad5dea9debae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_74bfdd72-4fd7-4777-9668-c661aa02cfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_74bfdd72-4fd7-4777-9668-c661aa02cfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6675bd3a-08a9-4e80-b076-d03719bc62f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_74bfdd72-4fd7-4777-9668-c661aa02cfa8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6675bd3a-08a9-4e80-b076-d03719bc62f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f4715769-0be7-4e7c-8162-afac21aba887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6675bd3a-08a9-4e80-b076-d03719bc62f0" xlink:to="loc_us-gaap_PrivatePlacementMember_f4715769-0be7-4e7c-8162-afac21aba887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c265a9f3-b4a7-4105-ad0f-fb5296c647bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_srt_CounterpartyNameAxis_c265a9f3-b4a7-4105-ad0f-fb5296c647bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_758fc3c6-d0ca-4ccf-b344-ba4349f0c4da" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c265a9f3-b4a7-4105-ad0f-fb5296c647bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_758fc3c6-d0ca-4ccf-b344-ba4349f0c4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoDirectorsMember_ee146b62-b4ce-40e4-a6c7-033e40e2b8e8" xlink:href="advm-20231231.xsd#advm_TwoDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_758fc3c6-d0ca-4ccf-b344-ba4349f0c4da" xlink:to="loc_advm_TwoDirectorsMember_ee146b62-b4ce-40e4-a6c7-033e40e2b8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8f73a6c5-f7a0-4c67-ab16-d57d1ba73cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8f73a6c5-f7a0-4c67-ab16-d57d1ba73cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3abbcc05-f2d3-45c8-abc3-45a5d51de29f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8f73a6c5-f7a0-4c67-ab16-d57d1ba73cd4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3abbcc05-f2d3-45c8-abc3-45a5d51de29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_PreFundedWarrantsMember_0b9f913b-3c8b-42e8-b354-337e2f599f3b" xlink:href="advm-20231231.xsd#advm_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3abbcc05-f2d3-45c8-abc3-45a5d51de29f" xlink:to="loc_advm_PreFundedWarrantsMember_0b9f913b-3c8b-42e8-b354-337e2f599f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3503044d-d09a-4a5c-9488-dfd80835130b" xlink:to="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9e4c16ea-53d1-4a83-83b0-0d18b847997f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9e4c16ea-53d1-4a83-83b0-0d18b847997f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7167d426-b51a-4d70-a02c-d0bf07daeb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7167d426-b51a-4d70-a02c-d0bf07daeb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8c2feb3b-6e4c-4b13-b821-015c1e783f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8c2feb3b-6e4c-4b13-b821-015c1e783f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0bc6a29e-c34d-456a-b5c8-60411b60ccbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0bc6a29e-c34d-456a-b5c8-60411b60ccbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SecuritiesPurchaseAgreementNumberOfDirectors_200b6b1e-8551-4c6d-87bc-244454b635f8" xlink:href="advm-20231231.xsd#advm_SecuritiesPurchaseAgreementNumberOfDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_advm_SecuritiesPurchaseAgreementNumberOfDirectors_200b6b1e-8551-4c6d-87bc-244454b635f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_63e2940a-2fe4-40f4-b7b0-9021f5e505c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_63e2940a-2fe4-40f4-b7b0-9021f5e505c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b05adc5b-b2cf-4aa6-a411-f5328d629813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_CommonStockSharesIssued_b05adc5b-b2cf-4aa6-a411-f5328d629813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_363d5d4a-97fe-4076-8455-14639beb97d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_363d5d4a-97fe-4076-8455-14639beb97d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_31e25d9f-d9cd-4480-acc2-6ee8b012bf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_31e25d9f-d9cd-4480-acc2-6ee8b012bf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_925b625e-18a2-4014-8dac-bddcc097b64d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d9cf0a6a-505a-4660-80af-63b4fa72c450" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_925b625e-18a2-4014-8dac-bddcc097b64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="advm-20231231.xsd#SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_80345873-3fe9-42fe-9265-f3598c4b84ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c5db979f-3753-4cbd-acba-b75b94140e32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_80345873-3fe9-42fe-9265-f3598c4b84ca" xlink:to="loc_us-gaap_SubsequentEventTable_c5db979f-3753-4cbd-acba-b75b94140e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5eb32bc5-30ee-46c3-b807-92e29ec8954b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c5db979f-3753-4cbd-acba-b75b94140e32" xlink:to="loc_srt_StatementScenarioAxis_5eb32bc5-30ee-46c3-b807-92e29ec8954b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_416887ce-230b-4151-bc71-c751e7b9fd58" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_5eb32bc5-30ee-46c3-b807-92e29ec8954b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_416887ce-230b-4151-bc71-c751e7b9fd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember_274bccdb-8fbd-4099-94ea-906f44f99817" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_416887ce-230b-4151-bc71-c751e7b9fd58" xlink:to="loc_srt_ProFormaMember_274bccdb-8fbd-4099-94ea-906f44f99817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c5db979f-3753-4cbd-acba-b75b94140e32" xlink:to="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0fef3b23-b4de-4698-bbe6-694402f68df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_NetIncomeLoss_0fef3b23-b4de-4698-bbe6-694402f68df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cf1290ee-3d46-496b-8e55-a6c72e7b8870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_EarningsPerShareBasic_cf1290ee-3d46-496b-8e55-a6c72e7b8870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a000adc2-15df-4384-98d9-f51c75d99b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a000adc2-15df-4384-98d9-f51c75d99b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d67e0ad-119d-4ace-ac8b-9678862405d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d67e0ad-119d-4ace-ac8b-9678862405d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_31dc6b74-c16f-447c-8c96-9be0b5d11b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fea01eb2-39a7-4eac-8834-44f973199e7d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_31dc6b74-c16f-447c-8c96-9be0b5d11b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>advm-20231231_g1.jpg
<TEXT>
begin 644 advm-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /9!I$# 2(  A$! Q$!_\0
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MH^TK95D^!FL/B\1+VG6RT7X/\SYEUC1=0\/:A+8ZI8W&G7L7W[>ZB:.1?JK
M&I?#OA[4/%FM6>CZ5;_:M1O)!%!#O5-['H-S$ ?B:_1?QYX#\*?M,?#6VO+9
MXY&N(#-I>JJG[VW<_P )[[=PVNA].Q (^)O@9IESHG[0/AC3KV,PWEIJWV>:
M,]4="58?@0:WP^8?6*4Y6M.-[H\W&Y(\%B:4.;FIU&K27G;_ #T[FA_PR/\
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MO3+7]F7XFWFGK>1^%+@0LN\+)/#')C_KFSA@?;&:+I;BI8>MB+^Q@Y6[)O\
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MDTF14M=._P +?&D<+2OX0UY8E7<9&TR<*%QG.=O2N8'6DRI4YT_C30ZBO0M
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MD3]H3_DMGC'_ +"#_P!*\C#_ .]5/ZZGW6<?\B3"?+_TEGGE%%%>H? 'U_\
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MXH>-]1\07N4$[;+>#)(AA7A$'X<G'4ECWK[A^#OA'2?@7\$QJ]U:F.]_L_\
MM35)0H,SL(R_EY_V0=H'3.3W)K\\J_42'Q0T'PMA\0:19MK)325O;>TC8HUP
M!$&" X."1QT//:KQ&BC%;'G\,6K5\1BJK]]*]]][W=O\O0^?/AS^VEJ'BCXA
M6.D:OH-G::5J5S':P/:R.9K=G.U2Y/#@L1T"X!)YQBHOVX/AK9Q66F>-;*W6
M*[:<65^8U_UH*DQNWN-I7/4[E'85)I_[=%WJ][#9V'P[FO;R9ML=O;ZF9)'/
MHJBWR3]*Y'X\?M(:IXY\$W'AG5? 5YX9DN)8Y%GO+ER1L8-@(T*9Z8Z]ZF,)
M*::C;YG3B,=A:V75J-?$^U;UB^22L^U[6_X?L;W[-_QO^&OPM^'ILKZXN;37
MIG>>]D:S=O.<$A$5EW<!< 9P,DGC)K5^%_[7'BOQ]\0K/2W\)P2Z-=7"0LVG
MQRR36BNVT22/DJ5'4G:O )[5O_!'X'>#?!?PILO%^MZ3%K^I3Z<-7EDN(!/Y
M<9C\U4BC.1N"XYQDMWZ 97A']KRX\9>.M%\->&_!JV]I>7L4+2R3[G2$L/,?
MRT4!2J;C]X@8[]*F7+)R<5<Z<//$X2EAJ>(KJFM+1C%MRVW>W_#EK]NO2;63
MX>Z#JC1*;V'5%MDEQ\PC>&1F7/IF-3^%3?L*_P#),M<_[##_ /HF*I_VY_\
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M>%[B01$HS-/"A."[DG:X[E0HX[FO>_C9;PVGP/\ %D%NBQV\6DRI&J] H3
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MF[QAMY72N=)\,_\ DI'A3_L+6G_HY*^V/VK/^2&Z]_UTMO\ T?'7Q/\ #/\
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M;<G(^W<\2@^$A;X[CP(\K"W&H&,RY^8VX'F9Z?>,?ZU]9?%OXCV/P(\"V/\
M9NF12.SBSL;)3LC0!22QQSM ';DDCZU\\?#_ .(">,_VJ=-\27%E_9'VR9H3
M:O+O\M_LA@ W;5R2P'8<G%>G?MH:3<WG@O1+Z*)I+>SO&$S*"=@=<*3Z#(Q]
M2*YX>[3G*!Y.#<</@\37PNZDTG_=TM^9>^#O[4%AXQM;^+Q;+IF@7ML Z3>=
MY4,ZDGA5=B=PXXR<YKYM^.$/AM/B-J,WA6]AO-*NML^+<$)%(WWT!(Y&1NXX
M&[':J?PS^%.N?%;4+VTT7[.AM(1-++=.R1C+8"Y"GYCR1[*:K?$#X<:U\,]8
MBTW6T@2XEC\Z/R)ED#)N(W<<@9!Z@=*Y:E2<Z:YEIW/)Q.+Q6*P<?;0O%/XC
MF:**6N \1#JFALYYUW1PR.N<95214ME8I=!B]U#;@=/,/)_"M..&2-%1-<C5
M%& JN0!7E8C%JF^6#U\T_P!$=E*BY*[V^7ZC+<&WC"G1S*>[2!B3^E/>X$:%
MWT5%5>K$'%/VS?\ 0<3_ +[:IO#OAW5/'7BBS\/V%PUY-<R[%<DE% &6<^P&
M3^%>51I?6:EEK\Y_K8[M5:,5J]%\(W1]+U'QEJ$>G:'HOVF\?G9;Q[CCU)/"
MCW->P^'_ -CGQ'?0I)JVK66E%N3#&IG=?8XPOY$UZ5XB\0>&?V6O!=MIFEVJ
M7VO7:;@'X>=AP993U" ]%'T'<U\T>*OC%XP\973R:AKMTL3'BVM9##"H] JX
MS^.37U,<-AL$N2=W+M?]=ST*E'"X.RQ5YU.RT2/8=0_8OOHXB;'Q1;S28X6X
MM&C!_$,W\J\C\=_!_P 4_#@[]7T\_8R<+>VY\R$_\"'W3[,!6+I/CKQ%H=P)
M[#7-0M9 <YCN7 /U&<'\:^C/@W^T:OC"9/"_C:*WFDO!Y$5ZR 1SD\>7*O0$
M] 1P>F.].*PM?W4G!_>@IQP&+?LXITY/;6Z/EJNL^&_PYU/XG>(O[)TQX89$
MB:>2:X8A$0$#/ )/) _&NP_:$^#:_#37(K[358Z#J#'RE)R8).IC)],<CVR.
MV:W?V/?^2B:K_P!@M_\ T;'7)##M8A4:G<YJ.#<<9'#5EU+7_#'/B,?\QS2_
MRD_^)H_X8Y\1_P#0<TO\I/\ XFL?X]^._$FC_%K7K2QU_4[*TC:+9!;W<B(N
M84)P <#DFO/_ /A9WB__ *&G6?\ P/E_^*K2I+!TYN#IO1VW.VI+ 4JDJ;IO
M1VW._P!<_94\;:3;M+;"QU8*,^7:SD/^3A<_G7 ^%_ .J^)_&=OX86+[!J4C
MLCK> Q^5M4LVX8ST!XQ75>"?VAO&'A/48'NM3GUG3PP\VUOG\PLO?:Y^93Z<
MX]0:]>_::T2UU#PCHWCK2F:UU"%XMMU"2DCPR+E"2.<@XQ]34>PPU:#JT;^[
MNGV\F5]7PM>FZU"_N[I]O)G)C]COQ!_T'=-_[YD_PI?^&/-?_P"@[IO_ 'S)
M_A7DJ_$[Q?C_ )&G6/\ P.E_^*KVO]E;Q=KGB'QEJT.J:Q?:C"E@76.ZN'D5
M6\Q!D GK@FBC]2KU(TU3>OF:X?ZC7JJFJ;5_,S_^&/=?_P"@[IO_ 'S)_A2/
M^Q_XA"L5UO36;' Q(,G_ +YKF_C+X]\2Z7\4/$5K9^(-3M;:*XVI##=R*BC:
MO  .!7%2?$CQ9-&T;^)M7=&&&4WTF"/3[U859X"G.4'2>FFY-26!ISE#V;TT
MW*NC>%[W6O%%OH$'EB^FN?LHW-\@;=@DD=A6S\3OAI?_  OUR'3KZ>&Z\Z$3
MQ309PRY((P>A!!J7X+_\E4\,9_Y_4_K7HW[7W_(Y:)_UX?\ M1JXHX>G+!SK
M]4TD8PHPEA9UNJ=CP9:NZ5I-[KE]%9:?:S7MW*<)#"A9C^ IND:7=:WJ5KI]
ME$9[NYD6**->[$X%?6,-OX<_9C\"K/*BW^OW8VEAP]S(!DJ#_#&O^<DUAA,'
M]9YIS?+".[_KJ+"X;V]YR=HK=GFOAS]D_P 2ZE DNJ7UGI 89\KF:0?4+\O_
M (]6[=?L?7*QYMO$\4DG]V6S*C\PY_E7EGB[XT>+?&5R[W.K3VENQ^6TLG,4
M2CTP#EOQ)KG;'Q7K6G7 FM=7OK>5>CQW+J?T-;2K9;!\JHN2[MV?W'7[3!1T
M5-OSN=7XX^!_BOP'"]S=V:WE@OWKRR8R(H]6& R_4C'O7!KTKWKX9_M.7EC(
MNG^,,W]BPVB_1!YL?^^H^^/U^M>7_$[4M U;QKJ%UX:M_LVDR%2B[-BEL#<5
M7^$$YX_E7'BZ.%Y%6PT]_LO=?\ SK4Z'*JE&7R>Z.6%*/O&D7K2KWKQ6<@M%
M%%1<#Q2E'6DI5ZU_<;/R<=1116+&%:/A_7M0\+ZQ::MI5W)8ZC:2"6&XB.&1
MA_,=B#P02#P:SJ<M822::8XR<6I1=FC[?^'?[<7AS5]/CM?&EC-I-\$Q)=6T
M1GM9>!D[1EU)Y^7##CK70V/[0GP$\-7$NH:2^G6M])DO)8:#+#,Y.3RWDKGD
MGJ>]?G_2U\[/)L,VW%N*?1/0^OI\4XZ$8J:C)KJUK^#1](?'K]KRY^(VE3^'
MO#%K<:1HEP-MU<7! N+E.\>%)"(>^"2>G R#Y'\&_$.G^$_BIX9UC5;C[+IU
MG>++/-L9]BC.3M4$G\!7%CK2MUKMIX6E1I.C35DSQ*^98G$XF.*K2O)--=M-
M;6['V'^U#\?? ?Q&^%LFC^'M=_M#43>0RB'['<1?*N<G<\:COZU\>TBTM98?
M#0PD/9P;MYAF&85<SK>WK))VMIM^+84445K(\P^B_P!C_P"+'A7X6W/BE_$^
MJ_V8MZEL+<_9Y9=Y0R[O]6C8QN7KCK7.?M6?$'0/B5\2K75?#E__ &C8)IL5
MNTWDR18D$DA(PZJ>C#G&.:\:%%>=]5@J[Q%W=_<>Q+-*TL#'+VER)WOK?=OO
M;KV-[P!JEMHGCSPWJ-[)Y-G9ZE;7$\FTMLC2568X ). #P!FOK+]H[]H7X?^
M/?A#K.B:%K_V[4[A[<Q0?8KB/<%F1F^9XPHP 3R:^+Z*SK8:%6<:DF[Q#"9I
M6P>'JX:FDXU-'>]]K::G0^ O'FL?#;Q/:Z]H=QY%[!D%6&8Y4/WD=<_,I]/8
M$8(!K[+\,?MD_#WQAHOV;Q;:2:/,PVSV]S;&\MG^A522/9E'XU\)T5%?"TL1
M9SW[HTR[.,5EJ<:+3B^CU1]]#]J/X-^!=)E3PV$9?O"QT;26MMS?\"2-?QS7
MRE\</CEJWQJUZ&XNHA8:5: K9Z>C[@F?O.Q_B<X'.    !U)\T7I2UG1P=*C
M+G6K[LUQ^>8O'T_8SM&':*LOU"K^@745CKVFW$S;(8;F.1VP3A0P).![50HK
MKEKH>!&7*TT?HAJ7[47P<UFQFLM0\007UG,NV6WN=*N9(W'HRM"01]:YK_A:
M?[-?_/EX<_\ "8?_ .1Z^%**\E9=3BM)/[_^ ?93XJQ536=*F_6+_P#DC[K_
M .%I_LU_\^7AS_PF'_\ D>O'OV5/%GPW^&LE[XB\4Z]';^()<V]K;_8[B7[-
M%_$VY(RNYNG!. .OS$5\ZT5HL'%0E#F=G_78XIY]6J5J==TH)PO:R=M;:O7I
M;0^B?VK/VA++XFS6.@>&+M[CP[;XN)[C8\7VF;L-K*&VH/4<D^P-<%^S[\79
M?A#X^M[Z5W.BWF+?485R<QD\2 #JR'D=\;AWKS.BM(T(1I^R2T."KF>)K8SZ
M\W[Z=UV5NGH?9'[0_P 5/A)\8/ DMI;^*(UUVRS/ITSZ==#Y\?-&3Y7"N!CT
M!VGM7QS3:=3HT50CRQ;:(S',*F9556JQ2EMI?7UNV?7O[,/Q[\"?#OX71Z1X
MAUW^S]1%Y-*8?L<\ORMC!RD9';UKYT^,GB"P\5?%'Q+J^ES_ &K3KR\:6";8
MR;U.,'# $?B*XNG5G"A&G4=1;LUQ&:5L5A:>$FERPVM>^UM=?T"BBBMCR#Z-
M_9]_:N;X;Z3'X<\36UQJ&B0G_1;FWPTUL"<E""1N3DD<Y'09& /;-0^/WP'\
M27,5]JTNFWE['RDM]H4LTJ=.C&$X_ ]J^!J*X:F$ISESZI^1]/A>(L9AJ*H-
M1G%;<RO;\4?;WC_]M;PMHFCR6O@VUFU;4#'M@EE@,%K">@)!PS8_N@ 'U%?%
M>JZI=:WJ=WJ%],US>W4K3S3-U=V)+$_4DU5HK2E0A17NGGYAFN)S*2==Z+9+
M1(^]O#_[7'PT\5>$XXO%%Q]@N9X?+O=-O+"2XB<XPP^1&5D/;...H%?.?Q)^
M+.B6/QXT_P 9> XT%C8)!MC%O]GCD*J4= N 0K)\N<9Y/M7BM*O6LH86%-MK
MJ=F+S[%XRG&%1*\6FFEK=?/]#[]M_P!J[X3^+_#_ )6O7!MDF7$VF:GITEPI
M]CL1T8?YXK/T7]KKX<Z?XAAT2PC_ +&\,6]LY%\MDZ1F0%0D<<,:DA<%B20/
MN@8KX4HK'ZG3\SN?%6/;3Y8W76VK\GK^5CVC]J[XA^'_ (E?$33M3\-ZA_:-
MC#I4=L\ODR18D$TS%<.JGHZ\XQS7H'[._P"UE8>%/#UMX8\9><EI9KY=EJ<,
M9DVQCI'(HYXZ @'C (XR?E>F5JZ$)05-[(\FGG&*HXR6-IV4I;KH_E_P3[J\
M0?M2_";PE'?ZMX9M(=6\072_,UGIK6KS,!\OFRNBG;_WT?:L;]H#]H;P#XZ^
M#.N:)H^O?;-7NEMO+M_L=Q'N*W$3M\S1A1@*QY/:OBZGUBL+"+3N]#T:O$N,
MJTZE)QBHS35DGI>]VM=]>MQT<CPR+)&S(ZD,K*<$$="#7ZC?"_Q5-XP^&_A[
M7;U#;W%Y8QS3[QM&[&&89_A)!(]B*^3OV9O#_P )M:\'SW'CE]%AUNUU%Q!_
M:6H_9R\/EQE<H9%5QN+]0:])_:!_:4\,:'X%N_#OA'4;?4M3O;<VBR:<X,-I
M"1M)#KQNV\*%/'7C'/-B+UI*$5L>WD/)E6'GC:U6/+):13UNOUZ==SY2^,?C
MAOB+\2M>UT.7MI[@I;<G @3Y(^#TRJ@GW)KHOV9_&VB_#_XJ6NL:_>_8-.2V
MFC:;RGDPS+@#:BD_I7E5%=S@G'DZ'PL,94ABEB]Y<W-KWO<^B_VO?BSX4^*'
M_")_\(QJO]I_8?M?VC_1Y8MF_P G;_K$7.=C=,]*^=***F$%3CRH>.QE3'XB
M6)JI*4K;;:)+S[$^GW]QI=];7MI*T%U;2+-#*O5'4@JP]P0*^U? 7[8W@_Q-
MX=6Q\=0'3;WRQ'<EK5KBTN?4A5#$9QDJ1@9X)KXCHK*I3C4W.G+\TQ&6R;HM
M6>Z>J9]T:]^UM\-? WAUK;P;;#495!%O96-BUG;HQ'5MRK@9_N@G^=?%WBSQ
M5J/C?Q)?ZYJTWGZA>R>9*X&!T "@=@   /0"LB@4J=*-/8K,,VQ.9*,:ME&.
MR6B'T4459XQL>#=0@TGQ?H=[=2>5:VU]!-+)@G:BR*6.!R< 'I7UE^T5^T%X
M!\=_"/6-%T/7OMVIW#P&.#['<1[@LR,WS/& , $\FOC6BLY4U*2D^AZ^$S.M
M@\/5P]-)QJ*SO>^UM-0KZ5_9W_:J@\ Z+#X9\517$^E0G%I?0#S'@4G)1U)R
M4&>,<CI@C&/FJBG*"FK,Y\%CJ^7U?;4'9_@UV9]\P_M%?!'2]0GUBSN;./5I
MA^]N+?194N)..C2>4,_B:^;/VB/VA)OC-?6UC86\EAX<LG\R&&;'FS2X(\Q\
M$@8!("@G&2<G.!XS16<:,8.YZF-S[%XVBZ$E&,7ORJU_75GV'\!OVM/#FE>"
M]/\ #_B]Y-+N-,A2UAO(X7EBFA4!4R$!96  !X(.,YYQ6CXI_:H^&O@>WN;C
MP+HUKJ>L79W/+;6'V*,G(RTCE%9CUZ YQU%?%=%+V$+W-Z?$F.A1C17+[JLI
M6]Y?I^!]?_M)_&CX<_%+X73Z;I7B(3ZM;W$5Y:P/9W,>YURK+N,87.QWZG&?
MSK'_ &3_ (V>"_AIX%U73_$FL_V;>3ZDUQ'']EFERABC7.41AU4\9SQ7RQ11
M[&/+R=#-Y]B7C%CN6/.E;9V_/?YG=?'+Q-IOC#XK^(M9TBY^UZ;=S*\,WELF
MX"-03M8 CD'J*X6BBM4K*QX-:K*O5E5EO)M_>%?=_P ._P!I?X9:+\./#&DZ
MEXB$=W::3:VMS UA<N%=855U)$1!Y!'!(-?"%%9SIJIN>EEN:5LKG*=%)\RM
MK?\ 1H^YO^%H_LW?\^7AW_PF7_\ D>L[Q%\3/V>+CP_J<5C9^'Q>R6LJP&/P
MVZ-YA0A<-Y P<XYSQ7Q514>Q7=GJRXCKR37L:?\ X"_\SO\ X,?&+5/@SXF?
M4K*);RRN$$5Y8NY59E!R"#V89.#@]3ZU]9+^T]\'?'&G6[^(ECC>,[UM=7TI
MKDQ-Z@JCK^(-?!U%5*E&;N]SAP.=8K 4W1A:4.TE=?H?9/Q2_;-T73]%DTSP
M%#)<WCQ^6FH2P&*"V&",HC %F'& 0%&1UQBOFKX1^)K3P[\5O#VN:U=M%:6]
MZL]S=.K2,!R2Q !8G)]":XNBG&G&*:1EBLVQ6,KPKU6O<=TNB/JS]J[XW>"O
MB5\.].TSPWK7]HWT.JQW+Q?99XL1B&92V711U=>,YYKS#]E[QYH?P[^)C:KX
MAOO[/L#8RP^=Y,DOSLR$#"*3V/:O(J5:E4TH\I=;-J];&1QTDN:-N]M/G?\
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MX/\ B9<^']1\,ZTNHW-JDMO<0FVGB(4D,C N@!&=P/.>1^'K7@;]H[X=Z/\
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MRM?B?75S<?\ "X/V99+J[_>ZA%9-*7;KY]N3EOJP4_\ ?9KS#]CS_DHFJ_\
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M1O[2M;>7R99/M4,6U\ XQ(ZD\$=*Z?\ X9+^*_\ T*O_ )4;3_X[7OW[!O\
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M#?[./Q$\7:'9ZQI/A[[7IUVGF0S?;;9-ZY(SM:0$<@]17FM?I/\ LX_\D/\
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M_LV&Z=HX6^TPR[F R1B-VQQZUU/[)_\ R7[PM_V]?^DDU>W_ +>'_(L^%/\
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MBCX9DE=8T%]&"S' Y.!^M>C?M=SQR>-]'C5U:2.P^=0>5S(V,UW4W_PFU?\
M$OT/2I?[A4_Q+]#DO@#XXC\#_$.UDNI/+L+Y39SL3PNX@JQ^C ?@37<_M2?#
M:>SUI?%MC"9+*Z"I>;!GRI  %8^S# SZCWKY^KZ&^$/[0EG'I*>&?&B^?8[/
M(BOI%\Q3'C&R5>XQQNY]_6L\)6I5J#P==V3=XOLQX6I3J4GAJSLMT^S/GRG+
MTKZ=UW]F3PWXN4ZEX2UU+6WE^81J1<P?16!R!]2:Q[/]D&_:91=>([9(>YAM
MV9OU(KGED^,3M&-UW35@>78E.RC?SNCP&RL[C4;N&UM89+BXE8)'%$I9F8]
M .M6-6T>^T&_EL=1M);*[C^_#,I5AD9'%?4%O_PKG]GFUDECG&J>("A7[RR7
M+>W'$2_E^-?.WC_QQ>_$+Q-/K%\D<+N!''#&/EC0=%SW^OO7-B\'#"4TISO4
M[+HO-]R:V'C0BE*5Y]ET.=_A-*.E)_#3J\5G(+MHIU%0.YXC3EIM.7I7]QL_
M)A:***Q8PK[0_8O^,_VZTL/AQ_8^S[';W-W_ &E]JSOS+NV^5LX_UF,[NWO7
MQ?7T)^P__P EJ?\ [!<__H4=>)FM.%3"3YUMJO4^AX?Q%2AF-)4W;F=GZ/\
MX8^E_P!H#]HW_A1=]HUM_P (]_;?]HQR2;OMOV?R]A48QY;YSN]NE>8?L/?"
M:Q;2;KQWJ-LD]\T[6NFF09\E5&))%_VF)*YZ@*?[U8_[?_\ R'O!O_7M<_\
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M#9^,-3>%DT^X:V@BE/221/,+ ?[H=?\ OKZURSH4X4?:TY:H]S#9IC<3F/\
M9^-HI1DM5OTO>^J?]=3YE^)W@:X^&OCS6/#EQ)YS6,VU)?\ GI&P#1M]2K+D
M=CD5R]?4GQ<\3^%(/VOK6X\21VTF@:? D&H?:;8W$3-]G<KNC"MNP70=#@CV
MKT;_ (6E^S9_SY>'/_"8?_Y'KM^L3C&/N-W70^4_L?#U:]:*Q$(*,FDI/6R^
M?R^1\*U]N?L8_&(^(_#[^"M3FW:CI<>^Q=LYEM<@;,^J$@#_ &2,?=-?-7Q_
MUGPEKWQ&N;OP5':Q:"T$2HME9FUCWA?F_=E5P<]\<UH?LK_\E\\)_P#72?\
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MF%=,F$@74--AE"6S*A<"5F9EY QGCDCCFN._;VTFUM]7\'ZE'$JW=U#=02R
M8+K&8B@)[X\QOSKN/A#^U-J'Q8^(UAX=T[PG'INDE9I+FX^T&5XHUC8J<!5"
MY?8._P!['O7)_M^?\R)_V_\ _MO6<%RXB*Y;'3C*D:^15I>V=6S7O.-NL=OO
MW/5OV1?^2">'_P#KI=?^E$E</\0/VPM*^'6O7_A70/#/VR#2E:R2Y6Y$,4<B
M#;M6,(<JI 7J.AP/7N/V1?\ D@GA_P#ZZ77_ *425\(_$1BWQ \3DG).J71)
M/_75J*=.-2K/F)S#,<1E^5X1X=V<HK6R>G*NYA7-S+>7$MQ/(TT\KF221SEF
M8G))/<DU'117IGYAN?JYXN\,VOC/PSJ>A7LDT5IJ$#6\KVY D"L,$J2",_4&
MO"_^&%O ?_07\1_^!-O_ /&*].^/7_)&?&?_ &#)O_0:_,FO(P\)2BW&5C]9
MXAQV%PM:$<1AU4;6[=K:^C/:_P!IKX)Z'\&-2T&WT2ZU"Z2_BEDE-_)&Y!5E
M V[$7^\>N:]Y_8U^%ECH'@9/&%W LFL:J7\F61>8+=6*@+GIN*EB>X*CM7PW
M7Z1_LYZK#XB^!/A@VYV^79FS<$_=>,M&<_7&?H16E?FC32;/%X>^KXO-)UHT
MU%*-XQWL]%_7J>)>-/VYKRQ\636_AS1+*\T*WE:,SWC/YMT!QO0J0$!.<9#9
M&#QTKVR>S\.?M._!^">2WVP7\3/ T@S+97*Y4D' Y5@1QPP]C7YW>(O#]_X4
MUR^T?5+=K6_LY3#-$X(P1W'J",$'N"#WK] OV5?#UYX5^"6D)J4;VTMP\MYY
M<QP4C=B5/L"H#?\  JBM3C3BI0W.[(\PQ>98JMA\9[T&G=-;:VL?.G['>G3Z
M/\>+ZPNDV7-K8W4$J^CK(BD?F#76?M\?\?O@K_KG>?SAK&_9CU2#7/VG/$FH
MVK;[:\6_N(FQU1YU93^1%;/[?'_'[X*_ZYWG\X:K_E^CBBE'AVNH[<__ +=$
M]V_9Q_Y(?X0_Z\__ &=J^(/V>_AO#\4OB=I^DWG.F0JUY>*K%2\28^4$?WF*
MJ>G!.#FOM_\ 9Q_Y(?X0_P"O/_V=J^5_V)=4@T_XQSP3.J27NE3V\(8XW.'B
MDP/4[8V/X5G!M*HT>ACZ5.M++*=7X6OTAI\SZ/\ CM\;K'X!^']+L=-TR&XU
M"Y0QV5D/W<$,2 #<P7L,@!1C//(Q7.?L]_M12?%C7)/#VO:=:Z?JS1-+;RVC
M,(I]O+)L8DA@O/4Y ;ICGA?V[O#=^^H>&]=2!Y-.2&2TDF49$<F[<H;TW G'
M^Z:\\_8^\,7VM?&C3M1MXV^QZ3%-/<S8.%WQ/&BY]26Z>BMZ4XTX.ES/<,1F
M>.IYW'"P?N72Y;=':[_7Y'2_M*>"X?@E\6O#OC'P]#]FM;R?[8+6+*(D\3J9
M%! X5PPX]W[<5[?^U%H,'Q ^ USJEEBY^QB'5[616X,>/F;W'ENQ_ 5YS^WG
MK4'V?PEI((:YWSW3J&Y1,*JDCW.[_ODUZ!^R[KUO\1O@.FC:ABY^QK-I%S&X
M'S1$?(,=QY;A?^ FI=^2-3L;4H4GF&,RR.D:BNO)VU_._P C$_8?\+#2?AQJ
MFNRHJ2:K>%4DSUAB&T9_X&9*XK]N_P +^5JWACQ''$<30R6$\@/ *'?&,>IW
MR?\ ?/TKT[X@0M\#?V5Y=*@=4OH;!+#?"Y3,\S8E=3UZO(P^G:NHU3P_9?'?
MX=^"]2G4;/M-CK.PX_AP9(SV^ZSJ124K3]ITN=4\'&IEW]DQ_B1A&7S;U_&_
MWE-G7X#_ +-X($<%WI6DCUVF\D'Y\S/^M?G2S%F))R3R2:^SOVZ/&7V+PSH7
MAB&0B6^G:\G"L/\ 5QC"@CT+-D?]<ZY3X#>.O@QH?PWL;3QG;:/)KZRS&5KS
M1&NI-I<E,R"%L\8[\5I3;C#GM>YX6<4Z>,QT< JJIPI1WD[*^FGW6^X^7*_1
M3]D[_DW_ ,+?]O7_ *5S5Y7\2_B)\!M2^'^OVOA^TT)-;FLY$LVM_#[PR"4C
MY=KF ;3GOD5ZG^R:1_PH#PM[?:O_ $JFJ:TG*&JMJ=.08.&#S&4858U+P>L7
M>WO1/@#Q5_R,^L?]?DW_ *&:_13Q5_R;EK'_ &*DW_I&:_//Q1I]U)XWU:Q2
MWE>];49H!;HA:0R>:5VA1R3GC%?HIX\L7TOX!^(K.7_66_AFXA;ZK:L#_*JK
M?9.;AR+MC';I_F?+/[#'_)6M6_[ <W_I1;U[M^T-\<[;X(RVQTW2;>_\3:M%
M_K9^$CAC)"E\?,PW.V%! ^^<COX3^PQ_R5K5O^P'-_Z46];/[=GA:\3Q5X?\
M1K$[V$ME]@:15)6.1)'< GL6$AQZ[#Z4I14JUF:X/$5L+P^ZM#XE+?MKN>P_
MLZ_M#?\ "Z8=0T_4[&"PUNRC65UMV)BGB)P656)88. 02?O+SS@?+7[4WP[L
M_AW\5KF'385M]-U*!=0A@1<)$69E=%]MR,0!T# =,5WG["?A^\E\<:_K8B8:
M?!IQLFD(.#(\L;@ ]\",Y],CUJK^W/JD=S\2-%L4Y>UTP,[9[O(^%Q]%!_X%
M3BE&JU'8SQM6>.R&&(Q.LU+1]];?E^1\W4445UL_/D?7'[ O_,]_]N'_ +<5
MPG[:O_)94_[!D'_H4E=W^P+_ ,SW_P!N'_MQ7"?MJ_\ )94_[!D'_H4E<:_C
M,^]Q'_)-TO\ %_[=(ZW]BCX6V&M3ZCXSU&%+EK"?[)8QN,B.4*KO)CU 9 OI
MECUP:ZOXV_M>7/@/QA<^'O#>EVE])8.([NZOBQ0OC+(BHPZ="Q/4$8XR=;]B
M/6(K[X4WM@,+/8ZE('7=DE71&5L=LG</^ U\M_M!>%[_ ,+?&#Q3'?0M&+R_
MFOX)"I"R12N74J>^-VTX[J1VI)*=1J1M5KU<MR6A/!NW._>?GK_PWR/M/X8^
M/-$_:2^&MXNIZ5&%9C::AI\C;U5L JRM@'!!!!Z@CVS7SM\*_$C_ +.?QRUS
MP<^G'5UU*_MM.CN&N?*,4;29CD(V'<=DJDCCD'FO1OV&?#%[IG@W7M9N%DCM
MM3N8TME?[K+$&#.H]RY7/^Q[5Y!\4-8M=2_:^^UP2K)!'KFGPLZ'(W1"&-Q^
M#(P_"E&*YI0Z'3B\15E@\'CYZ5N:U[+5._YJS^>A]A_&#XD?\*H\"W?B/^SO
M[4\B2./[-Y_D[M[A<[MK8QGTKX^\%_&'PEJ_[0%_X_\ %UA-I]O(BR6EK&/M
M2PSJB1AF("DX"L1\O!(] :^C/VP/^2&:M_U\6W_HU:^<OV3O@[I'Q2\2:M>:
MZIN=.T=(6^Q9*B:20OMW$'.T"-LCN2.V05345!R9MG-7%ULTHX2A9K2236EU
MS:OKHCTOXE?MJ-:ZY:V7@&RL]9M613)=7T$P+R$D>6D8*$$<<G.2>G'/O?A'
M4F^*?PSMKC7-%DTLZK;2176FWD9!7ED;A@#@XW#/8@UY!\3/V@O#?P!U^3PO
MX>\$PFZMT1Y&A5+. ;U# KM0E^",GCG/.0:]C^%/BS4?'7P_TC7M5T]=+O;]
M'E-JF<+'YC",\\\H$;/OVK.2M%-*Q[&7UI5,75HUL1[25M8J-HQU2W?W'PU^
MR?\ \E^\+?\ ;U_Z235[?^WA_P BSX4_Z_)O_0!7B'[)_P#R7[PM_P!O7_I)
M-7M_[>'_ "+/A3_K\F_] %;2_BH^1P/_ "3V)_Q?_('E?[&&L?V;\9DM2^T:
MA83VX7/WBN)>G<XC/ZUT7[=.@QV?CCP_JZ<-?6+0..Q,3YS]<2 ?@*X;]DNW
MDF^/GAMT0LL2W3N1_"OV:5<_FP'XUZ=^WI(IU'P9&#\ZQ7;$>Q,6/Y&F_P"*
MC*C[_#M7F^S/3_R7_-GRC1116Y\4%%%% !1110 4444 +3J:.M.H*04444F)
MA1112$%%%% !1110 4444%A1110 4444 %%%% !3Z93ZE@%%%%(:"BBB@844
M44 %%%% F%%%%0,**** "BBB@ IPZ4VG4 %%%%2/H.6EI%I:@H****@L?111
M4@%%%% T.7I10.E%0,****@L5:=2+2U(!1114#04^FCK3J3*"BBBLV 4X=*;
M3JEE!1112&@I],I]04%%%%0 Y:*%Z45)8M*M)2K4 +111290M.IHIU0QA2_P
MTE.[5#*%I5I*<O2L66%.6FTY>E0RQ:<M-IR]*R9:'Q[=PWABO?:<&M"./2V4
M$S7*MW&T'%9M*M<56E[3[37H;PGR]+FGY.E?\_%P/^V8/]:6QUB^T.3=IFIW
M5J3SNMY7B/Z&LY)&C;*G!J[#JUQ"/^6;_P"_$I_I7-R5:+O"3EZO_@&T9Q?D
M_+_ARY?>,->U6/RKW6]1O(SP4GNY''Y$UE5;FU,W0Q+;P$]F5-I'Y4W39H+?
M4K6:YB\ZVCF1Y(O[R!@2/Q%:1G.?\16?K<<O>?Q7)YO#^I6VFB_EL+B*S;&)
MWB(0YZ<^AJDC%2"I*GL17;:AINGWESKVHZE>1W"2.+BUNX;Q"90TR IY7WL^
M6S''&-M:]RVAV^H7 6UM'B6&^DM)7,!C9/(?REVH<D[MI!?YLY'6MW1\['3[
M#7>QYI6CHOA_4O$$KQZ;8S7TB8W+ A8C/3BNQLUTB\CAN"+5=5FTV-Q'&D(3
MS1.ZO\CX0/L5#CODD#)K-\.W=C#\3;.XB1+"Q6]#!7D4K&,\_,.,?I6#I)-7
M>C&J*3C=Z,P-2T'4-'4&]M);8%S&/,&/F"JQ'Y,I_&J(ZUW7A34K2+1_#UE<
MBSDAFUJ5+I;E58I"Z6ZL?F^X,;OF&"-O!XIK1Z/;^%E,4*W6;9UF;="KI<>8
MVULD^9@#9PHP1GWJ'235T_ZT*]BGJG_6G^9Q-/BD:*0.C,C#HRG!%>G0PZ/=
M^-+YWDTV+28KZ*U-M''"H:!F.^3<W8=RN6Y&, "J\%C9VNEZ&\\6G+IDNG7#
M7<C^7Y[$33JC+GYMWRH%*]<<\9J?J[[_ -7L:K#OO_5['G-2RV\MNR"6-HRZ
M"1=PQE3T(]C74>*%L8M%M+JWAA2?5]ER41 # (U*. /X0TN\\=E6M"ZN--L=
M'NYK>.P>[6QT[R]R)(1)M_>D*<@G^]D=^:YW1U:;_K<2I+5-G"].15JWAO-:
MU"*&)9KV]G8(B#+N['@ =R:ZKR]*M/&VMF-+22Q6UNI(%<AHMYA8H%[<,1@>
MPJU:W&F6K0ZS)+'!.=)VLMD$5_M+O)%D(" "(QN/3G![U"HINSEU_(TC2Z-G
M&1Z;=RPW4J6TK16N#.P0XBRVT;O3GCGO4]KH.I78M6AL;B5;K?Y!6,D2;/OE
M?7;W]*[S^U-,2\U2:.X1;+7);82;G ,:RI,)2R@\;),-[87U%.M+ZTGCAL(+
MB BUCU&RA8RJJOFS55(R1P\@<@]RU/ZO#3WOZO\ Y&T:,>_]7_R.'SK'A>X&
M&O-+F8;E9&:(L/4$8R*GNO&6OWT7EW.N:E<1GJLMW(P_(FK&HL-/\*0Z;//%
M-=F\-PL44BR"!-FTY920"QQQ_L#/6N?K@J.5/W8MV[&<FXZ)CARV3R:6D6EK
MD9"%["G4WTIXZUDRQU%%%0!XC3ATIM/K^XF?DX4445BQ@*]D_97\?:#\-_B@
MVK^(K_\ L[3S830^=Y,DOSLR$#"*Q['M7CB]:=7'B*4:].5*6S.G"XB>$KPK
MP6L7?78^A?VO_BMX6^*6K>&IO#&J?VG'9P3I.WV>6+869"!^\5<]#TKBO@/\
M=]3^"6O3310G4=&O %O-/+[=V.DB'LXY]B#@]B/+O6EKCC@Z4,.L,]8^9VU<
MSQ%3&O')\L_+;:W6Y]_/^TY\$_&MK9W6OF'[1"1)%!J^CO<20-_LE4=0?<&N
M&^,W[:FG2Z)<Z-X!CG>>>,Q-JTT9B6%2,'RD/S;L="0,>AKX[_AI*\V&48:$
ME)W=NC>A[-;B;'5:;@N6+>[2U?SN>B_L_>*M+\$?%[P[K>M77V+3+1Y3-/Y;
MR;=T,BCY4!8\L!P.]>R_M<?&SP7\3O!^BV/AG6?[2NK>_P#.EC^RS1;4\MAG
M,B*#R1TKY7HK>IA85*\<0V[Q^[^M3R:&:5J&"J8&*7+-W>]^FVMNG8*5:2G+
M6[/(/I[]D7XR^#_A?H/B&W\3:Q_9DUW<Q20K]FFEW*$()S&C8Y/>O*?VB/%V
MD^.OC%X@US0[O[=I=U]G\FX\MX]VVWB1OE<!AAE8<CM7G%%>?'#0A6E73=W_
M %^AZ];,ZU;!0P,DN2#NM[]?.W7L?97[-/[07@'X?_"73M&U_7OL&I13SN\'
MV.XDP&D)4[DC(Z'UKB?@7\2/ 7A7XS>._%VOZV+2*YN9QI;?9)Y/-26=G:3"
MQDJ=JH/FP?G/%?-=%<SP5.\W=^]O_5CL6>XA*@G"+]CMH^UM=?RMJ>__ +7'
MQJTCXJ:WH=GX;OFOM%T^!Y&F\N2(/.[8(*.JGY51<''\9KP$=:2E7K732I1H
MP5..R/+QF+J8ZO+$5?BEVV/JG]D_]H/PW\/?".J:#XLU1M.BCNA<63F"68,K
MKAT'EJV,%0W/7>:YSQ=X^\#_ /#46C>,]'UCS] DFAN[ZX^RS+Y,B@H_R,@8
MY"JW /+&OGNBN7ZI#VDJB;O+<[_[:Q#PU+#2BFJ;33UOIMUVZ;;'U7^UG\;O
M!7Q,\":5IWAK6O[2O(-26XDC^RSQ;8Q%(N<R(HZL.,YYK<_9J_:0\%^#?A59
M:%XGUEM-O[&>9(T:UGFWQ,V]6!1& &79<$Y^7TQ7QQ163P5-TO8W=KW-X\08
MJ.->.48\S5K6=K???IW/8?B7\4-.\6?M&P^*[>]:;0K74;-H)VB<!8(BA8A"
M-V,AVQC/->S_ +2G[0'@'Q_\)M1T;0=>^WZE-- Z0?8[B/(60%CN>,#H/6OC
M>BJEA8-P?\NQE'.<1"%>%D_;7OOU[:^?F?4O[)/QJ\&?#'P?K5CXEUG^S;JX
MO_.BC^RS2[D\M1G,:,!R#UKU'5OC7^SUX@U"6_U0Z+J5]-CS+J[\.RRRO@!1
MEF@).  .>P%?!-%8U,%"<W4NTV=F'XBQ.'P\,,J<)1CM=-_J?>MQ^U=\(_ ^
MD-%X;0W*C[EEI.F-;*3VSO5% _,^QKY$^,'Q>UCXR>)_[5U-5MK>%3':6,3$
MI;QYSC)ZL>,MQG'0  #A:*NCA:=%\RU?F<F/SK%YA!4JEHP72*LOU%6K.FZC
M/I&I6E];-LN;65)XFQG#*P8'\Q59:&KJ>QX%VG='Z ?M)QP?$G]FV;6].C^U
M1K';:O;\<JA(W-ST(C=\]^"*^%?"OB;4/!OB+3];TN;R+^QE$T3]LCJ".X(R
M".X)KZC_ &5_B_X?OOAWJW@'QEJ=EI]I%'(MO)J$ZPQRV\N1)%N<@;@S$XSG
M#<?=-?+'B+24T'7M0TZ.\M]1BM9WB2\M9%>*=02 ZE2001@]>]>7AHNGST9=
M_P #[#/*ZQ2P^8TI:M6=MU)?UIZ'VWX<_:]^'/C3P[]F\7P_V7-(FRYLKRS>
M[MY..=NU6ROLP!_G5+QQ^V)X*\)^&S8^!+<:E>",QVR):-;6EOZ$JP4D#KM4
M<^HKX@HH^HTKWUMV$^*,>Z?+[O-:W-;WOSM^!:U/4KK6M2NK^^G:YO+J5III
MG^\[L<LQ^I-5:**[CY)MMW85Z#\ ?%6E^"?B[X>UK6KK[%IEJ\IFG\MY-H:&
M11\J@L>6 X'>O/J*B45*+B^IK0K2P]6%:.\6G]SN?4O[6GQJ\&?$WP?HUCX:
MUG^TKJWO_.EC^RS1;4\MAG,B*#R1TKY<7I3:>*RITU2CR1.K'XZIF%=XBJDF
M[;;:>K9]<? _]L+3=+\.VF@>.%N%>TC$,.JQ(9@\8& )5^]N XW '/?'4^@6
M_P"TE\%/",=W>:));1W4V7E32]&D@EG;KRQC0$D]R:^!Z*Y982G)M['MT.)<
M=1IQIM1ER[-K5?BCTCX[?&F^^-'BJ.]DA^Q:59JT5A9YR44D%G8]W; SC@8
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MOJ\+GK1XHQZA9J+EMS6U_.WX'2_$3Q_JGQ,\67FOZNX-Q.0J1)G9#&/NHH[
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M*5J0=:Q8QU%%%9, IRTVG+6+ 6BBBL6 4445FP"E6DI5I,KH.HHHJ20HHHJ
M"BBBDR@HHHJ6,****D!R]*:W6G#I33UI,@<.E%%%0R@HHHI#"BBBI8!1112
M*?3:=4L HHHJ &GK24M)0 Y:6D7I2U !1114 %%%%# ****A@%%%%2 4ZFT^
MDP"BBBI **** "BBB@ HHHH ****"@HHHJ0"BBB@ HHHH **** "BBB@ HHH
MJ64@IU-'6G4@84444$A11106%%%% !1110 4445 !1110 4444 %%%% !111
M0 4444 .6EI%I:"@HHHI,3"BBBD(**** "BBB@84444%!1110 4444 %%%%
M"K3J:M.J6 4444B@HHHH **** "BBBD+J%%%%2,**** "BBB@ '6G4B]:6@
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MK?\ ^+H^KUOY']S#VU+^9?>=?17(?\+@\!_]#MX<_P#!M;__ !='_"X/ ?\
MT.WAS_P;6_\ \71]7K?R/[F'MJ7\R^\Z^BN0_P"%P> _^AV\.?\ @VM__BZ/
M^%P> _\ H=O#G_@VM_\ XNCZO6_D?W,/;4OYE]YU]%<A_P +@\!_]#MX<_\
M!M;_ /Q='_"X/ ?_ $.WAS_P;6__ ,71]7K?R/[F'MJ7\R^\Z^BN0_X7!X#_
M .AV\.?^#:W_ /BZ/^%P> _^AV\.?^#:W_\ BZ/J];^1_<P]M2_F7WG7T5R'
M_"X/ ?\ T.WAS_P;6_\ \71_PN#P'_T.WAS_ ,&UO_\ %T?5ZW\C^YA[:E_,
MOO.OHKD/^%P> _\ H=O#G_@VM_\ XNC_ (7!X#_Z';PY_P"#:W_^+H^KUOY'
M]S#VU+^9?>=?17(?\+@\!_\ 0[>'/_!M;_\ Q='_  N#P'_T.WAS_P &UO\
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MJ];^1_<P]M2_F7WG7T5R'_"X/ ?_ $.WAS_P;6__ ,71_P +@\!_]#MX<_\
M!M;_ /Q='U>M_(_N8>VI?S+[SKZ*Y#_A<'@/_H=O#G_@VM__ (NC_A<'@/\
MZ';PY_X-K?\ ^+H^KUOY']S#VU+^9?>=?17(?\+@\!_]#MX<_P#!M;__ !='
M_"X/ ?\ T.WAS_P;6_\ \71]7K?R/[F'MJ7\R^\Z^BN0_P"%P> _^AV\.?\
M@VM__BZ/^%P> _\ H=O#G_@VM_\ XNCZO6_D?W,/;4OYE]YU]%<A_P +@\!_
M]#MX<_\ !M;_ /Q='_"X/ ?_ $.WAS_P;6__ ,71]7K?R/[F'MJ7\R^\Z^BN
M0_X7!X#_ .AV\.?^#:W_ /BZ/^%P> _^AV\.?^#:W_\ BZ/J];^1_<P]M2_F
M7WG7T5R'_"X/ ?\ T.WAS_P;6_\ \71_PN#P'_T.WAS_ ,&UO_\ %T?5ZW\C
M^YA[:E_,OO.OHKD/^%P> _\ H=O#G_@VM_\ XNC_ (7!X#_Z';PY_P"#:W_^
M+H^KUOY']S#VU+^9?>=?17(?\+@\!_\ 0[>'/_!M;_\ Q='_  N#P'_T.WAS
M_P &UO\ _%T?5ZW\C^YA[:E_,OO.OHKD/^%P> _^AV\.?^#:W_\ BZ/^%P>
M_P#H=O#G_@VM_P#XNCZO6_D?W,/;4OYE]YU]%<A_PN#P'_T.WAS_ ,&UO_\
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M<P]M2_F7WG7T5R'_  N#P'_T.WAS_P &UO\ _%T?\+@\!_\ 0[>'/_!M;_\
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MM_\ XNC_ (7!X#_Z';PY_P"#:W_^+H^KUOY']S#VU+^9?>=?17(?\+@\!_\
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M_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\
MP)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW
M_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+
M_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L
M3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^L
MF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C
M%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/
M_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"W
MCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/
M_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^
M'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##
M"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G
M]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K
M[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%
M%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX
M_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H
M+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'
M_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\
MP)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW
M_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+
M_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L
M3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^L
MF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C
M%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/
M_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"W
MCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/
M_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^
M'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##
M"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G
M]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K
M[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX_P#C%?=%
M%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H+^'/_ FX
M_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'_#"WCW_H
M+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\ P)N/_C%'
M_#"WCW_H+^'/_ FX_P#C%?=%%'^LF/[K[@_L3!]G]Y\+_P##"WCW_H+^'/\
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M'PI<L]W;2MI40A,HC$#1.Y'+.I+?.?F.[DG P<J"[/TS\<>//#WPU\-W6O\
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MDE8$SUJBBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV^Z\3,X#J>Q7(-?GW\9_B_JWQL_X)<Z1K^O2FYUN'5[?3[RZ;K</#*RK(?\
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MR50 ^L=LBH?:44N4=S] ?%_Q#\*_#ZVBN/%/B;1_#5O,=L<NL7\5HCGT!D8
MU>\/>)M(\7:7%J>A:K8ZUILO^KO-/N$GA?Z.A(/YU^+<GQR^&OQ*_:,\;>,O
MC]I?B;Q5I3RR6^CZ-HT@5+>-96"([>?$RJB 8"-\S,S'W] _8K^,GAWPC^VQ
M!HOPR;6].^&'BPO:_P!CZ\Z>;%)Y!=#\LCJ2LJ;5;<6V.0<D\OET%S'ZG^,/
MBAX-^'K0KXJ\6Z%X9:<9B&L:E#:&0=,KYC#/X5H>&?&&@^-M.&H>'=;T[7K
MG NM,NX[F+.,XW(2.E?CK\3KK1/A[^UU\0KS]HSP'KGC+3M0O[AM/:"^EM1Y
M/F_N9(2K)YL8B**%#J%P >00/IO_ ()]Z5\%(?BYXCU?X7?$+7K>74+9L>!-
M8@$!2#Y2"S%G%PT;;L,C94,0<@DLG'0?-J?H-1114%!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YT_M9?\ )P'B
MK_MU_P#22&OT6K\Z?VLO^3@/%7_;K_Z20U]APO\ [[/_  O\XGS6?_[K'_$O
MR9^BU%%%?'GTH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?.G[='_))-(_[#D/\ Z3W%'["__))-7_[#DW_I/;T?MT?\DDTC_L.0
M_P#I/<4?L+_\DDU?_L.3?^D]O7V'_,A_[>_4^:_YF_\ VZ?1=%%%?'GTH444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'P[^W9^S=\1OC+\;OA9X@\'>'?[8TC1=GV^X^W6T'DXN5<_++
M(K-\H)^4&ON*BBG<1PWQV\-ZCXR^"/Q"\/Z/;?;-7U7P[J-C9V^]4\V:6VD2
M--S$*N68#)( SR17AW_!./X)^-/@+\$=<\/^.M&_L/5[GQ%/?16_VJ"XW0M;
M6R*^Z%W4?-&XP3GCIR*^JJ*+Z6 ^'?BG^S=\1O$G_!0SPA\3-.\._:/!%A]C
M^TZI]NMEV;(W#_NFD$AP2.BFD\6_LV_$;5/^"D&C?%*V\.^;X$MS!YNK?;K8
M;=MB8C^Z,GFGYSCA/?IS7W'13YF%CX<_;-_9M^(WQ8_:B^%'B[PKX=_M3P]H
M8L_[0O/MUM#Y/EWK2O\ ))(KMA#GY0?0<\5?_P""EO[._P 0?V@-"\!V_@'P
M_P#V]-IES>27:_;;>V\M76((<S2)G)5NF>E?:E%',] L?%'[=W[(GC3X\>$?
M &K>"WAD\3>%H&A?2KB=(O.#K$<QR,=@=6BZ,0"#U&.?(OCY\ OVM_VHO %I
M+XVT?0-/ET.1&LO#.EW,"37LK$(\[R&9HE*ID_ZP?>(5!FOTTHH4FA<I\-_M
M3? 'XG_&#]BCX5^#=)\)M+XUT>YTUM3TIK^T3R1!8W$$CB1I1&P+LA 5B<./
M0X^J_@3X;U'P;\$?A[X?UBV^QZOI7AW3K&\M]ZOY4T5M&DB;E)5L,I&02#C@
MFNYJ.>%;F"2%\[)%*-M8J<$8.".1]12OT';J?E+_ ,%:/ J>'/C5X4\4:1.T
M>I>)]+ELKNUMB?,D:$K&&(')#QS+'COY9%?HK^SA\*X_@G\#_!W@U543Z;8)
M]K91@-<N3).WXR._X8KYW^'O_!-V+3?BSI?COXC?%'7/BG>:3)'-90:M"X.Z
M-MT8EDDFE9T5OFV#:"1SD$@_:-4WHD)+6X5\#_M7?\$_O%/B#XJ/\5_@OK,>
MA^*II_MEU8?:&M7^T_Q3P3#@,^265L DL<_,17WQ14IV&U<_+;Q%\ ?VW?CS
M8Q>$O'FKKI_AIF1)I+O4+"."15/!D%GF27&,X<')P3SR/MO]GW]F;2OV;_@C
M=^#=$E.J:G>1S3WVHNHC:\NGCVYQGY4 "JJYX R>22?;J*;D"1^6/[-/[,?[
M5W[,\&M>)O"?A_1TU*\*VMUX7UF^MY8[Z)1NCF5XIPH9&9Q@R(1N/W@3CV7]
MEW]DOXFWW[0E_P#'3XX/9P>)B'-CI-M+',8Y&C\D,WEEHU1(LJBAF.2"2".?
MNFN;^(WA>_\ &O@37=!TO7;KPQJ&HVCVT.L60/GV;,,>8F&4AAV(8$'O3YFQ
M<I^>G@/_ )3 >(?K<_\ IL6N^^-'[*/Q;^&?[2-[\:_@*=.U2\U;>VHZ!J$R
M1;GD \X?.R*\;LHD/SJP?IQC'I'[,/[!]E^S_P#$;4_'NM^-]2\?^+KR&2$7
MUY 8 OF%2[L#)(SR';C<S]">,\CZIH<M= 2[GRI\!YOVL_$GQ$35/B?%X5\)
M^#\9GT6VBCN)FP" (6BE<KDX)9Y6QV4]*X+]HG]DGXG>&_VB(_CE\"Y[&XU^
M;YK_ $.^D6(2R>6(W(+LJ.DBCYE+*0WS Y(V_=%%+F'8^&_ O@G]L'XI?&+1
MO$?CS6K/X7>&;'8+K2-%NXI8KF-7W,JPK).I=^A>1OE'3T,?[='[,/Q1\=_'
M3X??%CX8:=9Z_J?AV&UC_LVZN8H"LMM=/<Q2'S'170F0@@.#\OOQ]T44<VMP
ML?GE^V!\!_C]^TI\&/A<;_P;8S^.]/N]2EUFQTR_MH;>V21U\@(99\-^[50<
M.QR#D\U]M>)OAY:>/OA'?>"];CV6VIZ0=-N1PQC+1;"PP>JGD8/4"NSHI7"Q
M^;_[ G[#/C_X2_'"Z\7?$?0X]-M=&LI8=';[;;W(FGD)0R*(Y&* 1F3[P4YD
M'O7T3^W-^R9/^U)X#TI=%O;?3O%V@323Z=-=%EAE20*)86902N=D9#8."F.A
M)'TO13YG>X65K'P9H^I?MY7\.C^'Y-#\*:(EDRI+XDNYK:9[Q5&,S!9I#@]2
M4B1N/K7W!X:AU:V\/:;%KUU:WVM);HMY<V4+0PR3!1O9$9F*J3G )-:=%)NX
M!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!^=/[67_ "<!XJ_[=?\ TDAKZ+_;H_Y))I'_ &'(
M?_2>XKYT_:R_Y. \5?\ ;K_Z20U]%_MT?\DDTC_L.0_^D]Q7Z1/X\L]/_;8G
MP\?AQWK^L@_87_Y))J__ &')O_2>WKZ+KYT_87_Y))J__8<F_P#2>WKZ+KX_
M./\ ?ZWJ?39;_N=/T"BBBO'/2"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *P_'/A"P^('@O7O#&J*6T[6+&:PN-OWA'*A1
MB/0@-D'U K<HH _*+P7H'[5G["&JZUX<\(^#Y/'7A6YNFN(3;Z7-J-I,V HF
M58&$L3%0N58C[HZ@9.AHGP7_ &@_VV?CAX5\3_%GPV_@_P *Z)*CO'<V36*I
M"L@D:&&"0F5GD( W/D =^ #^IM%7S$\I\&?MG?L]_$?0OVA/"WQ]^%6C_P#"
M2ZEIJPC4='C :5FBR@8)D,Z/$WED)\RXR.N5Z/P+^U=^T9\3/&^E6&G_ +.M
MQX8T5B$O[CQ-/<6H3D9D662*/"@9^41R,>U?:%%+F'8^%_VZ?V;?']]\6?"'
MQQ^%5B-7\1^'Q MWI2<R2^3(7CD5"1Y@(8HZ@YVA< \D8^H?M-?M8?%[7M T
MSP/\%[_X<F&3_B8W?B*U=K:XSQDO<0Q;(QRVU-SG P3T/Z 44<PK'P]^W#^R
MO\0?'&N^!/BS\/VM]2^(GA6&W2[M(%$7VIH9/.CFA5VQE9&DS&QR58 $E<'S
MSXM?%K]I7]JSP,WPNM/@7J7@<ZDT46KZSJ"SQ6TB*X8['EC18T+*I.&D8@$#
M.:_22BCF"Q\'_M+?LRZI\-_^"?\ I?PR\(Z9J'B[5[&_MIK@:3923S7,K2O)
M-*(T#-M#,0/10N:]<^$/A/7--_8#M/#UYHVH6FOKX.O+4Z5/:NET)FAE"Q^4
M1NWDD +C)R*^E**.8=C\_P#_ ()^_ '7-0_9;^*G@3QUX=UCPJ?$5[-;HFK6
M$MK*$>UC03(LBJ6VMR#TRN*X3X >(_VB_P!B^TUSX:#X*ZEX^L9KU[G3=1L!
M+]EBE8*I?STC=#&P16V,8V!)R1G _3NBGS"L?F?^Q'\)_BOX8_;:\5>)/B)X
M5U:RN-0L+Z>[U=K&86#W,TD,A2.<KY;8)8 *Q'RG!(&:YSX5^'/C?^QG\?O'
MEU%\'-2^)\NOM)';:U9Q2M&=TK.LWVE8Y @;=ET?:20,D8S7ZIT4<P<I^9_[
M)WPY^+/@G]O#5O$WQ$\$ZI9R>)+2[FN=4L+"673+>:X5+D1_:%4QC:5,1RW#
M#&3U/4?![X8^,=,_X*<>-_%-YX3URT\,7'V[R=:GTV9+*7=&@7;,5V')!Q@\
MXK]"**7,'*<C\7/AY9_%GX8^*/!U]M%OK6GS68D89$3LIV2?5'VL/=17Y*?\
M$_\ X9ZQ\4/VGO#6FZ^[76C_  WAN+O[-(0T<#I<.T:+VS]IF\SW"'T&/TN_
M:B\#_&/QQX;TRU^#OC33_!NH"25-1DU 86>%E &QQ!*R.I'#+M/)YZ5S?[%7
M[(</[*OA'5DO]3CUSQ7KDL<FHWL"$0HL8;RXH]WS$ NY+$ L6Z# IIV0-79]
M'UYA^TE\"]-_:*^$.L^"M0F^QR7(6>RO0NXVURAS')CN.JD=U9N_->GT5!1^
M4?P_OOVP/V+;6X\'Z1X%G\9^'(YF:TB33)M6M$+$LSPM;,LB*QR2K$ $D[02
M<Z/@_P#9?^.G[:'Q>TOQE\<K2X\.>%;$J&LKN+[([0JVXV]O;?>CW'[TCX.#
MU8@"OU+HJ^8GE/A7_@JI\-?%'CSX<^ K+P?X5U?Q%)9ZE,TEOHFG2W1@C\D!
M25B4[5[#M7 ^+?BQ^T]8?!(_!.;X*ZK?:S/IHT/_ (3#3TFFMY;,H(MWRQ[$
MD,?!=Y%P3DJIXK]***7,%C\^M=_9WO?V;/\ @F7X_P! U@Q'Q'J 35-36%@Z
MQ2O<6Z+$&'W@J1H"1QNW$=<EG[./P1;]H;_@F6G@R">.UU.XNKRXT^>7[BW,
M5X[QAC@X5L%"<' <G'%>O_MI? 'XT?M!+;^'/!/C/0]!\ 75K''J^FZCO2:X
MF68OO#I [%0!'\N]02IR*]@_9S^#-M^S[\&?#G@2WO/[2;3(Y#/>^6(_/FDD
M:61L=AN<@9)(4*,\55] MJ?$7PC^.G[2?[.7PUM_A=/^S]K/B;5-(5[?3=:B
MBFDM(T+LRB0PQM'*%)(!65. ,G/)^G-<\ ^.?VJ/V5]?\,?$OP]I_@3Q/K,6
M;:VMKHW*P/&R2P228!V$R)\R!F(7J<DJ/HJBIN.Q^:'P;^+7[2/[*?P[D^%D
MWP(UCQ?-I\LZ:1K%G'/-;0B21F^=HHW65-[,P^>,@-@XQ7U!^S=9_'/QM\%_
M$D'QH>PL]:U6VDM=,@%LD5S$C1.IDN?*.P%BRX55!4*<\G ^CZ*&PL?F=^P$
MGQ?_ &<_&=_\.M:^#FO'3M<U:%[SQ)+#*MI8HBE&8.(S'*#E<$2#'/7MU'[!
M_P ,?&/@_P#:\^,VLZ]X2US1-(OQ??9-0U'39K>WN-VH*Z^7(ZA7ROS#!.1S
M7Z$T4<PK'YX_\%0?V??%OB7Q)X/^(7P_T/6-8UDVTVB:E%H-G+<7 B*N8W*Q
M*6VE9)T9CV*#N*^D_P!ASX,S? []FWPOHE_:/9:Y?*VK:I#*I21+B;!V.IZ,
MD8CC(]8Z][HHYM+#MK<_-*Q^'7QA_8/_ &@_&7B3P3\.KWXG?#_Q*[E+725=
MYD0R&2-6\I'>-XRS+N*%&4D]?N_2_P"S;\;_ (X_%SQ;>R>-/A##X!\&A6>&
MYU">6*]4[?EC\IU#2$GJVR-0/4C!^EJ*+W"Q\#_%#XH?M*?#_P")&NV/C3X.
MV7QJ^'=P66PLM%TOS(2FX[)#MCG=6V_*RR*1D<'')X_]DO\ 9M\:^+/VL!\9
M-0^''_"E_"-AYDMKX?5&MV>1[<P>6D1"LJG<7<E$4YP!R<?I111S"L%%%%24
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?G3^UE_R<!XJ_[=?_22&OT6K\Z?VLO^3@/%7_;K_P"DD-?8<+_[[/\
MPO\ .)\UG_\ NL?\2_)GZ+4445\>?2A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!\Z?MT?\ ))-(_P"PY#_Z3W%'["__ "235_\
ML.3?^D]O1^W1_P DDTC_ +#D/_I/<4?L+_\ ))-7_P"PY-_Z3V]?8?\ ,A_[
M>_4^:_YF_P#VZ?1=%%%?'GTH4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEJ<7PG\!77CGPI^V!_PF7Q!TJ'[?<Z%J7BJSO-+U3;AI;>&S#Y0L-P4*22<
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M^SS>?%^;XW^,K?Q]8Z)_PD+:387:1Z)'&D/G-;BU(PY5 5\QV;<1DJ<U]7_
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MK****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_.G]K+_DX#Q5_P!NO_I)#7Z+5^=/[67_
M "<!XJ_[=?\ TDAK[#A?_?9_X7^<3YK/_P#=8_XE^3/T6HHHKX\^E"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YT_;H_P"22:1_
MV'(?_2>XH_87_P"22:O_ -AR;_TGMZ/VZ/\ DDFD?]AR'_TGN*/V%_\ DDFK
M_P#8<F_])[>OL/\ F0_]O?J?-?\ ,W_[=/HNBBBOCSZ4***\V_:/^+$7P/\
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MPP ^A_V*?CAJWQ3\/^,/#?B#7+'Q9K/@S5CIG_"2Z8Z/!JUJP)@N 4)7<0K
M[?0$\DT.-AW/3_V@/BS_ ,*+^#_B7QU_97]M_P!C0I+]@^T?9_.W2I'CS-C[
M<;\_=/2N"O/VK/['^(7P;T'5/"_V+1_B5I:W5KK7]H;EM+PQ"06C1^4-^=\2
MA]P),GW>*C_;_P#^3/OB3_UYP?\ I5#7G7[0WPYN_&7["O@KQ!HHV^)_!.D:
M5XGTR95RR-;V\;28_P"V>]L=RB^U"L)GV17RKHO[8GCGX@^'-:U_X=_!6X\:
MZ19^(;G1+6>+Q#';-=Q0J";K#P856+* H+<EN?EK1^/G[1\,?[%S>/M W?VG
MXMTNWLM(MX3ND%Y>*$V+ZO'F0X]8S7JG[//PI@^"/P5\(^"X542Z99*MTZ=)
M+ER7G?\ &1G(]L4;;C/F_P#X;L^*_P#PL;_A O\ AFVZ_P"$N^P_VG_9?_"7
M0[_LV[;YF?L^W&>,9S[5]'?!'X@>-/B'H-_>>-_AS-\-K^"Y\F"PGU2._,\>
MQ3YH=$4+R2N,?PYKP7_G*5_W3[_VXK[!H=A(****DH**** "BBB@#\Z?VLO^
M3@/%7_;K_P"DD-?1?[='_))-(_[#D/\ Z3W%?.G[67_)P'BK_MU_])(:^B_V
MZ/\ DDFD?]AR'_TGN*_2)_'EGI_[;$^'C\..]?UD'["__))-7_[#DW_I/;U]
M%U\Z?L+_ /))-7_[#DW_ *3V]?1=?'YQ_O\ 6]3Z;+?]SI^@4445XYZ0C*&4
MJPR#P0:P?"_P_P#"_@>2^D\.>&](T"2^?S;M]+L(K8W#\_-(44;CR>3GK6_1
M0 4444 ?GC^S[\5O%_[-NO?%?3=2^!_Q,\1)K7C"^U2UO-'\/S/ T+/M4AF
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M73C?W$$SR.P+1*00N&7DX[XR1BOK>BBX6/A3QM\(4^"/[0/CKQ5KWP17XU^
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M]G7X4V>I1:C;_#'P;!J$4PN([N/0+194D#;@X<1Y# \YSG/->$>&G\1?"_\
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M:*.8=CX^_:>\$>)_"_A[X Z[I'@9M:C\$Z];WVKZ'X$T_*PJ$&\6ML#DH&#
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MAD/\P[_*0-W=?LQ^$]<T#X]?M%ZAJ>C:AIUAJNO6DVGW5W:O%%>1K%(&>)F
M$B@D9*DCFOI2BBX['P'J'AN\^$_[4'Q2\2_$3X&^(OB_;^(KJ&;P[KFCZ/'K
M"6EN%*B HYQ!@%$+'!PAZJ03O?L^^'/'K?MR:WXT\3?#>Z\"Z!K/@MK73+>W
M@\VWM56Z@V0SS1+Y23L(9)#'G(#*.M?;U%',*Q\!?LN_$_XE_LW_  NN=#\3
M?!7QQX@L+S4[VZT>30=->2>(O.X:&ZA?:T*EE\Q9,%2L@]#2Z]\"?B"?V4?C
M[XE\0>'9_P#A8?Q'OH=2_P"$:TF-KN:V@2>/R8 (P2[JK2$XS@8S@YK[\HHY
MAV/DCXB^"?$5]\9_V1+ZVT#5+BRT.VU%=5N8K.1H]/+65LJB=@N(LLK ;\9*
MD=JTO@IX'\06?[1?[4MY=Z+?V-AKK:2NEWMW;/%!>[;6X5S%(P"N%9E!*DXR
M,U]2T47"Q\H?\$^[C6=!^"=K\*O%W@'Q-X;U7PTMTMU=:UIACTZ_6>[GDVP3
M$E9<+( PQ@]06%>2?LJ_"O6T_::O_ .JL;CP9\%;W4;K1OFW R:BRM:J_/58
MO.?OM8],DFOM_P"*7A;7?&G@74]'\,^*9O!6N7'EFVUVWM5N6MBLBLW[IB X
M959"">C9ZBN;^ /P-M?@9X8U&T?6;OQ1X@UB^DU/6=?OU"S7UR^ 6*@G:H
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M4/"MMIMMJ'VB(^9<)*C,GEAMXP >2H''6CQ1\+O$^H_ML>#/'MOIGF>$]/\
M"MSIMSJ'VB(>7</*[*GEEMYR".0I'/6O?ZYGXD^!Q\2/!>H>'3KVN>&!>>7_
M ,33PY>?9+Z'9(K_ +N7:VW.W:>.5)'>BXCXK^ WP3M/VAOV<_V@?!<]Y_9\
M]Y\3-6FLK\+N^SW$8M7C? /(R,'_ &6..:]$?QM^UP_A-/"D7PQ\.V_B3R1:
MGQZWB&![('&W[1]C*F3=_%R",_P$?+7O7P5^"WASX">!8?"OAA;MK)9I+J:Y
MOY_.N+F=R"\LC8 +' Z #@<5WE.XK'S'\;OV??B%XH\-?"_Q7HOB"PUSXP>
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M\#7,77QR^&]CH^G:O<_$'PM;Z5J186-]+K5LL%T58HPB<OM?#*RG:3@J1VH
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MA'U-17@/[/\ ^T9HFH? OX>:M\1?'N@6/BO6]-6XD_M2^M;&6Y<LPW+%E!V
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M^S[N.?[/<)C?%)L)V.,C*G!&>E &O1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7YT_M9?\G >*O\ MU_])(:_1:OS
MI_:R_P"3@/%7_;K_ .DD-?8<+_[[/_"_SB?-9_\ [K'_ !+\F?HM1117QY]*
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SI^W1_
MR232/^PY#_Z3W%'["_\ R235_P#L.3?^D]O1^W1_R232/^PY#_Z3W%'["_\
MR235_P#L.3?^D]O7V'_,A_[>_4^:_P"9O_VZ?1=%%%?'GTH4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#VMJ.MZ9;&&"TN5.Z(119!9%8MG)!<.1QUK*\6? ;]I/XN>"9/ASXY\<^
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M7;"#<02 @QUK(\&ZA_PS3X^_;&T?P9&NGZ-X?TBSUO2M/3/DVEU+8M)N122
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M(_Y1USNB_L1?:/@!\2?!7B;Q.-0\4_$"_;6-7UJTM?*@BO/-6:/RH01^[61
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M_9*TWXA0ZMI&NZMXA73-:CO(Y;2]=1F"7>&"NK2QJ23CGS,C(/.[^UU^S?X
M\,_$KX!V?A70+;P;'K7B#^P-2;P^GV)[NRE51+'(T>"Q9"Z;B<XD;.:]P^(G
M[-OB#Q!<? J/3_$1U>/P#K4.HZEJ/B*[EDO;]%4!F#!&W2$@G#%1T&:W?C]\
M%=<^*OCCX1:SI-UI]O:^$/$::O?I>R.KR0@ %8@J,"_'1BH]Z5QV/$?V@?A'
MX-^#?QX_9PUGP+X;TWPC?7'B8:3</HULEL+BW=%5EE" ;S@L-S9.&.2:\HTO
MQYX>\8_M0?&/Q'\1?A#XX^,;Z-K<OAW1K?1?#JZQINF6]O(\95D=P@D<J'P5
M/5CU8FOL7X_?!77/BKXX^$6LZ3=:?;VOA#Q&FKWZ7LCJ\D( !6(*C OQT8J/
M>N/\5_L]_$OP#\6O$OC[X)>(_#UB?%)CFUOPUXNAG:PEN5X^T1O#\Z,022!U
M).21@*[Z!8\U_9.N+[0_VHO$\'A#X8>.OAW\*/$&CB[DTWQ/H<MA;6FJQNH+
M0\O&BO'GY=PR3@ !%%9'_!.O]FOX=>._V:K/Q%XM\+Z?XLU/4Y[JU$FLPBY^
MR6Z3.HB@#9\H;M[DI@[I&.:^B_@;\*OB?HGC#6?&?Q2^("Z]JVH6ZVMOX;T%
MIHM$T] 02\<;D%Y#C&]E!P3DMD;9/V._@GKG[/?P'T?P3XBNM/O=5L[BYEDF
MTN222 B29G7!=$;.&&?EZTFPL?)?PZ\.:?>_L!_'WPYJ=E:ZO8>"O$6O6FAB
M^A$QLO*A1HY(]^[8X,TN&7!&]N>3GL_&OA7X>^'?V!OAC:ZKJR_#_1M?LM"N
MM7A\.Z2KWGB24VD;O;%8RA:24C)D))^09R,@^G_#_P#93U_1?@;\;/ >LZMI
ML5SX[U[5]2LKRQ,DR6\-U%$D?FAD0[P4.Y5R,8PQKC[S]DWXN>+?@OX#T#7?
M$?A'2_&7PUU&QNO"6H:2ES-:S16T:(BWBRH#OS&AW("#MQMY)IW$?//[6EQX
M</P535O!7[->M?"_^Q[RUGM?&&H:=;Z1<VS"1 N51C+*6) &XG!^;J*^H?'E
M\-4_;W^!-X$\L7'A?5)@F<[=T3G&?QKGOC9^S+^T-^TI\-[[0O''CCP3I#0^
M7-9:1X:M[I+.\N%=</=3RAI H7?A40C<5/\ #7K.H? GQ)J/[0WPH^(#W.EQ
MZ;X6\/W.F:A;+/*9GGEB*@PCR\,@)ZL5..W:E<#W'5-+L];TV[T[4;2"_P!/
MO(7M[FTNHUDBFB=2KHZ,"&5@2"",$$BO@G]E_P "^&M/^ ?[36L6OA[2K;5K
M/7_%&F6U_#91+/!:+9Q%;=) NY8@>0@.T>E?H!7R;\/?V:_BE\.V^,'A:VU;
MPEJ'P^\;3:QJ5K+-]ICU2WO+R$1H' 0Q^4NU0V,MQN']VDBF<U^R'^R+\+_&
M/[)OAZY\0>%=.UW6O$NG-+=:QJ-N)KN$L66,0R'YHA&H4 1E?NY[U\[3?$W7
MKS]@/X(^$Y9=:O;#Q#XFET748M#0RZC=:=%<2?Z)"F1O9@RJJY .Q5Z$U^C/
M[.?PXU/X0_ _P=X-UB>UN=3T>Q6VN)K%V>%F#$Y0LJL1SW45X-X)_8;U&/\
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ME_XPL;.021-:65PLULTVT]9)-L7J H/>ONRI8T%%%%24%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^=/[67_)P'BK_MU_
M])(:_1:OSI_:R_Y. \5?]NO_ *20U]APO_OL_P#"_P XGS6?_P"ZQ_Q+\F?H
MM1117QY]*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'SI^W1_P DDTC_ +#D/_I/<4?L+_\ ))-7_P"PY-_Z3V]'[='_ "232/\
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MJ];^1_<P]M2_F7WG7T5R'_"X/ ?_ $.WAS_P;6__ ,71_P +@\!_]#MX<_\
M!M;_ /Q='U>M_(_N8>VI?S+[SKZ*Y#_A<'@/_H=O#G_@VM__ (NC_A<'@/\
MZ';PY_X-K?\ ^+H^KUOY']S#VU+^9?>=?17(?\+@\!_]#MX<_P#!M;__ !='
M_"X/ ?\ T.WAS_P;6_\ \71]7K?R/[F'MJ7\R^\Z^BN0_P"%P> _^AV\.?\
M@VM__BZ/^%P> _\ H=O#G_@VM_\ XNCZO6_D?W,/;4OYE]YU]%<A_P +@\!_
M]#MX<_\ !M;_ /Q='_"X/ ?_ $.WAS_P;6__ ,71]7K?R/[F'MJ7\R^\Z^BN
M0_X7!X#_ .AV\.?^#:W_ /BZ/^%P> _^AV\.?^#:W_\ BZ/J];^1_<P]M2_F
M7WG7T5R'_"X/ ?\ T.WAS_P;6_\ \71_PN#P'_T.WAS_ ,&UO_\ %T?5ZW\C
M^YA[:E_,OO.OHKD/^%P> _\ H=O#G_@VM_\ XNC_ (7!X#_Z';PY_P"#:W_^
M+H^KUOY']S#VU+^9?>=?17(?\+@\!_\ 0[>'/_!M;_\ Q='_  N#P'_T.WAS
M_P &UO\ _%T?5ZW\C^YA[:E_,OO.OHKD/^%P> _^AV\.?^#:W_\ BZ/^%P>
M_P#H=O#G_@VM_P#XNCZO6_D?W,/;4OYE]YU]%<A_PN#P'_T.WAS_ ,&UO_\
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MO#G_ (-K?_XNC_A<'@/_ *';PY_X-K?_ .+H^KUOY']S#VU+^9?>=?17(?\
M"X/ ?_0[>'/_  ;6_P#\71_PN#P'_P!#MX<_\&UO_P#%T?5ZW\C^YA[:E_,O
MO.OHKD/^%P> _P#H=O#G_@VM_P#XNC_A<'@/_H=O#G_@VM__ (NCZO6_D?W,
M/;4OYE]YU]%<A_PN#P'_ -#MX<_\&UO_ /%T?\+@\!_]#MX<_P#!M;__ !='
MU>M_(_N8>VI?S+[SKZ*Y#_A<'@/_ *';PY_X-K?_ .+H_P"%P> _^AV\.?\
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M_<P]M2_F7WG7T5R'_"X/ ?\ T.WAS_P;6_\ \71_PN#P'_T.WAS_ ,&UO_\
M%T?5ZW\C^YA[:E_,OO.OHKD/^%P> _\ H=O#G_@VM_\ XNC_ (7!X#_Z';PY
M_P"#:W_^+H^KUOY']S#VU+^9?>=?17(?\+@\!_\ 0[>'/_!M;_\ Q='_  N#
MP'_T.WAS_P &UO\ _%T?5ZW\C^YA[:E_,OO.OHKD/^%P> _^AV\.?^#:W_\
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M_N9Z/MJ7\R^\Z^BN0_X7!X#_ .AV\.?^#:W_ /BZ/^%P> _^AV\.?^#:W_\
MBZ/J];^1_<P]M2_F7WG7T5R'_"X/ ?\ T.WAS_P;6_\ \71_PN#P'_T.WAS_
M ,&UO_\ %T?5ZW\C^YA[:E_,OO.OHKD/^%P> _\ H=O#G_@VM_\ XNC_ (7!
MX#_Z';PY_P"#:W_^+H^KUOY']S#VU+^9?>=?17(?\+@\!_\ 0[>'/_!M;_\
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M'/\ P;6__P 71]7K?R/[F'MJ7\R^\Z^BN0_X7!X#_P"AV\.?^#:W_P#BZ/\
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M/[F'MJ7\R^\Z^BN0_P"%P> _^AV\.?\ @VM__BZ/^%P> _\ H=O#G_@VM_\
MXNCZO6_D?W,/;4OYE]YU]%<A_P +@\!_]#MX<_\ !M;_ /Q='_"X/ ?_ $.W
MAS_P;6__ ,71]7K?R/[F'MJ7\R^\Z^BN0_X7!X#_ .AV\.?^#:W_ /BZ/^%P
M> _^AV\.?^#:W_\ BZ/J];^1_<P]M2_F7WG7T5R'_"X/ ?\ T.WAS_P;6_\
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M<P]M2_F7WG7T5R'_  N#P'_T.WAS_P &UO\ _%T?\+@\!_\ 0[>'/_!M;_\
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ML=&T:XLK:Z@U&.\9[YW1"BQ2H0"J,<YD';L>:^;O^&%O'O\ T%_#G_@3<?\
MQBONBBO<PF<8K!4O8T6K>AY6(RS#XJI[2HG?U/A?_AA;Q[_T%_#G_@3<?_&*
M/^&%O'O_ $%_#G_@3<?_ !BONBBNS_63']U]QR_V)@^S^\^%_P#AA;Q[_P!!
M?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#A
MA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S
M^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U
M]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONB
MBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$
MW'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_
M]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8
MH_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_
MX$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[
M_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%
M_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V
M)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_6
M3']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_Q
MBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?P
MY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X8
M6\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'
M_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!
M?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#A
MA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S
M^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U
M]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONB
MBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$
MW'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_
M]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8
MH_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_
MX$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[
M_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%
M_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V
M)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_6
M3']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_Q
MBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?P
MY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X8
M6\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'
M_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!
M?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#A
MA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S
M^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U
M]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONB
MBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$
MW'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_
M]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8
MH_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_
MX$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[
M_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%
M_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V
M)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBONBBC_6
M3']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_Q
MBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?P
MY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'_P 8H_X8
M6\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!?PY_X$W'
M_P 8H_X86\>_]!?PY_X$W'_QBONBBC_63']U]P?V)@^S^\^%_P#AA;Q[_P!!
M?PY_X$W'_P 8KZ1_:2^%&K_&+P-8Z-HUQ96UU!J,=XSWSNB%%BE0@%48YS(.
MW8\UZO17'6SC%5ZM.M-J\+VT[_\ #'52RS#T:<Z<4[2WU['PO_PPMX]_Z"_A
MS_P)N/\ XQ1_PPMX]_Z"_AS_ ,";C_XQ7W1179_K)C^Z^XY?[$P?9_>?"_\
MPPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?
M9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^
MZ^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W
M111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)
MN/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_
MZ"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ
M1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_
M ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX
M]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?
M"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/
M[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_
MK)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\
MXQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_A
MS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PP
MMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";
MC_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"
M_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\
MPPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?
M9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^
MZ^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W
M111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)
MN/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_
MZ"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ
M1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_
M ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX
M]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?
M"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/
M[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_
MK)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\
MXQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_A
MS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PP
MMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";
MC_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"
M_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\
MPPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?
M9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^
MZ^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W
M111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)
MN/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_
MZ"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ
M1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_
M ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX
M]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?
M"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/
M[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_
MK)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\
MXQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_A
MS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";C_XQ1_PP
MMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"_AS_ ,";
MC_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\ PPMX]_Z"
M_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?9_>?"_\
MPPMX]_Z"_AS_ ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ7W111_K)C^Z^X/[$P?
M9_>%%%%?+GOA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%>8_M%>&_B3XN^&=UI/PKU_3?#/B>XF16U+4BZB*##%Q&5C<J
MY.T9V\ L1@XKY+\7:IXO_9'_ &E_@OX7T_XM>*/B-!XSO$L==T?Q7??:_)5Y
MHH5N(@>8E)ED95'3R""S G%)7%<_0*BHKJ9K:UFF2&2X:-&<0Q8WN0,[5R0,
MGH,D#WKRCX(_M/>#OCM\.];\9:.FH:1INBW$]OJ-OK420W-L8HQ([.B.X"[6
MR#GL1U!J1GKE%>!>%_VUOAYX@^!=Y\6[Y-6\,^$H+M[&(ZQ!&MQ=RKCB&.*2
M3?DEE'(/R.3@#-2?"G]LSP5\4O'-MX.DT?Q1X)\2WMN;O3M/\7:7]A?4(<%O
M,@^=@PP&(R02%8C.#3LQ71[S17SI\0OVYO!/@7QEX@\,V/AOQEXXOO#J[M:F
M\)Z.+R#3>"2)I#(@7&#D\@%2,Y! U=4_;-^'MC^SV?C):?VIJ_A-9DMGALK9
M!>1RM*(RC1R.@!5B,_-C'(R",EF%T>[45XY\%/VG]"^/&M7-GX?\,>++/38[
M/[;!KVKZ5]FT^]3>J$02ER9#ECT7'RGGIGR__@HY\:/&?P=^$V@MX/OWT ZU
MJZ6%[KZ1EVL8MC-\I .TMM//7"L!R<@MK8+Z7/K.BOS;\!^'_C9X5\0>&/$W
MPG^/J_M$VDLZ-K?AV?6(E,4'!<;+JZ;;D;@"-C@[3MQFOL'XU_M3^$_@CXBT
M?PU>:;K_ (J\6:M&T]IX=\*Z?]MOGB!(,FS<H"_*W?)VM@<&G8+GL=%?//A/
M]M;PC\0? ?CC6O#N@>*KG7O"2#^T/"<VE8U9&9BB_N0Y# ,&W /E0C9 XS\Q
M_P#!/GXNZWX^U7Q1X^^(_C7XC3#2%O+JYO;ZZ(\'I;K' #$P/"W2F5I!&H "
M*#UHY6%S](J*^9/#?_!0CX:>(-<TBVFTSQ9H6AZS=?8]+\5:SHQM](OI<XVQ
MS[B>O&648[XKRG]I[]L3QAX%_:P\#^"=*T+Q6GABQN(Y]1L--TD-=Z^QW$"T
M._,T(&!@;<LK@YP*.5A='WC17D'P9_:=\-?&OQGXO\)V&DZ[X?\ $/A=HUOK
M#7[:*"1@Y8!D"2OD#:,YP1O7CFK/P;_:0\-?'3Q1XXT;PW8:L%\(WW]G7FI7
MD,26MQ+OD7$#+(S./W9.2J\%?6E9@>K45YQ\<OCYX3_9]\,VNL^*9;J0WMRM
MG8Z?IT'GW=Y,>B11Y&3CU('09R0#QOPG_;(\'_%3XC-X"ET#Q9X'\8& W,.C
M^+])^PSSQA=Q9 '?^$$_-C(!(SBBS ]YHKYAN/\ @H-X!7Q=XU\+67ACQOK7
MB+PK?36-QIND:,MW+=>5))'--"(Y3^Z0Q\M)Y?$B<') ]"^%/[4WP]^+WPHU
M+XAZ3JKV'A[2O,&IG5(_)EL3&@=A(H+#[K C:6!S@$G(HLPN>N45^?W[37[>
M^B>._P!FSQ=)X'@\=^$;ZZDMXM#\4RV$MA;7LB7D)F2VNHG)#>4LN5.T[0P/
MI7U_^SMJEYK?[/WPQU'4;N>_U"\\+Z9<7-W=2-)+-*]I$SN[L269B222<DDF
MBUD%ST*BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;_XBC]WYA[_D<-_PVY\%?^AT_P#*5>__ !FC_AMSX*_]#I_Y2KW_ .,UW/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^&[>0Y>'2+"*U1CSR1&H!ZG\ZK77PK\%7OBI?$]QX/T&?Q*I!769=,@:\!'
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M"',CJNTC_4L/F8@#Q#]CVZM+CX2_MKO9ZE<:O:S:#/+;W]X29[N(V^J%9GR
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MQ 7/)Z[PS_P4.^&GB+7-%M;C2/%WA_1=<NC9Z7XGUK1_L^E7L@.W$<V\G&<
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MTO;?"WQ8VH3W.N^'?%$<ME;R79=F<#SU43#>7(41RXW_ "G! *Y4%S[3T?\
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MP^;(X(I?#?QLL/VHOV0?&]O\?]3.C:)I&L0:?#XUT#3YI8[B8?,DOE1QMT8
M,=BH1*HPK&E9!<^A?"?[>'@?7O&F@>&M9\,>-O 5UX@=8](N_%VB_8K:_9B
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M6Y24JB78E=A*_P DGRL24 (;!Q7!?#'_ (8+_P"%:^$_^$P_Y&W^R+3^V?\
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MKNI+I4#:;;H9X9BLK,)4D=-@7R'!Y)^Z0"#FN9NO^"C7PLTGQ%!INMZ=XO\
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M?M:_]$O\*?\ @3'_ /)U1[-]U]Y?/Y,^K**^4_\ A8G[6O\ T2_PI_X$Q_\
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M5NW^'_A>T\77/BN#PWI$/BFZC$,^N1V$2WLJ!54*\X7>PVH@P3C"J.PK?HH
MP-%^'_A?PYKVIZWI/AO2-+UK5"6O]2LK&*&XNR3N)ED50SG//S$\U!IGPP\&
MZ+XHN?$NG>$M#L/$=UN\_6+7388[N7=][=,JAVS@9R><5TU% !1110 4444
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M_P#M]_\ 2V>M_P#ES\_T,O\ EY\CW.BBBL#4***R]8UZ+1UB:491VP6!''%
M%ZYNH[6)I)&"(HR6/:N.M_B&LFLF)PGV%V"1R8P>>,_G7,^,?%TFH3-%S%:I
M@JO=SV/'Z5E>&7DN-0$GEYY^7(SM^E 'M\<@D7(I]4=+W>0N[KBKU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RQ_P48_Y
M(EHG_8PP?^DUS7U/7RQ_P48_Y(EHG_8PP?\ I-<UI3^-'E9K_N57T/;_ (%_
M\D2^'W_8O:?_ .DT==Q7#_ O_DB7P^_[%[3_ /TFCKN*B6[.ZA_"AZ+\@HHH
MI&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /D?]G?_D[3XF?]Q/\ ]+XJ^N*^1_V=_P#D[3XF?]Q/_P!+XJ^N*WK?
M%\CYKA__ '67^.7YA1116!]*%%%% !1110 4444 %%%% 'Q?_P %$O@[_:6A
MZ;\1-.@S<:?ML=3V#K S?NI#_NNQ4GK^\7LM0?\ !.OX._8],U/XBZC!B6[W
M6&E[QTC!_?2CZL @/^P_K7V)XF\.V'B_P[J6B:I"+C3M0MWMIX_5'4@X/8\\
M'L<&H_"?ABP\$^&-+T'2XO(T_3K=+:!.^U1C)]2>I/<DFNCVK]GR&7LUS\QI
M7$HAC+&O#_$/C?3?%.J7D=C=B_-I.8&V-A48<$9Z$ @YKU#Q%(^L6UQ96[O'
M"RF.6X0E2,C!"$=_<=*\IC^%]GI-O%IVE6:V=C&3MC3)Y)Y))Y)/<GDUSFI@
M2-/X@O/(@^=2<2S*N/,]@.RUZIX+\%QV,*.R<_2I?"?@F/3U5F09^E=W! L*
M  8% !!;K"H %3444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7YX_MY>,O&]OXN;P;K<UO/X5>>/6-*DCM@CD;'CV
M,XZE"\BXZXVD]:_0ZO#?VMO@3-\;_A_;Q:5'&?$FEW"S63R$*&1R%EC+=@5P
MWUC6M:<E&5V>/FV'J8C"RC2;OV[^1RG[#/C+QOXX\#23Z[-;KX8TF"'2-)BC
MM@CR>4BAF9NI"J$7/<EO2OIVN;^'/@:P^&O@?1O#.FC_ $33;=80^,&1NKR'
MW9BS'W-=)4R:E)M'9@Z,Z%"%.H[M+4****@[ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XWXN>+-8\"^ ]
M1U_1=/AU2?3P)IK:9F&81]]@1W4?-]%-=E4<\,=U#)#,BRQ2*4='&0RD8((]
M,4UH]3*M&52G*,)<K:T?;S/SL^&/QGUCPY\8-7\3:7HL&HZKXCEFA6P9V"A[
MBX23"D<GY@ ,^M?HC9^>;. W0C%UL7S1%G9OQ\VW/.,YQFOF7X+_ +-,G@OX
MY:]JEY S:)I#;M'>09$IE!*G)ZF-25/^U@U]05T5Y1DURGR_#N%Q6'H3^LO>
M3LOGJ_FPHHHKF/K0HHHH **** "BBB@ KX\\=?\ !0G_ (0OQMXA\/?\(#]L
M_LG4;BP^T_VSY?F^5*R;]OV<[<[<XR<9ZFOL.OQY^.G_ "6WX@_]C#J'_I3)
M711BI-W/FL\QE?!TX2H2LV^R?YGU/_P\N_ZIQ_Y7/_N:FR?\%*A+&R'X<G##
M!QKN/_;>OB*BNKV,.Q\A_;>8?\_/PC_D?:J_\%'HTC6-/AP$11@*-;_^YZ1?
M^"CL2G/_  K?)_[#G_W-7Q711[&'8/[;S#_GY^$?\C[=7_@I4$X'PX_\KG_W
M-3O^'EW_ %3C_P KG_W-7Q!11[&'8/[;S#_GY^$?\C[?_P"'EW_5./\ RN?_
M '-1_P /+O\ JG'_ )7/_N:OB"BCV,.P?VWF'_/S\(_Y'V__ ,/+O^J<?^5S
M_P"YJ/\ AY=_U3C_ ,KG_P!S5\044>QAV#^V\P_Y^?A'_(^W_P#AY=_U3C_R
MN?\ W-1_P\N_ZIQ_Y7/_ +FKX@HH]C#L']MYA_S\_"/^1]O_ /#R[_JG'_E<
M_P#N:C_AY=_U3C_RN?\ W-7Q!11[&'8/[;S#_GY^$?\ (^W_ /AY=_U3C_RN
M?_<U'_#R[_JG'_E<_P#N:OB"BCV,.P?VWF'_ #\_"/\ D?;_ /P\N_ZIQ_Y7
M/_N:C_AY=_U3C_RN?_<U?$%%'L8=@_MO,/\ GY^$?\C[?_X>7?\ 5./_ "N?
M_<U'_#R[_JG'_E<_^YJ^(**/8P[!_;>8?\_/PC_D?;__  \N_P"J<?\ E<_^
MYJ/^'EW_ %3C_P KG_W-7Q!11[&'8/[;S#_GY^$?\C[?_P"'EW_5./\ RN?_
M '-1_P /+O\ JG'_ )7/_N:OB"BCV,.P?VWF'_/S\(_Y'V__ ,/+O^J<?^5S
M_P"YJ/\ AY=_U3C_ ,KG_P!S5\044>QAV#^V\P_Y^?A'_(^W_P#AY=_U3C_R
MN?\ W-1_P\N_ZIQ_Y7/_ +FKX@HH]C#L']MYA_S\_"/^1]O_ /#R[_JG'_E<
M_P#N:C_AY=_U3C_RN?\ W-7Q!11[&'8/[;S#_GY^$?\ (^W_ /AY=_U3C_RN
M?_<U'_#R[_JG'_E<_P#N:OB"BCV,.P?VWF'_ #\_"/\ D?;_ /P\N_ZIQ_Y7
M/_N:C_AY=_U3C_RN?_<U?$%%'L8=@_MO,/\ GY^$?\C[?_X>7?\ 5./_ "N?
M_<U'_#R[_JG'_E<_^YJ^(**/8P[!_;>8?\_/PC_D?;__  \N_P"J<?\ E<_^
MYJ/^'EW_ %3C_P KG_W-7Q!11[&'8/[;S#_GY^$?\C[?_P"'EW_5./\ RN?_
M '-1_P /+O\ JG'_ )7/_N:OB"BCV,.P?VWF'_/S\(_Y'V__ ,/+O^J<?^5S
M_P"YJ/\ AY=_U3C_ ,KG_P!S5\044>QAV#^V\P_Y^?A'_(^W_P#AY=_U3C_R
MN?\ W-1_P\N_ZIQ_Y7/_ +FKX@HH]C#L']MYA_S\_"/^1]O_ /#R[_JG'_E<
M_P#N:C_AY=_U3C_RN?\ W-7Q!11[&'8/[;S#_GY^$?\ (^W_ /AY=_U3C_RN
M?_<U'_#R[_JG'_E<_P#N:OB"BCV,.P?VWF'_ #\_"/\ D?;_ /P\N_ZIQ_Y7
M/_N:C_AY=_U3C_RN?_<U?$%%'L8=@_MO,/\ GY^$?\C[?_X>7?\ 5./_ "N?
M_<U'_#R[_JG'_E<_^YJ^(**/8P[!_;>8?\_/PC_D?;__  \N_P"J<?\ E<_^
MYJ/^'EW_ %3C_P KG_W-7Q!11[&'8/[;S#_GY^$?\C[?_P"'EW_5./\ RN?_
M '-1_P /+O\ JG'_ )7/_N:OB"BCV,.P?VWF'_/S\(_Y'V__ ,/+O^J<?^5S
M_P"YJ/\ AY=_U3C_ ,KG_P!S5\044>QAV#^V\P_Y^?A'_(^W_P#AY=_U3C_R
MN?\ W-1_P\N_ZIQ_Y7/_ +FKX@HH]C#L']MYA_S\_"/^1]O_ /#R[_JG'_E<
M_P#N:C_AY=_U3C_RN?\ W-7Q!11[&'8/[;S#_GY^$?\ (^W_ /AY=_U3C_RN
M?_<U'_#R[_JG'_E<_P#N:OB"BCV,.P?VWF'_ #\_"/\ D?;_ /P\N_ZIQ_Y7
M/_N:C_AY=_U3C_RN?_<U?$%%'L8=@_MO,/\ GY^$?\C[?_X>7?\ 5./_ "N?
M_<U'_#R[_JG'_E<_^YJ^(**/8P[!_;>8?\_/PC_D?;__  \N_P"J<?\ E<_^
MYJ/^'EW_ %3C_P KG_W-7Q!11[&'8/[;S#_GY^$?\C[?_P"'EW_5./\ RN?_
M '-1_P /+O\ JG'_ )7/_N:OB"BCV,.P?VWF'_/S\(_Y'V__ ,/+O^J<?^5S
M_P"YJ/\ AY=_U3C_ ,KG_P!S5\044>QAV#^V\P_Y^?A'_(^W_P#AY=_U3C_R
MN?\ W-1_P\N_ZIQ_Y7/_ +FKX@HH]C#L']MYA_S\_"/^1]O_ /#R[_JG'_E<
M_P#N:C_AY=_U3C_RN?\ W-7Q!11[&'8/[;S#_GY^$?\ (_4?]G#]JW3/V@+S
M5=.?2?\ A'=8LD6:.S:[^T?:(3PSJVQ.5; (Q_$IR><4?BW^U7?_  C\:7.@
MWW@G[4BJLMM>#5-BW$3=' \DXY!4C)P5/)ZU^='P]\=:G\-/&>E>)='D\N_T
M^82*&^[(N"&1O]EE)4^QK]%/BUX>TS]I_P"!NF>+O#*&;4H(6O+-,9D..)[9
ML?Q94C_>08X.:Q=.,)JZT9[-/,<9C,%-4)VK0UV7O+TM^7EW./\ ^&^O^I$_
M\J__ -HH_P"&^O\ J1/_ "K_ /VBOD>BNKV%/L?%?ZR9K_S^_P#)8_Y'UQ_P
MWU_U(G_E7_\ M%'_  WU_P!2)_Y5_P#[17R/11["GV#_ %DS7_G]_P"2Q_R/
MKC_AOK_J1/\ RK__ &BC_AOK_J1/_*O_ /:*^1Z*/84^P?ZR9K_S^_\ )8_Y
M'UQ_PWU_U(G_ )5__M%'_#?7_4B?^5?_ .T5\CT4>PI]@_UDS7_G]_Y+'_(^
MN/\ AOK_ *D3_P J_P#]HH_X;Z_ZD3_RK_\ VBOD>BCV%/L'^LF:_P#/[_R6
M/^1]<?\ #?7_ %(G_E7_ /M%'_#?7_4B?^5?_P"T5\CT4>PI]@_UDS7_ )_?
M^2Q_R/KC_AOK_J1/_*O_ /:*/^&^O^I$_P#*O_\ :*^1Z*/84^P?ZR9K_P _
MO_)8_P"1]<?\-]?]2)_Y5_\ [11_PWU_U(G_ )5__M%?(]%'L*?8/]9,U_Y_
M?^2Q_P CZX_X;Z_ZD3_RK_\ VBC_ (;Z_P"I$_\ *O\ _:*^1Z*/84^P?ZR9
MK_S^_P#)8_Y'UQ_PWU_U(G_E7_\ M%'_  WU_P!2)_Y5_P#[17R/11["GV#_
M %DS7_G]_P"2Q_R/KC_AOK_J1/\ RK__ &BC_AOK_J1/_*O_ /:*^1Z*/84^
MP?ZR9K_S^_\ )8_Y'UQ_PWU_U(G_ )5__M%'_#?7_4B?^5?_ .T5\CT4>PI]
M@_UDS7_G]_Y+'_(^N/\ AOK_ *D3_P J_P#]HH_X;Z_ZD3_RK_\ VBOD>BCV
M%/L'^LF:_P#/[_R6/^1]<?\ #?7_ %(G_E7_ /M%'_#?7_4B?^5?_P"T5\CT
M4>PI]@_UDS7_ )_?^2Q_R/KC_AOK_J1/_*O_ /:*/^&^O^I$_P#*O_\ :*^1
MZ*/84^P?ZR9K_P _O_)8_P"1]<?\-]?]2)_Y5_\ [11_PWU_U(G_ )5__M%?
M(]%'L*?8/]9,U_Y_?^2Q_P CZX_X;Z_ZD3_RK_\ VBC_ (;Z_P"I$_\ *O\
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M (;Z_P"I$_\ *O\ _:*^1Z*/84^P?ZR9K_S^_P#)8_Y'UQ_PWU_U(G_E7_\
MM%'_  WU_P!2)_Y5_P#[17R/11["GV#_ %DS7_G]_P"2Q_R/KC_AOK_J1/\
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MQ_R/KC_AOK_J1/\ RK__ &BC_AOK_J1/_*O_ /:*^1Z*/84^P?ZR9K_S^_\
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M5\CT4>PI]@_UDS7_ )_?^2Q_R/KC_AOK_J1/_*O_ /:*/^&^O^I$_P#*O_\
M:*^1Z*/84^P?ZR9K_P _O_)8_P"1]<?\-]?]2)_Y5_\ [11_PWU_U(G_ )5_
M_M%?(]%'L*?8/]9,U_Y_?^2Q_P CZX_X;Z_ZD3_RK_\ VBC_ (;Z_P"I$_\
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M/^&^O^I$_P#*O_\ :*^1Z*/84^P?ZR9K_P _O_)8_P"1]<?\-]?]2)_Y5_\
M[11_PWU_U(G_ )5__M%?(]%'L*?8/]9,U_Y_?^2Q_P CZX_X;Z_ZD3_RK_\
MVBC_ (;Z_P"I$_\ *O\ _:*^1Z*/84^P?ZR9K_S^_P#)8_Y'UQ_PWU_U(G_E
M7_\ M%'_  WU_P!2)_Y5_P#[17R/11["GV#_ %DS7_G]_P"2Q_R/KC_AOK_J
M1/\ RK__ &BC_AOK_J1/_*O_ /:*^1Z*/84^P?ZR9K_S^_\ )8_Y'UQ_PWU_
MU(G_ )5__M%'_#?7_4B?^5?_ .T5\CT4>PI]@_UDS7_G]_Y+'_(^N/\ AOK_
M *D3_P J_P#]HKT3X(_M3V'Q>\33:%<:-_8%\83+:@WGGBXVY+J/D3# ?-CG
M(#=,<_ =7M!UR]\,ZU8ZMITQM[ZSF6>&1>S*<CZCU'<5,L/!K1'1A^)LPIUH
MRK3YHWU5HJZ^21^L5%<G\+?B%9?%#P/IOB"RPAG3;<0 Y,$R\.A^AZ>H(/>N
MLKS&FG9G[)3J0K0C4INZ>J"BBBD:!1110 4444 %?CS\=/\ DMOQ!_[&'4/_
M $IDK]AJ_'GXZ?\ );?B#_V,.H?^E,E=6'W9\=Q)_"I^K_(X>BBBNX^ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M:7I=WK>I6NGV%O)=WUU*
ML$%O$N7D=B J@>I)%?1\'_!/GXH3:2MXT^@0W!CW_8)+V3S@<9VDB,IGM]_'
MO7A?PW\?:A\+_&NF>)]*AM;C4-/9VACO4+Q99&3) 8'@,2.>H%?3W[--UX__
M &@/VD$^)>H;K/3-/0I=RVYD2UQY.Q;:%69LY.'9<D#EC@E0<JCE'5;'LY?1
MP]:2IU(N4I.UEI9=6?)OB+P]J7A/7+W1]7LY+#4[*4PW%M,,,C#]".X(X(((
MR#7<?!/X$ZQ\=]4U#3="U?1K"_LXEG-OJDTL;RQDX+)LC?(4[<YQ]X5VG[2M
MO>_&?]H+Q==^!]"O_$5O9F&VGFTBSDN=[1QK&SML4X&Y64'H0@(K@O#LWC;]
MGWQQH/B2ZT/5/#]]!,988]4LY+8748P)8_G494JVTXZ;AT.*=VXZ;G.Z-.CB
M'SIRIIVOY7MN<]X@\"ZUX;\;7?A.[LG.N6]Y]A^S1@L9)"VU0G'(;(*GN"/6
MNX^-7[./B#X#V.E3>(M6T6>XU)F$-CI\\LDP51EG8-$JA02!]X\GC/)'W7;^
M&_AYX\UW0?VA&N$AL['2))Y@X! D08#R8/\ K(AYJ$8.2$Q]T9^*]1U35/VP
M/VD+2"2<V$6JW!M[57&?LEE$KR8 [L$5V/8NQZ U$:CE\MSTL1E]/#1Y4^:4
MW[FO3N_6]CQ&BONN3X3_ +-UI\28_A/+IFK-XJ:,0G5S=3;1.4#!"=^SS""&
MXCV9XSGBO$H_@UX$^&'Q^UOPU\3?$4UEX8TM1/;-';S-+J"N%:),Q(VT;6.X
M\<K@=<BE43Z''5RVK2M><6KV;OHGV=]CP&BOMOX;? WX9?M!>#?%,NE?#K6?
MAY<60!T[5KB^N)TNE8.4<"0[21L^=!G =</SD<_^R9\"?AY\2O@[XG\0>,]/
M+3:=J$BG45NYHC!;I!%(WRJX7C+G)4]?:CVBLRHY56G*$8R34DVGK;3?=7_
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MV3UZL\;\=?LP>*?A]\,[7QSJ-_H\VDW$D<:0VLTK3@N2!E6B"_PG^*H/@_\
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MOZ_0IT445N?,!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU7M6I6:TL<D<GA5PD:M.=IRJ<J3TZV2:L]>KUV\SY,HKZ _X5;X8_P"&M_\
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M:G14/W5^3FM[VR?R_$^V_P!E77=&^+'[._B3X07.JPZ/KK^>+7S.3+'(0ZN
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MT):3*]V<=!7P712]CI:_X'1#/(QK>V=)WM%:3:^'T5G?LUH?8'Q#;P@?VI_
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M (]1_P ,4_!C_H3?_*I>_P#QZCZQ$/\ 5S%_S1^]_P"1^6-%?J=_PQ3\&/\
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MB'^KF+_FC][_ ,C\L:*_4[_ABGX,?]";_P"52]_^/4?\,4_!C_H3?_*I>_\
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M_!C_ *$W_P JE[_\>H^L1#_5S%_S1^]_Y'Y8T5^IW_#%/P8_Z$W_ ,JE[_\
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MO_(_+&BOU._X8I^#'_0F_P#E4O?_ (]1_P ,4_!C_H3?_*I>_P#QZCZQ$/\
M5S%_S1^]_P"1^6-%?J=_PQ3\&/\ H3?_ "J7O_QZC_ABGX,?]";_ .52]_\
MCU'UB(?ZN8O^:/WO_(_+&BOU._X8I^#'_0F_^52]_P#CU'_#%/P8_P"A-_\
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M/]4,?_/#[W_\B?G717Z*?\,G?"K_ *%;_P J-W_\=H_X9.^%7_0K?^5&[_\
MCM'UF'9A_JAC_P">'WO_ .1/SKHK]%/^&3OA5_T*W_E1N_\ X[1_PR=\*O\
MH5O_ "HW?_QVCZS#LP_U0Q_\\/O?_P B?G717Z*?\,G?"K_H5O\ RHW?_P =
MH_X9.^%7_0K?^5&[_P#CM'UF'9A_JAC_ .>'WO\ ^1/SKHK]%/\ AD[X5?\
M0K?^5&[_ /CM'_#)WPJ_Z%;_ ,J-W_\ ':/K,.S#_5#'_P \/O?_ ,B?G717
MZ*?\,G?"K_H5O_*C=_\ QVC_ (9.^%7_ $*W_E1N_P#X[1]9AV8?ZH8_^>'W
MO_Y$_.NBOT4_X9.^%7_0K?\ E1N__CM'_#)WPJ_Z%;_RHW?_ ,=H^LP[,/\
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MQ_\ /#[W_P#(GYUT5^BG_#)WPJ_Z%;_RHW?_ ,=H_P"&3OA5_P!"M_Y4;O\
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MF'^J&/\ YX?>_P#Y$_.NBOT4_P"&3OA5_P!"M_Y4;O\ ^.T?\,G?"K_H5O\
MRHW?_P =H^LP[,/]4,?_ #P^]_\ R)^==%?HI_PR=\*O^A6_\J-W_P#':/\
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M==%?HI_PR=\*O^A6_P#*C=__ !VC_AD[X5?]"M_Y4;O_ ..T?68=F'^J&/\
MYX?>_P#Y$_.NBOT4_P"&3OA5_P!"M_Y4;O\ ^.T?\,G?"K_H5O\ RHW?_P =
MH^LP[,/]4,?_ #P^]_\ R)^==%?HI_PR=\*O^A6_\J-W_P#':/\ AD[X5?\
M0K?^5&[_ /CM'UF'9A_JAC_YX?>__D3\ZZZKX7_#^]^)WC;3?#]EE#</F:;&
M1#$.7<_0=/4D#O7W5_PR=\*O^A6_\J-W_P#':ZGP'\'?!_PRN;JX\-:,NFSW
M2".63SY9F90<@ R,V!GTQG ]!2EB8V]U:G1A^$<2JT7B)QY+ZV;O;[D=%X?T
M&R\+Z'8Z1IT(@L;*%8(8QV51CGU/<GN36C117G'ZG&*BE&*LD%%%%!04444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#;L/W.O/#;0D>)>+H_%?Q$_:>T+]GK3?B'XO\+>#_"OA=-6U+6K#5-FN:Q,
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M7_0X:#_X,X/_ (JC_A:G@K_H<-!_\&<'_P 57Y:T4?ZJTO\ GZ_N0?ZP5/\
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MO^APT'_P9P?_ !5'_"U/!7_0X:#_ .#.#_XJORUHH_U5I?\ /U_<@_U@J?\
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MU/!7_0X:#_X,X/\ XJORUHH_U5I?\_7]R#_6"I_S[7WGZE?\+4\%?]#AH/\
MX,X/_BJ/^%J>"O\ H<-!_P#!G!_\57Y:T4?ZJTO^?K^Y!_K!4_Y]K[S]2O\
MA:G@K_H<-!_\&<'_ ,51_P +4\%?]#AH/_@S@_\ BJ_+6BC_ %5I?\_7]R#_
M %@J?\^U]Y^I7_"U/!7_ $.&@_\ @S@_^*H_X6IX*_Z'#0?_  9P?_%5^6M%
M'^JM+_GZ_N0?ZP5/^?:^\_4K_A:G@K_H<-!_\&<'_P 51_PM3P5_T.&@_P#@
MS@_^*K\M:*/]5:7_ #]?W(/]8*G_ #[7WGZE?\+4\%?]#AH/_@S@_P#BJ/\
MA:G@K_H<-!_\&<'_ ,57Y:T4?ZJTO^?K^Y!_K!4_Y]K[S]2O^%J>"O\ H<-!
M_P#!G!_\51_PM3P5_P!#AH/_ (,X/_BJ_+6BC_56E_S]?W(/]8*G_/M?>?J5
M_P +4\%?]#AH/_@S@_\ BJ/^%J>"O^APT'_P9P?_ !5?EK11_JK2_P"?K^Y!
M_K!4_P"?:^\_4K_A:G@K_H<-!_\ !G!_\51_PM3P5_T.&@_^#.#_ .*K\M:*
M/]5:7_/U_<@_U@J?\^U]Y^I7_"U/!7_0X:#_ .#.#_XJC_A:G@K_ *'#0?\
MP9P?_%5^6M%'^JM+_GZ_N0?ZP5/^?:^\_4K_ (6IX*_Z'#0?_!G!_P#%4?\
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M )^O[D'^L%3_ )]K[S]2O^%J>"O^APT'_P &<'_Q5'_"U/!7_0X:#_X,X/\
MXJORUHH_U5I?\_7]R#_6"I_S[7WGZE?\+4\%?]#AH/\ X,X/_BJ/^%J>"O\
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MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?>'[$/_)';O_L+S?\
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MB^M5[WYW>]_GL>J^*OVC/$'BKP)>^$'TC0=,T*XD21+?2[)K<6X5U?;& ^T
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M8/L:^D/VBOALGC[XO>!=4T<;[#QE#"IF@ )^7:7D)Z<0LA_X :^6Z^ROV?\
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MWEJSA/!/PVNO#/[0'A_1?"OCO3+F6X266S\0:9'%>+$/)EW!X2Q4.0K#:6.
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M-I]#S<50HQP\:D%:6G75Z:]6OP5NIY51117T9X@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !3X?+\Y/-W>5N&_9]['?'O3*L:?/!:ZA;37-L+R
MVCE5Y;8N4$J@@E-PY&1D9'(S2>PUN?H+JFJ>*O!MOX:C^&GA/1]=^'?V59)Q
M9RJ+G9NRYC!D169E.0<.6;=GKS\U+\+]$^-/QYU71= M]0\!V;6QNWLM1TY5
MDMY%";D$(D&Q3NW 9XSP,8KT30_"_P /;BZT_7? /Q?_ .%<Z3-Y4MUH4E_M
M=I$/S;EFF'../G5U/494XIX^.O@RX_:NM=9BOUCT7^RO[&?5779"\Y<L)"?[
MG*IO( XS]WYJ_/L-[7#^T>&BW+EEKRM.][^\G>+?:Q]E7]G6Y%7:Y>9:735O
M[K5FEZGB/@WX(_\ "6:?\1[G^VOLO_"'P23;?LN_[7L$QQG>-F?)_P!K[WMS
MNZ3^SQHS?"[1/'.O>/(/#VFZ@Q1XY=->9T;<ZJJ!'S(24S@ 8&3_  UZ5X=M
M?"_P_P##/QI6;Q[X<U2_U^PN)+.UL;U6!C*7/EC<<!I6+D&-,E<+R=XJ/4O!
M]GXU_9-^'UA/X@TSP[<B[=[:XUB4Q6TC!KC<C2 '8=N6!(Y*[?XJ]*IF%=ST
MFXQ<HJ_+TY+NUUWZV_ X88.DHZQ3DHMVOUYK+9]OZN>=7W[,-W8?%3PUX5.O
MPSZ1XAADN+#7+>#>'5(C(V8M_7@=&((=3GJ!H?\ #*]GJ5YXAT/0O'NGZQXQ
MT<.\FBK9O$KH'P,3%L;MI7( 8*[;"W\5>FZ=XNT"_P#CE\'/".@:G'K</A>P
MN;6;4;<AHI7:SVX5@<' B!.,CYL9R#BOX?C\)?!_XM_$#X@7GC/2KNU+WD4.
MB6\N=1-PTX,D;0D C$B,JD9!!#$A>:PEC\;9+F:ERII<J]Y\S2OII=6[>5C9
M83"W;Y5R\UF^;9<J;MKK9^IS$=I-?_L26-M;QM-<3:N(XXT&2S&Y( 'N2:P_
M^&4K;^U/^$9_X3S3_P#A/OL?VO\ L'[')Y73.W[1NQG;SC;G'.,<UT&E?$[2
M=-_9MTF>74=/EURV\1)J;Z3'<H)R%O#*<1YW 8[XZ&O0?%WQ2NM>U9]>\/\
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M\14G.E%MP<9K5+I&Z>D5OZZ]$C*EAJ,(QJ224DXO1_WM5J^GIIW9\V?M"?\
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MG>OSC+ @<C&>=OO3?M&>$[3]H:VBCU*-O#\6CG1?[8528A<>:'W[NAC^4+O
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MOM^'S/I'XF:1XEU#]J"UNO#&GZ+=7MEX=29KK7U<VMF/.EQ)E#D/GA>O5CC
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MIUZ$8)WDK>2M:VUW^'J8U%%%?1'BA1110 4444 %%%% !1110 4444 %%%%
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MCRO_ (7T?^B<>/\ _P $@_\ CE'_  OH_P#1./'_ /X)!_\ '*]4HH]MA_\
MGU_Y,P]G6_Y^?@CRO_A?1_Z)QX__ /!(/_CE'_"^C_T3CQ__ ."0?_'*]4HH
M]MA_^?7_ ),P]G6_Y^?@CRO_ (7T?^B<>/\ _P $@_\ CE'_  OH_P#1./'_
M /X)!_\ '*]4HH]MA_\ GU_Y,P]G6_Y^?@CRO_A?1_Z)QX__ /!(/_CE'_"^
MC_T3CQ__ ."0?_'*]4HH]MA_^?7_ ),P]G6_Y^?@CRO_ (7T?^B<>/\ _P $
M@_\ CE'_  OH_P#1./'_ /X)!_\ '*]4HH]MA_\ GU_Y,P]G6_Y^?@CRO_A?
M1_Z)QX__ /!(/_CE'_"^C_T3CQ__ ."0?_'*]4HH]MA_^?7_ ),P]G6_Y^?@
MCRO_ (7T?^B<>/\ _P $@_\ CE'_  OH_P#1./'_ /X)!_\ '*]4HH]MA_\
MGU_Y,P]G6_Y^?@CRO_A?1_Z)QX__ /!(/_CE'_"^C_T3CQ__ ."0?_'*]4HH
M]MA_^?7_ ),P]G6_Y^?@CRO_ (7T?^B<>/\ _P $@_\ CE'_  OH_P#1./'_
M /X)!_\ '*]4HH]MA_\ GU_Y,P]G6_Y^?@CXI^.7@_Q;^T1X\75_"_@_5K:#
M3+&+3[F'63!9S++ODE'R/+D@K*IS7G__  R;\5O^A5_\J-I_\=K[J\*_\CAX
MU_Z_+?\ ])(JZRO?CG^(PD8T:,(\J2M>[W5^YX\LGHXF3JU)/F;>UN]NQ^=/
M_#)OQ6_Z%7_RHVG_ ,=H_P"&3?BM_P!"K_Y4;3_X[7Z+457^M&-_DC]S_P#D
MB?[ PO\ -+[U_D?G3_PR;\5O^A5_\J-I_P#':/\ ADWXK?\ 0J_^5&T_^.U^
MBU%'^M&-_DC]S_\ D@_L#"_S2^]?Y'YT_P##)OQ6_P"A5_\ *C:?_':/^&3?
MBM_T*O\ Y4;3_P".U^BU%'^M&-_DC]S_ /D@_L#"_P TOO7^1^=/_#)OQ6_Z
M%7_RHVG_ ,=H_P"&3?BM_P!"K_Y4;3_X[7Z+44?ZT8W^2/W/_P"2#^P,+_-+
M[U_D?G3_ ,,F_%;_ *%7_P J-I_\=H_X9-^*W_0J_P#E1M/_ ([7Z+44?ZT8
MW^2/W/\ ^2#^P,+_ #2^]?Y'YT_\,F_%;_H5?_*C:?\ QVC_ (9-^*W_ $*O
M_E1M/_CM?HM11_K1C?Y(_<__ )(/[ PO\TOO7^1^=/\ PR;\5O\ H5?_ "HV
MG_QVC_ADWXK?]"K_ .5&T_\ CM?HM11_K1C?Y(_<_P#Y(/[ PO\ -+[U_D?G
M3_PR;\5O^A5_\J-I_P#':/\ ADWXK?\ 0J_^5&T_^.U^BU%'^M&-_DC]S_\
MD@_L#"_S2^]?Y'YT_P##)OQ6_P"A5_\ *C:?_':/^&3?BM_T*O\ Y4;3_P".
MU^BU%'^M&-_DC]S_ /D@_L#"_P TOO7^1^=/_#)OQ6_Z%7_RHVG_ ,=H_P"&
M3?BM_P!"K_Y4;3_X[7Z+44?ZT8W^2/W/_P"2#^P,+_-+[U_D?G3_ ,,F_%;_
M *%7_P J-I_\=H_X9-^*W_0J_P#E1M/_ ([7Z+44?ZT8W^2/W/\ ^2#^P,+_
M #2^]?Y'YO7G[,/Q,L+JQMI_#7ES7TK0VZ_;[8[W$;2$9$O'RHQYQT]:M_\
M#)OQ6_Z%7_RHVG_QVONKQ=_R-7@;_L)S?^D-S765K/B;&146HQU79]VN_D9Q
MR+#2<ES2T?==EY'YT_\ #)OQ6_Z%7_RHVG_QVC_ADWXK?]"K_P"5&T_^.U^B
MU%9?ZT8W^2/W/_Y(T_L#"_S2^]?Y'YT_\,F_%;_H5?\ RHVG_P =H_X9-^*W
M_0J_^5&T_P#CM?HM11_K1C?Y(_<__D@_L#"_S2^]?Y'YT_\ #)OQ6_Z%7_RH
MVG_QVC_ADWXK?]"K_P"5&T_^.U^BU%'^M&-_DC]S_P#D@_L#"_S2^]?Y'YT_
M\,F_%;_H5?\ RHVG_P =H_X9-^*W_0J_^5&T_P#CM?HM11_K1C?Y(_<__D@_
ML#"_S2^]?Y'YT_\ #)OQ6_Z%7_RHVG_QVC_ADWXK?]"K_P"5&T_^.U^BU%'^
MM&-_DC]S_P#D@_L#"_S2^]?Y'YT_\,F_%;_H5?\ RHVG_P =H_X9-^*W_0J_
M^5&T_P#CM?HM11_K1C?Y(_<__D@_L#"_S2^]?Y'YT_\ #)OQ6_Z%7_RHVG_Q
MVC_ADWXK?]"K_P"5&T_^.U^BU%'^M&-_DC]S_P#D@_L#"_S2^]?Y'YT_\,F_
M%;_H5?\ RHVG_P =H_X9-^*W_0J_^5&T_P#CM?HM11_K1C?Y(_<__D@_L#"_
MS2^]?Y'YT_\ #)OQ6_Z%7_RHVG_QVC_ADWXK?]"K_P"5&T_^.U^BU%'^M&-_
MDC]S_P#D@_L#"_S2^]?Y'YT_\,F_%;_H5?\ RHVG_P =H_X9-^*W_0J_^5&T
M_P#CM?HM11_K1C?Y(_<__D@_L#"_S2^]?Y'YT_\ #)OQ6_Z%7_RHVG_QVC_A
MDWXK?]"K_P"5&T_^.U^BU%'^M&-_DC]S_P#D@_L#"_S2^]?Y'YT_\,F_%;_H
M5?\ RHVG_P =H_X9-^*W_0J_^5&T_P#CM?HM11_K1C?Y(_<__D@_L#"_S2^]
M?Y'YT_\ #)OQ6_Z%7_RHVG_QVJFJ?LP_$S1K47-YX:\F$RQPAOM]LWSR2+&@
MP)3U9E'MGGBOTAKD_B=_R*L?_83TW_TN@K6EQ-C)U(P<8ZM='_F9U,BPT8.2
ME+1=U_D?"O\ PR;\5O\ H5?_ "HVG_QVC_ADWXK?]"K_ .5&T_\ CM?HM167
M^M&-_DC]S_\ DC3^P,+_ #2^]?Y'YT_\,F_%;_H5?_*C:?\ QVC_ (9-^*W_
M $*O_E1M/_CM?HM11_K1C?Y(_<__ )(/[ PO\TOO7^1^=/\ PR;\5O\ H5?_
M "HVG_QVC_ADWXK?]"K_ .5&T_\ CM?HM11_K1C?Y(_<_P#Y(/[ PO\ -+[U
M_D?G3_PR;\5O^A5_\J-I_P#':/\ ADWXK?\ 0J_^5&T_^.U^BU%'^M&-_DC]
MS_\ D@_L#"_S2^]?Y'YT_P##)OQ6_P"A5_\ *C:?_':/^&3?BM_T*O\ Y4;3
M_P".U^BU%'^M&-_DC]S_ /D@_L#"_P TOO7^1^=/_#)OQ6_Z%7_RHVG_ ,=H
M_P"&3?BM_P!"K_Y4;3_X[7Z+44?ZT8W^2/W/_P"2#^P,+_-+[U_D?G3_ ,,F
M_%;_ *%7_P J-I_\=H_X9-^*W_0J_P#E1M/_ ([7Z+44?ZT8W^2/W/\ ^2#^
MP,+_ #2^]?Y'YT_\,F_%;_H5?_*C:?\ QVC_ (9-^*W_ $*O_E1M/_CM?HM1
M1_K1C?Y(_<__ )(/[ PO\TOO7^1^=/\ PR;\5O\ H5?_ "HVG_QVC_ADWXK?
M]"K_ .5&T_\ CM?HM11_K1C?Y(_<_P#Y(/[ PO\ -+[U_D?G3_PR;\5O^A5_
M\J-I_P#':/\ ADWXK?\ 0J_^5&T_^.U^BU%'^M&-_DC]S_\ D@_L#"_S2^]?
MY'YT_P##)OQ6_P"A5_\ *C:?_':/^&3?BM_T*O\ Y4;3_P".U^BU%'^M&-_D
MC]S_ /D@_L#"_P TOO7^1^=/_#)OQ6_Z%7_RHVG_ ,=H_P"&3?BM_P!"K_Y4
M;3_X[7Z+44?ZT8W^2/W/_P"2#^P,+_-+[U_D?G3_ ,,F_%;_ *%7_P J-I_\
M=H_X9-^*W_0J_P#E1M/_ ([7Z+44?ZT8W^2/W/\ ^2#^P,+_ #2^]?Y'YT_\
M,F_%;_H5?_*C:?\ QVC_ (9-^*W_ $*O_E1M/_CM?HM11_K1C?Y(_<__ )(/
M[ PO\TOO7^1^=/\ PR;\5O\ H5?_ "HVG_QVC_ADWXK?]"K_ .5&T_\ CM?H
MM11_K1C?Y(_<_P#Y(/[ PO\ -+[U_D?G3_PR;\5O^A5_\J-I_P#':/\ ADWX
MK?\ 0J_^5&T_^.U^BU%'^M&-_DC]S_\ D@_L#"_S2^]?Y'YT_P##)OQ6_P"A
M5_\ *C:?_':/^&3?BM_T*O\ Y4;3_P".U^BU%'^M&-_DC]S_ /D@_L#"_P T
MOO7^1^=/_#)OQ6_Z%7_RHVG_ ,=H_P"&3?BM_P!"K_Y4;3_X[7Z+44?ZT8W^
M2/W/_P"2#^P,+_-+[U_D?G3_ ,,F_%;_ *%7_P J-I_\=H_X9-^*W_0J_P#E
M1M/_ ([7Z+44?ZT8W^2/W/\ ^2#^P,+_ #2^]?Y'YO6W[,7Q,O+Z\LH?#6^Y
ML]@G3[?;#9N7<O)EP<CTJW_PR;\5O^A5_P#*C:?_ !VONKPW_P CWXP_WK3_
M -$UUE:U.)L9"5E&.RZ/JD^YG#(L-)7<I;OJN_H?G3_PR;\5O^A5_P#*C:?_
M !VC_ADWXK?]"K_Y4;3_ ..U^BU%9?ZT8W^2/W/_ .2-/[ PO\TOO7^1^=/_
M  R;\5O^A5_\J-I_\=H_X9-^*W_0J_\ E1M/_CM?HM11_K1C?Y(_<_\ Y(/[
M PO\TOO7^1^=/_#)OQ6_Z%7_ ,J-I_\ ':/^&3?BM_T*O_E1M/\ X[7Z+44?
MZT8W^2/W/_Y(/[ PO\TOO7^1^=/_  R;\5O^A5_\J-I_\=H_X9-^*W_0J_\
ME1M/_CM?HM11_K1C?Y(_<_\ Y(/[ PO\TOO7^1^=/_#)OQ6_Z%7_ ,J-I_\
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M<_\ Y(/[ PO\TOO7^1^=/_#)OQ6_Z%7_ ,J-I_\ ':/^&3?BM_T*O_E1M/\
MX[7Z+44?ZT8W^2/W/_Y(/[ PO\TOO7^1^=/_  R;\5O^A5_\J-I_\=H_X9-^
M*W_0J_\ E1M/_CM?HM11_K1C?Y(_<_\ Y(/[ PO\TOO7^1^=/_#)OQ6_Z%7_
M ,J-I_\ ':/^&3?BM_T*O_E1M/\ X[7Z+44?ZT8W^2/W/_Y(/[ PO\TOO7^1
M^=/_  R;\5O^A5_\J-I_\=H_X9-^*W_0J_\ E1M/_CM?HM11_K1C?Y(_<_\
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MZT8W^2/W/_Y(/[ PO\TOO7^1^=/_  R;\5O^A5_\J-I_\=H_X9-^*W_0J_\
ME1M/_CM?HM11_K1C?Y(_<_\ Y(/[ PO\TOO7^1^=/_#)OQ6_Z%7_ ,J-I_\
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MQ-UOP#^QS^R5\2O&'P4T7P_;K82R?\@EEN(O[0DNEMV\UE+$^3)*?W9.$";
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M<'Q.T3Q[\2_B-+\1M=\/6<]GH4<.C1:5:V)G4)/<&)'<O.Z#86W*H5F 09X
M.>\+ZD/"_P#P4-\;>&[0,MKXH^'^G^)KM /D^U6][+9!_P#>,1C'OL'H*^EZ
M^>/@CI<GQ$_:$^)GQ>93_8OD0>#/#TQZ7-M:22/=SKZHUV\B*1U$)/>OH>@
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MO#<GAQ[3^Q8["WAC-U%.A@5)6V*OEL"K;RS2%MXZ4 ?0M%%% !1110 4444
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M#Z4?L\ZM\ O'7QXG\0_#R"^^'OQ"M='DM-5\%RZ5_8IN[=G1A-/:M$!*\;
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MP/UWX1WGQ$U.\\.Q?#[PWXDOK6YT?P#;ZD+Y-'$<)6>0R*3&KSN0Q2,E5"*
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MO%>L?"2R^.7A)?#-KI=EHE]J=I%'H5XC$S2&WNF$,HE!7,B[G&S&,8S]G44
M?#_@O]FCXD_\*K_:?\.:GX7T'PWJ/CJ(/H-KHMS$-,4/8");=-H#+Y3 1LSQ
MH&8;E&T\?4OP-N/$,WPJ\.0^*/#$_A#6[2TCLY]+N+R"Z9/*4('\R!V0A@NX
M8.0#S@UW=% 'Q_HOP:^+?AGX7_$RUT32-(?4]4^*6J^)/^$?UQK:>U\0Z'/<
M;C;,Y$BPF9#D%@&4J 0N33OV>?@#K/A_]H27Q_IWPNM?@3X6_L66POO#MIJL
M%R=8NFD1HY6@M6:")(E#X8'<2V, $U]?44 ?.O[:'PI\5?%+PWX+&@Z%'XVT
M?1]>BU#7/!<NH+8KK=J$=1&96(0['97\N0A&QST%>=_"_P"!_C'3OVGO 7C>
MV^#GA[X5^!+'1]4TY])T2>R-S;32+$RSW?D;4?S"NQ1$92NPEB-_'V=10!\+
M:K^S[\4]8_9C^/WPE/A".WOM6UJ_U?0=7;5;9K;54N+\7(C50V^)PJ[?WJJ-
MQ'.,D>O^#_"?CCQ+^U=H/Q.USP;<>%-)?X=W.B75O=:A:W,EK?-JD4J0GR9&
MW9BC+[U!4 X)#<5]%44 ?$OQD_9S^(?BKX??M9:9I7A[[5>^.=3TZX\/1?;;
M=/ML<4%JLART@$>#$XQ(5)V\9R*ZWQ5X5^,G[0FK> _"_C+P/8^"/#OA[7+/
M7=>UZ'68;M-6DM#YD45E$@\Q$DE"LS3"-E4$#)Z_5M% 'RKI'AWXP_!/XP?%
M1O"OP]LO&_A_QQJT>MZ?K+Z[#91Z;.;>*&2.[B<>84!CW PJY(XZGCSGPY^S
MQ\6/"/[)/P'TAO"JZUXX\!^/6\3ZIH<>I6L,EU;B[U%OW4I?R=S+=1/M+@ $
MC@C;7WA10!\2>*/V=M6\*_&#QKXRD_9_\,_&O1_&OV?5%L]6?3%U/0KX0JDT
M#278*20.5# QO\I#?*V<F];_ ++GC_2_@AX4O],TGP?H_P 2_#OC+_A-K;PW
MH=E;Z;I."&B;3B\$*AF^S,$^T,I8LBY8@9K[-HH ^2K71?C-\4OVL/A1XY\2
M_#-/ _@SPO8ZS;.LVN6E[=K-<V\:^9(L38V.R(J!"Y&QR^S*BO7_ -JOX=ZS
M\6OV<_B!X0\/1Q3:WJ^E2V]G%/((T>3@A2QX&<8R>,GD@<UZM10!\C6_AGXN
M^%?B-X>^,.B_#9KZ\U+PRGAGQ'X#N=;LH[ZU-O<.]M=07.\P2!E9MR&1<!E_
MBR!WG[/OPY\:CXG?$7XJ^/\ 3;7PWK'BM+*PL?#=K=K=G3[&U5PGG3(-KS.T
MKL=A*J, $]O?:* "BBB@ KRC]GO_ (\O'O\ V..I_P#H:UZO7E'[/?\ QY>/
M?^QQU/\ ]#6N^C_NU7_MW\V<=3^/3^9ZO1117 =@4444 %%%% !1110 5YE^
MTLN[X&>+ADC_ $53Q_UT2O3:\T_:3_Y(;XO_ .O0?^C%KMP/^]4O\4?S1RXK
M_=ZGH_R-72? +-I=FW_"2^(%S"APMZ,#Y1_LU:_X5^W_ $,WB'_P-'_Q-=!H
M_P#R"+'_ *X)_P"@BKE9RKU+O4N-&%EH<G_PK]O^AF\0_P#@:/\ XFC_ (5^
MW_0S>(?_  -'_P 37644O;U.X_8P[')_\*_;_H9O$/\ X&C_ .)H_P"%?M_T
M,WB'_P #1_\ $UUE%'MZG</8P[')_P#"OV_Z&;Q#_P"!H_\ B:/^%?M_T,WB
M'_P-'_Q-=911[>IW#V,.QR?_  K]O^AF\0_^!H_^)H_X5^W_ $,WB'_P-'_Q
M-=911[>IW#V,.QR?_"OV_P"AF\0_^!H_^)H_X5^W_0S>(?\ P-'_ ,37644>
MWJ=P]C#L<G_PK]O^AF\0_P#@:/\ XFC_ (5^W_0S>(?_  -'_P 37644>WJ=
MP]C#L<G_ ,*_;_H9O$/_ (&C_P")H_X5^W_0S>(?_ T?_$UUE%'MZG</8P['
M)_\ "OV_Z&;Q#_X&C_XFC_A7[?\ 0S>(?_ T?_$UUE%'MZG</8P[')_\*_;_
M *&;Q#_X&C_XFC_A7[?]#-XA_P# T?\ Q-=911[>IW#V,.QR?_"OV_Z&;Q#_
M .!H_P#B:/\ A7[?]#-XA_\  T?_ !-=911[>IW#V,.QY;X:\#F7Q7XOC_X2
M+74\N[@&Y;P!GS;1'+';R><?0"NF_P"%?M_T,WB'_P #1_\ $T>%?^1P\:_]
M?EO_ .DD5=96]:O4YEKT7Y(RI4H<NW5_FSD_^%?M_P!#-XA_\#1_\31_PK]O
M^AF\0_\ @:/_ (FNLHK#V]3N:^QAV.3_ .%?M_T,WB'_ ,#1_P#$T?\ "OV_
MZ&;Q#_X&C_XFNLHH]O4[A[&'8Y/_ (5^W_0S>(?_  -'_P 31_PK]O\ H9O$
M/_@:/_B:ZRBCV]3N'L8=CD_^%?M_T,WB'_P-'_Q-'_"OV_Z&;Q#_ .!H_P#B
M:ZRBCV]3N'L8=CD_^%?M_P!#-XA_\#1_\31_PK]O^AF\0_\ @:/_ (FNLHH]
MO4[A[&'8Y/\ X5^W_0S>(?\ P-'_ ,31_P *_;_H9O$/_@:/_B:ZRBCV]3N'
ML8=CD_\ A7[?]#-XA_\  T?_ !-'_"OV_P"AF\0_^!H_^)KK**/;U.X>QAV.
M3_X5^W_0S>(?_ T?_$T?\*_;_H9O$/\ X&C_ .)KK**/;U.X>QAV.3_X5^W_
M $,WB'_P-'_Q-'_"OV_Z&;Q#_P"!H_\ B:ZRBCV]3N'L8=CD_P#A7[?]#-XA
M_P# T?\ Q-'_  K]O^AF\0_^!H_^)KK**/;U.X>QAV.3_P"%?M_T,WB'_P #
M1_\ $T?\*_;_ *&;Q#_X&C_XFNLHH]O4[A[&'8\M\5>!S#XE\&I_PD6NOYNH
MS+N>\!*8L[@Y7Y>#QCZ$UTW_  K]O^AF\0_^!H_^)H\7?\C5X&_["<W_ *0W
M-=96U2O4Y8:]/U9E"E#FGIU_1')_\*_;_H9O$/\ X&C_ .)H_P"%?M_T,WB'
M_P #1_\ $UUE%8^WJ=S7V,.QR?\ PK]O^AF\0_\ @:/_ (FC_A7[?]#-XA_\
M#1_\37644>WJ=P]C#L<G_P *_;_H9O$/_@:/_B:/^%?M_P!#-XA_\#1_\376
M44>WJ=P]C#L<G_PK]O\ H9O$/_@:/_B:/^%?M_T,WB'_ ,#1_P#$UUE%'MZG
M</8P[')_\*_;_H9O$/\ X&C_ .)H_P"%?M_T,WB'_P #1_\ $UUE%'MZG</8
MP[')_P#"OV_Z&;Q#_P"!H_\ B:/^%?M_T,WB'_P-'_Q-=911[>IW#V,.QR?_
M  K]O^AF\0_^!H_^)H_X5^W_ $,WB'_P-'_Q-=911[>IW#V,.QR?_"OV_P"A
MF\0_^!H_^)H_X5^W_0S>(?\ P-'_ ,37644>WJ=P]C#L<G_PK]O^AF\0_P#@
M:/\ XFC_ (5^W_0S>(?_  -'_P 37644>WJ=P]C#L<G_ ,*_;_H9O$/_ (&C
M_P")H_X5^W_0S>(?_ T?_$UUE%'MZG</8P[')_\ "OV_Z&;Q#_X&C_XFC_A7
M[?\ 0S>(?_ T?_$UUE%'MZG</8P[')_\*_;_ *&;Q#_X&C_XFC_A7[?]#-XA
M_P# T?\ Q-=911[>IW#V,.QR?_"OV_Z&;Q#_ .!H_P#B:YWQYX-.FZ';7/\
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MBK1ESM;&,\  ^IOV>_C-9_'_ .$.@^-[.Q?2VU!9([G3Y)!(UK<Q2-%-%O
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MG_@I9\+O$&N:)#=Z%XV\->%]=OGT[2/&VO:$;;0M0E$AC7R[C>2%9E/+HNT
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MCX;?".RU'PAK+:!J]WKVGZ=]N6VAN"D<TNQ\)*C*3@]Q7O%?,/\ P4.M!?\
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M-92S+;PM(&=YI2"1''&@+NQ /RJ">*\=_9?U:#XR>-O'_P :(U9M.UB2#0-
M:3JNGVBDR,OL]S)/_P!^Q]3-^U+\2KGP?XQ^%F@Z;:>%['6=>O[P67BOQ=;>
M=::*T,(+%,%2)Y5D*)\ZYPP.:FVMAW/1/AG^T!X!^+USJ=KX6\0+>WNF*LEY
M9W5K/97$*-T=HIT1]O\ M8Q[UA^'_P!K;X2^*O%%GH&F>,8)]0OKG['9R-:7
M$=K=S9QY<-R\8AE8D8 1SD\#)KYR\ ZR-8_;*\71:WXY@^*IM?AA>V^H77A_
M2XK2-<7L#-:1".1]\@5L\R$@R@9'(',^'?B%=_#+X5_#W4?#OCCPO\7/AO)>
MZ?!I?@;Q)ID$?B"Q+RJD<,)B9@]S 6.69>-K8SP37**Y]=>.OVIOA=\-?$EU
MH/B#Q2EIJEFJO>1065S=+9AAE3/)#&R0Y!S^\*\<]*W_ !Q\;O WPY\*Z;XD
MU_Q):6FC:F8QI]Q#NN#>[UW)Y"1!FEW+@C8#P<U\K^(+]M%^)'QEOOA]\4-%
M\'W4.I%_$O@KXC:= UC?2?9H_P#28I1()1!*GRXQR0W &W/)WOBW6?&'Q$_9
MZ\;QW^D_!;2M4\'W5KI,NH:.EWIME?&4;H8T:2%8?-A"&-BV2H"@')-'*%S[
M3\#_ !N\#?$CPUJ>O^'_ !):7>EZ5O\ [1DG#VSV.Q2S>?'*%>+"@GYU' )K
M!\"_M4?"WXD>)+30- \5)<ZK>JSV<-Q97-J+Q5!9C \T:+-A03^[+<#/2OF6
MRL]&U;Q5^T%JWBCQM>_$VRA\&IIOB6?P=X=BLK=@-[+Y<HNY!+=11[\@@*JX
M!/!6K?A7XAZ[X'\0?!JSD\<^#?CCX5UG4[33M'B?388=?TE)(BJW2>4SKB&,
M$2N0&QD'!)P6"Y]$>(_VMOA+X3\3WN@:KXQ@M;^QN/LEY)]DN'M;6;@&.:Y6
M,PQL"0"&<$=\5I>/_P!I+X<?"_Q(GA_Q+XE2PUN2P34X;&.TN+B6>W>1XU:(
M11MYAW1O\B98!2Q&WFOD34/$H\#^$?BKK7@3XA>'?^$3L]9U2?6_A;\3-,@,
MGVD2%KB*-UD,C+,P_=JP(.5!YW5ZU\.[BW\8?MH>'O$EQHG]C7<WP<L+J+3I
ME&[3S-?R,T6,##*#LX XR.Y%%@N=_=?MJ?!6TT>RU1O'-O+9W2EPUO974SPJ
M'*%IT2(M NX$9E"#BNW\=?&OP/\ #7POIWB'Q%XBM;+2-2*+831AKAKPNNY!
M!'$&>4E>1L!XKYQ^&>EV</PI_:_FCM84DF\4^)(I&5 -Z"PB8*?;,CG_ ($?
M6O(_#[:];ZO^RYK#^-+#P+82?#XZ=I>O:WI:7]I%?8CW0X>6)8I'@"!7+9.S
M: <G!9!<^WO#G[07P_\ %O@;7_%^D^(X;O0O#\,T^K2>1,D]BL2,\GFV[()E
M(56.TIDXX!K T+]K[X0>)?$&EZ-IWC2WGO-4D2"SD:TN$MYIF VPK.T8B\WG
M'E[MX/!&>*^9KRV;4KG]I_6'^(47C_4H/AQ=:=JU[HWA^.PTPS"VG:$&9;J7
MS9T3>I 4 *0-V1BNQ^,VCV>D_L)_"VWM+:.&.TD\*O!M4 HYFMLN#_>.YLMU
M.X^IHL@N=[I/[4UC>?M::_\ #FXU%X=%L=)C6!6TJX3-^)93.9)C'M$:QQC#
MDB,\X9C78^$_VLOA/XV\366@:/XOAN=1OI6ALC):7$%O>2+G*P3R1K%,>#@(
M[9[9KRCQ7J6B6G[67Q;MM=\VXLKKX:0(^GVCK]KO(Q)<F2.!21ND*9  /4CI
M7E_A7XA:C\./!WPGGTCQSX3^,WP_NM2TRTT3PQK6F01>(=-W$1PF$Q,P-Q;@
MD,S*",,,CK19!<_0.BBBH*.3\-_\CWXP_P!ZT_\ 1-=97)^&_P#D>_&'^]:?
M^B:ZRNBO\2](_DC&E\+]7^;"BBBN<V"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X+P7\"? GP\\<>
M)O&/A_P]#8^)_$DAEU34VEEEEF)<NRKYC,(U+G<4C"J3R1D5WM% !1110 44
M44 %%%% !1110 4444 %%%% 'FOQ2_9R^'GQFU6QU7Q9X?-YJ]C"UM;ZE97U
MS87:0EMQC\ZWDC<IG)VEB,DG')KI/AW\-?"_PE\*VWAOPAHMKH.BVY9DM;53
M@LQRSLQ)9W)ZLQ)/<UTU% !1110 4444 5-.TFQT>&6*PL[>QBEFDN9$MXEC
M5Y9'+R2$ #+,S,S-U)))Y-6Z** "BBB@ JI::38V%U>W5M9V]O<WTBRW4T,2
MJ]PZHL:M(P&6(1$4$Y("@= *MT4 %%%% !1110 4444 %%%% !1110 4444
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M_=6UDJ8:.7,<+H$0G*KG<T@9WQ@;OVAHH I:A$=6T6YBMY=ANK=ECDY&-RD
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M/U_1'B'[9?PGUOXP? 75]+\,)'-XHTZYM=;TJWE8!+BXM9EF6$DD ;PK("2
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M4 %%%% !1110 4444 %%%% !7)_$[_D58_\ L)Z;_P"ET%=97)_$[_D58_\
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MZ5+XD\1P6IU9=]A!:0RWD]VF =\44"N[I@CY@I'(YHU%H6K7X(?#FQ75%MO
M'A>W75$:._$6C6R_:T)R5EPG[P$\D-FNBL_"NBZ?K$FK6ND6%MJLELEF]]#;
M(D[0(24B+@;BBDDA<X&3@5Q:?M%_#F;X7:C\18?%%O<>#]..V\U""&61K=MR
MKLDA5#*K@NN5*9&02,5@P_MC?!J;4+RS_P"$[L89+:%[CS;B">*">-.&:"9X
MQ'/SQ^Z9\YXS1J!Z4O@?PY'XL?Q0OA_2U\3/#]F;6A91B\:+C]V9MN\KP/ES
MCBJ.C?"CP1X=\13>(-)\'>'],UZ;=YFJ6>EP0W3[N&W2J@8Y[Y/-<YX7_:3^
M''C+PQXJU_2?$@GT[PM ]SK0ELKB"XLHDC:0N]O)&LN-B,1A#NVG&367X=_:
M[^$/BSQ'INAZ7XTMKB_U)UBLV>UN(H)Y" 1$L[QB(R\@&/=O!^4C/%&H:'J%
MCX=TK2]6U/5+/3+.TU/4S&U_>06Z)-=F--D9E<#+E5 4;B<#@<5P?Q(\&^+-
M+\!G1/@];>$O#5W=7$@N3J5K)%;P1RAS+/$D PT^]@V&&UB26/KC?#[XC:UJ
MG[17QK\.:KJ:'PWX:M-#GT^"2..-;7S[>X>X8R!0S F-3\Y(&.,<U;\(_M8?
M"?QUXHM?#^B>,;>ZU*\=HK/S+:>&"\=>&6">2-8IF]HV8T:@=?\ "?X<Z=\(
MOAOX<\&Z42]CHME':)*RA6E8#YY& Z%V+,?=C6GXJ\&^'_'6EG3?$FA:;XAT
MXL'-GJMG'<P[AT.QP1D>N*^<]$_:PM/%'QD^-'@YO$<NBZ?H>E0G1;X:!<N;
M26.WNI+VXDW18;8R(55R%D$>(]V23Z>GQT\'_#OX0>"O$?B_QQ#J,&K:=9M;
M:R;!X9]9D>%&\Z*RC4R R9W^6JG9NQQBBS#0[71_AWX4\.W%A<:5X8T;3)]/
M@>ULY;/3XH6MH7(+QQE5!1&(!*C ) S5:Q^%'@G2_$\GB2R\':!:>(I"6?5X
M-+@2[8GJ3,$WDGZUB^&_VA/A]XN\#^(?%VD^)(;O0_#T,T^K2>1,D]BD2-(_
MFV[()E(56(4IDX. :P="_:^^$'B7Q!I>C:=XTMY[S5)$@LY&M+A+>:9@-L*S
MM&(O-YQY>[>#P1GBC4-#N?$WPK\%>-=3MM2\0^$-!U[4;; @N]3TR"YEBP<C
M:[J2O/H:U/$'A/1/%NCOI&N:-I^LZ4^ UCJ%JD\#8Z9C<%3CZ5JUXZW[7WP?
M7Q0= /C>S%X+O[";CR)_L(N.GE?;/+\C=GC'F9HU&>E>&?!^@^"](&E>'M$T
MW0=+#%A8Z9:1VT )ZG8@"Y.!VK.\._"KP5X1UFXU?0O!^@:+JUSGS[_3M,@M
MYY<]=TB*&;\37SM\5_VAM1U#]J[P]\*]#\<WW@O3HK)9;Z>S\-/?2WE\]Q''
M%:[Y8'1(BD@8SKA%.0S@\#WSXQZAXWT_P'>?\*[TRUU/Q7/+%;VWVZ1$AME>
M0+)<.&9=XC0L^P'+$ 8/2@1<U;X4^"=>\1P^(-3\':!J.OPD&+5+O2X);I,=
M-LK(6&/8ULCP[I2^(&UX:99C7&M18MJ?V=/M)MPY<0F7&[RPY+;<XR2<9KYX
MN?$7Q-^!OQ:^&^D>)O'\7Q'T+QG>2Z5-;W&CV]A=64ZPM*L\'D ;HOEPRON*
M@CYB3Q]!^*O$VG>"_#6J:_K$SVVDZ9;27EW/'"\QCB12SML169L $X )XH 9
M;>#]!L[/5[2WT338+76)I;C4H([2-4OI9%"R/,H&)&=0%8MDD  U7O/A[X6U
M#PK#X8NO#6CW/AJ&-8H]&FL(GLT11A56$KL  Z #BL_7_BYX2\,?#NV\=:CK
M"Q>%;J*VF@OXX)9?.6X9%@V1HI=BYD3 "YYY'!KG_B)^TU\,_A3XA.A>)O$\
M=GJZ0K<S6EO:7%V]O$>DDWDQOY2]]S[1@@]*-1G8:7\/?"VA^%[GPUIOAK1]
M/\.7,<D4^CVMA%%:2I(NV16A50C!EX((Y'!JQ?\ @[0-5T.VT6]T/3;S1K;R
MO(TZXM(WMXO*(,6V,C:NPJI7 ^7 QC%87B3XT>!O"/@>S\8ZIXGT^#PU?>7]
MCU".3S4NC)]Q80@)D9N<! 3P?2L_X9_M"> /C!JM_I?A77_MNJV$:S7.GW5G
M<65RD9( D\J>-'*9(&X C)'/(HU$=3J7@?PYK7B+3M?U#P_I=]KNF@K9:I<V
M4<EU:@YR(I64LF<G[I'4U1TGX4^"=!\1S>(-,\':!IVOS$F75+32X(KI\]=T
MJH&.?<URGPS_ &HOAE\8M8M]+\'>)&UN\G@:X3R].NXXPJ_>#2/$J*P!!V,0
MV"#CD5ZK1J,****0')^&_P#D>_&'^]:?^B:ZRN3\-_\ (]^,/]ZT_P#1-=97
M17^)>D?R1C2^%^K_ #845\9Z#\-?VF[?]OJ^\4:CXF>7X(,LFRT&HK]C-N86
M$4"V>[<LZR;2TNT9P3O(.VOLRN<V"BBB@ KRWQ!\</[!_:*\)?"S^Q?/_M_1
MKS5_[6^U;?(\AE7R_*V'=NW?>WC&.AKU*OEOXA?\I%/A+_V)FL?^C8Z /J2B
MOS%^%G[-_@W7/^">?BOXDZG;WEUXTTVP\2ZMHNKB_G271Y+2ZO&B6UPX$(,D
M)=MH!8R-DGC'KC6X_:8^.'PD\!_$*>;5/!Z?"VW\:76CF>2*#6-2EFCA)G5"
M!(L2Y<(3C,G0@F@#[>HK\^OVD/@CH7PW^%.K^ ?#7C:270;SXA^&Y+3PU!=%
M[CPHEQ-&IC1_-:1$=@TL:D(%YVYY8W?VDOA[IGPU\>?"'X,> /A[=:CX%\23
M:KKFL^$=#UE-.DUJ:V@@5$:>>9,HN1(Z;\OM!(X)(!]\45\+?!6+5/@K\:/%
MD$G@ZY^"7PLE\&7.K:CX?O/%.GWQL;B"3_D(6MM%<2O$AB\Q7(386C4GG@^#
M_&K0M'\-_LXW'Q0^'OP?\8:-?:8EIJ=A\8/%OB&"WU:X9KB()<M$)FEF$V\
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M36K=[VT\/V$\=NL-JC;6NKF>0[880WRAL,6;A5/-8_@[]I'6H?B=I'@#XG^
M9/AUKVO12RZ%=0:M'JFG:DT2[I85G6.,I,JG=L=!D X)XSR7P_;^S/\ @HA\
M6(-6D5;S5/!^CW.BK)PSV<;RI<!,]0)B"<9ZBO;O'WB;P-X?U_P9!XL;3QK&
MI:G]D\/"[M?/E^V&-B?)(5C&VP-E_E'.">0" >4>(/VHO&6M^._$WAOX3?"&
MZ^(\/A>\.FZSK%WKUOH]I%>!%=K>$R*[2NH==WRJ >_0G3\)?M)>(/B1\._$
M]]X4^&MW/\1?#6IKI.J^!]9U6&Q>";Y&)%T%>-D\M]ZL!AL8&.M<#8?"JY\9
M>,/&_CG]G7XS2^$KB[UVXM_$N@WVCK?Z7-JL&(IR8I@DD$AVKN>,D-@$9!%>
M@?LU_&;QGXU\3?$+X??$?3-)M/'/@6>R2\OO#[N=/OX+N)I;>6-9#O1MJ-N0
M]#@CK@ 'G6E?M;_'+6OB)KW@BU_9PL7\0Z':6U]>VY^(%N%2*XW^40YM<,3Y
M;\ \8YKZI\,WVI:EX;TF\UG3%T76+BTBEO=-2Y%RMI.R R0B4 "0(Q*[P &Q
MG S7@/PU_P"3[OC5_P!BQX>_]"NZ^D: *.BZYIOB32[;4](U"UU73;E!)!>6
M4RS0RJ>C*ZDAA[@UY_\ &+QS\3/!]QI:?#_X76WQ#AG20WDEQXEATG[*P*[
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MD,3=4) .#[BO@7X9WD#_ /!&N\E$T9C_ .$.U:+=N&-XGN$V_7=\N/7B@#]
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M]I/PKT+]E'XI:2U])\1O%7C'P]INO^)+B_FDNM4AU&VD:Z28LY#(6P53&U
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M^(?_  6/1_PL*+_H7_$/_@L>CV%3L'MH=SK**Y/_ (6%%_T+_B'_ ,%CT?\
M"PHO^A?\0_\ @L>CV%3L'MH=SK**Y/\ X6%%_P!"_P"(?_!8]'_"PHO^A?\
M$/\ X+'H]A4[![:'<ZRBN3_X6%%_T+_B'_P6/1_PL*+_ *%_Q#_X+'H]A4[!
M[:'<ZRBN3_X6%%_T+_B'_P %CT?\+"B_Z%_Q#_X+'H]A4[![:'<ZRBN3_P"%
MA1?]"_XA_P#!8]'_  L*+_H7_$/_ (+'H]A4[![:'<ZRBN3_ .%A1?\ 0O\
MB'_P6/1_PL*+_H7_ !#_ ."QZ/85.P>VAW.LHKD_^%A1?]"_XA_\%CT?\+"B
M_P"A?\0_^"QZ/85.P>VAW.LHKD_^%A1?]"_XA_\ !8]'_"PHO^A?\0_^"QZ/
M85.P>VAW.LHKD_\ A847_0O^(?\ P6/1_P +"B_Z%_Q#_P""QZ/85.P>VAW#
MQ=_R-7@;_L)S?^D-S765Y;XI\=QS>)/!K_V'KJ>5J,S;7T]P6S9W PH[GG/T
M!-=-_P +"B_Z%_Q#_P""QZVJ4*G+#3I^K,H58<T]>OZ(ZRBN3_X6%%_T+_B'
M_P %CT?\+"B_Z%_Q#_X+'K'V%3L:^VAW.LHKD_\ A847_0O^(?\ P6/1_P +
M"B_Z%_Q#_P""QZ/85.P>VAW.LHKD_P#A847_ $+_ (A_\%CT?\+"B_Z%_P 0
M_P#@L>CV%3L'MH=SK**Y/_A847_0O^(?_!8]'_"PHO\ H7_$/_@L>CV%3L'M
MH=SK**Y/_A847_0O^(?_  6/1_PL*+_H7_$/_@L>CV%3L'MH=SK**Y/_ (6%
M%_T+_B'_ ,%CT?\ "PHO^A?\0_\ @L>CV%3L'MH=SK**Y/\ X6%%_P!"_P"(
M?_!8]'_"PHO^A?\ $/\ X+'H]A4[![:'<ZRBN3_X6%%_T+_B'_P6/1_PL*+_
M *%_Q#_X+'H]A4[![:'<ZRBN3_X6%%_T+_B'_P %CT?\+"B_Z%_Q#_X+'H]A
M4[![:'<ZRBN3_P"%A1?]"_XA_P#!8]'_  L*+_H7_$/_ (+'H]A4[![:'<ZR
MBN3_ .%A1?\ 0O\ B'_P6/1_PL*+_H7_ !#_ ."QZ/85.P>VAW.LHKD_^%A1
M?]"_XA_\%CT?\+"B_P"A?\0_^"QZ/85.P>VAW.LKD_B=_P BK'_V$]-_]+H*
M/^%A1?\ 0O\ B'_P6/7.^//&D>I:';VPT;6K8OJ>G?O;FP=(UQ>P'ENW2MJ%
M&HJL&UU7YF56K!TY*_1GIU?//[=G_)"8?^QCT7_TOAKZ&K.U[PYI/BFQ%CK6
MEV>KV0D286U_;I/'YB,&1]K C<K $'J" 17$=1\W^"?$F@>!?VTOC0/%U]:Z
M+J>LZ=HUQH-UJLRPK<6$=L4G2!W(&%G5BRCJ>><<>">*+JRUKX8_&G7O#@5O
M!.J?%'1Y=*N+<;;:YD6XM4N98NQ5I0?G'#$<=*^^_&'P[\*?$*WAM_%/AG1_
M$L$+;HHM8L(KM4/JHD4@'Z5/>>"?#NH:#;Z)=:#IESHMNT;PZ=-9QO;QM&P:
M,K&5V@JP!&!P0"*=Q6/BGX[:5J^M:M^VE9Z'#/<:A)X?\,L(K<$N\:PSM* !
MR<QA^.XR*Z?]ISXA?#OQY^S=X0T7X?ZAIFIZUJ6J:,OA#3=,E1[JWECN86RJ
M*2T1CA$BL3C;G!ZU]<6?AW2M.UC4=6M-,L[;5=2$2WM]#;HD]T(@1$)7 W.$
M#,%W$X!.,9K&T/X4^"?"^O3ZYHW@[0-)UNXW>=J5CI<$-S)GKND50QSWR:+C
ML?'WQPL9-%^/WB?X411,-/\ B_J>@:G&(U^5(X9&75!]6BM(R?\ KI[\,_9G
ML[G7_CAH'PVN(&.F?!277&9Y 2LLEQ=/%I^<\?+;-*R^GUK[9O?">B:EK^FZ
MY>:-I]UK>FK(ECJ4UJCW-JLB[9!%(1N0,.#M(R.#1IOA71=%UC5=6T_1["QU
M35FC;4+ZVM4CGO#&I6,S.H#2%02!N)P"<4<V@K'P"NF6VM?!3PSIU["MQ9W?
M[0 MYX7&5>-]2E5E(]""17T'\<[>7_AK/X#O8A8M1FTKQ1$DP #$BUMR@)[@
M,Q(!X&37MZ?#KPI':0VJ^&-&6UAU'^UXH5T^()'?!BXNE7;@3;B6\P?-DYSF
MM"\\.Z5J.L:=JUWIEG<ZKIHE6ROIK='GM1* )1$Y&Y X50VTC( SG%%QV/A;
MPKX_^'?A_P#X)MZ_X;US4=-M=;M=%U+3=2T2XF1+[^V"TN%:-LOYOG;'#$'
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M .W+X<O+C3[2:[E^%S7SS/ A=K@:C;@3$X^^!QNZXK>_;L_Y(3#_ -C'HO\
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M#E/!-O;6/AV#7);KQ1;7DCL7F:(JI@E4?W2,KZ\U)X<^,WQ7\/\ Q6A^&7Q
MTWP@/$.O:-=ZAX;UKP^;K[#)/ .8;F&4F10,[BRMR!@<GY?/O%7@WQAXI_;R
MURR\(_$&X\#:A;^ K-I]2CTJVOWN4%TPV%)AM7)(;(YXQTKV;X9?LX7?A?XB
MGQ_XU\=ZI\1O&,5DVG65Y?6L-G;V4#-N<16\("AFX!8YX':GH!YEXH^)G[3?
MA7XG>!_!%Q)\)IK_ ,61:A+:W$=CJ?E0BTCC=P^9\_,)1C /0YQ78^,OB[\3
M_A4GPGT[Q5%X2OM;\5^+HM$U"31[>Z%M':.K,&A$DNX2C;U;<OM4OQA_Y/!_
M9W_Z\_$__I+:UE?MB?\ (\_L[_\ 90K/_P!%R4=@.E\:?&CQCX@^*^H_#?X5
MZ1H]YJ^BVT-UKVO>(I)?L&F^<-T, CBP\LSH"^W<@ QSR<.\ _%[QOI/Q;A^
M&WQ.TC2(]5U*PDU'1=>\-"86-ZD1 FA>.4L\4J AN692#U!P#R_P#N(?!_[4
MWQY\+:M,(-9UJ]LO$.FK,<&]LFM]A:/^\(W4H?3Z5[!K'QC\/:/\6O#_ ,."
MUQ=^)M8M+B_$5HBR)9P1 'S+@[LQJY.U#@Y8$<<4AG4:]XCTGPM8B^UK5+/2
M+(R)"+F_N$@C\QV"HFYB!N9B !U)( K-\-_$CPEXRU*]T[0/%.BZYJ%C_P ?
M5IINH0W$MO@X_>(C$KSQR!7A?_!0Z&RN?V:;Z'4I?L^G2:SI27,N_9LB-[$'
M;=VPN3GM61\;/ OA'X<_$_\ 9XN? FDZ?H?B-_$L>EQ0Z1$L37&CFUF-T'"
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M^A?%SXI?$'PI9:KH4H\/W<4.FK8ZC'/-?P^2K33@!OF19'V$J"%(P3DUY_\
M&[X;^%?AM\3OV<YO"OA[3O#TUOXI.FQR:;;+"WV9[.;?$Q4 L#M&=V>_J:U/
MV9_#^EV/Q[_:$EMM-L[>2W\06<4+Q0(IC1K&(LJD#@$\D#J:6@SZ6HHHJ1A1
M110!R?AO_D>_&'^]:?\ HFNLKD_#?_(]^,/]ZT_]$UUE=%?XEZ1_)&-+X7ZO
M\V%%84?COPU+XNE\*IXATI_%$4 N9-$6]B-ZD)Z2&#=O"_[6,5NUSFP4444
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MEO+EX8'F=8HT+N5CC5G<X!PJ@L>@!/%?.'[+?[8FB?%#X.>*O&'C'7[?3/\
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M>6=I+(L9N;:2UP'9&=24=>1GGN/L&*9)XDEB=9(W 974Y# \@@]Q0 ^BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/V>_P#CR\>_]CCJ
M?_H:UZO7E'[/?_'EX]_[''4__0UKOH_[M5_[=_-G'4_CT_F>KT445P'8%%%%
M !1110 4444 %>:?M)_\D-\7_P#7H/\ T8M>EUYI^TG_ ,D-\7_]>@_]&+7;
M@?\ >J7^*/YHY<5_N]3T?Y'?Z/\ \@BQ_P"N"?\ H(JY5/1_^018_P#7!/\
MT$5@?%F^U'3/A7XRO-':1=7M]%O9K-HOOB98',97WW 5R2^)G1'9'S-\:/\
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MU"-8[FUN(FP5=59AAE*2(P)#)(C#K765\T>%]2'A?_@H;XV\-V@9;7Q1\/\
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M4U\K>*/CQXAU3]L[P7K^B>(+I?A-:'2O#&H:>EPZVUS>ZM9W5U!,Z!MA9/\
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M0'./F(QR/H^Y^'OA:\\&CPC<>&M'G\*+ EL-"DL(FL1$A!2/R"NS:"HPN,#
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M#]!UO3++3=1T33K_ $ZREAGM;2ZM(Y(H)(B#$Z(P(5D(!4@97 QBLGQ#\(_
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M]N*XL_&'@/PA\&4UV\O_ (UZE>:7?:)<:=821E9$F\JYU!BH,<42Q?:BR[^
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M4 ?.NF_LK>(M6\4>$)_B!\4]0\=^%_!U['J6B:'-I,%J[742E;>:]G4DW+Q
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MS8**** "BBJNJ:I9:'I=YJ6I7EOI^G6<+W%S>74JQ0P1(I9Y'=B JJH)))P
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MVL:KI-CJMC>:KI+1KJ%C;W*23V;2('C$R [HRR$,NX#(.1Q0!IT444 %%%%
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MQ;6-5L=)6^NXK"T:^N4A%Q<R'$<$>XC=(YX5!DD]!6G0 444C,%4DG '))H
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M9RA"[]_\&7&4K+W?R.IHKEO^$)N?^AKU[_O[!_\ &J/^$)N?^AKU[_O[!_\
M&JGDA_/^#*YI?R_D=317+?\ "$W/_0UZ]_W]@_\ C5'_  A-S_T->O?]_8/_
M (U1R0_G_!AS2_E_(ZFBN6_X0FY_Z&O7O^_L'_QJC_A";G_H:]>_[^P?_&J.
M2'\_X,.:7\OY'4T5RW_"$W/_ $->O?\ ?V#_ .-4?\(3<_\ 0UZ]_P!_8/\
MXU1R0_G_  8<TOY?R.IHKEO^$)N?^AKU[_O[!_\ &J/^$)N?^AKU[_O[!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!R?AO_ )'OQA_O6G_HFNLKD_#?_(]^,/\
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M T>ZM++3;[7_ !O!XF\-2:H8[FSO!!#:[!/&I8^4[121LK@'!SM(X(!OZ/\
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MXUT7]MC3/'^F^%SKO@_5/!L7AB\O[>_@A?3)H[^6X,LD4C*TB%9% \O<<@Y
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MM==L[6XUBW-MXCBADN2ZPRH6,.Y+DX\X*01R* /ICQI\8M4\+_M'> ? 20V
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M]H:SUCP_8:5K-CKRV2ZA;WUHGEK>V[W@\O9*I_>)N4Y .6P!2Z;^R;XO\3?
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M\8?L\ZQ\8[3PW\/X?#WA]=2N+O3YS>K=:I;V<THE>!A(5M]L<14;_-+NC'"
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M+N+XC*\+M"R$[N%K'D_:@^(7Q#\4>,H?AY??#32-#\*:E-H;R>,[V9+G6+Z
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M-WH7C;PUX7UV^?3M(\;:]H1MM"U"42&-?+N-Y(5F4\NB[0"9-F&QY?\ '/\
M:,U;X/?\%)=#LKW4_%VJ>%'\&F2/P?X>%S>_VA>M]HV+%9H=CRML&&8 #:"6
M &:\<^*?QPT']I']CKX>_LZ> ]"UC4/C#"-,TB_\,R:5-"VC266(IY9Y'01H
MFY#E@V5$GS[,,![#+H_]E?\ !6CX?6-RZWD]A\.Q%]H=1DNL=RA<>A(W?]]&
M@#Z8_9[_ &N/ _[1EAXKDT>'5_#6I>%;DVVMZ-XIM5LKS3R-XW2J'95&8Y0<
MME3&P8+QGS+_ (><?"?^T/M']B^./^$&^W_V;_PL/_A'W_X1_P ['3S]^_K\
MN/+SWQMYKP?X5>"=3^)/QT_;Z\)Z*ZQZOK=B^G6GF/L1I98[I$5F[*2P!/8$
MUPL7Q\\/S?L##]F1/#FNGXYF/^P?^$'_ +&G%QYWVO[1]H+;-@79^\Z[L\XV
M_/0!]R_'?]N#P%^S_P"-O"OA;6=,\1Z]J7B>R:\TD^&[&.^6Z))6*% )0[R2
MN%1 JE29%RRC)'S/\:/^"A7C&W_:"^$FCZ7\-OB?X9\,RO+>:IX;O/#:1:SK
M?R'RTMXQ*Q=$/+*&0YSNSC%96N^ KWX>_MC_ +$WA#7&6XU+0_""V-S@AE$T
M%M*I"D=0K)@'T45UO[>'BK3OA-^VE^SC\1/%4DVE^"],2]BO-8%M+-%$^UL(
M1&K,6.X' !)&3V. #[]T^[^WV-M<^3-;^=&LGDW"[9$R =K#LPS@CUK\S_B_
M^UAXR^(G[>'PBTOPCKFJ:5\*;;Q4WAY)-/O)(+?7KJ&6#[<TBHP$\*F6*-"P
M*'#E3\S5]W_&S2/%'Q-^!/B33OAMK5GI7B+7=,\K2]6O'DBBB64+F3<J,Z'R
MV;:P4D,0>,5^7GQ>^&/QP^#'Q8_90\$WEK\+;/4-%OIK;PC'H9U$V;3>=;-+
M)J!D <[Y&5R8@"2TA[B@#]C*^5_!?[14.C?"/XE?M&>*)]9O_!<U\T.BZ-I[
M!_)TNUN#:1RQPO(L?FSRF69G)!*-&N2$6OI&.UU2_P#"26VI/:Q:U-8B.Y>R
MW>0LYCPYCW?-LW$XSSC&>:_/S6KH2?\ !&O4K)H?LUYI.E'2KVV;[T-Q;ZF(
M958=CN0G\: /J+PW^V)X5U[QKX;T"Z\,^,/#MGXHE:#P_P"(-<TC[-IVK2!"
MZK$Q<R*74%D\V--PZ9R,L\7_ +=/P5\!^*-4\.ZWXIO[75],N'M;J"/PYJDR
MI(IPP#QVS(W/=21[UB?ME0QVU[^SI#$@CBC^*VCHB*,!0+6]  K;\7_!7XU:
MWXHU2_T3]HR_\-Z1<W#RVND1^#]+N5M(R<K$)9$+O@<;FY- '"?';]I^+X@_
M"_P+'\(O$UUIZ>.O&UGX,D\3/IL]M+IJR*SS/%'<1H?-VJ%0E<?,2#E>+EK_
M &G^S'^T5\+_  =%XX\3^,/"OQ#CU&SFM?%^IMJ5Q97EK LT<\$S#>%D!9'3
M.T%D( I?CUX,U#PO^S<^G_%:]UCXTVJZ]:SWVNZ;:1Z3J&B6ID4"^@CM(R6>
MV(W_ "@,P9LG:"*\M^%GA'PI\7/VH/AIK_@/Q?XJ^*VF>"H;V^UGQUXDNWGB
M1I+=H;73[=Q'%"7+2O+)Y:9Q&N]B1@ 'T3\%?&&IZ'\8/B1\)]<U&ZU232&A
M\0Z%>W\S37$NF7C.3$SMRWD3I+&I))V&(9^6O<J^9=%M9=:_X*/>)]4M)7>Q
MT/X96.DWRK]Q;F?4IKB('W\I&(]F-?35 !1110!R?A7_ )'#QK_U^6__ *21
M5UE<GX5_Y'#QK_U^6_\ Z215UE=%?XEZ1_)&-+X7ZO\ -GQU^TI\8].O/C\G
MP_\ $'Q&U;X=^"M#T.'4]1_X1>>6/5]8OKF618+6'R$>XV)%!+(WDC=\PSQR
M.8U'QMXBTO\ 8>^-^N>'?BS-XYT&Q6=O"GBB&^G37;*(+&7MKURD<B3Q.3@D
M[RK@MC@#J?B->>'_ -GG]M^7XK^.H#8^#_$OA./1;;Q3) \L&F7\4^6@E*J?
M*66+85=N"49<XS7DOCR,^*_@C^VA\2]%L[BQ^'_BZ"S_ +"-Q;/;B_>VMA'=
M7R1N =DTC* V!N\LGKFN<V.@\)^'_@CJ7A71KO4_VRO%]OJ5Q90RW4+?&&-#
M'*R*77:9,KAB1@]*^G_B!KGC+P#\+?#.C?"[2)_B#X@NXH-+L=8UO4/,MX(Q
M#@:A?7'+2C"ACM!:5FXQG-?./@7]I3]BNS\$^'[?4KKP&-1ATZWCN1+X9W/Y
MHB4/N/V?D[LY-?:/@GQ)HGC'PCHVM^&KB*[\/W]K'<6$\$92-X&4%"JD @8Q
M@8% 'BW[ OBGQ#XT_93\(:QXKUFZ\0>(+BZU87>HWDC222LFJ7:#D]%"JJJO
M1550   *\Y^&GQ4^+7C3]L[PXOC/3IO WA+4_".I7ND^#6NR]PBI<VR"XOU7
MY//;)*H,^4IVYW%\]O\ \$Z?^30O!W_7]K7_ *=[VG>*O^4@GP__ .Q U;_T
MLM: /?\ Q),\'AW598G:.1+65E=3@J0A((/8U\6_LU_MQZ3X=_9E\ :OXPTS
MQYKNG6]G%:ZYX^FTZ2XT^WN3)Y;&>XED$L@5BJM(B.H/&[((K[0\5?\ (L:Q
M_P!><W_H!KX7AACM_P#@C>5B18U/@IG(48^9I2Q/XDD_C0!]+6OCSPWI_P"T
M;XQM+C7_ !'%=Z;X1L]4O;:\NX_^$?MK3SI\7$29W+.=C;W(P45.>*X/4/\
M@H5X%TKPW%XFO/!WC^T\)7LB1:3XBN-"$=EJS,X5! [2@KN!+*9EC#JK;=QP
M#YI\0/!NJ_$3XM?&_P ,:&N_6-7^"MA96D9;;YDKO=JJ9[;B=OXUQ_[0W[4O
M@#QE^Q59>!]+BO'\7PKH5CJ/AV;39XIM!D@O+4.;H;5$(5H_+0DX=G0 ,":
M/8M2_:#O/AW^V=\2O#MQ9^+_ !FLGAW1[C2O"WAZ![SRR#<?:)U1W2&$<Q!G
M9DW$H/F/%>__  9^,_A[XZ>#Y/$'AY;ZV2VO9M-OM.U2V-O>6%Y"VV6WGC).
MV121D D<CFO)_AO"C?MZ?&>4H#*OA;0%5L<@%KHD?CM'Y"E_8O\ ^0G^T/\
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M#7EG_"(_ /\ Z/0\7?\ AY8O_CE=]_P5'_Y,3^)O_<,_].EI7,_\-/?L/_\
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M1_B-\9T\,I>ZG=:YJM];)IFAF2 PB*3;81M)+*'*^4KJ5V@MP"*],_X*C_\
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M)K%8-6L9]Z+Y3PR.J[OWBG._:1G!.*X#Q?XZTC]G/]LGQ-XR^(!DT;P;XO\
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M^S_I/Q/_ &;-7\-?\)C:6>CZAK?@S321 WB72)Q(9K!I I!N$=VC9CEF#AL
M"O-_A3\1CX1U_P"&>D_ _P"*7C#Q3+?:G9V>M?"?Q7:M?MH=@>+D/</$DEHM
ML 0NYL':H 8<$ _2*BBB@ KD_B=_R*L?_83TW_TN@KK*Y/XG?\BK'_V$]-_]
M+H*Z,/\ QH>J_,QK?PY>C.LHHHKG-@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU7_MW\V<=3^/3^9ZO1117 =@4444 %%%% !1110 5YI^TG_R0WQ?_P!>@_\
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M%NAF*>9*4 YDVQA02< ,V!\Q-=#110 4444 %%%% !1110 4444 %<G\3O\
MD58_^PGIO_I=!765R?Q._P"15C_[">F_^ET%=&'_ (T/5?F8UOX<O1G64445
MSFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!R?AO_ )'OQA_O6G_HFNLK
MD_#?_(]^,/\ >M/_ $3765T5_B7I'\D8TOA?J_S84445SFP4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ((9J]4HH]KAO^?3_P# O^ 'LZ__ #\_#_@GE?\ PT-I7_0J^,O_  0S4?\
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M^A5\9?\ @AFKU2BCVN&_Y]/_ ,"_X >SK_\ /S\/^">5_P##0VE?]"KXR_\
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M ((9J]4HH]KAO^?3_P# O^ 'LZ__ #\_#_@GE?\ PT-I7_0J^,O_  0S4?\
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MP_X)Y7_PT-I7_0J^,O\ P0S4?\-#:5_T*OC+_P $,U>J44>UPW_/I_\ @7_
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MN&_Y]/\ \"_X >SK_P#/S\/^">5_\-#:5_T*OC+_ ,$,U'_#0VE?]"KXR_\
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M))+D^,M!^SW@\-:1 Z3RQS1B[0-;7$LY 5(#L=8W&U=IR >S_#O]N?P+X_\
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M%GJ%A/JEI<%9)HYK:$1[Y%:-6!R9H0HZR-(JH&)Q7YC?%S]H?Q):Z-\9(_\
MA:5SX4\77\^K1ZU\)_#OPVA\Y(PTELDUSJSQG>AA\F1YBQ8*^U-ORX^S?AA\
M.-*UK]J#0;*ZM(K^U^$7P\TG3=/\WYU@OKPR RKNYWB"T10?24YYQ@ N^"?^
M"@7P\^(GQNUSPCHNK0MH.D^&FUI]0N+"]BFN)5!EE7:T(\I(85#-O!9VF4*
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M*.5 #[]OW22 ?5GQJ\?:Q\,_AKJ_B#P]X3U'QQKT CBL-!TM&:6ZFDD6-<D
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M/4_'\%GX?\0/*NERR:=>>?="-V1W6W$/G",.C+YA0+D 9R1G.^/7AS3?BO\
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MK\=_#RV\<Z#XMBU'PM<:O#H2WT=I<*5OI98XHX7C:,21DM+%RZ@8=6)VG->
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M:M\1-#\96^H^$-)E$.H7T=K<"2U8LJ@20&,2KDLN"4P0<] 37P=K&M77[/\
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M<LS  _7VT\>:%?>.=1\'0WV[Q'I]C!J5S9&&0;+>9Y$BD#E=C M#(,*21MY
MR,L\#_$3P_\ $BQU&]\.7YU*ST_4;C2I[@02QQFX@?9*L;.H$BJP*[TW(2K
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M7^ WA#QAXYTSX(KH_AJYU*#Q@W@I/$K1ZK/.?/TV %7^S^7#(,NGWE^7<1U
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M3P5XOM8KZ^^$GPZCU*2!F$L=MJU].(U]58Q):3;6&<':P(P*EA^,6D6OBO\
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MF^!_V;?A7_9G@+Q%\9OB'XITY]?N!-J8M;:U@N'-PHGO[C<D9"3)''#U(C(
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M83Y9!42LCJ"-I(^C?%FO7^C^"-7UG1=(;7=3MM/EN[+29;A;$W<JQEHX6DE
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M+.@('R$T ?4=%?,GCS]K#QS\/_"W@@7OP@1_'WC:_EM]$\)MXIM[8"%(T?\
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MPKM@G"G2\"_M5^+=3F\>:%XX^$T_@3QWX;\.MXGMM!_X2"VU*'4+3]ZJ?Z3
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MZBKS7XZ?#'Q1\3/#^FQ^#/B+JGPS\1Z;>B[MM6L;=+R"0;&1XKBU=@DZ%7)
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M'2?VL/C-X5U?6;JXTR72]&\1Z3;7ETSQ6<+1RVURL:L<1IYENKD*,;I&)ZT
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M5^V9XT^'=UK/B&7X$Z[)\(M%NO(U#QI?:O;6%QY:R"-YX-.E FECW,-AROF
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MWX@:%/I0US5)M3TBZEU2*Z2XLI2?*2**-1Y$<2(B 'F0AI",N2?I2@ HHHH
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M% 'PA)X&_:4^)'@7X8_"GQ%\+]#\)^"?#>LZ);>(=6M_$-O=MK.GV4J.)+>
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MFFB5V$IW!2N&RI#<?\,?%7Q[N['XCZU\,/A_HGB&S^)'BW5;FQ\8:AK:6?\
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M!KL: /@#Q=\'_C]\0?%&B:-KGPQ\._\ "9Z/K44UI^T'9:S:V=TEG'*[C-G
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MTG6XS:W&DP_91);BYF8DN8_M,<CRE2SEW (*AMC]JG]ESQ%\5OB9X<^)NK?
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M3XNT6TUC0M4LM:TB[3S+>_T^X2>"9<D;DD0E6&01D'M0!\-_\,TZM\!?AO\
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M,TGRHRKN/W/10!\<_MR_ GQ3\5O&G@[5(OAC_P +N\%V-A=6T_@S_A*SX?\
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MCXF^#_!&JZ5IGB/Q7H>@:EJS^5IUGJFHPVTUX^Y5VPH[ R'<RC"@\L!WKI:
M/CR[_9J\;>)/VM/$[ZE9PP?!#4=6L/&4^;B-SJ6IVUI%!':M%NWK&)HQ<,67
M:QB1?IU/Q>_9TG_:F^-GV#XF^'Y7^#?A?3PVF6!U'R3K.JS'Y[HFWE$B1P1
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M>G>&?#@\26.O0>&G\/7 G,H@_LZ2 H%96D:W*2JI(\R3<3A0LOQW\*_M!?\
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MMJS1-&3C(S@-TS7B'AK]D6;PU^S#XP^%J>-'N_$?BRVN8-7\8W&FCS+AYHQ
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M!_[2?Q3^,WPE^"_ASPMJ.FZ-\1O'MMJ-W>^*[C3A)#I^F64[0F_6T)VM-.#
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M/AKX_B\'_$36->^(_C?Q':WR>)[[1XKJ>+F!728-NB$82.X_>,H6-) J(75
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MDO@CXY:A=_$Q/C!H7@_PNGB'3?%\GA7^P)/M$D=T!:BW(59$W6H*OMY9G!)
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M?A/X5_\ "-_%SQ]X[EU/[=/XH@TVTBM?L^S[%!:1R ('W'?NDFE?.U<;@.<
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M(S]6 ->E?&SXG?'#1_CUK=@?B9;_  BT..]M+7PC::WX.6\\.^)&>,NL5SK
MW-;3.\<L;QX1@H0Q[F.:]H^$7[/GQ*\,>++'6_B1\>-=^),6E1,FF:7:Z9%H
M=H&==KO=I;N3>' 78)20AW-@ELCSZX_8)\03QW7@P?&G6(_@9<ZDU_)\/UT:
MV\_8T_VEK==2SYJQ&?+8"_<.WKEZ /KFR:X:S@-VD4=V8U,R0L6C5\?,%) )
M&<X) ^@J>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XS7OBKI/A
M_P"*'A3P%-;WMQK7B.TO;ZWDMT0P00VHC\QIF+ C<9D5=JMDYS@#->+_ +5T
M2_$GXK?"'X,ZIK%UHWA'Q@VIWVMQV=T;:75X+**)AIHD!#;)3,3($(8I&0",
MY'SWX8B^'_[./Q<^/FO^!]1U-_ _PS\*6_AZQTZSOVO%TK5-1N=T]O:2W#2*
MI$\,32;RPCDED# 89: /T?KR[XE?M Z1\*='\>ZOKOA_Q''I'@^QM;V?4([%
M?(U SE@L-F[.HED4A0P.T*9$&[GCX#^%WPXU3X<_M1?!ZRE^$5[\*/'^KZQ)
M=:IXBU#XCGQ%JOB*R6UN9+QKF"+$8621$9Y2J@R;=BGYMOHLRCXC:;(& G7X
MK_'%4*NF/.T?1WYX'5<:5CGH9,XXH _06)S)$CM&T3, 3&V,K['!(S]#3Z^%
M_$'C+5O"OQ'^-WP7\)W1MO&7C[Q=:RZ3=)]ZPM;W2H&O[_;Z0+;3$<\R/'TS
M7U7X,^!G@KP#>>&KS1='%K>>'="/AO39A-)B&Q+QNZ>7NV%F>&-FD*[R0><$
M@@&Q\2/B/X<^$?@?5_%_BW4X]'\/:5$)KN\E5F" L%4!5!+,S,JA0"26 ')K
MQ'P/^W9X7\4>,M"\.^(/A]\2/AD^O3K9:5J7CKPX=/LKV[;'EVL<HD<>:XR5
M! !VD9R5![[]H2/P!XN\-6/PT\>ZO/HZ>.;C^SM+EM9)()OML6+B)HIU4I%,
MCQ+)'O.&=%4!\[3Y1)K_ (T^&/Q<^'OPU^*NJ>&/B_X;\57\K:%JEUIL=KKE
ME>6PEN4EFM5#0RQQ*D2BXB6-E=@64'!(!U7Q:_;*T;X6?$J]\#6GPY^(WQ"U
MJQLK>^O6\#Z"NI16:S%Q$LI\U61B(V(RN"",$\X[[X(?';PS\?/"]UJ_AY=0
ML;BPNWT_5-&UFU-IJ&F7:8WP7$)SL<9'0D>A.#CS']D''BC7/C;\3+@KGQ+X
MSNK*VFW @V&FJMG <^FZ.9O3YJXGP'X^\37GC+XZ?%OX1^ Q\4-.U[6]+T;3
M;>'5X-+AU(6%J\-U?17,V4DB$A$2LH(?ROE) X /JCQ_X_\ #WPM\&ZMXL\6
M:M;Z'X>TJ$SWE]<D[8UR    2S,Q"JB@LS,JJ"2 ?GOP_P#\%#? >JZMHRZM
MX-^(G@WPOK5Q%;:9XU\3>&WM-#NVF_X]V2YWG"2@AE=E5=IW,5 )'*_'#Q?J
MGBB3]G74_C7X/M?AOX=D\:SMK.CWNL0ZA;07,=G<G33-<1@1%&E ;!X' /0U
MZ)^WAXYT+0_V>?$OA"\$&I^*?&]G+H'ASP\"K76HWLVV*,Q1DY/E/+'(7Z+A
M<G)4$ ]"^.'[0'@[]GWP]::EXJN[A[K49OLFDZ+IMNUSJ&JW)'RV]M O+NQ*
MKDX4%U#,NX5R'P=_;!\,_%KQQ_PAMYX2\;?#CQ3-;->6&E^/-#;3)=2A0_O7
MM_G=7V<;@2#@Y (5BO#>#;.QTS]N6UTGQ?=P3>(-(^'.GVWA<7+G$Q,TXU&:
MW#=93Y409AA_+!_AW5[GJ7BWX>ZU\6M)\*7;:;JWQ TJVEU6TM_L?VJYTN)E
M6-YC($86N]9 HW,AD!(7<,T >(^.O^"@VC_#WQ8V@:G\%OC*]Q)J4NE6%S!X
M43R-3F0O_P >K-.IF#*C.N!DJ,XKVSX+?%P_&;PI<:X?!7B_P)Y-X]H--\::
M6-/O)-J(WFK%O;,9W[0V1DHW'&3YA\2@?&G[;OP@T!<M!X3T'5_%ERFS*[YM
MEA;DD]QYDY ZY&>W'T=0 45X=^U_#9^*OA/+\//^$NC\'^(/'$ZZ/HL]PMP(
M+VY'[XV4LD.&CCGCBDB8AE)61@NXD*WR-IMCX5_9E^%O[2>GZ1X>O/AGXNT#
MPFEOJ'A[2_$LNL:!>27BO'::E \X$\<Y8E/+?80A3Y7)W4 ?I517P1%^SSX,
M_9[^+7[.)\'ZOJ&H?%C4KF'3M5OX]4FG74]#@T]UG9X2WEI;QB*W6(*J@;4Z
ME<CYEU"W\;?&#P'K7QO\3?!^YU+Q!J%U<3Z'\4-0^+-GHL7AHK<-'9P06KO&
MD*V\N!Y<IW-(7)(+@  _9&N4^(OQ+T7X7Z7IM[K3S?\ $SU.UT:QM[:(R2W-
MW<2".*-1TY))))  4DGBOE"]^'.G_M;_ !P\5>%OC=+-<^'OAYX?T61O"<>I
MO:6LNIW5L\UUJ,WD.I)C!\E"'* >9C[QSA^,/V7_ (0_%+Q-^SS\.+/4;GXA
M^ [&/Q!K-K<2Z[)=)'I2+%&+.&Y@=<PK<2VJJ<LZI;[-^,Y /O:BO@G1? /@
MK4Y/C=^T'X^&H:MH7A?Q3=7OAW2K69Q#;OH\*6D=T(0RK-,9+=TC68M&@R1M
M\QZ\1T?P+K/A7XT?!W5K_P"$6H?#[XC^)?%EC*OCK5?B8NN:OK%KN,EZ6M+<
M)&8S!^[=MB(JNJX^:@#],=/^*FDZG\7-8^'EO;WKZQI.D6VL7=UL3[*D<\LL
M<<6[=N,A\EVQMV[2/FSP.SKYZ_9DV^*OBE\?O'?RLNH^+$\/VSKD@P:9:QV_
M!/;SWN3QQDMZUYQX^^'_ (,_:E_:.^*FA_%S47N? 7PRL=.-KX;EU62QLQ)<
M6INIM4G,;HV41C"K,VQ567U. #Z9\)?%72?&GC[QQX2T^WO!?>#YK2WO[J9$
M%O)+<6XG5(F#%F*HR;LJH!8 9YQV=?E_\(-%D\=>!_ W@J7QAK*^#/C%XX\0
M76HZ])=/%J&KZ1I\ MK6QDG;#'[2D";R/G=5<9.6SZ#I,?@W]D'XF?'/3_A+
M=3V/@OPS\/'UK5]"&HS7EI9:^7<6H#2N[)-+%'AEST$>>@  /O\ HK\TQ^QG
MI/@:Z_9@\/V6O^)-,^*VL>9'J7B?3]6FAN+/2(-/EDO+6U0'RX$#W$<:NJ!]
MTA8DLY-=-X2TWPO^RG9_M2/\/[35M)\(VU[HWAG1M)T?5&:7^VI;95D>*>[,
MBP.9+ZW0RN&5/)W%7VJE 'Z#5SVA^,#KGBCQ+HO]AZQIZZ');Q?VE?6HBL[\
MRPB7-J^XF54W!'.  ^5Y(./SC^ OP^O/AK^V-\*=+B^$DWP=\6ZA%J5[KUW-
M\0F\1W^N:>MI)N>[A0^6B270C;>P7=+&2B_NSC?O-)N?C)\(?#6@6FH7>DWG
MQN^+=]K3W]F1#<P:792RRB6%L';(L.GVQ0G."P/U /T>HKY$_9S^#_AGX4?M
MC?%73/A];WNE^&[+PWI8UVWN=2N;P7FL7,]Q.MP[3R.QD$ &>?\ EKG W'=I
M_M$^&;7X_?M'>#O@OXJU*\L_AZ_AVZ\3:CI-G=O:_P#"07$=S%#%:R.C*[1Q
M@O,40@Y"$_=!4 ^J**_,_P 12>'_ (2_!O\ :M\#_#O7'B^&,,^D>&-&BNM0
M>YL]-U&_)@U.&*9V9O+031O("QVMYO?(/J5C\$_!G[/_ .U]\&[+P-JFJR>-
M]6L=1F\9RW6IRW!U'2H[)DCNKR-F*1 74<*Q"-8TR&4+A % /IB7XZ:)-I?Q
M"O-&TS6_$[>")VLM0M-%L3/<7-VL*2O:VR9!EE59(\C@9<#/!QZ#:SFZM89F
MADMVD17,4H =,C.UL$C(Z'!-?FA\//@'X+\-?L[_  _'AO16LM4^-/C?3UNF
M\Z>=CHT6H3:C#'MED8*$M;=<M]YBQW%J]"TGX._#/]JB'XH_%+XY:RTD&C>*
M-1T'26N?$$FGVGA2UM)1 FW;(B)/(^V5FEW EHN.NX ^\JXSXO\ Q5TGX*^
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MAJR6*^NK>S\V;389W)%N]T$*QL[1;C!O#$*&*XP:\*_;AT?7?B?XV^!OPO\
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MG\"^"_$OA+0O!.GZ?X;\20I!JVG(TC1W2I"L*YW,2&V*"64@EB7)+L6/J]%
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M* .<^(?P[\-_%CP;JGA3Q=I%OKOA[4HO*NK&Y!VN,@@A@0RLI 974AE(!!!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>advm-20231231_g2.jpg
<TEXT>
begin 644 advm-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +8!00# 2(  A$! Q$!_\0
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M[2/YD"GTVG5SR *5>M)6MX6\*ZMXTUNWTC1+&74=1N"1'!"!DXY))/  [DD
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M ]:J_$[]G7P;8_#/_A-O GB]M3T]!O,&I2QAYER 0AVH0Z_W"N3]>#WOP_\
MBYXU^&_PITV'QY\.[K4_"$,26\.H1[#(L&W,8E@;.5 &-QVC&T')/-KQ)\(O
MAK\:OA3JGC7PIH\_A*ZM8)I(FDA^RQ,8D+D-&"4*'.-Z=QU.TBI=>M"KS5).
MW-NK./IW1E]1PE;#>SP]*//R7M+FC._\R;T:\K)>9Y-\#_V<;/QWX5O?&'BW
M66\/^%+?<J2QE5DEVG#/N8$*H/R]"2<CC'/2WW[,?@OQUX-U#6OA5XLN]=NK
M %I+&_ WR8!.S'EQLC'!V[EP<=NM>O?"W6+/_AD>PN;7PS;^+X[*V?S]"E5=
ML[I<%GR"C@D<R#Y220.YS7 ^$_VH8]#T^\U+PS\#%T^Q8A+F\TEA%$2N2 [Q
MVH'&3P3QDUG*MB:DYRI]':UU;YWUU*C@LLP]&C#$6M.',W:;E=]4U=)+M]_G
M\BU]5?L$ZYIMEX@\5Z9<31Q:E?0V\EJC\&18S+Y@4^OSH<>@SV-?,.LWT>J:
MQ?7D-N+2&XGDF2W#;A$K,2%S@9P#C..U>P_ ']GX_&'2=2U2P\7?V'K&EW"A
M+5+4NXRNZ.3>)%*Y8,. <;<^U=^,Y)4)*H[)GRN32K4\PA/#1YY*^E[75G??
MR/<O&7PL^-GA7Q3)XC\+>-[GQ3;K+YHTN^N#%N7(_=F$D1$8&"5*$\X ->%?
M$;X@7_Q.^)FAV?Q3TZ+PI#I[FVO9=/M98ITA8[LD.9"<'E<*1\QZYKT/P5XN
M_:,\(ZY#HT^AZAKT495-NJ6WF0[0<9^U# SCN7/KBMK]O2QTW^R_"=\ZQIKC
M2RPC:?F: *"V?4*Q7'IN/K7F4FX58PG9WV:W/J<;"-;!U<11YXJ+3E"=^5Z]
M+Z_C]QZ7\<='^'NI?"7P[;>+]=U#2O#,=Q;FRO+1"TLKBWD$88")^"A<GY1R
M!TZ'YU\+?L\^'-<_9QO/B!/>ZHFLPVMU,L$<L8M]T4CJH*F,MC"C/S?E7J'[
M5MK-=?LY>"4@BDF?[;8_+&I8\VDH'3U) ^I%2_"^UFU3]B74;6SB>YN6L=05
M88AN<GS9#@ =3CM7/3E*E14HRWE8[\72I8S,)TZE-/EI-K>]]+=>G3U/%OV8
M?@;H/QJN/$4>N7>HVHTY+=HO[/DC3=O,F=V]&S]P8QCO6=\,?V?Y_B=\4->T
M"TNWL]$T:ZD2ZOI 'D$8D9$4#@%VVGG@#!/8 ^Q_L%Z'J%I;^+M3GM)8;"Y^
MS0PSR*0LC(9=X7UQN&?K6_\ LDZA:?\ ";?%>QPJWW]KF?.!N>/S9E^I"G\M
M_O716Q%2$ZO*]K6\CR\#EF&Q%+!*K&SFYWZ-VNTOZZ&+X)^"_P +- ^+6E6O
MACQS<77BG1[Q99=.O71TEV9\Q$98U&\ ,< L1M.0.HK_ +17AG0?&7[4'A'0
MO$=Q=6FG:AH\5N)[.5(W64SW'E\LK @MA<8_B%>1?!OX?^*K/]HC2-.EM;J+
M4=+U,3W\S1L0(D8EW+$?=< @,>N\8ZUU_P"W!>3:?\:-!NK:5H+B#1H)8I$.
M&1EN9R"#Z@BIY'[=+GN^7<;KP>5U*CH*"5176MG;IKUZ,\[^/WPB3X1_$8Z'
MISW5WI]Q!'<63W&'E<-E2I*J 3O5N@Z$5V'Q\^ OAGX,^ _#]P-0U&Z\5:BR
MI)#)-']G&U 9G51&&P&*@ M_%U.*^CIO"MA^T#9_"KQTJQ_Z#,+NZ57X "%F
MC_VMMQ$BX]-U?,'[7GCS_A,OB]>6<$OF6.BH+"/:V5,@.93]=Q*G_<%%&M.K
M*$+[7O\ D89CE^&P-"OB%%-5'%4_)-<S:_)">*_AC\.M)^">G^(],\6?;/%\
MUO:R3:3_ &E;/L=]OFKY2KY@VY/!/&.:\5K;N_!'B.PT2/6;G0-4MM(D5734
M)K*1;=E;[I$A7:0<C'/.:Q*[H*U_>N?*8J:G*+5/DT6G?SU[GV?\#?\ DSCQ
ME_UYZM_Z(->8_ 'X'^"/C5X7U*&35M6T[Q=9*VZ%98C;E6SY<H4Q[BH/#*&S
MQU&X5Z=\#?\ DSCQE_UYZM_Z(->3_L>>#=;U[XJ6^KZ=<2V.FZ2I>^G0\2*P
M($&#UW=?8*3P0M>9JE5:=K,^UE&-2IE]*=/G4H6:_7Y;G1^"_P!E'2M)\#ZY
MXD^)VHW^A0V,LBI#8R1J=D9*EB71MQ=N$  SQUW#'GOP5^!5S\;O$VH)832Z
M3X<LWW2W=P!+(JL3LB& H:0J.3@ 8SCD _4G[5'AR\^)WPEFN_#.I?;8=)NI
M)KJSM6#+<"(LD@XY+1D,=O?!X)VUR7[%\R:E\'O&.D64R)K!O)6 W891);HL
M;'T&Y'Y]C4JO/V4JE];_ '&E3*L*LQHX)4_<46[]9O??_+_(YRQ_9T^#OBG6
M+KPWX>^(-_+XFB5@J2-')$7 .=H$:B3&#D(Y. :^??B1\/=5^%_BR[T#5U7[
M1#ATFCSLFC/W77/8\_0@CM75_ [P'XE;XX>'[*/3KRTO-+U*&>^$B,GD1(X9
M]YQP&5649X;..]>S?M(^-/"NA_M%^%;G7-.CUJPTO3R-2M5@BG+[Q+Y:,CD
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M2M#*,,JR732+D=CM93@],U*D^6.O4]*KEV'CF&*@J?N1IMKLG9:_F>*_ O\
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M.!K5J#J046G*,[V;OT;Z_/Y'GO[37[/GAWX+Z-HEWHE[JEU)?7$D4@U"6-P
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M_P -?V:=$N?AT/''Q#U^;P_HLR"6".U*B3RR<*[%E;EOX5522"#WP/3/BO\
M\F5:!_UX:9_[3I/CU93>+OV4/"=WH$+2V5JEC<S0P DI"MNT9!"_W&9<]AM)
M[5/M)-6ONQU,OPM.I*JJ:?)2C+EULV[ZL\T^)/[/'@^S^&W_  FO@;Q<VHZ>
MBES#JDL:M,H.&"':A#@_P%<GIUX/I_PA@DNOV,=;AAC:6:2RU)$CC4LS,2X
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M)+&+=<&W\L0@\ NJ&/YU#$ [9#C(!()KQO1?@7KFN?%ZZ\ 0R1K=VD[K<7C
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M]:6OU0_X4WX _P"A&\-_^"BW_P#B*7_A3?@#_H1O#?\ X*+?_P"(K-\04O\
MGVQ_ZFXC_G\ON9^5]+_#7ZG_ /"F_ '_ $(_AO\ \%%O_P#$4?\ "F_ /_0C
M^&__  46_P#\16;SZF_L,/\ 4W$?\_E]S/RP6EK]3O\ A3?@'_H1_#?_ (*+
M?_XBC_A3G@'_ *$?PW_X*+?_ .(K-YY3?V&'^IM?_G\ON9^6-.7I7ZF?\*<\
M _\ 0C^&_P#P46__ ,11_P *=\ _]"/X;_\ !3;_ /Q%9/.:;^PQ_P"IM?\
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M_:4/Y6'^IU?_ )^K[F?ENU*O2OU'_P"%.^ O^A(\.?\ @IM__B*/^%/> O\
MH2/#G_@IM_\ XBI_M*'\HO\ 4ZO_ ,_E]S/RXHK]1_\ A3W@+_H2/#G_ (*;
M?_XBC_A3W@+_ *$CPY_X*;?_ .(I?VA'^4?^IU?_ )^K[F?EQ17ZC_\ "GO
M7_0D>'/_  4V_P#\11_PI[P%_P!"1X<_\%-O_P#$4O[0C_*'^IU?_GZON9^7
M%**_4;_A3W@+_H2/#G_@IM__ (BC_A3W@+_H2/#G_@IM_P#XBE_:$?Y0_P!3
MJ_\ S]7W,_+NBOU$_P"%/^ _^A(\.?\ @IM__B*/^%/^ _\ H2/#G_@IM_\
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M4>P?ZG5_^?J^YGY?45^H7_"G_ ?_ $)/AW_P4V__ ,11_P *?\!_]"3X=_\
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M .A)\._^"FW_ /B*/K*[!_J?7_Y^K[F?E[17ZA?\*?\  ?\ T)/AW_P4V_\
M\11_PI_P'_T)/AW_ ,%-O_\ $4?65V#_ %/K_P#/U?<S\O:5:_4'_A3_ (#_
M .A)\._^"FW_ /B*/^%/^ _^A)\._P#@I@_^(I?6%V'_ *GU_P#GZON9^7]%
M?J!_PJ#P'_T)/AW_ ,%,'_Q%'_"H/ ?_ $)/AW_P4P?_ !%'UA=A?ZGU_P#G
MZON9^7]%?J!_PJ#P'_T)/AW_ ,%,'_Q%'_"H/ ?_ $)/AW_P4P?_ !%'UA=A
M_P"J%?\ Y^K[F?E_17Z@?\*@\!_]"3X=_P#!3!_\11_PJ#P'_P!"3X=_\%,'
M_P 11]878/\ 5"O_ ,_5]S/R_HK]0/\ A4'@/_H2?#O_ (*8/_B*/^%0> _^
MA)\._P#@I@_^(J?;KL'^J%?_ )^K[F?E_17Z@?\ "H/ ?_0D^'?_  4P?_$4
M?\*@\!_]"3X=_P#!3!_\11[==@_U0K_\_5]S/R_HK]0/^%0> _\ H2?#O_@I
M@_\ B*/^%0> _P#H2?#O_@I@_P#B*/;KL'^J%?\ Y^K[F?E_17Z@?\*@\!_]
M"3X=_P#!3!_\11_PJ#P'_P!"3X=_\%,'_P 11[==@_U0K_\ /U?<S\OZ5>M?
MI_\ \*@\!_\ 0D^'?_!3!_\ $4?\*A\"?]"3X=_\%4'_ ,11[==@_P!4*_\
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M'M5V'_JC7_Y^K[F?F)17Z=_\*A\"?]"5X=_\%4'_ ,11_P *A\"?]"5X=_\
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M  60?_$T?\*K\%?]"?H/_@L@_P#B:S>"D_M%?ZN5?^?B^YGYR+TIPZU^C/\
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M?^A6T7_P70__ !-0^&JW_/Q?<RO[)G_,CX*IPK[S_P"%;^$?^A6T7_P70_\
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M1_$3]F34]'UJ^\:W/CCPM?W<=I?Q:GOWQD[B-F]W*_+N.Y6&2H# @"NS\/\
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M+PQIFGW5U;6_A:XUF?6+&]^SRP+Y+,@C_=MM8@QD/V+@[3CGROQ-\:/%^E>
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MW\EN>VT5Y-XF^-VIZ?XBTSPOH/@Z?Q'XMFL%U"]TU+Y+>.Q0@9#3.N"0Q Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?$/C3X8ZCXDN-9T+1_ 'C#0-5OM4$B6?VOSO#T> -UR)-BC>0'
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M@F]L_C7JEQJ_@75_&NB?V7%;>&H[.-YK6UE$:(JRY;:B;@^XOGKNVG/')?\
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M@E\\Q^6HWA-N[;GOC%>I_%#POK.H?&CX07UKI%]<V5B%^UW,-L[QV_S+_K&
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MYCMM)&1D8."1T)KCO@+X=U31_BA\7[N_TR\L;:^U:.2UGN+=XTN$#W!W1L0
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M[.?\K#GCW-"BL_\ MZQ_Y[_^.-_A1_;UC_SW_P#'&_PH]G/^5ASQ[FA16?\
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M/_@+<?\ Q^NW_B'^=_RQ_P# C#_6;+^[^X^_J*^ ?^&_OB%_T!O#/_@+<?\
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MO#/_ ("W'_Q^C_AO[XA?] ;PS_X"W'_Q^C_B'^=_RQ_\"#_6;+^[^X^_J*^
M?^&_OB%_T!O#/_@+<?\ Q^C_ (;^^(7_ $!O#/\ X"W'_P ?H_XA_G?\L?\
MP(/]9LO[O[C[^HKX!_X;^^(7_0&\,_\ @+<?_'Z/^&_OB%_T!O#/_@+<?_'Z
M/^(?YW_+'_P(/]9LO[O[C[^HKX!_X;^^(7_0&\,_^ MQ_P#'Z/\ AO[XA?\
M0&\,_P#@+<?_ !^C_B'^=_RQ_P# @_UFR_N_N/OZBO@'_AO[XA?] ;PS_P"
MMQ_\?H_X;^^(7_0&\,_^ MQ_\?H_XA_G?\L?_ @_UFR_N_N/OZBO@'_AO[XA
M?] ;PS_X"W'_ ,?H_P"&_OB%_P! ;PS_ . MQ_\ 'Z/^(?YW_+'_ ,"#_6;+
M^[^X^_J*^ ?^&_OB%_T!O#/_ ("W'_Q^C_AO[XA?] ;PS_X"W'_Q^C_B'^=_
MRQ_\"#_6;+^[^X^_J*^ ?^&_OB%_T!O#/_@+<?\ Q^C_ (;^^(7_ $!O#/\
MX"W'_P ?H_XA_G?\L?\ P(/]9LO[O[C[^HKX!_X;^^(7_0&\,_\ @+<?_'Z/
M^&_OB%_T!O#/_@+<?_'Z/^(?YW_+'_P(/]9LO[O[C[^HKX!_X;^^(7_0&\,_
M^ MQ_P#'Z/\ AO[XA?\ 0&\,_P#@+<?_ !^C_B'^=_RQ_P# @_UFR_N_N/OZ
MBO@'_AO[XA?] ;PS_P" MQ_\?H_X;^^(7_0&\,_^ MQ_\?H_XA_G?\L?_ @_
MUFR_N_N/OZBO@'_AO[XA?] ;PS_X"W'_ ,?H_P"&_OB%_P! ;PS_ . MQ_\
M'Z/^(?YW_+'_ ,"#_6;+^[^X^_J*^ ?^&_OB%_T!O#/_ ("W'_Q^C_AO[XA?
M] ;PS_X"W'_Q^C_B'^=_RQ_\"#_6;+^[^X^_J*^ ?^&_OB%_T!O#/_@+<?\
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MO#/_ ("W'_Q^C_AO[XA?] ;PS_X"W'_Q^C_B'^=_RQ_\"#_6;+^[^X^_J*^
M?^&_OB%_T!O#/_@+<?\ Q^C_ (;^^(7_ $!O#/\ X"W'_P ?H_XA_G?\L?\
MP(/]9LO[O[C[^HKX!_X;^^(7_0&\,_\ @+<?_'Z/^&_OB%_T!O#/_@+<?_'Z
M/^(?YW_+'_P(/]9LO[O[C[^HKX!_X;^^(7_0&\,_^ MQ_P#'Z/\ AO[XA?\
M0&\,_P#@+<?_ !^C_B'^=_RQ_P# @_UFR_N_N/OZBO@'_AO[XA?] ;PS_P"
MMQ_\?H_X;^^(7_0&\,_^ MQ_\?H_XA_G?\L?_ @_UFR_N_N/OZBO@'_AO[XA
M?] ;PS_X"W'_ ,?H_P"&_OB%_P! ;PS_ . MQ_\ 'Z/^(?YW_+'_ ,"#_6;+
M^[^X^_J*^ ?^&_OB%_T!O#/_ ("W'_Q^C_AO[XA?] ;PS_X"W'_Q^C_B'^=_
MRQ_\"#_6;+^[^X^_J*^ ?^&_OB%_T!O#/_@+<?\ Q^C_ (;^^(7_ $!O#/\
MX"W'_P ?H_XA_G?\L?\ P(/]9LO[O[C[^HKX!_X;^^(7_0&\,_\ @+<?_'Z/
M^&_OB%_T!O#/_@+<?_'Z/^(?YW_+'_P(/]9LO[O[C[^HKX!_X;^^(7_0&\,_
M^ MQ_P#'Z/\ AO[XA?\ 0&\,_P#@+<?_ !^C_B'^=_RQ_P# @_UFR_N_N/OZ
MBO@'_AO[XA?] ;PS_P" MQ_\?H_X;^^(7_0&\,_^ MQ_\?H_XA_G?\L?_ @_
MUFR_N_N/OZBO@'_AO[XA?] ;PS_X"W'_ ,?H_P"&_OB%_P! ;PS_ . MQ_\
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MX/?]"UXX!]/L-G_\ETW_ (>]?!S!)\-^.!CUL;,?^W=?D9O"MZ$CJ>U,P-W
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MLQH^WQD8MV7+K][/@GPWX6UKQEJT6E>'](O]<U24,T=EIML]Q,X4$L0B L<
M$GC@"MVX^#/Q M=6TW2YO OB6'4]3:=+&SDTBX6:[:$9F$2%,N8Q]X*#M[XK
M[N_9Y\"Z3^SW^UA\;-#_ +">\MT\,W.MZ%J$%[);[--+I)Y$97.=WF1IYP.Y
M3;';]XXT_"C6OQ6\2_LC7%V=5L[36'\9796'6KI;R)6#2*IO4=)V8< ON!<
M[LAB*]VKG,HS;A#W+7O_ -N2GW_NV/.A@$X^]+WKVM_V\H_J?G)J'@_7M)T2
MRUF^T34;+1[V22*UU"XM)([>=T8JZI(1M8J000"2""#617Z%Z7-X&A_9C^!.
ME>-_ 5_X\LM5\4:II=LD.I3VD=H\NHRJ96>/YY),?=C+ -B0DY -:'A_]B_X
M2^ [CXBZEXE;1-<T[3O%"Z+81^*_%4NAVEK ;:&XP9X49GG'G;=K<,J9^4YK
M7^VJ<.958.Z;2M;6TN737[[V\KF?U"4K<DE:ROY75^WY7/SDHK[EL_@S\"_
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MD?!-QX2URT\-VOB&?1=0AT"ZF:WM]5DM9%M9I1G*)*1M9AM;(!SP?2LFOO\
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M)+75OE?8^7J*^GO"?[/WPTN='^&JZ]JGB>/6?&D#&%+!K?R(Y%QDL6CRJ_,
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M4,J #A=KC:,!< "NK_X=X_M!?]"!_P"5G3__ )(H_P"'>/[07_0@?^5G3_\
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M;2/^OR'_ -#%?1--T'_@GU\?;+7=.N)O 6R&&YCD=O[8T\X4,"3@3^E>T?\
M#'GQ>_Z%'_RI6?\ \>K[C)<YRRE3FJF)IK7K.*_4^<S# 8N<H\M&3_[=?^1X
MS17LW_#'GQ>_Z%'_ ,J5G_\ 'J/^&//B]_T*/_E2L_\ X]7T?]O93_T%T_\
MP./^9Y7]FX[_ )\3_P# 7_D>,T5[-_PQY\7O^A1_\J5G_P#'J/\ ACSXO?\
M0H_^5*S_ /CU']O93_T%T_\ P./^8?V;CO\ GQ/_ ,!?^1XS17LW_#'GQ>_Z
M%'_RI6?_ ,>H_P"&//B]_P!"C_Y4K/\ ^/4?V]E/_073_P# X_YA_9N._P"?
M$_\ P%_Y'C-%>S?\,>?%[_H4?_*E9_\ QZC_ (8\^+W_ $*/_E2L_P#X]1_;
MV4_]!=/_ ,#C_F']FX[_ )\3_P# 7_D>,T5[-_PQY\7O^A1_\J5G_P#'J/\
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M/#/BFVL%DCL+GQ#I8O)[-'Q\D;%L;01D!@>P^Z !J?\ #'GQ>_Z%'_RI6?\
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MB/P?H?A/2[.RTN6W\-7TM_:-/%(7>219 PD(D *XD;& #P.:UO\ ACSXO?\
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M/B]_T*/_ )4K/_X]1_;V4_\ 073_ / X_P"8?V;CO^?$_P#P%_Y'C-%>S?\
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MD!Y/MCM7C_Q8UZ'78Q;"ZC>>W 24J02#Z#USU]J_',IHNMB(N6T7>7IHE?\
M%?.W4^VX:P\:CIQ33BT]+/?[SO=4U+4+CP9%J\VN3/-QYJ*JJFTG#;2!P?Q-
M:'A+QQ)>:9';%U!M75HR&!XS@C\03^=>!:0VJ>)KFT\.Z=?3K!,PV1W,O[M6
M SDD#D?7-=GI/A_4_"OB^WT;4]L4X*S.T+[D90>,?4U]AB,KYL/*I"W)%MMI
M6LK+M;?5>5[=K_<8K 4XTZF%JSCSO6*MJE]_]+4]+\2727<SPR0JDL1.&SU'
MK7B'B#4_LNJ:E""IVRGE3GJHS7L/C9);6X$@7Y709SU!/>O#IC%+J5\[@;FF
M9@2< ]!_2M.#HSM5DW[O*E\[K_)G\\X%..<5XMW:5GI;JK'T9^REJ17X9?&2
M5PJ+!I$<FYE)&/)NSR!]*XU?'%DUJDL<EBXX3!WKN/KD\CZ8Q7I7['[PCPG\
M46:UCO8Q8P%[-VPDJ[+KY">P/(_&NE'A'P-]F;4I_"$:F5-QMXKABN,8(#;@
M<U^G3^"'S_,^KC\4CQ--=ANXP5BL)77Y6"W@'3G;@]..<TDGB*VM[B.:&PB5
M&7YI/MR,W'8$5Z;?>&?A,-/2\OM'O=%,/RGR92T4F?[Q*G:<<9%9^L?#7X3>
M*M'_ .):W]A.7#)<?:?M D4'.%7CDFL#0\\D\1VEJ/,CM(XT VM+/>J@.?X>
M.F?2L)_BM-,\D1$,%O"P^:W9IV/'39G ^IQ7I.N?L]^$]<M631?$LL09P[VM
M] -P8'DDIN!'IG%>>>)OV>]0M_$'EZ3XAT[5--:% 9&/E$<<@H^,?K0!Q/C#
MXJ+;3V$=HL8O;G[L6L7#! G]YD7Y<XZ9;CTKYA\83:]K'C+4+J^6XN=1DE.V
M:!21QPNP@8 QC&*^S;G]F74]7EM8;B?1Y6M5+1"%@Z[N>, >N.V*Z/PW^R;J
M<^FRRS:E8Z5=.Q5DFO/D([D\ ?A0!\\:1\1_%6@^ (+:5HTUA3L:1(Q]H$2_
M=#X[^YY]:Z/X=^/KBSN87UA8Q>R<"401PSX/=FVYZ=*[S4/V0?$T?B"*.*>U
ME#/Q=6UT@B1<9Y?^E4_B1^R[X@2YMI;2\M9/M/6..Z$S$KQRW'!(] ?K0!XQ
M\6?CYK-OKEYHVDW,EK;VK[/M$A#S,^<Y#8^4>PZ]Z[/X?_'"?Q'X9BN]1,W]
MJQRF-YK67RTE51PVT#Y6YZ].*NWG[(.N^(K2.^NM+N)-0A^^+5HXI'&."0[8
M;^=:WAW]ECQ%;XL8],FA1%;-NT7S=!P6W8Y^IH HM\4[/4[&XCCN]5G>!,JL
M;K&99!Z$DC/Y"J^G?%ZPU325,MW+:7;_ 'H+J%7*\X^=AU/TQ71V/[+OB6>T
M"7 AMHE)8?:9T0 ^ARW6KNE_LJZIJ,<-M>WVG:5;(N1([H22.HRIY&* ,"W\
M<6S2-*;S2_)C&QU#$-C'')SC\*I7?Q@@BD\F&[\\@>4%L[0L>>P9C@?EWKU*
MS_9A^'_AV-VU;Q&US,@WE;>%B".N>G0_6NIT_0?A;;::'TGP[-JC6\@+2/+M
M0^N0",CVS0!S/['MYKOB#XW:!>MH]U#I=N;@27=[,SL-UK,!@ !1SC\Z_3[0
M?^05!_P+_P!"-?%?PG^*%AJ'Q8\->']+>TLK:3SU:SM(5B5]MO*W89)!'4GM
M7VIH/_(*@_X%_P"A&NG_ )<?/]#+_EY\C0HHHKF-0HHHH I?VM#_ '7_ "'^
M-']K0_W7_(?XUDT4 :W]K0_W7_(?XT?VM#_=?\A_C6310!K?VM#_ '7_ "'^
M-']K0_W7_(?XUDT4 :W]K0_W7_(?XT?VM#_=?\A_C6310!K?VM#_ '7_ "'^
M-']K0_W7_(?XUDT4 :W]K0_W7_(?XT?VM#_=?\A_C6310!K?VM#_ '7_ "'^
M-']K0_W7_(?XUDT4 :W]K0_W7_(?XT?VM#_=?\A_C6310!K?VM#_ '7_ "'^
M-']K0_W7_(?XUDT4 :W]K0_W7_(?XT?VM#_=?\A_C6310!K?VM#_ '7_ "'^
M-']K0_W7_(?XUDT4 :W]K0_W7_(?XT?VM#_=?\A_C6310!K?VM#_ '7_ "'^
M-']K0_W7_(?XUDT4 :W]K0_W7_(?XT?VM#_=?\A_C6310!K?VM#_ '7_ "'^
M-']K0_W7_(?XUDT4 :W]K0_W7_(?XT?VM#_=?\A_C6310!K?VM#_ '7_ "'^
M-']K0_W7_(?XUDT9Q0!K?VM#_=?\A_C36UB!%)8.!]!_C7#:WXSL;*X6RBN5
M:]D.U$4YY[CZUS'BGQ5<0[!,S&-QA8D'&?0F@#T^W\:Z?<WAMTWD]FXP3^=:
M7]K0G^%_R'^->)>%9K[4-02:1"J Y4<X'%>J09\M<]: -K^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QH_M:'^Z_P"0_P :R:* -;^UH?[K_D/\:/[6
MA_NO^0_QK)HH UO[6A_NO^0_QJQ;W"W*%E! !QS6#6MI/_'NW^__ $% %VBB
MB@#@:***^C/*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(*+BNDHJHPDG=R;^[_(PJXFE4@XQH1B^Z<[_ (R:_ ****V//"BBB@ HHHH
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MEC>?_)=.7_@KU\82N?\ A&_ V3T_T&\_^2Z/:T.WX!R5>Y^P_P#;U]_SW_\
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M$DL3DDDFJO[5'_)L/Q?_ .Q/UC_TBFH_97_Y-A^$'_8GZ/\ ^D4- 'J-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '->/I/%<>C0'
MP?%ITVJ?:HQ(NJ%A$(<G>1M(.>GX9[XKI:X[XIZ*FN^';>W?Q7/X."WL+C4+
M>=86=@>(LL0#N)''<@<'I78UVU.7ZM3M:]Y='?IN]GY);==SGC?VL^UEUTZ]
M-U^H4445Q'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !6MI/_'NW^__ $%9-:VD_P#'NW^__04
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MG3U%<AN4VB95&]=J]5SZ4GEF,#Y6;WQS5OD@!L88=.C"D&_<PWJSKV!S^&*
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M **** "BBB@ HHHH **** "M;2?^/=O]_P#H*R:UM)_X]V_W_P"@H NT444
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M0:_IJ_$W5K7X1^(-?_X235/ *:?$RSW9D$C*+LMO2(LJ_NPO\(YR P^OZ**
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M110 5@^(_'_ACP?/!!KWB/2=$FN/]3'J5]%;M)SCY0[#/(/2MZOE/]DKX/\
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M3Q$^@9"1W'YUHU\?_$?PC?? O]J#PYHGP&M=$TW4_%6CW4^K^'-0\U-*A$3
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M\(^./V1]'L/B':?$SQ%X\\.VUY;6WB'1O%$R3!X9I%C::W;&8R'9,( >IR2
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M(X95(DDSR5V1[5W_ *!6F@Z;8:'#HMMIUK;Z/#;K9Q:?# JV\< 78(EC VA
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MU#8Z@]?\YJ9=>?7ECFGGFOCU6.883/\ NC S]17MUU^PN+I,'QM@XQG^RO\
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M0>I84[XG_&+X^>#YM,\ Z_X<\-Z1XC\97*:;HGBS0[R1K&V=B!*6CE!<2*K
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M<_:.OM46H?MW>$-)C22\\&^-[=6Z;]-@!_+[1FG^[_Y^/[R_?_E1]9?\2/\
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M'P\E_8U\7>!]5^$!NKNW\3ZG_85QX'U'59)+:ZE>-C%-&TA)CV,/F<L0-Z]
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M6Q%7$.]65[?<O1;+Y&U.E"G\"L%%%%<YJ%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5K:3_P >[?[_ /05DUK:3_Q[M_O_ -!0!=JOJ'_'A<_]
M<F_D:L57U#_CPN?^N3?R-5'XD*6S.)KXW^._A'0O''_!07X/:1XCT73_ !!I
M4OAC4FDL=4M8[F!RHE*DQN"I((!''!%?9%>(?&[]D[0OCAXZT/QA<^,/&7@_
M7]&LY+&UO/"6IQV,@C=B6RYB9LG)'! QQBO<J1<EH>;%V>IX1XTTCP]^S=^W
M)X9F\!V6D>$-,UOP9JEWX@TZ'%II@2UAEEAN)8XU(A7?$ 9%7HK8!);=Y_\
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MP_"#_L3]'_\ 2*&C]JC_ )-A^+__ &)^L?\ I%-1^RO_ ,FP_"#_ +$_1_\
MTBAH ]1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\_\ C;_PA+>$;9?'N[^QFOX1'M\W)G^;;Q'R1C?GMC/?%)\?OB<OP?\ A!XF
M\4C#7EI:E+*,C)DNI"(X5 [_ #LN1Z UC?M#_%Z3X7Z1X>L=+\.Q^+O%7B+4
MDT[2-&DD$:R2X+&1F(("H=N3Q]X<CDCP3XU7WQ6M?$OPNO/C=H_AW3/AQ;>(
M[>[N[CPS-+,L5SM;[-'=+(V2JO\ >905()ZG /TF%P[KTJ"J-\J<G9R6NVD8
M[INUF^KMV/)K553G4<5JTE=+;U?E>Z[?,^B?V;OAB_PC^#/AO0+G+:MY'VO4
MY&.6>\F/F3%CWPS%<^BBO3*SX_$6E3-"$U.S<S0FXB"W"'?$.LB\\J/4<40^
M(M*N&MA%J=G*;J-I8 EPA\U%^\RX/S =R.E>!5J2K5)5)[MW/3A!4XJ$=D:%
M%9]OXBTJ\:S$&IV<YO0YM1'<(WGA?O%,'YL=\=*2W\2:1>+9F#5+*<7I86IC
MN$;SROW@F#\V.^.E9%FC16=#XDTBX6V,6J64HNI&B@*7"'S77[RK@_,1W Z4
M1^)-(F6$IJEDXFF-O$5N$.^4=8UYY8>@YH T:*SE\2:0RH1JED0]S]C4BX3Y
MI_\ GD.?O_[/7VH/B32%5B=4L@%N?L1/VA.+C_GD>?O_ .SU]J -&BLZ3Q)I
M$:RE]4LD$4XMI"UP@V2GI&>>&_V>M$WB32+=;@RZI91BWD6&8O<(/*<]%;GA
MCV!YH T:*SKCQ)I%HMX9]4LH19LJW)DN$7R"WW0^3\I/;/6BX\1:39F]%QJ=
MG ;'8;KS+A%\C?\ <\S)^7=VSC- &C16?-XBTJU:Z$VIV<1M462X#W"+Y*M]
MUGR?E![$]:)/$6E0M.)-3LT,$0GE#7"#RXST=N>%/J>* -"BL]O$6E(T@;4[
M-3';_:W!N$^6'_GJ>>$_VNE'_"1:5N"_VG9Y-M]M ^T)_P >_P#SVZ_<_P!K
MI[T :%%9Z>(M*D:,+J=FQD@-T@6X0[H1UD'/*?[72B+Q%I4[0"/4[.0W$1GA
M"W"'S(QU=>>5'J.* -"BL^W\1:5=-:"'4[.8W:L]N([A&\Y5^\4P?F [D=*2
MW\1Z3>?8O(U2SG^W;_LOEW"-]HV??\O!^;;WQG'>@#1HK.M_$FD72VA@U2RF
M%VS);F.X1O.9?O!,'YB.X'2B+Q)I$ZP&/5+*07$I@A*W"'S)!U1>>6'H.: -
M&BLY/$FD2+&5U2R823_94*W"'=,.L8YY?_9ZT?\ "2:1M#?VI9;3<_8@?M"8
M^T?\\>OW_P#9Z^U &C16<WB32$60MJEDHCN/LCDW"?+-_P \CSP_^SUHD\2:
M1"LYDU2RC$$H@E+7"#RY#T1N>&/H>: -&BLZ?Q)I%JMT9M4LHA:NL=P9+A%\
MEF^ZKY/RD]@>M%QXDTFS%Z;C5+* 6.P77F7"+Y&_[GF9/R[NV<9H T:*S[CQ
M%I5HUX)]3LX39JK7(DN$7R WW2^3\H/;/6B;Q%I5NUP)=3LXS;QK-,'N$'E(
M>C-S\JGL3Q0!H45GR>(M*C:4/J=FAB@%S(&N$&R(])#SPO\ M=*#XBTI68'4
M[,%;;[:1]H3BW_YZGG[G^UT]Z -"BL]?$6E,R :G9DO;?;% N$^:#_GJ.?N?
M[73WHC\1:5,T(34[-S-";B(+<(=\0ZR+SRH]1Q0!H45GP^(M*N&MA%J=G*;J
M-I8 EPA\U%^\RX/S =R.E%OXBTJ\:S$&IV<YO0YM1'<(WGA?O%,'YL=\=* -
M"BLZW\2:1>+9F#5+*<7I86ICN$;SROW@F#\V.^.E$/B32+A;8Q:I92BZD:*
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MEP/E)[D=:(_#>D0K"$TJR00S&XB"VZ#9*>LB\<,?4<UHT4 9R^&](54 TJR
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M-(.KYNWR0$O980^\."P"S8&"5P?E3;Q<E=?97W_\ ]/ER[_G]+_P!?\ R?\
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M^;]ZP/!"Y(KH:0!1113 **** "BBB@#X6_;.%KI_[0VDZE*O[_\ X1J"!)"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNZG_ /)- 'U#17R]_P .R?V:O^B;?^5W4_\ Y)H_X=D_LU?]$V_\KNI__)-
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MZ)M_Y7=3_P#DFC_AV3^S5_T3;_RNZG_\DT ?4-%?+W_#LG]FK_HFW_E=U/\
M^2:/^'9/[-7_ $3;_P KNI__ "30!]0T5\O?\.R?V:O^B;?^5W4__DFC_AV3
M^S5_T3;_ ,KNI_\ R30!]0T5\O?\.R?V:O\ HFW_ )7=3_\ DFC_ (=D_LU?
M]$V_\KNI_P#R30!]0T5\O?\ #LG]FK_HFW_E=U/_ .2:/^'9/[-7_1-O_*[J
M?_R30!]0T5\O?\.R?V:O^B;?^5W4_P#Y)H_X=D_LU?\ 1-O_ "NZG_\ )- '
MU#17R]_P[)_9J_Z)M_Y7=3_^2:/^'9/[-7_1-O\ RNZG_P#)- 'U#17R]_P[
M)_9J_P"B;?\ E=U/_P"2:/\ AV3^S5_T3;_RNZG_ /)- 'U#17R]_P .R?V:
MO^B;?^5W4_\ Y)H_X=D_LU?]$V_\KNI__)- 'U#17R]_P[)_9J_Z)M_Y7=3_
M /DFC_AV3^S5_P!$V_\ *[J?_P DT ?4-%?+W_#LG]FK_HFW_E=U/_Y)H_X=
MD_LU?]$V_P#*[J?_ ,DT ?4-%?+W_#LG]FK_ *)M_P"5W4__ ))H_P"'9/[-
M7_1-O_*[J?\ \DT ?4-%?+W_  [)_9J_Z)M_Y7=3_P#DFC_AV3^S5_T3;_RN
MZG_\DT ?4-%?+W_#LG]FK_HFW_E=U/\ ^2:/^'9/[-7_ $3;_P KNI__ "30
M!]0T5\O?\.R?V:O^B;?^5W4__DFC_AV3^S5_T3;_ ,KNI_\ R30!]0T5\O?\
M.R?V:O\ HFW_ )7=3_\ DFC_ (=D_LU?]$V_\KNI_P#R30!]0T5\O?\ #LG]
MFK_HFW_E=U/_ .2:/^'9/[-7_1-O_*[J?_R30!]0T5\O?\.R?V:O^B;?^5W4
M_P#Y)H_X=D_LU?\ 1-O_ "NZG_\ )- 'U#17R]_P[)_9J_Z)M_Y7=3_^2:/^
M'9/[-7_1-O\ RNZG_P#)- 'U#17R]_P[)_9J_P"B;?\ E=U/_P"2:/\ AV3^
MS5_T3;_RNZG_ /)- 'U#17R]_P .R?V:O^B;?^5W4_\ Y)H_X=D_LU?]$V_\
MKNI__)- 'U#17R]_P[)_9J_Z)M_Y7=3_ /DFC_AV3^S5_P!$V_\ *[J?_P D
MT ?4-%?+W_#LG]FK_HFW_E=U/_Y)H_X=D_LU?]$V_P#*[J?_ ,DT ?4-%?+W
M_#LG]FK_ *)M_P"5W4__ ))H_P"'9/[-7_1-O_*[J?\ \DT ?4-%?+W_  [)
M_9J_Z)M_Y7=3_P#DFC_AV3^S5_T3;_RNZG_\DT ?4-%?+W_#LG]FK_HFW_E=
MU/\ ^2:/^'9/[-7_ $3;_P KNI__ "30!]0T5\O?\.R?V:O^B;?^5W4__DFC
M_AV3^S5_T3;_ ,KNI_\ R30!]0T5\O?\.R?V:O\ HFW_ )7=3_\ DFC_ (=D
M_LU?]$V_\KNI_P#R30!]0T5\O?\ #LG]FK_HFW_E=U/_ .2:/^'9/[-7_1-O
M_*[J?_R30!]0T5\O?\.R?V:O^B;?^5W4_P#Y)H_X=D_LU?\ 1-O_ "NZG_\
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ML^K_ /A&;K_GI#^9_P */^$9NO\ GI#^9_PKY0_X>2_LY?\ 11?_ "B:C_\
M(]'_  \E_9R_Z*)_Y0]2_P#D>CF?_/Q?U\PY?[K/J_\ X1FZ_P">D/YG_"C_
M (1FZ_YZ0_F?\*^4/^'DO[.6,_\ "Q>/^P)J7_R/1_P\F_9R_P"BB_\ E#U+
M_P"1Z.9_\_%_7S#E_NL^K_\ A&;K_GI#^9_PK=TVU>SL8X7*EESDKTY)-?-G
MP?\ VM_A/\>_$MSX?\">*_[=U>VM&OY;?^SKNWVP*Z(S[IHD4_-(@P#GGIP:
M^C=!_P"05!_P+_T(USXB[@GS75S6E;FM:QH4445YYU!1110!SE%%% !1110
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MFQM?4U/V)_CGK_QJ^'OB&#Q9=66H^)O"FNW&@7FJ:>@2'4!$%VW(4<+OR>%
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M823=E7G'UH UJ*S-%UI-6A9N ZMM.*TZ "BBB@ HHHH **** "BBB@ HHHH
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MP7\"_"2>&? GA^W\/:,LKSM#"SR/+(QRSR2R,SR-T +L2%55&%4  ':4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5_OJWJ.>:YSXM_L@?!_XZ>(H]>\:^"K;5M92,1&]BNKBTED48 $A@D3S,
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M$I;<"^TXQR>GIB@#ZH_98UC[;\1]2@W,^W2Y&RQ_Z;0_XU]KZ#_R"H/^!?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU=/^R5IOQ2U3P3H/C;Q]\5/^$XL?$N@V>HVVC_\ ".VNG_V?)/&DQ_?0G,N
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M_0C7YE?\$\65_C!K161I!_85P"6(R3]IMNH]1TK]-=!_Y!4'_ O_ $(UUO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "H+Y2]E<*H+,8V  ZG@U/133L[B.)_L^Z_Y
M]IO^_9H_L^Z_Y]IO^_9K7_X2K_IU_P#(G_UJ/^$J_P"G7_R)_P#6KU^>O_)^
M)P\M/^8R/[/NO^?:;_OV:/[/NO\ GVF_[]FM?_A*O^G7_P B?_6H_P"$J_Z=
M?_(G_P!:CGK_ ,GXART_YC(_L^Z_Y]IO^_9H_L^Z_P"?:;_OV:U_^$J_Z=?_
M ")_]:C_ (2K_IU_\B?_ %J.>O\ R?B'+3_F,C^S[K_GVF_[]FC^S[K_ )]I
MO^_9K7_X2K_IU_\ (G_UJ/\ A*O^G7_R)_\ 6HYZ_P#)^(<M/^8R/[/NO^?:
M;_OV:/[/NO\ GVF_[]FM?_A*O^G7_P B?_6H_P"$J_Z=?_(G_P!:CGK_ ,GX
MART_YC(_L^Z_Y]IO^_9H_L^Z_P"?:;_OV:U_^$J_Z=?_ ")_]:C_ (2K_IU_
M\B?_ %J.>O\ R?B'+3_F,C^S[K_GVF_[]FFRZ7/-&\<EG))&X*LC1$A@>H(Q
MTK9_X2K_ *=?_(G_ -:C_A*O^G7_ ,B?_6HYZW\GXART_P"8Y/PSX$T[P3HL
M&C^'?#UKH.DP%C%8:99+;01EF+,5C10HRQ).!R236K_9]U_S[3?]^S6O_P )
M5_TZ_P#D3_ZU'_"5?].O_D3_ .M1SUOY/Q'RT_YC(_L^Z_Y]IO\ OV:/[/NO
M^?:;_OV:U_\ A*O^G7_R)_\ 6H_X2K_IU_\ (G_UJ.>O_)^(N6G_ #&1_9]U
M_P ^TW_?LT?V?=?\^TW_ '[-:_\ PE7_ $Z_^1/_ *U'_"5?].O_ )$_^M1S
MU_Y/Q#EI_P QD?V?=?\ /M-_W[-']GW7_/M-_P!^S6O_ ,)5_P!.O_D3_P"M
M1_PE7_3K_P"1/_K4<]?^3\0Y:?\ ,9']GW7_ #[3?]^S1_9]U_S[3?\ ?LUK
M_P#"5?\ 3K_Y$_\ K4?\)5_TZ_\ D3_ZU'/7_D_$.6G_ #&1_9]U_P ^TW_?
MLT?V?=?\^TW_ '[-:_\ PE7_ $Z_^1/_ *U'_"5?].O_ )$_^M1SU_Y/Q#EI
M_P QD?V?=?\ /M-_W[-']GW7_/M-_P!^S6O_ ,)5_P!.O_D3_P"M1_PE7_3K
M_P"1/_K4<]?^3\0Y:?\ ,9']GW7_ #[3?]^S1_9]U_S[3?\ ?LUK_P#"5?\
M3K_Y$_\ K4?\)5_TZ_\ D3_ZU'/7_D_$.6G_ #&1_9]U_P ^TW_?LT?V?=?\
M^TW_ '[-:_\ PE7_ $Z_^1/_ *U'_"5?].O_ )$_^M1SU_Y/Q#EI_P QD?V?
M=?\ /M-_W[-']GW7_/M-_P!^S6O_ ,)5_P!.O_D3_P"M1_PE7_3K_P"1/_K4
M<]?^3\0Y:?\ ,9']GW7_ #[3?]^S1_9]U_S[3?\ ?LUK_P#"5?\ 3K_Y$_\
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M_P#;BOJJOE7]OK_FW+_LLWAS_P!N*^JJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BN;T?XE^$/$6L2:1I7BK1-3U:/.^QL]1AEG7 R<QJQ8< ]JZ2JE&4'
M:2L)24M4PHHHJ1A1110 4444 <?\+]:GUS0+N>X\(S>#)$OYXOL$RJIE ;_7
M#:HR']<<X."1@GL*Y?X=V?BVRT6XC\9W^GZCJGVN1HIM-C*1_9\C8""!\W7/
MU')ZGJ*[,9R_6)\EK7Z-M?)O5_,PP]_91YKW\[)_<M HHHKC-PHHHH ****
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M:Z/C#'@__A%!X?\ L?\ S$_MGVCS_/\ ^F,>W;Y'OG=VQS]B:#_R"H/^!?\
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M_.VGW'+A;>PARVM;IM^.H4445YQU!1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-_M2-XBA^-^J>/KC1O#OA[X?^*[W18K^)9(E^RPN51I2SMNE8X&$ W,0%7)
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MQ-_$#G.>HP1QFN8U/B:59[\N;;2;EU63.0[\%N?FY[\BFWMY-);+;164J77
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MKN3?\DUR@.UN^!^=:6N/'J'[J\$3JI)+<@_SKS[Q1!IFK1K;[(O+@.5]1UH
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MW\?:5XDL+[Q1?V&B7LFI:'X6U/5S/HVCW+G+2VUOM!5LG.69N<'J!CZ:H ^
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M>B>"=%GUCQ%K&GZ#I,!42W^IW26T$99@JAI'(498@#)Y) KD_C)\?/ ?[/\
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M,]U[^M+J'@7[>FK+_P )#KUM_:$\<V;>]VFVV8^2'Y?D5OXASFNGHH YC5/
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M_3/]:Z>B@#EY/ OF1W"_\)#KR>=J0U'*WN"F/^6"_+Q#_L?K1=>!?M27Z_\
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M (YOE^=U['C%&E^"?[,DT-O[?UR[_LM9EVW5YO%YYF>;CY?WA7/R],8KI:*
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MJC^Q;7_H)P_I_P#%4<N'[?F'-5[_ )'S-;_LI3P!1_PF!*K_ -0W'_M6I_\
MAEN8MN/BPENW_$O[>G^MKZ2_L6U_Z"</Z?\ Q5']BVO_ $$X?T_^*HY</V_,
M.:KW_(^=)?V8WDB5#XG'RC&3I^?_ &K4:_LNR*JJ/%. ISC^S_\ [;7T?_8M
MK_T$X?T_^*H_L6U_Z"</Z?\ Q5'+A^WYAS5>_P"1\W7'[+US/"(_^$M &<\Z
M;G_VK6)>?L;R7D@=O&0!!SSI>?\ VM7U9_8MK_T$X?T_^*H_L6U_Z"</Z?\
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M-05P!<S*WRQN8@% ?YBRHP)W#'MG[1]CX4O_ -I#X&+X8MK&Y^(L7B))KW[
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MS\FCZCHKY.\!_MY^%=#TFZT#XF7<]GX\T.^N=)U2/2M+N+B":6"5H_.0QH5
M?;G;G@Y[8KI/^&^/A;)_J$\3W7_7'P]='^:"G++,9%M>R;\TG9^C$L90:OSH
M^C:*^<O^&Z_ TG^H\,^.[KT\GPU.?YXH_P"&WO#\G^H^&WQ0NO\ KCX5D/\
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M&H544#   Z #M4E%%2,**** .;UCX:>$/$6L1ZOJOA71-3U:/&R^O-.AEG7
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MX3E3DIP=FB914TXRV9\VZS\&?C5\3])'A#X@>.O#7_"%38CU.?P[ILL&IZK
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M ^)E_P"%E34I-4\23>*HA?Z(SQ/Y45D64.B2,0C!4?Y202!S7G_[2O@WX+>
MOC)J5A\=--\::I;IX.AMO#'B[5=6GNUU2:!0K(!! A%T'D)8RR/&=P9@F]<Y
M2G-)WTU-(QC?N?H?X#UC7/$'A#2]1\2^'O\ A$]=N(M]WHOVV.\^R/DC9YT8
M"OP <@=Z\T_9_P#VFM+^,WP5F^(^M6EGX&TJWO+BVN#?ZFCP0K$^SS'G=(U4
M$D=1QGJ:C_8LM?&UG^S'X%A^(7VW_A*%M9/.&I%OM2PF:0P++NY#B$QC#?,,
M -SFOSH71=8O_P!B#X:Z@EU-8^$--^(%Y/K]ZFEKJD-E&9-L=S/:-\LT2$ME
M7^4E@I!+ 4Y5'%)^7^0E%-M'Z5_$[]I[P%\-_@UJ?Q*CUW3O$N@VK>1;MHNH
M6\PO;C.!!$^_:S]20"2%5C@XQ7GUU^WW\.+?6/A7I?\ :FD2S^,X?M%[=)K=
ML;30D$!=EN)<Y\SS=L2JRID[SD%=K?&>B?"_2_$'[,W[1NO^'=8N_'F@M;V=
MU:W[>!H-"TPW-LQ\RYL(8Y&VM'"9%D80Q8#$DG+&K?B;6/@GINL?LJ>/6T30
MXOAU#97FG>)+Y/#C>1+>Q6T8*3QB#,S"9G8':V3N8=S63JSWV_X<ODB?IIJ'
MQ2\&:3XMMO"U]XNT*R\3W.WR-%N-2ACO9=WW=L);>V<'&!SBJ?B#XU_#SPGJ
M=WINN>//#.C:C9R117-IJ&L6\$L#RH7B5T=P5+H"R@C) R,BOR1\9>!_M/CC
MXD>%O''BS5-)^(6I>+I9+3P[8_#R#6-:U)'F1H;BTU*22*2.,A00BRHNU3@-
MO8'ZX^#?PK\/^+_^"@'QLF\9:/8^*M4T71] $$^K6<<P2<V-J7F6-BZK)NB4
MA@25R0&P3FXUI2=DNI+@EK<^O8?BYX%N/&)\)1>-/#TGBL.T1T)-5@-]O52[
M+Y&_?D*"Q&.@S765^-MY_P (W\/_ (@)9>&M/_X33QE_PF NX_AWXP\(3Z=X
MGL)/.\Q)(M4LI?WQP<@22^41B3RSQ7[)5I3J<][DRCRV/GSXN^-+O2OB#/;V
M$OE36\:AN<DJ\0W$#Z8%>/Z/&+VQ>9I-A:1W93[L0,?@!6Y^T'<1V_Q@U>5@
MQ8+ F0> ##'UQ47PWT'2_%%G+Y]]'IDD4C(L9D^;&=P^O45\)Q)55+"R;7VO
M\SY/B;#U,3##TZ2UN_R1TFDZL='TV2"%O^/S9;,K<'!/)'X5C^-M0.E6JZC;
M$+,-L2VZ'Y9!T"'^A[5JWNEFQN)[EF-ZT+I)$ZD;2%QGCN2.*H^*([/Q+;I8
M6TOD\"7[21Q%W!^OH*_*,+*,J].4_P"'S>]Z:7O\MO/;4]W"X'&_V8Z=*"4U
MLOZ9QO\ PGVIR7!LG\E=I02%0V858X##/6M37$M+#1_,1?GA_>;F.6;/WB3Z
MD9JQ9_"F_:1KB&:UF!97=8V)\X*<A3G[H^E)XT2W?33;6RMNG^1D<8:/'+@_
M3_"OI,T>6_6*:RAWIZ<VC7K>_2U_+YW/GUA\9!S6)3Y5_.M?P/-M;?=>@1OY
MB+TP.![5YWKMJT.NW:.HC\Q Q+<\#'/ZUV%UO34+@_=7=G;GM7$:T\U_KEV4
M+'"B/K_GTKZ[AV=14'3E\-K_ )?J>1PFYO'U7;3E?YH^M/V<_#T?C/\ 92^(
MN@7,ACAU0ZE8/(C %5EL8T)R> 0&[U\D77_!.G0_LMO]D\:7=OJ)YE6[CA9&
MC'&4Q@DY[9Z9KZV_9TAFLOV4_B."/,F4ZD0N['/V&+C/:OFN/4YKF9YI=)N/
M+1E9YO,R6)R  #U _E7UM7X8>A^I0WD<E;_\$]?#]G(3>?$>ZA@DC8J/LD*O
MG'&07X&>OH*Y>7]AW0M/6-I_B/!')&2'46P8X!P.![?@:]4AUS3[R-_M,-Y]
MK\WD?[R]<'MU_*HYK^R5DW6MRS$;MZ@YV#'(_O#FN8U/(+K]D'PK:R2#_A.+
MN>1FVHL%G@#GD<^HZ?2L:\_9)L%D>.W\4W1);]W(UEF/GC^]7NUSJ=H8_,AL
MKB!LN3&HPRD$8+#/^UD'VJ:/5=#CA2-KV<?=P-A;&>.G;&30!\G>-/V:?%GA
M6$7<!@UJ#'/D$QRC!'6(\YQZ9ZUY883"TT4@*X9OO(5/7'0CCK7Z"VNKV6O:
MAF'[9/,H"K(R@YP#E0#QQBO/_B9\']&\?73F16T34L@1WC1?>XSAATQG'7D8
MZT ?&DZE&B1B%9SDX_N\#/U/-%NK/O#.P8XY*Y '8_6O2-8^!'BRQN+@65DN
MK1HQ#2Z?(KD'G&1D$>OXUTWA']F?Q-KFH#^V9H_#=G&/WSR2(\NT=<*#@'.!
MS]<4 >6>"O".J^/-9%AI]OYLHQYDC +%$J_QLWZ>IS7TS\.?@5I7A6[BFN;?
M^U]8C4 S7,(V1L5/* \=<<G)KN=-TGPW\._!(TS0Q#:V"RYEU"X7=))(%.2<
M<L?FZ=./:N=O?&-LC3^5<7NI*P+[1^Z1&(&#D9XQ0!T6I&VM/*V1/>WN-DUK
M#_>5CR2.G8''I7*^)O%!L[!1<.MH[DJ-+MP3(S]E8\^OZ54L-6\1:YMAT91:
M;V5?+5&:9]W3/_UR*]M^#'[*H:\?7?$Z3Q65OAY3.H&\^V3\QH X#P#^S]XR
M^+4::C>)+96[L&6&- L2)T ';G/?GBO:O"?[)'A?PO:E?$)MY+F8C,<CLT@7
MJ1A3\O:K7B_XZZ?HNM1>&]+B^Q649$<<*]<9^]]3UR:AD\0:E?7#0)MCMIFR
MUVQ'F+CH QYYQS]: /I;]G'3_"^EP^(+;PS L<4;P+-,J!1*0'VG _'KZU]*
M:#_R"H/^!?\ H1KY2_93D*_\)+;&59?(CLU)48R29\G_ #Z5]6Z#_P @J#_@
M7_H1KME_N\?7_,YX_P 5FA1117$= 4444 %%%% !115/6-271])O=0>"XNDM
M8'G:"SA:::0*I;;&B\NQQ@*.22!0!<HKYI^%7[:UGXVTSXR:IXH\&:CX!T_X
M:[)+V._N4N+R6)H7FR\*+B.0*@'EAWY;&016/\'_ -N:_P#''Q$\+>&?&WPM
MU/X;VGC+2KC6?"NJ7>J0WB:C:PQ&9C(B*# WE OM8DCCU!(!]745\=^"/^"A
MDGBSQ;X+EO/A9K&B_##QQK3:!X9\;SZA"_VZZWM'&'LPN^%7=2 2QS@D9P<?
M8E 'RK^WU_S;E_V6;PY_[<5]55\J_M]?\VY?]EF\.?\ MQ7U50 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >=_ VU\$VGA2_3P%
M>O?Z0=2G:>1Y)'*W!V[URX!QC;CL0<Y.<GT2N,^%>N/K_A^[N)/"%QX*9+^:
M/[!<Q+&TN"#Y^ H!WDGGN0>3UKLZ]',')XNHYMMWZM2?SDM'\CEPMO80Y;6M
MT32^YZH****\XZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOFJ^38_ OVV&I\])Z^OF^WDNGXFW#O&-++8QCBX72V:1:^%6L:QY=U#-;)%
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M: _\+G_[17U510!\J_\ # O_ %<;^T!_X7/_ -HH_P"&!?\ JXW]H#_PN?\
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MJJB@#Y5_X8%_ZN-_: _\+G_[11_PP+_U<;^T!_X7/_VBOJJB@#Y5_P"&!?\
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MO[0'_A<__:*^JJ* /E7_ (8%_P"KC?V@/_"Y_P#M%'_# O\ U<;^T!_X7/\
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M_: _\+G_ .T5]544 ?*O_# O_5QO[0'_ (7/_P!HH_X8%_ZN-_: _P#"Y_\
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M1'"^7YB9R$Q][C.>:]3TRS_LW3;2TW^9Y$21;\8W;5 SCMTK1_L^Z_Y]IO\
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M#HO"W@/P_;>'-#CF>X-O;EW:25\;I))'+/(Y 5=SL3M55SA0!VE%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <Q_PDUU_P \X?\ OD_XT?\
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M77_/.'_OD_XT?\)-=?\ /.'_ +Y/^-9%%'L:?\H>TGW-?_A)KK_GG#_WR?\
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MO@[GGKJ>.G_;&GG]KJ6,XD\(!3C("ZGG_P!HU'-AOZN.]1Z)GU#_ ,)-=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <#7+^
M-/BGX+^&[6B^+?%^@^%FO QMEUK4X+,SA<;BGF,N[&Y<XZ;AZUU%?"O[?5O<
MW?[2/[.T5GX&LOB5<L=9V>%=0G@A@U#]U#\KO.K1@*/G^8'E!WQ7OU)<L;H\
MR*YG8^PO!?Q3\%_$AKM?"7B_0?%+684W*Z+J<%X8 V=I?RV;;G:V,]=I]*KZ
M_P#&;X?^%/$2:!K?CGPWH^NN4"Z7J&KV\%TQ?[F(G<,=V1CCG/%? ^CS:I\/
M?VLK#6[[X1V/P$UJ;P+JT>@^']"DM;VVUV[ACEF;S9+4+&A VD IDF-06Y05
MZ)^R?^S7\)/BE^QY::]XPT;2]<UCQ1#?:AKGBW4%CDU&*X:6199%NI 6A,>P
M'@A<JS,"68G*-24M$M2W%+5GV4OC;P[)XL?PNNOZ6WB9+?[4VBB\C-XL.0/,
M,.[>$Y'S8QR*63QIX>B\51^&'UW3$\2R6_VM-&:\C%XT&2/-$.[>4R"-V,<&
MOB_X]>$]%_9I\=?LW_%/PE/)-X0T<Q>#M1OFO#<^;I<\9^S2-*20T: S,#G;
MS&%V@**X34?BP;/2_P!IW]I'[1BXDF_X0/P;*PVE$3;&TL7J"S1R\=XY,]P&
MZO*[/^D')?5'Z!>$?B1X2^(#7R^%_%.B^)&L&5+M=(U"&Z-NS;MHD\MCL)VM
M@'&=I]*Z*ORH_8U^*'PW^$7[1WPXT/P/XFBU?3/%_A>'1?$:+:7%NL6MJQD2
M7,R+OW,?*7;D?.?:OTW\=^()O#?AFYN+)4EU6<K::=#)G;)=2L$A#8R=N]@6
M(!VH&;H#54ZG/&[)E'E=C>CE292T;JZ@E<J<C(."/J""/PIU?/'[/,>I_#GQ
MQ\1O@_J.IW-U-92#Q+H.J7K>9+<6=\SF9L'J8KQ9\YZ^:M>N?"_P[XH\*^#;
M33?&/B__ (3K7XWD,VM_V9%IWG*7)1?(B)5=JD+D'G&>]7&7-T):L=75'7->
MTWPQI-UJNL:C:Z3I=JGF7%[?3K##"HZL[L0JCW)KX3_:4^//QST7]HCX4Z?9
M?#34=&LDUO48=-T^T\9P)#XNB41A?.5 %@ 7:X68-CS".H-:_P"W1X+\6?$S
M]EG5?''C&XU7P0VDZ6DLOP]L[^&XM?MINP@EN;F,?Z0 C(RH,*K*#SR#FZND
MK+8M0VN]S[&U[Q]X9\*^'8_$&M^(])T?09 A35+^^B@M6#\IB5V"G=VYY[5>
MT'Q!I?BK1[75M%U*SUC2KI=]O?6$Z3P3+G&4="589!Y![5\]^)_AWX ^)WPM
M^%NF^(8/#&K>/;;P[]H\'Z+XIOY%M+F\^Q1G,MHD@^TQ*43>-CE5W8QDYYS_
M ()SQQ^&? GQ#\$7D(M?%'AWQ??+K%M:$'3XY9"-@LA@;(-L8PAY!#$XW !\
M[YDA<NESZ?TSQAH.M:YJNC:?K>G7^L:28QJ&GVMW')<6>\$IYT:DM'N )&X#
M('%:]?GE?_&2[^ 'Q>_;4\>V%C#J.H:2OAX6UO<Y\HRRKY"%P""55I0Q ()"
MD C.:7X'_&K]HCQCXE?POK4OCJ;1_$FB7*IXN\2?#>'2XM O%@>2*6,Q.T5Q
M$Y&W][MR3'@+SF?;*]FM?^"/V;W/O63QAH,.D:AJLFMZ;'I>GR2PWE\UW&(+
M9XV*R+(^=J%&!#!B"",&M>OQ47PEXT'_  3OT;6SX]W>$)O%"16_A7^QH/W$
MHFE!E^U9\QLMAMI&!C%?3/QL_:)^.'AWXJW'PK\-^(O%6IZEX2T>WDU/7_"'
M@"UUBYU>\G19 \UNTBI:0A611L!.X.3N!4+*KZ7:[%.GV9^B5%? >I?M ?'S
MXB>*OV?_  M87S_"7Q-XSL-537+35- 1_)EM@_\ I"P7"^8/W<9D1-P4EE!W
M#KF_'SXN?M$_"7Q[?:5J?CG5O#OA'1=*L_(\<1^ XK[2-5N&CS+-?RQJ[60:
M<^2$AC<@;/D.?,>O;*U[,GV;VN>L_M8:@EE\2K;H9#HL( QDX,]Q_A7E.GZ@
M=8UB,P(MJL<6=@Z!F^4'ZX#?G6G\??%TGQ"_X0/Q-'>:==R:KX6L;N2[TAI#
M:N[/,7\KS560)DMA74..C $$4[X3Z1#J%U>W<T@,D:QLHV] "W^(_.ODL^K0
MHX*O5DKZ:?-I?DSCS+!5\=A8T,.O>;7_  3K_#VAI;S*\ES&^U@63OUY%='J
M5S%JSIJEE<BUN(F:.P^7*H =K9'?>0<^@ Q7'^+O$C^'3Y"0+;2.V1<L<C!%
M</X/US5=4L&\MOM0@8HC^8$PRL<\?K^-?DF"P.,KPG6IZ/1?)IW7SLD_*ZZG
MV>2\(U\/33K145;O^K.[N_&,L-Y*+BWN7O(VVSQ1(7$9Z]>X(.1]:O:?);^/
M+5X&5CI.XK,6!5IF[QC^Z >IZ]A7)^&/B-ID,,UOK7VNUN([N219HH_,2<-C
M.#_>7&!VXJU#\1;1H=3:VM;B&)YM[Q.VUU38JAO^!;<_C7=B,IK81.>'I-3C
M;7HG?I?[UK[NS]ZS.:EPWF3Q;BX<\/.WYWU+^N*+*.73HHC/]CPB[#UC(RAP
M/3E?^ YKS?Q8LEUHMS!)!('E.T,<@**W].L=+U36)[^P$DG$4;K+<D%7^8G/
M//#+^=:OB[4H[?1)X0R.S+@JP.5_$TL#C)8/,*<%!RDW%[VLW9M]>KN?%YMD
MM'"8Y8F#DG&27*XI*]]D[Z^JN>:?#N=Y/B7\/YR/FEUS32_'<W,6<5Z[^TI\
M)_AWXK^+VN:GXAMK,ZBP@$CO(R,^+>,+NP>?E"_E7COP[:23XE?#KY25_MS3
MF_ W49_K7;?M8^(HK'XXZ_;-?6MJZM;,5=<L5^RQ=2?KVK]MK145.*V4O\SZ
M)?&O0XF^_9M^#%^T:?:&@"?,T=O>, 3ZY(/'M6%>?LY_"UHS GB"]#_PNDHD
M8KGA2-O;UJ^NK2W=H;FTDL)YXCS&O&!T&1_6H9[RZG*A=*C\]5."9,@'ZUQ&
MIQU]\ _A3I"2237&O73(V!-NP1S_ '?Y57NO@_\ #0QQVL>EZC<7$I\Q;FYN
M3D <X ' KMDEO(UECN+6S679N_=R_=SV)K/^V2>8PDTHL\0YV.HW@C@B@#SF
MX_9\T#;#>6S7]LOF;A,[))QR,8'.!7$Z_P#"?5_"3FXLREUI[@QM-&/GY.<X
M;IQZ5]!6.IW,NEQ,]AY+9("^8 &';Z&J^H7!A@E,NGPP0H<()9\@D]>/6@#Y
M2F2&"ZVRH'*Y(6'YN,[>.^ZG-H<EO#<,S>3$&6-89QEXR2".O;\*]>\5>&="
MU*X@GM6^PN9"H:)"8P2.<XY ^E8UO\')=/62:\\2Z7-;S!O+.\LRYZ$<9P*
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MO=.T[6-/O]0LHH9[JTM;I))8(Y@S0NZ*2560*Q4D88*<9Q6K0 4444 %%%%
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M0+Z,$@+I,A"M][_70U]M:#_R"H/^!?\ H1KK?\!>I@OXK]#0HHHKD-PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _$[]NSXH:K\2OVD_%L5]-)]AT"\D
MT:PM2"J0QPL58@'N[AF)[Y'8"O ;:YFLKB*XMY7@GB<21RQL59&!R&!'((/>
MOT/_ &[/V$_%?B;X@:C\0_AYIW]M0:IMEU+2(7 N8[C 5I8U;[ZM@$@'<&+'
M&#Q\W?"_]A/XQ?$KQ!#8R^$K[PM8[\7&I:_ UK'"H."0K .Y] H.?4#D?M.7
MYA@E@H-345%*ZNM--=/ZN? 8K#8AXB2<6VV?I1\/_P!I1K7]B>Q^+WB4&>]L
M]$EEFC"%6O+N)V@1%']Z:9%48X)D&,"N;_99U#QK\*OB7=_"[XD^)-4\2ZUX
M@\.VGC"SOM5NWN1'=;4@U2RA=SD1QR^5(D8P LK$ <UU?C?]E]=>\(_"3X;V
M*Z=+\+_#>H0WOB"RU(M)-J:6T9:W@\O88Y(Y+@K)*'*C"  ,"5J/QU^R;H.C
M^(? OBSX0^%?"'@;Q7X<UR*[N)+/3H].CU#3G1XKRUD>"$D[HI"4RI =5/')
MK\=Q$H3K3E35HMNWI?0^ZI*4:<5/>RN8/A7]LGQ%KGPY\-?$B_\ AM;Z7\/]
M5UJ/1)[Q?$/FZA;R/>M9+.MK]F59(?.V DS+)@L1&0!NXJ;XY^,O#NA_M$:S
MXTTK^U]$T/QQINF6=KI/BV\M)[?S&TN)(8I([>-HX0)A,Q5AYC-+&RE6+MVV
ME_LM^*[']D7PY\+)-0T<^(--UZVU2:Y6:7[(T4>MB_8*WE;BWE#: 4 W\9Q\
MU4_B)^S!XZ\3:'\:?#NG3^'O[+\;>)]+\36&HW5_/'-"T$NFF:WE@6W90-ME
M*5D61MQ9 44$D8&I[[\8_!NI_$'X6^*/#VB:W?>&];OK&2/3]6TZYDMYK2Y
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MXI:AXP^.WB7PMI<=G-X3\.Z+9S7FH!&:674+IFDBBCD#[=BVR!V&TDF>,[E
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M;0?%'BW6O#/Q0\:>%/\ A*-4;6-0L=/BTB:#[2T4<19/M-A*ZC;$@QO(X]Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>advm-20231231_g3.jpg
<TEXT>
begin 644 advm-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &! JP# 2(  A$! Q$!_\0
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MD(Z[5)Q4ZZ?=?\^TW_?!K&2D:1C(C6GKVI/+=5)*L-IP>.A]*?&K.RJH+,>
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M/#:17^V%&>:/R(EV;F!*C#O]W!^8U\]W'C3Q#?:.FD7.NZG<:4BJBV,UY(T
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M:\ZI*4G>3NR[N3NV/7K3J1:>M<,C9'MO_# 7AG_H9=6_[YB_^)H_X8#\,?\
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M+_XFD_X8-\-?]#)JO_?,?_Q-?4./>C'O2^N5_P"8/[!RW_GTOQ/E_P#X8/\
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MDT<2R2P13B()/*BN,I'ENOR\&IY,3R*:3:?Z;_=U#^S<G4W3<$FN]UN>3?\
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M,4XV(89U*@M'\V-P^8UR>@_M=KJOAO7-0N?"K6>HV\5M)I>G?;]YU/S[AK=
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M^ABU3_OB/_"O4;CX^^"+;2(]1DU6Z\EYY[;R%TRZ:Y22%=TP> 1>8@0<L64
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M'\M?+H8PP>25%>*7S;73S/./^&&/#?\ T,6J?]\Q?_$TG_##/AS_ *&'5/\
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M^)\W?\,2^'?^A@U/_OF/_"E_X8F\/?\ 0PZG_P!\Q_X5](44O9P[%?V/@?\
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MDB9_+@7>S$X=CEFZEMW-9/\ PW1\-O\ J+?^ 8_^*H_X;H^&O_47_P# ,?\
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M[6W>] ;WKY#^!OQ4\4^*?'%UHGB+4A-)!;M+Y0MHT5^0-RE4!X]#Z]Z^9O\
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MD:2$8+ !0#^E=5/X)F%3XHG<4445RFX5EW&I2Q3.@"X4XZ5J5A7G_'S+_O4
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M:%WR ?,"2-&?KCXQ^#Y/'?A77M%MITM-0E"SV%U(,K;7D3K-;3$?[$T<;_\
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M4OC?)XI\%64EMXN6WDFFCOKR_P##F+6YLVFO4MKJ2&+3MT4PB6T>1#<P%68
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M^%+@9  &?I1[>/\ +^+*]F^_X']*G_"<Z!_S\Z7_ .!*?XT?\)SH'_/SI?\
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M"?<'3;Y;[3\YWYC9:T_"_P ,=OPG\.^&=3DETZZTM(7M9=/GS+I[Q-N@$<C
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M-KZ=EHON6A?LH=4>5C]FCP+J$US?:[IS^(]=NY3/=ZS>RF.YN'..3Y.Q5
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M S576/EW26)/&<1N.R9Q\WKYOYIZ'-JS%V%/VMH6;C'DJ0/?J35BB@"Q8_\
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M];'Q!X:\,V\B:1HVCZ8LR;2UM91*V.HSQSBMZX^/1TU8L7YN"4X:3;\F/[N
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M]*R/"GBJ36M8G@GMUVDF.)0/Y&OSQ<78B2DX4KJ/6_Y'N8# UL;0E7<5%)'
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M'#7/&.A:;=7^BM:WE_;V\H72U!V/(JM@YX.#7[/^%_\ CXE_W/ZU_-A\,_\
MDHWA7O\ \3:T_P#1R5_2?X5_UTG^X/YUT1E*5*7,S&45&<;'2T445Q'0%85Y
M_P ?,O\ O5NUA7G_ !\R_P"]0!#7R'^UMX7O?'WCR/P_X>TG5O$/B$Z8MT^F
MZU:Z9<>&%MPS+YTRW@\T,K%=S6I##*YY*U]>5\G_ ![^(VM?"SXW:AJ?@JQ;
M7-<U/2=+TO4+6YT%[R*)GN+E;&..X6XAV-*\DJE'.SY48M'SN /;O@3ILWA?
MX+^&+?4CHL4L-CYTK^'[N:ZT[#%I-T$LS,[1X;(R2 .!P!2V_P"T#\.[K3]'
MOE\6Z>EIK$Q@L)9F:,7# Q@E=P'RYFA&_P"[F5!G+#.;^SO9V<WP%T"UM&E=
M)(+B.X2\M%@,=R9Y1<1&%)&"*DQD0(LC *H <@!CYS9_L=ZE:S!QX[CCAE$E
MI-I\6DR-:6]@SZ>_V:R66Z=[?!T\')>1,SR'RQA< 'NWQ*_Y)SXJ_P"P5=?^
MB6J+X5_\DP\(?]@>S_\ 1"5G?&WPO8>*_A?XBM]1%R8H+&XN4^RWDULV]87
MRT3J6')^4DJ>XXK0^%?'PO\ !X_Z@]G_ .B$H ZFBBB@ HHHH **** "BBB@
M HHHIK<3V,GPIY__  C]H+K[<9P&#'5/*^T?>.-_E?)TZ8[8SSFM:N?\ M;-
MX1T\V;6+6^'V'369K?[[9V%N<9S^.:Z"M:RM4DB*?P)^2"BBBL30**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH L6/_ !])]?Z5M5BV/_'TGU_I6W0!Y!\7
MKR?3_A_XVNK6>2VNH=,OI8IH7*/&ZQ.596'(((!!%?(NC_MA>+=)L]6TM9=!
MU*WT70K*:UU:[MKQFNIG6R2Z:60N$D^P">2>YV.2R/'_ *DK(:^W=6N%M)+V
M=@YCC:1V6.-I&(!).%4$L?8 D]J\1\9?M=> ?"_@_6=6MY]2OM4L8;TIH4VC
M7]M>&6VMTGD6:)[?S+>,)- 6GE01JLJL3@U[/V5K8\];VM<Q]$^/'C;7OA?K
M&KZ+X<M_&%[8S:@+7Q+HJ0KHNHQVOSAXXWO#-^^ >%#&9E$JY9@N<<!'^V'X
M[U+Q?X-AT[PYHYT3Q.5U#2X[V:&TN-0TZ6^E@B$;7%Y$?M MXTN"D4,Y;[1&
MA6/[[>HV'[9OPMELXY+[6+ZPN%ADEN4_L34)88#"56Y_?BW\MTA9U#R [5!#
M,0"#5S2?VKO =Y);6-UJR1:Q/((A':V5_-9QN\TT4"R71M52-I&@D50X4EE8
M+OP"7=/[0_\ MTB_9E^-6J_&32+^YU:_\/W=U';6=U)::'!<QOI4LZ.TEA=&
M0NC7$+)M;:X;GYXHLIO]KKPO4OVOO!^G_#/5_%$45_K5WI&@P:W>6NBZ9?SV
MB>=;17$<0O'MD0%DGB;]X$<(V]D4!@.C'[2?@=K/5+F-_$5Q#I+QQZ@;?PIJ
MTIM'>(3;)0EJ2CK&RLZGE-R[PN1FXR25FR&GV/4:*\(L_P!L'P7?>(M1M#.-
M-TC3]1:SFUC5([JW@GB&EMJ!FMV^SM&^$0Y5I$^0!P3OB636U7]K7X7:':K-
M?ZWJ-HVVXDEM9?#^HBYMD@2&29YX/L_F0(L=S ^Z154I(&!*\U7/'N+E?8]A
MHID,R7$221NLD;@,KJ<A@>A!]*?5DD5X=MI,?]AOY5\D76H64NHQ./*295Y
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M@/<?^#.[_P#CM'_#//@+_H#W'_@SN_\ X[0!Z/17G'_#//@+_H#W'_@SN_\
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M>;PPS@CUJ?\ X9Y\!?\ 0'N/_!G=_P#QV@#T>BO./^&>? 7_ $![C_P9W?\
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M?W'QG8?\$Y_B-I^W9\2-#(';^S9O_CE;?_#!?Q'DN4EE^(.BOLC\L#[!-_\
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MJOB"UETQ[NZU&2:Z>WAO'$T;^7:1W3 ^0CJTA(0",?-F_$!OC#X]\3?$_1/
MH\12IIGB34TCU.VUV*UAA$GAE$MK1 UPL@Q=S0RC"[%=P^00Q&>EDW$O79,[
M+1_V)WL]:\-WFH>+8=5M=(@M;5K0V=];)*EK>3W5JX6'4$C,J23G+2I*A**5
MC3+;NBL?V6;[1['X4VVE>,?[*E\%6-GIUSJ-E:W4%UJ4$$D;O"?+O%A$4OED
M,DT4^-[%2"<UC_#'X5_$?PC\6(-1O-0\27/AZ/6KR#9JGB::^A.EG3H6A8Q2
MSOEOMIGPQ7S  !D1[17TQ6D8)K:Q,I/N8OC:0P^#-?<=5T^X(S[1M7Q%X.FN
M[ZW-WYRI'Y@783D=3U_SWK[;\=H\G@CQ$D:&21M.N J 9W'RFP,5\,>#;?6]
M,M5@?1[QACY_]'=1CTZ<\5\_GM&K7PKIT5=NWYG)B*+Q&&G32O>VFW4[CQQX
M/O/%WV"\MG6&>WC&58[?.(Z$?AZUSWBS0?$7]EPRS&%8XVS+#& -_N??WK5T
MGQ!X@CNIEAT:]F2-0RM-%)Q[ XINJ:YXA\30F!]!N[2U8?-)Y39'URM?F,,H
MS>-2*5-<B[O8^QR7,I8>C3I8JWN:)M7:7J<OH_CNXU#4K6R$LTBIDOA^!@<=
M:]G^+7A>V\>?LFWNE267]L07,ZGR&E$)DQ/G@Y&#Z5XOIO@[4K6<SV.FW"*V
M5\Z2%R 2.3C'->K?$Z:_TW]CN\;3]-N;F\CN !:B!FD/[\Y.W&?>OT?*<,\+
M1E3<>7?].QKGV*PV*Q$*F'=U97Z:W/AFZ_8YT-IB\WAWQ-IR'HL;AX_P;:?Y
MUTGA_P#8G\./&SMX8UJZC/ DOK@H,^V *I:7\2OB%:LD']A:]!;1<QB.UG&T
MGC^[Z5UUU\2O%K>&X+==!U[[0\HR[VL[<=\9'%=MI'A7.!\9?L6Z.MO+Y.BZ
M[H$BDA)HP;F)\>W_ ->O%H?V4_$,VJ>1_:NGPV6X@74XD0X'^QMSFOIO2?&O
MC+3-0O&73/$,D,B@",V\P&?7I7;77Q:\7Z;"N[2M5O4V#;;MI>Y0WKS&>?>B
MTAW/G70_V3_!VBVJ3Z]K5]JTAX*6JB&//ZD_I71Z?\"?A%?0L]MX>UFZ2$'S
M6%U(W3OPG>O8)?C!XQQYW]B:ET V-IC%1[@;.#]*SX?C%XUTJ-&L]'UR)CNS
MY=G*HQ] N*5I"N</I/P#^'YFC>S^&FIZ@Q(95DDNF]/0"OV*\*_ZZ3_<'\Z_
M*2_^./Q&OF2(:;KRP-MW*UI,<GN>E?JWX5_UTG^X/YUU4_X4OD93^.)TU%%%
M<AN%%%% !1110 45\G?$3X&^);_XB>*/$^G^&]3N=$DU6P@?P]IVMK!+K=F%
MDGN[C<]PJ(6N9H%$;-&=EDV!B3!;^S/\)OBIX+\;Z'<^.8M2N+NUT62UU?7K
MC7!=6VHN;73$@CCA\PMNCD@O,L\:C+.P9O.:@#ZSHKSGQKXL\1^%OB9X!LX;
MC2Y_#/B34I=(FLY+&07D,JZ?>W@F6X$VPK_HBIY9AS\Q._H*]&H **** $Z4
M45D^(_$^C^$-+EU/7=5LM%TZ(@27FH7"6\*$G R[D 9/O0DY.R$W;<UZ*I:;
MJ5KK%A;WUA=0WME<1K+#<6\@DCD0C(96!P01T(JY1MHQBT4E1R2)#&SNP15&
M2S'  ]30 _L:2J>EZM9:U9K<Z?>6][:L2%FMY%D0D'! 921P>*\E^.'[6/P\
M_9\UC2-+\6:C<17^HJ)$M[.V,S10EBOG/C&$RK#C).#@'%:TZ-2K/DA%N79&
M<ZD*<>:3LCTGP>K+HOSK*C&ZN>)KTW9QY[XQ)GICHO\  /E_AK>_2N3^&>J:
M?K7@VRU'2;BWN]-O'FN+:XM+)K6*6-YG975#UR#G?T?[XX:NLI54U4DGW"GK
M!>@ZO#]+_9)\'Z7J.FW;:EK]XVGIJ%O;PS7RK%]GOIKB:]@9$159)6N!G<"P
M^SP%64H2?<**S-#Q+1/V2O 6GZ/J-KKMM)XWU*\M9+ :YXCMK2:_MK5[1;,P
MP/'!&L2^0H0[5W/DERY-9 _8C^&\GB+X?:S<I?W]]X-L+>PMY+T6TTE\(7ED
MCEN)6A,HD\Z:65FA>(.[_.& "CZ$HH \^^$/PAL_@SX=&B:?X@U[6].ACAMK
M&'6KI)5T^UAC$<-M L<:*$15^\P:1NKN^!CT&BB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** .4O8[(7DPD:;?O).U1C.?K4.W3_[\_P"2_P"-9OC)M4CM-6;1
M8K2?5PC_ &2._D:.W,N/E\QD5F"YQG )Q7A'A?Q=\0/%7[*MKXIL=:MY?'=M
M%+?F9[2*.WOS;W+E[9TP1&DL<9BW*=R;@P;(R?8C'1:O8X'OL?1.W3_[\_Y+
M_C1MT_\ OS_DO^-?(7@?]J_Q/'J.BVVM>&KS61X@@M/$,\]O%-Y'A[3;^29;
M*-Y(;5XBD,<'F3S7$L6-TA3S A1-OX?_ +7&L?$+Q1IGAVR\$V4>I76IO:23
M2ZK=P6RVJV<%W]H3[1I\4SEDF8*IA56*J1(5?<!-/[3"S['U%MT_^_/^2_XT
M;=/_ +\_Y+_C5*BM>3S9GS>1=VZ?_?G_ "7_ !HVZ?\ WY_R7_&J5%')YL.;
MR+NW3_[\_P"2_P"-&W3_ ._/^2_XU2HHY/-AS>1=VZ?_ 'Y_R7_&C;8?WY_R
M7_&LVZ)%K,5.#L."/I7@,>K:I&JR3:_J"N-JG%Y*0_T&>H_6N6O4CAUS3EH:
M*UG)V21](;=/_OS_ )+_ (T;=/\ [\_Y+_C7S5X@\1ZK'>*NF:AK%X'4%C'=
MR@1YZ\ \C\*AM[;Q2UG/,_B'7(;B0@1HUS)L7CK@DX'XYKR_[7P76JOO1<(J
MI\#3]#Z;VZ?_ 'Y_R7_&C;I_]^?\E_QKX,^(O_"R]%W75MXJUP#)YAU>?RW'
MTW<?45M>&_'7B2;]B_XM:X_B35Y=;LK*^:WU"2_E:YMG6 $>7)NW(0>1M/N*
M[,/BZ.)7-2GS+NFF5*FX;H^V=MA_?G_)?\:-MA_?G_)?\:_G=_X:?^,G_16O
M'6/^QDO/_CM'_#3WQE_Z*UXY_P#"DO/_ ([5_6%YC]D_(_HBVZ?_ 'Y_R7_&
MC;I_]^?\E_QK^=W_ (:@^,?_ $5KQT/^YDO/_CM3V_[3WQB:&Y)^+'CDE4!'
M_%1WG]X?]-*3Q"7<3IM']#>VP_OS_DO^-&VP_OS_ )+_ (U_.[_PU!\9/^BL
M^.?_  I+S_X[2?\ #47QC_Z*UXZ_\*2\_P#CM/ZPO,?LGY']$>W3_P"_/^2_
MXUI:']F6Z<0-(6*9/F  8R/2OYRO^&G_ (Q_]%9\<_\ A27G_P <K]O/V!?$
M&J^+/V:_ 6K:WJ=YK&J7.FR//?7\[SSRMY[#+NY+,< #D]J'-3C+<.1Q:/IB
MBBBN$Z0HHHH **IZC>'3]/NKH02W1@B:7R;==TDFT$[4&>6., >IKP?_ (:F
MU6'Q7%HMS\,]0M[J5OETS_A)-%?5MF"=WV(7FXD %BJLS8!P">* .MU+]I+P
MCI]YJUK&NIZC/I^HKHX33[)IFNKTLRM!"HY=E*2;C@*/*D^8[&P_X=_M'^"/
MBIKUGIGAN]O+T7MD;ZSOFL98[6Y18K:5U21E +JEY;DKQ]\CDHX7DI/V//"$
M_BR]\6:?K'B#0-<NKZ75;6XL#:(^GW$\S33LFZW;>9'D?(G\T*'8)M%;WPK_
M &8?"OP?UO3K[0=0UI[+2[)K'3M)O+F.2ULU>&UBD=,1B1F=;*$G>[*"7*A=
MQH T_B]_R4#X(_\ 8X7'_I@U>O4*\9^+WAG2O^%S?!'Q#]@@_MO_ (26XL?M
MVW][Y']A:N_EY_N[N:]FH **** &U\E_\%!/A/>?&SP]X!\*:+J7V?Q)>ZTR
MV5G*2+>6,0.TTTI )58E4'< ?O[<$L,?69/KQ7CGPOC_ .%D?$KQ'\2)QYFF
MVOF>'?#O<?9XI/\ 2[E>/^6LZ[01U2W0]Z[<'4EAY_6(_9_-[?UV.:O%58^R
M?4\;\%^.KK]@#X/Z7X9^)6GSZMH=NSC3==\/D3QRSR%I7M'BD*-$P)D96Y5U
M!)*-\M1_%;]K+4/C=\!M1?X#6'B:_P#%%PH^U-::8XFTN%6S(ID&4\]E&%6)
MG?#9&#@U]$?&[X'^%_V@/ \GA?Q5%<-9&9;F&XLY1'-;S*"!(C$$9VLR_,",
M,>*E^"_P5\-? 7P/!X5\*P31:?'*T\DMR^^:>5L!I)&  +851P ,*.*[?K6&
M:6(G&];FNU]E^J_0YO8UD_9QE:%K>:/C/P%JG[62?LH^(S]@NIM665OL5UJT
MLP\1"WRGF"&)HSYG\95G<2<ML!_=U?\ @[\.OVC?C9^S9XH\+^+O$LGAN._,
MD-I)XFL+AM4N$PK&-Y3(K1P,PV[F21BKO@$ "OOSBD-.6:.TN2E&+<N:]MOO
M!8)77--M)6M<^*OV2?V'_%7PMT'7+?QIXSU6PBO;F.2+2?"NL36T)"JP9Y70
M*VYL@80CA>23C:[]JS]BOX=7N@Z/XF3^VK2]M=6TW3[N9M5FNWN;6YOX()-S
MW+2-N19F*D$ $G((QC[3KR7]JEA#\!/%5R>EBMO?G_MA<Q39^GR4J688FKBU
M5YK.35[:+ML$\+2IT'"UTD]S?^&_@?2]!\(66FV5O=V5E9/+;6UN=6EN!'%'
M)LC57#\*%BC 3^ #;UW9Z1O#-FT;1DW6&4J?],FY!4K_ '^N&//K@]0,5/ L
M<<>@XB\K;]KNB?(L&LESY\F?W3<YSU?^,Y8<-71UY5:[J2;[G;2^"/HC);P[
M9R%BWVG+$D_Z5,!R7)XW>LC\>F!T5<*/#]IN#YNLJP;_ (^YL<,K=-WJ@X^H
MZ,<Z]%9&ICIX;L8XU -T H4#-[,>BHH_CYXC7ZG)ZL26MX9L71D/VK# J?\
M39@<%67KO]'/Z'JHQM44 9$GAVSD9CFYRS$G%W,.27)Z-QS(WX8'0#"CP[9K
M(&Q<Y5@PS=RD9#(PXW>J+_X\.C-G6HH QH_#=E'$J@W6U0%'^FS$X"JHYW\\
M(OU.3U))'\-V3QLI^U892I_TR8<%74_Q\<.WT^4]57&S10!DMX=LV8M_I/S$
ML?\ 2Y<9)8GC=ZNWZ#H!@_X1^SWA@UUN5@PS>3$9!0C(W\\QK_X\/XFSK44
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M_P (U9>7L_TH+MV_\?LV<;=O7?Z?X]:5O#=DVXDW7S9S_IDW?S,_Q\?ZU_\
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MQ#.Q&?\ C]MX01ZX,1K]2OV.]#T?PU\%?"6F>'S.VCV]BR6YN91))M\TGE@
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MK?,(\^/,W,8WC,G&?E]>.>*.5KH',GL6:***1044E+0 4444 %%%% !1110
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MK !]/NU#:?&2?4;CR[32)95V%O,:YVCC_@.?QKYRM;B?4KI8[H-- !^[61B
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M(++0_%=\T-O+X?*1;%5$ #11PO\ O8S"2YR%8Y4.?J7;^5&#0L747;I^&WW
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M[2.YL_"WB6UB^VZRQ5F !29L+(R^2GE%F#ABP;A*Z]?BE\2KJ,-;_!F_A)'
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M_?>F?_(5 'I]+7E__"F-:_Z*YX\_[[TS_P"0J/\ A3&M?]%<\>?]]Z9_\A4
M>H45\S_'?1_&?PD\"3^(M(\;>-O$JVN^2[6ZU;2=/B@A6-WW%SI\CN[LJ11Q
MQQL6DE0':,L.[TSX3ZWJ6G6EV?BI\0K0SQ+)]GN?[,66/< =K@61PPS@C/44
M >NT5Y?_ ,*8UK_HKGCS_OO3/_D*C_A3&M?]%<\>?]]Z9_\ (5 'J%%>7_\
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M\8^(+6TU+P_;:;$FAV^F ^2EH]VXCDG%RZR.6NV_>* H"+A<Y)^P_P"THO\
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M%?$7CY[R+1;/0-:NH[JPM;&2&ZO/,\VX>62XNDL;623(EC"K-Y[KL;]\<U]
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M8RJ-CP?=7.2"S>_6QF:",SHD<Q4&1(W+JK8Y 8@9&>^!GT% %BBBB@ HHHH
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>advm-20231231_g4.jpg
<TEXT>
begin 644 advm-20231231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /!!J@# 2(  A$! Q$!_\0
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M*D84445+&%*O6DI5I"!J%H:A:EB%HHHJ&4%%%% !1114 %%%% #EI:1>E+4
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M[25CTWPW.I3E/"UX5&NB9\$T4Z6)X)7CD1HY$)5D88*D<$$=C3:Z3XX****
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M/#5949[H*<M-KZ4_8[^%^F^*9]=U[6],M=3L;<+96\-Y"DT9D.'=MK C*@(
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MZFJ^&-*OM2DM$GN)KZPBEEWR?.59F4GY=VT>@ J(QYCCR[+:F8U)0B[674^
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M0J*/T45SGC3X'_!CQ%XNUG4]9^)+0:K=7<LMS"VNV2F*0L<Q[60LH7[H4]
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MES<'IN>)XUC'J3N)^BGVKTC]O/Q-:?9/"_A]&C>]\R2^D4$;HTQL7/H&)?\
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MYTD6)!-"H;*,IZ.W&<<U?_:U^&?AKX8^)M"M/#6F_P!FV]S9M+*GGRR[F#D
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MTMI;;6Z^]GAO[6/@GP-\-]4T70_"VCK8:C)$UW>2_:9Y2(R=L:_.[#DAR>_
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M*#<9N%QXZC0QV!HYE&FH2<DFEL];?I^AUO[17[/O@'P)\(]8UK0]!^PZG;O
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M%SH-WL4>X5&*9^JU\Y_'[]EZ;X2Z8->TC4)-4T+S%BE6X4">W+<*21PRD\9
M&"1QWHIM<VC8LXH8F6#E*I0A)+52AI9>G7SUL>V?L,_\DEU;_L-S?^B+>O.=
M%\.^$O&7[5GC+0/%NF+J$5]<3?8V-Q-$4F0!L?NW7(*!^O=1CK7HW[#/_))=
M6_[#<W_HBWKYM^+VO77A?]HG7]8LFVW=CK'VF+.<;E((!]CC!]C32O4DD88F
MK"AE>!J5(J44U=-7NK.YV7[67P1T?X8W&AZGX:L&L=(O%>WGB\YY0LRG<IR[
M%OF4GCI^[]ZROV4_A'I?Q2\7:JVO6?V[1=.M09(?.>,F9VQ'RA!QA9#U["OI
M_P"-6BVGQE^ -W>Z<GVAGLX]7L,)N?<J[]H'7<4+IZ_-6/\ LJ^'8/A[\#CK
MFI'[+]O,NJW$DI $<"KA#GTV)OY_OFI]H_9^9O+)Z+SF,XQ7L7'GV]WM;MO9
MGS?^U)X7\'>!O'%IX?\ "6EKI[6ML)+YENI9BTC\JA#LVW" -QC/F>PKQBMS
MQQXJN/&_C#6->NBWFW]R\^UCG8I/RI]%7"_A6'77%-))GP6-JPKXF=2E%1BW
MHDK*W30*^L/V"?\ C]\:_P#7.S_G-7R?7UA^P3_Q^^-?^N=G_.:LZWP,];AW
M_D:4?G_Z2SDOVWO^2OV7_8(A_P#1LU4OV3?AIX;^)GB;7+3Q+IO]I6]M9K+$
MGGRQ;6+@$Y1E)X]:N_MO?\E?LO\ L$0_^C9JVOV$?^1S\3?]@]/_ $8*SO:E
MH>DJ<*O$+A4BFG)Z/5;'L]O^S[\*OASJUWKVI66EVFG2(D$,&M7&^UB/.YOW
M[$%V.!R> HQC)SX+\1OA_P"'_BU\?K/PQ\/[;3;#3DM$>]O]-4&WQC>\BA#L
M("LBC;C+'!/IH?MUZU/-XZ\/:021;6^F_:U&>"\DKJ>/I$/SJU^P?:0OXF\5
MW+1J;B.SAC23'*JSL6 ]B47_ +Y%0KQCSMGHXF6'Q6/64TZ,8PYM6EJ[*[7E
MV/7+[P+\%_@7H-I%X@L-(7S!A9M6MA>W-P1@,P7:S=QG:H SVK)\??LY> _B
MUX..L>!X[#3[]HV>SNM,(6UG*Y'ENB_*.<@D ,".<XQ5_P"-WPO^&GCKQ;!>
M>,?&IT/4H;1(4L_[5M;<"/<Q#;)5+<DGGH<5J?"JZ^%_PA\/W&CZ/\0=,N[2
M:Y:Y)U#6K5V5BJJ0NW: /E!Z=2:SN[73=SW94*4ZT\-6I4U1M9:KF1\/_#OX
M=W_C[X@Z?X50-:7,T[1W#2*<P(F3(2/4!3P>IP.]?:FI^!_@M\#=#LHO$&G:
M2BRY5)M5M?MMS<,,;FQM9NXSM4*,]J^7/%WA.Z\??M$ZYI_@6XBNWO+Y[F&]
ML[C]R@90\DGF(2 H+-R/H.2!7M&H_LM:3:Z?;WOQ-^)U[.(ALB>>Z6%(AW1'
MG+YY] /I6TVG:[/ELIHU*$:WL:"G)-KGDURJWK^C['HTWP=^%'QB\)?:]%TK
M3([6X#"'4=&A6V>-P,=% Y']UQ]17S%\!?!7A6U^-.M:%XXGL_(TI9HH)+J[
M-JC7<5S&B[2'7)(WX7)SSQQ7U[\$M)\$:'X5N[/P%=+>Z4EZWVB9)FF#7'EQ
M[OF/!^7R_N\?CFOA7QM_R<!K_P#V,]Q_Z5M4T[N\;G?G$:5!87%NG!ROK;X7
M_F?H3\0M+\-ZUX/O[/Q<]O'X>D\O[4UW<FVB&)%*9D#+M^<)W&3@=Z^*?$WP
M>T+QS\>H_"OP]GLTT)[>.:2[M;HW<4*!<ROO+L2<D#&>I XKZ=_:P_Y(#XI_
M[=?_ $KAKQ']@^TA?Q-XKN6C4W$=G#&DF.55G8L![$HO_?(J*=XP<D=V<1IX
MS,J& G!>]9N76RYO=OVT/7+[P+\%_@7H-I%X@L-(7S!A9M6MA>W-P1@,P7:S
M=QG:H SVK*\??LY^!/BUX..L>!X[#3[]HV>SNM,(6UG*Y'ENB_*.<@D ,".<
MXQ5[XW?"_P"&GCKQ;!>>,?&IT/4H;1(4L_[5M;<"/<Q#;)5+<DGGH<5J?"JZ
M^%_PA\/SZ/H_Q TR[M)KAKDF_P!:M796*JI"[=H ^4'IU)I7:5TW<[94*4ZT
M\-6I4U1M9:KF1\'^'?".I>)O%EEX<MH2FIW5R+41R@CRVSAMW<!>2?3!K[LT
MCX(_"_X.^$3<Z[8:9=QPJ/M.J:Y$DQD<\?*K A<GHJC/U/->,?#6'1;W]L[4
M+C3KJVO+%IKN[M9K:97CDD>$LQ4@D-R[]/3VK?\ V\[ZYCT_P99K(PLYI;N6
M2/'#.@B"$^X#O^9K6;<I*)\WE]&CE^"Q&-E!3E"7*KZK=*_X_<>G_"_P[\,-
M?\4#QAX ELXKB"![6YM[!#"A5R""\+ %#E>#@9YZ\8\A_;T_X_?!?_7.\_G#
M7(?L3W4T/Q<N84D989M,F\Q ?E;#QD$CV/\ ,UU_[>G_ !^^"_\ KG>?SAJ$
MN6I8ZJ^*CC,@JU5!1;:NEM?FCJ?*%>W?L<_\ENL?^O.X_P#0*\1KV[]CG_DM
MUC_UYW'_ *!6\_A9\7E/^_T/\2_,];_;N_Y%GPK_ -?DW_H KYU^"?@W7_$_
MQ$\.RZ187,L=OJ$,TMW&C".%4=69F?H, ?4]!UK[O^+7QFT7X-V.GW>M6M_=
M1WLC11BPC1R"H!.=SKQSVS7E]Q^W-X*6,F#1=>D?^[)# @_,2G^580E+ELD?
M<9I@\#/,77Q&)Y6K>[;71+K?KZ':_M3W]M8_ OQ*+E5D\]888HV.,R&9""/<
M8W?\!KP#]E;]GO3/'UG/XH\30-=:9%-Y-G9;BJ3NN"SOCDJ"0 ,X)!SP,'SW
MXW?'W5_C->01S0+IFBVKE[>PC<N=Q&-[MQN;&0.  "?4D]-^S_\  _QOXZTY
M]6TOQ+=>$-$:1E2ZMY9 \SC )1$9<@8P6+#D8YP<-1<8:NQP5L;2S3-HSI47
M5C%62VOYN_37J?0RZE\!5\3?\(N-/\*_VMYOV?R3I2$>9G&SSO+V[L\8W9SQ
M7F?[5G[/OAWPSX5;Q=X;LUTIX)T2\M(2?)='.T,J_P )#%1@8!!/?KJ:?\!_
M@W\/M<@;7?&+:AJT,BD6<U_&K>9N&#Y48\S.>Q->A_M;?\D'\0?]=+7_ -*(
MZA.TE9GMUJ/UG XAXJG!2BFUR[JR>_W?,R_V3=#\'6'@6TO=$DLV\275HG]K
M+#>F652';;OCWGR^_89IW[1WA7X:ZEI>NZEXAFTU/&$&BS'3TN-4:&<E4D:'
M;") '^?./E.3QSTKR_\ 8/\ ^0YXO_Z][?\ ]">N9_;<_P"2O67_ &"(?_1L
MU/E_>6N<KQD(Y#"JZ46MK6TZJ_KU]3N/V9?@3X&^(7PQCU;Q!H?V_4#>31&;
M[7/'\JXP,(X'?TKP6^^'+^(/C?JO@SP_"L"MK-U96R.Q988HY7Y)))(5%)Y)
M)V]S7UO^QG_R1:+_ *_[C_V6O-/@+#'+^UUX^9T#-'-JCH3_  G[6HR/P)'X
MU2DTY'%5P%"MAL#!12<VKM))O3N>H6_PF^$GP+\)PS^);73+G.%DO]9@%Q)/
M)CD)&0WO\J#IUSUJOKGP/^%_QN\(O?\ A*/3["8AEM]0T>,1+')@';+$ !Z9
M5@& /&,UJ_'CX>?#_P >7^D?\)IXM_X1^:UBD^S0?VC;VV]6(W-B523RH&1Z
M55^$EG\*_@W;ZE!HOQ$L+N&_:-WCU#6[1PC*&&4"!<$AN<Y^ZOI65W:]]3Z*
M5"DJ[PLZ5-4+6W7-M_G\^MSXJTWPK)I_Q(LO#NLV^'CU6.QNX<D9_>A& (P<
M$9P1ZYK[0\3_ +)?PWFL8GMM/.AQ0S":ZNA>S,?)4$LO[QV5<\98C@9KY]^+
MUYI.I_M0V>H:-J-KJ=G=W^GR^=9S++'O'EJP#*2/X<GW-?3'[5MU-:_ GQ$8
M96B+FWC8H<$J9XP1]".#Z@D5<F[JQ\_E>%PU&EC'5@IJFW:]ME?KTO;H4O F
ME_ [Q5--H'AW3/#NJ7-HF&1[(22LHP"PDD7=(.F6#'KUKYV_:K^"^F?"[7=,
MU#08W@TC51(#:DEE@E3!(5CSM8," >FUNW Y[]EN1H_CQX6*L5R\ZGW!MY>*
M]Z_;JA5O!/AN8_?74&0?0Q$G_P!!%/6,TKCJ3I9GD]7$2I1C*#LK*W;]'8]B
M^$.A^#- \+/!X'DLY=+>X,LYLKTW:?:"B!@6+M@[0GRY]..:\&_:F\*_#.V\
M/Z_JNGSZ:?'+W<9FCCU1GN-Q<!\P>80..OR\5U/[#O\ R2?5O^PW-_Z(MZ^7
MOV@/^2T>,/\ K_?^E3%>^]3JS/&0_LBE/V4??T2M\.CU7F?5'@']G_P!\*O
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M ZT4J]:X&!]Z_LX_\D9\.?[DO_HYZ^+_ (C?\E"\3?\ 82N?_1K5]H?LX_\
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M*RA@_8XAU:;M%]"L1G*QF6QPF(3E4B[J5_/KUV=C'K]#?V-_^2#Z3_U\W/\
MZ-:OSRKHM&^(WBSP[8)8Z3XHUG2[)"66VL]0FAC4DY)"JP R:K&8=XFFH)VU
M.7)<RAE>)=><>9--:>J_R+OQB_Y*[XX_[#E]_P"E#UR%37EY<:C>3W=W/)=7
M4\C2RSS.7>1V.69F/)))))/7-0UTQCRQ2['CU)^TJ2FNK;'5^E_[2/\ R0WQ
MA_UY_P#LZU^:-=+J7Q.\8ZS8S66H>+-<OK.9=LMO<ZE-)&X]&5F((^M<.(P[
MKSA).W*_\CV\KS2&7T<12E%OVBMZ:/\ S-[]GK_DMG@W_L(1_P!:^J/V[/\
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MVN#L!/[OS4RWT .?H":\Q_9/L?A?XW\*QZ5J/A[2)?%UF6\]+Z(2-=)N)61
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MFC6/6->U/5HU.Y4OKR28 ^H#,>:QJJG"4=9.YCF&.PN)C&GA:"IQCUZOU?\
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MNLBZ-KFI:0LARXL;N2$,?4[2,U4X<UFMSSLMS:.#IU,/7I\].>ZVU/N[X-_
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M<6W-WO\ =_D?6O["^L6LG@GQ!I8G7[;%J'VEH,\^6\2*& ^J$?@*Y_\ :2^
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M[4,,'REZ'\3EOQKU<3'ZK@%1G\4O^'/>Q$?J>7QH3^*3_6YS?AO_ )&+2_\
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M7=1Q-[*6&X_@,U]W^+/%VD> =#&H:K*;:Q5UA78A<Y/0 #V!_*OEO]E?P_\
MVK\1GOW7,6FVSR@XXWM\B_H6/X5V7[7OB#;#H.B(WWB]Y*N?3Y$_F]<>7S>#
MP%3%+=O3\OS;.? R^JX.=?J]CNO^&EO '_00G_\  .3_  H_X:5\ _\ 00G_
M / .3_"OC&G=JX?[?Q7:/W/_ #,?[6K]E_7S/T%\.^(M)\?^'!?:=+]JTZZ#
MQ'<I4GJK @\BO@_Q)H\GA[Q!J6F2@[[.XD@.>^UB,U]%_LC^(/M&AZUHKOEK
M:9;F-3_=<8;'XJ/SKSO]IKP__8WQ,FNE3;%J,"7 /;<!L;]5S^-;YI+Z[@*6
M+ZK?]?Q1TXR7UC"TZ_7K_7J>3_PTZF_PBG5\4SPAU%'>BLF4CQ*BBBO[J9^2
MA3EIM.7I63 6BBBL6,*?3*?6+ 2EI.]+6,@ZBK24H^[25DRAPZ4445DP"E'6
MDI5ZUBP'4445BP"BBBLV 444#K2*0^BBBH)"BBBI ****EC"BBBD4%%%%0 J
MT-0M#4F2P6EI%I:EC04445(PHHHJ6 4444@"G+3:<O2DP%HHHK-@(U-IS4V@
M!5ZTZFK3JD HHHJ "BBBD 4445 !1114@%*M)3EI,!:***D HHHH **** "B
MBB@ HHHH*04445(!1110 4444 %%%% !1110 4444F-!3EZ4VG#I4C85I>'/
M$>H^$=;M=7TBY-GJ-JQ:&=55BA((/# @\$]16;10$9.#4HNS1Z9KG[2?Q*\1
M:?+97OBJX^SRKM=;>"&W8@]1NC13^M>9T44DDMD=%7$5L0^:M-R?FV_S"BBB
MF8!1110 4445 !1110 4444 %%%% !1110 4444 **=35ZTZ@I!11128F%%%
M%(04444 %%%% !11106%%%% !1110 4444 %/IE/J6 4444AH****!A1110
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MQM]""*]YO8[:X8SV9V@\M W5#[>HKF=>\+6FN*78>3<=I5'7ZCO7UW#W$_\
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M'_H+^)/_  )M_P#XQ6;S7#=W]P_]5<R[+[SX3HK[M_X81\ _]!?Q)_X$V_\
M\8H_X81\ _\ 07\2?^!-O_\ &*S_ +4P_=_<'^JN9=E]Y\)45]V_\,(^ ?\
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M %5S+LOO/A>BONC_ (86\!_]!?Q'_P"!-O\ _&*/^&%O ?\ T%_$?_@3;_\
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MO$7_ ($V_P#\8H_X88\!_P#06\1?^!-O_P#&*/K$"O\ 5;,>R^\^&:*^YO\
MAACP'_T%O$7_ ($V_P#\8H_X88\!_P#06\1?^!-O_P#&*GZQ /\ 5?,>R^\^
M&:*^YO\ AACP'_T%O$7_ ($V_P#\8H_X88\!_P#06\1?^!-O_P#&*/K$ _U7
MS'LOO/AFBON;_AACP'_T%O$7_@3;_P#QBC_AACP'_P!!;Q%_X$V__P 8H^L0
M#_5?,>R^\^&:*^YO^&&/ ?\ T%O$7_@3;_\ QBC_ (88\!_]!;Q%_P"!-O\
M_&*/K$ _U7S'LOO/AFBON;_AACP'_P!!;Q%_X$V__P 8H_X88\!_]!;Q%_X$
MV_\ \8H^L0#_ %7S'LOO/AFBON;_ (88\!_]!;Q%_P"!-O\ _&*/^&&/ ?\
MT%O$7_@3;_\ QBE[> _]5\Q[+[SX9IU?<G_##/@/_H+>(O\ P)@_^,4O_##/
M@/\ Z"WB+_P)@_\ C%'MX!_JOF/9?>?#5%?<O_##/@/_ *"WB+_P)@_^,4?\
M,,^ _P#H+>(O_ F#_P",4>W@+_5?,>R^\^&J*^Y?^&&? ?\ T%O$7_@3!_\
M&*/^&&? ?_06\1?^!,'_ ,8H]O K_5?,>R^\^&J*^Y?^&&? ?_06\1?^!,'_
M ,8H_P"&&? ?_06\1?\ @3!_\8H]O /]5\Q[+[SX:HK[E_X89\!_]!;Q%_X$
MP?\ QBC_ (89\!_]!;Q%_P"!,'_QBE[: ?ZKYCV7WGPU17W+_P ,,^ _^@MX
MB_\  F#_ .,4?\,,^ _^@MXB_P# F#_XQ2]M /\ 5?,>R^\^&J*^Y?\ AAGP
M'_T%O$7_ ($P?_&*/^&&? ?_ $%O$7_@3!_\8H]M /\ 5?,>R^\^&J*^Y?\
MAAGP'_T%O$7_ ($P?_&*/^&&? ?_ $%O$7_@3!_\8H]M /\ 5?,>R^\^&J*^
MY?\ AAGP'_T%O$7_ ($P?_&*/^&&? ?_ $%O$7_@3!_\8H]M /\ 5?,>R^\^
M&J*^Y?\ AAGP'_T%O$7_ ($P?_&*/^&&? ?_ $%O$7_@3!_\8H]M /\ 5?,>
MR^\^&J*^Y?\ AAGP'_T%O$7_ ($P?_&*/^&&? ?_ $%O$7_@3!_\8H]M /\
M5?,>R^\^'%I:^XO^&&_ G_06\1?^!,'_ ,8I?^&&_ G_ $%O$7_@3!_\8H]M
M ?\ JQF/9?>?#E%?<?\ PPWX$_Z"WB+_ ,"8/_C%'_##?@3_ *"WB+_P)@_^
M,5/MHA_JOF/9?>?#E%?<?_##?@3_ *"WB+_P)@_^,4?\,-^!/^@MXB_\"8/_
M (Q1[6(O]5\Q[+[SX<HK[C_X8;\"?]!;Q%_X$P?_ !BC_AAOP)_T%O$7_@3!
M_P#&*/:Q#_5?,>R^\^'**^X_^&&_ G_06\1?^!,'_P 8H_X8;\"?]!;Q%_X$
MP?\ QBCVL0_U7S'LOO/ARBON/_AAOP)_T%O$7_@3!_\ &*/^&&_ G_06\1?^
M!,'_ ,8H]K$K_5C,>R^\^'**^X_^&&_ G_06\1?^!,'_ ,8H_P"&&_ G_06\
M1?\ @3!_\8H]K$/]6,Q[+[SX<HK[C_X8;\"?]!;Q%_X$P?\ QBC_ (8;\"?]
M!;Q%_P"!,'_QBCVL0_U8S'LOO/ARBON/_AAOP)_T%O$7_@3!_P#&*/\ AAOP
M)_T%O$7_ ($P?_&*/:Q#_5C,>R^\^'5IU?<'_##G@0?\Q;Q%_P"!,'_QFE_X
M8=\"?]!;Q%_X$P?_ !FI]K$/]6,Q[+[SX>HK[A_X8=\"?]!;Q%_X$P?_ !FC
M_AAWP)_T%O$7_@3!_P#&:/:1'_JSF'9?>?#U%?</_##O@3_H+>(O_ F#_P",
MT?\ ##O@3_H+>(O_  )@_P#C-'M(C_U9S#LOO/AZBON'_AAWP)_T%O$7_@3!
M_P#&:/\ AAWP)_T%O$7_ ($P?_&:/:1#_5G,.R^\^'J*^X?^&'? G_06\1?^
M!,'_ ,9H_P"&'? G_06\1?\ @3!_\9H]I$7^K&8]E]Y\/45]P_\ ##O@3_H+
M>(O_  )@_P#C-'_##O@3_H+>(O\ P)@_^,U/M(C_ -6<P[+[SX>HK[A_X8=\
M"?\ 06\1?^!,'_QFC_AAWP)_T%O$7_@3!_\ &:/:1#_5G,.R^\^'J*^X?^&'
M? G_ $%O$7_@3!_\9H_X8=\"?]!;Q%_X$P?_ !FCVD0_U9S#LOO/AY>M.K[?
M_P"&'? G_06\1?\ @3!_\9I?^&'_  +_ -!;Q%_X$P?_ !FCVB#_ %9S#LOO
M/A^BON#_ (8?\"_]!;Q%_P"!,'_QFC_AA_P+_P!!;Q%_X$P?_&:GG0?ZLYAV
M7WGQ%17V]_PQ#X%_Z"WB'_P)@_\ C-'_  Q#X%_Z"WB'_P "8/\ XS4\R*_U
M9S#LOO/B&E6OMW_AB'P+_P!!;Q#_ .!,'_QFC_AB'P+_ -!7Q#_X$P?_ !FI
MNA_ZM9AV7WGQ)17VY_PQ%X&_Z"OB'_P)@_\ C-'_  Q%X&_Z"OB'_P "8/\
MXS2N'^K68=E]Y\1T#K7VY_PQ%X&_Z"OB'_P)@_\ C-'_  Q'X&_Z"OB'_P "
M8/\ XS2'_JWF'9?>?$M%?;?_  Q'X&_Z"OB'_P "8/\ XS1_PQ'X&_Z"OB'_
M ,"8/_C-(?\ JWC^R^\^)**^V_\ AB/P-_T%?$/_ ($P?_&:/^&(_ W_ $%?
M$/\ X$P?_&:FQ7^K>/[+[SXGHK[9_P"&)? W_05\0?\ @1!_\9H_X8E\#?\
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M!7Q!_P"!$'_QFC_ABGP/_P!!7Q!_X$0?_&:GV4AKAW'=E]Y\5+3J^T_^&*?
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M]7F/_5_'=E]Y\8+2U]G?\,7^"?\ H*:__P"!$'_QFE_X8O\ !/\ T%-?_P#
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M;X1_Z".M_P#?^'_XU4O(<;V7WE?V9B.R^\^3E[TY>E?5_P#PR;X1'_,1UO\
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MN>M4445R&X4444 %%%% !1110 4444 %%%% !117R)XJ_;^_X1G]IZ#X0?\
M""?:?,URST;^V?[8V8^T-$OF>3Y!^[YOW=_.WJ,UV8;"5L6Y1HQORJ[V6GS,
M*M:G12=1VN['UW1117&;A1110 445B>./$O_  AG@KQ!X@^S?;/[)T^XO_L^
M_9YOE1L^S=@[<[<9P<9Z&JC%R:BMV)M)79MT5\O_ +(_[;/_  U-XEU[2?\
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MQC_F>7_:>$O;G_!_Y'Z)T5YI\!/V@?"G[17@S_A(?"T\H$,GD7EA=*%N+27
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB)J7Q:_X)VZWXOU>"UMM2U?P_P#:)XK)&6%6\X#"AF8@<=R:\F_X*\?\B_\
M#+_KZO\ _P! @KL/^<5O_<L?^UZYJ.'I1P6#KQC[[J6;^;-:E6<L17IM^ZH[
M?)'RG^Q[^U)K7P,\%^(O#?@[P;=>-/&>N7\<UK:Q122QQQI&06*1 O(<G[JX
M[DGH#[M\,/\ @IYXAT_Q]%X<^,'@VU\.Q/,L$]U8P3VLM@S8PTL$S.Q7G)P0
M0.<'I2_\$B]'TTZ/\1M5$2-K GM+4R'ED@*R, /0,P.?78/2N?\ ^"NFAZ;:
M^)/AOJT$4::K>6U];W4BXWO%$T!BW=^#++@G^E>U66"Q>:SP-6CK+[5W>_+?
M[K'!3>(HX*.(A4T72VEKV/>?^"FTJ3?LKW$D;K)&^JV3*ZG(8$M@@^E5O^";
M6JV>@_LC-J6H7$=G86>H7]Q<7$IPD4:!6=V/8  D_2O/_P!J.^O=3_X)I_#^
MZU '[7+::(S,QR7'DC:Y/JRX8_6N(^'^H7.E_P#!*'QQ-:,R2MJ#0,5S_JY+
MVVCD'XHS"O,IX;GRN.&;WK<M_P #KE5Y<8ZUOL7_ %.B\5?\%,/'GC3QK=Z/
M\&?ARGB*T@+>6]U8W5[<W$:_\M?)@93&I]"2<=<=!Z)^R_\ \%"A\6/'47@/
MQ]X>C\*>*;B1H;6:W+K!+, <PO')EHGX.,L<GC@XS\R_L-Z]\>_"_@WQ%=?!
M_P  >&O%.GW6H+%?7VK3QI<)(D:E8P#=PML ?(^4C+-@\$#7^('[-_[3GQ4^
M-NG_ !(U7X::9HNMQ7%I,[:/J=G''N@9=LA#7;L6PJ\Y_A%>A7P&71E/"R4(
M)+27.N:_FOZ_RYJ>)Q34:R<I-O5<NEO)GZI5C^,M8F\/>$=<U6V6-[BQL9[J
M-902A9(V8!@"#C([$5\S_M8?MW_\,O\ Q%T[PK_P@_\ PDOVS2H]3^U_VM]D
MV;YIH]FSR),X\G.<_P 6,<<\=\*_V_O^&E)/%WA#_A!/^$<QX:U&]^V?VQ]J
M^Y%C;L\A.N_KGMTKY"GE.,E26)]G^[WO=;>E[GN3QM!3='F][T9YAX!_X*I>
M.-4M]3L]4\$:9K?B&X\J'1+#0;>XC$DA+;S+NED9@ %PJ $DGD5I>$?^"GOC
MCPO\18]$^+7@2ST'3O-6.Z2TL[FTOK)6Y#M%,[%P 0=N%)'(["N _P""4>BV
M>H?'SQ!?7$"RW-AH$KVS, ?*9YX49AZ':67/HQ]:B_X*O1I'^T9H#*BJS^%K
M9F(&"Q^UW8R?4X 'X"OMI8/+Y9C+ >P6L;WN]-.G];GSZKXI858GVFSM;_,]
M%\?_ /!3#XE[9/$?@WX8QP?#U;@P1:UKEC=2K.0V/]=&Z1(Q_NY;&>IKZS_9
M1_:6T_\ :<^'<FNPZ>='U:QG^R:CI_F>8L<FT,KHV!E&!R,C(((YQD\M^T=H
M-CH/["/B'2K.WCBL;/PU;10Q!1A0GE;3C&,Y .?7FO!?^"1\\=KX9^*,TTBQ
M0QW%B[R2,%55"3DDD] !7@UJ.$Q.6U,11I<CIR26K=UIO]YZ-.I7I8N%*I/F
M4E?TWV+_ ,6O^"E'B.3XE7G@[X/>"H?%4UK.]LEU<P3W3WDB$AS#! 5;8"#@
M[B2.<"L/P?\ \%.O''A7QY;:'\7? %MH5LTBI=&TM;FRNK1&Z2&&=V+ =<97
MC./0["_MJZG\2/BUJ&G?L_\ P:TG7]?2*1#XAU")(I98-X#.^WRRD1;8?GE&
M25R >*^4/VVH_BE_PMC3)OBX=+7Q+<:+#+!!I(7RH+7SIPJ$KU;>)3G+<$<]
MA[6#R["U91PU;#J%X]97G?O9;?A^AP5\56@G5IU'+7M[OH?J=^T[^TKHO[-7
MPY3Q'>VS:O?7LHMM,T^&0)]ID*ELE\':@49+8/4 #FOCJU_X*#?M%ZYIQ\0:
M1\'[2Z\+G+K>Q:%J,\6P'G_2%E"'ZX_"O>_VO/V8M4_:3^!_A&/P[<0Q>(]#
MBCN+6"Z;9'<H\*K)'N_A8[4()X^7!QG(^2-'^-G[5W[*^DV>BZMH6H3^'M+B
M6"WBUC2?M=I%$@ "+<Q8.P*  /,X &,5YF5X7"5<-[L8SJW=U)M:=+'7C*U>
M%7WFXPMHTK_>?;G[(?[5%_\ M(:-?C6?!][X8U2Q57-P(I&L;M&)&8I&488<
M90DG!!!/./A'XJ?\I.K+_L>-&_\ 1EM7V1^Q[^W59_M*:Q=>&-8T5?#_ (KM
M[=KJ,6TADMKJ-2 Y7/S(PW#Y3G(R<\$5^?O[9NI7VB_MD^-]0TR>6VU*TU6W
MGM9H?]9'*L43(R^X8 BNS*L-*GF.(HNG[.\'I>Z5VNO8PQE92PM*:ES6EO:W
M?H?9W[4G_!0K4_AW\3+;P'\+=)TSQ/K4$WV;4);Z&6>/[0Q"K;PK%(A9P>&.
M2,D*!D&OI+1?B)KOP^^",GC/XR2Z1H^HV=L;S48=%AD6&U4D!(1NDD,DF2JY
M!P68 #N?S$_8HUBT^!_[5^F:=\1M ^Q:E>1_889M40K-IMS.J/#*0QPI<,%)
M(R!)GCG/V'_P54U"YLOV;-,A@9EBO/$EK!< 9^:,07,@!_X'&A_"N'&9?0IX
MC#Y?3CI*S<^LO3^NWSZ*&*J2I5<3-ZK[/8\DNO\ @I5\6_'FLZC)\,_A7!J6
MB667D\VPN]1GCB'\<K0.JQY'/(('J>M>\_LA_MTZ;^T=J4WAC6M)7PWXRAB:
M9((I"]O>(OWC'N^967/*'/ )!/('S9^R#XH_:7\*?!6PC^%GPT\*:]X5NKJX
MG74KZYB2XGE\PH_F#[;$05*;1E =H7J,$R_"_P#9E_: C_:ST+XHZ_X LO#D
M,^N"^U-M,U*T\B&.3*W!6,7+N059R0"Q)8_2NS%8/+^6M1:A!Q3Y6IKFNNC5
M^IA1KXJ\)WE*^ZY=+/LSZ;_;!_;:TO\ 9E%GHFG:='X@\8WL/VA+.24I!:PD
MD+)*1R<D'"#!."21QGYLO/\ @H%\3M4^'>LK\1OAB=/\)^)-+NK&QU[3-.NK
M:$/+"Z(P:9G25<D9VL#C)&<8/F_[1=NOBW_@I$FE^((Q+IT_B;1K"6"<80VK
M"V7&&XVLC$^AW$]Z_3CX]>'],U[X&>.],U.*+^S7T.[WAU&V/9"S*X'8J55A
MZ%17)*G@\NI8:,Z//*HDV[NZO;;T_K<W4J^*G5<9\JC=)?YGY_\ _!)'_DI7
MCS_L$0_^CA7Z@5^7_P#P21_Y*5X\_P"P1#_Z.%?J!7G<2?\ (RGZ+\CIRG_=
M8_/\PKP_]L7XX:[^SW\&9_%WAVTTZ]U)+ZWM1%JD<DD.UR<G".ASQQS7N%?)
MG_!3O_DUN[_["]G_ #:O*RVG"MC*5.HKIR5SMQ<I0H3E%V:1\V:A_P %9/'8
M\.Z2EEX6\.'7?WC:C-/#<?9OOD1I%&)]P^0*2S.<DD #'/T-\7/V\+GX,_!C
MP-K&M^&8)?B'XJTY=1CT.*=EM[2%N5ED8@L,@KA.N=PR-N:R/^"57@G3]+^!
MNK^)1:1_VOJFKS0O=D N8(DC"Q@]0H<N<=R?I72?MJ_M7>!_@S=6/A;4O!5C
M\0_$MW +A--OXHVM[:-F*J9"R.<L5.$ R0,DC(S]-7AA*F/6#P^%ORMWL[7_
M ,DGY_<>33E7CAO;U:UKK33;_-GS_??\%&_C_P"'],M/$.M?"S3++PO=$&&^
MGT?4((IE;[NRX:78<^H!SZ5]M?LR_M"Z7^TI\,HO%.GV;Z9=13M97^GR.'-O
M<*JL0K<;E*NI#8'7ID&OBC]J3Q5^TQX^_9_\0ZGXV\*:#X&^'T8M'N-/CVF]
ME4W,0B&&=V4B1HR1B,X7&.H/HW_!)7_DD/C3_L.C_P!)XZK,,'AI9=+$PA&,
MXRM[LKKIH^E]186O56*5*4FXM7U5CS_PA_P52\5VWB+Q!:^*_"ND7\,-O+%I
M5IH<$\,UQ>>=&L:2.\L@";#(3A"20H'6HM0_X*:?%_P'XFMH_&_PNT_2=-GQ
M*EA<6=Y87;Q9'S))*Q!X[^7BO*OV -$L]9_;,L7O(%G^Q#4+N%74$"54=5;!
M[C<2/0@'M7TI_P %;;.%_A;X'NFC4W$>LR1))W56@8L/Q*+^0KT:V'R^EF%/
M!?5T^=:N[TWV7R.2G5Q4\++$>U^%GU_X5^+'ASQ9\*[+XA07HM?#5QIW]IO<
M70VF"(*6DWXS@IA@<9Y4XS7PEXC_ ."G7C[QEX[FTCX2?#NWUJR5F\B*[L[F
M]O;F-3S)Y4#KY8(QQ\V.YK5M=6O8_P#@D.UQ;Y$_V5[8^6#_ *HZT8GZ?],\
MY_&M'_@DCH]@OP]\=:JMO%_:<FJ16SW&T>9Y*PAE7/7&YF/_ .JO(HX/"X.A
MB<55AS\DW!)O31[O[SNG7K5ZE*C"7+S1YFSY,_;(_:&NOV@M<\+W.K^&[GPI
MXDT6TEL=3TVX# +(9 X90P# $'[K#(QWZU^J7A/XA:%\*_V8_"?BGQ+>KI^C
MZ=X:T^2:4C)/^CQA551RS,2  .I(KX1_X*T:)IUG\4_!>IP1QQZC>Z3)'=%%
MPSK'+^[9O4_.PSZ*!V%=5^WMJ]]:_L;_  0T^%F6PNX+%[C:.&9+ >6"?3YF
M./8>E>C7HTLPP^!I07)&3>G;O;]#EIU)X6KB)R?,TD,OO^"EOQ5^(&N7T?PK
M^%46I:=:_,RSV5WJ5PL?.'D%NR"/.,XY Y&3UKU']F'_ (*)6?Q;\90>"?'6
MAQ^$_$]S+]GM)H&?[-//G'DLK_-%(3D $D$\9!P#WO\ P3Q\.:5H?[*7A"ZT
MZVBBN-4^TW5[.@&Z>87$B98]RJHJCT"U\4_\%/M+L/"?[3&DZMHC+9:M>:/;
M:A=-;@*PN$FE1)21_$5C3W^0'O6%*C@,=BJF70H\G+=*5W>Z[FDZF)P]&.*E
M4O>UU;34^H/VY?VR/&G[,OB[PUI7A?3-!O[?4[&2ZF;5[>>1U99-H"F.9 !C
MU!KRKQI_P4N^)E]I]QK_ ($^&43>#+-EAN-<U>PNIX3)P#EXG5(LD\*68].:
MY#_@JM/<77C+X:S7:&*ZDT%GF0J5*N9,L,'ISGBOK^\T&PT7_@GQ?:?:6T<=
MK'\-YI!'M&"YTYI&<_[1<EB?4YJ(4L'AL'A:M2BI2FVGKY[^?D5*=>K7K0C4
MLHJ_X'A^E?\ !4B;Q)X$L+70OA_=ZQ\4;N=K9-%LQ)-;$  B9=H,CYR1Y8&0
M5;+8P31^#W_!2[Q7/\5++PA\5?!UCH2WEVEB\UC!<6L]A(Y 4S0S.Y*Y(S]T
M@'.#C!XS_@DCHMG=?$3QYJDL*O>V>F00P2, 2BR2L7QZ9\M:X7_@HA&D?[93
M,JJI>WTUF(&-QV@9/KP /PKT%@<OECJN7*C]F_-=W3TV\E<Y?K&)6'ABG4ZV
MM8^]/VW?VA/$?[-?PITKQ-X9LM+OK^[UJ+37CU:*22(1M!/(2!'(AW9B7G.,
M$\>G,Z7^TI\3/%'[%ND?%/PYX5LM>\>7T[I_8^G:==7,!1;Z2 E84D,O$:!B
M=YYR>G%<M_P5B_Y-U\._]C5;?^DEY7HG_!/65(?V-_ 4DCK'&@U!F=C@*!J%
MSDD^E?.*E1I952Q3IIR]I9^:L]#U>>I/&3HJ5ER_<]-3YFUS]NW]J7POI-SJ
MFL_!NTTG3+9=\][?>%]5AAB7(&6=IPJC) Y/>NW_ &._V[OB)^T-\9K?PGK^
MB>';72FLI[J6?2K2X25"@&WYGG=0"2!R.]>#_MN?M/ZE^TO\1+/X<^ 3<:AX
M8M;Q;>WBM 2VKWI.T. .J G"#H>6[C'W5^QW^RWI_P"S7\/%AN$ANO&.J*LN
MKWZ\X/58(S_SS3)_WFR?0#U\=#"8;+^>O0C&K/X4KW7F_P"O(X</*O5Q/+3J
M-PCNWU\CR?\ :<_X*(M\,_'T_@/X=>'X?%?B2UE^S7=Q<B1X([C.# D<9#2N
M#P<,,'CDYQQ'@_\ X*7^-?!WC:UT3XT_#H>&K>?;OEM;*YLKBV1CQ*8)V8R+
M]"#W&<8/RO\ LGZS\39OCS=:]\//#>D^+O&ZVUU=M:ZW(B(H=U6652\T7S@R
M8X;.&;@C)'T%^T7\+?VKOVG-.T:U\4_";P[8MI,LDMO<Z3J%K'+AP R$R7KC
M:=JG  Y45VRRW+\+..%K1A:VLG.TK]TNQA'%8FM%UH.5[Z)1NK>I^@'Q&^+W
MAKX8?#.]\=ZO?*V@6]LES'+;X=KG?CREB&?F+EE [<Y.!DU\%:=_P4M^,/C[
MQ'>OX&^%-IK&B6?[V:TM[.\O[J*'/WGEB8*F?4QX^M0_M?Z+XQ\ _L%?"+PM
MXIM9+#5+34TM+^#S5E">5%<B",R1LR$>7M. 3]T>E?2/_!-W1=/TW]DSPO=V
M<,4=WJ-Q?7%[(@&Z21;J6)2Q'<1QQCGL!7BT\-A,!@98NI!56YN*UTLKZZ=[
M?D=\JM;$XA48RY$HW??^M3\Y?C%\8+;X[?M1:5XRMM.GTC[;=:9'-8W!#-!-
M&(HY%SQD;E.#@'&,@'BOVXK\@OVT-#T[0_V[I!IR1Q"ZOM+N[B.,8"S.(BY/
MNW#GU+DU^OM//Y0EA\)*FK1Y=%VV#+5)5:ZD[N_^84445\8>\?F]<?\ !4/Q
M=X5^)WBO1]?\,Z)?:-I=S>6EG#IL,\5U/+'*8X0TC3.H'&6(3L<#H*K:C_P4
ML^,G@;6["Y\:?"FSTGP_>XE@@N+*\L;B>+@YCFE8JW'<1XY%>4?LUZ+I6O?\
M%#TM]72.6"/Q%JUS#%*N5:>(7$D7XAU##W45]Y_\%"-"T[6/V3_&<U];QRRZ
M>+:ZM)''S0R_:(TW*>Q*NR^X8BOT3$T\OPN+HX9X=/VBC=W>EW;3]3Y:C+%5
MJ-2LJMN5O\-3T?P3\?/"7CCX+K\3K6\-OX;2REO+HS8\RU\H'S8W /WU*D8[
M\8R"*^)[S_@I5\5OB)XDO[;X3_"N+5["W.1'+8W>I77E\@/(MNR!,XZ<@=,G
MK5W_ ()N_$C3OAS^S;\4=;\43-'X6T?41=2?N]^XO BLB@\,S$1J%]6&>M6O
MAY^U/\4_C%?:XG[/_P %?#NA::9U6\U:\$:9;'RM(RF)"^W^']X0#WZUQ4\O
MIX6OB(NBIQB[*4I6BKZV?=ZG1+%3K4Z34^5M;)7;.A_9C_X*+:G\3/B=9^ ?
MB#X7M=!U>^E-K;76G"2-$N1G]U+#*69<D$ [N#@$<Y'4_MT_M?>,OV8]<\)6
M?A;3-#OXM6M[B:<ZO!-(RF-D V^7*F!\QSG-?$'@VW\46O[?OA^/QK/:W/BL
M>+[4ZE+9 "$S&1"=N !CD#IVKVW_ (*Z_P#(V?#?_KRO?_1D5=\LMPBS2A",
M%RSBVUNKV>QS+%U_J=23EK%VOUW)K/\ X*A_$#QA\2-%T+PEX*T.YM-0N+>Q
MBM[P3_:;B9RJ$JRR;8U+DD J^!U)ZUZM^U)_P4(N/A'\0'\ ^!?#<'B7Q-;M
M'%=S732/#'.X!$$<<>&D?YAGD8)Q@G./>/V3?!&G^ _V=/A]86%I':O<:-:W
MUT449DN)HEED9B/O'<Y&3V ':OG;XW?MH:7#\<QX,^&OPMT_X@?$.PNWM(M7
MNX4+1W**PD2'"[SL 8,V]  K=1S7F4UA<5BW"AA;QII_:LGYR;Z>7YG7+VU&
M@I5*UG*W3\$><R?\%*OC)\.=>LX/B5\+++2K6<AA;-I][IER\8/S,AG=PV,C
M^''YU]8_M >--,^(O[&/C/Q/HTCRZ7JWAB6\MVD7:X1X\@,.S#H1V(-? '[=
MEU\=-6TWP?J/QBLM#T:WEFNAIFE:0R.T#8C,A=E9\\; /WAZ5]8:'_RB[D_[
M$^X_F]=>+PF'C#"XJE&,9.:3Y7>._P#P#&A7JN5:C-MI1OJK,\__ ."0_P#R
M+_Q-_P"OJP_] GKRCX!_\I3=3_[&KQ+_ .BKZO5_^"0__(O_ !-_Z^K#_P!
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M^P1#_P"CA7'3I4Z&"Q].E+FBG&SWTN;SG*IB,-*:LW>Y^H%<I\4OB7HGP?\
M .L>+O$,[0Z5ID7F2! "\C$A4C0$C+,Q"@>IKXH\9?\ !5[_ (1+Q?KFA_\
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M1^R#_P % (?VA/%2>#/$NA1:%XGEA>:TGL9&>UN]B[G0*V6C8*"P!+ A6Y!
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M,8[$&OH2OG\SE1EBZBP\;03LK>6GXGIX15%0C[5WDPHHHKRSL"BBB@ HHHH
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MP<G/&#FOTYHJ*><5*>*GB53BN:/+9*R2*E@8RHQHN3T=[O4\[_:&UCQ7X?\
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MGAG[27AW5==_9%\4:-INF7FH:O-H44,6GVMN\MP[CR\JL:@L6X/ &>*^>O\
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MN3"9K/#TI4*D%.#=[/H_*QM6P4:LU4C)QDM+KL?C7XP_9Y^.DGQOT/Q%XO\
M"FOZ_K6K7=KJNHWVGZ=+<PVY:;'EO)$AC4HB+\JG"*0.,5]W_M\_$GXK_"_P
M-H.K?"YM1A:.>XDU>YL=)COD@MDBW;Y=\3B-!@DL<#@Y-?4M>2?M)_"WQ?\
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M'[;?@'X_ZM=67B#X2>*=6.CI;JEWX?TR=;6XC<$GS4(VM(&!&5+%@1P"#@>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^'O OQ \5/X:OKFQUO\ L318YUT\PRO&7=O. 8-Y;.JH6D*C)09 KMY/VK/
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M]%U&TU..-'+A%=)X]CN##(K91CAB <J* .^HKPE?VSOAW#\,?$/CZ];5-/\
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MIU_X9_MWZ_X/UK6]3U+PG\1-!36?#L%_>/-#87MGE+JUMT8G8&C;SB%P.GX
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M/E&7."<'*GB@#TBBN$^%OQBT;XO3>+1H=IJ$=KX;UNXT">\NXT2&ZN(-HE:
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MM%?#[P?J7CK7OB#\,/B$]QIUK)XLN%NM1T?4HX]\8%R%#2QRC"!7Y!&<Y!W
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M 4444 %%%% !1110!\2_\%(/ VE?$SQ5^SIX4UV.2;1M8\;+97D4,AC9X7C
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MCU^S1_V4RQ_]$S5[ZWPI\$MI,^EMX.T Z9/J']K2V1TR#R9+W<'^TLFW!FW
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M*FL7%QX6TBU%QIF)1J$L"2"X6(C[Y*QM",9R5XSQ6KJ^IKXT_9'M[36OVI_
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M@D4Y5T=8PRL#T(.:[;Q#X:TCQ=I4VF:[I5CK6FS?ZRSU"W2>%_\ >1P0?Q%
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M7PW\'>$_C%IFL^*=&\/:IH_CS7K[4X=0NX[=S$]R2D^&(++M4)D9Y3'IGA?
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MPT3PZ <<X,$G^ _*OI/Q'X5T3QA8QV6O:/8:W9QS1W*6^I6J7$:RH=R2!7!
M93R&Z@]*+/PIHFG>(-1UZTT?3[77-22.*]U.&U1+FZ2,$1K+*!N<*"0H8G&>
M* /ST\>?\DK_ &^?^PP/_26&K.KV/B3PO^UUX*UJ/XAZ3\,T\0?#+3],T37-
M?T1-0M+AHG5Y[)&:>$1RY*R#)^8-@<XS]*?M/? 7Q'\3/A_KW@_X=:?X/\-P
M>-'9/%>M7T3Q7;+F,"6-88B+B4HKKF5UP-N#Z>OZK\.?#/B/PI:^&]>T'3/$
M&BV\4<*V.JV45Q 0BA5S&ZE>@]* /B6;X=:A\0O'/QTO=-^->E_$_P"(\WPP
MO/#,ND^&O#36-M&TI=[9I+E+B6(S[A)&$SO"OG "\^@?"S]I#X/>&_V'O"-Q
MKUSINHZ=I?AVST;4/"!$,]]->Q0I%)8BTE(,DID4C:P&[[QX.:^HO"/@;PW\
M/]+_ +,\+^']+\-Z;NW_ &/2+**UAW>NR-0,_A6:?@_X#;QC_P ):?!/AT^*
M]V_^W?[)M_MV[U\_9OS[YH ^</"FM:?I_P#P4;U'[4J>'_[2^%VGBQT^^*6\
MIS?MB)4S@LN"I5<X*D=J^<'L[B']GK4O$KVTUUX=\)?M&3>(?$201-*1ID%R
M1,[(H)95+HQXX )[5^E>O_#OPIXKUK2=8UOPSH^L:OI,@FT[4-0L(I[BR<,&
M#PR.I:-@0#E2#D9JSH?@_0?#-G?6FCZ)INDVE]<2W=W!8VD<*7$TG^LED50
MSO\ Q,<D]Z /DW]MKXD>%/BUX!^'W@SP/XATSQ+XR\1^*])N=#31[J.ZEMUB
MG$LEZ50G;&D:OEFP!N//!KHOV744?M8?M6N%&\ZSHH+8Y(%@<#]3^=>]^$?A
M'X%^'^HW>H>%_!?A[PW?W>?M%UI&E06LLV3D[VC0%LGGGO6QI?A31-#U;5=4
MTW1]/T_4]6=)=1O;6U2*:]=%VHTSJ 9"J\ L3@<"@#\\O#J> YO@+^T[%\2(
M];B\+2_'75XY=4\/D+=:3*9[417H<D;%B?:2V&P/X6SBN^\+_$CX@?!GXZ?#
M'P?9?&O3/CQX3\97<EL=/N+:!M6TVV6)G^U_:;=B)(QA26D'/(49Y'V3I?@?
MPYHEKJ]KIWA_2["VUBZFOM2AM;*.-+ZXE $LTP50))'P-S-DM@9)K-\&?"/P
M+\.;FYN/"?@OP[X7N+G_ %\NBZ5!:/+_ +QC12WXT 7?B%X-LOB-X#\1^%=1
M4-8:WIUQIT^1G"2QLA/U ;/X5^7/A?2=;_:D^&?B^RU"*9?$'P9^&W_"/(''
MSQZ_!?/+YD;XY8QZ5;C(_P">IW=:_6:L/1? _ASPW-K$ND^']+TN769VNM3D
MLK*.%KZ9L[I)RJCS'.3EFR3F@#XE^"?B>3X\?";]I7X[W$#P0^)]$ET72HI0
M08K2RTQA(4ST5[B:8GW3VKG?#^HVFB:#_P $^]2U&ZAL-.AM+A);RZD$<,;/
MI:A SL0 6/ !/)K[ZT7P#X8\-^$SX6TGPYI.E^&?+EA_L6RL8H;+9(6,B^2J
MA-KEF+#&#N.>IJGJ_P )_!'B#PE9>%=4\&^']2\,601;71;S2X);* (,($A9
M"B[1P,#CM0!X!\&=DO[?_P"T-*NU\Z'X<VN.>#!(>#Z'BO"/'G_)*_V^?^PP
M/_26&OT'TOP9X?T/6;W5].T+3=/U:]BAM[J^M;...>>.)=L2/(H#,J#A020H
MX&*J7'PT\(75KK]K/X5T2:V\0/YFL0R:="R:DV -UPI7$QP ,OG@"@#Y4\(*
M&_;C^$)(!*_!PD9'0_:8A_6NK^'O_*13XM?]B9H__HV2OHJ'P3X=M]<L]:BT
M'3(M9L[/^SK;4$LXQ<06N0?(20+N6/(!V [<@<5+;^%=$L_$5WX@@T>PAUZ\
MA2VN=4CM46ZGB0DI&\H&YE4DX4G SQ0!Y)^UA\&?&'QT\%Z1X<\,:YH^EZ<N
MI17FL6.N6TT]MJL$1#K:RB)T?RF<*7 8;@,9QFOG";3OC=;_ /!03P;#J.K?
M#UM?7P+/A['2+Z.S&GB^021B-KDL)L_=;=L ZJ:^_P"LJ3PIHDWB:'Q')H^G
MOXAAMFLHM6:U0W:6Y;<85EQO"%N2H.,\XH U:*** "BBB@ HHHH **** "BO
MFS]KSXE?$/P5XN^#.@_#W6;/1KSQ9XAETF[DU"S2YA\LV[$.RD;LQG]X K+N
M*!2<$UP,^O?'OP_^TO;?!4?%>RUBQUSP]_PD2^*K[P[:QZAI<<4QBEAAAC58
M9"[;-K2JVT,V0Q7Y@#[1HKXHMOVL_%GP(\._M):?\0-2B\?ZG\)WTN6QU9;.
M.P?44U*)6M8IDB&Q2LC*K,BC@DXK2^(M_P#M%_ GX2S_ !9UKXAZ;XMN='AC
MU+7O BZ#!;V(MLKY\5K<H//5HU+$/(S@[<E1TH ^Q:BN;F&SMY;BXE2"")#)
M)+(P544#)8D\  =Z^1O&7Q6^)GQ*_:WT/X>_#OQQ;^%?!VL?#BW\6R7LFDV]
M[/"&OI(_-@#C!D=6@7YR\:@,VPFJFB^-OB3K"?M&?!OQ3XV74]9\*:1;7^F>
M,[72K>&YEM;JWDD:*:WV^3O41E-RKR')X(% 'T1JWQ^\ :)\/=(\<W7B*+_A
M$]6N8+.QU2""::.XEFD\N(*$0MAGX#8V]\XYKT&ORSU30_%&C?\ !,/X970\
M1GQ!<WNM:#/H]CJ%K#!!IY^U82#?$JO(A?!+.2W)YKZ6\4^*OC!^SW\5OA-_
MPE'Q'MOB%X<\;ZXGAS4-+?0;>P^PW$D3M'-:O%\^P,I!65G.!P23D 'UM17P
MMXH_:.\1>(OCS\1?!NK_ !TTWX!W6@7RVF@Z+J>C6CIJD!B5DNY;B[!#+(Q(
M"1,A"@<Y.:^P/A?)XIF^'N@OXUN-&N_%+6JF_N/#[NUA-)V>$N VUEP>1U)Q
MQB@#J::[K&C.[!549+,< #UKYJ\=_$3XA?%/]HS5/A+\/?$EOX"TSPOI-OJG
MB#Q)]@BOKV26X)\BUMXI@8E&Q2S2,&ZX &,GG=,\;?$RX\5?$[X#^*_&\:^*
MK/P_#XET#QSINE6\5Q=::TWES+-:.K0[U=3$65<$2$@*P% 'N'PI_:+^'WQO
MO]2M? ^O/K_]GY,UU#I]U':L Y0F*X>-8IAN!&8V;I7I-?+W_!.'PWK6B?LI
M^![O4O%-QKFGZAID,UAITUE;P)IB9?=&CQHK2!B02TA8\=>:?^TA\=/$MC\;
MO!7P=\&>)M(\#:AJ^G3:[K/BG5HXIFL+!',:+!%*0C2R2!E!?( 4G!YP ?3U
M%?*'P[^.GBCPI\9M5^%7B3QOIGQ(CO/#<_B#0?%EC;V\%PKPL5FM;F* ^46
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JO>2M#$"AP=V*L55U#_4K_ +W]#0!5^VS?W_T%'VV;^_\
MH*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_
M]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H*
M* )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;
M^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_M
MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\
MZ"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%
M'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H**
M )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF
M_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?
MW_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z
M"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!
M1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G
M^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9
MO[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W
M_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@
MHH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#0
M4?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^
MVS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O
M_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]
M_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@H
MH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]
MMF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_
MMLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\
MH*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_
M]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H*
M* )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;
M^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_M
MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\
MZ"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%
M'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H**
M )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF
M_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?
MW_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z
M"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!
M1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@HH G
M^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9
MO[_Z"H** )_MLW]_]!1]MF_O_H*@HH G^VS?W_T%'VV;^_\ H*@HH G^VS?W
M_P!!1]MF_O\ Z"H** )_MLW]_P#04?;9O[_Z"H** )_MLW]_]!1]MF_O_H*@
MHH G^VS?W_T%'VV;^_\ H*@HH G^VS?W_P!!1]MF_O\ Z"H** )_MLW]_P#0
M4?;9O[_Z"H** )_MLW]_]!6I6)6W0 4444 %%%% !574/]2O^]_0U:JKJ'^I
M7_>_H: ,ZBBB@ HHK'\*^,M \>:.FK>&M<TWQ#I3NT:WVE7<=U 64X90\9*Y
M!X(SQ0!L45RWB;XK>"?!.K6VE>(O&&@:#JES&TT%EJ>IP6TTL8SEU1V#,HP<
MD#'!J[9^.O#>I7&C6]IX@TJZGUJT-_ID4-[$[7UL%5C-  V9(P'0[UR,,O/(
MH W**SM!\2:1XJT\WVB:I9:Q8B62#[387"3Q^8C%'3<A(W*P*D=000:T: "B
MBB@ HHHH ***;+*D$;R2.L<: LSL<!0.I)["@!U%0V=Y;ZE9P7=I/'=6L\:R
MPSPN'21&&596'!!!!!'7-34 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 445P'[0'Q U'X4_!'QSXQ
MTF&UN-3T/2+G4+:*]5FA>2.,LH<*RL5R.<,#[T =_17YN^&?VP_VS_$'PXM/
MB/:?!KP;JW@=[8Z@US8LPGEMD)WE(OM[2AL*W_+)CQG::^T_V>?C_H/[1'P;
MTCX@Z4ITVSNHW%Y:W4@)L9XR1-&S\ A2,AL#*E6P,X !Z?17P9^RW_P40\2_
M&S]HK_A$?$6@Z5I/@GQ$-0?PAJ5O;S17%V()6V+*SRLK$Q))NVJGSJ !SBO5
MOVO/VDO&_P"R_P")? OB7^R-*U3X17UXFG^([D6L[ZCISLQQ*CK*$V%.@,9^
M:,KNS(N #Z=HKY:^-'[57B:#]H3X<_"#X1VFB:_K6N1#5-;U/48I;FUT[32
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=>!@ [JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_9-*TNTBL;2WWL_E0QH$1=S$L<*H&223CDFM*@ HHHH **** "BBB@ HHHH
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MX>/IWP:N-*N?"!O996?1]7;4X?M)5!(/.:60[L!,KNXXXYKU.N'^#_P4\&?
M3PFWAGP)HW]A:(UR]V;7[5-<?O7"AFW3.[<A5XSCBNXH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K\N?B/XD^,/A?_@I[\4[KX)^%=(\7^*G
M\-6D5S8ZU*L<*69AT\O("UQ -PD$(^\>&/RGJ/U&KPKPK^S#_P (S^UYXQ^.
M7_"2_:?^$AT./1O[!^P;/L^T6O[SS_-.[/V7[OEC[_7CD \6^,GB3XP^*/\
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M8M3\)W'BA9[^P\.W[:E%H[F-[&\F,31H;F)T;S FXLH!&& )R.* .@\'>/\
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M&G7TU]$D%Y),,PI"Y;;(SC[H4DMVS7SK\,+>UO/VYOVC(+Z.*6RET'0$GCG
M,;1FWE#!@>,$9SFO!_V4UT2Y_:0T+2=2O=4O?A9ILFKO\'CJ87['=.DV+MD8
MG=(T2EE@+=(]S#! H ^]_%WQ4\%?#^^L[/Q1XPT'PW>7O_'K;ZOJ<%K)/SCY
M%D8%N>..]=/%*D\:21NLD;@,KJ<A@>A![BODG]FGP/X0^(WB_P#:&U3QMH^F
M^(?%/_"<:CI-ZVMVR32P:5&J+91 ./DA,/S#'#<\_+QSG[-_Q&^(W@O]G'2(
MOAE\-9?BWHT'B+6M/TXR>)(-,%MID-VZVI26X5O.0C<HQT" =,4 ?9,/B;1[
MCQ#<:#%JUC)KMO;K=3:8ERAN8H6)59&BSN"$@@,1@D&HHO&&@SZAK5A'K>G2
M7VB+&^J6RW<9DL%=#(AG7.8@R L"V,@9'%?,GQ-\0:G\/OB3\%OCAXKT1?!$
ME]%+X.\7Z<;U+P6,-UF6UW3Q@(RQW,8RXX_?5X7\2+'Q%<?LHZ%XRDAMH9OB
M[\3+'6M?AUF62&S72+AW%G;7,L:EX[<QPV2L0&P)&ZYH _0'P=\3O!_Q$-V/
M"GBS0_$QLVV7/]CZC#=^0WH_EL=I]C46N_%CP1X7\26GA[6?&/A_2-?O-OV;
M2K[5((;J;<<+LB9PS9/3 YKY*D\"^+O"O[3'P5O=6TWX4_#S51/=V4%GX.N;
MYKO5[#[,WG6QB%DD9CCPDBF1E5"O!!-._9U^&?PZ^)O[-/Q,UCXFZ?87.MZI
MK.O?\)CJU[$CWEC)%<2J LC!FB\F%8F0  *<$#U /MVBN7^%MSI5Y\-?"DVA
M:I>:YHDFE6K6.IZAN^T7<'E+Y<TFY5)9UPQ)4$DYQ744 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5XS^TM\9M;^#?_"JO[%M;"Z_X2KQ
M[I7A:]^WQN_EVMUYOF/%M=<2#RQM+;E&3E37LU?+G[>'_-N__98O#O\ [<4
M>Y^(OC)X!\(2ZC%KOCCPWHDNFRQ0WJ:CJUO;FUDD3?$DH=QL9T(90V"0<C(K
MAOVF?VD](^ _P3N/&]G?Z+J-U</;1:3;W5^B17QEGBC9XR#F41QR-*0G\,9Y
M ^8>9_"?X8^%_%W[;'[2VM:]H6GZW>VDGA^TM6U&V2<6Z/I49EV!@<%]J!CW
M" >M>'Z_H>G6_P#P3K^(^G)90?8M#^($]EID+1AA9P#Q' HCCS]T;68<=B:
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MNX?CC_PDF/+T+^Q?[!^P=>O[WS_,]_N^7^->XQR+-&KHP=&&Y64Y!!Z$&G4
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M/C\VN[;FUT_[-_88L1AY_L[VXG,_F=HGQM*'E0=W3'T310!\8VO_  3F6U^
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MB2ZE"P:.XV"0*K;@"0H"N1\P:N[T?Q1HWB+?_96K6.I[!EOL=RDN![[2:TZ
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M7HOPO2_CM]/DMQ*]^+FT:W9GE#*$?<[2L0AW$D87.:]OHH ^:K[]DWQ5H?\
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MA&Z=*^./^'B7QK_Z,W\>_P#?=[_\KJ /O6BO@K_AXE\:_P#HS?Q[_P!]WO\
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M_P"5U'_#Q+XU_P#1F_CW_ON]_P#E=0!]ZT5\%?\ #Q+XU_\ 1F_CW_ON]_\
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M_P#E=0!]ZT5\%?\ #Q+XU_\ 1F_CW_ON]_\ E=1_P\2^-?\ T9OX]_[[O?\
MY74 ?>M%?!7_  \2^-?_ $9OX]_[[O?_ )74?\/$OC7_ -&;^/?^^[W_ .5U
M 'WK17P5_P /$OC7_P!&;^/?^^[W_P"5U'_#Q+XU_P#1F_CW_ON]_P#E=0!]
MZT5\%?\ #Q+XU_\ 1F_CW_ON]_\ E=1_P\2^-?\ T9OX]_[[O?\ Y74 ?>M%
M?!7_  \2^-?_ $9OX]_[[O?_ )74?\/$OC7_ -&;^/?^^[W_ .5U 'WK17P5
M_P /$OC7_P!&;^/?^^[W_P"5U'_#Q+XU_P#1F_CW_ON]_P#E=0!]ZT5\%?\
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M_CW_ +[O?_E=0!]ZT5\%?\/$OC7_ -&;^/?^^[W_ .5U'_#Q+XU_]&;^/?\
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MX_PKB,<M(P /:OV2_P#@H#X2_:5U2Z\-:E82>"?&R,T]KHVH2<7UJWSQ/"Y
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M1[?R+"SM[*#.?+MXEC7\@* .5^$GPX@^%_@VWTA'6>Z9C-=7"C'F2G&<>P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW27-GX:M?.0Y5KAWN,'U D9AFN\4!0 !@#@ 4 +1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>)_M1?LF^#?VI?"2V&N1'3/$-D-^D^)+- +NQD
M'(&>-\9/6,G!ZC:P##VRB@#\S+?X+_M-?M">+-+^!GQAOY(/AWX5F6]U?Q59
M[E;Q%:[O]&C,N?WK_(W) *_>D!=5S^COA/PGH_@7PUIOA_0-/@TK1M.A6WM;
M.V0*D2#H /U)ZDDD\FM:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_/I_X^O^-'V74O\ GT_\?7_&@"UFC-5?LNI?\^G_ (^O^-'V74O^?3_Q]?\
M&@"UFC-5?LNI?\^G_CZ_XT?9=2_Y]/\ Q]?\: +6:,U5^RZE_P ^G_CZ_P"-
M'V74O^?3_P ?7_&@"UFC-5?LNI?\^G_CZ_XT?9=2_P"?3_Q]?\: +6:,U5^R
MZE_SZ?\ CZ_XT?9=2_Y]/_'U_P : +6:*K+::CGFUP/]]?\ &GQR'<R,,,IP
M1[T 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444UVVC- "[A1N'K581W5TK-!%Y@!P3N Y_$TS[%JG_ #Z_^1%_
MQH M[A1N%5/L>J?\^O\ Y$7_ !H^QZI_SZ_^1%_QH M[A1N%5/L>J?\ /K_Y
M$7_&C['JG_/K_P"1%_QH M[A1N%5/L>J?\^O_D1?\:/L>J?\^O\ Y$7_ !H
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M1_J)AO\ G_+[D'UI]C]:O^%X?#O_ *'SPS_X.+?_ .+H_P"%X?#O_H?/#/\
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M #_E]R#ZT^Q^M7_"\/AW_P!#YX9_\'%O_P#%T?\ "\/AW_T/GAG_ ,'%O_\
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M_P +P^'?_0^>&?\ P<6__P 71_PO#X=_]#YX9_\ !Q;_ /Q=?DK11_J)AO\
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MH_\ R&I/^N)_]"6NAKGM'_Y#4G_7$_\ H2UT- !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (WW37X]_'#_ )+5X_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]Q_O?T-6ZJ:E_P >X_WOZ&@#)T?_ )#4G_7$_P#H2UT-<]H__(:D_P"N)_\
M0EKH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 1ONFOQ[^.'_ "6KQ_\ ]C!J'_I3)7["-]TU^/?QP_Y+5X__ .Q@
MU#_TIDK]/X$_WFO_ (5^9Q8K9'$T445^S'GDEO;R7=Q%!"C2S2,$1%&2S$X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO)GYZ_\ #,?Q,_Z%D_\ @=;?_'*/^&8_B9_T+)_\#K;_ ..5^A7_  E'@_\
MZ&71_P#P/B_^*H_X2CP?_P!#+H__ ('Q?_%4?ZY9O_SYC_X#+_Y(/J7DS\]?
M^&8_B9_T+)_\#K;_ ..4?\,Q_$S_ *%D_P#@=;?_ !ROT*_X2CP?_P!#+H__
M ('Q?_%4?\)1X/\ ^AET?_P/B_\ BJ/]<LW_ .?,?_ 9?_)!]2\F?GK_ ,,Q
M_$S_ *%D_P#@=;?_ !RC_AF/XF?]"R?_  .MO_CE?H5_PE'@_P#Z&71__ ^+
M_P"*H_X2CP?_ -#+H_\ X'Q?_%4?ZY9O_P ^8_\ @,O_ )(/J7DS\]?^&8_B
M9_T+)_\  ZV_^.4?\,Q_$S_H63_X'6W_ ,<K]"O^$H\'_P#0RZ/_ .!\7_Q5
M'_"4>#_^AET?_P #XO\ XJC_ %RS?_GS'_P&7_R0?4O)GYZ_\,Q_$S_H63_X
M'6W_ ,<H_P"&8_B9_P!"R?\ P.MO_CE?H5_PE'@__H9='_\  ^+_ .*H_P"$
MH\'_ /0RZ/\ ^!\7_P 51_KEF_\ SYC_ . R_P#D@^I>3/SU_P"&8_B9_P!"
MR?\ P.MO_CE'_#,?Q,_Z%D_^!UM_\<K]"O\ A*/!_P#T,NC_ /@?%_\ %4?\
M)1X/_P"AET?_ ,#XO_BJ/]<LW_Y\Q_\  9?_ "0?4O)GYZ_\,Q_$S_H63_X'
M6W_QRC_AF/XF?]"R?_ ZV_\ CE?H5_PE'@__ *&71_\ P/B_^*H_X2CP?_T,
MNC_^!\7_ ,51_KEF_P#SYC_X#+_Y(/J7DS\]?^&8_B9_T+)_\#K;_P".4?\
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M"O\ A*/!_P#T,NC_ /@?%_\ %4?\)1X/_P"AET?_ ,#XO_BJ/]<LW_Y\Q_\
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M /0RZ/\ ^!\7_P 51_KEF_\ SYC_ . R_P#D@^I>3/SU_P"&8_B9_P!"R?\
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M_P#D@^I>3/SU_P"&8_B9_P!"R?\ P.MO_CE'_#,?Q,_Z%D_^!UM_\<K]"O\
MA*/!_P#T,NC_ /@?%_\ %4?\)1X/_P"AET?_ ,#XO_BJ/]<LW_Y\Q_\  9?_
M "0?4O)GYZ_\,Q_$S_H63_X'6W_QRC_AF/XF?]"R?_ ZV_\ CE?H5_PE'@__
M *&71_\ P/B_^*H_X2CP?_T,NC_^!\7_ ,51_KEF_P#SYC_X#+_Y(/J7DS\]
M?^&8_B9_T+)_\#K;_P".4?\ #,?Q,_Z%D_\ @=;?_'*_0K_A*/!__0RZ/_X'
MQ?\ Q5'_  E'@_\ Z&71_P#P/B_^*H_URS?_ )\Q_P# 9?\ R0?4O)GYZ_\
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MCP?_ -#+H_\ X'Q?_%4?ZY9O_P ^8_\ @,O_ )(/J7DS\]?^&8_B9_T+)_\
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M?H5_PE'@_P#Z&71__ ^+_P"*H_X2CP?_ -#+H_\ X'Q?_%4?ZY9O_P ^8_\
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M_B9_T+)_\#K;_P".4?\ #,?Q,_Z%D_\ @=;?_'*_0K_A*/!__0RZ/_X'Q?\
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M8_B9_P!"R?\ P.MO_CE?H5_PE'@__H9='_\  ^+_ .*H_P"$H\'_ /0RZ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(>,_^">_PA^(/PB\'^ -?L=2OK;PG:_8]*UK[4L>I11DY(:1$".">=I3;GD
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MOJ2_$J34?@=\7M(\06NIWNK:?=0DA+ZY:>3R=W[R'<QR0-P92>Y&<X)/J?Q
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MXV[6;/W#UQVKQ,-ETX*B^6S:FI?.]KJ_X'%2P\H\FEF^:_Z'T=_Q>+_J1_\
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MV-NK0R-)^[B&Z5X<B-F. K,0<D@GH/\ @H2P;_@G_P#LID'(_LC31Q_V"HJ
M/NC]EO\ :W\2?M,>)M8#?![Q#X*\$0V:WNE>*M9D98M41W C$:&%02RY?*22
M  <GE<\C_P %2OB?XA^'_P"R[K>FZ'X8U#6;;Q'&^FZCJUF7$>D6YVEI9ML;
M#8_,7S,@^?J3Q7U3X-MHK/P?H5O!&L,$5A!''&@PJJ(U  '8 5X+_P %'?\
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M_P#D-2?]<3_Z$M=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M545 3DX50%&>YQS@>E7_ /A4_BO_ *!)_P"_\7_Q5'_"I_%?_0)/_?\ B_\
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M['_P)?YA[>E_.OO1R-%==_PJ?Q7_ - D_P#?^+_XJC_A4_BO_H$G_O\ Q?\
MQ5'U["?\_8_^!+_,/;TOYU]Z.1HKKO\ A4_BO_H$G_O_ !?_ !5'_"I_%?\
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M&BNN_P"%3^*_^@2?^_\ %_\ %4?\*G\5_P#0)/\ W_B_^*H^O83_ )^Q_P#
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M>WI?SK[T<C177?\ "I_%?_0)/_?^+_XJC_A4_BO_ *!)_P"_\7_Q5'U["?\
M/V/_ ($O\P]O2_G7WHY&BNN_X5/XK_Z!)_[_ ,7_ ,51_P *G\5_] D_]_XO
M_BJ/KV$_Y^Q_\"7^8>WI?SK[T<C177?\*G\5_P#0)/\ W_B_^*H_X5/XK_Z!
M)_[_ ,7_ ,51]>PG_/V/_@2_S#V]+^=?>CD:*Z[_ (5/XK_Z!)_[_P 7_P 5
M1_PJ?Q7_ - D_P#?^+_XJCZ]A/\ G['_ ,"7^8>WI?SK[T<C177?\*G\5_\
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M3ZU[;110 4444 %%%% !1110 4444 %8'B;_ (^+'_@?_LM;]8'B;_CXL?\
M@?\ [+0 0_=_"M^L"'[M;] !1110 4444 %5-2_X]Q_O?T-6ZJZC_J5_WOZ&
M@#'M9ET^\:=U9@4*X0<]0?Z5;/B: ?\ +O<?]\K_ (U"R!NM-\A?2@"?_A)K
M?_GWN/\ OE?\:/\ A)K?_GWN/^^5_P :K^0OI1Y"^E %C_A)K?\ Y][C_OE?
M\:/^$FM_^?>X_P"^5_QJOY"^E'D+Z4 6/^$FM_\ GWN/^^5_QH_X2:W_ .?>
MX_[Y7_&J_D+Z4>0OI0!8_P"$FM_^?>X_[Y7_ !H_X2:W_P"?>X_[Y7_&J_D+
MZ4>0OI0!8_X2:W_Y][C_ +Y7_&C_ (2:W_Y][C_OE?\ &J_D+Z4>0OI0!8_X
M2:W_ .?>X_[Y7_&C_A)K?_GWN/\ OE?\:K^0OI1Y"^E %C_A)K?_ )][C_OE
M?\:/^$FM_P#GWN/^^5_QJOY"^E'D+Z4 6/\ A)K?_GWN/^^5_P :/^$FM_\
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MX4?VE<_\]/\ QT?X4<C#^T*79_U\QO\ PCL?I1_PCL?I3O[2N?\ GI_XZ/\
M"C^TKG_GI_XZ/\*.1A_:%+L_Z^8W_A'8_2C_ (1V/TIW]I7/_/3_ ,='^%']
MI7/_ #T_\='^%'(P_M"EV?\ 7S&_\(['Z4?\(['Z4[^TKG_GI_XZ/\*/[2N?
M^>G_ (Z/\*.1A_:%+L_Z^8W_ (1V/TH_X1V/TIW]I7/_ #T_\='^%']I7/\
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M'_".Q^E._M*Y_P">G_CH_P */[2N?^>G_CH_PHY&']H4NS_KYC?^$=C]*/\
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M%&T4 <__ ,(['Z4?\(['Z5T&T4;10!S_ /PCL?I1_P (['Z5T&T4;10!S_\
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M-;0]IHKYF\6?M_> _#NL>(+73/"_CGQEIOAZ=[?6->\-:$;G3K!T^^)9F=0
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MCRU_NBO6_AC^V'X&^+,?C74=&MM8@\(^$A(U_P"+KZWBBTN3RP6;R6\PR/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/"^C:=KU_P#\?>J6FGPQ75Q_UTE50S_B32Y37V\4HSZZ_B?%FDJK?\%=]:)
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MS%<> O#$\6M3K=:FDNC6[+?3*S,LDX*?O'#.Q#-D@L3W-.SO<S]M#DY+6V_
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MSL22#$?8>M;/3@<"LI2Z(];"87FM4J;!1116)[@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6W6)6W0 4444 %%%% !574/]2O^]_0U:JKJ'^I
M7_>_H: ,ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH JZG_QXR_A_,5@UU%%7&7*CS\1A/;R4N:QR]%=
M115>T\CF_L[^_P#A_P $Y>BNHHH]IY!_9W]_\/\ @G+T5U%%'M/(/[._O_A_
MP3EZ*ZBBCVGD']G?W_P_X)R]%=111[3R#^SO[_X?\$Y>BNHHH]IY!_9W]_\
M#_@G+T5U%%'M/(/[._O_ (?\$Y>BNHHH]IY!_9W]_P##_@G+T5U%%'M/(/[.
M_O\ X?\ !.7HKJ**/:>0?V=_?_#_ ()R]%=111[3R#^SO[_X?\$Y>BNHHH]I
MY!_9W]_\/^"<O17444>T\@_L[^_^'_!.7HKJ**/:>0?V=_?_  _X)R]%=111
M[3R#^SO[_P"'_!.7HKJ**/:>0?V=_?\ P_X)R]%=111[3R#^SO[_ .'_  3E
MZ*ZBBCVGD']G?W_P_P""<O17444>T\@_L[^_^'_!.7HKJ**/:>0?V=_?_#_@
MG+T5U%%'M/(/[._O_A_P3EZ*ZBBCVGD']G?W_P /^"<O17444>T\@_L[^_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6W6)6W0 4444
M%%%% !2,H;A@"/<4M% #/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_
M .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #
M/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D
M*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0
MI]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_
M^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_
M .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #
M/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D
M*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0
MI]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_
M^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_
M .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #
M/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D
M*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0
MI]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_
M^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_
M .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #
M/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D
M*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0
MI]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_
M^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_
M .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #
M/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D
M*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0
MI]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_
M^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_
M .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #
M/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D
M*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0
MI]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_
M^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_
M .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #
M/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D
M*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0
MI]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_
M^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_
M .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #
M/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D
M*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0
MI]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_
M^>:_D*/)C_YYK^0I]% #/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_
M .>:_D*?10 SR8_^>:_D*/)C_P">:_D*?10 SR8_^>:_D*/)C_YYK^0I]% #
M/)C_ .>:_D*/)C_YYK^0I]% #/)C_P">:_D*/)C_ .>:_D*?10 SR8_^>:_D
M*/)C_P">:_D*?10 SR8_^>:_D*?110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPT]\,/\ H;;;_OQ-_P#$5^;M%'^J^$_GE^'^0?V_B?Y8_C_F?I%_PT]\,/\
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M ,11_P -/?##_H;;;_OQ-_\ $5^;M%'^J^$_GE^'^0?V_B?Y8_C_ )GZ1?\
M#3WPP_Z&VV_[\3?_ !%'_#3WPP_Z&VV_[\3?_$5^;M%'^J^$_GE^'^0?V_B?
MY8_C_F?I%_PT]\,/^AMMO^_$W_Q%'_#3WPP_Z&VV_P"_$W_Q%?F[11_JOA/Y
MY?A_D']OXG^6/X_YGZ1?\-/?##_H;;;_ +\3?_$4?\-/?##_ *&VV_[\3?\
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MVVW_ 'XF_P#B*_-VBC_5?"?SR_#_ "#^W\3_ "Q_'_,_2+_AI[X8?]#;;?\
M?B;_ .(H_P"&GOAA_P!#;;?]^)O_ (BOS=HH_P!5\)_/+\/\@_M_$_RQ_'_,
M_2+_ (:>^&'_ $-MM_WXF_\ B*/^&GOAA_T-MM_WXF_^(K\W:*/]5\)_/+\/
M\@_M_$_RQ_'_ #/TB_X:>^&'_0VVW_?B;_XBC_AI[X8?]#;;?]^)O_B*_-VB
MC_5?"?SR_#_(/[?Q/\L?Q_S/TB_X:>^&'_0VVW_?B;_XBC_AI[X8?]#;;?\
M?B;_ .(K\W:*/]5\)_/+\/\ (/[?Q/\ +'\?\S](O^&GOAA_T-MM_P!^)O\
MXBC_ (:>^&'_ $-MM_WXF_\ B*_-VBC_ %7PG\\OP_R#^W\3_+'\?\S](O\
MAI[X8?\ 0VVW_?B;_P"(H_X:>^&'_0VVW_?B;_XBOS=HH_U7PG\\OP_R#^W\
M3_+'\?\ ,_2+_AI[X8?]#;;?]^)O_B*/^&GOAA_T-MM_WXF_^(K\W:*/]5\)
M_/+\/\@_M_$_RQ_'_,_2+_AI[X8?]#;;?]^)O_B*/^&GOAA_T-MM_P!^)O\
MXBOS=HH_U7PG\\OP_P @_M_$_P L?Q_S/TB_X:>^&'_0VVW_ 'XF_P#B*/\
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M'_0VVW_?B;_XBC_AI[X8?]#;;?\ ?B;_ .(K\W:*/]5\)_/+\/\ (/[?Q/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K]<Z_(ROUSK\_XL_Y<?\ ;W_M
MI]EP[_R]_P"W?U"BBBOS\^Q"OR,K]<Z_(ROT#A/_ )?_ /;O_MQ\=Q%_RZ_[
M>_0****_0#XT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@?,F9>0QSD $<%2<9(KK-/\ VW/"NH:XNE7?A>XM?#\CB);R21'*J3C<\.W
M49R<,3CL>E3?"^SE\6?L67FE:5NGU!+2^B,,/+M()Y) F!W9648[[A7QAI^F
MW6JZE;V%I ]Q>W$JPQ0H/F=V. H'KFOBZ.$I9IB,3/%MMPDTM;<J74^HJ8BI
M@*-".'5N9)O2]WV/6/VF=%\":=XQMKOP)J5C<VMY&S75GIS!X;:0$8*$?* P
M/W1T*GL0*G\"_LD^/?'6BPZI'%8Z/:S@/#_:DSQO(I (8*B,0#_M8_+%07WP
M#UCX8_$KP/I_BL6%Q8:OJL$/^C3^8LD8FC$@*D!L8<=1CFO1_P!NCQ%J]OXD
M\/Z)%+-;Z)]A^T^7&Y6.6;S&!! X.T(A&>FZNQ8FHO883"5%+F3?.]=%]UWT
M.=T(/VN)Q,+6:]U::L\6^*7P-\5_"%[=M=M8GLKAMD5]9N9(&?!.S) (; )P
M0,X.,X-=5X3_ &3/&?C3PGI/B#3;O2&M-2 :.*2>59$4DC+CR\ #!Z$U[-X5
MO+CQQ^Q;K4GB.1[UK:VNOL]Q<L6=O);=$=QY)# +]!BI]2UR\\/_ +#UI=6$
M[VURUC# )8SAE5[D(^#[J6'XUR3S3%\JI1LJBJ<C=M'YG1' 8?F=1WY.3F2Z
M^ASGP<_9)O\ P_\ $H2>+3H6M:;8P"26SCDDE#-('$9*M&H(!5LAO;@U1^/G
MPB\0>&OC+I7C/3Y=)6VU37+"UTVV=I!Y<RH@3S5" !-T1SM8G!&*XO\ 8U_Y
M+A8_]>=Q_P"@5=^*G_)Y*?\ 8<TS_P!!@IM8F.92C.I>U.^VC5]K7TUZ_(2=
M!X&+A"UYVW_';\"']K1?&K>*-!'C,:$;PVC"W&@>?LV;SG=YO.[/I3/#/[&G
MQ!\2:/!J$G]F:.)EWK;:E/(DP!Z;E2-MIQV)R.X!KVOXX:;::M^TW\*K>]4-
M;X,FUC@%D=G0?]]*O'>O,/VV/$6JP_%;3+-+VX@M;.PBN+:.-R@20O)F08_B
MX S[5.#QE>I3P^%P]H.47)NUUNU9*Y6*PU&$ZV(K7DDTDK^2W9X]\3/A1XC^
M$NL1:?X@M5B,ZE[>YA??#.HQG:WJ"1D$ C(XP03W'@7]DGQ[XZT6'5(XK'1[
M6<!X?[4F>-Y%(!#!41B ?]K'Y8K%TWXB>(?BY\0O!VG^,=7FUC3CJUK$UO,%
M6+:\J*^54 $E21DC/6O6OVZ/$6KV_B3P_HD4LUOHGV'[3Y<;E8Y9O,8$$#@[
M0B$9Z;J]*KB,9&I1PEXJI)-MV;6G9::G#3HX5PJ8FS<(V26SU[O4\6^*7P-\
M5_"%[=M=M8GLKAMD5]9N9(&?!.S) (; )P0,X.,X-;OPW_9>\;?$[0TUBQ2R
MTW3I?]1-J4S1^< 2"5548XR.I ![9KW/PK>7'CC]BW6I/$<CWK6UM=?9[BY8
ML[>2VZ([CR2& 7Z#%4?A[\5_AG\3/A%HW@7QK>OHD]A#' 5DF>"*0QKM202K
M\N"#DJ_?/!P#7#+,L;[&2C&\H3Y9-*^G=*YU1P.%]K%N5HRC=)NVO:]CP[XI
M?LY^,/A)IL6I:M%:WNFN_EM=Z=(TB1,>@?<JD9['&,\9R1GZ7^%'[.XTCX'Z
MO9R6NDOXJUVPG6'4QN;9'-$!&I<IN4#/(48^M<S\8?A-K-G\%99/"'Q N_$/
M@S3X?-?3;B2&820J^XE9XP-X0\[3P O!X J;X-?\F9^+_P#KWU+_ -%5QXK%
MUL5@X25574TG9->ET_Q6J?<ZL/AZ6'Q4HNF[<C:NT_6S_7<^?1\!/%EQ\3+W
MP-900:CJUEL-Q/;NWV:-616WL[*"  P[9)X -==XH_8W^(/AK1YM00:;K A7
M>]MIL[O-M')(5T7=CT!)/8&O6?V);.RM?ACXOU-W:UG:[:*:ZA&9$B2%64J,
M'D%W(X//8TGPQ\<_!3X5:Y?ZIIOQ'U^_DOD*W$.I0SRQ2,6!\PA;927&,;B>
MC'UKIKYEC8UITJ*YO9V6D&^9];V?N^6YA2P.%E2A4JNW/?>25ETWW\SYT^$?
MP3USXSW6I6^B76GVKV"))*=0DD0$,2!MV(W]T]<5N^.OV8?%GP[\$R^)M9N]
M)BM(S&&MHYY&GR[!0,>6%SS_ 'NQKWC]ER\TC4OC%\4[W09Q<Z/=2QW%M(J,
M@*O)(V K*",$D8([5\]ZG<GQE^TD%UIVO+>Z\3K;2K,=P\G[4$V<_P (3C'I
M79#&8JMC*D$^6$%&35M=5=KI8Y986A3PT)-7E)M7OIH[7-?P+^R3X]\=:+#J
MD<5CH]K. \/]J3/&\BD A@J(Q /^UC\L5RWQ2^!OBOX0O;MKMK$]E<-LBOK-
MS) SX)V9(!#8!."!G!QG!KVG]NCQ%J]OXD\/Z)%+-;Z)]A^T^7&Y6.6;S&!!
M X.T(A&>FZNG\*WEQXX_8MUJ3Q'(]ZUM;77V>XN6+.WDMNB.X\DA@%^@Q7/#
M,<7&E2Q=1IPG*W*EJD]M;ZLVE@L,ZE3#03YH*][Z.WD>=_\ %>_\,?\ _,N?
M\(/_ -O']I?\A#_OW_K?_'/>N ^%?[//B[XNV<U[I$5M::=&WE_;=0D:.-V'
M55VJS-CN0,>]>V_\X_O\_P#05K8\<7MSX3_8MT$Z%(]C]HM+,3RVS;& E(:4
MY']YR0?7<?6L88VK24Z=%)2G6E&]M.FK[LUEA:=1PG5;<8TE*WWZ>AT/[*_P
M<\1_![4O&-IKT<#)=K9-;W5I(7BEV^?N ) ((W+D$#J*^#:^S_V$=>U34/#O
MBC3KJ6:;3+&:W:T\PL51G$GF(I/ 'R(=HZ;L]Z^,*[LL518[%JJTY>YJM.C.
M3'\CPF'=-67O;^J/JO\ 8)_Y#GC#_KWMO_0I*ZB__;>L]*\6WVC7_A"86EK=
MR6LES;WXD=@KE=PC,:@YQTW5R_[!/_(<\8?]>]M_Z%)73:I^TA\'O"_BK4"O
M@*9-:L[J5'O8-(LU=I5<AG$GF;N2"<]:\3&485LRKJ=!U-(VL[6T/5PM65+
MTG&JH:O=7OJ<]^VY\/-%TNUT/Q5IUI'8WUY.UK=+"@03?(75V _B&"">IR,]
M!7)M^P_X_6\C@%]H+(R%S.+F;RTP1A3^ZSDY[ ]#G'%<M^T!\?;KXU:I9QQ6
MC:;HE@6-O;,^YW9L9D?'&<   =.>3FO<?V\?$%W9>'O"NCQ2.EK?SW$\ZJY
M?RA&%!'<9D)^H%=U&6/PL,+@^9*4^:]];):KKT1R55A,1/$8FUXQY;6TNWH_
MQ/G31?@9XI\2>/=4\)Z1#;ZE>Z9*8KR[@E_T6$@X):0@=P1C&3M. <&NXU[]
MBWXA:+I<MY"VE:LT:[C:V%RYF([X#QJ"?8')[5ZE\!'_ .$3_9/\4Z[HK>5K
M31WL\EPN"Z2(F$//]U0& ]R>]>4?LE^+M=C^.&G6J7]U<6VJ"<7\<DC.)<1.
MX=LG[P95^8\]1WKHGC<9/V\Z4HJ-'35?$TM>NGD8QPN%C[*%1-NIV>U]NFOF
M>>_#3X5ZQ\4O%DOAW39+6QU".*29_P"T&>-5V$!E.U6(;)Z8[&O3;']B7X@W
MC7(:XT6U6&1HU:>YD F _B7$9.T]MV#[5ZWX5TRQTO\ ;:\2)8[%6;2S/-'&
M  DKI"7_ !).X^[&O%/VCO''B+3OVAM4N;?4KJ"XTF:); (Y @7RD;"KZ,3D
M_P![/-$<=B\9B%2P\E%."EJK[] >%PV&HNI63DU)QT=MCD+7P+K7PY^,&@:+
MKUF;.]CU.U8<ADD0S+AT8<%3@\^Q!P017U3^U!\$_$OQB\3>&XM"CMXX+.VG
M\^[O)"D2%F3:O +$G!Z ].<<53_:MM+9_%WPEOI,1ZBVJB/9G&Y/,A)XZ_*V
M/^^CZUSG[>.N7UO-X3TR*ZDBL94GGDA1B%D=6C"EAWQSCTR:\Z.*K8_$82M"
MT9M3Z76ET]/^"=KH4L'1Q-.5Y13CY/N>&?$[X"^)_A)=:>NNFS^PWK^5'J5K
M([VZMW#':&! Y^[R <9P:3XM? GQ#\&XM+FUF>PO+?4=XBFTZ221%*[3ABR+
M@D-D=<X/I7T+\=KB36/V0O"-[>NUU=M'ITIFE^9RYA(+9]2">?<U5O()_CU^
MR+8&V1KWQ!H$D<?EJY+L\/R')/4M"X;ZFN^CFF(Y*56K;EYW"7Z/R\SDJ8"C
MS5*=.]^52C^J\SP?3/@+KVI?"FX^(+7^E6>A0K(P2ZFD6:3:_EX4!"I+/\HR
MPR:]P_YQ_?Y_Z"M)^UEJD7P]^%/@WX<6$O6)'N.1N:.%0!N'^W(2V1WC-+_S
MC^_S_P!!6N>KB*N+I4*]39UH\O\ AU2-J=&GAZE:E#=4G?UT/&/A=^S?XQ^+
M.EOJFEQVECIFXI'=ZC*T:2L#A@@568X/!.,9XSD'$WQ/_9G\9?"G0_[8U,6-
M_IBNJ2W&G3,XA+$!=X9%(!) SC&2/45WO@_P'XH'P+2Z\8?$%O"?P^NMC1V'
MV;[3++&S[@%QAE#'D*"<@Y(Q7J>I'11^QSJT?A[4;_5='BLY8K>ZU(8E8+<8
M(QCA0<A1V %;5LSQ%/$+EDI0<U&RB[+_ +>VYO)7,J6!HSHOFBU+EYKMK_TG
M>WFSYLTW]G'Q+KGPS;QOI5[I>JZ:D+3/:6LLINEVG#J4,8&Y>21NY XSD9;X
M=_9T\2Z[\.9_&\][I>BZ%%&\P;4I94D>->-ZJD;9!/"]R>@Y&?1_V'->U^/Q
MAJNC6T)N?#LUO]HO"[$+;R#A&7MN;[I'&0,_P8KJ/VX+S6='\/>&]&L+9;/P
MBQ(<V_RJTR#]W$R@8"A<LH[D'CY!6D\=BXX_Z@I+5W3_ +MKVMW[$PPF'EA/
MK=GHK6\^]^QQ'P9_X3W_ (9W\=?V#_PCG_"+_P"G?;_[1^T?;?\ CT3S?*V?
M)_J]NW=_%G/%>=?"KX!^+/C!'<7&BPV\%A;MY;WU](8XM_!V# 9B<$$X''?J
M*]S_ &=_^32?B;_W$_\ T@BK+_9V^-/@FV^&5SX \932:7#+)(%N1O6.:.0Y
M(+IRC Y&3@8QSUK.6)Q%+ZS+#0O)32T5W:VKMU9<:%&I[!5Y63B]W;7M?H>?
M_$#]D_QQ\//#USK5S_9^J6-LN^<Z;,[O$G=RK(IVCN1G YZ FO&J^X9?@R\W
MPZU6R^$GQ(N7TN0R.VFK<0W,+EE.Z)94&^+/ID^_7-?#U>IE6,EBXS4Y*3B^
MS3^:?Z-GGYAAHX>47"+2:[IKY,****]P\D**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "OUSK\C*_7.OS_BS_ )<?]O?^VGV7#O\
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MQ"OK>65YM&LRCNBQW%S)ND"L0&&V,X#8R-V#@C('2NU_9I_Y.H^(O_7/4?\
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MVB:UTA;8W$[H03$F1AAQE@GS   D#''HOQ<DTV3]CG_B3WEYJ&EK%:);W-^
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M<1AX>S@]%M=7MZ'=?%7XO:U\5O&0UZ\<V1@PME;6[G%J@.1M;@EL\EN"3Z
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MMN[?S9E7Q-3$64[66R2LD%%%%=QR!1110 4444 %%%% !1110 4444 %%%%
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M:FDU9\RU=D_);'0\SQ#BXNVJL]%=KU"BBBO;/*"BBB@ HHHH **** "BBB@
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MKZ(HH_M?'_\ /YA_9N#_ .?:/G?_ (8:\ _]!+Q!_P"!4/\ \9H_X8:\ _\
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M _\ 02\0?^!4/_QFOHBBC^U\?_S^8?V;@_\ GVCYW_X8:\ _]!+Q!_X%0_\
MQFC_ (8:\ _]!+Q!_P"!4/\ \9KZ(HH_M?'_ //YA_9N#_Y]H^=_^&&O /\
MT$O$'_@5#_\ &:/^&&O /_02\0?^!4/_ ,9KZ(HH_M?'_P#/YA_9N#_Y]H^=
M_P#AAKP#_P!!+Q!_X%0__&:/^&&O /\ T$O$'_@5#_\ &:^B**/[7Q__ #^8
M?V;@_P#GVCYW_P"&&O /_02\0?\ @5#_ /&:/^&&O /_ $$O$'_@5#_\9KZ(
MHH_M?'_\_F']FX/_ )]H^=_^&&O /_02\0?^!4/_ ,9H_P"&&O /_02\0?\
M@5#_ /&:^B**/[7Q_P#S^8?V;@_^?:/G?_AAKP#_ -!+Q!_X%0__ !FC_AAK
MP#_T$O$'_@5#_P#&:^B**/[7Q_\ S^8?V;@_^?:/G?\ X8:\ _\ 02\0?^!4
M/_QFC_AAKP#_ -!+Q!_X%0__ !FOHBBC^U\?_P _F']FX/\ Y]H^=_\ AAKP
M#_T$O$'_ (%0_P#QFC_AAKP#_P!!+Q!_X%0__&:^B**/[7Q__/YA_9N#_P"?
M:/G?_AAKP#_T$O$'_@5#_P#&:/\ AAKP#_T$O$'_ (%0_P#QFOHBBC^U\?\
M\_F']FX/_GVCYW_X8:\ _P#02\0?^!4/_P 9H_X8:\ _]!+Q!_X%0_\ QFOH
MBBC^U\?_ ,_F']FX/_GVCYW_ .&&O /_ $$O$'_@5#_\9H_X8:\ _P#02\0?
M^!4/_P 9KZ(HH_M?'_\ /YA_9N#_ .?:/G?_ (8:\ _]!+Q!_P"!4/\ \9H_
MX8:\ _\ 02\0?^!4/_QFOHBBC^U\?_S^8?V;@_\ GVCYW_X8:\ _]!+Q!_X%
M0_\ QFC_ (8:\ _]!+Q!_P"!4/\ \9KZ(HH_M?'_ //YA_9N#_Y]H^=_^&&O
M /\ T$O$'_@5#_\ &:/^&&O /_02\0?^!4/_ ,9KZ(HH_M?'_P#/YA_9N#_Y
M]H^=_P#AAKP#_P!!+Q!_X%0__&:/^&&O /\ T$O$'_@5#_\ &:^B**/[7Q__
M #^8?V;@_P#GVCYW_P"&&O /_02\0?\ @5#_ /&:/^&&O /_ $$O$'_@5#_\
M9KZ(HH_M?'_\_F']FX/_ )]H^=_^&&O /_02\0?^!4/_ ,9H_P"&&O /_02\
M0?\ @5#_ /&:^B**/[7Q_P#S^8?V;@_^?:/G?_AAKP#_ -!+Q!_X%0__ !FC
M_AAKP#_T$O$'_@5#_P#&:^B**/[7Q_\ S^8?V;@_^?:/G?\ X8:\ _\ 02\0
M?^!4/_QFC_AAKP#_ -!+Q!_X%0__ !FOHBBC^U\?_P _F']FX/\ Y]H_+;XJ
M>%K3P3\1-?T&P>:2SL+IH8GN&#2%1_>( &?P%?J37YG?M"?\EL\8_P#7^_\
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M+_T0E=97)_"7_DE7@S_L"V7_ *(2NLKSL1_&GZO\SLH_PH^B"BBBL#8****
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M+X]?L92:SXST+3/$'BKXC#4=2UC6KVU5KEKB2XF6)DE(9T$0"!-I^4KD 9H
M^VZ*\#_8,^(FH_%3]D/X:>(]7N9;S4I=/>SGN9SF25K:>2VWL>['R<DGDDY/
M6G:#^T1J.F?$[XZ>&_&5M86=AX"LK;7M.NK2-XVNM+EMGE=Y"[L"\;Q2(64*
M.G% 'O595OXJT2\\17?A^#6+";7K.%+FYTN.Z1KJ")R0DCQ [E5B#AB,''%?
M'GPW_;J\4Z_^Q=XY^*/B/0=+T_X@>'[@V$.BV\$RP2W,Z0-8 Q-*9"'^U0Y
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MN$/L1 #T)&"0#ZLKF+7XH>#;[QE/X0MO%NA7'BR!2\N@Q:E"U]&H )+0!MX
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M"B@#YUL?!NLW7[9OQ%U-M,O(-%U#P#I^GV^JR6SBU><7-T6C63&UG4.I*@Y
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M*' U&[)"^=,W.U""B GKG)]P_:&_:<\>?\,]VVN?"WX:^/8?%.N:@=+CBO\
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M8:@[P[;6*&SN&+-(LGS%U 10.">A^]Z* "BBB@ HHHH **** "BBB@ HHHH
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MXST[X2_L5V=WX1UVUN_#_B"[FUBWFTV9)--C(N</<*5S"IW+@O@<CUK]$**
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MYO6OAGXPE^ O[:6GIX4UM[_7_%6H7&D6JZ=,9=2B:. +);IMS*I(.&0$'!H
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MMXH^,7QF^)?QHN?".M^$]&_X5_+X*T#2]:M3!J.HYE>YEN'MN7B_>;416PS
MYP* )/A9^U-\3)OV?3\=_B5I_A'2OA^F@/J(TG1([EM4FG4JD9#R2&)4EDW;
M4()4-'ES\V)=5_:&^.OPT^&MA\6O'_A'P@G@%UM[K5/#^BR73:UI%G,ZJ)3*
MY,4[1AU+HJ)CG#<$T+^S]KGQ>_X)HZ+\+)[:70_$USX1T^)+35(GMWAO+?RI
MHXIE8!D_>1*K9&1D\'&*\;_X5KX%U_PE8^'I?V8?BQJ/C>Y6*TO="U/Q%K5M
MHD;Y E9M2>Z> PCD@J&)X&T<X /I7QY\=_''BCXS1_#'X/V/AVXO[/1H=>UG
MQ)XF,TMC9PS,1;PQPP,KR2R %^750O//2O%/A+X\\7Z!^T=^UCXC\1:+I^F>
M,-!\)Z7/);6\CSV$\L%G.\<L;'8YBD"JVTX9=Q4G*YKO=9T/6OV8_P!I34?'
MUCX)USQ5X"\6^'K#2;V/PK:R:E>:/=V0*0Y@ \R6%XV WJ"0P.X#J>&\&P^/
M?B-\2?VKO%&J_#KQ)X6L?$'@VVLO#]KJ>GNL]XB6ETBJ-H(:9BP)B!+)YBJ1
MD4 :7_#4O[0-K^SCI/QWN_"_@+_A$%TZUU._\/1R7:ZE/;$*)9X9BYBBRQ+I
M$RR$(0"[-Q7J7B'XM6TG[5WPRTRW\.:+>V>L^#]0UB/7+C3R^KV\:F-A##+N
M^1'#99,') YK@M>\!^)IO^"6,7A./P[JS^*AX%MK,Z&MC*;[SQ&@,7D;=^\$
M'Y<9XK13P3XI7]J+X':M;Z%?I9Z=\.KVRN-0GLI3:VETRP[(IG  1B0?D)#'
M!Q0!E?"_]IKXX_';P&/B)\/=)^&^N:1)</Y?@5K^=-<2!9C'MFNC((8IMHW[
M6BVX(Y.0*]+^)GQU\;7OQ@T[X3_"[1-(D\6C2%UW6M6\3-(UAH]JS[(T*0,&
MFF=@<*KJ  #DC)'R?\3OAM9_$#PMJ<US^SCXN\'?M+J95M==\!6,]CI1ORY$
M=VM^D@@,1R'<R'S/O#.?FKVV3P_\0/V>?CEHWQ-UGP]JWQ'TS7O!FG^'O%$_
MA>U-W?V>IVV";E;9?FEAD+-G8"RG)QP P!V?@S]HOQGIOBWQ]\./B)H^BV7Q
M"\.^''\4:=>:&TK:;JUAED$JQR'S(BLJA&0L>O#<9/E^D?M2?M"ZG^S39_'7
M_A&/A_'X7MM-&IWN@.]X-0O+>,8GFAEWF.#)#LD;+(=@&6+'%;VD^&?%GQL^
M,OCWXPWWA#6O"GAVS\!W/A+PWI.N6WD:EJ$LCM--<M; EXQD+&J/R00=H.:B
MT'P'XFA_X)8R^$Y/#NK)XJ/@6YLQH;6,HOO/,;@1>1MW[R2/EQGF@#N_B1^T
MWKUYXB^&G@OX5:)8:MXP\<:5_;Z7.OO(ECI.F!%8W$ZQX=V)8*J*1D@Y(XSJ
M?"[XV>,;;XS77PE^*6FZ+;>*I-)_MW2-8\-F9=/U.U63RY4\N8L\4T;%<IN<
M%3D$=_G;XF?LZ3KK7P/^)>O> O$GC/0K#P':>%?$.B>';N[L]8TUD198KA(H
M)8I9=KO+&\0.1D':Q QZ/^S7\./!LWQHE\3^%O@KXS\)V.F:9);P^+O'>LZE
M'<R22, ]O!I]W+(Q3:,F5MG(P <@D ]U_:$^-5A^S]\*-8\9WUC/JSVIBM[/
M3+4XEO;J618X85/;<[#)P< $X.,5XMXR^/7QO^ /A_2_'?Q8T'P1/X!DNK>W
MUJW\,R72W^@I/(L:2O)*S1W*H[HK[%3D_+D<CT#]LGX1Z]\9O@7J&D^%?(D\
M3Z=?6>M:9;W3;(KF>UG640LW;>%903@9(R0,FO&_CSXX\9?M<?"EOA)X>^%?
MC;PAJWB2>U@U_5?$VE_9+#1K:.>.2X9+ASLNF/EE4$6[<&S\IP* .S\7?&[X
MQ:Y^TYXI^%'P\T[P;#:Z/HEEK/\ ;'B2.Z?R_-+JT3)#(#(7;9M(VA KD[R5
M%7_&GQ9^,EUXT\1:7X>L/!O@/PYX?6&!O$_Q!CN1!K-PT8>3['''+%B%"0ID
M9VR> #SB]\-?"&IZ+^V-\5]3;1[ZU\/W'AK0;2QOY+>06\S1&Y#QQRD;79 R
MY )(W#/6O AX%M-#_:#^+&I_&7X'^)?B]KNI:R9_".JVVA?VOI@TK:/LUHK.
M?)M70Y#F78"23G') '?&']H2;]HS_@G_ /$G5;ZTTZVUC0?%ECX=U%]&NC<V
M%Q/;ZO8'S[:4\M"Z2(RGGKU/6OO^OS0T7X2?$"S_ &+/VA?#NH?#W4M'\4ZM
M\3HM9MO#NEZ?+*GV>2^TN4_9-B;9H8Q'*-T8*@1,> *_2^@#X#_X*6?#/QGK
M'@O5_&.M^-I%\&:3J^CIH'A'3(?*C:1YX(YKB]D.3*^YY0B+A5&PYSN%>L_M
MYW$NMZ+\)? ,DC1Z)XV\>Z9I&M*C$&XL1OEE@X(XD,: G/3/!S6C_P %"/"F
MM^-/V9]2TOP]H^H:]J;ZOI4JV6F6KW$Q1+Z%G8(@)PJ@DG' !)K3_;(^&OB/
MQIX-\(>)?!^G?VUXH\!^)[+Q3:Z2)1&VHQP%EFME)X#/&[8[Y4 =<$ X#]I3
MP?X>^!GQ>_9X\=^#]$T_PS?77C"V\$7JZ1:I;+=6-]%(HAD1%"NB-$K+G[A&
M17T9\9=>\1^%?A/XOUOPC;6=[XFTS2[B]T^UU")Y(9Y8XRXC9496.[;M&&')
M%?.OB#5/$'[6WQ<^$L5K\/\ Q=X/\%^"M8'BK5]0\8:6VG-)>Q1,MK;6\3G=
M*P>1BT@&Q0O#$G%?73HLB,CJ&5A@JPR"/2@#XU^/_P"W=JOPX^!?P;\=>%-&
MT_5[[QI'%JE_9W,4DBVVFQ6HFOV0(ZD/&7106+ <C#$BN_\ C'\9]7OOBI-\
M-O#T.G76AGP%JGB77KV6-WECB93#9I"ZN%4N_F,=RME5XQUKY\_9]_9E\4:Q
M\1/B5\/O%^@7VG^ /!OA[6?"7A6^OK:1(;R#5KV6?SX9&&',<*QQG83LR <?
M+CH_V*?AY\0KKX._%+QC\1O#NJZ1XUU71K?PO9Z;J%M(ER;/3M.$$;HC*&_?
M3/*YQD,W(R,4 9W[)_[0^N:G\&_@O\)?A)9Z;K?B^VT>UN_$^JZI')+IWAZQ
M+'_6B.1&DN9!_JX0P]6('->N^+OVB/'OB;]HKQ1\)OA]<^!O#VH>&;.QGN+G
MQM]HDEU62YB,@6S@ADC)1%VAWW-AF V]Z^?_ (6? 'Q-^S9\%O@M\8_ 7@?5
MH?&.EV2V/COP?:V4HU#6K"XF)D8P$;VN87*NH(!VC'W4 KU#]H31O#_CWXB:
MK:_&#X :EXZ\&75E:R>%_%/A+0+JYU2-6C)GMKSR6%Q RN<KPJ8)SALB@#Z<
M^$&N>-O$'@>VN?B%X9M?"GBI)98;FRL+U;NVD"N0DT3@Y".N&"M\RYP:[6OG
M+]A7P5XU\#_"?6;3Q;'K5AIUQK]Y<>&='\1W7VG4=-T<[!;P3ODX;Y7;9D[0
MP&>P^C: "BBB@ HHHH **** /S._:$_Y+9XQ_P"O]_Z5^F-?F=^T)_R6SQC_
M -?[_P!*_3&OM,__ -VPG^%_E$^6R?\ CXGU7YR"BBBOBSZD*_.S]DG_ )+]
MX9_W;K_TEEK]$Z_.S]DG_DOWAG_=NO\ TEEKZ_)?]RQO^'])'S6:?[UA?\7Z
MQ/T3KS?XK?'SPQ\';S3K36UOI[F]4R)'8PJY1 <;V+,HQG/3)X/%>D5R7CGX
M3^$_B3)9R^)-&BU.6SSY,C2/&R@D$@E&!(R.AR*^2CRW][8]G%K$2HM85I3Z
M7V.CTO4K?6=,M-0M'\RUNH4GA?!&Y&4,IP>G!%?)?_!23_D6/@3_ -E:T'_T
M"ZKZYM;6&QM8;:WB6&WA18XXXQA44#  '8 "OD__ (*.:'KVJ^ ?A1?:#X9U
MSQ6^A_$;2=8O++P]ITM]<K:PQ7)DD\N,$X&5&3@991GFI.N-[+FW/K6OE_2/
MCC\8/CGX@\83_"#2O!NG>#?#6ISZ*FJ>,1=2RZS>0$";R%MW7R80WRB1M^>H
M7@@=!X9_;"M/$WB32='7X0?&#3&U"[BM!>ZGX*N(+6W,CA/,FD)PD:YRS'@
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MUSX\:/\ LI>._AY=Z-::/KOB^TGL8=;MI99(-2"S+MF\J50T4965&5<,6'#
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M% !1110!P'QC^"^B?&[2?#^GZ[=:A:0Z)KEGX@MVT^1$9[BV8M&K[T;*$GD
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M[MU_Z2RU]?DO^Y8W_#^DCYK-/]ZPO^+]8GZ)T445\@?2A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@6J
M?L=Z+)KNO7_AWX@_$'P)9:]>2ZAJ.C>&=;2"RFN)6+2RJKQ.T+.22QB9,D^P
MQZO\-OAQX>^$?@?2?"/A73DTK0=+B\JVMD8L1DEF9F))9F8LQ8G)))-=-10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')
M_"7_ ))5X,_[ ME_Z(2NLKD_A+_R2KP9_P!@6R_]$)765OB/XT_5_F8T?X4?
M1!1116!L%%%% !1110 4444 %%%% !1110 4444 <A\8/^22>-O^P'??^D[U
M-\*_^27^#_\ L#V?_HA*A^,'_))/&W_8#OO_ $G>IOA7_P DO\'_ /8'L_\
MT0E=_P#S!_\ ;WZ')_S$_P#;OZG4T5D^*_%%AX+\.:AKFJ2-'86,1EE9%+-@
M= !W)) _&N9^$_QFT#XR:??76AI>0FRD6.>&]B5'7<"5/RLP(.#W[5Q<KM?H
M7+$4HU8T)27.]4NIWE>6S?M5_!2WF>*7XP> 8I8V*O&_B>R#*P.""#+P:]2K
M\V/V.?V@?@/\,?V>([?XB11P:G::MJ;W=Y<>$;V]B56OI2F;F.U>,\%1]_CI
MP>*DZ#]#O"GC3P_X\TE-4\,Z[IOB+3'.U;W2;R.ZA8^@>,E?UK9KXQ_94T>.
M^_:$^*?Q3\$>#]1\)?"'6M%LTL[9].:Q_MN^CR[7EO:%595V$J&VKO+Y&23B
M/QE^U!\;_"?PTU#XF:OIOPW\$Z3;03:A'X#\4W-S#K\MM'DB,S>8J)<2* 5C
M\EN64=3@ 'VE17RI\3OVKO&:Z]^SQ8?#3P[H^J'XM:5>ZA#%K\DL7V4):6US
M$[21GA$2:1G78Q;8 NTG-;OPX^.WC_0_CUJ7PI^+5KX9^V-X=;Q/IGB#PNL\
M-K+;QS"*:*:&9Y&1U)W!@VTJ#W.* /HFZNH;&UFN;F:.WMX4:26:5@J(H&2S
M$\  #))JIH'B#2_%6C6FKZ)J5GK&DWB"6VOM/G2>"9#T9)$)5A[@U\A+\=_C
M5\9/@GXF^)>@>$_"T7PQN["_-AH=U+<C7[ZQ19(S<K(/W*.0I=(2AW  ;UR&
MK%^!WQVUCX;_ +*?[./@CP5HEMXA^(OC73&ATFVU"9HK*UA@4R7%U<LOS>7&
MK#Y5^9B< Y% 'W/17SEX;^.'Q'\ _&SPK\.?B[IWAF<>,(+EM \1>$EN(K=K
MBWC$DMM/!.SLC;,E7#D-@#&20/._"?[27[0'Q0\*?$KQ%X5T#P#9Z9X(US5M
M-/\ :XO#+JRVCL?+B5)0(6\K8#*[,K.Q^10* /M&LG_A+-#_ .$J_P"$8_MG
M3_\ A)/L7]I?V/\ :D^V?9?,\O[1Y.=_E;_DWXV[N,YKXZU;]L#XQP?L_6'[
M0$/A#PE:?#@1VUU=>&Y[FXEUF2U>1(9)HK@,L*G>Q949"2@!)#':/2[[XC7=
M]^VW<>#]$T'PL+Z;X4MKECXHN].9M1\PZD8H[9YE<,;/)$AB !W9.X4 ?2%%
M?%GQT^-_[2/P9F\,:/!?_"OQ5XS\47RV.C>&M/T+4EN+G!!EF9FOL1Q1K\S.
MW X^H]"\;?'3XD77Q;T;X/\ @#2O#=YXXM]!CUSQ-K^L"X_LG3E8^6J10HPE
MD=W#%5+C"XR3\Q4 ^D:S]?\ $&E^%=&N]7UO4K/1])LT,MS?:A.D$$*#JSR.
M0JCW)KY]\,?M6:AX2_X6CH7Q;TNPTCQ7\/M*&O7,V@R.]EJVG,C,D]LLGSHV
MY3&T;$X;&&8'CP[]I?XB?'?Q;^Q?XS\7>)_"OA*T\'>(M#$HT72YKDZQI5O/
ML,,TTC_NIB-R^8BI&5!)!)4J0#[^M;J&^M8;FVFCN+>9%DBFB8,CJ1D,I'!!
M!R"*YGQI\6/ _P -YK2+Q=XR\/\ A:6[_P"/>/6M4@LVFYQ\@D==WX4_X6_\
MDR\(_P#8'L__ $2E>467[/O@;X<Z]\5?B=\2KW2O%4FNW,E[/J?B*PC,6D:5
M'$JI9+YC.-B .2PV[]P!7(R0#WFSO(-0M8;JUGCN;:90\<T+AT=2,AE(X(/J
M*FKXU_8OO/&/@_\ 96\8>(/"?@J[U^PO?$^I:IX"\(WM^FG.=%EF3[/$)9@5
MA7'G2+NX(((^\#7OWQ:\,_$'XB?#_2]+\)>)(OAQJU_/"=8U#R1>7-G:F)S-
M%:GA/.W^6HD/ 7>P&=M '>:/XBTKQ#]M.E:G9ZF+&ZDLKK['<)+]GN$QOADV
MD[77(RIP1GD4:_X@TOPKHUWJ^MZE9Z/I-FAEN;[4)T@@A0=6>1R%4>Y-?*O_
M  3/T"+PI\'_ !]HD%Q<W<&F_$#6K..XO)/,GE6-XT#2-@;G(7).!DDUWO[>
MW_)G/Q9_[ DO_H2T >]13)/$DL3K)&X#*ZG(8'D$'N*?7S;XJ^./C2X^(/AS
MX1_"K2=&N_%*>'X-<UC6O$AE.G:5:,1'&ICB*O--(P.$#+@8).,X=X(_:<US
MPOXP\>>!_C)IVDZ1XD\)^'6\7C5/#K2M8:EHZ%EDGCCE)DB9'4JR,S<G@D#)
M /I"BOD;2?CU^T/K_P ,['XN:7\/_#&I>"[^.+4;3P3:-=2^(I].D(*2I.#Y
M)E,;"01"/E3C=GBNW^(WQ:^*=UX^FT#P1H6A>%- L=,M[^\\8_$&&X6REFFR
M5M+>.-X]\BJI+DR?)T(Z9 /==:US3O#6D7FJZO?VNE:79Q-/<WU[,L,$$:C+
M.[L0JJ!R23@58M;J&^M8;FVFCN+>9%DBFB8,CJ1D,I'!!!R"*^'?$_[1FI?'
M#]DW]IO0M?7P_-XB\&Z9=Z?=:EX4NFN-+OXY+5GCFA9B2IX=60LVTKU[#Z_^
M%O\ R3+PC_V![/\ ]$I0!U%%>'_!7X\:EXH\6?&'PKXX32]*UOP#K!!>Q22*
M*72)H1-9W3AW;#% ^_!P"G;->4:5^V=XXO\ X)^!-?A\(Z;?^._B;K]Q8^#=
M##26L$>GAV\NYO7+N2%B7S'*8R'4!5Y- 'V/17SKH/QK^(_P[^+_ (2\!_%Z
MP\,SP^,EN$T/Q#X26XA@6[A02/:W$,[.5+)DHX?#$8VCMA? _P".'QF^.'Q&
M\>065AX)TKP3X,\<ZAX8N[BXANWOKZ"WF Q$%EV1RK$R$NVY69^$0+R ?4]%
M?&7PU_:>^-GQ\\'ZAX[^&NE_#O4=+@NIXX? FH7=Q'K[113M%B>?S!%;RN%W
MJKQE0&7+<U[7=_&+7K?]I3P?\/)--L[72M8\)WFNW0E!>[@N8IX(Q$'5]A4"
M5L_*<D @XZ@'L5%>!:M^T1J^@_M*>-? UUIUK<>&/#W@-?%@>UAD-_+,)W1H
MP=^TJ53A0@.3U[5Y[\*_VA/CO\6O!>@_$/POI/PV\6>'=2EADG\(Z1J$R:Q9
M6\C@,'NY91!YT:DEHVC3." 2< @'U_69H?B;1_$RWS:/JMCJRV-W+87;6-RD
MPM[F,XD@DVD[9$/#(<$'J*TZ^&OA?\<HO@%\*?C1K<>DR^(==U/XT:]HFAZ+
M#((FO]0N+L+##O/"J2&);L%. 3Q0!]RT5\MZY\<?C+\"]6\(ZC\6])\%ZAX,
M\0:K;Z-<WGA'[7'<:+<7!*PM*)V99XMV%9UV$9R%Z ZFK_&WXF_$OXP^,?!'
MPBT_PM9Z?X+,%OK/B'Q<MS-%/>2Q^8+:WA@=&^1<;I&;@G 4\$@'TA17S<_[
M0'Q8;X0VUVGPANH?B7)XB;PU+I\YE&E0%6(;5&GV;C8[1N#@9).T$_>K!\-?
MM.>-_"?[07@KX:^/=3^'OBA/%XO(K6Z\#S31W&FSP1&3;<P2S2DHX5E5P1\P
M.1QR ?3FB^)M'\2-J*Z1JMCJC:;=O87JV5RDQM;E I>"7:3LD4,I*-@@,,CD
M5IU\V?L7_P#(3_:'_P"RL:O_ .DUE7I7QD_:+\ ? '^R/^$YUBYTG^UO.^Q_
M9]*O+[S/*V>9G[/%)LQYJ?>QG/&<' !Z317QU^QG^W9X6^*G@7PEH'BWQ==:
MI\3=4O;Z!D_L"ZBCD O)_LX\V.W6W7_1UBYW#I\WS9KZI\<>,M,^'?@O7?%.
MM2M!I&BV,VHW<B+N811(7? [G"G [G H W**^0Q\?/VA;GX2R?&2W\%^"T\$
M?8CK<?A&>>Z_MQ],">8)/M()A$QB^<1^7T.-V[BK_P 0OVJ/&>M>.O@GH/PD
MTWP_J%I\3="N]6M[[Q(DZBR6.*&9)'$3@D!'<&,#+-M&]!DT ?5M5]0U"UTF
MPN;Z^N8;*RM8FFGN;B01QQ1J"6=F/"J "23P *^?/&/Q*^-NEZUH7A'3M&\)
MV6I1Z.=3\0>/-:@NX_#L,OF%%MK:,2"1Y"!N(:4;5YR>E<)H/[2&L?%?P!^T
M9X"\3MX9O_$7@[P[.[:UX.N6FTR_AN+*9EV!V9HY$*%71F.">.F: /KO2=6L
M=>TJSU/3+RWU'3;V%+FUO+25989XG4,DB.I(964@A@<$$$5;KRK]D[_DUGX-
M_P#8F:-_Z0PUZK0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?F=
M^T)_R6SQC_U_O_2OTQK\SOVA/^2V>,?^O]_Z5^F-?:9__NV$_P +_*)\MD_\
M?$^J_.04445\6?4A7YV?LD_\E^\,_P"[=?\ I++7Z)U^=G[)/_)?O#/^[=?^
MDLM?7Y+_ +EC?\/Z2/FLT_WK"_XOUB?HG117F_Q6^/GACX.WFG6FMK?3W-ZI
MD2.QA5RB XWL691C.>F3P>*^147)V1[U>O2PT'5K2Y8KJSTBL7Q5XT\/>!=/
MBO\ Q+KVF>'K&:=+:.ZU6\CM8GF?.R,-(P!8X.%')P:T-+U*WUG3+34+1_,M
M;J%)X7P1N1E#*<'IP17R5_P4\\+VWCCX*>!_#E[)+%9ZQX]T;3YY(2 ZQRM)
M&Q4D$9 8XR*1LFFKH^NKJZAL;6:YN9H[>WA1I)9I6"HB@9+,3P  ,DFJF@>(
M-+\5:-::OHFI6>L:3>();:^T^=)X)D/1DD0E6'N#7R;\"_BIKD'PT^)?P1^(
MMSO^)'@'1[F!;N0MG6]*\AA;7Z%N6RNU7Y)#8W8+$#!^$/QXO?@G^PS\ [7P
M]H:^)O&WBR.UT+0=*EF,,+W$A<F69P"5BC4%F(YZ#@98 S[@HKYML_C5\4?A
MC\3/"'A'XM67A.:R\:O+8Z-XB\*)<QPVFH)'O6VN89W+,' ;9(CC)4@JN<UQ
M5]^V=XRL?V,[CQ__ &#I$_Q;AUYO"?\ PCT,4QLWU8:@;;RE3S/,(,8WA=^<
M\9H ^QZ*^9/^&J-:\3>$_P!G";PK9Z5-K_Q1N;>6]@NHY)(K2QCM3/J+1!9%
M.^,X12Q(!/(->Q_'#Q!XJ\)_"'Q=KG@BUL;_ ,5:9ITU[86FI1/+!.\:[S&5
M1T8EE5E&&'S$$\<4 =Q659^+-$U'Q!J.@VFL:?=:YIJ1RWNF0W2/<VJ2 F-I
M8@=R!@"5+ 9QQ7@/Q,_:NNK/]F'P5\0? =GI^I^*O'4^EZ;X>TW4=[0/?7;J
M&BD",K'RU$V<$<Q]<5SNM?M#CX8_&#]I"]O/"&AW1\#^&-*U634-)L3;ZGJK
M-;R-Y=Q.6;=&A&$R/D4G[U 'UK659^+-$U'Q!J.@VFL:?=:YIJ1RWNF0W2/<
MVJ2 F-I8@=R!@"5+ 9QQ7SI\+?BQ\=_&$/@SQ,EE\-O'/@W7)8?[0A\(WLT5
MWH\$B[C*9IYC'<;.C(JHQ/0=2*NH?M%:1\,OCK^T5>Z[X=T2RTKP5X?TC4YM
M7TRP":MJ7F0N5AGF+8EPP"1@A0N_KWH ^JJ*^1=>^/7[0G@/X7K\7/$W@SP6
M_@N&!-3U#PGI\]U_;=CI[8+/]H=O(EE1#N9-B#@@-D5K_$+]I#X@WWQ^\'_#
MWX7Z7X:U2P\4>#_^$DM]6UWST6T_?@"9Q&V9(_*X$2A6+R(=ZJ#0!]1TUW6-
M&=V"JHR68X 'K7@GP%^-GC;Q!\6/'GPN^)6FZ'!XK\-6]IJ5OJ?AKSELM0L[
MC<%;RY69XG4K@@L<Y..!DZO[:"ZT?V4?BR="FL8+E?#&HM.U_&[J;86TAG"!
M&4B0Q[PC$D!BI(8 @@'I>H>//#.E6&B7U[XBTFSLM<N(+32KFXOHDCU">8$P
MQ0,6Q*\@!*JF2P'&:W:_,SXC77CO1_V,?V/[R^@T77]8A\<^#Y_#VGZ8LMHL
MUN-.8VMO</([_OBP*O(H"?,"$&#GZ;TWXV_%CX<_';P#X&^*>G>#[W2?'27D
M6F:EX2%U&UC=V\/G-%.L[,949>%D4)SU510!],45\L_"OXW?&CXP_%KXA:/I
M%CX)TOPAX*\82Z)<WM]#=O>7MJIC)2)4EVI,J%V,C?*Q>-0B[68T/!7[0GQM
M^/N@ZUX\^%7AOP:GP^M;RXM]'MO$<ET=1\0I Y226*2)A';!F5U3>K\CYL#F
M@#ZUHKYR;]J;7/B'\"_ OC3X5>"YM>U;Q==BR\G4V=+/0F4NMS+?R("5CB:-
MUXP6.,8SBL'P/^TWXRT7]HSPI\*?'FI_#_Q1+XKM;V6PO_ LLT<EC-:Q>:\=
MW;RRRE5= ^Q]PR4(QP: /J*VU*TO+FZM[>ZAGN+5@EQ%'(&>%BH8!P#E200<
M'L:LU\#?LC>,?&/PRUC]IWQ?XXU+PY)X6T'Q1JE]KRZ78W*W,EY%;Q.S6Q>9
M@(2BD"-@S[B/G[5V\?[1WQZL?@_'\;=4\%>$5^'OV1=9F\*V\]S_ &]%I3 /
M]H%PQ\AI%B/F&(QKP/O@\4 ?85,EF2")Y976.- 69V. H'))/85\P_$O]I?Q
MQ<?&+X:>#/A7I?AW6['QSX:FURUU36VF2.V56C=)V,;9>/RF;]V%W,S)\ZC)
MK1^&/QT\=3?$[Q_\*_B;I?AN3Q-HFA1^(++4O#JSK8:A92%T(>&9F>-E<!2"
MYW9., 9(![[X;\3:/XRT2UUG0-5L=<T>[4M;ZAIMREQ;S*"5)21"589!'!Z@
MUIU\)>#_ -JSQIHG[/?[-]WX)\!^#K?4?B!?W6EG0+&WDT[3;1@9_+:$([>2
M@=5=^')&_ R1CUSP;\:_B?X3_:&T'X7?%2Q\*7:^*-+NM1T36?":7,*K);;3
M-;S13NYSM;<) P!X&,DX /I&BOD_PK^T#\:OC5I>N^//AAX:\'W'PZT^]N;7
M2[+6IKG^U/$26[M')+!+&?*MU=T98]ZODCYMHYKTO]CWXU:O^T1^SMX5^(.N
MV=GI^IZP]]YEM8(Z0HL-[/ @ =V;.R)2?F/S$XP.  >G_P#"6:'_ ,)5_P (
MQ_;.G_\ "2?8O[2_L?[4GVS[+YGE_:/)SO\ *W_)OQMW<9S6M7Q#\5+WQW;?
M\%-+"#X>V.BW.MW?PF6"6Z\022BTL;?^V)':=DB^>4[D1 @9<F0$L #7HOP[
M_:FUW0[KXS:%\7M/TFPUSX8V4.KWFH>&1*;/4+"6!YD>*.5F=) (RI1F.2PP
M3UH ^F:*^/8_VCOCU8_!^/XVZIX*\(K\/?LBZS-X5MY[G^WHM*8!_M N&/D-
M(L1\PQ&->!]\'BNB^)7[2WCBX^,?PT\&?"S3/#NMV/CGPU-KEKJFM-,D=LJF
M-TG8QMEH_*8_NPNYF9/G49H ^H**^0O"/QX_:!\6?%+QI\)(]"\ 6WC#PJ+>
M\N_%+F\;29+2XC#VZI:"3SO-8[@<RA5V-U^7=;T/]MR\T_\ 9Y\5>+O%'AF&
M?QYX;\57'@6;0-$G/D:AK*2I%&D#R<K&_F*Q+9*@-]X@ @'UE17RKXH^.GQK
M^ L?ASQ+\6=%\$WO@;4]1M]-U-_"C74=YH3W#A(I',S,EQ&KLJN5"'G(!Z5+
MK'QN^,WBS]ICXA_"[P!8>"K;3_#%CINH#5_$45VYQ<0LS0LD,@WLS8VN-H18
MVR'+# !]2UD^'_%FA^+/[2_L36=/UG^S;V33;[^S[I)_LMU'CS+>783LE7<-
MR-AAD9'-?-W@7XV?&GXI_&WXC>%?#]CX(T[PQX(\00Z?=:EJ<-V]Q>6[QQN8
MXHTEPLJKYK>8QVG=&NSAFKR/]EV^^-4FN_M(6GPRLO!D&G6_Q6\0W+WWBPW4
MIN[EGC'V:..!D\L*J(QE9F_UJ@(<$T ?H'17S!X;_:P\7?$;]FOP=XY\%_#V
M35/&?B'4CHLVER2N;#29TFDAGNKJ9%)%LAB+9')#*,YR1G^&OVG/&_A/]H+P
M5\-?'NI_#WQ0GB\7D5K=>!YIH[C39X(C)MN8)9I24<*RJX(^8'(XY /J^BOE
MS1_CG\8_C5X@\:7WPET7P;%X*\,:K<:)%<>*7NC<ZY=6^!/Y!A(2"+<2BR,)
M,D9P.0.9\,?MV:[)^S"?B)K7@^&3QGJGBZ;PCH/A6S=H?.O&G:.W@ED=FPP5
M6+L, E#@+D8 /LFBOF:3XW_%CX,^+_!%M\8]-\'W/AGQAJ46AV^J^$/M4;:5
MJ$H8PQ7"SLPEC<J5$JE,$<J!C/T=JVJ6NAZ5>ZE>RB"RLX7N)Y6Z)&BEF8_0
M F@!^H:A:Z387-]?7,-E96L333W-Q((XXHU!+.S'A5 !))X %1:+KFG>)=(L
M]5TB_M=5TN\B6>VOK*99H)XV&5='4E64CD$'!KXO\2?&WXW?%K]FGQE\2;/P
MCX6M?AMJN@ZC):>'Y)KDZ^^GF&5!=^:#Y&_;^]$ 3YEX\P$BMC]GGXN:QX+^
M'_['/@JQMK&72O&F@W$.H37$;F>);72OM$?DD.%4EU ;<K9'3!YH ^Q:*\5\
M8?&[5_#?[4W@KX<+!IX\.:QX=U#6+N[F1_M,<ENRA0C!PH3#'.5)]Q7EW@O]
MHCXZ?&SP3J7Q.^'/A+P>OP_CEN#H^CZ])=#5]=MX'=&D21"([9G*,$5T?GJ0
M,,0#Z[JLVIV<>I1:>UW NH2Q/<1VID42O&C*KN$SDJI= 3C +J.XKDO@K\6=
M'^.GPK\->/- $B:7KEJ+B.*;'F0L"5DB;'&Y'5T..,J:^6=5A^(;?\%58QIM
M_P"&H[8?#B&1ENK*X=O['_M=!-&"LH'VLR!RLF/+"[04)!) /MRBOEGP[\<_
MC-\>KKQ-K?PCT?P7I_@?1]0N-+L;SQ>;J2XUV:!BDLD7D.JV\.\%59@Y.,E1
MTKU7]F_XX1?'[X9P^(WTJ30-7M;RXTK5]'ED$AL;ZW<I-$''#+D ANX89 .1
M0!ZC17SA\</CK\2/"_[0W@GX7^ -$\/:C-XET6[OS>:ZTR)920R)F5S&V7C"
M;QY84,SLGSJ,FKWP3^-GCK4/C7XM^$OQ-T_P^OB;2-+M]=LM6\+B=+.]LI9&
MC.8IF=XW1P 07.>2.!D@'LNN^.O#?A?5M'TK6?$&E:1J>M2M#IEE?7L4$U](
MNW<D",P:1AO7(4$C</45?UK7-.\-:1>:KJ]_:Z5I=G$T]S?7LRPP01J,L[NQ
M"JH')).!7P-\;OAWJW[67Q,^-GBS0)9!-\*[&#0_!LT1!!UVVFCU"[=.#B0-
M'#;'V8].M>P_%SXKV/QR_P""<WC#QWIVQ8-<\$7=R\2'(AF\EEFBSZI(KI_P
M&@#Z0\+^*]$\;Z%:ZWX=UC3]?T:ZW&WU'2[I+FWFVL4;9(A*MAE93@\$$=JJ
M3?$+PK;^,H?"$OB;1X_%DT/VF+07OXA?218)\Q8-V\KA6.X#'RGTKY)_X)MR
M-\.-#\4?"B[E;RK"WTWQ;HYE?.[3]2M(Y71,\E8KA)E)/=^IKRKX3R-X\_;\
M^'7Q=D>22/QW+XG;2]Q^4:3901VEF0O;?Y<LOOYH//4@'W!JW[3?P>T'5;S3
M-3^*_@?3M2LIGMKJSN_$=G%-!*C%7C=&D!5E8$%2,@@@UW'AWQ/H_C#28M4T
M'5K'6],FSY=[IUREQ"^.N'0D'\#7R#^Q7\+_  ;XVO\ ]HJ^\1>$M"UZ]C^,
M/B*%+G4]-AN9%C!@(0,ZDA068XZ98^M.M?"^D?LR_M]^"- \#V<>@>$_BGHF
MH#4/#NGH(K**_L8S,MU'$!MC8Q@H0@ Y)QDT ?9]%%% !1110 4444 %%%%
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M$_B;P;JOP7^"'COX,_%E=6LWU?4$L9])T2SMED!NED)?[/<Q$!@J0C+@C/\
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MP?\ ))/&W_8#OO\ TG>E^%=U OPQ\( S1@C1[,$%A_SP2N__ )@_^WOT./\
MYB?^W?U.NHJ'[9!_SWC_ .^Q1]L@_P">\?\ WV*X;,Z[HFHJ'[9!_P ]X_\
MOL4?;(/^>\?_ 'V*+,+HFHJ'[9!_SWC_ .^Q1]L@_P">\?\ WV*+,+HFHJ'[
M9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ
M'[9!_P ]X_\ OL4?;(/^>\?_ 'V*+,+HFHJ'[9!_SWC_ .^Q1]L@_P">\?\
MWV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO
M'_WV*+,+HFHJ'[9!_P ]X_\ OL4?;(/^>\?_ 'V*+,+HFHJ'[9!_SWC_ .^Q
M1]L@_P">\?\ WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_SW
MC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_P ]X_\ OL4?;(/^>\?_ 'V*+,+HFHJ'
M[9!_SWC_ .^Q1]L@_P">\?\ WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,
M+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_P ]X_\ OL4?;(/^>\?_
M 'V*+,+HFHJ'[9!_SWC_ .^Q1]L@_P">\?\ WV*+,+HFHJ'[9!_SWC_[[%'V
MR#_GO'_WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_P ]X_\
MOL4?;(/^>\?_ 'V*+,+HFHJ'[9!_SWC_ .^Q1]L@_P">\?\ WV*+,+HFHJ'[
M9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ
M'[9!_P ]X_\ OL4?;(/^>\?_ 'V*+,+HFHJ'[9!_SWC_ .^Q1]L@_P">\?\
MWV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO
M'_WV*+,+HFHJ'[9!_P ]X_\ OL4?;(/^>\?_ 'V*+,+HFHJ'[9!_SWC_ .^Q
M1]L@_P">\?\ WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_SW
MC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_P ]X_\ OL4?;(/^>\?_ 'V*+,+HFHJ'
M[9!_SWC_ .^Q1]L@_P">\?\ WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,
M+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_P ]X_\ OL4?;(/^>\?_
M 'V*+,+HFHJ'[9!_SWC_ .^Q1]L@_P">\?\ WV*+,+HFHJ'[9!_SWC_[[%'V
MR#_GO'_WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_P ]X_\
MOL4?;(/^>\?_ 'V*+,+HFHJ'[9!_SWC_ .^Q1]L@_P">\?\ WV*+,+HFHJ'[
M9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ'[9!_SWC_[[%'VR#_GO'_WV*+,+HFHJ
M'[9!_P ]X_\ OL4?;(/^>\?_ 'V*+,+H_-3]H3_DMGC'_K_?^E?IC7YF_M!,
M'^-7C!E(8&_?!'X5^F5?9\0?[MA/\+_*)\OD_P#'Q/JOSD%%%%?%GU(5^=G[
M)/\ R7[PS_NW7_I++7Z)U^=7[)CK'\?/#3,P5=MURQP/^/:6OK\E_P!RQO\
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M^A6T7_P7P_\ Q-'_  K?PE_T*VB_^"^'_P")KHZ*/;5?YG]X>RI_RK[CG/\
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M]"MHO_@OA_\ B:Z.BCVU7^9_>'LJ?\J^XYS_ (5OX2_Z%;1?_!?#_P#$T?\
M"M_"7_0K:+_X+X?_ (FNCHH]M5_F?WA[*G_*ON.<_P"%;^$O^A6T7_P7P_\
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M/;5?YG]X>RI_RK[CG/\ A6_A+_H5M%_\%\/_ ,31_P *W\)?]"MHO_@OA_\
MB:Z.BCVU7^9_>'LJ?\J^XYS_ (5OX2_Z%;1?_!?#_P#$T?\ "M_"7_0K:+_X
M+X?_ (FNCHH]M5_F?WA[*G_*ON.<_P"%;^$O^A6T7_P7P_\ Q-'_  K?PE_T
M*VB_^"^'_P")KHZ*/;5?YG]X>RI_RK[CFE^&?@^,L5\*:&I8Y.-.A&3ZGY:Z
M6BBHE.<_B=RXQC'X58****@H*YIOAGX/9E8^%-#++]UCIT.1GT^6NEHJXSG#
MX78F48R^)7.<_P"%;^$O^A6T7_P7P_\ Q-'_  K?PE_T*VB_^"^'_P")KHZ*
MOVU7^9_>1[*G_*ON.<_X5OX2_P"A6T7_ ,%\/_Q-'_"M_"7_ $*VB_\ @OA_
M^)KHZ*/;5?YG]X>RI_RK[CG/^%;^$O\ H5M%_P#!?#_\31_PK?PE_P!"MHO_
M (+X?_B:Z.BCVU7^9_>'LJ?\J^XYS_A6_A+_ *%;1?\ P7P__$T?\*W\)?\
M0K:+_P""^'_XFNCHH]M5_F?WA[*G_*ON.<_X5OX2_P"A6T7_ ,%\/_Q-'_"M
M_"7_ $*VB_\ @OA_^)KHZ*/;5?YG]X>RI_RK[CG/^%;^$O\ H5M%_P#!?#_\
M31_PK?PE_P!"MHO_ (+X?_B:Z.BCVU7^9_>'LJ?\J^XYS_A6_A+_ *%;1?\
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MFNCHH]M5_F?WA[*G_*ON.<_X5OX2_P"A6T7_ ,%\/_Q-'_"M_"7_ $*VB_\
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M ,%\/_Q-'_"M_"7_ $*VB_\ @OA_^)KHZ*/;5?YG]X>RI_RK[CG/^%;^$O\
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M (+X?_B:Z.BCVU7^9_>'LJ?\J^XYS_A6_A+_ *%;1?\ P7P__$T?\*W\)?\
M0K:+_P""^'_XFNCHH]M5_F?WA[*G_*ON(;2U@L+6&VMH8[>VA18XH85"I&H&
M J@<     5-116.YJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBKI/P?\ #EGK&KV]Y>1WFJ66D6]MIZ(\TMQ=3I#$ '95P&?))/ !QDX![.@
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M9:7ECINO6$.I6MOJ$:I.L,J!TWJK,H)4@\,1SUH Z:BBB@ HKR#X?_M+Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(U(CW[J^[? ?P:\%_#/0=<T7PYH%O8Z5KE_<ZGJ=K(SW"W=Q< "9Y/-9L[@
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M<L 6.5!)% 'D?P@N9_%'@#]F3P5%<:EJ?AMO&NL:_HTVH*9+E]!T=KEK#=N
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MK D+,T38S@A2&!7(/>^*_P!GWX>^-O&G@WQ9K/AFWNM>\'$G0KJ.66$67W<
M1QLJ.!M7:'5@N.,9-:OQ6^$OA/XW^![[P?XVTA-<\.WK1O/9M-)"2T;K(A$D
M;*ZD,HY5AD9!R"00#X_TW]EGX>^,/C7<? .^BO+3X3>!/#MKK-MX-AU2YA76
M;Z]FG\Z]G<2^;(L1C4* V$>3@@$J?3?V"&T^W\)_$C2_"FKW6M?#/2?&-WI_
MA*>XNFN8X[)(8"\5O,Q)DMTF:98VW-E1G<W4]M\3OV+_ (+_ !DTWPW8^+O
MEIJ<'AVR33=,:.YN+:6"U10J0^;#(CNB@<*Y(!+$<L2?5?"?A/1? OAVPT#P
M[I5IHFBV,?E6MA8PK%#$N2<*H&!DDD^I))Y- 'Q1^UE\,=!^/GQ.USQ0UAI7
MQ;T#X<:8^G^(/ .JZ[?:#-I5SC[3]KM)DVQ.TL+@-YF$(MU DR"%J:'X5\+_
M +2/BCX4?""^\2>)M<^$%O\ #R/QF--US4C#J&OF>Z,5M#>/#L9TM53.$;[W
ME$EL9/T9\6/V+?@K\</&D7BWQMX"L]9\0HD<;7JW-Q;F8)C9YRPR(LN  N9
MQV@+T %:7Q?_ &4?A+\>-)T/3?&_@FQU6ST-/*TU());)K6/:%\I&MWC81X
M_=YV_*..!0!\Q?$WPOX(^&_PETOX-?!D^(OB3I7C;Q!>?9O!NA>-K>VMH[>U
MB634M.&H2AVA@;(:6#?YC&64!EWMGSCX%Z\/@3;_ +2M_HO@J+X3:3X5\%1M
M=^#;7Q9)X@ABUIVNQ%))<EBJ3LJ1(40G"[,X;*C[E\>?LH_"7XE?#C1? 7B#
MP1I]QX2T5Q)IVFVK26BVK $91X61QG<V[YOF)RV3S5#PW^QO\'/!_A/7O#.B
M>"H-+T/75L%U.SM;RY077V-@]N6(EW9##+,#F3)\PODY /B;XC> ?%^M^+/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!/VG/BY\0/!?B'
MX;^"_A7;>&KKQQXRO[M(O^$L2X:RBM+6V::>1C P=2"8E!PPRX&,D&N7\#_&
M+XX^"/C9X0\$?&JR^'4EAXNM-1ETV^\#RWJO:R6<22R&X6ZZHR/@%>A')&0#
MRGQ4^%!_:B_;/U32T\9^+/!5A\.?"MM$VI>#-3^P7GV[4)GD,9E*-A#!"A*@
M DE><#!M?$+]GOPW^RS\%_BK\1K;7O%?C_X@OX;N=+L?$GC?5VU*_MUE7RX;
M:%]JA(_.D5L ;B6(W8/ !ZUX>_;.^"_BD:@VG>/+)X=/T2/Q#>SSV\\$-K92
M,JQO+))&JQNY=-L3$2,'4A""#3_A;^V-\&_C1I7B+4/!WCBUU:W\/VKWVIHU
MK<6\T%NJEFE\J6-'= !RRJ1D@=2!7AG[0GPO\+_ 'X&? G1-2T*2Y^$?A'Q%
M9W'BZ&SLFN4*+;3 7=W%&#YL7VIDDE!#!B1\K<"J<GQLTSXT?%KQ/\<OAYH]
M]>^"?A]\/=6M4\5R:=-;?VY?2%)TM8%=%DDC@\F3)Q\KR$8PP9@#TGX*_MZ?
M#SXE?"OQO\1-:U[3_#OAOP_K$UH7FBN%:.V'%N6+H#--,J-((XE)42(F"RDM
MZA\&?VEOAE^T%H6JZQX!\76>O6.E.$OR8Y+:2URI96DBF5'5"%;#E=IV/@G:
MV/C%?&/P[\'_  W_ &1O&VL276M?!+PS8WJ7NL_V3<RV]OK:11107=Q 8]_$
MZW81PC8D<$=F#/BIJ6I?M(>&_C]\6OAUX:UD>$+[POIGABRO8;![>Z\36T5^
M9=2N8(G 9U6U9X59@"V"O52J@'UE\-/VTO@I\8?B)-X%\'^/[#6O%$8F*V:0
M3QI<>4?WGD3/&L<^ "P\IFRBLXRJEA$W[;GP-3XM?\*T/Q%TW_A,?M8L/L@C
MF,'V@KGR?M03R-^?DV^9G?\ N_O_ "UYSH/QX^&?[0G@B_\ #?P-\.7/B*Z\
M,^'[M]!UV'0#:Z?X=OEM6BM88Y;A8WCG.Y0H@5CMSD@9KP33/B=\.?BO^S#X
M0_9H^%OAG4+SXA2KI]KK>DOHD]LWAN:&>$W^H7DDB*JNDBN-RL29)%'?:0#[
M=M_BIJVH_M/7?PZL[>S?P_I?A2/6M1NS&YN$NY[IHK>$-N"JICBF<@J2?EY'
M?2^-/[0?P\_9XT&UUCXA^)[;PY8W<WD6_F1R32SN!DA(HE:1@,C)"D+D9(R*
M\_\ V;,^*?B_^T#XW))CNO%$/AJV^<,!#IEJD3 8Z#[1-=>^2WM7@G[97Q@U
M/P;^TQ86EW\2[?X))9Z%$?#VN)\/U\2WFMR3RR"Y@BE*,8-A2%?+7;N,@+9&
MS !]7:1^TU\,M?\ @[<?%/3/%4&H>!;;(FU.VMYY&B8.J;&@"><'W,@V%-WS
M*<8(-<>W[?7[/J?\)3_Q=#2&'AK U%E29@<OL'D$)_I7S#'[CS.H/0BODGX<
MZ=+\5/V>?#7AG7I=1U*?XO?&.YN=:BU:*.TO)K.TD,LZW$,8"1R;--C5DC 5
M6/&*^C=#T;PSK/[8_C?Q5<Z7I]OHOPD\(V&AV#K;($LIIUFNIVBP,(8[;R4X
MQM65@/O-0!ZW8?M,?##4O@S)\5X?&-@/A_'')(VLS!XE&QBI3RW42>86&T1[
M=[$@*I+#+_@A^TA\-OVC]*U/4/ASXIM_$=OIDRP7B+!-;S0,R[D+13(CA6 ;
M:^W:Q1P"2C ?GU\1M!UC2OV9_P!GOQK?^(YO /A>^\1:EXVUSQ&_AQ=>BTN]
MOC)/IT\MF00R@3-$KX.UY(R!DBNE\%^+_$,'P]^./QY?XG:S\3X(_![^&]$\
M2W?@B#P[::E<.Y\HVP27S;CR;B0Q$R0I\[,J.V#@ ^L/"O[>'P%\;>,?#OA7
M0_B1IVH:[X@"_P!G6T<%P!(S%U6-Y#&$BD)0@1R,KG*8'SKG=\;?M;_!_P"'
M/Q.L?AYXD\>:9I7C"\,:IITOF,(FD ,:S2JIC@9@5($K*2&4CAAGQ;Q%\)=)
M\ P_LJ_ [1[&"U6SUN+Q'?O%&H9CI5J9I9W*_P <MU)!EAU+D=":\ OOVDO
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MR;B=V 4!Z3X)_"VT^#7PST;PM;SM?7%LC37^HR<R7U[*QDN;ER>2TDKNWMD
M< 5\4>*H%^*'@'QU;LYD'QF^,L/AD36[,))-'L9(X)&4]<>3IUP<\ "3'!H
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M]F]A@N5(49)Z8KYA_8IT'5_BC=>%K/7;2:+PK\$VO= LH;@?+>:XD\]OY_\
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MK\VWVLZ[)(4A";MFTA@&$F\B/RB-^\[-N[BOAO\ :S\3:I\*_P!LK5_%>O\
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M![/XQ_;3^"7@#XG0_#[7_B%ING^+))(X39M',\<,CG"I-.J&*%L]1(ZD @G
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MX4\,?V?';6VA/+&L<\Q=26N9652JN^-BRR  [AM]AHH **** "BBB@ HHHH
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MF'Q*\6?#G5+C5/LMAX0UMM=;3_LPD^VS"UG@A^<L/+V-.7SM;.,<9R/0:**
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-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>advm-20231231_g5.jpg
<TEXT>
begin 644 advm-20231231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" .^!M8# 2(  A$! Q$!_\0
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M, HHHI *M.I%I:E@%%%%( HHHH **** "BBB@ HHHH904445(!1110 4444
M%%%% !1110 4445!8Y>E% Z44$A1110 4444%!1110 4444F 4445(!1110
M4444 %%%% !1110 4M)2CK0 ZBBB@L****D@**** "BBB@ HHHH*04444#"B
MBB@ HHHH **** 'T445 !11104%%%% !1110 4444F)!1114C"BBB@ HHHH
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M\,@E(^7:Y@&TY[Y%>-_\,G?%7_H5O_*C:?\ QVN9\=_!?QE\,]/M[WQ)H_\
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M5%)\KO;Y!7V7^S]^R_X?M_"=CXG\8VJ:E>WD0NHK.Y)6"VB*Y7>O&YBIR=W
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MS0K]+_B=_P D#\2?]B_-_P"B#7YH4879CXN_C4?\/ZCJ_3KX8W+6?P3\)W"
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M UQ]8U^\^WZBZ+&TWE)'E5& -J*!^E?3?_# _P#U/7_E(_\ M]>2?'SX!_\
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M_E/M?_C5>6:A?SZI?W-[=/YMS<RM-+)@#<[$EC@<#DGI7U;_ ,,%_P#4\_\
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MU+'DU77K0W6N;DC'5(VE5J32C*3:7F:?A_Q-J_A6\>[T75;[2+IXS$T]A</
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MM9N;C6;EW1IY+R=WDF50!M9R2WW0%SG@ >E9]%3RJ][#]I-Q4&]%TZ?<??\
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MTE*.M?/,\I'U;\??^2"Z)_O6?_HHU\U^$=!D\4>)M,TB([6O+A(=P_A!/)_
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MMU8JG!VYF]&_(_/2BOT4U'X'_"GXQ^#UO-#TO3;:WN58VNJ:)"MNR.,C)50
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M:.O-]UOU_$\_HHKZ^_9C^#?PU^*GPS2]U;P]]IUNSN9+6[F%[<1[SG<C;5D
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M#_"&.+3]9TWP[:S*HQ!=6?VZYP>A8;7?GU-=Q>&'X/?!NX:RA4KH&CLT49.
M[QQ$C)_VF')]S7YFZIJMYKFI76H7]Q)=WMS(99IY#EG8G))KQX<V+DY.5HH_
M1\5*APY0ITH4HSJR5VY*_P#6NR\M3[Z7X4?!CXVZ+*^@VFE_*/\ CYT+%M-
M6'!9 !@^@=2..E?(/QN^"^I_!CQ*ME<R?;=,N@9+*^5=HE4=58=F7(R/<'O5
M?X&^-KSP'\4O#^H6LS1PR74=M=1[B%DAD8*X8=\ [AGH5![5]F?M>>&(O$'P
M3U2Y,7F76E2Q7D+9P5^<(_?IL=N/8=\4_>P]50;O%F4H8?/,OJXF--0JT]7;
M9JU_Q5_.ZW/._P!C'P+X:\4_#O6+G6O#VE:O<1ZJT:37]E%.ZKY,1V@LI(&2
M3CW-=OXJ\4? #P3K]WHNM:1X<LM3M2HF@_X1PR;2RAA\RP%3PP/![UB?L)_\
MDQUS_L,/_P"B8J^<OVJ/^2^>+/\ KI!_Z3Q5FH>UKRBVSJEBO[.R;#UZ=.,I
M/3WE?N_+L?8&C^ ?@U\7=#N'T31= O;8@)))IENMM-"2.,[ KH?J!G%?(?Q,
M^%<'P3^,.F:=J$OVSPZUQ!>17%Q%OWVWF#>LB@88KM8$ <C!P-V*]8_8>\$^
M(]+\2:YK=Y9W5AHDEC]F47"-&)YC(K*R@CY@JJXSVW^YJM^WIJ%M-XD\)V2.
MINX+6>650>0CNH3/XH]%.\*SIIW1EF$:>+RF.83I*%2+6RM?6WW=3T'_ (6E
M^S;_ ,^7AS_PF'_^1Z]/_P"%<?#;^Q?[6_X0[PY_9_V?[5YW]CP_ZK;NW8V9
MZ<XQFOS(K]/O^:,?]R__ .VU95Z?LK6;U._(\Q>9>U]M2@N575H^O=L\I_X6
ME^S;_P ^7AS_ ,)A_P#Y'KG_ -E/PCX1\:2^/;NYT#2=6LUU<FR:[L(Y!'"V
M\J$#KE1C'&!]*^-Z^S?V"_\ D6/%?_7Y#_Z :UJT_94VTV>3E>92S3,:4*U*
M"2YMEY=;MGBO[6&A:;X<^,5Y9:3IUKI=FMK PM[.!88P2O)VJ ,FNZ_9U_92
M@\::5;^)_& F32IQOL]-C8QM<)_ST=ARJ'L!@G@YQUS/VEM#3Q-^U%I^CR,R
MIJ#Z?:,RG! D*H2/?FOIO]H3Q-+\/?@GKMUI7^BSI!'96QB)0Q;V6/*D="JD
MD>X%3*I)0A".[-<-E^'GC<9B\1&\*3>G1[O\+;'*ZMJO[/G@74%T:^L_"R7:
M-Y+1G31=M&P.")'$;[2#UW$=\]*B\9?LQ_#OXJ>'1J7A06FD74R9MM0TE@UM
M)C/#1J=I&<@E<$?ABO@FO2OA9^T!XJ^$.F7^GZ(;.:UO)%F,=[&T@B< @LF&
M&"PQG.?NBFZ,HZPEJ<=+/L+B).EC</%4W_*M5_7E8X7Q#H-]X6UR^TC4H&M[
M^RF:":-NS*<<>H/4'N"#5!>M;GC;QIJGQ \276NZS)%+J-SM\QX8EC!VJ%'"
MCT &3SQ6&M=6MM3XJKR<\O9?#?2^]NEQU%%%(S"BBB@ HHHH **** "BBB@:
M"BBBI8PHHHH **** "BBB@ HHHH ****3&@I5I*5:D;%HHHH)"BBB@I!1110
M,**** "BBBI ****0!1110 4444 %%%% !1110 4^F4^@:"BBBDQL****1(4
M444 %%%% !11104%%%% PHHHH **** "G#I3:=4L!:***0T%%%% PHHHH **
M**!,****D84444@"BBB@ I5I*<O2@ HHHJ2A5IU(M+4 @HHHJ2QU+114#"BB
MB@:.L\!W.'N[<G[P$BCZ<'^==)JV3I-Z!U\EOY5Y]HFH'3-2AN/X <./53P:
M]*9%N(F0$,DB$ ]B".OZU^I<.XA8K+IX:_O1NOD]OU/M<JJ>VPLJ/57_ !/%
M/$ZEM#NL=<+_ .A"O-J]8U2S::VNK5AARK)^/_ZZ\ID4QNRD8(.,5ZG M5?5
M:U!_%&5_O27Z'1P_)>QG3ZIW^]?\ [_P6 -&7']\Y_2M^N5\!W0:UN+<GYE;
M>![$8_I^M=57YKQ'2E2S;$*765_D]4?,YE%PQE1/O^9[Q\"_+_X1&ZV??^UM
MO_[Y7'Z5Z+7S_P#";QQ%X5U26UO7V:?>8#2'I$XZ,?;G!KW^.198UDC97C89
M5U.01Z@UZ66UHU,/&*W6C/L\IKPJX6,8[QT8M<_\0!&? ^M^;C;]F.,_WLC'
MZUT/)Z5Y#\9/'5O<6_\ 8-A*LQWAKJ1#E1CH@/?GD_05OC:T:-"3EU5CJQ]>
M%##S<^J:1Y%1117YTS\R"E6DIR]*3*"OT'_9G_Y(CX9_ZYR_^CGK\^*_0?\
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MK@,SPQ>E+2"EK^^V?D04#K10O6L6)#J***Q8PIRTVG+TK)@+7Z:?LZV<&E?
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M[S^<-:SCRYK33Z1_1G'"7-PY7DM+S_\ ;HCO^"?LC_:?'$>X["EFVWWS/S7
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MO4C4KRW>A\UF[AA*V#RVEM%J3^;T_7[SZH_;J_Y)'I'_ &'(?_2>XJA^P?\
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MG+TIM.'2AF0M%%%2 4444 %%%% !1110 4444%!1114@%%%% !1110 4444
M%%%% !1114LI!3J;3J0,****"0HHHH*"BBB@84444 %%%%0 4444 %%%% !1
M110 4444 %%%% "K3J1:6@I!11128F%%%%(04444 %%%% !11106%%%% !11
M10 4444 *.M.IJ]:=4L HHHI%(**** "BBB@ HHHH%U"BBBH&%%%% !1110
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M .31_P SY :D%?8!_P""?>?^9]_\H_\ ]OH_X=]_]3[_ .4?_P"WUF\UP?\
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MG_R:/^9\AT5]>?\ #O\ _P"I\_\ */\ _;Z/^'?_ /U/G_E'_P#M]3]>P_\
M-^#_ ,@_U;S7_GS_ .31_P SY%7I33UKZ]_X8!_ZGO\ \H__ -OI/^& /^I\
M_P#*/_\ ;Z3QN'_F_!D_ZMYK_P ^?_)H_P"9\BBBOKO_ (8!_P"I[_\ */\
M_;Z/^& ?^I[_ /*/_P#;ZEXRA_-^#*_U;S7_ )\_^31_S/D2BOKO_A@'_J>_
M_*/_ /;Z/^& ?^I[_P#*/_\ ;Z7URA_-^##_ %;S7_GS_P"31_S/D2BOKO\
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MT?6J/\WYA_JWFO\ SY_\FC_F?(RTM?7/_# ?_4]_^4?_ .WT?\,!_P#4]_\
ME'_^WU/UJEW_ ##_ %;S7_GS_P"31_S/D:BOKG_A@/\ ZGO_ ,H__P!OH_X8
M#_ZGO_RC_P#V^I^LTN_YA_JWFO\ SY_\FC_F?(U%?7/_  P'_P!3W_Y1_P#[
M?1_PP'_U/?\ Y1__ +?1]9I=P_U;S7_GS_Y-'_,^1J*^N?\ A@/_ *GO_P H
M_P#]OH_X8#_ZGO\ \H__ -OJ/K%+N'^K>:_\^?\ R:/^9\C45]<_\,!_]3W_
M .4?_P"WT?\ # ?_ %/?_E'_ /M]+ZQ3[A_JWFO_ #Y_\FC_ )GR-3J^M_\
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M1_\ ;Z/:P[A_J[FG_/K_ ,FC_F?)%%?6_P#PP/\ ]3U_Y2/_ +?1_P ,#_\
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M1_\ ;Z/^&"?^IZ_\I'_V^CVD.X_]7<T_Y]?^31_S/DJBOK7_ (8)_P"IZ_\
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MG_[?2_\ #"__ %.W_E)_^WTO9R[#_L',?^?7XQ_S/E2BOJO_ (87_P"IV_\
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ME8Y,1-Q22ZA=7D]],\US/)<3.=S22N69B>I)/6H:**_;MM$>:%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTL-\#]0HHHK\[.L**** "BBB@ HHHH **** "BBB@#YG_;^_Y(WHW_8>A_\
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M/ULDU%_?=VZV/!J*]-_:$N_ >I_$&74/A[*6T>[B66:!;9H(H9\D,(U8 A2
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M***^&/HPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^'?VD?^2T>(O\
MMW_])HJ^XJ^'?VD?^2T>(O\ MW_])HJ^JX<_WN7^%_FCU<M_BOT_5'F=%%%?
MHQ]&%%%% !1110 4444 %%%% !1110 4444 %%%% !7N/[(7_)2M2_[!$O\
MZ.AKPZO8_P!EG7M-\/?$#4+G5=1M=,MVTN2-9KR=8D+&6$A06(&< G'L:\O-
M$Y8.JDNARXI-T9)'CE;_ ,/W$?CSPVS'"KJ5L2?^VJUZ;_PH/PK_ -%8\/\
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M+Y^7EU;WDN:[;O=]-1*I&4FK;GSK5C3]/NM6OK>RLK>6[O+B18H8(4+O(['
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M.:\&_P#;Y_Z13U^IE?AW'/\ R,J?^!?^E2/2PWP/U"BBBOSLZPHHHH ****
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MF:+"([>+#7FH3 ^3:H<\L>Y.#A1R?8 D>P?&[XF>&OAGX!?X1?#N3[1#N/\
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MC[PQK7BO2/#5SK$LMO&VI7<43!7MU3S CNI8 YZ>G6N>_P"&6/ W_1=O"?\
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MGHFF2G,EE8P6S'W2-5/\J^,XEDO9TX];L\;,G[L4:]%%%?!'@!1110 4444
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M]KS4[BXDB\-Z7!9VW1;B^!DE;WV@A5^AW5Q$O[2GQ$D;*Z\L0]%LH,?JAK]
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M )(VW_QNCV><?SP_'_(.7&?S1_KY'2_\,A>,?^@EH?\ W_F_^-4?\,A>,?\
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M_AI'XC?]#%_Y(VW_ ,;H]GG'\\/Q_P @Y<9_-'^OD=+_ ,,A>,?^@EH?_?\
MF_\ C5'_  R%XQ_Z"6A_]_YO_C5<U_PTC\1O^AB_\D;;_P"-T?\ #2/Q&_Z&
M+_R1MO\ XW1[/./YX?C_ )!RXS^:/]?(Z7_AD+QC_P!!+0_^_P#-_P#&J/\
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M_F_^-5S7_#2/Q&_Z&+_R1MO_ (W1_P -(_$;_H8O_)&V_P#C='L\X_GA^/\
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MX5_\"[G_ .1Z/^'=/Q(_Z#?A7_P+N?\ Y'KQ[_AO#XY_]#Q_Y2;'_P",4?\
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M>RM'&/UKPW_AO#XY_P#0\?\ E)L?_C%:FB_\%!_C1I<T;W.N6&KJK;C'>Z9
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M^TLO_P"@5_\ @S_[4^O?^& ?B%_T&?#/_@5<?_&*/^& ?B%_T&?#/_@5<?\
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M']I9?_T"O_P9_P#:GU[_ ,, _$+_ *#/AG_P*N/_ (Q1_P , _$+_H,^&?\
MP*N/_C%?(5%']DYW_P!!\?\ P3_]T#^TLO\ ^@5_^#/_ +4^O?\ A@'XA?\
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M $&?#/\ X%7'_P 8KY"HH_LG._\ H/C_ ."?_N@?VEE__0*__!G_ -J?7O\
MPP#\0O\ H,^&?_ JX_\ C%'_  P#\0O^@SX9_P# JX_^,5\A44?V3G?_ $'Q
M_P#!/_W0/[2R_P#Z!7_X,_\ M3Z]_P"& ?B%_P!!GPS_ .!5Q_\ &*/^& ?B
M%_T&?#/_ (%7'_QBOD*BC^R<[_Z#X_\ @G_[H']I9?\ ] K_ /!G_P!J?7O_
M  P#\0O^@SX9_P# JX_^,4?\, _$+_H,^&?_  *N/_C%?(5%']DYW_T'Q_\
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M ">N?_CE'_#-WPY_Z%W_ ,GKG_XY7IE%'U[%_P#/V7_@3_S#V];^=_>SS/\
MX9N^'/\ T+O_ )/7/_QRC_AF[X<_]"[_ .3US_\ '*],HH^O8O\ Y^R_\"?^
M8>WK?SO[V>9_\,W?#G_H7?\ R>N?_CE'_#-WPY_Z%W_R>N?_ (Y7IE%'U[%_
M\_9?^!/_ ##V];^=_>SS/_AF[X<_]"[_ .3US_\ '*/^&;OAS_T+O_D]<_\
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MYG_PS=\.?^A=_P#)ZY_^.4?\,W?#G_H7?_)ZY_\ CE>F44?7L7_S]E_X$_\
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MZ/\ A@_X&?\ 0C_^5:^_^/U[[17D_P!MYI_T%5/_  .7^9?LX?RH\"_X8/\
M@9_T(_\ Y5K[_P"/T?\ #!_P,_Z$?_RK7W_Q^M+QKX5^.-]\9M+U+PUXQT33
M_AO'<6C7NCW,*FZEB5E-RJL;9CEEW ?O!UZK7M===?,\SHQA)8Z4N97LISNO
M)WMKZ7)4(/[/X'@7_#!_P,_Z$?\ \JU]_P#'Z/\ A@_X&?\ 0C_^5:^_^/U[
M[17)_;>:?]!53_P.7^97LX?RH\"_X8/^!G_0C_\ E6OO_C]'_#!_P,_Z$?\
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MZQ0Q'^MG#]98E+VM.^OFE=/RNM'\_(X7'V%56V9^S5%%%?A1Z04444 %%%%
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MHY/)# <XKRWX+Z'^RMJGP1M-;\9VEI#XGT^V*ZG9S:O=175S,N?FAA69=^\
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M:0YX7CS.-]NJUT"HFZL5%V.J_9__ &]?^%Z?%'3/!W_"#?V)]MCFD^V_VO\
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M -*8Z_82OU[Q2_WS#?X7^9\!P1_N];_$OR"BBBOQ$_20HHHH **** "BBB@
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MO^PO+_Z)AK[C%?\ (EI_(]RK_N4?D>XT445\.>&%%%% !1110 4444 %%%%
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MON;!1BG=(\M^(7[,'PO^*FO'6_$_A*WU#56"J]U'<36[R8&!O\IUWX'&6SP
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M***FOB:^*G[3$3<Y=VVW^(TE'1(****YAA1110 4444 %%%% !1110 4444
M%%%% !7#_'/_ )(G\0?^Q>U#_P!)I*[BN'^.?_)$_B#_ -B]J'_I-)7H9?\
M[Y1_Q1_-'+B_]WJ?X7^1^6?P,_Y+9\/O^QAT_P#]*8Z_82OQ[^!G_);/A]_V
M,.G_ /I3'7["5^O>*7^^8;_"_P SX#@C_=ZW^)?D%%%%?B)^DA1110 4444
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MA=7D<<]SDX_=QLP9^>. :VJ4H2BDY*U]AA1114 %%%% !1110 4444 %%%%
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M?\3_ #.R/PH****XB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M78#.02JX(^8UQ'A7PC>_LK?M/?"K1_#GB#4+W3?%MG:/J=M=N-DC3NT;_*H
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M:XCMS*7\F&&'>H"@1ODY'3)R37ZEZA>6VGV%S=7DB0VD,32322?=5%!+$^P
M-?E-\/Y?&M_\8O%MY^S+9ZU::2P82+.;<H(BS%0PF'EJ,AO+5LN #@YS7Z3P
MCSQH8R=!JG42CRU)6Y8ZZIM[7]'^!QU[7BGJNQZS^QCXT\8_"S]H[5_@WK>J
MMK&EJUU!L:5I(X)H5+B2+=RJLJD%>/O GD4?\%++VZ\3_$[X<>#;1E,[6[RQ
MQD\&2YF6)20!GK#[]\5E?L.ZQI'AW]HC7;#X@VVJ1?%*^>:&&ZU*0%!*07F5
M@1D2N <-D@C@8R,]C^U!^RA\3OC1^T:NNZ-#;67AXQVMO#K#WB*;58T#,YC#
M>9D.6QM'7'0<U]'.6&PO$D<1B'&GRTK\SLHSDU;FCWO?U=F9:RHV6NIYG_P[
M&^*/_0>\(?\ @9=?_(U>Q_M]>)/$'ASPC\+O 5CJ<FG6NO2O;:C):.5\T0BW
M15SP2F9BV.,[5S7@GQ:^$'CO]ACQ1X>\2Z!XR_M"*_E8"XBB: /(@5GBFA+L
M'0AO4YP>AQ7UU\9_@^G[9'P;\#>)M&U&/0?$$-O'JFGRS M$AF1&EA<@;AAD
M7Y@#@IT.:SQ>,G];P.88RO&KAKRM)0<;2M;6.KT=G\GH.,?=E&*LSQOX*:#>
M?LW?MM6WPMT+7-0U#PKJUDSS6]\X.6%H\X?: %W!HR P .UB*ZS]I*\G_:._
M:,\)_!;3)6;0-'D&J^(I8CP, '82#U5&"C_:G]JIZ;\(?$G[/^K>(OCY\8?%
MECXG\3:58-#IUO89V2SO'Y$89F2/J&V[57HS,3QSS/PA^(UI^S!\*W^*'C"P
MN/$/Q"^)5Z]S:6"/LEDMPV[<6(.U69]_ .=\8QQQSS7UBNLPPS56M&$:<6MI
M5FGS2UM\$=;NW0>RY):+?Y'WY;V\5I;QP01I##&H1(XU"JB@8  '0 =JDKY]
M^ '[7-I\9O&.I^#]9\*WW@;Q=91&8Z9J$A<NJD;AEDC97 93M*]#GL:^@J_+
M<9@\1@*OL<3'EEOT>CZIJZ?R.V,E)704445PE!1110 4444 %%%% ' ?M!?\
MD%^)/_8M:E_Z2R5^1/[/O_)>OAM_V,NF_P#I5'7Z[?M!?\D%^)/_ &+6I?\
MI+)7Y$_L^_\ )>OAM_V,NF_^E4=?L_!/_(KQG]?99Y^(^.)^VM%%%?C!Z 44
M44 %%%% !1110 4444 %%%% 'X]_'/\ Y+9\0?\ L8=0_P#2F2OU,^!G_)$_
MA]_V+VG_ /I-'7Y9_'/_ )+9\0?^QAU#_P!*9*_4SX&?\D3^'W_8O:?_ .DT
M=?OOB%_R)L!\O_2$?E?"?_(PQ7]?:.XHHHK\"/U0**** "BBB@ KXA_X*._%
M[Q+X<;PQX&\/WL^EP:O$]S>S6TICDG&\(D6X8(7.XGGYLCL#G[>KX?\ ^"EV
MI>"Y-(\-:9>P7<_CP;Y=-^QD*([=F"MYQ(.Y69?E4<Y5N1SGZ[A2,)9Q14X<
MZUZ7MH[-^2W,*_\ #=CQ'XQ?LO\ C;]DGPSH?CW3O&_F7TMU'!=?V>KV[V\[
M*SJ VX^<GRL"2%[?*03CZ^\7?M+:AH?[&]E\31%%#XCU#3X8H$VAHQ>2-Y9<
M#IM!#R!3QP!S7Q+\9+3XYQ^%?"DOQEM]?G\#V\T:Q(TD"2#((^<J"1+M# &<
M%NOJ:^@OVMM>\+^)/V'_  5>^#$,/AK^T;.&SA8 /$L<4Z,C_P"VK*P8]R"<
MG.:_0,?AWCG@(XZ4:TG5:<X6Y>7^1M=?ET?J<L7R\W+IH>+^!?V5O'?QR^%.
MK?%ZY\7R-JY^T7-E!=>9+/>B$L'/G;AY9+(ZJ,$9')45])?L'?M":QX^^%_B
M?3?$5V^K:MX519HI[B3]]<6S(Y568Y+%6C8;N>&3/OZ7^Q=Y7_#*W@?SMOD_
M9;C?YF-NW[3-G.>V*^4_^"8,*W'C[QQ%*@E@DTF-9$<95@90,$=#QG]:X,?B
MGFN#S*GB8JV'FN2R2LN9QMIY+\?0J,>24&NIYKI?A/5/B]\(?B1\;-:\4ZK_
M ,)=H.H0?9O*EPGSNFX _>0 2?*%("[>AK[9\+?M%7'AK]B_2?B5XBG6[UD:
M:T4?F'F[NQ(\,6?4L5#-CMN/:O'M4_8&^(^CQ^(/"?A'Q]IMG\-]<NDGNK.\
M$GVC:C;D! C(8KA>CJ&VC(JIXP\%V'Q ^+G@/X :-=/+X"^'UL+[Q#>2,%62
M11NE+D< _-M]FF?^[71CJN7YQRP512IPE[316Y*2@DX;*S<M$E?<45*GK;7;
MYGM'["_PMO?"/PSNO&&O[Y?%'C2?^U+J:8?O/)))B!XSEMS2?]M!Z5]*5\8W
MO_!1S2["^N9=(^'&K:AX&L+I;)_$$,WEQIG.P"/RMJD@$JC2*2!VKZ[\,^(K
M#Q?X=TW7-*G%SINHV\=U;RC^*-U##Z'!Z=J_/L]PN81KO&8ZGR>T>FSMVCH]
M+*VCL['53E"W+%[&G1117S)L%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?(G[8_[(GC']H;QYHNM^'-2T.RM;+319R)JD\T;EQ+(^0$B
M<8PX[^O%?7=175U%96LUQ<2+#!"ADDD<X55 R23Z 5ZF6YAB,KQ"Q.&^)::J
M^Y$XJ:LS\>/C=^RKXF^ S:-;ZWK6@:GJFKR^5::7H\\\URXZ;RK0H NXA1SD
MD\ X./OOX;?#SQA^S9^R5>:=HMHVO>.5ADO(K*WC\SR[J8JNT#^,1YR?78>U
M>%_LVM-^U-^U]XB^)6J(TNB>'0)=/AD!*Q?,R6B=L$*))?\ ?7..:_06OON)
M\YQ,5A\!BK2E'EG45K*^ZCZ);][G+1IK64?D?E]8_L?_ !,^(O@#Q/\ $KQM
MXCO-#UZP6XNX[+7H9?M$PB7>S,[,/)4@':0"/E'0<U]!_P#!.7XN>)?B'X%\
M1Z+XANYM3C\/S6ZV5]<L7D,<JR?NBY^\$\H$9Y ?&<  =S^U=^SGXK^/EG;Q
M:)XVDT"QM+1U;1BLA@U"8L"/-*R!0 !@$HV,FO,/^"=/Q8L;K3M:^&<OA^TT
M76=(5KUKBS#9O%#K'(TVYB?,5F09'!!P NWG;&9A+.<BKU9<LY1<7RI6]E&_
M?[5[=+VOY"C'V=5+^F?/EKX9U']HC1?C1\4?$7B34X]:\*E;G38()!Y4>6D/
MEC(RJJL84!<<\G/?Z]^ G[04UA^QO!X_\7W+7MSH\%Q!)/*^9+QHY62%2?[[
M9C3)SD\GK7FWBG]A7XAZ3K?B_3_A[XXTW2O _BJ0-J&GWX=91'N+",!8F#!2
MS $,A(X/>N?^(7P]BU/Q+\-/V7/"][)<Z7I+?VIXFU!%"L[,3*Y;!XPKL0"3
MS)$,_+7;C*N7YS"%"%1.G&2G9*SITHP]]/16O+9:ZM,F/-3UMK^;/6_V$? .
MI-X=\0?%7Q-^]\2>-KIKE7<<I:AR1CT#L2<?W4CKZHKXSUK_ (*":+X1U"^T
MOPE\.]1U[P5X=:.PFUNUN#%! @_=IA?*8!25(3>Z[L=J^KO OC72OB-X/TGQ
M-HDS3Z7J<"W$#.NU@#U5AV92"I'J#7P>?87'NL\=BZ7)&;]W;16]V.CT:C;1
MV9TTI1MRQ>QO4445\L;A1110 4444 %%%% !7#_'/_DB?Q!_[%[4/_2:2NXK
MA_CG_P D3^(/_8O:A_Z325Z&7_[Y1_Q1_-'+B_\ =ZG^%_D?EG\#/^2V?#[_
M +&'3_\ TICK]A*_'OX&?\EL^'W_ &,.G_\ I3'7["5^O>*7^^8;_"_S/@."
M/]WK?XE^04445^(GZ2%%%% !1110 4444 %%%% !1110 4444 %%%% 'FW[1
MD33?!GQ&J#)"P-^ N(R?T%?,?[.<R0_&;PXSG:"TZ_B;>0#]2*^S/&7AY/%G
MA35M'<A1>VTD*L?X6(^5OP.#^%? -A>:CX(\407"H;;5-+N@QCD'W9$;E6'I
MD8-?<9':O@J^&3U=_P 5;]#W,#^\H3I+?_-'Z+T5S/P^^(&E_$;P_#J>FRKN
MP!<6Q;+V\F.4;^AZ$<UTU?%U*<J4G":LT>+*+B^66X4445F2%%%% !1110 5
MY3^T[\'9OCI\']6\,6=RMKJ9:.ZLI)3B,S1G(5^.C#<N>Q(/.,5ZM173AL14
MPE:&(I.THM->J%)*2LS\S? _BC]I_P" GA.Z^'^D^!=3N+)))$MKI='FO?LA
M=B6,,T1,>"Q9OFW#+$U[G^P9^S/XE^$9UOQ=XQA.GZQJT"VMOI[2!Y8X=P=W
MEQD!F8)@9R,'/)P/K^BOJL=Q-5QF'JT*="%-U;.;BG>5M?S_ *W,(T5%IMWL
M?G3XX^!?Q:_9;^-FH^-/A3I%QX@T/4&D,<-I;&Z*Q2,':VFA3Y]JL!M9>RJ<
M@Y%3?#+X&_%3]I+X_67Q$^*.B2^&M+T^:&X>"ZM'M?-6)MT=O%"YW[<CEF/0
MGDDBOT0HK9\68ETOX4?;<O)[2WO<O^?F+V"OOIV([BXBM+>2>>1(88U+O)(P
M544#)))Z #O7QI^SK;2?M)?M,>*_C+>Q,?#6@L=*\/)(IPS!2H< YY",SD=F
MG&.E?9]%?.8/'_4Z-:$(^_47+S7V7VE:WVMKWT5^YM*/,U?H? 7Q6UJY_9:_
M;4U'XDZUHFH:CX2UVS;R;BT56.]H(T=06(4,)$'RD@[6!Y[]O_P3F\&ZWI^D
M>/O&.JZ=-IMGXFOH'LHYU*LZQF9F=<\E<S[0>^TU]C45[&)X@>(P'U/V24W&
M$92OO&#O'2VC[N^O8SC2M+FO_3"BBBOD3<**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /DG]NC]F'7?B\ND>,?!L?VKQ+H\)MY;(2
M!'G@#&1#&3CYT9G.,\AN.1@^ ^-KS]IK]H[0=)\ :[X)OK2TMYT>6^N-)DLE
MG=00LDTTGR$#)/R 9]"<5^FE%?98'B:M@Z%.C.C"HZ=^1R6L;_U_6ASRHJ3;
MO:Y\F?%7]C.YUC]ECPU\/_#]Y#-X@\-R?;HI)#Y<=[.^\SID_=W&0[2>FU02
M!DU\^Z3XR_:?\)?#.3X76W@+5CIWV=[".^_L.:2:&%MP9$G4^5C#$!B"0,8(
MXK]-:*,+Q-6I4W2Q5*-9<SFN9;2>K>GF$J*;O%V/F;]AG]G76?@1X)UF\\2A
M+?7_ !!)#)+8QN'^S11!_+5B."Y,CDXR!D#/6NN_:\^,H^#'P7U6]M9=NO:H
M#INEHI^?SI 09 ,Y^1-S9_O!0>M>UT5Y%3,Y8K,?[0QD.>[3:V3MLNNFB770
MT4.6')$^9?A3^S3<>$_V/]:\$F+RO%7B32[BXO-Q"D7DL7[N)B1P$Q&ASW#G
MO7Q=-X\U2X_9_M_@&/".L?\ ";Q>(3/Y(M_X,D[=OWM^\D=,8&<]J_6NBO:P
M7$U3#U*E3$TO:.4U46K5I*]NCNO(SE1322=NAR_PM\-W/@WX9>$?#]X5:[TG
M1[.PF*G(+Q0HC8/IE374445\=4J.K.526[=_O-UHK!11168PHHHH ***RO$W
MBC3?!^CSZIJUTEK:0C)9CRQ[*H[D]A51BYM1BKMC2;=D?*O[74JR?$RP53DQ
MZ5$K>Q\V8_R(KU#]D6-H_AG?L1@/JLK+]/*A'\P:^9?B+XTG^(/C+4-;F0QB
MX<"*'KY<:C"+]<#GW)K[/^"?@^3P/\-])TZX0QWKJ;BX4]1(YW8/N!A?PK[C
M-%]5RNEAY_%I^&K/<Q7[K"QIO<[JBBBOA3P@HHHH **** "BBB@ HHHH ***
M* "OQ/\ VBK>2U^/WQ(21=K'Q'J#@>S7#L#^1%?MA7Y5?\%"/AC<>"?CO=:]
M' RZ3XEA6\AE'W?/50DR9]<A7/\ UT'X?I_ &(A3S"I1D]9QT]4[V^Z[^1QX
MI7@F?HC^SK=1W?P!^&[Q,'4>'=/C)']Y;=%8?@01^%>B5\._\$]?VE=-NO#-
MO\+_ !!=QV>JV<C?V-+,V!=1.Q8P9/\ &K%L#/*L !\O/W%7QV>8&ME^85:5
M56U;7FF]&OZWT-Z<E*":"BBBO!-0HHHH **** "BBB@#\K?"6J>.OV ?BYK4
MFI>%SK.E741M?.<M'!=P^8&22*<*0K<#((.-Q!&<5K>#=/\ &G[:'[36D>-Y
M?#\FC>'K&YM9)[B,$PV]O P<1B5@!)(Q!Z#JV< "OT\HK]#GQ=S<V(6&2Q$H
M\KJ7>W^':_S_  T.3V'2^G8^<O\ @H!XFE\._LT:Y#"VQ]4NK:P+9P=ID$C
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M<9K[NHKV<IS.IE&+CBJ<5*UTT^J>Z,ZD%4CRL_+KXQ?M>>,OVH/!MI\/=/\
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M8)-<RRQY!Z9213^->C:Q\,O!_B'6DUC5?">AZGJR;2M_>:=#+.N  ,2,I88
M&.>U=+7M9UG]/-*#I4Z3BYS4Y7=_>4>6T=-K:ZF=.DX.[?D%%%%?&'0%%%%
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M_#2/Q&_Z&+_R1MO_ (W7TM_PS=\.?^A=_P#)ZY_^.4?\,W?#G_H7?_)ZY_\
MCE']J93_ - __DL?\P^M83_GW^"/FG_AI'XC?]#%_P"2-M_\;H_X:1^(W_0Q
M?^2-M_\ &Z^EO^&;OAS_ -"[_P"3US_\<H_X9N^'/_0N_P#D]<__ !RC^U,I
M_P"@?_R6/^8?6L)_S[_!'S3_ ,-(_$;_ *&+_P D;;_XW1_PTC\1O^AB_P#)
M&V_^-U]+?\,W?#G_ *%W_P GKG_XY1_PS=\.?^A=_P#)ZY_^.4?VIE/_ $#_
M /DL?\P^M83_ )]_@CYI_P"&D?B-_P!#%_Y(VW_QNC_AI'XC?]#%_P"2-M_\
M;KZ6_P"&;OAS_P!"[_Y/7/\ \<H_X9N^'/\ T+O_ )/7/_QRC^U,I_Z!_P#R
M6/\ F'UK"?\ /O\ !'S3_P -(_$;_H8O_)&V_P#C='_#2/Q&_P"AB_\ )&V_
M^-U]+?\ #-WPY_Z%W_R>N?\ XY1_PS=\.?\ H7?_ ">N?_CE']J93_T#_P#D
ML?\ ,/K6$_Y]_@CYI_X:1^(W_0Q?^2-M_P#&Z/\ AI'XC?\ 0Q?^2-M_\;KZ
M6_X9N^'/_0N_^3US_P#'*/\ AF[X<_\ 0N_^3US_ /'*/[4RG_H'_P#)8_YA
M]:PG_/O\$?-/_#2/Q&_Z&+_R1MO_ (W1_P -(_$;_H8O_)&V_P#C=?2W_#-W
MPY_Z%W_R>N?_ (Y1_P ,W?#G_H7?_)ZY_P#CE']J93_T#_\ DL?\P^M83_GW
M^"/FG_AI'XC?]#%_Y(VW_P ;H_X:1^(W_0Q?^2-M_P#&Z^EO^&;OAS_T+O\
MY/7/_P <H_X9N^'/_0N_^3US_P#'*/[4RG_H'_\ )8_YA]:PG_/O\$?-/_#2
M/Q&_Z&+_ ,D;;_XW1_PTC\1O^AB_\D;;_P"-U]+?\,W?#G_H7?\ R>N?_CE'
M_#-WPY_Z%W_R>N?_ (Y1_:F4_P#0/_Y+'_,/K6$_Y]_@CYI_X:1^(W_0Q?\
MDC;?_&Z/^&D?B-_T,7_DC;?_ !NOI;_AF[X<_P#0N_\ D]<__'*/^&;OAS_T
M+O\ Y/7/_P <H_M3*?\ H'_\EC_F'UK"?\^_P1\T_P##2/Q&_P"AB_\ )&V_
M^-T?\-(_$;_H8O\ R1MO_C=?2W_#-WPY_P"A=_\ )ZY_^.4?\,W?#G_H7?\
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M] __ )+'_,/K6$_Y]_@CYI_X:1^(W_0Q?^2-M_\ &Z/^&D?B-_T,7_DC;?\
MQNOI;_AF[X<_]"[_ .3US_\ '*/^&;OAS_T+O_D]<_\ QRC^U,I_Z!__ "6/
M^8?6L)_S[_!'S3_PTC\1O^AB_P#)&V_^-T?\-(_$;_H8O_)&V_\ C=?2W_#-
MWPY_Z%W_ ,GKG_XY1_PS=\.?^A=_\GKG_P".4?VIE/\ T#_^2Q_S#ZUA/^??
MX(^:?^&D?B-_T,7_ )(VW_QNC_AI'XC?]#%_Y(VW_P ;KZ6_X9N^'/\ T+O_
M )/7/_QRC_AF[X<_]"[_ .3US_\ '*/[4RG_ *!__)8_YA]:PG_/O\$?-/\
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MCG_T/'_E)L?_ (Q7WS_PP?\  S_H1_\ RK7W_P ?H_X8/^!G_0C_ /E6OO\
MX_1_K-PO_P! /_E.G_F'L:W\WXL^!O\ AO#XY_\ 0\?^4FQ_^,4?\-X?'/\
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M_P",4?\ #>'QS_Z'C_RDV/\ \8K[Y_X8/^!G_0C_ /E6OO\ X_1_PP?\#/\
MH1__ "K7W_Q^C_6;A?\ Z ?_ "G3_P P]C6_F_%GP-_PWA\<_P#H>/\ RDV/
M_P 8H_X;P^.?_0\?^4FQ_P#C%??/_#!_P,_Z$?\ \JU]_P#'Z/\ A@_X&?\
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M>/\ RDV/_P 8K[Y_X8/^!G_0C_\ E6OO_C]'_#!_P,_Z$?\ \JU]_P#'Z/\
M6;A?_H!_\IT_\P]C6_F_%GP-_P -X?'/_H>/_*38_P#QBC_AO#XY_P#0\?\
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MO_4%_P"5/_M _P!1O^HG_P D_P#MC\1**_;NBC_B*O\ U!?^5/\ [0/]1O\
MJ)_\D_\ MC\1**_;NBC_ (BK_P!07_E3_P"T#_4;_J)_\D_^V/Q$HK]NZ*/^
M(J_]07_E3_[0/]1O^HG_ ,D_^V/Q$HK]NZ*/^(J_]07_ )4_^T#_ %&_ZB?_
M "3_ .V/Q$HK]NZ*/^(J_P#4%_Y4_P#M _U&_P"HG_R3_P"V/Q$HK]NZ*/\
MB*O_ %!?^5/_ +0/]1O^HG_R3_[8_$2BOV[HH_XBK_U!?^5/_M _U&_ZB?\
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M'VT6V_L>2^U7X@ZE)LM[&':^Z&T0?-)<E4/S=$W*>"0R_2U<Q\4/^29^+?\
ML$7?_HEZ /&/^"=C%OV+_A>2<DV4Y)/_ %]35\U?M^>-?C#\0/!5S<SZ WP_
M^%&D^);.Q$&H2?\ $R\12BY"I,8UXBME*[U5CEB$;GC;]*_\$Z_^3+?A?_UX
MS_\ I5-7,?\ !3O_ )-GA_[&72O_ $>* /K6BBB@ HKY-_:*^'/[7GB3XF75
M[\'_ (I^$/"O@AK>%8--U6R1KA)0N)"S-93[LMD@AAP0-O&3RO\ P3H^.7Q;
M^)?CCXZ>#?BUXGM?%.J^!-5MM+CNK.R@MXQ)YM[%/L,446]"ULI4LH./3.*
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M)N[-F!*^8F2,, <,I93M8 Y4@ 'K-%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445Y_\=/CAX7_ &=_AS?^-?%\MU'I%JZ1
M;+. S32R.<)&B\#)/=B!ZD4 >@45^/.C_MM_$WX]_MQ_"VY2]U_P/X&U+5;.
M&Q\.6]]-#;WMD9V4RSJI5)R[!P3@K\NT9VY/Z$?MQ?M%7'[,?[/FL>+-,6%_
M$%S-'I>D+<+N074H8[R.^R-)'QT)0 \$T >_45^+VK7O[8_PM^$NC?M&7_Q)
MU.[\.Z@;>\;3;C5I+A8K>=E$,LMDR^0L4A:,#9\P\P<+G-?J[^SS\7K;X]?!
M/PAX]MHDMQK5BLTT$9RL,ZL8YXP>X65'49]* /1**YWXB>/M%^%O@?6O%OB*
MX>TT32+9KJ[FCB:5E0>BJ"2<X'XU^/W[3O\ P4-\??&SXD>%+CP)=>)OAY\/
MHKXVUE+:WDMG-JSAX_-:9HF"MM#(/+#,%WY));@ _:.BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \O^/3?%6[T&PTGX41:/
M9ZKJ4S0W?B#6GW1Z3#M_UR0@9FD/(5?N@C+<5\[_ /!-[PG<>!/$7[0GA^[U
MBZ\0WFG>,V@GU:]_UUY((SOF?D_,S98\GKU-?;%?)7[$O_)7OVH?^Q^F_P#0
M#0!-^V?X5^+OQ+\+^,]#TG5+'P3\+=/T&YO=1U2W?SM4UED@=S:(HXAA)7:[
M'E@<#*Y![;]@_P#Y,^^%/_8%C_\ 0FKO?CY_R0KXC?\ 8MZE_P"DLE<%^P?_
M ,F??"G_ + L?_H34 >\T45\V_M3?L%^ /VN/$>C:UXPUGQ/IMUI5HUG#'HE
M[#'"R%R^626&0;LD_,N"1@'.!@ ^DJ*_*/X?_LS>&OV1_P#@JC\'?!W@W4]:
MOM*U+P[>:G<2:S<122F1[74T*9BCC79_H\; %2<Y.>F/U<H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#SCX^?'GPK^SK\.=1\7>*KZ."&"-A:67F!9KZ?:2L$
M0/5F(], 9)X%<5^QA^U1_P ->?"_5/&/_",?\(G]AUF72?L7]H?;=^R""7S-
M_E1XSY^-NT_=SGG ^<_VLOV$5\::Q\;_ (T>.O%5UK%EI_AS4+WPUX=AED\N
MS:'3R4:1V/ $J%Q$@"DX))R5.C_P1A_Y-=\4?]CC=?\ I%8T =[^V!_P4:\)
M?LI^)(/"L6@W/C+Q:T*W,]A!="UAM(V^YYLQ1R'8?,%"'C!.,C.I^QS^W]X2
M_:XN]0T6'2+GPGXNL8/M;Z3<W"W$<T 8*7AF"KNVEEW HI&X$9&<?*_[)=I;
M_$G_ (*O_&?5=;MX[VZT)]9DLFG42&)X+V"RC9<]"(F(![?K2^-M-M?AC_P6
M/\+2>'X$T^/6C#+=P6X"1NUQ9R12DJ./F(WGCEN>O- 'ZFU\J_M??\%"/!G[
M)NI6_A^72;OQ9XPN+<70TJUF6"*")B0K33$-L+8.%",<#)P",_55> :A^Q7\
M.K[]I#_A>&HR:I>^*XV\[[/>7$4E@K+;B!&\MH\C8JAEPW##- 'CO[,'_!5+
MP;^T!X^T_P &:WX8NO NN:I)Y.G/)?+>VMQ+_#$9/+C*.W105P3QG) /W#7Y
M1_$ZWT?]L3_@IAX.?X86J76D>$9+*?Q#XDL4 AE-K<M-)(''#?P0H_.YNF5
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MJ/P=\'>#=3UJ^TK4O#MYJ5Q)K-Q%)*9'M=30IF*.-=G^CQL 5)SDYZ8_5N@
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MXC6<MWX3\4:+XHM8FV23Z-J$-VB-Z%HV8 UT5 !1110 4444 %%%% !1110
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MJ!T &!5VB@ HHHH ^ /C)_RF2^!/_8F7/_HG6:^_Z^ /C)_RF2^!/_8F7/\
MZ)UFOO\ H **** "BBB@ HHHH *_(/XT>&8_VOO^"F&K?#?XA>*KS0/"^EE[
M+3K>WE2-@L=NLGEP^8"HDE8LY8JQ/3! 7'Z^5^=O[9G[//P _:._:*M?#;_$
ML?#_ .-%T([2XM5TR2XBO<0"6(R@[$$GE;0K>:-WRIAFVB@#P3P9I]M^P/\
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M1O.6Z  '[I5^37[=S3_'S_@H)X0^#_BWQ+-X;\!PQVL,3K(J1K)-"TKRC?\
M+YKL5A#'.,*,=0?UEKX,_;^^$?P ^-7Q(\->'?&/Q!7X>?%>XBAM=/N5L9)U
MN899'6%9EVA"OF!P&,B;22">: /D_P"+G@;2_P#@FO\ M>> ;SX?^-;[4M+G
M6*?5[&^GB:X2U:;9-#/Y8565T!9<H,%<CE0:_:.OP8_:I_9%\-_ KXG?#WX5
M^%_%4WC#QGK$H35+KR%B6-YYHXK:)85=MAX=L%B3O'.,5^\] !1110 4444
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MO^"JGP9\7>$=/UC3M-LO#][I4D6MPQ13&5+35)2P$<L@V[9DYSG(/'0G]7Z
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M@_"6V^'GBRUL_M&FZVEIA-;L=L;2&*1E#*%<@%065O+)SE2!]9T %<Q\4/\
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M!$EYJBI&B* %55  4#   %?H57P!_P $X?\ DZ;]M#_L<U_]+M5H ^_Z***
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M* "OR-^-W[=GQR\(?&CQ]H6D>-_LFE:7X@U"QM+?^R;%_*ACN9$1=S0%CA5
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M_P!)9Y6:?[I/Y?FC\YJ***_:#X$**** "BBB@#]8/^"3O_)NOB+_ +&JY_\
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MBCYU9@HVY +9;@?A!\,1H/\ P4EFCA\3:IXYUK0_!DESXJ\2:HZEI+Z>4)%
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ML:/?1B:VOK*42Q3(>ZL.#SD>Q!%:E !7P!_P3A_Y.F_;0_['-?\ TNU6OO\
MKX _X)P_\G3?MH?]CFO_ *7:K0!]_P!%%% !1110 4444 ><?M)?\FZ_%/\
M[%75?_226OP3K][/VDO^3=?BG_V*NJ_^DDM?@G7Z=PE_ J^J_(^1SO\ B0]
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MDLZ^TZ_#LZ_Y&%;U/T3 ?[K3] HHHKQ3O"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HKYX^,G[6&H>#/BE%\,?AY\.=2^*GC];)
M=2O-/M;Z+3[6QMV.%,US*"J,>" 1CYEYRPK9_9Y_:>MOC=J_B;POK'A;4O /
MQ \,-&-7\-:HZRM&D@RDL4J@++&?[P ZJ<8920#VZBBB@#X ^,G_ "F2^!/_
M &)ES_Z)UFOO^O@#XR?\IDO@3_V)ES_Z)UFOO^@ HHHH **** "OBS_@K%_R
M;KX=_P"QJMO_ $DO*^TZ^+/^"L7_ ";KX=_[&JV_])+RO:R7_D84?4\_,/\
M=:GH?D_1117[B?G@4444 %%%% ']&=%%%?SH?J84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?BS_ ,%#O^3P_'__ '#_ /TWVU?.
M5?1O_!0[_D\/Q_\ ]P__ --]M7SE7[SEO^XT/\$?R1^;XO\ WBI_B?YA1117
MI'(%%%% 'T;_ ,$\?^3P_ '_ '$/_3?<U^TU?BS_ ,$\?^3P_ '_ '$/_3?<
MU^TU?E'%G^_0_P "_.1]IDO^[R_Q?H@HHHKXL]\**** "BBB@ HHHH ****
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MX6TOP/\ 'W]K?PWHEK]BT71_$UOI]C;>8\GDP176J1QIN<EFPJ@98DG'))H
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MO?\ I+/*S3_=)_+\T?G-1117[0? A1110 4444 ?K!_P2=_Y-U\1?]C5<_\
MI)9U]IU\6?\ !)W_ )-U\1?]C5<_^DEG7VG7X=G7_(PK>I^B8#_=:?H%%%%>
M*=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? GC
M;Q9KWP]_;V\8ZS\$_#4GQ:\1ZMH]K;^,_#GFK8PZ:\<:+;N+^0^6CM&B?NRK
M=&[\+M?L@Z]J'C+]K?XK^(_B1;R>#/BQ<Z9;VD/@9XLI;:4C)MG2Y!*W.6V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XL_\%#O^3P_'_\
MW#__ $WVU?.5?1O_  4._P"3P_'_ /W#_P#TWVU?.5?O.6_[C0_P1_)'YOB_
M]XJ?XG^84445Z1R!1110!]&_\$\?^3P_ '_<0_\ 3?<U^TU?BS_P3Q_Y/#\
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MII'896*,8!Q\O3).?T_H **** "BBB@ HHHH _!+]I+_ ).*^*?_ &-6J_\
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M=Z^>_A;^U'^S'\:_V=_ 'A[XN7NGZ9JW@^UM8I=&U=;B$P75M"(?-B\O[ZL
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M_L5=5_\ 226OP3K].X2_@5?5?D?(YW_$AZ!1117WI\T%%%% !7T;_P $\?\
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M-\7_ +Q4_P 3_,****](Y HHHH ^C?\ @GC_ ,GA^ /^XA_Z;[FOVFK\6?\
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M_I)%7H]?S[B?X\_5_F?IU'^''T04445S&H4444 %%%% !1110 4444 %%%%
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M*** "BBB@ HHHH *_.7_ (*_?\TE_P"XM_[95^C5?G+_ ,%?O^:2_P#<6_\
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MRBBOF[]J;P-^TUXK\1:+-\"_B+X8\&Z-%:LFH6NMVBR2RS[R0ZNUK<97;@8
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M%3_$_P PHHHKTCD"BBB@#Z-_X)X_\GA^ /\ N(?^F^YK]IJ_%G_@GC_R>'X
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MUGXPZG=:;-H'_"*1^'M*M8YI&NHG\Y99'=#&%49\P##D_,<CGCWNB@ HHHH
M*^ /^"</_)TW[:'_ &.:_P#I=JM??]? '_!.'_DZ;]M#_L<U_P#2[5: /O\
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M]/QD^(WPH\2S:\NG67@75Y-8;3&LC-]OEPGE?O/-7RMA0G.U\[NV#GV&BB@
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X)?M)?\
M)Q7Q3_[&K5?_ $KEK][:_!+]I+_DXKXI_P#8U:K_ .E<M?>\)?QZOHOS/F\[
M_AP]3SFBBBOTX^0"BBB@ HHHH _>S]FW_DW7X6?]BKI7_I)%7H]><?LV_P#)
MNOPL_P"Q5TK_ -)(J]'K^?<3_'GZO\S].H_PX^B"BBBN8U"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "O,OVF_!VL?$+]GKXB>&?#]G]O
MUO5M#NK.RM?-2/S97C*JNYR%7)/5B![U7_:<^%.E?&GX/:KX4UKQ1-X.TZZF
MMY)-7@D2-XBDJN &<@#<0%Z]Z^'M6_9'^$/QI^*'BZWM_CYKFEZCX>33]/O8
MS/!%;.5LXT1H79\296+<Q'1F(H ^R_V+_AWXA^$_[,/@/PEXKT_^RO$&F6LL
M=W9^='-Y;&XE<#?&S*?E93P3UKVNOSY_9[_9S^&O[/?[5/@JUTOXM>(/&OB/
M4M/U":SLR\,]D52$K()61R48*VY<C!VGFOT&H **** "O%_BU^V5\&?@;XB7
M0?&OCNRTC6B%+6,<$]U+$& *^8L$;^7D$$;\9!S7JWB36%\.^'=4U5T,B6-K
M+=,@ZL$0L1^E?F]^QK^T9X%^&?PCNM=O_"?BOXH_$OQA<76M>,KKPAH)U1[)
M)9Y1''=2%E5$,:!_+R<>83MYR0#]&O!_C+0_B!X;L?$'AO5;76]$OD\RVOK*
M0212#)!P1W!!!'4$$'FMFOGW]BG1?A99_#+6-8^#^LWVH^$M?UNYU1K&\8*N
MEW+A?,M8XMBF)$ 3"-N."#N(()^@J "O@#_@G#_R=-^VA_V.:_\ I=JM??\
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MES)N]D_+4]ZU3Q[H6C^)K#P]=WVS6;X!K>U2&1RP)(R2JD*.#U(Z$UT%>"?
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M@FF^9[=&K*^ESGG5Y6TE>Q^I-%?/_P"Q3\<[_P".'PB\_7)EG\1:/<FPO)L
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M^%GPW'ASQG-!</;:@-!@M=B+$S2#S$<D90,.G.:^ZJ "BBB@#/\ $.CQ^(=
MU/2I7,<5];2VKN!DJ'0J3^M?"_[!/QD^'O[.'P<U?X6?$77M)^'WCGPIJ]Z-
M6M-:G6T:]W2;H[B(OCS@T915VY)5%(&"I/WQ7)^,/A+X&^(=Y;77BKP9X?\
M$UU:_P"HGUC2X+MXN<_(TB$KSZ4 ?-/_  3WA'B#4OCA\0=(L9=.\#>+_%\M
MYH$<D31"XB3<)+I%;D+(S#MP5([5]A5%;6T5G;Q6]O$D$$2"..*-0JHH& H
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M6;N*\+ XFI&#G4G>%/5+O+I]SU\K'!0JR46Y/2.R\^AA:OXF\4:9XRL/A?\
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M!\?B#4]/MS:6]T+ZZM76(L6V$P2IN 8L1NSC<<8R:]CHH _,"'X"^!/V=O\
M@K1\$_#?P]T+_A']%NO#-WJ$UM]KGN=T[6VJQL^Z:1V&5BC& <?+TR3G]/Z^
M /C)_P IDO@3_P!B9<_^B=9K[_H **** "BBB@ KXL_X*Q?\FZ^'?^QJMO\
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M.5?O.6_[C0_P1_)'YOB_]XJ?XG^84445Z1R!1110!]&_\$\?^3P_ '_<0_\
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MV_Q?M?"UGXE%\XMX_")G-J;3RX]A;SF9O,W^;G!Q@+WS7HU !7P!_P $X?\
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MPR 0"1G\:=?!XC#)2K0:3'4HU*:O-6-*BBBN,Q"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HKX^^.'C/XQ?$+]KB#X3?"GXB0_#ZQTWPB->U2]ET6UU
M%7F>Z,:QD2H2IV%",$=^#UKU/X$_#?XU>"_$.H77Q,^,%M\1M*FM?+MK&'P[
M;::8)MZGS-\0!;Y0R[3QSF@#VZBBB@#X ^,G_*9+X$_]B9<_^B=9K[_KX ^,
MG_*9+X$_]B9<_P#HG6:^_P"@ HHHH **** "OBS_ (*Q?\FZ^'?^QJMO_22\
MK[3KXL_X*Q?\FZ^'?^QJMO\ TDO*]K)?^1A1]3S\P_W6IZ'Y/T445^XGYX%%
M%% !1110!_1G1117\Z'ZF%%%>9^/OVDOAS\,?$#Z'XF\1?V;JB1K*UO]AN9<
M*PRIW1QLO/UKHH8>MB9<E"#D^R3;_ 3:CJSTRBO$/^&U/@S_ -#E_P"4N]_^
M,UWWPW^+OA+XN6-Y>>$M6_M:WLY!%._V::'8Q&0,2(I/'I716R[&X>#J5J,H
MQ75Q:7WM$J<7HF=C5/5]'L/$&FW&G:I8VVI:?<+LFM+R)98I5]&1@01[$5<H
MK@3<7=;EE#0]!TSPOI4&F:-IUII.FV^1#9V,"PPQY8L=J* !DDG@=2:S/$WP
MZ\*>-+F"X\0^&-&UVX@&V*74]/BN'C&2<*74D<DGCUKHJ*TC5J1G[2,FI=[Z
MBLMB.WMXK2WC@@C2&&-0B1QJ%5% P  .@ [5)1160PHHHH **** "BBB@ HH
MHH **** /Q9_X*'?\GA^/_\ N'_^F^VKYRKZ-_X*'?\ )X?C_P#[A_\ Z;[:
MOG*OWG+?]QH?X(_DC\WQ?^\5/\3_ #"BBBO2.0**** /HW_@GC_R>'X _P"X
MA_Z;[FOVFK\6?^">/_)X?@#_ +B'_ION:_::ORCBS_?H?X%^<C[3)?\ =Y?X
MOT04445\6>^%%8?CK_D2?$/_ &#KC_T4U?C!7V&0\/?VY&I+VO)R6^S>][^:
M['/5J^SMH?MW17XB5^S_ (%_Y$GP]_V#K?\ ]%+1GW#W]AQIR]KS\]_LVM:W
MF^X4JOM+Z&Y1117QYT!1110 4444 %%%% !1110 4444 %%%% !17S!\8OVN
MO&G@_P".=[\,OAY\'9_BAJ>GZ/!JU_-!K\>G_9A*[*$*O"P/ 0YW9._IQD][
M\!/BQ\2_B5>:S%X_^#MQ\+8K1(FLYI]=AU+[8S%@Z@1QKLV@*><YW>U 'L5%
M%% 'P!\9/^4R7P)_[$RY_P#1.LU]_P!? 'QD_P"4R7P)_P"Q,N?_ $3K-??]
M !1110 4444 %%%% 'X)?M)?\G%?%/\ [&K5?_2N6O.:]&_:2_Y.*^*?_8U:
MK_Z5RUYS7]!8;^!#T7Y'YC5_B2]6%%%%=)D%%%% !7[V?LV_\FZ_"S_L5=*_
M])(J_!.OWL_9M_Y-U^%G_8JZ5_Z215\%Q;_ I>K_ "/I,D_B3]#T>O.?VB/A
M_?\ Q2^#/B;PSI;1C4;R&-[<2-M5WBF24)GMN\O;D\#->C45^=X7$U,'B*>)
MI?%!J2]4[H^HKT8XBE.C/:2:?HU8_-OX1_M-^+/V8_#NH^"M4\&>?.MS)- M
M\SVTD,K!00PVGS%RH(Q@_-][&*]$_8:^%/B:Y^(&L?$G7[&?3K2X@F2W\Z/R
MC=32R!G=5(SL #<]"2,$X-?<%%??X_C"GB</B(87!QI5,1;VD^9N_HFDE?\
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MHHH **** "BBB@ K\$OVDO\ DXKXI_\ 8U:K_P"E<M?O;7X)?M)?\G%?%/\
M[&K5?_2N6OO>$OX]7T7YGS>=_P .'J><T445^G'R 4444 %%%% '[V?LV_\
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M+3P>'=:,VVK?F=F(P4:--S3/H2BBBODCR HHHH **** "BBB@ HHHH ****
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M\"GZ_H7F7P1]3L****_/CY\**** "BBB@ HHHH **** "BBB@ HHHH ****
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MA#IE"&X8T =M1110!\ ?&3_E,E\"?^Q,N?\ T3K-??\ 7P!\9/\ E,E\"?\
ML3+G_P!$ZS7W_0 4444 %%%% !7Q9_P5B_Y-U\._]C5;?^DEY7VG7Q9_P5B_
MY-U\._\ 8U6W_I)>5[62_P#(PH^IY^8?[K4]#\GZ***_<3\\"BBB@ HHHH _
MHSHHHK^=#]3"OS._;V_Y.#N_^P=:_P#H)KZT_:B^$_C;Q5I#>(/A]XLU_2=;
MLX_WND6.J3PP7B#^XBN%60>W#=#SS7YK>)M=UOQ!J\MSXAU#4-2U1/W,DVIS
M/+.-O&TER6XY&#TK]7X+R^'M7CH54]&G'JF[?AIN<.(EIRM&57WS_P $W?\
MD2?&/_81A_\ 15? U=[\([CXAZIX@@\-> -8UJQO-1D!:#2[Z6V0X',DFQ@
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MXCV^0:_9SQUX%T7XD>%[WP_X@LEOM-NEPR-PR-V=#_"P/((K\N?V@OV?=:^
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M4J]5RBT]'Z,^PJ***_FP_8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_,_XP_MF_&#X+?M.?%.>?09/'_P5\/ZA96.HZ<]O'C3?-MXY$=9%7<I+;R#
M)N0G"Y4E2/O;XU?&;PU\ OA]?>-/%LMQ!H=G)%%-):P&9PTCA%PHY/S,*^0(
M?VROV<_@C\6/B9J&HZUXAO=2\<_V?J&I6-QI/FVT:&R3RE3 Y#12J6#9Y)%
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M &]_Z2SRLT_W2?R_-'YS4445^T'P(4444 %%%% 'ZP?\$G?^3=?$7_8U7/\
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MF8HBX55&%'.%&37&?\$SO!7CVTU/XI:K>_$C[?X;LO'>LV&I>'_["MX_[1U
M);[K_P"T!M\6[*_N5&P;>O- 'WW117S=^U-^P9\/_P!KCQ%HNM>,-8\3Z;=Z
M5:M9PIHE[#'$R%R^626&0;LD_,N"1@'.!@ \1^,G_*9+X$_]B9<_^B=9K[_K
M\H/ ?[+_ (5_9-_X*J?!GPCX1O\ 6-1TV]\/WNJR2ZW-%+,)7M-4B*@QQ1C;
MMA3C&<D\] /U?H **** "BBB@ KXL_X*Q?\ )NOAW_L:K;_TDO*^TZ^+/^"L
M7_)NOAW_ +&JV_\ 22\KVLE_Y&%'U//S#_=:GH?D_1117[B?G@4444 %%%%
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M ".\'_U\C^9XN=?\BW$?X7^1^9]>I_LM_P#)P?@;_L(K_P"@M7EE>I_LM_\
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MXDO5A111729!1110 5^]G[-O_)NOPL_[%72O_22*OP3K][/V;?\ DW7X6?\
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MH *^(_B_XD_9A\*_&SXK#Q?\1#H>N^+M"7P]XIT'R[@Q.WEIY5P-L9"RK$0
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MM*T^!K<K(NY=KRSQEN."5! ((SD$#Q'_ ()/^-K'XE?&C]JOQ=ID5Q!INO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _%G_ (*'?\GA^/\
M_N'_ /IOMJ^<J^C?^"AW_)X?C_\ [A__ *;[:OG*OWG+?]QH?X(_DC\WQ?\
MO%3_ !/\PHHHKTCD"BBB@#Z-_P"">/\ R>'X _[B'_ION:_::OQ9_P"">/\
MR>'X _[B'_ION:_::ORCBS_?H?X%^<C[3)?]WE_B_1!1117Q9[X4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!Y#\9/VMOA%^S_ *E!IOCS
MQM9Z)J4R"1;%(9KJX"'.':*!'95.#@L #BNY^'OQ)\+_ !8\+V_B+P?KMGXA
MT6<E4O+&3>NX=48=589&58 C(XKR'Q'X<^$G[(VK>/OC7XJO[R&\\3W<0O\
M5M0B:]DB)!2.V@6*(ND9 "X.1\JY. *\N_X)UW-CXS\5?'7XC>&+>WTGX?\
MBO7[=]%T>.>,RPO"D@N)I($8B RLZ-M.#\O3;M) /M2BBB@#X ^,G_*9+X$_
M]B9<_P#HG6:^_P"O@#XR?\IDO@3_ -B9<_\ HG6:^_Z "BBB@ HHHH ****
M/P2_:2_Y.*^*?_8U:K_Z5RUYS7HW[27_ "<5\4_^QJU7_P!*Y:\YK^@L-_ A
MZ+\C\QJ_Q)>K"BBBNDR"BBB@ K][/V;?^3=?A9_V*NE?^DD5?@G7[V?LV_\
M)NOPL_[%72O_ $DBKX+BW^!2]7^1])DG\2?H>CT445^8GUX4444 ?.'[0'[&
MFC?&+Q-9:_I=XGA[4Y)E&J.D>Y;J+NX4=)0._0]^F:]N\!^ ]$^&OA>S\/\
MA^R6RTZU7 4<M(W\3NW\3$]3_2NAHKV<3G&/QF%I8*O5<J=/X5_6]ME?9:(\
MZCE^%P]>>)I02G/=_P!;7Z]^H4445XQZ(4444 %%%% !1110 4444 %%%% !
M1110 4444 %?@E^TE_R<5\4_^QJU7_TKEK][:_!+]I+_ ).*^*?_ &-6J_\
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M^1A6]3]$P'^ZT_0****\4[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3]%%%?N)^>!1110 4444 ?T9T445_.A^IA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!^+/\ P4._Y/#\?_\ </\ _3?;5\Y5]&_\
M%#O^3P_'_P#W#_\ TWVU?.5?O.6_[C0_P1_)'YOB_P#>*G^)_F%%%%>D<@44
M44 ?1O\ P3Q_Y/#\ ?\ <0_]-]S7[35^+/\ P3Q_Y/#\ ?\ <0_]-]S7[35^
M4<6?[]#_  +\Y'VF2_[O+_%^B"BBBOBSWPHHHH **** "BBB@ HHHH ****
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MV?LV_P#)NOPL_P"Q5TK_ -)(J^"XM_@4O5_D?29)_$GZ'H]%%%?F)]>%%%%
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M3@.5#,K+GC<C, < XR,^VT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M A1110 4444 ?K!_P2=_Y-U\1?\ 8U7/_I)9U]IU\6?\$G?^3=?$7_8U7/\
MZ26=?:=?AV=?\C"MZGZ)@/\ =:?H%9GB3Q+I7@[0;[6]<U&VTG2+&)I[J]O)
M1'%"@ZLS'@"M.OEK]K+]B^[_ &LOB'X,DUGQA=:-\/\ 1H':^T>R=S+>SE\@
MJ#^[0[>/,(9NH [UXIWE;]E7]OK2_P!JSXO^,?"&B>%9--T?1+:2[M-;FO\
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M\:Y7'",GR_W=S8QDT ?IQ16-X+U:77O!VA:G<?Z^]L(+F3&/O/&K'I[FMF@
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M%%>&?M9?M;>%/V3? )UK6 FK:]=$)I?AV*Y$4]ZV>3G:VR-1DM(5(' &20"
M>YT55TJ^_M/2[.\V>7]HA279G.W<H.,]^M6J "O@#_@G#_R=-^VA_P!CFO\
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M%W<^M &_I.FP:+I=GI]L-MM:0I!$#CA54*.GL!5NBB@ HHHH **** "BBB@
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M %%%% 'P!\9/^4R7P)_[$RY_]$ZS7W_7P!\9/^4R7P)_[$RY_P#1.LU]_P!
M!1110 4444 %%%% 'X)?M)?\G%?%/_L:M5_]*Y:\YKT;]I+_ ).*^*?_ &-6
MJ_\ I7+7G-?T%AOX$/1?D?F-7^)+U84445TF04444 %?O9^S;_R;K\+/^Q5T
MK_TDBK\$Z_>S]FW_ )-U^%G_ &*NE?\ I)%7P7%O\"EZO\CZ3)/XD_0]'HHH
MK\Q/KS%\:>#M'^(7A/5_#/B"S^WZ)JUM)9WMKYKQ^;$XVLNY"&7(/52#[U@_
M!_X)^"_@'X2;PSX#T;^PM#:Y>[-K]JFN/WKA0S;IG=N0J\9QQ7<44 >6Z?\
MLQ?#32_C5<_%JU\->5\0;G<)=8^WW)W;HA"?W)E\H?NP%X3WZ\U+\9?V:?AC
M^T%#:I\0/!]CXADM1L@NG:2"XB7.=BS1,L@7/.W=C/:O3:* //OA#\ /AY\!
M=+GT_P  ^%+'PY!<;?/D@#233[<[?,F<M(^,G&YCC)]:]!HHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "OP2_:2_Y.*^*?_8U:K_Z5RU^]M?@E^TE
M_P G%?%/_L:M5_\ 2N6OO>$OX]7T7YGS>=_PX>IYS1117Z<?(!1110 4444
M?O9^S;_R;K\+/^Q5TK_TDBKT>O./V;?^3=?A9_V*NE?^DD5>CU_/N)_CS]7^
M9^G4?X<?1!17S/\ \-_?#W_H#>)O_ 6W_P#C]'_#?WP]_P"@-XF_\!;?_P"/
MU]%_JKG?_0+(\K^VLO\ ^?R/IBBOF?\ X;^^'O\ T!O$W_@+;_\ Q^C_ (;^
M^'O_ $!O$W_@+;__ !^C_57._P#H%D']M9?_ ,_D?3%%?,__  W]\/?^@-XF
M_P# 6W_^/T?\-_?#W_H#>)O_  %M_P#X_1_JKG?_ $"R#^VLO_Y_(^F**^9_
M^&_OA[_T!O$W_@+;_P#Q^OIBO*QV58[+.7ZY2<.:]K];6O\ FCMPV-P^,O["
M:E;>WF%%%%>2=H4444 %%%% !1110 4444 %%%% !7YE_M??%[]H#6O'WQNU
M/X>^.$\*>"_A2NFPW.EV847=W]IC5GF!V'=M+.3N91M08!.<_II7QC^U)XV_
M9N^ _P 2O%6M^/KR\/BOQUX;.B:SH6DH9WO;,[42>1.D<@5-BN77(7@$KD '
M!_L[6/QK\$_M9>!="^*GQBG\8:%K?A^[UK1(=/D9[346$84I*"(RI1)/-4E6
M4X&,'I^A5?!'[#'P%^"/A/XOZCJ_A7Q_KWB_QIHVD0QVFC^(RL<VEV-S%'*C
M(H4!_P!W*J%D.U=[ J"PK[WH **** "O@W_@H5^SKX)\%_LR_&KXA06$VI^-
M-:FL'FUG59S<SV\;:I:_N+?=Q#$ =H50.  2:^\J^;_^"BOA76_&_P"QO\0=
M%\.Z/J&OZS=?V?Y&G:7:O<W$NW4;9VV1H"S8568X' 4GH* /?/"O_(L:/_UY
MP_\ H K4K-\-Q/!X=TJ*5&CD2UB5D88*D( 01V-:5 '@_P 6OVYO@?\  OQI
M<>$_&WCJ/1_$-M''+-8IIMY=&-74,FYH874$J0<$YP0>]?,7_!+7Q3I?CCX^
M_M;^)-$NOMNBZQXFM]0L;GRWC\Z"6ZU22-]K@,N58'# $9Y -?;GC#X$?#3X
MB:Q_:WBKX>>%/$VJ^6L/V[6-$MKN?8N=J[Y$+8&3@9P,U\7?\$R])L=!_:2_
M;$TS3+*WT[3;+Q;%;6MG:1+%#!$EYJBI&B* %55  4#   % 'Z%4444 %%%%
M !1110!YQ^TE_P FZ_%/_L5=5_\ 226OP3K][/VDO^3=?BG_ -BKJO\ Z22U
M^"=?IW"7\"KZK\CY'._XD/0****^]/F@HHHH *^C?^">/_)X?@#_ +B'_ION
M:^<J^C?^">/_ ">'X _[B'_ION:\W,O]QK_X)?DSKPG^\4_\2_,_::BBO./C
MM\1]3^&'A&TU72H+6XN)KY+9EO$9DVF.1B0%93G*#OZU^&T:,\14C2ANS]+A
M!U)*,=V>CT5\A?\ #7OC'_H&Z'_WXF_^.T?\->^,?^@;H?\ WXF_^.U[G]@8
MWLOO._\ L^N?7M%?(7_#7OC'_H&Z'_WXF_\ CM'_  U[XQ_Z!NA_]^)O_CM'
M]@8WLOO#^SZY]>T5\A?\->^,?^@;H?\ WXF_^.T?\->^,?\ H&Z'_P!^)O\
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M7_!/TNHK\T:*W_U9_P"GW_DO_!+_ +,_O_A_P3]+J*_-&BC_ %9_Z??^2_\
M!#^S/[_X?\$_2ZBOS1K]"/AC_P DU\)_]@BT_P#1*5X^995_9\(RY^:[[6_5
MG'B<)]72?->YTU%%%?/GGA1110 4444 %%%% !1110 4444 %%%% 'CWQ:_9
MT\$_$/Q9_P )[XGL)M>U31M(>VTVPOIS)I]HZF23[0EO]TS$N 7;/$:8 *YK
MSO\ X)A_\F-_#7_N)_\ ISNZ^D_$D3S^'=5BB1I)'M955%&2Q*$  =S7@/\
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M97V@@+%A23T Y'["44 4M%TF#0-&L-,M=WV:RMX[:+><ML10JY/<X J[110
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M^ /^%R?\%#/^B$_#_P#\#H?_ ):T?\+D_P""AG_1"?A__P"!T/\ \M: /O\
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M ) K]C_UYRW_ )]S^Z/_ ,D>?]6GW1YE17IO_#L;]J;_ **)\/\ _O\ 3_\
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M_P""AG_1=OA__P" ,/\ \JJ /O\ HKX _P"%-_\ !0S_ *+M\/\ _P  8?\
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M46/_ ,=H_P"&L?@A_P!%D^'_ /X5%C_\=K\3/T$]5HKRK_AK'X(?]%D^'_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWAGQ=H/B+4-..+VUTG4X;J6U.XKB5(V)3D$?,!R"* .HHHHH **** "BBB@
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MC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\
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MUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\
M1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH ^5?^'7'[,7_1,_\
MROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\ \K^J?_)-
M'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B
M9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\
MY7]4_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*_JG_ ,DT?\.N/V8O^B9_^5_5/_DF
MOJJB@#Q_X(?LC_"?]G'5=3U+X=^%/^$>O=2A6WNI?[1N[KS(U;<!B>5P.>X
M->P444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'QM^W(O_  K_ ..7[-?Q41'CCTSQ0WAZ^N(^OD7R!/F]
M@JS_ /?1'<8^:_A;\2K[PK^U?I_[2VKWRCP-\2==U[PWYN?]7I]M%$MDQ/ )
M9[8+CD8A]^/T!_:I_9[M/VG_ (+ZMX"N=5_L*2[F@N+?5!:_:3;212JV[R]Z
M;LJ'3[P^_GVKS;XI?L':)\1OV2_"?P3B\0?V6?#GV66TUXV'G'SXPPEE\D2+
M_K/,E^7?QO'+8H ^2/A3^U!J/[*_[,OAOQ&(='M_'7QD\2ZKXADU;Q-'=2:=
M8P1RHCR3):JT\F[ V*@ZRECP,-ZWX0_X*A?:/V<?B!XOU;2]'UGQ=X4U&WTN
M.303=0Z5J+71D^S7"K<()XHP(I=RL"Q\K(V[P$]K\??L66VO?#_X3Z9X4\87
M7@CQC\,X(H=!\46UC'<XQ'''/YMN[!9%D$>2I; )YW LK,O_ -BV?QM\"?$W
M@7XA_$_Q+XX\1:[?_P!K-XGN6\H:?=(Y:#[':;FCMXEX!C4_-N?!0% @!X;\
M'?V]]2^/$7Q)^'GB2Y\(ZY>MX/U#4[#7/!4&HVUF=D++);217\:2^8 =^]1M
MQQUK'_X)Z_M/:WXTT?X6?!CP##HT5MX=TF?4/%VIZZDC2F+[42+>QB21"TF)
M5!E;*+OS@[0K_3?P_P#V9?'.EP>+IO'_ ,;=>^(FIZUHLNAVJR62Z?IMC$Z%
M3+]ABD,<DV?^6I(8C([YKEO!W[!-M\/=#^#$GAOQ='I/C#X=74WFZ_#HRA=9
MLIWD:XM9X1,"-V\ .78K\Y RV5 /HKXF6?B[4/ ^J6O@74--TGQ5.J16=_JT
M+36]MND422F-?OLL9=D4_*7"AOES7Q]^P'>'X:W7[3=QXR\4/JO]@^+[@ZKX
MCU$",S""-O-N'4$A 0I;:,A1@#I7W17@'@/]D/0] A^-%AXEU'_A*]!^)FN3
MZO>:;Y$EG]GCD))@\R.4L^,_?&P\=* /D7X=>-/%WQ8_X*.?"3XB^(HIM-T'
MQ-I>JS^%='F!#V^D):W"03.#T><[YB.>'3!(P!^G-?&J?\$L_A%I/QH\(>,O
M#]E_8OA[0PTMSX:\V\G^VW0):&?[2]SNC\M]C; I5MF#P37V50 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?E7XV\87GP-G_:\
M^$&EJ]OJWBWQ!8?\([;!L)(VL?+.%.. (G &,\KCC;FOU4KYL^)7[%.C_$C]
MK3P3\;KC7#:-X=@B2;0UL0XO9H3*T$WG>8-A5I(\C8V1$!D9R #X0U+^U/#W
MP%UC]D:6_,^N+\5+/P]"T0PSZ7<O]JCF(/0>;'O)Z#=[9KUOXR?\%/-2^&/Q
M.\4^&/"-MX*L/#7@B\_L5M%\01:FVJZN]NYCG%I+;QM;P+\IC3SB?N;SD-L'
MTAK_ .Q'HVN_MFZ1\?CKGDRV=NHGT'[#N%S<I;O!'.9_,^7:ABPNP\Q#GFL7
MQ1^Q#XE'Q"\9:O\ #WXUZ]\-/#'C6_CU3Q%H>EZ?%)/+<[RTTEK>%U>U:0'D
MJI.2=V]<( #SG]HC_@I2W@W6/!6D^"I_"^@_V[X<M?$\VM>.K?4+BT2&X7,5
MJD5@CR^=CYBS#8 I'4UYC\;/VO-(^+?PQ_9C^+^MVG]C0Z-X]W:W;V>Z98WM
MMC2-$" Q5DVNJGD;]I)QN/UG\6?V1-7\2?$31/B!\./B=J?PT\;V.BCP[=ZK
M+81ZP-0L0=RK*D[C=)N )D)).T'&0#4'B/\ 8K'BCPW\'-*U;Q]JWB.3P#KL
M>NWM_P")T;4[C6W#!GB=I)1Y2$_*H^<*H PQ!) .A_9#^-7B[]HGP+?_ !!U
MFUT+2_"NJ7DJ>'=-T[?)?0VT<CQEKV4R,AD8K]Q$7:!R3NPOF7[;7P=^'=YJ
M5S\4OCGXON[_ .&>BZ0;+3? L+2VPDU1F)2:*2.93+.Z[E";  !N9@B-7L7P
M0_9X'P)\<?$2]T37]_@WQ7J(UBW\+FR"+I5XPQ</%*'P4D./W>P!0B '@Y\T
M_:6_8O\ %WQ^^,OAOQYI_P 6X_"T?AJ)?['T>X\,1:K!:SY)>XVS3B-Y&.TY
M,>1Y<>.5!H ^2_'&J?$SP?\ LA_LX?#?QC9Z]JK>+M<E@N?#<5Z;;4+[3U=?
ML>ERS-@QJXEC4Y_U:!1CY-H^H?\ @GG<>']!A^)?@;3?#WB/P#K7A_5HWU'P
M+K6MQZM::/YRNT?V*X5%9HY I9MQ;YAD$YR>M\>?LE^)/BM\*?#^D>,_BK=:
MK\1_#>L#6]$\>6>AV]E):3*<HIM(VV.@&,C<"Q523Q@]1^SC^S:_P.NO%_B#
M7?%ESX]\>^+KN.ZUOQ%<64=F)O*#+#'' A*QJJL1@$Y/H,* #VRBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNP7ZSN/V&_A?<? BQ^%2VNI0:38W8U2WUB&\*ZJFHC.;X3[<>><G)V[<' 4
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MOS\^,/[97PS_ &G/CQ+X7^(/C<>#?@/X/OUG.G0V-U=7/C&[BD8*7:")Q':
MKG:Q#,K*0-SAK< ^I_C?^V[JW@'XB:]X1\ _"V\^)5WX:T ^)-?NAK$6F0V5
MF4613'OC<S,4;<54!N@4,=VWW[X3?$S2OC)\-?#GC;0UGCTO7+-+R".Y4++&
M&ZHX!(W*05."1D<$U^;'[;&J^&F_:2^(=U\0/$'B?X7:%<^ TT_PEJ7A2VDB
MC\5;HA)+;W;)&WFIYDHB,3E%VQIN9,@M]Z?LA?V^O[,OPYC\4:!%X7UN+2(H
M9]*AMOLPA"96,F+ \MF0([+@89R,#I0![!1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[2FA>*?ASXH_:R70M,\)^._#7C#2K6]UG4V\0VL=YX8,<,FV.XLR3,SLQ_=
M  DQ-N^\%^XOV04U"/\ 99^$Z:HLBWJ^&; ,LH(<+Y"[ <\YV[:A^)'['?P;
M^+WQ!M/&_B_P'I^M^);?R?\ 2Y99D2?RCF,3PHXCG  "D2JV5 4Y4 5[#%$D
M$211(L<: *J*,!0.  .PH ?1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX_D=WV@C;ZMD#I0!]24444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ;/80Q/;PLKQH3,S2JRC,B_=5NAKU^@ HJAKVLP^'="U'5KE9'M[&VDNI5B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5\%_\%3/^:8_]Q3_VTK[TKX+_ ."IG_-,?^XI_P"VE>IEG^]P^?Y,\C-O
M]RJ?+\T?!=%%%?>'YR=[\ /^2\?#?_L9=-_]*HZ_8/XI?\DR\7?]@>\_]$O7
MX^? #_DO'PW_ .QETW_TJCK]DO&>CS>(O!^NZ3;-&EQ?6$]K$TI(0,\;*"Q
M)QD\X!KY+.OXD/0^TR'^%/U/P[_8=U"U^"VM?!SXOW$J6.F7/CK5?".MWDC;
M46";3[$P;^VU6FGD)[;,\]FZS9R>,OBM\%?C->!OMOQ(^*6I7D6]<%+*"^TZ
M."//?:SS+] />OKZ/_@F;XYN/V&)/@]>:SX7_P"$TM_%G_"1V5]'<W!L0IB6
M%E>0VXD#;#)P(R,A>?3LO&7_  3\\4:EX!_9;T+1=1\/PW7PMO$O-9EN+B=$
MG9Y;>>Y%MMA._=)$Y&\)GY>F2!\X?4GEG[07[5UAXL_:Z\:^ O'_ ,:/$_P3
M^&WA.!;:R/@S[3'?ZE?%4+-)+!#*P0;G^4@#"ICDL:ZK]D_]K/7?BE^SK\:-
M'USXOVFBW/@F\CM;#XI:IIGF%M/N))$MYW@=HRTS>3(%W8;,D>Y68$-ZS\0O
MV5?BEX*_:.\0?&/X$^(_"MCJ7BBR6TUSP_XQAN#92R*% G1X 6W?(K8P,-NY
M(<J,_P 1?L*>-/'_ .R;XF^'GC3XL:GXJ\>Z[J,>L/K6J3S7%C:S1N&2VAB9
MLQP8W#Y0#EL[<*J  ^/=6_:+U#X6_$OX2:I\,/C9\6/B18ZKJ\=GKE[XT6==
M#U &6)76TBG0; 0\GR_,4!7#9%>^?&+7?B)XS_X*<V/PQT/XG^)O!?AC4O#J
MR7,.DWA*QJL$DCM#$^Z))6V!?-V$KDD<XJ+XD?L._M(_%_0/A@/%'C#X<FY^
M'US;+INCZ9%=V]K/!&$WRRW!A9O-/DQ*$6()@L1M(P?<+[]E7Q;>?\% M+^.
M@U#15\)VNBG3I+(SS?;O--O)'D)Y6PKN<<[P<9X[4 >6_L9^//&W@O\ ;:^,
M'P(UKQUX@\?>&-#TS^U-.OO%%V;N]B8/:C:93R05N\$<+F,$!<D5[_\ M[?\
MF<_%G_L"2_\ H2UR'PK_ &4_%O@?]O'XF_&R_P!1T6;PKXGT<Z?9V=O/,U]'
M)FR.9$,00+_HLG1V/*\<G'KW[37PQU3XS_ /QQX(T2XL[75M<TY[2VFU!W2!
M')!!<HK,!QV4T ?FK\!_VK/BW;?LCZ)\+_#G[+_B#QMI4VEW.GVWB2:"YN--
MNQ))*2YC%KL959R"/.QE>H[:WQ.\ _$G]C'_ ()AZ#8'Q!JGA'QI>>+([ZZ_
ML349+>:T2:.7_1S+$PS\L:,P!(W$CG -?H-^R;\(]8^ _P"SQX+\!Z_<V-YK
M&BVTD-Q-ILCO;LS322#8SHC$8<=5'.:XK]OK]F[Q-^U/\"XO!?A2^TG3]435
M[>_,VLS2Q0>7&DJL,QQR-NRXQ\N.O- 'S[^U!X+\?? ']C'QCX\_X7+X_P!8
M\9ZXFC2W$T^M/%!IT[W*&<6*0[?(C;S-FT$_*F,X.*J^/OCM\2?%F@_LF?!C
MPGXNO_#FN?$#PMIFI^(/%H<RZ@83:(SE)7.?,;9.[-G<S!/F&6S],_M@_L]^
M(OV@?V7=0^&_AV]TNRURX^P[;C4Y9([8>3+&[Y9(W;D(<?+UQTKSGXC?L,^(
MO$WPY^!%]X;\46'AGXN_"O2+"QM=4,;SZ?=M#!$CQOE0WE[XV(;9DJ[ K\W
M!Q=KXL\;_L;_ +9'PX^&=[\2/$GQ*^'GQ @,2KXQNOMNHV%WN9%9)]H)4OY?
M' P[9&5#5R7@_1OB)^T/^W+\?/ ,WQA\>>$?!.C.ETD/AW6GAFAE&U88H6;<
M(8SOD9UC W;5![$>X_#O]E/XD^,OVAM$^,GQX\2>&]2UKPU:-::#X>\'PSKI
MULS!@9V>?#E_G8XP>=IW80+6]\"?V8_%/PP_:P^,_P 3M5O](N- \:>5_9]O
M9S2M=1;2"?.5HU5>G\+-0!](:/IYTG2;*R:YFO&MH$A-Q<N7EEVJ!O=CR6.,
MD]R:_%SQG\:O@Y\>/BM^T[XE^)'BV'2[G5M-_P"$?\#(]C=W2A8'#13@PQ.L
M8:2VMV.2"?.E[$Y_7;XY>'_%7BWX0>+M#\$7=CI_BK4].ELK"\U*5XH('D&P
MR%D1V!569AA3\P'3J/%_V;OV"OAM\*O@MX:\->,_ /@KQAXLM87;4]9O-&@O
M6GG>1G(66:+>44,$7('RJ.!0!YE^Q7\?+KXE_P#!.CQ"R:A-!XF\$Z%J.CO<
M0R,DT7D6K/:RJP.01$8P&!^]&WI7SQ\-8/BOX\_X)^Z]\9+_ ./GQ"MM<\,R
M74NEV=GJK+#(L4REQ=N<RW!8LP7<^U%"C:0"#]+_  Y_8;\9?"'XH?'W_A%+
MWPS8_"[XB:-=6VGZ.L\\<UC=O$PB)B6$QI$CS7"X1CA"F!QMJ[\+_P!BWQOX
M*_8#\5? ^^U30)?%FJK>+!>6]Q.;%?.D5EW.80XP!SB,_C0!\_?M6?M-?$:\
M_P""??P%^(FG^*]5T'Q5JNJ)'J-]H]Y)9M>&.*Y1O,\HKE7:(,5^[GM75?'N
M\^)G[(/[2'[/]Y%\8_&'CF/QUJQL/$.EZ]<HVG/MFM(Y3;6R*$@5ENFV@ E"
M@.X\BN@^+W_!/?XB^/\ ]BCX3_!_3]:\+P^)?">H/=7UU=75RMG(K?:,")UM
MRY/[Y?O(O0^V?7/VS/V4_%O[1/Q0^!GB3PWJ.BV5CX%UB74-2CU2>:.6:-I[
M.0"$)$X9L6TGWBHR5YY. #D?^%@^*?\ AZY_PB/_  DNK_\ "*?\(?\ :O["
M^WR_8?.V9\SR-VS=_M8S6'\$_B9XMU+_ (*D?'+PM?\ BW5IO"NF^&GN+/1[
M[4)I-.LY =-_>) 7V(1YDG( .';GDUW/QZ_92^)=_P#M1^'_ (Z_!_Q%X;L?
M$5MIO]E:AI7BU+@VD\>'7<# "QRKCY/EP8U.[G%<Q\'OV&?B-H/[27Q7^(/Q
M!\7Z'KFG^//"MUHD]QHZRP744]Q]EW[8638L48AD1#YC,0L989+8 /EGX^?&
MK_A'O"/BSQ1X/_:@^*7Q)^(NG7\<AN/#%K-8>$K.-YT4I+%\T07:Y5&61E9B
M@P<YKM/VU?'6I_$[X5_L6>+-:9'UC6;RVO;R2- BO,ZV9=@HX4%LG X&<5U]
MK_P3Y_:"M_V==>^!"^/O ,'P]>XDOK2ZBL;K^T;Z02B:*&X)7;#&941BR>8Z
M[< LHVUVWQ0_85^(WC[X1_LV>&8=4\+VNJ?#26/^UGDO+DPW"1F$*;=A;[F8
MK#DAU0 G&3UH DU;XC>+(_\ @K7HG@]/%&M)X2D\-M.^@KJ$PL&D^RS-O,&[
MRRV0#G;G(!KY[_;"\/\ B/X5_%+P?\(OA!\<_C7XO^*.N7"?:+/4O&LLMO90
MN/D#B)$(=A^\)+82-"S## C["US]E3QG>?M\6?QSL]2T-/#=MH3Z:MG---]L
M\\V\D:ML$6S9N=2?GS@'CM7@OP7_ &*_VI_@K\6/$_Q+AU3X/^+?&_B#?]HU
M;Q-<:K/)!O;=)Y(BAC";OE7H<*H5=JY! (/VK/CEX@^ _BCX+? +Q'\7=<\*
M:$VA1ZCXP^(UKY\^K70S.@6*15DE4M) X# ,PWQDG"MFY^QS^U[%:_M >.OA
MWIGQ)UOXQ?#2#09M=T/7?$23?VG#) BO-;R22QQNX(,GS%<?(N,9(KV+XN?L
MJ_%;XE:W\,/B[I_B'PCX;^/W@^"6VN6M8+F30K^%VDQ#N;,R($ED!."3YTF,
M<$=O\ ?@?\5-+\;>,/&WQF\?1^(]3UZ$6<'A/P_=W8\/:;!M4,8H)B 78(!N
M*Y&7)+%R: /D[X"Z/\7OVJ_@3\0_CEJWQD\4:#K,K:C'HWAG3[E?[!$$,1)B
MGM&4JRL2T>X8< !B6:O:O^"17_)F>D_]AB__ /1@KF/ O[$OQV^"WAOQS\,/
MA[\0_"=K\)_$DMS-%=ZI:W,FMV"S1^6T<04>4"555,A9L<NJ \5[M^PM^SWX
MB_9C_9_L? WBF]TN_P!6@O[FZ:;2)9)("LCY4!I(T;..ORT >#?MV?\ )\/[
M(O\ V&9O_2BUKE]5OOB'\5/^"H?Q/^&%G\6/%_@_P<NB6\\EGHVH-^ZC^Q6#
ML+59-T=O(TC[C*J;L&0#[Y-?0_[2?[,/BGXQ?M&? OQ_HM_H]KH_@74)+K4H
M+^:5+B96EA<"%5B96.(V^\R]15#P?^RGXM\/_P#!0;QQ\=;C4=%?PCKFCQZ?
M;644\QOTD6VLXB70Q",+NMGZ2$X*\=0 #QG]D7XI>/=)\<_M/_"G7?'&N>,K
M#P5#=/HVL:W<M-J$.PSIS,3N)($9ZX!0E0N<5YMX7_;"^(?PI_X)?67C5?$.
MH:YXXUKQ//H%KKFM7+WT]J&$LGF;I2Q8JD+A0<@%@<$#%>WV/P-N_P!F'XB?
MM*_%OQ]XL\+:5X4\=6UW'I0:_=)Q(YED2)UDC13(PX"HSDD'&:\V_9*_9?L_
MVI?^"9-EX*U.Y?1;F;7+O4])U-H/,$%Q'*R+)MR-RD&6,X/1FQR* ."\-_M=
MZ5\'_B]\*Y? /[0_BWXT6.NZA%IWC+1O%4=VT,7FNB_:+/SX(_*4%W(C4D_(
MH)() ]XUK7O'/[77[:WQ"^%]K\1?$_PV^'W@&QCW?\(;>BROKZ[;RQN>;!(7
M<\G&",1KP"Q-=]X)^ O[2/BKXB^"-3^+'Q5TJS\,>$06&G> ;J^M)?$$@*E6
MU$ML5@2BEE *XW*%&]C2?$K]E'XE>$_VDM7^-?P*\0^&+#7O$5@MAKFA^,HK
MAK&? C E1H 7#?NHSC Y#'=ABM 'FGQ^^"_Q=T/]A;XGZ'\5_B--KP\.ROJ>
MAZSH.HRQW>J685T%KJ@>$"1/W@<J&;+!<M^[!;Q/[/XB^"O_  2?TKQGX6^(
M7C2RU;7;ZS=476I(XM,5;J>-HK(1[6AC<<NNX[CS7V/X6_9%\<ZI\!?BIX5^
M)'Q2U#Q;XN\?13![F2XN)M,T<MO:..T@D?Y(P[DD*$RH5< **\>O/V&_CMXB
M_8ON_@7K6N?#[&FW=F_A^[L9KY084GGEN#=R-"<N3)&$$<8 "G)[T 3?&KXW
M_$7Q)=_LR?!+P=XKO?#&K^/-"LM1UWQ5&WF7PM_LZE_+D8Y#D1SN6SN+!.1E
MLVK7Q9XW_8W_ &R/AQ\,[WXD>)/B5\//B! 8E7QC=?;=1L+O<R*R3[02I?R^
M.!AVR,J&KT/XR_L4Z]XZ\*_!K6_"OB>R\+_%CX:6-K;V>I21//8W7EQ1J\4@
MP&V;T)#;?NNP*_-POP[_ &4_B3XR_:&T3XR?'CQ)X;U+6O#5HUIH/A[P?#.N
MG6S,&!G9Y\.7^=CC!YVG=A M 'AW@E?B+\=_V]OCS\.7^,/C;PEX.T^,W(M]
M#U)A-&%:)$CMFD#K;+F4LS1J&.T#(R33_P!E'XZ?&.Z^$_[4OA"RU[4_'WBW
MX<SO!X;U#4U^UW\S,UW'@[LF5A]EWJK%B6;;R,"O?_@?^RKXL^&G[97Q<^+6
MJ:AHT_ASQ=;F&QM;2>9KR,^9"W[U6B5 ,1M]UVZBN=_9P_8X^(_P9U[]HK4O
M^$STG0-0^(6HQWV@:MHL9OIM.*SWD@:>&XA6-CBXC!4%@?GPRG#4 ?)GP%^.
M&G>-K_P\=1_:K^)?PQ^+D5RHU73_ !\OV[P]<2C[\45OOCCA0G _>NIZ@ $@
MU^O<9+1H2RN<#+*, ^XYZ5\ ?%S]C/\ :(_:4T33?"/Q/\3?"J71K6XCED\8
M:7HUP?$$RIQ]TJD*;@3E8RHZ#IQ7W?X9T&W\*^&])T2T:1[33;2*SA:9BSE(
MT"*6)ZG"C)H TZ*** "BBB@ KYH_;-_YD_\ [?/_ &A7TO7S1^V;_P R?_V^
M?^T*]S)/^1A3^?\ Z2SNP/\ O$?G^3/FBBBBOU0^J/3/V;O^2T>'?^WC_P!)
MI:^JOCG_ ,D3^(/_ &+VH?\ I-)7RK^S=_R6CP[_ -O'_I-+7U5\<_\ DB?Q
M!_[%[4/_ $FDKX3-_P#D:4/^W?\ TIGS69_Q/E_F?CY1117] 'QX5^P?P,_Y
M(G\/O^Q>T_\ ])HZ_'ROV#^!G_)$_A]_V+VG_P#I-'7YAQW_ +M0_P 3_([,
M+\3/@?\ ;#_Y.,\7?]NG_I'#7C->S?MA_P#)QGB[_MT_](X:\9K]CR'_ )%.
M$_Z]P_\ 24?B^9?[]7_QR_-A7V7_ ,$Z_P#FH'_</_\ ;FOC2OLO_@G7_P U
M _[A_P#[<UX7&_\ R3^)_P"W/_2XGH\/?\C.E_V]_P"DL^;?^"B_P[@^+7_!
M1/X8>#;B-95UOP<ED@8X D:;4Q&V>VU]K?A7 :=\1!^U'\%/V</@Q<2>8_A^
MTUG4=?MSR;==-MITLMZGL8P5P>,MBON_XK?LH^+/'7[>'PR^-=CJ&BQ>%?#&
MCC3[RSN9IA?22!KTYC01%"O^DQ\EU/#<<#/ ?LY_\$\=8^#7[17Q;\=:GJ.B
M7OA[Q'::E9:%9VLLQGMX[JX$G[\&)54K& GR,V<MTK^4S]H/E+X,_M(>(_V;
M_P#@F4M[X1N8].\0:_XZN=(AU26/>+"-K9)))E7!RP$84<'&XG&0*[3P)^UQ
MI'PG_:"^%5A\/?C_ .+OC;X:\47R:3XITWQA'=,;2662...XM6GA0HNZ1FV(
M3@1X);<,>Q^"?^":.M3?L6W'P@\7>(M*LO%MKXCD\1Z1K>BM-<06TWEHB!MZ
M1/@CS%.!QN5ADKBO4/A_\#?VB_$WQ6\)^)/B]\4-+M?#_A>(B+0_A_<WMI'K
M<PQMEU -L5^0"4 *'!4* S9 /'?VK/'&A2?&;Q5INI_M(_$<:U;VF-*^'OPC
MLYK>;3W5>EU-$9%F8D@L&,;#/88%>>>$?VG/B7X^_P""3?Q.\7:CXNU6/QAX
M>UZVTBT\0V=T]O?>3]JTU\F:,JV[;<R(6SEEX).37MT'[&?QL^&/QP^+?B+X
M6>-O!UEX:^)US)<ZE=>(;*>?4M,:2261C;(@\MRK3R8WN%(V[ERH-<_X-_X)
MY_$7PE^P]\5_@7_;GABYU7Q'X@AU72=3^TW*P>2DUDS"X'D%HVV69P$#C+XS
M@9H \?\ C%J'Q;^%/[&_PF^/MK\=?'%]XLO/[-CDTNXO0=*:"2!V17@Q^]D
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M>(-%T7X@:#:'39[/Q,LS6%_;$2#]XT09PP6613QR-OS*5R>>^$7[(OQ<T/\
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M^R?X-\16VI:U:ZQKWB/4/[1O1IMN;>QML A8H(R?NC+<X7J!@!10!])T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%HR4Z=*,6NJBD_R"BBBO).T**** "BBB@ HHHH **** "BBB@ HHHH ****
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M3VIOBG6Y?AO\+]7U>XN;C7)]!T::[DN;M8UFO&@@+%W$:H@9RF3L55R3@*,
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MSWI&E:U9>%-9\4>%[GQ7XKNH=-2X"V7E110F".3(21Y;E9$8DJK1@LLJ!HG
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MMVDGN-4OXRX,2.8!!!%( <3[R"SHJ?I)0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\1O"/C*]N+PZAX7BO8["U1T%MNN42.25U*[BX1"JD, !(^0<\=?110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>advm-20231231_g6.jpg
<TEXT>
begin 644 advm-20231231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /:!J # 2(  A$! Q$!_\0
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MQ7JG[,_P-3XM^(I[S5=Z^'=,*F=5R#<R'E8@>PP,L1R!@?Q9'T]\3OCQX0^
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M6W=Y%G"TKX'?:H)QR/SJE7WK^QUX>L-,^#MIJ4%NB7VI3S/<SX^=]DC(HSZ
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M2PUZ=^PSX)^T:KKWBN9?DMXQI]L>Q=L/(?J%"#_@9KS']J[_ )+]XI_[=?\
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MPWR'^9-#CS3:84,9/ Y%3K4TN:[M?I[TM?N/2_@A\25^*O[3WB76[<2II_\
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M/3/,\X6=U+;^9C&[8Y7./?%>B_L]_"33OBUXBU&TU2[N+6UL[838M=H=V+
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M_)5_"/\ V%+?_P!&"OLK]JG_ )(CKO\ OV__ *.2OC7X-_\ )5_"/_84M_\
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MZ,<TJ#N>1PS&<LS@X;)._I9_K8\8_;4TN#3_ (U//"H5[W3H+B7 ZN"\>?\
MOF-?RK[C\976CZ?X7U*\U]8VT:UB-Q<B5-Z[4^?E?XN5''?I7P7^UYXH@\2_
M&S4DMG62+3((K#>I!!906<<>C.RGW4U]?_M,:7=ZQ\"_%UO9;O/6V2<[2<E(
MY4DD''^PC5YU>-X4(R_K8^LRVJH8C,ZM)7MK;NUS_FSS[P7^VMX=\4>,K;1)
M]#NM(L+J5;>UOY)E?YFX421@?("<#(9L9YP,D9?[:?PETZZ\+GQS8VZ6^J6<
ML<5\Z# GB<A%9AW96*#/H3GH*^.-&L;K4]6L;.Q#&]N)XXH IP?,9@%P>QR1
M7Z*?M37<%G\!O%33QK*LD<,:JP!^=IXPIY]#\WX5=6G'#5J;I]3CP>,JYQEN
M*CC;/D5T[6ULWT[6]=3#_91\%Z9X2^#=AK=K9K<ZMJD4EU<31H/-DPS!(E)[
M *!C.,DGO7.?\-I0Z3XHBT[Q+X'U7PW8R/M^TW3GSD7(&]H3&IP.2<,3QP#7
MEG[/?QT\8?#?PZVGR>$M2\1^%8B\Z36MO(&M%.6D(<*5*\EL'&,DY%>[Z'^U
M=\+O&\,=IJ5TVFM.=AMM:M/W?_ F&Y /<D>^*RJ4I*I*4X<R?9G=@\=2J82A
M2P]=4916JE%6;]7;?NG?4\$_:H^)/PX^)D.GWWAIII_$4,NR:Z6T:))8-IX<
MM@E@=N.#P2*[K]B_X-Z=+HK>.]5MH[N\DF:+35D&Y850X:4#^\6R >P7CK4G
M[5O[/GA;1? MYXP\/V,6B7EC)%]HM[5=L$Z/(L?"=$8%U.5P" <CG(]._9)D
M63]G_P ,*K E#=*P]#]JE./R(_.G4J+ZLE3;M>VIAA,%4EGLGC8QYE'F7+L]
M4D[/KO\ -')>(/VV/#6A^.)M&71KR[TNVG:WGU2.5>&5MI9(\?,O!YW ^U,_
M:X^$NE^+O $OC72K>,:OIZ+<23PJ!]JMCC=N]2H(8$\X!'>N<U#]H#X'6-_<
MV]Y\+WCNX96CF230+#<K@D,#^\ZYS4OCC]L3P)XB^'^O>'[#1M<MY+W3)[*V
M5[6!(HV:)D3.V8X4$CH#@#I4QIRC*,J<&NYI5QM#$8>O1QV)A-/X4E9IZ_\
M ,O]@3_C]\;?]<[/^<U>U_$KXN>"/@/JTUUJ-M<RZQKSK<31Z?$LDSK&BQ*[
M%F4!0$  SUW$#K7BG[ G_'[XV_ZYV?\ .:N-_;:D9_C+$"<A=+@"^PWR'^9-
M5.FJN*E%[?\  1SX?&SP'#]*O22YKNU^EY2U^X]N^!O[1*?$[XN>*M+W21Z7
M<QI<:1%<*JNJQJ%D4X)Y;._'.,-7A/[8W@/_ (1/XK/JL$>RRUV+[4,8P)EP
MLH'X[6/N]>4_#WQ?/X!\;Z+X@@W%K"Y65E7&7CZ.G_ E+#\:^[/VB?ANGQJ^
M'6DR:0PGNEN[:XL[B,!@89F5';W78XD."/\ 5BJE%8>LFMGH<E*K4SW*ZM.>
MM6F^9?/7_-?<8G[&_@=?"/PKEUV[4176MRFY9V&TK;IE8P>>GWWSZ/7B7@W1
M8/VH?VD-7U#4#*_A^(M=,@W+OMXRL<,>?X2WRDC@_?Q@\U[_ /M+>*;;X4_
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MI2;_ -(S55(*FXN.YR97CZN94L70KI<B6BLDDM=/P/S8HHHKO/RT_3GQ-,?
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M0.?PHK:SBEN'#Z<,MQDZOP-?H[_FC@_V$O\ D0?$/_83_P#:25Q'[0G[/?Q
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M>#O^A#\*_P#@GA_PK3HI6#V-+^1?<C,_X0SP=_T(?A7_ ,$\/^%'_"&>#O\
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M9G_"&^#O^A$\*_\ @GA_PH_X0WP=_P!")X5_\$\/^%:=%'*@]C2_D7W(S?\
MA#?!_P#T(GA7_P $\/\ A1_PAO@__H1/"O\ X)X?\*TJ*.5![&E_(ON1F_\
M"&^#_P#H1/"O_@GA_P */^$-\'_]")X5_P#!/#_A6E11RH/8TOY%]R,W_A#?
M!_\ T(GA7_P3P_X4?\(;X/\ ^A$\*_\ @GA_PK2HHY4'L:7\B^Y&;_PAO@__
M *$3PK_X)X?\*/\ A#?!_P#T(GA7_P $\/\ A6E11R1#V-+^1?<C-_X0WP?_
M -")X5_\$\/^%'_"&^#_ /H1/"O_ ()X?\*TJ*.2(>QI?R+[D9O_  AW@_\
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M#_\ H1/"O_@GA_PK2HHY(A[&E_(ON1F_\(=X/_Z$3PK_ .">'_"C_A#O!_\
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M^"B'_"M*BCV<>P>QI?R+[D9O_"'^$/\ H1?"W_@HA_PH_P"$/\(?]"+X6_\
M!1#_ (5I44>SCV#V-+^1?<C-_P"$/\(?]"+X6_\ !1#_ (4?\(?X0_Z$7PM_
MX*(?\*TJ*/9Q[![&E_(ON1F_\(?X0_Z$7PM_X*(?\*/^$/\ "'_0B^%O_!1#
M_A6E11[./8/8TOY%]R,W_A#_  A_T(OA;_P40_X4?\(?X0_Z$7PM_P""B'_"
MM*BCV<>P>QI?R+[D9O\ PA_A#_H1?"W_ (*(?\*/^$/\(?\ 0B^%O_!1#_A6
ME11[./8/8TOY%]R,W_A#_"'_ $(OA;_P40_X4?\ "'^$/^A%\+?^"B'_  K2
MHH]G'L'L:7\B^Y&=_P (?X0_Z$7PM_X*(?\ "C_A#_"'_0B^%O\ P40_X5HT
M4>SCV#V-+^1?<C._X0_PA_T(OA;_ ,%$/^%'_"'^$/\ H1?"W_@HA_PK1HH]
MG'L'L:7\B^Y&=_PA_A#_ *$7PM_X*(?\*/\ A#_"'_0B^%O_  40_P"%:-%'
MLX]@]C2_D7W(SO\ A#_"'_0B^%O_  40_P"%'_"'^$/^A%\+?^"B'_"M&BCV
M<>P>QI?R+[D9W_"'^$/^A%\+?^"B'_"C_A#_  A_T(OA;_P40_X5HT4>SCV#
MV-+^1?<C._X0_P (?]"+X6_\%$/^%'_"'^$/^A%\+?\ @HA_PK1HH]G'L'L:
M7\B^Y&=_PA_A#_H1?"W_ (*(?\*/^$/\(?\ 0B^%O_!1#_A6C11[./8/8TOY
M%]R,[_A#_"'_ $(OA;_P40_X4?\ "'^$/^A%\+?^"B'_  K1HH]G'L'L:7\B
M^Y&=_P (?X0_Z$7PM_X*(?\ "C_A#_"'_0B^%O\ P40_X5HT4>SCV#V-+^1?
M<C._X1#PA_T(OA;_ ,%$/^%'_"(^$/\ H1O"W_@HA_PK1HH]G'L'L:7\B^Y&
M=_PB/A#_ *$;PM_X*(?\*/\ A$?"'_0C>%O_  40_P"%:-%'LX]@]C2_D7W(
MSO\ A$?"'_0C>%O_  40_P"%'_"(^$/^A&\+?^"B'_"M&BCV<>P>QI?R+[D9
MW_"(^$/^A&\+?^"B'_"C_A$?"'_0C>%O_!1#_A6C11[./8/8TOY%]R,[_A$?
M"'_0C>%O_!1#_A1_PB/A#_H1O"W_ (*(?\*T:*/9Q[![&E_(ON1G?\(CX0_Z
M$;PM_P""B'_"C_A$?"'_ $(WA;_P40_X5HT4>SAV#V-+^1?<C._X1'PA_P!"
M-X6_\%$/^%'_  B/A#_H1O"W_@HA_P *T:*/9P[![&E_(ON1G?\ "(^$/^A&
M\+?^"B'_  H_X1'PA_T(WA;_ ,%$/^%:-%'LX=@]C2_D7W(SO^$1\(_]"-X7
M_P#!1#_A1_PB/A'_ *$;PO\ ^"B'_"M&BE[.'8/8TOY%]R,[_A$?"/\ T(WA
M?_P40_X4O_"(^$?^A&\+_P#@HA_PK0HH]G#L'L:7\B^Y&?\ \(CX1_Z$;PO_
M ."B'_"C_A$?"/\ T(WA?_P40_X5H44>SAV#V5/^1?<C/_X1'PC_ -"-X7_\
M%$/^%'_")^$O^A'\+_\ @HA_PK0HH]E#L/V5/^5?<C/_ .$3\)?]"/X7_P#!
M1#_A1_PB?A+_ *$?PO\ ^"B'_"M"BCV4.P>RI_RK[D9__")^$O\ H1_"_P#X
M*(?\*/\ A$_"7_0C^%__  4P_P"%:%%'LH=@]E3_ )5]R,__ (1/PE_T(_A?
M_P %,/\ A1_PB?A+_H1_"_\ X*8?\*T**/90[![*G_*ON1G_ /")^$O^A'\+
M_P#@IA_PH_X1/PE_T(_A?_P4P_X5H44O90[![*G_ "K[D4/^$3\)_P#0C^%_
M_!3#_A1_PB?A/_H1_"__ (*8?\*OT4>QAV#V5/\ E7W(H?\ ")^$_P#H1_"_
M_@IA_P */^$3\)_]"/X7_P#!3#_A5^BCV-/L'LJ?\J^Y%#_A%?"?_0D>&/\
MP4P_X4?\(KX3_P"A(\,?^"F'_"K]%'L:?8/94_Y5]R*'_"*^$_\ H2/#'_@I
MA_PH_P"$5\)_]"1X8_\ !3#_ (5?HH]C3[![.G_*ON10_P"$5\)_]"1X8_\
M!3%_A1_PBOA3_H2/#'_@IB_PJ_11[&G_ "A[.G_*ON10_P"$5\*?]"1X8_\
M!3%_A1_PBOA3_H2/#'_@IB_PJ_11[&G_ "A[.G_*ON11_P"$5\*?]"3X8_\
M!3%_A1_PBWA3_H2?#'_@IB_PJ]12]C3_ )0]G3_E7W(H_P#"+>%/^A)\,?\
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MLB_PH_L'PW_T)_AW_P %D?\ A5FBCZIA_P"1?<'+'LON*W]A>'/^A/\ #O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>#/ NABZ2SU*,O*(ML<(P^0(2&8J&!.6;H.4\*S(O_!*3Q]9,VV\M/%T<=Q
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MALHBJM_K9%*LV'0D':/G49)R!XM^P[XK_P"$W_;._:!ULZ;>:-)=)"9=.U%
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MN7^K&32Y;GH?[8OQ@N?@;^SKXO\ %.GR>5K"P+9Z>X )2XF81HXSW3<7_P"
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M'2/QEXJT_7_%&G+- VMVEI+%+!::AY;+)]A<;<32@J4R3L(8;2&]8_X*-?\
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M_P ]9_\ OI?\*/K$ ]E(Y"BNO_X1"S_YZS_]]+_A1_PB%G_SUG_[Z7_"CZQ
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M_P ]9_\ OI?\*/K$ ]E(Y"BNO_X1"S_YZS_]]+_A1_PB%G_SUG_[Z7_"CZQ
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M_P ]9_\ OI?\*/K$ ]E(Y"BNO_X1"S_YZS_]]+_A1_PB%G_SUG_[Z7_"CZQ
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MZ^WB8:.CP6^H/:_9W,&]FCC9=[<HI"YSR%' KW'_ (1"S_YZS_\ ?2_X4?\
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MF/CS1M<\0^$=3T[PWXB;PGKEQ'MM-:6RCO/LK[@=WDR?*_ (P?7UKRW]FO\
M9>MO@#<^*M:U#Q->>-O&?BBY6YU;7KV!8#+M+$*D89MBY=CC<>PX"@5]0?\
M"(6?_/6?_OI?\*/^$0L_^>L__?2_X4O;4[W'[.=K'(45U_\ PB%G_P ]9_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4IQ:3VNM_05TQU%%%9#"BO//C-\=/#7P-TG3;K71?W]_JUT+'2M%T>U:ZO\
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M6,I0IU<'SI:V<K)/RLG^AG'#RB[J1^=G_#Q;XD?] 3PK_P" ES_\D5J>&/\
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MM;O]6@FU>_U07 %Q,TFUA';A<@$=/S->_?!V7XRR7&J?\+5M? MO;A(_[/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_#R&S^*,>A > 8O"/]E'5%NH %N/FQ'Y._S.XYV8]Z^;_"_[%_QDT[_@G?\
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MKP3#\1(?#&GW5C=Z'_;-OIDFYUF57\V<[=I%P?NACF,@@9!H T/%7[4'Q?\
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MP)X1N"&N="T*QTV9@<@R10(CG\64GB@#MJ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JMJ6HV^D:==7]Y*(+2UB:>:4@D(B@LQX] #5FN,^-'C*
MS^'?P@\;>*-0TXZO8Z/HMY?SZ>/^7E(X68Q$X. P&"<8 .: /!-*_;>UMM!\
M.^.]<^$]]H/PAU^]AM++Q5)K4$EU''/(([>XGL0@,<3LR\B1B 0<<C/??$3]
MH;7=-^)UW\/OAUX!D^(?B?2["+4]9$NK1Z7::?%*6$"-,Z/NFDV,50+C R6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%?+7[4WC+7_#_Q T^VTK7-1TRW;3(Y&BL[N2)2QEE!
M8A2,G  S["O'/^%G>,?^ALUS_P &4W_Q5?48;(:N)HQK*:5SU*> E4@IJ6Y^
MA%%?GO\ \+.\8_\ 0V:Y_P"#*;_XJC_A9WC'_H;-<_\ !E-_\573_JU6_P"?
MB^YFO]FS_F/T(HK\]_\ A9WC'_H;-<_\&4W_ ,51_P +.\8_]#9KG_@RF_\
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M[F']FS_F/M?X@_"'PE\5+KPU/XJTA=8?PYJ4>L:8DD\J1PW: A)2B,%D*Y.
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M?[2M;H^:Y+%FPH7(+$]0V1TK3$RKQBOJ\4VWUV2[^?R*JNHDO9K4XGQ=\/\
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M (*%_#K]K+X+Z+X1\(Z+XHT[4K+Q!#JLDNMVMM%"8DMKF(J#'<2'=NF3C&,
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M<%?"^GG_ 'X]W\S1[;*%M2D_G_P0Y\)_(_Z^9Y')^V7"/]7X3D;_ 'M0 _\
M:9JI)^V5<-GR_"D2G_:ORW_M,5[E'\*/!<7W?"FCG_>L8V_F*MQ_#[PM#S'X
M:T=/]VPB'_LM'UK*EMAW_P"!/_,/:X7I3_$^=Y/VQM6/^K\.62_[T[M_05PW
MQ.^/6N?$[2X-.N;>WTZSCD\UX[4M^];'&[)Z#GCW]A7V9'X3T2'_ %>C:>G^
M[:H/Z5B?$)?!.@^$;VZ\6Q:;9Z"@_>O<Q@+GMMP-Q;TV_-Z5T8?,,%"K%T<+
M[U]+.[^2[E1Q6'IR4E3M;S/ASP9XNU#P+XDL]9TV3;<6[Y*'[LJ?Q(WJ"./U
M'(%>V6_[8VJK_KO#EG)_USN'7^8-<]^QOX@\,^)OBI\3X(IK&ZM5NU/AV&X4
M>;]B\VXR8PXWGY/(W$\],U]93^$="NO]=HNGS?\ 72UC;^8KU,XQ.&HXIT<5
M0YFDM;VW5_PO;UN.>-P^(?,X7/ ;?]LN-B!/X391W:/4 WZ&,?SK1M_VQ-%;
M'G^'[^/U\N5'_GBO6KCX6>#;H'S/"NC\]2MC&I_,+6;<? WP'=9W^&+(9_YY
MAD_]!(KP_K&4RWH27H_^"1[3"/>#^_\ X)Q5O^UUX.EP);#683[P1$?I)_2M
M*W_:F\!S??N+Z#_KI:$_^@DUHW'[-OP\N,D:"8F/>.\G'Z;\5FW'[*_@2;.R
M&_@_ZYW1/_H0-'-D\NDU]W_!"^#?22-.W_:0^'EQC_B?^4Q[26<X_79BM*#X
MX^ [C[GB>Q'_ %T+)_,"N(N/V1/!\F3%J.LPGM^^B8#\X\_K6;/^QWHK?ZGQ
M#?Q_]=(D;^6*/991+:I-?+_@"Y,&_M-?UZ'K=O\ %'P=<X\OQ5HQ)[&_B!_(
MM6A_PF6@&%Y1K>G-&BEF9;I"  ,YX->!7'[&B\F#Q81Z+)I^?U$G]*S+C]CG
M5U!\CQ%92'MYD#I_(FCZIEDOAQ+7K%_Y#]CA7M4_ Q_B=\=M-\9>/O">H6MA
M.FF^'K_[1YK,/,N5\R)CA.-O$7&3SGG%?2NF_%3PEJFCVVIIX@T^WMKA2R?:
M[A(7&#@@JQ!!!!KX<\4> ]<\&^)+#0M6LFM-0U"<6UBKL MW(650(FSAN77I
MTW#.*]FTC]CO5+FWA?4?$-O8R,H+Q0VYF*''(SN4'%>YC\'ET:-)2J<L5>W6
MZZ_CU.RO2PW+%<]DOF>V7OQT\!:>2)?$UFV/^>.Z7_T &N>OOVI? =J3Y5U>
MWN/^>%HPS_WWMKFK']CO1(R/MGB#4)QW\B-(OY[JZ&Q_95\"VI7S8M0O,=?/
MNL9_[X"UX?L\GI[SG+^O1''RX./5LPK[]L+P_&3]CT/4K@=C,T<6?R+5SU]^
MV1=,Q^Q^%X8AV,]X7_0(*]@L?@+X T_;Y?AJV?;_ ,]WDE_/<QKH++P!X8TW
M'V7P[I5N1T,=E&#^>VCZSE4/AH2?J_\ @A[3"1V@W\SYCF_:K\<ZI)LL=-TV
M(] (;:21OU<_RIC?$7XV^(/^/:VU9(VY'V?20B\_[1CS^M?7<<20H$C144=%
M48%/H_M3#0_AX6/SU_0/K5-?#27YGR#_ ,(E\<_$'S23:U&K=GU);<?]\[Q_
M*E'[,WQ%UQM^H:A:*QZF\OGD/Z*U?7M%']N5X_PX1CZ+_@A]>J+X8I?(^(/B
M'^SWXE^'>COJUQ)9W^FPA?/FM92#$68*,JP!.68#Y<^^*Z/PG^RKJWB;PQIV
MKMK=I9F^@6YC@\IGPCJ&7+9'.".,<5O_ +:WQJG\!>'4\+IX=DU*#6+=9WU)
M;@QK;>7.A"E?+8'.W'WAU[UU_P"R=\7I_BM\/5CFT"30UT2*VL(WDG,HNE$(
M_>#*+@''3GKUKWJF*S199''623>^FVRTOW\BGF$W!13][TZ?D>>3_L>^(ESY
M.MZ7)_UT$B_R4U3_ .&5/'FG\VVHZ63_ -,+N5?YQBOKVBO 6?8WJT_D1]?K
M]7^!\A?\*'^+-A_Q[7TAQ_SPU4K_ #(H_P"%?_'/3_\ 5W6M,@_YYZTK#\O-
M_I7U[13_ +<KOXJ<'\O^"/Z]4ZQ7W'R%Y7QWL>^N-_P))?ZFC_A-/CMI_!M]
M<8>^CK+^OE&OKVBC^V(OX\/!_(/KB>]./W'R%_PNOXP:?Q<V5T2.OGZ1M_DH
MH_X:A^(.G?\ 'UI]@<=?M%E(O\G%?7M%']J85_%A8_+3] ^M4NM)'R7;_M@>
M)U_UVC:3(?\ IFLJ?S<UH0?MD:BO^N\,VLG_ %SNF7^:FOIRXT^UNN9[6&;_
M *Z1AOYBLZ;P9X?NO]=H6FR_[]G&W\Q1]>RZ7Q87_P F?_ %[?#O>E^)X+;_
M +9438\_PFZ>\>H!OT,8J_!^V+HS8\[P]?1^OES(W\\5ZU<?"KP9=9W^%='R
M>I6QC4_F!6?<? WP'<YW^&+(?]<PR?\ H)%'UC*7O0DOG_P1^TPC^P_O_P""
M<-;_ +7OA&3 ETS68C[11,/_ $9_2M&']JKP++]Y]0A_W[7_  )K8N/V<OAY
M<<GP\$/K'=SK^F_%9TW[+?@*7[MG>0_[EV_]<T<V3R^S-?=_F%\&^DD68/VF
M/A[-]_6I(/\ KI93'^2&M&W^/WP_N,;/$MN/^ND4J?S45RL_[)/@J;[EUK$/
M_7.XC/\ .,UFW'['OAUO]3K>J1_]=!&_\E%'L\GE]N:^[_(.7!O[3/3+?XP^
M"+K&SQ3I:_\ 72Y5/_0L5HV_Q!\+77^H\2Z/-_USOXF_DU>)7'[&]DV?)\47
M$?IYEFK?R<5GW'[&MPO^H\5Q2'_II8%/Y2&CZKE4ML0U_P!NO_(/985[5']Q
M[EXL^)WA_P (^'KG5[C4(+J&$ +%:RJ[R,>BJ >_\LFOG7X>?&C3+CX]:EXF
MU.W?3+76;9;%1O$BP-^Y4,[8'R_NN3CC=Z#-,US]D?Q)I^GSW%AJ5EJ<T8W+
M;*&C>3V!/&?J17FGAOX7^(_$_BR3PY;Z=);:K"GFSPWF8?)3Y?F;/./F7& <
M[ABO;P."R]4:O+5YKJS>UEIT]>IVT*.'4)6G?_(_0.BOD+_AG;XGV?\ J+^,
MXZ>3J3+_ #Q1_P *E^--CS;WFHDCIY&MA?YR"O$_LO#OX<5'\OU.+ZK3Z54?
M7M%?(7_",?'?3^/.UQ_^XDDW_M0T?;/CM8X^776_[8K+_0T?V.G\.(@_F'U.
M^U2/WGU[17R%_P )_P#'2Q/SVVM,O^UHBL/S\JC_ (7?\7K+_7V5P>W[[2"O
M\E%']AUW\-2#^?\ P ^HSZ27WGU[17R%_P -/?$.Q_X^-/L3MZ^=92+^>&%3
M0_M@>*E_UND:._\ N)*O\Y#2_L'&=+/YB^H5NEOO/K>BOE:']L;6%_UOAVQ?
M_<F=?\:O0_MERK_K?"2-[IJ!7^<1K-Y'CU]C\5_F3]1K_P OXH^FZ*^=(?VR
M-/;'F^&+E/79=JW\U%7H/VPO#K8\[0]3C_ZYF-OYL*R>3XY?\NG]Z_S(^IUU
M]D]]HKQ"']KKP;)P]CK,7^];Q$?I)5^']JGP+)]Z74(O]^U/]":Q>68U?\NG
M]Q/U6LOL,]@HKRZ']ICX>2_>UJ2'_?LIC_)#5^']H#X?7 ROB6 ?[\,J_P T
M%9/ XJ.]*7W,CV%5?8?W'H5%<5#\:/ TWW?%&G#_ 'YMO\ZOP_$WP?<8$?BK
M16/]W^T(L_ENK%X>O'>#^YD>SFMXLZ:N)^+OAW2=4\!^([V]TRSO+RUTJZ:W
MN+BW1Y(2(F(*,1E2",\=ZWX?%VA7'^JUK3I/]RZC/]:\I^/7QNTCP[H^H>&K
M6/\ M2_U*QEA=H90([=9$90Q.#EN<[?3N,BNG!T*\\1"-.+O?TT-:-.<JB44
M:W[,^CV%M\*=%U"&QMHK^Y$ZSW20J)90+B0 ,X&6  &,GM7J]>*?LM>-M-U;
MP';^'(W9-4TH2-+&X WH\KN'3GD#< ?0X]17M'FI_?7\Z>91G'&55/N_NOI^
M 8E25:5^X^BHVN(EX,B#ZL*:UY O)FC'U<5YUF<Q-15?^T+4<FYA _WQ3?[4
MLO\ G[@_[^K_ (T^5]AV9:HJG_;%@.#?6W_?U?\ &D;7-.7K?VH^LR_XT<LN
MP69=HJ@=?TQ1DZC: ?\ 7=?\:;_PD>D_]!2S_P# A/\ &GR2[!ROL:-%9G_"
M4:-_T%K'_P "4_QII\5:(O!UBP!_Z^D_QI^SGV8^678U:*R6\7:$O)UK3Q];
MJ/\ QIO_  F.@#DZYIO_ (%Q_P"-'LY_RL.678V**Q?^$V\/?]![3/\ P,C_
M /BJ;_PG7AK_ *&'2O\ P-B_^*I^RJ?RO[A\LNQN45@MX^\,KP?$>DCZWT7_
M ,52'X@>%U&3XDT@#_K_ (O_ (JG[&K_ "O[@Y)=C?HKGO\ A8GA3_H9M'_\
M#XO_ (JLWQ!\8/"6@Z+>:@-?TV^:WC+K;6M[$\LI[*H#$Y)Q].M5'#UI-14'
M=^0U3FW9(X'Q9_R=EX+_ .P1)_Z!=U[C7Q1)\>KK4OB[I'C34-,AV:?$ULMI
M;.5/E$2#ECG+#S2>P.!TKZYTWQYX=U:S@N;;6[!XYHUD4&X0-@C(R"<@\]#T
MKV<TP=>C&CS1VC;YW;_4[<51G!0NNEC>HJM#J5G<_P"INH)?]R13_(U9KY]I
MK<\X****0!1110 4444 %%%% !1110 4444 %%%% !1110!\[_MIZ'XJU'P%
M8ZAX:TR'48=):XOM1::5$$%ND19G 9U+8 /"Y/'2O*_V+_#_ (]U;Q9I?C&^
MT.VA\'W5K<I%J,4T>6=6,>/+\PN/F1ARO;TKZD^.?_)$_B#_ -B]J'_I-)7$
M?L5_\FR^#?\ M\_]+9Z^TH8Z5+(9P4(OW^2^M[24F^N^FGY![:JG[-2?+;8]
MOHHHKXL HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y"_:
M]_Y*5IO_ &"(O_1TU>'5[C^U[_R4K3?^P1%_Z.FKPZOUO*O]RI>A]=A?X$?0
M****]4Z@JQI^H7>DWD5W8W,UG=1',<]O(8W0XQD,#D<57HI-)JS ]]^'_P ;
M8;#X3^*;'6_$]^WB6?SO[/:9YY91F%0FV3!V?/GN,'FN;^"OQ,OX/BMHUUXA
MUJZO+>19+0S:A=/((@Z\8+$X!<)FO)J*\S^SJ'+527Q^FFEM#E^KPM)?S'U]
MH_P@U?3_ -H:\\7S>6NACS+J.?S5RSO$4*%>HQN8YZ8 YZUY)J'@J_\ V@/B
MAXNOO#]W8Q00S*1)>2,JR(!Y:LNU&SD)GZ$5YK-XT\07&F_V=+KNI2:?MV?9
M7O)#%MQC&S.,8[8J#1O$FK^'7E?2=4O=+:4 2-9W#PEP.@.TC/4UR4<#B*5Z
MGM%SJ*BM-$D^OFS*%"I&\N97M9>AZ;\)_@[HOQ$L?$5C<:K-;>*-/:1;>WC=
M1"X PKG*EBN\$'&, CIFO4?AMX=OO@?\*?%5WXK$5L9RS16:RJY8["BC@D9<
MD<#MU]OEFTU6]L+X7MK>7%M>@EA<0RLLF3U.X'.35G6/$VL>(O+_ +5U:^U/
MR_N?;+EY=N?3<3BKQ&!KXB3A*I^[;3:MJK=$_,=2A.H[.7NNW](S*^D_C_>#
M5O@7X#OT7;'(;<D9SM8V[?+GV(/Y5\V5ZWHOQ"TC5O@9JO@_6[O[+?V4@N-*
M<Q.XD^8OY>0#M.=ZY.!AQZ&ML=2E*I1K15^66OH]+_(NO%N4)I;/\SIO"?[6
M'_"+^&-*T?\ X1;[3]AM8[;SO[0V;]BA=VWRCC..F376_!3X;H+2^^(M[I)U
M#5M1DEN]-TW>N8E9V((9R%W-GACC Y[U\HUT-I\0_%6GVL5M:^)M8MK:%0D<
M,-_*J(H&   V !Z"N;$97'DDL)[CE\6^J[;_ )&53"JS5+2^^YZ%\;/#_P 2
MM<>?Q+XKTH6.EVI"111W4+QVRLP4 *KEB2<9;'/L  ,;Q'\ _$?AF;P_%-/8
M74NMSK;VRVLDC%6(!R^4&  <DC.,&N1U/QUXDUJS>SU#Q!JM_:28+P75[+)&
MV#D95F(." ?PHF\<^)+B6TEE\0:I+):'=;N][*3"2,90EOEXXX[5U4J.*I0C
M"+BDKZ).VVG5]=S:,*L8I)I6\CZSF\%ZW\*/ D6C_#[0UU36KE<76JRR0Q[6
MQRY#N"3R=J\J.^>A^=O^%.^,=:^(*Z#JRPV6OW\+Z@9+ZX#JZ[FRQ:/?R2K?
ME7/_ /"SO&/_ $-FN?\ @RF_^*K0\&_$6XT_QUI^O>(M0UG5!:H5WQ7S^>5
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MN_Y(OX=_[>/_ $IEKTRO,_V;O^2+^'?^WC_TIEKTROQW'?[W5_Q2_-GQU?\
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MF/6,/_ ?^"'U>!^=?_#'_P >8^%U92/]G7'%'_#)_P"T%#RFJRG;TV:^P_\
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MC=7;B5W\R8VZ;C\Q..2>!@>U?E]\3?&7B;QYXROM5\6R3/K;E4ECFB\HQ
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M6BB.73[N>5 "2=LJD2%L$!A@MZ<#OR7P%M(?#&I?$/Q,(V$&B64T4*=B2S,
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M&H[)-==>IQE%%%>F=04444 %%%% 'W%^S=_R1?P[_P!O'_I3+7IE>9_LW?\
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MF_FM8=Y\!?AK? B7P#X;R>K)I4"-^:J#1_:603^/ M>DW_F@Y*O21\J>/O\
M@HD=8\'WMGX8T"ZT37IP$BOKB:.5( 3\S 8Y;'3(P"<]N?G3X:_'OQ3\//B@
MOC9M0GU?4;@"'46OG\U[RWRFZ-G;)'$:8(Z;5[#%?H9XK_9!^%?BC2;JS3PO
M;Z//,N$O=,S%+"W&&7JO;H01UKY1^&/[*N@7/[47B/X=:_J-SJ^E:%IRZAYD
M*_9C<EEMR$;!8J!]HY*G)V=LXKZO*<PR#ZKB(4:+BE%N2:NW'1:.[ZM:76NO
MF85(U>9-L^@X/V_/A7-]Y]:A_P"NEB#_ "<UI6_[='PAFQOUR\@_ZZ:=,?\
MT%344_["/PDF^[I>H0_]<]0D/\R:S;C_ ()^?"Z;.R378/\ KG>H?_0HS7RG
M_&,2_P"?J^[_ ()O^^\CJ;?]M#X-W&,>,50^DFG7:X_$Q8K3@_:O^$EQ]WQQ
MIX_ZZ+(G\U%>8W'_  3I^'<F3#KGB:(^C7-NP_\ 1']:RY_^"</A)O\ 4^+-
M:C_ZZ1PM_)11]7X9EM7J+U2_2(7K=D>ZV_[1WPNN I3Q[H(W=/,O43^9&*T[
M?XU_#R[8+!X\\,RM_=36+<G\M]?,EQ_P39TQL^1X[NX_3S--5\?E(*S+C_@F
MK,N?(^(4;^TFCE?Y3FCZAP[+;&27K!__ "(<U;^4^P;?XB>%+S_4>)M'F_ZY
MW\3?R:M.WUW3;K_4:A:S?]<YU;^1KX8G_P"";>O+_J?&FFR?]=+.1?Y,:S;C
M_@G'XV7_ %'B;0)/^NAG3^49H_LC))?#F%O6#_X >TJ?R'Z# Y&1R*^:/VJO
M^2R? /\ [#Q_]*+*O C_ ,$^OBCIY+6NM>'B>H\B^N%/ZPBO/O'WP(^('@+Q
M=X7T35=8L[C6=4N E@MOJC.T#F1$5V)P8P7(PWJC?W:][(\GP-#'1JX?&QJ-
M1GI:SUA)7W>U[_(\S,7[7#N%3W5>.K\I)_CL?JM17YU?\,X_M+:;S::EJI*\
MC[-XE"']911_PK/]J_2_F^V>*GS_ -3)'/\ IYYKP?\ 5S#2^#'TG\TOU/3]
MM+^1GZ*T5^=1M?VKM,[^*GQ\W^MCF_J?RH_X3C]J_3/^7;Q4^./^0+'-_P"T
MC1_JK*7P8ND_^WO^ P]OWBS]%:*_.K_A?7[4.F<W>G:\0O)^T^%E3^4 H_X:
MT^/^G?\ 'UI3G')^T:"R_P @*/\ 5#&OX:M-^DG_ )!]8CV9^BM%?G5_PWA\
M7M-_X^M&T<XX/VC39E_E(*GMO^"C/C]2/M'A[PW*._EPW"?SF-)\'9I]E1?I
M(/K$#]#J\5_:@\<:KX=^'GB32[/PO>:Q9ZAH5ZD^HP%_+LPT3J6?$;#@'=R1
MT_&OF^W_ ."CWBA<>=X.TJ3U\N>5?YYKQGX^?M'>(?CQJUL]Y&VDZ3;1A8M)
MMYF>+?SND;@;F.<<C@<>I/HY7PCF$,7">*@E!:WO?;T=_P!!?6J2OU/L[]A?
MQ1?WWP;T;19M"N;2PL8[AX-6?=Y5T6NY257* 94D@X8].U?25?EW\ ?VI?%?
MP+TZ\TN.P_M_1IOG@L;N9D6UDR26C.#@-DY7&"<'@YSZ/??\%&O%X;;!X1T>
M!O2:29_Y,M:9OPGF=?'U:U"FN23;3OWUZZW_ *1C3QV'DE&,E=+:]_F??M%?
MGC<_M_?%&X'[K1O#5L/5;:8D?G-_2J</[8_QSU\N-+M+>XVG!.G:.9@I/0'[
MW/%<+X(S:$>>HHQ7F_\ @&=/,\)5GR4ZBD^R:/T:HK\Q;G]L#XTW.0?%L=MZ
MK'IMJ,?G$35OPY\4/VB_B5]H/AW6M;UE+<@3/80Q(L9;H"0H S@_E734X$S'
M#TW5Q%2$(KJV_P#)&%+.,'7J*E2E>3Z'Z7T5^5NJ_$3XSPZE<Z;J'B[Q=;:C
M YCGM8[J='C8=1A2/TK8\'_#GXZ_%5KC^S=6\2S10X\R;5-3G@CY[ R-\QXY
M S6U7@>KAZ/M\1BH1AW]?FB*6<X:M5]A3NY>CZ?(_3JN8\>?$KPU\,])74O$
MFJQ:;:M(L2EE9W9CT 106/ )X'05^;FN?L]?%VUU6:PO]#\1:E/$<&>W,EQ
M_NL@RI'XY]:K2?LR?$C2-+N=3E\'ZFMO#_K/E#28P26V [B!@Y..X]:[,+P7
M@)3A+$9A#E=M$XIN_9N3_)G%BL\E3C.-"C)R7>+L?1O[)WQ6\,?\+*^+6I7^
MK6NBP:]J*7]DNJ3QP%XS-<L1\S8W 2ID GO7T==?'/X<V.?.\>^&D(_A_M:
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M/KTZ%9TK*5[PV?6R:?X#AFU"I6^KQJ+GO:UGO]QW5S_P4:\"K_Q[^&_$,O\
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MS)=O<*  J@D=A7J%%%>#BL9B,=5=?$S<Y/JW<]*C0I8>"IT8J*[(^9_VJO\
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M=2OKD*VWS(;%]K>XSCBO6O!O@70/A[I']E^'=+@TJQ,AE:*$'YG.,LQ)))P
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M=O\  >UT:2;0KC67U)Y%7RY1#'&$"YRY5N3N&!CH">U>I6^EV5K('@M((7'
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MAX*\-'Q#JLERD4ELT+SF&,JQ+&.-@S<A1P<#.:]'AACMX4BB18HHU"HB#"J
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M>;'!<JD0V7$D:[1LS]U!G)/)-?3W@7X-^$/AWH)TC1]&@6U9F:1[D>=)*S
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MVG.P2_)UQG/..E>"6WC;]J?3KJ))_#R7QWJI62TMBC<]VC88'J<C\*^QZ*6
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M'_#:GQF_Z'+_ ,I=E_\ &:/[)SWO2_\ )_\ (/[;G_+^'_!/:O\ AF[XC?\
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M_P <KQ7_ (;4^,W_ $.7_E+LO_C-'_#:GQF_Z'+_ ,I=E_\ &:/[)SWO2_\
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MKQ7_ (;4^,W_ $.7_E+LO_C-'_#:GQF_Z'+_ ,I=E_\ &:/[)SWO2_\ )_\
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M8\_Y-S\(_P#;W_Z635[-7C/['G_)N?A'_M[_ /2R:O9J[\^_Y&V+_P"OD_\
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M11W2JLBKDC#!21GCL36[7Q]2G.C.5.:LT[->:/>C*,XJ<7=,****S*"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!A>./$%[X5\):IJVGZ1/K][:0F2+3;
M7=YEPV1\J[58Y^BGI7R#X-\<>/K/]HK6/'\WPC\21Q:]:Q::]F]O<*MJO^CJ
M93*8/F $&<;1][KQS]MT5]'E>;4<NI5:<L.INHG%MRDO==G;1VW2=]_.QY6,
MP4\5.$E5<5%W2LGKKKKY/T"BBBOG#U0HHHH **** "BBB@ HHHH _.K_ (*+
M?\ELT3_L7H/_ $IN:^6:^IO^"BW_ "6S1/\ L7H/_2FYKY9K^D^'?^15A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P
M=^WI\-?%WC#XNZ/?:#X7UG6[--#AA:XTW3Y;A%D%Q<$J2BD X93CW%?-G_"C
M/B1_T3[Q5_X);G_XBOL;]K_X]>.OA=\2M,TGPQKG]F6$VDQW4D7V2"7=(TTR
MELR(QZ(O ..*\-_X;"^+W_0W?^4VS_\ C-?T-D&%SJ>5T)8>-+D:TO*:?SM%
MK\3XK&9Y@\/B)TJBE=/HE;\SRO\ X49\2/\ HGWBK_P2W/\ \11_PHSXD?\
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MB?>*O_!+<_\ Q%'_  HSXD?]$^\5?^"6Y_\ B*]4_P"&POB]_P!#=_Y3;/\
M^,T?\-A?%[_H;O\ RFV?_P 9H^I9_P#RT?\ P*?_ ,@'^L6 _EG]T?\ Y(\K
M_P"%&?$C_HGWBK_P2W/_ ,11_P *,^)'_1/O%7_@EN?_ (BO5/\ AL+XO?\
M0W?^4VS_ /C-'_#87Q>_Z&[_ ,IMG_\ &:/J6?\ \M'_ ,"G_P#(!_K%@/Y9
M_='_ .2/*_\ A1GQ(_Z)]XJ_\$MS_P#$4?\ "C/B1_T3[Q5_X);G_P"(KU3_
M (;"^+W_ $-W_E-L_P#XS1_PV%\7O^AN_P#*;9__ !FCZEG_ /+1_P# I_\
MR ?ZQ8#^6?W1_P#DCRO_ (49\2/^B?>*O_!+<_\ Q%'_  HSXD?]$^\5?^"6
MY_\ B*]4_P"&POB]_P!#=_Y3;/\ ^,T?\-A?%[_H;O\ RFV?_P 9H^I9_P#R
MT?\ P*?_ ,@'^L6 _EG]T?\ Y(\K_P"%&?$C_HGWBK_P2W/_ ,11_P *,^)'
M_1/O%7_@EN?_ (BO5/\ AL+XO?\ 0W?^4VS_ /C-'_#87Q>_Z&[_ ,IMG_\
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MQ8#^6?W1_P#DCRO_ (49\2/^B?>*O_!+<_\ Q%'_  HSXD?]$^\5?^"6Y_\
MB*]4_P"&POB]_P!#=_Y3;/\ ^,T?\-A?%[_H;O\ RFV?_P 9H^I9_P#RT?\
MP*?_ ,@'^L6 _EG]T?\ Y(\K_P"%&?$C_HGWBK_P2W/_ ,11_P *,^)'_1/O
M%7_@EN?_ (BO5/\ AL+XO?\ 0W?^4VS_ /C-'_#87Q>_Z&[_ ,IMG_\ &:/J
M6?\ \M'_ ,"G_P#(!_K%@/Y9_='_ .2/*_\ A1GQ(_Z)]XJ_\$MS_P#$4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,_>LM_W&A_@C^2"BBBO"/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#=M 'ZJ45^5?\ PXQ_ZK9_Y:G_ -VT?\.,?^JV?^6I_P#=M 'ZJ45^5?\
MPXQ_ZK9_Y:G_ -VT?\.,?^JV?^6I_P#=M 'ZJ45^*W[4G_!*7_AFOX$^)OB/
M_P +1_X2/^Q?LO\ Q+/^$>^R^=YUU%!_K?M3[<>;N^Z<[<<9R#]EO_@E+_PT
MI\"?#/Q'_P"%H_\ ".?VU]J_XEG_  CWVKR?)NI8/];]J3=GRMWW1C=CG&2
M?M317Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VT ?JI17Y5_\.,?^JV?^6I_
M]VT?\.,?^JV?^6I_]VT ?JI17Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VT
M?JI17Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VT ?JI17Y5_\.,?^JV?^6I_
M]VU\J_L,?L,?\-I?\)M_Q6W_  AW_"-?8?\ F$_;OM/VC[1_TWBV;?L_OG=V
MQR ?O]17Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VT ?JI17Y5_\.,?^JV?^
M6I_]VT?\.,?^JV?^6I_]VT ?JI17Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]
MVT ?JI17Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VT ?JI17Y5_\.,?^JV?^
M6I_]VU\J_'W]AC_A1O[4WPX^#7_";?VW_P )A_9O_$Z_LG[/]D^UWTEK_J?/
M;?L\O?\ ?7.<<8S0!^_U%?E7_P .,?\ JMG_ ):G_P!VT?\ #C'_ *K9_P"6
MI_\ =M 'ZJ45^5?_  XQ_P"JV?\ EJ?_ ';1_P .,?\ JMG_ ):G_P!VT ?J
MI17Y5_\ #C'_ *K9_P"6I_\ =M'_  XQ_P"JV?\ EJ?_ ';0!^JE%?E7_P .
M,?\ JMG_ ):G_P!VT?\ #C'_ *K9_P"6I_\ =M 'ZJ45^5?_  XQ_P"JV?\
MEJ?_ ';7S_\ MK?\$WO^&/?A7I7C+_A8G_"6_;M:BTC[%_8GV+9O@GE\S?\
M:),X\C&W:/O9SQ@@'[J45^0'PG_X(U_\+0^%?@WQE_PM_P#LS_A(M&L]7^Q?
M\(SYOV?[1 DOE[_MB[MN_&[:,XS@=*ZO_AQC_P!5L_\ +4_^[: /U4HK\J_^
M'&/_ %6S_P M3_[MH_X<8_\ 5;/_ "U/_NV@#]5**_*O_AQC_P!5L_\ +4_^
M[:/^'&/_ %6S_P M3_[MH _52BORK_X<8_\ 5;/_ "U/_NVC_AQC_P!5L_\
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MT?\ #C'_ *K9_P"6I_\ =M 'ZJ45^5?_  XQ_P"JV?\ EJ?_ ';1_P .,?\
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MM'_#C'_JMG_EJ?\ W;0!^JE%?E7_ ,.,?^JV?^6I_P#=M'_#C'_JMG_EJ?\
MW;0!^JE%?E7_ ,.,?^JV?^6I_P#=M'_#C'_JMG_EJ?\ W;0!^JE%?E7_ ,.,
M?^JV?^6I_P#=M?*O[<_[#'_#%O\ PA/_ !6W_"8_\)+]N_YA/V'[-]G^S_\
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M3_A$OL.M2Z1]B_L3[;OV002^9O\ M$>,^?C;M/W<YYP/H#_AQC_U6S_RU/\
M[MH _52BORK_ .'&/_5;/_+4_P#NVC_AQC_U6S_RU/\ [MH _52BORK_ .'&
M/_5;/_+4_P#NVC_AQC_U6S_RU/\ [MH _52BORK_ .'&/_5;/_+4_P#NVC_A
MQC_U6S_RU/\ [MH _52BORK_ .'&/_5;/_+4_P#NVC_AQC_U6S_RU/\ [MH
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M@C^2"BBBO"/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKY$\-Z+XB_:P^(WQ=U"7XD^*O!V@>#_$$WA+0K'PEJ7V)8[FWAB>X
MNKC;G[0WF2@!)/D 4@KG)KU7]D/XJ:Q\7_@/HFL^(Y8;CQ/9SW6CZM-;@!)K
MFUN)(&E   7S!&LF,#&_ &,4 >S4444 %%%% !1110 4444 %%>1_&;X8>-?
MBIXJ\,Z=I_C2]\'?#^".>;6_^$>O'L]8O9_E%O%',J'RX1^\+E65S\H'J. _
M9SU;7/"_[0OQ5^%@\7ZMX[\)^'K+3=0M[[7;DW=[I=S<B0O927)^:4%$21=Y
M+*#C)Y- 'TW1110 4444 %%%% !1110 456U/4K31=-N]0O[F*SL;2)Y[BXF
M8*D4:J69V)X  !)/M7QG\ _C-XW^+/[;,NJZA>WVG?#K7/A_=:IX9\.R22(A
MM8]3MX8KZ:$G;YTP,CJ<96*1%SUH ^U:*** "BBB@ HHHH **** "BHYYH[:
M&2:5Q'%&I=W;@* ,DFOS4M_CEIOQ6\$W7CG5_P!HG7O 7Q(UJ62Z\.Z78W=P
MGAS0(S(PL+;41#"\ ,B>6TC7)+8DRHX&0#]+Z*S/#+:G)X;TIM:-FVLM:1&]
M.GLS6QGV#S/*+ $INSM) .,9 K3H **** "BBB@ HHHH ***^//VC?%D5Q^T
MOI_A;XA_$_6OA)\,U\,G4-+O=*U<Z+'JNH^<RSQR7P(YBC\IA#N!._."#@@'
MV'17S_\ L2>,/%/C7X.WUWXDU&]UZPM]>U"S\.^(=2C"7.LZ/')BTO),*N6=
M=WS;1N"AN^:^@* "BBB@ HHHH **** "BBOC7X:?%3XM>-/VSO#B^,].F\#>
M$M3\(ZE>Z3X-:[+W"*ES;(+B_5?D\]LDJ@SY2G;G<7R ?95%?*']GZ[^T]\?
MOBKHLWCWQ1X0\'^ WL]'TZU\'ZF=/EN+Z6W$\]S/(@+/L+HBQDE/E)*YS7>_
ML@?$O7/B%\-=:L/%&H)K'B?P=XDU+PEJ6IHJI]LELYMJS,B\*S1M&2..23T(
MH ]RHHHH **** "BBB@ HHKXX_;>^*OQ9T6.*Q\):;-X3\&:7K>BQZIXK:[,
M5SJ9N+N%?LMFJ?,$7>/-D8@'E!_%D ^QZ*\J^-_P\\;_ !,O_">D>'_%\_@W
MPC]IFF\2W6D7#6^KSQ"/]Q#:RA&$8:0GS&RK!0-IR37F/P8NM:^'/[6GBGX4
M6GC+7O''@^+PI!K\A\27K7]WHM\UR(EMS<N-[+-%NE".Q*[,C@\@'U'1110
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MZ'H **** "BBB@ HHHH **\%\7? ;QE\4/B3XDU3Q1\2?$/AOP;"D$7AS2/
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M.^);?&#QAK_Q5M+O3TGTNZU5KC1]<O)IDCEL8;$H$1&WOL*(KJ$#$Y!-?<M
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ME<8R;D]'TYGI?L=F89E['ZO&#4I1M*33NFTDEKZ+7U/T2\4^%?B;;?%:\O\
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M>++ZV<ZIK>H7 F>]OKB5L/=7,LB+O=V&/8    5])44 %%%% !1110 4444
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MF3]AG2FL]$^(^H:+IE[H?PTU3Q3/=^#]-OH)("EF8XQ++##( T4$DPD=$(7
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M"'A+7K7PY?ZK8R07%Y=QR.CVIO)O/A_=LK 2)E"5(.UFP0<$9NK>'?C3X?\
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M _@C1;I[F\TOX97GBW4?)8-YEZML8UC.1C<;BU5.>@G)K9C^(G_#4NG?L+>
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M^!_$'PW_ &8?AMX:\4J\>O:?I$27,$OW[<DEEA;WC5E0_P"Y7L=%% !1110
M4444 %%%% 'S9\?O^3O?V6?^O[Q)_P"FB2N"^*&N>$_AI^VAJWBGXV01#P9=
M^&[6U\(:UJ]FUQIEA.'?[; 6PR13R'8VX@%D &>Q^T** /E[]B+3XUN_BQK'
MA?3KK1?A+K'B%+KPAI]S;R6R>7]G07=Q;PN 8X)9]S(NU1UP!7U#110 4444
M %%%% !1110!^?\ ^T]^UQX.\<?&G6O@MK_Q#A^&_P .]%18O%.IPB8ZAK4K
M ,=/MFC1O)B XED/+9*+QDGI_BCXA\ ^(_A;\&OB3\((!XB\ ?"_Q=;B[M]!
MM)F:UT\0M!<-'$5WR&(2PR$!22 QSU-?;-% 'R)I_C/0/VIOVOOAAXI\"2R:
M]X2^'&E:Q/>>(XH9$LVO;^*&".UC=@N^18UD=@,A0<'!Q7UW110 4444 %%%
M% !1110!\O?MP?M;Q_LYZ3X:\/:9J>FZ/XM\6S20VNKZPCO9Z3;IM\Z\E1%8
MR%=RA(P/F8]PI!YC]F_XY_LZ_#+P/XUD\(_$1O'&OV>GW'BSQ9KES#.VH:EY
M6T23N711C=(B)&IPN\ 9RQ/V110!^;'PK_:V^#?Q2\<:=\6_C9\3-+M=:T^1
MY/"W@:&*YDL_#L;<":4K%B>\88R_1/X0"!M_2>BB@ HHHH **** "BBB@#@/
MCU\9=&_9^^$?B7Q_KR23:?HUOYGV>(X>XE9@D42GL7D=%ST&<G@5\:?LY?M&
M?![QI\2])^(_Q.^*>DZ]\7]6(T_1=!L[>Y-AX<BG8*MI:@Q8:9BP62<G+$[0
M=HRWZ%44 ? 'Q^^#/QI^'/P1_:#URZ\3>!-8T[Q/:W^I:O=W&E7IU5[582D-
MM'*+@1JL40"1CRR!R2"6)/UQ^SO'XIB^#?A5?%]SH]UJGV" QOHEO+#!Y'E+
MY0*R.[;POWCG!/0#I7H]% !1110 4444 %%%% !7YJ>*_P!K[X1_M,?$[5;'
MXF_$*Q\,_!WPWJ/EV/A,1SO-XFN(7R+J]:.,@6H8?)!GYR-S] *_2NB@#XJ^
M+'B3P=I/[07P8_:-D3^V/A6V@7FBGQ#:VDDD.CR.V^VNWC";TC8--%OVX7<,
M[<@GJ?V?]4LOBQ^UE\2/BGX,BE_X5[<^'M/T/^U_LS0P:YJ$4TKM/"6 ,BQ1
MLL7F8P<X!(%?5E% !1110 4444 %%%% !7Q5^V=^U_IW@_XE:9\&;;QQ;?#=
M;ZS%[XC\8S1R23Z?:/D+;V:(C?Z5(.1(?EC4AN6(Q]JT4 ?!GC?4OAWXX_8C
M\2^#OV;[V;Q-H7AVXL3KFGZ&EP+Z\LVN%DO%+,$>666-92V#E@&7N!3]8\5?
M"OXK_$[X'Q?L^6-J/%6@^(;>75+S0=*DLDTO0EC<7EM>-Y:JN\!46)_FW\C'
M.?O"B@ HHHH **** "BBB@ HHHH **** /@']O[_ )+)HW_8!A_]*+BOF>OI
MC]O[_DLFC?\ 8!A_]*+BOF>OZZX5_P"1)A?\)^'9U_R,*WJ%%%%?5GBA1110
M!U?PY^%_B3XK:Y_97AS3VO)U >:5F"10)G&YW/ 'MU.. :]COOV#?B19V+W$
M5UH-[*J[A:P7<@D8X^Z"\2KGZMCWKT[X)Z[%\&_V-=5\:Z9;*^K7$DLK.Z[L
MRFX%M$3SRJ_*V/\ >]:^>_#/[4'Q'\/^*H]:G\3ZAJJ&57N+"\G+6\J9!9 A
MRL>1QE "*_.I9AGF:8G$_P!E\D*=&3A[R;<I1W]%_7I]4L+EV#I4OKG-*51*
M6FR3V]3BK?P!K+^/K3P;=VW]EZY<7\6G&&]R@BED=44L0"=OS Y .0<C/%>Z
M_P## /Q"_P"@SX9_\"KC_P",5ZG^TYH]G'\>_@;K<,02[O\ 58897Q@LD=S;
M,F?<><U=9\=/A#\4_'7CRSU/P9XW_P"$;T:.TCADM1J=U!F4.Y9_+C4HV591
MR><8->#B.+,77AA*E*K"A&K"3;DKKFC+ELNNK3L>E2R6C3E7A.$JCA))6=G9
MJY\9_$K]GOQ?\*=9TNPUN"W,6IRB"VO[64R6[.2!M)VAE(R#@J,C.,X->F_\
M, _$+_H,^&?_  *N/_C%>H_MG:NOAOX*>%M U755U/Q8+JWE6[4".5GBC827
M 4?=!)QQW;VKB/V*/B)XK\5?%R]L];\3:QK%HND32BWO[^6>,.)80&VNQ&<$
M\^YKI_MK.L5DG]JT9PC[/FYO==II/1QOMU^9E_9^ HYA]2J1D^:UM?AONGW.
M0\5?L2^.?".@W6K7FJ^'Y+:WV[U@N)RYW.%& 80.K#O7!_&7X$Z_\#[S2[?7
M;O3;M]0222(Z=+(X4(0#NWHO]X=,UO>-/B5XNO/C-K.CS^*=:FTC_A(I8/L$
MFHS-!Y:W1"IY9;;M  P,8X%?2_[1WAJT\7_M"?!W2K]1)9RRSO+&RAED5&23
M80>"&V8/L379'-\TR_$8:./J1G"I&I-\L;:1@I)>NYSO X/%4JKPT7%Q<8J[
MOJY6/G3P#^QS\0_'^AP:M'#I^BVEP \']K3/&\J$9#A41R >V[!_#FN6^+?[
M/_B_X+M;2:]:PS6%P=D>H6,AD@+\_(20"K8&<$#/.,X./<_VSOCAXN\/_$*/
MPMH.LW>A:=:VD4TC:?(8999'R<F12&V@;1@$#KG-><:W^UEK_BSX077@CQ#I
MMOK=S<?*=8NI") H8,AV* "ZD?>SSQD'G/5EN,XBQ:H8]QIRHU&KP6DHQ>SN
M]VMVNO;MEB\/E=!U,,G)5(?:>SDNEEM_7S\+KN]'^#NMZO\ "_5_'S36=CH&
MG2B#-VT@EN7)5<1*J$-\S*,D@9SSP<<)7UW^U9:I\-?@#\,_ MKF-9/W]P8A
ML65XHU,A8?[4DY;![CVKZ+-,PJX?$83"4/BK3_\ )8KFE\[:+U/*P>&A5I5J
M]3:$?Q;LCY$HK[*M?@I\(=!^ GA3QYXJTV\A_P!%AN+S[#<S-)?R.A B"E]J
MY8[OEV_=Z@9SSGQR^"_P[G^!NG?$KX>VUQI=HTB;[>6:242([^6RL'9BKHXQ
MPV/O=>#7FT>*\'6KQHJG-*4W3YG%<O.NE[]>FGK;4ZZF2UZ=-U.>+:CS6OKR
M][6/EBBOLO\ XQ$_S_:]>9_'_P#X45_PAMG_ ,*Q_P"0_P#;T\__ (__ /CV
M\N3=_K_E^_Y?3G\,UMA>(OK5>-#ZE7AS.UY4[17J[Z(BME7L:;J?6*<K=%*[
M?HK'"?!WX$^)OC=J%];Z"+6VALHP\UY?NZ0 D@*F51B6/)QCHI]L\C9^&;N^
M\5P^'H3&U_->K8(<G89#)L'.,XR?3\*_0WX"?%_PAXN\2:AX1\ Z.NG>&-'L
MA,MQY1B\^1G RJGYL8R2S_,Q/.,<_'WP;;2(/VEK&[UV]L].TNSU2XNY+B_F
M6*-63>T?+'&=X3%>5@<_QV(K8[V]'D5*"E&#^+5-Z^;LM.FQV8C+,/2AA_9S
MYG.33ETW6WDNYVW_  P#\0O^@SX9_P# JX_^,5YIX;_9^\2>+-=\:Z+IMSIL
MVJ^%6E6YM/.</=^6[HWV<;/F^9,?-M^^OKQ].>.OAC\*OVD?B1K)T[XA7%QX
MN:W40P6C)):1HD8 V?N_WH!RS;9/XCTKQW]FNQU;X3_M46OAJ_5$N2]SIEV%
M)*NOEEU93Z%DC89['M7G8'.\PJX'$59UDZ\*:GR2IN%K:O5OWDU=727?L=6(
MR_#0Q%*$:?[N4N7F4^:_3MH^MCYXHKT[]I;PG!X+^.'BO3K6(PVC7(NHEQA0
M)D64A?8%R!],=J\QK])PF)CC,/3Q,-IQ4E\U<^3KTI4*LJ4MXMK[@HHHKK,
MHHHH _3#]CS_ )-S\(_]O?\ Z635[-7C/['G_)N?A'_M[_\ 2R:O9J_C?/O^
M1MB_^OD__2F?O66_[C0_P1_)!1117A'HA1110 4444 %%%% !1110 4444 %
M%%% !1110 45\R?%SXE>(/ _QR%Q9WM[-I-G!!-<::L[>2\9 #_(3M!.[KC@
MX-=?;^,KC6OVAM#CL-5N9=!O-%^U);).WD.2KD,4SMW<#MGBO8EEE2-.-6^C
MBY?=K;U.QX62BI7T:O\ \ ]LHHHKQSC"BBL+QQ9Z[J'A>^MO#=S;V6L2J$AN
M;EB$CR1N/"MSMSCCKBKA'FDHWM<<5=I&[17S_P##'5=6T_XPGPU9>)]2\1V-
MK8$ZW_:DYE$=TA96\@N P0.R#CKGDG (PI=>\2^+_#7C;Q]!XFU72SI%_P"5
MIMA;7 6U"1LI(ECQA_E<=>IZY'%>O_9DN?EYU;W==?M.R5OZT.SZJ^:U^WX[
M'T[16)X)\0GQ9X0T?6&01O>VL<SHH("N5&X#D\9SBMNO(G%PDXRW1QM.+LPH
MHHJ!!1110 4444 %%?,GQ&N_%_@W5(+J]\:7 \8:EJ2&PT>QN'734M2=HWAU
M5.&POS'W.221V?C35M5\9?&#2O \.LW^AZ?!8F]OIM)E\B:27:V LF"=HRO'
M0Y.1D CV'EKM&2FN5IN^NRW]>R\SL^K/1\VFK^X]HHKRKX ^+-3US2=<TG5[
MN34+W0[][,7DARTL8R%+'J3E6Y/)XS7JM>?B*,L/5=*70YZD'3DXL****YS,
M**** "BBB@ HKQSXTV>MV]U/K5_XKN/#GA&RM2L4>D3R1W<UTP^4/M3!4M@=
M< #MDFN9OOB5XKTW]G72-2GO!_;6J72V$%^I!D$3;R')'&_:A7/4=3\W->M3
MR^56$)PDGS-+KHW_ )=>QUQP[G&+B]W8^B:*\4\-S:Q\._C-IOA*?Q#J/B'3
M-6TXW&[593+)%,@<DJQZ*?+/'^USDC->UUQXBA[!JSNFKI^1C4I^S:UNGJ%%
M%%<ID%%%% !1110 45R/Q.T7Q-XA\.K8>%]2ATB[EF43W<DC(ZPX.X1E5)#$
MXYXZ'FO,/A/XWNX=:\=/8ZWJ/B;P=H]I]IAFU:8/<F8("1N(#!3Y<F.,# XR
M3GT*6#=:C*K&2NNGS26NUW?1>3.B-%S@YI['OM%?+/\ PD7BO1/AWH_Q.E\4
M:E=7MUJ1$VE239LC!N="@BZ _(>1T!XP1FOJ.*59HDD0[D<!E/J#1BL&\+;W
MKZM?-;H*M%TNM_\ -#Z***\\YPHHHH **** "BJ6M+?R:/>KI;0IJ30N+9[@
MD1K(0=I; / .#T-?//BY?$_PE/A6^N/&NHZQXKOK_9=:2]RTUG-&S'/EQE1M
M RB].K?+MQ7?A<+]:?*I)/HN^E_DO,Z*5+VNB>I])T5\]>(]2UWXA?$#QS81
M>(]3\/6?ANQ9[2'3K@P^9( #OD(Y920>.P(P>N?1_@=XXO/B!\/;+4M1(?4$
M=[>>15"B1E/WL#@9!&<<9S5UL#.C255N^UUVNKK\!SH.$.>_;\3OJ***\TY@
MHHHH **** "BBO$?B/X7\3PP^+?$^M^-KS1=.LX6.D6NC7;Q(,$[!,-HW,S%
M1P2<MC=@ 5U8>BJ\^5RY?UZ:6-:<%4=F['MU%?.FH_$3Q-XI\*_#+2GU&?2;
MKQ-.ZWVI6@$4Q2.4*/+(P%+ AC@#MV)!Z;X/>(M4T_XB>+O!&H:I=:W;Z:?M
M%G>7LOF3*A(RCOC+'YU^A4X&#QV5,NJ4Z<IN2NKZ>2?*W]_X&TL-*,6V]O\
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M#$X&2!@C('&*YC5$\0_"KQ=X"MCXPU37M:U:X6+4].NKLS6Y1G0$QJPRBY+
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M=_1:+70UIU_8/FY;O\CJ_B8L/BSP-X<O(_ ^O&UBN!LCL@+34]*5'"AHX0K
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M W@ZVL_-D\0M:V]_+=W!Q^Z$+ME0,]<+]UCN.56N%^&'QM^)GQ+_ &?]=OM
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MB<MP=/!PH1:@K7NSX[%\-4<77G7E4:<G?9'Y.?\ "E?B%_T(?B;_ ,$]Q_\
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M - \?O8?ZHT/^?K^Y'Y.?\*5^(7_ $(?B;_P3W'_ ,11_P *5^(7_0A^)O\
MP3W'_P 17ZQT4?\ $2\7_P! \?O8?ZHT/^?K^Y'Y.?\ "E?B%_T(?B;_ ,$]
MQ_\ $4?\*5^(7_0A^)O_  3W'_Q%?K'11_Q$O%_] \?O8?ZHT/\ GZ_N1^3G
M_"E?B%_T(?B;_P $]Q_\11_PI7XA?]"'XF_\$]Q_\17ZQT4?\1+Q?_0/'[V'
M^J-#_GZ_N1^3G_"E?B%_T(?B;_P3W'_Q%'_"E?B%_P!"'XF_\$]Q_P#$5^L=
M%'_$2\7_ - \?O8?ZHT/^?K^Y'Y.?\*5^(7_ $(?B;_P3W'_ ,11_P *5^(7
M_0A^)O\ P3W'_P 17ZQT4?\ $2\7_P! \?O8?ZHT/^?K^Y'Y.?\ "E?B%_T(
M?B;_ ,$]Q_\ $4?\*5^(7_0A^)O_  3W'_Q%?K'11_Q$O%_] \?O8?ZHT/\
MGZ_N1^3G_"E?B%_T(?B;_P $]Q_\11_PI7XA?]"'XF_\$]Q_\17ZQT4?\1+Q
M?_0/'[V'^J-#_GZ_N1^3G_"E?B%_T(?B;_P3W'_Q%'_"E?B%_P!"'XF_\$]Q
M_P#$5^L=%'_$2\7_ - \?O8?ZHT/^?K^Y'Y.?\*5^(7_ $(?B;_P3W'_ ,11
M_P *5^(7_0A^)O\ P3W'_P 17ZQT4?\ $2\7_P! \?O8?ZHT/^?K^Y'D_P"R
MKH>H^'/@+X7T[5K"YTR_A^U>9:WD+12INNIF&Y6 (R"#SV(KUBBBOR?&XJ6-
MQ57%25G.3E;M=W/M</16'HPHIW44E]RL%%%%<9T!1110 4444 %%%% !1110
M 4444 %%%% !1110!\?^,O".F>/?VW=3\/:Q!]HTW4/##03(#@@&/AE/9@<$
M'L0#7 _LZ:#X@\&?M<Z=X4\12>?<^'M-NM.MIMI EM@'DC89Y*D2<>@P.U??
MU%?71XAG'#RPSIWBZ:AOLTFN9:=4]5Z:F'LM>:_4****^1-PKC?BYXWU;X=>
M!K[Q!H_AN7Q7<695I-/@G,3^5GYG!".3MZD =,GM7945K2E&%2,IQYDGJM5?
MRNM1/;0^-O"_BG2OBU^TWX+\3?"JP>QMH[%Y?%UY:VCV\.9=[F&Y.P"60LIP
MV#N8*0?DRO#KXB3X5_##XN_"#5[6\/B[5-9=]%LH;.5WU))VBC5XBJD$8B#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 45FZ]J4NEV:2Q*K,T@7YP2,8)]?:L+_A+KS_GG!_WR?\
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ML3KZ*Y#_ (2Z\_YYP?\ ?)_QH_X2Z\_YYP?]\G_&CZO,/:Q.OHKD/^$NO/\
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M+KS_ )YP?]\G_&C_ (2Z\_YYP?\ ?)_QH^KS#VL3KZ*Y#_A+KS_GG!_WR?\
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M\:/^$NO/^><'_?)_QH^KS#VL3KZ*Y#_A+KS_ )YP?]\G_&C_ (2Z\_YYP?\
M?)_QH^KS#VL3KZ*Y#_A+KS_GG!_WR?\ &C_A+KS_ )YP?]\G_&CZO,/:Q.OH
MKD/^$NO/^><'_?)_QH_X2Z\_YYP?]\G_ !H^KS#VL3KZ*Y#_ (2Z\_YYP?\
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M3D8/565F!7FIYI-^ZM!\J2U9]<T5\R_%C]I3QM=_'I?@Q\']$T+4O&%II_\
M:FKZIXHDF73["$A"JE8?WC,1)'R.GF)P><8GA3]LKQ%JWPG^-#:UX>T[1/BC
M\,K:=KW3U:2;3[AE1S'*GS!S&S1ME=V<;3N^;BN=7L+E9]:U7U#4;32+&XO;
MZZALK*W0RS7%Q((XXT R69B<  =S7P/_ ,-L?'R7]FVQ^-L?@KP/'X/MI5AU
M!)KBZ^UW>;K[.9;>,/MBC$A$?SN[9!;&*Y'_ (*7_$OQ-\0OV=_A?XFTJ2ST
M_P"'WB9;6]EL_-F&H?:Y())1%)C$3PJOX[U!'%0ZJLVBE!WLS]+J*^,OCE^U
M)\9_@3K7P>\*ZAH/@O7_ !CXPENK6^M],%VMH9_M"1V@MY)'#(I$L>\NK<AL
M8&*]%UKQA^TGH/@&PA7P9X)USQO=ZC(D^HV=_);Z)I=D%3;-,LTHGE8DOD1C
M@*>,X#7SK8GE9]$5@^%_'_ACQO+J$?ASQ'I.OR:?+Y-ZFEWT5R;:3D;) C'8
MWRMPV#P?2OF7]GO]KCQCXL_:(UOX/>/[/PC=ZQ9V)O(-:\$W4TMDY549HB)2
MS9VOR<K@H1@YS7#?\$P?^1F_: _[&5/_ $.YI>T3:2'RV3N?=MS=0V=O)/<2
MI!!&I=Y9&"JJCJ23P!7)^&_C)X!\9:N^E>'_ !QX;UW5$SNL=-U>WN)UQURB
M.6&,'MVKQ#_@HO\ #KQS\3OV;[K2? <%S?7L>HP75_IMF?WU[9HLFZ-5_C(D
M,3[1R?+XR< _"_\ 9O[-'B23P[I.EMXJ_9N^(VG7D,SZQKMO<7T>]0<!LSCR
M_GVD2%8P-IR,'B9U'%VL.,5)7/V'HKYK^.?[1WBCX4_&[X'>"-,AT?5--\:7
M)MM2OKF"0RX#PKO@V2A5SYC'Y@XZ?C%\2_VFO%'@W]M?X=?!^RL-(E\->(M)
M%_=W5Q#*;Q),W@Q&XD"!?]&3JA/+<],7SHGE9[[HOCKPWXDUG5=(TCQ#I6JZ
MMI+B/4+"RO8II[-B2 LT:L6C.5888#H?2MROS8^">L?$ZR_:^_:5L?A=H>@Z
MAJ]UJWF3ZAXFN)8[&T2.:;"E8AO=Y"V% ( V,2:]5\/_ +4GCKX[?L[_ !DT
M^ST;1O"WQ2\%)/8ZS:7DLS6BQA91-)$4)=9,0W"J"6 =%))!J543W&X'TPOQ
MX^&C2:E&/B)X4,FF(9+Y1K=MFT0,%+2C?\@W,JY;') [UUFAZ[IOB;2;75-'
MU"UU73+I/,M[VQF6:&93_$CJ2K#W!K\H/V?/#<_A_P#8+^)/C75O!?@76M%^
MSM;6MQ-;W*:O<M]MA\V&ZGB>-O(!5"BQR Y49XXKZ4T3]J1_A'^S'\"]*\(^
M$;&Y\;>.((['0=!AFG%C;'>JL[O)))+Y:F1.&<DY)W *:4:G5C<.Q]LU@>&_
MB!X7\97VJV7A_P 2:1KEYI,@AU"WTV^BN)+.0E@$F5&)C;*.,-@Y1O0UX#\+
M_P!I+Q]I/Q\MO@Y\9-#\/Z?XFU73CJ>C:MX5EF:QNT4.6B*S$N' BE.<_P !
MXY!/@W[$/CG3OAGXV_;$\6:L7_LW1=56^G6,9=ECGU-MJ_[1Q@>Y%5[170N7
M1GZ$:YKNF^&=)NM4UC4+72M,M4\RXO;Z98885'\3NQ"J/<FC0]=TWQ-I-KJF
MCZA:ZKIETGF6][8S+-#,I_B1U)5A[@U^>?Q0^/WQP^,G[(GC7QQJ?@?PO:?#
M+7+.:WMH+.[N/[8M8?-\M;A]V8Y8PXP<!&Q\V,"OJO\ 8D_Y-/\ AA_V!X_Y
MM1&?-*R!QLKG=^*OC9\// NK'2_$OCWPQX>U-460V6JZQ;VLP5ONMLD<-@]C
MBJ.E_M%?"G7-2M-.T[XG>#;_ %"\F2WMK2UU^TDEFE=@J(B+(2S,2  !DD@5
MYC^U5^RG\+/B1X;\9^/?$?A?^T?%EEH%R\&H?VA=1;## [1'RTE5#M([KSWS
M7AG_  3N_91^%GC+X(^"/B3K'A;[9XUM-3FNX=3_ +0NDVRV]VQA;REE$9V[
M%X*X..<\TG*?-RA:/+<^Y?"?C_PQX]BNY/#/B/2?$4=G+Y-R^DWT5T(9.NQS
M&QVM['FK?B3Q1HW@W1;G6/$&K6.A:1;;?/U#4KE+>"+<P1=TCD*N695&3R2!
MWK\O?V)?%WQ?\,^!?C%<?##P_P"&+V+3]5DU"]O?$]S,%?8CG[/!%%@F0JI.
MYW51D"O;?B7^TM:_'K_@F_XJ^(&I>%--O)TGM;/4-!O)[C[&\R:C;+G=#+%*
M%PR2 !P0< E@#N4:MXWZC<+.Q]N:/K%AX@TNTU/2KZVU+3;N-9K>\LY5EAFC
M895T=20RD="#BKE?%K?M2W?PG_9^^ ?A[P3X3T^]\<^.--M+;1M%,\RV%FNR
M-2SO([2% 9% #/D@,2_R\^F?!WXN?&(?%B[\ _%GP%:0%[,7ECXN\(6MW)HK
MG!)ADDE!V/@'[S#E<8^92;4UL3RL]J\*>.O#?CRVN;CPUXATKQ%;VLQMYY=)
MO8KI(I0 3&YC8A6 (.#SR*W*_)W]EG]J4_ ;X4^,?#WAC38O$WQ/\3>-I;;0
MM"DW%&+)"GFRX*X3<=H&Y2Q[@!B/J?\ :=_:>^*'[,GPP^&NIZGIGAC6?%>M
MZA]EUBUM+6X6V3Y-YCM\S[MPSMWL2"1G:,XJ(U4XW93@T['UW17QUJ'[5GQ<
M^%?Q^^'W@[XI>$_"=GH/CJ=;73CX>NYYKJQE9TC5)I'PDA#R1@[45<-D,<8K
M;\6?M+?$KQ]\</%'PU^">@>&;N?PC"KZUK7BZ6<6QF;I!"L!#;LY&YN,H_
M!-^T1/*SZJHKY#TO]OE&_9?\9?$;4O"C6OBWPEJ T75/#JW'[M;QI$C5A)@X
MC)?)X)!1EYX8R?"#X\?M >.+SPUK?_".?#CQYX'U:2/[;-X'UEEO-'C8C)G^
MTRA7= 3F-!DE&''%'M(] Y6?7%%?('Q>_:\\:6_[2&I_![X?IX%T34]*M(9Y
MM4^(-[-#!>2R1QR+!;K"02^V5>I.</P,9/NGP(\5_$GQ1X9NS\4/!=IX0UZU
MN#%&VFW\5U:7T6,B:/;([1C.1M?GH>Y :DF[(3BTKGH]S<PV=O+<7$J001(9
M))9&"JB@9+$G@ #O5'1/$VC^)M#@UK1]6L=5T:=#)%J-C<I-;R*"066125(!
M!&0>QKY=_P""F?Q*U#P/^SBVB:1(T6I^+M2AT,.C!2(6#/+R>S*@C/M(:\]_
M;4TV^T71_@#^SAX8U"70]"\27$.E:A=6QV,]K#Y$(4X^\#YCNP/5D7.<FIE.
MS?D4HWL?8FB_&CX?>)-=_L32/'?AG5=9R5_LZRUBWFN,CJ/+5RV?PKJ=2U2S
MT6PFOM0NX+"R@7=+<W,BQQQKZLS$ #ZU\@>,O^"6'P=UCPO:67AE-4\(Z[;/
M&ZZ[%>S74LFU@6WQN^S) ."@3!(/(&#F?\%!/@WXYU[X'_#W3-#CUSQ]HWAR
M\B;Q#96\G^GZG"D:J)F"+\S?+)DJI(,@;:<$A<THIMH+1;5F?6'A'XL^!_B!
M=36OA?QEX?\ $ES"-TD.D:I!=.@]66-R0/K4/BWXS_#[P#JBZ9XG\=>&O#FI
M-&)A9ZMJ]O:S&,D@/LD<':2#SC'!K\RO!-G^SAXH^*W@67X?:QX@_9Z\=Z/J
M,;26OB&TGO(KZ7<N(6=KG$1."IW%58.05YK[I_:0_91^%GQ<M-<\8^+/"W]J
M^)++1Y8X+W^T+J'8L22/&-D<JH<,Q/*\YYS2C.4D[#<4GJ=S8?M'?";5;ZVL
MK+XH>#+R\N9%A@M[?Q!:/)+(Q 5%4299B2  .2378>&_%6B^,M)CU3P_J]AK
MFF2,R)>Z;<I<0LRL58!T)4D$$'G@@BOS^_X)S_LH_"SXB?!/P_X_\0^%O[0\
M6V>L320:A_:%U%L:"56B/EI*(SM('5>>^:]$_99UA_A?^V;\=O@[&VS0KF5?
M%FFP$;4A>986F6,>A%Q&,#IY/UHC-Z-]0<5JET/M&N,\0?&GX>^$M6&E:YX[
M\,Z-JA;:++4-8MX)LG'&QW#9Y';O7G_[;?Q5U;X-?LR^,O$N@RM;:TL4-G:7
M*]8'GF2(R#T95=F'^T%KPOX!_P#!-[X3^(/@SH&M>.+#4/$WBSQ!I\.J7>IR
M:G/$T$DZ"3;&L;A3MW@%G#EB">AP*E)WY8HE)6NS[CMKJ&\MXY[>5)X)%#I+
M&P964]""."*DK\W/V5/%WCOX'>.?C]\$?#&H1^)YO"5A=:QX8@UA'ECW12(#
M$51D(\U9H\JI #@D=6SZU>_MY7%O^P[:?&*.QTUO&%S<#24TMD?[+_:'FE67
M;YF_9Y2M*%WYQ@9I*HK78W!WT/LFBOE7XC?M1>/O"<WPK^'6D>'-%U/XW>--
M.2]N+6Y,L.EZ8/+9I'<!FD95,<HP&SB)SGH#H_!W]IKQ?J'Q,\9_"GXFZ'H^
MD?$'0--.K6]UH,DKZ=J-OM4[HQ)\ZXWIP3D_-PNTU7.KV%RNUSZ9K/\ $'B+
M2O">CW.K:YJ=GHVE6JAI[[4+A(((@2 "[N0JC) Y/4BOCS]DS]I[X[_M/Z?I
MVOV_AWP-IOA2QU7^S]<NI/M:W$R_*[BTC\QE5EC=,F1B"6X'&*^LOB!X!T'X
MI>#]2\+>)[#^T]!U)%CNK3SI(O,4,& WQLK#YE!X(Z4XRYE="<>5V9RG_#3W
MP<_Z*SX&_P#"DL__ ([6I8_';X:ZFVEK9_$+PK=MJMP;/3Q!K=LYO)P54Q0X
M?]X^9$&U<G+KQR*_/7XA_LD_"C0_^"AGPP^&5CX4\CP1K/AV:_O]+_M&[;SI
MECU$A_-,ID7FWAX5@/DZ<G/<?'_P!\/_ -G7X[?LU^$/"?P]TAM.OO$ZSPS:
MA?:E+/8S/>62M+"1=A2W"'$JR+E!\N"P.7/+5OH:<L=+'Z%45\<7G[4WQ@\3
M?M1?$7X/>!?#7A&\GT.WCN;'4M:DN8(K>/RXB[W!C9C*2\R*JHJ=<D\&N0^&
MO[:/Q[^,GA'QDOACP'X,MO$7@DRMK=[J5U<_8IMH?;#;0JV[S3Y4G+2[>%Y&
MZK]I'8GD9][45\@0_P#!0*SM?V0]*^+E_P"'"_B#4;YM%MM!M924GO@7Z-@L
M(]J%^A(^[R2#5K2?VFOBM\+OBQX$\)_&_P ->%['3_'4AMM)U/PK-.1:764
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MU%?('C#_ (*$:;8_LFZ/\7M"\/?:-1U34UT(:3>3XBLKW;(S^;(HRT86,L"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF[-?;%%-T[IIO<.;8_.3]G7X;ZUH'[=UGXJL?@YKWPU\ ZGH<L6FPS::WEP
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M^('[-OBCQEI*VR)I_C3P#*UY?R\?ZN6!!&4"DN/WC.. 0.>-?_@G9\.OB/\
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ML];^OXAS'Y=:7^RGX_\ B!_P3QT308O#.HV7B_0/$UQK"^'M6MWLYKN'YT9
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MF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5W'AO_D"V_\ P+_T(UP]=QX;
M_P"0+;_\"_\ 0C7+B/@1O1^(TZ***\X[ HHHH **** "BBB@ HHHH @O+*&_
MC$<Z>8@.X#)'/X?6J?\ PC>G?\^__C[?XUIT52E):)DN*>Z,S_A&]._Y]_\
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MNO$$/AWQ;=>#-!M3>30IH\=I##YDUN$*[)GED9C+RWR@ XZG//N'+'L?7O\
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M\:/^$;T[_GW_ /'V_P :TZ*.>?<.6/8S/^$;T[_GW_\ 'V_QH_X1O3O^??\
M\?;_ !K3HHYY]PY8]C,_X1O3O^??_P ?;_&C_A&]._Y]_P#Q]O\ &M.BCGGW
M#ECV,S_A&]._Y]__ !]O\:/^$;T[_GW_ /'V_P :TZ*.>?<.6/8S/^$;T[_G
MW_\ 'V_QH_X1O3O^??\ \?;_ !K3HHYY]PY8]C,_X1O3O^??_P ?;_&C_A&]
M._Y]_P#Q]O\ &M.BCGGW#ECV,S_A&]._Y]__ !]O\:/^$;T[_GW_ /'V_P :
MTZ*.>?<.6/8S/^$;T[_GW_\ 'V_QH_X1O3O^??\ \?;_ !K3HHYY]PY8]C,_
MX1O3O^??_P ?;_&C_A&]._Y]_P#Q]O\ &M.BCGGW#ECV,S_A&]._Y]__ !]O
M\:/^$;T[_GW_ /'V_P :TZ*.>?<.6/8S/^$;T[_GW_\ 'V_QH_X1O3O^??\
M\?;_ !K3HHYY]PY8]C,_X1O3O^??_P ?;_&C_A&]._Y]_P#Q]O\ &M.BCGGW
M#ECV,S_A&]._Y]__ !]O\:/^$;T[_GW_ /'V_P :TZ*.>?<.6/8S/^$;T[_G
MW_\ 'V_QH_X1O3O^??\ \?;_ !K3HHYY]PY8]C,_X1O3O^??_P ?;_&C_A&]
M._Y]_P#Q]O\ &M.BCGGW#ECV,S_A&]._Y]__ !]O\:/^$;T[_GW_ /'V_P :
MTZ*.>?<.6/8S/^$;T[_GW_\ 'V_QH_X1O3O^??\ \?;_ !K3HHYY]PY8]C,_
MX1O3O^??_P ?;_&C_A&]._Y]_P#Q]O\ &M.BCGGW#ECV,S_A&]._Y]__ !]O
M\:/^$;T[_GW_ /'V_P :TZ*.>?<.6/8S/^$;T[_GW_\ 'V_QH_X1O3O^??\
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MM*LXC-<WMY*L4,*#JS.Q  'J:.>?<.6/8C_X1O3O^??_ ,?;_&C_ (1O3O\
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MBCGGW#ECV,S_ (1O3O\ GW_\?;_&C_A&]._Y]_\ Q]O\:TZ*.>?<.6/8S/\
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MO3O^??\ \?;_ !H_X1O3O^??_P ?;_&M.BCGGW#ECV,S_A&]._Y]_P#Q]O\
M&C_A&]._Y]__ !]O\:TZ*.>?<.6/8S/^$;T[_GW_ /'V_P :/^$;T[_GW_\
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M?%']F@-LZ!]KL"_S$#"!C[4 >>?\%7O^3(_&/_7YIW_I9%4G[8D*_$3]HO\
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MJDG[(@D+A_C,LKV@7:3X<)^W;<<8.X;LCCVY!KS']GSX\>)OV;O^"?/C^_\
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MJ1A2TMU-M0KE&"*K%6(#KUH ^F_VPG63]DWXONC!E;PEJ9#*<@C[+)S7'?\
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MV36_VP(1<JV6N7\QV;=*S+LVQ[2HK[<^#?[!NK?#;XJ_$'X@>(/BK=>-]?\
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M+OV>=#^+'[1_BKQ&/BUKFF:K;:!8:/>>'?".IBPO;"/S)IXGFGC8S*LA9G5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/'7[ /A35/V2S\"/!VL3^%-)-W#>OK%W;"_N)YEE$CR2J'B#.^T#(*@   8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH_L#!=G]X?V?0\SZ]_X:]\'?] W7/\ OQ#_ /':/^&O?!W_ $#=<_[\0_\
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MB--[[>=M 'MM%8G@KQGHWQ$\):1XF\.WT>IZ'JULEW9W<8($D;#(." 0?4$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/)S4^2"C>*>G=J__  QU8CEO'E26B?WA1117D'(%%%% !1110 4444 %%%%
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M[RUE7]L2/=&PWSI(N1]Y?L@Y'MP?R-4OB-JF[]JS2/L[%7AO]/MW; P=QCW
M?@^/SKR:,9+]W&3M.ES/5_%W.6"?PIO6%_GW/(/'GA67P/XPU70Y6WFSF*HY
MZLA 9&/N5*G\:P*]F_:PACC^*:,@^:33X6D_WMSC^0%>,U]3@ZSKX>G5ENTC
MU*,W4IQD^J"BBBNPV/I?]C+_ )G#_MS_ /:]?2]?-'[&7_,X?]N?_M>OI>OR
MO._^1A4^7_I*/E<=_O$OE^2"BBBO#.$**** "BBB@ HHHH **** *&O3W-KH
M>HS6<MK;W<=M(\,MZQ6!'"DJTA'(0'!/MFOSTU3X VGQDD>^^,G[9\>I33$L
M=&\(ZW9Z=I]N#U1%,C*XQP&:,-C&<U^AVL:7;ZYI-[IMXA>TO('MYE5BI*.I
M5AD=.":_/'X,_LC_ +%?Q^\8^-?#G@K0M4U2[\)RQ0WUP=6O$@E+F1<P,9<R
M*&B8%L =""00: )_#O[%/P^T?5K>#X1?M;^)M"\03.!:PKXFM-0$LG7!MXFB
M\T''W>^*^U_@GH7C[PSX#M],^)'B/3_%OB2WE=#K.GVOV87,.1Y;/&  LF,Y
MV\5\@_!;X'_LD>"_VNKGP/X3TG4M+^*OA!TO;7[7J-R\$[&!9&$):0K(R))\
MRL >&(R%)'WU0 4444 ?%OQ\^,GP_P#BA\:K_P !^*O'?AOPYX,\ 1KJ&IZ?
MK6K6]H^N:R4+VML(Y7!D@MQME;@AI3&O.QJ\C\/^+M,\3?L5_LGZ/H^JZ;K$
M5M\0O"VG>(;6UNTE:T4SROY4ZJV48L(OE89P<X[C]!?$/PQ\+^)(=0-WX>TB
M6\O(W5[N;3XI)-S*1N)(R2/KVKR71/V-_#EE^R]IGP=O=0=FLH+?'B32K5;*
MZ^V02"6&[49?#JZJ>6;(!!.#0!D_M0&:W_:)_9@NK*-6OQXFU"#?T80/ITHG
M .1P5&2.^T=:C_8E:XNM<_:-N]0C5=1;XKZO;ELY8V\<%JMN#R>-A!'U/3I7
M3^ OV<_$-K\3-%\>?$GXBR_$77?#UG/9:#''I$6EVUCYZA9YVC1W\R=T4*7R
M% ) 09XJ>+OV9?$T?Q \5>)_AK\4+KX=#Q<(VUZQ.D1:C'+.D8B%U;%W7[/,
M8P 6^=20"5R* ,?_ ()XF:/]G9[4QK#86GB;7(+!(_NK -1G( &> &+@#CI7
MM/Q>\;:K\.?AGXA\3:)X8O/&>K:;:F>VT#3RXGO7! \M-B.V><\(W3I2_"/X
M6Z'\%?AOH/@GPXDJ:/H]OY$+7#[Y9&+%Y)'; R[NSNQ  RQP!TKKZ /QX\8?
M%KQY^U1^V9X>T?5_A+J?PQ\2ZQX7^P6>CZ])(L\JVK7UV)@TT,)"/F6/[N-T
M8^;J!T&@V>J?#GQQ%JNH:0\X\+ZU!'?P[@46>.5CY1=<C),,@!&0=IZUZ3^U
M%XTL?AW_ ,%8?@_XEU**XGL=-\#74\T=JJM*RB+6!A0S $\]R*ZOX _%;P9X
MF^*'Q T'6]'OM0T_XD:J'LH)(DVHGF7$G[X^8"C 2I@IN((.#P#7[+PEG&,P
M^4XF$Z?M*-.VBT?O27.K^46Y?J?#YSEM.OC*,Z;Y:DV]>FD;K3Y6/M;P/XTT
MKXB>%=/\0Z+,T^G7T>^,NNUE()5E8=F5@0?<<$CFMVO&O&OQ"\&?LG>%O#FD
M1:+>II%U-)'#'8CS/+P0TCNSMDD[\XSD\]A7K&BZS8^(M)M-3TVYCO+"[B6:
M"XC.5=&&017Y=C,'*FOK5*$E0FY<C?5)];:7[_@?64*ZF_8SDG4BES)>:_(N
MT445Y9V!1110 4444 %%%% !1110 4444 %%%% !1110 445XM\5/VK_  C\
M(?%LGAW6-.UJYO8X4F,EC!"\>UQD#+2J<_A7?@L#B<QJ^QPD'.5KV78YL1B:
M.%A[2M+E1[317GGP;^.&A?&_3=1OM"M-1M(K&989%U".-&+%<@KL=N,>N*]#
MK'$X:M@ZTJ&(CRSCNGT+HUJ=>"J4G>+ZA1117,;!1110 4444 %%%% !1110
M 4444 %%%% !1110 5!?7D.G6=Q=W#^7;P1M+(^"=JJ,DX')X':IZCFACNH9
M(9HUEBD4H\;J"K*1@@@]013C:ZOL)WMH>267[6WPGU"\@M;?Q7YEQ/(L4:?V
M==C<S' &3%@<FO7Z^2O G@/PTW[;'CK23X=TDZ59:-#<6MC]BB\B"799'>B;
M=JMEF.0,_,?4U]:U]-GN#P.!G1C@N?WX1F^9I_$DTE9+;J>1EN(Q&(C4>(Y?
M=DXZ)K9V>[84445\P>P%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 45PWQ"^-W@KX5WEI:>*=:_LNXNXS+"GV6>;<H."<QHP'/K1\/?C=X*^*EY
M=VGA;6O[4N+2,2S)]EGAVJ3@',B*#SZ5Z']G8WV'UKV,O9_S<KY>V]K;Z'+]
M:P_M/8^T7/VNK_=N=S1117GG4%%%% !1110 4444 07U_;:7:2W5Y<16EK$-
MTDT[A$0>I8\ 5CV/Q \+ZI=Q6MGXDTB[NI3MCA@OHG=SZ!0V2:T=<T2R\2:3
M=:9J,/VBQND\N6+>R[E],J01^!KY[^ OP_T&7XG>.W:PRWA_5!'II\Z3]POF
M3KC[WS<(OWL]*]+#T*-2A4J5&TX]K==%^/X'33IPE"4I-W1])4445YIS!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>8^/OV@O#OPY\1/HVI
M66J3W2QK*7M8HV3##(Y:13G\*WHT*N(ER4HW9I"G*H^6"NSTZBN;\ ^/+#XC
M>'4UG38;F"U:1H@ETJJ^5//"LPQ^-=)6<X2IR<)JS1,HN+Y7N%%%%02%%%%
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MUGHJ=XWZ>85JN8*M:E&#AYMW\SZ^\2>,-"\'V\4^NZS8:-#,VR.2_N4A5V]
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MGL%!/H#7F?[//ACPQ\:O%VN:1+X@^SC3E!@6#"27X)<&2$2#=L7:I.4!PZY
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M5'_TG]&;QSAR7,IIHA_X9-\<6G,.I:03U_=74J_SC%)_PSC\3+7_ %-_"?\
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MW7EM,\3$<\1W=KG_ ,>5O_9:\YTW_@I!<W&1-\/$DQU:+6-N/P,!_G716_\
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M]';F=UO;\-C[YHHHK\1/T(**** "BBB@ HHHH **** /,_VD?^2+^(O^W?\
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MOP \)^#M0M;I-;USX^V%CX[\/7%JL$.G37-XUS);1HK.K6WR0A&#8;.>#\@
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M./@[$N%\%PG_ 'KVZ;^<M6X_V2_A'&01X(L3C^])*W\WKURBLWFN8/?$3_\
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MX/\ BNRUGQ;#_P +3\1>)8O&DGB:RM,6MEJD+H]LD$+'=Y$8C"?,2Y#N<Y(
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M3T_2"ONN,,/BZ-;#2Q5]:</_  ))<_XO4\;+*JJPJ^\G:<E\KZ?*VP4445\
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M7R;_ ,%$]'L(_A/H^IK8VRZE)KL$+WBPJ)FC^SW)V%\9*Y XSC@5]95\L_\
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M=/4"BBB@ HHHH ***RO%/BC3/!?A^^US6;G['I=C'YMQ<>6TFQ<XSM4%CU[
MU48RG)1BKM@?-WP^_P"4@WQ-_P"Q>A_]%Z?7U-7PU\/_ (\>!5_;2\8^+#KF
M/#^M:5#I]A>?9)_WTY6R79LV;EYBD&6 'R]>1G[EKZ;/Z-6C4H>T@X_NH+56
MU45=>JZ]C"DTT[=V%%%%?+FX4444 %%%% !1110!\S_M5?\ )9/@'_V'C_Z4
M65?3%>!^./V,/!/C[Q;JGB'4-4U^&]U"8S2QVUQ L:L0!A0T)...Y->O^!_!
M]GX \):7X=T^6>:RT^$0Q273*TC+DG+%0!GGL!7U>:8C U<NPE##U7*=---.
M-E[TG+>[V;MY[Z;'BX.GB(8JO4JP2C-IK6^R2[=;7_ W:***^4/:"BBB@ HH
MHH **** /$/VU/\ DV7QE_VY_P#I;!7;_ S_ )(G\/O^Q>T__P!)HZ\=_;@D
M\?WWP_N='T#0[*^\(7<,3:K?RR*L]O(MS&T80&5<@L%!^1NIY%=G^RG>>.YO
MA?IUIXST6RTBVLK.TM]'>TD5VN;18%"R28E?#$ =EZ]*^KG0MD4)<\?XC=KJ
M^L8K;>^E[=M3*SY^:SMM?H>ST445\H:A1110 4444 %%%% ''_%3P5JOC_PE
M)I.C>)[SPC>M,D@U*Q#F0*IY7Y70X/\ O5YG\"_V8]5^"GB 7:>/[S5='*R%
M]%6U>WMWE90OFE?.92P"CG;G@<\5[Y17L4,WQF'PD\#2FE3GNN6+O\VK^FNG
M0X*F!P]6O'$3C[\=G=_E>WX!1117CG>%%%% !1110 4444 %%%% 'B'[:G_)
MLOC+_MS_ /2V"ORSK]3/VU/^39?&7_;G_P"EL%?EG7[CP-_R+:G^-_\ I,3S
M<3\:] HHHK]$.0*]=^ '[-_B+X[:NLEK&;'PU;SB.^U:3 5,;6:.,?Q2;6!Q
MT&021D9]5^%7[!O_  LWX>:'XH_X3G^S?[3@\_[)_9'F^7\Q&-_GKGIZ"O.M
M+^(7BKX3:UJOPDTK5U30XO%4L=Y=0P^5->;94@8$[CM1A"#M!_B()8<5\S6S
M2..C5P^65%[6&]T_=6S>UFUTZ?(V4.6SFM#H?VUOA'X4^$/BSPY8^$]+_LNV
MNK!YIU-Q+-O<2$ YD9L<>F!78^&_@9\*_@[\&]"\:?%RTU#6K_7O*:#3;222
M,PB1=ZJ%5XSD)\SEFP", $XW)_P4@_Y'[PC_ -@R3_T::]X_:2^(/@KX>>!O
M"&M^(O!\'C99"(-/L;K:T"*\:,\AWJRY"J,94GD@$ DU\A]>Q<\OR^C&4Y.K
MS7<96D^79<SV\W?9'1RQYYOL?'7[3WP]^'/A/4])U+X;>(K'4M+U!&\_3+>^
M6Z>S<!2#G<6"L&Z,<@J>><#PZOJW]L/X2^$=-\%^#OB5X-T]-$L/$"Q"33HH
MQ''B6#SHG" X0A00P'!R.G.?)?V:?A"GQJ^*UAH5U*(M+@1KZ_\ F(9X$904
M7'=BRKGC )/;%?899CZ4<K6)JSDU!.[E\6C=T[;OIY^ISSB^?E2/?/V1?V1=
M#\;>#9O%?C[2I+ZUU @:78M--;D1@G,Y,;*3N/"@\8&>=PQ\A>)K.+3_ !)J
MMK;IY<$%W+%&F2=JJY &3ST%?J]X'B\8-\4/$AU/1/[#\%V-G!8:#&LT#"0*
MS>9)MC8E,X0 ,!A57@'-?F-\9O >N_#SXA:II_B"Q_L^\N)7O(X_.CDW1/(V
MQLHQ S@\$Y]J\+A[,ZN.Q^(]O53NHN,5*Z2[+S2LI6Z[FE6"C%61V_[)?P2M
M/C/\1I$UJ)I/#&DP&ZU!0[)YN<B.+<I#+N.6R.R-TR*\L\;76CWGC#69O#]H
MMCH37<GV"W5I&V0!B(\F1BQ)7!.3U)Z=*^N/V0XQHG[+?QAUZS"Q:FL-X!.!
M\W[FQ+Q\^@:1C^)KR?\ 9M_99_X:$T?6K[_A)_[ _LV>.#R_[/\ M/F;E+9S
MYJ8QCWKTH9G"CB\7B,54<:5+E@MVM=6[*^K;M?L3R-QBHK5G)_L\>!?"/CWQ
M^MKXX\16OAWP_;0FXD>XNDMS<L&4+"KN<#.22>N%.,$Y'T=IOP.^!_Q\\)^+
MH_AK9:AH>L: =JWUQ/,T4[%7,;8DD<&-BC=-K#&< 8SX9\:OV7]>^%_CRV\,
MZ%_:/CB633HM0DET[2I T6^66,*41I/^>6<Y&<XQQ7T?^S+XVT?XU_"?6/AC
MHVGW'@6_LM)ACN-5TMHMUXQ01R3-\@(9F'/5BI^\#7F9SB9SHQS+!5Y<ON[.
MT8J^LI1WE?:UBZ<=>22/E+X)_L_>*?CIK'D:-;_9M)AE5+W5[@8AMP>2!W=\
M=$7U&2H.:]0_;6^"OA#X-OX*@\*Z:U@;V&Y^UR-<RRF=H_)"L=[$*?F;[N!S
M]*\NTWXM>-/A)X=\3?#_ $J_BTV&>_D6_N+4'SV91Y3(DA^ZAV]0 WOVKZ"_
MX*,_\TU_Z];S_P!MZ[Z];&K.L,IS2HRY[)7U2C>\N^KT72W<A*/LWIJ?&5?9
MFG?"_P"#/PH_9]\#^+OB+X4U#7M2UQ49I-.NIED;S5>9"4\^- JQA5R.<XXY
M)KXT52S!5!))P .]?:&O?MN>,OA_8>'+!OA4/#5M!$L*+K7GYG@0!2L),<>W
M "@GYQTXKJSV&-K.C2PE]VY6GR-I+:^_7HGMJ*ERJ[D?/?QNU[X7:[>:4WPR
M\-ZGX=MHXY!?)J4C.96)785S-+T&[N.O>O,J^O/V_/AYHFEW'A3QGI%G#IUQ
MK:21WL,2A1*P5'23 &-V&8,>^%KY#KOR7$0Q6 IU:?-9W^)\SO=WN^NNWD14
M3C)IA6KX5\*ZMXV\06>AZ'8RZEJMXQ2"UAQN<@%CUX  !))X !)KTK]F_P#9
M^_X:"U[5],_M[^P/[/MEN?-^Q_:?,R^W;CS$Q]<FNU^*'PIU7]B7QCX.\3:)
MXC@\0:I=K?"$W&F^2D!$2Q$[?-;<<7!(Z %1G(.**^:T(UY8"E-?6+/EBT[7
MM=7=K6^8*F[<SV/0?$'['N@?##]F?Q'K/B.U34O'%O;FZ%Y#<RB.U)9 (U4,
M%? SDLIR6/8"OBJONKPOXHU7QI^POX^UK6[Z74M4O)[F2>YF.68[X@.G
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MM/%593MMS2;MZ7;,*.'HX>ZHP4;]DE^04445Q'0%%%% !1110 4444 %%%%
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M)WOK>_WV\MC=UFZ?L[*WXA1117"8!1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >(?MJ?\FR^,O^W/\ ]+8*_+.OU,_;4_Y-E\9?]N?_ *6P5^6=?N/
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MFD >$HR0=1DNX$&1)Y> A<.?G^7A>37TWX"CD_:&_8JU;PR%^U^)?"$H>SC
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+-ZV'G4=1KE]Y[N\8O\ "]C[[*\4\;@X5W&U[Z>C:"BBBOECU0HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM)O?:UW^I4US]EW6_"?P1N?'^O7C:5=QO%LT.6U_>^6\B(K.^\;&^8G9M)
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M&;X"^(/@;-I,>O7FFW;:DLK0_P!G2R.%\O9NW;XUQ]\8QGO7NWP1O--^)GP
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M_+O&_P#R4&)_[<_](B?L7#W_ "+*7_;W_I3"BBBOACZ,**** "BBB@ HHHH
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MP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\
M_"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL
M?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM
M'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6
M/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_
MZ+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\
M/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\
MPJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'
M_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".
MT >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >J
MT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5
M_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -
M8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#
M_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLG
MP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\
M_"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL
M?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM
M'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6
M/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_
MZ+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\
M/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\
MPJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'
M_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".
MT >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >J
MT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5
M_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -
M8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#
M_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLG
MP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\
M_"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL
M?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM
M'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6
M/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_
MZ+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\
M/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\
MPJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'
M_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".
MT >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >J
MT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5
M_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -
M8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#
M_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLG
MP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\
M_"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL
M?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM
M'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6
M/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_
MZ+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\
M/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\
MPJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'
M_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".
MT >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >J
MT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5
M_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -
M8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#
M_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLG
MP_\ _"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\
M_"HL?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL
M?_CM'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM
M'_#6/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6
M/P0_Z+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_
MZ+)\/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\
M/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\
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M_P#R'1_PY4^"'_0T_$#_ ,&-C_\ (=??]% 'P!_PY4^"'_0T_$#_ ,&-C_\
M(='_  Y4^"'_ $-/Q _\&-C_ /(=??\ 10!\ ?\ #E3X(?\ 0T_$#_P8V/\
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M_10!\ ?\.5/@A_T-/Q _\&-C_P#(='_#E3X(?]#3\0/_  8V/_R'7W_10!\
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M]#3\0/\ P8V/_P AU]_T4 ? '_#E3X(?]#3\0/\ P8V/_P AT?\ #E3X(?\
M0T_$#_P8V/\ \AU]_P!% 'P!_P .5/@A_P!#3\0/_!C8_P#R'7RK\??^":/_
M  @/[4WPX\$^"="^('B/X;:U_9O]N>(_L?VK[!YU])#<?Z1%;"&+9"J2?.IV
M[MS94@5^U-% 'P!_PY4^"'_0T_$#_P &-C_\AT?\.5/@A_T-/Q _\&-C_P#(
M=??]% 'P!_PY4^"'_0T_$#_P8V/_ ,AT?\.5/@A_T-/Q _\ !C8__(=??]%
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M_P AU]_T4 ? '_#E3X(?]#3\0/\ P8V/_P AT?\ #E3X(?\ 0T_$#_P8V/\
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MK6_A%9_$#QWXDN-:BLKC3O*CU'R[5H)W:7R[:U5QAXXEW$[1OQC)%?K_ $4
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MQC?\NWO7G-E\#?#]]\'?B39KIRCX@^";Z59;Y9YO](MD?<)/*W% &190,#^
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M'A[P!XH^'>C:&([&UTOQ+H+Z2?+"?+Y,;?>0#C([T >I4444 %%%% !1110
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MMK2<R!OL[2+-%'*&. S8W8(IO[8/Q&\6>*OBW;?#.[\$_$J7X06UJESXAO\
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MQ3=M[J]K7=E\C?$9,J'/^^3Y&N;1Z)O?;7?H?)%%?=G@SQS\/?%WP7\4^/\
M_A3OAFT_L.9H?[/^S6[^=A8VSYGV<;?]9_=/3WK#^!^I^"OCAXE\::FOPWT'
M0K2QT2"*.P%M!/&)0\[&9?W2!6(95X&?D'/3$OBFK3IUZM7!RC&BTI>]!V;M
MIH]?B6JT&LFA*=.$*Z;FKK26VNNWD?%]%?3GP5\">!_ 'P9F^*WCW2U\0"YN
M6M=,TQP&1\,4^XV%9BRR'G("ID#-.UGXJ? _XG>!=7AU7P5#X#U^",M8/HUL
MKEY"&VD-$D88 XRL@ Y&#GD>E+/I.O.G0PTZE.$N24XVTEULK\S2ZM+0Y%EJ
M5.,JE:,927,HN^W36UE?H?,-=9X ^*GBOX775Q<>%]:FTI[A0LRJJ21R8Z;D
M<%21DX.,C)]37)U]!_%CP7I/PI_9Y\$:<^F6K^*_$LAU2[OYK53<0PA%80JY
MRR ;X@0",E7]2*]3,,1AXNEA*]-3]M+EY6DU9+F;:>EDE]]CCPM*JU.O3ER\
MBO?\$EZW/./'OQT\=_$[3X['Q+XAGU"R1Q(+=8HX8RPZ$K&JAB.V<XK@Z^\/
MVM/V=]"O/A[)KGA+0M.TG4]#!N;BWTRUC@\^V/WRP4#)7;N!/97 Y->=?&'X
M=:/-\ ?@Z='T?2].UO69+*WEOX[5(I)GDM^LLBKN8;B"<Y]:^5RGB7+:F'H+
M"4?9QG)Q<59<K2YKM+HUV_0]K&Y3BX5:GMY\SBD[N[OK;KV9\J5W7@7XX>-_
MAGHUWI7AG77TNQNI3/+&EO"Y+E0NX,Z%E.%'0CI7KW_# /Q"_P"@SX9_\"KC
M_P",5RUG^R[?Z?\ %:7P=XF\1Z3I$5KIAUB[U.%V>&.W#!2 75/FY[X '.3T
MKU9YYD684Y4YU(5(Q7,U;FVZVL[G%'+LQPLE*,)0;T3O;?SN>*W-U->7$MQ<
M2O/<3.9))9&+,[$Y+$GDDGO45?5?[6G@KP;X8^%?P^N?"&FV4-I<E@FHPVZ+
M/=Q>4I5Y'"AG)^]SZUW'AWX4WWA_]G?P3=>%?AOX8\9^*KY5NKR37K"!R()5
M>4$L[H21NB4?,> >/3D?%6'C@J.+]G;VDW!*34;<M[MMZ):?B;K)JKQ%2CS7
MY8J3:3=[VT26KW/ARBOHSX7W-IXD_:/E\/>./ FA:,NJ6LNDSZ3::<MO%:2B
M/<DL2G<4<[0 ZGG?D'I7BWQ&\&7'P\\=:WX<N6\R33KIX1)C'F)G*/CMN4JV
M/>OH,-F4:^(>%E'EGR1FM4TT[K1KLU^*9Y=;".G2]LG>/,X[6LUW]5^ISE%%
M%>P< 4444 %%%% 'V7_P3K_YJ!_W#_\ VYK[+KXT_P""=?\ S4#_ +A__MS7
MV77\I\;_ /)08G_MS_TB)^T</?\ (LI?]O?^E,****^&/HPHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **^8_B)\4-=\"_'Z\N([N]NM!LD@>ZT[SF,
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M*Y/U/%*LT22(=R. RGU!I8K!RPMGS73;7S6Z"K1=*VM]_O0^BBBO/.<****
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M33V/H2BO(_'WA'Q%J&L:[K>K>,KKPYX7L[,M8Q:/>O"ZN%&6F^0!@2#P"3R
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MJ6VF6,+RO([$#+!%)"J,L>.V.,UT8>,IUH1BDVVM'M\_(:DHOF?0\WL8=?\
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MGQ>_Z%'_ ,J5G_\ 'J/^&//B]_T*/_E2L_\ X]7Z845]!_Q$C-_^?5/[I?\
MR9Y?^J>!_GG]Z_\ D3\S_P#ACSXO?]"C_P"5*S_^/4?\,>?%[_H4?_*E9_\
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M4K/_ ./4?\,>?%[_ *%'_P J5G_\>K],**/^(D9O_P ^J?W2_P#DP_U3P/\
M//[U_P#(GYG_ /#'GQ>_Z%'_ ,J5G_\ 'J/^&//B]_T*/_E2L_\ X]7Z844?
M\1(S?_GU3^Z7_P F'^J>!_GG]Z_^1/S/_P"&//B]_P!"C_Y4K/\ ^/4?\,>?
M%[_H4?\ RI6?_P >K],**/\ B)&;_P#/JG]TO_DP_P!4\#_//[U_\B?F?_PQ
MY\7O^A1_\J5G_P#'J/\ ACSXO?\ 0H_^5*S_ /CU?IA11_Q$C-_^?5/[I?\
MR8?ZIX'^>?WK_P"1/S/_ .&//B]_T*/_ )4K/_X]1_PQY\7O^A1_\J5G_P#'
MJ_3"BC_B)&;_ //JG]TO_DP_U3P/\\_O7_R)^9__  QY\7O^A1_\J5G_ /'J
M/^&//B]_T*/_ )4K/_X]7Z844?\ $2,W_P"?5/[I?_)A_JG@?YY_>O\ Y$_,
M_P#X8\^+W_0H_P#E2L__ (]1_P ,>?%[_H4?_*E9_P#QZOTPHH_XB1F__/JG
M]TO_ ),/]4\#_//[U_\ (GYG_P##'GQ>_P"A1_\ *E9__'J/^&//B]_T*/\
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M7U,L_I2E*?LW>[<=>LH*#<M-7IS:;N_J8>R??^KW-ZBBBOBSI"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGCA;)M;M_&-K<R3:?/;0"V6>S\CB0F(*2DI"[D'9C@ UYOC=\2=%M?@QX?\
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M@'$?&GQ)KVE_M;>,OC!I4US)HGP?L=%TC6+&,;X[K3KP3SZD0!SO@CEM9_\
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M?%7CBP\+Z+%+XD\"^$(WDF\2:D888]Y\F1'?RI?,D5%902=Q.%P>+\'?!O\
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MZ-XLUF/4?B#<ZDA4R6]]#:R7<$LP/4&\OX 0>/E(_A&/9?$'P+_:8^-NCP^
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M]E?Q1X;TSX"V&L:AH]S%X,U+5?$7B-K:69C>ZI<I/Y30!X_G19+N9BSE6 5
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M<3,67Y)25;;BNA^.7Q.U;X7R_#R?3[>RN+#7/%UAX?U/[6KEXX+H21H\15@
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MG=)?6T.JV<=RD%P@(29 ZD+(H9@&'(W'!YK:HH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>advm-20231231_g7.jpg
<TEXT>
begin 644 advm-20231231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" .Q!I # 2(  A$! Q$!_\0
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MY(CX0_Z\_P#V=JRE4?(FF>_EN3TZ>9UL/B:?NV;BGKIS63W_ #U/S9HKZ]\
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M8V3R1C :)CT0=^N:^8=:LTT[6+ZTC+-'!/)$I;J0K$#/OQ7OGPH_9&_X6?X
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M7?@O>:A\3OCEX-B\2ZE>:T8I]RR7\[S-MB#S!,L2<;AT]S7NO[>W_(L>$_\
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MN-#OY_-2&/7)(/L>[EE*LX&P$G 3.!@8XHVF]2*<:=;)J"5.51+=0=G?7?\
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M4KN2U3R[5YG:),8VH6.T8^F*K5V'Y,]'8_1#]E'_ )(#X6_[>O\ TJFKY7^
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M;YH9#'LD7V(.<?@>]?)>L_L=_$33]7-K96=IJEF7(6^BNXXU"YX+*Y# XY(
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MR6IICL;.$UA\.KS?X&AJNL27!:XO;C@=W.%'L!7,WOCBT@)6"-K@C^(_*/\
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M\7_'_HNH>"IT9N&)J<KZ:-W7<7U.G1FX8FIROII>Z[GSV-#U'_H'W7_?EO\
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M6=V)R6)/))/.37J/PY_::\<_#338]-L;RWU'3(AB&TU*(RK$/16#*P'MG [
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MSU_6H;[:=DTYADB#=B4"*2/;=^-?(_Q!\"ZE\-_%U_X?U15^U6K#$D>=DJ$
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M?2=::L[6BCT\-"6!A+%5])/2*ZW[G._LWR--\:=&D<[G<7#$^I,+UM_M;?\
M)4+7_L&Q?^AR5A?LU?\ )9-#_P!V?_T2];W[6Z[?B=:'UTR+_P!&25BO^1=+
M_%^B,H?\BR7^+]$>*4J]:2E6O"9XZ'4J]:2E6LF6CU3]F?\ Y+!I7_7*X_\
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M9U4D@''(Z 5Y/^T)\+_BIJWBK^VO 7B'538W$:+-I=MK#VOE2*-I9%+JFT@
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M\-^%_B/JND>%9)Y=+LF$+//*),R@?O I ' /R\Y.0>:TA*#F^7<\+'8?,J.
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M,G'->A_L^_$;XM6^C_V#X'T6UUG3;9V8FZM@L<3,=Q#2[T&><X))QTX%?/\
M7Z/_ +.-G96OP+\,C1S$GFVC2/(IW#[06;S"WJ0^1CMC':NBJU".Q\KD5.OF
M.-E*5:46DVVGJ]5IJ>,^ _V6_B-#X^M/%FN^*;:SO4N4N9I()Y)IYL.&:-N%
M7:0,8R1@XQBO3/VPE#? O520"5N;8CCI^] KS/P_\%_C7XB^(5K<>+O$,Z:/
M:WD4\TO]H[X+A%8,5C@0@#.,?,J]<\]*]-_; 4M\"=7(&0+BV)([?O5KG;O.
M.MSZFE1C2RS%<E*4$T_C>KT>MNGZG(_L)?\ (@^(?^PG_P"TDKQC]K7Q]K&N
M?%C5=%DO)4TC2VCBM[1'(3=Y:LSL,X+;F//8 "O9_P!A+_D0?$/_ &$__:25
MC?M)?LO^(O&'C:?Q1X4CBU WX3[5923+$\<BJJ;E+$*5( )&<@YZYXT3C&L^
M8X*]#$XC(*$<,F^Z6[6OWZV.W_8W\;:KXN^&=W#JUU)?2Z;>M;0SS,7D,916
M"LQY."6 ]L#M7&?#'P?IUE^V=XRC2%=EC;3:A IY"2R^3N(]/]>_TS7JG[//
MPKF^"OP]N+;6+J$WUQ.][>/&^8H0% "AB!P%7)/J3VKP#X2_&#3[O]J_6=;G
MD6/3_$#2Z;;SL< +N3R2<]-WDH/8O6>[FX['=4?L*&7T\7\:DM]]G_G$]I_:
M.^$OCCXM?V;8^'M8L-.T2&-C<V]U<S1&>0GC<$C8,H &,GJ3Q6_^S_X#\7_#
MGPI<Z/XKU:UU8)-NLFMYY)?*C*@%"713@$9 YQDUSW[1WPY^(/BB33]5\!:_
MJ%E/!$8+G3+74Y+19ANRKKA@F[E@=Q&1MYXKA?#?[/?Q@U+0Q=:O\4-7T746
M/%C_ &C<7 5<#[TBR@ YR, ,.!R<X$K6%FT=E3GHYC*M3P\Y2MO=<K5O/3Y=
MSS+Q=H5OX<_;&M;*U3RX3XDT^X"@\ RO#*V/;+GCM7T%^V=_R167_L(6_P#[
M-7R5I=]-H_QXTFYUK7AKLEAKMJ+G5Y)WD658ID!;?)\Q 5<9/&!QD8-?<'[0
MWP[U'XH?#*\T;2&B&H":.XA29MJR%3RN[L2"<=LXSCK6D_=E"YXF6IXG!X^-
M*.LF[+UO9'R7^QS_ ,ENL?\ KSN/_0*]*_;SE>"7P%)&[1R(;YE=3@J1]G((
M/8UJ?LN_LY^)/A[XIF\3>)XX+"1;9[>WL5E663<Q&79E)4# X ))W<XQ@Y/[
M?'_,B_\ ;_\ ^V]/F4JRL1'#5L+P[5C6BXMM.SW^*)ZW^ROKFH^(O@UIE[JM
M_=:G>O/<!KB\F:61@)& !9B3P*^+/C)XRU_6O''B73-0US4K_3;;6+DP6=S=
MR20Q;975=J,2%PI(&!P#BOKO]C.\%U\%((PZ,;>_N(B%/*Y(?!]_GS]"*^9/
MCY\&O$_@O7->\3ZK;0PZ1J&MS):RI.KM+YIDE4[1R!M4YS@Y'XT4[*I*X9LJ
MU7*,-.%VDO>^Y;GV/XI_Y-SU?_L5)O\ TC-> _L':/;W&N>+M4>-6N;6"WMX
MW/55D:0MCZ^4M>_>*?\ DW/5_P#L5)O_ $C-?-/[$?C:TT'QQJVA7<@B;6H(
M_L[,<!I8BQ"?4J[D?[N.]9QO[.5CU<9*$<UP3J;6?WVT_&Q#^VGXPU2\^)*Z
M ;N9-(L[2)UM%<B-Y&RQ=AW/0<]-O'4TSP%^V3KG@OP9::+<Z0NN7=KN5-0O
M+QMQ3.55EVY.WIG=T KT7]J/]G/Q'\0/%5OXE\+PQ:A+);K;W-DTR1."I.UU
M+D*1@X(R"-HZYXM?#G]CWPWI_@7=XZM_,UQF>::>VO'1+:/ PF00IP 6)(/+
M$9( JN:'(KGEU,'F_P#:=>>&;C>_O/:W17LU_D?&FJWPU35+R\%O#:"XF>86
M]N"(X]S$[5!)PHS@>PJI6IXH32X_$FJ)H;3/HZ7,BV;W#;G:(,0K$X')&#TX
MS6774?GT[J33=S])OV<O^2(^$/\ KS_]G:N%U#]MGP/IU]<VDFE>(&D@D:)B
MMO!@E20<?ONG%=U^SE_R1'PA_P!>?_L[5\AZ]^RS\4+W7=1N(?#&^&:YDD1O
M[0M1E2Q(.#+Z5Q1C&4GS'ZQC,5C\+@L,\#!RO%7M%OHK'UY\.?CIX2^,7VFP
MT2^N;;4%A\Q[6XC\J=4/!93DJ<$@'!.,BOC;]I#X,W'PE\612K?3ZIIFK>9/
M!=73;I]X(\Q9&_B;+ [N^[ZU[1^S#^SGXJ\ ^-#XD\21PZ:L5M)#%9I.LLC,
MV!EBA*A< GKGD5F_MV^)[2:7PQX?B=9+V'S;R90W,:L J C_ &L,?^ ^]5&T
M9VCL>?F2J8S)WB,?#EJ1>G3=KIY_I<^B-%\-W>A?".ST3PW-#;ZC!I"V]E<7
M(P@F\K D? /\1W' //:O!/AS^S;\5/!/Q!L?$<GBG2YLW,;:C_IUS(]W#G#J
MP:+#G:3C<>#@Y&,U[)X!U\?%[X(6LFFZF^GW]WIILY+NT9DDM+H)L8C!!&&Y
M'(R,<\YKP70_@=\>+[Q&;'4O&NK:9IB'YM437)9D88ZI&) Y/LP6HCI=-GJ8
MZ,*OU:I3HSFDERN+LEZ]O5GH/[;'AR'5/A3;ZH547.EWT;+)CG9("C*#Z$E#
M_P !%;/['_\ R0S2?^OBY_\ 1K5\[_M$> ?&/PVT>QAUSXCWGB>SU"4JNGW-
MW/N;;\WF&-G92H.WG/!85]$?L?\ _)#-)_Z^+G_T:U.2M3W.?!UG6SV<I4^2
M7)JFT^J[>5CY'^.'Q#U_Q'\6-=FN-2N$&FZC-;V4<4K*MNL;E%* 'AL+DD<D
MDU]R^'KRX\8? NQN;]Q-=:EX?4SR2 $.[V_S$CW))Q[U^>WQ0_Y*;XN_["]Y
M_P"CGK]!/AE_R07PY_V+\/\ Z(%55TC$\_A^I.KB\4IN][_F?/\ ^P?I-O/K
M'B_4WC!NK6"VMXW(Y59&D9@/J8E_*NY_:!^!OQ ^+7BJ.?2]<TVST"WB1;>S
MN+J>,^8.6D95C9=V3@'/0#I7F/[#_C&TT;QEK>@W+B*76((WMV8X#20ESL'N
M5D8_\!->E_M!?#'XI:MXH_MGP'X@U0V5Q&BS:7;:N]KY4BC:612ZIM( )P<Y
MR<<T2NJAM@XTZV1PCR2G9NZB]=W]_30]6^$GAGQ'X9\ VFC>+K^WUC48"\9N
M(I'E#Q$_*&9U4D@''(Z 5\/^%;S4O 'QZ.@Z+JE]INGCQ*EC-!:W3HL\<=T4
M59 #\XP2/FS]X^M>X0_L^_%2+PX+_4?B[J6G7J1M)/;OJ%RT,(&3S+YG/R@$
M_+QSUQD_-7@&XFN_B]X<GN+MM0GEUVV>2[9F8SL;A27)8!B6/.6YYYIP6^IP
MYMB*G^RTY4I4W%Z-M-VT737UN?:O[6>O:GX;^$<MYI.HW>EW8O8$%Q93M#)M
M.[(W*0<&O(/V)]6OM<^(7BN^U*\N-0O9K",R7-U*TLCX< 99B2> !SZ5ZA^V
M9_R1:7_K_M__ &:O)?V$_P#D<O$W_7@G_HP5$?X;/3QDI?ZP4(WTMM\I%/\
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M444 %/IHZTZI8!1112&@HHHH&%%%% !1110)A1114#"BBB@ HHHH *=3:=0
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M?_%4^>'\IZ/]IY=_T"K^OD?2?Q>_9>\)>"_AWK&N:9=:C'>6,:R(+B971OF
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M\;O%GQ"C:WU"_P#L]@W6RLU\N(_[W.6_X$37"+2,-K$9S[BNTO\ 1([6ZO\
M1;'3[.XFM;;S9+NXF83.5C\QWC&\+@#) P>!WK.3G7;E)W.-NIB&YS=V8OA#
MQ7?>"?$5EK6FE!>6K$J)%RK @J01Z$$BKGCWQ[J?Q'\1/J^J^4LYC6)(X%*H
MB#. ,DGJ2>3WK2M?AG+-=65M+>?9III;>.3S$&U1,!@I\V6*Y&1@?I5.Q\$_
MVG%:W-E=//:R1SO(QA"NABV[@%W<YWICD?>YQBFXUE#V?3L:J%=0]GTO>QR]
M.6NA%A'X;\26\$T%OJ<4RQD1W(/ ?!^8(_##D8R:Z#5M/T:X_P"$F$MM#I$&
MGZI#:126<32/LW7 /#/R?E7/(^[7-[%N^NHHT6[ZZH\_I5KL%^&]RDEQ%/<+
M&R74]I'( /++18RSL6&U22 .#WS59_",$-Q91&ZN)FFLX[R;R+8$0JZJ0"6<
M#^+D\#IZX&3H5$M4/V-1;HJ^"_%U]X%\26>M:=Y9NK8G"R@E&!!5E.#T()J?
MQWXXO_B'XDGUG45BCGD58UC@4A$51P!DD_GZU=D\"0V,Z6]_J7D3R:E/IJB.
M#S%#Q^7\Y.X?*3(.F3[&JE_X/;3;6>YEN?W4=NKY"=9O-,;1=>H*R'/HN<<T
M2C7C3=-_#O8WY:RA[/IO8YVIK:9[6:.:,[9(V#JWH0<BNDL_"D5]I-I<O<+;
M+]@N+UV6,LS;)2FT_-@D]L8]_6HH?"(F\4:7I27?[C41"\5RT>"$D (++D\C
MD$9[5RNC45FEO;\253FK,V/B7\7M7^*$>FQZC!;V\=DK;5MU(WNV-S')/H.*
MXBNFTOPA%J%_H9MYWN;.^ED60M'Y;)Y6&EXR<C800<]^U;R>&=-C\4737EBM
MIIUUIRW,4+2-BV:1TBR#G)V2,V 2<A>:TJ4Z^)DZE1ZNRN_3_*QTRA5K/GF]
M?^ <!:W,UG<)/;RO!-&P9)(V*LI'0@CH:]=\,?M/^+-#A2"^6VUJ)1@/<J5E
M_P"^EZ_4@FL#0/"-E]GTNUO[56OGU:W2Y!=@PAD,J^7P?^F6[/7YA6!Y=IK6
M@ZG=BQBL;FR,;*]N6"2*S;2A#$\]P1CA6SFBD\1A%S4I\K?3TU]#2FZM!7A*
MUSV2;]KV]:/$7AF!)/[SW;,/RV#^=<!XS^/'BSQM"]K-=KI]B_#6UB#&&'HS
M9+$>V<>U>=?Q4Y:QK9IC*T>6=1V^[\BIXRO45I2%I:2E%>,SG1XI1117]OL_
M)!5ZUZM\(_VCO$OP7T>]TW1+'2KJ"[N/M#MJ$,KL&VA<#9(HQ@#M7E*TZN.M
M2A6CR5%='1A\15PM15:,N67<^C_^&\O'_P#T"/#?_@-<?_'ZR?$7[:OQ(URR
M>WMY-,T4MP9M.M3YF/0&1WQ]1S[UX+2UY_\ 9^$B[JFCTY9UF,TXNO+[R>]O
M+C4+J6ZNIY+FYF<R2S3.7=V)R69CR23W-:?@_P 9ZWX"UR+5] U&;3-0C!43
M18.5/564@AEX'!!' ]*QFI!UKJE%27*UH>3&<H24XNS77J?1D/[=/Q!BMQ&V
MG^'YGQCS7M9MQ]^)0/TKRCXE?%[Q1\6-0CNO$.H>>D.?(M85$<$.>NU1W]SD
M^]<917!#"T*,N:$$F>A7S/&XJ'LZU5N/:YZA\(?VA/$?P6L-1M-$LM+NH[Z5
M99#J$4CD%00-NR1>.>^:Y3XA^/-0^)GC+4/$NJ0VT%]?>7YD=FK+$-D:QC 9
MF/1!U)YS7-4Y:7L:<9NHE[SZG//%UZE&.&E-N$=4NB_J[/<O#G[7WC'PQX-L
MO#5KINAR6-I:"S22:"8RE NW)(E SCV_"O(/#6O7'A;Q'I6M6B1R76FW<5Y$
MDP)1GC<.H8 @D9 S@CZUFT5C&C3A?E5K[E5<;B*_)[2;?)MY?U8]@^*'[47B
MKXM>%FT'5]/T>VLVF2<O90RK)N7.!EI6&.?2O*M)U>^T'4K?4--NYK&^MVWQ
M7%NY1T/J".152BHA2A37+!61-?%U\3456M-N2ZGO^B_MN?$72[&.WGCT?5G4
M8^T7MHXD;Z^7(B_I7$?$O]H'QG\6(1:ZSJ"0Z:"&_L^Q3RH"P.06&26_X$2!
MCBO-Z5:RCAJ,'S1BKG55S3&UJ7LJE63CVO\ GW.@\"^,KWX?>+-.\0Z=%;S7
MMBYDBCNE9HR2I7Y@I!Z$]"*[?XM?M'^)?C)H-II.M6.E6MM;7(ND:PAE1RP5
MEP2TC#&&/;TKRJBJE2A*2FUJCFIXRO2HRP\)M0ENNYV7PI^*FK?!_P 22ZWH
MUO9W-W);-:E+Y'=-K,K$X5E.<H._K5_XO?&W7/C1=:;<:W::?:O8(\<0T^.1
M 0Q!.[>[?W1TQ7GU%3[*'/[2VH+&5U0>&4WR/IT/2/AG^T'XT^%-J;/1]02?
M3,EAI]]'YL*L3DE>0R\YX4@'))&:[^Z_;F^(-Q"42PT"V8C_ %D5K*6'_?4I
M'Z5\\45E/#TIOFE%7.JEFN.P\%3I5FH]KFQXL\8:UXZUJ75M>U&;4]0D 4S3
M$<*.BJ  %')X  Y-=5\*/CMXJ^#LETNAS6\UG=$/+8WT9DA9Q@!P 00V..",
MCKG QY[15RIQE'D:T.6GB:U*K[>$VI][ZGK/Q2_:8\6?%SP^NC:O;Z7:V F6
M<K8P.I++G'+NQ[GI6QJ'[7WC'4O!-SX7ETW0UT^XTYM-:1()O-$;1&,D'S<;
ML'KC&>U>'45A]7I62Y=CK_M3&\\I^U=Y*S\UV%6O6/AK^TYXV^%NDC2M/FM-
M1TU#F*UU*)I%ASR0A5E8#VSCVKRA>E-/6M*D(U%:2N<-#$UL+/VE"3B_(]C\
M9?M6>/O&DEEYUW;:9;6TZ7'V738FCCE=&#+O)9F89 ^7=CVI/B=^T[XE^+7A
M=M"UK2=#2V\Y)TFM8)EEB=<X*EI6 R"RGCHQKQ\45A[&G&UH[';+,\;44U.J
MVI;WZG:_"_XO>(_A#JT]]H%Q$HN5"7%K<Q[X9@,[=PR#D$G!!!Y/8D5U_P 1
M_P!JKQA\3O"MWX>U*TTBUT^Z*&7[%;R*[;'5QR\C8^91TKQNBATH2ESM:F=/
M'XJE1>'A4:@[Z=-=SN?AG\:/%?PFN)6T#4/+M9FWS6-P@D@E;&,E3T/3E2#P
M 3CBO3+K]N+X@W%LT4=EH-JY&!-%:REQ[C=*1G\*^>J*F=&G-WE'4THYGC</
M#V=*JU'M<U/$OBC5?&.M7&K:U?2ZCJ%P<R3S'D^@ '  [ 8 K+HHK1::(\Z4
MI3;E)W;.A\ >-K[X<^+M/\1Z;%;SWMBSM''=*S1G<C(<A64]&/0BNV^+'[1W
MB7XQ:#::3K5CI5K;VUR+I&L(94<L%9<$M(PQACV]*\HI]92IQE+F:U1TT\97
MIT98>$VH2W7<]ZT7]LKQAX<T&TT?3-$\.65C:0""!([:?**!@'F8Y/?)SD]:
M\:T_Q1JNF>)8O$%O>RIK$=S]K%V3ES+NW%CGKDYSGKDYK*HJ(TX1ORK<NMCL
M3B.559M\NWEZ'N7B_P#:^\5^./#=_H6KZ%X;N-/O(_+D7[-/N'<,I\[A@0"#
MV(%>,:+KFH>&]4M]1TN\FT^^@;=%<6[E'4_4?R[U2-)1&G&"M%"Q&-Q&*FJE
M:;<EL^I] :1^VU\0].L4@GBT;4Y%&#<7=HXD;W/ER(OZ5P?Q+^._C#XK*(=:
MU%4T]2&73[-/*@R.Y&26/^\3CMBO/5I:S5*G%W2-JN:8VO3]E5JR<>U_S[A1
M115'F!7KGPN_:<\6_";PT="TNWTR]L?/:=/[0BE=HRP&54K(H"Y&<8ZD^M>1
MT5,HJ2M)'3A\36PD_:4).+\C<\;^,=0^('BO4?$&J>7]NOI/,D6%2J+@!550
M23@  #))XZUD6MU-97,5Q;RR07$+B2.6)BKHP.0P(Y!!YR*BHJ;65D8RG*<W
M.3NWK?S/>- _;1^(FBZ?';3_ -E:RR# N-0MF\P^F3&Z ^F<9]<FN:^)/[2G
MC?XH::VFZC=P6.F/_K;/38C$DO.1O)+,1[9Q[5Y9162IP3ND>C4S3'5*?LIU
MI./J%>R> _VK/'W@/28M-BNK76+.%0L*:M$TK1*/X0ZLK$>Q)QC Q7C=.IRB
MI:-'+A\57PDN>A-Q?D>V>+_VO?B%XMTR6Q6XLM$BE!61]*A9)&4@@C>[,5Z]
M5(/O7BE%%3&*CLAXC%U\7)2KS<FNX44451R'JWPI_:0\3?!_P[<:-HUCI-S:
MSW37C/?0RNX=D1" 5D48P@[=S7#>.?&-[\0/%FH^(-1B@AO;YQ))':JRQ@A0
MORAB3T ZDUA45*BD^9+4ZZF,KU:,:$YMPCLNQT7P]\=7_P -?&&G^)-,AMY[
MZR\SRX[M6:([XVC.0K*>CGOUQ75?%K]H#Q#\9;'3[36K/3+6.QD:6,V$4B$E
M@ <[Y&XX[8KS.BCE3?-;4(8NO3HRP\9M0EJUT>W^2.[^$OQCUKX-ZG?7VBVM
MA=37D(@D6_C=U"AMV1M=><U7^*WQ6U?XP>(K?6=9M[*VNH+5;-4L4=$**[N"
M0S,<Y<]^PKC**.57YK:E?6Z_L/JW.^3>W0] ^&?QU\7_  G5X=$OU:PD;>^G
MW:>; 6]0,@J?]TC..<UZ!J'[;GQ!O;5X8;;1+"1E($]O:R%U]QOD9<_45\_T
M5FZ<6[M'31S/&X>G[*E5:CVO^78O:YKE_P")-6NM3U2[EOM0NG\R:XF;+.?\
M,8 '0  "O8_"_P"U[XQ\)^%-/\/V>FZ')9V5LMK')/!,9"H& 21*!GZ 5X=1
M3<5+1HPH8S$8:<JE&;3>[[A7HOPM^/GBWX1QS6^C7,,^GRMO:QOHS)"&_O
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M><<G/EU%'*K6%#&XF%=XB,VIOJ>B_%CX[>(_C%%8Q:W%800V;L\4=C"R#<P
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MC17T?_PP?X^_Z"_AO_P)N/\ XQ1_PP?X^_Z"_AO_ ,";C_XQ63Q^%_Y^(?\
M8>9?\^&?.%.7I7T;_P ,'^/O^@OX;_\  FX_^,4[_AA'Q]_T%_#?_@3<?_&*
MR>.PW\Z#^P\R_P"?#/G&BOH[_AA'Q]_T%_#?_@3<?_&*/^&$?'W_ $%_#?\
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M";C_ .,4?\,*^/?^@OX<_P# FX_^,4OK-'^8/[#S+_GRSYSHKZ,_X85\>_\
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MMX]_Z"_AS_P)N/\ XQ1[>G_,']AYE_SY9\Z45]%_\,+>/?\ H+^'/_ FX_\
MC%'_  PMX]_Z"_AS_P ";C_XQ4.M3[A_8>9?\^6?.E%?1?\ PPMX]_Z"_AS_
M ,";C_XQ1_PPMX]_Z"_AS_P)N/\ XQ2]M3[A_8>9?\^6?.E/KZ(_X87\>_\
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MLGQ__/IGS^O2EKZ '[$_CC_H*^'_ /P(G_\ C-+_ ,,3^./^@KX?_P# B?\
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M $%-!_\  B?_ .,U#P]7^4O^R\9_SZ9X,*?7NP_8U\:_]!30?_ B?_XS3O\
MAC;QI_T$]!_\")__ (S6;PU;^4I99C/^?;/!Z=7NW_#&_C3_ *">@_\ @1/_
M /&:7_AC?QI_T$]!_P# B?\ ^,UD\+7_ )2O[-QG_/MGA*]:=7NH_8Y\:?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 0WDS6]G/*H!:-&89Z9 S7
M+?\ "7WG_/*#_OEO\:Z75/\ D&W?_7%__037GU=E"$9)W1SU9.+5C<_X2^\_
MYY0?]\M_C1_PE]Y_SR@_[Y;_ !K#HKJ]E#L8>TEW-S_A+[S_ )Y0?]\M_C1_
MPE]Y_P \H/\ OEO\:PZ*/90[![27<W/^$OO/^>4'_?+?XT?\)?>?\\H/^^6_
MQK#HH]E#L'M)=S<_X2^\_P">4'_?+?XT?\)?>?\ /*#_ +Y;_&L.BCV4.P>T
MEW-S_A+[S_GE!_WRW^-'_"7WG_/*#_OEO\:PZ*/90[![27<W/^$OO/\ GE!_
MWRW^-'_"7WG_ #R@_P"^6_QK#HH]E#L'M)=S<_X2^\_YY0?]\M_C1_PE]Y_S
MR@_[Y;_&L.BCV4.P>TEW-S_A+[S_ )Y0?]\M_C1_PE]Y_P \H/\ OEO\:PZ*
M/90[![27<W/^$OO/^>4'_?+?XT?\)?>?\\H/^^6_QK#HH]E#L'M)=S<_X2^\
M_P">4'_?+?XT?\)?>?\ /*#_ +Y;_&L.BCV4.P>TEW-S_A+[S_GE!_WRW^-'
M_"7WG_/*#_OEO\:PZ*/90[![27<W/^$OO/\ GE!_WRW^-'_"7WG_ #R@_P"^
M6_QK#HH]E#L'M)=S<_X2^\_YY0?]\M_C1_PE]Y_SR@_[Y;_&L.BCV4.P>TEW
M-S_A+[S_ )Y0?]\M_C1_PE]Y_P \H/\ OEO\:PZ*/90[![27<W/^$OO/^>4'
M_?+?XT?\)?>?\\H/^^6_QK#HH]E#L'M)=S<_X2^\_P">4'_?+?XT?\)?>?\
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M_?+?XT?\)?>?\\H/^^6_QK#HH]E#L'M)=S<_X2^\_P">4'_?+?XT?\)?>?\
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M_?+?XT?\)?>?\\H/^^6_QK#HH]E#L'M)=S<_X2^\_P">4'_?+?XT?\)?>?\
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M_?+?XT?\)?>?\\H/^^6_QK#HH]E#L'M)=S<_X2^\_P">4'_?+?XT?\)?>?\
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M_?+?XT?\)?>?\\H/^^6_QK#HH]E#L'M)=S<_X2^\_P">4'_?+?XT?\)?>?\
M/*#_ +Y;_&L.BCV4.P>TEW-S_A+[S_GE!_WRW^-'_"7WG_/*#_OEO\:PZ*/9
M0[![27<W/^$OO/\ GE!_WRW^-'_"7WG_ #R@_P"^6_QK#HH]E#L'M)=S<_X2
M^\_YY0?]\M_C1_PE]Y_SR@_[Y;_&L.BCV4.P>TEW._TF\>_T^*>0*'?.0O3@
MD?TJY69X;_Y MO\ \"_]"-:=>9/232.V/PH****@H**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJG_ "#;O_KB_P#Z":\^
MKT'5/^0;=_\ 7%__ $$UY]7?AMF<M;=!11178<P4444 %%%% !1110 4444
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MAITQB:[UR4F67 !P#Y\*[\$$QIYA&X<GO[5^R'^V=9?M)3ZUX;UG0W\(^/\
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MA?X;N=$AO%LO$.M3N\-O&YE))MU>Z#82!HV8#S&+9X&5%-U(II"Y7N??E%?
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MZ?\ M6Z]X3\,QVLD-_HH>=;320I97AD_TY$5,<\JH*L#C!KV'0/V:+7]FO\
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MP03G/->/^/O^"6_P2\<>))M8@BUWPMYSF26QT&\CCM68G)(26*38/]E"JC/
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MN-N>*^E/@[\9M&_:I_8=U^\^.E]:Z'I4EU)HNHZPQ2T2=D,4D-Q&""HD#LF
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M^T2ZO#>PF\N/E*A'9X60(,DX1%R>N<#!*$[22ZA&4=&^AF_MM?#/X.?%30?
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M7$#W%N+B 02F%EA51\H!&Y6 ;G')%3&$KW?8IRC:R/E;_@GK_P H_P#XR_\
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MLY[UR%[K'[(7Q<^(FLZQX_TGQE\'->BN&DU#1809+.YN-Y\U-L<$DD;;@=P
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MP;^TQX1M_#_C"&[$-K/]IM+S3YA%<6TFTJ2C%64@@\JRD' .,@5S7PJ_8O\
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M<HN/*?&WP%\8:)X/_P""IGQ%.MW<%BNI7VJ:?:37!"I]H:565=QX!8(RCU+
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M_P#'E_QH_P"$9O\ _GE_X\O^-'MH=P]G+L95%:O_  C-_P#\\O\ QY?\:/\
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M_CR_XT?\(S?_ //+_P >7_&CVT.X>SEV,JBM7_A&;_\ YY?^/+_C1_PC-_\
M\\O_ !Y?\:/;0[A[.78RJ*U?^$9O_P#GE_X\O^-'_",W_P#SR_\ 'E_QH]M#
MN'LY=C*KF=<^&/@[Q-XET_Q%K'A+0]6\0:?Y?V/5K[389KNV\MS)'Y<K*63:
MY+#:1@DD<UW?_",W_P#SR_\ 'E_QH_X1F_\ ^>7_ (\O^-'M:?<.278RJ*U?
M^$9O_P#GE_X\O^-'_",W_P#SR_\ 'E_QH]M#N'LY=C*HK5_X1F__ .>7_CR_
MXT?\(S?_ //+_P >7_&CVT.X>SEV,JBM7_A&;_\ YY?^/+_C1_PC-_\ \\O_
M !Y?\:/;0[A[.78RJ*U?^$9O_P#GE_X\O^-'_",W_P#SR_\ 'E_QH]M#N'LY
M=C*HK5_X1F__ .>7_CR_XT?\(S?_ //+_P >7_&CVT.X>SEV,JBM7_A&;_\
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M=C*HK5_X1F__ .>7_CR_XT?\(S?_ //+_P >7_&CVT.X>SEV,JBM7_A&;_\
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M=C*HK5_X1F__ .>7_CR_XT?\(S?_ //+_P >7_&CVT.X>SEV,JBM7_A&;_\
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M=C*HK5_X1F__ .>7_CR_XT?\(S?_ //+_P >7_&CVT.X>SEV,JBM7_A&;_\
MYY?^/+_C1_PC-_\ \\O_ !Y?\:/;0[A[.78RJ*U?^$9O_P#GE_X\O^-'_",W
M_P#SR_\ 'E_QH]M#N'LY=C*HK5_X1F__ .>7_CR_XT?\(S?_ //+_P >7_&C
MVT.X>SEV,JBM7_A&;_\ YY?^/+_C1_PC-_\ \\O_ !Y?\:/;0[A[.78RJ*U?
M^$9O_P#GE_X\O^-'_",W_P#SR_\ 'E_QH]M#N'LY=CSGQ5\&O 'CN^%]XE\#
M>&_$-Z!@7.JZ1;W4F/3=(A-;_A_PWI'A/34T[0]*LM&T^,Y2TT^W2")2>X1
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MOB>.U9FMTUG3H;L0EL!B@D5MI.!G'7 KH8XTAC2.-%CC0!551@ #H /2M?\
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M%:O_  C-_P#\\O\ QY?\:/\ A&;_ /YY?^/+_C1[:'</9R[&516K_P (S?\
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M_&C_ (1F_P#^>7_CR_XT>VAW#V<NQE45J_\ ",W_ /SR_P#'E_QH_P"$9O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% &=XB_Y 5_\ ]<6_E4NC_P#((L?^N"?^@BHO$7_("O\ _KBW
M\JET?_D$6/\ UP3_ -!%5]DGJ7****DH**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7A;X3>%[CQ'XQUZQ\.Z);D*]Y?2A%W'.$7NS'!PJ@DXX%?EU_P %8O@5X.^
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M0=*]2J'N4M@HHHI#"BBB@ HHHH **** "BBB@#.\1?\ ("O_ /KBW\JET?\
MY!%C_P!<$_\ 0147B+_D!7__ %Q;^52Z/_R"+'_K@G_H(JOLD]2Y1114E!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@'
M[9W[(VB?M>?#&/0;RZ72/$&FRM=:/K'E[_L\I7#(XR"8W 4,!_=4]5 KX/\
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M1/M/A?5H%2R\41WMLZWCPSML8Q"5ID,B2LWS+P5()Z9_0BB@#X$_X)\?LO\
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MMO@5IV@^.O ?B"?S(XM9NHD6V4%A$TJ/-"XE16*EHRRN "1T4?J%10!^7_P
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MVT,.DHRO;>0D<LJ,XB@*/E V?F'S,,MP_P#P42\*ZOXW_P""DWPXT/P_J_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,/\ Y(?-F7\L/OE_D=-_PM_P-_T.&A_^#"+_ .*H_P"%O^!O^APT/_P81?\
MQ5<S_P ,M_"[_H4;7_OY)_\ %4?\,M_"[_H4;7_OY)_\51RY%_/5_P# 8?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<YYZ<5]@UXN<X?!X7&2IX&?/#36]]>JOU-*;E*-Y+4****\,U"BBB@ HHHH
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M\=?AW;;A)XVT,%1DC[=&3^0-9EQ^TM\,;7&[QCI[9Y_=LS_R!J2']F_X90*
MO@S3&P<_/&6_F:T+?X&_#^TSY/@[1TW<G_1$_P */^$)?\_7_P" +_,/^%)_
MR+_P)_Y'FWC_ /;2\!^'?#=Q<^'[W_A(M8X6"S6&6)"2?O.[(  .N.IZ>XYS
MX??MW:%K&DS'Q/H]Y8ZI&WRQZ7$;B.5<<$9(*GV/Y^GN>N?!WP5X@T6ZTJ[\
M,Z:+2Y&'\BV6)^H((=0"""!R#1\/?A#X4^%^GR6?A[28[5)'\QY)"99&.,<L
MV3C';I7IQQ?#<,'*G]6J2J7T;FMO5*R].5^O;D=#-I5U+VT5"W2+_)O]5Z'E
MDG[:7AR5MMAX0\77[9'*6"!<>O\ K"?TI!^U1X@O!_Q+?@_XJO#R!O0ISZ<(
MU?0H 4  8%+7F_7\JC\.!OZU)/\ )1.OZMC7OB/NBOUN?.Y^/7Q8U'']G_!6
M^M\X(^VW97C\46E7QY^T1J'^H^'6A6*$?>N;Y&(/X3#^5?0]%']KX6'\+ TU
MZ^TE^<P^HUI?'B9_+E7_ +:?/#1_M*:HWRR>$='!/\99\9^BOTI__"O_ -H'
M4AB\^(>AV.<9^Q6A;'8XS&M?0E%']NSC_#P]*/\ W#3_ /2KA_9L7\56;_[>
M?Z6/GQ?@'\4;S!O_ (TZ@/5+6QV=_42#^5*/V4;V]YU/XH^++H]_)N?+'MW-
M?05%+_6+,5\$HQ](07Y1#^RL*_B3?K*3_-G@4?[&OA*7/]H:YXCU3.<_:-0Z
MY[<+6A:_L;_"ZUD#MHUS<-G)\Z]E;/U&:]MHK.7$.;2T^LS7H[?E8I95@5K[
M&/S5_P SS"S_ &9?AC9* O@^QDQCF;<YX^IK=T_X,^!-+Q]F\(Z/'C@?Z&C=
M\]Q7945P5,SQU7^)7F_63_S.J.#PT/AIQ7R1DVOA'0K+_CWT73X/^N5K&O\
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MMOS:/H>BOGAOAG\?;PE9_B?I4"$YW6]D-V?3_5CC\:;_ ,*@^./_ $5JV_\
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M&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK1JXYCEF'_@X63_Q5'^4%'\R7A<95_B5DO2"_P#;G(^/[SP7\1/&1WVOP/\
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M +*P+^''T_\ P&HO_;#K^NXCKAI??'_Y(^BZ*^=/^%,_&W_HKZ?^ 7_UJ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3=9 X_2H?^%9Z5_T+/AK_P  1_A1[3(W_P NJO\ X''_ .0#ES'^>'_@+_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ]CF'_/Z/_@'_P!L>$-^VAX,8YM]*\07,?:2.QX_G2?\-G>$O^@%XB_\ ?\
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MH>G6OM&BNK"\5YEA*JK4N1-?].X+\DG]S,*V2X2O!PGS:_WI/\VU^!PGP/\
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M_P##4GPL''_"8V?_ 'ZE_P#B*9)^U1\*XXRW_"7VK8[+#*3_ .@5Q?V-F?\
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M^@[+_P" DO\ A1_8&;?] L__  %_Y!_:>"_Y_1^]'M=%>*?\-B?"W_H.R_\
M@)+_ (5=_P"&L_A7Q_Q548_[=YO_ (BI>19K'?"S_P# )?Y#698)_P#+Z/\
MX$CUZBO(?^&LOA7_ -#5%_X#S?\ Q%'_  UE\*_^AJB_\!YO_B*7]AYI_P!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$X=4.3_9[<OE:WX"  < 8I:**X#I"BBB@ HHHH **** "BBB@ HHHH ****
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M-G\5=R]5&7YIF']DX+I3MZ-K\F?/1^ _Q5T__D'?&6_DP,#[;;>9]>I:G_\
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M2?\ "E_A]_T(OAK_ ,%%O_\ $5V=%9?VAC'JZTO_  )_YE_5J'_/M?<CC/\
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MFRA@_P#0\5UMCI_[4&J6Y$FH:/IA8=9A#N'_ 'RK5]3T5Y=;B:,W^[P-"/\
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MX'X\6?#)M7MD^]>^'Y#)GWV#<0/KBMKPO^V!\/->NA9ZA>7/AJ_!"M#JT!C
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M_BDX4Q_<N)A_[/52Y_9!^%EQMQX=:''_ #SNI1GZY:E[/(G_ ,O:J_[<@_\
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MMX<NP+=-L,?F%PH<1_O-_,BJ3V.*X7PSXV_9\@_:*^ =Y\-;1O"NFZ=?7/\
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M\F_QHSJ7I;?DW^-%@N7Z*H9U+TMOR;_&C.I>EM^3?XT6"Y?HJAG4O2V_)O\
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M_P#0147B+_D!7_\ UQ;^52Z/_P @BQ_ZX)_Z"*K[)/4N4445)04444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"IK%NOVROA;#Q%K-U=MS\L.GSY^GS**[X9'FE3X<+-_]N2_R.6698*.]:/\
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M\9<8@B9A_&V!M/'/;K7QC#\7/ 6GZ/;^)KO]B[RO 888UUE+,8@<"4YMPA)
MS@MC_:[U:2:);9^A_P"SO\7F^/'P<\.>.FTA]";5XY'-@\OF^7LE>/A\#<#L
MR#@<&O1ZX_X0^*O#'C?X9^'-<\&)#%X7O+1'L(88A$L48X\O8.%*D%2.Q!KL
M*@H**** "BBB@ HHHH **** "BBB@#.\1?\ ("O_ /KBW\JET?\ Y!%C_P!<
M$_\ 0147B+_D!7__ %Q;^52Z/_R"+'_K@G_H(JOLD]2Y1114E!1110 4444
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M3RS1_P -->-&XC^"OB-G/"J96 )_[\T?ZN9EUA'_ ,&4_P#Y(/[6PG\S_P#
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M\D?0]%?/0_9K\=2?--\:]?>4_>98&4'\/.XH_P"&7?$MSS>?%_Q+.XX5D!7
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MM^&7_/EJ)_[?WH^K9*M\5-_]PU_\F'MLP_Y\Q_\  W_\B>Q?\)3HO_07L?\
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M )DUZ117)/.<RJ?'B9O_ +>E_F;QR_"0^&C%?]NHY&Q^$/@C35 MO">CQ #
M_P!#C/'XBMBW\)Z'9\P:-I\/.?W=K&O\A6M17#/%5ZGQU&_5LZ8T:<?ABE\B
M*&VAMU BB2(#@!% _E4M%%<UV]S8IPZ/86M[+>0V5O%=S?ZRX2)5D?ZL!DU<
MHHIN3ENQ));!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>R:76QF*<D] FQ]Q&,[L8]^:TOVGO#OQWT[X6W+>)O$6FZ[H#S(+N'2+<!T
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MGOCA_P!%;@_\ ?\ ZU)_PH7XO=_C7=9_Z\3_ /%U]%T4?ZQ8Q;1IK_N%3_\
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MG:QB.+PUI*(.PLH_\*Z2BLWC,3+1U)?>RO84EM!?<CG_ /A7WA?_ *%S2?\
MP"C_ /B:L_\ "(:%_P! 33O_  $C_P *UZ*AXBL]YO[V5[*FMHK[C*7PGHD;
M!ET;3U8="+5 ?Y5+_P (_I?_ $#;/_OPG^%:%%1[:H]Y/[RN2/8I1Z+I\.?+
ML+9,]=L*C^E/_LNR_P"?2#_OTO\ A5JBIYY=Q\J[$8@C4 "-0/\ =%.6-%.5
M50?84ZBINR@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#YX_;T\>:W\-?V;]9\0>'?$4OAC6+6[M6M[N%"S2'S1^ZX!X?H<\8
MZUY9X7_X*>? J[TRRU#5;35--UMHP;A3I*NZR8^8[T.#DYZ5](?M%?%#PW\'
M/A'K?BOQ3IZ:OIEBJ[-/>-7^T3,P$: ,, EB.3TY-?*'PU_: \6ZOJ/C^3QE
M\$_#>A1:3X/;Q7I&BPZ<#=S1F0JAD<G&TA6)^13QG':K6Q+W/LKX3?%/0?C5
MX!TSQCX9DGFT74?,\A[B(Q.?+D:-LJ>GS(U=?7G?[/?Q$TCXL_!GPMXMT33(
M]&L-4MC+_9\*J%MY [+*@V@ X=7YP,]:]$J"@HHHH **** "BBB@#Y;_ &K/
MVT4^"\DGA_P=I$GB7Q;;7EC'J<LEK(VGZ1!<3QH'N) 5&]P^$16SE@3P,'TC
M]I'XTZC\'_#&B0>&](A\0>-O$^JPZ'H.FW,AC@>XDR3+,PY$4:*SMCT R,Y'
M"?\ !0J%(_V:=2=457?7-%+,!@M_Q,;?KZTG[6EY!X9^+/[.OBC4YDL]"T_Q
M;-9W5Y,VV.&2YLY8H2Q/ !?C)X&: +OPM^,7Q/T'XRVGPR^,>F^&O[3UK39M
M3T+7/"7GI9W/DE1/;/'.Q=9%#*X(.",]*^BZ^9?BU>0>(_VWO@1I&GW*S:AH
M.GZYK&HPQ$$PVTMND$;/Z!I& '3.*^FJ ,[Q%_R K_\ ZXM_*I='_P"018_]
M<$_]!%0^),_V#J&WKY+8S]*K:5_:?]EV>S[+M\E,9W9^Z*O[)/4VZ*SL:KZV
MGYM_A1C5?6T_-O\ "E;S'<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^M
MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVG
MYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?F
MW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?
MX48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A
M1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&
M-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U
M7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?
M6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];
M3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/
MS;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-
MO\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_
MPHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"
MBWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+
M>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMY
MA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%
MS1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-
M&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:
M*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK
M.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[
M&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:
MKZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJO
MK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^M
MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVG
MYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?F
MW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?
MX48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A
M1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&
M-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U
M7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?
M6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];
M3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/
MS;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-
MO\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_
MPHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"
MBWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+
M>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMY
MA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%
MS1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-
M&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:
M*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK
M.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:KZVGYM_A1C5?6T_-O\*+>87-&BL[
M&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJOK:?FW^%&-5];3\V_PHMYA<T:*SL:
MKZVGYM_A1C5?6T_-O\*+>87-&BL[&J^MI^;?X48U7UM/S;_"BWF%S1HK.QJO
MK:?FW^%6[7S_ "_](\OS,_\ +/.,?C2L!-1112&%%%% !1110 4444 %%%%
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MNBB@#.\1?\@*_P#^N+?RJ71_^018_P#7!/\ T$5%XB_Y 5__ -<6_E4NC_\
M((L?^N"?^@BJ^R3U+E%%%24%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"OX8Z#\&_ .D^#O#,$EOHNF(R0)-*9'.YV=F9CU)9F/XUUE9%A1110 4444
M%%%% !1110 4444 9WB+_D!7_P#UQ;^52Z/_ ,@BQ_ZX)_Z"*B\1?\@*_P#^
MN+?RJ71_^018_P#7!/\ T$57V2>I<HHHJ2@HHHH **** "BBB@ HHHH ****
M "BBB@ HHJ&\O(-/LY[JZE2"V@C:6660X5$49+$]@ "::3;L@VU9-17C;?M@
M?")&*GQ<,@XXTZ[(_/RJ;_PV%\(?^AN_\IMY_P#&:]S^P<V_Z!*G_@$O\CSO
M[2P7_/\ A_X$O\SV:BO&?^&POA#_ -#=_P"4V\_^,T?\-A?"'_H;O_*;>?\
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M4$ 1(Q49=!N;"C<.:[C6]<T_PUH][JVK7UOINF64+7%S>74@CBAC499W8\
M#))K\/OVB_AO\9]'^+?P5^(7QQU?S_%?C'72(-$!4C2K6WGM"D8"'8F3<M^[
M7.-N6)9FQ]H_\%G/'-[X=_9KT'0+.X:"/Q!K\4=VJY_>P0Q22[#[>8(6_P"
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M'[2/P;\&^+OCA\*O#;^-I+27[3I^N^'5+6'[YQL6.[#R1 JJL03SG/I7P?\
M OX.^"?VVOVVO$?B;1/!NA^'O@KX D6&TM-"TV&QAU6=7;R6D,*KYGF,KRG/
M(C6-#][- 'Z91?&SP5-\7)OA@-;5/'46GC5#I,EM,A>V) \Q)&01OR>BL2,'
M(X..XK\Z_P#@J3J%S\$OBI\!OCIH^8M0T/4Y=,O2B_-<6YQ*(B?0I]K7'_37
MC&*_1"WN([JWBGA<212*'1AT*D9!_*@"2BBB@ HHHH **** "BBB@ HHHH *
M**JZIJ5OHNEWFH7;^5:VD+SS/_=15+,?R!II.3L@*'BOQEH7@72FU+Q!JUIH
M]BIV^==RA 3Z#/4^PYKSW1?VL/A+X@U%;&T\:V2SL=J_:HI;9"<X^_(BK^M?
MFY\:?C!K/QH\;WNN:G/,+4R,+&Q9R8[2'^%%'0' &XCJ<FN"K]?PG U*5!/%
M56JC[6LO+5._X'GRQ+O[JT/VZ5@RAE(((R".]+7PS^P)\=+^35Y?ASK%U+=V
MTD37&DO,Y8PE!EX!G^ J"P'0;6_O5]S5^;YMEM7*<5+#5'>VJ?=/K_74[*<U
M4C='A'[57[8W@O\ 9!TWP[>^,=,U[4HM<EFAMET.WAE9&B"%M_FS1X'SC&,]
M^E>[U^87_!<3_D4?A+_U_:C_ .BX*_3VO'-#PG]H;]L;P9^S3XP\$>&_$^F:
M]?WWBZ9H;&32;>&2*-A)'&3*9)D(&95^Z&X!_'U;XA>-K'X:^ ?$OB[4XKB?
M3= TRYU6ZBM%5IGB@B:5U0,R@L50X!(&<9(ZU^<G_!6?_DX#]FW_ *_Y?_2N
MSK[F_:Q_Y-9^,G_8F:S_ .D,U '+^#_VTO!/C7]FC6?CA8Z7K\7A/2A.T]G<
M6\ OF\E@K;4$Q0Y)XS(/PK9_9A_:N\$?M:>#]0\0>"_[0MET^Z^R7FGZM%'%
M=0,5#(S*CNNUAG:P8YVL.H(KX5^ '_*&WXA_]<]4_P#1R5\T_L:?$;Q%^QCX
MP^''Q1U-I)/AA\0%N-,U5HU8I$(;EXF+ ?\ +2(A)AQDH[J.<T ?KKX5_:Z\
M'^+_ -I?Q)\#[/3=<B\6:#:F[N;R>"$6+H%A;".)2Y.)TZQCHWMG9_:4_:3\
M)_LK_#D>,O&$>H7.GR7D5A#:Z7'')<S3.&8!%D=%.%1V.6'"GK7Q3\!;J&^_
MX+$?%JYMIH[BWFT%I(IHF#(ZF#3R&4C@@@Y!%0?MX71_::_;F^#GP!M6^T:/
MI,J:EKL2D[?W@$TJL!W6UBRI_P"GC% 'V[^S7^TEX2_:G^')\9^#TO[?3TO)
M;":TU2...Y@F0*2KK&[J,JZ,,,>&'3I7JU?F/^PW=-^RK^W;\5_@%>NUOH&O
M2-J&@)(3M)13/"J9/):VD<,PSEK<#MQ^G% 'S+^TA_P4.^$/[,/B;_A&O$=W
MJFM>)$1)+C2?#]LD\MLKC*F5I)(T4D$-MW;L$'&"">Q_9K_:\^''[5FCWUWX
M'U*X^VZ?M-[I.I0^1=VP;.UF4$JRG!^9&89X)S7.:=^S1\*/V?/BQXY_:"U;
M6+R#5-0@N)]1OM>N8I+2R5Y!(S0CRPZ, HC4!B=OR@$GGXY_X)\Z3??'+]L#
MXZ_%WP=#=>#?!-_:WFG65Y!!&'2XN)8GB98V4QEU6+SF4A@&= 00V: /U2HK
M\I+S_@HI\7_V6]0^+OP[^,TA\4^/-/C#>%-673H+:"5F(5'=8416B*,)EX)R
MCH2"0!]2?"72_P!I'7/V-];U/Q%XNDO_ (P^(K'[1HT$UC96(TA7 $2-LA0>
M85)=BX)4D* "I) /1/B7^V/X ^%_QV\&_"._&I:CXO\ $TD4<2:9'%)#9>:^
MV,W+-*K)NY("JQVC..5SWGQD^,WA+X"> [[QAXUU5=*T6U*IOVEY)I&^[%&@
MY=S@X [ DX )'Y(7/[-.J_LT_MT?L[V7B;Q//XN\9>(-0M=8UO4I)&D1KEKQ
MT*H[_.X 09=^6.3@< >\?\%@M0.O>,OV?_ ]PTG]CZIJ]Q->Q*V!)^\M84(]
MPLLW;^.@#W_X!?\ !3'X-?M#>.[?P?I$FM^']=O&*6,/B"SCA2]< G;&\4LB
MAL X#E2<8&3@5L?M=?MV>#OV58+33C;?\);XVNI(2OANTN3"T%N[;3<7$H1Q
M$G("@C<[,H QN9?E;_@L+8:;\-=3^!'C'0M-MM.UC1[^X6"6SC6$^7;FVEAC
MR!PJ,#M&,+N; YKVW_@JIHNGV?[+NJZE;V%K!J-[KNDK=7<<*K+.(Y2(Q(X&
M6"AFQDG&3CK0!ZM^UI^V1X._9.\)_:M5QKGBRZA:;3/"]K*4N+M5/S2,P5O*
MB4!B9&&/D8 ,1BO9/!?B+_A+_!VA:]]G^R?VI807WV??O\KS(U?;NP,XW8S@
M9QT%?//_  4<T73U_8_^*NKBPM1JK:3;VK7WDKYYA%Y$PC,F-VP,2VW.,DFO
M;?@O_P D=\"?]@&P_P#2=* .RHKXE_X*"_M!?$S]E_QU\)O&>AZ^T/PQO-27
M3O$FD&PMY0Y5Q(2)&C,JM)#YP&Q@ 80<<G,'[=?[3'Q \._$SX,_"[X,>(H]
M)\4^-+E;BXODLK>\"6<CK'"^V:-QL)\Z0L "!#UQF@#[AHKX$_:T_:O^+LG[
M1_A_]GCX#RV4'BZ2TCFU+7M2@BE>)VB,V"&0Q(JP@2,QC))D 4#&&\H^)W[4
MG[5OP1^.OPA^&7CW7M%MY]0U2U2\UC0;&"6WUVSFNHH\'S8 8Y$Q*I\M8^'4
M[> Q /O[X[_M&>&_V??^$.37K'5-3NO%>M0Z%IUKI$44DIGDZ,PDD0! =H)!
M)RR\5ZI7P]\>_P#B['_!2KX%>"@//T_P5I-WXLO!U5)7+"+(_O*\%N<GH)/P
MKA_%O[3O[0_[3W[1?C?X<?L[ZAH?@[0O!4CV]]KVL0)(;B5',;;O,AFVAI$D
M"*L?(0LS#.  ?HS17YZ_!']J[XV?%3PW\:_@]KLEKH'Q]\%:9/>:9JFFVT#K
M>-"Z@JT3JT1+,8TW!=I6<$!2N3VW[)O[;=SXX_8?\2?$[QKJ$6J>*/!L=]'J
MTGDI!]JEC4RV_P"[C"J/,62*/Y0 6#=.< 'VI17YS_!_]L[XG?#G]@_7OCI\
M4M5_X3#6M6U0V7A?3YK&WM(MH/E*S^1'&2ID6=CG)*PC:06KB-<^/_[;'PE^
M$^D?'SQ3J/AC5_A_??9KN?PK]CACEM+6X91"S[8ED0-OC Q,[*9%W+P0 #]3
MZ\^^/'QR\,?LY_#+5/'/BZ6X72;$HGD6:*]Q<2.P5(HE9E#,3ZD  $D@ UJ?
M"7XCZ?\ %_X9^&/&NE1R0V&O:?#?Q0RD%XMZ@E&QQE3E3CN*^"O^"EFK'XG?
MM2?LZ?!6=U.B7^J6^J:G;,05F2:Z%NI(]5CBN0/7S#^ !^A?A#Q$OB_PIHVN
MI8WFF)J=G#>+9:@J+<0"1 X20(S*' ." Q (/)K7KX;_ ."G?[3_ (^_9?L/
MA=J'@75QID%_J-RNIVOV6WE%W#$(6$6Z6-_+R&8;DP?F]A7B?QX_::_;'_99
MN_"7Q"^(-WX6E\):]<A&\(Z?;1LMHVWS#;2R^6)5DV!L,LLBY4YST(!^J%%?
M$/[86H?M@ZK\0?#][^SL,>![G0+>:YYT8_Z:TLQ?_C\_>?ZHP?=^3TYW5X3_
M ,;.O\_\(Q0!^G_BKQ1I7@GPWJ>OZY?0Z9H^FV[W5W>7#;4BC099B?H*\T_9
M?_:@\*_M9> =0\7>$=/UC3M-LM3DTJ2+6X8HIC*D44I8".60;=LR<YSD'CH3
M\\_MO?LM_$K]I#X@W3:AXPFT+X(:#H7]H2Z5;3#S;_4(Q,Y C P>!&-\I.W/
MR*236-_P14_Y-9\4_P#8YW7_ *0V- 'VG\5?B=H'P9^'FN^-?%%U]CT/1[9K
MBX=0"[]EC0$C<[L551D99@*\\^#?[6WA;XZ? O7OBGX8T+Q%)HVD&[633+BV
M@&H3M;Q"1UB19F1BP8!07&3QQ7Q'^W1XWUK]L;QMX_\  7A"]:+X9?"/0=0\
M0>(]3MR#'>:I!;3-#;@\A@KH4 XZ3MSL2O8_^".*AOV0[D$9!\27H(/_ %R@
MH ^J?@3\;_#/[1'PQTGQUX2EG;2-0WJ(;Q%2XMY$8J\4JJS!7!'8D$$$$@@U
MW]?G!_P3,U:3X:?M)?M%?!2.7&BZ7J]QJ.EVN1B)(KEK=F !XW1O:Y]-@K]'
MZ "BBB@"KJ>J6>BV,MY?W4-G:1#+S3N$1?J37$1?'[X?S7GV9?$MN),[=S12
M*G_?97;CWS7RW\<OB==_$#QA>1I/(-%LI6AM+<-\AVD@R$="S')SV&!7FU?<
M87AV$Z2G7DU)]%T/<I9<I1O4>I^E-M<PWEO'/;RI/!(H=)8V#*RGH01P14M?
M'O[,_P 3KKPWXLM_#MW,\ND:F_E1QLQ(@F/W64=@Q^4@=20>U?85?,YA@9X"
MM[.3NMTSS,10>'GRL*R/&'B:U\$^$M;\17T<TMEI%C/?SQVZ@R-'%&TC!02
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M1#]@V?9_/QO\WS,[>/\ 5]>^.:\%_P"".'_)HMS_ -C+>_\ HJ"N"_YS8_\
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M&)V/QQ7?_&#XR>$/@/X%O/%WC;5X]&T2U98S*RL[RR-]V.-%!9W.#@ = 2<
M$C\>/C)^S#XF_9[_ &A/V?-5\>^+9O&'Q \7^)8;W6+MIFEBC,=Y:+'&CN S
MD!VRQP.@"@+D_JG^U!^R?X0_:T\-:3H?C+4-;LK+3+AKN#^Q;F.$F5EV;FWQ
MN"0"P''\1H \:^&?_!6;X$_$KQI;>&S+X@\,2W<RV]M?Z]8Q1VDLC-M4;XI9
M"@)Q\SA0,\D<U[MXJ_:4\+>"?CWX6^$VM6NJ6.M^)[)[S2M4DAC_ +.N&0N&
MMQ)YFX3?)G:4Q\R#=E@*^ ?^"I_B+PM\3/$GPP_9_P#AOI5IJGC>PU!(A;Z9
M$@33HWC\J.TRH^3.1(R\!%C4MUX]#_X*R>%K[P9\!_A'XWL+QO\ A*O!.O6M
MO!J:\."T!9I 3SGS;6$X_P * /T3HK!\ ^*H?'?@3PYXEMPH@UG3;;48PIR-
MLT2R#!],-6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!X_\9OV2OA9\>)9;KQ9X5MIM7D39_:]F3;W?  !,B_?P% &\-@# KY6\5?\
M!-'Q=X$UW1O$7PA^)=Q%?:#,]QI6G>(AOCM68\B-P&49'7]WS@5^A-%4I-"L
MC@O@;<>/+CX8:0WQ,@M+?QJ#,E\MCM\DXF<1LNTD<QA#]3T'2N]HHJ1A1110
M 4444 %%%% !1110 4444 9WB+_D!7__ %Q;^52Z/_R"+'_K@G_H(J+Q%_R
MK_\ ZXM_*I='_P"018_]<$_]!%5]DGJ7****DH**** "BBB@ HHHH **** "
MBBB@ HHHH *@OK&WU.QN+.[A2XM;B-HI89!E71@0RD>A!(J>BFFXNZ%OHSQM
M_P!C_P"$4CLQ\(@%CD[=1NP/R$O%-_X8\^$/_0H_^5*\_P#CU>S45[?]O9M_
MT%U/_ Y?YGG_ -FX+_GQ#_P%?Y'C/_#'GPA_Z%'_ ,J5Y_\ 'J/^&//A#_T*
M/_E2O/\ X]7LU%/^WLW_ .@NI_X'+_,/[-P/_/B'_@*_R/&?^&//A#_T*/\
MY4KS_P"/4?\ #'GPA_Z%'_RI7G_QZO9J*/[>S?\ Z"ZG_@<O\P_LW _\^(?^
M K_(\9_X8\^$/_0H_P#E2O/_ (]5W1OV4_A7X?U6UU*R\*1I=VLBS0O)>W,J
MJZG(.UY"IP?45ZS14RSS-9)QEBZC3_OR_P QK+L%%W5&-_\ "O\ (****\0]
M *^#O^"MW[._B;XO_"?PQXO\(VEQJ6K>";FXN)K.SW&<VLRQ^9+&HY9D:")L
M#G;N(Z<_>-% 'YF^ O\ @MAX/C^']J/&/@C7Y/&D-N$F&D"W-C<R@8+[WD5X
M@QYV['VYQDUC_P#!.[PKXW_:2_:T\8?M.^*M*;1]%F2>#3S\P2>9D2!(HB>9
M$A@0HS]"VT#G<%_0S6OV?_A?XCUO^V=6^&_A'5-8W!_[0O="M9KC<.A\QHRV
M?QKN;:VAL[>."WB2""-0J1QJ%50.@ '04 ?D%^S3^SS\/_VC/^"@'[2.B_$/
M0/\ A(=,L=7UF\MX/MMQ;;)?[5*;MT,B$_*Q&"2.>E?I)\&OV2?A#^S]J$NH
M> O UAH6I21F%K]I);JY"$Y*"69W=5)QD @' ST%=MX?^%O@OPEXDU3Q#H?A
M#0=&U_56=M0U73],A@NKQG?>YEE10TA9_F.XG)Y/-=10!P/[0'_)!_B1_P!B
MUJ7_ *2R5\J_\$</^31;G_L9;W_T5!7W!J&GVNK6%S8WUM#>V5U$T,]M<1B2
M.6-@0R,IX92"00>"#65X-\!^&?AUI!TKPIX=TGPQI9E:8V.C6,5I 9& #/LC
M55W$ 9.,\"@#\X?V;?\ E,%\9?\ KPOO_0K2O+?"'Q'U[_@E9^U;X_T_Q5X9
MOM9^'_BZ4SVMU9, \]NDLCV\L18A'=!*Z/&Q!!;.<8+?K+IOPM\&:+XPO?%N
MG^$=!L?%5ZK)=:Y;:9#'?3JV-P>=5#L#M7.3SM'I6AXI\'Z#XYTF32_$FAZ;
MX@TR3[]EJEI'<PM]4<%3^5 'YH>,?^"I'CSX_?%#P;X,_9O\+W=G=W5UBZ?Q
M)9Q2M< X&'2-W$4*#+M('SQV Y_4*U$RV\0N&1[@(/,:)2JEL<D DD#/;)^M
M<[X+^%_@WX;PRQ>$?"6A>%HI?]8FBZ;#9J_.>1&JYYKIZ /RY_X*;?MF7-U\
M1(_@%X<\3KX+T;,*>+?$Y6:38LJA_LX6%6D*+&RLX0$N6V< -N]B_8-^)7[*
M?P[.F?"[X0^,6U_QEK@9[F]NM'O8+K5)88I)69Y)(%1%1%E*IN  R!N8DM]/
M^(/V</A+XLUJ[UC7/A=X+UG5KM_,N;_4/#]I//,V,;GD>,LQP!R32^'_ -G'
MX3>$]5BU/0_A?X,T;4HDDCCO-/\ #]I!,BNC1NH=(P0&1F4C/(8@\$T ?E9^
MVI=:Y_P4&_:*\0Z7\*-$M]7TCX9Z)<^?K$:?/J#(Q9XTD ._<X9(8_XB)&!P
MQQ]U?\$X_P!IK2?V@O@#I>FK#:Z9XH\(V\.D:GI=L@C141-L$Z(,!4D5.@ "
MLKJ. ,_0W@?X7>#/AC!=P>#O".A>$X;ME>XCT/38;)9F4$*7$2KN(!.">F34
M/A;X1>!? VNWVM^&_!7AWP_K-^&6[U'2]*@MKBX#,'822(@9\L QR3DC/6@#
MX%_X*W_\E:_9=_[#=]_Z/TRO0/\ @K_\*=6^(7[,MEK6C64M]/X6U9-1NXX8
MR[K:-%)'*^!SA2T;-Z*&)X%?87B[X9^#_B!=Z7=>*/"FA^)+K2G:73YM7TZ&
MZ>S=BI9H6D4F,DHA)7&=B^@KHW19$9'4,K#!5AD$>E 'X_?MF_M9>%/VSO@?
M\'?A=\.([S5O'=_J]E<WFE_8Y8_L=PMM+!Y)=@%?+SD[D+ *A)(Z5^JVE_#7
M1!\,-*\#:UI=AKVAVNFVVG36.H6ZW%O.D*(JAHY 0PR@/S \@4WPO\'O 7@C
M6KC6/#O@CPYH&KW(Q/?Z7I-O;3RYZ[I$0,W4]3WKKZ (+*RM]-LX+2T@BM;2
MWC6*&"% B1HHPJJHX     Z8K-\)>"_#W@'18]'\,:%IGAS2(F9X]/TFSCM;
M=&8Y8B.-0H)/)..:V:* ,'QYX,TWXC>"=>\+:S")]*UFQFL+F/'6.1"C$>A
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M6UI<^J)"(&6.8L&5Q*R#(&3UQ^X^GV%OI5C;65G"EO:6T:PPPQC"HB@!5 ]
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M'O"^I_LN>,?$'Q8B$-GJVFVNKW\2RRJ LDL:K<F0.Q^;RO*4 MC=@ G]RZ*
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M'CG_ ()N^$_#=TVRVUC3M;T^5L9PDM_>QDX^C&OC'X-?M*>(OV&?@_\ $KX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.\1?\@*__ .N+?RJ71_\
MD$6/_7!/_0147B+_ ) 5_P#]<6_E4NC_ /((L?\ K@G_ *"*K[)/4N4445)0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!EHLNX7\C;HK$_L[6_\ H+Q_^ RT?V=K?_07C_\  9:++N%_(VZ*Q/[.UO\
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M7\C;HK$_L[6_^@O'_P" RT?V=K?_ $%X_P#P&6BR[A?R-NBL3^SM;_Z"\?\
MX#+1_9VM_P#07C_\!EHLNX7\C;HK$_L[6_\ H+Q_^ RT?V=K?_07C_\  9:+
M+N%_(VZ*Q/[.UO\ Z"\?_@,M']G:W_T%X_\ P&6BR[A?R-NBL3^SM;_Z"\?_
M (#+1_9VM_\ 07C_ / 9:++N%_(VZ*Q/[.UO_H+Q_P#@,M']G:W_ -!>/_P&
M6BR[A?R-NBL3^SM;_P"@O'_X#+1_9VM_]!>/_P !EHLNX7\C;HK$_L[6_P#H
M+Q_^ RT?V=K?_07C_P# 9:++N%_(VZ*Q/[.UO_H+Q_\ @,M']G:W_P!!>/\
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MX7\C;HK$_L[6_P#H+Q_^ RT?V=K?_07C_P# 9:++N%_(VZ*Q/[.UO_H+Q_\
M@,M']G:W_P!!>/\ \!EHLNX7\C;HK$_L[6_^@O'_ . RT?V=K?\ T%X__ 9:
M++N%_(VZ*Q/[.UO_ *"\?_@,M']G:W_T%X__  &6BR[A?R-NBL3^SM;_ .@O
M'_X#+1_9VM_]!>/_ ,!EHLNX7\C;HK$_L[6_^@O'_P" RT?V=K?_ $%X_P#P
M&6BR[A?R-NBL3^SM;_Z"\?\ X#+1_9VM_P#07C_\!EHLNX7\C;HK$_L[6_\
MH+Q_^ RT?V=K?_07C_\  9:++N%_(VZ*Q/[.UO\ Z"\?_@,M']G:W_T%X_\
MP&6BR[A?R-NBL3^SM;_Z"\?_ (#+1_9VM_\ 07C_ / 9:++N%_(VZ*Q/[.UO
M_H+Q_P#@,M']G:W_ -!>/_P&6BR[A?R-NBL3^SM;_P"@O'_X#+1_9VM_]!>/
M_P !EHLNX7\C;HK$_L[6_P#H+Q_^ RT?V=K?_07C_P# 9:++N%_(VZ*Q/[.U
MO_H+Q_\ @,M']G:W_P!!>/\ \!EHLNX7\C;HK$_L[6_^@O'_ . RT?V=K?\
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MKXGT/QCH,/AGQ]X2OQIVLZ?:3&:U<L@DBN+=S\QBD0Y&X9!!'.,T >Q4444
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MMZW?0Z9I.GPM<75Y<-MCAC499F/H!0!I45\[?L^?M8C]H+XP>.M!TO1)]/\
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M&-U2;@ ?,#D=:]JL;&WTRS@L[2".UM+>-8HH(4"I&BC"JH'    P* )Z***
M"BBB@ HHHH **** /F+XE6__  N']L[P)X+N1Y_ASP'I;^,+ZW()274)',%D
M'!X.P"61?<5ZS\:OC;H_P5\/VMS=VMUK>NZG-]CT7P[IB>9>ZI<GI%$O8#JS
MGY5')/KL:1\+_#^A_$7Q!XYM+65?$>NVMM97UPT[LKQ0;O*54)VKC>W0#.>:
MXKXR?LH_#[X\>*=)\1>++;59=7TJW:UL[C3]7N;(PHQ);'E.O)S@GJ1Q0!0_
M9]^$/B+0_$7B7XF?$.6UD^(OBQ(8Y[&Q.^VT:SBSY-C$_P#RTV[B7D_B8G'
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MPA^&?C2T\4:%X9>+4+%Y)-/AN;Z>XM=/=\[FMX)',<1Y/*@8SQ7N5 !1110
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M^SQ\.OAK^T!J'QF\0?#CQ;\5?%/BO4/"U]X<_M[QP8C97BSQ!4*RK"C;@RJ
MK$$#/R]*_2N]L;;4K=H+NWBNH&ZQS('4_@:;8Z;::7;B"RM8;2 '(C@C"+GZ
M 4 ?B+\,?%WPX\+?!.;X:?%/QU\;_#WB6&ZDTN^^'V@2Q"SF1Y<$QQ20$8Y)
M96;)(.W.17K/[<WP9T2/PK^R/\--!O\ 6K'0KRYDTVUO-<A']H017$MOAI8P
ML8WKYGW<+T K]6IO#^EW%\M[+IMG+>*05N'@0R#'3#$9J6\TFQU":"6ZL[>Y
ME@;=$\T2NT9]5)'!X'3TH _/[]C^ZF_8W^/_ (Q_9K\37,M[X;U2-]=\(7UP
MF9+Q2A\R#@ ,[*A^4#[T;#N!7SIXNT7X->'9/&OB[X._&;QG\"?%^GSW++X(
MUB"6*2]EQE$MXE99%20_*-WF$<@@#BOV,N-)L;N\ANY[*WFNH/\ 53R1*SQ_
M[K$9'X5#=>&])OKP7=SI=E<70P1/+;HSC'3YB,T >3?L;^+O'_CK]G/PAK?Q
M,M3:^+;J!FG\R#R9)(]Y$4DD>!M=DP2,#KT%>U444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5Q/QPU"ZTGX+>/[ZQN9K*]M?#^H307-O(8Y(I%MI"KJPY5@0"".
M017;5P/[0'_)!_B1_P!BUJ7_ *2R4 ?E'_P38_;S\5Z'\;HO!WQ.\9ZSXET#
MQ68[.UO=?U&6\:PO02(=KRN2B2%MC <;C&3@ FO7_P#@L;\7O'?PQ\1?"Z+P
M=XU\1>$X[RUU!KE-#U6>R$Y5X I<1.NXC<<9Z9/K7RQ\"?V4V^/O[#/CKQ5X
M>LVE\=^#O$DMY:>0I\V[M/LENT]N,<LP"^8@Y.Y2H^^:Y#]JW]J-_P!IKX5_
M!A]7F,OC+PW:7^F:P[#FX(-OY-S_ -M$'/\ MJ_ &* /W\\4>*]&\$:!>:YX
MAU6ST31[-/,N+Z_G6&&)?5F8@#GCW)KPCP__ ,%$OV=/$WB1-"L?BEI@OWD\
MM6O+:YM;<MG&!/+$L77OOQ7R3_P5P\0:IXT^,WP4^$+WLNG>&-8N8KF[>,@"
M26:Y%LKG(QF)-Y';]X<CI7M?[6O[#'P5TO\ 9,\:G0O VC^'=2\+Z#<ZGI^L
M65NL=X9+:$R!99\;YMX3:?,+9W9&#@T ?:J.LB*Z,&5AD,IR"/6N<^)'Q&\.
M_"/P3JOB[Q9J']E>'M+C66\O/(DF\I6=4!V1JSGYF4< ]:^5?^"2OQ*UGXB?
MLCVL&M3273^&]7N-#M)YN6:V2*&6-<]P@G*#T" =J[S_ (*._P#)D_Q3_P"O
M&#_TJAH FU+_ (*)?LZZ3X<T;7+KXFV*V&KJ[VBI97;W#*DKQ,SP+"98AOC<
M R*H.,C(P:Z+QC^VE\$/ ?@O1/%FL_$;2(M"UI6;3I[7S+M[D*VURL4*O)\K
M?*WR_*>#@U\,?L?_ ++OPT\5?\$W_&?B_6?">FZKXJU/3=:N%UF\MDEN;-K=
M94A-N[ F+:8@WRXR2<Y'%9__  2/_9K^''Q=^%GCWQ!XX\*:;XLO/[2&CP+J
MT F6U@$*R,8@?N.S2GYUPPVC!'- 'Z9?"OXO^#?C=X53Q)X&\0V?B31FD:$W
M%HQS'( "4=& 9& *G:P!PP.,$5\N?LAZII%Y^TU\58+']HWQ!\5+N,WGG>"]
M3T[48+;0\7H!$4EQ(T3^6?W0\M1D'(XXKP+_ ((JRSZ3XN^-V@)<22:?;O8,
MD<AR-ZR72;L= 2,9QUP/04G_  31_P"3^/VB/][4_P#TZK0!]Q7'[;'P2L_&
M/BWPM>>/K/3];\*12RZS#?6UQ;QVRQRI$X$LD8CD;S)44*C,6+< \U/\'_VR
M_@Q\>O$4F@^!O'MCK&M*&9=/DAGM)I0H)8Q+/&AEP 2=F[ !)XK\WO@_\&O"
MWQM_X*O?%+2O&&F0ZUHVFZAJVJ'3;E=T%Q(DRHBR+_$H,N[:>"5 ((R*O_M1
M?#CPY\"_^"I'P+@\!:19^%++5KK0KN>STJ%8( \VI2VTH2-0%4/$@!"@#D^M
M 'U+^TYJND6O[:'PGMKO]H[Q!\.;^3^R?)^'.GZ=J,UGKV=1E"^;+#(L">><
MP-YBG"Q@ME<"OH#XF?M2?"_X.>/?#W@SQEXJCT+Q'X@\K^SK6:SN'2422^4A
M:5(S'&-X()=E QDX'-? '[?7_*4W]G+_ +ES_P!/EQ69_P %7/#-IXT_;,^"
M/AZ_+BQU:TL["X,9PWERZBZ-@]CAC0!]U^&/V\O@%XR\=P^#M'^)FE7FO3S"
MWAC\N9()I"<!([AHQ"Y)( "N<D\9I-8_;T^ .@^/9/!M_P#$[2+?7HIOL\JE
M)C;12!MI1[D(85(((.7&,<XKX!_X*]_ 7P!\&]#^$U[X%\*:7X2ED>^LY_[(
MME@-PJ+ T;2E1EW4EOG8ECN.2>,=-_P48_99^&?P?_8K\#:EX5\*:=I&N:?J
M-C;2:Q;P*MW>I);2F3SY/O2;G"O\Q."N%P,B@#])/BM\7?"7P1\#W?C#QKJW
M]C>'+1XTFO1;RW&TR.$3Y(D=CEF X'>G>#/BSX4^(/PUMO'^@:K]O\)7-M+>
M1:A]GECW0QE@[>6Z"08*-P5R<<"OA']I[5+K6O\ @CWX5O+V9KBZDT/PZ'ED
M)+.1);KDD]20.2>IKV/]C3_E&SX:_P"Q9U+_ -&7- 'LWPE_:@^&7QT\*Z]X
MD\#^)O[;T70R1J%S]@NK?R,1F0_++$C-\H)^4'\ZX6'_ (**?LZW'A&3Q,OQ
M-L4TF.Z:SS+8W<=P\H17(2W:$2N '7+*A49 SGBOC_\ X)*_\FL_'?\ ZZ2_
M^D+5SO\ P2!_9S^'?Q5\+_$+Q)XT\*:9XLO+>[ATVVAUBU2YAMXS&7=D1P5#
ML2OSXR O!&3D _06']M+X(S_  P?XA)\1M(_X1-)Q:M>$R"43E=PA^SE?.\S
M;\VS9NP,XQ70?!7]I+X:?M$6-[=_#SQ;9^)$LBHNH8TD@G@W9VEX95610<'#
M%<'!P>*_++_@F9^SOX%\??M.?%&Q\4Z%:>)=(\*)-'I^F:M$+BVWFY:(221O
ME7*HA W CYL]0".V_9 \-V'PK_X*O_$KPIX9@&E^'UM]2@2QA)$:1$PS",#/
MW5;&!V % 'ZQ5Y7\:/VI/A5^STUK'\0?&EAX>N;E/,ALV62XN73)&\0PJ\FW
M((W;<9!&>*]4K\]_VE&_9CTS]K>/4=:\(^)?B[\89(52?P;H=K_:ULQ\@)'Y
M\$Q\M=L8#;%.%!WLG() /JWX+_M9?"3]H6\N+/X?^-K+7[^WC,TECY4UM<B,
M$ N(ID1RH) + 8&1ZBMSXQ?'SX?? '0H=7^('BFR\-V4S%(!<;I)IR,9$<,8
M:23&1G:IQD9K\HOA;:IH_P#P5H\)&P^';_"*"YF,J^%UDB!MT?3),G;#\D8D
MY8QKP-V*[3XK^'+3]I;_ (*_VW@?QNGVWPIHJ1PPZ7<.P66*'3OM?EXSR'F8
ML0,90F@#[8N/^"BW[.EMX4@\1M\3+-]*FN?L@,-A>23I)M+ / L)EC! ;#.H
M!VD D@UZ#\9/VE_AM^S_ .']'UOQ]XC_ +!TO5Y/*LI_L-S<^:VS?C;#&[+\
MO/S 5^9'_!8/]GGP!\)9_AUXA\%>&]-\*3ZL;RSO;+2;9+:WE$0A:.01( JL
M-[ D#YLC/(Y]+_X+)?\ )O\ \'_^O\_^D@H _0SQG\6?"GP^^&MSX_U_5?L'
MA*VMHKR74/L\LFV&0J$;RT0R')=> N1GD4WX4_%WPE\;O ]IXP\%:M_;/AR[
M>1(;TV\MON,;E'^25$8892.1VKYV_;+_ .4;/B7_ +%G3?\ T9;5\FZ#X^U;
MX?\ _!%L3:-.UI=:IJ-QI3W$;8=(9M1D$H'^\@9/HYH ^XM6_P""AG[.NA^+
M&\.77Q2TK^TED\IG@AN)K56R1S=)&80..N_ KW_2M6L==TVVU'3;RWU'3[J-
M98+NUE66*5",AD=20P(Z$'%?B-\)]0B;]FN#PK#^Q#KWCJXU.QE(^($%M<R7
M-Q+)NVW$$RV#%%0E=J))MPG.<DGT[X2^-_B[^S]_P3+^,&F:]H7B3PCJ>G:C
M#9Z,^MZ=<64EO:WTD4<QA,B+P&:8@J<J\N>.,@'WIX\_;^_9^^&GB:7P_K_Q
M,TV+589#%-#96]Q>K"X.&5W@C=$8'@AB",'/0U[#X#^(7AKXH>&;7Q#X2URQ
M\0Z)<Y$5]I\PEC)'#*2.C \%3@@]17PY_P $Y?V-_A'XA_9/\.^)O$_@K1?%
MVN>)Q<SW=YJUJERT*K/)$D<)8'RMJQC)3#;BW/3'F7[ WG_ 7_@H3\6_@UH%
MW//X'D%X\5G(YD$+0NC0.2?XECD:(M_%QGH, 'W[\,_VHOAC\8/'WB+P5X1\
M3?VOXF\/&4:G8_8+J'[/Y<ODO\\D2HV'./E8YZCCFC7_ -J#X9>%_C)IGPIU
M/Q-]F\?:D(S:Z1]@NG\S>"R?O5B,0R%/5QTKX"_X)H_\G\?M$?[VI_\ IU6G
M_'O_ )3)?#7_ *YZ?_Z)FH _0#XS?M,_"_\ 9[AM7^(/C&Q\.272EX+60237
M,J@X+K#$K2%<C&[;C/&:S?@S^UU\(/V@M2ETWP#XXL==U..-IFL&BFM;@Q@@
M,PBF1&8 D9(!QD5^??[>7P@^)'@']LV7XUCX7Q?%_P  S6UMMTV\L7O[.!8[
M989(IXDR4PZM*KLI3,@^\<BLK]F+XZ?LQ?$;]J+PMK]]\--2^#_CXSPV>F6V
MBWJIH8O-S(N4B2)D>3>$*E?+(&&ZDL ?KS7YM?\ !33XL>-O /[2'P-TWPUX
MRU_PYIFH.GVVSTK5)[6&Y'VR-3YJ1N%?Y21\P/!(K]):_)W_ (+$:#'XJ_:
M^">BRRM!%J5NUF\J %D62[C0L,]QF@#[CN/V^/V?K3QU_P (A+\4-'&M^=Y!
MPLS6HDSC:;H)Y .>.9*]$^,7QQ\$_ 'P>GBGQYK?]A:"]S':+=BUGN<RN&*K
MMA1VY"MSC''6O@#_ (*G?LO_  M^$_[+?A_5/!O@K2?#6IZ;K=K9)>Z=:I%/
M/"\,P99Y -TN2JMN<DY'7DYI?MG:I=:Q_P $F_@Y>7L[W-U(FA;YI#EGQ9RC
M)/<X')/)H _1>V^+GA.\^$Y^)<6J[_!(TE]=.J?9IA_H2Q&5I?**>9P@)V[=
MW;&>*YKP#^U)\,/BA\*_$?Q'\,>)O[3\&>'?M/\ :FI_8+J+[/\ 9X%GF_=2
M1+(VV)U;Y5.<X&3Q7BWAO_E%#-_V26Z_]-<E?-/[ O\ RBR_:-_[F/\ ],=O
M0!]C3?\ !1+]G6#PA;^)I/B;8II5Q.]M$#8W?VEW3;N(MO)\[:-P^?9MZ\\'
M'1ZE^VC\$=)^&=IX_N?B-I \*W4S6T%W&9))9)E +1B!5,V]0RDKLR P) R*
M^%?^"3?[+_PT^+GP"\=>(O&/A/3/$FJW6M3:''-J=LLYM8$M8) T.X'RW+7#
M'>N&^5>>*\__ ."/?P'\#?&+Q!\2]4\;>'-/\4KH5O8P65EJUNMS;1FY-QYD
MGE/E2^+= &(R,G&* /U5^#?Q\^'W[0&@W&L?#[Q19^)+&V<1W'D!XY8&(RHD
MBD59$R <;E&<''0U5^,G[2'PS_9^M+>?X@>,=/\ #9N5+P6\Q>6YF4<%D@C5
MI&4'C(4C-?G5_P $T=,A\ _\%"_CYX)T8-:^';"#6+>"T#$J%M=6AA@ZGG:C
MN,GGDU0_9/\  VC_ +8_[?7QB\3?%.QA\20Z"]Q]BT6_&^W4+<_9X$:,\,D4
M2$;2,%F#'GJ ?HK\&?VKOA+^T%<36W@#QOI^O7T*&1[';);700$ OY,R)(5!
M(^8+CD<\U-\5OVG_ (9?!'Q9X=\->-_%":%K/B!@NFP26=Q*LV9!&"9(XV1!
MN8#+LH'7IS7YQ_\ !3CX6^'/V2?BE\)/BI\)],LO!.MR75PTMEI40M[9Y+<P
MLCK"F%4,LKHZJ &4@$<G+O\ @K]IO_"<?&KX':?\UK_;%@8/FZQ^;<QKSQU&
M[]* /T1^$/[67PG^/7B?5?#W@'Q?#XDU;2XC/=0V]I<(BQA@N]9'C5'7<0,J
MQZUZVS!5))P!R2:X;X7_  ,^'WP7L1;>"/!NB^&2T$=M-<:?8QQ7%RB#Y?.E
M WRGDG+DG))[UJ?$Z/P[-\.?$\7BZ\73_"TFFW$>J73736PBM6C82MYJD,GR
MD_,"".U 'BGB;_@HS^SCX1U^;1M0^*&GO>POY;FQL[N\A#9QCSH87C//<-BO
M3]0_:"^'FG_"&X^*+>*;.Y\!01":36K%7NHPID$?W8E9R0Y"E0N0<Y P:_-2
MQM?V?;WX%_$;1/@M^S[XH^*-G]FOI7\>:YIUO##I["$D-#?38E01 !_+"JWK
MDM7I?_!''P_I?C3]E_X@Z#XATVTUW0[CQ,PFTS4X%N+:0?9K8_-$X*GE5/(Z
MJ/2@#Y>^'_[27C?]ISXZZS_PD7[3?B/X1I>ZBD/AS3]+M;ZXMKMY9RD-N(;=
MD1%4; 7FZ[AG/S$?37@+XJ>-Y?\ @KQKW@F?QIXBN?"%O',(]!GU6=[$;=+1
MP?(+>7G?EON_>.>M>:_\$C/AOX2\7?%OXP2Z[X6T76I=%GLYM,?4=/AN#8R"
MXN"'@+J?+8;$Y7!^4>@KHO '_*;3Q-_NW'_II2@#WS^U=(_X>3?8O^&CO$']
MJ_\ 1'/[.U'^SO\ D#Y_U_F?9?N_Z5]S[W'W^:\A^*'QR\3^$?\ @K/I6@WW
MC_5]&^'MO!%<7NESZS+#I4<8TMY'>2(N(@H8;R2.HS7/?\YU_P#/_0L5RO[2
MOPST/XQ?\%>-)\(>)8FN-"U$V'VN!7*><D=@)?+)'(#&,*<8."<$&@#]"?AS
M^W)\"OBQXR3PIX7^(NFZAK\C^5#:2PSVWVA^<+$\L:)*QQT0DFO6/&WCGP_\
M-_#-[XA\4ZS9Z!HEFH:>_OYA%$F3@#)ZDD@ #DD@#)K\R_\ @K9^S;\/?A'\
M+_!'CWP)X:TWP5KD&NQZ4W]@VZV:RHT$TRR%8P!O1K<8?&[YSDGC'G__  48
M^,7B#XF:7^S!I.IV%YK5EK7AK3O$U]H=C*R2ZE=W0C5HEVH2'P'1"%)!F;"]
MJ /T8^&O[=GP'^+GBF/PYX7^(^G7FM2OY<-K=07%D9WS@+$T\:+(Q[!"2>U=
M?\;_ -H[X=_LXZ3INI_$3Q#_ ,(]8ZC.UM:R_8KFZ\R15W%<01N1QW( K\B_
MVC=+\0_&/P?HVF^"_P!A_P 4?"?7=*NDEBUS1-*O&DDB"D&.14L8O,).QA(S
M%@4X/)KU;_@IMK?B'Q'^QC^SSJ/BZTO+'Q3.8SJL&H6[P7"W0LP)?,C<!E8N
M&.".] 'Z!^"_VQ/@[\1/B>WP\\->-K;6?%Z^9FPM;6X*_NP6D F\ORB5 .0'
MXP:I?%C]M[X'?!#Q%)H/C+X@V.FZS$0)K&VM[B]EA)&<2+;QR>6<<X;!Y'K7
M!^ /@[X*_9;_ &0;CQGX2\(:);^-=$\!3ZD^O)81F^NKA;$SN7G*^85:1<[<
MX P   !7S'_P28_9W^'_ ,8?A;X[\?>/O#6F^./$-YXAETTR>(+9+T1HL$,S
M2*) 0)'>X;+XW?*.>M 'Z+_"OXR^"/C=X=;7/ OB:P\3:8C^5)+929:%\9V2
M(0&C;!!PP!P<UQ'QA_;.^"WP$UQ=%\<>/;'2-8P&?3X8)[R>($9'F1V\;M'D
M8(W@9!![USWPH_9)^''['MKXY\8> ;'4H]0N[&XGF@O=1DD@\M"TR0K&,+M4
MC:K$%PI(W'<V?RA_9+^(-Y-JGCGQ;K?[,VI_M+:WK%X'N=5DMY+J"R=]SN/+
M%G.@D<MNW'! 4!<#.0#]OOAK\5O"'QB\-QZ_X*\16'B32';9]HL90^QNNQU^
M\C=/E8 \CBO+F_;P^ T=UXJMI_B)96<WA><VNJK>6EU;^5,'>/RT+Q 3-NC?
MY8MQ(4GIS7Q'_P $X= ^(O@?]K_Q;='X1>+_ (7?#?Q797#_ -DZIIMY]CLI
M4820+]HDA0$K^^52P'$A')Q7"_L4? WP=\;?^"@7QD7QKI-MX@T[0[S5[^WT
MN]0202SG41&K2(>'55=_E8$$E2>G(!^G'P6_:P^$O[0UQ=6OP_\ &MEK][:K
MYDMD8IK6Y" @%Q#,B.5!(&X CD<U\1?MP?\ !0V\\'_M&>$/ W@KQI_9?A31
M]4MT\9RVVGRK<1R1W>)X#(R;F01+D^2#NR1N.<5PG[9?P\T#]E']O+X*^*OA
MEIEOX8_M:XMIKG2=-3R+8M]J\F4(B\(DL4FPJH X) R34G_!2/P%X9L?V\/@
MG!;>'-)MX->GL)M7CBL8E749)-3*R/< +^]9EX)?)(X- 'Z??"?XN>$_CAX(
ML_%_@G5?[:\.WCR1P7GV::WWM&Y1QLE17&&4CD=N*^<?^"CG[83_ +,OPM&G
M^%]<@TSXDZOM?3(;BP>X_P!'#[9I58J8@RY& Y_X":^IO"?@W0/ >APZ-X9T
M/3?#NCPLS1:?I-I':V\99BS%8XP%!)))P.2:^,/^"OWA/0[S]E>Z\07&C:?/
MK]EJ5G;VNJR6J-=01/)\\:2D;E5NX!P>] &)\//VPM-^*O[ 7C6'2?'NHZA\
M6/#G@FYOM9NXTNK>ZM+@K)MD6X**I8-C!C8XP,8K)_8+_;4\+_#W]E2/6_C=
M\4;F35KKQ!>16TVN7=SJ5_+$J0<*@$DIC4L>0-H)/K6EX$^'OA7P[_P2DUKQ
M!I/AG1]+U[5OA[<G4-4L["*&ZO,1R$>=*JAI.?[Q-</_ ,$G/V7?AE\1/V??
M$/BOQCX.T?Q;JVH:S/IROK%FEP+:WCBBPL0<'8Q9W)=<-RHS\M 'Z%_"GXR>
M"OCCX67Q'X$\16?B31RYB:>U+!HY  2DB, \;8(.U@#@@XYKRS4/^"@G[/\
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M ().?&A'D9UBT_Q,D:LQ(1?[.W8'H,L3]2:[K_@BI_R:SXI_['.Z_P#2&QH
M^[?$DSP>'=5EB=HY$M965U."I"$@@]C7Y@?\$T_VR+7PC\-?B5XA^.'Q5U&X
MM(;^QAL)?$FIW.H39,<Q=((R7D;HI(13T&:_3WQ5_P BQK'_ %YS?^@&OR,_
MX(^?L[_#_P"+5S\1/$?C7PWIWBNXT@V=G966K6Z7-M$)1*TDAB<%68^6@!(X
MPV.M 'Z@_!G]HGX<?M":7=7_ ,/?%EEXDAM2HN(X0\4\&[.TR0R*LB X."5
M.#CH:K?&C]IKX7_L\PVC_$+QC8^'9+L;X+5UDGN95S@NL,2O(5SQNVXSWK\Y
M-+\'Z=^R]_P5VT'P_P" 8O[)\.:^B)/I,#$1)%<VS%X@.?D$J+*J]L*!@"O'
MS\3M1\8?MX?%?Q9KGP2U#]H2>POKVRM/#=NLD\-A##<""&22-;><.J1H$PRA
M=TA;KB@#]A/@W^T3\-_V@--N+WX?>+K#Q)';X,\,):.XA!Z&2&15D0'!P64
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M5H_!O]I#X:?M!6=S<?#[QAI_B3[, UQ;P[XKB%3P&>&15D4$\ E0.#7YL?\
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MQ\+/B?J<G@C6GT];J'P_K$\-I<L=2*2)/$C*"VW"LKKG& 1BN7_8P^'?A_\
M:J_;Q^-/B?XFZ=;^*#I-Q=3VVE:H@FM]QNO)B#QL-KI%$FP*P(Y4D9 K$_;8
M^!G@_P""?_!0'X-#P5I%MX?TW7+W2;Z?3+*,1V\4ZZAY;-&@X165$^50 ""?
MXN #]D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KD?C!H-]XI^$OC;1=+@^U:EJ.AWUG:P;U3S)9+=T1=S$ 98
M@9) &>37744 ?&'_  2Y_9[^('[.?P?\5Z)\0] _X1[5+[73>V\'VRWN=\/V
M>)-VZ&1U'S(PP2#QTKY"_;+_ ."6WQ(N_CIK.M?!WPG%K?A#6C_:'V>/4+2T
M&GW#L?-@"SRH2F[YUVC #A>-M?L910!\G_M^?L5S_M8>%]#U'PWJL6A>/O#3
MR2:9=7#,D4R.5+1.Z@LAW(K*X!VD'CYB1\^>-O ?[>?Q[\$?\*J\6:7X5\.>
M'+I$MM3\517< EOH05W"3RII&PV.0D*;N0>"17Z9T4 >7_LU_ /1?V:/@[H?
M@+1)I+R*Q5I+F^E4*]W<.VZ24@=,DX YPJJ,G&:P?VUOASXB^+G[+OC[PCX3
MT_\ M7Q#JEI%%9V?GQP^:RW$3D;Y&5!\JL>2.E>W44 ?(7[+'P&\=?#?]@'4
MOAMXBT/^SO&DVF:U;IIGVN"7,EP9_)'FH[1_-O7G=@9YQS6;_P $N?V>_B!^
MSG\'_%>B?$/0/^$>U2^UTWMO!]LM[G?#]GB3=NAD=1\R,,$@\=*^SZ* /@+_
M ()G_LN_$[]GWX@?%K4O'WAG^P;+76MSITOV^UN?/VRW#-Q#*Y7 D3[P'7ZT
M?L._LN_$[X/_ +77QF\:^+O#/]D>&?$+7QTR^^WVLWVCS+\3)\D<K.N4&?F4
M8Z'GBOOVB@#X"_9U_9=^)W@3_@HI\4/B?KGAG[#X&UI=3%AJOV^UD\[S;B)X
M_P!TDID7*JQ^91C'.*;^UY^RW\3_ (H?M]?!7XC^&?#/]I^#/#O]B?VIJ?V^
MUB^S_9]5FGF_=22K(VV)U;Y5.<X&3Q7W_10!\ ?M>?LM_$_XH?M]?!7XC^&?
M#/\ :?@SP[_8G]J:G]OM8OL_V?59IYOW4DJR-MB=6^53G.!D\4[]N+]EWXG?
M&#]KKX,^-?"/AG^U_#/AYK$ZG??;[6'[/Y=^9G^2257;"'/RJ<]!SQ7W[10!
M\(_\%4_V9_B3^TCX<^'EK\.?#?\ PD4^DW=Y+>+]NMK7RED2((<SR(&R5;[N
M>G-=C_P4,^ WCKXY?LKZ/X/\$:'_ &WXCM]3L;B2R^UP6^V..&17.^5T0X+
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MO''Q6U/PS]F\ ZDEX+75OM]J_F;XXU3]RLIE&2IZH.E??=% !7YH?$O]E/\
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MVM%\/NAU*Y^WVMOY&+J.0_++*K-\JD_*#T]:^^Z* "O-/VE/A#)\>O@7XR\
MPZ@-*N-;L3!#>,I98Y5973<!SM+(H;'."<<UZ710!^6/P;_9U_;/\)_"G4?@
M)%8>%_"OP_O)+B";Q9-<Q7%Q';3D^>L CE+D,&<C?$K?-]].,>X_\$N?@'\3
M/V<? _CGPO\ $3PM_8(N-5CU"PNTO[6Y2Z#1>7(!Y,K,N/*0_.%SO]B!]NT4
M ? 7_!,_]EWXG?L^_$#XM:EX^\,_V#9:ZUN=.E^WVMSY^V6X9N(97*X$B?>
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M-)6:1HHI;90A2(2*"8W1HU9&QC)8'&05^S** /S^T'7/^"A?BK5-'TR^\/\
M@7P9:V<BBYUJY:WF6]4 @F5(YYFY^]B-(^<=!D5M?\%./V;?BA^T1\*?A[I'
M@O18O%>NZ7?M/J307%O81\P;3(JSS#"E\X4,Q /4]:^YZ* .4\.>$TN/A9I?
MAG7;17C?1HM.O[1V# @P".1"0<$?>'!K\[/ O[,_[5_[#?B;Q1IOP.T_P_\
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M(;;[7!<[H&M;2-7W0R.HRT4@P3GY>F",_8%% %#7[66^T'4K>%=\TUM)&BY
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M(?VBKCPEXZ^'>JV^C_$CPD^;0W4GE)<QK()8P),'9)'("R$C:=[ D<$?9-%
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MT\+:W<^,O$*ZO8:@!J,L&G0W$C0R7E^JJTGV.**&V$20@LL00$YX'T9^S_\
M$KXO?$+P3XGN/$-M\.]9O5@,GAKQ5X(U=[KP_J<I5U,,F6>=#%*@#N 00Y"C
M*'/':?\ !#]H'PS\'_A/%X;\6>#=&\>>!;>;3)=#C-__ ,(SJUDT:0Q"X (E
M:6-(DD#[!B1G VJQ)VO@E\#_ (J?"C0/&&NR7O@8_$'QIXDM]6U;3M-M;FWT
M"Q@4I%.;91B1[B2%&D+N%W2N-V=I=P#Z&\.?VL/#VEC7S9MKOV6+^T#IH<6Q
MN-@\WR@_S>7OW;=W.,9YKY^_8YSXJUCXV?$.0;V\2^.;RVM9CR7LK!$LH.>X
MS%)C'0&OHC51>-I=X-.,0U PO]G-P2(_,VG9NP"=N<9P#Q7Q7\%?A)^V)\#/
MAOHG@?0[CX&W&D:7YNRYOWUF6YD:69YI'<JJ*6+R.> HYH ]-\6,?''[>W@/
M2<;K7P+X/U#Q [@ @7-],MG&I/9O*BG/;AO>E^)Y7QU^VU\'O#*YD@\):)JO
MC"]B)^3=+LL;1C[AGN"/H3_":;\5?@W\7]"^,^I_$OX+:UX,_M#7]+M=*UG1
MO'5M=&VQ;-(T4\,ML=X;$I4H1MZG). K?AU^SY\1-$T+XH^,/%GBC2->^-7C
M/3)+&WGM(Y(-&TB-(I!:6D.5:0PK+(6:0KO8$94LI9P#QO\ 9)\7:OX2^)4/
MCW5;R:7P7\=M<UA[7[01LL-1@NIS8(K?W;BSC=5]3;+SR,^@_!3XE:)\/O ?
M[0WQT\1R^3I%YXOU&9)OES/:6*QV%NB$=6>2%U7WD ]SW%_^S+-_PR7X;^%^
MG7MK;>)_#.FZ?+H^KD$10:O9[)8;C(7<$,\?S$+NV.PQDUQ'AK]CO7I/ /P2
M^''BFXT*^^'OA%'U?Q181/+,=>U<L\B1&-XE1K432RS-YA/F-L!C7&: /'_V
M0_%.DM^U%X4\3R>--!\3^,_BCX8U;4/$MKHVI07G]GWBSVL]M:,(W<QB"V!A
M4,<'RY".<X^]?B%XN'@'P+K_ (C-LEX-*LI;S[/)=PVB2;%+;6GF98XEXYD=
M@JC))P*\=\1?LE^&M$^*GPN\:?#3PGX1\%7?AK5KB753INFQ6#WEC-9S0/&/
M)B_>.&=" Y 'S'(.*ZC]J?X.ZE\=O@MJWA31[O3[;57N;._M8]9B:73KJ2VN
M8YU@NXU!+P.8]K  XR#AL8(!X-\%?VQ/'_B3XW>#_"?BK5_@]XHTOQ;]KCM[
M3X:Z[-J&HZ,\5NUP&O"6:-DVH8R4V@LVX' P1?VK?C1X@^/'BKPQX;T/X=R6
M?A_6FL&\ ZMJ5Q9>+]0M$(S=VQF*6SH\9-PI&5$>%+$X)?\ !/\ 8_\ B%X=
M^-F@^./%UK\+_"VF:?I>HV*Z%\+]+ETR*"XG6-%NU=HPTLK('4ER!&$38"68
MA++]E_X^>*=2\!>&?B%XT\$Z[X'\%:U;ZM8^+(;6[D\67@MI=\2R/*3'$T@"
MK(Z,6PO)?+9 /J#XQ?%#2_@M\,?$7C;6(YKBPT>V,YM[9<RW$A(2.%!_>>1D
M09XRPKY^\/\ QT_:#\%^-O UU\6O!?@O3O _C75$T:UM/#MY<R:OHEU.&>V6
M\:3]S, $:-S$ -QW @ (WMW[0OPD/QT^#OB+P4FIG1;G4%AEM=1$0E^SW$$\
M=Q#(4)&X"2)"5SR,BO(O!/P2^-OQ#^)/A/Q-\=O$O@YM*\&SG4-(\.^!H+GR
M+V_,4D2W=W)<@,&B61MBQC!+Y^4 AP#R[X$_"GQC\;OVT/''Q8^(^F>$=3L/
M!>IR>&M&NM/NM12XLI[9 R"WC+K$\9%T_FM*&_>AO+"C)KZ9_::U[QEX9^%>
MOZMX4UC2_#-MINEWNH:EKEY"US<VL4,#.JVMN<1M(Q!&^1]J8!\N7=@3_LV?
M"O5/A'\-&TOQ!/9W?B74=6U'6M6NK&1I(9;BZNY9B59D1CA71<E1]VE_:<^%
M^L_&GX)^(? ^AW=I87.N&WM;BYO)'14M/M$;7.W8K$N85D51@ LPR0,T >(7
M6A^*OAS_ ,$U[+1-"TW5M?\ '&L>&XK=H-/B>\O9;W4F#7<W7+,K74\K.Q ^
M0DGO7GG[*'P\^&_P5^.TMAKO[/5]\&?'-IX?N=5TC6;KQ4^MPZA91D173$K*
MT,,P#(2@W85VY4;=_P!8?'WX?>-_%WA/19/AEXIA\(^*M U.'4K..[,HTW44
M1'1K&\2(Y-NX?G +*44K@@$>*WG[-/QG^(6D?$'Q3\0/%/A.X^)FK>%KKPIX
M;T_0DN8=$T6"X&+B;?(K3/+*0A+%"5V8!8$! #C?V$]>UWX=ZMH1\2SS/I'Q
MO@OO&EA)<?\ +#6#.\LUN"/^>MD]O*,XR8)2.^$^$/QF\0>$_A;%J'@7P_;^
M)?B5\;/&^O:QH5KJ4GE65M:I,8_MERZ?,;>&"* X4[GWJ%.6%>[_ !B_9ONO
M%G[.OA_P1X1OK72/%'A&&QD\-:G<@K#;7-K&L2[]JL1&\7F1L%4_+(>#TKC=
M;_9;\=^#? _P2NOA9K7ANR\??#;1FT8P^(H9WTK4XIX(8[K>8AYJ'S(1*K*
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M^&^A>/-4TH&.5Y;C4/#MK/(@TXW+.K1Q$_(7Y_=QA,8-:?[(_P .]!\.^/\
MXEK\#[S4M*^"-YID-KI]V\\M[82:]')/'<W6G&X9_-B1%A5Y 3')(FT,PC 6
M?XN_LK_$FP^$_P -?AE\(;KPC/X*\/B237K#QQ<WB)KTI.]1.MJFYXVE>::1
M"X61F4,"@96[BQ^&WQR\;_ _Q#X7\7^)?"7P^\6+);GPYJOPQ6\C@L4A9'19
M4G(W(2GEM&!L,;$8- 'S1X2^#_A;X5_M?_#GPAX,TKQEI7Q0M[R2_P#$WQ'\
M5WMQ#:>,K)+827T=NLDSBZD>2:-F55'EF,L2VTM7Z/U\P>#/A3\8?$'Q.T3X
MC?'GQ)X&M;+P3;W=QHVC^"X[F.S^T30O%+=W<]W\P"0LZA5^7Y@V1L(;V/X%
M^(O%OBSX3^'=8\<VVFVGBB]A::ZCT>*:*UVF1O*:-)B9%#1>6V'PV6.0I^4
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M,%2!D $^L2EUB<Q*KR8.U6;:">P)P<#WP: /SM_9R_X)]_ /XG>(/B]J>I^
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M&_BF^^+VI>-/ASX6^#OB>TURQM+6^TGXI:%)<QZ>]K&(8FLFA1BB/%M5HS@
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M?$=U8^(-%T_XG3?$23X@Z9>2K)<6 DC/E6EM,2@?RQ;*B-M4[6)(W=3#X;^
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M_P (U'\(9=+\3:I>ZU9>,O$NA2W?BK39IQYBP0RE#&B)*!&D@):-#O4;E5:
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M"\9^8D;<:W_99^)G@'X6V,G@GXF)<_%H>)I/%FLZKK4<L.E^(;F:,Q36US#
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MM+;5/MMRDY9"OG%4ACCC0! %*F0C!H R/V=_'7Q=^$/B;X'?##Q3X5\+Z3X
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M7XC>&?V@XKS6M.L]:\?WUB^D.K22V\5G81P&U@N04&%DE282JH<;)FP6)(H
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M7G@C1O$]G8#5]>_LV*!+FX9$+*+FYBS+$') ."1MV   _2&BO@3]E_XG>*/
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M'?#RY\<:WHNI^$_AH^K^(O$UK.)M5^T7WE6KB"YEW&.=_)N )2K%$WXPS(P
M/O2BOG?]AZXUQOAGXLLM6\4:QXQT[2_&6L:7HNL^(+O[5?W%A!<>4IFFZR'S
M$FP3_#MP% "CQC]JKXFS^-OC3>>$M/U7X\3Z)X=BAMKN/X):2L,5OJ,BB1A>
M:D\@#$121GR@H1-P8N6W*H!]J^,?&FB?#_P[=:YXAU&'2M*MRJO<39Y9F"(B
MJ 6=V9E544%F9@ "2!6P[K&C.[!549+,< #UK\XX]#\0_M5? ']E_0?$'C;Q
M9:7VN^(;^>2^L-12&\FTNS^TRPW-PZH5DN8Q!9A9>1OD+G<S9K[ _:0\4O\
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MCZ7$L$DK7%TZ.X3"*VT;8W)=L*,<D9&?$_%"GQO^WSX)TYU+V?@7P9?:X">
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M/<8'FX\N.1>!L60#TH ^FJQ?&/C31/A_X=NM<\0ZC#I6E6Y57N)L\LS!$15
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M8,\#0^#?$NAW_B;QMK]_XG%O!KOB;6M:^UZOJ-E#)O2Q>=XSY<!SM81+&S*
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MSZYXH^)7A'P0UPOB+Q3HN@-;VOVZ8:IJ,-L8[?S%B\YM[#$?F.B;CQN91G)
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M^QCX2^)WCN?QIIOBCQK\,_%=[$L&IZKX!UMM,EU1$"B,7(VNK[ N 0 <'!)
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M3Z5!<?&3P!9ZQ9Z1/XY\-P:K>WLFFVMC)J]NL\]W&ZI);I&7W-*KLJE -P+
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M 20*YS]FWXU-^T/\(-)\?CP_/X:M=5FNA:V-U/YLWDQ7$D*2/\JA6?R]VT9
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M#_$*R^'_ ,./AE>_%3QL^FC6KVQCU6'2K6QL3(T22/<S H9'D1@L0&2%9LC
MSD/^V=9?\*"TCQU#X+U:?Q?JFL-X5MO R2I]I.O*\D;V9G^XL8:&1C.1@1KN
M*AODH ZK]H;]F/2_VB[CPM/J/C3QEX/F\-W$MW92^$-2CLI//= GFL[1.VY5
MWJI4K@2/US6O\#_@:/@C8ZK;?\+ \=>/CJ$D<GG^.-;.I26^T$;83L78ISDC
M') ]*YOX#_M#>(_B-XS\0>"/B!\-KKX7>.-*LH-632Y-7@U2&ZL)7>-)TGA
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M\%_$N'X?ZEJ/B/QD\5MHG@_3;GSI)IYF?R!)<F-5BB*('>5EVH#_ !<;MSX
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MPUU31/B9X=U>V\//X AU"&[ENM0NPC6,<5T@"-'*LJ,9-OR!9,*^U=^S\/\
M]KR/4?AWXWU[XA>#[OX?Z[X/U0:1J'AZ&^BU:6>Z>..2W@M9(0%GEE\Z-5C4
M9WMCWH N^&?V+OA[X;^%/C?P.\NN:T_C:)H_$7B;6-1-SK.I-AA'))<$8+1A
MOD 4*,$E26<M!\+_ -C'PI\+O'VC>.1XF\9>,_%^DZ?=:;!JGB_6C?S203,I
M$;,4&U8\.$5-JCSI"0Q;(]D\$ZEKVK^$],O?$^BVWAS7IXA)=Z3:7_VZ.U8D
MXC\_RXPY QDA<9R 6 #&OXH^)7A'P0UPOB+Q3HN@-;VOVZ8:IJ,-L8[?S%B\
MYM[#$?F.B;CQN91G) H _,[5_@+-\<O%5QX,L/A3\9_ \VK>(H[[7=%\0ZBP
M\"Z/MNUDOKJQD&!=2R!)%C&"C"Y=D "IM_2'0?A3I7A_XF>,/'4%U?2ZWXFM
M;&SN%G=&BMHK591&L V97)F=FW%LMCIC%3:I\8/ >B>)=+\.ZCXV\.V'B#5%
MB>PTFZU:WCN[M96*Q&*)G#2!V!"E0<D$#-7O&WQ"\*_#72HM3\7>)='\*Z;-
M,+:.\UN_BLX7E*LPC#R,H+%4<[<YPI/8T 9OP@^%FD?!7X<Z/X,T.:\NM-TQ
M9-EQJ#J]Q,\DKRR22,JJI=GD=B0HY/2O)OB3^PWX-^)GC[7O$EQXL\=Z#9^(
M@G]O^&?#_B![+2-8*Q"%FN8%7+%XU5&VLN0OJ6)[3P_^T)HVJ>-OB?IFI&QT
M+PWX&DTZWF\37NI(EM<2W-NL[*2RJL8020+G>VYI,87 SZ-=>)-)L=<L=%N-
M4LK?6+Z.6:TT^6X1;BXCCV^8\<9.YU3>NX@$#<,]10!XS#^Q[X6L[/X06]CX
MF\7Z7_PK%##I<FGZHMNU]"3$7AO-D8$D;^2@95"9&1T->B_%CX6Z5\9/"(\-
MZY<7D.EF_L[^5+-D4S-;7,=PD;[T8%"\2;@ "1T(ZU-I/Q:\#Z]XOO/"FF>,
M_#^H^*;/>+G0[35();V#80'WP*Y==I(!R.,\UY9I_P"V1X/\3Z;\7+GPQ>:+
MJ[> 8V51<>(;.TBU*<0AQB5VV0VYD:.$7#G;O\P8^3Y@";XO?L>^'?BQXZE\
M7VOC/QU\/-=N[:.TU.?P-KITT:K''GR1<KL8.4#.JD8.'(.<##_&W[&O@'Q/
MX#\%^%=!GUWX;P>#7D.@ZEX)U$V-_8K*I6=%G8.2)=V9"V6<\EB22?0/$/QB
M\(?#ZST8>/?%/AWP/JFI0"1+'6-:MX"S@+YB1M(R>:%9@NY1W' S71:WXHT;
MPR;(:QJ]CI1O9C;VHOKE(?/D"-(43<1N;8CM@<X1CT!H \/\$_L-_#GP=X;^
M(>AW-QX@\5V7CZWM8?$#^)-4:[GNI(%<"?SMJN)79R[-NP& VA ,5)\)?V+_
M  M\+O%7_"27WC#QW\1=:AL9-.T^Z\;Z\U^VEP2#$RVNU$\LR *"W)P@"E<G
M/L/@OX@>%_B1I+ZIX2\2:1XHTQ)FMVO=%OHKR%9  2A>-F4, RDC.<,/6LWQ
M'X\N-'^(_@_PM:6%C>C6DO)[R:75H;>XLX((P5DCM6_>7 :1XXSLP$W;F/0$
M R?@#\#=,_9W^'5KX,T?7_$7B'3+60O;S>);\7<\";5588RJ(J1*%&U%4 9/
MJ:COOV??"VI?M Z?\8;DWLOBG3]%.B6\!E7[(B>9(PGV;=QF"S31ABV-DC#;
MGFMFS^-'P^U+6])T:T\=>&KK6-7B:?3=/AU>W>XO8PTBEX8P^Z10T4JDJ",Q
MN/X3CLJ /*_A#^S;X-^#/@_Q-X;TJ&YU/3_$E]<WVJ-JS)+)<&=0C1$JBCRE
M0!%3'"CODD\'\._V$? WP_\ %>C:M-XF\<>+],\/SK<^'O#'BG7WOM(T.9,B
M&2UMRHPT*$I&7+[0<_> 8>Q>$?C!X#\?ZQ>Z3X7\;>'?$FJV2E[JQTC5H+J>
M!0VTETC<LH#$#D=3BH]8^,_P_P##]TMMJGCKPUIMRU^VEB&\U>WB<WBJC-;8
M9P?-"RQ$Q_> D0X^89 /)OB%^PUX,^(/CK6?$)\6>._#>G^()%E\0^%O#GB&
M2RT?7&VA)3=0*NX^=$!')L=-RCLQ+'TS1_@EX:\/?$+1_%FF1RV,FC^'3X8T
M[2;<1I86EH94E)CC";E<^5&N=VW:@&WJ:WO$WQ$\*>"Y'3Q#XFT?07CM7OG7
M4[^*W*VZ.B/,=[#$:M)&I?H"Z@G)%(OQ&\)R>%+7Q0OBC1F\-731K;ZR-0A-
MG,9)!'&$FW;&+.0@P>6( YH S/A#\)])^"OA%O#.A7=_/HRWMU>6MO?2(_V-
M9Y6E-O%M1<1(SL$4Y(!QN->0?$+]AS2_'WQ4\1>/H?BW\5O"&LZZMO'=P^%?
M$4>GV_EPILBC55@)VJ-Q 9C\SN>K&OH.3Q)I,/B"'0I-4LDUR>W>\BTUKA!<
MR0(RJ\JQ9W% S*"P& 6 SS6#X?\ C!X"\6>*;WPSHGC?PYK/B2R,@NM'T_5K
M>>\@\MMDF^%'+KM8A6R."<&@#AO'7[*WAOXC?"OPSX,UOQ'XMGOO#<L5SI7C
M)-89?$%M<H"OGB[V\NRLRME2IR#@%5*Q>"_V3?#7P_\ AMKGA71/$OB^VU/7
MKZ+4-7\:-K!;Q!?S1RHZF2[*_=V1B+:J@;&? #.S&'Q-^TO+H^K?&&PL/#MG
M>-X BTV**:_UV#3H=3OKR/>EKYLRB. C? NYG.YI@-H.,]5K'[2?PG\+ZI<:
M3K_Q0\$Z+K-HWE7>GWGB.TBFMY!]Y&5W5@1[@'VH ]'=2R, Q0D8#+C(]^:^
M1/#O_!-_1_!^CPZ3H/QX^.6B:5"SM%8Z=XP2W@1G=G<JB6X4%G9F.!R6)/)K
MZ3\5?%?P1X%T6PUCQ)XQT#P]I&H;19W^JZI!;07.5WCRY'<*^5^88)XYK6OO
M%&C:;X<D\07FKV-IH$5M]L?59[E$M4@V[O-,I.T)MYW9QCG- 'DOQB_9+\,_
M&'5M&UT^)?&'@KQ=I=D-,3Q3X/UIK#4I[($L;::3:PDC,A\SE<[AD$9(-SX1
M_LL^$?@SX5\3:9I%]KFI:WXF60:UXNUJ_P#M>LW[$.J/).RXS&KD( @ QD@L
M6+68?VB-#U_XI>!/"GA.33_%VF>)],U+5FU_2M3CFMK:"TDBBROEAEEW32&/
M[RA2C=3Q7H7BKQ?H/@30[C6O$NMZ=X>T:W*B;4=5NX[6WC+,%4-)(0HRQ &3
MR2!0!R6D_ ?PII7P'@^$7D37?A&/1/[!9;AE::6'RO+9V8*%\PY+%@H&XY '
M KE/"O[(W@[PKIWPOTU-1US4M*^'<L]YI5AJ%Q%)%/>RES]LN<1!I)E,LA4@
MJH+D[<\UZ9I/Q(\):]X/F\6Z9XHT74?"L$4L\NN6FH0RV,<<6?-=IU8H%3:V
MXDX7:<XQ4.C_ !5\%>(O$EWX>TKQAH.IZ_9VPO+G2K/4X);J" A")7B5BRIB
M2,[B,?.O/(H J?$KX3Z/\4IO",VJS7EM-X8UVW\0V,EDZ*QN(5=0CED;,;+(
MRL!@D'@BI?BM\,=+^,/@FY\*ZU<7EOI=S<6MQ/\ 871'D\BXCG6,EE8;&:)5
M88Y4L,C.:\ITC]LSPMXV\$_%#7_!DFB^(9/!NH_V9;6LWB2SLTU21O+2*3SG
M8QP0S3.T44CDB0QDJ.0#]!1%VB0RJJ28&Y5;< >X!P,CWP* /.?CG\!M ^/G
MARPTW5]0UK0-0TR\6_TOQ!X;OC9:GITX!5F@F .-R,Z,&!!#9P&"LM?X'_L[
M^&_@3;:I+IU_K?B;Q%JSHVJ>*?%5^;_5;\("L22SD#Y(TPJJH  '0DDFY\#/
MB^OQD\"W6O3Z6- O++5M1TB]T\W/GB"6TNI8"?,V)G<L:O\ =&-^.<9/C^O?
MMJ:FGPSLO&'ACX<MXG7Q'XO_ .$6\&V/]M):/KZ#S1]MWO#MMXF,$I3?G*A6
M)7<* /1O@O\ LP>%/@/X+\2>'/#-]K##7II)KG4[ZY26\CS&(HXXW\L*J1(
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M ! TWQ%X1BFM]/\ &VF^(6BUZ2&7_7137.PB17(3JG&P!=H+!N^^"/P)\*_
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MZB6>&4 @.C ,IY]015F@ HHHH **** "BBB@ HHHH **** "BBB@#\X_@/\
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M6J3/:3 $"6)F!,;X)&Y<'!J3Q!X<TGQ;H]SI.N:79ZUI5R )['4+=)X)0&#
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MU&9_%NO:F%M_[<NK&S:2QBU*Z)'F(\SR2;)6*?NPH   &'^TA_PJ6/\ 9_\
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M>%?"&@^&;K4F5KZ?1],AM'NF!8@RM&H+D%V(W9^\?4T ?F5\5]0\(_$#PO\
M'/XA>*/C9J_@CXDW6HW^BQ?#'PSJ*6#7JVLC6=C:7MC&/M%^\J[0\V0 DI'R
MI&<?I3\,M<TA?#^D>&(/[(TC7=(TBQ-[X7TV6,-I*-"!''Y"L3%&-K*F1@A.
M,XJ>X^$7@6\\;)XSG\%>'9O&"%67Q!)I4#:@I5-BD7!3S 0GRCYN!QTIGAOX
M;V6@?$#Q;XQ(MI-8\0):6TLMO:B$BVME<0I(<DRR!II<R'&5,:X C&0";XJ?
M$33?A)\-O$WC35PS:=H6GS7\T<?WY!&A8(O^TQ 4>Y%>,^"?A[XG\"_LO>.]
M?F1KOXO>+-'OM?U2YMUS*^I26K&WMH^^R!1%#&HX 3(Y8Y^@->\/Z7XITJ?2
M]:TVSU?3)]OFV=_ D\,FU@R[D8$'# $9'! -:% 'Y5?"WP?\'=#\-?LWW_PA
M\9W7B'X\7>I:3!=36.M2W%PM@"7U.WN[3<4MK2.)I<+Y:MB-3N<[V;]0=!\4
MZ+XJBO)=$U>PUB*SNI+&Y>PN4G$%Q&<20N4)VR*>&4\CN*R_#_PM\%^$O$FJ
M>(=#\(:#HVOZJSMJ&JZ?ID,%U>,[[W,LJ*&D+/\ ,=Q.3R>:K_"_X<V?PS\/
MW=C;_9GN]0U"YU6_GL[1;6*6ZGD+R,D2DA%&0H&68A069W+.P!\R_MF:EHOB
M[XW_  Z^'WC;X@?\*C\&1Z==^)HO%<%U#87L^H0ND$=M:WTP*VS*DS2,5^9E
M(3HV1X-IW]B:?\#_ !C>C6;SQ=\+Y?C#HMOJ_P 1->9[B[UG28)+7?)=7#9\
MZ&&=4@615$9 .T EC7Z0^-OAUX4^)>FPZ=XO\,:-XJT^&87$5KK>GQ7D4<@4
MJ'5)%8!L,PR!G#$=ZMKX0T&/PI_PBZZ)IR^&OL9T[^QA:1BS^RE-A@\G&SR]
MGR[,;<<8Q0!\PZQ\5_#'Q^_:F\##PEKNFZWX)^%UG?>)O$7B6TN(Y=-BN)[5
M[>U@%RK;-RH\\S$$J!'@G*L!]4Z/K.G^(M)L]4TJ^MM3TR\A6XMKVSF6:&>-
MAE71U)5E((((."#7+_\ "J?#^B?#S5O"'A'0M \*:7?PS1&SM=&A-B#*NV1G
MM5V))N7@AN#WR.*W/!WA73O GA'0_#6D1-!I.C6,&G6<3-N*0PQK'&I/<A5'
M- 'P;\:-0\&_$+]I#XH:A\1_CAJ7P*N? ]G!H^BV_AO5(M'U/4+%X$NY9WE*
MF:]1I3A((L[3'P-TA+<Y<7%EJ/[/O[+OPX\::M!\%?".N6T^OWWBA$BL;I+J
MS*S6ABNIBZV=S<&3[2TQ;>6!4'YV4_H!XJ^$?@7QWK5CK'B7P7X>\0ZO8!5M
M-0U72H+J>W"MO41R2(63#'<,$8/-:/C#P-X;^(>CG2/%7A_2_$VE&1938ZQ9
M17<&]<[6V2*5R,G!QQF@#Y&_8MUCP=X)\5?&O4HO'LGC+P?'K6FZ98?$SQ=J
M:SW6I3FW57L/MSL%GCBD*>7L503<$#?P:^U:\^\5_!7P]XA\)^'?"=IIFDZ/
MX5TK4[:_.E6NF1B,) YECCMP,+;GSA&2X5CL$B@*SB1/0: /R:\:>,/$NI>!
M]0^"WPC^+/@KQ;X,^(FMW4.AZ7I]G<-XJMH[RZ\V\@O8FVK:V\0>Y9I)5\QE
M7 "!B8OL/XT?M-Z5X \10?!_POXV\(^#O%%G86YU'Q+XRU&""UT6W90$:."2
M1&N[ID!98@0BY5I& *J_O6@_"WP7X7\4:EXET7PAH.D>(]3W_;M8L-,A@N[O
M>X=_-F50[[G 8[B<D GFL3Q)^SK\*/&6N76L^(/ACX-UW6+M@UQJ&I:!:7%Q
M,0H4%Y'C+,0 !R>@% &9\%HOAW\._"GA[0?#GC/3]=E\337FJ6FHW&K07%WX
MBN"WFWETC(0)FRVYO*&U!@84 "O4Y8DGB>*5%DC<%61AD,#P01W%<'#\%_#U
MGXR\(ZS9:9I>EV'A.RN+71M.T_38X/LC3@+(5=?NQ[!M$2JJY)9MQ";._H ^
M;/@?HNFWO[57Q>O]*TZUTW1/"&E:-X)TJWL85B@@58GO9XXT7"HH:YA7: /]
M7]*\7^&_[37A'X+_  #^*45YJEI<?&?4O&&OA_!\3@ZI>:O<7DD5HBVWWS&4
M%L-X!4*N 21MK[JT?PYI/A^34'TK2[+37U&Z:^O6L[=(C=7#*JM-(5 WR%40
M%FR2%49X%93?##P:WCA?&;>$M#/C!4\M?$!TV'^T NSR]HN-OF8V$KC=T..E
M 'QE\'9_"W[*OQRT?0OBCXDTGPO+X?\ A1I.FZ1>ZK<);6UPPN)GU$0NYVO)
MYJP_(#O*@84@9KU/]D_Q=I^O7'C7XIZU=VV@1_%;Q/O\,6FJ.MK<W]C:VT=K
M:LL;D,SR);O*$ )V,&Y!S7O7CCX8>#?B=;VMOXQ\):'XL@M7:2WBUS38;U86
M(P602JP4D 9(]*J^+_AS:>-/&'@[6;\VSP>&KB>_MX6M%:<W31^5&ZS$YCC5
M'FW(JY=C$=RJC+( =A7S5X,T'2KS]MC6K71=+L],T3P!X,ALXK2Q@6&&&\U2
M\DN965$ 56*6RD\9)D)/6OI6LZP\.:3I6JZIJ=EI=E9ZEJCQR7]Y;VZ)-=M&
M@CC:5P,R%4 4%B<  #B@#XT_:L^/OPM^+7P=\?:->_%_7?@YXG\(W]_92Z3;
M:G'8:G>W4,;QHC6R,TEW9R^8CKY9 <$$LI5MM7P?XJ\/?"KXY?!&Y^)46B?"
MO3;7X2[=+LM1D6PL;'5)9[<WUNCRD!9$C6-=K-NP[9+$YKZZU;X2^!]>\7V?
MBO4_!GA_4?%-GL-MKEWI<$M[!L)*;)V0NNTDD8/&>*M>-OAUX4^)>FPZ=XO\
M,:-XJT^&87$5KK>GQ7D4<@4J'5)%8!L,PR!G#$=Z /G?]FGX@Z+XR\??$WXS
MWVH6NA^%_'&M:=X7\(2ZNZVCZI#9QR1QR0^807-Q/+<>6F Y"8*\5]55Q7C;
MX6Z7XW?PA;W<%FFD^'-4@U>WL_L:LRSVZG[,87S^Y"$\[1EE^3(5F#=K0!\T
MS^']*U#]N+PMH^E:79Z;IW@[PGJ7B.9+&!8D;4-4NT@\Q@@ \QDM[EBQ^8^8
M3SN)KYZ_;%\1?&_2M>^(_B;6?@Y_;7A6SM)?#_@[7O\ A)K..'2?MH%G]N%C
MEY)KJ62=5#-MV(0H5<R,WZ%6OAS2;'7+[6K?2[*WUB^CBAN]0BMT6XN(X]WE
MI)(!N=4WMM!) W''4T:]X<TGQ18K9:UI=GJ]FLT=PMO?VZ3QB6-P\;A6!&Y6
M56!Z@@$<B@#YT\+_ !NT+X0_#KX<_#7XJ6DGP4U34_"\UK;75SJ]J;&R^R!+
M<0K?@B,7'E-',HV;1G&XL &XC]B35/"'@C4?C1JX\:?\)3X5;Q-::98?$[Q7
M?[[O7'%O'']F:\E(6X2&4^5$T>$?>2@(8$_6WC+P'X9^(ND#2O%?AW2?$^EB
M59A8ZS8Q7< D4$*^R167< 3@XSR:Y[QA\&]!\4>%?#GA6#3]+TKPOI.HVM[_
M &7;Z;'L$=LQDBBMP,+;GS5B)<*3L$B*%+B1 #OJ^:O'V@Z5J?[8GPG\-Z7I
M=G91:9;ZSX\U86L"Q_:+IHXK"":3:!ND)FD^=LD^6.>*^E:SE\.:2OB%]?72
M[(:[):K8OJ@MT^TM;J[.L)EQN,8=F8+G +$XR: /CS]H2R_9M^)GQ^\36/QN
MU^ZT>_\ #6@6UDFCZ[K?]DZ9J%K,XN_M%MY,J2W+B2/8REL!HDQ$2%<^&-IM
MK>?L^_ &T\5^)=>\-_!:3XDWLVE:Y?7;V]U:Z.@N3HWG3GYH%.T!9#M$:E&5
MD"J1^C?C;X2^!OB5<64_B_P9X>\53V(86LFMZ5!>-;[B"WEF1&VY*KG&,X'I
M6WXA\.:3XNT6[T?7=+LM:TB[3R[BPU"W2>"9<@[7C<%6&0#@CM0!\8_LHO\
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MBMH?#/B[X@2Q7,D;W%O-+>>*=0\[:DUW/%"(;9)=JK$Q8X>7Y?T?U;P9X?\
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M]G7PS_:)U3.[]R',V(L;?O$#KTKO_#_PH\$^$ETE=#\':!HRZ09VTX:?I<$
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M8/$.O>-KKQ]-X@U:3PKX/UJ?0XM&.H6=R\%DES'!&BLH9YYV&[+ 1>O%>T^
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M7A.3QO\ !C5/B-X9\:ZOJWB'Q]X>T^PFD\0V-U=W!FL9+:$21NK1Y6.3&'4
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MGXR\=>)_$^NW/B/0/$.DV2S:5<6[6L:PPW-SN!B,(@91%@LQ(50"ZE@#W/\
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MX,\.>!+[X@^*/$UGJ%U::;87J6S(;98M@D>1=B1NTO,CLH18V(WMM1N4TO\
M;<LM/^$OB+Q%XU\#ZQX6\;:#KJ^&+GP+:R+J-[<ZG*%:U@M'C %QYT<B," /
MX\;@ S 'TU17S[\'_P!ICQ=XF^)T?P_^)_PFO?A3XEO].EU31P=:M]7M=0AA
M=5G7SH0 DB%T.P@_*<DCY0W*?"7]M/Q;\6/$&E7]C\$=8_X5?JVJMI-KXOT_
M6K:_N()"Y1'O-/A!EM5! \PNW[H$%N* /JVN/^(7POTKXE7GA&?5;B]B7PSK
M<.OVL-K(J)-<11RI&)LJ2R#S2V 5^95.>,'PO]FGXL?%'XH?M$?&23Q)X2GT
MGP#I=Y_86E71UJ">&UN;/8)(E@10SO,+AIFF/";%ARQ0XZ?]L[Q-JVF_#GPQ
MX;T#5;S1-<\9>+M'\/V]]IUS);W,*272RSLCQD,H\F&4,0?NEJ /?:*^=O&O
M[7T7@/4/&WAS4/"DEQ\0-+U2VT_PYX7L[]7F\2I=)NM)HG:-?*0E)A*2K+#Y
M$AW/QEGQ$_:B\7Z+XR3P%X ^$\WQ/^(6G:=;ZCXET_3M=BL=-T43+\D9OKB-
M1)(QR40QHSQ@O@8( !]&45YY\!_C)9?';X;V?BFUTN]T*Y\^>QU#1]14"XL+
MR"1HIX'QP=KJ<'C(()"G*A8?BVH^.6K?#J[TP6B6GAR#Q%!JS7(*3QM<2PRH
M4VC9Y9C0[MQR).@QR >A45\O3_MIZAJ'A'1;[PM\-+_Q;XC\6ZA>IX.\/V6H
MI$^IZ;;.%?4[J:2-4LH6SE=V_=OBY^<E-CP[^V):Z?\ #CQYKGQ*\':E\/?$
M_@AX8]8\+)<Q:G,[7 !LA:S182<SEE1?N@2!E) 7=0!]$T5X'\'_ (_?$OQA
MXVM-"\?? C7/AQ8ZG;2W.F:PNJPZM;MY85FCN_)4?8W*NNU9/O$.HY4UU'QZ
M^.R?!C3]"M--\.WWC7QKXDNVT_P_X8TZ18I;Z=4+N7E?Y8844;GE;(1>2,4
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M93+$*05 !]-?#+X>Z7\)_AWX;\&:*T[Z5H-A#IUM)=,&F=(T"AW( !=L9)
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M5U=^%M%\1ZCH.L>,)M6CAM+7[-D(\<;)ON'D=6!2,%4#Q,TGS,$P?VOOBO\
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M/:9/JAT[[1]G\](4+N/,VMM^56.=IZ=* .UKC_ OPOTKP!KWC36+&XO+J_\
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MXA@N.5D+^3-&DZ;=BMYOR%<  ^V**^8?%7[6/Q";7I_#OP\^!>H?$+Q#H=I
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M[96CSPOFG/W/GK[1\/>'X?A_X#TS0]'M7NX-$TV*RL[;>JM*L,02--QP 2%
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MWQ UKQ5X6NOA#X=^)EO>W[3^#OB9)K=KI-YX1BD=&B7"1K<EK:6,2%HFS(H
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M:_;+;%MIEO*[6:L5D/F;A;6/RH68;CNQ@XH?8/VE_ 7C_P"+,_A/X8:)J_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>advm-20231231_g8.jpg
<TEXT>
begin 644 advm-20231231_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /2!IH# 2(  A$! Q$!_\0
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M2%%%% !1110 4444%A1110 4444 %%%% !3ATIM.J6 M%%%(:"BBB@84444
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MX+=[C??.Z1[5(!&55CGYAVKV+_A@[Q__ -!?PW_X$W'_ ,8K._8=_P"2U/\
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MQH^!,T6K:2VFZK=:<+V.TND*R6=VJ;E'(###94\ [21WQ7S%^P?_ ,E=U?\
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M<01_V[UYM^QO_P EPL?^O.X_] KTG]OK_F1/^W__ -MZZ)?QT?)X;_DFJ_\
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M)<L,B!>/]X\#],UZ+7G\?9Q4GB%EE-VC%)R\V]4GY)6?J_(SSC$N4_J\=EN
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MX=D=P2&C48PA[]Q7E-?>W[8GAS4_%GP^T#2M'LI;_4+C785C@A&2?W%QR3T
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M,5>E/["F#I3_ $KA9F+11163+/$UI:1:6O[D9^1A1116+&?0G[#_ /R6I_\
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MNQR2H=H]E;<H]E%>S_L/_#?6/"^CZ_K^K6<M@FIF&&TAN$*2,B;BTFT_PDL
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M>U%VC!@058 %@5YV@###@=T_:*^)GC;X6Z;INJ>&='LM4TQO,6_EN;>64VY
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MH)6#'<V.P57/O@#O7D?[+?[0GBOXB>-KW0/$ES#J,;VKW4,ZP)$\3*RC9\@
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MKY@06655V[SCHQ!23I_$*<M.69CA/9XJ>-RN.S;<?6_Z.QYE^PQX+\C3-?\
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M([K"GY".ARI.W_:QSC->%_MO>-]7_P"$JT[PJER8M%6SCO7@CX\V5G=<N>X
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M_KS_ /9VK\WJ_2']G3_DB7A'_KS_ /9VJ:NQU<)_[W4_P_JC\\?%'_(S:O\
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M>_4T?%/[1?Q*^(6N6[_#31-4MM# 50YTQ9VF?^/>Y#HJ@\<$=,D\X'TIH/\
M:?B+X<0IXJL([75+JP:._LQ@H&*E6'4C!'.,GKBO$_CA^T7XR\ ^.&\+^'O#
M$.W""VNKF"28W644GRE4J/E)V_Q=.U>U^![K7+[X=Z=<^)(_)UR:T,EU'L";
M&;)V[1TP"!CVJ'LM#W<OGS8FM3E6E4DM[JT5Z+^M#XO_ &._^2V67_7I<?\
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MO80Q.@1HHD )>13G,9[=QS7BWQ4\5VGCGXB:_K]A'-%9ZA=-/$EPH60*<<,
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MT\ST'XB?$UM<^,&H^-?#<MWICR727-I)*%6:,JBKR 67J#QD@@\^E?1'@_\
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M1B:O))]5:WH[IZ&UXO\ VS+?4K/^S/!NA:@=<NG%O$^I(B"-V.T$(KMN;.
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M_!SQ]_T(_B3_ ,%-Q_\ $4O_  IWQ]_T(_B3_P %-Q_\163JT_YE]X?5:_\
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M(_\ P4W'_P 12YH]P^JU_P#GV_N9R:]*6NM_X4_X\_Z$GQ%_X*;C_P"(I?\
MA3_CS_H2?$7_ (*;C_XBIYEW#ZK7_P"?;^YG(T5UW_"G_'G_ $)/B+_P4W'_
M ,11_P *?\>?]"3XB_\ !3<?_$4<R[A]5K_\^W]S.1HKKO\ A3_CS_H2?$7_
M (*;C_XBC_A3_CS_ *$GQ%_X*;C_ .(HYEW#ZK7_ .?;^YG(T5UW_"G_ !Y_
MT)/B+_P4W'_Q%'_"G_'G_0D^(O\ P4W'_P 11S+N'U6O_P ^W]S.1HKKO^%/
M^//^A)\1?^"FX_\ B*/^%/\ CS_H2?$7_@IN/_B*.9=QK"U_^?;^YG(T5UW_
M  I_QY_T)/B+_P %-Q_\11_PI_QY_P!"3XB_\%-Q_P#$5+DNY7U6O_S[?W,Y
M&BNN_P"%/^//^A)\1?\ @IN/_B*/^%/^//\ H2?$7_@IN/\ XBES+N'U6O\
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M<E176_\ "H?'?_0E>(O_  53_P#Q%'_"H?'?_0E>(O\ P53_ /Q%%T'U:O\
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M_P#XBBZ#ZM7_ )']S.4HKK?^%1>.O^A*\1?^"J?_ .(H_P"%1>.O^A*\1?\
M@JG_ /B*EM#^K5_Y']S.2IXZ5U7_  J+QU_T)7B+_P %4_\ \13O^%1^.O\
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M_P"(IR_"7QQ_T)GB#_P5S_\ Q%(OZO6_D?W,Y6BNK_X5+XX_Z$SQ!_X*Y_\
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MG_D5=;_\%TW_ ,363H5?Y']S-/9S_E9SRTM=&OPV\7?]"MK7_@NF_P#B:/\
MA6WB[_H5M:_\%TW_ ,363P];^1_<RE3G_*SG1UIU="/AOXN_Z%;6O_!?-_\
M$T[_ (5OXM_Z%;6O_!?-_P#$UD\/6_D?W,OV<_Y6?>=%%%?N1]T%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYA^WE\>[/X;_  OU+POIFORZ3XUU:")[6*"*42&U,NV5EE5=J'"N.6!ZX[4
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M.6B6=IXQNC\,H_LD$EQ#;SHENK./M$_D,@9W4$G[I)V@"@#]6J*\-_9#\$>
M/"/PUN;GX;^(-3\2^'-3O7F2]U4%9%9%6-HP#%'A0RL?NC[QZU1_;U_Y-/\
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MGPT^+W[/?Q%TSPGXLM=4U%=,9_LCQ2V\K*'3)5)44L!WVYQ6-_P31U&WT?\
M9Q\4W]W)Y5I:^(;J>:3:6VHMG:LQP!DX /2@#[(HKQ_1_P!KOX0Z]X=U+7;7
MQK:KI>GR1PW$]U;SVY#N&**JR1JTA(1CA >E:?PU_:6^&?Q?U1M,\)^++74]
M152XLY(I;:9U R2J2HI; Y.T'% 'IM%<SX^^)7A;X7:.-5\5ZY9Z'8LVQ)+I
M\&1L9VHHRSG'9037FFC_ +;GP1US4([*V\>VL<TAVJUW9W-M'GWDEB51^)H
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MQR&*1889IHT<'!#2QHR*0>N6XKXV\5:K9ZY_P4STW4-.NH;ZQN=2TN6&YMY
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MY(I%#*ZF>(%2#P01VKZ@_P"">7_)K^A?]?EY_P"CVKYC_P""7/\ R6#Q7_V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9OB:%[CPWJL42-)(]I*JH@R6)0@ #N:^(/^":_PW\6^!?$GCF7Q+X6U
MKP]'<6EJL+ZKI\UL)2'D)"F11DC(Z>M?>-% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&&_LS^S(1.><>;YI\K_QWS?UH _1ZOR]_P"*5_X>,:Q_PFO]C_\ ",_VK?\
MVO\ M[ROL7_'G+L\SS?D^_LQG^+;CG%?J%7Y6Z]\+]*^,W_!0+7_  =K=Q>6
MNF:EJM[YTU@Z),OEVLDJ[2ZLH^:, Y4\$_6@#Z?^,C_LM)\,_$)C'PY-U]BF
M%K_PCXLS>>=Y;>7Y?V?Y\[L>W3/%<'_P2ST/6[71/'6JS++%X?NIK6&V#J=D
MLZ"0R,GT5D!QUR/[M=#K?_!+SX>2:;.-+\4^);*]VDI-?2V\\2G!^\BPH2,X
M_B%<+_P3I^,_B9?'>I?"_5-0.KZ%;6<T]BS2;_LK12*I6-N\;!B<=!@8QDT
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M*%'4]=O<?L5Z7;Z5^S#X$2WC5!-:27$A  +.\SLQ/J><?0"O@OPEIOQ(UO\
M;4\8VO@O7-/\.>.)-6U4I>:H@:(*))"ZJ&BESE!QA3P.H% 'TMH?[:WCKX;_
M !$T[PM\=?!%GX3BU #RM3TQF,40+8#G]Y*KH#PQ5\KUP>E>X_M*?M$:3^SG
MX%76;VV;4=3O)#;Z=IRMM\^0#)+-@[44<D^X ZU\N_%;]CW]I#XW1Z;'XU\>
M>#M:733(UI]Z QF3;OYBLESG8O7/2N5_X*/:3JN@Z1\&]-U2;[3/9:/-;331
MDF)[A%MUE920.I"GH#C'% 'H>D_M:?&[4/ =UXS\3?"JT?X;74#JVH:46CNH
M8F4CSMCS,SH,@[MBJ0/O#K7'_P#!*W_D:/B#_P!>=I_Z')7VRS:7_P *+)/D
MC1?^$<R>T?D?9?\ T';^E?$W_!*W_D:/B#_UYVG_ *')0!T.B_\ !03QS-\5
M?$_A%_!NG^(+B*>YT_0['1X9H[BXNDG"1^:[2N-@C$C-A1RHY49(FU7]NKXJ
M?!_XA6.C_%SX>:9H^FW067&G,_G)"QQYBR>;+'(5[J,'(QP:\S_9%A23]O#7
M69 S1W6L,A(^Z=[C(_ D?C72_P#!5+_D:/A]_P!>=W_Z''0!],_M@?'_ %OX
M!_"K2/%/A>VTS4;F^U:&RQJ4<DD1B>":3<H1T.<QK@YQ@GCTKZ-^U,-'_91T
MOXM^+;*%KVZB;_B7Z6K1I-.9WCCC3>SE00H)))P QYX%>0?M\$M^Q_\ #<GD
M_P!HZ;_Z;[BNI^%'P9M?CU^P3X4\)7%ZVFRS023VUVJ[A%,EU*5++_$IY!'H
M>.<4 <MI7[4W[2WB[PFWC3P_\*-#G\(;&G21][SO&I(8HOVE7?H>5C/2O>?V
M7?VA;G]H+PA=7^H^&;SPWJ=DZ)*KQN;:X5@=LD,C*,CY6RO)7CDYKY%T_P"'
M'[5W[,=L;3PS/-K_ (;M2Q2"P:._M]N22%@D'FIGK\BCJ>:]S_9?_:\UC]H;
M0?%>A7VD0Z9XSTO39+F":QW>1<<; =A)9&#E.,G.[C&,4 9_Q/\ VX-<N_B=
M-\/?@YX2B\9Z[;R/#->7)9H#(G#A%5ERBD8,C.JYZ<8)S=+_ &X/''PP\=V?
MAOXZ> [?PNE[@QZEI18QQJ6QOQYDBR(.Y1\CT/2O-/\ @EK]E_X6#X[\_9_:
M?]FP^7O_ -9Y?FGS,>V[R\^^*[__ (*F&T_X5_X(#F/[?_:DWE9^_P"7Y7[S
M'MGR\_A0!['^V!^T!K?P#^%6D>*?"UOI>IW%]JT-E_Q,$>6$PO!-)N7RY$.<
MQK@Y(P3Q7CFG_MC?&SX@^ D\1^ ?A=9:E8:?:!M6U2Z5_)>X50TRV\/G*[*N
M<<,[<=!7'?M0#4!_P3[^#HU,,+O[9I_W\Y\O[%=>7G/^QLKZ;_8?AC@_99\"
M"-%0-!<.=HQEC<RDGZT 8_[(/[6?_#25AJ]GJ>E0Z/XBTD1R2QVKLT%Q$Y(#
MINY7!&"I)ZJ03D@<G\6/VS_$C_%>X^&_P>\)0>,?$5F[Q75U=EC LB8\Q556
M3A#E6=G4;ACW/@__  2Y)_X6_P"*QV_L(_\ I1%7GO[*>B_%CQ!\7O%%O\._
M$NE>%_%WV29]0FU>-7$D?GIYB*&AE.?,*D_*.G7M0!];_#/]M#Q-IOQ8M_AS
M\9O"-OX/UV\>.*UN[)F\@R.<1A@7<%'/ D5R,\'N1]=U^??Q(_8P_:)^+FO:
M;K7BOQSX/U35--01VMPK20&-0V\#$5FH.&YY!K]!* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\\_VK_VC/&_Q2^,A
M^#GPRNKFRBCN_P"S;B2RE\J:\NAGS%,@P4BCY!Y&=C$Y&*BD_P""8OB^'26U
M2'XC6C^*0-_DBVE6,OCH+G?OZ\9\NN*_8U8?\-P7WVW NS-JVWS?O>;^\W8]
M\;_PS7ZC4 ? /['_ .TUXT\*_%9_@[\3;FXO9S</8VEU?2&2XM+E <0M)SYB
M/C"DDX)7!VGCZ9\:?MA?"+X>^*-0\.^(/%O]GZS8.([FV_LV\DV,5# ;DA*G
M@CH37Q!^T8W_ !L-L?[(P+W^V]%'[GKYVVW_  STS^O>OMC]H2R^$WPU\':Y
MX^\7^!?#.KWH&%:\TFVEN+ZY(Q''O9"23CJ<X52>@H R_P#AO3X$_P#0\_\
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MVI?L]Z7H<GAVQDUG4-)CG?7GB'VQ;J2(-YBRXW*H=N$^[@ $'O\ /'_!+/\
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MNI_[Z[5Z#\!_^">-EX+\60^*OB#KD?B[5;>;SX;&)&-MYH.1)*[_ #2D'G!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\3>)K;3K_:'-JL<D\JJ>A98U8KGW XH ]"HKC?AY\8O!GQ6BN'\*:_;:N;<
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M8?\ ".I68N/%^L:[XH\1RC?<:K-?LI\P]3&.<#/3=NZ4 ?1U%?/'P-TGQ_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4+);HS@@N[LJL>N<8ZXYP,$ YCX<Z38G]NCXHPFRMS#%H]H\<?E+M1O*LSN
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M^!OC1\1_%]_=6$VF^))4>TBMY':9 &)/F H .O8F@#BOV ?^24^*?^QHNO\
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MGD[O[/OP \2_";X@^,M?U_7[;Q%_;L4#&[7<L[S\M,70KM5=[,%PQ^4#@=
M?/W[-NH_$#4-'UGQ9H_PITOQ[?ZMJ,SW.OZCJ=O'-OX)B596W*HSGCKN'7 Q
MZA\%_ /Q'T7]H6?Q5>?#VV\">&]5L&MM2M+#4;::W:506201H^02P4<+U+'/
MS&MF/]GOXA_"GQ/K5Y\(_$^CV6A:O.;J;0]?BD,,$A[QLBL<8X'0X !W8!KI
M_@]\"]?\.^.M4\?>/?$4?B/QA>PBUC6S0QVMI".R @9/8' P"W4L30![;111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI:FQ:%A.)OL(7R]F-V_=\NW&<\55_9%T/4O#7[//A/3=7T^ZTK48?M?FVE[
MT,L>;N9AN1@",J01D="#0!YO^S_XDU7Q#^Q_XSBU>]DU";2X-5T^*>9BSF)+
M?<H)/)P7(&>@ ':N:^ _[+^C_&+X'Z%K7BW5]5NKV:WEATM(;HI#IL22.B;(
MP,%MRESGKG\:ZO\ 9]\'Z]HO[,/Q"TK4-$U*PU2ZFU4P65S:21S2A[=0A1&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUK2_B'%XKU*SC-PVAW>@V\,-YMY:)&B_>*Q (')R<#CJ,SXJ74?@7]I[X?\
MB_5]EOX>O=-GT)M0E&([:X9F>/>W1=V[:"?]KWKLOB]H_BYH+C7]#^)?_"&:
M196):2U;2K6YCDD4LWF&67E=P*+CI\N>IH O:A\;?#WA/PIX<U?QG+)X2N-8
MAW+97T$I>*58]\D3;5.".0,XW<8Y.*LM\;O!,/@Q/%<^N+::%),;:.XNK::%
MWE!(*+$Z"1FR#P%['TKYZT_Q#J/Q/T?]FO6?$MP-2U*\UB[GGF,2(':/S-AV
MJH48V+T';UKT?]H;6))/B%\,_#ND:5IESXMO+JYN=,U36VE^RZ?Y<8+N(T91
M)(01M!S@@<<B@#O_  1\;/!?Q%U:?2]!UH7.IPQ><]G<6LUK-Y>0-X29%)&2
M.0#UK&\4?M$^ ]'OM4T1/$]NFN6RO"0D,CQ0SX(5'E"&)6W#&UF'/%>-W5OX
MHTW]J[P/9ZUXNLO$WB,:+J#"*SL$M$M-T+F-" S%@6&?G/;H,UT?[.K>'6_9
M*NX]7,*QK%J(\0+<8WK/YDGF>:#_ ![=F,]MM '6?!_XRPK^SOX<\;^/]>@@
MEN4D^TW\Z+'YC^=(JJJ1J,MA1\JKG@G'6NT\"?%_PA\2KB[MO#NLK>W=JH>:
MUE@EMYT4]&\N55;;R/FQCD>M?'/A^/6)O"'[,Z6D>D26JR:F\":Y))'9O>"5
MC$)616(/]SCELBO;[OPSXZU/X[?#_7O$M_X%T2_L5NH1:Z;J4YO-1MGC.Z-8
MY8EWA#\W'3)- 'N_B37;?POX=U76;O\ X]=.M);R;']R-"[?H#7SLOBGXO2_
M"1OBROB:T6+[,VLCP>^EQ"W^PC+[/M'^MW>4-^[..V.]>V_%[3;C6OA-XUT^
MT3S;J[T2]@A0?Q.T#JH_,BO*M.\<:1#^Q#%J@NXVMX/!XT\_./\ CX6V\CR_
M8F3Y?QH ]O\ "_B"W\6>&=(UNT#+:ZE9PWL(;J$D0.N??#"M2N'^!NAW'AOX
M-^"M-NPR75OI%L)DD7#(YC4LI'L21^%=Q0 4444 -DD6*-G8X5023["J/]O6
M/_/?_P <;_"K&H?\>%S_ -<F_D:XFKC&YY^)Q$Z+2BCNK>XCNH5EB;<C=#C'
MM7A>E>,O'/QQ\4:\/!VNVW@_P7HMX^G+JPL4O+O4;A /,*+)\B1J3@'!)SWS
MA?:-!_Y!4'_ O_0C7AG[(=W%X9T/Q)\/]1*6?B70M8N6FM'PKS0R,&CG4?Q(
M0>H[ >HS+.RG)R@I/JCH=$NOB9X#^(VCZ-KMZWCWPKK"2*=9ATU;:XTR5!D"
M81#88VR &P#G/3'.Y??M#?#_ $_Q+/X?FU\G68+O[#+9Q6-Q(Z3948.V,@+E
MU&_[I)QG@UY9XQU;XC?"OX@?#K3[_P"*O_"20Z]K<-E<Z;)HME;.8"?F;**6
MP?NY&.O6NE_9[L84^)7QJO0@^T2>)!"SX&=JQ @9^KFD:':>+_CUX$\"ZU+I
M.L:Z(]3A0236MK:3W3PJ1D&00H^S(Y^;%:\'Q2\)W/@?_A,8]?LCX9V%SJ1D
MQ& &VD'/(;=QMQG/&,UX3X$NO$OCCQ9\1]3\"WN@_#W1(-<FMM2O[RU>^U"[
MGB4!YG620)&G4JN !EN.M>0>$[B.;X0^&I=0NX[_ ,)CXI[M3NG0)#)"0I5W
M4<+&222/NC(H ]V\:?M*:?KOB3X=6G@3Q()(]0\16]GJ=N]DT<DMM(#C"SQA
M@IQPZ?G7I7C7X[>!?A[K!TK7=?2VU)8Q,]K!;S7,D2'G=((D;8,<Y;'!!KSC
M]I8Z2_Q(^"3%HCK1\3P^3C&\V^1O/KMW>7[5QWP1_P"%AQ^./BQ/H-IX/N-9
M?Q-<+?\ ]M7=S%=)&#^Y"JD;?N<$[#GGGTH ^I]!U[3O%&CVFJZ3>PZCIUTG
MF07-NX9'7U!'OD8[$$5YS\</'VNZ#?>$/"?A66&T\2>*[Y[:&^GA\Y;.")0\
M\PC/#E5(P#QSS69^S%X5O_"6C>+;>ZU;P[?P7&NSW45IX;O&N;?3V<*9+<EE
M4J0W\!Z9]ZJ?&ZXCT/X\? [7+UU@TR"\U2PDG<@*LUQ:JD*DGCDJ?RH G\/^
M*/&/P\^,.A^"O%NOIXNTWQ+:7$VF:FUC%:3PW%NH>6)UBPK+L.X'&<D"O1OB
M9XH_X0GX=^)=?#B.33M.GN8R0#^\6,E!SZM@?C7F'Q6*>(/VE?@]H]J^^YTQ
M=1U:\V<F&'R52,L.P=P5S7<?';4] T?X2^)+OQ3I-WKGA^.!?MEA8DK+*AD4
M<$.A !(8G<, 'KTH \D^%]]XT\:6.@R3_M!:<VN75M#=W7AZWTO39)XBRAVB
M8##@@'!.!CFO=_B!XWL?AOX-U7Q-J<5Q/8:;%YTT=HJM*PR!\H9E!//<BO O
MVDO#'@31?V>;;6O"VG:=I6H0M93>&[S2XECN3*TB%!&ZC<Q*%B>3G&3R,UJ?
MM(?!O5/%GPV\1:W#K7BZYUV33XO^*<TV_=[&650BLHM4!#9(+$#J>: /H+3[
MQ-2L;:[B#+'<1K*H8<@, 1GWYJQ7FWPE^$__  @4,%\WB?Q7J\L]BD3V.O:H
M]S! 2%8[(V V,",>P)%>DT %%%% %#6-<LM M5N+^;R(6<1AMC-\Q!., 'L#
M6/\ \+*\-_\ 01_\@2?_ !-9GQA_Y%FV_P"OQ?\ T!Z\>KIITU*-V?)9EFU?
M!XATJ:35EO?_ #/HCQ-XBL?"/AW4];U.7R=/T^WDNIW[A$4L<#N>, =SBO&?
M!*_%CXOZ##XJD\7Q?#[3-203Z;I%CI4%W*L!&4>:28'+,,-A0.".G2NY^/WA
M:^\:_!CQAHVF1F;4+G3Y/(B R9'7#A![MMP/<BL;X6^(O^%G_ ;1T\*:\OA_
M5HK"WLI+B.VCGDT^XB5%DC:%^,_*P ;LP/I7,?6DOPV\2^-]*U[Q-X?\>0+?
M6VDQ+=6?BFULV@@OH""65E&5$J]U7W],G2\%_'WP'\1-8M]+\.ZZ=4O)XC,B
MQV=PJ;0-Q!=HPJL!_"2&YZ5Y;H/B7QCI/QF\2^!=<\?KXVTZ'P;<:F^-.M;5
MK>Y\]8]C>2,Y"<X)_P"6@XZ&MG]G^;3_  C^Q_IFH36C3V5OHUY?W4$)VO,,
MRNX!'.2,@'KTH ZF^_:>^&.GW\MI-XIBS#-Y$ES%:7$EJC@X(,ZQF(<_[5=1
MXT^*7A3X>:59ZCK^M06-K>L%M2H:9[@D CRTC#,_!'W0>H]:^6;NV\5M^RMJ
M&L-K_AOP5X%N-'G>S\/:;IYN7D60-Y<#3S2$B1V."P!8$DC!''1?#.2!?C!\
M%)-9(^S2?#2W727G/!OL)YNTGJ_DGMSR* /0/!_QI'C[]HE-&T'7(]1\'MX0
M;43;+ $9+Q;[RB7W*)48)@;&P.0<<YKH;G]I3X:6>M2Z5+XKMEN8I_LTDHAF
M:V27.-C7 3R@<^K5Y-XW^SK^TQ\0SX8VGQ!_PK.[,PM\[OMOG)Y6<<[]OD].
MVWO6)\*]'\:ZO^S':Z5IMM\.O^$.O-+E2YNK[4+F.1-P/FO-B$JLBL22<\%1
MSP#0!]@*P90RD$$9!'>O+OCA\8+WX<Z;]@T#0KSQ#XHN[6:XMH88C]GMHT'S
M3SR=%1<],Y)&.,YK;^".F7>B_"7PKI]]JUEKEQ:V*0G4-.G\^WG5>$*28&X;
M0HSCM6O\0O\ D0?$W_8,N?\ T4U '/?L_P#BK5/''P;\*Z[K5S]LU2^M?-N)
M_+6/>V]AG:H"C@#H*V+/XB:=??$;4?!<<%T-4L;"+499F1?(,;L5 4[MV[(Y
MRH'O7GO[/6@CQ/\ LM^$]+:_O]+%UIVS[9IEP8+F+]XQRD@Y4\=?>N!TG]G.
M];X]:]!)XI^(4&DKHMNT6O+J\RRSR>8VZ$W&W#A1SL[9S0!]4T52T731HNCV
M&GBYN;T6D$< N;V4RSR[5"[Y'/WG.,ENY)-7: "BBB@#SS5/V@? .BZG=Z?>
M:]Y-Y:3/!-']CN&VNK%6&1&0<$'D'%;G@OXE>'/B']L_X1_4?[0^Q[//_<21
M[-^[;]]1G.UNGI7PS\4/^2E^+?\ L+W?_HYZ]S_8O_YG'_MS_P#:]=]3#QC3
MYT?F65\3XS&YJL#4A%1;DM$[Z)M?:MT['<?$;XC>)M4^)%E\-_ 4EG9ZRUG_
M &CJNM7L1FCTVWW!5"QY >1CT!XP1ZY7-\66'Q@^&>GQ^(-/\4M\28;>5!>>
M'YM&AMYIHF8*Q@>  [AG.&R, GG&#0L[N+P#^V!KLNM%+.T\7Z/;KI=Y-A4D
MF@VH\ 8\;R!NQW^7U&;?[1!\>>"?#_B;QEI'Q0_L+3;6 26FAR:/9R*9 @'E
MB:0%F+L&;H3\V!P*X#]-.^\8?&[P9\/[RRL_$6KMI5[>6WVN"UDM)GE=-P7
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MYKOC.U\0QVTMO_:OAQM+@@B"2R*C)!,GSED+C!8D$ GM@^_^)/$6G>$=!O\
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MAZ3<7:V,5Q]EFN-TS([JFV)'8?+&YR1CCKR*[>OB/_@KA_R;?X;_ .QLMO\
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M!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>W4^\R1F/'ONQ6)^UY>W4GP_\/\ AZ"Y^QV_BCQ)8Z'>3;]FVWE+L_S=@?+
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M^S+\-="U/3M1L_#>R_TZXCNK2XDOKF5X7CSL +R'Y1G[GW?;BM3QG\"_ _Q
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M#T/XD^&[C0/$=D=0TFX9&EMQ/)#N*L&7+1LK<$ ]>U>=+^R#\)U4 >&K@ <
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M9CQR23P*VZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA'Q]X0L;?5=<T SV]QI<\X@^W6DR@,BR,=JNARRYXR3G.,'UNB@#QCP7X/\
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MU&+1[^-M,AM&L9Y0?+EB:/!9 P((<$X'J>/?: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>L^(])TB[F ,5O?7T4$C@G *JS GGTK8EO((+1[J2:..V1#*TS. BH!DL6Z
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MRKQ'!;NRC+  L #S@\' !]X45\F?'[]O4_!GXD>)?#>C_#?4_&^F>#;*TO\
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M+]M+X"Z;\,E'_"](8)KJS?5&QI T[$Y;[1@;SQ%=?ZO!V[NI*8@_8C2[T/\
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M1P01WJ2@#A_C%_R*5A_V,.A?^G:TKN*X?XQ?\BE8?]C#H7_IVM*[B@ HHHH
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M10 4444 %%%% !1110 445PGQ(^,.C_#74O#^F75M?:IK&N7'D6>GZ;!YTK
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M>-?,O+ZX?S;N]=;W2P'ED/7&3A0 JY. ,FOU0KY__:._92_X:"^*GP7\9?\
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MR_F^MV]?3/[//P&\8?!O0?%UCXF^+.M_$BYUJ[:YL[S5EFWZ8A0J(H_,N)>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\],@8KYIT)(].TWX9_#KQO?0Z7X9^&MC'XE\837#EHX[J21C9638SN8>8"4
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M.0.^6QUX^AJ\!_:E\-_"FZ32-6^)NMZAIBHK164%G-(/.93N)$:*Q+#</F.
M-PY&: (O^&$_A)_T";__ ,&,O^->\Z7IT&CZ;:6%LI6VM84@B5CDA54*.>_
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M_M>OIJO%Q'\5G]#<*?\ (FH?]O?^ER"BBBN8^M"BBB@ HHHH **** "BBB@
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M#?"C3O[<U"S89BN;YA$ZAN<,-TMJNT@\1S#HQQ])_L;_ +,7_#)7PBD\#_\
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M#_M[_P!+D%%%%<Q]:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&?$7_F'_ /;3_P!EKC*[/XB_\P__ +:?^RUQE !1110 4444 %%%% !1110
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MB@#7\,_\?\G_ %R/\Q73US'AG_C_ )/^N1_F*Z>L9;GOX+^$%%%%2=P4444
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M\;]%%4E8YYU)5'S2>MDON5E^""BBBF9GTS^Q?_S./_;G_P"UZ^FJ^9?V+_\
MF<?^W/\ ]KU]-5XN(_BL_H;A3_D34/\ M[_TN04445S'UH4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?*O\
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MXU0HI\S,OJ]+^4O_ -LS_P!V/\C_ (T?VS/_ '8_R/\ C5"BCF8?5Z7\I?\
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M$?4&@#ZUHKY4_P"'D/PP_P"A?^('_A)W7^%'_#R'X8?]"_\ $#_PD[K_  H
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M)M%_Y#-A_P!?$?\ Z$*]9H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .)U#_C_N?^NK?S-5ZL:A_P ?]S_U
MU;^9JO6ZV/E)_$PHHHIDA1110 4444 %%%% !1110!K^&?\ C_D_ZY'^8KIZ
MYCPS_P ?\G_7(_S%=/6,MSW\%_""BBBI.X**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"CKFE_VUH][8?:KFQ-S"T0N;.4QS
M1$C =&'1AU'TKY"UCX#>(;7X^>'=%?XM^))M1NM&NITU-G;[5 BR+F,'. C$
M_P![J.E?9=>"_M(?#G5O$&N^'_$VG_$+3/AZ-(CDB2_O L;EG^\OFEERI4#*
M'(XSB@#/OOV3=<UVUDL-;^,7B_5=)N!LN;*27"S)GE3EB,'Z&OH+3K"'2M/M
M;*V3R[:VB6&)<YPJ@ #\A7R5_P ))XVMX?\ DZKP251?^??3G; 'XDG]:^K?
M#L[W7A_3)I+M=0DDM8G:[1-BSDH"7"]@W7'O0!H4444 %%>8^*OC]HOAWQ-?
M:!I^C:]XNU73XEEU"'P[9+<BR!!($K,Z@,0,[02WM5Y?CKX-D^%__"?+J>?#
M^W&?+/G>;NV^1Y?7S-WR[?QSCF@#T"BO-?!_QWTGQ3XJMO#=YH7B#PIK-Y U
MQ96OB&Q%N;M%&7\LJ[ E1R5)# =J]*H *X?2/^2V>*_^Q>T?_P!*=3KN*X?2
M/^2V>*_^Q>T?_P!*=3H [BBBB@ HHHH **** "BBB@ KQ[XP_P#(S6W_ %YK
M_P"AO7L->/?&'_D9K;_KS7_T-ZWH_&?/Y[_N;]4<+1117<?FX4444 %%%% !
M1110!Z;\%O\ F,_]L?\ VI7IU>8_!;_F,_\ ;'_VI7IU>?5^-GZ=DW^XT_G^
M;"BBBLCV@KY5_P""7'_)B?PR_P"XG_Z=+NOJJOE7_@EQ_P F)_#+_N)_^G2[
MH ^JJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /DSXV_!+Q7\$_B!??'+X&V/VO5+C#^,
M? 49*6_B2!22TT*@?)>*"Q# 98D\$EEE]V^"7QM\*?M _#^Q\7^$+[[7IUQF
M.:WE 2XLIU WV\Z9^2121D=""""5()[VODSXV_!+Q7\$_B!??'+X&V/VO5+C
M#^,? 49*6_B2!22TT*@?)>*"Q# 98D\$EEE /K.BN"^"7QM\*?M _#^Q\7^$
M+[[7IUQF.:WE 2XLIU WV\Z9^2121D=""""5()[V@ HHHH **** "BBB@ KS
M_P"('_(9A_Z]U_\ 0FKT"O/_ (@?\AF'_KW7_P!":@#F:*** "BBB@ HHHH
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MH **** +NB_\AFP_Z^(__0A7K->3:+_R&;#_ *^(_P#T(5ZS0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M<:KK'EZI>)Y.=LSC.[_:/M53^V_^F/\ X_\ _6J#6O\ D,W_ /U\2?\ H1JE
M5<S.1X6BW=Q_,U/[;_Z8_P#C_P#]:C^V_P#IC_X__P#6K+HHYF'U2C_+^9J?
MVW_TQ_\ '_\ ZU']M_\ 3'_Q_P#^M6711S,/JE'^7\S4_MO_ *8_^/\ _P!:
MC^V_^F/_ (__ /6K+HHYF'U2C_+^9J?VW_TQ_P#'_P#ZU']M_P#3'_Q__P"M
M6711S,/JE'^7\S4_MO\ Z8_^/_\ UJ/[;_Z8_P#C_P#]:LNBCF8?5*/\OYG9
M^#-1^V:I*GE[,0DYW9_B7VKLZ\_^'_\ R&9O^O=O_0EKT"EN;PIQIKEBM HH
MHI&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7SI\<- T/Q5^T1\.-+\9I%-X8DTZ^>VM[R0I;S7H*?*>0"VW:0._'KBO?
M->URR\,Z+?ZMJ4ZVNGV,#W%Q,W1(T4LQ_(5\K^+OVDM&\>:39ZQXD^#/B'4/
M =I=)=6WB":(_NMK +.H &!G XDP>F3TH \_U/X8^!=-^&_Q=:33=/M/$G@K
MQ)-+ILTR*2UN71[>&1#\LB,-Z;6!X_*ON3PO>+J'AG2;I;9;-9[2&46Z+M6(
M,@.P#L!G'X5YMK?P%^&/QEUO2O'U[I$>JW%U!#<1W"S.L5U'M!C,B X;Y<#D
M<@ '(&*];50JA5   P .U "T444 ?)'[/>K?$G6M/\=W?A+3O#]M++XEOI[W
M4/$7G.]U<%AB%%BV[51=OS$X!; 7@U4USQE8^.=(^%=I%X=M?#$L/Q%2RU[1
M;6)%A^WP\R'Y0-P)8-SUS@YQFO55^&/Q ^'7B;Q+<_#N_P##TVA^(+M]2ET[
MQ!YZ&RNW \QXFB4[E8@':<8P /4U?^&9YD^$HT)/$+?\)B-:_P"$I&O&(;3J
MN[=YA3KLQ\OKCGVH E_:81+?Q!\'+^(_\3"/QK96R*",F&57$QQUQA5SVYY[
M5[E7B^G_  Q\=>-/'GAK7OB)>>'UL?#9>XLM-\/^>RSW3+M$TK2A2-O55 //
M4FO:* "N'TC_ )+9XK_[%[1__2G4Z[BN'TC_ )+9XK_[%[1__2G4Z .XK"\1
M>//#/@^_T>QU[Q%I.B7NLW M-,MM1OHK>2^G)4"*%78&1R64;5R<L/45NU^/
MWQO\!_&71_VK/V6O&/QM\1V=_P")O$GC*V2W\/:4/]#T2""^L"(T(.TLQG.X
MC=]Q<N_8 _775M8L- TVXU'5+VWTW3[==\UU=RK%%$OJSL0 /<FL?P3\2O"/
MQ*LY[OPAXIT7Q5:0.(Y9]$U&&\CC8]%9HV8 \'@U\"_\%2O'=DWQC^!/@3Q9
M<W4?PVN;U]7UZQLUD=]16.5%6'9&-S$@.B@?Q39XP".Y_9&E^ NL?M->+-5\
M!^'_ !=\)/B"-+2"^^'^NZ=%H]O);#9^_CLT!&<B-C\P(SNVX9B0#[+\7>-O
M#OP_T5]8\4Z_I?AK24=8VO\ 5[R.U@5F.%4R2,%R3T&>:X3_ (:Q^"'_ $63
MX?\ _A46/_QVN[\7>"?#OQ T5]'\4Z!I?B727=9&L-7LX[J!F4Y5C'(I7(/0
MXXK\V-0^!7P]_:J_;VNO!'AOP+X:\._"WX61;_$!T'2+>R.JWY;!MY9(55BN
M]2FT]!!/C!<$ 'Z.>(OB9X/\'ZUINCZ]XKT31-7U,XL;#4=1AMY[LYQB*-V#
M/SQ\H/-7_$GB[0_!ME#>>(-:T_0[2:=+6*XU*ZCMXWF<X2-6<@%V/ 4<GM7Y
M6_MT:?HMA^T!\?;/QQX<O-9\1>+= T6W^&<B:?)=.9D$:SI;.JGRW$H=FY!(
MW#^/:WORZ[#\3?CIX(T[Q[K5EI_@OX&Z+9:CXFU+5KN.&SF\3S6ZK"CR/A28
M%WR;MW#M@CF@#[JKQ[XP_P#(S6W_ %YK_P"AO7J.@^(-+\5:/:ZMHNI6>L:5
M=)YEO?6$Z3P3+G&Y'0E6&0>0>U>7?&'_ )&:V_Z\U_\ 0WK>C\9\_GO^YOU1
MPM%%>*?M$^/O&W@G7?A]'X*A749KR_N7OM':-"VHVT-NTTD,;$920JC;"",N
M%!R"17:W97/SRE3=:?)'^NI[717CMK\8)O$7Q*\.2>&YY-?\+:IX,O==@L+%
M8!)=3)<VB1[7D*;7"RR+M9U4$G=@CCLO#WCC6M:U:&TO/AYXDT&WD#%K_4+C
M3'ACP"0&$%Y))R1@80\D9P,FBZ*E1G%7?YG845X[\+?'GCCQ'\9/&^C^*[&S
MT73K/2],O-,TBUF6XDMUF>Z5VGE"@-*QB&50F-0JA2QW.WL5"=R:E-TI<K\O
MQ5PHHHIF1Z;\%O\ F,_]L?\ VI7IU>8_!;_F,_\ ;'_VI7IU>?5^-GZ=DW^X
MT_G^;"BBBLCV@KY5_P""7'_)B?PR_P"XG_Z=+NOJJOE7_@EQ_P F)_#+_N)_
M^G2[H ^JJ*** "BBB@ HKF?B=_R37Q9_V"+O_P!$O7XL?"CP/^S3J_P9N=2\
M?_$/Q-H7Q&5+HQ:3IMHTMN64-]G_ .75E.[Y<@S+UZKU%*-R6['[FT5^>?PE
M_;"\3?L\_L-_#_QAXOT*]\8RWVM3:1:M=WYMYS9@2O'+O:-RX7RV10<94+\V
M!7O/BC]KS5_A;\+[[Q=\2?AG?^$+RXOH[#PYX=AU2&_O]8DD0LF4C4"#_:#%
MF7!&"=JL<K'<^DZ*^:_ /[7VL2?%;1OA[\5/AE??"O7?$-N)]!DDU6'4K:^(
MW[XVEC51%(-JX0Y)W#=LRF_P_P#9;^.7Q3\4?M??%9O%7A69;&,PVVJQ7?B*
MW,'A*WB$I54& LRDC#&/;SEVSDFCE87/T$HKXXF_X*#:MJ&B:OXZ\.?!G7=?
M^#VDWHMKKQ>-2A@N&C4HLLT5BR[W52QP=X&!\YC(8+Z1\6/VQ/#O@;P7X$U7
MPOI5UX^UOQZ8U\,Z+82+ UWN"$M([ ^2J[U5LJ2&."  Q56871[_ $5X!\%_
MVI[WQUK'CW1/'G@'4?AEK/@R(7>IFYNA?V"6YB63<;N-%0/M.[9SE/F4MA@O
MFS?\%!M8D\,S?$.U^"VO7/P8BO3:GQ@NIP+<,@;RVF6Q*[B@DRF[S-N1@L&!
M4%F%S[(HKX5^//B'3O%O[<G[+^MZ/=QW^E:C937=I=19VRQ.KLC#//((ZU]D
M?$+Q@? /@O5O$"Z-JOB%[&'S$TO1+1KJ\N6)"JD<:C)))'/0#)/ -%@.BHKY
M2\,_MI>*[/XI>!O!WQ,^#=]\.1XT!72+QM=AOV:3Y,++$L:-%]]00QWJ2 4Z
MXHZQ^W5XED^(_P 3/!?A/X-7_B[4_!,K27$\&N16\$EI'N$LKM)%\DF?+V0H
M)&<&0@CR\,^5A='UW17Q"W_!2F^NOAC9?$;3?@SK=WX&MYH;+7-8FU:"$6-T
MS*K1P)M+7*C<N)"(P20IVD\>N_%C]K)?">O>"?"W@3P=>?$;QOXML/[7LM%B
MO8]/2*QV%A--/("J;MK!01@E'!*G:&.5A='T#17S?X6_;+M?$'P@^)OB6[\(
MW6B^,?AVLRZ[X0O+Q2T<B*Q39<*A#1OL<!]G5&^4C:S>92?\%(-:L?A[X6^(
MNH_!35K'X<:K=QV-UKYUJ!V@F,DBR>3 (]\R*L9Q(WE*S IP<%CE871]NT5\
M]_'+]K.3X;_$#PI\/_!/@JZ^)/CKQ#;_ &^'2[>_2QBBM,/B5YW5@"3&V 0!
MA22P^4-\[?LP_$F.+]LO]HKQGXJTNZ\')8Z*MSJMCJ#+(]D8!$)AN0E9%!C8
MJZ\.I5A][%%@N?H;17R!H_[?U_\ 9_#?BOQ+\)=6\+_"7Q)J/]GZ9XRGU6":
M3YG=(I)[-5W0H=C$G<0 ,J9.,]Q\:?VL+[P'\7-'^%W@3P!=_$GQW>VC7\]A
M'J4>G06MN%8AGGD5E#$*>#M'*C)9@I5F%T?0]%?!?[!GB";Q5^U9^T?JMSI-
MYH5S=75NTVFWX7S[:02S!HWVD@D$$9!P>M:7_!2SXI>/O!L?P^T/PYIUU%H&
MJ:M ;F]M=3C@_M"8.<:>Z8W!& 5BY.PYP0<4^76PKZ7/N*BOF[X@?M<:SX(N
M/!7A&#X9W>M_&+Q+;&[/@>SU>#981 L&::]VF,#"N00N#L;)7@GH?@#^T]%\
M8/$_B;P5XA\+W?@'XC>&R&U+PY>7*70$3$;)8ID $B$-&20H'[Q<%@0Q5F.Y
M[A1112&%%%% 'R9\;?@EXK^"?Q OOCE\#;'[7JEQA_&/@*,E+?Q) I)::%0/
MDO%!8A@,L2>"2RR^[?!+XV^%/V@?A_8^+_"%]]KTZXS'-;R@)<64Z@;[>=,_
M)(I(R.A!!!*D$][7R9\;?@EXK^"?Q OOCE\#;'[7JEQA_&/@*,E+?Q) I)::
M%0/DO%!8A@,L2>"2RR@'UG17!?!+XV^%/V@?A_8^+_"%]]KTZXS'-;R@)<64
MZ@;[>=,_)(I(R.A!!!*D$][0 4444 %%%% !7G_Q _Y#,/\ U[K_ .A-7H%>
M?_$#_D,P_P#7NO\ Z$U ',T444 %%%% !1110 4444 =G\.O^8A_VS_]FKLZ
MXSX=?\Q#_MG_ .S5V= !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!ROQ8DO8?A;XRDTXN-071KQK8Q_>\T0/LQ[YQ7R'_P *Q^&N
MG>$?@1X@L],TV^TK4+V+3-=N)6#K+-<6_P PF)/RLD@8@<;?:OH+XJ?M&Q^!
M/&4/A'0/"FJ^-_$[0BYGL=,&%MHCT+OM;!/7IC!&2,C/+?"67X;?&3POXL^'
M\W@6;PC<K<_;=6\-WBM$\<KA0)XB,%?N)T"XXXPW(!H?LX:#HO@7XD?%SPCX
M?MK5-*TV^LKB&:) 9%\Z%V:W:3JXB96 #$E=Y'K7OM<?\,?A+X7^#^AR:5X7
MTT6-O-)YTSL[22RMT!9V))P. .@_$UV% !7SA^T=JVKP_'3X-V>DZ/'J]YOU
M&:SM[J0I;O<>4BK)(0I(6$$R'&37T?7G'QB^%]_X[_X1[6/#^IQ:/XL\.7;7
M>FW5PA>%@Z[989 .=CK@$CD8H Y2Q\8>(?#_ ,8O"VC?$C0O#%W>:M%<KH'B
M+18'#V\JH#- WG%G3<A'S*0&X&#SM9^QK9PWW[-F@RW$:SR:G)?2WC2<^>S7
M4R,6^JJ!^%:6A_#/QGXH^)6A^+_B#=Z&H\/PS+I>DZ#YTD(FE4*\\CRJ"6VC
M  '& <Y!SA6/PA^)G@"R\0>&O VM>'H_"FIW$T]K-JBS"]TOSB3(L2QKLD )
M)7<1@]: -']C&XFF_9[T"-\O!;SWD%O*>?,B6YDVG/0]QQQ\M>WUS/PU\!V/
MPQ\"Z+X7TYVEM=-@$0E<8:1B2SN1V+,6;';-=-0!P_QB_P"12L/^QAT+_P!.
MUI7<5P_QB_Y%*P_[&'0O_3M:5W% !1110 4444 %%%% !1110 4444 %%%%
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MXRT&]T76;5;[3+Q/+GMV9E#KD'&5(/4#H:\P_P"&/_@__P!"5;?^!5Q_\<H
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MU>RT[65/]F7EQ82QPWW^O_U#E<2=1]TGJ*^V:*?,+E/S,T7X2>.8O^"6NO\
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M??'+X&V/VO5+C#^,? 49*6_B2!22TT*@?)>*"Q# 98D\$EEE]V^"7QM\*?M
M_#^Q\7^$+[[7IUQF.:WE 2XLIU WV\Z9^2121D=""""5()[VODSXV_!+Q7\$
M_B!??'+X&V/VO5+C#^,? 49*6_B2!22TT*@?)>*"Q# 98D\$EEE /K.BN"^"
M7QM\*?M _#^Q\7^$+[[7IUQF.:WE 2XLIU WV\Z9^2121D=""""5()[V@ HH
MHH *\_\ B!_R&8?^O=?_ $)J] KS_P"('_(9A_Z]U_\ 0FH YFBBB@ HHHH
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M.,;VZ>M=E0 4444 %%%% !1110!P_P 8O^12L/\ L8="_P#3M:5W%</\8O\
MD4K#_L8="_\ 3M:5W% !1110 4444 %%%% !1110 4444 %%%% '&?$7_F'_
M /;3_P!EKC*[/XB_\P__ +:?^RUQE !1110 4444 %%%% !1110 4444 7=%
M_P"0S8?]?$?_ *$*]9KR;1?^0S8?]?$?_H0KUF@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W_\
MU\2?^A&J57=:_P"0S?\ _7Q)_P"A&J5 !1110 4444 %%%% !1110 4444 =
M-\/_ /D,S?\ 7NW_ *$M>@5Y_P##_P#Y#,W_ %[M_P"A+7H% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&_&*W\
M177PO\21^$I)8O$?V1FL6@8+)Y@P<*3W(! ]S7@5K^U=XFM_B%X=L+[P%XXA
MM/['D:^T5-#$EW<7*L!Y\62K-$.03P,D<5]7UXG\</%&LVOCKPQX;\"Z3I,G
MC_5K>8IKFI0*W]FV*$&1MV"V&8_=Y&1T)(H 9_PU'_U2/XI_^$U_]MKV?3[S
M^T-/MKKR)K;SXEE\FX39)'N .UU[,,X(]17S;XDU#XZ?!'2V\6ZYXGTGQ_X=
MLF634].2P2TGCA) =XF1!G;G/)_ \U]):??0ZII]M>VS^9;W$2S1O_>5@"#^
M1H L4444 ?,>M?$C7O$WQ9\<Z?%\7M/^&V@:+<VUA90WMI8R&ZF,6Z?!GPWR
MO@<$]>U=CX]\:>*/A9\,]$LH?$,'C+QEXAU2'2M+U2XM(H(RTY)64Q1?*51!
MG/0_+GW/AOI'PL\<ZI\0KFU\(6T&J0ZO/;:ZNN0I+,\F,M)\[.$B8[\!2 =I
M.!7S[H,B:=X*\(ZNEV[^"?#_ ,5I(M.NIY"RQ::2!$X)_P"68;?D^IZ4 >[R
M>)/''P?^(G@[3?%/BN/QIX?\47#:;YSZ9#9SV=WMS&5$6 T;'((;)'J>_NU>
M&?M&7*ZQXO\ @WX=M3YU_-XMMM7"1G<P@M4=I&P/X</U]J]SH *X?2/^2V>*
M_P#L7M'_ /2G4Z[BN'TC_DMGBO\ [%[1_P#TIU.@#N**** "BBB@ HHHH **
M** "O'OC#_R,UM_UYK_Z&]>PUP7CSPW;:QK$,TTDRLL"H!&0!C<Q[@^M:TG:
M5V>)G%*5;"N$-[H\AHKNO^$%L/\ GM<_]]+_ /$T?\(+8?\ /:Y_[Z7_ .)K
ML]I$^$_L^OV1PM%=U_P@MA_SVN?^^E_^)H_X06P_Y[7/_?2__$T>TB']GU^R
M.%HKNO\ A!;#_GM<_P#?2_\ Q-'_  @MA_SVN?\ OI?_ (FCVD0_L^OV1PM%
M=U_P@MA_SVN?^^E_^)H_X06P_P">US_WTO\ \31[2(?V?7[(T_@M_P QG_MC
M_P"U*].KC_A[H5OHOV_R'D?S?+SYA!Z;NF /6NPKBJ.\FT?H.5TY4L'"$MU?
M\V%%%%9GJA7RK_P2X_Y,3^&7_<3_ /3I=U]55\J_\$N/^3$_AE_W$_\ TZ7=
M 'U51110 4444 >1_&[XS>+?AWJV@:'X(^%FM_$K7=5,CM]GF%AIUI"B,29K
MV1&C20D +&V-W/(.Q7Y#X+_ME:7\1O"GQ,U'Q5X<NO FK?#EY%\0Z;+=+>B%
M4$O,<B*OF',$HP%Y(&"V0:\S_;.7XCM\=/ QETGXA:[\%/L$JZKIGPT:7[7=
M7!+[XKE8F5FB<"!2&91L:78P;->6_LV_LV^)[CPW^U+X(D\"ZQ\/+;Q3:6Q\
M.VNJ([P(BF[>*'[42RR%?-A5B&8C+9Y!J[*Q-W<S?VO/VHO%'QV_9/O]1N/A
M)JWACP1J^I0#1_$LFI0W(N/+G8CSH %>$,J-AOG4MA0QR"?IOQK^U-)\']-^
M$G@+POX-NOB'\0O$VD6\MKH=O>I9)';K!S*\SJP&2CX&,8CD+,H4;OE;XA:U
M\4_$W[$NG_!>+X&>.HO$.A/;VFHWQTMVM&A@G.Q[8KEKAF(3.Q2H!9MQ7!KU
MWXI^"?&7PE^/'P2^->F^"=>\::/8^&8O#^MZ1H-F9]0LV\B0!Q#PQ_UQZC ,
M15F0NIIZ$ZF;^RWXJU'QI_P4>^+^KZOX=N_">K2^%[>*\T6]E25[6>--.CD4
M2(2LB;D)208WH5; S@?4_P"TM^T-H_[-/PUD\4ZI8W&KW,UPMCINE6K;9+RZ
M=69(]V#L7",2V#@#@,<*?G;]FFV\;^+/V\/B9\0O$'P]\0^"M#UGPU#'8-K%
MD\89!]B\I7D&8Q,8TW/$&+1MO0\HU=S_ ,%"OA'XH^)/PN\/:SX/TV77=;\(
MZU%K0TB ;I+N%%;>J*.6<?*0JY) ( )P*74KH>!_%CXD>+OB!^V%^S9_PFOP
MXOOAQK%O?-,EG<:A#?PSPR21[&6:,##@QL&C90RY0G[PKJ]0^+%GH7B3]JV7
MX:?"Z2Q\<Z/ PU77H?$SA[I2L^Z]6.5=D1A :01QG+8P.<51^('BCQW^T%^U
M%^S_ .);?X/>./"OAC0;]_M-YKNE/&Z2NT9E,BKN\N)0B;9'V[\O@#::N^#O
MAKXNM?B1^VA=3>%=;AMM?TJZCTB:33IE346,-R MN2N)22R@!,_>'K3$?)$G
M@6"U_8%O/&$_@(Z-J.I:O:PIXP?6C=-KZ?:KSS ;7<?LWDM'&F2 9/O>M?I=
MH?[2GV']H;PK\%?^$<W_ &SPU%J_]N?;L;,1L?+\CR^?]7][?WZ<5\H>,/A+
MXYNO^"6?@;PG#X,\0R^*;?69)9M#CTJ=KZ)#?7C!F@";P-KJV2.C ]Q7HGQ4
MT3Q?\(?VPOAY\64\ >*/&?A7_A%!I-U'X5T]KV\MIUBE!5H01CEX^6*@@M@D
MJ5+>HEH>OZ'^V%_;7BKX[Z-_PB7D_P#"KK.:[\[^TMW]I^6DK;=ODCR<^5C.
M7^][<^8:?_P48\37GPNT[XFO\"=87X=K<+;:MKD>N0,;5_M!C8P0F-7N$"F/
MYSY2^8S1DC;O/!?"WP[XV34/VR/%7BSP-K/@R'7M O+BUCU.W81L/)NCM28#
MRY2%*Y*$@$UP_P .?'WC[Q=^P#I/PBT'X3>*=>U+Q 9K32O$%C;))I)M6U%R
M[SSA\02+(LT>V0* JK(6VGE60[L^L/C%^V\/A]XY^'/AWPKX&N/'Y\>:6FHZ
M1-::BMJTC2@_9T*O&0$8["TC, BEF(.W!E\3_M<^+]!U7PGX*M?A#/J_Q@UJ
MUEU*Z\'6WB*W$&FV:-*!)+?E/+WMY:D(%Q\Q&[.T/Y1J7P&\3^!OVG/V6K"#
M1M1UO2/"?AT:?J>N6=C+)90S)%*"6E"[4!8Y4,0<%>]5?VQ/V>DN/VG]%^)/
MB3X::_\ %?X<ZCIBZ;J.E^%Q+)?V=TBR&.010R([(0J_,6"@E@2#L#%D&I[Y
MX#_;*\,^(_A+XW\9>(M*OO">H>!I9+7Q'X?F*SW%I<(<".-AM63>WR*QV@L#
MG &:^,/VX_VBO%WQN_9A\.7^N?"?4?!'AW5M;MK[1=:DU2&\BO(Q!<@B1%5'
M@9E970,I#J'(.%!;V#P]^S);_$#]DWXM:-X,^#UY\';WQ.8#IVF:QK<]S>:D
M+.83P--%<'%H78,FTMGYB6.T(Q\D^/WB3XH?%S]D/P/\-;'X&>/K/5O#<EA;
M:M=W&C2^4WD6\L,9MD&9)0^W<S[0L> I)WJ::M<'>Q]9?%W]L?4_AS^T-9?"
M31/AK>^--;U'2OMUB]CJD<#2S%92L3K(@6.,>42TI?Y02=IQ@Z7P*_:\_P"%
MK6_Q(L=>\#:IX5\7> Y674O#MG+_ &I-,H#X$#1HOFN6B=0J@@Y0JS!N.(UK
MP/XDE_X*9:!XH3P_JC^&8O";6SZTME(;))=L_P"[,VW8&Y'RYSR*X+P?X%^*
MN@?%;]KO5_"?A_5-,US5D5O#FH7=FT,-XX>4DV\D@".P4_*02,E<U.@:G?S?
MMT>+O".O^##\0O@;J_@7PEXJU'^SK+6+K689;I&;B,RV7EJ\1R5+*[ A=Q7>
M5P?/O%_QH^+'_#Q2QT&V\(76K:=IFGR1V'AW^WX(8)+9RRMJ>2NT.4)/EMEP
M!M!YKY\\2?"_QEXT\-_#3Q _PK^+NK^.]%U2U_X2GQ-XNCN[F9X]^^."S@9F
M=X%(E8L(QY9VAF8R U]3_%33?$_PU_X*#:%\1SX%\4^*/"E[X>72Q=^&=,:^
M\B8LR'S<$"-5R&))Z'(S@@59!J=#XB_;RU-9O%VM^$/A-J?C+X:>$;XV&M^+
M8=6@MC&Z,OGM!;,I:8(K*V0PR""VP?-7T_X*\8:7\0?"&C>)M$N/M6D:O:17
MMK+C!,<BAER.S '!!Y!!!Z5^7&@_LQ:3\']4\9>%_'W[./C#XM^(6U8R^'-=
MT*XNXM.N;20A42XGAD"08VER2C,-Y#;0 :_3'X0^$[?P+\,?#>A6N@Q^%X;.
MR1/[%BOWOULF/S-$+A_FEVDD;CUQQQBIDET&KGA'CO\ ;5UJS\8^.M*^'GPI
MU#XC:/X$!3Q)K4>KPV,=M*H9I8X8W1FG*!'!"X;<A&,;6;1U3]MW18=0^"]]
MIN@27W@CXERFUA\037@A?3;H.(S!-#L92PD.TD2 95\%@N3\F>*OV;=)^%?Q
M@^*[?$'X!^,?C%::Q>S:OX5U3PJ;MH<2M(_V>Y:WD7ROF959BC,-C,J,I7/O
M'QR_9SMKC]@:ZT;3O!Z?#O5_#43^)[/0X=9?4O[,GB=YI5%TYR[-$TOW3@,_
M!( )=D+4]@U;]IZVL?VEI/A1:Z(MU:Z;H3Z[K_B%[[RTTN(*653%Y9WDYA.2
MZX$N><8/E*_\%"KQ-%MO'MS\)-8M_@I<:B=/3QN=3A:;&YH_--@%W[/-4J3O
MQP<$M\AYW]BKX>ZK\=/A'\8/B7XGE6'Q%\5C>:;#<JN5@LTB>W79["0NN/2%
M/P\&^&?[.>C^&?#]EX)\7_LI^+O&OQ/@U&2UGUQ=3O+#0KF!G9TF-['(8DVH
M0N!'@[!EMQ(HL@NS]7K>XBNH(YX)$FAD4.DD;!E92,@@CJ".]252T/3(=%T6
MPTZWA%O;VEO';QPK(T@144*%WM\S8 QD\GJ:NUF6%%%% !1110 4444 ?)GQ
MM^"7BOX)_$"^^.7P-L?M>J7&'\8^ HR4M_$D"DEIH5 ^2\4%B& RQ)X)+++[
MM\$OC;X4_:!^']CXO\(7WVO3KC,<UO* EQ93J!OMYTS\DBDC(Z$$$$J03X5\
M;OC=XJ^-/Q OO@?\#[[[+JD'[OQ?X[C&Z#P[">&@A8??NV&0 #\G/1@S1^Z_
M!'X(^%?V?_A_8^$?"-C]EL(/WDUQ(=T]Y,?OSS/U=V/4]N ,  4 =[1110 5
MY_\ $#_D,P_]>Z_^A-7H%>?_ ! _Y#,/_7NO_H34 <S1110 4444 %%%% !1
M110!V?PZ_P"8A_VS_P#9J[.N,^'7_,0_[9_^S5V= !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\U_%3XM>.OA+XJ^)COX>\1:OH
MEYID=SX?U33;,75IIDJ6A61IL\(GFC>VXG@$X(K0\*?M4W5QX7T>6]^%_P 2
MM1O)+.%I[RS\.!H)Y"@+21D2 %&.2" ."*]K\9ZAIND^#]=O=9MX[O2+:PGF
MO;>6,2)+ L;&164\,"H(P>#FOGOPEIWQZ^(OAO3_ !!I7B?0?A[HUU DNF>'
MX=+CG$=M@>4KLR';E<<+V/0=  >R_#3XI?\ "RO[2_XI'Q5X5^Q>7_R,VF_8
M_/W[_P#5?,V[;L^;TW+ZUW%>4_ OXB^)/%$GB7PSXUL[:U\7^&;B*&\DL<^1
M<Q2H6AF0'IN"MQ[=!T'JU !7C_[2WC[5_!?ASPW::!K47A_5M<URVTX:C-'%
M(EM =S32L) 5VJJ\Y]:]@KR;XT3> Y_%WP\TGQOH+:L^H:A*FF7$W-I;W 08
M$PW@,7)554JP)!Z8H B^$\&NZEK1OS\:K/XAZ5 K)-8V.GV**&(^4M) 2RD'
MG'>N0\+^(OBC\:/#NM>-_"_BRW\/:6+FXCT+1#I<5Q'>QPL5#33/\X\QE9?D
M("X[T[QUHNE>%_VHOA:OA*UMM,U>^AODUFVTY%B66R6,%&F50!PP;:3R2H S
M@5<_9'UZP\-_LYP6NHW,=M-X7GU"WU578?Z.R7,LC;O3Y6!YH ],^#?Q$3XK
M_#'P_P"*U@%L^HP%I85.525':.0#VWHV/;%=G7BO['>EW&F_L_\ AZ:Y1HI-
M0DN;X1./N)).Y3'J"NUL_P"U7M5 '#_&+_D4K#_L8="_].UI7<5P_P 8O^12
ML/\ L8="_P#3M:5W% !1110 4444 %%%% !1110 4444 %%%% '&?$7_ )A_
M_;3_ -EKC*[/XB_\P_\ [:?^RUQE !1110 4444 %%%% !1110 4444 7=%_
MY#-A_P!?$?\ Z$*]9KR;1?\ D,V'_7Q'_P"A"O6: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R;6O^0S?_
M /7Q)_Z$:I5=UK_D,W__ %\2?^A&J5 !1110 4444 %%%% !1110 4444 =-
M\/\ _D,S?]>[?^A+7H%>?_#_ /Y#,W_7NW_H2UZ!0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X[\;/ /BVX\4>
M'/'O@$6ESXFT2.6UETR^?9%?VLF-T>[@!@1D9('/7@ ^Q5F>(O$VD^$=)FU3
M6]2M=*T^$9>YNY1&@]!D]2>P')[4 ?.WB>3XV_'729?"&H>"++X?Z#>,+?5=
M5GU)+F4Q @NL*KS\PX!P0?[PY-?2>FZ?#I.FVMC;*5M[6)(8U)SA5  'Y"N8
MT/XO>#/$EGIEUIWB.QN+?4[IK*RD+[!<3J,F--P&6P>G?M784 %%%% 'GOC'
MX ^ ?'VMR:OK?AZ.XU*5!'-<0W$UNTZC&!)Y3J)!P/O9X%=+-X&\/S^$3X6?
M1[,^'3!]F_LWR@(?+[*%[>N>N>>O-;M% '">!O@=X'^&^J2:EX?T)+34'B\C
M[5-<37,B1_W$:5V*+QT7 KNZ** "N'TC_DMGBO\ [%[1_P#TIU.NXKA](_Y+
M9XK_ .Q>T?\ ]*=3H [BBBB@ HHHH **** "BBB@ KF/$W_'_'_UR'\S73US
M'B;_ (_X_P#KD/YFKCN<.,_A&11116IX 4444 %%%% !1110!O\ A7_EZ_X#
M_6M^L#PK_P O7_ ?ZUOUC+<^BPG\&/\ 74****DZPKY5_P""7'_)B?PR_P"X
MG_Z=+NOJJOE7_@EQ_P F)_#+_N)_^G2[H ^JJ*** "BBB@ HHHH **\B^/'[
M3WA']GV?0+#6+76-?\0:]-Y.F^'_  Y9B[O[G! ++&648R54<Y8G"@X;'S;\
M"OVBM1^(7[=GQ/N1J7BFW\'6/@S[:OA76?.MSI]S%]@$R&TD;9',K&921P2S
M88ALFK,5S[OHKYQ^"_[<WA/X^:QIMEX3\&>.I[6YDDBNM7GTB-=/TUD1G(N;
M@3%$)500 6)W*.IQ63J'_!1;X8V>H7TT&D>,-4\&V%^FG77CO3]$:;0H9B$)
M!G#[SM,BC C).05#!E)5F%T?4E%>&?&K]L;P!\"KSP1'K@U34K/QA&TVFZAH
MENEU!Y8\O#MAP[!A,A7RU<GTZ9=\'?VO?!_Q?\;ZIX-.C^)? _BW3[87C:)X
MQTX6%S+#@$NB[VX 920Q!PV0" 2"SW"Z/<:*^5+C_@H_\,[>22^'A_QQ-X+C
MO_[/;QQ%H);10^0"?-W[R!G[HCWGLIXKZFM;J&^MH;FVECN+>9!)'-$P9'4C
M(92."".<BBS0&7XT\*VGCKP?KOAN_DFAL=8L)].N)+=@LJQRQM&Q0D$!@&.,
M@C/8US_P3^$.C? 7X8Z-X%\/W-]>:1I7G>1-J4B/.WFSR3-N9$13\TC 84<
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M.U[H7B&S-AJ=GF%FBEV!C@'&00V1QD#*Y\%_91_; M? G[-?@-O&M_XE\?\
MC?Q-K5W8Z?IMI)_:&J7($I 8^?*N(U.%R6[\# ;#LPN?>=>6?'[]GW3?VAO#
MUMHFK^*O%7AS38_,%Q!X:U%;5+Y' !CN%9'61!MX!'&3ZUZ?;R--!'(\3P.R
MAC%(060D?=.TD9'L2/>OSJ_;N_:>\63?%+0/"_@#6M2T;PYX=URTL-=U;2KM
M[8W&HS;F%IO1@72.)&+J. SX89"T+5@S[]\$>"]&^'/A'2?#/AZR73]%TNW6
MVM;96+;$7U8DEB>2222223R:W***D84444 %%%% !1110 5\F_&[XW>*OC3\
M0+[X'_ ^^^RZI!^[\7^.XQN@\.PGAH(6'W[MAD  _)ST8,T9\;OC=XJ^-/Q
MOO@?\#[[[+JD'[OQ?X[C&Z#P[">&@A8??NV&0 #\G/1@S1^Z_!'X(^%?V?\
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M444 %%%% !1110!=T7_D,V'_ %\1_P#H0KUFO)M%_P"0S8?]?$?_ *$*]9H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /)M:_Y#-_\ ]?$G_H1JE5W6O^0S?_\ 7Q)_Z$:I4 %%%% !1110
M 4444 %%%% !1110!TWP_P#^0S-_U[M_Z$M>@5Y_\/\ _D,S?]>[?^A+7H%
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M &:NSH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ HHHH **** .,^(O_ ##_ /MI_P"RUQE=G\1?^8?_ -M/_9:XR@ HHHH
M**** "BBB@ HHHH **** +NB_P#(9L/^OB/_ -"%>LUY-HO_ "&;#_KXC_\
M0A7K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV7=.\+_![Q3;>%M5\97,HM)I8-&@U>>6&XE;D@P+Q(6/48YI=7^#>MZ7\#_
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M&AV.B7HMX-4N9"KEKA3_ *]#O$04Y&2G^T&]6\0?%KQ9\?=5_9Y^'>C:I?\
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MU\1_^A"O6:\FT7_D,V'_ %\1_P#H0KUF@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_ )#-_P#]?$G_
M *$:I5=UK_D,W_\ U\2?^A&J5 !1110 4444 %%%% !1110 4444 =-\/_\
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M+.JKLDQT'(/8FO6: "N'TC_DMGBO_L7M'_\ 2G4Z[BN'TC_DMGBO_L7M'_\
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M##0_C[H#^*-16U^U@:G-+%=(GFR_97\V-ED5S;&('YLG/S9.:\)\006FE_\
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MQKZKHH ^5/\ AV]\,/\ H8/B!_X5EU_C1_P[>^&'_0P?$#_PK+K_ !KZKHH
M^5/^';WPP_Z&#X@?^%9=?XT?\.WOAA_T,'Q _P#"LNO\:^JZ* /E3_AV]\,/
M^A@^('_A677^-'_#M[X8?]#!\0/_  K+K_&OJNB@#Y4_X=O?##_H8/B!_P"%
M9=?XT?\ #M[X8?\ 0P?$#_PK+K_&OJNB@#Y4_P"';WPP_P"A@^('_A677^-'
M_#M[X8?]#!\0/_"LNO\ &OJNB@#\X/VX/V//"7P&_9=\:^.O"GB7QQ#K^E?8
MOLSW7B:YEC'FWL$+Y4GGY)&_'%?H_7RK_P %1_\ DQ/XF_\ <,_].EI7U50
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MPS\/=+_LWPKX=TGPUIV[?]CT>QBM(=Q[[(U S^% 'B^O_M&?!GXX_ KXEZC
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M0O\ T[6E=Q7#_&+_ )%*P_[&'0O_ $[6E=Q0 4444 %%%% 'E7QT_P"%W_\
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M>&HUM+VV78X#QW;%BF?.F)'EY^?&1CGF_P#@G_\ %SQM<?%#XS_!CQEXDO\
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M!;&$4=A5+5O@WX U[Q1%XEU/P-X;U'Q'$0T>KW>D6\MVA P")F0N#CWKL**
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MUK?K&6Y]%A/X,?ZZA1114G6%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'RK_ ,%1_P#DQ/XF_P#<,_\ 3I:5
M]55\J_\ !4?_ ),3^)O_ '#/_3I:5]54 %%%% !7R?\ &KXU>*OC9\0+_P""
M'P0O_L>HVV$\8^/8QO@\.PMD-!"P/SWC ,  ?DP>00S1GQJ^-7BKXV?$"_\
M@A\$+_['J-MA/&/CV,;X/#L+9#00L#\]XP#  'Y,'D$,T?NOP5^"OA7X _#^
MP\(>$+#['IUMEY9I#OGNYFQOGF?'SR,1R?8      /@K\%?"OP!^']AX0\(6
M'V/3K;+RS2'?/=S-C?/,^/GD8CD^P    '=T44 %%%% !1110 4444 %%%%
M!1110 5Y_P#$#_D,P_\ 7NO_ *$U>@5Y_P#$#_D,P_\ 7NO_ *$U ',T444
M%%%% !1110 4444 =G\.O^8A_P!L_P#V:NSKC/AU_P Q#_MG_P"S5V= !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S'Q0CNIOAI
MXMCLKE+.]?2+M8+B201K%(87VN6/"@'!R>!BO!?@9:_L_P!W\,- 2YM?!9U6
M*TC34$UQ+4W@N0H$N_S?FQO#8(^4CI7TAXDCTV7P[JB:TL3Z.UK*+U9QF,P%
M#Y@8?W=N<^U?(G@N7P)XX^)/A33(/@;IFE^#_$C7::=K6H*JS70@@>4NL('R
MJ=JCD]\@]@ ?37P[L_A]:?VA_P ()!X:AW>7]L_X1U+=<_>\OS/)_P"!XW?[
M6.]=E7BG[,^I^%-0L?$<.C>"(_ /B*QN4M-;TE4 8.H8Q-N'WE(9R#[GJ,$^
MUT %1W'F^1)Y.PS;3L\S.W=CC..V:DK@?BI\*1\1I-"U&RUJZ\.>(M!N'N=-
MU2V191$SJ%=7B;AU8  @X^N"00#R/2AXE\)_M.>'KWXE_8]5OM=L)].T"_T5
MFBL[(IF26-H7!?>V0 Y<\-CG^#J/V+Q'_P ,U^&?,"^:7O?M.[&[?]KFSO\
M?;CKVQ6]X9^"^H+X\LO&/C/Q7)XOUK3(9(-,2.P2RM;,2#$C+&K,6=AQN+=.
MW3&%=_LZZUI[^(-/\*?$&[\,^%==GDN+K2!IT=P\32?ZX6\S.#$&R?X3C/%
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M( !] *Y*NS^(O_,/_P"VG_LM<90 4444 %%%% !1110 4444 %%%% %W1?\
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M=LLH^QW<>\%HIH\?,6X YZXX[U[!X?U-M:T'3=0:(P-=VT=P8CU0NH;;^&:
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MWSS/CYY&(Y/L    !W=%% !1110 4444 %%%% !1110 4444 %%%% !7G_Q
M_P"0S#_U[K_Z$U>@5Y_\0/\ D,P_]>Z_^A-0!S-%%% !1110 4444 %%%% '
M9_#K_F(?]L__ &:NSKC/AU_S$/\ MG_[-79T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &%X[\.-XP\#^(=!27[.VJ:=<6(F/\
M 98F3=^&[-?'TOQ;U3P7XL^$=GXM\#>(+&_\"17EG>"PL_/BNT:S^SPR6[9
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M;=MV9X(_O5TE<9\.O^8A_P!L_P#V:NSJ6[G;3IJG%004444C0**** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^:O#7Q+\*_#O\
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MT32M*%(V]54 \]2:]HHHH *X?2/^2V>*_P#L7M'_ /2G4Z[BN'TC_DMGBO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Y_P#$#_D,P_\ 7NO_ *$U
M>@5Y_P#$#_D,P_\ 7NO_ *$U ',T444 %%%% !1110 4444 =G\.O^8A_P!L
M_P#V:NSKC/AU_P Q#_MG_P"S5V= !1110 4444 %%%% !1110 4444 %%%%
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M:XRNS^(O_,/_ .VG_LM<90 4444 %%%% !1110 4444 %%%% %W1?^0S8?\
M7Q'_ .A"O6:\FT7_ )#-A_U\1_\ H0KUF@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W_P#U\2?^
MA&J57=:_Y#-__P!?$G_H1JE0 4444 %%%% !1110 4444 %%%% '3?#_ /Y#
M,W_7NW_H2UZ!7G_P_P#^0S-_U[M_Z$M>@4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%><
M?'KXCZA\-O \,^BV\5SXAU:_@T?2XY@2GVF8D*2!R< ,<=\4 >CT5X-?:]X^
M^#7C+P6GBCQ9'XU\/>)-0319F?3(;.6SNY%)A:,Q8W(Q4@ALD =37O- !7#Z
M1_R6SQ7_ -B]H_\ Z4ZG7<5P^D?\EL\5_P#8O:/_ .E.IT =Q1110 4444 %
M%%% !1110 5Y_P#$#_D,P_\ 7NO_ *$U>@5Y_P#$#_D,P_\ 7NO_ *$U ',T
M444 %%%% !1110 4444 =G\.O^8A_P!L_P#V:NSKC/AU_P Q#_MG_P"S5V=
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>?\ Q _Y#,/_ %[K_P"A-7H%>?\ Q _Y#,/_ %[K_P"A-0!S-%%% !11
M10 4444 %%%% '9_#K_F(?\ ;/\ ]FKLZXSX=?\ ,0_[9_\ LU=G0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%>#VOQ6^)/Q$F\3:G\/]+\.2>&]%O)K" :P9S<ZI)%CS#$8V"QJ3PI8
M')QG'. #WBBN4^%GQ$LOBKX!TCQ181/;17T9+VTART$BL4DC)[[65AG R,'
MS75T </\8O\ D4K#_L8="_\ 3M:5W%</\8O^12L/^QAT+_T[6E=Q0 4444 %
M%%% !1110 4444 %%%% !1110!QGQ%_YA_\ VT_]EKC*[/XB_P#,/_[:?^RU
MQE !1110 4444 %%%% !1110 4444 7=%_Y#-A_U\1_^A"O6:\FT7_D,V'_7
MQ'_Z$*]9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /)M:_Y#-__P!?$G_H1JE5W6O^0S?_ /7Q)_Z$:I4
M%%%% !1110 4444 %%%% !1110!TWP__ .0S-_U[M_Z$M>@5Y_\ #_\ Y#,W
M_7NW_H2UZ!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG_Y85W%% '#_ -D?$C_H:_"O_A,7/_RPH_LCXD?]#7X5_P#"8N?_ )85W%%
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M^6%=Q10!P_\ 9'Q(_P"AK\*_^$Q<_P#RPH_LCXD?]#7X5_\ "8N?_EA7<44
M</\ V1\2/^AK\*_^$Q<__+"C^R/B1_T-?A7_ ,)BY_\ EA7<44 </_9'Q(_Z
M&OPK_P"$Q<__ "PH_LCXD?\ 0U^%?_"8N?\ Y85W%% '#_V1\2/^AK\*_P#A
M,7/_ ,L*/[(^)'_0U^%?_"8N?_EA7<44 </_ &1\2/\ H:_"O_A,7/\ \L*/
M[(^)'_0U^%?_  F+G_Y85W%% '#_ -D?$C_H:_"O_A,7/_RPH_LCXD?]#7X5
M_P#"8N?_ )85W%% '#_V1\2/^AK\*_\ A,7/_P L*/[(^)'_ $-?A7_PF+G_
M .6%=Q10!P_]D?$C_H:_"O\ X3%S_P#+"C^R/B1_T-?A7_PF+G_Y85W%% '#
M_P!D?$C_ *&OPK_X3%S_ /+"C^R/B1_T-?A7_P )BY_^6%=Q10!P_P#9'Q(_
MZ&OPK_X3%S_\L*/[(^)'_0U^%?\ PF+G_P"6%=Q10!P_]D?$C_H:_"O_ (3%
MS_\ +"C^R/B1_P!#7X5_\)BY_P#EA7<44 </_9'Q(_Z&OPK_ .$Q<_\ RPK(
MUCP#X^UJZ6>?Q?X;1U0(!'X9N ,9)[WY]:]/HH \A_X53XX_Z'+P_P#^$U/_
M /)]'_"J?''_ $.7A_\ \)J?_P"3Z]>HH \A_P"%4^./^AR\/_\ A-3_ /R?
M1_PJGQQ_T.7A_P#\)J?_ .3Z]>HH \A_X53XX_Z'+P__ .$U/_\ )]'_  JG
MQQ_T.7A__P )J?\ ^3Z]>HH \A_X53XX_P"AR\/_ /A-3_\ R?1_PJGQQ_T.
M7A__ ,)J?_Y/KUZB@#S31?!/Q T+SO(\7^&G\W;N\SPS<'IGIC4!ZUI_V1\2
M/^AK\*_^$Q<__+"NXHH X?\ LCXD?]#7X5_\)BY_^6%']D?$C_H:_"O_ (3%
MS_\ +"NXHH X?^R/B1_T-?A7_P )BY_^6%']D?$C_H:_"O\ X3%S_P#+"NXH
MH X?^R/B1_T-?A7_ ,)BY_\ EA1_9'Q(_P"AK\*_^$Q<_P#RPKN** .'_LCX
MD?\ 0U^%?_"8N?\ Y84?V1\2/^AK\*_^$Q<__+"NXHH QO#=KX@M89AX@U/3
M=3F+ Q/ING26:JN.0P>>;<<]P1]*V:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\'_ &-"+/X+RV\Y$4UEJ]_#<HYP8G$Q)#>F 17O%>2^
M(OV:] US6M;O[37/$?AR+7&\S5=/T34!!;7S$89G4H2"PR&*E<Y.>M &)^QE
M&Y^"XN@I6TO-6OKBT&,#RC,P&/;*MTKW6L_P_H&G^%=$L=(TFTCL=-LHE@M[
M>/.U$48 YY/U/)/)K0H Y?XD>']0\3>%Q:Z4+9M0AU"POXH[R5HHI#;7D-P4
M9U1RNX1%<A6QG.#6?_:_Q(_Z%/PK_P"%/<__ "OKN** .'_M?XD?]"GX5_\
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MXK_PB/Q(_P"@)X5_\*&Y_P#D"C_A$?B1_P! 3PK_ .%#<_\ R!7M5% 'BO\
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M'_0I^%?_  I[G_Y7T?VO\2/^A3\*_P#A3W/_ ,KZ[BB@#A_[7^)'_0I^%?\
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MPJGFR,^W_A(;DXR<X_X\*A_X1'XD?] 3PK_X4-S_ /(%>U44 >*_\(C\2/\
MH">%?_"AN?\ Y H_X1'XD?\ 0$\*_P#A0W/_ ,@5[510!XK_ ,(C\2/^@)X5
M_P#"AN?_ ) H_P"$1^)'_0$\*_\ A0W/_P @5[510!XK_P (C\2/^@)X5_\
M"AN?_D"C_A$?B1_T!/"O_A0W/_R!7M5% 'BO_"(_$C_H">%?_"AN?_D"C_A$
M?B1_T!/"O_A0W/\ \@5[510!XK_PB/Q(_P"@)X5_\*&Y_P#D"C_A$?B1_P!
M3PK_ .%#<_\ R!7M5% 'E'A_2_B1H5X\_P#PCWA6?=&4V_\ "1W*]2#G_CP/
MI6__ &O\2/\ H4_"O_A3W/\ \KZ[BB@#A_[7^)'_ $*?A7_PI[G_ .5]']K_
M !(_Z%/PK_X4]S_\KZ[BB@#A_P"U_B1_T*?A7_PI[G_Y7T?VO\2/^A3\*_\
MA3W/_P KZ[BB@#A_[7^)'_0I^%?_  I[G_Y7T?VO\2/^A3\*_P#A3W/_ ,KZ
M[BB@#A_[7^)'_0I^%?\ PI[G_P"5]']K_$C_ *%/PK_X4]S_ /*^NXHH X?^
MU_B1_P!"GX5_\*>Y_P#E?1_:_P 2/^A3\*_^%/<__*^NXHH X?\ M?XD?]"G
MX5_\*>Y_^5]']K_$C_H4_"O_ (4]S_\ *^NXHH J:7)?3:? ^I6]O:7S+F:&
MUG:>)&]%D9$+#W*CZ5;HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAABGB:W5GE@E2$[#\BE@V!Z4 >]ZMJMKH6DWNI7TOD65G ]Q/+M+;(T4LS8
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M/B!JUCJWQ&TGX7>'K2*+^SPL5K?7VHEAEY&B?>8T!X'R@GKZT >W>+_&&D>
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M49MW.3GWKJJ* .#^*GPGM_B5'H]Y!J=QH'B/1+@W.E:Q:J'>V=@ ZE#PZ,
MRGK@<]<X_A?X+ZC'XZLO&'C3Q9)XPUK3(7@TQ$L$LK:S#C$CB-6;<[#C<6Z=
MNF.FN/BQX5MO#>N^('U7_B3:)/);7]XMO*R1R(0'"X7]Y@L 2FX9R,Y!QM^&
M_$FF>,-!L=:T>[2_TN^B$UO<1@@.I[X(!![$$ @@@T <-X-^!]CX>^%>K^!=
M3OFU?3]4DO&GF2'R&"W#LQ"C<V"N[AL]1G%<7=?LS^)=8^'Y\$:Q\3[R\\+P
MVGV6UM8-*C@E 52(1-*')E1"$.T;=VP FO8O!_CG1/'MG>W6A7OVZWL[R6PG
M?RGCV3QXWIAU!.,CD<'L:WJ /,9_@N]S_P *N,FM+O\ !.W)6TP+W%N(>GF?
MN^F[^+T]Z].KD/'?Q:\)_#62TB\1:PEC<7>3;VL<,EQ/*!U*Q1*SD#UQBKGA
M?XA^'O&OA=_$.@ZFFJZ2@<M-:H[NI0993'C>' _@V[N1QR* .CHK.\/>(-.\
M5Z'8ZQI-W'?:;>Q+-!<1YPZD<<'D'U!P0000"*T: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***XN^^,?@_3HO%<EQJ_EIX5,:ZP?LTQ^REQE.B?/D?W-U '
M:45Q?B[XR>#_  +I>CZAK6L"TMM77=8!+:::6X&T-E8T1GX#*3QQD9K0\&_$
M3P_\0%OVT&^:]%A*L-R&MY83&[('"D2*ISM8'CUQUH Z2LCQ=X3TOQSX;U#0
M=:MA>:9?Q&*>$DC(Z@@CH00"#V(%:]% 'C-I\&?'VBZ:NB:/\7+RVT")/)MX
M[K1H+B^ABZ!!<EAD@<!BA(QQVP_5_P!G.W@^#=]X!\*>(+KPY_:$QEU#6)8O
MM5S>%CF4R'<F2^ "01P,8P:]CHH \;\*?"7XB>#]+TS2=/\ B3I=OH]@B11V
M</A1$'EK_"&^T$Y//S')R<G)I^H? O7-/\9>(]<\'>.YO"T'B)TFU*S;3([O
M,JJ5\R%V8>62">H;GGT ]AHH \(TS]EF#1_A^?"EMXDE:V7Q0OB.*XGM-\@5
M75A W[P;FPH!DXR3G;VKTCXI?#73_BKX3?1K^:>RECF2[LK^U;;-9W,9S',A
M]02?J"1QUK1T'QSHGB;7-=T?3;W[3J6ARQPZA#Y3IY+NI91N90&R ?NDUO4
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M* "BBB@ HHK$LO&FC:CXLU+PU;WGF:WIT,5Q=6OE./+CDSL;<5VG.#P"2.]
M&W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=G1-&L;?P^=4?5HO#\:VMC:-/;,JB*)FW$%VP=H/)+'&:G\:>"_%?A#XQ?\
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M<4 <S^S?X<O=)^&L6L:N@77_ !/<RZ_J/&,27!W*OL%CV#';!KU.D50JA5
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MV]O-:!5P(I!(-P4'',8/"].@'M]W\0O"UAKR:)=>)='MM:=@JZ=-?Q+<,3T
MC+;B3]*U;C5K&UU"TL)[RWAOKP.UM;22JLDP0 N44G+;01G'3(S0!\JQ_!+X
MBR_"CXM:3J>EP7?B+Q#K]KJEN;2YB6"X'VB"64H6<%0H1^'VD@#&2:^M:**
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MCT(#I^HZA#I&G2J>)([-#')(OJK/T/\ LG%>WT %%%% !1110 4444 %%%%
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M+G_A(T\03;3S%#9H6+-Z F3'/4\#FO;Z "BBB@ HHHH **** "BBB@ HHHH
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MLHQ%!;QY(11[DDD]R2<DDDUI444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHHH **** .;\*> ].\%ZEK]SIDEQ'#K-Y]OFLF=3!%.5
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M@DL9%DM(S=3MYDJ[<QKA@<L ,$5]D44 >/?$W0]2U#]H;X+:E:Z?=7.G:?\
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M_P 4O!?Q"O-2M?"OB[0?$UUIK*M]!H^IPW;VK$L )5C8E"2C ;L?=/H:_/\
MT&:XO/ACKOP@\&23:-X8\=_&K5/#-DMB^P6?A^.-9M06VX^5&,5RH4< 2MSV
MKV?5OA3X)^#_ .V9\"-+^&OA?2O"-S<:)KZZRNC6JP"XL8X(!!]IV@&4^?L(
M9B6)4Y/2@#Z9M/BEX,U#QI<^#[7Q=H-SXMME+SZ!#J4+W\2A0Q+0!O,4;64\
MKT(/>M27Q1HT/B.#P_)J]C'K\]LUY%I37*"ZD@5@K2K%G<4#$ L!@$@9K\U_
M!'PE\6_ 6_\ !_C#XD_"_1?"<7P_U#4-3U#QCI]_;ZEK_P 0-4N1-%:VULL:
M^:OFRSY\J4\[DQY>TX^N/V;5T33?%/B:3Q/XS\.ZW\=?$#"]\1:/8:K#//I$
M$>!#I\4(<ND%NL@7<1\[R.Y.7& #Z$HKSG]HKXJ/\$?@7XX\=0Q03W>AZ7-=
M6L-UGRI+C;MA5\$$J9&0$ @D'@YKQ&W_ &A/CIX+^(7PWN/B-X+\)Z5\/?'6
MI6^@VMOIUU<'7-,OI8"\;788F+#M%*3''N\L$*9&*9D /J*'Q-H]QX@N-!BU
M6QDURWMTNYM,2X0W,4+L525HL[@C%6 8C!*D=JTJ^0=8_:C;PGK/Q9\2:9X#
MTK7_ ! /&5I\._#%OI<2V^HZY?1VR.\5W=$D>7')),0Q 5%5@><FK'A?XU?M
M#^&OC]\/_AG\2?#_ ,/I%\3_ &S4&USPD]Z\,5G:P,98O+G8,LWFM;XD.4VR
M8P3R #ZVHKX'\0?MH?'N3X9^+/BKX>\$>"&^&GAWQ#=VD=QJ5S=B]UZQ2^6U
MA%FD9*K(&#JTLAVLSC;'^[(?U7PG\=/C38?M#^$_"WQ"\,>#M$\)>+]+U+4[
M*STN\N)]6T9+5(7_ -/E;$!),P0^4"NXG#D)\X!]1T5^=FK?\%)O%VO:?K/C
M[P?>?!^S^'NE33M#X7\4>)S;^+-:MH&.^6"%&VP-* PCCE0OE<[7#)N]Q^+7
M[3GCN;XA?"SPC\&_#>C>)-1\:>'KO7YF\12RVT>FVQCB%I=2M&21&))&WH%+
M/M"(REMP /J*H+.^M]0@\ZUGBN8=S)YD+AUW*Q5AD=PP(/H017Q/XR_:,^,4
M?[,G[0/_  D5IX(LO'_@6Y72I+[2&NVTJXBFMX)&$*N3*;@)<;5#$+YA3(P#
MGFK?]HCX@?LP>!_AE\!KBZ^%ND_$NUT!+FXUKQ-K$MAX?TS38<16XF:1EEGN
MY?+8%(L;6._;Y>2 #]!*S/$?B;1_!VBW&KZ_JUCH>DV^WSK_ %*Y2W@BW,%7
M=(Y"C+,JC)Y) [U\G_#_ /;R<?!SXCZWXNL] \2>+O!%_;Z9M^'M^;W2M?GN
MPIL19RG<R[W?RW!WE#&S'GY%XGXR:_\ '[Q0WPY^'_Q<\.^"K32/'GB[21 ?
M"-W<O-8Q6LZWD]M>+,=LC%(AAX3M!@?KO0@ ^^:*X#X\?&#3O@-\*==\;:E9
MW&IIIZ(EOIMF"9[VYED6*"!  3EY'1<@' ).#BO*? WCS]I70_%5AJ?Q3\(>
M +?X=W=O//?-X9U&<ZEX=58C*CW1G;R[@+M,3BW!)9MZ_*NU@#Z5K,U+Q-H^
MCZII>FW^JV-CJ.JN\6GV=S<I'->.B%W6)"09"J@L0H. "3Q7Y^7?_!2GQA>:
M7>?$;3)_A%;_  ZMIBZ>"]1\4@>,[RT5PAD2-7\I)&&9!"R[@%*_,=K-[5\0
MO'%CJO[6WAS6Y29- ^'GPXU/Q?*S,%"O>.L2 YZ-Y-M.>>@;_:.0#Z:T'Q-H
M_BFUGN=%U6QU>W@N)+26:PN$G2.:-BLD3%20'5@0RGD$8-:5?G]H7QB\;_LT
M?LA_ B/1;?PY::OXX>34=2\6^-OM*Z+ILUZ[7@^UO;KN1IFN=BLQ"KL.XX4D
M?5G[./C3X@>./ ;7OQ%TKP[;ZHMP?L>L>#]0%YH^M6;JKPW=J2S2(I#;"LG)
M*;QPX50#U6BOCO\ :"_;2UKP[\9M1^%_P]U?X9^'-7T&VAN]:U[XI:X;&P#2
MKNCM+>*-UEEEV,LA<911\K8++6IX5_:R\8^/OV6-:^)'AW1=!U3Q1X-U62R\
M1:=ILSWUCJ45HR&\DTV9'7_60-YT);S .$._[U 'UA17S)I/[7$OB+2?&GQ3
ML8;2#X!^%K"4QZM-92G4/$%Y&#YALB9$18$?$(=D;?(' ( )$?P]^(7[4NL>
M(/#&O>(_AWX&@\!:Y=1+/H>FZE.-?T6UE!*SW$DQ2"7RA@ND8WMG"J#D  ^C
M+'Q-H^I:WJ>C6>JV-WK&EK"U_I\%RCW%HLH+1&6,'<@<*Q7<!N"G&<5IU\.>
M&_BUK7@W1_C)\2O#]I9:CXE\:?%:V\(:"FH!I()H8);?3T8A&5B ([IP W&
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M'^S#\5-6^-WP!\$>.=<TV#2=6UO3UN;BUM=WDAMS+N0,2P1@H< DD!@,MC)
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MK[?LQP>*Y])TV]^*-_KEUX2TS0+4/';7>KI?2VL:A6<N(E6/SI,N"$20Y'%
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MLPWN'B#XB>'_  OXJ\,>&]3OS;ZWXEDN(M*M5@ED-PT,1EE^95*H%09RY4=
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MOPO\2/'\GPE\;>#M&\%^/K^+4]1NM=LKB35M$N&AC@N);(1_NIB4B5U$I49
M7Y<%VG\>_#?5O@7?:I\5[_Q#+KNA> /A9=Z1IT^JWDESJUWJ._SIKJ:1UP6D
M$,"@AOO.XV@8KZ5L_%VC:CXFU+P]:ZE;W.MZ;##<7UC"^Z2U27=Y1D ^YOV.
M5!P2%)' J;Q#X<TGQ=HMWH^NZ79:UI%VGEW%AJ%ND\$RY!VO&X*L,@'!':@#
MX>^'O[*WQTUCX&>#?A!JOC3PMIOP:FTRT.JW-G9W">)98759KFP&?W"H7=XA
M+]\( 6#'<K=-\;?V._&6M_&B;Q9X)T3X2^)M"O\ 2+'2'TSXGZ--?_V.EKO5
M38*@( 99"2I*@E1]1]E(BQHJ(H55& JC  ]*=0!\;^"?V+_&7A_X%Z+\/]5U
MS1-0N)/B+'XJ\1:A;![=-0L8[D3A4B6+"2L8;=?*&$0 [7(50?<]>^%>K>(O
MVE/"GCR\N+-O#7AKP_?6=C:AW^T_VC=2Q"24KMVB,00[0=VXESP ,GU6B@#Q
M#]DOX7^/_@[\/]2\->.[SPWJ+1ZM>7EA>>'UN/,N([B=[B26Z,V/WS22OP@V
MJH49-9?CSX$^,O$7Q,^+'C33=1TBWU'6/ D?A'PJTLLBM:2$W$LLMP1$=J^=
M)"1LWDA.0,"O7M6^(WA[0_'/A_P=>ZAY7B37H+JYTZQ6"1S+%;A#,[.JE8PO
MF)]\KN)PN2"*Z6@#Y^\4?LW:A?\ P6^$/PSTN[L5T+POJ6B2ZW]JD<&\L[ +
M(8XP$.YI)HH2=Q4;=QSG KZ!HK#\;^-=%^''A'5_%'B*]&FZ%I-L]Y>W9C>3
MRHD&6;:@+-QV4$GL* /ES3O@1^T5\ VU'PW\$O%7@#5/AS--+=:9IOCVWO$N
M=#,DCN]M;O:@K)""VY3)R,[=N!EM=OV7_B1X ^"_C]/ OC^WU;XZ>-[F&XUC
MQ[X@B^R!PF(PD4<,<GDI'#O2)0IV%V(*C:%]ZMOBQX5N_&MGX2CU0GQ#=Z+_
M ,)#%9-;3*18>8L?G.Q3:GSL%VL0W7C@X\[\"_MN?!7XF:Y'I'A?QH-9OI-4
MBT:-;?3+W8]W(DSHBR&$(P*6TS;P=@"9+#<N0#D?V1?A+\;/@K';^%_%6G_"
MK3O <,$TS-X0;5)=4NKYV4F:>2Z.)"WS%G.6X4# &!Y';_L6_'[5?@K9_!K6
M_&W@6W^'5AJ\,TC:3!>C4=<LVOFN+K[7))N6)VW&0)$"&<A2X4$M]^44 >3^
M'_A+J5K^TMXJ^).HRV#:=-X;T_P[HD-NS>?#%'-//=>:I0*H:1XMNUFR$YQ@
M9\0UO]G7]HCPGJGQ+T#X8>._!>C^!?&FK7^OC4M6M;I]:TNZNP7EB@" P^69
M !O;+*LC,!N4 _8]% 'Q9XR_89UYOA'\$+'P\G@77?%WPYTJ73IM(\<::]_H
M&J&YBB%RSC:9%*2Q^9&RJ"3PP )%=-\)_P!G/XC?"3PCXO\ $>E:3\)].^*V
MMV_V.PT_PWH,>CZ%H\8XR+B.U>\NMQ5)F24[2XV+L"AS]6U@^//'6A_#/P?J
M_BKQ+?#3-!TFW:ZO+LQ/)Y4:]3M169OHH)]J /#O@C^S'K_P#^)5OK6D>)#X
MDTWQ%I;KXXN-:NI1=7NKH[21:C;H$9!N\V6%HMR!8TA(+E3GL/VKO@SJGQ\^
M">K^$=&OK"RU22XM+VW35XFEL+F2WN(YU@ND7EH7,85L XSG#8P?6K6ZCO;6
M&XB+&*9%D0LI4[2,C((!!]B,U+0!\4?!S]CSXB>'_CSX#^(/BG3?A+X8TW0$
MU!9O#OPUT>73H&EEM_*ANF9X]UQ+B25"KE5B504W&605O-^R#XUA^!/A^RT[
MQ)H^E_%C0_&5YX\AU#RY)],N;^6>Y;[/-\BR>4T5P(V<+N!7(':OKFLCPSXN
MT;QE:7-WH6I6^JVEO<R6<EQ:OOB\Z,[9$#CABK94X)PRLIY4@ 'SW\/?@7\6
MO$7Q,M_BA\8_$'A6^\6>'K&[L?"OA_PE%.FDV+SQJLMW)+.#*9I!F,C!"H,C
M=NVK%_PROXEM_P!B72?@G;ZMIW]L7$=O!KVI//+Y4B2W@N-2,3"/<S.'G5=R
MKG>,[>WU!10!\@_M$_LC>*O%7Q@D\?\ @+0OA3XJDU'2K?2[_1?BIHLEY;6O
MV=G,4UH\2LR%E?8R8 ^0'+<!?9OV;?@B?@;X!?3;PZ#-KVH7+WNHS>&_#]IH
MUDKL?DABAMXU+1QKA0\I>1N26 (5?6** /D+]I']E7QWX\^.:_$#PCI/PI\9
M6UYHL&D7.E?%;2I[Z.P\F:219+3RU;&_SFW [>5[[OES?!O[$_C#0?@7?_#O
M5=9\/:J=8^(MOXCUJ]MXGM8KS2(;FWE$4<"1;8)-EK$JP+F*,#:K[0*^SZYK
M1?B-X=\1>-O$GA'3M0^T^(/#B6LFJVBP2 6PN$9X 9"H0EE4G:K$@8R!D9 .
M.\>?"G5_&GQ\^%_B]KJSC\->#[?5)GM&=C//?7,4<$+A=FW:D9G^;<#EQP>H
MP_#?P=\7Z#>_'OQ']KTEO%OC>Z;^PY%N)1#!;06"6]BD[>7N0B3S6<(K@;R0
M6)->Y44 <+\"_AL/@[\&O!7@GS8YY-!TFVL9IHL[)94C D=<@'#/N(R!UKC/
MAY\(/%G@>3XWZ\;S29O%WC36KG4-(E2200P0):1V]A'.WE[@R^7E]H8#=\N[
MO[;10!\7>.OV*/%LGP8^!6A^&SX'U[7_ (=VTL=]H?CBTFN_#^JRW%MLGFD1
M5+LR2EI(R5!RY)QT,_P:_8I\4:+=?%L^.;GP986GCKPI'X<M['P'IK6%IHR.
MEP+F*" H,INF#ARVYVW%E7BOLJB@#X8O_P!EO]I3Q_X7\"^!?&WCCP#_ ,(#
MX6U;2VF@T6WO%O-<L;65&S=.Z[4E58D*I& C,Y+,-BD_9/C[PNWC?P+XC\.+
M?3:6VL:;<Z>+ZW&9+<RQ-'YB\CYEW9'(Y%;U8NB^,M(\0ZYX@T>PNFGU#0+B
M*UU&(PR((99((YT4,RA7S'+&V4) W8.""  ? 6B_\$__ (K3:1X0T35-/^"6
M@Z9X>U#26N;[PKH<T&J^(+.VFC:5;RZ>+(=A$DA"+B23[Q4"OO[QIX?F\6>#
M]=T.WU.[T2?4K">RCU/3Y#'<6C21L@FB8$%70MN4@@@@<U2\!_$CP[\3K'4[
MWPUJ!U*UTW4KG2+F7[/+$%NH'V3(/,5=X5LC<N5.#@FNFH ^+]/_ &9?CYX\
M\4?#6R^*GBGX?ZCX:\ :O;ZK8^)M'L[MO$NH_9V&V*:2;Y(1.%0S&-LDHHRP
MR3T,G[)OBS4O!=YH^H:IH[7'B'XJ#QOXA:&64))IJ7(EBMHCY66D"V]JN&V@
M8<[S@;OJ^N;\/?$3P_XJ\4^*/#NE7YNM7\,S06^K0""15MY)H5FC7S&4(Y,;
M*QV%MN0#@\4 <3XH^&>I:M^T5X:^(FHW-H?"OA3PWJ%O:6J&1[L7]S+%YLNP
M)@H+>':,,6)<C&!S^<_BCQIXIM?V?;KX2_"_XW_#KQ5X!\1W@TKPUIVEI/)X
MPN8;ZZ&ZSN;9BH@B5)9]\C)NVH!A?, 7]<JX6'X5_#?P/KVI^.K;P5X9T;7L
M7%Y>^(+31X(KUM^7GD>9$\QBWS%CDELG.: . @_9K>X^,-_K5[/:Q^#XOA]%
MX&TNSM'(N8D:5VN9""FU,H(%7#-]PY [_/7@/]@/QYIDFB^$]>TGX%Q^#-(>
M*$^+--\#0W/B;4[:)@%$RW43VZ2RH,/)^\*DY^<Y)^X_!7C+2/B)X1T?Q/X?
MNFOM#U>UCO;*Z:&2$RPNH9'V2*K $$'D \UMT 1V]O%:P1P01I##&H1(XU"J
MJ@8  '0 =J^;?A#^RSK?@_X_>*_&WB75]/U+P[#JVI:KX0TJT\S?93ZBP:^N
M)]R@>:0#&FTL DDG0L:^EJ* /EJY_9E^(\7@GXEW&@^.;?PO\1->\=3>,-+U
M&QDF-HT,0C2SL+S 1GA:*)5E7#KEV.V0#:<'1?V;_C;XD\9>-/B-XVU/X=:5
MX_NO!U]X7T:'P;;7<5I/).%,=Q?SS*97$;1H @5@ ,C!&&^PZ* /EZW_ &;O
M'O@OQ%^SD_A#4?"\VB?#S1GT36H=:6X\QTE2UCGN+01 !IV2&8 R%57S"<-N
M('T#\0O"X\<> ?$OAQB@76-,N=/)DSMQ+$T?/M\U=!10!\/?\,+>.XOV:?"W
MA&#Q5I$'Q*3Q+#K6M^) TAB6-;66Q"VI,6XM#9O$D88*-R$DKFO<?$O[/3W'
MC3X%0Z#_ &?IW@'X=/=7$FFR%O/>1;/[-9",!"I";Y68LP.0N,Y./<** /CG
M4/V5_BSX@^''QB\!:KK'@XZ'XT\7KK-K?6OVI;U[*6_6:[6YW(4\S[/%##&B
M+MP""_1J]N\??"?6/&7QT^%?B=9]/B\)^#4U*ZDLW9_/EO9X!;P,J!=FV.-I
M^2P(+C [CUBN<^'?Q$\/_%;P?8>*?"U^=3T&^,@MKLP2P^9Y<C1.0DBJV-Z,
M 2,$ $9!!(!4^+7@>]^)7PW\0>&M-\2ZEX.U+4+8QVFO:1*T=S93 AHY%*LI
M(#*-R!EW+N7(W9KP'PY\#_CQ\3O'G@S4/CCXI\%CPSX-OX]8L=*\#P70?5=0
MC4K#->/< ;!&27"Q?*S,<@;5(^B%^(GA]OB*_@1;\GQ5'I2ZV]B()<+9M,T*
MR&3;Y8S(K*%W;CM)Q@9KI* .(^*_PCT?XQ:9H-CK-S?6T.C:Y9:_;M8R(C-<
M6LOF1J^Y&RA(^8#!(Z$5V]%8^H^+M&TGQ!I&A7>I6\.M:L)6L=/+YFG6)=TK
MA!SL48RY^4%T!.74$ \)^'/[)>E:SK/C'QC\:_#'@_QUXW\2:HUP/M%BFI6F
MF6,:B.UM+=KF$, J+N=@B[G8D@X!J[\,?V6K'P#XL^-^G1Z?HVG?##QXEFMC
MX?T93;_9?]":VOE,2HJ1B0[6!0G.6SMP,_0-% 'Q[X5^#/[5OPVT&U^'7A;X
MB_#Z7P%IZ+8:;XLUC3;J;Q%9684!!]G'^BR/$/D7><,%!;&<#Z*^"_PCT?X'
M_#G2O".BR7%U#:!Y+C4+Q]]S?7,C%YKF9^K22.S,2?4 < "M7Q-\0_#_ (/U
M[PSHNK7YM=4\27;V6E6ZP22&YF2)I77**0@"(S%F(''7-='0!\H>,?@/\>O#
M/Q/\?7WPB\9^#M)\*>/KJ"^U*;Q%97$FI:+<"!+>6:R$?[N8E(U<+,0NY0N
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M O\ PI)X7U+PI'HHCU07/]HVMQ";F2)8M@\L1---&\C-N8A<!1@$^=I^R/\
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MEH5_\.=?\)VWAR[^V-<-KD A%QA86 \K:[W#2.[EB2  HQD_0=% 'Y_^"?\
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M$KWALXR]W?S<RWUU(Q>>XD/=Y)&9C]<=JR/$'P9GUSXX6OQ&'B PR:?X7NM
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M/A;3-#-M@1,TL;27)EW\DQPQ1[-G&"=QR  #Y=C\?>*O#G@W]H/Q]X8UA/\
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MV:] TKQGXT^(#BRU^WU*'XF,DFL7&AZFK,T%[=)NRMOO;RA'&NW]XJ !F#4
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MQ5T72M=^(4WF_P!I'PX;BP\$64$8^T>2D*--?SR/*@1I5"%H^4B5B0S]GO\
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M,[:(+^X\%MKVH^(KR(*EQ/.$@\BW19$=5$04DER5QL"^K>&?VMOB+\;O@O\
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M3'PNTS3]8_:!2Z\27%]%KMC\9$A@TZZMHK1YY9+*TRS1%95BPR\(&$>XAR"
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MOB9I_P"TIHWP^L/VA/'M\WB#PC=:GXPOIIXMMM"LT$"-I<&PI822.955QO=
M&(8L-U<J?C1\0?@/^S;\24\+^)_%7Q U2;XER^"_".K:TO\ ;FK(JA%FD5"!
M]I8/#="-#A2VWC;P0#]&**_.C]FGQ5\0M!^/W@6PT:T_:.U/PWJ_VJV\5/\
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M2+%!"C222,<!5 R2?8 5PWA?P]:? 'X,C3_[7USQ-8^&=.GG-_KUY]JO[B-
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M">>N>-[GQ)J9\9?$&]O?^$?DDO)/M%M)J5\\5E#;-DM&(X62153&P*VW&T4
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M4^.M2;XA:%XBL?B8O@_2KBSE\-:C\6=/-OK<RS)*;F*23I.L<B JV20LJKP
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MCXA:]K^C:CJ,7P[^$&A7'B37%TZZ>W76M4-FT]O8.T; O%% ?-=,E2\D2LI
M(KXWM?B]\:]4T&#XC6UI^TQ?_%BX>+4(-,MO#!7P-(A*C[.MFK,6A,&5$H&Y
MF(D(W9- 'ZY5R'Q&^)VE_"^'P[/K$%Y):ZUK5KH27%LB,EM-<$I"\VY@1&9
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MQGIGBX>+_&W@#Q19:>VE-J_@?6O[.N+JS,GFK!,VQ]R+(68 8Y8YS@8]OHH
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M!8'J_@Q\#_#/P+\.7&E^'UO;NZOIS>:IK6KW37>HZI=$ -<7,[<NYQVPHR<
M5Z!10!Y?XW_9_P!'\<?&#PA\2'U_Q)HNN>&X)+1+?1M1^S6NH6[R)(8+I-I,
MD>]%;8&4' W;L#&-I'[)W@_2/#_A'1Q?:Q=6WAOQ9-XSB>YFB:2]U&1[A]UP
M1$-RHURVT*%/[N/).#GVFB@#B](^%.E:/\6?$7Q#6ZOKG7-:TVTTJ2*X=#!;
M6]NTKJL("!AN:9F;<S9(&,8KB+C]D?P1>_ M/A;=3ZQ<:9#>RZK!K7VM8M5M
M]0>XDN1>QSQHH69996*G;C&%(*Y!]KHH ^:K']FW2_V=?"?C7Q[IFJ>./BK\
M1;/0;Q-*U3Q7J$FM:I&HB9TM+150;0\H!PJ[B7.6QP.'^$O_  3I\&)\//A_
M!XFU;QB=/M]*T^XUGP"=9D3P]>ZBD*-)+/9%<[O. <J&4%D&X'+;OLVN)\+_
M !:TCQ=\3/&_@>QMKW^T_""6)U&YD6,6Y:ZB:6..,ARQ8(H+;E4#>N"<T </
M\:_V2O"_QH\4:;XI7Q#XL\ >+;&T_LT>(/ ^KG3;R:SW%_LTC;6#1ASNQMSD
M#G'%1Z7^QO\ #O0_AOH'@C3H=1L])TW7[3Q-=3+<B2YUB_@D$GF7LKJQE\QU
M4OC;]U0NQ0 .^\3?%;2O"_Q,\%>!I[6^N=8\5)?36LEJB-#;1VL:O)).2X95
M)=$7:K99@#@<UVE '$>#_A+I'@GQ=X\\36-U?2ZSXRO(+S4+BX:-O*,-LEO$
MD0"#"*B @-N.6;G!Q7G&O_L8>$=:^"7@OX9VOB3Q=X?L?"-\NI:9KFBZFEMJ
MJW(68-*TPC*EV^T2EB$!RQQBO?J* *UQIUM>:;+87$0N+26(P21S$N'0C:0Q
M/)R.N>M?*$'_  3-^&B_V?:W7BSXA:GH.DZA%J.B^'=0\1&?3=(9)O,$=M"T
M> A&8SO+-L8_,&.ZOJ/Q5XDLO!OA?6-?U)F33M*LYKZY9<9$42%W(R0/NJ>I
M%<AX5^-%OXP7X?2V/A7Q.MIXRTAM9BO9;!1;Z7$(HY$CO9!(5BED$H"HI<DJ
M^< 9H XGXG?L:^$?BI\3+[QE?>)?&FC'5K.'3]=T/P_K\MAIVN01"142[2,!
MW&R5TPKJ,$]V8G1\,_LG>#/"?@/X8>$+&YU4:+\/M5_MK38VEAS<W6)_FN (
M@K?-<R/\@3YL'MBO0?AI\2-#^+?@VS\4^&YI;K0[V29+6YEB,7G+'*\1<*WS
M!2R-C(!(P<<U3TSXK:5J_P 7-<^'EM:WSZOHNE6NK7EYL3[*B7$DJ11;M^_S
M#Y+M@IC;@Y[4 0ZM\'](UCXL6GQ#FO=137;/0KC0;2..5/L]O'-*DDDR*4)$
MV8U7<21M&-O>N7_X99\(#]GG2?@RESJD7@_3TM(RT<L0N;E(+A+C;*WE[2)'
M3]YM5<AF VYKV*B@#X/_ &PM-0_'8:W=_#/XWVFHVNEQ6>F^-/@C=[Y=8M2W
MF2V=^%4-;I',%V@%BX);C:HKW']AGX(7OP#_ &>=)\/ZKI46A:S>7EUJUYI4
M-P;A;)IY2T<'F$G>8XA$A;)R4/)ZGW^B@#PKXU?LBZ#\9?'5IXRA\:^.OA[X
MEBT\:7<:AX%UPZ:][;+(9(XY_D<,$9G((P?FYSA=M7PW^Q-\/O"7PYF\"Z9<
M:U#X8E\6Q>+VLY+M)29XY8I5MFD>,N\&Z%,[B92 ?WG>O?Z* .,UCX5Z3KGQ
M6\.>/[RXO9-6\/Z=>:=86F]/LL8N6B,TNW;N\PB%%SNQM)X)Y"?&/X3Z+\<?
MAMK7@GQ#)>P:5JBQ[[C3;@P7,$D<J312Q/@[722-'&01E>01D'Q+7/\ @H-X
M*36M3L_!?@;XC_%K3],F:UO==\ ^&VU#38;A"=\/GET#,!M;<FY"KJ0QSQ[K
M\+OBIX6^-'@C3O%W@W5XM;T"_#&&ZC5D.58JRLC ,C @@JP!H \N^%?[&/@_
MX6_$C2_'Q\1^,/&/C&QTZXTS^V/%VLG49YHI75AO9E&#& R($VJ%D?*LQW5O
M0?LP^&;7X!Z_\)8=4UJ+0]<%]]NU-9H?[0E-W.\T[;_*\O),C+_J^%P/>O7Z
M* /$?C-^R/X2^,5]X<U2/6_%'@'Q%H%L;"QU[P3JS:=>K9D$&U+[6!B)P<;<
M@C@@%@<S_AB#X<M\&[KX>R2Z_.MUJO\ PD,WB>;5';6VU<8QJ/VHC_CX&!SM
MV_[/)SZ7\9?BUI'P/^'6I^,M<MKV]T^Q>",VNG+&US/)-,D,:1AW12Q>1>K#
MO7;4 ?/7A_\ 8C\$:#\/_'GAR;7?%FNZKXXL_P"S]<\8:YJHO-;N+?;L6+SW
MC*A53Y0-F,8SG QZ)XI^".@>+)_AX;F:^MK/P-J$>IZ986LB+!)-';O!%YH*
M$L$21B-I7GKD<5Z#10!\]?$K]BGPM\0O'VJ>+++QIX_\!7>L^6=:L?!GB%]/
ML]69%"![B,(V6,8"$J5R.?O$D[/C[]D'X>^-?A;X6\"6$6I^"-.\)S1W'A_4
M/"=ZUG?Z7*F07BF(8EG#/O9PQ8N6)WX8>V51UW6[+PSH>H:OJ<XM=-T^WDN[
MF=E+".*-2SM@ DX4$\#/% 'B?P>_8P\#?!OQ!XIURTU/Q-XFUCQ1IB:7K%_X
MFU5KRXO$4MND:3:K>8X95)! Q&FT*<D\GX5_X)U_#WPW?>$[F\\5>/?%*^$]
M3MM2T&U\1:^;NVTP0<K;00&,1I"2L1.%W_N4 <+N#?1G@KQ;8^/O!^B>)M+$
MW]EZQ90ZA:&XC\MVAE0/&Q7JI*L#@\C." <BMJ@#S#_AG3P;=S?%%M6MKC78
M?B0\9UVWOY!M:-+5+9(8C&J,BJB94[BZL2P8'&.%^&/[$/A'X>^*](U_4_&'
MCSXCW&AL)-$M/'&OMJ-II,@4H);>$(BJX4X!8-MP"N" :^B:* /FOXC?L$^
MOB1XV\1Z_/XD\;Z%8^)L/KWAG0=>>TTG5I0A3S;B *2SD;<X8 E <<MN]J^%
M?PWTKX/_  Y\.>"M#:XDTG0K*.QMI+MU:9U08W.5506)R3@ 9)P!TKJJYJZ\
M;?9?B#I_A0:#K<YN]/FU!M:BL\Z9;A'5!#).2,3.7RL8!)"L3@"@#CO&?[-?
MA#Q[\;O"GQ1U<ZA-KWANW\BTLUG464C*TC12RQ[<N\32R%#N 4L3@G%:M]\#
M_#6K?$[7/'&HBZU'4=7\.KX6GL[EU-JMCYLDCHBA0P,C2'<2Q!"K@#'/H-%
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M!\CI&-RL6R2><<5XG9_\$W_AW;E-*F\8?$:_^'J2F1?AS=^*9G\/!-_F)%Y
M42%$DVR &0G<H)+<Y^K:* (+*RM]-LX+2T@BM;2WC6*&"% B1HHPJJHX
M Z8KYQ\:?L"?#KQQXZUK7KO6?&%CHNO7JZEKO@O3M<>#0M8N@0QFN;8+EF9E
M0G#J,HIP.<_2M<3>?%G2+/XQ:9\-?L]Y-K]]HL^O>;$B&W@M8IHX29"7# L\
MJA<*0<')&* .%^,7[(_A;XM^(-+\06GB+Q9\./$>GV(TI=8\ ZL=+N)K$-O6
MUD(1E:)7^8+M&#WQQ3]-_9!\ :/X%\/>%;)=2ALM+\1VWBN[NI+H37>M:E"_
MF>=?S2*S3&20*[XVYVJHVJ-M>VT4 >2ZA^S!X&U[3OBA8:Y;76NV?Q%O([S6
MXKR8+_JX8HHHXFC5&18Q"C+DE@V3N[#EOA%^Q9X7^%/CC2_%MYXS\>?$36M&
M@EM]%D\<:\=032%E3RYC;($14,B (V0>% &*^@Z* .$^-7P9\._'OX?WGA'Q
M,+N.RFDCN(;S3IS!=V=Q&VZ*>&3!VR(W()!'8@@D5YO\(_V)_!_PD^*%M\1%
M\3^-/&'C*+3IM,?5O%VL_P!H3312,I&XE!@H%*KMVC:[9#'!'3WO[3W@Z+X:
MZ/XZL$U+6=#UG78O#VF"SMU6:\N9+PV:E$E9#L\U7Y."54L >,^N4 ?)^I?\
M$V?AIK=GJ6F:EXF\>ZCX9N-1.IV7AFZ\0-)I6E3-<-/(;:V*;!O\R5"9!(VV
M9R"'(<>C_&[]E7P[\;/$VF^)_P#A)?%W@+Q;96;::/$'@C6#IM[/9%_,^RRO
MM8/%YGSA<9##.>M>TT4 <'\&_@KX8^!?A5]$\-PW+M<SM>ZEJNI7#7-_JMX^
M/-N[J9N9)I"-S'@9.%"C &7XI_9_T?Q3\;O#7Q1.O^)-)US1+)M.-CI>H^18
MZA;EV<1W404F10[E@ P!(7.<"O,O%G[?W@_0_$.NZ=X?\!?$GXC:?H5S)9:G
MX@\&>&VOM,M+F+F:%YS(@W1@JS8!&&!!.:]4/[1'@*;X;^&?'5AK7]J^'/$U
MY:Z?HUQ9P.S7ES<2^3#$$(!1C)E2'V[2I#;<&@#R?Q!_P3Q^&_B#Q)J]R^O^
M.+#PCK.H-J>I^ -/\0R0>'KVX=@\C/;!=PW2*KX5P 54*%4 #Z9T_3[72;"V
ML;&VALK*UB6&"VMXQ''%&H 5%4<*H   '  JQ10!\Z_$7]B'PIXV\>:QXPT+
MQK\0/A?K6MLDFLMX!\0MIL6IRHNU)9HRCJ75<\J%R68G+,2;U]^Q7\/Y?@G+
M\---NO$&@6DVIPZY<>(=-U(C6;C4HY$D^VR7+J^Z9G0$L5P/X0F%V^^5RWQ2
M^(VE?"+X<^(_&FN+.^DZ%8RW]S':JK3.B*3L0,RJ7/0 L 21R* /(_B%^Q9X
M>\>^(=&\06WQ ^(_@[Q!8Z1!HMUJWA?Q(UI=:M;P\Q_;)"C&5P2YWC:27).>
M,>;?$+]D;P]X+\(?#OX->$]#UG5O /B+XA'7M>ANE>Z@M+&.*2=[>2=4!2)I
M([>-3*Q=N078G-?8.BZFNM:/8:BD$ULMW!'<"&X $D8=0VUMI(W#.#@D9'4U
M=H \+^#_ .R!X4^$?CJ3QE-XC\8>/_$Z6S6-AJ7CC6FU.32[9SEXK7*J(PW
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M!\K2?\$Y?AL^J7$0\2>.T\"7%[]NF^'">(7'AN1]XDVM:[=Q7S5$NW?]X#L
MM>I?M77VNV/[-OQ'_P"$9TN_UGQ!=:+<6-C9Z9:O<W#S3KY*E(T!)VF3<>,
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M2L 1&C>1*H9L#=L7.6 KT[XA>,A\/?!>K>(FT36O$8T^+S?[*\/61O+^Y^8
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M8 ]YHH BM;<6=K# KR2+$BH'E<N[8&,LQY)]2>M2T44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7S#\'X;+Q5^W#\>M6U@17'
MB#PS::+HNC)*07LM.EM/M,IC'82S2,6/^P!ZY^GJ\0^-G[(_A/XU>*['Q8-=
M\5> ?&=K;_8CXE\#ZL=-OI[7)/V>5]K!X]Q#?=W94<XXH U?BI\4/AWX1\27
M,NKV=EK/COPCX<U#Q59V_P!@,UU96:QLDTB7'EL+?S0ICY92^" & -?G+;_&
M#XU^(O#*_$:WM_VEKGXL71CU&QT_3?#!'@4H64I +0,6E@,.5$OWB6$A!8$M
M^C?PC_9A\#?!_P .^(--L;>^\0WOB12OB#7/$MVU_J.LY0I_I,S?>&UF&U0J
MC).,L2?/_!O[ /@/PGKVFW%WXI\>>*_#>D7"W.D>"_$GB%[S0M,D1LP&&V*C
M/DC*H)&< 'G<>: .+^*'Q DTW]H3XJ>/Y$>WC^%_PHPD++N\K4KYY+G ;C+;
M+6%1T^\<XS7O'[*O@,_#']F[X:^&9(_*N;'0K47*;0N)WC$DW'_71WK-\6?L
MI^$?&FE_%&RU&_UC'Q&O+.ZUN>*:$2!+9(4CMXB8B%B*0!2&#-B1\,"01Z]>
M--::;.UE;)<7$43&"V+^4KL!\J;L':"<#.#CTH _/RXD\>?%7]GWQ+^U%J/Q
MJ\5>"+FVM;[5O"_AK0[N.+1+:TMY)1:P7EL4(NY967#,QR?,5<80*.AM[3XG
M^)M=_9F^%NF_$'Q!HFHKX+NO$7C;6OM<D][)'+!# ,-(2'E\Z:94:4,(VV2!
M28@I\$U+]GN3XSW@^'VA_"CXW> SJFM13ZKH/B/4"G@;P^JW*R7MQ8NN!<.0
MLB1\%6$[LH^5,?IEIOPGT?2_BSJWQ#2:\DUO4-'M=#,,CH;>WMH)9956)0@9
M2SS,6RQ!PN .X!\)?%;Q$\GCB7P'I_C7]I?Q1X7\%1QZ*^I_#:W7(U$#S+E]
M3UB60>=*!+'E2L<<*A<=6-=)X%^+GQ0^*G[//[/O@:#Q;>Z'XG^)T^JQW7B^
M4(=2M]$L_.<E&  %W)!Y"B8 D$E_O?.OM'C;]@OP1XV\:>)M;D\6^/M%TGQ/
M,]SKGA/1/$3VFC:E,\8CDDF@5=S,X"[OG .T<8XK9\3?L7^"_$WPE\!^!1K/
MB?16\#HB:#XFT745M-8L]J;&*S)'MRZ?*WR<]>#S0!\X:MI-Y^S[^TK<M<^/
M?$WQ/T/X6?#G6?&\2>+;];V_@O+C;!]G>X55+*\<)**RY0,YSAQ7CFG_ !8^
M-EUI-A\0;2Q_:9U3XLS30W_]E?\ "-F/P/,C,H:V6T4L?),!*B7&XMB3 8Y'
MWG\)/V*_A]\([CQS/#<:]XJG\;:?%IVOS>*=1-])?(J2K([N5#%IA*V_)QPN
MT(,@XW@3]@KP/X,\1Z/?WWBKQYXVT;094N-"\*>+/$#WVC:/-'\MO);VVU<-
M#'NCCWE@JL>"P#  X+]KJS\;>-_B';ZCX>\2^.]1^&'AO3YK;7=.^"_B.UM-
M?T_55)D)N(7YN%:%H0L*MO4[FV\@-]!?LSW;7_P-\)W(\>R?$ZTFM2]GXJN+
M,VL][;%V\DS(Q+&54VHS-AF9"S ,37 _%#]AKPE\1_'VN^+;#QIX_P#A]J'B
M&.)-=M_!?B V%KJQC3RU>XB*.&.SY?EV@@DD;F8GW'P/X)T3X;^$-(\+^&[!
M=+T'2;9+2RLT=G$42C &YB68^K,22<DDDT ?GW^T-\7Y/B%\4O&4T7B']H>3
MPGX=G?3;*\^$FFQZ5H5I+"N+QKO49)?WX61<-(ZQI$$?&Y3O;O=8\0_%KXU?
MLA?"2PT3Q9<2?$?5K&P\0^(M+\.ZW;:+XCU+1F;:9K.61=L)WR6[LY"*P5DW
M_/L?OO%?_!._P%XMUGQ7)-XR^(>G^&?$US=7M_X,T[Q&T.B-<SJ2\PMPF=PE
M(G"LQ3>J@J4'EUT_Q!_8O\'^/=#\"6L/B'Q=X0USP9IT>D:9XH\*ZL-/U3[&
ML0C,$CJA0J^U6.$!RORE5+*0#(_8CF>30/&,,7Q \;^++&RU-+,Z#\2K;'B#
MP_=+$&GAN+C<1.D@>*2,J-BJ2 S'=CAOVU/BM/=>/=(^'VDZK\7GAL[+^TM<
MT_X*Z&+C5$\QBMJ9KXN/LZ$QR$1HC%P#N*C;GZ*^!_P+\._ /PO=Z/H,^J:G
M<:A>/J6IZSKMZUYJ&I73A5:>>4XW,0JC@ <9QDDGC?BY^R%X?^*WQ$C\;0>-
M?'G@'7WM([&^G\$Z\VFC488V+1K< (Q;;N8 J5.&/H, 'AO[,_Q(\::Y^SU\
M5-*LO'6J:7JD?B2Z\+>!-3^*E[;MJR7S6T;K;W,H#+-,)Y) JXD9=I3!$>T5
M_P!F%M4^%OQ.2T\>?$WXF>%-9T_0)M2\2>%?BUJT&L:;>6X6,?:].U-'$420
M2./,)RQ#A65=I->V:?\ L+_#+2_@7?\ PFMTU>/PO-JLNLV4RWVV]TJZ9MT<
MEM,%!!B.-ADWG PY<9S)\//V*?!'@N?Q'=Z[KGB[XGZIKNDRZ!<ZEX\UI]1N
M$TV0YDM(F"H$C9OF.!NR3@B@#YM\-Z#\2/"_QB\/7WQ&^*GQ)\+^)M>\2L-#
MUJTU"'6/ &N0,ZM#9BSCV-:R30NT:++@9B:5'+85>,^(7QK\:?&_XH>/[G48
MOVCM.\+Z+K%WHGAJ+X*Z3LL2MNYBEGNKG<#<2/(F?+X$8! ;YB!]8?#?]@OP
M5\._%OA_69/&'C[Q;8>&Y!-H'ASQ-XA:[TK1Y5&V*2W@"+M,:91-Q8 -T) (
M3Q;^P1X'\5>+M;U2/Q9X^\/:!K]V]]KG@S0?$<EGH>JRRX^T&>!5W?O@,2;'
M7(Z8H \U\1>(OC5\:/V5?AQH\6I:GH/Q9N#%J7BOPUI>I6_AWQ3>Z5%<O;O/
M;><H6V9G^SRL2(T(W1A@'V-8^#NM:S;?!'XD:3X3^,WB$^)[R_\ [ \.Z;\8
MA'#KNAZVT!<VLMPQ871E4K+$(T954'&_#X]E^+7['O@GXHQ^$Y+'4/$/PXU;
MPM;?8-)UCP'J7]EW=M9%-IM 0K+Y1^4XVY&T $ L&SU_8<^&[_!V^^']S+X@
MO_MVJ?V_/XHN]5>36WU4#:E_]I(_UZ@#'R[>.5.6R ?/'P?\3:]\ ;[Q;J/B
M3QM\5H/$_AKP;>:_K?P\^)VH1:Y!J:Q0JZ3Z7J,+>6$25O+<@%FW@,J;,CQO
M3_BQ\;+K2;#X@VEC^TSJGQ9FFAO_ .RO^$;,?@>9&90ULMHI8^28"5$N-Q;$
MF QR/O7X8_L:>#/A[=>([[5];\5_$S6->TF30+S5?'NL-J5S_9CG<]DC;4"P
MLQ+$8SECS6)X$_8*\#^#/$>CW]]XJ\>>-M&T&5+C0O"GBSQ ]]HVCS1_+;R6
M]MM7#0Q[HX]Y8*K'@L P .;\2>'O%O[5GQ\^(7AG_A9'BKX<> / #6FG10^!
M]0&GZCJ6I30)/)--/M8B%$D""/&&8[L@K@W/^">]M?ZMX-^(_C'5M<_X2F^\
M0>,;R.+7MBI_:%K9)%903$+\N7^SNQVX'S\ #%=-\4/V(/!'Q2^(VJ^+Y_$'
MC+PV^O0P6_B31_#6N/8Z?XBAB4QB.^C5=SJ8F:([63Y&;&"2U>F? _X.:%^S
M_P#"O0? 'AJ2\FT31DD2"2_D5YW,DKRNSLJJI)>1CPH'/2@#YQ^(WPXU7]HO
M]M3Q!I5AXVUCP3HO@GP;:6-_?>&I4M]4^T:A<2SA()V5O)4I:Q%G5=V%V@@.
MU<4GQ(\::)^QKXYUC_A.]7U^7X;_ !!6RLO$TERR7.KZ79ZC;+(+B5"/.4H\
MZ,QR)!'SG.:]K^(7["?A+Q]XS\3^+8?&_P 0/"/B7Q)<B74M2\+Z\+&2>!;>
M*!+1@(RK0*L08*P+ LWS8.!B?M%>%X_!'P+MOV>?A5\+M9O8?%.ESZ-IMQ86
MK'1=%C=P)9[Z[9B48"2689#M*ZD$[FR0#L/!_B+5?C9^T9K>K:=JM]:_#GX>
M^9HD,5G=/%!K6M.%-T\@1@)8K5"L05P1YS2$<H*K?MD0^-/%O@W3O"'PT\12
M6?BN6]@U'4]#T/7K?2=?OM'1BDQL9Y01$PE:$ER%4A67=\VUO5_A'\,=(^#/
MPU\/^"]#5O[.T>V$"RR??GD)+RS/ZO)(SR,>[.:XSX\?LN^&?CYJ6@:S>:WX
MF\'>*=#\U+#Q)X.U5M/U"*&48E@W[64HW!.5R,<$!F# 'R-JVLWMI^R=\7_#
MFE_$+QWXGNM:U2Q\'0>&_B;:B3Q!H5]>31P31S7(?;/'+%*LL>SY O1B2V.Y
M^,GB2^L]<_:*M++Q/XB\/>$?AM\-K'2+6VT6_:T"7\B27:R1G[HF\I;:+>%R
M$D(&,U[/X7_8O\"^%= T#34U'Q%JD^F>*H?&=UJNKZ@+N^UC4XD*127DKH2R
MJ"I"QA!F-3U+;M/Q%^RCX1\3^$OBEH-YJ&N!/B)J:ZIJM]#=(EU;R(L*Q);N
M(\*D?V="H8.>6R2#@ $?['OP%;]G3X&:#X6FUS7-:NWAAN[J/6KOSEL9W@C$
MMO:KM BMUD5V6/D@NQ+'-?/5Q\5)O!^F?M*?$S3]4U#2?$GB;QQ!X(\-S:5H
M2ZO>W$MA ENJVMH719WW?;2JNX7*,QR/E;[4\"^%!X&\'Z1H"ZMJVO#3K=;?
M^T]=NS=7UU@?ZR:4@;W/4G ]@*\CUC]C7P3K'P9L_AT^I^(K2&QUN3Q)9^(K
M&^2WU>UU)[B6<W4<R1A5<&:1 =G"MQR P /F+]EWQCXETO\ :A\%>&M)U7X\
M?V/JNF:G<Z_IOQPEC9VB@CC^SS647,D8\Z7#.<*WW06*L!C^+H?B/XR^ ?Q@
M^.,_QF\<:%IJ>);^X\#^'_#^H^1#A;O[#;I.Q5FEBDD2-5@0J@.YOF,IV_5W
MPH_8O\+?"7X@2^.;7Q=XV\2>+Y]%GT*XUGQ1K(U"XGADF257+/'\KQ^6JILV
MKMSE6))K=M_V5_"-G\'? WPS@N]6A\,^$K^PU"W598O-O7M)Q.B7)\K:R/(
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M,_V8X?!&@_"OQ%XX\*2:HD^IKX5O2WB*TE9F?^UH2X9[JY681Y!/1N?W2LH
M.'OOA+XO^#7[2GP4\):=\=?B%XOL_%%]<ZGK^F>(]8-QE+"!IEDB**K0P/(_
MEM#DI)O0-N\L8QK+0?&_[07P0\0?M%ZW\<_&/P\0VM]JGAO1/#.H+:Z1IMC;
M23&W6\@VD7<C%-SEF!8,$/"A1J?L5_!._O/C[K'Q7NM%^)>G:19>'AX?LKWX
MOW;2>(-1N9+CS996C)_=PQ1JD2   [F/S'=M])D_X)T?#.;7I6;6_&I\#RWQ
MU%_AM_;SCPRTQ._)M-N[;YO[W;OQNXQL^2@#@[OQQ\3_ -H#Q7^S5X<TSQ/J
M'@2^U7P7<^*_&=SI>8Y/(EMX;=#'&?D#M)++L\Q6$3,L@5C$ >6\9?%CQI^S
M]IOQZN_"NO\ BGQL_@ZVT#P/X937KV74I;G5;G][<7+J<B6X4W<8X3YO+1,;
M<5]J:1\(]$T7XJ:IX_MY+HZO?:-:Z"MLQ3[-:VMO)+(BPJ$#+EIF+98CA< 8
MYY*Y_92\"ZEX%^(/A/5(]0U73O&^N7'B'4IKFX N(KN5D9&@D15*"$Q1>7U(
M" $MSD ^-O@CXP^)FA?&CX>3Z/;_ +2VMRZKJ267B]?BEH7D^'S:RQMYMQ;(
MK/\ 8RDVQT4$@+E-^,A^A_:(;Q9JGQ$\3?$?4_B;\1=.^#K001^'/%WPCUV"
MZT71S'OCG.J:?&/.G$=PDKR2QF0%6$9*[=J?2OPC_8_\,?"SQE!XNU#Q5XU^
M)7BBSBD@TS5?'VN-JDNE1R#;,+4;56,R  ,VTM@$ @,P/'ZM_P $Z_AUJFO:
MJZ^*/'UAX-U6^.H7_P /K'Q')%X>N9&*M(&MPN_:[KO($@P>%VJ%4 'T7H-Q
M+H_@O3I];UNVU:>UT^-[[6HH5MX;EEC!DN @9A&C$%]H8@ XR<9K\LOB]\?/
M$NM:3XD^*&E>)/VCX=12;[;X:U*QTB'1?!!B\Y19(89'?[3&Q91EP7GW &,9
M*U^KUUI=I>Z7-ITUO&]C-"UN]OC"&,KM*X';'%?*2?\ !-/X?MI]KI=YXZ^)
M6JZ!IMW!>Z-H6H^)/M&GZ/)#+OC^S6[1%  F^+]X'.R1\88[@ ,^)5G\0/C)
M^U+I7P[TOQUK7@C0-'\"_;/%%YX;N##,UQ>7&Q$@8Y5)L6S%961BB-)LVLP9
M?F#6OB9XR^(WBOQ5IU]<_M.-X4\*WLWAKPS<?"FR::.Y2T/D2W>H7I<-=W$D
MD>YE.-GS8;YR%_2;PM\*])\)_$7QOXTM;B]GU?Q<;$7JW+HT4*6L)BBCA 4,
MJ_,[D,6^:1B, XKQSQ;^P1X'\5>+M;U2/Q9X^\/:!K]V]]KG@S0?$<EGH>JR
MRX^T&>!5W?O@,2;'7(Z8H ] _98\5>-?&O[/_@S6/B+IUWI?C6>T9=3M[^R^
MQSF1)7C$DD&U?+9U59"H  W\ #%?-\'PAU/]HWX\?M ^+!\4/$7PX\,Z3J%I
MX8ANO"=XEC>&6QLTEF,]PREA DEU(2BE-^<LW[M:^U]!T'3O"^B6&CZ18P:;
MI5A EM:V=K&$B@B10J(JC@    >U?,^K?\$Z_A_JU_J,Q\7?$"RLM:U&YU+Q
M'I5AXB:VL_$3SW+SNE[$B .N':(%-C>7@;BP#4 >2ZI^TEXG\0?L@_!^WO\
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M7]EKPU\=M8T77I]=\4>"?%FD(]O;>)?!>JG3M0^S/DO;,^UE:)F(;!7(*\$
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MV+_"7P>\1-XC_P"$H\9^-_$L.GMI6FZQXRUC^T)](MF&&CLQL5(LX'.TD $
MA68,:Y^Q1X'U;X0>!/ %EK'BCPW'X)._1/$6@ZDMGJULY5EE<3+'MS(';?A
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M  G^%6D_!_PS<Z)I%Q>7D5UJ5[JT]UJ#H\\L]U.\\A9D500&<@<9VJH))YH
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M/#J^HZYX>U?1;HWFD^(?#-^;+4M/D8;7,4N& #K\K J>.F" 0 ?.GCZXUO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>advm-20231231_g9.jpg
<TEXT>
begin 644 advm-20231231_g9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /1!M # 2(  A$! Q$!_\0
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M:\@/4>E>>+UJ%.,FTGL;5*%6E&,ZD&E+9M-7].XX]*:O6E;I0M#.86BOTY^
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M0,<=6R>]?%7Q,\66/C7QE?ZGI6CV>@Z6S>7:6-G;1P*D0^Z6"  N>I//)QG
M%?7_ .W!#XDD^'5B=-VGPZMR#J@3/F9R/))[>7NSG_:V5\+T\"G-.M)W;_ P
MXCG##SAE]&'+&"6MM9?/K_G?L%>B>$/V>_B!X\T"WUO0M ^W:9<%A%/]LMX]
MQ5BK?*\@88((Y%>=U[/\./VK/%OPP\(V?AS2M.T6XL;5I&22\@F:0[W9SDK*
MHZL>U=M9U%']TE?S/G,#'!RJM8V4E&WV=[_<_,^O_P!FOP7K/P_^$VG:-KUG
M]@U*&:=W@\U),!I"5.Y&(Z'UKXW7]DOXK_\ 0J_^5&T_^.U]K? /XB:E\4OA
MK8^(=6@M;>]GEFC:.S1EC 1RHP&9CT'K7RR/VZ_'I_YA'AS_ ,!KC_X_7BX=
MXCVE3D2O?7\3]"S2GE4L)A5B9S4%'W;6NU:.^GH?.]Y:RV-U-;3+LFA=HW7(
M.&!P1D>]1+4^I7KZE?W%W*%62>1I6"C@%B2<>W-0+7NGY7I?38_3KX"_\D8\
M&?\ 8,A_]!K\QJ_3GX"_\D8\&?\ 8,A_]!K\QJ\?!?'4]?\ ,^_XF_W7!?X7
M^4#Z-_8:UFYL_BEJ>G)(?LEYICO)'V+QNA1OJ SC_@1KH_V^=-ABU7P9J"HH
MN)X;J!WQR5C:)E'X&1OSKFOV&])N+KXJZC?I&WV6STR19),<!G= J_4@,?\
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MA'S I7[4V-W3/EOC\<XJ:,+Q]K)ZHVSK&<F*65T8*,:G+S.VNKZ=-C[$\/\
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MV$+C_P!EKX%K[Z_8O_Y(K%_V$+C_ -EIXCX##A3_ )&#_P +_0Y[XA?L9?\
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M9;Z7,A55)RZ,1PJ\9QQ7B/PSU/3-:_:\AU'1IOM&F7FI7ES#+M9=P>&5B<,
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MGPX\"?#+X$^*+31=(O#=^*M9+0(UU.L]V8U#2$$* (TPG7 W%5ZD5Y7_ ,%
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MCJ?2O'%I*<O2LHTXP;<5JSIK8JM7A"G5E=0T7E_5A&I5Z4UNM.'2J.1'Z<_
M7_DC'@S_ +!D/_H->8I^POX!5E)U7Q$X!R5:Y@P?;B&OA2BO)6$G&3E"I:_E
M_P $^XGQ#AJU*G3Q&%4^165Y>G]WK8_1E-2^&'[,?A>Y@M[BWL-W[UK6.;S[
MV[8<#Y2=QZX[*,]J^%?BM\1KWXJ^.+_Q#>KY(F(C@M]V1!"O"(/YGU))[UR%
M%;T<.J3<F[M]3R<RSB>/A&A""A3CM%?TOR/TL_9O_P"2'>#_ /KS_P#9VKX6
M_9[_ .2V>#O^P@G]:\\HJ*>'Y.?7XC3%YS]:6&_=V]CY[_#Y:;>9]Q_MV_\
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M_ /6QXEEN9([\OLL8;^Z$C1NPVA(4 !8D$C+;B.3D=:M_MA_\D*U;_KYMO\
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MPK&&/908B<?4FL?_ (88\!_]!;Q%_P"!-O\ _&*^&:*S]G/^8]B6<Y?.3G+
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M\9O"_P :O 2>'/$<]LFL/;?8[VPNI!']K&W!DC.1G(&>.5.?8U9T']EWX9>
M[ZXUB[A-[!M8B/7)XY+:!2#G *@'@]7+8Z]>:^ **CV?9GJPX@C*$/K6'52<
M=I-_\!GK?[1FO> ]2\4PV?@32+2TM;,,MS?V8*QW+G'"+G;M7!^8#DD]L$^^
M?LI_';2=8\)V7@W6[N*SU>P7R+4W#!4NX>=JJ3QN4?+M[@ C/./BBBK<$X\I
MY>&SBMA<9+%PBO>WBM%;M_P3[XO_ -G7X4^"->;Q=J)_L^T@<7"VMU=A;-'!
MW JI&X\]%W$=L=J['XF:Q;>(O@-XCU6S9FL[[0)KJ%F7!*/ 64D=C@BOS6I5
MK/V;W;/8CQ%3IQG3HX91C)/9]7UV_ =5[0=4.AZYIVI+&)FL[F.X$9. VQ@V
M,]LXJC16I\9%N+370_2C[3X._:&^'\EJMRNH:5>JK2112[)X'!# ,!RK*0.O
M!]P:X_P'X3^%_P "O%UCHNF7S7?BK5R;5'N9UFN%3EL-M 6-25 Z L0.N*^!
MZ*Q]GTN?:RXD4Y0K2P\74C]J_P"6FGWNQ];?MT:9=PS>#]9CC#VL+3V[.R!E
M60E'4$'@Y"MP1CY3FO1_AWX\^'GQQ\!-HL]MIUC/<P".^T1ML+JP(.Z/&,J&
M 8,O3C.#Q7P%13Y-$KG)'/I1Q=3$JDG&I:\6[[*V]OT/T \'_LP^ OAKXBB\
M1Q7%])-:N98/[1NT\F!N>1A5S@'^(GI7BG[7GQJT7QP--\,Z!<QZE:V4YNKF
M^A.Z-I-I541NC !F)(XY&#P:^:J*%#6[=R,5G4:F&EA<+15.,M[.]_P05Z9^
MS5_R7+PG_P!?#_\ HIZ\SHJY:Z'S^'J^PJPJVORM/[G<^X?VXO\ DD^D_P#8
M;A_]$7%?#U%%1&/*K'?F>/\ [2Q#K\O+HE:]]OD@KV?]F;XW0?"3Q'=VVKF0
M^']3"B=T4NUO(N=L@4=1@D, ,D8/\.#XQ13:NK,X\+B:F#K1KTG[R/T+\8_"
M'X=_M _9];%X+F<*$_M'1KI-TB@_=?A@<=.1D=,BF:MXP^'O[,W@PZ98O"DJ
M;I(M,AF\RYN)3_$YR2 2,;FX &!T K\]Z!UK/D[L^IEQ%&+E5I8>,:KWE_P+
M?KZG0ZMXRO?$'C:;Q/J/^D7LUX+R10<#A@0@ZX  "CT %?HCK%AX9^.WPZEM
M%OS=Z'J2(_GV4H61"K!AU!VL&7D,.,$$5^9]%.4;GFY;F[P7M8U(>T53>[MW
M\GO?4^B[+Q)I/[,_[15];:?(UQX4E@BM[A4E\Z15:-"7.,999 3C^Z2!UKZ"
M\9?##X??M$VMGJOVX74L<>R/4M(N4$OEYSL;(8<$GAER,GIDU^>5/J7$Z,/G
M2HQJ4:E%2I2;:C?:_1.VWR/NCQIX4^#/P<\&>1JNC:9>30HWDP2A9;^Z?/3=
M][J>O"K[<"OF_P#9KFCN/V@/#DL,"VL3SW#) C,RQJ8)2%!8DD <<DGBO)Z*
MFQC7S15J]*K"DH1@TTEY6W=O+L?:/[<?_(A^'_\ L)'_ -%/7FO[$7_)5M5_
M[ LO_H^"OGE:=46Z%U<V]KF$<?R6M;2_9=[?H?2_[<O_ "./AO\ Z\'_ /1A
MKUC]D7Q=I6I_"/3=%AO(CJFFR3I/:E@) 'F>16"]2I#CD<9!':OA"B@UHYU*
MCF$\<H?$K6OZ=;>78^@?VF/@GX5^%6DZ5/H$TWVJZNY%EAN;D2,J%<J%7 .U
M<$9.3R,DU]-?M#_\D5\6?]>G_LZU^<E.I%T\XIT775*C95$E9/:R:[:[^1]>
M_L<_%#1K?PW/X0OKJ*RU-;I[BV$S!5N$8+E5)ZN"#QZ$8S@X[#QG^S[\+M/U
MZ\\8^(9Y+*WDD:XN+>>\"6LDC-N+8QN))/W0V#G %?"5%271SJ,<-'#UZ*GR
M[-_Y6_R/T@UB]M/BE\%]6D\-D36VJ:7<PV0V[<MM= N.WS#&.U?._P"PZI7Q
MCXD!&"+% 0?^N@KYGIXZ5+>I57/'6Q-'$RIZPWUW_#3\3Z"_;:_Y*KI7_8%B
M_P#1\]?/M%%9O<\/&8CZWB)U[6YG>P4JTE*M2SF'4445# ***!UI%#J***@
MI1UI*5>M2RQU%%%0 4^F4^I*$K8\*P^;K$;'_EFK/^G_ ->L>MWPA_R$I/\
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M#ABD/A^SD8+UP+9"<5Y-_P -W> ?^@1XD_\  :W_ /C]>)''U*C:ITKV\_\
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M* "E6DIRTF M%%%2-!1110,**** "BBB@&%%%%2P04444@"BBB@ I5ZTE*M
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MNK3P_J=Q90A+:"2.V<JRJO)!QR"Q8UP"_"OQC_T+&J_^ C_X5] ?\-=^'O\
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M#D;L<^59C+*\0JZCS:--7M?YZ]3ZB_;P\4F\\7>'?#Z,WEV-H]W( ?E+RMM
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MMX_\CIX9_P"P>_\ Z,-?,%%>A[/]Y[2Y^;+-+9:\NY-W>]_.^UOU/TJ\5?\
M)N.L?]BG-_Z1FOB3]F7_ )+KX2_Z^'_]%/7F%*M1&CR1:ON=&-SKZYB*%?V=
MO9VTO>]G?MI^)]M?MV_\B#X>_P"PG_[2>N?_ &!?^9[_ .W#_P!N*^1Z*GV/
M[OV=RI9YS9HLR]GM]F_DUO;]#W;]KJ]GTWX^37=K(8;FWM[66*1>JNJ@@CZ$
M"OI7P7\2O!'[2'@$Z/J[VPO;B)5OM'FE\N5)%(.^/G)7=@AEZ9 .#D5^>E%.
M5%2BE?5"P^>SP^)K5N1.%5N\7_G;]->Q^@6@_LV?"SX717NI:G'%?0LAW3>(
MYHI(H4R#A0551T'S$%N2,\U\@_'37O!VN>-I/^$(TB'3-&MT\KSH59!=/DDR
M!2<*O0# !XR>P'G=%.%-Q=V[F./S6EBJ*H4,/&G%=M7]]D?I;\,?^2">&_\
ML7X?_1 K\TJ***=/V;>NY&:9K_:4*,.3E]FK;WOMY*VQ^E'[1W_)#_%__7G_
M .SK7YKT44Z5/V:M<>;YI_:U6-7DY;*V]^M^R"BBBK9X04444 %%%% !1110
M 4444 %%%%)C04JTE.7I4C84444$A11104@HHHH&%%%% !1114@%%%%( HHH
MH **** "BBB@ HHHH *?3:=04@HHHI,&%%%%(D**** "BBB@ HHHH+"BBB@
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MM/K)@)WI:2EK&0=11]TTE+_#25DRAPHHHK%@%*O6DI5K%@.HHHK)@%%%%9L
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MBBB@ HHHJ6-!3ATIM.I#84444$A11104@HHHH&%%%% !1114 %%%% !1110
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MP_LO ?\ 0/#_ ,!C_D>/?\,B_";_ *%3_P J-W_\=H_X9%^$W_0J?^5&[_\
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M?^&3?A3_ -"K_P"5&[_^.UZ[11[:K_,_O#^S,!_SXA_X"O\ (\B_X9-^%/\
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M9-^%/_0J_P#E1N__ ([7KM%'M:G\S^\/[,P'_/B'_@*_R/(O^&3?A3_T*O\
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M?_#)_P *_P#H5O\ RH7?_P =H_X9/^%?_0K?^5"[_P#CM>N44<\NX?V9@?\
MGQ#_ ,!7^1Y'_P ,G_"O_H5O_*A=_P#QVC_AD_X5_P#0K?\ E0N__CM>N44<
M\NX?V9@?^?$/_ 5_D>1_\,G_  K_ .A6_P#*A=__ !VC_AD_X5_]"M_Y4+O_
M ..UZY11SR[A_9F!_P"?$/\ P%?Y'D?_  R?\*_^A6_\J%W_ /':/^&3_A7_
M -"M_P"5"[_^.UZY11SR[A_9F!_Y\0_\!7^1Y'_PR?\ "O\ Z%;_ ,J%W_\
M':/^&3_A7_T*W_E0N_\ X[7KE%'/+N']F8'_ )\0_P# 5_D>1_\ #)_PK_Z%
M;_RH7?\ \=H_X9/^%?\ T*W_ )4+O_X[7KE%'/+N']F8'_GQ#_P%?Y'D?_#)
M_P *_P#H5O\ RH7?_P =H_X9/^%?_0K?^5"[_P#CM>N44<\NX?V9@?\ GQ#_
M ,!7^1Y'_P ,G_"O_H5O_*A=_P#QVC_AD_X5_P#0K?\ E0N__CM>N44<\NX?
MV9@?^?$/_ 5_D>1_\,G_  K_ .A6_P#*A=__ !VC_AD_X5_]"M_Y4+O_ ..U
MZY11SR[A_9F!_P"?$/\ P%?Y'D?_  R?\*_^A6_\J%W_ /':/^&3_A7_ -"M
M_P"5"[_^.UZY11SR[A_9F!_Y\0_\!7^1Y)_PRA\*_P#H5O\ RH7?_P =H_X9
M1^%?_0K?^5"Z_P#CM>MT4<\NX?V;@?\ GQ#_ ,!7^1Y)_P ,H_"O_H5O_*A=
M?_':/^&4?A7_ -"M_P"5"Z_^.UZW11SR[A_9N!_Y\0_\!7^1Y)_PRC\*_P#H
M5O\ RH77_P =H_X91^%?_0K?^5"Z_P#CM>MT4N:7</[,P/\ SXA_X"O\CR3_
M (91^%?_ $*W_E0NO_CM'_#*/PK_ .A6_P#*A=?_ !VO6Z*.:7</[,P/_/B'
M_@*_R/)/^&4?A7_T*W_E0NO_ ([1_P ,H_"O_H5O_*A=?_':];HHYI=P_LS
M_P#/B'_@*_R/)/\ AE'X5_\ 0K?^5"Z_^.T?\,H_"O\ Z%;_ ,J%U_\ ':];
MHHYI=P_LW _\^(?^ K_(\D_X91^%?_0K?^5"Z_\ CM'_  RC\*_^A6_\J%U_
M\=KUNBCFEW#^S<#_ ,^(?^ K_(\D_P"&4?A7_P!"M_Y4+K_X[1_PRC\*_P#H
M5O\ RH77_P =KUNBCFEW#^S<#_SXA_X"O\CR3_AE'X5_]"M_Y4+K_P".T?\
M#*/PK_Z%;_RH77_QVO6Z*.:7</[-P/\ SXA_X"O\CR3_ (91^%?_ $*W_E0N
MO_CM+_PRE\+/^A6_\J%U_P#':]:HHYI=P_LW _\ /B'_ ("O\CR7_AE+X6?]
M"M_Y4+K_ ..T?\,I?"S_ *%;_P J%U_\=KUJBCFEW'_9N!_Y\0_\!7^1Y+_P
MRE\+/^A6_P#*A=?_ !VC_AE+X6?]"M_Y4+K_ ..UZU11S2[A_9N!_P"?$/\
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M_#/_ *%K_P G[G_X[1_PS'\-/^A:_P#)^Y_^.5ZE12]E3_E7W!]1PG_/J/\
MX"O\CRW_ (9C^&G_ $+7_D_<_P#QRE_X9C^&G_0M_P#D_<__ !RO4:*/8T_Y
M5]P_J.%_Y]1_\!7^1Y=_PS)\-/\ H6__ "?N?_CE+_PS+\-?^A;_ /)ZY_\
MCE>H44O8TOY5]P?4L+_SZC_X"O\ (\O_ .&9?AK_ -"W_P"3US_\<H_X9G^&
MW_0M_P#D]<__ !RO4**7L*7\B^Y!]2PO_/J/W(\O_P"&9_AM_P!"W_Y/7/\
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M+O\ Y/7/_P <KTNBCZIA_P#GW'[D/ZIA_P#GW'[D>:?\,W_#K_H7?_)VY_\
MCE'_  SC\.O^A>_\G;G_ ..5Z712^IX;_GW'[D'U7#_\^U]R/-?^&<?AW_T+
MW_D[<_\ QRC_ (9Q^'?_ $+W_D[<?_'*]*HI?4\-_P ^H_<@^JX?_GVON1YK
M_P ,Y?#O_H7O_)VX_P#CE+_PSG\//^A>_P#)VX_^.5Z311]2PO\ SZC]R']5
MH?\ /M?<CS;_ (9S^'G_ $+W_D[<?_'*7_AG7X>_]"__ .3MQ_\ '*](HI?4
M<+_SZC_X"O\ (/JU#_GVON1YO_PSK\/?^A?_ /)VX_\ CE'_  SM\/?^A?\
M_)VX_P#CE>D44?4<)_SZC_X"O\@^K4/Y%]R/./\ AG?X>_\ 0O\ _D[<?_'*
M/^&=_A]_T+__ ).W'_QRO1Z*7U#"?\^8_P#@*_R']6H?R+[D><_\,\_#[_H7
M_P#R=N/_ (Y1_P ,\_#_ /Z '_D[<?\ QRO1J*7]GX/_ )\Q_P# 5_D'U>C_
M "+[D%%%%=YT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1165JWB2TTI2"WFS?\
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M;;3T(/')KYL^!/P,_P"&BOVG/$'@ZYU2[TK1FN;V^U&2SP9&ACF.% .5R7=
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M9D$D4T+AT=2,AE8<$'U%35E^%_#ECX/\-:5H.EQ>1INF6L5E;1_W8XT"*/R
MK4KY>5KOEV/85[:A1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M/U[7K'PSI,^I:C.+>SAV[Y""<;F"CIZD@?C6A7F?[23%?@KXB(."/LY!_P"W
MF*JBN:21S8JJZ%"I5CO%-_<C,UCXZ:)>;H[;5(X(NF0K[C^./\^]<ZWQ%\/,
M<MJL9/\ NO\ X5\]:7?#4+-9/XQ\KCWK9TBQ^W70##]VGS/_ (5V^RBC\_\
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M%6888'@D=ZJKFU"5!T*<)?&I7;NWW_X 0P515/:2DMK:*Q\7_P#!([_DG_Q
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MA;)XLN/BYHT4_B"%XWTV6^TM[W&T,'B1-K!)-V/F8+_O#%3_ +,?C&V\2?\
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M+&UL5R.TX<MONU_ YUE\EAX4>;6,K_F?$'_!7C_D7_AE_P!?5_\ ^@050_;
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M*.",\GMWK>.=PAB</74/X<>5^>EKHS>7RE2JTW+XG<^0OVE/$'A[]N/]F'Q
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M#VK*.94XQQ$8P:51)+6]K=V]64\)-NDW+6+N]+7^X^=/^"G?_)K=W_V%[/\
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MQA6C8%2.!P1CBJ?A'P'X9\ 6<UIX8\.Z3X;M9Y/-E@TBQBM4D? &YEC4 G
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M[?.OM1N$MX(MS!5W.Y"C+,JC)Y) [UAO\7_ D?AN'Q"_C7PZN@3.T<6JMJL
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7[/?[.'Q8^)6@:[\'OBG<>";^S*RIHEO+(MX9U(*O$;L^9GJ" '4]L#KO?\
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M!FVX8EPPRQ&.*C^+'P/U?XS?\$\?A?+X>M)+_6_#VGVNHQV4*%Y;B$Q%)4C
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MP< #/%>L_L0?!+P7X;_9MT_XB:=HOV?QCK&@7UK?:E]JG;SHO/?Y?+9S&O\
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MQ!X/T'Q9H9T;6]$T[6='.W.GZA:1SV_RD%?W;@KQ@8XXQ61_9GCS_H9/#O\
MX3]Q_P#)U']F>//^AD\._P#A/W'_ ,G5?/+3WMMM]##G>O[IZ_X?_DC1T7P'
MX9\.>'9] TGP[I.EZ%.)%ETNRL8H;60.,.&B50IW#@Y'/>H?!_PV\(_#W[7_
M ,(KX6T7PU]LV?:?['TZ&T\[9NV;_+4;MNYL9Z;CZU4_LSQY_P!#)X=_\)^X
M_P#DZC^S/'G_ $,GAW_PG[C_ .3J.>;33EOOOJ'.]/W3T_P__)#_  _\)O _
MA+7)=9T/P;X?T;6)0RR:AI^EP07#ACE@9$0,<D GGFM7Q+X1T/QIIIT_Q!HN
MGZ[8$[C:ZE:QW$6?7:X(S^%8_P#9GCS_ *&3P[_X3]Q_\G4?V9X\_P"AD\._
M^$_<?_)U#G-RYG+7YASM*RI.W_;O_P D1M\&/A\WA\Z"W@7PT=#\U9_[,.D6
M_P!F\Q00K^5LV[@&8 XSR?6NDT70]-\-:5;:9I&GVNE:;:KL@L[*%888EZX5
M% "CV KG_P"S/'G_ $,GAW_PG[C_ .3J/[,\>?\ 0R>'?_"?N/\ Y.HE.4E:
M4K_>"FXZJD__ "7_ .2.NKD-2^#O@+6=>.N:AX(\.7VM;M_]I7.DV\ESN]?,
M*%L\GO2_V9X\_P"AD\._^$_<?_)U']F>//\ H9/#O_A/W'_R=2C*4-8RM]XW
M4E+>D_\ R7_Y(Z74=-M-8L9K*_M8;VSF7;+;W$8DC=?1E(P1]:YKPY\(/ ?@
M_4SJ.@>"?#NAZ@W6[TW28+>4YZ_.B ]SW[T?V9X\_P"AD\._^$_<?_)U']F>
M//\ H9/#O_A/W'_R=1&4HIQ4K)^H.I)N[I/_ ,E_^2.NJ"^L;;5+*XL[RWBN
M[.XC:&:WG0/'*C AE93P002"#P0:YC^S/'G_ $,GAW_PG[C_ .3J/[,\>?\
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MWC*S^8.I*2LZ3_\ )?\ Y(U?#'@SP_X)LFL_#NA:;H%HQ!-OI=G';1DCH2J
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M(_V9X\_Z&3P[_P"$_<?_ "=1_9GCS_H9/#O_ (3]Q_\ )U%EW#VT_P#GV_\
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MHKD?[,\>?]#)X=_\)^X_^3J/[,\>?]#)X=_\)^X_^3J++N'MI_\ /M_^2_\
MR1UU%<C_ &9X\_Z&3P[_ .$_<?\ R=1_9GCS_H9/#O\ X3]Q_P#)U%EW#VT_
M^?;_ /)?_DCKJ*Y'^S/'G_0R>'?_  G[C_Y.H_LSQY_T,GAW_P )^X_^3J++
MN'MI_P#/M_\ DO\ \D==17(_V9X\_P"AD\._^$_<?_)U']F>//\ H9/#O_A/
MW'_R=19=P]M/_GV__)?_ )(ZZBN1_LSQY_T,GAW_ ,)^X_\ DZC^S/'G_0R>
M'?\ PG[C_P"3J++N'MI_\^W_ .2__)'745R/]F>//^AD\._^$_<?_)U']F>/
M/^AD\._^$_<?_)U%EW#VT_\ GV__ "7_ .2.NHKD?[,\>?\ 0R>'?_"?N/\
MY.H_LSQY_P!#)X=_\)^X_P#DZBR[A[:?_/M_^2__ "1UU%<C_9GCS_H9/#O_
M (3]Q_\ )U']F>//^AD\._\ A/W'_P G467</;3_ .?;_P#)?_DCKJ*Y'^S/
M'G_0R>'?_"?N/_DZC^S/'G_0R>'?_"?N/_DZBR[A[:?_ #[?_DO_ ,D==17(
M_P!F>//^AD\._P#A/W'_ ,G4?V9X\_Z&3P[_ .$_<?\ R=19=P]M/_GV_P#R
M7_Y(ZZBN1_LSQY_T,GAW_P )^X_^3J/[,\>?]#)X=_\ "?N/_DZBR[A[:?\
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M_P#DT?\ Y(.9'V'17QW_ ,/"O^I!_P#*S_\ <]-/_!0S'_,@?^5G_P"YZ?\
MJOF__/G_ ,FC_P#)"YXGV-17QN?^"A__ %('_E9_^YZ3_AXA_P!4_P#_ "M?
M_<]'^J^;_P#/G_R:/_R0<\3[)HKXT_X>)_\ 5/\ _P K7_W/33_P46Q_S3[_
M ,K7_P!ST_\ 5;./^?/_ )-'_P"2#GB?9M%?&/\ P\8_ZI]_Y6O_ +GI#_P4
M:Q_S3W_RM?\ W/1_JKG'_/C_ ,FC_P#)"]I'N?9]%?%W_#QS_JGG_E;_ /N>
MF_\ #Q[_ *IY_P"5O_[GI_ZJYQ_SX_\ )H__ "0>TCW/M.BOBK_AY!_U3O\
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M )(7/$^QZ*^-_P#AXA_U3_\ \K/_ -STUO\ @HEC_FG_ /Y6O_N>C_5;-_\
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M'UBGW/OJBO@7_AZG_P!4P_\ +@_^Y:/^'J?_ %3#_P N#_[EH_U.SS_H'_\
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MA'^/5]%^9<=SEJ***_3S4****" HHHH **** "BBB@ HHHI@,HHHJ@"BBB@
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M";[3=AEW+Y,?S,&'HV O_ A7T?\ M)?"_P *ZU\+-4U;PAH^EV-]X?O2+O\
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M>6]K''--NLV9M[@9;+<G)Y/-<.(QD<-5I4FK^T=O32X'S*U,;K3VKZB_:?\
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MW&E:?I\NI/:JY07!62*,(Q'(7,N3@@G;BO?_ !=\5/A+X ^(\O@_QI\ =/\
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M5\.M*NP$O;5;>"6//\26NUOR->D_%3XG/\*_^%>ZG(2VF7#M:WR#)_<M&F6
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MW>/EEFU-I(P?4H(E)'_ A7K*CFF6UJZPE%5(U).2?,ERM[W3W7H1[LK7.O\
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M,*^S_P!M#_DEVE_]AF+_ -$3U\85X'#'_(N7JSV8[!1117UA3"BBB@D****
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M:;3DW'88U1MTJ1JC;I7K&;&4QJ?3&JD21MWIE/;O3*I %%%%, HHHH ****
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MPI7X<_\ 1//"/_@@M/\ XW3_ .(@8;_GQ+[T'U9]S\;Z_7;]@_\ Y-2\#_\
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M_B:?)X#\(*L9'@SPY\R[C_Q*H?4_[-'^MM'_ )]/[T'.C\]Z*_07_A!?"/\
MT)GAO_P50_\ Q-'_  @OA'_H3/#?_@JA_P#B:?\ K;1_Y]/[T'.C\^J*_07_
M (07PC_T)GAO_P %4/\ \31_P@OA'_H3/#?_ (*H?_B:/];:/_/I_>A<R/SZ
MHK]"9_ 7A".4J/!GAS&!UTJ'T!_NU'_P@OA'_H3/#?\ X*H?_B:7^MM'_GT_
MO0<R/SZI&K]!O^$%\(_]"9X;_P#!5#_\31_P@OA'_H3/#?\ X*H?_B:?^MM'
M_GT_O0<R/SXHK]"(_ ?A!I%!\&>&\$@?\@J'_P")I9/ ?A!9'4>#/#> 2/\
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M_P#XFG_KMA_^?,OO0O9^9^5S4QJ_5/\ X5?X#_Z$#PG_ ."6W_\ B:/^%7^
M_P#HG_A/_P $MO\ _$U7^N^'_P"?,OO0O9^9^5+=:97ZN7'PJ\ QSR(/A_X3
MPK$#.BV__P 34?\ PJWP%_T3[PG_ ."2W_\ B:?^O&'_ .?$OO0O9>9^4=,;
MI7ZO_P#"K/ /_1/O"7_@DM__ (FD_P"%5^ ?^B>^$O\ P26__P 35?Z\X?\
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M_P#!!;?_ !%'_"F_AM_T33P9_P"""V_^(H_XB#AO^@>7WH/JS[GXU45^RO\
MPIOX;?\ 1-/!G_@@MO\ XBE7X,_#8L!_PK3P9U_Z %M_\11_Q$'#?] \OO0?
M5GW/QIHK]F)O@Q\-8YI%'PT\&X5B!_Q(+;U_W*9_PIOX;?\ 1-/!G_@@MO\
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M>)<YIYYC(XBG!Q2BHV?DV_U.VC3=.-F%%%%?)FX4444 %%%% !1110 4444
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M&M6,EE>6T@4,!)"XRN596![A@:%[VP/W=SLJEN/O)_US7^515+<?>3_KFO\
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M  PLX=/^&GA*UM[R+4;>#2+2*.\@#".=5A0"10P!"L!D9&<&MK+WK=&E^?\
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M=C?66L_;K>]N8EF,T;6\\T "R,K0;@S ,1(,YZGW&MI=+?U_6WZO<R5[N_\
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M_@=AU-&O-W_/^M>Y[+4UY_Q]2?6H:FO/^/J3ZT^HBK=2O!:S2I$UPZ(S+"A
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MEHOQ M?$%YXAL+-V4R,5=XUM[;>F$_=8(R$Q@TH:S<?GY^OI<<](7_X;KO\
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M%_X[U#Q['\1+_5[6.TM-2L;>&WL8+1&9O+@6)W# R,[%V=CDX& ,5Z;7R_\
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M--5N1=MJ#QO,UYE?,),1,.,;,>3\F ,#K4TOALNBM\O=Z=%HM;O8=31W[O\
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MB_88/L*_-Q;^6OECYOF^[MZ\^M5#X';O^-K?+;1:Z$RTFO3^OSU\S;M?OO\
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M)NM+U>RAU73+I#%<65[ DT,R'JKHV58>Q%<$G[+GP8C963X5>"U93E67PU9
M@^H_=UZ911S-.X6Z#/LL/]Z3\A4MO;Q"0X:3[C=A_=--J2#[Y_W6_P#031S,
M+(A^RP_WI/R%9/BCP/X<\<:/)I/B/1[/Q!I4C*[V.J6<5S S*<J2C@J2#R..
M*V**5V]PL>>Z/^SC\)?#NJ6NIZ5\-O">F:E:R":WO+/P_9PS0N#D,CK&"I'J
M#FO0/LL/]Z3\A3J*?,]@Y4.6WB^SR#=)C<O8>]1_98?[TGY"IE_U$G^\O]:C
MHYF%D<KXR^$?@7XC26K^+/">B^*'M0RV[:UI=O>&$'&0GF*VW.!G'I4'@_X*
M_#SX>ZA+?^%?!>@>&;Z6/R9+G1](MK25XR0=A:- 2N0#CIP*[&BA2:V!I/<;
M]EA_O2?D*D-O%]G4;I,;SV'H*;4A_P"/=?\ ?/\ (4<S"R(?LL/]Z3\A7'>+
MO@C\.?B!J:ZCXH\$>'O$FH+&(EN]7T>VNI0@SA0\B$X&3QG'-=G12NPL<QX-
M^%/@CX<BZ'A/PKH_A<76W[0-%TR"S\[;G;O\M5W8R<9Z9-=+]EA_O2?D*=13
MYF'*B&\D@A:.(^:=JYR ._/]:K_:+?TF_(4FJ_\ 'TO_ %S7^54ZU6QX=7$U
M(SE%/9F99>!/!FF^)KSQ):>&-,M?$5ZI2YU>'3X$NYU)!(>8+O8$JIY/8>E=
M!]IMSU\X_E5*BGTL9?6ZN]R[]HM_2;\A6A<6\+3.2T@)YX ]*PJWIO\ 6'\/
MY5$M#T,)5E5<N?H5YK&VN(GBEW212*4='52&4C!!'<$5B^$_ASX3\!6LUMX9
M\/Z;X<MYI3/+#I-A#:H\A !=A& "V !D\X K?HJ.9GHV0W[-#_?D_(4Z*WA$
MJ'=)]X=AZT4Z/_6)_O#^=',PLADEO"9&.Z3J>PJIJF@Z9KFFW.GZE;)J%A<H
M8I[6ZA26*5#U5D;(8'T(JZ_WV^II*5WL%K&/X9\$^'?!.EQ:9X=TBST'38BQ
MCL]+M(K:%"Q+,0B  9))/')-:WV:'^])^0IU%/F8<J'6]O$LFX-(=H)Z#TJ/
M[+#_ 'I/R%30]7_W&J.CF861A>+/A]X6\?:<FG^)]"T_Q'8))YJVNK6,-U$K
M@$;@L@(!P3SCO6O;:;9V4"06Z&WA10JQQ(JJH P  .P%344<S"R&_98?[TGY
M"I([>(0RC=)@@9X'K3:DC_U,OT'\Q1S,+(A^RP_WI/R%8/B;X;^$?&EQ87'B
M'P]INO3Z?)YMG+J>GPW+6SY!W1EU.PY .1CH*Z"BCF860Q;2!%VJ9%7^Z% %
M+]EA_O2?D*=11S,+(=]GA6W W289\]!V'_UZC^RP_P!Z3\A4S?ZB/_>;^E1T
M<S"R.>U3X:^$-;\1V/B#4?#NF:AKUB-MIJEUI\,MU;CGB.5E+)U/0CJ:WA:P
M*H4-(%'0 #%/HHYGL%EN-^RP_P!Z3\A4DMO$5BRTG"<<#U--J27[L7^Y_4T<
MS"R(?LL/]Z3\A7/Z3\,_!^@Z]J&N:9X<TO3M;U DWFI6NGPQ7-SD[CYDBJ&?
MGGDGFNBHHYG>X66PTV\)ZO(?P%'V6'^])^0IU%',PLAUQ;Q><P+297"]!V&/
MZ5']EA_O2?D*FN/^/B7_ 'C_ #J.CF861SOA?X:>#_ [7;>'/#FE^'VO)!+<
MMI>GPVQG<9PS[%&X\GD^IKH/L\)ZO(?P%.HHYF%D)'9PR.J[Y!N..@I98899
M7?=(-Q)Q@=ZDM_\ 7Q_[P_G4=',PLBO>:58ZA9SVMU']IM9T:*6":-721&&&
M5E/!!!((/7-9?A3P!X7\!Z>;#PUH>G^';$R-*;72;&*UBWG&6VQ@#)P,GVK<
MHHYF%D-^S0_WY/R%26]O$LG#2?=;L/[IIM20?ZS_ ("W_H)HYF%D0_98?[TG
MY"LCQ1X'\.>-]);2_$>CV>OZ8SB1K+5+.*YA+#HQ1P5R,GG'>MFBE=O<+%/2
M]"TS1-/@L=.MDL+*WC6&&VM84BCC11A555P     .!5K[+#_ 'I/R%.HI\S>
MK8<J+%AI\4_FC?)C:%/0=\_TJQ_8-O\ WY?S'^%+H_\ RV_X#_6M*CF861QW
MBWX1>$/'UO;V_B?P_IOB."V<R01:O90W2Q.>"RB1"%/N*W8_#MK"FR,NB?W5
MP!_*M2BES,+(S/[!M_[\OYC_  IRZ'"J,F^3:Q!ZC/&?;WK1HHNPLC,_L&W_
M +\OYC_"L#7O@_X/\5:MIVJ:WX>TS6-3TU@]C>ZA8PSS6K!MP,3NA*$-S\I'
M/-=E11=[A9&8OA^V50JO(JCHH( _E1_8-O\ WY?S'^%:=%/F861G-H<#*BEY
M,+D#D=SGTIO]@V_]^7\Q_A6G11S,+(XRU^#W@ZR\477B:W\.Z7!XCND,=QK$
M=C"MY,IQE7F";V'RKP3_  CTKH?[!@_YZ2_F/\*TJ*.9[!9;F9_8-O\ WY?S
M'^%.;0X'VY>3A0O!';\*T:*7,PLC-_L& <B27\Q_A7/:!\'?!OA34M0U'1/#
MFEZ/J&HL'O;O3[&&"6Y8$D&1T0%SEF.6)ZGUKLZ*?,]PLMC-.@P'K)*?Q'^%
M)_8%O_?E_,?X5IT4<S"R,Z31()'+%Y 3Z$?X55U+P?IFL:?<6%_ M]8W,9BG
MMKE$DCE0C!5E((8$=C6W12N]@.6\+_#+PUX(TM--\.:19Z!IT99DM-+M8K:)
M2QRQ"(H )/)XYK6_L&W_ +\OYC_"M.BGS/N%D4;?1X;6995>0LO3<1CICTJ]
M112&4M7&[3Y![C^8KGO+-='JG_'C)^'\Q6#7BXS%U:%11IO2QV4:,*D;R1%Y
M9H\LU+17#_:.)_F_!'1]6I=B+RS5BUC!28.2!M'W>OWA3*FM_N3?[H_F*Z,/
MCJ]2K&,GH_)&53#TXP;2&_9H?[TGY"N1^(7P=\&?%:UM;?Q3I3ZFEMY@A9+B
M6WD59%V2)OA=&*.O#(3M8=0:["BOH&[[G M-C!7X?^'([_0KR/3_ "IM#A>W
MTP1DI':QN@1@D8.S[@"Y(R!D C)K<^S0_P!Z3\A3J*?-)[L7*AS6\7D1C=)C
M<W8>U1_9H?[TGY"IF_U,?U;^E1T<S"R/&OB7^QK\%OC%XJF\2^,?!,>MZY-&
MD4EX]Y<PEE084%8Y57@=\9KI/A'^SW\.O@/9:C:> O#W_".VVHR)+=1QW$TW
MFL@(4YED<C )Z8ZUZ#12BW'2.@/WMQOV:'^])^0J26WBVQ9:3A,=!ZFFU)+T
MC_W/ZFGS,+(A^SP_WI/R%>$^+/V$/@)XZ\2ZEX@UWX?PW^L:C,UQ=W7V^[C,
MLC=6*I,%!/L!7O%%+K<?2QR/PR^$/@WX->%8_#?@S2/["T..9YUM(I7E'F/C
M<VZ1F8DX'4]JZO[-#_>D_(4^BJ<I/=D\J6R'7%O$TQ):3.!V'H*A>SMY$9&,
MA5@5(P.0:L3_ .M/T'\A4=3=CL?.UU_P3O\ V<[ZZFN9OAM"\TSM([#4KU<L
M3DG GP.3VKV_P?X'T#X?^%],\.>'K(Z9HFFPBWM+.-BRQ1CHH+$L>O4DFMJB
MFI.*Y5L#2;NQ([>'S$^:3J.P]:66WA,CDM)G<>P]:='_ *Q?J/YT2?ZQ_P#>
M/\Z.9A9&7X@\,:3XJT._T;5;=KW3+^![:YMW.!+&PPRD@@C(/8YKP,?\$Y?V
M;U((^&D/'_43OO\ Y(KZ.HI7UOU'TL5[/2[/3[."UME>&W@C6**-<85% "@?
M0 5:M[>(3*0TF>>H'I3:DM_]<OX_RI\S>[)Y4M$B#[-#_>D_(5E>*O!ND>--
M#N='U7[<]A<#$JVE[-:2,/3S(71P#W ;!'!S6Q12;NK,I::HXWX?_!7P!\*K
M06_A#PIIGAY?*2!Y;&SC2:5$^Z)9<;Y"/5V)R2<YKL/LT/\ >D_(4ZBJYI/=
MBY5V'0V\($N&D^X>P]JC^S0_WI/R%30])/\ </\ 2HZ7,PLCE?B)\*O"_P 5
MM ?1/%%K>:AI,F?-M(;^XM$F!&"LGD2)YB_[+9'M5GPC\-_"7@"RDL_#'A[3
M?#EK(_F20Z38PVR.V,;F"*,G QD\UT-%',UL%D[7Z#?LT/\ >D_(5)]GA^S@
M;I,;_0>E-J3_ )=Q_O\ ]*.9A9$/V:'^])^0KA?&WP%\ ?$K7K#5_%>@_P#"
M1W%ADVUOJ=Q+/9(2I4M]D9S 6PQ^8QD].>!7>44KL90T?P[I/A_3;?3]*LHM
M,T^V0106MG D,42#HJHH 4#T J[]FA_O2?D*=13YF+E0Z2WB\F'YI, '' ]:
MC^S0_P!Z3\A4TG^IB^A_F:CHYF%D>=:]^SG\-/%GBY_$_B'PO!XDUAHVA5]=
M>34((5)5B(K>=WABY4',:*>OJ<]_#I]I;1+%"K11J JI&JJH X  %344*32L
MM@LF[L;]FA_O2?D*DFMXBR9:3[B]AZ4VI)NJ?[B_RHYF%D0_9X1SND_(5YS9
M_LV_#"T\577B:7PG;:KXBN)(Y6U36V?4[B-D)*>4]R\AA"EC@1[1T]!CTBBC
MF=[A96L,6U@48!D ]@*/LT/]Z3\A3Z*.9A9#KJWB:XD):3.X] *K7.GVUW;R
MP2-/Y<J,C>6Y1L$8.&4@J?<$$=JMW/\ Q\2?[QJ.E=[!8\[\'_LZ?#/P)K$V
ML:/X3LUUV:=[E]9O@U]J#2,H5F^U7#23<@ 8WXZ\<FO01:P#@&0#Z"GT4^9[
M!9;BV]O"+B(AI,[QV'K3/LT/]Z3\A4L'^OC_ -X?SIE',PLC/UOP[8>(=)N=
M.O'O!:W"[)#:74EK+C.?EEB970\=58&N4^'_ ,!?AS\*USX4\(Z;HUR59'OH
MK97NY0S%V$EP^Z63+'/SN?T%=W11S-.Z"RM8;]FA_O2?D*DM[>(2'#2?<;L/
M[IIM20??/^ZW_H)HYF%D0_9H?[TGY"L+QIX T+XA:!/HNNI?3Z9/_K8;6^GL
MS(,$%6>"1&*D$@J3@]P:WZ*3=U9C6FJ.4\"_"/P/\,;$VGA+PQIGAR!D1'_L
MVRBA:4(,*9' W2,!_$Q)Z\UU/V:'^])^0IU%5S2>[)Y4MD.6WB^SR#=)C<O8
M>AJ/[-#_ 'I/R%3+_P >[_[R_P C4=+F8[(XGQ_\$? _Q4NM/F\6Z1)KT=A(
MLL%E=W<QLRZDE6DM1((92"3S(C<<=.*Z+P_X1T'PGI<&F:'IEKHNFP B*ST^
MVCMX8P3DA40 #D]A6I10I-:(+)ZL;]FA_O2?D*D:WB^SH-TF-[=AZ+3:D;_C
MW3_>;^0HYF%D0_9H?[TGY"N!\7?L^_#OX@>)K?7O%/AQ/$M_;J4ABUB:6[LX
MLKM)6TD<P!B.K"//?.>:] HI7&5=/T73M)LX;2QMULK2%!'%!;Q)''&H& JJ
M.  .PJQ]FA_O2?D*=13YF+E1;CTE+J")Q*R@+MZ#U/\ C3O^$?3_ )[-^0J[
MI_\ QYQ_C_,U9HYF%D>2:A^RS\-=:\7W'BC6/#-KX@UR88^TZZTFHK" ^\"&
M.X=TA ;D")5Q7H:>&XHU"I)L7T50!6Q10I-*RV"R;NS)_P"$?3_GLWY"G2:&
MDC;O.8< =/0 ?TK4HHYF%D9!\/(01YS?E7G>A_LK_#3P_P"))_$4'ABSO/$,
MTRW!UC6#)J5ZDBC"E)[EY)(\#@!& ]J];HHYG>X6TL9"^'8U&!*P'H%%*- 0
M$'SF_(5K44<S"R,N30DDD=_.8;B3T'>JM_X1M]2L;BTGGG$,Z-&YAD:%\$8.
MUT(93_M*01V-;U%*[V"QY7X(_9C^''PYOFU#P_X6T^TU9WDD?5IXC=:@[2'+
M[KJ8O,V>X+D5WW_"/I_SV;_OD5K44^9[!9&7'H:1L3YS'*E>GJ,4W_A'T_Y[
M-^0K6HHYF%D<MXD^'NG^+-%N=*U&:[-E<#;*+.[FM)",]!+"Z.OOAAD<'BN?
M^'_[._@'X50"/PCX7TK0&\I87N+2S07$R Y EF.9).3G+L3FO2:*.9IW06NK
M&3_PCZ?\]F_(4Y=#15=?.;Y@!T]\UJ44<S"R,G_A'T_Y[-^0KD?B)\!_"7Q8
MLK:R\66<VL6%O()19->7$5O(P(8>;%'(J3 %1Q(&'MR:]$HI7;#;8Y'PO\+?
M#O@C31IWAS2=/\/Z>':06FEV45M$&;[S;$ &3W..:V/^$?3_ )[-^0K6HI\S
M%RHK6-F+&)D#%\MNR1["K-%%24%%%% !1110 4444 %%%% !1110 5@:G_Q_
M2_A_(5OU@ZEC[=+^'\A7E9C_  EZ_P"9UX;XWZ%6HY+B*%XTDE2-Y#M168 L
M>N!ZFI<#UKX6_:"\$>+;/]J2'QOI'P]N?B?=Z;?:;<V,VE:Q$DND6Z0S+-:2
M0.X$8E=UD$A7!"GTKP:<%.:BW:_]?U_GH=\FU%M=#[HHKR/]DOPWJ'A7]GWP
MGI^JO:?;0EQ.\%C<K<0VHDN)9!;I(I(81APG!QE2.U>NX'K1.')-QO>PHRYE
M<MS2#SI/W:'YCZ^OUIGFC_GDGZ_XTD_^OD_WC_.F5]F>,2>:/^>2?K_C1YH_
MYY)^O^-1T4 3V\@,T?[M!\P]?\:9YH_YY)^O^-%O_P ?$?\ O#^=1T 2>:/^
M>2?K_C1YH_YY)^O^-1T4 2>:/^>2?K_C3X9!O/[M!\K>OH?>H*D@^^?]UO\
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MTZ/_ %B?[P_G0 ]I1N;]VG4^O^-)YH_YY)^O^-,?[[?4TE $GFC_ )Y)^O\
MC1YH_P">2?K_ (U'10!/#(/G_=I]P^O^-,\T?\\D_7_&B'J_^XU1T 2>:/\
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M*0J>5C0DHH/0(!7K?'K3KK][)>9%+X$69KB432 2.!N/\1]:9]HE_P">K_\
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M_P!\F@!ZW$ODN?,?.Y?XC[TS[1+_ ,]7_P"^C3U@D\EQY;9W+_"?>F?9Y?\
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M** '^8/^><?Y'_&CS!_SSC_(_P"-,HH GFD'F']VAX'8^@]ZC\P?\\X_R/\
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MYQ_D?\:D\P?9Q^[3[_H?2H*D_P"7<?[_ /2@!/,'_/./\C_C1Y@_YYQ_D?\
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M"BBB@!*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _"_\ :ZFD7]I[XF 2R ?VS+P'/]U:\B^T
M3?\ /:3_ +[->M?M>?\ )SWQ,_[#,O\ ):\BKYJI\;/VO"_[O3_PK\C].?\
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MR%'V=_\ 9_[[7_&I#"_D*/ESN/\ $/0>] %?-&:D^SO_ +/_ 'VO^-'V=_\
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M 'VO^- !#U?_ '&J/-3Q0.-_W?N'^,?XTS[._P#L_P#?:_XT 1YHS4GV=_\
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M(_PH^SR_\\V_(T?9Y?\ GFWY&@ ^T2>H_P"^1_A3Y)W CY'W?[H]33/L\O\
MSS;\C3Y+>0B/$;?=]/<T ,^T2>H_[Y'^%'VB3U'_ 'R/\*/L\O\ SS;\C1]G
ME_YYM^1H /M$GJ/^^1_A1]HD]1_WR/\ "C[/+_SS;\C1]GE_YYM^1H ?-.XD
M(!'0?PCT%,^T2>H_[Y'^%/FMY#(2(V(P.WL*9]GE_P">;?D: #[1)ZC_ +Y'
M^%'VB3U'_?(_PH^SR_\ /-OR-'V>7_GFWY&@!R7#^8O(ZC^$?X427#^8_(ZG
M^$>OTHCMY?,7]VW4=J)+>7S'_=MU/:@!OVB3U'_?(_PH^T2>H_[Y'^%'V>7_
M )YM^1H^SR_\\V_(T 'VB3U'_?(_PJ2"=S,H)'?^$>E1_9Y?^>;?D:D@MY!,
MI,; <]O:@"/[1)ZC_OD?X4?:)/4?]\C_  H^SR_\\V_(T?9Y?^>;?D: #[1)
MZC_OD?X4?:)/4?\ ?(_PH^SR_P#/-OR-'V>7_GFWY&@!\<[GS.1]P_PCVIGV
MB3U'_?(_PI\5O+^\_=M]PCI]*9]GE_YYM^1H /M$GJ/^^1_A1]HD]1_WR/\
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MK_A1Y(_YZQ_K_A0 6_\ Q\1_[P_G4=6+>(":,^8A^8>O^%1^2/\ GK'^O^%
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M^>L?Z_X4 1U)<?Z]_K1Y(_YZQ_K_ (5)/$#,_P"\0<^_^% %>BI/)'_/6/\
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ME3S0GS#\R=OXQZ#WIGDG^\G_ 'V/\: (Z*D\D_WD_P"^Q_C1Y)_O)_WV/\:
M&1_ZQ?J/YTLG^L?_ 'C_ #I\<)\Q?F3J/XQ_C1)"?,?YDZG^,>OUH BHJ3R3
M_>3_ +['^-'DG^\G_?8_QH CJ2W_ -<OX_RH\D_WD_[['^-/@A(F7YD[_P 8
M]/K0!7I:?Y)_O)_WV/\ &E\D_P!Y/^^Q_C0!'14GDG^\G_?8_P :/)/]Y/\
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M9OA(8O$.EVMM<0^.=4"WBM&K*'"%3M0@XV9VMC-?9TTT=O"\LLBQ11J6>1R
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MB3_>7^M1U.OE>2_W\;E]/>F?NO\ II^E $=%2?NO^FGZ4?NO^FGZ4 1U(?\
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MVH KT5)Y:_\ /5?R/^%'EK_SU7\C_A0!'14GEK_SU7\C_A1Y:_\ /5?R/^%
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MHWQ_\\O_ !XT 1U)<?Z]_K2;X_\ GE_X\:DN&3SGS'GG^\: (**DWQ_\\O\
MQXT;X_\ GE_X\: (Z='_ *Q/]X?SIV^/_GE_X\:=&T?F)^Z[C^(^M $3_?;Z
MFDJ5GCWM^Z[G^(TF^/\ YY?^/&@".BI-\?\ SR_\>-&^/_GE_P"/&@ AZO\
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M'^-&V+^^_P#WP/\ &@ G_P!:?H/Y"HZGF6+S#EWSQ_"/0>],VQ?WW_[X'^-
M$=%2;8O[[_\ ? _QHVQ?WW_[X'^- #8_]8OU'\Z)/]8_^\?YT]%BWK\[]1_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P : (Z*D\[_ *9Q_D?\:/._Z9Q_D?\ &@".I(/OG_=;_P!!-'G?],X_R/\
MC4D,N7/[M!\K=CZ'WH KT5)YW_3./\C_ (T>=_TSC_(_XT 1T5)YW_3./\C_
M (T>=_TSC_(_XT "_P"HD_WE_K4=3K+^Y<^6GWE['W]Z9YW_ $SC_(_XT 1T
M5)YW_3./\C_C1YW_ $SC_(_XT 1U(?\ CW7_ 'S_ "%'G?\ 3./\C_C3_-_<
M*?+3[Q['T'O0!!14GG?],X_R/^-'G?\ 3./\C_C0!'14GG?],X_R/^-'G?\
M3./\C_C0 3?P?[B_RJ.K$TOW/W:'Y1V/I]:C\[_IG'^1_P : (Z*D\[_ *9Q
M_D?\:/._Z9Q_D?\ &@".I+C_ %[_ %H\[_IG'^1_QI\\N)G_ ':'GT/^- $%
M%2>=_P!,X_R/^-'G?],X_P C_C0!'3H_]8G^\/YT[SO^F<?Y'_&G1S?O$_=I
MU'8^OUH B?[[?4TE2M-\S?NTZGL?\:3SO^F<?Y'_ !H CHJ3SO\ IG'^1_QH
M\[_IG'^1_P : "'J_P#N-4=3Q2\O^[0?(>Q_QIGG?],X_P C_C0!'14GG?\
M3./\C_C1YW_3./\ (_XT 1U)'_J9?H/YBCSO^F<?Y'_&I$E_=R_NTZ#L?7ZT
M 5Z*D\[_ *9Q_D?\:/._Z9Q_D?\ &@".BI/._P"F<?Y'_&CSO^F<?Y'_ !H
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MFHZL.T7EQ?(^,'^(>OTJ/=%_<?\ [['^% $=%2;HO[C_ /?8_P *-T7]Q_\
MOL?X4 1U)-U3_<7^5&Z+^X__ 'V/\*DF:+*Y1_NK_$/3Z4 5Z*DW1?W'_P"^
MQ_A1NB_N/_WV/\* (Z*DW1?W'_[['^%&Z+^X_P#WV/\ "@ N?^/B3_>-1U8N
M&B\^3*.3N/\ $/\ "H]T7]Q_^^Q_A0!'14FZ+^X__?8_PHW1?W'_ .^Q_A0
MD'^OC_WA_.F5/"T7G1X1\[A_$/7Z4S=%_<?_ +['^% $=%2;HO[C_P#?8_PH
MW1?W'_[['^% $=20??/^ZW_H)HW1?W'_ .^Q_A4UHL4DZH%<;@1G<#V/M0!5
MHK5_LF+^\_YC_"C^R8O[S_F/\* ,JBM7^R8O[S_F/\*/[)B_O/\ F/\ "@"/
M1_\ EK^']:TJ@MK1+7=M+'=ZU/0 4444 %%%% !1110 4444 %%%% !1110
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MZG69_)<Y7.Y?X1[^U,^T/ZK_ -\C_"@".BI/M#^J_P#?(_PH^T/ZK_WR/\*
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MC[0_JO\ WR/\*D29_+E.1T'\(]?I0!7HJ3[0_JO_ 'R/\*/M#^J_]\C_  H
MCHJ3[0_JO_?(_P */M#^J_\ ?(_PH &_U$?^\W]*CJPTS^3&<C.6_A'M[5']
MH?U7_OD?X4 1T5)]H?U7_OD?X4?:']5_[Y'^% $=22_=B_W/ZFC[0_JO_?(_
MPK9LSNMHSWQZ8H PJ*Z.B@#G**Z.B@!*6BB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH @O/^/=OP_G6;6G>?\ 'NWX?SK-VFO*Q7QKT.JE\)7O
MKZTTZV:6]N8;2W8B,R3R"-26.T+DD<DD >YKE_ ?A'PS\'?#NC^#-)G6RMB\
MYL;2[N=\\Q+-+)MW'<V-S'CH*Y3]J[1Y-<^ ?BFRC\.Z-XG:6*,?8O$%]]BL
MD'F+F>2;*E!%_K,A@<J,$&OD[]C+X.ZAX*^+WA;Q-JGB#PS\8;+5;.ZM=(\7
M6FOW$D^BB&(K-;6]O.Q\V(9$>]1N4-\QP<5C1@I\R;M^NC?]=/GH54ER).UW
M_7]=_P!/T+H?_42?0?S%+M-*WRPR$J&&!P?J*=%?O$.?PLIT5)YB_P#/)/S;
M_&CS%_YY)^;?XU[1Q$=%2>8O_/)/S;_&CS%_YY)^;?XT #?ZF/ZM_2HZG:1?
M)3]TO5NY]O>F>8O_ #R3\V_QH CHJ3S%_P">2?FW^-'F+_SR3\V_QH CJ27I
M'_N?U-'F+_SR3\V_QI\DBXC_ '2_=]3ZGWH @HJ3S%_YY)^;?XT>8O\ SR3\
MV_QH CHJ3S%_YY)^;?XTGF+_ ,\D_-O\: %G_P!:?H/Y"HZGFD7S#^Z4\#N?
M3ZTSS%_YY)^;?XT 1T5)YB_\\D_-O\:/,7_GDGYM_C0 V/\ UB_4?SHD_P!8
M_P#O'^=/CD7S%_=+U'<_XTLDB^8_[I>I[G_&@"&BI/,7_GDGYM_C1YB_\\D_
M-O\ &@".I+?_ %R_C_*CS%_YY)^;?XT^"1?.7]THZ]SZ?6@""BG^8O\ SR3\
MV_QI?,7_ )Y)^;?XT 1T5)YB_P#/)/S;_&CS%_YY)^;?XT $/23_ '#_ $J.
MIXI%_>?NE^X>Y]O>F>8O_/)/S;_&@".BI/,7_GDGYM_C1YB_\\D_-O\ &@".
MI/\ EW'^_P#TH\Q?^>2?FW^-/\Q?('[I?O\ J?3ZT 045)YB_P#/)/S;_&CS
M%_YY)^;?XT 1T5)YB_\ /)/S;_&CS%_YY)^;?XT $G^IB^A_F:CJ>21?*B_=
M+T/<^OUIGF+_ ,\D_-O\: (Z*D\Q?^>2?FW^-'F+_P \D_-O\: (ZDFZI_N+
M_*CS%_YY)^;?XT^:1<K^Z4_*O<^GUH @HJ3S%_YY)^;?XT>8O_/)/S;_ !H
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MM,^SR_\ /)_^^323_P"OD_WC_.F5ZYR$GV>7_GD__?)H^SR_\\G_ .^34=%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH*PX9B9HQM3[P_@'K]*W* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY"F9J>:XD$A D8<#O[4S[1+_ ,]&_,T 1YHS4GVB7_GHWYFC[1+_ ,]&_,T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MFR2/]GK]N75/&/AZZ\.V/C6\\*W']FZEJ%QIDMO);R;I$V0WFU'/,;_ZM\8
M/0BOI.ORH_9#_:5\,?L*?$[XO_"CXR"\\-O-X@EU2TUS['+<).K *I98E9]K
MH(Y$8*1\S9P<9 #]I']D'0?V(;W2O&'PN^-'B;X5RZ_?KI\,%Y'+<Z<TN"R1
MSSPC*Q@%R!+'*>&/8FOU0L4GCL;=+J19;E8U$LBC 9\#<1QW.:_*;_@H%^U]
MX(_;$\-^#?@W\''NO&.MZMK]M<?;#I\]O#&P22-442JK[LRY9MFU55N>>/U7
MTVS.GZ;:VK2&9H(DB,A&"^T 9_'% 'P1\9O^2K>*?^OY_P"0KC*[/XS?\E6\
M4_\ 7\_\A7&5]!#X4?RWC_\ ?*W^*7YL^J_V-?\ D6_$?_7XG_HL5]$5\[_L
M:_\ (M^(_P#K\3_T6*^B*\?$?Q&?OG#'_(HH>C_-A17AVF?&CQ;=_M 7_A*7
MP)K<6B1Z7:3+(SV6(6>[N8FNV(GW&)DB0A0"XV'Y1GGW&N<^H"J5P/WS?Y[5
M=JG<?ZYO\]JYL1\*-*>Y!(R0QL[L$1069F.  .I-?GQ\0/C%\#?BAJGCC7;G
MX-?$SX@>&=:>)+WQAIF@236$)M T8N+.8$-'MY)<$9QR*^_=:TN/7-&O].E9
MDBO+>2W=EZA74J2/P-?'7P[\1_M&_L__  ^T_P"&5E\#+/QN-!@.GZ7XFT[Q
M!;6EG=0KGRI)89"'5L'YAQD@XSUKACN^ZV\^^OEIVO?R-Y.T5^/EV_7TMYGT
M+^S7X?\ !OAKX&^$;'X?:C/J_@W[*9]-O;F0O++')(TA+$@'=N=@00",8/(K
MTS;7EW[,/PMU/X,? SPOX2UJ>VN-8LXI9;QK($0+-+,\SI'G'R*9"HX'3.!7
MJ5:UOXDG>^I%/X5_7X=/0IS1CSI/WB#YCZ^OTIGE#_GJGZ_X4D_^OD_WC_.F
M5Z1SDGE#_GJGZ_X4>4/^>J?K_A4=% $]O&/.C_>(?F'K_A3/*'_/5/U_PHM_
M^/B/_>'\ZCH D\H?\]4_7_"CRA_SU3]?\*CHH D\H?\ /5/U_P *?#&-Y_>(
M?E;U]#[5!4D'WS_NM_Z": #RA_SU3]?\*/*'_/5/U_PJ.B@"3RA_SU3]?\*/
M*'_/5/U_PJ.B@"=8QY+_ +Q/O+Z^_M3/*'_/5/U_PH7_ %$G^\O]:CH D\H?
M\]4_7_"CRA_SU3]?\*CHH D\H?\ /5/U_P *>8Q]G7]XGWSZ^@]J@J0_\>Z_
M[Y_D* #RA_SU3]?\*/*'_/5/U_PJ.B@"3RA_SU3]?\*/*'_/5/U_PJ.B@">:
M,?)^\0?(/7T^E,\H?\]4_7_"B;^#_<7^51T 2>4/^>J?K_A1Y0_YZI^O^%1T
M4 /\H?\ /5/U_P *DN(QYS_O$'/O_A4%27'^O?ZT 'E#_GJGZ_X4>4/^>J?K
M_A4=% $GE#_GJGZ_X4Z.,>8G[U.H]?7Z5#3H_P#6)_O#^= #VA#.V)$ZGU_P
MI!"&X$B$_C_A7C7[1.MZ=I<WAJ#Q'KDWAWPG<2WAN[V*\:S#7"6[M;1M,I!4
ME_F5<C<R*O.=IR?&&M1>)O@!IL?B#QKHWAC5;<Z?_:]WK%^]K$DN$D,$[Q2Q
M21M(A4X#*?F!P0:5]&^UOQ_K\NX^J7>_X?U^9[WY('65/U_PH\H?\]4_7_"O
MFOP_\6/B,N@O>6'@:STGP;:^%)[^SOIM7FO'$D>[RWR\&Z3<%!$;2%BIW;CT
MK*T/]H_5M46P@E\=>&5T:ZG@$OC:.W3[#;W#VS3-I_+^6'#A$RS;MLF/OXJK
M7V_K5K]/Z>A-[;_UHG^O]+4^K(8Q\_[Q/N'U_P *9Y0_YZI^O^%,M&+Q[B58
MM%DLGW3QU'M24ADGE#_GJGZ_X4>4/^>J?K_A4=% $GE#_GJGZ_X4](QY4O[Q
M.@]?7Z5!4D?^IE^@_F* #RA_SU3]?\*/*'_/5/U_PJ.B@"3RA_SU3]?\*/*'
M_/5/U_PJ.B@"=HQY,?[Q.K>OM[4SRA_SU3]?\*&_U$?^\W]*CH D\H?\]4_7
M_"CRA_SU3]?\*CHH D\H?\]4_7_"MFT&+:,9SQU%85;EG_QZQ?2@">BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*Y_U+52VU
M=N/]2:J5P5_C-Z>Q\J_\%$/'7@C3?@C-X(\4:\-/U'Q-<6ZVFGP6TMU<7,<5
MQ&\NV.+YL;05W<<D5XK^R[;:#XY_:0\+1>#?B=J>I^%O RW\]KX)\<6<L&MZ
M:EQ;^24@D<9E@&4P&.4 QC')]C_: GUKX-_M/>'/C"W@35/'WA63PT_ARY_L
M&U^U7VDS?:?-$RQ8R5=25)7I@Y[9P_"7C+4?VG/VKOA[XQT'X<>(_!_AWP79
M:C_:'B'Q)8&PDOOM$2QQVT:'YG ;+'.0,'IW,/M==>:_EHTK]]$FO73S=9NS
M716MYWM?]5\KO0^R]M-E0M!(!UX[^XJ2H[C_ (]Y/P_F*SI_&ARV*GV>3T'_
M 'T/\:/L\GH/^^A_C4=%>F<Q)]GD]!_WT/\ &C[/)Z#_ +Z'^-1T4 3M _DH
M,#JW\0]J9]GD]!_WT/\ &AO]3']6_I4= $GV>3T'_?0_QH^SR>@_[Z'^-1T4
M 2?9Y/0?]]#_ !I\D#D1\#[O]X>IJ"I)>D?^Y_4T 'V>3T'_ 'T/\:/L\GH/
M^^A_C4=% $GV>3T'_?0_QH^SR>@_[Z'^-1T4 3S0.9"0!T'\0]!3/L\GH/\
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M>W_:3_OM?\:I:KTM_P#=/_H1K/K11NCRZN,=.;AR[&[M_P!I/^^U_P :-O\
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M_=>DGYC_  H_=>DGYC_"HZ* )/W7I)^8_P *DA\K><!_NMW'H?:J]20??/\
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M *:1_F?\*/)_Z:1_F?\ "HZ* )/)_P"FD?YG_"I((@)E_>(>O<^GTJO4EO\
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M)R?4Q]0\)VVK"$7MM8W@AD6:/[0@?8ZG<K#(X((!![$5:&DR*  \( Z ,?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8'T05\8?$#XD?%[3_'6OVVG2:LFGPWTR6ZQV&Y?+#G9@[.1MQS7V?7#^(_\
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M<?6@#XQ_X7%\8/6^_P#!;_\ 8T?\+B^,'K??^"W_ .QK[.W'UHW'UH ^,O\
MA<GQAVD9O\<9_P");_\ 8TG_  N+XP>M]_X+?_L:^T58^1)S_$O]:9N/K0!\
M8_\ "XOC!ZWW_@M_^QH_X7%\8/6^_P#!;_\ 8U]G;CZT;CZT ?&/_"XOC!ZW
MW_@M_P#L:;)\7OB_,H#_ &\J"2/^):?;_9K[0W'UJ0L?LZ\_QG^0H$TI*S/B
M?_A:WQ:_NW__ (+C_P#$T?\ "UOBU_=O_P#P7'_XFOM3<?6C<?6G=F?L:?\
M*ON/BO\ X6M\6O[M_P#^"X__ !--_P"%V_%&U_=R>;O7KYFG?-_*OM;<?6C<
MWJ?SHNQ>QI_RH^,/^&@?BHJJN3A1@?\ $M[?E1_PT%\5/4_^"W_ZU?:<SM\G
MS'[B]_:H][?WC^=(UVT1\8?\-!?%3U/_ (+?_K4?\-!?%3U/_@M_^M7V?O;^
M\?SHWM_>/YT#/C#_ (:"^*GJ?_!;_P#6IS?M"?%5F)).>_\ Q+?_ *U?9N]O
M[Q_.I+AV\]_F/7UH ^+/^&@OBIZG_P %O_UJ/^&@OBIZG_P6_P#UJ^S][?WC
M^=&]O[Q_.@#XP_X:"^*GJ?\ P6__ %J5?V@OBHK @G(/_0-_^M7V=O;^\?SI
MT;MYB?,?O#O[T ?%Y_:"^*A).3_X+?\ ZU)_PT%\5/4_^"W_ .M7VB[MO;YC
MU/>F[V_O'\Z /C#_ (:"^*GJ?_!;_P#6H_X:8^)EG^[D:WW=?WNFC=7V?O;^
M\?SI?,;^\?SH ^,%_:C^)*YP]GR,?\@T4G_#47Q)_OV?_@M%?:D,CY?YF^XW
M>H_,?^\WYT ?%_\ PU%\2?[]G_X+11_PU%\2?[]G_P""T5]H>8_]YOSH\Q_[
MS?G0!\7_ /#47Q)_OV?_ (+12C]J/XDA2-]G@]?^):*^S_,?^\WYU)'(_DR_
M,W0=_<4 ?%?_  U%\2?[]G_X+11_PU%\2?[]G_X+17VAYC_WF_.CS'_O-^=
M'Q?_ ,-1?$G^_9_^"T4?\-1?$G^_9_\ @M%?:'F/_>;\Z/,?^\WYT ?&'_#4
M?Q)*@;[/ _ZAHI/^&HOB3_?L_P#P6BOM1I&\F/YF^\W?Z5'YC_WF_.@#XO\
M^&HOB3_?L_\ P6BI(_VJ?B%$N)8[&0^IL=O\C7V9YC_WF_.HY(DF;,B+(>F7
M4&@#XZ_X:N\>_P#/OI__ (!G_&K</[7GCZ.,*;:R..FVV(KZW^RP?\\(O^^!
M4DEK!MB_<1?<_N#U- 'R/_PV!X]_Y];/_P !S_A1_P -@>/?^?6S_P# <_X5
M]:?98/\ GA%_WP*/LL'_ #PB_P"^!0!\E_\ #8'CW_GUL_\ P'/^%'_#8'CW
M_GUL_P#P'/\ A7UI]E@_YX1?]\"C[+!_SPB_[X% 'R6/VP/'V!FUL\]_]'-'
M_#8'CW_GUL__  '/^%?7%Q:0?:)?W$7WC_ /6H_LL'_/"+_O@4 ?)?\ PV!X
M]_Y];/\ \!S_ (4?\-@>/?\ GUL__ <_X5]:?98/^>$7_? H^RP?\\(O^^!0
M!\EG]L#Q]@XM;//;_1S1_P -@>/?^?6S_P# <_X5]<6]K!Y\?[B+[P_@'K4?
MV6#_ )X1?]\"@#Y+_P"&P/'O_/K9_P#@.?\ "I8?VQO&\(/FV%E*3TS$5Q7U
M?]E@_P">$7_? J.33;.;!DL[>0CINB4_TH ^6/\ ALSQE_T"[#_OEJ#^V9XS
M[:78 _[C5]2?V-I__0/M?^_"?X4^'1=.\S_D'VOW6_Y8)Z'VH ^6/^&S/&7_
M $"[#_OEJ/\ ALSQE_T"[#_OEJ^I/[&T_P#Z!]K_ -^$_P */[&T_P#Z!]K_
M -^$_P * /EO_ALSQE_T"[#_ +Y:C_ALSQE_T"[#_OEJ^I/[&T__ *!]K_WX
M3_"C^QM/_P"@?:_]^$_PH ^6_P#ALSQGG_D%V&/]QJ/^&S/&7_0+L/\ OEJ^
MJ%T73O)D_P")?:=5_P"6">_M4?\ 8VG_ /0/M?\ OPG^% 'RW_PV9XR_Z!=A
M_P!\M1_PV9XR_P"@78?]\M7U)_8VG_\ 0/M?^_"?X4?V-I__ $#[7_OPG^%
M'RW_ ,-F>,O^@78?]\M1_P -F>,\_P#(+L,?[C5]2?V-I_\ T#[7_OPG^%2?
MV+IWV<?\2^T^^?\ E@GH/:@#Y7_X;,\9?] NP_[Y:I(?VTO%L.?-T;3Y0>F=
MZXKZ@_L;3_\ H'VO_?A/\*9)X?TJ;'F:78R8Z;[9#C\Q0!\S?\-M>)_^@#IO
M_?;T?\-M>)_^@#IO_?;U]*_\(OHO_0&T[_P$C_\ B:/^$7T7_H#:=_X"1_\
MQ- 'S4/VV?%'?0=-_P"^WH_X;:\3_P#0!TW_ +[>OJZS\(Z$UK&3HFG$X_Y]
M(_\ "IO^$/T'_H":=_X"1_X4 ?)?_#;7B?\ Z .F_P#?;T?\-M>)_P#H Z;_
M -]O7UI_PA^@_P#0$T[_ ,!(_P#"C_A#]!_Z FG?^ D?^% 'R7_PVUXG_P"@
M#IO_ 'V] _;9\48YT'32?]]Z^M/^$/T'_H":=_X"1_X4?\(?H/\ T!-._P#
M2/\ PH ^2_\ AMKQ/_T =-_[[>C_ (;:\3_] '3?^^WKZT_X0_0?^@)IW_@)
M'_A1_P (?H/_ $!-._\  2/_  H ^2_^&VO$_P#T =-_[[>C_AMKQ/\ ] '3
M?^^WKZT_X0_0?^@)IW_@)'_A1_PA^@_] 33O_ 2/_"@#Y+'[;/B?'.@Z;G_?
M>GQ_MN^(XR3)X>TUQV_>R+7UC_PA^@_] 33O_ 2/_"HYO!'AVX4"70-+D Y
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M/_B:^B?^%<^$O^A6T3_P70__ !-'_"N?"7_0K:)_X+H?_B: /G;_ (;.U?\
MZ%>P_P# N3_XFE;]M#5VV_\ %+:?P,?\?<G_ ,37T1_PKGPE_P!"MHG_ (+H
M?_B:?)\.?"6(_P#BE=$^[_T#8?4_[- 'SG_PV=J__0KV'_@7)_\ $T?\-G:O
M_P!"O8?^!<G_ ,37T3_PKGPE_P!"MHG_ (+H?_B:/^%<^$O^A6T3_P %T/\
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M /0KV'_@7)_\37T3_P *Y\)?]"MHG_@NA_\ B:/^%<^$O^A6T3_P70__ !-
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MD"N/"NB?=7_F&P^G^[0!\Y_\-G:O_P!"O8?^!<G_ ,31_P -G:O_ -"O8?\
M@7)_\37T3_PKGPE_T*VB?^"Z'_XFC_A7/A+_ *%;1/\ P70__$T ?.W_  V=
MJ_\ T*]A_P"!<G_Q-'_#9VK_ /0KV'_@7)_\37T3_P *Y\)?]"MHG_@NA_\
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MXM;_ .A5T_\ \#'_ /B:]\_X5SX2_P"A6T3_ ,%T/_Q-'_"N?"7_ $*VB?\
M@NA_^)H \#_X;BUO_H5=/_\  Q__ (FC_AN+6_\ H5=/_P# Q_\ XFO?/^%<
M^$O^A6T3_P %T/\ \31_PKGPE_T*VB?^"Z'_ .)H \#_ .&XM;_Z%73_ /P,
M?_XFC_AN+6_^A5T__P #'_\ B:]_7X<^$O)<_P#"*Z)G<O\ S#8??_9IG_"N
M?"7_ $*VB?\ @NA_^)H \#_X;BUO_H5=/_\  Q__ (FC_AN+6_\ H5=/_P#
MQ_\ XFO?/^%<^$O^A6T3_P %T/\ \31_PKGPE_T*VB?^"Z'_ .)H \#_ .&X
MM;_Z%73_ /P,?_XFC_AN+6_^A5T__P #'_\ B:]\_P"%<^$O^A6T3_P70_\
MQ-/;X<>$O(0_\(KHF=S?\PV'T'^S0!X!_P -Q:W_ -"KI_\ X&/_ /$T?\-Q
M:W_T*NG_ /@8_P#\37OG_"N?"7_0K:)_X+H?_B:/^%<^$O\ H5M$_P#!=#_\
M30!X'_PW%K?_ $*NG_\ @8__ ,31_P -Q:W_ -"KI_\ X&/_ /$U[Y_PKGPE
M_P!"MHG_ (+H?_B:/^%<^$O^A6T3_P %T/\ \30!X'_PW%K?_0JZ?_X&/_\
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M]"KI_P#X&/\ _$U[Y_PKGPE_T*VB?^"Z'_XFC_A7/A+_ *%;1/\ P70__$T
M>!_\-Q:W_P!"KI__ (&/_P#$T?\ #<6M_P#0JZ?_ .!C_P#Q->^?\*Y\)?\
M0K:)_P""Z'_XFA?ASX2R/^*6T3_P70__ !- '@?_  W%K?\ T*NG_P#@8_\
M\31_PW%K?_0JZ?\ ^!C_ /Q-?3/_  J_P;_T*6A?^"V'_P")H_X5?X-_Z%+0
MO_!;#_\ $T ?,W_#<6M_]"KI_P#X&/\ _$T?\-Q:W_T*NG_^!C__ !-?3/\
MPJ_P;_T*6A?^"V'_ .)H_P"%7^#?^A2T+_P6P_\ Q- 'S-_PW%K?_0JZ?_X&
M/_\ $T?\-Q:W_P!"KI__ (&/_P#$U],_\*O\&_\ 0I:%_P""V'_XFC_A5_@W
M_H4M"_\ !;#_ /$T ?,W_#<6M_\ 0JZ?_P"!C_\ Q-'_  W%K?\ T*NG_P#@
M8_\ \37TS_PJ_P &_P#0I:%_X+8?_B:/^%7^#?\ H4M"_P#!;#_\30!\S?\
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M@.3-%<,[#"D]"H]*^C:P]-\"^&M%O$N]/\/:5872?=GMK**-USP<,J@BMR@
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M^%'E+_SU3]?\*CHH D\I?^>J?K_A4D\:F9_WJCGW_P *KU)<?Z]_K0 >4O\
MSU3]?\*/*7_GJGZ_X5'10!)Y2_\ /5/U_P *='&OF+^]3J/7_"H:='_K$_WA
M_.@![1KN;]ZG4^O^%)Y2_P#/5/U_PIC_ 'V^II* )/*7_GJGZ_X4>4O_ #U3
M]?\ "HZ* )XHU^?]ZA^0^O\ A3/*7_GJGZ_X40]7_P!QJCH D\I?^>J?K_A1
MY2_\]4_7_"HZ* )/*7_GJGZ_X5(D:^7)^]7H/7U^E5ZDC_U,OT'\Q0 >4O\
MSU3]?\*/*7_GJGZ_X5'10!)Y2_\ /5/U_P */*7_ )ZI^O\ A4=% %AHU\F/
M]ZG5O7V]JC\I?^>J?K_A0W^HC_WF_I4= $GE+_SU3]?\*/*7_GJGZ_X5'10!
M)Y2_\]4_7_"GR1KMC_>I]WW]3[5!4DOW8O\ <_J: #RE_P">J?K_ (4>4O\
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MH8?X#CK?$)12[:-M=)@)6GH.WS+C=G'ECI_O"LW;6EH@P]Q_US'_ *$*RJ_
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M1_S'^%1T4 3V_E^='@/G<.X_PIG[KT?\Q_A1;_\ 'Q'_ +P_G4= $G[KT?\
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M6/)-;-5R1Z$/'8B^D_P7^1W=UX\:.PT^3^SH3YJR';YK<8<C^E4_^%B/_P!
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M6<JF'ISD[MQ3_ I_V7!Z-^=']EP>C?G5RBI.HI_V7!Z-^=6D4(JJ.BC IU%
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MM-Q=:>=/EU2/3[:.\.8]AF#K& )/XMP YZ"O3Z**R/7"N-\0*?[7N/\ @/\
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MF)_SR'_?1J.B@"3S$_YY#_OHT>8G_/(?]]&HZ* )YG3Y/W0/R#^(^E,\Q/\
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M\0/'&F^';S1+&VM=0$T,DL$DN]5\ESQEL=L?C7S77HW[._\ R6?PS_UTF_\
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M@_\ 0A6=3X&:4_B1H^=_TSC_ .^:/._Z9Q_]\TS:?0T;3Z&O..\?YW_3./\
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M_IG'_P!\TL2G$G!^X?Z5'M/H: '^=_TSC_[YH\[_ *9Q_P#?-,VGT-&T^AH
M?YW_ $SC_P"^:KZAIUGJUK&MY:0W"I(2H8' R!SP:EVGT-2;3]G'!^__ $I[
M;$RC&:Y9*Z,;_A%=%_Z!5M^3?XT?\(KHO_0*MOR;_&M7:?0T;3Z&GS2[G/\
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M -\T>=_TSC_[YJ/-&: )/._Z9Q_]\T^&7+GY$'RM_#[&H,U)!_K#_NM_Z":
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M?_?-/27]U+\B=!_#[U!FI(_]3+]!_,4 'G?],X_^^:/._P"F<?\ WS4>:,T
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ME1]FE_YYM^5 ">=)_P ]&_[Z-'G2?\]&_P"^C2_9I?\ GFWY4?9I?^>;?E0
M]9I/)<^8V=R_Q'WIGVB7_GJ__?1J1;>3R7&QL[E[?6H_LTO_ #S;\J #[1+_
M ,]7_P"^C1]HE_YZO_WT:/LTO_/-ORH^S2_\\V_*@ ^T2_\ /5_^^C6GI;L\
M#%F+'=W.>PK,^S2_\\V_*M/3(VC@8,"IW=_H* +E%%% !1110 4444 %%%%
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M3_>3_OL?XT 15+<?Z]_K2>2?[R?]]C_&I+B$F9SN3K_?'^- $%%2>2?[R?\
M?8_QH\D_WD_[['^- $=.C_UB?[P_G3O)/]Y/^^Q_C2QPGS$^9.H_C'K]: (W
M^^WU-)4K0G>WS)U/\8_QI/)/]Y/^^Q_C0!'14GDG^\G_ 'V/\:/)/]Y/^^Q_
MC0 D/5_]QJ94\,)^?YD^X?XQ_C3/)/\ >3_OL?XT 1T5)Y)_O)_WV/\ &CR3
M_>3_ +['^- $=21_ZF7Z#^8H\D_WD_[['^-/2$^5+\R=!_&/7ZT 045)Y)_O
M)_WV/\:/)/\ >3_OL?XT 1T5)Y)_O)_WV/\ &CR3_>3_ +['^-  W^HC_P!Y
MOZ5'4[0GR8QN3JW\8]O>F>2?[R?]]C_&@".BI/)/]Y/^^Q_C1Y)_O)_WV/\
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MIR;"Y=POR,X^4+G&TKQ6D9J4_9]?^ W^G]69,H\L.=_U_7];H^].?2KFF_\
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M_P#/5/R;_"@".BI/+7_GJGY-_A1Y:_\ /5/R;_"@".K%A_Q^1?4_R-1^6O\
MSU3\F_PJ>QC5;J,B16Y/ !]#[4 ;%%%% !1110 4444 %%%% !1110 4444
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M 'C_ #IZ"+S%^9^H_A'^-$@B\Q_F?J?X1Z_6@"*BI,1?WG_[Y'^-&(O[S_\
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M@FC$7]Y_^^1_C3X1'O.&?[K?PCT/O0!!14F(O[S_ /?(_P :,1?WG_[Y'^-
M$=%28B_O/_WR/\:,1?WG_P"^1_C0 +_Q[O\ [R_R-1U.HC\E_F?&Y?X1[^],
MQ%_>?_OD?XT 1T5)B+^\_P#WR/\ &C$7]Y_^^1_C0!'6KI/_ ![M_O?T%9V(
MO[S_ /?(_P :T]+V^0VTDC=W&.PH N4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'%ZI_P A&X_WS56K6J?\A&X_WS56MUL?*U/C?J='X7_X]Y_]\?RK;K$\+_\
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MQHVQ?WW_ .^!_C0 +_J)/]Y?ZU'4ZK'Y+_.V-R_PCW]Z9MB_OO\ ]\#_ !H
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M%_??_O@?XT;8O[[_ /? _P : "'J_P#N-4=3PK'\_P [?</\(_QIFV+^^_\
MWP/\: (Z*DVQ?WW_ .^!_C1MB_OO_P!\#_&@".I(_P#4R_0?S%&V+^^__? _
MQI\:Q^5+\[=!_"/7ZT 045)MB_OO_P!\#_&C;%_??_O@?XT 1T5)MB_OO_WP
M/\:-L7]]_P#O@?XT #?ZB/\ WF_I4=3LL?DQ_.V,M_"/;WIFV+^^_P#WP/\
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M?YFHZG=H_*B^1NA_B'K]*9NB_N/_ -]C_"@".BI-T7]Q_P#OL?X4;HO[C_\
M?8_PH CJ2;JG^XO\J-T7]Q_^^Q_A3YFCRN4;[B_Q#T^E $%%2;HO[C_]]C_"
MC=%_<?\ [['^% $=%2;HO[C_ /?8_P *3=%_<?\ [['^% "W/_'Q)_O&HZL7
M#1^?)E&SN/\ $/\ "H]T7]Q_^^Q_A0!'14FZ+^X__?8_PHW1?W'_ .^Q_A0
MD'^OC_WA_.F5/"T?G1X1L[A_$/7Z4S=%_<?_ +['^% $=%2;HO[C_P#?8_PH
MW1?W'_[['^% $=20??/^ZW_H)HW1?W'_ .^Q_A3X6CWG"-]UOXAZ'VH @HJ3
M=%_<?_OL?X4;HO[C_P#?8_PH CHJ3=%_<?\ [['^%&Z+^X__ 'V/\* !?^/=
M_P#>7^1J.KUE;Q72R+AU (/W@?7VJQ_9,/\ >?\ ,?X4 9-%:W]DP_WG_,?X
M4?V3#_>?\Q_A0!DUJZ3_ ,>[?[W]!2_V3#_>?\Q_A5BWMUMD*J203GF@"6BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH Q;JUT]KB0R)(7)^;![U%]CTW^Y)^9IUY
M_P ?4O\ O5#3NS'V--ZN*-72X;>&-Q;A@">=QJU-;Q7*!)HTE4,KA74$!E(9
M3SW! (/8@53TC_5R?[W]*T*1K&*BK(****!A7-ZL/^)A-QZ?^@BNDKG-6_Y"
M$WX?R%;4OB,ZFQ3VCTKXO_; \??#ZZ^-GA#P9XE^#NG_ !"NO/TZWO-<U&X$
M']FQWMP8XE0 ;I<E'8C.!M]Z^T:^$OVOI/AGK'[1]MIOQ3\*ZY=:1::';W-C
MK?A.WOS=>>)6/E7#0_(R@99"H)4ELE<\W4^*"\_T;(BO=GZ?JD?3W[,_CK2_
MB9\"O"/B+1O#L7A/2;JV>.UT6"421VD<4KQ!58*N1\F?NCKWZUZ<%&>E</\
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M?\: (Z*D\Q/^>2_]]'_&CS$_YY+_ -]'_&@".I)?NQ?[G]31YB?\\E_[Z/\
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M[>B?]\#_  H ;'_K%^H_G1)_K'_WC_.GI,V]>$ZC^ ?X4LDS>8W"=3_ /\*
M(:*D\]O1/^^!_A1Y[>B?]\#_  H CJ2W_P!<OX_RH\]O1/\ O@?X5)!,QF48
M7O\ P#T^E %>BI//;T3_ +X'^%'GMZ)_WP/\* (Z*D\]O1/^^!_A1Y[>B?\
M? _PH (>DG^X?Z5'4\<S?O.$^X?X![>U,\]O1/\ O@?X4 1T5)Y[>B?]\#_"
MCSV]$_[X'^% $=2?\NX_W_Z4>>WHG_? _P *?YS>0#A/O_W!Z?2@""BI//;T
M3_O@?X4>>WHG_? _PH CHJ3SV]$_[X'^%'GMZ)_WP/\ "@ D_P!3%]#_ #-1
MU8>9O+BX3H?X!Z_2H_/;T3_O@?X4 1T5)Y[>B?\ ? _PH\]O1/\ O@?X4 1U
M)-U3_<7^5'GMZ)_WP/\ "I)IF!7A/NK_  #T^E %>BI//;T3_O@?X4>>WHG_
M 'P/\* (Z*D\]O1/^^!_A1Y[>B?]\#_"@ N?^/B3_>-1U8N)F$\@PGWC_ /\
M*C\]O1/^^!_A0!'14GGMZ)_WP/\ "CSV]$_[X'^% "0?Z^/_ 'A_.F5/#,QF
MC&$^\/X!Z_2F>>WHG_? _P * (Z*D\]O1/\ O@?X4>>WHG_? _PH CJ2#[Y_
MW6_]!-'GMZ)_WP/\*DAF8N>$^ZW\ ]#[4 5Z*D\]O1/^^!_A1Y[>B?\ ? _P
MH CHJ3SV]$_[X'^%'GMZ)_WP/\* +NC_ /+7\/ZUI5GZ7(7\W(4=.B@>M:%
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M-N <X.,\9Q7L==M32;3W.6&Q;G_U\G^\?YTRIII3YTGRI]X_P^],\X_W(_\
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M_O#^=+YQ_N1_]\BG1RGS$^1.H_A% $;_ 'V^II*E>4[V^2/J?X13?./]R/\
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M NZ/_P M?P_K6E6?I<CR>;N8MTZGZUH4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &%>?\ 'U+_ +U0U->?\?4O^]4- &GI'^KD_P![^E<[\7?
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MSIF:GFN)!-( W&X]AZTS[1)_?_05YQVD>:,U)]HD_O\ Z"C[1)_?_04 %O\
M\?$?^\/YU'FK%O/(TT8+<;AV%1_:)/[_ .@H CS1FI/M$G]_]!1]HD_O_H*
M(\U)!_K#_NM_Z":/M$G]_P#05)#/(7.6_A;L/0T 5\T9J3[1)_?_ $%'VB3^
M_P#H* (\T9J3[1)_?_04?:)/[_Z"@!%_U$G^\O\ 6F9J=9Y/)<[N=R^GO3/M
M$G]_]!0!'FC-2?:)/[_Z"C[1)_?_ $% $>:D/_'NO^^?Y"C[1)_?_05(9Y/L
MZG=SN/8>@H KYHS4GVB3^_\ H*/M$G]_]!0!'FC-2?:)/[_Z"C[1)_?_ $%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?)D_YYO_ -\FCR9/^>;_ /?)KH** .?\F3_GF_\ WR:/)D_YYO\ ]\FN@HH
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M:/(?_9_[['^-1T4 3PPN)HS\OWA_$/7ZTSR'_P!G_OH?XTD'^OC_ -X?SIE
M$GD/_L_]]C_&CR'_ -G_ +['^-1T4 2>0_\ L_\ ?8_QJ>QB9;J,G&.?X@>U
M5*L:?_Q^1_C_ "- &W1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5B:A_Q^2?A_(5MUBZ@/\ 3)/P_D*U
MI[D3V*U%+MHVUO<QL)12[:-M%PL2S1EII#N4?,>K =Z;Y)_O)_WV*2?_ %\G
M^\?YTRN,Z23R3_>3_OL4>2?[R?\ ?8J.B@">WA(FC.Y/O#^,4SR3_>3_ +[%
M%O\ \?$?^\/YU'0!)Y)_O)_WV*/)/]Y/^^Q4=% $GDG^\G_?8I\,)#GYD^ZW
M\8]#4%20??/^ZW_H)H /)/\ >3_OL4>2?[R?]]BHZ* )/)/]Y/\ OL4>2?[R
M?]]BHZ* )UA/DO\ ,GWE_C'O3/)/]Y/^^Q0O^HD_WE_K4= $GDG^\G_?8H\D
M_P!Y/^^Q4=% $GDG^\G_ 'V*>83]G4;D^^?XQZ"H*D/_ ![K_OG^0H /)/\
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MO=:HNBBQ\.R2RQZ=?-=B26X\J5XI#+%M'E99"R[6?*X+;&^2NUE^[%_N?U-
M!Y)_O)_WV*/)/]Y/^^Q4=% $GDG^\G_?8H\D_P!Y/^^Q4=% '14M)2T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQC"W49\Q#UX&?3Z54JQI_P#Q^1_C_(T ;=%%% !1110 4444 %%%% !1110
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MU,\M/^>J_DW^%"_ZB3_>7^M1T 2>6G_/5?R;_"CRT_YZK^3?X5'10!)Y:?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_KT;(_\ GJ?^^/\ Z]1T4 3(D?F+^\/4?P__ %Z)$C\Q_P!X>I_A]_K4<?\
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M,VQ?WW_[X'^-)/\ Z^3_ 'C_ #IE<IL2;8O[[_\ ? _QHVQ?WW_[X'^-1T4
M6+=8O.CP[D[A_ /\:CVQ?WW_ .^!_C1;_P#'Q'_O#^=1T 2;8O[[_P#? _QH
MVQ?WW_[X'^-1T4 2;8O[[_\ ? _QJ2%8MYP[_=;^ >A]ZKU)!]\_[K?^@F@
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M\:-L7]]_^^!_C4=% $FV+^^__? _QJ1%B\N7YWQ@?PCU^M5ZDC_U,OT'\Q0
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M** '_NO23\Q1^Z])/S%,HH GF\OS#D/T'<>@J/\ =>DGYBEG_P!:?H/Y"HZ
M'_NO23\Q1^Z])/S%,HH EC\KS%X?J.XHD\KS'X?J>XID?^L7ZC^=$G^L?_>/
M\Z %_=>DGYBC]UZ2?F*910 _]UZ2?F*DM_+\Y<!\\]QZ5!4EO_KE_'^5 "?N
MO23\Q1^Z])/S%,HH ?\ NO23\Q1^Z])/S%,HH GB\K]YP_W#W'M4?[KTD_,4
ML/23_</]*CH ?^Z])/S%'[KTD_,4RB@!_P"Z])/S%2?NOLXX?&_U'I4%2?\
M+N/]_P#I0 G[KTD_,4?NO23\Q3** '_NO23\Q1^Z])/S%,HH GD\ORHN'Z'N
M/6H_W7I)^8I9/]3%]#_,U'0 _P#=>DGYBC]UZ2?F*910 _\ =>DGYBI)O+RO
M#_<7N/2H*DFZI_N+_*@!/W7I)^8H_=>DGYBF44 /_=>DGYBC]UZ2?F*910!/
M<>7Y\F0^=Q[BH_W7I)^8I;G_ (^)/]XU'0 _]UZ2?F*/W7I)^8IE% $T/E^=
M'@/G<.X]:O?V2G_/1OTK.@_U\?\ O#^==!0!0_LA/^>C?I1_9"?\]&_2K]%
M%#^R$_YZ-^E/@TU()5<.Q([&KE% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5EW@_TE_P_E6I6;>?\
M?#_A_*KAN1+8K[31M-.HK4S&[31M-.HH CF:+SI,H^=Q_B'K]*9NB_N/_P!]
MC_"DG_U\G^\?YTRN<W)-T7]Q_P#OL?X4;HO[C_\ ?8_PJ.B@"Q;M%YT>$<'<
M/XA_A4>Z+^X__?8_PHM_^/B/_>'\ZCH DW1?W'_[['^%&Z+^X_\ WV/\*CHH
M DW1?W'_ .^Q_A4D+1;SA'^ZW\0]#[57J2#[Y_W6_P#030 ;HO[C_P#?8_PH
MW1?W'_[['^%1T4 2;HO[C_\ ?8_PHW1?W'_[['^%1T4 3JT7DO\ (^-R_P 0
M]_:F;HO[C_\ ?8_PH7_42?[R_P!:CH DW1?W'_[['^%&Z+^X_P#WV/\ "HZ*
M )-T7]Q_^^Q_A4FZ+R%^1\;S_$/0>U5ZD/\ Q[K_ +Y_D* #=%_<?_OL?X4;
MHO[C_P#?8_PJ.B@"3=%_<?\ [['^%&Z+^X__ 'V/\*CHH L3-%\F4?[H_B'I
M]*CW1?W'_P"^Q_A1-_!_N+_*HZ )-T7]Q_\ OL?X4;HO[C_]]C_"HZ* )-T7
M]Q_^^Q_A3YVC\Y\HQ.?[P_PJ"I+C_7O]: #=%_<?_OL?X4;HO[C_ /?8_P *
MCHH DW1?W'_[['^%.C:+S%PC]1_&/7Z5#3H_]8G^\/YT /9HMS?(_4_QC_"D
MW1?W'_[['^%,?[[?4TE $FZ+^X__ 'V/\*-T7]Q_^^Q_A4=% $\31_/A&^X?
MXA_A3-T7]Q_^^Q_A1#U?_<:HZ )-T7]Q_P#OL?X4;HO[C_\ ?8_PJ.B@"3=%
M_<?_ +['^%2(T7ER_(^,#^(>OTJO4D?^IE^@_F* #=%_<?\ [['^%&Z+^X__
M 'V/\*CHH DW1?W'_P"^Q_A1NB_N/_WV/\*CHH L,T7DQ_(^,M_$/;VIJRI&
M<J)%/J),?TIK?ZB/_>;^E1T 22-%+N#H[[A@[G!S^E0:79V6AZ;9Z?I]L;*Q
MLXE@M[>%@J11J %51C@  #'M3Z* )"T1.2CD_P"^/\*U[''V6/:"!SU.>]8E
M;6G_ /'G'^/\S0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH @O/^/=OP_G69MK3O/\ CW;\/YUG5K#8SEN-VT;:=15D#=M+
M]V&0X!X'7ZBEI'_U$GT'\Q2EL..Y#YW_ $SC_P"^:/._Z9Q_]\U'FC-8&Q)Y
MW_3./_OFCSO^F<?_ 'S4>:,T 3M+^Y3Y$ZMV^E,\[_IG'_WS2-_J8_JW]*9F
M@"3SO^F<?_?-'G?],X_^^:CS1F@"3SO^F<?_ 'S3Y)>(_D3[O]WW-09I\W2/
M_<_J: %\[_IG'_WS1YW_ $SC_P"^:CS1F@"3SO\ IG'_ -\TGG?],X_^^:9F
MDS0!8FE_>'Y$/ [>PIGG?],X_P#OFDG_ -:?H/Y"F9H D\[_ *9Q_P#?-'G?
M],X_^^:CS1F@"5)?WB_NX^H_AHDE_>/^[CZG^'WJ./\ UB_4?SI9/]8_^\?Y
MT .\[_IG'_WS1YW_ $SC_P"^:CS1F@"3SO\ IG'_ -\T^"7,R_(@Z]![5!FI
M+?\ UR_C_*@!/._Z9Q_]\TOG?],X_P#OFHLTN: )/._Z9Q_]\T>=_P!,X_\
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M_#^57'<F6Q!MHVTM%:F8FVC;2TM $$TI6:0;4/S'JH/>F><?[D?_ 'P*2?\
MU\G^\?YTS-<YL2><?[D?_? H\X_W(_\ O@5'FC- %B"8F:,;4'S#^$5'YQ_N
M1_\ ? HM_P#CXC_WA_.H\T 2><?[D?\ WP*/./\ <C_[X%1YHS0!)YQ_N1_]
M\"I(9B7/RI]UOX1Z&J^:D@_UA_W6_P#030 ><?[D?_? H\X_W(_^^!4>:,T
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MQ_A0!16XD\ESO.=R_P!:C^T2_P!\UIC3(@I7+X)!ZCMGV]Z3^R8?[S_F/\*
M,W[1+_?-'VB7^^:TO[)A_O/^8_PH_LF'^\_YC_"@#-^T2_WS4GVB3R%.\YW'
M^0J]_9,/]Y_S'^%+_9D6P+E\9SU'^'M0!F?:)?[YH^T2_P!\UI?V3#_>?\Q_
MA1_9,/\ >?\ ,?X4 9OVB7^^:/M$O]\UI?V3#_>?\Q_A1_9,/]Y_S'^% %&:
MXD&S#G[H_E4?VB7^^:TVTR)L9+\#'4?X4G]DP_WG_,?X4 9OVB7^^:/M$O\
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M\ZB_LF'^\_YC_"K4,0AC"+D@>M #Z*** "BBB@ HHHH **** "BBB@ HHHH
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MV?;_ ///]30!C^:_]]O^^C1YK_WV_P"^C6Q_9]O_ ,\_U-']GV__ #S_ %-
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MS_4TK6,#8S'G QU- &-YK_WV_P"^C1YK_P!]O^^C6Q_9]O\ \\_U-']GV_\
MSS_4T 8_FO\ WV_[Z-'FO_?;_OHUL?V?;_\ //\ 4T?V?;_\\_U- &7<2.)Y
M,.P^8]S4?FO_ 'V_[Z-;+6,#,6,>2>3R:3^S[?\ YY_J: ,?S7_OM_WT:/-?
M^^W_ 'T:V/[/M_\ GG^IH_L^W_YY_J: ,J&1_.C^=OO#N?6MZJZV,"L"(\$'
M(Y-6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/ _A?0M=TV/6O[2U6+Q),L>D+';02&VBNHP&DEA:=HB8HT)81;244EAX!?\
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M_APP )[=:^0M<^(W[27ASX5VG[1.J^.=!L_#,QL]3/PGCT6)X5TZX>.../\
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MG&,U\H>*OB9JWA0?M<_%KP]-)_;T6IZ=X$\-E%29TO((8H55(V!5C]KOV;#
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M/S*9.20I(!^G%9^@>(-+\5:-::OHFI6>L:3>();:^T^=)X)D/1DD0E6'N#7
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MUDN?[-T6U-S>W6U2?+AB!&^1N@&1R>HZUIZ?=&^L;:Y:WFM6FC60P7  DCR
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M_:D\)W?PT\'_ !Y^+2:Q)>ZOK?@^W\,Z/8QVY1M/.9HT"ON/F-)<7@8?*N"
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M+X^\4W_@?XX:_P##OP5XNO3J6O>'-+TNWEN7NG0)/+:7S_O+1I%1#E58JP+
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M_BO]F/X7>-;/P1::MX-L)+/P5<K=^'[>U:2UBL)%*D;5B90RY1"48%3M&0:
M*GQSURP^ ?[+?C&]T:+^S[+PSX7G@TN!9#^Z,=N8[9 S$GAO+7)R?J:^4]!_
M93T/X'^//V48[*YU.?XKS7?DZGK5SJ$[?\2VUTR>2ZM$@W"*.$,\4:X0'YAN
M+,[$_<OQ ^'^@?%+PG=^&O$]A_:>B7<D,D]KYTD6]HIDFCRT;*V \:'&<'&#
MD$@FH?#[0-4\=:1XQNK#SO$>DVEQ8V-XTTF((9RAF41[MF6,2?,5W87 (!-
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M/J,EE9 B(3RMND*J20B\ !%PJ@!5   H ^-_VR&/QN^+VI>%8OA)K'QE\/>
M+"&XUK29O'=OX9TBQNKF-IHKIP=LDTBP!@)#($17D&W+,:X3PK:ZA\0?V*?
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M?$GX7_L[Z WPE^$EQ\4?">K:[KMSI5O<>++?3?['TI;UEL8@USN:8.@D8$=
M 3G=6KXT\#V'[4G[5FC^'?B'%+HMAX?^&Z7NN^$;35V!>YU"<>=:O<0E&>&+
M[/&6:,IO(BSE&96^NO!7@S1OAWX1T?PQX=L5TW0M(M8[.RM%=G$42*%5=SDL
MQP.K$D]22:^<9OV-?#'QR\<?%76?C-X+@U6WU+Q+!-H :]:.5;*WL(;=)%EM
MI%=%D?SB8V89*J67*J: /"_ \-AK'P9T+X:^&;Z[U;X=^(/C4NF>&3/*;E7T
M"Q=+Z812,?G@6:SN%1B6XQ][DTGB+POX+^)7PA^*?[1OQ*\37\/CK0]6U>V\
M,7$6KRVO_",2V4TD-C:6\"N$\YWCB=@ZG>90<<DG[KA^#G@RUU#P7>6V@6UG
M)X,CGBT".U+PPV"S1>3($B0A#F/*@LI(!;&,G/P?XO\ V//&'QN^)>IP>*?V
M>/!_A75M7U)3KGQ4T_Q$9K2[M$N%DDDM-)+LT-Q/'&$,C#=EY&9@7) !T?AW
MX#Q^/_%G[/7PAU74;RRTCP3\/9=>\0QZ;/);SW<U[Y=L;<S+AXED(NPVQE9H
MVD7(W<>37_[-/@6X_9-^*WB\+K%YHECXFU+3_AEHLVMW0L](8WPLH9X%$GSR
M27)8DR%QA%Z'>S?IKI_P[\/Z7XRUCQ7:V!AU_5K.WT^\NQ/(=]O 9##&J%ML
M84RR'Y "2W.<#&#;? #P%9^ /#?@F+0 GA;P[>VVH:;I_P!KG*Q3P3>=$[,9
M-TN)/F(D+!C]X&@#X>_:+T;QO\;/VBM6^'U]\*M1^.7A'P%HNEH=!'CB+P[;
MO?3PL[:E*"1).Y4M$K!MJ;9!U<TS2;?Q+X\_8Y\"?"JXG_L6S\;_ !!CT/1#
MIOB6WUV33-!@F-Z5BU"!G24VXM7B3)R B(0 *^P_C;^R!\(/VB]9T_5_B%X+
MM]>U2QA-M!>)=W%I+Y1.[8[02(74')4/G;N;&-S9[1OA'X/_ +6\':C%H%K:
M3^#TGCT&.SW6\&GK-%Y,@CAC(CQY?R#*G:"=N,G(!\3:Q\)/ /P1^+'[0<7A
M^SU'_A#[3X43W'C.WN]7O+IM6U&[EGDBDE=Y2_FM##/E@PS]H;&,DG@O'7P/
MO_A'X:^#'P)\$?#R^\76?B+29?%'C7P_9^+!HA\1WD,%M"Z-<S,=L2L2[6\1
M&1L( V%J_0?6/@3X%\00>/8=1T%;R/QU''%XB$MS,3>K'"(8QG?F+;& !Y>W
M!^8?-S7+>*/V./@WXT^%WAWX=ZSX'M;WPCX>).E61NKA)+3.2VR=9!-\Q)+9
M<[CC.<# !\3^"?$GC3X'_"'XS:3HVAP?!;PW+JNAZ%IVG1^-K;Q'_P (M=W=
MP8-0G\U)"]N?+>.79+MPYW*>H'?:Y^S3\-?A;^U3\#/ O@&_U&WU.XU*;Q7X
MITZXU>>]-]]BMW:UO[I7=@DIG9PI4(K&23CY1CZZTO\ 9S^&NC?"&X^%UGX.
MTV'P%<P-!/HVQF24'&7=R=[2Y56\TMO#*K!L@$87PC_8]^#OP'URWUKP+X(M
M=!U:"WGM4O4N;B:4Q2LC2*S2R,7YC7!;)49"X#," <W^V9KFIR:'\// NGZ]
M<^%8/'WBRU\/ZAK5E.(+B&T:.6:6.&0CY)91$(E/K)T/0^,_%KX;_#O]B?X6
M_%OQ#\"-4F\/>,;31+>RO?"MMXA^U0V\EU<Q10:C/#</(\4D:RLR2,RIMW9!
M&37V#\4OA1X2^-7@V\\*>-M#M_$&@715I+2X++AE.5='0AT8=F4@\GGDU@?#
MO]FGX8?"GX>ZEX&\,>#--T_PMJ8D6_T^56N?MH<$,)WE9GE&"0-[' X&  *
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MS\"_BYX<U#PUX@U+2/B8UI-/?+/XD>:]\3PLFV>6\MYF;S5,F)2T2(!(%/&
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MWXT?L_\ P^_:&\/6VB?$+PU;^(]/M9OM%NLDLL$L+XP2DL3*ZY'4!L' SG%
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MP8^)GQ*E\?\ B?P'9:OXMF@^SRZA+/.HD41&%6:)9!&9%0@+(5WH40JP**0
M?)%G\$?#/[1'A+X$6OB[2#>R_$/QCKWC[4(S/- ?[.DCEE"?NW7[R'34W?>
MSM(R<_6W[46K1_"W]E#QV-$B-LUKX??2=+AC8DI+,@M;902<\/)& 2:V/$'[
M,?PQ\4GX=G5/"=O=?\*],)\,?Z1,G]G^4(A&!M<>8H\B+Y9-P^09'6NQ\;^
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M5V9Y'\Y+976!0C,50*)9/N 9+$G)YK,^+GP:\%_'?P=+X6\>>'[;Q'H<DR7
MM[@NC1RIG;)'(A5XW ++N1@=K,N<,00#Y$\)Z3X"_9!_:%^(VG_"V6XL?!7A
MWX=7?B+Q5X<749[RSM=1CE1[5LRN[I<20+*"F[E AQR"570[32?V;?V=_@9>
MWL%QXJ\=ZIIFJZSIV]6N)+99FU?49F7KM+Q-'NZ$OCD U]/_  ^_9D^%WPL^
M'>K>!O#'@S3]-\+ZO')#J-D=\S7J2!E99I9&:20;791N8[0<# K%^%?[&?P9
M^">L:;JW@KP-:Z)JFG2SS6]ZMU<33!IHA$^YY)&+C9D*&)";Y-H4N^X ^1_&
M'@G0OAW8_M$_'3PM$F@>-=4\:R>$=)\1R7DQ32HI9[2ROKHAI"H/VEKI\D?+
MM4*57@>M7_[.WPC_ &29M:\:^ M5U&Q^*6B^%]4UN?2YO$3W-WXI2.VD+27E
MM*S&53,H?="L8$F/]VO<M%_99^%7AZ'X@0V/@RR2#Q],9_$D,TDLT>H.6D;)
M5W(CPTLC 1A0"V1@@4GP9_98^%7[/ECJMKX!\&6>AQZKQ>R/++=RSKC'EM).
M[OY?^QG;DDXR2: /BKQE\"_!7@'X*?#SXS6?BO5-8_:-\4:AHUQI7BU=9E>Y
MU>^NYH4EMHX5?RFMQ!+)%L5.(E"DD?*W;_$;X7^$?CI\5/VD_'OQ$FO-0^'O
M@K3[?04TBSOI;2&ZDLK/[=,\S1%6<Q2W)"Q[MN[YF4D)M^AOAK^Q3\$?A#X^
MF\:>$OA[IVD^)',A2\\V:=;<N<L8(I':. ]5!B5<*2HPI(KKKWX#>!M0\%>+
M_"5QHKOH'BV]N=0UJU^W7 :[GN&#3,9!)O0,0!M1E4 ;0 .* /AKPC^S59>$
M[#]D?Q#J&HZUJ7QGUG5],:35]0U:X>2STFWL)KNXL(X=_EK"L2"(C;DF5R6.
MX@^:>.+/Q9\=+[XD?%#Q7\%[OQI;6.M:A8:)XPN_BG;>'H/"D5M,T$*Q6S,@
MADC=4D9I?OOAL -S^I>H_#GP[JWB_P .>*+K35DUOP[!<V^E7 ED5;5)U19@
ML88(2RQH,E20 0",G/FNN?L3_!#Q+\5C\1]3^'FFWGB]K@7;W<DDWDR3 8\Q
M[;?Y#MW+-&26^8Y;F@#YX^*7PXU7]I_PW\*/#&OS:1X[\;>#?#MMK'C#X;:Q
MK-WIMOJ;W5J%CO8+ZS+1O.DL4B*W[R+%R^3'N&_WW]B-_"UQ^SSHESX+EUQ/
M#4]S=_9-+UV^2]?2=D[QO8PS+GS+>)XW6-BSDI@[CGC;^-W[)'PC_:.U+3=1
M^(?@RVU_4=/B:WM[U;FXM)Q$6W>6TD$B,Z!BQ"L2%+N0!N;/I'A/PGHW@7PW
MIV@>'M,MM'T73X1!:V-G&$BB0=@!^))ZDDD\F@#X7^,VL7NN:+^U9K>FX-_X
MIUG2/A3HWFKM&?+B@G&>N/,U"Y)(X.P#J*Z/P;^SCX5^!_[9OPJL?!-QK,_B
M(>%=4O/%^LZGJUQ=3ZM9HEM:VHG#N4'[[#!4"J/)4 ':NWZ7A_9]\ P6=E:K
MH/[BS\2OXPB5KRX8G5G=W:Z<F3+G=*[;6R@.W"C:N.BM_A_H%KX_O/&T=A_Q
M5%YIT6DS7[32,3:1R/*D00ML4!Y';*J"2>2<# !Y%^V1\6O&7PQ\!Z7;>"?"
MGBKQ!J&NWOV&ZU'PEH[ZG=Z/:[<RW$<(PK2X^6/S&50S;CNV;&\-_P""?OBC
M1->^./Q8_L#X<>-O"NCQVEEIEI?>)M,,7E-:#-U#=S&1B;Z6XO99G3DD LQ!
M.*^\:Y[P9X!T+X?6NIV^@V1LHM3U*YU>[W3R3&6ZG<O-(6D9B-S'H#@=  .*
M /'?CYGQ=^T)\ /!H!>W@U6_\77:A,[5L;1HH23V'G7D?XC/85\<^*O@KX:^
M(W[*_P 1OCUX@;5M6\5^+?$EWJG@NUAU:XMX=+N+B^6QL9888W5#,X2W9G8,
M2D<8^7::_1_5/AAX:UKQD?%=YIS2^(/[(FT(7@N95*64LBR21JH<*I9E4[P
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M0^DF37_ =JMKI5_]IGPNHQZ-NN'$?F;&++=6\(##:ICRH!.X^T>#?^"?_P
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M\S!E7_6LP(55((  ]3H *^</V'6&M_#GQI\0)3\OCCQEK&N12R*$/V59_LL
M]=HBM5(S_>)[YKZ*NK6.]M9K>4,8ID:-PK%3M(P<$$$'W!S7.>$_AGX:\#?#
MVS\#:%I@T[PM9V9L(+".:1MD)!!7S&8N2=Q^8MNR<YS0!^;?B;X':%\1/V3/
M$GQIURXU:^\<^+?%<^I^#<:G<01Z1/>ZJEO;20Q1%5:1D6%B[!CMCC"D!!70
M_M#6/B[X^_M*?$71-8^#=W\:O!7@&*QL;?1V\>P^&K2PGEM5N)+Z6+*R2/('
M94?<$"*X^8\K]X?\*-\$#PAX-\+?V(/[!\'W5G>Z)9?:I]MK-:#%LQ._=)LZ
MXD+ D G) -<K\7OV._@Y\>?%=EXE\=>![37=<LXUBCO/M%Q;LZ*<JL@BD02@
M=A(&P"1T.* ,;]A>?Q'/^S;X=_X21HW=)[M-.\O6[?6@M@+B06T9O8':.<QQ
M[8]X.3LY /%?+W[37P_\&_$;Q7X^^.6K6<7Q9^'FALNCW7V/Q!>Z-KG@VYM&
M$-W]BA<K;W&UOWXCDV%Y'&TLI&[]%M,TRST73;33M.M(+#3[2)+>WM;6-8XH
M8T4*B(B@!5    &  !7BGBO]AWX%^./B6WC_ %SX<Z;J'BAYUNI;AY9U@GE4
MYWRVRR"&0D\MO0[OXLT ?(WQUTGQ7\<OCM=> E^&FM_M ^ ? OA_2!;Z7>^.
M8?#_ -INKBW,G]JW0Q')<3.C&,,NU$*R_*#(15GX<WGB7QK\'O@]\']7U)_"
MW@GQKXLU:RC.D^++?5W'AZT@::/24U*W=A(K.3;\,'$<7EX XK[!^-O[('P@
M_:+UG3]7^(7@NWU[5+&$VT%XEW<6DOE$[MCM!(A=0<E0^=NYL8W-G>^(W[._
MPV^+'PZM? ?B?P?IM]X1LVB:STNW0VD=F8^$\@PE&AP,K\A7Y693\I((!\K?
M$KX<_#_]E/X>^-M/^!WC"?P;=:QJ6C>&M<T^UUXWMOX<:\NEC;4F25WEMK@P
M.P#M(HPB$#*@U:L?@-\/OV8_VKO@OH7PIN]3TWQ5KPU"7Q78OJT]X=4TM+20
MB\O4D=@C?:57RV4(K.TH .W"_2WAS]F7X6^$_A)??#'2_!.F6_@6^#_:](9&
MD6Y9MN9)9')D>0;$Q(S%U\M,$;%Q0^$/[)7PD^ UEK%MX$\&6V@_VO$T%[<K
M<SSW4D3  QB>61I$3@':K 9&<9YH ^$_%7P5\-?$;]E?XC?'KQ VK:MXK\6^
M)+O5/!=K#JUQ;PZ7<7%\MC8RPPQNJ&9PENS.P8E(XQ\NTU[5JGPY\&?M)?&#
MXK0?&W6WU3PG\*H-.L;;19M8EL+2U=K);F?5K@Q2(VYRSHC,VT+')]X_=^H_
M^%%^!QX)\)>$!H2CPWX4N;.[T>P%S-MMY;4@V[,=^Z7:0#B0L&(RP)KE_B;^
MQW\&OC)X\M/&?C+P%I^N^)+9$C%W-),BRJGW1-$CB.; X_>*W  Z "@#@O\
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MXT/XJ?!'XR>&=,N[@>*O'7Q83PWJ\)MYHI+..>_CM$CWNH5B+"S+%5)"%CN
M/RG:_;RT)OAGXM^!U_8^*U^$/PV\*P7L5KK]KX337K/2;X)"MJKVA!"EHUD$
M<@!*L#C&=P /K3X3?M$?#GXY>#K[Q5X)\5V6LZ#8NZ7ETRO;&U*C<QE294>,
M;?FRP (Y!Q7-_"W]L[X+?&KQS<>#O!?CVQUKQ'")&%D()X?/$9.\PO+&J38
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MR0N=J]Q\1O\ BLOVSOA)H 57@\*:'JWBNY5CD>9+Y=C;';GJ/-N2"0>G&,4
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MS4_#FDWDBI)+-:FX&CV4*G'W=ZERO([G(6O3V^&NA>%/CE^SA\)] LH;?2?
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MXY)'B<_,R Y7 [GZ>U+4(-)TVZOKIQ';6L3SRN>BHH+,?R!KX:M_A+IWP_\
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MA_:Z=^P;\-O"\UA OB?XS>(]'N-6N8XU66YDO;U=0FD<@9_=VT;*.Z*@[C-
M'Z%UXGX5_;2^"?C;XI-\.]#^(6FZEXM\QX4LXHYO*FD49*17!00R-[(Y)P<9
MP:Z+]I;3_$FK_L]_$>Q\'QRR^)KG0+V&PCM_]:\K0L L?^V<D+[D5^=?P)@O
M/B_??#'X;>&?CSK'C/1_#>J:?JMSX6TWX3VVF1^'FM)!.#=7CR1&)MZO&7B:
M1W=FX?<<@'Z<Z'\1O#GB*Z\46]CJD;2^&+LV.L><CPK:2B%)R&9P 5\N5&W*
M2N#UR#CS;QE^VI\%_A[X#\,>,?$7C:+2M"\31^=I#3Z?=_:;N+!(E6V$1F$>
M!_K&0+\R<_,N? _B9I.N>(OVK_B/\$]*@N+72OB9;Z+X@US4(3M6#18H9K34
M@&ZJ]Q]FMK48_P">[MV)KS']HG6K[X(_M@^+M:O_ (QM\"+.ZT32],\)W2_#
MY/$,=]IT4(\ZVMY=K>08[G>7C  ;S(B2<+@ ^\=4_:+^&VB_!^#XIWGB_3X_
M ,\"W$.M*6=) QVA%107,FX%3&%WAE92H(("?!+]HOX<_M&:-J&J?#OQ1;^(
M[73YA;W82&6WE@<C*[XID1PK#.UMNUMK $E3CXPOK72?@_\ LT^"K#XQQ>-;
M3PSXK\0WWB:^\<QZ8-$U7P?J+.LUG*UE9FY6%I9&DVA3A"X#1@EE7WG]B7QY
M<_%:+Q[XIDDC\6Z0=36QT+XD7/A]-(O_ !%8(I8+,JQIY@MI7D@$BHBML;Y%
M;>* /6OBM^T)\//@>T"^.?$UOX?,]E<ZC'Y\4K[H(&B61OD1N=T\2JOWG9P$
M#'(KB_&O[='P+^'5_H%CXC^(%II5[KEI;W]I;2V=TTB0S*KQ-.JQ$VVY75L3
M;" <D#!K(L?#>G?$C]NC7=:O[2.\7X<^%K&RT_SE#""^OY9Y995ST<011*".
MTC<\C'P]=^(_%/@;XA?%KPI>_&O5O!_C_P 4^)-0-Q\/K#X5P:Y>ZY!([+;&
M&[DPLL+P,-BNZ*@WC ') /TC^,7[2WPS^ /AW2M=\>>+K/1-,U9_+L)%CENG
MNOEW%HXX5=V0 J2X&T;ER1N7,<?[4'PKE^#I^*B^-M-'@':6_M=BZC<"1Y7E
M%?,\W(QY6W>3P%S7R5\4->\%_L^Q_"7P9\2_$7BSX8:EX*\*P+X5^*>EVS3_
M &N8QB"ZTZ>U2*ZA(416[M$S2 A5VNHP7QI_'%KHNC_L]?%;XQ^$4T3P3'J6
MN:MK>H6?AUX(9M6<QQZ9K%]9Q!V26:-&8,0Y$D@(P-I4 ^ROA3^U)\+OCAX3
MU[Q)X'\76NO:7H0+:D5BEMYK50A<,\4R)(JE5?:Q7:VQP"2K8ROV:/C\?B]X
M)\*IXD>ST_X@:KX=M_%-SHUC;S1Q16%S+*MM(C.6# J@!PY.1DA0P%?*/Q(^
M(A^+&B_'OXR>"=(O-,\+Z_X5T_X>>'M6N[9K)_$5W<WCP-=QJX#E(_M4<8D*
M@X1AU0A?0/VDM4U3]GCXL?#9/ UJUWXA\1>";WX?^';=HV*+?+=6'V224@$*
MD:R3RL6X"Q/SDB@#W+Q9^T)I=ZNDVG@K7=)DU*X\9P^$I7U?3[YX))D+27L,
M#11X>5(8IL/N\E73:[C!%9OC;]NCX$_#KQ%<Z#XB^(NGZ9K-KJ3Z3<63V]P\
MD%PJQLWF!8SLCQ*O[TXC)#@-E'"^=V_@'1/AO\<_@3\.+.XWZ)\-O"FL>*]0
MN[K)::9PEH+J7MYDDD][,2<Y8N1C%>6V>@I#_P $_=0U)+"*#QU\=];C%Q.\
M2F2>75M1(B!;J5BM9&91T!#$8W' !];_ !I_:J^%/[/,.ER>/_&5GH1U,;K.
M%8IKN:9,']X(X$=]G&-Y&W/&<\5U_P /_B=X7^*FGZA?^$]9@UVPL+U]/FN[
M4,83,J(Y".0%D7;(A#H64YX)P:^.G^,W@3]EG]ICXRR_$'2]8D\3ZG9:;!X.
M6UTF>^DU;2(;%<V=FZJ50BX23S YC5G*DLVW*^Q_\$^_#,/AW]E#P9<PZ?'I
M?]N_:=>-G",1PK=W$DT:*,#"K$\:C  PM '2?&K]L;X.?L\ZY9Z+X_\ &UMH
M>KW4)N([*.TN+N41YP&=8(W,8/;?C=@XS@XY/]HK]M[P/\#F^&L2:Q8WW_"9
MW]K)%?)'/=6\>DE@TUVA@5O-)7;'&H/WI5?#*C _'/QF_:(\1>%_B9\:Y(_B
MG/\ #[QJE[=Q2_#?P]\-H+S4=5L+2 _9[F759(V^0V@,YDD+"&+>47:%4^Y_
M"O5/#_@7XK?LG> M;O)+>ZT_X<S7&DJEM/*E]J=Q#;I)AU0JNR&&[;+$8$N#
MU&0#Z7_::^)>L?!OX!^./&V@6]G=:OH>G/>V\.H1/) [*1D.J.C$8ST85YA^
MVY^UIJ7[.7PQT^]\&:99Z_XTU5)+RSL=01Y+>"Q@0275U,$D0[%4H@PXR\J
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M$]_#?A?2]1^+&K?"W0[[1?@GJNH6)\,MJ44JO>3QV[)>W$+3CSVMV80[3(S
M.)@-OS* #[%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\^OOA,-2^/.
MD_$BXU3S$TOP]<Z):Z2;<822>XBEDN/-W9R5A1-NWH2<\XKT&B@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
MIJ]O=WFDWL%A>#3[Z6!TM[QHA*()"I"R;"0&VG!VD\XQ7FOP#^"%S\(=/UR^
M\0>*;GQYXZ\172W6N>*+NT2T:[,:[((T@0E8HHX^%0$C+.>-V!ZK10 4444
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672744780992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cardinal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001&#160;per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,549,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672854844176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672744337344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 68,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">21,526<span></span>
</td>
<td class="nump">117,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,247<span></span>
</td>
<td class="nump">5,006<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">102,773<span></span>
</td>
<td class="nump">190,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">52,266<span></span>
</td>
<td class="nump">78,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,764<span></span>
</td>
<td class="nump">34,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,976<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Deposit and other long-term assets</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">173,010<span></span>
</td>
<td class="nump">308,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,921<span></span>
</td>
<td class="nump">2,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">12,584<span></span>
</td>
<td class="nump">16,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">10,409<span></span>
</td>
<td class="nump">13,241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,914<span></span>
</td>
<td class="nump">32,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">64,627<span></span>
</td>
<td class="nump">93,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">89,541<span></span>
</td>
<td class="nump">126,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2023: 101,433 and 100,117 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,003,709<span></span>
</td>
<td class="nump">985,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(473)<span></span>
</td>
<td class="num">(1,531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(919,777)<span></span>
</td>
<td class="num">(802,612)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">83,469<span></span>
</td>
<td class="nump">181,518<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 173,010<span></span>
</td>
<td class="nump">$ 308,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672833657008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">101,433,000<span></span>
</td>
<td class="nump">100,117,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">101,433,000<span></span>
</td>
<td class="nump">100,117,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672852412144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">77,676<span></span>
</td>
<td class="nump">99,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">49,915<span></span>
</td>
<td class="nump">57,858<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">127,591<span></span>
</td>
<td class="nump">157,135<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(123,991)<span></span>
</td>
<td class="num">(157,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">5,748<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(118,243)<span></span>
</td>
<td class="num">(154,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(117,165)<span></span>
</td>
<td class="num">(154,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="nump">1,057<span></span>
</td>
<td class="num">(788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (116,107)<span></span>
</td>
<td class="num">$ (155,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in USD per share)</a></td>
<td class="num">$ (1.16)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in USD per share)</a></td>
<td class="num">$ (1.16)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">100,824<span></span>
</td>
<td class="nump">99,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">100,824<span></span>
</td>
<td class="nump">99,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672738508288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 316,185<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 964,965<span></span>
</td>
<td class="num">$ (714)<span></span>
</td>
<td class="num">$ (648,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">20,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss (gain) on marketable securities</a></td>
<td class="num">(788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (154,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(154,536)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">100,117<span></span>
</td>
<td class="nump">100,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 181,518<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">985,651<span></span>
</td>
<td class="num">(1,531)<span></span>
</td>
<td class="num">(802,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 17,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized loss (gain) on marketable securities</a></td>
<td class="nump">1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (117,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,165)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">101,433<span></span>
</td>
<td class="nump">101,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 83,469<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 1,003,709<span></span>
</td>
<td class="num">$ (473)<span></span>
</td>
<td class="num">$ (919,777)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672744663856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (117,165)<span></span>
</td>
<td class="num">$ (154,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,644<span></span>
</td>
<td class="nump">6,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">17,569<span></span>
</td>
<td class="nump">20,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of discount on marketable securities, net</a></td>
<td class="num">(1,935)<span></span>
</td>
<td class="num">(880)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">13,027<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">1,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable', window );">Deposit and other long-term assets and deferred rent receivable</a></td>
<td class="nump">182<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(369)<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(5,206)<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(3,222)<span></span>
</td>
<td class="nump">13,607<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(90,902)<span></span>
</td>
<td class="num">(108,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(36,718)<span></span>
</td>
<td class="num">(104,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">134,401<span></span>
</td>
<td class="nump">257,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(808)<span></span>
</td>
<td class="num">(11,816)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">96,875<span></span>
</td>
<td class="nump">141,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred offering costs</a></td>
<td class="num">(420)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock pursuant to option exercises</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">6,042<span></span>
</td>
<td class="nump">34,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">70,934<span></span>
</td>
<td class="nump">36,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">76,976<span></span>
</td>
<td class="nump">70,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">68,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,976<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">76,976<span></span>
</td>
<td class="nump">70,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash investing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue', window );">Non-cash settlement of operating lease liability</a></td>
<td class="nump">14,903<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities', window );">Remeasurement of operating lease right-of-use assets and liabilities</a></td>
<td class="nump">13,711<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets in accounts payable and current liabilities</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deposits and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Non-cash Consideration, Leasehold Improvements, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Re-Measurement Of Operating Lease Liability And Right Of Use Assets and Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672742934944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the Business</a></td>
<td class="text">Description of the Business <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of the Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $919.8 million as of December&#160;31, 2023. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of December&#160;31, 2023, the Company had cash, cash equivalents and short-term investments of $96.5 million, which the Company believes will be sufficient to fund its operations into late 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672742980336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income, net.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement. See Note 5, Leases for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All short-term investments in debt securities have been classified as &#8220;available for sale&#8221; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#8217; equity until realized. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#8217;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#8217;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses available-for-sale debt securities on a quarterly basis to see whether any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flow model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were no credit-related losses recognized for the periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Interest Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Accrued interest receivable related to the Company&#8217;s available-for-sale debt securities is presented within prepaid expenses and other current assets on the Company&#8217;s consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its available-for-sale debt securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to securities having specified credit ratings. Management believes that the Company is not exposed to significant credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support growth.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:f-260">three</span> to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. If there is an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss The Company recorded within research and development expense in the consolidated statements of operations and comprehensive loss impairment charges of $0.2&#160;million and $2.1&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. See Note&#160;3, Balance Sheet Components for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on the Company's consolidated balance sheets. The Company determines if an arrangement contains a lease and the classification of the lease at inception. An arrangement contains a lease if there is an identified asset and if the Company controls the use of the identified asset throughout the period of use. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that it would pay to borrow equivalent funds on a collateralized basis at the lease commencement date or modification date, as applicable. In order to determine the incremental borrowing rate, the Company determines its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. It bases the ROU asset on the lease liability adjusted for any prepaid or deferred rent. The Company elected to combine lease and non-lease components for all underlying assets groups. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For short term leases, the Company does not recognize a right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. The variable lease payments primarily consist of common area maintenance and other operating costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;), the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents approximate their fair values due to their short-term maturities. See Note 3, Fair Value Measurements for the methodologies and assumptions used in valuing financial instruments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and employee stock purchase and using intrinsic value, which is the closing price of its common stock on the date of the grant, for restricted stock units (&#8220;RSUs&#8221;) and performance stock units (&#8220;PSUs&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term assumption represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Expected volatility is based on the Company&#8217;s historical stock price volatility. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability method. The Company records deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2023 and 2022, the Company has recorded a full valuation allowance on its deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Comprehensive loss comprises net loss and other comprehensive loss. Other comprehensive loss consists of foreign currency translation adjustments and unrealized gain or loss on marketable securities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, and employee stock purchase plan (&#8220;ESPP&#8221;) are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#8220;Topic 326&#8221;) and also issued subsequent amendments to the initial guidance. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted ASU 2016-13 on January 1, 2023, using the modified retrospective approach. The adoption of ASU 2016-13 had no significant impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672833389568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value Measurements and Fair Value of Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,513&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,465&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,972)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,503&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2023, all marketable securities had a remaining maturity of less than one year. The Company held 19 debt securities in an unrealized loss position with an aggregate fair value at December&#160;31, 2023 of $71.3&#160;million. These are highly liquid funds with high credit ratings with final maturity of less than one year from the balance sheet date. There were no individual securities that were in a significant unrealized loss position as of December&#160;31, 2023 and 2022. The Company has not recorded an allowance for credit losses as of December&#160;31, 2023 and 2022 related to these securities. The accrued interest receivable on available-for-sale marketable securities was immaterial at December&#160;31, 2023 or 2022. The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. The Company has not recorded any impairment charges on available-for-sale securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis was based on a market price in a secondary market place for similar laboratory equipment. The fair value of the assets was lower than the carrying value and as such impairment charges of $0.2 million and $2.1 million were recognized for the years ended December&#160;31, 2023 and 2022, respectively. The assets indicated as impaired were written down to their estimated fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets was nil and $0.2&#160;million at December&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672854883888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. Upon execution of the agreement, Lexeo paid the Company a one-time, non-creditable and non-refundable upfront payment of $7.5&#160;million.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, Lexeo notified the Company that it had achieved the first development milestone; accordingly, the Company received and recognized $3.5&#160;million of license revenue during the year ended December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672744021056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redwood City</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease for a facility in Redwood City, which provided a total of tenant improvement allowances of $6.8&#160;million. Related to this lease, the Company provided the landlord with a letter of credit in the amount of $2.7&#160;million. The Redwood City lease expires in December 2031, with an option to extend for a period of eight years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to September 30, 2023, the Company had two facility leases in Redwood City with the same landlord (the &#8220;Redwood City Premises&#8221;). In March 2023, the Company entered into an amendment to accelerate the lease expiration of one of its Redwood City Premises from December 31, 2031 to September 30, 2023. Concurrently, the Company entered into an agreement to increase the tenant improvement allowance towards the second of its Redwood City Premises. The Company accounted for this amendment as a lease modification in accordance with ASC 842-10-25-11(d). As a result of the modification the Company revalued the lease liability based on the new and remaining lease terms, which resulted in a reduction to the lease liability with a corresponding reduction of the right-of-use asset of $8.3&#160;million. The estimated value of non-cash consideration, composed primarily of leasehold improvements and furniture and fixtures, was $14.9&#160;million, which was fully amortized as of September 30, 2023. There was no charge recognized in the consolidated statement of operations. In October 2023, the Company entered into an amendment to the letter of credit which reduced the amount to $1.9&#160;million, which is classified as restricted cash under long-term assets on the Company's consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">North Carolina</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company entered into an operating lease agreement for a building in North Carolina (&#8220;NC Premises&#8221;). The lease commenced in April 2021, when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with two options to extend the lease term for a period of five years each.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the NC Premises through October 2037, the remainder of the lease term, and concurrently changed the lease payment terms of the head lease. In addition, the remainder of the tenant improvement allowance under the original lease of approximately $22.7&#160;million was transferred to the subtenant. This change in the Company&#8217;s payment terms with the landlord at the time of the sublease was considered to be a lease modification and the Company remeasured the lease liability and right-of-use asset on the modification date, with no amounts recognized in the consolidated statement of operations. The base annual rental rates, payment schedules and amounts under the sublease agreement are substantially the same as the original payment terms by Adverum to the landlord. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2023, the Company entered into an amendment of the lease of its NC Premises with the landlord and subtenant. Under this amendment, the parties agreed to substantially reduce the total tenant improvement allowance in exchange for lower monthly rent. The Company accounted for this amendment as a lease modification in accordance with ASC 842-10-25-11(d). The Company remeasured the lease liability, resulting in a reduction to the lease liability with a corresponding reduction of the right-of-use asset of $5.7&#160;million in the quarter ended June 30, 2023. There was no charge recognized in the consolidated statement of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, management reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. Management assessed the collectability to be less than probable and the Company recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December 31, 2022. The deferred rent receivable was zero as of December&#160;31, 2023 and 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the weighted-average remaining lease term was 11.6 years for the Company's leases and the weighted-average Incremental Borrowing Rate (&#8220;IBR&#8221;) was 11.7%. As of December 31, 2022, the weighted-average remaining lease term was 10.2 years for the Company's leases and the weighted-average IBR was 9.9%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the undiscounted future non-cancellable lease payments under the lease agreements as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payment Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed Interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,179)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rent expense for the years ended December&#160;31, 2023, and 2022 was $25.3&#160;million and $17.2&#160;million, respectively. Included in rent expense for the years ended December&#160;31, 2023, and 2022 were variable lease costs for utilities, parking, maintenance, and real estate taxes of $2.4 million and $2.3 million, respectively. Cash paid for amounts included in the measurement of lease liabilities for the twelve months ended December&#160;31, 2023 and 2022 was $12.8&#160;million and $6.0&#160;million, respectively. Sublease income was $5.3&#160;million and $(0.3)&#160;million for the years ended December&#160;31, 2023 and 2022, respectively, which was classified in general and administrative expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672743930480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,638&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,382&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,276&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,921&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,512)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,994)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,764&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,927&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672833389568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various agreements, principally relating to licensed technology that requires future payments relating to milestones or royalties on future sales of specified products. During the year ended December&#160;31, 2023, the Company recognized $3.5&#160;million of license revenue during the year ended December&#160;31, 2023 for the first development milestone in the Lexeo License Agreement. See Note 4, Revenue, for additional information. No milestones were achieved during the year ended December 31, 2022 related to any of the Company's agreements. Because achievement of these milestones is not fixed and determinable, such amounts have not been included on the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, Lyudmila Pazyuk (&#8220;Plaintiff&#8221;) filed a derivative complaint (Pazyuk v. Machado et al. C.A. No.&#160;2022-1062-MTZ) (the &#8220;Action&#8221;) in the Delaware Court of Chancery (the &#8220;Court&#8221;) on behalf of Adverum against Adverum&#8217;s nine current directors and four former directors (the &#8220;Individual Defendants&#8221;). The Action asserts claims against the Individual Defendants for allegedly awarding the Directors excessive compensation. The Individual Defendants have denied, and continue to deny, any and all allegations of wrongdoing or liability asserted in the Action. Nonetheless, solely to eliminate the uncertainty, distraction, disruption, burden, risk and expense of further litigation, the Individual Defendants entered into a Stipulation and Agreement of Settlement, Compromise and Release (the &#8220;Stipulation&#8221;) on January 24, 2024. Pursuant to the terms of the Stipulation, the Defendants have agreed to implement and maintain certain changes to Adverum&#8217;s director compensation policies and practices. If approved by the Court, Adverum will also be responsible for the payment of the plaintiff&#8217;s attorneys&#8217; fees of up to $0.6&#160;million. The proposed settlement, as set forth in the Stipulation, is subject to final approval by the Court. If approved, the proposed settlement will (i) fully resolve the Action by dismissing all asserted claims with prejudice and (ii) release all claims related to the allegations in the Action. On January 31, 2024, the Court entered a </span></div>Scheduling Order With Respect to Notice and Settlement Hearing, which, among other things, set a date of April 9, 2024 to consider the settlement on the terms set forth in the Stipulation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672742962336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock Plans</a></td>
<td class="text">Stock Plans<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2006, the Company adopted the 2006 Equity Incentive Plan, which was amended by the board of directors on November&#160;15, 2012 (the &#8220;2006 Plan&#8221;). The 2006 Plan allowed for the granting of incentive stock options (&#8220;ISOs&#8221;) and non-qualified stock options (&#8220;NSOs&#8221;) to the employees, members of the board of directors and consultants of the Company. ISOs were granted only to the Company&#8217;s employees, including officers and directors who are also employees. NSOs were granted to employees and consultants. In July 2014, the Company&#8217;s board of directors and its stockholders approved the establishment of the 2014 Equity Incentive Award Plan (the &#8220;2014 Plan&#8221;). Options may no longer be issued under the 2006 Plan after July&#160;30, 2014. In addition, the 2014 Plan provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with the year ended December 31, 2015, equal to four percent (4%) of the number of shares of the Company&#8217;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company adopted the 2017 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Company reserved 600,000 shares for issuance pursuant to stock options and RSUs under the Inducement Plan. The only persons eligible to receive grants of stock options and RSUs under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance, that is, generally, a person not previously an employee or director of Adverum, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Adverum.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2006 Plan, 2014 Plan and Inducement Plan are referred to collectively as the Plans. As of December&#160;31, 2023, a total of 41,905,487 shares of common stock were reserved for issuance and 3,158,755 shares were available for future grants under the Plans.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options under the 2014 Plan and the Inducement Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a 10% stockholder may not be less than 110% of the estimated fair value of the shares on the date of grant. Stock options granted to employees and non-employees generally vest ratably over four years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except exercise prices and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining Contract<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,028&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,352&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#8217;s common stock as quoted on a national exchange.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2023 and 2022 was not material.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the year ended December 31, 2022 included 2.5&#160;million shares of performance-based stock options with both performance and service vesting conditions. No performance-based stock options were granted in the year ended December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of options granted during the years ended December&#160;31, 2023 and 2022 were $0.80 and $0.93, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $16.1 million of unrecognized stock-based compensation expense related to stock options that was expected to be recognized over a weighted-average period of 2.3 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#8217;s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company&#8217;s common stock on the grant date. RSUs granted to employees generally vest over a 2&#8211;4 year period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except grant date fair value and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted during the year ended December 31, 2022 include 0.4&#160;million shares of PSUs with both performance and service vesting conditions. No PSUs were granted in the year ended December&#160;31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, total fair value of RSUs vested was $1.5&#160;million and $2.8&#160;million, respectively. The number of RSUs vested includes shares of common stock that the Company withheld on behalf of employees or sold to cover to satisfy the minimum statutory tax withholding requirements. As of December&#160;31, 2023, there was $1.0&#160;million of unrecognized compensation cost related to unvested RSUs that is expected to be recognized over a weighted-average period of 1.4 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, the Company approved the establishment of the 2014 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The Company reserved 208,833&#160;shares of its common stock for issuance and provided for annual increases in the number of shares available for issuance on the first business day of each fiscal year, beginning in 2015, equal to the lesser of one percent (1%)&#160;of the number of the Company&#8217;s common stock shares outstanding as of such date or a number of shares as determined by the Company&#8217;s board of directors. During the year ended December&#160;31, 2023, 824,223 shares were issued under the ESPP. As of December&#160;31, 2023, a total of 6,219,258 shares of common stock were available for future issuance under the ESPP. As of December&#160;31, 2023, there was $0.1&#160;million of unrecognized compensation cost related to the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Recognized in the Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,569&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,079&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672748528080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text">401(k) Savings Plan<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company established a defined-contribution savings plan under Section 401(k) of the Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. The amount of contributions that the Company made to the 401(k) Plan during the years ended December&#160;31, 2023 and 2022 was $0.9 million and $1.1 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672744790512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Restructuring</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#8220;Ixo-vec&#8221;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the restructuring plan, the Company reduced its workforce by 75 employees (approximately 37%) as of July 6, 2022. Below is a summary of restructuring costs during the year ended December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Benefits Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the year ended December 31, 2022, the Company recorded $4.7&#160;million of restructuring costs, of which $3.7&#160;million was classified as research and development expenses and $1.0&#160;million was classified as general and administrative expenses. The Company completed the restructuring in the fourth quarter of 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672742963936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents domestic and foreign components of loss before provision for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,089)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,002)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,243)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,462)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income tax (benefit) provision were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax (benefit) provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (benefit) provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision for the years ended December&#160;31, 2023 and 2022 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax benefit at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,437)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of internal reorganization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax (benefit) provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company&#8217;s deferred tax assets and liabilities:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserve and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 R&amp;D capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,649)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2023 and 2022. The valuation allowance increased approximately $17.0&#160;million and $39.7&#160;million during the years ended December&#160;31, 2023 and 2022, respectively mainly driven by net operating losses (&#8220;NOLs&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had U.S. federal NOLs carryforwards of approximately $493.0&#160;million to offset any future federal income. Approximately $57.3&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2023, the Company also had U.S. state NOL carryforwards of approximately $300.8&#160;million to offset any future state income. U.S. state NOLs expire at various years beginning with 2037. At December&#160;31, 2023, the Company also had approximately $49.3&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had federal research and development tax credit carryforwards of approximately $20.3&#160;million available to reduce future tax liabilities which expire at various years beginning with 2036. As of December&#160;31, 2023, the Company had state credit carryforwards of approximately $17.6&#160;million available to reduce future tax liabilities which do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code Section&#160;174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses. As a result of this provision of the TCJA, deferred tax assets related to capitalized research expenses increased to $29.5&#160;million, net of amortization on research expenses capitalized as of December&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 and 383 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to the ability of the utilization before expiration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal, state, and foreign jurisdictions. The federal, state and foreign income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December&#160;31, 2017 through December&#160;31, 2022. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has total unrecognized tax benefits as of December&#160;31, 2023 and 2022 of approximately $24.6&#160;million and $24.7&#160;million, respectively. If the unrecognized tax benefits for uncertain tax positions as of December 31, 2023, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. A&#160;reconciliation of the unrecognized tax benefits is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the beginning of the year</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,745&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,944&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to tax positions taken during the prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to tax position take during the current year</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease related to tax position taken during the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the Company accrued interest and penalties related to uncertain tax positions of nil and $0.3 million, respectively. There are no ongoing examinations by taxing authorities at this time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672747721648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672743860608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2024, the Company entered into a securities purchase agreement, pursuant to which the Company sold 105,500,057 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase an aggregate of 750,000 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) to certain institutional and accredited investors in a private placement (the &#8220;Private Placement&#8221;). The purchase price per share is $1.20, or $1.1999 per Pre-Funded Warrant, which represents the purchase price per share minus the $0.0001 per share exercise price of each Pre-Funded Warrant. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the Private Placement, the Company also entered into a securities purchase agreement with two directors of the Company. The Company issued and sold 230,000 shares at $1.35, on otherwise substantially the same terms as those set forth in the Securities Purchase Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the close of the Private Placement on February 7, 2024, the Company received total gross proceeds of $127.8&#160;million, before deducting placement agent fees and offering expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2023 and March 8, 2024, the Company&#8217;s stockholders and Board of Directors, respectively, approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse split of all outstanding shares of the Company's common stock (the &#8220;Reverse Stock Split&#8221;). Such amendment will not change the par value per share or the number of authorized shares of common stock. No fractional shares shall be issued as a result of the Reverse Stock Split, and holders of such fractional shares shall be paid a sum in cash equal to such fraction multiplied by the closing sales price of the Company&#8217;s common stock as reported on the Nasdaq Capital Market on the last business day before the date the certificate of amendment is filed with the Secretary of State of the State of Delaware, such amount rounded to the nearest whole cent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Reverse Stock Split will decrease the number of issued and outstanding shares at the time, in thousands, from approximately 207,549 to approximately 20,755; it will decrease the number of outstanding warrants from 750,000 to 75,000, and will change the exercise price on these warrants from $0.0001 to $0.001. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading is expected to begin on a split-adjusted basis on March 21, 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shares and per share information presented in these consolidated financial statements does not reflect the upcoming stock split. Adjusting for the Reverse Stock Split, the number of issued and outstanding shares as of December 31, 2023, in thousands, will decrease from approximately 101,433 to approximately 10,143. The following unaudited pro forma financial information presents the Company's basic and diluted net loss per share upon effectiveness of the Reverse Stock Split for the periods indicated (in thousands except per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,165)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.62)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,082&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672747853936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span>&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income, net.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement. See Note 5, Leases for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All short-term investments in debt securities have been classified as &#8220;available for sale&#8221; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#8217; equity until realized. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#8217;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#8217;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses available-for-sale debt securities on a quarterly basis to see whether any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flow model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were no credit-related losses recognized for the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedInterestReceivablePolicyTextBlock', window );">Accrued Interest Receivable</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Interest Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Accrued interest receivable related to the Company&#8217;s available-for-sale debt securities is presented within prepaid expenses and other current assets on the Company&#8217;s consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to securities having specified credit ratings. Management believes that the Company is not exposed to significant credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support growth.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:f-260">three</span> to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. If there is an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss The Company recorded within research and development expense in the consolidated statements of operations and comprehensive loss impairment charges of $0.2&#160;million and $2.1&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. See Note&#160;3, Balance Sheet Components for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on the Company's consolidated balance sheets. The Company determines if an arrangement contains a lease and the classification of the lease at inception. An arrangement contains a lease if there is an identified asset and if the Company controls the use of the identified asset throughout the period of use. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that it would pay to borrow equivalent funds on a collateralized basis at the lease commencement date or modification date, as applicable. In order to determine the incremental borrowing rate, the Company determines its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. It bases the ROU asset on the lease liability adjusted for any prepaid or deferred rent. The Company elected to combine lease and non-lease components for all underlying assets groups. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For short term leases, the Company does not recognize a right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. The variable lease payments primarily consist of common area maintenance and other operating costs.</span></div>Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;), the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></div>The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents approximate their fair values due to their short-term maturities. See Note 3, Fair Value Measurements for the methodologies and assumptions used in valuing financial instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and employee stock purchase and using intrinsic value, which is the closing price of its common stock on the date of the grant, for restricted stock units (&#8220;RSUs&#8221;) and performance stock units (&#8220;PSUs&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term assumption represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Expected volatility is based on the Company&#8217;s historical stock price volatility. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability method. The Company records deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2023 and 2022, the Company has recorded a full valuation allowance on its deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span>&#8212;Comprehensive loss comprises net loss and other comprehensive loss. Other comprehensive loss consists of foreign currency translation adjustments and unrealized gain or loss on marketable securities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, and employee stock purchase plan (&#8220;ESPP&#8221;) are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#8220;Topic 326&#8221;) and also issued subsequent amendments to the initial guidance. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted ASU 2016-13 on January 1, 2023, using the modified retrospective approach. The adoption of ASU 2016-13 had no significant impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedInterestReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedInterestReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672748370016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash Equivalents and Short-term Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,513&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,465&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,972)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,503&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672744075936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Undiscounted Future Lease Payments under Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the undiscounted future non-cancellable lease payments under the lease agreements as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payment Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed Interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,179)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672742967632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,638&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,382&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,276&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,921&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,512)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,994)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,764&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,927&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical, clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672852400064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except exercise prices and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining Contract<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,028&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,352&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#8217;s common stock as quoted on a national exchange.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Option Issued Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except grant date fair value and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,569&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,079&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672747721648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring Cost</a></td>
<td class="text">Below is a summary of restructuring costs during the year ended December 31, 2022:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Benefits Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based Compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672854858064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Loss Before Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents domestic and foreign components of loss before provision for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,089)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,002)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,243)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,462)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax (Benefit) Provision</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income tax (benefit) provision were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax (benefit) provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (benefit) provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision for the years ended December&#160;31, 2023 and 2022 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax benefit at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,437)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of internal reorganization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax (benefit) provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text">The following table presents significant components of the Company&#8217;s deferred tax assets and liabilities:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserve and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 R&amp;D capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,649)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">A&#160;reconciliation of the unrecognized tax benefits is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the beginning of the year</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,745&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,944&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to tax positions taken during the prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to tax position take during the current year</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease related to tax position taken during the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672748175216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672744989168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Unaudited Pro Forma Financial Information</a></td>
<td class="text">The following unaudited pro forma financial information presents the Company's basic and diluted net loss per share upon effectiveness of the Reverse Stock Split for the periods indicated (in thousands except per share data):<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,165)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.62)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,082&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672742960112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the business - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 919,777<span></span>
</td>
<td class="nump">$ 802,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 96,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672833448080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 2,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_SubleaseIncomeNet', window );">Sublease income</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNet', window );">Deferred rent receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_SubleaseIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease Income, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_SubleaseIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481123/840-20-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479341/842-30-25-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672744624688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 21,541<span></span>
</td>
<td class="nump">$ 118,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">21,526<span></span>
</td>
<td class="nump">117,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentAmortizedCost', window );">Less: Cash equivalents, amortized cost basis</a></td>
<td class="num">(70,972)<span></span>
</td>
<td class="num">(56,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedGain', window );">Less: Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedLoss', window );">Less: Cash equivalents, unrealized losses</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Less: Cash equivalents, estimated fair value</a></td>
<td class="num">(70,939)<span></span>
</td>
<td class="num">(56,240)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember', window );">Total cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">92,513<span></span>
</td>
<td class="nump">174,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">92,465<span></span>
</td>
<td class="nump">173,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">10,204<span></span>
</td>
<td class="nump">10,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">10,204<span></span>
</td>
<td class="nump">10,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">64,693<span></span>
</td>
<td class="nump">102,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">64,658<span></span>
</td>
<td class="nump">102,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">17,616<span></span>
</td>
<td class="nump">59,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 17,603<span></span>
</td>
<td class="nump">58,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672854848880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities, unrealized loss position | security</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Marketable securities in an unrealized loss</a></td>
<td class="nump">$ 71,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">$ 2,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure', window );">Fair value of laboratory equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672836732688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember', window );">Lexeo Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fees received</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672737063216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 08, 2021 </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>lease</div>
</th>
<th class="th">
<div>Oct. 26, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,976<span></span>
</td>
<td class="nump">$ 2,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseNumberOfLeasedFacilities', window );">Number of leased facilities | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated', window );">Leases with accelerated expiration | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,222)<span></span>
</td>
<td class="nump">13,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue', window );">Non-cash settlement of operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,903<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities', window );">Remeasurement of operating lease right-of-use assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">13,711<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNet', window );">Deferred rent receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_SubleaseIncomeNet', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance', window );">Leasehold improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance', window );">Leasehold improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LesseeOperatingLeaseNumberOfRenewalContracts', window );">Number of renewal contracts | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years 7 months 6 days<span></span>
</td>
<td class="text">10 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average IBR (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Leasehold Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseLeaseholdImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseNumberOfLeasedFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Leased Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseNumberOfLeasedFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Leases Expirations Accelerated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseNumberOfRenewalContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseNumberOfRenewalContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Non-cash Consideration, Leasehold Improvements, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Re-Measurement Of Operating Lease Liability And Right Of Use Assets and Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_SubleaseIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease Income, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_SubleaseIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481123/840-20-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479341/842-30-25-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672833555792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 11,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">11,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">11,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">12,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">12,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">82,047<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">141,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest</a></td>
<td class="num">(66,179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">75,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Sublease Payment Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2024</a></td>
<td class="nump">5,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2025</a></td>
<td class="nump">5,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2026</a></td>
<td class="nump">5,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2027</a></td>
<td class="nump">5,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears', window );">2028</a></td>
<td class="nump">5,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter', window );">Thereafter</a></td>
<td class="nump">60,509<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total undiscounted lease payments</a></td>
<td class="nump">$ 88,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672744427520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 29,276<span></span>
</td>
<td class="nump">$ 51,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(14,512)<span></span>
</td>
<td class="num">(16,994)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,764<span></span>
</td>
<td class="nump">34,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">14,638<span></span>
</td>
<td class="nump">14,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">13,586<span></span>
</td>
<td class="nump">34,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 1,010<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672741750672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation</a></td>
<td class="nump">$ 8,040<span></span>
</td>
<td class="nump">$ 8,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent', window );">Accrued nonclinical, clinical and process development costs</a></td>
<td class="nump">3,367<span></span>
</td>
<td class="nump">6,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">State income tax payable</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 12,584<span></span>
</td>
<td class="nump">$ 16,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672833410640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 22, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=advm_PazyukV.MachadoEtAl.C.A.Member', window );">Pazyuk v. Machado et al. C.A. | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Payment of fee</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember', window );">Lexeo Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_LicenseAgreementsMilestonesAchieved', window );">License agreements, milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LicenseAgreementsMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreements, Milestones Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LicenseAgreementsMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=advm_PazyukV.MachadoEtAl.C.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=advm_PazyukV.MachadoEtAl.C.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672736721872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">6,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair values of options granted (in USD per share)</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense related to awards</a></td>
<td class="nump">$ 16.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation, weighted-average period (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock shares authorized for issuance (in shares)</a></td>
<td class="nump">41,905,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="nump">3,158,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum', window );">Award price as a percentage of grant date fair value, minimum</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember', window );">Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NSOs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum', window );">Award price as a percentage of grant date fair value, minimum</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold', window );">Significant stockholder threshold ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares of performance units both performance and service vesting conditions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation, weighted-average period (in years)</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares of performance units both performance and service vesting conditions (in shares)</a></td>
<td class="nump">560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair values of RSUs vested</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted to employees and non-employees vesting period (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted to employees and non-employees vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan', window );">Number of shares available for future issuance (as percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandSeventeenInducementPlanMember', window );">2017 Inducement Plan | Stock Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember', window );">2014 Plan And Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted to employees and non-employees vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember', window );">2014 Plan And Inducement Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options granted period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember', window );">2014 Plan And Inducement Plan | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares available for future grant (in shares)</a></td>
<td class="nump">208,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="nump">6,219,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage', window );">Percentage increase in shares issued</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued (in shares)</a></td>
<td class="nump">824,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award increase decrease in number of shares issued percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement increase in number of shares reserved for issuance percentage under plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandSeventeenInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandSeventeenInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=advm_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=advm_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672741071264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Schedule of Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">19,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">6,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(2,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">23,028<span></span>
</td>
<td class="nump">19,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">23,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">10,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in USD per share)</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in USD per share)</a></td>
<td class="nump">2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in USD per share)</a></td>
<td class="nump">4.87<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest (in USD per share)</a></td>
<td class="nump">4.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share)</a></td>
<td class="nump">$ 8.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contract Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contract Life (in years)</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672833633872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672747667776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Schedule of Restricted Stock Units Activity (Details) - Restricted stock units - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested and released (in shares)</a></td>
<td class="num">(491)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in USD per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested and released (in USD per share)</a></td>
<td class="nump">3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="nump">2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in USD per share)</a></td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted- Average Remaining Contractual Term (in years)</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672833535456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 17,569<span></span>
</td>
<td class="nump">$ 20,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">4,969<span></span>
</td>
<td class="nump">7,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="nump">$ 12,971<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672742909552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution by company</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672833382864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 06, 2022 </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent', window );">Number of employees (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 4,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672744395648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Restructuring Costs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">$ 4,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments made</a></td>
<td class="num">(4,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash</a></td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance and Benefits Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">4,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments made</a></td>
<td class="num">(4,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_StockCompensationPlanMember', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments made</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash</a></td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at December 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672854844176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (118,089)<span></span>
</td>
<td class="num">$ (154,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(460)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">$ (118,243)<span></span>
</td>
<td class="num">$ (154,462)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672748355584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes- Schedule of Components of Income Tax (Benefit) Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">$ (1,078)<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax (benefit) provision</a></td>
<td class="num">(1,078)<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (benefit) provision</a></td>
<td class="num">$ (1,078)<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672835165856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income tax benefit at statutory rate</a></td>
<td class="num">$ (24,831)<span></span>
</td>
<td class="num">$ (32,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">6,001<span></span>
</td>
<td class="nump">3,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(1,810)<span></span>
</td>
<td class="num">(2,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">18,479<span></span>
</td>
<td class="nump">31,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges', window );">Impact of internal reorganization</a></td>
<td class="nump">1,323<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition', window );">Uncertain tax positions</a></td>
<td class="num">(1,078)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">831<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (benefit) provision</a></td>
<td class="num">$ (1,078)<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation change in state uncertain tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672740979760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 127,961<span></span>
</td>
<td class="nump">$ 111,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals, reserve and other</a></td>
<td class="nump">1,760<span></span>
</td>
<td class="nump">2,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">24,702<span></span>
</td>
<td class="nump">21,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">7,305<span></span>
</td>
<td class="nump">10,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_DeferredTaxAssetsLeaseObligation', window );">Lease obligation</a></td>
<td class="nump">17,708<span></span>
</td>
<td class="nump">26,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital losses</a></td>
<td class="nump">9,850<span></span>
</td>
<td class="nump">9,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_DeferredTaxAssetsCapitalizedCosts', window );">Section 174 R&amp;D capitalization</a></td>
<td class="nump">29,455<span></span>
</td>
<td class="nump">23,697<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">218,752<span></span>
</td>
<td class="nump">207,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(205,103)<span></span>
</td>
<td class="num">(188,141)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">13,649<span></span>
</td>
<td class="nump">19,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(12,335)<span></span>
</td>
<td class="num">(19,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(1,314)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(13,649)<span></span>
</td>
<td class="num">(19,394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DeferredTaxAssetsCapitalizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DeferredTaxAssetsCapitalizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DeferredTaxAssetsLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DeferredTaxAssetsLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672745253776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance due to net operating loss</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 39,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_DeferredTaxAssetsCapitalizedCosts', window );">Section 174 R&amp;D capitalization</a></td>
<td class="nump">29,455<span></span>
</td>
<td class="nump">23,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">24,614<span></span>
</td>
<td class="nump">24,745<span></span>
</td>
<td class="nump">$ 21,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_OperatingLossCarryforwardsSubjectToExpiration', window );">NOL carryforwards subject to expiration</a></td>
<td class="nump">57,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic tax authority | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">300,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State credit carryforwards | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 49,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DeferredTaxAssetsCapitalizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DeferredTaxAssetsCapitalizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672833508448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits as of the beginning of the year</a></td>
<td class="nump">$ 24,745<span></span>
</td>
<td class="nump">$ 21,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to tax positions taken during the prior year</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to tax position take during the current year</a></td>
<td class="nump">3,301<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Decrease related to tax position taken during the current year</a></td>
<td class="num">(3,475)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits as of the end of the year</a></td>
<td class="nump">$ 24,614<span></span>
</td>
<td class="nump">$ 24,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672745265216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">24,740<span></span>
</td>
<td class="nump">21,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">23,028<span></span>
</td>
<td class="nump">19,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672737476816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 05, 2024 </div>
<div>director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 21, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,433,000<span></span>
</td>
<td class="nump">100,117,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,433,000<span></span>
</td>
<td class="nump">100,117,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares outstanding and exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ProFormaMember', window );">Pro Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,500,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Total gross proceeds | $</a></td>
<td class="nump">$ 127.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private Placement | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issued upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private Placement | Two Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advm_SecuritiesPurchaseAgreementNumberOfDirectors', window );">Number of directors | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pro Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares outstanding and exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_SecuritiesPurchaseAgreementNumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Purchase Agreement, Number of Directors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_SecuritiesPurchaseAgreementNumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=advm_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=advm_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=advm_TwoDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=advm_TwoDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139672748352800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Schedule of Unaudited Pro Forma Financial Information (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (117,165)<span></span>
</td>
<td class="num">$ (154,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in USD per share)</a></td>
<td class="num">$ (1.16)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in USD per share)</a></td>
<td class="num">$ (1.16)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute net loss per share - basic (in shares)</a></td>
<td class="nump">100,824<span></span>
</td>
<td class="nump">99,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">100,824<span></span>
</td>
<td class="nump">99,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ProFormaMember', window );">Pro Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (117,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in USD per share)</a></td>
<td class="num">$ (11.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in USD per share)</a></td>
<td class="num">$ (11.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute net loss per share - basic (in shares)</a></td>
<td class="nump">10,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">10,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M.4&WS#_5033K-:5H2ZV,<:_Z=>M@A+%R =.2J!EZ@F82,AKB HUYRJ1XA<]
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M.RW-+C%Q.IW5.=%HS9O?:^XI]K61M9M^UDK,&XGPBL0P1$^"ZU*A1YY#_K^
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MG.W>\FG[%M3SECG)SH /AP!YR+>HSTY71X?J8^5OZS1JG4:-/;_/Z9IS4DJ
MA2!2G-O\V1H([ 9T;9V+"F?D8J"*1Q"^(8/INS<P\C[:O'LE8P>^^JVOOLOZ
M=(;%&JBO!C)]07[6=(-SY;SU*VY-Q8TIW0 VTSCT/&\RWNR[8TI%2>##5NH
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M@-E1%M\JBH$6Z[S=?Q!:BS2_7 &/0!H#?/XHA'X=F!>47XPF_P-02P,$%
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ME*PREVM*<LJU@'J_8DP^W^@/=/^FL/@?4$L#!!0    ( $"!<EBTE_8(( 0
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MZ3%%%S9J8/YYLW70T"AN)^BC+X@MB>8H5+1TB"9]3:(-,H!454&G&?Y86A
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M'AST*-C#)2N9KY84"8N,#\0VS9T,,,\UFX>)638ZOEHU(0=J@L143F[R#66
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M]1KK- 2)'$R7@$_2->9HY J4F(CCE7P7?'>-/WURU3K^M%'YP2;O>C?JR$N
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MAYN?IP;(#Z'5/6[1!.PFY 1</HP7,WB8#M/) E>GN#:!Y^EP$D]Q988K,,;
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MWPD\2[7@XEG!J4$*!IGZ8=@!$W%&N6Q][R2&EQ3P<( $O61L0"[N8)@[L:!
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ME:3G(WL-U;8='R04;.W;Q4<$SU9+Q6LFQ88?P]@>1)T*\8C'%/B. CFVZ:J
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M=FZ&$=CZ):TWWI3A]:+10F]A6/* 0<L"=+\TQA\V[*#Y.S/Y&U!+ P04
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M,& 4)NP;'&$<M @>,MI*W& ;8-5X_ U<8QC8"J0>G%3P?"4NF\CH) BH\=@
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MS[G=BMF:,@.$$L87K%%\D".J-(9019O)&5L+B, '/\@:B6T4*.;O(P#A>JT
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M2^VHP81I31T=C3>@\TIKMUOX /O_B,D?4$L#!!0    ( $"!<EBE;L]"VP8
M -X0   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;)58;6_;MA;^*X17
M[+: 8DNR72?-"Y"D*[8!ZX)F]Q;#Q?U 2\<V;R51):DXV:_?<TA)D1,UV[XX
MDGCXG.>\DSG;:_/%[HB<N"^+RIY/=L[5[V8SF^VHE':J:ZJPLM&FE ZO9CNS
MM2&9^TUE,4OC^.VLE*J:7)SY;S?FXDPWKE 5W1AAF[*4YN&*"KT_GR23[L,G
MM=TY_C"[.*OEEF[)_;N^,7B;]2BY*JFR2E?"T.9\<IF\NUJPO!?XCZ*]'3P+
MMF2M]1=^^2D_G\1,B K*'"-(_+FC:RH*!@*-KRWFI%?)&X?/'?H';SML64M+
MU[KXK'*W.Y\<3T1.&]D4[I/>_TBM/4O&RW1A_:_8!]GT9"*RQCI=MIO!H%15
M^"OO6S\,-AS'W]B0MAM2SSLH\BS?2R<OSHS>"\/20.,';ZK?#7*JXJ#<.H-5
MA7WNXK996_K:4.7$#W?XM6<S!UA>G&4MQ%6 2+\!D:3B%UVYG14_5#GEAP S
M\.E)I1VIJ_1%Q/>43<4\B40:I_,7\.:]D7./-_^[1HK_7JZM,TB)_XW9&] 6
MXVA<)N]L+3,ZGZ .+)D[FEQ\_UWR-CY]@>NBY[IX"?WO!>1%B'&"SWUP8]2=
M="1N"HB6O/!K)3[0VC2H3K'TWE]$PNU(7.NREM6#@! 9RH6JG!926,H:HYPB
M*^K&9#M4AY!;0QXMXF^VD<"%\'ZGLMT!EM5%+I)X&2WC.(J7*V%W$FR%W@@%
M=IDN2U0M"B#[(F251U J"D4-"PP7H<?0T:;AW!-[:8QDXZ#RD1**?PM:6[86
MNU=+*(SC@<(#9:^9Y???':=I?'H#Z \!^G,+[5>2TS>L(B/CT/A S3KE&NXS
MLF"VZ#89'*6<=]8= =E8MD"";7![W;O]4.&3H'3JIN(W2/4V 27#+YE@A5!6
MO$JF:1P);?@I.3DY\<O/+8C:8!CRV>&]]1(TNDX31%[%4_@M&:S1/9E,]9O@
M2I* ?JYTBKA7R!8#?<4#FIP+V?#,WL.$DX75_RCK6N2]%KDRZ/SL=K :8 9'
M=@J4M0V@.60^(=/Y06Y(Q\Z<HQB0'AHH9L_66A23@U5*%C"&P:TL28!FB3WL
M+,U2F*D8F^"#P+/0[2/SFX[Y9<=\*BZ=E\H*WMR2?EZD>E"DJ[$BA=F$29<C
M01VR<6NTA:>,SHAR[XQ72;J:'B.N18&$C<2:P)(PR_(&,[+:#E(3<QF_&V)7
MP$5ZLR'#$G2/4X$E.Q6?Z(X,^-[ZVKFM"^7[R,]-1>(D='"_]1<)@\7Q"&'.
M\&1U:D/Y[1 % /H]5UH:5BK>=[&,8)VMR8_RXB$2LH9A=SZ  A&H<L\::3*&
M?\D";; _H20E5^<U2EAM5-;VAI^J3)M:&^G/#  BF)S!$2(Y@I>.DA@,@L76
MVXH]2 *!\PYG1,[.>>PK Q;_LM_N,B,^?"S[VP9^>[1MCZB)2CN!]*FV%$I7
M&G$GBV98M6@#O%0UY1K?F&6#K#3J#]@\WOBFXJ,6&QZ*H8VU4O@#C6OJ2P6Q
MX2C@V-.9.,(_\E[N@@DYRV:\@%Y+E7-Q-R572R;M3F!<01 Q.-@K2FA6T $N
MZX>^8KSC9<%-H6M%8SEP.%8L-T%4**!T*-&/TN;RJ[B6M>+B0=9^(=<M%M(Z
ML6Z@BU!2N7SH2H<7<\X@S^8PHQY#AQZ]405/J:[[H2$8<ES)$+QU[0Z_TKV\
MIT)BJE$4O"!+W0#*Z-!=VTROB)V)Y(##F0!WD]_& Q,2*&?%W'X.<V30#4<2
M6H;^Y' HCT)+TXV%"*IR8W09BO%>X:B,VD2=KZ+EXH0I/EV(5LOEJ?@++D,"
M_5CW>KKY#>35DI]"LGFP054\G4T^AG@]!.MF&L#\8P+/&>FU(E[<YS(7'+VF
M+8SFFT0H_2.9_Q\'=$Y#:2&+E=#DTG!R7:"C%WVB,\/!N*["?8KSN9W"?L"U
M%#-=81JIW'>HC:IDE2FN&4Z*TD_L7 .3VP N,7S#\18W-=+;!\S'V[,$"4^3
M/V_:IC!:K_\H$VQ(34P)EN^.ZD^SXC"\(SF2Q$FTF,^?YT@21\EB'I)XHPM<
M'5E[4\DFG*D@*[P'!]X9\:E]TH$Y4)DW*E=%PT 5JKOP [*/35,#(+1]3!E?
MZM_N<[U/L5_IG,]XN2_]7+P>.@.9E%'M!FH07/GFG?@=I2O"7#KPY\>.V"OQ
M.DE64?)V^>;QXR/,T8A1?LOT;?I&?/:W4LJ/))ACF/?]KYT @]". 2$,\7$J
MQJXUL\&=LR2S]3=K[J]H3^'ZV7_M+^^7X<[Z*!YN_J@:5)85!6VP-9ZNEA-A
MPFTZO#A=^QOL6CO<A_WCCB0F"PM@?:.UZUY80?\OC8L_ 5!+ P04    " !
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M@#=VXO^Y6/C6@>#\[]B)&=Y/X_!0FU[XK2KUJR-0%Z_=K3YZ_;>_G#T_/9_
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MD30J0<AV?&OP1A"@F]%MFC, MI::98&'JC-*5 $:U8-#VZW9=NW^N"EW:2F
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MDHV:;G+UR($U-6 JI7WIJCJB.ZK5?57!Q@\[RC0^WZ?%[.''BK3/:T3AUJ,
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M7._1KWWL&,N<&[A4U>]B8=?38!20!2QY6]G/:OLK[.+)'%ZI*N-_R;;3+9*
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MT$X!SY=*V?W&.>B_>&9_ U!+ P04    " ! @7)8K&RG;_H"  !V!@  &0
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MFN:4-9?T84!I$BA>"*$W"[/!]E,S^0=02P,$%     @ 0(%R6/BDA:#1 P
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MY8;^9Z!V!O2^4<KN-R[ ^,]E^2]02P,$%     @ 0(%R6)W5F&AH!0  P T
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MNF*A9@'ZOE"T\VU?V$!S:9O\ U!+ P04    " ! @7)8I0UC7*\"   #!@
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MX\5M6P4_E*J+VAAD<-2GA:(<A-F4XITE\$D[7F(K\U;/$NF6X()+L1!H7/2
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M+PFF^9.AN7%Z[5_LY]HY7?G+E> XOI !_K[0VG4WM$'_3\_I?U!+ P04
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MC8Y/A@'H=HBU&ZMJ/SCFRM(8\LN2YCYJ%T#WA5)VLW$)NG^2]"]02P,$%
M  @ 0(%R6&\3MLB0 @  / 8  !D   !X;"]W;W)K<VAE971S+W-H965T,S N
M>&ULK55;3]LP&/TK5H8FD$IS*RVP-%)IA>!A6D7']C#MP4V^-A:.'>PO+=NO
MG^VD41D%,6DOB2_?.3GG^))D*]6#+@"0/)5<Z+%7(%:7OJ^S DJJ^[("8696
M4I4435>M?5TIH+D#E=R/@F#HEY0)+TW<V%REB:R1,P%S171=EE3]N@(NMV,O
M]'8#=VQ=H!WPTZ2B:U@ WE=S97I^QY*S$H1F4A %J[$W"2^G UOO"KXQV.J]
M-K%.EE(^V,YM/O8"*P@X9&@9J'EM8 J<6R(CX['E]+I/6N!^>\=^[;P;+TNJ
M82KY=Y9C,?;./9+#BM8<[^3V!EH_9Y8ODUR[)]FVM8%'LEJC+%NP45 RT;SI
M4YO#'B <O *(6D#T7D#< F)GM%'F;,THTC11<DN4K39LMN&R<6CCA@F[B@M4
M9I89'*8ST)EBE8M4K@@60):U-D5:DU,RR7-FIR@GMZ+9,K;P> 9(&=<GIN1^
M,2/'1R?DB#!!OA:RUE3D.O'1B+.?\+-6R%4C)'I52-8G<=@C41#%!^#3]\.C
MYW#?1-+E$G6Y1(XO?H7OBUI3P7X[OSTRE4)+SO+&OC%(Y@HT"*2[X*Z9H")C
M)JB%&02SSU&3'Y.E1F5VZL]#>30"!H<%V--[J2N:P=BK[+?4!KSTXX=P&'PZ
ME,Y_(GN65=QE%;_%GDZRK"YK;FSG]@2QC.$AOPW)R)'8RV637H07H]$H\3?[
M3EZ6G0?1,(RZLF<:!YW&P9L:IU07/9*9)X''FFTHMRO4<VNI"ZGP%$&59@]O
M0*-;O4,6!B\M#,^"X"\';RKYU[7P]\ZVO5<_4[5F0A,.*T,?]$=G'E'-7=5T
M4%;NN"\EFLO#-0MSO8.R!69^)27N.O8&Z7X8Z1]02P,$%     @ 0(%R6%;N
M;2Z; P  W X  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULO5?;;N,V
M$/T50ET4"=!$-U^RJ2T@CK=H@*8-UMWVH>@#+8UD8BE2)2D["_3C2TJR+#D*
MDTV-?;%)BG-XSLR(FIGMN/@L-P */>:4R;FS4:JX=ET9;R#'\I(7P/23E(L<
M*ST5F2L+ 3BIC'+J!IXW<7-,F!/-JK4'$<UXJ2AA\""0+/,<BR\+H'PW=WQG
MO_"19!ME%MQH5N ,5J ^%0]"S]P6)2$Y,$DX0P+2N7/C7]_Z(V-0[?B#P$YV
MQLA(67/^V4SNDKGC&49 (58& NN_+=P"I09)\_BG 77:,XUA=[Q'_ZD2K\6L
ML81;3O\DB=K,G2L')9#BDJJ/?/<S-(+&!B_F5%:_:-?L]1P4EU+QO#'6#'+"
MZG_\V#BB8Q ^9Q T!L&101 \8Q V!F$EM&96R5IBA:.9X#LDS&Z-9@:5;RIK
MK88P$\:5$OHIT78J6M7A0SQ%*Y(QDI(8,X5NXIB73!&6H0=.24Q H@MTDR3$
M.!]3=,?J%#*A.%N"PH3*<_0.$89^W_!28I;(F:LT0W..&S=L%C6;X!DV?H#N
M.5,;B3ZP!)(^@*NEM?J"O;Y%8$5<0GR)0O\'%'A!B#ZMENCLW3F2D.E45 ,$
M;U\/%^SA+#3#-@QAA1N^$(;?7@[#7[]H6W2G()=_#WFX/F@T?)"Y%:YE@6.8
M._JUER"VX$3??^=/O!^'O'$BL)Y/1JU/1C;TZ-<R7X,PF2F@X$+A-85]Y"3Z
MUQ+$10T\J8#-1;:-_)F[[0JS'OU&8>-6V/B5PO1M+' 5WM?I&K^HRWKR&W5-
M6ET3JZZ[O,!$&.Y&&^4LNZ#ZCDX0EA+4X'50 TX[@H)@="1I8(_?V=2C.FVI
M3JU45Z5.)GW[Z_LJYCD,49L^\?4X]+PC;D\W770W];A=M=RNK-R6D((0VFW"
M>%) #&1K<G^(Y-43WQPSM.WHT7O?TGMOI7=/&,G+?(B-U?!KKYX3@?4T^M[A
ML^A]JPNY.>E$;CD56M\OG7+!MT;_@U1$?_9U=I82TI(B2E(PKWO]CJ,S70!\
M 2SD^: K[.!A;3HHVVKY5MG!079@3WK\^%S2VRV_.KPG0NOK/)0A_C>K0_R3
M%B*G0NO[Y5"*^/9:Y'^FO1U\;$G[D]8I;J=/R$%D5?LD417;NJ1N5]L6[:9J
M3([6%Z9UJ_J/ TS=]]UCD1$F$8540WJ74UV0B+J5JB>*%U4WLN9*]S;5<*/;
M3Q!F@WZ><J[V$W- V]!&_P%02P,$%     @ 0(%R6).+!8C[!0  VR$  !D
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ME22,Q"MEXVYU#5Z^> 5>@# !G_<L%4I1S"=2>9CAG&P*;]Z>O$$=WES3S07
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M=5!DFW*GJ)>L*+*D?+EF-&1<%A"?+[.L>#^0%>QW<5O\#U!+ P04    " !
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MJ[:?JH&@>;F#\TB%H&EYN ,2 5,!\OJ&4G$<J$VA9A,P^ ]02P,$%     @
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M0F.!9!]S+'I!F@'X?B6$?FD8!VT9'?\+4$L#!!0    ( $"!<EB@\LZL1@D
M -!+   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;,5<76_CN!7]*X2[
M*&: 22Q1DNU,$P,9:]L&Z,RDDZ;[4/2!D>E8&$GT4G0^%OOC2XJR*<HR'<U>
MUR^))(N'Y-'EY3V\E"Z?&?]>+BD5Z"7/BO)JL!1B]7$X+),ES4EYSE:TD+\L
M&,^)D*?\<5BN."7SJE">#;'GC88Y28O!]+*Z=LNGEVPMLK2@MQR5ZSPG_/43
MS=CSU< ?;"Y\2Q^70ET83B]7Y)'>47&_NN7R;+A%F:<Y+<J4%8C3Q=7@VO\8
M1R-5H+KCWRE]+AO'2'7E@;'OZN1F?C7P5(MH1A.A((C\]T1G-,L4DFS'KS7H
M8%NG*M@\WJ#_M>J\[,P#*>F,9;^D<[&\&DP&:$X79)V);^SY[[3N4*3P$I:5
MU5_T7-_K#5"R+@7+Z\*R!7E:Z/_DI2:B40!'>PK@N@!N%?##/06"ND#PU@)A
M72"LF-%=J7B(B2#32\Z>$5=W2S1U4)%9E9;=3POUW.\$E[^FLIR8W@F6?$>W
M&2E*=(:NY_-4/0Z2H9M"&Y5Z..]B*DB:E>_E+?=W,7KWTWOT$QJB<DDX+5%:
MH/LB%>4'>5$>?TZS3)8J+X="-E!5,TSJQGS2C<%[&N-C])D58EFBGXLYG=L
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MT0SI/Z@UF#1?YYU<Z_I\OQF>M@<]J/"!0K,9--+'=VN?FT+QE3Y1I)>1:B>
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MO#I<4C*G7-T@?U\P)C8GJH+M1[RF_P-02P,$%     @ 0(%R6.,V\9K(!
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MT+2Y.3&$XV;SX2;^W /^=OG^N9)"JAP%\;PN2ZF3=KT3O?5OQ9)Z,++4WA;
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MN;F<@;0.9GXIA'X;V!>TU[W9OU!+ P04    " ! @7)8)T)+?>,#  !=$
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M$L."YXEYD-N_H03J6;U()MK]DFTY-O!(E&LCT](8/4A%5ASYMW(A:@8L?,>
ME0;L5(-N:=!UH(5G#NN.&SX9*;DERHY&-7OBUL99(XW([#;.C<*G NW,9&YD
M]$+N$YYI<D7F^);$>0)$+L@#:*-$9" FQ:#'3!A-;NVZ"_-*/MR!X2+1']&N
M-E:[L;D;>T5^)3[1*ZY [PXB(U]6,M<\B_7(-XA@'?&CTMUIX2Y[QUW*R&>9
MF94F?V8QQ&\%?&2O%H#M%F#*6A7O(.J0+OV=L(!U&QR:G6[.6MSI5OO1=7K=
M=_3^S=-G4';]W7(WK5 A$#8+V+"_T6L>P=C#N-:@-N!-?ON%]H,_FN@N)/:&
M-:Q8PS;UR126(LM$MB13CB]@!.0#OAW%>_*QB;R0ZSLYFY\V$]H?XJ9MZD2M
M<YY)U*N(>JU$?RF>V2#X#D?OB*/7#PXP6B<Z$Z-?8?1;,9XPG)$"0Q0S=0*8
M);^+U#]"N@J']("I==8SF085TZ"5"9/^ L0)FS,X)F%T>$#2.M>9)-<5R74K
M"6:^'XB9Z^.8Z86',=,PJ!Y8;]P<5FX.6S/95_<%A?B*W&Y 84E 7'00_$P!
M^<2%(D\\R:')Y^$E,]R%Q-ZL 0WVG]?@C!SW.+\C:TSS;M\:MZV4'=:VA'4.
MW\+VN<]EJY4.].1L=P)168BP&E+0&0P.F5KG/)>)[9G86:GO!#YVS-?MT/"0
MKW7^<_GVY05M_:(?I,$3J+K'5*P3'.W:SZ@CZ+Z0H.V51$-*/ $M; @Q>D36
M-&K8G!KIODZ@O1],C@]@FRY+,<,"5V%[D_.$? &5.IQ7X*HYP=,+50HE[L^H
M.^B^\*#ME<<EUZ5])NI,24C2HI]@(8GY:U/!/3M-B>V4L$<Y5BK6PZ\U:BFH
MI>M?-8EDGIFB9:GN5CWRK>L,#^Y/;>_L&L"]3-%X?^8*OSB:)+! 24RPN*&J
MZ&6+"R/7KAU\E@:;2W>ZPOX?E!V SQ=2FMV%G:#Z1V'R/U!+ P04    " !
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MR5\88&J"_#ZG5*P[RD'U4^3_!5!+ P04    " ! @7)8,BJ2#U #  #$#
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MF*K##' =H)XGC,GM1+^@.1Z%?P%02P,$%     @ 0(%R6'$9+U3W P  #PP
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MQFIK&L+,7YPJH;\2K:>2&Y;R M ]?@*)+M!4[Y*LHH#X'#TP 2E?,/(+,B.
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M'=Q .-USW<IA6.(/B#-_6FT-_%NY@]CL^")=A%BN#XES/>K-?T(?$W- 2.P
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M<5*_&-A513%Q92NY4#Q__GSG^=.CK[\ 4$L#!!0    ( $"!<E@,/Y#\Y0$
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M$U!+ 0(4 Q0    ( $"!<E@'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 0(%R6&NXZG[O    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ 0(%R6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " ! @7)8Y[75>C<'  !P+@  &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ 0(%R6.)Y85H_ @  P04  !@              ("!>P\  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( $"!<EB++7B9\ 4  )\8   8
M              " @? 1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " ! @7)8_SJ H_@"  !5"@  &               @($6&   >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 0(%R6"^5:-H$!0
M/1(  !@              ("!1!L  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( $"!<EBY4/>'WP8  #TP   8              " @7X@
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " ! @7)8<\ED
M!&L'  "R(   &               @(&3)P  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ 0(%R6+27]@@@!   _0@  !@
M ("!-"\  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $"!
M<EA=K,KD%AL  (Y3   8              " @8HS  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " ! @7)8K4U#A7,)   3&@  &0
M        @('63@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( $"!<EA[Y[A:% 0  *X(   9              " @8!8  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 0(%R6*26180<"0  _QD
M !D              ("!RUP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " ! @7)8.N>5+;,#  !-"   &0              @($>9@
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $"!<E@FU2,1
M'08  !H.   9              " @0AJ  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ 0(%R6&,U-5;W"@  =R   !D
M ("!7'   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !
M@7)8Q^7\-^@"  !C!@  &0              @(&*>P  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( $"!<EA-(L0.#00  -H(   9
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M970R,2YX;6Q02P$"% ,4    " ! @7)8HK)W4+L#  #]"   &0
M    @('!L@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M $"!<EBL;*=O^@(  '8&   9              " @;.V  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ 0(%R6/BDA:#1 P  Q0@  !D
M             ("!Y+D  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " ! @7)8G=68:&@%  # #0  &0              @('LO0  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $"!<EBE#6-<KP(
M  ,&   9              " @8O#  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ 0(%R6"JFSL!S!@  ]1$  !D              ("!
M<<8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " ! @7)8
M/ HC@04#  !\!@  &0              @($;S0  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( $"!<EB?6.$\X@(  %4&   9
M      " @5?0  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ 0(%R6&\3MLB0 @  / 8  !D              ("!<-,  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " ! @7)85NYM+IL#  #<#@
M&0              @($WU@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( $"!<EB3BP6(^P4  -LA   9              " @0G:  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 0(%R6'62Q;Y:
M P  +@L  !D              ("!.^   'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " ! @7)8%.3?J>0"  !;"P  &0
M@(',XP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $"!
M<EB>GIP]% @  -%-   9              " @>?F  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ 0(%R6+>NFL%* P  O@L  !D
M         ("!,N\  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    " ! @7)8_&?9>@4$   0%   &0              @(&S\@  >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( $"!<EC9K(&9'@,  +((
M   9              " @>_V  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ 0(%R6+ ^_U)Q P  4@\  !D              ("!1/H
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " ! @7)8H/+.
MK$8)  #02P  &0              @('L_0  >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( $"!<ECC-O&:R 0  !P8   9
M  " @6D' 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M0(%R6)SE]+B0 P  ^@T  !D              ("!: P! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " ! @7)8)T)+?>,#  !=$   &0
M            @($O$ $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( $"!<EBWQ89X+@,  +X+   9              " @4D4 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 0(%R6%>''MY@ @
MI 4  !D              ("!KA<! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " ! @7)8U&;+!#P#   @#0  &0              @(%%
M&@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $"!<E@R
M*I(/4 ,  ,0,   9              " @;@= 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ 0(%R6-TA:4^N @  #0<  !D
M     ("!/R$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $"!<E@5'T?L%0,  "0)   9              "
M@0$U 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 0(%R
M6",##=9D P  > \  !D              ("!33@! 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " ! @7)8-%=W3ZX'   ?40  &0
M        @('H.P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( $"!<ECVI9T*JP,  + /   9              " @<U# 0!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 0(%R6#V^Q@U& P  \!0
M  T              ( !KT<! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !
M@7)8EXJ[',     3 @  "P              @ $@2P$ 7W)E;',O+G)E;'-0
M2P$"% ,4    " ! @7)8LRY#8($$  #^)   #P              @ $)3 $
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 0(%R6 P_D/SE 0  ?R$  !H
M             ( !MU ! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 0(%R6(_AMVG3 0  -B$  !,              ( !U%(! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $  0 !W$0  V%0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>118</ContextCount>
  <ElementCount>321</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlans</Role>
      <ShortName>Stock Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/A401kSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/BalanceSheetComponents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Stock Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansTables</Role>
      <ShortName>Stock Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/StockPlans</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/Restructuring</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/NetLossperShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Subsequent Events (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SubsequentEventsTables</Role>
      <ShortName>Subsequent Events (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/SubsequentEvents</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Description of the business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails</Role>
      <ShortName>Description of the business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adverum.com/role/Revenue</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails</Role>
      <ShortName>Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adverum.com/role/CommitmentsandContingencies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Stock Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansAdditionalInformationDetails</Role>
      <ShortName>Stock Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Stock Plans - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails</Role>
      <ShortName>Stock Plans - Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails</Role>
      <ShortName>Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Stock Plans - Schedule of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock Plans - Schedule of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Stock Plans - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock Plans - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - 401(k) Savings Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/A401kSavingsPlanDetails</Role>
      <ShortName>401(k) Savings Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adverum.com/role/A401kSavingsPlan</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Restructuring - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RestructuringAdditionalinformationDetails</Role>
      <ShortName>Restructuring - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Restructuring - Schedule of Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails</Role>
      <ShortName>Restructuring - Schedule of Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Income Taxes- Schedule of Components of Income Tax (Benefit) Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails</Role>
      <ShortName>Income Taxes- Schedule of Components of Income Tax (Benefit) Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareDetails</Role>
      <ShortName>Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adverum.com/role/NetLossperShareTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="advm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Subsequent Events - Schedule of Unaudited Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails</Role>
      <ShortName>Subsequent Events - Schedule of Unaudited Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  advm-20231231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="advm-20231231.htm">advm-20231231.htm</File>
    <File>advm-20231231.xsd</File>
    <File>advm-20231231_cal.xml</File>
    <File>advm-20231231_def.xml</File>
    <File>advm-20231231_lab.xml</File>
    <File>advm-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>advm-20231231_g1.jpg</File>
    <File>advm-20231231_g2.jpg</File>
    <File>advm-20231231_g3.jpg</File>
    <File>advm-20231231_g4.jpg</File>
    <File>advm-20231231_g5.jpg</File>
    <File>advm-20231231_g6.jpg</File>
    <File>advm-20231231_g7.jpg</File>
    <File>advm-20231231_g8.jpg</File>
    <File>advm-20231231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="583">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "advm-20231231.htm": {
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "advm-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "advm-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "advm-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "advm-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 297,
   "keyCustom": 24,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 35,
   "memberCustom": 11,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 2
   },
   "contextCount": 118,
   "entityCount": 1,
   "segmentCount": 50,
   "elementCount": 478,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 583,
    "http://xbrl.sec.gov/dei/2023": 37
   },
   "report": {
    "R1": {
     "role": "http://www.adverum.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.adverum.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.adverum.com/role/DescriptionoftheBusiness",
     "longName": "0000008 - Disclosure - Description of the Business",
     "shortName": "Description of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments",
     "longName": "0000010 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.adverum.com/role/Revenue",
     "longName": "0000011 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.adverum.com/role/Leases",
     "longName": "0000012 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.adverum.com/role/BalanceSheetComponents",
     "longName": "0000013 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.adverum.com/role/CommitmentsandContingencies",
     "longName": "0000014 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.adverum.com/role/StockPlans",
     "longName": "0000015 - Disclosure - Stock Plans",
     "shortName": "Stock Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.adverum.com/role/A401kSavingsPlan",
     "longName": "0000016 - Disclosure - 401(k) Savings Plan",
     "shortName": "401(k) Savings Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.adverum.com/role/Restructuring",
     "longName": "0000017 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.adverum.com/role/IncomeTaxes",
     "longName": "0000018 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.adverum.com/role/NetLossperShare",
     "longName": "0000019 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.adverum.com/role/SubsequentEvents",
     "longName": "0000020 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables",
     "longName": "9954472 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.adverum.com/role/LeasesTables",
     "longName": "9954473 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.adverum.com/role/BalanceSheetComponentsTables",
     "longName": "9954474 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.adverum.com/role/StockPlansTables",
     "longName": "9954475 - Disclosure - Stock Plans (Tables)",
     "shortName": "Stock Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.adverum.com/role/RestructuringTables",
     "longName": "9954476 - Disclosure - Restructuring (Tables)",
     "shortName": "Restructuring (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.adverum.com/role/IncomeTaxesTables",
     "longName": "9954477 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.adverum.com/role/NetLossperShareTables",
     "longName": "9954478 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.adverum.com/role/SubsequentEventsTables",
     "longName": "9954479 - Disclosure - Subsequent Events (Tables)",
     "shortName": "Subsequent Events (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails",
     "longName": "9954480 - Disclosure - Description of the business - Additional Information (Details)",
     "shortName": "Description of the business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails",
     "longName": "9954482 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details)",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
     "longName": "9954483 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "security",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "security",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.adverum.com/role/RevenueDetails",
     "longName": "9954484 - Disclosure - Revenue (Details)",
     "shortName": "Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-43",
      "name": "us-gaap:ProceedsFromLicenseFeesReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.adverum.com/role/LeasesAdditionalInformationDetails",
     "longName": "9954485 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-47",
      "name": "advm:LesseeOperatingLeaseNumberOfLeasedFacilities",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails",
     "longName": "9954486 - Disclosure - Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)",
     "shortName": "Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
     "longName": "9954487 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9954488 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.adverum.com/role/CommitmentsandContingenciesDetails",
     "longName": "9954489 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-66",
      "name": "us-gaap:LossContingencyDamagesAwardedValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
     "longName": "9954490 - Disclosure - Stock Plans - Additional Information (Details)",
     "shortName": "Stock Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails",
     "longName": "9954491 - Disclosure - Stock Plans - Schedule of Stock Options Activity (Details)",
     "shortName": "Stock Plans - Schedule of Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails",
     "longName": "9954492 - Disclosure - Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)",
     "shortName": "Stock Plans - Schedule of Fair Value of Option Issued Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails",
     "longName": "9954493 - Disclosure - Stock Plans - Schedule of Restricted Stock Units Activity (Details)",
     "shortName": "Stock Plans - Schedule of Restricted Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-83",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails",
     "longName": "9954494 - Disclosure - Stock Plans - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Stock Plans - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.adverum.com/role/A401kSavingsPlanDetails",
     "longName": "9954495 - Disclosure - 401(k) Savings Plan (Details)",
     "shortName": "401(k) Savings Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
     "longName": "9954496 - Disclosure - Restructuring - Additional information (Details)",
     "shortName": "Restructuring - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails",
     "longName": "9954497 - Disclosure - Restructuring - Schedule of Restructuring Costs (Details)",
     "shortName": "Restructuring - Schedule of Restructuring Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PaymentsForRestructuring",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails",
     "longName": "9954498 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Components of Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails",
     "longName": "9954499 - Disclosure - Income Taxes- Schedule of Components of Income Tax (Benefit) Provision (Details)",
     "shortName": "Income Taxes- Schedule of Components of Income Tax (Benefit) Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails",
     "longName": "9954500 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails",
     "longName": "9954501 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9954502 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "longName": "9954503 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.adverum.com/role/NetLossperShareDetails",
     "longName": "9954504 - Disclosure - Net Loss per Share (Details)",
     "shortName": "Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "9954505 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails",
     "longName": "9954506 - Disclosure - Subsequent Events - Schedule of Unaudited Pro Forma Financial Information (Details)",
     "shortName": "Subsequent Events - Schedule of Unaudited Pro Forma Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-117",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r593"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net accretion of discount on marketable securities, net",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "advm_AccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Expenses And Other Current Liabilities",
        "documentation": "Accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "advm_AccruedInterestReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "AccruedInterestReceivablePolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Interest Receivable",
        "label": "Accrued Interest Receivable [Policy Text Block]",
        "documentation": "Accrued Interest Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "advm_AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued nonclinical, clinical and process development costs",
        "label": "Accrued Nonclinical, Clinical and Process Development Costs, Current",
        "documentation": "Accrued preclinical costs current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r133",
      "r473"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r71",
      "r136",
      "r469",
      "r487",
      "r488"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10",
      "r27",
      "r389",
      "r392",
      "r422",
      "r483",
      "r484",
      "r630",
      "r631",
      "r632",
      "r639",
      "r640",
      "r641"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r499",
      "r639",
      "r640",
      "r641",
      "r695",
      "r712"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r310"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r350"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r135",
      "r153",
      "r185",
      "r197",
      "r201",
      "r237",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r384",
      "r386",
      "r400",
      "r465",
      "r523",
      "r593",
      "r604",
      "r659",
      "r660",
      "r701"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r137",
      "r153",
      "r237",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r384",
      "r386",
      "r400",
      "r593",
      "r659",
      "r660",
      "r701"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "advm_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.adverum.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609",
      "r610"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.adverum.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609",
      "r610"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.adverum.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609",
      "r610"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost Basis",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r245",
      "r464"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r245",
      "r459",
      "r646"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]",
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets in accounts payable and current liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "advm_CashAndCashEquivalentAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "CashAndCashEquivalentAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Cash equivalents, amortized cost basis",
        "label": "Cash And Cash Equivalent Amortized Cost",
        "documentation": "Cash And Cash Equivalent Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "advm_CashAndCashEquivalentGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "CashAndCashEquivalentGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Cash equivalents",
        "label": "Cash And Cash Equivalent Gross Unrealized Gain",
        "documentation": "Cash And Cash Equivalent Gross Unrealized Gain"
       }
      }
     },
     "auth_ref": []
    },
    "advm_CashAndCashEquivalentGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "CashAndCashEquivalentGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Cash equivalents, unrealized losses",
        "label": "Cash And Cash Equivalent Gross Unrealized Loss",
        "documentation": "Cash And Cash Equivalent Gross Unrealized Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r131",
      "r563"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Cash equivalents, estimated fair value",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r101"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "totalLabel": "Cash, cash equivalents and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r79",
      "r151"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r79"
     ]
    },
    "advm_CashEquivalentsAndShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "CashEquivalentsAndShortTermInvestmentsMember",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents and short-term investments",
        "label": "Cash Equivalents And Short Term Investments [Member]",
        "documentation": "Cash equivalents and short term investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental schedule of noncash investing information",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price (in USD per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued upon exercise of warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrant shares outstanding and exercisable (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r599",
      "r600",
      "r601",
      "r602"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r58",
      "r466",
      "r510"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r265",
      "r266",
      "r559",
      "r655"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares available for future grant (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r639",
      "r640",
      "r695",
      "r711",
      "r712"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r511"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "verboseLabel": "Shares of common stock (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r65",
      "r511",
      "r529",
      "r712",
      "r713"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2023: 101,433 and 100,117 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r468",
      "r593"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "presentation": [
      "http://www.adverum.com/role/A401kSavingsPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) Savings Plan",
        "label": "Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]",
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r139",
      "r141",
      "r146",
      "r460",
      "r478"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Other Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r119"
     ]
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate bonds",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails",
      "http://www.adverum.com/role/RevenueDetails",
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r280",
      "r284",
      "r423",
      "r564",
      "r566"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r638"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax (benefit) provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r373",
      "r379",
      "r638"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities in an unrealized loss",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r247",
      "r573"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities, unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r248"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r638",
      "r694"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax provision",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r98",
      "r124",
      "r378",
      "r379",
      "r638"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r103",
      "r367"
     ]
    },
    "us-gaap_DeferredRentReceivablesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRentReceivablesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred rent receivable",
        "label": "Deferred Rent Receivables, Net",
        "documentation": "Amount of excess of rental income recognized over rental payment required by lease."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r700"
     ]
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital losses",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r693"
     ]
    },
    "advm_DeferredTaxAssetsCapitalizedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 174 R&amp;D capitalization",
        "label": "Deferred Tax Assets, Capitalized Costs",
        "documentation": "Deferred Tax Assets, Capitalized Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets before valuation allowance",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "advm_DeferredTaxAssetsLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "DeferredTaxAssetsLeaseObligation",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease obligation",
        "label": "Deferred Tax Assets Lease Obligation",
        "documentation": "Deferred tax assets lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r693"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r693"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r693"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals, reserve and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r693"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r693"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r693"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/A401kSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution by company",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r43"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.adverum.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.adverum.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609",
      "r610"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609",
      "r610",
      "r612"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic tax authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share - basic (in USD per share)",
        "terseLabel": "Net loss per share - basic (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r173",
      "r175",
      "r177",
      "r178",
      "r179",
      "r183",
      "r396",
      "r397",
      "r461",
      "r479",
      "r568"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share - diluted (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r175",
      "r177",
      "r178",
      "r179",
      "r183",
      "r396",
      "r397",
      "r461",
      "r479",
      "r568"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r180",
      "r181",
      "r182"
     ]
    },
    "advm_EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation Change In State Uncertain Tax Position",
        "documentation": "Income tax reconciliation change in state uncertain tax position."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation, weighted-average period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation expense related to awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance and Benefits Costs",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareDetails",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "verboseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r127",
      "r143",
      "r144",
      "r145",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r184",
      "r238",
      "r239",
      "r287",
      "r343",
      "r344",
      "r345",
      "r374",
      "r375",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r422",
      "r483",
      "r484",
      "r485",
      "r499",
      "r549"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r399",
      "r430",
      "r431",
      "r432",
      "r574",
      "r575",
      "r584",
      "r585",
      "r586"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r300",
      "r305",
      "r399",
      "r430",
      "r584",
      "r585",
      "r586"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r300",
      "r305",
      "r399",
      "r431",
      "r574",
      "r575",
      "r584",
      "r585",
      "r586"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r430",
      "r431",
      "r432",
      "r574",
      "r575",
      "r584",
      "r585",
      "r586"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r249",
      "r250",
      "r282",
      "r285",
      "r394",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r477",
      "r573",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r648",
      "r649",
      "r650",
      "r651"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r533"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r608",
      "r609",
      "r610"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "IncentiveStockOptionsAndNonQualifiedStockOptionsMember",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NSOs)",
        "label": "Incentive Stock Options And Non-Qualified Stock Options [Member]",
        "documentation": "Incentive Stock Options And Non-Qualified Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r380"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r72",
      "r107",
      "r185",
      "r196",
      "r200",
      "r202",
      "r462",
      "r475",
      "r570"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r380"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r256",
      "r534"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r534"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r353",
      "r359",
      "r364",
      "r371",
      "r376",
      "r381",
      "r382",
      "r383",
      "r498"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxBenefitProvisionDetails",
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit (provision)",
        "totalLabel": "Total income tax (benefit) provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r125",
      "r169",
      "r170",
      "r188",
      "r357",
      "r377",
      "r481"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r355",
      "r356",
      "r364",
      "r365",
      "r370",
      "r372",
      "r495"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income tax benefit at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of internal reorganization",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "advm_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "advm_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposit and other long-term assets and deferred rent receivable",
        "label": "Increase Decrease In Deposit And Other Noncurrent Assets And Deferred Rent Receivable",
        "documentation": "Increase (decrease) in deposits and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r634"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r491",
      "r492",
      "r493",
      "r494",
      "r553",
      "r554"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "advm_LesseeOperatingLeaseLeaseholdImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "LesseeOperatingLeaseLeaseholdImprovementAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvement allowance",
        "label": "Lessee, Operating Lease, Leasehold Improvement Allowance",
        "documentation": "Lessee, Operating Lease, Leasehold Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Undiscounted Future Lease Payments under Operating Lease",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "advm_LesseeOperatingLeaseNumberOfLeasedFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfLeasedFacilities",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of leased facilities",
        "label": "Lessee, Operating Lease, Number Of Leased Facilities",
        "documentation": "Lessee, Operating Lease, Number Of Leased Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "advm_LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases with accelerated expiration",
        "label": "Lessee, Operating Lease, Number Of Leases Expirations Accelerated",
        "documentation": "Lessee, Operating Lease, Number Of Leases Expirations Accelerated"
       }
      }
     },
     "auth_ref": []
    },
    "advm_LesseeOperatingLeaseNumberOfRenewalContracts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfRenewalContracts",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of renewal contracts",
        "label": "Lessee, Operating Lease, Number Of Renewal Contracts",
        "documentation": "Lessee, Operating Lease, Number Of Renewal Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal term (in years)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.adverum.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease Payment Receivable",
        "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessor, Operating Lease, Payment to be Received",
        "documentation": "Amount of lease payments to be received by lessor for operating lease."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Five",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessor, Operating Lease, Payment to be Received, after Year Five",
        "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "advm_LexeoTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "LexeoTherapeuticsIncMember",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails",
      "http://www.adverum.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lexeo Therapeutics, Inc",
        "label": "Lexeo Therapeutics, Inc [Member]",
        "documentation": "Lexeo Therapeutics, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r153",
      "r237",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r385",
      "r386",
      "r387",
      "r400",
      "r509",
      "r569",
      "r604",
      "r659",
      "r701",
      "r702"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r104",
      "r471",
      "r593",
      "r637",
      "r652",
      "r697"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r130",
      "r153",
      "r237",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r385",
      "r386",
      "r387",
      "r400",
      "r593",
      "r659",
      "r701",
      "r702"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "advm_LicenseAgreementsMilestonesAchieved": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "LicenseAgreementsMilestonesAchieved",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreements, milestones achieved",
        "label": "License Agreements, Milestones Achieved",
        "documentation": "License Agreements, Milestones Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Axis]",
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Domain]",
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesAwardedValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of fee",
        "label": "Loss Contingency, Damages Awarded, Value",
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r657",
      "r658"
     ]
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing Facility",
        "label": "Manufacturing Facility [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gain (loss) on marketable securities",
        "verboseLabel": "Net unrealized loss (gain) on marketable securities",
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r306",
      "r457",
      "r482",
      "r501",
      "r502",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r572",
      "r576",
      "r587",
      "r594",
      "r661",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r306",
      "r457",
      "r482",
      "r501",
      "r502",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r572",
      "r576",
      "r587",
      "r594",
      "r661",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r81",
      "r108",
      "r128",
      "r138",
      "r140",
      "r145",
      "r153",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r176",
      "r185",
      "r196",
      "r200",
      "r202",
      "r237",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r397",
      "r400",
      "r476",
      "r531",
      "r547",
      "r548",
      "r570",
      "r603",
      "r659"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r196",
      "r200",
      "r202",
      "r570"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r592"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability, current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "advm_OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash settlement of operating lease liability",
        "label": "Operating Lease, Non-cash Consideration, Leasehold Improvements, Value",
        "documentation": "Operating Lease, Non-cash Consideration, Leasehold Improvements, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r417"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average IBR (as percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r592"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r592"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "advm_OperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards subject to expiration",
        "label": "Operating Loss Carryforwards Subject To Expiration",
        "documentation": "Operating loss carryforwards subject to expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.adverum.com/role/DescriptionoftheBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of the Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r99",
      "r489",
      "r490"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit and other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r100"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments made",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r633"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of deferred offering costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r148",
      "r206"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "advm_PazyukV.MachadoEtAl.C.A.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "PazyukV.MachadoEtAl.C.A.Member",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pazyuk v. Machado et al. C.A.",
        "label": "Pazyuk v. Machado et al. C.A. [Member]",
        "documentation": "Pazyuk v. Machado et al. C.A."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PendingLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PendingLitigationMember",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pending Litigation",
        "label": "Pending Litigation [Member]",
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ]
    },
    "advm_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r283"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r511"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r283"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r511",
      "r529",
      "r712",
      "r713"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r467",
      "r593"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProFormaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProFormaMember",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro Forma",
        "label": "Pro Forma [Member]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r615",
      "r616"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from employee stock purchase plan",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total gross proceeds",
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r496"
     ]
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLicenseFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fees received",
        "label": "Proceeds from License Fees Received",
        "documentation": "Cash received from licensees for license fees during the current period."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r647"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock pursuant to option exercises",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of laboratory equipment",
        "label": "Property, Plant, and Equipment, Fair Value Disclosure",
        "documentation": "Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r132",
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r463",
      "r474",
      "r593"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r120",
      "r123",
      "r472"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life of assets (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r299",
      "r306",
      "r337",
      "r338",
      "r339",
      "r433",
      "r457",
      "r482",
      "r501",
      "r502",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r572",
      "r576",
      "r587",
      "r594",
      "r597",
      "r653",
      "r661",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r299",
      "r306",
      "r337",
      "r338",
      "r339",
      "r433",
      "r457",
      "r482",
      "r501",
      "r502",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r560",
      "r561",
      "r572",
      "r576",
      "r587",
      "r594",
      "r597",
      "r653",
      "r661",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ]
    },
    "advm_ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of operating lease right-of-use assets and liabilities",
        "label": "Re-Measurement Of Operating Lease Liability And Right Of Use Assets and Liabilities",
        "documentation": "Re-Measurement Of Operating Lease Liability And Right Of Use Assets and Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails",
      "http://www.adverum.com/role/RevenueDetails",
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r280",
      "r284",
      "r423",
      "r565",
      "r566"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r352",
      "r709"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r627",
      "r636"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareDetails",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.adverum.com/role/Restructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r255",
      "r258",
      "r264"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date",
        "documentation": "The number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees (as percent)",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent",
        "documentation": "Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring charges",
        "terseLabel": "Charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r259",
      "r261",
      "r654"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r261",
      "r262"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance at December 31, 2022",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r260"
     ]
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveSettledWithoutCash2",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash",
        "label": "Restructuring Reserve, Settled without Cash",
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r262"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.adverum.com/role/DescriptionofthebusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r88",
      "r470",
      "r486",
      "r488",
      "r497",
      "r512",
      "r593"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r238",
      "r239",
      "r343",
      "r344",
      "r345",
      "r374",
      "r375",
      "r388",
      "r390",
      "r391",
      "r393",
      "r395",
      "r483",
      "r485",
      "r499",
      "r712"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/CommitmentsandContingenciesDetails",
      "http://www.adverum.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r195",
      "r198",
      "r199",
      "r203",
      "r204",
      "r205",
      "r296",
      "r297",
      "r458"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.adverum.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r298"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r562",
      "r567"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in USD per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r307",
      "r615",
      "r642"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Equivalents and Short-term Investments",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax (Benefit) Provision",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unaudited Pro Forma Financial Information",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Loss Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.adverum.com/role/RestructuringAdditionalinformationDetails",
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.adverum.com/role/RestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Cost",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r50"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Option Issued Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r691"
     ]
    },
    "advm_SecuritiesPurchaseAgreementNumberOfDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "SecuritiesPurchaseAgreementNumberOfDirectors",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of directors",
        "label": "Securities Purchase Agreement, Number of Directors",
        "documentation": "Securities Purchase Agreement, Number of Directors"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r204",
      "r571"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards granted to employees and non-employees vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of performance units both performance and service vesting conditions (in shares)",
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in USD per share)",
        "periodEndLabel": "Ending Balance (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair values of RSUs vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award price as a percentage of grant date fair value, minimum",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage increase in shares issued",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase Decrease In Number Of Shares Issued Percentage",
        "documentation": "Share based compensation arrangement by share based payment award increase decrease in number of shares issued percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contract Life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled/forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average fair values of options granted (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in USD per share)",
        "periodEndLabel": "Ending Balance (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Vested and expected to vest (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant stockholder threshold ownership percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares available for future issuance (as percent)",
        "label": "Share Based Compensation Arrangement Increase In Number Of Shares Reserved For Issuance Percentage Under Plan",
        "documentation": "Share based compensation arrangement increase in number of shares reserved for issuance percentage under plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails",
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails",
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled/forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r315",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r346",
      "r347",
      "r348",
      "r349"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options granted period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofFairValueofOptionIssuedValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted- Average Remaining Contract Life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested and released (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and released (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.adverum.com/role/StockPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Plans",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r92"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r628"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r152"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State credit carryforwards",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r25",
      "r127",
      "r143",
      "r144",
      "r145",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r184",
      "r238",
      "r239",
      "r287",
      "r343",
      "r344",
      "r345",
      "r374",
      "r375",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r422",
      "r483",
      "r484",
      "r485",
      "r499",
      "r549"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r184",
      "r458",
      "r491",
      "r500",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r532",
      "r533",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r549",
      "r598"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r307",
      "r615",
      "r616",
      "r642"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r184",
      "r458",
      "r491",
      "r500",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r532",
      "r533",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r549",
      "r598"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)",
        "verboseLabel": "Common stock issued (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r88"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued upon release of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r88"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.adverum.com/role/StockPlansScheduleofStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued upon exercise of stock options, shares (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r88",
      "r321"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r64",
      "r65",
      "r88"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r25",
      "r88"
     ]
    },
    "advm_StockOptionsAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options and Restricted Stock Units",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "documentation": "Stock options and restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r83",
      "r513",
      "r529",
      "r550",
      "r551",
      "r593",
      "r604",
      "r637",
      "r652",
      "r697",
      "r712"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "advm_SubleaseIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "SubleaseIncomeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails",
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "label": "Sublease Income, Net",
        "documentation": "Sublease Income, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r426"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "advm_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "advm_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r282",
      "r285",
      "r394",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r477",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r648",
      "r649",
      "r650",
      "r651"
     ]
    },
    "advm_TwoDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "TwoDirectorsMember",
     "presentation": [
      "http://www.adverum.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Directors",
        "label": "Two Directors [Member]",
        "documentation": "Two Directors"
       }
      }
     },
     "auth_ref": []
    },
    "advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Employee Stock Purchase Plan",
        "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand and fourteen employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "advm_TwoThousandAndFourteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "TwoThousandAndFourteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Equity Incentive Award Plan",
        "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]",
        "documentation": "Two thousand and fourteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "advm_TwoThousandFourteenPlanAndInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "TwoThousandFourteenPlanAndInducementPlanMember",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Plan And Inducement Plan",
        "label": "Two Thousand Fourteen Plan And Inducement Plan [Member]",
        "documentation": "Two thousand fourteen plan and inducement plan."
       }
      }
     },
     "auth_ref": []
    },
    "advm_TwoThousandSeventeenInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adverum.com/20231231",
     "localname": "TwoThousandSeventeenInducementPlanMember",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Inducement Plan",
        "label": "Two Thousand Seventeen Inducement Plan [Member]",
        "documentation": "Two thousand seventeen inducement plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.adverum.com/role/RestructuringScheduleofRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r261",
      "r262"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsScheduleofCashEquivalentsandShorttermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government and agency securities",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Unrecognized tax benefits as of the beginning of the year",
        "periodEndLabel": "Unrecognized tax benefits as of the end of the year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r361"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease related to tax position taken during the current year",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase related to tax position take during the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase related to tax positions taken during the prior year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r117",
      "r118",
      "r121",
      "r122"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in valuation allowance due to net operating loss",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r592"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r179"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.adverum.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.adverum.com/role/SubsequentEventsScheduleofUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "terseLabel": "Weighted-average common shares used to compute net loss per share - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r179"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481123/840-20-35-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479341/842-30-25-11"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001628280-24-011648-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-011648-xbrl.zip
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M:NNS6 @/4MI.1#)&-?56!*2AAM[U.(K3&QE/SL-;F:3X_.9 H;8^B49"OT0
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M-IS>NV.<,^> P?'GV(=/K@R??(HQJG@BLG^X ">) M^;R]C\D6Q])5EFO?Z
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M645$AQXB)'#50WEPI[^-[I,* 5RS"M+'-*Y>=ZFKO?^QJ/QZD1+R8T#KJ81
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ME<.M=[W=7N= HXO>T#L'H!S /UH.Z]@16W=N$"6HIDP!IY:^*/7;RA(!_+(
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M4S>+8^W2-,JSB?2(283^-A6*A'=CA&$<P0L"/TDYXJC"43A)U.Q&Y4;KT-0
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MS'O"]'(]Y=+-4I +9J[P<3;")L?][19N>[MEIO$FZ+,&T*(00Q03@9Y); P
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M5<F5]]S/TTD!2S%:2253Y9HMNW($JY7)D46*'OF0\G>)Q+Y3C,-U=$W;6FO
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M(AH%,RR<>/6WZ\O?58-K$:1T7?B168@Z3I)J4>Z/GTQCI1OABU4,1&5A\ 4
MU\'@C-UAJ94?&H^BN+=*L2S&<EG!X()_;(9-_!*W-)$38(^A++X,V>XXB[V
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M@7Z5RBM_DV>\ ]0M975>_>V=I74,WN+P22.@+H)L,=VE1YA/ VD<"3I'X'K
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M]XS16%DL;[&G?\J:YE\>:IJ',)0_1TWS%.?R'#W^)QR&/Y4:!K-X)V=7\+H
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M$43>..[9>>Y<Y]V_ B6,\[7#5F_ZZ2Y\D69@T<5Q^MZW=-C^G?]GQ'<]??*
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MJXUSJ&:$*+U]?U,VG=)R=YB C&L"K[,:7;ZKW(/.AMG9@)883$<X4K?D>R5
MO?;L%9K(+WIC.>S3>PJ?AJ?*>B'5^3)6>I4,375JGK-!9GXLH[/$=4DP0A_B
M%XK)%F(:2?%@"@5\$^C[PRJ:>FBRUA+B@,JN\[<$9VH'*9:'3F5B UA+^NVR
M*[Z2409DJ3N91!O$V D [6[3V\_O3S_25FF0GCA</=DEF,^S/DXZ6=(U8C<E
MA_N5>JTA3V=N48><.C6"O>PF/%;":&MM0/A5#TG&NCV"7VX9QADRKH'L;QK9
M5/4YIC%G*M#&P[<$89[%/;DV<IA'^7%E Q3&9IXU)WR0CJB4N76:I/CJ,%>:
M,+6WZ"*%M!WEB>7-H).&EHSC^STZ7[LP7?T$7WCV0\D_EOR?/93\#V$H?XZ2
M_^G^5)2SQK7*/?OLJY-'A:MS7/SP3BHSA;6[)\AT4&,!"FH"'3NDLD<G3[48
MC2O5+B?EM+T&>&S&.M'^(862U0:YDN@B? %!OK0)WE!$UR+7S@J2VC^2Y5-!
MFRT>&B+BSI #9*U?$Q-D:!A=D=V!B1NU\U#)RO[[@_)U"7V>W"]&<WK$ ](B
ME#5XARG* MN5=C@@HY"&U*+0\?2Y5<PTFFB40D\1B3<KF7\$$BP+5\@0D,^3
M:\Z':8!55#QLW0_<-[1.GE>GHT?>&,)3TE3(I,@2/_VF@R_7OW,+!\WYZ.>Z
MN6&*S]<3NJE64]D /U7EY(I;H#=EM7K,4DB ;::#UV*AL3[2&A@20[;7'/&[
MI^H-1^F<@A9OEY@WA7@<[VM+ -"OG)\J):?'3ZF%*:.<S).T]ZBUZPAH"&6E
M.6J^4!M]C]0'DBC$0V>4M68E3.OI7*A(Z*FOSB4_BKC+W5D/4 :>M[?KH=<A
M\&BYW6RE![6>KZJ\?8?QE8,O@>&L@K\O?X:#?NXG0I= EE9+.C[!3FZ2FJAI
M]]T[A?T\."[_H+6J9KM/6,W:L])2^)&:#3I.4UK*^I8Z52],P_FI4MK:IA=W
MCFZ1>EVMM)ZN["YI"YUKR.Y["6TD4I%%O(7E2+\<QWQN?G8K!*\C[=OB0H.M
MS&>Y,&?A)2]\823K-)5" 9JN-(K;[-9R3A+2R.(VNC$V9,A6[#;L!HS8V/B4
MC0)DZ$.C1XI#MZ<.4I(_YN.UYMMC\&>X0C=@0VD^Z!4D?\-Q4B%]C2GHYNW%
M;>Q203>^R-&B^E".?GC]MR].7[]\-V9;/.$L[ZJD?30M542,GS3E6B=Y1C2&
M:46!*/H!66[DJ%HNMZLR :I'^H?IKIUM5Y.4?[ZN6-K&?EJB07\#A.9[QJZA
M<JC&9VPL\JO^2IK"D<=ZW]D5[0UF@EBMR&V1X]3@<=J-TS_%G&C,&%X:9DL(
M["_C+FFUMCMN]MH$[D%9J]VL5W["/43_[$Y9PC+MN2G4.#F>Y"PKYI_[3KZP
M!>,__P 0_B^MW#1G/[!$HV>H9#64WB?OILS5E_A[:,83@8($FG0N53Y!R#]D
MRRA%<(3]PF@9"%GLY"++D_UX7@8!'P687[0H A8Q+?>QA7^/Q,&OU7*[!! '
M+46^O7-5(W@NIT''8^_F>GHB^CYC\8.E[K*H)Q^@6M$JN?1>&,F-4KN 38&Y
MT7YE 0<'<5E3;7[UI$L=^6Z%)=!GDTZ0]5W1@AQZE?J7%2QB=Y;S'=+9W[F;
M='X:UB1PBULK:.?2%Y.^* M),<5/&6W[^':O#O#LCFN7-[&ZNVMK:,5#:Z7-
MP7I2"9\(<JT'SF&#>F/PF5[(^,I\[(^SC 9,LR"P^SK:R0V.]H:B@GCX !'F
M/[8I&!6[NBP =%DXUH[6>$C_"K9#7)\,;_;>Z\>X6--/*I5-U. *&EC#O;I\
M^FBU=23?ZD!21E#;TV@S,6V?(Y?JK/#3'T-JOP[OJQ[DWK'P/=^M*=WST:9$
MY1)4402LB")YRO,QJ(@R!DOBEI]<+EQ75\NXB?F-Q_4#C@;-4R<ZHMVOMPI=
M*C4W/LA>^YZVVEIN%PENWH;@AE_II1_7-OJ%PF!X<O)<KA^Y>LY?7HT#[$P)
MA<@Q$=IVK):A</>YWQ6[CYYW'R)6.'2CB,OJEDC18IU.%@5XCZ+OKCIL)5<D
MX0"WNT^]<5ENQJKMZX1<EC:H?]X5 E>6,NLOP$]F]??&O)N[)H'7.2)/ G3V
MKL!<TRB#Z95S(:@:F,:[GKKO77DY60=.6Y=2**_!>V+O&HA/^[^V4Q^ENW8!
M.*_EX+1\FUU:-'M+;K>]OCV/H3\U^&*'?H@D.7)5H'\E-4"/14A _%G<0?J:
MJ85)5BQE5NB*+&\\.Q9:G;K-[IQ#.,I]25R/9)&/C$/VLEC$+<KW-\M-W+H"
M ]LU=S@<(TY/XU;\F(XS%9:.8S&V;: [$Y>AD=B&D>T;EL:/G#*O1:2& DX*
M5\-[GX&Y=O2> WFX-R^U=TY_AW?J=DW;Y AX<:1\]9JSS+/+J-\M 9LQB2T6
MZ-S3Z""0N;25P2+SJ8(V&WF%S%;'V%<M((8R*WU^(@&O&$'L'=DJ0[?0WJF[
MS00)+AD."3U"0DT&2"I96G;WKYFYI9C01,XK;*FQTA"[=B0LO%6I>=M* A_;
MF<V:=)-8#,11$C"CZ;H%;? ,AP6,^'H0?.NT5X4@"\27T[:X[4J9\[U4<+K:
M=>X1SWJS5R28[1#A3&#UC5!*)ZMOCVO+)EMST"/)-N?1P6-)YFKI&)\SV)T.
MB7^D>[S4;131F*P0D[U'?T>,'J'\71\Q=A24>RMF2YHLBFU;/K[%:/XIZ]!?
M/M2A#V$H?XXZ="#0\WJR<S@G"O5^28411SCGBCY?F(ZD@0T'+B<I8"H2?D<6
MP-6N]]\9_+-6-P@#2W6TO@VL9JJ^&20"IIJ%77BU6"PLLE.Q&659;O[J.GGJ
MH!PA?C0O9:_MY9J(UDF>JX*=$)^17[_8)3QBRE89"LVT[<S70-VSO%+69DQ;
M/TF(W]"!]@<SVRYF]/16;A]N.\!G& E,=^%S5=F[SM[3J:66_%ED@&2!0"X3
MB3)OG80YJ&J#\ RFKUKQ1EEYP9/A2KHH'0 S,&4J0&-])>\EK1&7/^\0]7^T
MFT<G0!/V5D50'PJ[BS6K%# -(*9@\(3(T#?PDOZ+(_/CT>M0G;(V6S@/2-8J
M+,W]8I!@0PN"L0N033#*J#32U(W@HU6' P U1<I%=0;+?%H^+IL1A2O07\GK
MW#AI)7-(A8\%04VCGTHCLM.99L]O_3(DB?GZ#MYZ#L/K5)33878G2>@=A#"R
M#M/V><1/CO,-YE!-I^3'RU\YZM:>M:HA!U][1<V<)N1JL@4@W;VJ;[0.BLVV
M7=W#,I"1= L;^'YD*"O.K2_B"M/)W2I=Q4"346+/37D19:YT4M:$7?6TE7#Y
MIIC"M0[BV\O$,9Y#5-I,CD!* E;A6DV[;2,T5;1;R=66=H_IV$Q(NU'F],3?
M./JPJF]HV\Y+%W+F73O6">6M[>)?>Z<UE"20@L/X@@7!M"?5!SI>TM.76BXE
M[\*9Q1[9F.9YNK?96,$AX7[=NXWX39A'JKE6ZS90C8V,L;GP+H*;6+O$O'KI
M$FKMW?NB#67*?-M.ZU*FE6/FV!V*26I+4]-N1[UV9KG6A?C>FL0S\[0-A9#^
M9*4Q])/]=\T>6DYC3!<;=V+$'R\*"MJB\!HMUL>=^LHCZRR$'.]/B-QVRVHC
M>+IJDDJY6=C+TGL"G8L[^QT1[\%\0!N#8^+BFGQAN&2';8O?*^Q+%HN+VIS2
MV:XDF\!;PO%R&N)&7)Y=QK3<YZ=,B+&N#2HI],W89:%2/W#$<M$G-D";A3S2
M,)<8;T)4=@&4&-S)DRXN,\=8ONQ\";>V9VBT,;'-!$#R=+/F T!T8-4M\X/T
M!8,ZA @>N0*]] <U9%@S[NMF'Z02*@CAK7-Z!3[KV3EU+E.?YP3=Q-UDR @;
M1?[+7)+N D?3,=CS<K'&PX6^J57">YM$LT$^QT4DQA@>43!*_.812X@;<M/V
M@7_J(_I&@%=(^W,-:D>;0,O/2BY^,XA7]4?**YE@%]T$$:<J*NCUA.*WT(*5
M>!\DKK(D&;X(-]*P O3S)R<ZUFHVSE"Q54-^<&?;TX*SHT=W*/[4S;(*-E*4
MU[+-T>6R85S.9E#<J)5]D@TE^ 0A_0S"$JTC5)U;0UAYKLJ%7)HBDY-QT'LG
MF1E0[<MBIT;[.!+$8F/D9^%&V\#Q$X,[WQ8XQ2Y?ESJ$Q'8'FFKGK_>MO.>\
MZVV/N9I<E4L>[1<!:@XKI5>%&S+3Q1 QDUTRGN$P"/G_85\)(9GA$UV(OXJ*
MV;Q2?$L 7X_U -L$#=AYQV^U21@A$I4/5,6VZO9,:^WZ5YHFN_>-,\F,2.\1
M@DR+??A.W>*]Y%'BEFR4;\X!]N>@BF2,[5X$42:1CA%G1^S[Q#_K9N@5JF1,
M>"4AX6X-LTY;!SM+V .\SZG9^842?QT;K)K-)"'@F,=^2\1G2)QV:B#,]PJJ
M' "8N9T^[/-TCU?!\5%(J?7(#4)*,W&#FH.KR6A22M:P\T&^OJ4#LUS1))2P
M@+XA<+-YZ) Z67H!@/D]$>$9,*K7E4CAB#XY?@_!#P^J'8;'#H59;<;?'N1$
M'KTZ>SSZN3X>G3S[]LLOGCYY\@U'ZCI5C#W0R^/20".X/9(<B'\?NB!_>=:#
M=UQPET?A\",O,&[)O>.^4-/(Y(AX98!!3L:PC\R,05)1Z[_4\1VOD8#S;4H&
MB&!.IU39N5ZCD @NH&ZYKD=2/ 0_'MP]0^[Y'?OH/'2LBSV]!WQ:\5%1>O9>
M%=DJ;,( 4_.:WU#\R3TI"K=/O*J=DK6$_\.'8']2'<>G%6:7V;9%:F;O.5K
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M8CFXTUMO4QEI8$0=C4?G.<)OYS*.L(OF=Q;MK1,)$Y*[AKR%!IU"ZQ[21("
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M2T/OUJ."=U.[6927B_JF;!Y;TGM5+/VV&H@+TB,2#CY[$ ;=7L$C6<%)X9E
MKXDJ$>^8299Y0O+K?;"3+MWY0#FK#\&:=#S=6OS /TG%8!K(OA:!AZXM-YM%
MV6&O'@A_TF(,GT&53 '[BX@%%XM%.2_3EHE-AR&4\:OYKR&U.6O*I%G!Y<IM
MNZF70C2I8QR6ADZ?$WYT[CNWMW%OS6C%UB;.EWZ8UF<IF'9U"4H>HT@ECV58
MFZ:PSK^.#FS> )G\7_K44OO:%=&^2;WQH7 O?6O/M4EGILETVJ/BIC#'@**"
M=-OBG[1U35NZU:LQDP@ETE:E1,J-<C^J96H0R<K*AJ4><'!O][K8B071/7A_
M!G<'<P33(9P7G%C/_)B]ONPL&$(Q>4I0M['0WG3J^'1K<Y_ITOE6DS]4H2D1
M#$ZKG+AQ<[5MP1]' ?WRDEY%KGLNR1R/7I0\##_[HIRI9$2<0%*@2ZBFL:^3
M\NN\]_=?%=& C^/<P]O9Z^C/6#.'7KI>0#&(R\RI_9P=;NY>;%OKH5RX+X]R
M=@>ID.AIEMR6 X:HCS%!TMZ:UT?DXW;VP@(ZD:&>^^RRYD-F=[W1[X2?Q.QI
MC\BB+</5I_&#NH6J&\6M=K2HO;WMBI6VOV_)9C^X;_^>^_9==SD'VI?)3^=X
M ?7[EBZK92DX.5ON7=P#G;63:L>'9"5"<U$L2(8GT'9GRJL'E_WW6G.4X_P*
M A;Q#M_<=X D@&A].'"3E9-_*\>_P>;@WNT)N_WU5ISP8([#OMD#;F+= 7;3
M1BQ/%CS\&4>4_4&PD1O(-MRV)7O\4W=D! LC4;)X9I=($%:E7/O2!?=OIEUX
M2B3!9D_DM(#>OREC\G"D_H@HV.D;1Q>Z ]]M5RV=I#)&PZY(8HF<'E&9$FE/
M2W49$\LEG )CCMPF@*$XH?3/*ZGW&P 5I5=QK3S]^1_%<OT\)4#?V0EP7._Y
M.X/U=BKBJ1<="69K6I?_T$,7"49,QAXO=5TLMF7'%7]$U@*@ Y'Z!"0P< 32
MP8'4=;WFX&'3R'^M:Q%#;/6W)E<5TP-(T?SQ^"YRDT>6$XZ<*"H7JD]<@;%
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MIDEUD,@3E]8[<5V&0X =&O-N>>N8&3)SA:]!]-*5FO(ELM()+&E/)Z5=#)?
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M4X-L3R,<.;J&--)BG-(B)@,"I84FG,DAF,CLNH06)FY:Y%E#5"G?D^;K3%$
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MQ\^?/_OJX</%]>6?BUUA;_O%LX</[5!>@2RF:$6.B'[]_/MOGG___,W_Y<>
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MRW7>AW?)PSF2;Q!0UK*HZ2Z\09NJR/DP"<:ZD(2 /G38B;/8+?X@\UTEPX:
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M<P>Q.U:FE!GH9UE44R8,1NX%$!64;;I',V03AW]\P+V!0:_D1&5\2W"M&U%
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M%UL, D9%DV7"@MT!$8V<]B[X(%(()3&6,8J.P;CH<IO"T''F6V!T:?)7V73
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MBN$;/$@CPBMELR.QFK2),L33B!MX@Q.)*_*E.R8]GTN.'O@R?VXLUAP7"PH
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M7^9-LQMP6*#;FU.-8&/FR_+Y9EW'-5R'\KH02IJ80=0KPZ\3#;;I94!VI6B
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M5?<\"M*Q\[5@8@;F>_NIEWMFLF1LB4AM P3DNCLR%.]R-0&T1E9-,#O<-:=
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M"VX1W\G=6Q(X<^W[\\AN*\2XU%_20,MM*KL!OJ8IPLE?V6T$!<N)Z[SRW(I
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M"->H ;GN*^(#F?VJH.JO=FUDX[*O.O9_\I_T1:P[9,:9EL8;PJ$;7$SE^M:
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MN++N6QY3\-+KRK[GT^D("1 +_&:4 &R8NDLQK-,/YJ![DSP0"\ G^E8+ UR
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MBA=K+9_'&Z[J,-'9\*T92;1>"Q[ML)U2<0D[ASTT]7)3+]^I/^LE \A@)@[
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M)@+[I%R=.BFH*I&\XN]UH$8R+J/B8M55@AK&\I!!.P$-K0XA"S4T=8*(N4E
MN31,QI^409 I3J;(1'+=.#4..!M3HT.XK(^QD/KN6/L%Z+)5W\3N'.40Q9J;
M>>=)5'TV>6-#WN8Q>(\/C#<@XH4=$S&$M<G.WF6QKR6HX_;2@:\8?1:M <96
M0PT[^7&+2*1#*TI_5X;'5CW:Q)&=#%0T1XM?"%.JI;/U)>P-Y>$??^4]5ZXM
M=4E+@@[H4\;]TC(:S#[N5ZR><M+%'H<*!I9@X!5H)5/M^%%',!D*0B%3]85I
M;J1 BI)>Q[H(_B\I74@9%M$;V3K%K&7"QO&Y#R[*N#KPH#8]% .6>$@+%&$5
MQ==603)J TH;LO+2Z#MWN\U>B0VE$$2/LBKR%9G8=N+3!K)-%YE15@TA.P @
MN:NTX2LM$<W&VXF_*CQ,47^NB[)X,"].\%D<VT-))<J6KPHMC2J.$NC)6[YG
MV%S3;(R'XG#1.+5M64>M8*TT# PW[;:)6T]KZFHJWIF/B=)ZA%.ZLK%'O]^+
M4%"3/E/4&N.4P6\@$?Q])3NMY&[:P&R3+.#)^["-&^G"9OOV_$=,9EQ\X1?3
MV3$614=W-60#M!4/:L7YWN1G*:\5SL^.ZX; ],U_DQ.Q%(BU2N&*<F*SHS6$
M'AR?T(T/K=D]>MQ^4_@'?=/OM&A)5=:X4YX5C2@C>H:^" IE' /I\_8M15O6
M=#O_:DB&)N_ST27F8@^L[T&-H B7?FHFD"K:VQ7_Z7G)H#WM\3B7A0>0IR6
M3) %L:[J@-6H *8*F7;%PVV^E FQZNUJH+*PV3-8A;/&1[[)V81/$B0D!$7!
M_T:-0"GAC& )4X4$?26%G9U#(IFD9=*2YG+6YLRLPBG&] 7=83^7>[/C)^1I
MYQS%?!FV7A'%-1K-Q9/[LHB*J)82U#D/U_E\/._$%UEOA' >KP._SO):UH!;
M>F>/D75<&08H3]%$&S)%$>DD4)C!?;D"H F>NMIM<O3B2=*'+Z6=2B&.#9X3
M&^>?^]65 M#B'<X7?VVX)XUC'[MSQ"-P4HV9P.D1*1\6=4*V1='I>M&J%C4Q
M])("BQZ)3\^%AQ8D5EA65(FL+V_*NF^19:^%71%NQ$= +IZ,8#4Q60"-Q4;L
MX8"Z8B*U2-!R7I+TY=*(XSS322JC3']&\ZKYC9[YP(( ;H^ >TTW#A.X8=JY
M;3C[@I/*5/_ADBP#:?RN>E<Z1ST4SHZN)B>W5*-;67X.X"/5,2K@)0T&Q%L3
M/#NF!HY0(3JMM64^^F:BH*3#V*9+6*SZ8-!1EG5UM?/%3]-50KX&/$EX?(F/
MGTC[:#U46E%CWL-@.3QJY-?G++881;[%GS 7,RS$"E)'392CGAKW%VMTUZC)
M4).K&$.(!@[&9SP\4S8DBYD6,"40C5]!506:8SXJ@Q=[G>]:9K=+UYT+$*B<
MC;[*H=%5%@2Z?CL=7-P>I$50OVA BW#<UN %F711I4Z./P&53C3.4XT"#7(=
M_:UO64Z 3'?DV^4=/$W&P2U/4E2AY2=<2ZX59ZI$YQRL*< L#O,ZMOTZ8JF+
M*L$\I"07J6;8DG"9$N]SN"#]M(X&EKMY(Z/O6 .C[*(MDZ7/=6V0;;ST-5KS
MVK@T2][9U+=B2S+K E!G5U33N(/U\<B7((T'3 9/GG-$XE2C#RY=H,9\@TZH
M0HI\'H7(NC]W8<*9040)PP_QAXR;+2.L ^CG2'4L%=$!I\G]"%4<;H+/*P8Z
MT)F=["33LD-"(6W)S]*_FO(']TI,L7?J8G*W.,3IGG'\8W*D"7?[B'I=7/#K
M<I> 18(KL$/W^Z%R+'A=*%(^\F6L96;2[M&X$4X^&9YLL*R%41TGX<%5/F3W
MN[,3CM-_O:B,40^^1W=*+[[O'DAV0%0TSQ,=<R=PKI:M;#3O3(::)))F](;8
M]S!#M^LOPUI;D)]"VV>K8;)4K#4I=1T6+(U V,:U6?C8)M.4VV2<4DF;5OF?
M49@H13<MW^Q;/D!8"8B2;Z9^Q.VL^@#,'%[!VZ70?$C^[(W)>!?+R;:TPXB#
M'VJQ6;X3/V-@YMRKF/JEW@%JV=PRP*5PSM>1JUD;%7XX?'M!*IAZU" #/D.D
M+1&T!*/$ 4&#'KM\&EXBY>60NS!I(\' N%I43#RZ-A%]+K9>V.GMX<%0$ _U
M";UQ5*'#!*K#![5]:WR0;.B52V/^-JPRYM3?-&O+S?B:4Y=UKWI<\1WMU:@'
MPY\)$QI%DG_0:I(8:DNIC^/QR*PR6B4T#.&ZI:P,=W1HPZT,!,\GPN\37B'!
M*_SYA%<XAD?Y-/ *DL#= B^>VI7T3#%H%R7@*9EOV:D5YV>1<4%02J[FM%L0
M;8CKE,JYL= 2.-&B5FLN]@,;'],RCB--C0WB/'JR< #U,16 _'^WWQ43B1)S
M 92X\]?Z =DO<@20DOA07L !1_X.%^"CJXO@[#W<_2,$R!$S*BI"3MW4!-(@
M\J)+&R)M+'SKB%XHXF%D LLC<$ZJC\(?L;=0L>Z^5*<<F4*.MJ7PYZRLA!3-
MJ#0U2]84RA3BD\!<_:1H7%,DY$=18EQ:XJRQA1E!2$-K62CH<'F=/!%8/@E_
M(6AWY>YT$D+QS\E)7K&#CLM2KAF(&,<9> B#>!1F[\4]%/0,U^DS[S8]_-&!
MP)=O*[^X^,?YG[9_)N'3MEP)#1MCI#NWP!"UL\T=,@O1@E-<;,X)8>[L23B&
MY8$FEMP M&I]&>X6MOX'[]7-*$(OBNUEO2IC,#G&J4]$S%!WS"M+&W^=[Z_/
MOJ'23Z0-_,)H Y._&F<@XB=M=^5MX5Z4"5Z&;Q>[]".)D*7TQ"A'M7OWS;-T
MK\>20ZI0D^&?82]4[9H;5<-2:;@K%;THU.IX2SE[I^+4MX5_C+5$._'F--S,
M6#B1X)EBG[(^)"<S*6G0)/%(?^;V:?<&2)\@I'._K&<$NKB)WY11TS=!CZXO
M389PEZ@=-+_*F9;_7'Q6/HJM$&U7[-K(/N2TMD;:+]VUN]W3<)EP'3<2PKI;
M#I)2*+#)T1Z.[DT'M=DV7Q?A"4D6JGU*OPA7N__E$HN,=AB^/A(=6$Q3!\!G
M7/$ARZVJ/:/30):LKGJNZ SG'-<933R-V@+H!]EFZ>R !CE3-(!#E.CRR")M
M-_M1@Q'7S>L?I%K9E];$G9KV\?-R9&*R \VZ@OM*Q6SYY+&=[7XERO7H] ,J
MI*BD&0Q.8!SQ3%)&>]<KYEJT%M-G0+308[.P&)J%EN=BPAQ/']^L=>T/9:YP
M>4'XOCTP20)X(T"C]\Y=M'^GQ9#[*,2F,JW)EHW[WCHE3:)45X!U'4V?7]-?
MNO0:9L4XCQ0?\NWU4.[,^3EN&)60\#:']J!4*-!X&26;I^:6OM>2>*!P$UA5
M@I#8'MAB/>[1-T3EUPQH%"2MK'HK@LMUPA6*CQ5)DAEBD.^0TZD3HN7YD5%P
M=P0+IVVIJ^ ,MUVP0/YRPHR65&+6U&V*<NY;"HTF_,C4C1OXB%;[U >26**%
M_>-7S0ZXB.H;I/=8QVZV!'$]K]X9'C_1E'. F[%#,KT6K&'MESECF012M4+B
M9,&E+@V-FBR+#4-,[R=B<501EN12U<##<NU50-W&V\LH\/*TMEDG^. ]0"OJ
M6[FPX7WF2..7EEDXS"KK]1 ]CBU6V9B+@POH4]^+2$,+GL69_T@*YG_'* K]
MU>Q:)_PN91S ,R"BQ\MB^*JJ]4'UHE99!;@JE#D,+WH.D%6G,@[C_L+1\XWJ
M<0#>TI1(7% 3NQ;3[@HN!O)(2% G+J6/Q,AFHY73.@C^\YX3]71')V1U=;8I
MUMU_?DF_01JP!-_#?YX]_O/O-IEP_/[X]/<33$W'YO%7YW^@L4@P[LJ7)FC_
M>";I?K9]/V"2B^!GXSCGI?-T=N).,_4K9DH.13.UTSK;HEIMC/)S-"=ZPD47
M5'JC:/,-^+0V9HML#9SF]F%WH7I:8O 5>60;C7?G:=0?;-1I]ZR"VWM5, '*
MT-V9M'SDC>1)45O[C1@3-GE!(32L^;NZBQE#YF[+?-]0*%EQ=0%R!^0QTW<:
M,"J$.]>Q)T_**21U>%H9#[H?$TT[EV[)4ZWZ4<T=/#P24TO$,6U]@6@,*V,#
MF'X3^:IC6H^+]DY,[C3''\#S 5*MCYV&# '=,\ L;L_3V#^HY15GD_N?19J@
M=&HTT<^@"3J-_8=?][ZQ<*"A6.30!Y*V)*0P=7J./(A^L8YJDM!:FQ&V&+A9
M::G9UYDM@S%&JD;5LT:8&(<%5A/(]0DMYULW32YTV$A YLMEL>LBO-HS ,5F
MXIC=!+OAO$AN$>5O?PD'Y">)U?K+":MU#(_RR:K;'\0Q")N?UB^)U328>K!S
M$N];+%-PTZD)1'IR,*/</7(#3K6CR),:H0@C&@:1>3^LRM#&1@H#Q1W\AMC_
M;=GY4$ZAR!$SG' %6M:5M>.HR-*W8_L_.1N>B.V4]_Q@'BBS% WPW!"MH.(1
M$#GYSL1;F31<JH&S8JM,^R0?YPJ=E;P0&G(7J-*%>SKU6P2<5C Q?,8FYLY/
M\<>#S3XW\Z>Q=BPKIO+MS#-H?0>,8R&P0=FTG2V:!%#1#B<^X4]@H^ E U-H
MQ6DY?-3+ 7"9J;91XX#2\T=2#7'9G*;T0]AW&B1A?'?QD>.=RS?(K>(<'G+Q
MKGJ>P<)7QI,/4=J.1#><!-Y=;LAIGA]LGIU:<K+9DO"=MJ1AQ+$_$\!8Y XN
M<F3I4[J;TVP]Z&PICBNE%+KOJ:<>&Z@]YHB'F/5%H2+4(,):"LK<TFJLX%K[
M3K/\;YSE>^_*.^B=?8(K8:-4_TN<]-/D/FCJ/NF(A3^D+;:SW?^N7NI5#ED5
ME@5U/5:0_@&(0^;$"[QPK.MD"?-=H=+&/GCL)@OFO*DT4<LUA?@43O)VBC*=
M=9ES7I1,V/!S[1><M+F>[,:#NN%Z$EL66P#/XD-I!T[B@%G$S4N##H!3R>C!
M2T:>93#ZUMR=6,W0BWPD.,LWU]PMZKM?1%BG7BY[YHG=*UE"I+@0E9.[:5"S
M&0I4P6NQ_N='"R-.&R0EQY6<]+<DW\WEJ6N4SHA'6+AN% L:SQ1/>"YAN1'C
MC*[72U5..UM61L4WVV1,EV\(\]\6RZ:P3N 21] VTO <?:OCA:AZH=LW:H\-
M 8'34F09U!&=8E4RSCAV@ZN<7_&Q&I[PIH1,UIII0S?4SJ#*KR6D7O41$GZ>
M.7[*\\7W+J".\RLT%78#]%92695($*F5C3])!)B9^H[L%\3/B":'^9:7GFN6
M_X@T#-\&#'_Z>EV=166YE(EK3F?. 9>'OA%]*VI"QC\8FPG$36>WCUX.PK;I
M,(&2,HX3U!9)<9C?,6'&'N^0P>J/+>YQCR2';3VS/:2;*?ZECC7MY:;DGOB_
M1W*1:8XV(O S!E0VOCP(RIR]%LG@*+QM%-C\P=%2WN5H=0K;@M] 5(2M>HX6
M.-)!$[;2PYT(QD>4-B)$IFK'4FPGGDD!"?6WZT!*7V7BQ1,&I_OI35,-P^B5
MW(9VM$I=D6\_OC/FA63<:,F2QRTN/U9PE6]%TF>Z%%>PP%4U(+/78L]E7VY6
MN CU'-975:F4M#QR<.\5OD>$["/.<RL??6RDY2]!U,;]FX7D3]R_W6C;8<F#
MK>;46)TS@YF''[EUC3PGQ:\*5:.(3O'OI&EX)9P7/F]:B2G"O1/.IQE1MMAW
MPAMH?IUDL3N)>H,/+( \V(TK9[B-U1GFK>V"Q689R)EE<KZXZ-#6*DVAGCLJ
M7]7$Y.A&M$X6=UIC;!-AU\+.& <HXG>X;-#> V]'P$R[NJ5^P/U"66R-W Z>
M4=^JV,8\>UI$$=CS)H]K4\^MFT)Q&_DZ13!3(X;%X17&_^(6A&I9-SNJN)"9
M;LJ(0ZM_Y<(]7[R\441W+2HAF3//$4P5)C#\2**[HX7!/!P2VQQ::0>,CG)E
M.0*PL9;" ;L"2L\IG>9F*/%KY_>8T"(^>Y8Z QGUFT(^,Y?EN]O'@S#V^XR/
M2V.RMQ=SO']W,V/2>YK.AU'*V05F12(FCMY?$H%E,FYS$1A;Y__Z7Y?-Y_]U
M@L>Y ^2/7\S#X^AQR]7__H^[(5M???$?)TS="5/WF]?HM.OXNFR#<7X=S=ZS
MJ6H!V=-7$IX^L_#TH_.3+Q 2M3N5$%IGUD!D@3F2U\)_MN!D]FY3=/KY :\O
M*UE- YV&9ETY0U=BU-'EF_'MZ4Z39%/:I+\ :+HO)O5_C-!,LNYC8_U[F+][
MD:K]?N[]3S[AP0WXU01]$RHQZ:2?+[[F4IOPD9J R>3B4*;0X?)(5#V<PQU.
M?UH' ]J]JJ[BU44P5IH,OOWF@ANDKJ0[:I2HR"]KUEH</P>4#__T-*S6ZV);
M<LXK)2%13M2FWK3FA)%+@S1)^LIPK^HP@R@N[T3&( S1BQ^^B5)L"7\0''Y(
MFCD2VN% >NT',%-(T-,4S!3"=ZK\*+FM2@\=HEYL*:@]1>:+X( _>_VR=9T-
M::_"&C)C)E&%N6FC#OA<VNZ%9LC3JTF)3N5P160:CS1_-= <WI:;C5H*^M0F
M=T\0!C=Y,K%:>:-,PV'95RGR Y,Z7-5XZGKNJ07!5[:BF&54QF+'2 ^"GE+(
M7;"C7/V0(-<QJ>67<_(LN+9$#R$TLH 45Q;DB2?0%N/-Q W"R>QSJT8X/+GZ
M)_B"2#_2,21/JI,-^(K<PG6EN*D=JVQG\\J;4?R$)%(V]:U1A\_8&*%I"A>E
M94"HZ/!<-_D&7;AT.Z:':0DVC<2TC72:@7[QOCZ[*9;QW:=5IV-\MR0E[J:R
MTB*(2UJ!\,H]E"D*_^>&>^KZ62=3..0\0FN^D%:U0DVR4E8OO63FJ*-T7;C!
MGUH6"?\T#;^?(3<:)#R*;QO7R\0RP(F=4P_S7NAN?,7+'<LZA'ZXL?'#@61W
MNH_O@2<9SKZ6@,@@W.V+_**'Q%#!THH!H'Y>@B)@==SY,-BQER1)!?K5DM,B
MPEH;7HH741N.G54/XL UENIFPT18R5!(FY8;B^&MA1)+>\'KQKHE17\]7U3]
M]I(9LICY*E&4DO7BO@<S&=,!IR:##UDWOX_1'?D 3LV46<G01((S4#*@$("N
M<5PNE=9MX+"$SU[7FQ-._.'F<Q?V#C-#QODIJN ];EBS=<M$I)(?!%NS>+MT
MO-VR N,)C?8A9F1Y7=?<0ENE>&[J?V.:MUJI*E5K.J+,- TLA\2\1 PG#"&S
M7NY8& -P-M7/'1COTTP_V$RK,*+QRRJ'LI<G&EO!TPP\_%XC*]:$'Y<,G2"D
MK4"P8=Y$V-R8P%)LV&E//"#0FMB .)\V3&P<"L1BI,;H#3)?=86I925FZJ=U
MW6N)"^.(,^M[.S1@#B45N[KA;F7IB\TKSE&UUWWPT G[O^H1#MV4]296_?[Z
M_:OX #.R[AG++*RY*Y@S!4W=MF=D'/+H]Q*SUFS&:C)>DRM/?$!&7T#-D9)M
MX@8:ZYU6_\.M?D[3\/KG/.(9ZVP(=@8@;2X<8CVTI$_.2DE*X2$^P>G8_I"]
M()KOB)BDB:0((NP10@PUC);FZC0GQ[9QDGE\.E\2.<W/+TX;E,WJC-F6S#+%
M"2(LT:8VW5@E+,^$::+E<UE!% G:,GR"2B?3,I[D8>M%;74,I/3"X0MD">/L
MPKY>;8K94 D% ;ZCH6.'U0_1(:TDH"(6><F;<9:P(G!Q(7K>4UF.6);Y:UVO
M%L_TKZ^ A&1DC/-21B[#5&ED\.!(W%,7./L6V:(%.8>EON%/D=93"3\@U^H'
MZIG40$#A2E@I5=&<K-B#[9*R0B%8G;K!LFC+CML\?VT.S@0UUB7'F<BNVE>=
M@_I;;T(UQ-=?TT_/PS)<ML IE%U7%*IF(+(.7"Y!5022(,NZ:11KQ:C?2$<)
MK%6$ S1#BCWAG(08I0T=#YKF2;8*2T+8'3]%2475'9/"C!;B8H'&FCC"_KPN
M+\DL*>\W2UZS'ER#XIG4L+#/\. [HC'7"";J@_HZWVDG?9CSIF9Y!Z:8#9$A
MEQ N\T;PEKRJI+LB=AF$WX%E[@&#1C@9:2 X:\@M_%I2.4RAEP([H!VL0KIE
MUU.ET=Z2P9?36$WJ*9U;IJ:6HFH6?N#NO8;#E4_+^,$ZDYU)"P:UG;*HY,*N
MV0"I-T.J6+*HY3 W4RG.D*7R\]149M1TI&4VK@-HR=GWK4K:+%..WU63W\)$
M$_H53Y#;VL*M3DR,"=3T\8F)\1@>Y=-0S7TU!Q?@JK\A+KAU $@@![)T 8';
MV >SL9G 1AQ,3J.TK7!>;,+ %./8";KA!$BHJ"_@PBP.=11HR@5Z99-GIC2)
M;$A#G6$_TNOLST-YH'Q;C$!5%GBU+ :WWJ"#D=O8^.[AH>B+$0R7 HO(6;U4
M7.BABTO/!*$EHKN0';#Q#&V[*<.20 PF<^&!-=(X8,"9C((VF3O7JS> J0P>
M4SL4K2!2C!&W[NN34;?._OTA6A/)]>MB+H3([%HT''Q0=3* *6)K*H"RDS&!
MG<Q_BWM?)O&Z\Q >H_3)FRUZPU>S2&']KB*&Y9N"C1E WK:.AT95$Q"2@/43
MKR_P*G[J)$)J)M#4N< 4?Q6<.F,X*(D*4HBVY0R*XKNX;[HJV6#XB?=V9!+E
MM^;=^FY8G."P;"N2B<,D[)0A&NSZ">!?VP5GAR]RV92K*\[];.L5RSM.U#T(
M(9&' R0L0>GQ"69!I,F!C)H,1,7"<4E^ O>4C5JM!T2>EYI;9C*7V/MV:?#F
M59TI?8Q?L#>ERXP>A)P1[T&".@L1$H4$1][[^9,<6S#JQ>JP]84.*'C.">5&
M"Y7^#\(FGD,Y&PY>Q'"5.;KY"AY;V9(V"?'<B$W]?>4S@Y0-#"=( 6%$R1P.
M,4]]1QWU'R&9QK=E9:1"$B?RQC\ ??P-F2=<UBW[OAU:T\STUU"$J4KZE9A4
M <T,^N =ZG+*>$O;'8138;Z/?*,,.O@GV?85\3F9W,Y9RY5<G'SQ]=\OL-0_
MYXS?]Q<7F319,&Z^6)4DJBD85 "3N(D4?F=]*=JSXX-AI*8\9][%L>,[2K<O
M&</,[HY34-P@=EN%BDTGC""S\L3WN6?8OQU)3++BK18.YI:HJ/^2GR)N@,3G
M*[V"UOU]#L4_4]ZV]+3[NN>#GAM-)F^&4;798QR$N(Q>02TF\SE_[[EI[IJ8
M@UT4WE&Y-:Z[@1<)-_9G37*S&85>BCN2$_U?%4AFFRV3MZ'^Z(WY-?DJ3#"8
M(GSFF*Q!C!DL+C!5HU]E8U;LB0#;'EZM7GGTA8NPQKUG-/OAEM;",]WW,?T<
M\J4T\*&9A;,T8V&=6K)OD&H/6L.1N =<C,EVC.Q>?BT1SI$CIO[%KR26.*J#
MS9E1DO8N;XJIW8)=$*+GS68J$SNTN<[RW!%<JX>G$8-N7AMZK/#!^)<P?EGT
M\V3N/Y(#R[O4\T[LP<E DXY.!%'4Z.(611HR4L*3<;UO@ZW(J>D@ICJOBWS3
M72^9E<]Q!2VV=-(P&]*VKTH2?'Y&%HQ:>&BNPL;>7O9AS1^FCV+7)Y8M^":^
M[<'91?NCB+KSW--2BL7Q@3LD"XX;-J+ZQ'@0YI]0^MHX>JZ2+@US?>UQ3ST8
M'ZHJL"K",N73;M!?4ZPI<ELFTL.)');]'8Y<OBZZO9Q"&B"/>4,SJ1BICPS<
M'VU$XQ6!.Y-7,\OF5-9\T.Z;*-QBW.V43.V8D[B$=:AWZC7%5EDG^ )?/&^J
M</T65;X<Y$7D&X:C9Y-?%IOH30@TZA?$:PF<]9[YOKA>X6LPTT_!OVXM5XEI
M^>+I)9#SE_5[?0O\_O'3&=_NUSQ/.#4;N%3>[',G<(/D2Z02HOFM>R(Z6ADB
MG/SV>EDBQ@?,APMT,=TU@T@@@H?%<_"XV?1]'YG3WM"F+Z[VB\]D)%X___Z-
MO/RC&8^RY>^4IXWXD'C#Y+BDYML.ZCJ@4ES4.X/13"X?\>#*QMR+T]0\++-O
M\(T)L[-D#PP-'9+_) MW:M_X4(-?:;(A>!V,N]H6P<RNN*G?&M<\,II=":/8
MHDH$Y(8YW\\U-DI"2Z?;DBCA>-O=!K_UXOMO'.;1R+$<W>A,YP)Q?B%9#/*P
M<,/3*GBXMJJF7$8RDK8[L^DE-K/30#^HK4O&5EU"2?],R3UI+@F) 5'^T_S1
MR5?X0/(2+D,FZ54>>)%.;'L*S$HVC1ZY.)M&@*?K$@+L9RS4T2#2C21W\#V2
M% U?BO_!*C-CG"ME/9KP<U?H5<N*DM#-B'@GR52<! H>?&M3OB7\03>V=:LR
M'S1%+6?U^FQ7+RF#(R7\_++5\_%^2^D$S4N@>4].T+QC>)1/ YKW8CU?I;'L
MRR4:B:6')U]>EX4*E AMP(;*3HAM8E0:0D^?QKZNVQV5-^;RV#'-[7#C5E!P
MQY,6'233PMT0@X?W:L(B!Q"Y1,+'UR44;<;$O^$Z.9<NQTEU"9J'IXYV;5R&
M9UV7S!;%ND@SJ"P%['E.JY2?EP%#Q*U\Z4GN!Q7.P:G^:\LYPYSZJ/ZF^*>D
M($U$E&7P^QJDH+KT;SPWD< C?H<5K%B=(/QG1,MW24RSP6> N;_3QU>Y$^Y]
M#[-2RCN+3EOKH>;$JJ-7:0],I&DVZ<;-Q+$FA;\ZT4L@."MJKIK'-^9X2LDW
M5NF*43$QQ>4M0<[ G,;E;KAALVEW Y1I :A&^P9O)N'[4GP7KD\)8D#1CKPF
M^)/B;I LN Y_$=2*%B[:XFJKPDX="\@,E$Z$XAY B["]BOAU!1H :6E[;"'V
MP7O4 F%FJ8HN3,89T;<40W6:;$%@T3#^9+(&?TD$67A[.J7N?11D 4'G;=B@
M]']6%UH2WWFY)-\<'4#,_>TB M#=E85*,K%#CY_[R[!9HJZ=OP+;Y$E:RW5J
MXV3;#& M642A$ @%J>^T3*0:Y.Z%\"GD4.,6]!FBDNA,K35IL']1SVP$S^3!
M>$38DB1]TM$5AHN$5[$1LI#$?D_==()Y*1+J<6:)Z4%(.L&K OEK !R4PBVO
M: #"HC*Z]VSB%$M0)@E -AN$\Z[/F>P$$*+GB[_3PAUJ_V 9)_I 40U(E$L[
M@@[?)-#PA&U7.@40(R+&Y4>81A'1[ Q!0\$T 5#;_9)56T2@K"408U&,!&30
MW)!3CX.4/<DA,1P$K8&2>DX3&R U&Q@(%-CI'LFJ9GAGW5R%,?J7K@#J %@V
M?=DYE9I@ . ZE:T>P9.DGB;)@WMB%^'&T^9IBJ\VO(EMM3%QEZ+?55JB9*GV
MT@Z\$;B;Z3A%@F.]U[D-]I_[\^D7T[2CYXMOZ4!YCY[R;/'Z^5^?__!_OG[Q
MDL%'QD?V^J__Y^S+QU_1G187%_\X8S188@%7X502B7$F @Y.R[)FF:&DY$*@
MVLMZM0_#D\/Z>]V1)LS19?FO?IM?+C[[^X_/GO_P]L6;#Q+P_Y&"]WM$_*-0
MFH[4LR_Q;1*]HHF0<)A&A:.S__G_//[35[]CHN(__NM1=(TLEQ\3\2)\D8?C
M$#LUF(,Z++'K?529P@:*YK,E/9(8>Q 6?X^%&DT7KT/;'71>"/GM^>+-EC1[
M&O:.FLW^C'ESH^6R_@2<3NIC.<_?V>-,2/""N6J(W_H:JB\N=PIH8=/DH@XC
MYQ;< ':GW3EGCW#DOA1=QEFA=EB('PK?=6,=N9'7DBB9XD :E(" 2F&[G'&+
MEB:O#CI(XSN)\!_N0X!D.M;)'B[!U1O?BD[P86=%4X"*>8Y/C/)5 $$S\7#T
M+@G<%8TQG1[D9_AQ F4&'99#PNI;"E,W"-_A*TPA<Q#Y5\ %-!VOT(J !?+)
M)*SGG:$V'.#JR!FI@W2^^*Z^I6C6RPZ#'-B'Z?A%.&YK#C H)V'XA@C+I@4Q
M]<P')!'I_+1^AQ1GC)--1LIS/XL'9F.<MT/G$ E"(2]C]!K++%#F8Y6N/\D_
M&/_YD>]'ARS]53!L;OM*V)#$D8K /K<3M!9DJ0-VBUC;@O=_>*55Q)SRA0;M
M \MKLH'9071XXA#H$;SX3-Q..:M;1O!W]:-L\?R??W]^@?O^X^+K?[[Y_B5N
M&34@(J.]DV:PYWS^(Y\Q$Z=4]*]\/BW1J@(E=LG!X[V D=CRX 3A<(&'R2]B
M.?#">1^^JE=S6YE22.$\"8<D_+OB?<G>]'3Y?+[AC7LOW87EJO253HGB8;)L
MSH&3KZ$D@ [6HKF9[7Z@0:6^FC#F"AYGA;P6+R7Q8XA>8@HKC07UO="->,F]
M3QUD(2S&&SV=5IPT;&,L.7=\&:N7@3I4/RO5:\YBV^:DFI;4128$M<Z/7!D%
M ?N4)*ML#))8X,.VC>U0YH-7->6.X]CZN/L!DU$# \ 6SCAN9U0.)%PKBG>C
MCJ#,%! ..:11C"-9A$F:(+YZM"V6MY,0R#\6");U\KU2EED<LJU7N?!G<AJZ
M)?M&A]&2'%QR6,-G-D5P,VF[D@[,&06NS&I/L0Y2*^5RG+'8'_G9]4+L< 6S
M\*9C@[2MVRXZ*8K0K]?K,^!,PSJ[R9<<FWGG,XQ;'O9ITW9G=*<XO9)/L2M>
MU0MFD-=+/P\OG6?\O\5W')3\([_<M]N: ZC%9^N< "KACH]P&,#Y ?S2AP81
MVSY-KCK('-'M^6#RJ-EEB"(J#8:\O6F5"*O=U9PL(C?I[!_/__JM3K<?#EEQ
M)TS]ARJW1R<D3D2[^*PXOSK/%M_^\^LG7SQ^=,+$/.!P(RL>MMKB<S+.E\I2
M\#G%2V=<U$.,1[LH!AH- A!Q+L))3SL-.U!F2C8Z-OW+5V_/OOSBR6G:'A+>
M&89'RL+L-*G-6M\Y-6J03_/Q@ H"\^Y#V$EI5J8.SL9MX6.B=</4 WN=HJ^^
M.7O\AR\R3<QB%[WIVYMR6VL*+T0ZK^OE=52B>T64<-_HO=_L@R>X93?+95T?
MG<!A#PLI1$1D?N1")*81@88(K[[)6^0Q5124N 0E1RM3W>T;2A0%YR=87@1T
M^#*%#>JWOOS;V[.W?WN!5?#\GZ_.'O\EG($GM%B"%OORA!8[AD?Y--!BL="-
MAA:"=$C7@]8[?"J,F+-Z O*P-;:8UF=6[.>)('<45#]P+(/"?5LD3T\?*<(Q
MM/B>35OPQM_&X#I$DQ>7E_\H0_3_-8&_LL6SX%(TZ+O[NJP%,D:>1O&J+L-#
MOTK*">'K?ZM79?YN\6:)\G7XQ0_!5#9=&7YZ.;S=^_"[77C\$$N^[+M-7;\;
M/,OK IX09?9CA9.,)0[(CP\;-<X]'R"6.,!/@$;[R"?57_X,&CWD%KL0>,<6
M5&$.I<MJXR;?,J'L2R\"5EZN=^-12;=,TXR;O7@>,_R 1DOH( PI'U-XGV <
MME+;FV45HU(+<D/&A!B>?9N@OXX\6:.3/55>*%M9 (3G<=VT]Z8K88U-,%^@
MP76$MG3+H(I(3?,I!55#U#!0 8CKD*(,(GHI+WM-J\L=@B=<,^#$33BM5LN-
M B76=L)B3QPX)*33]B 'VE&;DHV D,)E_&LI,K5]<U.$=^+L_0@P02E.DH#U
MV\4)96;WH,UDUF4#^D002+H%]%5I6E1L<S0O;A08%&;B"M+>3?7NY;O\"C^V
M80ISJN'XT<V4(<"_><:)]F S^1IAX];\X89.YM6[HM@I5*0IJ(HIW$MRK=A"
MXL?6Z5^/*0\5 =NTANNR@RNVTCKE(AR1<;PDSQQFRC%H,GL/ ^B,=-]UL\?G
M_(7T8[M-B14""T(R3\E<>"CM +NEHM<BWQU_ 0ZH7)M909&/DQ;UH1P55*TH
M\1SPL*SJ98^;*J,B^!XGU7'#K*-!I$7G+'6SAUW25Y08K08VT79K9H&"M=/>
M*.HR-:JQ_;:),6<F_H>[M+!:<@;A%LZ.)QXJ6[\8J"@Y_3+"A4I&86AJ/& ]
MD_-F0OT*3]HG8 @\=BNHNF7.\ICN !MH5@_.LQ'Y9GK?(S\K;/7,#IB*KT\W
M,UA-Z0 _S^0Y/DW<D-+DSR^"4[+\@^F4!(-4*/?&8@/T<\MZB5W9;<*6E]^=
M4GT/-N8H@Q(LH?JYKY8#YV=9WI0;U@<$B'_CW&34;ZNB R44U<)/D_)PD\)4
MTAD5E/?^1)@R<:=Q?^AQ9W]:O.&3X.&'&FWHBQ1.762ARB*>M=14]6*PG?QY
M76X8'-6?YN9!)<-$ (@AHY"R.@WPPYN:>-@.@XH(%?,!@Z0:"&Z7NLS>?3VI
M)3VLBP3>9FJL[*356!I?HP5C04GC7FL0FA7O5=C*T;-)Q"?*'N%LX4[;V%?,
M<>"1QVY$]@F(?:.L$'1F(E)GQ>H*G8FKH@VNXR5!WB[)P".&EGKBH"7Y7BS9
M"EUKF!Q;J+;?2F[E.F\96VOA&K+#W)B=+XC4CC&XX7/4E,'@K*__CBPD2FAS
M BBT/Y7&?YCZ'2<#BE$RD58)QBC"N"C?%',=0+UR5S4/F>1REB1@2&LN(F]!
M?B5=["A22IU$9 !617-%M+;2'HI.PZ[AMKDLWB=!_3JP?QTN7G1V7\JNG='3
MAV<"(%82<#0$=IEBE7"(L+X74X)S6UBS/U^\$1A4,ES:B8D1QBE^1P9XF!T[
M[EV29!S+._*TGIPA2SX34ZLN1RH ?$F31B+LI# RKV<4\]HCZN^WOSI5R3,+
M?0]\P1)M_)"T8C=YN4WAP*3U3N:A[W3Q@^8PL@%0XC;V4&7.5#K^:[Z)P",I
MO1\;YX''-]:+O<J8B%#29)HG;U6GB?E+70[.J@EV29T>S8=J.FJNS#5%>>[V
MM_%$A)MNT#8@)J$@V#$KX#B*1]YGPKG/@ V4/"?T@-,GUL>E(5K7/5=8841L
M+&&=(J:6JR96/D,'C%MNOABS46V8=#GYP8Y,$=N!8-5X87$/;EA8RBW!%8?;
MUE\5%F4G(JI&^6H[A#;>X%70WR.5XKT-7CH8@)R%XWVSC^.27F>BFNB'(AB0
MI2#^WUI.OUBAT.Z9MN@4H!VXDMX_3KX@-:_9%^19%CFQC+>=JW"O67:SN*+5
M*L_KWIRN09<OJI]K,/)JG=]= =TAU17J-NAUME>TZZ0'+0I(XLPP4;-_(FZE
M*BLND[3T@JMBV12<.!J67INP?-'B9DFHED\R.84%U%FL4ELBJDMAREB0 =YT
M\$G"R;4Y5"G])"%%7YT@1<?P*/].2-%1P4 .:!>(_72R(7V5].&I-ZH5<R5B
M.=2PJ*WAY!9!\ZWL0+Q"7D0G7@),-;&%S'AD1BJU/_9NK>_'FA-@XB<4Y_U(
MHE+&$(ECDHY/B/4*-]A=%)(3C%IW0GRL<YA(-T3$A?PU:^ZCOPOUJ.>EA#;3
M-L0M.=%)AF/VKXZMQGD5TTQ?,08[Q$XIOTO*XIZC(Z/CC5P67G:@(6'$$L:8
M:!7Y_5T__V#<0+=V[(W]KY-'#I.3CX<4<RBKBC68QH(> SZ T37,RUX57FP2
M7H8&TY/\=J?J[ ?CIN=-3WN22?'$12-V/-D>E%PYY8@?+O&8KT-H&!MDF?0"
MJ1^OR',:\8=;XTY[S\ADM*-,(NY3S\F##GE*Y'[DQ]]+(R [X #=E>T1ICT?
M_#LV@N%A2EG!(:I4"? Y)T%F0.-O\G93[7"1!T$-55"30AP6UK23$]1K#HC?
MPP/GMA7DY.U2C<D)9!;+-.,%T H](52GSX4;>*+RFE74G"LKX&O@*;E4,$LZ
MO?CINMQP=QK8;JN:Z-_@'QZ8,8@X[E6FC=U5U_,0B<N5'#;$QE48%<+E1@IT
MNX%>#C0Z>W;NG$H2I=6+3C-499CZVVKP0(VQW(A>)S(F3:'3+#>"1J5XY.D%
ME(@SAE%WNM].;'JPGK=U'W7I33.#.5SHNIF"^)0/)IN]Q8OUX.*E\ _;<]:\
MY.._*]!X6'3(;G)"*.Q655I%TKAQ/N2($1[KE@NFNA 8^T>"NK]P#O82[)=#
M2BL#-AN? )*;ET51C7+CWWYS<;ZX"/X<B,HL!_M,BDVTD&S-_\]\NWL:B?_?
M% US3*B0U#.G(V7W(8\1' Q"0X/'/A!0AAM.OHQ ;7$-IO*BQ"3>R<.TKRDU
M6EV!O'I;T#BUDE.Y:J!<* \I\<:R;(4>ZJ"IX>1#%<V?<6F'0%0B%<+S:ON_
MS8!NS6)37I5Q9^;A!4CNZY!QNV@G+9O8&P:*SQ]+9-W:;BHT3VR=KOTP*CIE
MAY[J/JT[)?9Y'T*^(J><+@T-3IDH("KDVC;\&"6LT3%[]9341?* ,T81YZXT
M"20&_<BW]]OQC+'4D/*:40N*K/)8]R@E"43L.*6U:6CIF*,')?(:J^D 3"Z?
M3;HB6MGB&0I/4MV,92G7CJ'T"BC@U<V*B7UD\NZQH'0E<;&0Q@.6WO.@4((K
M'@6%BDUR78"ZL9A:5OC_ZB+\J29V8VG$0:%#'\S19O_BD4HYU,<#@Z^UZIFM
MW#A, #IGV9+]@:?\?<5D2,AM58EC34?OQ-87YCZ]G/-7F=4RO4HBZBDJB'92
M&^710!074YVT,:18"R;E29,*4N/<Y%0V(P^#:=/VX7G9ZILX@7I8;FQ2;S*'
MES:=[!6"1_8"7'TNNN;4P\1B""P-3AE&+APJ4B%^5KF7K\FA\R5 2AH2[@&\
MMUN!,BJ:2Y4RV1,5C1WP*AA=WE53WU+?X-K=+$QCN4KRH%AC'BNF=''H^P%<
M*46J)-LN<\@.U^9&;&I*XXT'(/0-!<.F"D#UO"9GBG)?OV<JYN.VK%_O%[<Y
MCJ[((58MO@<3]),O'G_!:^V5Z)^^:H@VU$JJ%R0QL<+2?T;C?T'G&:WE+2O
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M&\[  ,QSRG%"V]7+=U+Z93DI\EJ.71[D6[B'- VTG<+_,V\!=)+(N*N*QI)
M)P1(4]^?'#RB@9_2Z$BX=!P.10GHAPLC=B+AM.KPJF@(%3ZX, 3AX>HJNJ#Q
M-]I^B.Y>6S:5J+4R=BX<A+)^3 )B6!EC_9 P+IGW3-5+A)76%'1'U#7&>$+^
M.A'*R?IT;[YFOI1P'D\.-PY60ODMD5&330 G5%Q#-PFM=-QW@[<G 83-U!_L
MH#(W/G'*P_'4;W=.[I4X1.C=_+2G%Z0B!+AD5F'KYIU0=R1$VV%#6&R0Q<99
MN(;KVBQQ>*Q]+290,)F:8Q>+ FWOT1.0]MUPP%;WLQ7M1V(3CLK(?],;'KJJ
MJ4A8(4C3<>HB6E5',P:C\W@7K)3UFGULI;2PR!4JT=S&,$#V8M.LJ8/ H)[=
MWC-QS9=?1OWR7NOEN$WU#,,^^@X*I;:+*D4N&S QN,)G/SV^O)K1VTKEW,PP
MO]-C>N^SF)HSL'U$ZP)=I"@ZN%U+SG.3,Y,CT-]3)3?5T] K29@R)$K(#M*$
MB6?+D-1Y2=6(H1T'$&^9>(F$S.DR7$"G<IUP?@]T@V1N1 E"<9=NX<X\@I0Z
MD;=,9VHP]H#/L$O["%DX\&)N:8ASE"^K.:$1$.>3<+4^%=DK2N'AFJKU3M:M
M;*-<ZZ2GZ\9;AAAO.SO"'Y\Y3/7!XJ)"AD-Y+G2S:'F8R\PNIZI1"2MX7"&2
MVP1/1 H4 WST74/MJ\$I;\(T9X(U2]JQ2K_]G,[F>I]O(D_PL=O%,!G(921H
MG5\TT!P]7I;UX!P;M E%K7@)7W:Y<%'B; _6I6:E^V'_RFM+2Q(BB;-%W(3
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MUD585'2(05*5.P:T_B,2-(-A2JFE5L$>G:%FPT"C]R1PME<5Z#\^?_P8'X%
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M-XLW?;[>E)<\3O2MKB@K3QU$34OL%[*DH&Y#L";^\^_/+U"'$;*+NHD4&$!
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M@P5W\&-(7=&#2E=B 7F82GI0:6Q\!U0SL=0 J<'51^PSK+'!PT[P-FT^$W9
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MLE,C__^Q]Z[-;2-)F^A?0?3V^ZX= ;%%R;(L>]^)4,MVCV9\.[9[^LPY<3Z
M)"BA#0(<7"2S?_W):U46"%*26[8H-S=V=]PB"=0E*RLO3SZI?@+^YT69<66A
MM%1R.M[]_.HQZ,;ZL0QP1\D@]M9F=\/5-AT1BTN#A>3XM6/0J!4^_!=)&N*5
MC?;9?]HL:I*9@&JHV[>[=KU4:!BE2&;.0K7C^I>:B"LM.<H^^$R7!08Z4$H0
M?L.NE@P-HQS"('JWBOK?7%2^9IQL1;@\J>Y\&3NT;*[WGQ_VD?N.# 9 SM()
MG0H$0K*1D?J&6[9,TU^X3$Z5>!0K,:_Y[W&P!0/Y.C!GO2HON[Y 7#DS$CT<
M-C(E)P4<H5G6$+5 &&%R2Z:E34%XS[YORF0<TC-,H6LM<G 5.U6:S49M52=$
M+8@$/AW/1%T/R4)-L#W*1 ;'XY4^$2M@;S!'%EOC:@80+7O"0_ET_2I5[\"I
MS&JNJ>CNMTE^U9ZS&0/X 54+O<&&0;2%A*ZN]>$$*2L[&(AU-P6-/OF$)^=/
MPYQJB=V6!HKMIN>"D T=4JD@QA(*#WI90:FT.0H(LM/#HR9R;S"7G^AUL:S+
MIGM=/;EI%[Q)M+,';"=Q+IIR19,E$&?41W@I9.[I<B;<GM+W)>[=/5?>R0VK
MCA&],"&;Y00_IFN^]U8GQVY"D)H5N$88T:1JS\* 4MRC'M_I&*-W.OP/+1)H
M%S( <Z\'/-G"1%J["!M/F^^E66?Z#WI"=)-2&! ICX>DB5&)K8_3IN+_FI=8
M%2+_0>DS<!=+"@7![Q[&+O+4M[ N2&_98/R0,'J2$=D[3ZH@6E<.,^%^IO0"
MYB[ =BFPON=E3;U.0O)V#--7R#<N\%/T),4Q [65(M#D/,V)^*4C#AS5R&9:
M_,*RKHSAJ,*<OF0EKSL<<G"&?8Z"CE!T\RW?PK'>+FY?X[[MQ""MFQR%=7OF
MYEI.8L2-RW)B+)EH*^F\R$@2POI0[EL(*8F$&_YO@48(3:]FQ:U(?@D-X>^1
M"TB3]JCE6)6:.BUW GV>G5^:42#%9^]<RHFZX'@8:QAV1<TYY2SS#EIO0J/)
MQER3I=J'T^>M*"3+P44\=>Z(+J79ELZD)0CWZ2\%PU.1"/SYDW+P^]..)G8V
M;82<R?5X\0?4YA^6E=%/=.'ZMX F$Y29Z++P\F%"<\1(D2^0<.>NS5;S;X6=
M"J?W:T&56!^$*97D5TW&%:%X<[6Z#&#4HUVX*3N()=LES/$D8L:WK*J?0C';
ME&\<41!?TH6PXB]:]#(2*N4IX.<X3O>+6E5R!2Y7'8=)<&>CU&D^W3%W$O(O
MUH(6<Y:EEP,U#-W7@MRF_";00]9NXUQ@3[V"5T8!4!T)M&*%7: D97B.ZR7^
M?*NFB-^<08WP<V:"VG"I^ZW3I&+49ODDK"H"&Z,<88.#91W%2XO$66G%J%7W
M#7=H^^Y[BZ1*BQ!(99Y!@*\RI[L5LY8*N"7,ZB0H0.W'56D-5F) J(Y#+HXN
MP&8J _Q,IR$(C@DO+,UST-&@?++RQ)BZ S(VB96,O0E8NB!E(3A5]PS708O>
MO**E<S>WT*Y"D=B;U,CD%>Q"H3#'<@?3+;@$1C$X.BEJ89\1;Y7<MX=53@O1
M^EW4<@?*PIR6V=RQ)"U;K;W %GO$I&KJ.L4SOG)&&N$*=V% ;3LNJWE9<>1!
MF,=](TU;/.K_R/!9JKDB-]@'(= I-2)M=!%KV^NBEPV^NP]%SI.S?7-$L=W#
M!LBGKK>]<8-QM=I,L)\:5=+S;4X%XX9-:Z0015DX,AEGG<**TI&X"81X\[4Z
MQIS09LV*<];-RJF]O+0="F,ZU0[;KNW@5X*I-;'DWDC(WS,B]*_XK7S4KM/"
MIX/-MYHNG2CU4-\@@M@3P_0Y )(5O[?50JL%K7[VG8O 6@'1X@I05EPN>*8$
MRRM;35%V/D\'T7&W/;U?8 EBB'@RX"/4$LC CG<4=T6S;S*?<*T_QY>=C7.9
M5 67MA6$H7#[K8BS[F+%6*\B5)FQL_Q"\'9"@*_QN1"_(YE1MO%"+]$S4SF#
MN&9"'3A@!-\H" UH018=+(1Q()L^04:EBMD4=$LB G_2_W!M4#-X48RK9/&:
MZA*$NU=3DC>92'CQ^U&;+RXHI.:7UG5&N!17@3U0:VOY^Y;O%E>QZG@&$ YV
MEE23W.,CHQGRAG&."XO6,*H IAES7_?J#>>E/+WF$CZ;HT%4G.WDZ;1YNH]_
MH31E1MW>G^X,G]S9,A/BX_$SG<BW'T*X-L-'@P-<"\F14>?WF28U;!6:H/4[
M,OULY89L=^"&.R!WM=3D>'=\N\2WML3H?R!B$17.4KVC<\; 6]JN^:VMN:O?
ME&N: YA<?V;ZXVT7_+86/%E%(^$RL!CZ=RZSNZE7;\%?$D/V:(LAVX2A?'4,
MV5:_W%"_6'?)Y2N)5;AF(K#N9<J85L[%;?7\K>V#&N-5"C8,I@F\=4-+GB>C
M-%^.UV#A?NE"Q3[CN=V96]N93FO>[<K>VLHR4^T-.Z-3,<!V#V[1ODS'U-Q6
M:=N;<OPIHLJ[#0]Q_489.PP0YXL(&0JC'X>[V!<TE_S;<L30,5O8!HP8@E1>
M"P(D(R\-8G1L^%#I4ER@<54O>9=K[F'1H'(Q0T*!WI24;2(D9X;P T^Q87H.
M8&;-S\+E<I%((^76),$Y*D><[2;8"F-Z?$YYS:K0  OB79TW?H0]66@'XUR=
M(N#@M:&RR@K"R]\XT.JK)V']YWE2!,M,>0JSK[A4C.ETRS3JR[(M0282ZC#>
M1+^WDS.7'4V;)G?5/GZ/Z-%9+1PRV+YPLJ(0=[3H4*HHSTA&>1 LC?2A5(I(
MN^S^L@#I5NO?%4K 22O*$Q!(6^FL7(*Z=FT=EK/MR:HM-(7'RL]=E&8L(O_T
M@:#MJ<T%+5'-1B1C<G1I2^0B.P-[)5$@FEUA6A9<D'0BZ DY-@&93A4"WV3U
ME]8YF+"VT(DE"Z!GE<]);$_'."&DH4Z( 40\H_N7??XM[>*2T4(LSAS1U+F4
MK?\Z^# (>!LXH1]@G03_I,Q%%.?WA$)=7 LC02S5K*$I6LGV(VV6Y.F5841=
MQ]QJWQ(2MQI@>TAFRO32,G(?N%+@$R%S#%@D;!,:@!4L(*2GU6?'>A2;72K_
M+(VT/'>Y!:E;3&5V=:\.Z&@W^ZX^E7+X"BP0;MI-J%^8M"?2NTS7-QX+RE@M
MW6OLEX3_$QO*$PETE>HZ$XU1R_<5_%BSPR2)E-"G+PB#4(_7VU/LV=DJEET1
M;4=<:VKR]1@*SS)F;5%)7XNORT,95;?WG-"S%FY,TGT>ERC\V(16 FDK)+E'
MHD>0J%[.+7>4[6FW *2UAUR*R59.S&YD0,0M-I9N!EX_S.]E-Z<3Z)=5M5C1
M$.%_K:V[%Z<'M;0K$(D9 !![G+;!W4FQ%F@P(M^^AJQUJE*4E(N0$T0)KAS)
M_,7@_+DG\F=]D 0""3Y(!V<P@0_RMP-7V"8XN8]T;$_ -&1(.E9!/.SK<VV?
M=IFAB3N?XZ#Q[P\[N!LJS*>Z@03Y6-A4P+>ZJG\O@!\]$SS:/B]@)N4L&],(
M3E1DY'=8V>2+_S^^./F[5O_'KOS?T4P$V#U[1AC60JL7F_/!Q7H@,;H25 VC
MI8.F P19,K+.CL$E(*Q7,TU\@N5O,'@Q0(MZ;>,XH#)AH&!-XTPP8UKTBE4P
M<<:MT(:$1KT:<XZJQSR6ONX@K8D<8!C7W+U7:P6U*L"U>_1%]HZ+T]:?A7:P
M+PXCC!<SA"9@&.890]<EA9Z<<9F/V(YMS6:ED(2F:_:I9^W5C5$[F6:[HT8M
M%0TOV% &)5*D5>!Y^-X<8BMI.>)"%_E>J#7J)CV%1RY U!!ZK]J*K%*N1J%L
MU]XSKY].D&&FK(H,KOM_93@9_-<)CCQ!?LX3T?CC5C"UOS;)N3PET(W46BX]
M1X/C(@TTF:PUEY.X@B=SV1'.7]P/,4!"!C4OFDX3V*8$%*+@]Z&*'8OAF5 Q
MFC"P"6$TWUHRA@K7L.;29U@!9IC*JE IPPFK#<6?'&GYJ87O40J78,3H#!)<
M"'5X52GOXR3%$B)?<Q.:7@F#$,MYLR-\GN.P(TB/*>3U2P-R2'1-9-PV&3-K
MD87,T6Y:D+8I9^0[:)7I#A>Q<_%>^ADC";6A2;.S]"S6 ;[81$MLUQ6'CPGI
MIKJE4>AIBV!PS#VM0E4W93M?I[YB[;RDK#!X=9FD(L1=S"HV,CM$!M;US++L
M,3J0J>WRO+RD$7FN*79S\&\%2)'#=/?P2?N#AF>*+_9W\GHAPMG;'3[INV'-
M3_47[WEGW _W=MTE>O+N_;&_0A^(T4=4GW&DWSEYYTEV2+BEM4M@CG#9#0VU
M-KY!IX9*N'VUA )C-W01F5&[\Z?MO6B':W/:K?S<Y(R?@V7!(D.U?%I+84DC
MF/.')=O7N_&C6,!9_'%-PGIH*=Z9(N\-/.7'P_A@=Y=*GIGNBOU37]!!YP&%
MQ',XL4M,81SMX *;&IQL-@[3@,W;H@F]L#F^@<V^CBQ)&Z\JK/]L#FM ?(Y6
MG7'TB@.9U/QZ&8$D-27T'"UDKL.*H%KTC ^F^@A<U\IA RB4<XIN:643^49]
MLCN(/EBSF<F'2"EA/YU)RE6M'7+16LKU3+FM$"O8HA9V.W*D+_<11J9C8.)*
MT9<43$.WW@Y$%I")E;5?;^.5%P5F/J5N%6-6N[PG?V)+ZH">OW8L[+PU8P95
MNUT27GMM<2-4]LR<0 4!KLS6[BKQ.GA2T:NZC6VQ.A:K<[#%ZFS"4/X:?$]!
MJ3+%5ZC0R%$,@3,R8I;6GH ;ZX1NJ$WB,.NBW$M6EBM!_K6 1SMLGU(+/<='
MO?/AE/>^TAB,K\<_/3X\<G;4BU^C7YZ_>^]-*5.%_4^8TJ2<^>?#%]T/?_UG
MYX<_5\D?67[E8%XEE]&#5VD&7\"/83'IP__^7WO[PV?P_^\=/D.\*/QN4M;1
M.]#599*Q/RUO?O7+N^?.K'N SWM3#J+A?GRX>_036I<2!3HYSXK$C>>=7H8V
MA-,=E[SAW>F[5QUV1JT76F>W=SRJ8-L\H0>N6FRJUM'OH HRY&^$@\4U6\3#
MP3;^*!%.@JZ'Y")=XG\1';T@>KIFW9[/=:/T6 (F$8$X&AX.#MRWYE@PAJRY
M=,#/S/=EYR,D9L+X"0;]QD16_.B_N-R7R"+.\G)$<6!*94@*'<T&#$A(E=PS
MSG!8*Y(VPV1_S(2QAB\P:0S'%O5JXPG31R[0RZQ?2R%&2_E?V]C(B-QY-E/%
M U &$"73&."2,?V'\_&47$"3A3GR-'#I-+868K! Z2)JN'?8/J@A5EGCPVD>
MTI6=!U7\8D*A0<0=1N"K4A3[?:1T\# HQ4EGLRGPR)K/B/[OH"/KB3)W2(R4
M0D&NM-WQ- RN^GD0ZA'N>SSNSI/F^DGF.9% &J6;E;?;#7U)5)U1;D9S6DC6
M"+1S)9K]Q;&S ^&<">&N;9"DN+UT<O4;W5I852&O1YNR[H2PLD9[6E&\$_SE
M"Y%MV#0!F@RBMSTK1_B228FF-EOM^<)DCQW3=D!1ETG^2Y;3=-\ _53OC)CQ
MG.>BLV0*@LT6]1[Z;H\\TH3<+,5T>E;/#-F"Z3>R[@Q8.0$9L?O,[-Y!R3VL
MF F@\4_=I>@:XMK,':C2ME:6@U__Z;Y\REE "0C0O?Y1AWGL" %^BHXGX$E.
MVIGOK?KBUQT:GM@"+'$OJV267I;5)ROPU,*KYO0>+![,[0%C2B3BP 1N2H%$
M2EHZS^(+=D8)ET!;W8Z1&B)<P7@$\HR'7!V&B"%5G] -[:'Z@&:[.HD,=NY<
M/X;:S1I/3=W?10LI^!2L18$=OAN:L,4\/IPZ:.<K=:+=^\T^%*?38$UX8IJF
M$ ?X>G*O<ND5_,H[@!L13:7NJ&.X);QU^<*Q5#3^]0F!1TJD],?D@DD)D:EF
M(U?]+71]L)9QJQ:[@=;=695, BB;1880TZ?PTH!PE&,F2J\:88E&N.$2LF0M
MFL!=/^%:.<8UOA@?8MC&SHVZB-?<DT%*1.%/W-PN!,PX>(PM$>B%QRSA>-VB
MT_C) $*M0-K+]X<6RAK+;!<F(=F]^KTM9&X*WI- O3,BO0*I>HW*(L6O)M5*
MQI$!:CAA7,%HLS?EF4^T7X0EW;&LO'OV)39V@6/65X<S5#]^8UQ[!3HL;FL"
M<F$?J95<"4D(+-(92/D<@W\8*'/NI7\(6R)T(V,6S'>2T)DC]UU-+><EN9@4
M?.%QN;S^(J"OZUT@,=%"7E6)/LMI4K^3;J5UQH)' FZ\>@P[/UV%O) LN+FU
MPS1X3YB!K#/V;]RGO.OX GUDS%3WBQYZH"7P7#<DFWHO:$1L(Z/%*OS?M>!]
ML:M3U':A5\'Y#,#:4QELN&/T]H:K$CW@&+)DK)0;+OB^X3BN']*NP-TW_H2G
M43"<,6\P8ZHT?&5M=B'R1#>=O7\YP1B/"M4?6RW=;0C1$DR41G>2:9[JL67>
M-[!0>Z(2H[Q#W6B#X[*8YAB'8;K50&L.P+1$7ULZ*_E8.W9[L%YT*(B2I6NE
M4/FB;,+[W17)!E4 =$ED3*J":RIW;- B.4"K*5B($]J+&OLX='OF2':\(<],
MB--ZB-D4]]C1GUR1,4K!%)TZ((_2P6Q/Y$TJ18C]L#YWB^ ACKZ>3NFNK4GB
M*)9Q/9'Z9"D''T9V3Q6#8%^@CRV#YW5)G#! 2"#T&.X$)A[5^U4:W!'Y/;92
MNJ#XXS3)N-O8+*O#Y+:OIG#$IKW8_P 4'??2NH\6UFAP%GJ?C;SY4D#GA]ER
M:^Z)^8 K CS0O"F5Z#[+T\E#+8M:<3QNT'#W=5FEF!C 340ZX]0^E]%F?/R+
M-.<R!ZLF.BE#B3$O-_7LGM<XH./K;^_>@V4G0;Z4:I5N I/&(F4A-!@<2*R\
M9*N6DKKK@4E4B6^SHA7I->'0J[VW55[;"*Q15%QD0]+HGMJF%'VR+Q#3L'3
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MV:()@\?S"O1)-B<72 $,] %'I$]>OPUCSZ0;%)2-=X6$[;"16U9K(UL?(M,
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M6QJ/@WF90$DPCGL9%;JRH%!J!Q6/IME=T."PZJ3*SS&=7RT<@**19SE0GII
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M*3R.<+AIP]5PERF53FN,CJ]:"A=W)O3WU-X&_Q@\EZ.!2N??, &K^CG\0^'
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M<#SQEO5+!!H<7=1482;3:4KWL+H3(!R32<;CRQ>TYHGP]BS8(:QAWVO#,_8
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M*U8?]JDH8"W,+G37[A2/1U;+8#A A&Y)2AH<'GU9E<696]H143N.>7TGX!:
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M77>Q!0EMEJL]S")I[-^*KX)!\]/QQTD_W$?YX8JR1[\V[ _4SOX.]8MQP%T
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M0!),2&_%TW_M-]7ZHI7*;:V:2)<,LJ],RP? "&73MMROA!5^W0OBY.Z7Y^@
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M#E*79?C#.&U6R?WS/TQW7(6!]#02N7$);\<^<(FY++=U>50;8FN3!HOL]F+
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M(VX&;&.:6* QKG7GQMQ 445BX$O,LD+NTW[=K)?$E.P%210U[D#BW]*605P
M+LW),A"?CNG^*7PRLV5X)>PE!FYZ+1[@P4W_]/4962]F,-2(&WRO8%XX9$C&
M#_?U@C,[:G7):8F#_+1$F6!XZ@F&^;$_+3/VU\KW/I,^4.U\$G2?\A2%X+R\
M GE]18;^ZHF++@Q%9!2!*.(>6Q!9+FAI[U/&_<06GCSA"4J'&5QE^&3(<.ET
M%1R=$[#L;?0=?.._A&86E^ &0QEO6MP'$3Q?,6'EIL/EIKOZR'A<"0A'>.<C
M#T8DAT/1'!W^^#RRQ;PIOH=<MJ['-ZIBX@+"DF3OPJ?4*#S\A)2FQ VXBKLS
MZ"(S.+/(M\'=P@@?X5'''"]0=P40(GW"%IZ?<7#T33 #!($HX($7D0L^M?D(
M,NP7JNC)% _*8A"."^Y.YVLG)(7GOQX>P8'JCRDJ8#@:; 9F8-X;.7EL)B+N
MC1G;KQ81".HV%AK5]CL=H*@LQ)85G&VP5=L!6(+F0X=9S)4&\-KSJ$^>]%R[
M6:7AX)3BD#=Y$M8J^-W0%;194\S1_O@FLI0W@-L[(]_7ZGM#/U4(U:0;S45U
M"X/N\*1-"2E;64E4H7L-6IN/DWDYD3^Q,0,#''"?:S&UJV\;B4U%ZF:TK2H8
M2&)UD6 )5[<J/E8I?PO.-&-T0EQGBO0%,PHW<D64TZTHNA4!.'L+CDO$$%9R
M02G_<,;&8@_"B"+;(&_+9%^!'LDE>TR,A_&WI(DR"G)0M@!&R$&^ ZS/W7;"
M&*( )+Z"BU+^US(F"I,;>X<GTOV3M9NQ>8XEP6%5T-->$,R!X.&" >^K*]?!
M._ 5K@B?Y+XF$+_DKQ[QS%$P-ZC[GK@ZD*.!/,$OXR>%H 45/9<HE^<C3*80
MYANB _9OBPB1-TVGKN)BX6#F$+&6ZY:+Z8^N/3;U@"3I4-Z,OC)=0<^,PM!/
M9(T'66K+7"'7J;Z0$SM2PBU50+3%.4:$0KFPX58R3UX8!74,0$FY6:<NW]W:
MLNW[']]28^=]S)!]F'"@('4),"5336&;8TPW?0<. E$99IHV(@KHKBE1W7-Q
M81N,7=<&AI!ML502;#HKU@EH@TO\,#-9;"#(EA4QYQ QZ,#AJ<C!K2 ?@,TP
MQ89+DEBJ/R7A)X^!Z-R8FFP"H@98FO*E;4R\90Z^UP[>RJ^)UH8@I+PT3,9Q
M*%_&9)A<'2;YQ+S%I*["?Z^O#N9DQQ-0XC(?-=,Q?SS()IX>PF.<>-3P+Z+G
MPU+H!2#+2PV#X.%@>5Q!?3+=/[D6CK]%J-TV!_28T;[X/GBZ)S]7G@(?%R6_
M*C^#5)IX)X\C"J=O,0)R ;C<WJ&C>6&CC<F3#%Q_](\@J2N096@>QS*1QRD(
MQ+U\(K(2B[6($$NAI/PZ@3-]=&8_2,USIZ*F,(?3])6K;LMMW9I<,&"*I>>N
MN8>21>P5ASY)&.Y[3IG6R82V(#,_U(\"@ L-"904V^6J9 +^$;2WK<2L@),&
M]A32%EA_G#=H$YP._#B_Q'R^*@AFC\!!Z.#@B#DHZ+#EN1(3&TUP$MJ8QI>&
M:PAQGL5&T1<='?2P/6",P)LADH9LK%.A^KR8< Q,:-L)4^(2EO=GKNCRUDYD
MUX]HH\DG6:]?@G1EVZ$T/L=^PQ60LA#$M=F",@[A!4&&I#D?^;#"(,]%S:3-
M=.W9E[A0Y] R'>,*<VV6"CJ$*'TR+,:Q8^6?H0+CHX\'MN# T^*5.A@ST5'+
M19Q8;(8OPY*T<:!-HTH\0Z,(TPCA*UB*M_RBS#A;"EB.9U2RIU.T:@5I@5,G
M\T&JLM ].LS%MM4X8.')W- 3#JHOH5F5LBTCC&&&E(Y)8P1RPAZ;+V;VDL$N
M+=#K71?K,Y K_05J&,JK8[^#R5#B:?DHMO<XP^H2R\#,@,7:4.Z@^D=GL"F>
MBQ_LJ )G8V)A+%A8TL[4/3+ (Z=8HF)P =>943U(/%185V[C7\<<;(I/1BMY
M2H'DJ%,HKE&$*!6,<W$GL$BNQ3O8Q)\!\[RQL-0@R+..BBX2L$2-^LK\=34U
M#;#]/P.M=!NU(:7O"- C*:\E3VVP-7W^I 5^-R<LK=8;OA.J]8)LN\W:<(*Z
M\1)$3ZJ@J:Z$?7/1-1$VSA6A;^I[PSVP$<Q9#&ZD%<#O(A60P\MT1(DC>ATY
M'/G5/',#=0@\IO]!$GXQT\?!.ZWUBR"M <QX@0:%O$Y.(#^I^I?$+P^OD_N!
M7,>F:-93:NI'Z,=Y<&Y-%TXM??8P^6Y;K]]AQP9/[KT/CMA["\Z95Q/,1?[%
M>N] =]M4I.,5:D7;1YSCMJ]HWPK?7P4D#JUI1FL*V#>*<B]RQ)%%=4B@ XD[
MS1!OX4.XR$*347C08^$4+"= 3QD=AD3UB;H&A9DB! $L8)$<L1V*/XF_YCH5
MIV,>!8MTJV0Y@\A'YHX^O $5MQ$7HY@M2]Z^>^)#AT)5E+QL!+D9J"Z$"TYZ
MWCQ*&9@05XIG\1-[Q#.C=2>0I3%I:<7"0$(#BQ4LAV( Y!]7YJ+L6-]E"?D:
M^*3#[8ITZL0UMB-^P099BV"CF5^NQL(H09+O'44)+\0>"W=$-IQS'TWR+UXH
M8ZS$!U.QJQB5D'LTKKB'IY5PI^?6; <9TR)NM4]*2GQ!H%<ZKZQXF79S?9DV
MB8)(4-SPMQ0MR>ZV:L-&/:_3:EA\#YLLM/;NAZR]C47/>;T:@[4'000ZH!7>
MP2*[%I^V";]HJ(*C!8Q.K]DRRH 4EZO*5Q%#>:8ZC)L@&6R/Q$B9W[/:\P?G
M8,L$G^,OY:,3?#)2>N'3=M'BWN^84<-XOG*N)MA)OZO;.87T89&'70%%\&.6
MD V%H^[_&Q4G@19,3MN5L1DK23^AOH))Q.F)&MS\6QVQM1+-__<"<?Q0,0-%
MA.NSCH,.1U'V9GD\ISK(]1<NI2"%.])E(ZM2]^(]BZXW/-%<49!% G-@+'!3
M--EG )_AV#-W57E-W0N&O^V_3H-JY,@TAILX%%;AF-14=?X*D641::-"O>8W
M+_0E5_9 F?7'W/4NMD:Q S2[50[;I2K<(+#12%]U1 51&$_G*4M@Q)#G%IY/
M*K/M./9[+!) [6Q$DE]4T4&*+@^-":.%KX7">A:W[T7-DH,Y8A$.>0( ZLB+
M!<A 8;Z@QY)*P^T(,"(Q;^P$8P+YVBCFELHBB-.7YR9C!*K("W/CV6V"-P)=
MS$JTC8LVRMW$(]C3%+W((JZ96$CH8K5'P+@\GV)ILAF'&C>DZ,/5S&PX4$T0
M [HC/"0O6^SWZ>%GC&*]#-KB]JJ(0Z+%MB#<\<OBJ "P!RT DD\67)YZ<")S
MWUJ&64#PI\$F##TNBI-*=(EE[_"D$!9C<JQ\#BDGH;+.9KQ;P(R;ACR;B(RQ
M?,F2=#D%E)FFR5%4N1=/(H6ULW> N[V(#"G^;"%^@L^=6%,#RI6E"E*; M/.
MV$2N1UE,OC*^E"P1;-@L2-L1LCA?%*=P08[T4(1'&P\LQM!AQ\^"N. D<DAZ
M1XF3*Q[Y>HH;Q$@BJP?<BAF>M\T(-'%2X;T1$X4BX>/#++>@#*9H,0B2*_;-
M("FP(LY3!704W 62Q?4#E24=G6&:7;0Z=*%ORFRJ&B[SE&U2=8?/V,A<G&R8
M]9J'[&2!E\Y/QD!1<%;\)VET<KSPOAO4X63$O'<L''-7WA\%+(*R6IZ*EJC(
M]T>$)$_DK;E\20FY&,M@JRNW?NA=0S_ .C> MJJZB>Q\0Z@-]BC4SR9T=$61
M0BH=SEE#UN)#WH!#2.<I]H$ T4.XK#0&C2]&O#T6^ANQ6.X\7ZL8SQ)WF5DK
MJ=MA+Z;U.R 8!QFG0N]*/F@%EVJL;)\BW?S Y1>$<092?@TL,7 I)^.-13+
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MB>U$36?XQH(J9$[J/)*1[I2L*B/3^%UW_^2L0:7#\<1%T6B90NK8CIAZA8
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MZ?^I?$)<:HTOCS,<86M.)O1W\\MO0"XS)!<@%L=\XZ,6$8ETG?))W/Y65_X
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M@-CVP_&_X= 0&E,+521^)O A?2:9T^((5/!&?F O+.#L(=?<@3X?6(I\\:%
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M/E#\)\+!:H9ZRE<_O+CJM]LJ'$?>82]0)$/_BY2O)BN&R UT][N?8EQ+P.-
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MG>8=18(#E?!Q8F7@,7)>G/*YKW0'#-J%>#Q>C\?C93Q^_W-A<;?9+2TA@[@
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M/WCN_(:KRP"09#3FDJK._$A9KYMRW&FC=3-4V\-\8[\:R4=RHHZDGF?/O6L
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M[=X@Z:-)>]MA [:U5)%'_.'%U2"?;-*DMKVRZVH9YM!T,&7"#[W,=[91@I<
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M"]3M&QZ?A]JRO6:<;C8+JHM(_?%WUXUVT+NX&JB==C[K6NK-QX^ V^O-^T=
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MV),GI]SW^"<G D[DHAL/BQTZ#==:T]&-J65SO0;4+SH CX$JZ<0XG/8:JOP
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MRUX+*>?]3^9-+)_1[N,?8W+1"@#1;6-*,Q!$OC]#:C-,/%CL$FB$&0"+/)1
M\#=:U-RX3M(%F]I?XPGER*Q@!F(=&<2?7'KLIN6Q";" //5I)?R2IC<E_/!6
MO/$Z>F'$,M^))V<Y(P!K@MSQ$31GP-PB+- NKH)'-X\"T5+]9% +P83SGPA
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MF7! J<[DB3K+3-SY6(Q7) ,[^I5HF9KS5,4MXD"$DP'-<;1X96 LS$&B@O[
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M.1/2V[$-+/A0#Y'H.KP/_4#PY5]1!;=$$V2TY>%Y\5)>I%RB/QRPPW'/UY,
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M7NQB% 2+UZ]>15%@OV68(,G">0MD"(A+1J+;H0@Y-A3PIT^QR+-='UVL&8[
M49W&H_=:[5Z:?CZXWEP97OX3Z1_HF)?9* ;<9Y*N&;C8/ -40A3NI&JHHK+
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M#?S\),%PB/1%\GX<T-L>CV/RVP->/)([W4Y2C9<XN_@*T0Y>!WH+-1E+B %
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M->W6IQ7)' ;9P!68#L#M@B4AVO'HOQI5HNQ7!T@Y-FT.)#]W6FV]UZQ2_^$
M8-$U]$X-"X1%"Y2"EW&.(?WW/.:P3/->+X=P?8=I-\G ]:.8N_[&;OAWGG_#
MO_H%_^<<VK8A:O5;G?NPVY];O7:^\L2>;W=)@9*5.?/.:"FW/&8A'VFW?,J=
M[^R_?.R^1"+MT''_W.H\'[MW<;L]ZX"V:S7Z&U0I-K'C?[C1* BU:XQ :;?!
MA(7?V?.LCMUCW3^WNI9N'HRD^KG5;^GM@]ENJ]$NH>6*E20^54L]JJM-[&JU
MB=Y+JTVLQ>RJEGWV+6KD[#^5&^*HS,4(X\4BGOE%9/(Q+XUG,HS=:T$28\J
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MR428ND,YN)@GP;W@,07(;L1M>XVF::X4(5W\O=5;'B"MNBC3PNSD;5Q4MPX
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M:D"H82P:MN,F=6P@3;@F$P5)U&7\LH@SLN,T=B 5,C9KRTE)^3!H@2A$[=P
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M\H?@NSA+$#U<ZJ*VQ]QQE!:;E%<!I&Q5_KUY'8)0F90#FI?E'GD,$L^1RK@
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MWS*7\86/5C^]HN*)OK'A$+DS\&O7$V.!F!<>%S7)$XG#&V28*[*7IUFH=AW
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MV*BGI+8 4QGYI30 Y1?!E\[@YO:W""]+J],5HZDCWD4\MA;B,3; 2\^4ZE,
M>F57&(&@+P'5")T%R_AM(I]3K1C$@\5QY/5\+'&>K_Y!+>SL_R0 [ID*$257
M\N?A+&#W"R7RSQ^"Z_S?3T_?UVWU6]T>;,3L]-JMGS;9A&WI/=QS8+V W,BA
M;6#8\52[>L3J/R-W0C>-01=@KFJ01.Q:_"YZ03*?W8M>0/CQ1I:6O\U*4< C
MV/"U6B^Z3E$;^7<2Q>YPNB' O P>V]T#I>R2<L1C*LLDR_/+)HRXJPD/\:H-
M]CA6$C\G3):4NL"R^[I4(F@B(?E='Z89BZO/48+ZAVA)EF!)G9#+?E$(6V^J
M!8^^J)>#S2%G+TF[XDIU]@(]3O(PJXG1_JM:7'[9^87*-I$EH\MF][".K*"/
M+CM#"NG)QMB1+VW<$ QA(=C@F,J*/+RG)I%RE!SWIU::LR]%XK8W-84 ]N=[
M/(I$AYA'-T*P88\,H"\A^D$$A/A >GE<GDV^#HPJ,2).>,#AP&E7'P+MV $U
M/QEKGUW0RNR1#YAW[V*/B7/?;H"X XYYPO#8 *A_L*D.Q.T\!H&CG0!-Z/";
MY\+,OLNT?JO9 79]]L/FDYB6DS]@O!_FH(R[M4?<26!/FF%])0 8UJGL8)@]
M#A3@ 8RDAA?X/K?3SNATAD/7DP5O1$6Y>]!31%4%8#M2C\3IOL"0VNV1I;TK
M/',9-#3+LHXTL]OM6*WW^.@WJDG7(J';(BTX!;4"X# (8A\ !?"913;B# !4
MTF+IPCZL[0L?A D6-C'[8MC-=TM\DB',Z9+E=$BX1EU;L>LJ48N>U10J=#%1
MQ. 6>G>4V!74#X1P0Y[K[=F):$ YRR]D(2U "\!]T35.'I:8L/QX5/$ZV6Y)
M%/1"$D,)195D:/9%AZM:O> 0BMUA3:BLN3RNX<%UT"S#3B51X,E&MPSKUCT$
M9*1,@D<>"G,,J^6(%GKT';SRR(%1L,(<U+6D9'2"%AY>7LN1/7X[33  I^4X
MB#6L@N1>K!A.*;1=T3F6YLQI3SHH_*&LL:9Z5-&$44KF; %GHHX86;?XS+HD
MAIOX*% G80!X W]X[#'255OB"&T[P4X+7(MJ^Q! )1@%RYB!X&P_1&2[F60J
M2"5E_8@&6S3Q,ZESH8?W+<FV*)T7DRY03LJ+S697MWHMO=.VELGOO+PL\C6A
MTJ?,3;M=/$@.&Y2C@"!/38]3\8K'B6L+%6**4C=AH74/C,L7/*G0?W.54G_Z
M19*>:+8^1WUZGLK)\,NV1L6S9BAX\3 AMH'C8Z$T#1;I2QE9::@-D*J6KYFE
M7"N2&ZJ&<HGRI\P@5I#7@FD@.3@6(\,E4;>YD*=",(<[*TZ5X]1/4.=A%N_J
M%.%1%^_:]^)=.1?!3E1NZEH-H]/?MGI$1L/H+:]'M*%%69LHDO2JK*OWE$>%
M< C+(R$!S/I.WJ2@SEL6"ZD&#E$!;\Z1!"+V0 %R7= "R(F8 X\G/''.JV0C
M+"R1L&J>PMAU'(^_O8N2 -;^*QE#7TGK"O-NUXVF;3X-W)>&KM]@9:_+=E,T
M>8/:='-*C. V)U^UDS"((O)<? '8:.?GNG;1N&ZLQ6:J4+*NV7QNJ2GMG7$P
MA:;*C]-LZMV.I;>[YMX)BXH0Z#?Z?]U$9MKF2?D,G:\N^B.'Z TGBYO\7U]"
MYG^'Y]&Y[T8Y*; [E+U*!;E-9$AM(2$87=WH6KIE];8TJVP+8=9K6"LQC_WA
M$;]S/T3%^E?.O'ADH^?NA$VP*XUVS<+8WTVN<3@E;!?P@+;>[K1TT[ .51WH
M-MJU.E D]8O@/HBTKUXP8-X.TG2KU@16YP(PP1;GXF\AS+H-<[\U@=_=AT"[
MFF!^N0B_D^W_JP@)1L(#H.T@>VC7(K\ZL>\E!%8EW?T1^5^^W6@7%R<[2+6=
M6JBO2N>FWFDW]5;S>37+#A)FG8:QWT(=&R8'3I SWK^Q"&- %]<[R!2ZAR[*
M3=VP^GHGUY;OP"#0KIWY)<[\_V+SS MWR+5;V^6^S7?1-=>K)?ZJ[ "DO='!
M*XNUQ*_.0)IO(O$WD>9Q24GQ9^FUBJOTNA#>055WBEY?=*SIL8-A[1<LH6M?
M7]S(SC7TV"'>W:]Y]XIGWM*-%M9MKQ*'J4$F4EG>B'5OC@^XOL.TFV3@^F"C
MN?X.,@*C>> FFM7JZGVCBD*VE]O_W\,TSFYYS$(^TF[YE#O?V7_YV-U%XETA
M6;*628+<>SV]V^W60GPM#&+G^, _W&@4A-HUIS3[8,+"[VP7]7GC</KS+G"M
MZ*V.I1OFP:9)':H@G^D_O$LTNT)N8RV,A#,0LZ&WM<;F%L)KOX5W24_=72+_
M%=(@]U)B6>VJO5WV<OL'*K 7]*+=)<)=(4&QED/">6YV]';;J 7W5@GNC>0W
M/:</[%[R___Y2\\TS$^'NOT#%7^+FY#ND@2LDWUKRW6+V,/.<8&2-J"[1/Z'
MGM9KF;V*U+R7VS]0T5W:/7.7R+9.V%TYJM1]?OOA@P38?HOMLOZ5N\0 5LCZ
MW$O!U:L=SH<GMDO;/NX0U9HK9&C64DB*[;I61BVVT]T=/Z]3C_;.L%3_BO>[
MR#@.O91F5^_WFWJK<["5-*W2R[<+>ZS.M41YXYKT9J-K]%<M2=_O-?K-Y=7?
M)3]3/TH066*+Y6Q=[%4UDT!">[JF<+7>M697H8UJZHC?;*:IX_\N:NFHG<O&
M/U%YXZ1@J%$/,VK#9OQ5-7>*J?#YHF9L%;M>;@F J$_QDN:^GU7+'98V0*/^
M9T/74Q>]9;\K:EJFNKT8;=FR230&1AB50GBFVUA/]>,Y 6'D1C']^H[)U6&;
MU)ZE6_WV4ZV1EA2+%IWM!N^U3J^I&]WNHJ'<*$J(+R38QC/?;6H2\J,A-M%P
MLC9352:^&V&[/\(=_D-VY.KT]9YIK;X&6[9Q+%O+@-LLB;AH3%/R^YA-J=G-
M(&NBY:C6AH"/J#Y09Q\GP&.+ NTQ2&!WL,#$BU5O*]D=4U)$V33OXN">4Q><
M%$O$2Q01[G[*50P06LILVQSXUA8-LS)=9=&8FFJ0-EP^T?NY9D,X0=9KL=_H
M]U,Z7W J\)-?H'YW/.8.#H]M%JGKT;W[@#^ ABP[1U'#(07MQ@R:?+T62')Q
MHAI"WL,B0\"3B:AHBDMX"J7Q5 ?YQDK4=TRT'--S_<9$BS,49J1NP3/E#<A$
M1^I(-!%UL1?P">[[GXE:([4T&V/#4 (A5\WW%NZM=)4$XY)E/GN5U%(L='W;
MG0  !TD$W Y8.)/=)L711EG'-M*/50T+V%JWV=9^!=ZHW<8AYP"N:^8%VK$7
M![IV<JSU6U;3V$46O[A!-_&E?(]"[)8=#)"_P!D-PV \VY=S@[TM?61$0VRQ
MN4!FSTB4[@*)HK6!\39UJVL\)4O2HN2WN$Y8KZW=PA' &\1?C$_9$_E>I%/M
MU(ULI %9L? =/FXV/WVYO:6_C$_O=1)$AJ%;;5-O/2W6THGNL"$WC^&!\XQB
M<)9G+^KN_(M:E9"0]GNMU34KKVC1++??CM-)X&\U1T,[>P :^&:?))X7P EC
M7\BL/^('8.?SQ$\,1;%W+/Y()WU[JVNX?%HV3-' _NFYD6$<VV/N>+&.1\PY
MXR$ZBF?L$5F4B;*Q&W">Q'<1M5PTA+#Q'0HD[OJ-^?KUHANMXIAY[B8>*#2_
M+=G)2YG9E<^S15VS\/LC=L*]1<@#*BN.UFHN:=5^F"WJNC,NA;I%W;ZVJ%M=
M8J^O:VI%46XM%.5K<=]56]4"0_'#\9.F8FL54_&4VT+3M QZS2JO_;OI,YK5
M-D#&-SN6WFPMM/641*W0WT [^RH5?R59?__UY!J^+>H5+;W9-_2>]:00KS+E
M>6ILY.?<(+YMY;$#E.:UJ&8?>YL\>0AXA"?!44ZA4S6N)?#!A"J<]TF@Y>9K
MB!&^H4$F%&W"DIF7ON6PI&#(E5B<$JGF!RY=SK>5AH4ATO;HF2&9>T!LKJ&=
M@B[W.0">\(]@1&]<NF,W&F'#YA&U[<41I.(H;-!(C8%[I5?H@U"FBIJ3Q@:@
M4Z)! 0J<;_.<\H3O*:T*K4+M<SAEL'=4HH#Q6*&C??&"(-0)<_X9X+?J+PTD
MN]%[32-QTWC]KK5#(N<I@6.:S_)-=A99DBW=Z%"UPZ=(7/2SR$K9(YX)1\[O
MVL5U2DTECQ69"MJ,36#LE&M=;5+11$,5V:5)<S/*7_'KC)V4K186^O6Z0/IE
M3WV]GN4%)6R@Y,7&[&)3CC,''?'([#2S!A:V[0ZTW.X6SU"Z+?G8"OL1;S2T
MXQ#PVM7^<#W/96/9Y9*-X,\_F#>./#Y-F5>.:Y4#D]Y&FU:-YJ(_U ;R" -/
M=3&?60&],[.)1F&0=%"U'C)#E;&\T%:6#C?"N<6&,HZ5>E]++&:P1H71+<=Q
MR;:>M7=SS+H,,@34[&P1+(9VP6.8 S@+2 ZP3G7M<^**YO$G8/@F;@RZC75D
MM9O"#$;CV$9GA32%#;._5WR[O4-\^[5-A7D?X#:JC'EIDK7$>%);K- 41<>@
M"#U8^+$Q]S(I<]G3A5\6,[RRD>_*E;'9Q2+K^P=_ "YPREQ=>*BT?R08 2"V
MY-HCQCWM9,3P*S_PR:A_' 5C\A,"P;D/KI/ >N1D09CG_4M#!0*NY"B3?C<:
MMZJ7D%Y_F2YI?P@$2)211= W^J9V,8W1IWO\P/V$[TWDH7/@D8<[0KPA>><I
MSFG;P&Y@%"0#8?<038N<+8'+\N\H&42N [+3%;Q ]DT!_6+@WC,7[/.&]O=@
MY*,&0%J!JJ:L$QR @%R2A<K4.AFY?#A?B;DP]+>,</$5-;Q #0S18>@:@3V_
M!CU5:B8A=X*QZZ/))""DR_UAU!6]^,!R[X'+APGP/IWZI8N@RF=%TXKOI8Q0
MKE!'[@]?(7G!8ZTL7BM?E,&"W);NYO8AP\ET')XGP\[I"FA.V8A<Q%')&PW'
M!!I, &#./R#UG#1Z<1]R@6[DQ 3N MR,)EF^P4?0RS T"C_2/(0FH0/J"<\$
MXIC].PB1@^)33P(-T(3&@!_PY%*8 WF&1=Y6NB*%-#)[4"B9:5S\B=WK>0$P
MCT?%0+ N887/Y?P?)\%X@B&78YN42J/? JT-X(_\(M. B?#%<<ZR_ ("S 5-
M2B@2:,ALM4%/'(^I'[V( '\.@ ,!<G\[UII@!C1WD0EW#YP)%]2LM%W)4VK6
MDC8UC9(?P4R=MT259POP<<EPY=D1L\DJ^;242FM4JM0_0C9FX7]IEIL Z#+6
MSD"GTX[C[RZ196J-JH2.B?+\4CBE9*<RL5BD).7VBYI4R#/,6*""+8 ?CKH,
M3,2-:00G%R^NGBE2KK\]:REPU*U6"[Z R7-:F]7&YB=SOL%_HE?0-'>1=_1>
M.SNP_ZK)@1I:35@4LTK^Q'Q+&NTZ&7BN3:;,3(CCR\5M_M=B>,7$1$3TPKUH
MUJL'L*ON^:+9\S_GIK=Q^HJF8OGT?\Z&<W"V/V>B%\Y[S=";1E?O-I^,7RR8
MIFR6S,?XY==O%[?7\IG%IN;,.=#BLE<O&B=+7\[/<>P1[P/%6-=$=8)+8 ;!
M!,PSM+=$S:Z_-[1?>1@(M5D\]1GTU-$\D\RN610FHA5)]0G$%;*/?)X;_31G
MKZ;9+3/\?6;S(B1"&\ _U-K1E9<MFJ(FM.0J#KTG9ESHY1.*Y+Q[+UKHWQ,@
M4EBMW!3+#SY/ KF3SP]2"0.*LZX&Q1)?[8)5O.:IYW?^1L=> /8KGWO*#):?
M]Y]Z=LKBE2K'FPX^#Q$!JX5GF)OC-0_OST9A<NEM%RM[[NG\^?I'<E[M3,X+
MAW)>_53.9X]%GP7+*?-=T%#/(LH#7WA(Y^LYI?/&$GK"3V)=SSZQ\U<\LDK9
M@-7]D!BE!ID'U/X-?0\W3B,7+0%CZS;FP$[*W)"M7=1B^PNUV'-?WL:P]!;:
MA>TT8R9*!O^6]D,P09,F$E<C$.6D[8,I9[K*6;VY_4T^@:9<Q.,8?T0]&,ZT
MT]0<-BWJM*94A7<1H$;S:8B:HNU,#<\J\%Q\"RO#4*NM&TVKAF<5>"Z^\I#"
MT]"-7EMO6ZM2_-[";'%N:0JS=B'OY- !MC@S*F."9CMOJ!\ZQ!;G).387$^W
M.OT:8@)BBR.H-5&6 FQQM*,FRG*(+?;Q9K)R Q [S-M'O?KVT7:L90MO'[T9
M1ZA@+_=J%IJ[8%W!')85NVJ("8@M-GCS(;X2UQIF&Y27NE+?SI>\RJ<N84;A
MW!-4%$,\PQWA1LN_T]%;/4LW6ZN>WCJ-[UPI(\-\_7.<8Y_=4H%U]I\$<Y(P
M78?[D4CFN/887DY/LTJJ;*'S!CLH%[GH61T&GA<\XDF+>E"3,'APD6A5K95\
MCLR"RXCZ7-H!99<-"6&Y ).=!],$P$0.7UDJ)/!E[146\U6._8U+6#6;C:;0
M'U:I8=6&'_KFTAI6U;^W>JV5WEBT**/5,-O+"VO5B\H6U:E2@NR52BJNIZA<
M[RF>)OIW(?\ZP7H?03C=N\)ZU6!PF:B:/K=I<0R1E::=1U$"0O(WK$MUEJM+
M=94KBW0EA**N_:%*0E'V&4X0_6T0?OCE'7M_H)#]@SYPYXC@<"R"[O1W"LSK
M$'02^BH8TO]RH!6?)7CI@P(Q?9@%\^!0P9PB,,$A0V+Z>,/'(-45-(\?F.N1
M$ 4A3]]\2>(D%)B.2=CTW6^4IBST'?HBK_/0%\@W)-C/?DC5L7QVRF*E5&\Y
MDI>,?<QG>R]>MXNG]MQ"UE(9(%VAO+SC%A:X+3_.17IFI!U/4%L3URANLT3E
MG6Q?\?[="DW.UU;8^6FT>6G)Z(->V6J*DD;_[Z] HYLHPRL%TM[)FJK5V'MZ
MV^KHG?;!-DSZV6ITNX>Z^;(^EZ_4?&(WR)_DKG;\R$*G"@^H6Q((KJ&W6Y9N
M6E7HI@;9BAUE:X ]ES7M)@=*!E1>^U!%$-9'[_;U7K]*!_*]A,!!:R!=O6TT
M=<OJ['L#K%6] Y=!O&D/0=F2G^LA:&V!>Z!^_T4&_5:+T0.WXUMZJV_H9JM_
MJ #XN=]H'6POJ36:\5M-]+7U7INB-<!V V![I&L<NLE>*QN'K&P8>J_3U3LS
M+HO]4C?*C?6[BD1?2P'AV6OI[:ZA&ZVZV7-USM)JM#LUN*J"JZ];W9[>-*RZ
MD^YV==(U>K-7-O";S7327=(H-KWC@M<UCL><FH%2)B*/L/BCHYG-9D?FSF%;
M-"Q+\L#)18O)\T9+W!E054?IF[/QQ NFG N7K7:=A/:(1>(E[1T^)NN*G=U>
MIT7Z*UZ%V2JX+NO.R'/0P9JGS*5.;VKK'.@$JZ[Z<O_BXD+D8JF=21)B]B+=
M1!"%:!%F?IK7NZ"F&U;7#=%9CNWI7)D 265[0]CC$#NTY@9FY#3(E7#-E@OC
MBZJVKF^'7!4+Q&>&;ACA-8>I:A>@33D+X5%@ M23U?5QG+9L:>>D7V$94/X?
MK/TM*^I@AV:QFW?'[[464/U\_U:QK7S/UG=4X@?O<0!(D=-@:(!%;O1>K=!C
MV0*II&>NR^LDY#:G<89N!"Q*+)YJYGU^+XOWC&'K>*FH!-AB.3"WP[%9 15:
ME;>:/@< S$_J\HFC:Z/@$4]8%_="_"#7K-9HZJV6H7<ZUMS8LI*H*]*TJ7VP
M+.6;IFJ[*0E*Z BW[RY2S^*B%6>JT?+\G:V0,J0+2)&A,/(3/*!2<DG;,N>I
M0-07E8/:S)<=EG,GO/#.$):T!U3C$XX%B1$QQZ(<,54X=@=)+/!CON^RG$[Q
MS GFC%.C2ED62]X\*A#W O2>*-XZ@3,(G%U$@PJE.-1%O9F3PXKKB2T*%-]C
M(KVLVH4Q1($4ERQRV'^T"S>B0F,W6.FTW;':[^SW,"^UJ/;SHQ"U8B7E,7",
MT$W9E1MJG(0:/46WQ1(LU.U%@;I[&"DFVL7^]&I (1P=V$"&#,0LD"U>V3$6
M]:671)VPTM?3*VW#0*"YV"M@@ ]  2F=Q$$X+?(#77&K"3(]5\15!=YA)?8(
M2V;BDN13) M*?L#&#^FOB*^BY#K>J".R*+L<]PXU1BPR_<"Q?GE^AO>ZNEDG
MQ)KD=[0?43I9%3I#.H25/[A!$GF"QW*I540:M9F5UT>I 49V"9!I@\!GP-\=
M11(23D?9^>GSYSYSW+E>%6FI=-+]A3R#A^:Q05T)%77PF"]K:B_'P"6G/J+^
MZ8(A2,FN47=><:O5F"LC.\LR&MHYL90,_BF@"T)_?FK^8^*& LYTWH\H>P1#
MI+;ON%-@P.HL<T*;%IAA>G[N$7L0)8.Y+P4<'9T;R3NU1!$VBT;TM2IF'XIK
MU'2#&/N. XI%0QB<_1#?BQXF6C  8X-)S(^QXWE1DYACIXA?S ;LQ=4&83;)
M+(O);X'=XX526?(?AN,:R]\_H;X/0!$(QU3]6@[JNH1&L81&?R9'8J;\@NO\
MWT]/%W5HM_K==KMGM+M=ZZ>Z L<FUK+V"AS;<87^/.9CS; :VHF\;'Y#U E<
M:.1.Y,5)_ 9XS!W:8,R6+(HJJ$H1ACR!E$BL^UGI]OA;W+@OW_!J^]R6O91S
MFS-1X961 $+^#6)\P$&/T+5'T-B9@V9;G-N.T ZIE4%@4\4*4)/0'M/^SGS1
MZ8QL U-H]LIVA\$>02B"*,8ZN]2+)V?5"Z,!R]\&'MKNJ,%R=,(4C>2?#5/(
M>QS:2&UE)@L_2Q%'03G8$6P(3B4F^_8(,"O5',E\B!\#TM@\C@>6,X4C68E7
M=;_QIVK@G+HU7Z(#Y:=JNP//9Y9N^Z^I[)5M&$B:DH!'M7B(K4=83#Z*U$Y/
M6\T(>XM*!@=#';>#"XH!!41[DUF@2X'M,-%C)\8&*:)5@4ZG25(>1#<=("OK
MVY1J@:JHKR[U7=H-Z#R@!C$/)(<S!;LOLL'($VH+S05J^@_4PE7+E$SRC^ -
M%SL"2]_/6K(7,ZRG$3\BO%V[ AU<@G*<>NQ2IE2X(KO>]2Y=G7*/(69N)?BR
MMES; K*&A-GFZ\\L!.4"Z0),-O'(3CI.^W&1>?7EXFO:U'R[I<HY=D1Z$+P+
MV1()DYD^9':V3[9XGR5NX.+/TMFH;,_\L&@N F^.&NA\+]@S97/K8)[Z#@/C
M=.#Z4<Q=87U*;S(ZP("%BR9T7[ Y'-515TWHA 1,_6.X9[ \?558!\QPYCK%
ME?_<Z;;T7L<BL52RZASK+%]N5MY)";;T5>#\WV#;V5:H\8RJ+T5P*OZ.;<1
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MO#0'W%SCP:)<-9IMO8TAJG97A6'R ]W25^G;*3Z2IIM21SYBHZ/W3'M@'HB
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M[C:: $O/HU2NGXUF]I'F_]DP&^WL 5ET5@;+X71N9;;*@G-ZDC]O&SO+K&\
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M#PJ44//=;7JLO S5\A8$15 <6,'[[N*"]Q\&@3.%_XWBL??+_P-02P,$%
M  @ 0X%R6$1VWFC[#@  MI8  !$   !A9'9M+3(P,C,Q,C,Q+GAS9.U=ZY/B
M-A+_OG^%CJNZVE2%&9C'SN-V-L4PD*7"#F1@DMRGE+ %Z-;81)*9(7_]M60;
MOS"R@<F2,U=7V<%6/]2_EM3=DNV//[S.++0@C%/'OJO43VH51&S#,:D]N:L\
M#]O5Z\H/G]Z]^_B/:O6W^Z<N>G ,=T9L@9J,8$%,]$+%%(DI0;\Z["M=8-2W
ML!@[;%:M?E)D36>^9'0R%>BL=G81- ONLML:&=6OSJ^,ZOGU!:E>C"ZNJ]?D
M\D-U?#4>W]3,\;AV<_7]Y-:H77PXNZF?5S^<DWKU@IB7U6L\NJA>GGVXN!P1
MXW*,KQ735W[+C2F9801=L_GM*[^K3(68WYZ>OKR\G+R<GSAL<GI6J]5/?_O2
M':BF%;^M1>VOL=:O(V8%[<]/Y>T1YB1HCLW%+-8<+A#FSDX,9P849^=U^'_0
M6+*B&YA3FPML&ROFIF!5L9P37E]/!/=/Y7TIJ%:MU:MG]12IGO*L6CNOQI4T
MQ8HLJN'EJ7>S@K 0C(Y<0=H \P,98]<"$M?^P\46'5-B@@]91'I)K$'DML!L
M0L0CGA$^QP;1V_#3.X0DLG0V=YA =HIRC/E(:<J94&05Y'E!US&P4,XM6_*@
M4ZGVI\027/ZJRE\GK]RLG.:7ZO+J!.-Y(<E1&D^Z?Z6(!A&7KM_<W)R^2A]=
MK\%:KU/MJ_+/:OT,'*& V"SWS2\;?E4#NGWH$([/8CH$=#OJL'9$9OF"CE+]
MYKNJL1K>A=7P*0NIL7ZZR(E%0"!!N"PBD!/C9.(L3DU"\XR_9'/YQYH1AVW;
M$8I>7O&OS>?4'CO>!;@D_>8V<)XG,@XFT=0RLF:$JG]N,3.88VF&\^F<.7/"
M!"4\N@0I!E-&QG<5N1!5@\GR]SDC)Z!)T"0E(#X"Y&V00#C,UZJ_W;!# 0OI
M!'<5#CA8Q#/1(???)..B_0<2:M/_B]Y;>%2T]T!"K+]]QPUL%>TXD!BNM8W7
M2_(AW$?4O*LT'0A9^G@"ZLGKST^=S(A&B0W;!TP#MJ$??JJI_]51-8RYJTA1
M(DGZ\31)D&#E<F+V[$_J[^3P]HG])AL($P;*31<?3VO)_(N!(3>8M^&:5'1L
MF50H37):.46F-?99W-B* 8IP*)'-F[W'0:_;>6@,6P_WC6[CL=D:?&ZUAH.\
M+IY)KT7A'$P_ +N1P.<CK)#/"WG,CH ,!WW,H%=3(BCHN2LZ<69:J"[R0X7>
MQWA_5U+H!D/X[Y?6XW#0:_?ZK:?&L -W&X\/S=Z7_E/K<^MQT/FEU>T-MAEH
M!9AKH;W<!&TH"/7:*!2%0!:*"4-2VA'K]F#8:_[TN==]:#T-6C\_=X;_V1'?
M-0RUF'[(CVF4_;_^>7U6O_HW\L0<P6PW&X//[6[OUUW':,A'"]U5?N@D5Z38
ME@BJ!\(-1N>2FS.&1>;>Y=0FG.=$*)-<"\RUC!DI-RR'NXS('R$KY(Q5:3S@
M5B(\!NYLAMG2&0_HQ*9C6/)MT3 ,Q[4%M2=]QZ(&Y'4YT<G)3(O531(KG['$
M*<(:A;Q1P+Q$T+4Q9;]@RR5?")9VDC,.Q[:YNNZ,V]3&MD&QU;&Y8"I?RHOE
MMMQUX-9K27 E1Z18HJ@L!,*B]P#[E4 4D5@BQ)_(@MANWNI%T%J+2#V)B$]9
M(LMVP?%R3W-^8ZU=SY)V]0A+9-9[;,D]H\&4$-%T9G/'+C #91!KS7Z>-+O/
M""E.*&15(B"@TS,J@CF\Z:A%D]@%UO9-'+207"0AB7!3\WR,7XEP&0C'^-H'
M]\P=8H4$6JM?IL(H28P4=8ELW+BHU;\.\ +\B\N^YRU+)\FT]OZ0M#=P>/_U
M.^0S488OD=V?B(S1#.$RZ'WNF"5*H[7X53IRB="7R-8=&TQ(AO@U]WP>I=#:
M.94\>]1(D9?(S(]$=!W.YX0-IICE#<235%ISI_)?X( D"P0\D&)2(J,/W!$G
M?[C0@=:B0/B8(M.9_2R5F88LD,>C5%;/4\MYDP)1GD+1S<WEQ<55*G/-7RA"
M[X._RK3%M6559XA'5FZ0=Y.AQ3R55>]8/T+O/<EE<@.O$%$(U1B)%J14#NZ1
ME]'6Z\L8A6R_D846BU3RG54/*2,Z83Y=")$4F1:%3<EX&0T?R]0*V7X=I=;\
MJ=P\QJ6, $02P$+F3]-IC9]*TZ/I8QEMG\@("]E_/:T6@U0*G\XIRXA$,DLL
MM@JL)]9BL69_.Y%HEA&*Y-F.D7\:HV&:2H3,%E9'?!^(P-3:]MA(+M8Z&*]3
M]8(U1TH"2?*8\DI8]*PR>N_+*Q/4^>H >P!^#X*T;K!+$>+H%;L7)^2CP:9K
MP=TFYM/6'RY=8,LG'4P=)@1ALXZ]@(!/M2_F07^Q4EIOVWOY _S5UU6VD=JB
MB+J*C5*X*C5&$96//IK?'?8PE;V%9*VWI>HXNWO;<<)+GN<JY@<)(BV$J?*/
MSZ"4%O?*D'L8C3D8:9%)E83\(NEQC*00"Y?3MBO 6(^.;<@:IF7)-$FUZ>.E
MFF)<VR2L!TDMEJ&6NK4-M/N1J/6!5%UJY0/15=E3 8$.U8@27EL4J(&4'FBE
MB'^[C$ZSOF >0MKWGEA>PJHE8YVYM-\C$<7\9$<A6M=(5<TRZ_9Q9PGDJC5Y
M)?E[5? Y.D,:)\C+F$O,UNN<V##TP&H]R-Q9TV7R.<@NQ2-J4?ET^W[=H[!8
MK<.D2GPY'<;7! 6J*,=1RB!?&Q11IY0^M.'T:S&OR,%(BW.J?+CQ-&TI\0KW
MY_911,K'3(?;3?I\460+\!CTK84OG"_5M9XJKO*&(>B"BN6V..;CJ@4T7?F+
M 1J=8[T[OB 42#J"&\3881'#LU&'<UB2Y"6E;0-^SCSC[8[Y%L*TKI JRV6[
M0KQ,XFF /!702@<44>+H)3YP:L^>&H*8ZNXS"-OC5)"'N]8/4@6S;#\(Y?F-
ME,3CW+!VBI:O?#)E! L1JM+1#U;WM +HV&MQ3U79-$M!54E$49%!_%U*X)-/
MVQ3#-8M:"UNJ!+?FD9U2XA$['A5&IG3;&#H_/RUFFJ-<L4":ECR0CIDFL=0%
MEYL.+[HI6IBM%M3-3W*M6SE7]Y2@4J(;.8H7V6]>E7F<L3S?=4]@")!(TV)0
M[R9#B_O&)\N2>]-A 0M^J;-KGN#$><*C)Z116C6X)S8(%GWF+"@O/(WO+D?K
M$:GJ5A3<30X1MD/O?>G?H97\HUN$L[3AV :UJ%(N ID??TJKNBH+PL(5#ENV
MB4F8+'GY[>2A@V!S?_6NJWU,*V^LF<;U+FNI MV&R2BN:\+_@D@^4!BM-$:^
MRM'6ZNS$ZK1$J/?190/'>"!CPA@QX7*#<[(79\ODJ7635-EO@YL$4A30GIRR
MP[J'BGQ>;EHH4V6[!)3'FOSF@?EL,Y@')S;]4PTD?]G=Q_#4<-8BFRK$;1BD
M45EJH ;22@ETX@&38EAF$&OA2M7/UCV>4D(PDH^8[.5,? &66N#2SS6FGF4Y
M3J,; (W.>%B^R)Z8D+/(#S+AR''>/4&]I3"M$Z1*<NN<(#[C^N)E@H:4 K$#
MPZ7QD8^G\>_5>+]CW[217[3QO].E/$A^3>-W>4Z_89OQAPL:,X<)N8C)DE@%
MX1$7#!OBKC+&EOPFA_PPSUTE#ZE-O2.&=Q7!Y LGU4?1;F$JIHXY5)_;\+X'
M)8);(^^HT5W%)",J/R8$#B HY#S0B1^9X\[O*EY# 'U60=XG.[PK,TCA!6;+
M#MR1O,-O^Z1ZW24009/X4<M'=S8BK#=6/\PV-OQS2IG]+\:D@"4*])G:@DP(
MR]-E:LA4LC%AQ,L*OU"+< $VXPUC2LE"?J<MJZ=Y:+]U!UOC,9%;GF'Y\ D2
MX'AZW9QB>P(-5&[\#'[&8$ZPH6G?X6K099I@3]SU1C)=AKVV?^6 &+XXPZGC
MRK-D,*3;CLL$(79K-K><)2'>=J?+C*D\K0SZ?"'2S:/&\KKCV6I+9D5LD\L*
MX1<5;TUG!E#D,\0#A2A>.(QK>YEJ^79=R-\#<%#X#9X:.Y)DFX^._7/P1<;H
MK<V]W);;08"9_")0P^]B5F>SV^^].]X5>7##GN3H29^1MCR6;_Z*&<-R!MZ(
M6F;S0W#0=>NF^L_4L<S.;,Z<A:)H6);SXGUBLL *K.&T?4!B,&*^W02<.,7=
MR#S%G6F, AP.U0B;(JHG8I,7;,DCR;+SVX5E:29O-+#SARV1Q7(@'ZB32V7'
M-EU#M2NTV&KH#V)*7ILT@ 3.9?$,%A1('62YIEC6L9;!@>8>_CCM %*07 H(
M(0GT O14#_,OA^15W%NPH.H&>@X&;SC;BT!*GL4+_[ETO_YR\@5#S&<Z+9B/
M3YHGC1/-&J:A.H2E++7WT\1S*CPG5,=),D',07F@_MLEKP2F')A>YP18&QQ"
MQ,U(;J(XB$EI0 R7J;4QR$M6J6ZP<JQ"_4Q$BS'YUMER9-D($C2Y5L#,NN7B
MDXO+0: =V2;J4IM("KXA_5G3]EMG XE<;-V!\\VX%6!P$)#Y;\+I;7[]CGK5
M56:7B[#80Z=-<3N%ELQP1\IMMH5:[EC=)T^5-V16-U%-[Y=A$_\)[L8+9C
M(5973Y![_W;L8!92[;GWH$@?%)3U[4EVDO47:K#O23'B:G-/3+[I(:'V YG+
M EZ04<DG^+VDRENYX7JPFD-^$8G',DVZ3Q$[5!3?-IG3^DU@A:1?P&Q$V(+
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M"\()YNO55EDHH_ECFK6*<4C'? ;'M:V5^#A4&W_&4>&@N7*:><%K18'V-!<
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MV)>RKAYC:NG17&5*(RFK9IY@L7B(F (!-1:E5+_^>@#@#I  $0< 29FE*;F
MYWSA_D6$NX>[Q[__]V]G@Y^^XGC2'PW_]C/_"_OY)QRF4>X//__MYS\^O0;W
M\W__CW_[MW__?P#^]Z\?WO[T<I1F9SB<_O1BC&&*^:<_^]/3GZ:G^-,_1N-_
M]K^&G]X/PK2,QF< _S'_LQ>C+]_'_<^GTY\$$^K\8^>_'?^58>16V@32*005
ME0.'VD"QI7B62V'>_K^?_YJ8,L)S"48B!X59@PM1@19&Z8A)E^#F#QWTA__\
M:_TGA@G^1,,;3N;?_NWGT^GTRU]_^>7//__\R[<X'OQE-/[\BV!,_G+^Z9^7
M'_]VZ_-_ROFGN??^E_EO+SXZZ:_Z(#V6__*_?WO[,9WB68#^<#(-PW3Y GI]
MGE[\X54T^I?%+^FCD_Y?)_._?SM*83I7T+U#^&GM)^IW</XQJ#\"+D#ROWR;
MY)__X]]^^FDAN3!.X]$ /V#Y:?GE'Q_>W$;:'TY_R?VS7Y:?^24,!H1X_H3I
M]R_XMY\G_;,O SS_V>D8RUKTYT.NH'2%\]_JTW[9&=,I 1FG642@G^*P4KPA
MQE5/WQWSQ;,@8PFSP;0AXMO/;HIW=!;Z+05\Z]$-T,X?!&=X%G'<$NJUYU[!
M>0[R)L+ZR)!IW9V=_26-SGZ9HWOQ[O>/[]Z^>7GRZ=7+CY_HW]]>_?[IX[O7
M'S^]>_'__8]W;U^^^O#QU?_ZX\VG_W,_='KX&>$3DHO%%/]O6SS]R@"(*?UA
MORX^;^G;Y2LJVFZ&@M^F.,RX6)#.,0Q&Z=J'!G4Y'%WH;Q B#N8_[<TF\#F$
M+[V/4]J;ZC9%H/$-?3GI&9&#T*E "=: RE:#EXS1 E@BRRHR*\QM[4_.V53"
M),[UOWS%+U6VO^!@.CG_R5S:<TFO1[&0;(-Q?0IQ@#V3I2K&!3"B[HFT"X)G
M%B%H)W76Z(6-78UICN#Z>"ZY<C(^']ERYFVU@93QZ*RI/J>C9F)<:(I __S3
M:)QQ3#83_6J^'/PU#483S'_[>3J>X>4/1\,IL?K58/Y"FJSXN7[1C FO_FO6
MGWY_,3K[,AK2MY.3;_U)+RNMH\4"PAD+2C 23DH14$5>G'6>(>^*&*L ->3)
M'9OZ';QY@*+7<69G@:^BT(YLN('IY7P[V@A4[X:9T8@-*P$U9,%:,^D.#NRN
MN%%74M\;)3RY5C+J# E=I!D@.00LDL Q+UR*5GCY>*EPS0(]/!.V$78'#" X
M9Z/AQ^DH_?.WN6':DXQ'Z74$[F@15,P6<"K6KS(WS'"636JL_5L@6FI^E35_
M6^T-E#-J*=G;JF:[JOHDY[D0P^!]Z.<WPQ?A2W\:!DMPQI%%%$P$6Q$J8VFH
M@<;KA,I<.><TVL9JOQ/04Z! .XEW,/-/4IJ=S08U/O=N>HKC.O QGM9E\BN^
M&9*7ADN@J'A1)GK@R7IB:S(0K5>0<DF.?I.25:VIL2FX)T&33C1QFS)B5\I\
MP"F-%?.K,![VAY\G2U1.F.Q#<L"%=Z"\8F0Q2T/+G!$VE^)I9VS,C]5(G@(9
M&LCXMN;EKIHG%HXQ3/ E+O[_9K&QG8X&]/S)0@H?1H/!Z]'XSS#./6&2D2*3
MXRU5(@GX1$1U'(S/.3L=E96Y,26VA+A_KC2.3W2ID@ZLCROFT,?3,,;)N]FT
MGG?40Z1>+#H9ZPW-$(V@:'Y H*$#BP*E0,\B]]W9G+?P[)\;G2ISO6&ZFR8Z
M,$INC[K'@Q.2V02Y. 4*9:"AA@)6D0A*3B6*UMRXC>)I,V)'J7=@:9SD_SN;
M3.MB.?DT6F-&S\E;SRESW7_)6IH??WY &L"D/\6/./[:3_@>Q_U1_H!I]'FA
MLK^'P0Q[Y*TCBUE#8)J#"EY#S()V[, JQ5VRV#K&T?68GC9'CXH1'5A8<\F]
MF4QFF%_.QK04+V N5NCY+]]]J6 GK[[A./5IC#WELY)6,IJC21)B9R%H%L$E
M5F(*BCG3_K1J6Y1/FY4=:^TVSU1'/)O/@=6 I92&HPEDE1K:"@+SX*SW(%F.
M293,&':R 6\#\EFRK)'.;I-,=[J8O3K[,AA]QP7R][-Q.B7QO1^$X:3GI,-H
M4P;/#?E#!0MX4V@-3D*')+-P0N]S15L/]5D2KJG^;M/.=+FVK47=R\EGSVT!
M##*#\C1KO#<()KJD;?$%=6M3\$% GR7E&NKN-N%LI^O<!YQ,Q_TTQ3S_V$D5
MT>\X?5=(7 7[TQE]IB>#\EXK6IYYU* X%Q"QT+K-; F1<Y-5V>>*MPGH9TG$
MCG1ZFY1N5U+^%L;_Q&G-9?F(B48P[>/DCR');=#_%^;_)'F_'4TFO:BM\2)&
M\%K36HWD]$3#'!!=2@@R129$8^9MANQITZL#[=SFD-^50^O.H4@"V/\\?#$;
MCW&8OG\:TZX?TEP[PSS_;C#WN2^]]?GL^!2^O1^-Y[^8TOR)L[D /HW>TYP:
M3GO(>18B%$A<T82Q14!P6H".!D,0(9G0FHI['>#39O3Q<F5%@'KG<PS"N!C>
M?)H*F;U+Y,++(GP]PR<TI4C0-DCTB4>A6Q^-7P/PM)GU<%FOT'S+5*G;YR8^
M\^*)?*!+J>MU2!"\]!"+$I9)Q8-J?0:^^0E6DW.8E)C/SCDHR$G\P5IPQ3H:
ML'56<T9#;)T7MNX<YM]_N4'WM_3M ^LI/L[.SL+X^ZA\I+6J7_HI#*<G*8UF
MPVFU_4:#?J(=^C+@_&98Z];F"]?+>E0_F#RDSJ+!6W>OOV@]]!WK,JJ4>DM,
M[^[&='F"KC3-?*\+"$,6=EU,R-9F]!66F N3J(*\3QD/>?%#)]@6[UJDHT<9
MA5-< 0L%:5@TMLB% V=3E$(S@SPU'.!>*C8ZU_3Y1M*IM ]=Y3$93WL?PO S
MSC.3@Q/&.9'!8:JI81*!Y!5 :&L3ERF4M-$&1$^]LC33=Y?+\K47[KM:HUM5
MCG85:<-<B L0R]2O36!L4Z&QB8;;Y]/=7XNQ@_!OJF\'R76H2*%XT=&3[>N$
M!94U X\RU:Q?F0O/M(J%QZ# -144[?6WC< :Z^TWDM39[&P)Q.J@&68.A2FR
M[JW/$ 0-B[FD#"HOB]DH0'&/YJZ]='^NW4YB'[606<-\PSF0\.T*D&)X2M&0
MNT*>* U'%?HJJ1H[(,<EYT \;:&\JR]]A,I[L,PZ2 /\?591O"L?\,MHO R6
MSFVE"2W7Z&WADA:2[$ Y[2%$SR!&@LM]B?3;UA&7M6CVI^:]F<R-5=!!)O$Y
MLG=D-88Z\ M@SI?$(\'1I610]0PZ(D;:>%1!33*(MO5)[EHPSX :NRF@@V7C
M_7A$D*;?Z]'P]&28:\SH2T7VQP3+;/"V7[ G4LC>!@Z>,4WD1;)0A!90? K>
MJ1!*\W3B#6 ]8;:T5DH7V<:3"4[?G'T)_7$%]N(TC#_CI&>-5F2H"O#:D0>9
M3.T$0,L>HA4ZF,1<\\20U4B>,#L:B+YA,NYR^+39S4\VZM'#[SCM)5V$"H)>
MGWT"5;(![Y( 5$D(IQ33^D:GC+4QN!N/?H*:;2###M)>7V+!\1CS!R+9!TS8
M_UI-FDE%9I@EEG'R3#013B4FP9N H'G0629.!G7K@XWU:)X@(1JK8&VZ:LM3
MH=>T'LU3SWXC%L_&\X#M) SSQ<]'Y75_&(:I7X]%)M/QO-_AI';RR[,!_?9%
MF)S6G>YK&"S_].,IV=%3')^]&7[%927##B=(>T:X^VG3(47:JF/8$LN[<O*5
M7E+I^WHT_ABNYO)<SA4K4A:%&3 H:,43ANS@&,G&0<.%3KQPQUH?F&X#<-<E
M]4)Q\SU\0J;=VWZ(_<'\+4LEYW?##_7--8^./O#[:#@^__;7,.E/ZM_/#Q0_
M83H=]O]K=AZ]MYK';+@#I!4 %.,U;8 Y2,PJZ6S43&T4*]U">%V.9V\]T#IC
MZ,W5_&BT?^ACN%L"^?7[Q9?_HT\>\CB=?G^+7W$PCXL[9S %CE"DX4"C(1M7
M:@1IHW/!"AGD1M'(AQ#[3F2':K]V/$1:Q_!V"NT@YK%R6[V-=]F98A.P'75[
MVPKH8;K =:'Q=:3J3%T'YYAT7F8M&)A4&.TJTH%/CH%CTJ4D11*Z=>^/(^#6
M/6WECHY:VVBI2TJ]&7Z932=S"?#EX5-,3@4E(P3A'"B=:RXE28)ILE-*U,Z7
MUB':.^#L/\6V0T6NH\R.6NC@E&<5-''>#"D$%5)(8'3T=<@98F(:)(LI.RNS
M$:T#LW? >6X$>8@6NEA!;@<+YDNH"4*(Q!)8M,1;DS@XG@U8PZ.)*?$@6H?S
MUD#Y85'?9%,#E75P_#.O12DXKI):] @A*;Q;&8WZ1(^<K/[5<K9M,I:.+.R6
MXSB0 =Z"(*,CTVX':U_3,646@C!UX78N@0I%U!Q92;L]SXIC) .T=1_XXV?J
M?>;\L1-U&Z5V0-#?1D/\OBAU?3T;YO,NEHG5D_ZHP#A#IHB)%@(S#FA#\<YD
MD[UN'?Q:C63_-MOAM'NS 'EWU734'K(VKZD=O<C468)BCF:0%1F*\+JF(4KP
MGLP.'J)#4U#3+.N@JNX6D&=,E]T5T\'R\L?'_QQ]Q?%PGC(R&G\9C>>V:A76
MR6<<UC/KR_..<W?%!*N3*V"RY*!\X1 XR22%PG7,B?/0NK?0 V ^8Z9UK=0.
M/(=SF/CKJ KO!KB2G/;)&!"\3A)=2 Z1,V!2!6<X_=N\8O9.0,^86^T4U3K;
M[$96P\DRJ^'3]:R&\V4W6>N#04 GYGDRY'QG,C2E]%9YM%:9&T5^:Q+1MGGK
M,Z1-MYKI(+WMYFG_2XS32YJ?G-6&&O^J;5$GTWEXIQ>YB"&+!#I+<E0L5^2H
MJ 32&BM-L<64UBU7ML5X@ [M>\N>Z%1?7=P=<S?>RPLL_G,\FMSH9_0KEM$8
M/X5O/8M2VF@DZ&!IDOC P&5+4]$&3Y-')9U:-ZQM OP9,[$#S79QE\T#!U'[
MREP. C,/"EWM65GG&&8!42H%(@@M-'G QK:VUYH _T'/EIKMHKYDK9"N#Z>G
M.:K,D8'5A7#&4/N_60XBQEQ"XDKDYI=P;8CM.9&LB7ZZ<!3(!KUNE5ZS%'I"
MHK:BU,O$:JUNM!:B%1*<,#P%D4DH8F/WX.YW/44Z="'FAK;^>G@KMN:>=#H+
MQ6O'2$9(/?DB3AL/04<M,TJ2P;TU!EN]\7DQ8E>1-VRZOC'(16-13NI5,4-B
M]6*7VDK/94X,9B8K+-XYM\,:L>*-SYH76XN\@Z[H*W%>I@N][$]JFOQL7%LF
M&8Y)._"<>3*3/(,0(P--]I,*2N>LFU_#M2FXITBC;C6TMM_Y$13*M>ZGV 6,
M@Y6\[:WCXCG_UI;H7]+;2&L2L0R*$;RF?9%O7[P$26R4(K/"8NNV*_>CVKG+
MZ<4,7_NN9=*;BX)EX4"61*,G0Q]"=HDFMQ922HLYM*Y&VQ3;OBK+&G/D5M?]
M+E1Q+*5A:X?TZ_=Z?K&X6=ZY(!GGM:BZ'B!XL@\R?64<9R8EX:5L?3R] :Q#
MI;!V0X=-.Y,\4"W[[&A3 9X?<&T L:.,TPW@'2:1M+EJ-Z7.CGHY%(5R3H(6
M;Q R!%#.UOX[T0&/3J@8C9-V;XM/U]2Y)[/S*)BSA3HZ8,P%I.79MK8)/<<
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MI3:D)\[GZ)J'=4\-W[4FSUWX2 Y+0CLA#B#\Q6 UE&SU@VA-+[##3<*G\>+
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MC>_E/\G1#YGIZOHX&#]Z',0G@Y"+*,C6F$BKC*FU1_FR$V*RULJ\:C3%<G@
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M?"'JL.4!IGM!818JQYEP?D@4 _-(M.B*HMNV["NZ#"+!]@7 AE_BZ2N;8ZI
M&,,(]/UO@1AOV>5<00'HZ_07:_0\?P-\C)?1C4>[TZEWUK=RJ-M>*=+E'UV%
M-05E_896=MW-H2:;@,IG[SP# 4'Y\VX#6$"#]F#2D_UFL^:LK>G&@ZMDWI^:
MR*/WZY_>,XE\2!HT-KPU"[8'4G;:HF/*M'L&;GCCHT>U5N(2DS@*\=/U#UH_
M1I:A%)&#B(*/,H)E#D9F=A%\907W5@:O:/[2$W_KY?VGUWZ?P)OKG:VF&KL?
MVD\FYN<XUPZW7N[>\4Z1XU0+K&Q8.G0,@@N^?</_1@<(#ATV+KBQ@-_*LUA
M(FQIHV%C<$I_>V2@$=;DS\<'93@T$3-EY0TRII.PL\D/<>KOY@I=9!&"RP]J
M0A3J9D6XG"]NR\(Y6L/M/G\;^<\I>(Q0QN2NB:3#+E>OG':OQ1@IM*GU2K5,
M3UJ@YP4BJ)7>P+.!/ >PW+,ZS/0<J89XZIZ*P.C@!\_X@;HS"[0/%D#5S7'8
M0W/W1G3MW?J/Y>-7&;>\NC.RW]4(22>]_K)<CAJ7LK@:3K?!6R/4#%.^KD1<
M="/_BHC(XNLAQ$J9(U.M/2JLQJ[>-D6/[FW@MW0%&D#J"X;4BO[2]B?2T@^
MS+GNXK.@51!;>< !AABE4NY8UY_B&#@(<FEO-;Q>TGKC\7&_,E%6@^5RAV'D
M9&L;>-(LY19YL=A8ZBF3,YQ<0^^UEAY>,>)2SG+9=QG;]&)'F7NB[;)N#$XG
M(RJUE&[*93#/B3N&<OO76, PB.Q.&X[<>H:@B?,IS=QB2Q=F+%#R2+>Y$)V"
M'91'7EH2(J-1&M13?PKRQ(TBBO-G+(05G]?I-]7-F]B:O+V0,=Z;APZ$Z)UM
M\UU%.!]#10,:;P_X7+4*7&>DAE,#W/@!TLH>8YOO#74&@S0J*D7<_[1)];4;
MOIS9B]#LR&T4\UI5E*E38*LS_Q:0]R@]08. (,FZ+>W]U5._;TX7)#L"_9;R
M_;BX;(F^D]WLH1B=U4#J\1U;@VOXZ5W?L>< &C[CR<()W_)L^<&UHXMAJ8HA
MA :6C@IM(@L-GRUJE\V?RW9$+Q,=_'QBK-SII-14.)'U6]1S^7.I0$!C?IQ&
M\WQF2+S/@8:YU%5XL-*6B76J^4\?61;)&)-US ]5_.0Q0'M\0:G25Y2Q&<)@
M9J#H@/9F\!?_-6MM<\ 2K<380_('3E:V3JN(KG0M5RWCT(6YB1+'&5BP>"7*
M"L'GD\=_I=KN_;B*=N$,O_[QJ[=5>*Q/XV\9>C;/HKI941'!R'SF&7X?M<]V
MBL0?DF]</5_7A(Q.:0LUG7W=42\I/]ZA^;V\C!XFJZYJ@>FL]'?\R5H0L0C+
MX "\OX45^C<@ U ?-T$4:T?9?\*0?/PP^SSY%9?=E;9YVM]J)$P->+UG1J=R
M^*BK7JF:U&].^8RM377FBXJK2FQ>1<$[&8(-+BQ[][I'T%4]NQMWN-/FVG-C
M3.9I )W@_&9:%B)&^,*P=C&[-9US/-<U8XUQ7C0T7V5/DWIV^4X D7<9;]R\
M_ACFREL:K\$\:.8\Q5A(3TK'_Y U%R9H2:MM\X==R_MXCZ:&REBQ^$X* 8JN
M>GRK#A]NJ%B2?.;J?'%MFQ M\52H@I PMK <96\RWV0_4^6=<[2F)]1W7'V2
MKY8&72< K IN)'('9'K<<F<'02T;-WY.%37=*6RB@_I#59#K,14.&PYKNSB>
M:*9&F-7"V'R&+[$JG)C%TI2L?K48HZP37&]D;5D0'DJ&FMT6[5CU#QJX$D>.
MN[L2F11QL+V5B3!(3GPEXU<#&1#SE8J*$:FTU#LZ-G.&Z:KX>$)^IRGU^NX'
M\FN&3"& R&1XYH! U()BG[B4<HM[*1\?+U\-56D[@;QP4=[**QW!834FF*CI
M.!]G97/0DA4^66R"^F)[Y^<H)\L;R #PJ?_$IELB!KB8L^8WD"F6H7AFH3PF
M \;\59ZD10RY-]U(PO&W!S>8.@F# BH/?)%_%=T7Q 65210D%JM4C7[@4827
M%$!%X2W#VL1+*(YMW%0U90IJE]=J(]1^#+ZEXP\Z66N1FZ<ZE%0;UC!PR_YM
MX-[(M0U/]2R7N\7DAY!+.E7 @0/ Q\&:[>W-\(7\[(2A[T3LT6N*) 0<]/=4
M+.(OASV2\XO:; \L50:T@: [(419WC:93$:0_6"M*W?#H+__RF+2Z(<@H_JN
M OZ]L"@D?Y71\[O,A945!*__U18P+I2N- >5J1(BRC_Q$/0C%L>.1R>=>UE4
M".GO>#Y#9T! E(T*NK#[47IMMF1Q=YB;R$H9\+ ,<#)=+JG,_(I7"C8$O(\A
M7P_^!U64#^QI25F?U4HO,")]*%CB$AG_V=_.NN%C<DJ0$=61EU*;:U+1Y+FD
M=9W(@;5Y&K<YCH[T@2!?-R@P4SV4=[I%2X?+;I'+(7+G@KR/FWYWVOZ\<($^
M?4NAFSSZI_-(IRY'HZ>MH=70/"[ C)Z:V>*!GL( U]/XQ*^?@XS7>YHXAEHQ
M-"@B$4WV!3(GP^B5%5Z+D.Q5,NC3$<5PZD!/3[D#:&2P\):L_7!V$;B=)<>C
M8KWG.8\W7QCZCRQ54"ZQ]QY7#=@AWBNXAR*LFI2??MSKUMQMB0VZ!RM,50I,
MOSKN02AJ-01E!7-(_U/9&LW_-AT1#X_^'8/$%_TC3G.^M*IQ'R'S9'"(+5&)
M>[1W,YSB-87CDIJ&G;]/[3P<B?SIT>,-^Z.BY(0"]4O!$IJ49KWYQ'8,NJP[
MQEO>G%CE?+G0'=W]+ E][;:DO9T]\@=(W+S>2KLPB+%R!4LJ2S>H2\AH/?/2
M+><28-O8#1"E+M\6(#U<IYQGFVVJEMMYTYV42C9IRTC_E#+_Z^:YA*C]:[A
M3+"NXY64>%23I=6Z^/FZ$R.7O9(S?F.Z'EX?(<MVY'R-[?%W24_.#F1S&3/U
M&DI[$Y0DXYP)+?%W/;2M3Z_>^[O$AU0M)RWHLIW [\-/7F^3#7HU%RQ090DV
M:\IM9HBH=,Y>MX[4_Z"RJ7"?LN\^I?YD3KWM-(59+K5:W[>N'*WI/SI031SF
MV_5$WS1_=*E:1GE-S;JZ9)QS=:\YB_\SSFP.3F7]_70S'I9E?% ^L'']3(X>
M"ZAS7<$"U(SJ*W7[%V3ODGB+LWZ4.(FU&5ZT'&9=9RI1&>U-$E!Q9[P%C,D
M>&9%0$O0;5 TKTU'(SQO9N#I./J[2?67),MZJ98#O=WB#BG.K:-WS-_ZQJY?
M8 &LD_LU!<,%I,&&\%-5V* 9\\*7>O=4U<(BF^E[2NQJFXC<A0<%Y9:'L)]+
MB\M300'"SK'KZ\)LB>NQ7]\7E$J7?W_N_5V_H"'7+-.NB>>7)7DQ_&@H6WJY
M% N(%,WA:$]3=&UA"*[+*I&E%.H1#B)WJ@/68P%#^._Y>[:>%(RO=+@MO_TK
M?Y9PVW 2.YWE8__FI7]VIDXYA\MQUN_MV.SS\1W-]HR%4R(75^MW*8I"5-[6
M<]0R'R^K040H 0O$PC>1$_PWK?/\B-82GGX*(YO^),]7Y7\\AY_DMCVON?41
MY(0J(.Q[@=$L1#/OYRZ3R*;=;.@F4Y5X]:-'*@.<5U3:MFM=Y1A1[=-O7-0A
M)$XZ!Q/ 7)@G>);WM8Q]@&?K2J)7KMX?;3LW7O[GN6WVFF5-\\*Y1;'<B>X5
M-=4<=9GC;9$: ;Z5Q^G$>56%:9M(;@7"UJ>P>4@]19\YF3KC!B6J> !&(>-&
M<A"E&Y9!F)#6DAT[0+%"-LI$>60!/#'>A#Z:0GP<,EL-)"^[X32WP_PRER1K
M)FA4U\YJ<<6_)W5)5Y7^S^_QH":A[+E:RN&)$VFS-=%Y]$B$KMDZ/3R_;D=6
M5V2-0K-U[@Q4P+U&\A82D*2$@\".B;.EJ.W0 KLK(92>;X*QQZ/5/IX=^BW*
MB2?'#QQ+V5KLL[1)HJMII0Q^L[67+/UN-,C\GX=5^/\\K"N_0H&H\L&,UW_5
MX O0[V8T7,@X'B*[)/=#<>[D9(5/X!]N&=S'O44=9\1WA(BK!)%KJ'<2F<6T
M"VDU2><T$U J5RB,E8N-Z6/\9KA4[$@+RF:'I*-RQ<F-Q$G<:^G-VS8-)R+;
M\Q)\:7/'7*9'H9\8+";:.OJW'^MYK^4ORX:0V\4>!W/ (<.A$MU=C;\Z90.\
M9-,2R$8_/[POA!^>.$.-%W98LANH+^,#SQG:(#,B1+R(D<NAVG/V<E6SL1OV
M/5.V_8$G\<-?Q(MG>?NF&F)_$I+S^\S>K<<FN:B+]5]M4#[H1@7V<)2"1)RR
MS!BN)GGPZM"P%+[W>4=ADQAD3+\-(CE<)Y\OG;GLD@L1P_";T<,("0N9HV6C
M-W]-YL=$O!$-U#'DUG<4L)O5.!/Z5M1X)UA4\-@_4VWFGWRUGH[(.;7XX_4M
MKT34E/##H;%OU4OEFQN1W9RH"-Z8K9/'1_J4\//APG>*(P2+$83)?9(UXR"<
M,$SO#+7Q-QR_83]I (ZJ:H84[K@$O4'G8QZ/^92"65P2,Y+["')=:FGLB.E7
M""LD^<;8;K)QK+<?TB(&Y8A^KDWID!WH,*-*75+[F/?G,WG_4SN*L$6"'SQY
M!KE-L3]O8]N4C</2.'><U P<;YQ["-&^<O;_\=/:S:=FAKSTX8(@RH&5U6$;
MGYN/!I47),@*E)?UCEM$>V35\WC';!'E\_5=O-;ASM%/5WIM$I?WN@'A1/QE
MB70V8+OD<#:/"CL[#@! *L5)53O/ M[@W&QJQ[H$RA+U'M:U*BW'3,H_N=0P
M.7T&+QEC_-!K8=%'\O>P9BOJ9^R?3C"\8 @+(-])U'ZT;VSF_9BY4G*%S?1B
M_=,WN:4IIHFVO6F"V'(*L)2>[NELR[JGX4&VP#$,P3/(X&V\$$K3>BOSG9EL
M$-X[R!+EG%A]HQ^*AP+J(E0&D\A6:Q)"0HK-#W49*[^XY&TF@2EBF.Y]=1>B
ML &YW;D@6F+N2+8D!&38MPYD5+Y/>==>$[GP'CUVL1,24OE+F8[_#2AN-2(Y
M5?X^Z%I+5X4ZJB)V2))SY-H("K??RXR7>5*-(C3"3,(NKD56=NC2%%EY;(F>
MON1697UZ=6+BLQILCBCK00!'4JV.VNV1OK6/I95G=R)^#H\+MMBD]&:P;?[]
MP6.CC?Z"X7#,$%P;V-*(B%4BOW_UJ!_%*E/<^C8D>@H<Q*=-;F)J5"VQN<4U
M)#?5$;#$ E)R1E7VM6^$^[!:UQQD,EBN"SW>>DD76+$_L/J89T[>3OZ3Q]UK
MQ."3HW:^$UAD4:0:P4C:D0O;N#%EXX>WEQP.DA(7A6/LGNXH]=;8(S)JL+A+
M8&"^)'O>H%CMZMC]"A=!VUB[UY3C.^[Z/Y.3<[U'OSD=G:TP;B$KOPN$5\L(
M;'5,3/#0N=J<>^?0IDA0?6FN8=6C<G>730B>IAB@H+<P*3VV>@QCJ_<?G'#/
M=AX6BX^/(FLA\/@1^"[M?4F-KTW]<JO,/]^4),V65\;$KW.G<*RZY$X28==C
MS8S,W$JPUZM/?<;O(H)CU;6J$K9ZY ]9#[F3^!_EJ3CP]+#F%Q6(")E/(M03
MJ.KJC%7N"WUV5V!.$,K"4_*Q(D*9;_=$=X/AIS%>%2J4RW_YYV+,Z9<MHRTV
M$X7SG2JZT)D8C@/DF4PW55:R IN"S_UJ%+>JVAV!MI"EUKB_C*%)D+IWR<[:
MBU^_+PQ:C!I,5C7<O$@SKB@%U9ZGJ]>_Q*7%IPO;=]((<[#\<O$ P]C,74$C
MNA%\?BUGM+9NA^[PW<E;&I8L\1K.W5V.=1V15?+#/$$1[6 !C."*;PX8AM;\
M<84O?[)53Q84#KMM^+=.A7CR$5%A,@J;S K.G0JE%F _<O&G7\AJ"/6JA*KC
M$S_-M"^NFSC"PRNY790N&UK6W_[2;FG)./3?BA3/!M,]5V'(L'OG#L"O>-$E
M!$/:HG("RJMW0ZE:']6?D;#!1U[('^5(O VIR^;/V"Z-JH[NJ?N8WO$O[+/V
M8@'W[\ (5K5,??B?!'2Q#=6?I=^W!I3O7GT?<C\M+X9*C(A.H#Z^ZH$W-P64
M''X.R=1I^#PD(SV/?'DH5/(1Q7#KA!28=;V 1+;_3D=7+1A_/FI@:[YZJ/OS
MFN:.6B;VVACY 0M(^;5#<8,%0 YTZ<5?)'DQ9LP,V%YXZ+IE!Y6W@%BGCYK@
M GT%='?JLZ<"P>+%..FS8CZQ.\&Q7!CGM,EDO::VF9@^9+P,J>VYBY9[A@74
M%F!FU%]<&_YX4T"@_7+H.[6YVH;+!4BXKV<KK9L+"_A9C06DDX PTBIW0IE#
M\C?4/>>%3EC B--2J%CHO!4OR@TA;0K_DU6^/[NX%"!GD>G^9H89KO)LS-3
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M*]KKX!L#W^XTMMNLH[1O=6@#TQ>!PM<.U!"%7F;3)"]0-A9 (;\+@4^C/YU
M+AQA..8V<O<9] CRG\2MK5(A2,FU'/9>XAK'70W38,)%.0EHEH+L"U\Y%E0I
M@OQJ.RKA$OC(ZO?]D_IUTI1G$?[_ *,XF-5LUKNW4-);S!R;H#[!RC6S+V<0
M'/%K$E5[_5&X-KXGLP"IL$SX9O?J18],Y>5C()4(D,0:\2#9;GE,D]W-Y83U
M78+[?85P_(_A*LP4LM\1#)Q#S@%W@H[S"+KOT WUJXV@M96[+HH".2;,LEE4
MK-PSDP.&[H_VX%)'8\'E7F2]9/9:[HG>+GRSCOG>YN. 86Z!E8];U;E&9O8)
MSM4+/,VYIJ O,+0#]QO7]1VPQ:5TFB_UBX);;\O#J]JEQ6#I;.2YW0IS5W?9
M^^3IHF\M8_+JNZ$RH3,,Y8G!3SRV\HQ[C?/I4[9-=DW/^"V2ZSZ^97V==9#8
M=6A#Q%56[)8U&SUB[60[_PTV>&MT&;>;TG 29(X!UG7=BM^YH9S@+5L']=VM
M;8VP,K]\I'*#[]_<QY34F7YX[@_<A=1V7C2%TF)@+#R(JT$>6;X[COOMHO/]
MKZ?*1WA3S7B:?[$EI92JZ/E" ?GS/7"53;^/P;3PLHFAF_54FIX*[7(R*U/^
MIT^N/;[<S:L62S*&[^2^;PG]8.NO@NQL160F-H+(_-WZ*MW  4%4?+RII]Z?
M:O\")Y3PU,MVKJ+ISF;*+.H]/8REW/\.;G%95VSS?'?24!9TF7!9WX#_AJY
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M]I;LT5J][^/$+^W86B;)%8[]J6E/IG$;EJF&(\J[\C?:'E8\MU2X(+2#W#[
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M T3!PV:S,U)\8N>PT#+(\5BAR9TF8B1.CG,#/$8U Z)S=LF[^^7R3 E,)_;
MG/0#$ZEM10^MO#/)&?[=JXZ?WI8,/Y"S6CEC[=D'&]Y5@-6*QH0ODO32[=[5
M\HMVAQPHFVKS!P\<+J.2,UN-PA]1;.OV<-L/NBW?G&V-)(B"**S\F<:1GNF)
M7M^=GR@'J '.M<2Y".DE=M]OE\%RC-I6B.L*T_4J3]"I.1V9 J(K'0<M=R3,
M+8F-S,+(2!1#2^WRM9^X$<AM=K)UX_Z6&DD',Q$!Q3>.Y<X"I "JHDOE Z0>
M46??@_EYJV*EXWR.O+U<0QF53I_$0,T.ZC96@[GFK&=_QZMGZEFIUDE1?NY+
MZ'[(FGLQ%&!\#!(:0>09)I)F>Q]V^D@JWH45*IUW?)D?T:W(LG:T+@^0]]5.
MKZSF:S^J&9G98.EQH$#I"3O480%OL0 7")AWJJ Y@ 64H8_):O;J62E]'SHJ
M)PVBO>.Q?/%'*>-*,?4XL4KAQ8.QZ.2#A#$LP/GHA[R;-@H-!Z&].C'NL%S,
M6*@L#D#%MX=*<\^/:Q=2CQ_?6]1])AE3=]3J CS+=B2:;>=N!ALE!AT[:EPY
MK35G>W'V_%C)M1]R VAN]L0&CD16?_4E\6L>%[V?F?B:X:FL%KW*',-MT%#F
MKV "= %;XM*\J\B4)!_?*D6/YR9G,*1[:'I'!Q?>F^/^#3M^X<&FORO-#@XX
M5A19JBDW7%]=KN_)C?.,]+BZ,07 ;B@^%0:7$/LPIH\@FO6>7>)/RL.?*:&+
M8]FM>VH/; 2EQ:ZM]R_1D'/]WU*<U13D^^?^<8,,=NDD57H;EDJ.B6O4>?WA
M(6TUJ7]-_N-OETB:@EO=8&D4!-Y-)M\/%KEJ?LEKM.PRU=#_/CCAQRF>18KI
MM$SNS<+>\1[B=A!'G9J<)F3=!GZNF)60B9CE?1(J84Q/#V[HK.7U>S( H="Z
M+/Z.4ND%-LA_(&_M9K#4"])+9BR/8&_/4'[F1^O62G04C[=H*!\&:70M1N0,
MTYJ]\W>4Y5!O; #OYMF#8[M_&[Q>,516<!5,;=PIK!&WRU%%NZ:K7W@8.&P[
M?1L?_QEOF?T7LK#,(GCKZB#6[C=8+:S3DO N4V>VK\ QK.O7DF+JZLGR_Z#K
MO:.:^,*OWZ@H%A1I(EVE*0B(2)$6%>D"TCL1$"%$0'H-$9$B54! J4J13J0C
M+?1>I 826D+OA!(":3??W_O>==NZ?\UDS4JR9LXY>^_/S#/G*$>);O*%^=2F
M+EQHDG2#<7N:#?UZSM/I$9.K9GLNE/&%%$B6,@<Z>.H'H331Z$F-\TP*DTWZ
MZG8#-GV>CWSS?FIK3"6A<)70F9)"!?"WYY#K"I*ZI_#_G&2^$HR&_Z0F3%M%
MGM@/#ON4LV=^5TYO1!8&(RUX:DOVU4T;4LZ)=6>+-7<UV@O>[D^H.'OO0\O4
M%@A@R5$$/II&<(+8O;-#*F!FJEA?W[GGDGDL_,>;BH3.@;31\?Y-T'+\!7)D
M,!]J4SZE"CO0R^Q8(0I^:YF9^&B./R3NLL%//C7G;67YX"EVV(T@1^$(K^OB
M8V<0I? #[-%?Z\$+MT>-XEXDGU;Z"]A'1>/9)WXFM5+N_3&]M,JCZN@U<I=7
MT!B8X7)J^CEX J4TGX1K[&2V:A_M\;/_&S*BR2]9V$OS/U'&PB<[0[*>#TR+
M/O:N3[0K/%4"+5!,E&<(0!SG !;^Z0WN>GYA91J84Z'Q0UN,YWW IU;/@YT[
M61]4@[B(SV!]3K@(,@QQ!"^E NSU&.>=8/0Q2/<G*@83@LTA9C=?.?#'\$)?
MO8U__1R>!'1B/!7CI>$M_(3R[5<>ZGG69!%(I,.X!">33LQ>]2=#"XC7:-SY
M/UF'"M@1@$>+[@"G0927_ST(FZ8A"5C06B>>*QRV;,^G?LH#Z^0[1V*;:@+!
M_+'H3$[@S;X5<I'K<7?M5SOI*]\[!^J6KTV_?7-2'DAA@VTO40' K/]N&253
M :?W6OS();#EEO\5?U,X#RS"V%U&5#@R]/._E.A@WJ"23,'6,[M'2O9=:3T1
MRFR4?SI%!*UK4.T.E'57$_X/RN:'?=+)9:LK7V!+8ENA":B6)8+AT@+!?/[<
M&$D'3\M+=?Z(]1;?]*JW<+YYU-_AP2,>R"$S0@7A('%Z)_@6+=_"R2)IR:HY
M\GZ.;/+?^ZNGOB9ZK%@*>]?E_,,%(M#1.Q:980NDNY;! ZM!V:B_<W_=D7U+
M;$>K-4MZV[ (=AJI\:4O@R/TB<+I=3[\"U7!\TI2\>T("<B16W?V@:L\G!PM
M1@7D3>2SEMD7\ _B_ KM!"U\W4TMQ+:)$OQM3<*X7 J[Z<[=104J8!NV[5;1
MXTZ?BH<#@VV3JS*CH[9IXG-ZLPE(!=A*40$Y64T7\"!:9][!@,XV@)2D/ALJ
M@.@)ZPW#T+97LLFL1\ME @E#X7!#EB2[$F/?I!2$5R#G0B5C1[0$ TDANG.\
M-1N%ZCXYG+T^:AE^]S5OZ\X\U$/JGRFC/_'#;,^24LH96W76+?,8AP$@*B_>
M1[%5\^J-I].F:*4M%!7@./>"QW/1+9QSKMZ2K[(V4/Y6;!6A+#C .4UL-[[4
M"FSJ,Z92:#GX)O&\\IO%I=M[(VNO:UQ7_X:+U%I^:G_(5>F\-S0#[-X^6\,7
MXH ="SQ^=,T%7YXT(FZ::53.0%/T1>4$KO +GFL5'9'CT.]=K=^;\<7V="R$
MRU_?G]IU?7B,IKE&X(>IV'N7GW$Q:;G*#6LN>D##W&T>DI-)[HM4P UKB*]V
M@9XCA!XE?-/:=NGU8P\>4X$ !N*[YA*\(^$"YHLBO3TV$Z83:C$A?='?/FI#
M<=HV4A)P>:1_T&=-@+>>YZ"Z(I/]NUV5M.6,&LO*9F99#3F PX)^)PRKQT(X
M$^61:O\S[V1@1<>DP@WWNR<6_^B/X/.V89FEVD#DKV D2KK\U_X[_(%3<OD3
MXG?!3Z\\\O/,T-DON"DJ8_40$/J<!.FYXT^"7ILM?WV]MI\%^'R=6/SQ_:8W
ML!J;6*(9K.\JD@K8RJ^C?%/7./YE;/?H=MX6T5(8_SXEWKX79@>/D G('"["
M$J<3_1_FW_+16E*V2E=1S+9Z_!&*:@#%+-3DGWPD^;ICR(R:54WQ>M[:C='=
M]JN2@$HUUMCZ85GN T9N3T\\7TN47@3GRG=OJ:Z2)Z5_ET4[;AK&>\2><IXN
MX!-&=ZMAL;R"[))/[%9AU>V=-WEE7ZLPZF?$%SYIR++6FGS$(<V! 8DF39*I
M@!4"GQX!C8WH@$5E7WD;:H:LWKKBMDU:KDVT%<#[ AP\2@X=+-$)6=U_J  [
M.#<5X.RG;K#?M$?<$0=56X:&?'\K\%4A0\X.MO43?F-_8;MN*9[-3ZVC4X9I
MNJ9Y.]C+9&SV]JIHXKD[Y?//9I5=/YN8MNIQ9D< ;WE%]^495Z48VOL8AX#$
M5>J>TM.)NKP/)3V)6?IA9Q_[*[++<%G'@@H8S*PY=34CYS6QT]!9KVONW>5Q
MA_S#ZVH+V9AOB0O/N.5X6TV1RE?J(A9AVT0W=[_T=^-'J\WUL9$#NHN(U&SK
MP9O0BZHX^.(921.G'@+'N\5UO$8'Y)TO>Z_^W=>17-A.!:!5K/AV*I8\"PB.
M&OM-S';6+T U5L4)E&)@P^4C<0]&LE1>0$+'P]]^30[51* 23(%_^1IQXUA[
M*WV@B %IROQDK'?.>CJQDZPI?7E#IV#J/6FN=F[F!-$J<1X,O!+,TE4.$E&!
MTOXLOW!>'I.HU-@>\#$:_;</?K^>7.\M0="\]APS8/CS4FN4YFWKQVM[;O1.
M<A2>@FRL]%YJ/Q5PL^7B<(-!>*K)/RUT+M^2WR/6;*L,T[57M;XW;93ROFKR
MC&G8.7%<]O[PP0C^VK/[01_:?N_PO?'[VBS>E.L'[>A\Q#%BD+BU1!]R!(OC
MNZI6Y, Y$% +<QLKQ^\D?5M8R2+8MM'_:ML4I7GM6V!T-BH-FOH16!D$WT9K
M1\-W^*K7!@>)M:>!<E2 9<PNT'<AWF)?J9&D0.#[75YI,7<TQ#_48'[CU=N[
M[VR4Y-TW0(\H78@#$S?@-HLL)38J?8XW_)Y'?GS[9'RC?-38T?C9WJ\]( _"
MB8]@>)8<ETX.)9?AB>]2AXB.256KHC'^+MF#IFTU1]D[;;3X$!%.&TRTG2-;
M>+HH9[SABN>VJD5]GT%ZDVU=\MC?L2":H"8F8/2(URQ@Z\OP6J#SR.G=AA.R
M5RT5,(I#TB(7 Q6PG.=G2&F?RCY[*KH3CZJB:/@T_U?H@3@*\EK:KQJC"=*R
M9?01[$Q;40^O3:#AQN7=XI;KD[^O_5[03.=XZWHW(_L8MHMPPR/FX1]PPMOD
M/+]H+"5U25.F]'7!#V_'..'Z5_X25$!7P+;-4VF:*F9?V 0Q*8)L<\#^FJO0
M$?=/+YE"#S6@$9L?%) ;TM_ MFZ0MT@QQ;[+K\<?/>YG!5B=9:GI%9T4Z,V;
M..8G@+C"\&;?YQ]!DA$#*V?3IPA\/:'_R<"M?;6$#\HS'C\W/=1FNYC:F-SG
M(H3)&8S8<BD\D&#KB(T-H#%>0W[#+!K\\ N8-53$E7&H*8X(N#WB0U]8KH+_
M1G I]&/$\JPLC^GX%T"8F^=J9O.JF'5M9)2+]99-%WC'B4S.?S1I&LP$_H48
M>X.P# ?A>1\5P^10N=BBHAXMPZXUDRZ)<+Q-.NP';*E@1U6B \[4A]ECG+8$
M.<M@=":[UCU9'3Z^"3$JLJ_^I/M!*LZ_QWH_%/O[!^ZP73ZY)?>W"ENGW"<J
M0,]S56U]<<<VX1^F?O,J^7I0'?&U7S M2Q*Z2F?G+)M\4"':T>:1IPX@,:/%
MLW ZIIU=T2F8'?#&/'J&D&J1(A37O=[A=J'NO)K.2N_Q!8^8LT0%3OX'\BF.
M)EQ\T25I XR&9C9:4S.BZ+,MS]9@23^&(%G"EQ(G=W:(QJRV\]Y$Y^+CPP4.
MT6QCZ1[3,1B;HCXFF5Q<NH:[7)?^8ORG)62A&IT>&>TOWLIZ%?UG[/[Z!_4:
M7RI@OQ+AB#@]W*<"*"SQ5$"W*+N.S'$%=D LUZ3&TB2&.4E3EAS :TWD)FP1
M67K8@WGJOT5;VXG]*Q(^[]=F&]?Q "'<,LF;++&3O!B_'<]AYA=W&8_>_'/J
MF6RC2&CE$)Z[2@4L7*J'164]VB<CNNJEJ8!S9:7RWC_JTLZ!G5UR#PWI2.E&
MQ]RX(:@#CK^]%L';PCP##9FT.-P^F?*4ZXL6<!UIZ7:/MR@L=Y+S4>)6 I8M
MEKQA,4B6]:M!CN.(PS"\_GY0\$V"F7=Z]4VKS5W7Y836BV^L(@^@DG][B,?8
ME@N5$?A0<HZ$]W5-Q;G[3U*'7!=)4[ADC5Q^I4/>/5#Z5/, /A&G5-<!#W7)
M!6_6[L$X-TS^%=[6>($A'%V6(=YBPP(K,B=\J  VN/ZTJ$[>$+<]<6BU?9KT
M+;L]HS2?TU%7T# L2-RZR?X=:>'X-&L!=[A41>**?S7NE2D_OZ7?$-E;HOSR
MD5J>"*GDDX<'@,[>!4RZ2TAPQ&VUGD4Y-UCIRTM6-U</$_(8_C+\73XOU?-:
MW0*.JUJJ0;8-J>C&-CWVAHA._TC<VVG18'YPFL1KZ751UW-8C]N4Z3<%R3E5
M82^X$]&A0$3+3>?.6LXK)I0 KEP,:_F?MW2K/?73FUI,E+2^]WNY)\9:G+GT
M]1)]%;48/X>U*,2?5RP5Z_YI_WAM56;1_\?&20RLC-8*;EBE^-;X\_^556\D
M:&QCA[O[='O_712HZ%%XQO-7(+XL"$?K+MCS?B/XHO$@37<'<@*^+XW%^6#O
M8&$['"#K8I78ZL.=85H0C.+4&5K[=*2]G@,6V]Z[_:K_RC3/A[PSAABH1KE?
M8/7:?5[=ZSV,H9W(]MV\,=C<V,*/P,6]G>>V2UR6A"9+\1\_;=" #=G,%17Y
M1#]C'^$/2S$9JRTN! QC^#A6)E<VS,VV::R\=B3ZPPM5?N@179R:VJX<5P6J
MB"1%,"P/,IF0<'D"JOI5_5GG89UNW^V!-^(OLK\?J%>FE>$N8+IK]D?,HG6F
MQNCJ4X#RP'L.7Q^[\OMRAWP-"!G[ZVR4L5'N4.#9UXG%F95R0ZLE6"G\/W*B
M+!857\K_#A_V1WI]Z-W*<#!*,)@QR_]G=_(:'3(^J)C=7KT4KC&J+]T[R?I&
MY"_ -#FRJ]@MA1'TA IXZ6.0LUR./PW.%6NKBWDP.EC0J'$[Z<QP?E$M;$%5
MU7BSD]L03]/IYS1];T']WM^+\-;C\<L9Z<"S7_>7'FQDZQ-D/9?BN7U)#V-C
MS DR+W* #\/*XG:,<]E*1H/XO: 2^KB47[R9O]81X*9@'\N>^J6)I/9X3YL.
M6@2?7NOT_9>75EOFD']KN8/SQQPT[A$B07K#YAZ./ASF +^(!J=9%X,@2' ]
M/6;-MBW%<.*.$BN4WA/TQ*]DB3U&T<'KP)ES9ZRS)QIBSO"H\.AJ_<A2$LB0
M6X:+[J^PKSB2[*MT]=N'>H6'QFN&E:/\T]Z,TRUG<E\J<*I-8_9A]=5.;205
MV0,X/VZ!9GRL)#F%8Z@B.29#;.?OX5W@_MT3O:IS9@UZ<4VJOV:O;$L/O9AZ
MYOE]U^K",4<;";(^$@JK=B:TO]U'Q.;4I6FW+:L&]-)Y)O6DBAS1'=%]"+!O
MEBL5@WD+TY_\+."^)$:4*]#5<W&-3RDI);CMKQD2,K$2VYF2F/"77PH2(>%W
MF<Y=4#RO)\#8W<B(8EE$D9X@[[6,&\>%%DH>?,OX+K!I+SS.'?\^;J9L8?J$
MHB540@6\J:,Y;P52X-&.'1MGYK"SG"SWVP^3J09(DN1(9 ^IYPFB7X\B%$^P
MSV:B OYY:I/R:.,#PK>T$$?2S"59(,L>>I-U^\=DHM_>.O&X)V[[XL.YUN4T
M&O33>)#FL;\*S*F UE,8H7@L[X_7ZN)&,T^=@K/V.:V\H@8W=9=A*L"*G*SH
MDH>NKFWO,;DJM8(:5J'HL@,S/RBS[]\HP<(XT 1;.^*E?/Y*^?D+?,DUVC*8
MF"/Z&%/CQ6P45S<OR\2;P#)=J*,>@R+:<NWPF@2T/-A!.6-I@O-X#P5Y63.A
MR)_KMZ7UKF;BKE_MW LMC?W>OR\TUNXL\1GJ;S^:_+DYBFAL@#;] )FV(W]O
MO?Y?'_KBI_<Z^8YXQF%[/X#MJ93;AS3^^[F;3@4$]5'8EDMP"ET$*B"AP(QV
M:ANT4\,C9BR[4&N100XE*L40=E3,@S?6]@WU_FR6@\^_7MGZY)1[+'+,KV,8
M<)J&H>3:%/\NJH%) 2FW3_YO/\L:3^0C?!9EFSJ:>O]!\@XMY+1 T@D#2PO,
M&S!6156((_:Z[A1*-+:(0=9#Y#ZJ"7#CHKM!D ;N[6BU&];%>C2<0^?H.__X
MG@F;X\>"I\_' L!_I05#"IZJS#0_F2W)];,YL<"IMH30ITC\_DN\/[MPQV5:
M(&':9*1S+SR5"KAVW.NUM8%I./S%TO6$HT-<@Y_^%QUGZB*"E*S'X$B!&9XA
M<X.1"P=/G;*/:6.NAK,^-Z+@(??6L8Z _=5'*;>\&PKLVU+*-RQT=O]"V5*R
M(=([LP57&.Z;QR\^:%!+]2[;-&F ?E,+;/QQZWZNS;;N1:C]=40$\!WP?.E!
MSL+6B3W8MF.V]Y)6*$D2?MHG'<Y"?YP%'CIH5T!L%?ZI=W/S[T.)^OC#(X!O
MJ0#FS=<"#?G'65]O._:O@NDG) :H@'B3'>0VU*-B%=V)TQ0^<:@2 3Y:.S5-
M\6M<4H\.<O#8\RS1 [OVK%17>K)J*3VZ88D3^HOF8]NR\&Y-0YJVU"4'*/J*
M%QQ)5Y<X_ DJCD[<G<N>]2:^8O4R0A_^G20L+<*B2/379N=FRE8^D;<&A![?
MBS>YS8 PD-RSXCR"!Q <B;HV9KT-L!@IF%V'$^(E[WO87B%QZ?@,F4K2G:B^
M;MG=$(8,+Z,,Y?4:Y6Q/Y_^190-AZ-;B5ZS\&N1L5"VO*U$&YF"M4F6Z$2)%
M:B#AAJ>V6LJX/)OJDODF$X]KJJQ&5HRL^3S@!Z9E,/>J_ZGQM^MFR\60 U_O
MMU2 2\"F'F:;,HE7;.LC,0D1ASR1BC<U%#F'"\1L!=+ <8_=G?5]G(@PS,).
M%V8(I!>'[$Z1 LNV20I.5JL%FOMQ**A9:ZZM=-R01ZK8$U\$T>U/=C:$)YYY
MEQW]D! ,#WTH]?2I8EWBW^6L@N9@V!AR>$2H0V;6,@K*\N_L+,@P[K/=[URA
MAAKXXNA11 \<=;"&E4D&1C1)0MSSG%(ON$QVM9W'KBCTA G<XR4(9&4PA"[#
M+I%4"@AZV()P[UB3I>T&[TSL@"*: W]_6'>2+KO5]);\6)W%3D%8OEI2KHZY
M5"?\AYV[W'=LB=:!CC1:Q\6U9QI6P]BS<(ZD1K 4BL?L^!)5]&6_]M\E\G2"
M1-:$/;MS$65!@1K5-2E\UQD$E#*XZKZ_XPBS&JZK*TWTJ4T/%@MCU;?H/63,
MH0+LJ8!H7C:"I2<V%:=<0OY>5_1>;&1F)=5?17SOV&FZ>V4KKF8X>#+[IA?C
M%Q!SF3?H!FW4.DT+I;,UZBSWW1)@UM#H*,Z*^6_.1$Y6T\QC,Y$])E_?$][.
M*JVQUAX)L(=PX!84O>?:'+L'<$Y!"<<KRA;.]RW/S&R:(%GZJFM[QXS?R0&2
M/C("WK54DG,13J (BA)!I70][18"OZ.+V1E\#8W"*K6]4W/[L73UT3G%-$)+
MU' M)YLC9Z(KCD$(;$D?41+^.RE6AV</6O:[0&51@A?"=[U)#P)W\N55W>:X
M:/;NZ6ORLO?(8,'X--.G<_!*DB3Q+4D)%QZ-=[N%TLP=['B//Y'I/IBAA!DE
M*OU07P)=&=4'7=-F<E0BYKYJE.MR*.J.UI7(G>2#,J+B%Q="O'X8=MAR!.]7
MC%:GU,XN[ O$PKB1_2!NY:?."YPUZZ[B.;<XC7^*.A;D[E[);MJ&?1FFEP,
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M1(G:]RK'DK-ASJL$M[P>S B+I94SIX P^=;JPG7I/\*"EP5<=36YE[TX;E]
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MZ=2D?-L#P<F_&80KJ] <7X%C!;*G?TVH668X9+'Q@O<%4X5V^VZ+K*,G!Q=
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M_9-8\N=A!,!K>875/9&P-LE:]#"B=\BH:72$UYN^H+ZI\OT[JCMIDA!O*?D
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MYP1X(Y@X/Q] 6H0( %?(F9IX '27J.7L0V&@[0-7' #\]O_\W' $SZ^@<HD
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MNBC?!90@C*9G-OV9AF@SFJR:O+O,O^(A6=V:,GG"P<Z+_%<$)IF1:=FE;03
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M$*E;8->7[D-C0P#0^I_LM*X.D"TO=O>.MR@&X;(+TQF>'[9\Y#J=?O_ZC6X
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MN!:=HNVSLA"-[6FYOIF[1:)A2JR1GR[L"%!&+E"OWHA+^7$_4,LJC_0\3*Z
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MC/42 9 SVY6-EB#.H2O$*3VL8PETQM(B30"$.D+QPG%_2KF+&H-_#/H-4?(
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MCD<.3.<G09*)JENBWG;JLS P;M@)N-&VU0 &SFR?D5DV9J,C\1;6Z*7\UY@
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M>#5J3>4J'K0-Z^%DHADIKZ+VI_%S2+$.$?J=PR(='X)B*A82WVY9K%-K__M
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M%V>:\.I]J=A$G'%BNRQND0CF]7@\0C/8)D[]V-=S7+]S!)!*EVT\O?J+]4=
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MMG>"#'"WSNE<NBB3]CZ2+_X*2&F_O2;]N4U>0<"&ENPV&/_]2PE,F>H7BM<
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M[0;4VHDL/0@] N :=K2>0Y%WWV+G'.T'GN7?ZNW7-[Y:RQSUM5-3.Q[6FG
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MVF)JEG*.0&PBI+J-7PML]VSC(RELR.P_VD<@<P]7OEAO)&?ZW>"4,+BE928
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MSW8HO&X/8(E'H+/Z1"TCHV&)X-YS+VQC8F,M+L_47DI[V "J>GKSU!>EO71
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M)47-W"&/^;+R[08DBB-Z!<K&H6N_5K+&]_G7!"#DW!8ALBS.7G4/#_12G&R
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M_?7:3G[P#1L5WG'+W$,>QF3H*>*ZIR_]Q#K*@: @4/E'U$4J.XV-;/'>-Z0
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M*B(?)OKVWA SU'SQ3+94KBSLXR(:!.A0ZG MET?]P3ST[U!RNOME#96)8V'
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M%-?>5+$]+[./G\.=EF4"?;/%#UD]?]WA8.U']=UT'/15PS"!>!(L_C8%G8J
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MT^[VK^_ZR%E4EU?$*)4JY=O<B3T3DR( ?&![#7#05@=TA?TH*F3KEGV%G,@
M*I9ZVO3$6K1GV@I]I\SUNY5ND3FU3O-#CN%.+S*53>,TF=_?@.57K2)?4'BG
MT#@H'SQ7Y9&D B5P*[IJW,C1,@ C9A#@VB^;)=:BPFKV_LL79U9@2LOY\<@4
ME%]%7Z23 3!_ U-\*,6V@VHJW+CWHV<^#:$UM+TQ178Z]CX$]=?=QA/=Y& -
MM?6X)0\&(&L\!=L5EJ9;#NODTUM@[N !JAS.29:J.:![@WIPKRH%9E=9M?HZ
M<:W+MF UCQFY=/>\R=?Q)UMPIBQJUN+"KBGB)F@<3EEHS=6AF%<G"*:-3-;V
MO:ZS;[3JY3UV?SI @?_^3;?5QQD')-8L+HC7M/,>)""N5.RE-*B\=S#W+?0,
MFC ?B;IQI(-M,_QSIA+^L<SYKWXC79YT O800F)7#U3!806:Q,'[/<W[ JJI
MWE7<YS6AA'5SO,,ZRNH*NQD75[5-<M2#M@_T033/QL] Z(@.+E.;THLP=7TP
M='I!R./7&^%KA-'(X\4'&C4*+[+>G$SUZBV#NJ&2(:(-CJ1L?75X87,&W  ?
M3)U_X(X\7%T+6]*)7Y4.RWPA=B;C\KL+'4PB7\,C9@(MHI'B((X!L/!0$4C%
MJC3KOH T+H^M N-:G=+E^QH"*3-I;Q(CWVS;)W_<$0FT8/V-K6A?FJ6T$;^$
M.O\654FK;+S8;].G6OLH*'F36EG>7:XL:*+C'P%8.;-]'\%3LV(1864HW,4&
MES#*?B:/C"$[:C0+^1\*?"YISPGF7+H5]0"M77:YUG5:0+)J$<:.<L.*=5$3
MFA1I,*I0>BE81VBM')>^3%D\:_QNSD]+WT7:;*W^HXQK[/E['??57^M?K0%C
M2A%:>Q%()4<0^<M+R>(:=6/S><VMQ5LV&;;._ +2CR^S.J0:+:9ZTAOS:"=?
M3#9,\/1A7=.2AK07A4XH(LSW5<-I\PN^@OIF<;6V5^*V(LXX/,-)<=VV[D/S
M0ETR&4!L"'4+SRLY;CN&)YN';EDE+ABGCXTJIHDU3WY-2N K8$X^''HWRNLD
M78 ^Q ^:Z_(Q $Z%+YL[\H]LT<(7/(+JMC)8QW&H079U!G#X]LAL4$AA@)!N
M''D#$T]71JCL9502XZ_-$XSJB^$Q 5V>.E]G*AL#1:(<25%UE>5%,E/H<])2
M:_6[CL@N.D#I:<%$!"$%>Y4:Q"2KR+R+W*8-^FCGL/J35I?*O_9-EM]5?I'0
M+>/]JQ%/EEL<)?,>=D!PI%E0^0:G*#Q5/ 5%GOK'ZS/-1M>M#CP_;31^3.KE
M&<O>>S5(*$)P6/\4.$42JG@S[K&YV728*NJY-1<F7=QQ"!",/W5:I=WHE-Z<
M0Y"N\68D:#Q)C$9)0MVXW;XTB?4CI,/]R'?>C.FG>&<VD\?[K#*O1?AJ*FJH
M7STZG;.:HM*>*TE-6[I 36M!\2$/@U-38K\)8TT2?:7K,)ZR\G=SF9NKNJZV
M$LWLXN\1@GHV&\Y>B[ T(DM@3V*3)FA8,J=A%]Z(>:1KE-.XX_1U?O4BP.+,
MD<Q)[4M,"YVB6>_JT<PHO*T8?G!W,BN>IN>,N.[RPIXRG)3WJN3$9R?]/C'\
M6L%A4ZE F>GTB+(=EC2UO2=E*I500E(+!6Y BDMMDJ#)4UE3E:?[$19YG7=\
M/#ZTS7,:=+8E4F=GQLY>!0X(W#*F'<%L>H&!4]B1#STM3DJ4)C2YR^)&[OR
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M+!;)]A3Y \:AADIV8BWOJ_1*4O!ZKW9T163E51^'XO4\X,.9[KL2]9)>OU;
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MKO(>T'@ +]N:<EM*FH1&U&$>>6^ @6&_:9:^)[IB)IYX9_$)7'MS5X0I8W=
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MOXJKT06'U!SM+U$FT@OFZRIC?2[N-#?+RS4\;$VZ\COOS8GL5)LGF7*-DD=
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M2KU:F _A<?+Z;^R]=U137;\NNA24*B!5:E 01+I(+Q$50A$15! 0HM*[B$B
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MSG^'2PB5>[!D%<7V";44Z+_FY :+/))0P396$J@T)-R; K">P=62I)$'XA0
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M%7<<-PX62FGF63=3CW0M2+=^;)#D?<MFRPIS7?B^8V<E2DBKBTS\35R?D]H
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MEH6D@<O+SI[UW):!MW ?QP_5]NP7H9EC506_2N;=>19K]SXD5=(9:3<$E:
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M2PL^<=8UF3X5+.!UC:?,([OZ54YBR(78%,WB^%IBQ&=7,7$& L^CQ.Y8(=C
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MHT OW\3J2Y:<5<Y9O;G+=397EB\:0UTTLRHOJ]YW[CD;^\;4*+^T:LX'\>V
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M9;/:NO3OAC +P61;YCLI=WKW&0X^JYY,<"HYVU-LX"+_UM*Y:BN[YG""N-V
M/$/BP9M':]"4PH;'VI_@QI)B'9KJ7@LG!M\Q55QZ1T)_<%_OAZ%RJU$A%.!T
MT&7R0),8OA:=H6 Z*/M<-!-R]'"XH?)ZB&[\33_!IUW:S)&Q";J6NZ@PRW%T
M 06PY?U=5B5XW9C):NK ?R:I:];G1T]4VQ;O3C#C\#.Y[L['PWGWKPX)7KV2
M/NI5K.AA+CHR1!940W[XL4X!Z!#V"$&XV_#BCZM6 89G+C[L2#W,*>4T+3]J
M.5FL8/M)V%:5M^M"XWA[*I_1<K3/^UU^"[<J"4^' ":+[BLW/!Z^2XS_U4L[
MQ?K=3]#8\BB;$#"N<08_0/"J(%H7K#]SLJPNNLIA:3G#Y+<D9*N2>$7^0KGG
M^Z=^XIIQ]_55BK/?R+0.MYD_7]-\\_EKV='#@VELZH8KG@-C'/%;<7IB]]CV
M5@U_F?VPN-\MAF."^4WW["_ 0N&W7W4@&I(@WKA-EI48:CWLICWTG-^B; N5
M]S3Q8[S8ZZQ]Q\N- *O)!YJTPYB.N9/DJZ03.)E:QWD$=P(;44PO-^"KQE3;
M^-FVGIOOXG40J9Y0Z6"-C*QZ"C!YUPP'(ET9B($><1]MF+WPA>+>0!I_-UWX
M695IO 7[_L D%*25X0IV&O7\LBI5\Q9_^6W6ZLJTT9YUVHPO6.L2JHI,2Q(F
MWL"GR;ZRG$D-^YT]Y&8?Y:RTGYIZMM>CV:$W8E)^YCU7>HH'_>IPW=Q$_GQG
M:)",!1%/LLBF "XU[P73+4'51JPI#Q]Z4@"S]0\'SN.:FGW.FUSI&WX5O9?[
MGR_PB@_TN6_^)C4M+*WM@4(0E0-19(T;*/V/-JLO7+.EI+V.<Z6BK+ZSNT]^
M5AXXS.OW&@T2*CR2)P\$G1D/XE]O9B>+5@U@>D\GGJ^,A\19VP*-L;;GIZ5>
M7 Y1I2O3"3Q[1)4*K47-PR3G(I)<J,G(A3J]\\W#/N)28[_DY>-U>E71D8@%
ML/='X='^W#<5XR][CJM6ZS<O]?P>WT^K'"4-9S5E),QOA<)]CH2Z%Q!G5CK&
M.RP%&GSTSS>\)PWQ/[G>M7''05S_]J!\+,M\60S.NR63\SAAJQ&!_2H\2TR_
MGZ2WZYCTR^F6U4#J6?HR+OQG_:9'S[+KB@DQNRJ(RK4Y'P^;@'77P.D#D-R0
M#M>GI?#_6T'\O[5 G2-FDA^(M=%NEF5,1LF);[=(V!<L78UI+22P,TOL,PPZ
M-%GGTA;2/G6QY[KHX//8BZ/5+,[)H[D8](0\-D>/P #X6L+OC--]3)8O7M.>
M>R"CU@TJ!\,"'[!P-PHU#1/%L=.(J1&"?S..T+0Q>W[DOKN'K"##]V\<I[JT
M<F3.T;R)7#EGWJDVENB-.7YR9-AX)_7%W:]5/27GZ'0O?SL[:B?DE"TV+E4+
MT0H(#>>K:!\D"UJ;OUEK1@WFZW":+7__=Q?W/]I\$&?(/,10;$W=E$VP2Z4^
MG]\;8P6W:*[^*YM[*X H08!O2;( 9]RVQ4%2M<)C^N[O#M06Y79T93_#^+H?
M]7C%;8X(.AL0]GW5Y,B=4YWK/(OK[A2 HX88=R1-G,;D1RZ.H70B<O/1H1II
M;OV_V&XK7_DLT1$0N_#5[TQ@+2@2@;$A?Y^5JL#]SIEC<VBR"O7S\O3BOUB8
M)%<I0&>[S5QQQY!;=4$#'I=#4L9[?,UO1^3!K"Q'W1P&4KV=\_NDC$/N89+U
M5(03"A3C5'?$7P3XE4$%- U<6>G\=#?A9KO.+C[UB(U]K+0M!MZD-B);]15B
M&"&68F7E9W=TZS&+Z"E+N2\F24$>U[KZ=9]J\9"DQL@RL%=5@6S7WD"8C*7;
M1ZZ@V6.9*^[;=@L#)];W4$;'[X+$'U(I+(G,C><TG5CU+\F:Q<YN*^E6?UF)
M[4$OT:E;B7PRA5D2/'FU/P9UVYS "XZ%M51OG;6N*]>7KS]/$O;JN7XNTS\%
MV"M,UM>IVPL0K'.K9'B5S6P%+P\_SFJJM;(B03IMU'!ALS1X'4*X-\*^8,:B
M-O5J?4!#&RK^KE21OB"K@$#\CU";Y2-U./\P64RI&8L\9W.K26CXAOXS^'"I
M1KIA@_KQ?%&V5Z?XT^50Z_;F5F@XF+\1A.K#8<>.;HQ?#6Z$^(C&BF&B/5BV
MMIO&@!!Z8;L72FN7&A0&\M^:M6N;Y?8*N=:U-_OE3I//)"1?0MD0/=UQZ-NX
M>[53>Z5SL8V/O61Z/<]8*?;5Z9R)?6_R5)_7@V&!AK?O!5(HB)[H>(-HG 6;
M0Q_JS$4XUCF9K>O5I^DK,7!^ "E(\3XX,<%F?+)X2G1C:("YK/261@7;!^CE
M7\Z:ICO#X]M?20GI3J@*DC4N?WX<#3U)]&T7NC#H:1__:_926G_'FH-K84X<
MU/=*7,/U+YBW\,["*<E%%(>U<VJF\*CC4,F<\;!=QM3P&$0&WXY\*R^ZN,"[
M.,08'7#!:])M^^AR98QGE@?A]RZDD*1ZG-QH@5=O50JZ,+QWAF^V9S7G7ORV
M7XIVQ23+]39T4>;>, 5 ,\-VR"&S@O_7QZ]MT#AQM#+YRG'R\TW0K7$9N'*@
MM^BL3:%S0U^D^X)JQ]C=+M-FV-/.58OZN8VMA3Z03G,S!0B?QDHT]7J*DJ&'
MUW]/Y58@JSXX<GU?:W+X4A(8KI'*NN=RWTSH[J_H-R[.+F/U2G CG8#]C?%Y
M"A YQUFR!V6"1=YB@WWHV*;2_9E;L6L0%:,CID\'%;6)HX(Y&<U1(+I&'IPD
MAMD(:W7.9TMP36K5Q>RWTT(L!8!=_KS$]F@QWN+E"FS%ASU5]NZ2\Q)7T6-R
M3;Z0H=+,;,K*[LSN;U@&JG7@K#5<\RN^L.H!7-.M)P1K#GSOT!8ZZ_]!?O$#
M"ZLJ]LOEHZ81*Z('\O.B\K@0:!3ZK279;H1;]TC[S::Z/EU_O\9<^M;NYE0C
M&@VF)_,1C3&-<VPD+]< []RU5*DIFS><)66O*^7#M<Q/Y5S*C8<"K$]<5<9F
MUPM7L%<DU5S"]29;#(R^\F3.,4WZ;&M!LYHBB ,XSY9MN%PY,1&WEU\[9.<3
MC^W 3-:<7%(^N5C^B )(T+[V#^W47(YM.DL2)/K.-S,3\]O4C' 1 <\A%>5U
M[Z<(?B*ZW3/"4YR2F;R0OKE@\\WLO$B^+KS R&TO PF#_:'\RMO3(*$AJ $)
M1N2=/P9KXZ!1),ZMO-7ZXU'N$-7%)#W"]]SAAU^DZH!%CM41.LW(V"8>$@]1
M[= C'0ME6C],ZN-[[_/C2+LV0=S#SB[QGL!.-><'VWA=\YJXY)0EQ.,GG,N\
M_?(FM8W3M5^KJXY9WS8*8JR:^8G91H-N=A&2O0=A9S717+'RO]M.>NV>KFZZ
M!)?_H<5.?.?D_[4]HV\R6$9YHJ$JX,'KTQ;WEI<TBZLK<9WH@;,D.(Z<B(EH
M'"6)!WKQ&9WY1>P2K5G4[0JLFPYYZK_M/^Z''9A$Z8Z#G0(0]$YL6J\^ZN1!
M"FRJGC66%7]YNWF%^^#=6QIQFC>AL=QK%Z4#. PE,RS9J63XX9I$H=]SLTH;
M7YO([YSFXTJS9XZ1BBA^HWE)JS.Z9UP#+//R:A7\W-46.<T<)>O8_/.&_3G2
MEK0$R /U#LBC&RXV#'BCBK&K76YV];6(*WKP'Q>5M$R"NWI/*L2&0FHL9V@_
M&Y &8\5Y)0Q35F<D7O@'1?9?-9\X%&_="GX#UVLD^C]?/YICDTC1]K[XO9!=
MKO<=VZO3!N)%F3PIXHH[/.W&I_+1 U&6RY%/,GX_JJB;Y/S,_'^P]QY 37_O
MOV<4 14%I2,E*"!(5;JTB'P! 2'2.U$1$! B'20DBM*;@(!2OS3I1+K4B'20
MWFLHT@DDE!!(6W[_G?^=>[]W[_[OG=W9_^RNS#PS3/C,DW.>USGG>3_DY!R9
MF^=2?)670CTZ77(-=:;6.AU\OIDD6>I*FWO RO&NN4/0-E3HF8KKX/4B2K7A
M$2^_F,,JNV=OA<C$#,R'U0GBZ9HA1N0(./_45(\'6V<4XM:=9VYN/OSQWXFY
M,)?ZTX^BZV?BD^,!UK=^F5?8MEE?@?A<D;9Y;'"U\P;H+JL423!"\3[0K]S#
M+K$0_HLB@C6K\EB&AK3(QDONGG.L&_OB</!N .&O(9[AO]#$Y^=8D:&C9=8<
MYR75^XT0S>.ZKY3@=B#2(\PW 0[<J]\'AS4Q(/T+.@3:4MV_R)Y.',>4<5YX
M.2V#@N_0=C)ZQ>F^[UC@:,)"(N2N,CUYF8KO-+[RE5T\+<R&F0XA>FJ.=QC+
M2UF9C&#IQ'. 5S;#=LLOB^LPMC]3]'E8<B"55!WRU..CEJ<3SBX"N[<LC-',
M\_=5/;]C(S=^NHWQ4(G@_1WE;B? 9:GSA(LS_<*6TGB@6;YC=44/3R;;Z_@2
M ]_T8L^\P^T7J563)9-0F=^]8AM,!-,63BH@M.Y?FR6),I0[6<I.4_!A*7#%
M21;"EPI #2[@-ZT@V$$KJ0@JP!GC]Y/]NEZ^/T0OF+O>/E3;]^+3#Y_,/;O$
M]YT2_.=CD^ 3H) !H<1E![BU D8UB]S<C)\]K5AJ.8?5/VZ'<#A3>$<=ZH+Q
M)QGV"9M?[+D-TW\75VP4_"V[%VY'BR*XKES5:'N3/G& M@R OTB.[K^.OM%]
MU]+DT&.VW'4;&%8+HA6GR$V_I+!7C\GNL3@;_XJWX1(*="UBO\_^:']WGFXE
M743(7SA;;_ <06'9#\.-$VNC"(S"R,8[$RGR''HJPY7G7"^C+K<:, A<>8\N
M+"77-1>/=!57LHG+FHAJCOG<=T];)5C7SL[[JDGD-!/Q4 *PX*Q<SA2+ZC1[
MZ";55M'$8<B5%Z'9N:^VSZ9HR/-E?:1)K]U/*6@]7([K, W\;=/3YM%$;<>7
M: ]W9=9DP<1H)\$#ZZ+;,]H#IJUCN0_9UE_DS>B5IZ'T-IP,-=FT+_[?_(6@
M<[OH2DC''L&<HGCC=K9:/X.U3T@4,)DA-KYGA]&W;HSEV'6OF!2''$)/>RTW
MH5A:>//\=O9=E>Y;ZQ59 -&2(+_;@0FY]"TFF<O?[[%29D"/EQX/;"Z*@A0I
M)4?$0?N<2+$/9,%_OZA:#+>^4D!*1H>#\'>W@*?&0O V\Y7!+O")!.H:8N?9
M&.CPJ^Y6V^Y@[#)XR?@($=]VINWG8/]A'Q9@C 1[X4ZFR!O"(1]&K*WGNP>]
M/#AI<T-8&^,S94)^#'+=0CV$2\$$<)C)=]5[-#"1AB'8S:7/3_?+A5*77^Z^
MX%F3N\/B1K\GLSO7GKZ2@4XQ,3-ZGVBP7O&^R_CG2(:"P:YU]0YFUC'H7#ZA
MJ@OX[3CNJ)^1DP0J<3&OG< H-PS*WH0[VG[@C(7;IT?^5E.$#U$$"$3Y..'P
M5]6-\B,3IF%$Z3O7%#X;^V+VU>"+G?<6FAHB\]D"FP=TEK<4E>ZZ&5-L3^>(
M:3] ^['-@93Z>2I@TQ0V2[Q+TJHD6..JVF;6BNZ$Z<X+E<V]\ZJ\?STQ &\F
MVL6S!+9+6O4V>C)<,+;P5<DXB:O#<E3GS119$^<7!I?P3^M(V%:[1FC,W50#
M-(3KLR"<K&V:4=V*9O?B;R6O>WQ\JJ 1"T/A/2=E]UCA0W9R"$[_ DT<*NI5
MF1M&UO:9VW+DG7A8FU1"<7'^NQ<7R@T4GL9#: TMB1(27D/)'OUF<B9\L9C[
M\BTZ&TW50V0] KTK3I([B[T+IV%7U3BQ]Y8R,(Q9#S^YIF6C4AR/O?ZK(CHK
M[7)C_7*3!OYY36H77HTPZN;!HJ$B5MPEZ'ZWNPW\1)TW7 ['RTI./HU8.VV;
M@R;IN(K5]<_/_FT^G%4![E(5.Y-'L37<5^&&SCG;N(XK*67';FO1=<F#&V&_
M7H-?!;\^)W>0P5::DU<ZR,$4GLE>ZFH\#X1OH[\!@YN>+=^>/&3B5,M8:BR0
M:4Y*OS?(:>3YEPS].8Y1T2FV'O@4D+U)8 GUKP/.F"[8M 705D1 ^1;4Q5]K
M7N_MM &F/ER4>>-V__=DQZ&92UJ#IU_%ELFO(N+]-B9-]4&_P,W5*6(=_@/.
MMW%Q;YIFB7;A79G+#=ZQY-,78+4T'Z'&2H13Q8SE1<$7-''/(.R$Q"X^ 5S<
M)Q\JX)I+ZOHGG3BB+EXOYLOB2B"/-S#IN:$IITAN'%=TLJC.3FD2<FI'C1'1
M8X<%D<->(0ZSQ6:I@,5L]+ZM+!5 /&=-!6QL;J]=OK-/[-7R:-]?R@^K:Q]%
M91\K=")/[H(N("95E:D =9?-:CTJX )E-HO^T(W)?$(K;H57_(Y_K@.+8&_:
M#<V8N+U;L/=O_16Y+IBO9[!E58X&@?6(UNBFH@5)40E(H ]*X_#\+#Z(H$.4
M\A>V&H<%!#BO<$\OS[)RX(=S&Z\DQ<Y(_&K]')\\_X.K]ZWKHEZ146!17B1;
M;<Q<Y<\/2=$L/X/;$^@-=.38V#RB8G?7Z:38KFB+.QL_B7[C3H$6'2-^J!H<
M:)(_D"!!!?.#]H'N<I=NUM?&YR;(7_[NX, ?K*H)\RB'&>&R(G;L^BQPOLTE
MEFH*UF@78WWNI[\=+,-5WMDTLVJQNR6%=_;6*'E/1(K.[@8U$EDTG@FW9MU0
M" %5=77P'T0Y-EW_8@K+OXLYFV'BQ^[;G8M>G6)C@I6XZ*Q*1.P.S+E$LXPP
M2%3:7=[GO!UK7F/,=8<E "%RTR1=B@>767"@&QFFNWNLO+&VT)F0WU/I&BCQ
M9F8VRW4>T2OK!MHNH@)&JTS!4U++OAD.2U0 &^%RD N(R54I.L8O'_+HVII9
MN-:L1DSIAIG\1:_&S+M784Z:(*=<VU\"7WK9BLRBX1<+]YI14D-D)AP\"]>W
MM/?^*,:KG0K@J>:5D%"0JT9,X7_5B=#W7KI+Q]@5$XD\DNO[UXVRB30X%-EK
M#''(A@Q]F;]S6-./JD$$#.1@>B<JH? &2C@1@K<X>TR.T$4%V-2 R0I"+O!?
M;V[!3,AQ)-/%&#'#JO<VJ<O+ KQ]'P4D5AMDWC)<4.Q<9-*8O&#^\Y.Q]U[0
MXTU'EZQ;KQNB;>P:T:L%RZ\(?6TR!*F.AH%W7N)>@U_M]%X>:&8DL'HV3JK&
M2JO&!.DM M^"KE !+Z6"&XP(2EN3;5G72T?DQLRVMIROC(@F>0[+?"RZV1:J
M^4/%OA#(/VPN4EOM1,?7K"23F"$GTA)7D+LQ."(5\L:@B"A,H(&T$+)7MH/L
MYN/A'7GY?;^N?U+HN?2)[OF)8;4(S84LPS54!5M-770+/>P)]O&-D.;:JF)!
M;!=/5Y)EV6.]VPOY&C3I;P(C"9F1@],;1^.9J?TF3OJ=68T7QI%^>U DB69O
M<)I>X_U27(2:$$QLPL>59?D<WOGZ8N*] 3X:5._<.;>T216:05T,P@'U#HC-
MKM[CVIP\)8>6(2'AJZD+K3W7K/_^]/ 7YWFN*)TQ^]4?PA<FUWQ8\W4:M^N]
M95R\34 ^< /7P%GA?1*XE@IPL/73(E00E0F)2[0#)8QQY:A,"=C XXINC9*W
M'HVOOES)3;>?:-;&6Q$NJYV?(E1VF4P>DHW;9Z+O]:EF9MU\45L'OJO5]?IJ
MLN3<1_J^=^DLD%1OXR3Y/:=Z1=B$;'-Z@5[J$S,#_.A(USCBFT(T!K4DC@.V
MD<U?-9A'[$!>2,N;YFL^W> HZ&?1R3I=$P7/-G:PIZJN?U#CV.BOTL6.?X"*
MNZB3EQ[$B_G-593O-IV,AQ&589X$,!;ZL&9<#D2W]2:EG1MZW]CHO>M?IA$S
M=">OPYQG++33F:75D5<)[U=<J8#P!?D)F'Y1/+Y?=ZG P2Z^:.E)H&B(X4Y.
M"/?8VN7/A:-]N6%&!N"Z1WM.!_>W1'+JU/S_72+\CTR4\CX;[9]F53'BW>?7
M.";U5<__IGI?(\^YD]1LB">\%77A^?#A;%:DW:T(MZZ46\Y:*ZO7V\\QS_$<
M=L_]?>JN>E&.)>56/?K=3STN6R-KGZ#XC8;>373%\<ZQ6XZSIQ9%J(7VPM;]
MY,U/ 5540,-[0- U/SF<>()LI4PCA^]]1_L$G2T=Y%^$ YP1- IR3?)(SO&&
M*>I4/HO!H_8:',=7ZMFU1>]R4%S\9-4\L*IOH +7:?X[EZ3H##PXH9A=%LFI
M58/]1UW\7S&Q681C%@-,#3>.+_F;T'*3KTR:;E22;^O1I_1KO8"G##0U;U4#
M#I',.5_UOECAE; U*Z%E-RJ#4ZT+JM2FL< /;H@7*!K"S[,BZ<91QDY#\GA5
M5:VPS"OF"^>LZ;WV3KY=?(+R?Y>*18>A:ORBX#<((#!VX4O!RZJIZ8!,FY37
MCT<R]F7#A!P,QP?=/R,Y<ZI,DIMFYHY<UMG,JV*O!HJTRI;N'OGY0?NY^>[A
M3-$Q),,BU\GA-K954F> T;QN)R?^B8[B:2+D,04-Q!$7D:?K :0E9&)A\>OC
MQ!V/T:Y>SC>'@N5;^XUH5V72WKY:(3D&SF\QL]$B@'TQ4_KF=@EL;=V@,='Y
M5PRG1K7BC*5N+NW]^4&>&QB2O@,NL%6-<UP.<0UF-UR]6CLW)(RWN5)5R'/^
M\8,PX9CBLU431\O&G!O@!0\KTE!)$A=_O1_59*Q3U*M\K!?X)A<#"KTV7[<S
M[ )GK8GT;TKBV%=(D*0Y"?LU!WG[H',>W1;M%5E%U)C=8H'WU?8%%6J4;ID9
M6Y5G!T!%XJ^TUNH<,&F_\@:J0ZX/ZTT1)U'6*>2&3*XA?&!;XO+HN-;L\:3Q
M]MX,FO((VD8%G&[24Q)OG-!%BEEY_#93@75QD[,AL_O[&TG(H*2FN#H*$X&>
MPAZV$^6\]*_=^XY!#3J@D:8L!<>^4>'YN?J!7SZ\KI_/:C%:*J!HCPJX R2W
MM&CG5.*]]/=[)_=5G1VG1,<VNUA"UC_=RH7[5MOI ,&47Z#+;B35HFW0-9*V
M0GR.?]!Z[(@S:V'2J&>/O')Q]-O[?2SS 5L4B9>G4(PZ-I:)V]^1P]9/^X!=
M[_;-?!%&.V9ZLT[>(*^X963,RZ^;=9*N6PYZ"@5@AB.0_:[L7GFYP402)K\L
M1ZV+ %DR.UOH;E$!/X7SMN2?; 4O-0U6/WKXTVROOPUS(?KKQ97OY<@?5OB2
M9?2')_[FK0MBE4--;DMUE($,AQ@ARPNTN5SF6FK6;\N:33YJG0D ;DUAK>/)
MLH'(^\>53VHD3%BYC5PVW5RE?,I/LPPIP_HK>U=@('WE#@CSX;S;$5V,NZR(
M+,'^8]+3$VV3*Z:6ZG,/G0I@O*C_+O@N267E77(V*S-:U0&\Q8(UB8EF?O-[
M\!F![;B86MP\O!?!P)^Z)'$K845?^_M'YHH[U9_8;ZH+GAL$9(HU8:$A:F(O
M\4K/AEL$7O))#MD)H>6+:-3:CV*&DA/%YM.]V;"VK,VQR:A%;PV5:-= )YV%
M82M]9-BP);K*"O@4I@&]")S)^B&V5%-U(V$>T3XV]6[U)*U%?];_0 V_2Y:Q
M!47 A3:S&!$N73?&>RTW&S)#KI;8]/S4%$[]%=U5B?V1^9X_': /NZ?)U^$3
M),X 2K<I,$C5[P?W:;I:S;]IS')T1E>2K*0ZJE9F]U@VT=A(:W3&<P5)TV.H
MM&A5T(_B*>4ZGG=#CG%AH&L[<"'XI%5R07Z6C/Y[[82!A5?7UT6E';"![(Y=
MW]AP&:R!MX_A?Y5N9=S1V#H,>)X_,"FW2W;+.9'9W+M(!?0<@:F 9PQ[9,'D
MIEE\/A60<+2,^K<@=]B9:CIS6ME,;MH/(#\37\E^(R6O%:X''IO5HN,6 ^-V
M5I:R0BDJ-1,PU>5#/54XW+O_H5[]+6)?G4M,*T/)L[=/_5X<T;#M@"XAG%!L
M,#[<BS?-9X4 1J+ICHN5#G]H )NDR9GVLHC[8/?:*WFS V:M^;BHWFY0RWM)
M1HG3?]3K[_2EZL15%*&T1JT"BVHOHVG/JC5)K<D?N[=9]6#BKFW%3 JS^$V_
M%Z=)_'P$R!/1W>8E%FP!OG@(]JQLR]<YS[7N./2V.?_L;MU4BS,_;9]>=+ 6
M:X(V]..9W*H9/JS(&4@+V[NS8#<Z(QQH.>_L7K(6A$73ZB,Q0L!VO;(W';+;
M"5?S,Y>%D[V@OW=HLFW.G]"K> ,<Z_4@X:G0MU3 JRQ.S9(Y;2?[XIF9F:@(
M18M5=OQ.6EIE^MW!(EY:F(.F;BYI,#_VRSK.S/^-"G(F4'O/#O,U=1KJA4%>
MH@P L2$D3SZ9,16=IS,FDR.#!;/!9@&K:?X6W2JPQM.B^UT/Q'ZIB?I/D93)
M%7MR^QU/:[Y7<?"P?+8:$4Q\-X9Q[/K.=I#OAZ9O4E\$,[F:*_ I#Y4?;4M$
M3@Q;[1L]F>ZCN45GI-@JR+><5>6ZD-B2+$,9S;>[V[:T6!1((@WHE^0=CYZ2
MP*4@YR ],,$>6]>^[^SDF+TB-J[]+/CN\*U>;>)MQ4'299O)GW);J&KAS@Y"
M_[(RUZN=WZ.'MO(L;/E-LWX)[1R^-&\-QCDO+(H<(46+<SDXM^O[,^V?Q734
M:2_&1AU UV;_+8O^AT+A?]6JOCK7*0WDNSYS8+"QG=?]UL9\)<57$0"_C=)K
MN4*2J248+HI=99:HM%T9:,[0/IV>@G5M*)Y)F18?<A3\&KE\"\J[E7P2>G[(
M.7)E#Z0C1%+;4,MO%MM1.JA@DSRY?HJZO)K9F=@Y;G=8NV]+0:04&FJR=09A
M_\N!+/_\_P<Y%,D[B7@!^M B-"EW%6*$S9KQX7VXK-?X!55=/ODK64L<$_+I
M7++@(D!5S,7XB5O5CWXLFP?V@[-LZ2D5T":S'QM)-CC+"7<(]ZB AU"*J12"
M<&3OKXVW(6>I!.2TE1 "SW3<X6:H6:#M<]Q;T/RS=0<+/^-@Y<A-/&X'UG5:
M'T5Y2=XCQ?TJ%CM2IG 6+':1+Z%.3,YFW,H8HHV5Q$D%9"M0 :(I*-*;N-*_
M0.._( ?:>XC?<(MA2!$:VP&B VWH4P&]^6<9B2_W'PZ"GM^DE#^G E)!@52
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M!:YY)##Z1N.B/WK2"<?*VM*H3S#/MF4*4@$?OO[X63Z)>I8P^.K#1V/[! ,
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M$.[@XSJ7TV99,SMH7U''$:=@6M:TT9M769KER%TU%^Q\;$;1=K)O0VT1.:I
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M30HBA@&.(7]]#.9VMTAFJ$&OBC]X]MW>EZ:)K8  7A;>:5LZT[-;F2K#,+%
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M@K]<K/GG"K3%U386F<I@(&SY/AI,R%XDEA2MU-:\MZA*MEQ['7%#?,/R2QP
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M-*?]C[HDCJ\S9MGUZ)DOY=3^-+:*L%!B3BC;!H5K^2C^KXTMJ(G=$ST\J4+
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MHJCUGK^(:JZKGES_L<.$(*Z@#/=X^3F\JGS8ALV_?K1(\E;=TSZ\]TG<9[0
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MDP$KL:26-C) IOF(I/6O]-0Z&TXD/2(.4ER)8>>*Q('.'G@EU(="Y+<)QF3
M5Q,R0%@N]Q_%XA;C%@^%R8!5S5'*)$UNP*]#2]D75Y+GR(!3OK\Q_[^*N7:T
MOM..E6K;ZIJ!T@=X@Q\/S<)FT4DGC%41KW2Z^Q("NO7-:_Z=C7<N[LM"N$AM
MWM!-^@'?M!)<%@<+:QZ/B<-\&4G3L^?7B)?ER/")5<;[T]%_Z@M"IH:*0(>*
M_ZI]J$]2!G\;,P9O:\J?\I^ 2(]&\=1TA!'\Y"DP&X3I1; @-HS^J@]8^%^J
M#,JC:HB7$:<&511^AI^):0#_6S_0K[N( 8DFZ+\"9_!OKA3^-]S?</\-KNAG
MZ&\0LXR+@7< $G:;6=0C"A]2&;S_J/Q+RX<C>P-T#@0VPKE"$H3V% .)$8>+
M1/$P>$''5.]8 K=ML17P]--8SZ_A\)0/55:405W^5SR2)>/?G%GF_W_4\S?F
MWYA_8_ZK,EVSTXF5VC_;[P/2N]=53@GJU\S29V5X[=NU]AP60_^) F'UC92$
MD7\Q ;1 H<!AV0ECN$(6QR4S367QY)_Z=9^E1&72Y@H:MAK._B7ZM/LWWDW\
MWX:O_X;[&^YON+_A_H;[&^YON+_A_G>&.PLZEA_9K9*("FS."F%['^10-F\Q
MR+HT*Z"1:.9UB9:&5[TSJ#- :^>$#."U5B4#RKN?D0%#$^6=]N,'H@)(HUOV
MU8BMZ3*@>,';CK;GL_[Z0= 45>LX(5B:VIO_[LWZ ,@)='JC68(,@*F3 7FL
M3>+_[CUZ#37I2(=@0!CNCR,#_(LV*'$B8IARUXRV9( E,QF@SN+UU\G]B^5D
M0-DE,N!+7)UE"N[3,,\[ S /@1+LAOT,OH:36 Y"T.G<;D+-W^_,%.EME'6Z
M,G%\<.?&-RD=&?6/MME9'WP$^=X>RK<"DW*N$+^IT+I3!G!NJ[_8<?_1Q+Y;
M8E[ZC.]E:PZ#**,QJ<\^-]+>"K=\$MK[\:TQ'7^<CNF,1M\J)#"EM!NK"3>-
MZ%7RH-K9IA[R0_O OQ<1)ZY=O[T4OS"8_Y<?,) JKMB&-B #P7N)#+BP=98S
MR(RK0"Z-5$T];4R),!SDMXW0H-Z3Y%"Y\CD.L+OQK='A*;$D^)(M_K$3D/IE
M^L%3;"FQ),-0-E/SN%KY1D!C0[34!3-.F;GK(AX]>M34]W@'-%AZ(0XHZS34
M'B<$UA[XRN19/S*CI@:!F$+8L4EUKX5\XO);>\\O69E8:R!U);56B-;B'P79
MO<@ 9K5;N" D0Q@<R +YAL>#M,J-#@2>._',?Q36XA02W=WI^_GE58K(6YP+
MWM 1=*TQ !@N09! +5)!,M=ZX5STH,ZSE]/-7]WR:2&/'VT]WN5Z'U=_8A#^
MUZ"\H%>;;SF!F79\S:IP925EA]F/E[7'9-#W99/6)E"W6TV,[-GM[MR\*R#U
M*$%ITNP?W_^X<R.A*QY8&#'4@@S8%#":,!%$@D^Y55S( ' ZQ4"T67S3AL$H
MZ_>$]XD2D6>(@4B6-3";&F@#?/%(E^UAQN-)%1-4MMVK]/;V9HX*-O^13MY%
MJ9<<[_D3=80D^'_TMO1>J.L'S>!;37+/-]IA^<Q<TH^;&0)>3/K0%<M&&Y?G
MJ#9\A5BU[;;?H0T=8:!O+?.VG1."?2J!ND[#192#&L#3^&7+XTG&DG(=8!3Z
M<?W=OE\@EPWU"TUKDUT3=$O*4-;M._*1/A.CJ88-\59T[N*Y' F/^CWD6;3N
M/;*I??-\WY'ZR[=:]S H>Q5#<BZ]#X('8FF52/LL957,_/@&=Q)?7?I\KJ-M
MI'WL)R_OJH0W7N>9L?@V!NP(,,)O,CEHF;I I\2R\S4CJB*24Y9.VJVOA^1H
M]Y2A[Y*RNE4+;[*&R9@$LVYY7<,':2UWKL>M6@)" LN+<6MJC 2]$9(T019S
MDGBH$]1O)6@)MVAP]*5YF'TM!>"1T,? \W&(%JSA[=<LBS?IX'G0AIA2F@/9
MCB(1I-GT0;=/H(^[.0^]=T^_6V5]DFRQ4URK?PP0*A-\@(/G;2^R!AM@CA=F
M3F5A#*9F6VS/>CGI_)-6>O@9?WEU1G^8[GLC=5??;>;-9:$R_C8@FPR4,U@+
M>Q)6X@K[-A[,)I:@%#')^"7,N+Z:C?%40-&>BOW"7''X*'\F +WQ3Q]85PA6
M%#(P>8O8$90GO9N;-+/,C4>L.&/DB1%K9, (5^:V2&#N%560L:T^*A>V$197
M4.IBS,LUO =W-=[G47Y2_G;7K6S74N!I1YS9_$?,=8"VX$AS2/+Q,F9\[4.P
M>F&P*B[U)XZ;09K$3 >B3RW\J&4V_B0,B:+.WK[$OEY>0I^<MU&2?!'7H(G=
MB_)99(3X&]9,R.@^9JFM:H:'#/=%?Z4]Y-N_R+<4-_GE7-PZZ09DIAL)>Q.L
M@T+KB<0>SE,_J1MW^U9EY)0C=-/)ZJFTD*C152H^!P[^4H_0F\2B9EZ(OCK&
MOJ!XV^_,)T=85\U%56EK=T&D]D4#&6#B*>,J-,M$F)UCI7:Q5?C"8/FM:./L
M3RY*[/;@\Q%8*5Q5:I^EMKJI\I-]%&3*SHI'V]CP(E]X&+TE92@'L"N$8$QR
M0K,D)!=9ENAW%AVC(F]'OU8HP,4Y<^']],/S[0X#[.<SW  V?[QH69;=9[G:
M%ABQ\K$R\4 Z7'^7),0J#!)NA)EX)_ZZ*GV*)]W$Z7J#,,_O<M%(K:<,UZGV
MGAOK1Q",\G'K[4HF,3Y<&T>J;,^KD_;_['.C,P6?]K7S,;X+O'9QXY[LH#;6
M6RMY^160;@!^<DQ8X$WM*/9>+9P._9UQQ^UI-7'!_I2JZ_<+8);*4UKW?Y#4
M_T6SS.W8.V6AR,&OG"PRH&#(Q.S?G=$$XH:.P)\2W9']P]EVUPTLUUK_HZO]
M)QNM(!)QRDNP(1T5DF++*NI ]&1 S\DRPTDIZ%#WG]GI?R7P_^/-V@!/D?;N
MC&3HCN<8&7 H"S.!"1%S*&%$?S?B6&$+>L8Y&0(\<48<[ZW]4<KM+CSX2^++
MJ'_]KU?XMUA[O,&H&@NN[T#+B<VD9MC=OM*Q&??IA3<'.*3%F)1,!O#% \^6
M<L\N%J?U2L1F,TX#KY,!K;=4E)$]4-MY9</RJLI4TW$XW7"9I9!)>H"AO^F(
M[63,XVN%"8H*I[&J_AWS[BV@\L&=-*Q(%_"\#)AAMC2B MIS*QTE@;XDGC[?
M.&'8<2KU&.JG=^UV"XLF[6?<*.F2MUANO&RVUM)Z5^[U8/9AV>\'< :&S7-.
M8M:6-7/[92\Z7DA2 4/GJB\:7@\"MBY.Z2-KVO2GR0 KW-/J$\[=3RB%++S_
MT\87-6P5:=2!:/:8&X"N/.6[5\UJI+6U>J'7Q$)%27^@E5IO$4XB[HD+4EC]
M.'>P_K@OXJI+QD)HI"\]EHD+XNJ'NO9-0[</0I40:M+'>M(Y>'4+R@%:*LRY
M6#&BHE^,XU2U1>X/^!8YEKW?8K10\1<=;N?/"_!B>A[PQLWZ46MGX,(G,H!F
M;?Q(3+X]E X[V=7DW;5(JR+O)RXS2-.?W^J\RM@;QI4UYG70%?>8$0[!YY@"
M&"R;B>G&!\<M(Z&*A;$/10HW:!_P\EJ!HFA_$]=SU["DRMU3:/MD)N TZ]@+
MM[D,#F=;A".BCA#778!,,HC(X?ZB#6]<YF:9NX6S)>/URMQ/'TX-SFD";GPR
M\F>T=#]V[R0#<+8(G#,89TV2)@,B3MR/UX]I9R9)C(N5 23]:5)[C;U?\#2^
M 1$-4@T)P@P>JXX2&+$6R_[QLB%N(&8GT'5)GK5PN=R5@D:!QQ4/1P)*UZ+,
M'H&$0^&K!M!6>=D(S!#N-1G 37@@V/(VY!B!4X=6++'=D@]H5A^3=]\G+.:Z
M9]1,R0_>XS7#9J%JDIN5@P.)Z3)D  -NN2/WJL]>3 Z+#MIZLGTFX=U/T?*&
MN0!GO78^W6WNDORO4\MI+/VA0V1 )1/._7@&1XNDP95B'QB0YL)6>/P-L2+Z
M/TVO&_?"/W?C2Z=.?UU45#C7/(KUWWEK PL=@EXD"3@%;CF:.[0W*1[V@Z]V
M%WYB=7SBI?E&=RU95+B6?6IZ=C(3AM<E]7(F=TO$6)_#GD2&\NEBMKMR& XF
M!@TX'YI_?I)R53U*RVA.<67%)IGG(N!$U[;]A&WA2M,06M:B6*2NZJ0BVDC4
M&B4H^<&LXG+*TKMIFE=)WQ RP;1X)5S0,<7QPKX2N#"PZ-TC>H/=QEM!/YT#
MJXL5T]=(QT9C':D@NU.#Z^>I(VAV7_Y>+#Q[+<\ZXULBGW%S?U<A[78=8TQ'
M&> *7EW9R\LS1]J:!X68=B Q06>96W-YR "D(%Z>P%]_/5/BF/8XE RH<F.#
M-N&U,N66T5#_?I W3 40E%00*#,OMX7^4#_;L9_&S5S%G#S23 .]YM+,2AF9
MWG:.PJAL,5JZBW.UJEF@?J(*GQ&VC?8/?/=^_M5]CD<FEUKQ/\^'OE42C>G9
MXC!]47PE3%5D68(FF [*$3I "7*A=O%HNT90R!=K67A2P2W8#-TF&YOF?M>J
M[4)6%\T[X$>;)<_4I'MB$'Q;LS@Q)]@3\ZS#,U@/"XWU!5Z'-(^V6_./PDNU
M!D?=)M86_)UN5+<D3>6UR5T,PWAHK^0HHT[05&3 13*@D^&Z$P(SD7D2$=K_
M0Y?MF 71-EC3;1/%WVN17%Z3R?:=V*T&/W+O2@Z'8FK*FGEUB3 BA1HO)L>+
M$@QJ=A;\9P@QA<D]^.U*_^QL,D!.CCB:HWK[#4B1)$:XCV5+;&8B,&:T0Z]%
M=S;@%^,FTM^YY-S$S#I6;WJ)K<IMRE;DWQJY<S'KN^5WJK[)RE[Y1#5&TBCP
M<M5@#.^-$=*=S05ATDCEB&P6^MQ(OR'F:'_VM$QL@67PO8RC0;18VZZ7$CZY
MFR%<2:L;3-6+'#!<V];-X?KHRR-O7/ZB1LEW1ZR9[F/LLE>-[1B3\B3S$FAZ
ML,,C6&]8)0@K@9)!,,(7&<P&';YJ74UD37-YZ? T=8[]_5SC;KB-:]]7LS?J
M.0#%/;JM!VUD .;I(A?$;4AJ!I>').6B7*JH5_!&33O5%+E8D&3O;F[=$-D,
M/%U>2LH0[-"?848Y=*X](\:OJ"\-,CP)M)PUU^:?_]/\8]+]YAV>AP(GL*\;
M__C+/14#(R3QRE)DIQ]*%(BK[ULAB%"$)3H1NKV_2 9HWRRKJ!<AZ(R 4B0+
M, B3TTH4@M&I&83-(%P'=@5J1<+Q4%H!7MK1='U&U3!K:XO9D&_V^ZZV&9*D
M??M^91$ 'S4'7Q(_"AH+=R0!2)/-Y["OS-4*EMWIIJ?[0U #$KIQ7;I^,UMS
MJODU=]B[<V*YONX G@*X<XM"Q4,':TA2N+=YA <8_00!''29J-99]4D6M+,R
M)@8KX2 ,5EI:5-Y>@AV(B!09ZEO/-4WN^/)^Q5B@HB-E&3BLG',D<8F?9!?9
MK4V_.KR[F6\C]C[-6&CX7+X-KO>T^//4&@DX&SH1W6+-)<>9W.I;3OI=C5>H
M&SVR%4KNLVKHR>4J3UA.F*P-?H"3^$)P'FI4M%G&:XRC#_L_PCD.:^U\?M77
M/>0+*&?&3Z7%ODA^_T[JJDC/(90B6\<Q0X=98G*CQ^FC(R-_:&HB+9#CQ==B
MOCY_->_=PG((BO A6FACFC/L8"YT*'KGA7G^QG'^*@NC^@]79,)8[!G# F8N
M=9<"(&P$YFQ6T!1%GW_$L;">F%,]?T%%A 5T>O)>Q-U!ZK^%5J^_J=*_/-5X
M!_06'E^\C:][<I(9V6X]DY&#LC\M>)_L/?H% !#9D)@>75HD" $CE$!O$7 R
MH 9:N=Z4A28#[/&@3\?QO66>JWO!K@?5Q.7LNF4%NI\$'M(8\4LC" O"@_M(
MO4/BAZ =6*7#P,%:'%A^8'$?O5]>X_1G9\66AKH*:T*(Y^PF!E#HX@LG80'#
M]I9@M03""<I%8KWU< 4H/,/U#<Z;6X'6V4ZA_,.HMX*G8OF51I?N.I(.M.MJ
M)!5;Z, %@:7)QSD9 0Z(?OQ#"5:"@]LJO\+>1*,TB<."='>==!U$N 4\H"%U
M4>0M' \BEISF.AQ L8O2V"\,<MB3;GU&".TR;9=5*-=L<;$8+5(U-T:TRJS,
MJB3EX'>]<H?9S"7AMQ^OI%DZO+64Z$J.!ET+Y2#U4;)B9K2:'&1KN\N$<=-$
M:6;.Y?QK<>.MM?E723-7A.!3=EQ7;ND(I[G.;F\D,X4.UH=DQ#:&+.N:SD,J
M=<8;Z8!1XHTBMJ\0C@UQ5,J_8F>><FH_+&"Y.G15+12"2^[*<,':(DVB2-<A
MRLM)==C+SWYL>CCQTJ:V ^W&2F[&;3$MSK*Q"W2[,R%NV9Y_SY[1(D-U>&NR
MG8L,B /69'1:,"XS7(-8/ AOFQ'(*(<X'^S(RZ>PUEX+]\C[_=!@+:6\8O>6
ME\?=$(EC2:Q$C"_H"N$19CW&%[]W'11&\"Z".'<;C;.KKAQ["C!UKM=2_WYW
MJ2]#)?M;PR(]@:(L$4'+B,10 :@+,8_$I"NA/PJM5!NHV2$#[*1Y2&X'"/^L
M4<>NA4(5P58HA7!_N#7?&* 0;BD9<,D_7D+E+\+5GU;!?:$0+AKAGDHA7''_
MD.&D>RJ%*,-M,H +Y/P=]Z)98I( I# /Q)PG$ >Q)I9(^'(UQ'^Z&<N)O' 4
MR71;V>A#I;PBRY(4I+@+6CE1BC<C UY!DG2]NZC-,#GQWW'AIHF\IJ1QURO7
M=.]>9M6^&6?4.QOM,Z<E8#)!!K!"'8@ZE-"'T2<Y)N<2]D,.%78^*O=VLAAV
MU'9,S'W'K".,+H;C775W/S^%&KK+7-Y@!G<DG!> N/8"R$&W4G0R0T>1:)F[
M[R71O(JZJKJ:9#I1#?8OLWPFB?<!<3'1H9?XV$%,C5PHZ+0A-#KG[G"S(&ZP
MLWP!DJ4WU/B@ %=IY++M>I^N]Z&8Z*-VUA'^7[Z,KI8>ZBSKBQS!!BB&*X2G
MN'CY3O?K!&O,^8Q94YQ.9RB]]AJF,S+Z0X[.W ,WAD]"(6M&G_3NM:6QR^Y.
M@"H&XX-U41(7YP@&N$IO+.U]3,%AX/>LO.ZO[867=E$T#U17XG8=' ]JSS.&
MS;T+-'0!4GH<S@=U#2Q)Q/M;,V &$_:^CQV%<*X_B#:$E#G<J^QU4NYIUL-(
M1YD!5-XH/:5]3W#%87_@DE')[;G1'I"LKC-$A!W&TEIT7$4=D_<D4X?HIO5Q
MMCW\-0^Z=*I;-.%IDAFSGX?6M] >-6ELY&"RBB_2 @^.,5F@J@H;P;?7=W=8
M\:Z-/DW,]9HS5SG0+/5@"5,J[S__DKWF0@U<?VIW\'X%+L@7,]KI'PK FH3Y
MY.Z(B-GL+(\Q';?^LJ:KM?SQ@0TL+=QC]"EN.<$70:-&/1]\=X+P#)7+A*O>
M[K96Q,J\(P,<7:3-2_/O7!$VY@H*\K5GU/P:V[4FJJ<M0[7]X;_NB>45*DX&
MO"]N63QFIF2PC]Q<2LKT_^DOMB;]*-[<8LE"K/[DH58_14<-MF-MB1_=71<T
MHS4;)V7B=:TU7KXQ4SV\?^^WTAWEYWA)GNW-!A?'UVA434TL7Y@ 8_=U9Q:#
M>RU/:0%4,^6-_DLAS"APN&_N95Q2IZP8@TEUD$Z#V26J99OP,$5#I2CN,"KV
MFXU2L\?.N,)\Q[RV3'TT;8D%1(P?+W/']\NLI<M3BV5>\ZWS;P2NTB32*1S]
MN=@R=6H\:(AE3<04=JAQ8H"QOA(7-Z5"AQ&8I(W),XUV]16S0:G8&_<N3+ZU
M\V][US/%%YX4^@8W^&4#>-&5P(,4>[8,[B@.XNHMV]4,S]</^(E+M7SW$\"T
MQ7?"J,[VV^\'( /?#C#YM@VNT(]^ANQN!]'@S'=P[IH8_3B916:MM7MN^4U!
M9ID.9NSUV0?2DDZ*K8*K_''EV/#CH F" U:GG0Q@4F%<SL6IJ]@5;*8Z5LQ9
M;M[Y:3X_K7VS=U5%3,#.]-'7<)'PJ96GM/V<#,GP_L%H!'PPS+X9.S\9*3,(
M&"C:I 2D3"QD !S=B.=J%1*[(?7Q8U?!0\3=;O5>T(--4&5N1+-:\"6<9O!S
MWPM6$FT380.B9<'OSW>DOZ-IL+QRBD'?OOWG6L-G)LC@*,*6#G<;U^U?%*S=
M/'D$CEU@5;I0 /VQ6;Y7D]N7<ZLVUM9'G2F_[QL@CVBJ9B.J&T0&4&[@,AG0
M1K<$HL>YH\%NI.Y1UZH]>$ H.'OU8?G>;&J-LG?"9X>B+_3%%KY5U5$TBH^&
M^'JHWTA.V>[_;.8;7L:RAA<Y&0YZNK <5:7#5#]_5\R[&JFCN;S[ZX_ZSCW9
M5ER;/B>L&QA=[EB?. )11?L*3NZPZ2:B%U\[BLV7?71+["CY^O*)^P5-%:WP
M31^J?<$6:&0S.TX1[P09;"-=&[$9/G0! YPT7B:+[BLVUL\+)'F-/.I.V=%6
M@V_E\JI0+9\&4Y<ZD0'G]2-5Q$I<Z'V]B^; 4Q6]OC+O(Q<2@7V"KP%V:>#=
M,G4THB"8A]1/T6_UO_1[@#0Q)";SEW[;]NW?3O]+OP_<#CQK'+OF5M:I_\ E
MIOV[S!EB56R\,9,HXOJ;0PE6L/9/9_,G,Z+FJ>H!0N><2M92-.ZRM2@_\GW6
M]_8>+Q>&#$!QX!(QL.,7.!/,GL%D*#<NJ .S53W3- !'D0$N%AKY7:Q!D-W[
M+V0J[ZHY"V<WOJF;M4*T0Z-KR !ZZ-+782=I2+$9UOIC*)N5KHU\C)ON.+HB
MVWQ*1DR1J^!INU=E2GL S;OS@>*E>"Z<7S\2UKY(C^,W:\885V)(JWLJJBBA
M/)TB5*:&IY>#5EM?ZFG"*W"&)S\-59Q[V^!T= >)D?AEMUD<UX[R:5:<=&N4
M%XSF'<6S*M-!;.4-]*+.:UN\A*6W%+N+CK N4*AQJ.H_V&^/I9>@1R$78Q#^
MTB;BS.J\;]H_G?"Q(0,2&8Q./TZ0N)LX)@PT6/Z\_A]NXO<O-J]02C#P?J\+
MN&<.W<C<%DG%+!*20^^2 8&C9,##23,K%M*M36 O^P@.7$R8,@ +.2(P3\68
M+8B5;LT +23]8\6OZ18:DPLV475QK)_&6BMOBOV\EQHP2.M(*WL4XIWUCV5#
M]D!FQVV4!@8[_EJS>2**Z .K*IQ)_.41Y<GJ'V S)4ZP%;BR,I$=/.W[?[#W
MGE%-?=WZ:!"E]RHU4A24)M($ A$1$!$!E2(M(M*;4H,$0I$N(""@*$2DB92(
M-&D)D$ 41 2DA9H@O24(N(40+K___]XQSON>,>X]Y][[Y98/^TO&WEESSSGW
M6L^SUES/.@*=!P]#U[.GD2ODF6C]['=M8WN)P#?4"7WA&:! _57(H7F-TLZA
MVO4$ S'GF:D;M09"VUP_[L4HQ45S,5P67-A&> +=E-0>_9--0$,I7/,/SEEU
MY-T/5PPE@UB<9XIY ZXC7"QX>3,=Y_&R]6*XPI>3C"L?%.:/0( W=XHSA'H$
MPBLID&@P+CR=9U0Y.*F-EZPP432VBY(1R97[+73YMBOJ_"N)ZSV+XIF#-,_#
M4H@3"9M:* P$%)G-#9Q8W2]/[&G7K*">")<<^77I):;35RI+57'U;EW4[\V<
M,Z*@_= 4,H9G;4:-RASG^IFZ&>-*VN(E/%;G,RF=2:TT>S_X)7U1Z/M"NC7N
M)+(@*$$$?8DZU@-+BCH'3'R@700LRN&ANK-<*WO$C"2( ;FTT,?!]3%V?6_0
M@+&X[=G[@<^?+1E6/1EG553.#&_(M;3DZ_IX\I;F>KV1-DZY].T;' 0R/5=+
M$YO?XD 8#_WZ29,CZ\GA]WV#-%IG/,<&G;H^O3]5K")VD8/QO(SVW\1JA,6!
M"<*3NH5'3XC-HQ-"S+4,*0/I"+YY"ZKUI[]CFDVAESK.ID><XZA*L(9/(*8G
MK1UY3$]&>E"8<3KHIW0!3YVH!C_2I)/!?9N'E(:XB0G?#EZR5JA4XRF.H*_B
M]Q]?D4PT0GA1XWI0_%C7EUL($Y5N)#LPWSELIO0MZC25ME:^^J%9T>536Q*_
MZOK)S#<<;#LY(VU.!XX(1DIA!2G-T!: NI'E0D=O;__D?*!PUDL&7OV25JM>
M:JB(?VC<V\L  444)J)7"L\-YUD.[HJ9VW>69)UMJ2UP3VH+5 ^4=Y-U<Y(X
M'>IV9IO3=04JT":"AG_XC=/Q2*U7,L'GAFOIZ)65<C0]=ZT!K%-K]+H1'A1H
MMRV2#3F7_:2FMMA"HV$OKQ1(4ZSAK9.]A/1R)HA'_PHLS:G;,#VX@KA$2>R
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M]#B61=:2N028/VZ7+F+OX 3'=3\!QROYO^D^25PLYLR_,??P0WU54;IV1U4
M&_T'F)T64F54 OB039XB##_<8$TGW!CS\_= A'0=V[D 8X9GDVGZRH#*@2"P
M1A;3+&+WN83T[AT-A.D1<DY^?"5Z>G#&V/7T T$+6:J3UH;$?$ "K+X\X3Z
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MF>5>SMJ45/NO$*)BED9"L5?@LQ^.7;)_A\]*V&LJWD7/:,\Q$M__4X_7"_7
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MNX$E%RMG=Z3@<8S,J-E[04 B&9TXVY#[JA0>L6&+T?ZYLY;!;;0W&7S@^]C
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MY\#J[.Y"08IUBK>^7#O*/.O[C&EQLFFJ9>.K\?IG'TZ4^(_+%7P6D64#+98
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M?"\EPA_\J$GJ5I_Y4?K_>(K9H?YB[H;,6@<RU'\M6KI9_@_DNE1G@3.+9^"
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MX>2Z4=3;;0)S1!UGYUP7!\F"9?6F]=4#JX'O FKI5D.ALF2=(XAR+ UA(D@
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M/E?*6W6UK>8$JRJWB<)(UW$)Z(2H^E(\#1I:G9;0MEIEH>%@83#98HIRC-5
MI+I?TK$78%N4GT^L>)G40]O.K1I[T**'D[KP/KUGT%XH34EY"[=*0NFO(,8X
MVT">OYN,FG/. E)^DOILG&UJE=-7;U\5.?*)!@%;A/M31Q+,"!_\6CQ""@OA
M DXUP[3KQNWP[='N8B-E>5W&G[)KHQ6U==_IF\5<1W2!T'2!<?]7_N6E :"9
MI%E.AIQ_XGYVH_$?VK;_F#;U1X7-/Z@$C>I5A4[PW#BU)PK-DNX@KLP<M=,*
M>,)SGS36SAX5^YF2-S34?G(PU1&XU"+"*Q!,<QG./+H4M(:DX9^X/U,P*PWE
M$(!G=*29:PS,IFY =E@N\;R\MZ[P VS5X0C1GC#EA&3ZUW>+(;N0U"3(+Y+,
ME.8GK/X[",0K@1GJ=+CG:<,],FY::AF?;ZO1KTQS1UEDOAWF'IO>%T(2APMU
M*]0G2*C0(Z1FI)>*,\;8YDU[E>I9!_C>5C+J<D6Y'C+>/&QT;Q+Y=?N?D=!=
MGRHG%;3 , _C$<%?17GCFD<K9Q%.PQ+>VL:39QQ8::<-D:MG@\V&)K$A$>RG
MOPC("UP QJV1>DOE+JR'7=E)-.B'-RJ:AQUW#NH!7P/XSD%&ATKZ6#9Q-^DA
M2/7@FE/\BOKCI:X/5MF1M!V?\>D[Q9FS2F"[,OA0-XF_.7U[WTN@D<6GF)<%
MJY-B^-4>;39#EO-YG>KE>A+EST*RS0/J<]#%/.9%SH?DG8.V[6?L$.IGA6U,
M \@-Z%6$!Z[&GYF4XOW:N6#;O#9L1W5I5CQWJ*%*A(5M4%ZR2#3\OJUBX',-
M4) 7G+%;110 KX,7=/O:Z6M6M)VLP6E6-3,Y2;?$R[Q$]-0H*U+M#889V";L
M/&/1 C1+%!-M; A[7#EZ#!"NWEF]EJ5GI%D#6+QVD$ET%3"PEI\I77@KNJ/4
MH[?N9AG7&[P]MBC]G]=9_N\N7^T #^OFD(L1S:V>D\[@=IB\EX01^T/S,DLF
MY9IA5P/OW2RU'?"CJ7+064V;DA61!GA2KR#[Q6N,8:?>PVQ^I2Y#<.?^5Z=9
MYT??/BP7?O_6OBH/DL16R"KO[,QR_G(N+;.)QZZ^E!R@_<;.K=UI3!%*N7&U
MD0#8KV_B8H.85!C'Q\)S1T=HMRO.HM[TQO,N5=A_2GB2E_7GQT48P[Z.C."Y
MBFN"#V'UUJ*\7<VIQ/?*"L;S8PR:(X<1VK.RXQ113'2?G.84KSWQ?-:FA C2
M!PR,5>X!]EB81:%;;:OLJ/*C&?[,QV^LM9@F4A*?S"X.YUUG]YR?<!#)JD)<
M<L0<7-Y1@>!$C57(_%Y\,-/+VQX7-4ZNPMA?=SU<HB /O4?&_/LSLFHM7LF^
M:-LX2W12A17PU$DPK)VN+85V+KZ*^@:+<^<;3!QH$C!-^:[A^/<S'BTR123#
MBYA,JSJYQV5!9F5,^R*4)!VSETU[[VHPF%/M[0LT^+P7MJ6*TUGM$5^](V6B
M)'AJAKB)[XO:4U+-A:-7MYZV)F97_W9UXPW%3Z^7, YP]$H2XC*4BW8H/+'E
M$21Z_$QO2E\40BP'B, .U)L/?=L>7ZZAN#?(^O39=S*TPE-4I HC[-ZKL? C
M(V?9[+-RP78"0L5B=1],R&GV<%@F\T,%\-\K>4>2A=_6IP;:>Y!+:E[NE"M6
M9C!?!HO'$:,P;[J[3,+L_;1YKV@Y/9::^;+6.)38E%371SQ@CTX<8]W$2KWN
MY=9_&OE>G9TD.,_XQOYYE#C3S6M[-;67]UMQY9W6M^=*:T=@G2?7RDLMKEQW
M,3EYR;C<&Y98I_ET*'Y>Y@5"$9>3PM_-<4?D&_<K9$^;N,QE2KFP'^<@:S75
MUE-B%FRX10*_T=5&AQ-<;;TPS5&O84VOVFXUCF-GA296NQ2=AX>+' :+)L7R
M'^^%W_!EX8;E IZGVA>8LA)+=:1* R1*_(&_.#69WZIIJ$TR]4R0O2'MO/E5
M^^^4QW?/$8Z0;>]^>#?&/9P(]3C)/XCPTCV@5W?#F^W,U='KO';KU7Z:E"(>
M#-E/Q]:6+]&L'T>VJ!7^G"/)UD;\?I*(:4IT=>-9O&6H*WT38R?)[E%P;'.<
MW$&.MR[-AOE8"XX?G4'U,O84?++=N5=JEM@1_7D&_?,O* ??>]Q7J7&1&FZC
M(8+#NE#5%W$Q%WQ#?Z)%]^R3;>I<ZN%]\=U\;ULUFMMTW8DS&KX*X.YR:K@Q
M]M81E-9I40FW$*=P[Y4T\.5E[37+^]3"?,J[(Q6(1H&-FPT)7!<XD#J("TC?
MZB;QXA$L_OEEG;Y<QO6L] L'Z+4:7:97[QWYS^PD*&2J\8P;6\$JS!;;3X'D
M'@_S3#/?>35GVOKDE:^7UI@,1)J_4OX-3>S?C-/(=IE;C^S.8)YA6>K@8:VW
M,N10Q+/$O6J'/7AC;"ET<$GI_4)9]%A7DSBJ1*?8?)N%9;$D=<#A>'R)[\GX
M#4$^\:O8:)T;GB')(9;F01/(:PZ 52%1([*7Y9@'/!6_-/* TCZQ=.E-V<"-
M9W>+0W^EW$I\K]W[HOO4#L&18=!2?0YZNX]F%\L.2)#%4F%#X5,13C?A/9Z_
M^_8__<Z2TOSB_Q2 ="<"E42#-LCD7,\8>"'#G,4P!AV3L/*I[D"DXZ]G_.WX
M.%QN)P\WGFF5=Q+!C3F3LL[P_?3-;-M#W>NTP77RV]5[!\DCGEFL9WD7BACJ
MYKD]=X1BH#HZH+E_K#">.HBEB1%.DGW?O#3 ,13WKL?FVEX!NTP:9FWQ  ..
M4=+Z^M,?&B=6)O%'R+1D8<^-+]2/DOQA=8LMOP0OV[$[Q0]^)<-")__PA$BO
M4@GCZ3^ZRG='IXRFAUV1?E>:!.8<I!?84SJ&4@R8W(3(0GH]D Q*G-@1B0['
MAX"R*T:"SFK%4EO\23Y,P!BG)>PIBA<@HU,AT$5PFB:9GFP@5("X4A=4C0FZ
M_9I+4SJ$#G"94D?IAVIOQ+DB3@,B&^QX#8:IXO1'M=DVN&;:*4FS$"JB-S8&
M"OZ9)5G?-%W.G5/]6ZP@@J;/FOU%EO;LK8Q%63O-+][G("H2U_8:91LGX-G9
M9"AAE[.@Y914%>YL"L[2),OV$>U;B7,&BCO;(/C95*\U!B=S]W=>V,Z1K&)'
M[F'%2/7*3G:>AO+/1_J+75.]$'85:?B]%BWQF(*?_L^$--HXK@QEZ-C5-R41
ML'H3-G5W;SQ_PZ+&P[^2I%]0T*=/050$U-;+Z8'VONL[=UP6O3,L8#<[,2BS
M1(SF[YRJN,?! YDD\Z*%9B[;F#OC>U[(R" FW%YO.#H%$\?Y&*4?LO?J1_44
M-KPT^PU-'_OS*_3OR L[!&AG8)!P'JI)HKY0E&@+]Q=S>/0#LS]PZ0:&O:B=
MQYUR24&U,9CV14;,<4P+& MA=581B#A0QQU)Z1?K?'^</)^G/:F:X=9_\RFS
M:?BMY+!@&,6#L_*VZ_"T'@[KN +XY&K R-.'H:.:-0VZ?E]?R'95U]A*R'WV
M"Z@/ZV3'QJFK-^+ENMJOP.>,ZJ9;U#%T%-;3KA6\S=-'_>+V,13\L*:DEA..
M:3S%VR-]EI\'>;!T653)MG[PK$+X-WTRNZ]V'L\V+J#&1NDI% &!,G&#@-5A
M:YKVBHP$/F1%3'R6R9)2.[\/O.]3N@S[MC4[+BALO977V9IG0GJ%0I?6U'0[
M-7'I/M6.#R]-<LAB=8LBKKC3FG[632:0IO/D:DRQY=98^U1-O]A6FK*O=C1[
M.R-4$6%REEW+K4XHPQUWM8+[Y%9IIG*JS-P+JG%3:[I^B&/Z/N:ROR^\M*.U
MV48;-.[1KN.4?V_P9&\$JG;XHG!E1T-6^KV>0\RM]4MY#R,6K.]76<H[6&&E
M14\O#5V_"GY$;CG3Q@0(6>.Y5'BGB=Q?7!2( FRUNJWB5&[)W+*#_:9V\[/]
MN/T/;;RN<.=4.TN8H>TB:F%J[^;RO==4:9PM%=_KEC<$/CNTP1OQK#UK(>TL
M;9S;/#?Q1"C]D03[JFZ^GOOKW*5Y*[,G%37%2CSW.7/^>@R>1H>JV.I#U(#B
MGD7?4*+,-]A)SYAKWG;JI+75&)>$9+S T]$E>K,,$&,P%3:8W77][.KHF$E-
M_83TO)AW5'[#])?X21G=[9<&54J#5P4<#9AC7KX'R5C_QAR$UX*INS$QY71.
MQRH<$3+1RAPPRJP1>DUF8X9F$-D7LNBQN0N0K-L-N;;7XEWXBX8UW"VG+IT&
M6$^%WG-C9Z%+S$FSW7S809/EQ\6Q1>(+FH+2DIB MS^M;^*5?/R;'M1+F5LL
M6EJUMFCE)?M)MG]H/5:9" 4_DF&?=T:"$6+9@/56M[E[1$V@:G>:Y #3B7+I
M6T/S1TGB"\S9SRD[TT(IOWNX])Z#PFKH3-3K)MR]E&5_:]8=ML0I8"?EZF,&
M>7OK[LJ6=7TS(?O1@98TM18 )M;=*0&>,;1"0=01H"03^.,LP2!>7T8\%O7:
MAI(J,>,S.3DN4$05@]JC6@?'<I22TC!6R+VFTK<PF5&4M^-K^S>)2:#DP2SI
M-Y]XW4"QB6-\<0^]%=)"B/=*X3%/YOZ P=N^B_OIU LN:;*& ]XNU][PI7RH
M<A3:3YR>X1;"Z(=Z0>A'L'12G8M7,\N'==*>U4RN1V__GO/Z%A(?./(&17L1
M%TI$0-EJ8P(E.E<%7-T.X1P8I5:%??FN\E4Z_I["DDL4=M?G>3<2K8LU<ZF%
M<][_]V;WFZ#]P=W01;<UPDD;7C,7ZYBV'B::(78UI]U.=I.%_GY=0+WHKYN3
MDWOLG8K]BK#=P2W9B]<$4Q^N74=XD#K/<EH$<=6GK&.DM8ER&>2>>ZWKH5+$
M\T-B::3/WEH '*W \>?V7W<L*S'/""-Q%I7>1XJ+#U;)RVF7#&()&B'1S:FN
M9P6) ,E%2ZM6\"F]"KQX:<X.EN25II4TN8//L;"4OQXF(+CD="4V+@G>5R;3
M</9511XA@(/TW-J<4>)!T;@2G;US/WV/IK-[FNJ$N>G]@#R&X4<78^S >*C3
M/V56?O\BO ?XLQ%R@%$Q0-%M+9MD=?4W%A+QO08WS:JQKR2<QJCY51HID_?0
MAT[4Y<&5+3<_.U]"$A#P%2&#W^J"A/& @ #O0H"U)]FE:;,:PPTVTU/0<X$Y
M\3[3S/)+%FYD4' ?VB./I^*%( RA- CFF&> "#ZW][W.^B]4*)1&$&<_6EH(
M!/WN50C$5S:$ZO^E-%_2>"W2$R$A:?EVWEQ&* L<1G09KT'2D4;E($PJ/$0(
M/B(N\*O@UP(;?%AOVXW0->,&AX9W@D,/;SH[,+J#^#7?/?Q\I8/ITDFW!D+B
M5 .AV(P7VF/%!KJ; ^Z0O2L8Q<"[Z$5E\",\M7HA\$@O?K2KO[\Y:YTY\>53
M@:YU+FJL4B"> \(!@ EO@-?K%E .X+C3_,]^M7O)3W]T*4M&V2KW/3(ZV1VL
M5I2)7;^OL(>96,>5!.E+)ZJ6<_$R:_1.DDYQF#6:<U"7P;%_;6GFR3G(2<N1
M0"/T2L\OC6+D,&WSXA,4/#> JBZ((&K@Y@B?ZR=KD!''$$HB50D0A-4]H(+"
M"_1;X\JP*;0F=745RP-\##1]-S0HW^01E^=R2$MKA[2 X#G(WJY;]>2I$]FV
M@@@6'(FL+@AMDR--06LR^^*/%I1T"LQ_+2)8FO1ZIXN<:2.?O&TAF=^Y^E16
MV#,I^\FD'-=)_2Y=T0[K6K5;&JQP1\Z_V%FAK#AO:07ZR/[STM+:&-/M_2#\
ML^>6)\)?KI5OL.Y1HJZUF.7 ^;NSV-OP!SUZ+BL'KDJJ-DH^O^B^R<XV-6:I
MU[&I([(K>C/"C4;L $5"XFPVD)D')\,B@U\"WN6P"5WQ<.^KI3Q%!2YZ#/NI
MS)EVL7F#!3Y]:N^O46THI7432,/GH-!W"-,PXT3CW\]P00F>.26?I1;0A_D=
MC_]<MJ5"^T<3#B#PC(Y5R!R1G2*&4Y\#G5]TEMS=M3\WEK87(2LT<,,4O41F
M3S(<I?I^^=(/'MZSPA;[4N"@9Y43T,-%_,(JJ;"V*+A5EUC]FCU1SC,)85Y<
M9>1K?K3#[8OX=NE@/%.5*FC2FA=(Q!WT'*\R 3!?U1XHG0LL;Z>-8M;;])4U
M59NF@-45^()2_6K)54XVME^6=)%=Q2AV>#>:=.\L,TA*%R,2T^J#7>MIHB/$
MUY]8+I:P1;^Q_2CP7MNG;"OV_3SY2WKKD%,9H@,>%8?0P]-@CGL"I71J\&,A
MCE6Z0P?@YDP5$DU#NH6?G=FU(]?"I?='\OQE((I,9VAM>Y\8#'NS=3T&NM#5
M2U3/7K2 6B^AWK%@GHK$D0RON7KT_'7O4+)+/RGHEEM,S<>TWOQM-L6J,2LN
MQI=ZK*>;^*8NN8I,@,\ ])Z?H;GC4N5GVKE@HLPY*'D?F#D'V?9%MA^)-)UH
M!@O_;-K,P.J)+QE-RM!8F>@UJ@FPIAJ)C@\6Y(H4W8ALD-DZ![&U>.*E.H\Y
MS!&J@)4K_AK[I+J?8%^4S6308$=9!UD/R6'=(C'6];@\&F%X#J*D( JRGH-P
M?2A<!K+K]29*E<1,4L70_\;W+07-D2+KV?J2 <_TDS4TBKG%"*=*>#R#\,9?
M\5I0@N4XB;T.X,E$5>D$:<XG>H[.)N8:_9'_0@M9.""DX^O1X.@L:9QOE J+
M!7 73'T_S&"F%*''4T2]JH+6U4\BYR16[?=(+M2J@TQ-[N'6",7 &-ZSN\DQ
M6DGD5'EQ%=!ZEK@X9-2 GVEAT'6KJ@ER#B^M%W^0NJB_857>B7I;B6 _^["F
M/B<S/>$=,W+[US.\4)0WQ?/#/S0?%RV:&S,_:?7O!CG8'*+O:HITM"!QOD9G
M'U3M]12Q$L$J4G"422O.[9.CMSOW?@YG]TGK5Z OF< \[)3$3XS-&TAJ3(P2
MNP\),'Q^=/JUK:*NT2G]:KK@^YX5@_?7P WE(4'LJ_<O^DRS>>#AQ,=_4FAG
M<E8:[.!9&-DS7T3#'VRPZOW"\G"B(:Y9$V@\?8*X.DY\("XN+0,X>WKZ%O1Z
MX+40WPA?U&6[:/H:4P890PU>TO>^)$J<I2$N8<M9@\9)#+,UIR-&G23Z&6/(
M-7C0AF&#K/^]++1BE/4*&<:T61PL>!G4,/22[& '[RJWL=F,12X*]:#H6I37
MO=LG6H1?3?7P"#;/S*[M3EI9G.4(ABX-.J"^BR19W=$YVI(C@/$.!1ON"S28
MH/(2JY' PH'\OW>7E[5?)NG?-HDR^WCX9)I=*/VOISD@M X%PZL)>]-':[3S
M"VL_@SA4%^KIL^E@A/9K X*CH_#?W L9T\GW(;G3)EOH6ERU%B!S*DR\G=;E
MN0QX]B 9RI7$,&N,0-?BIAJ",&=/>TC%/I8V7=C)^2R<'"2Y@M $Y#"J"^I8
M9">=+\:U)(LIN8='/*QK<33-U5=D::<NC>5W92I\)?ZOG5/*6U2 V("2 <5"
MC<FF>R32L9T*7DRP.,M%($L[?0OAN3JS1*M")U\TX:6"4FJ5GJC#O,@E]KO9
M/KSV]2^20,Q3\&8,(1E7_N#L0] M9[% H1YW9GA?]Z);.U8WYF]>T\R-:=<\
M6-['ZO?]%E>,. U WT!?P U!HO!?)&9D5SL[?&A7=1'Y3_WZ]/;YEC61/8AC
MR(_#XSW7YCH[GZG8+8I\2P")+0>>M%!@VAD"TW95ESA<ZW()4*GA0\1\JEY&
MA9R=CU3(9R_F'M*LZB%,E5UU]_$L\BC"!3CH4R4C2N'D""*X-/0:M274@F@T
M?M3*:)+0D^3"J*.2-UG;U/KY2QL/A<YCV'4V@^L@OWZ*GR/,>$?T'J0#Q:*B
M#*_6A= 0+?!;/0K*^9GYFVGBN>ZP+TZB_2^?QWU-%63L+V_M9[C3%6R2:&VS
MKB?7VR9_%H]0P] H:ZX.!HI@PV>CG#%Z%CV;-XKFU=ZP_91T$8BP'6IE[ENE
M&K^U3G84'0U08 YBB7(XO@VLW4\4+=$,9])'(%V=E@F DENO:'ECSG1V-YR#
MIEY-I)ED6KC(KGPI#IS4D?DA&W09_WBM>O03'JP#:&'IY+#>Z S7<B&TR!B/
M\VMVMSRJ6^E&8NN79Q_X_+V6_4"6>G\S6(68L.%-R,8[8E6#:]IISMJ?XKZ&
M.Q8OUA-"^\[RQ;I&GZ[1?HS<?"M^.*R">"\YE@W7-YR12:#^.7>RFGAAT4BU
MWO:TQXOZB\9;NT8U+I-JFU^6;J(%?<OIZOG#H)P[]?4*:;WNBT'[!&%,2P-@
M]%57VJ-?X*%/39LH<\B-8('U4+4_92(/ 5@^T10OMVOQ!9;@=<))%$NU^"4"
M^\3+6ED:%W$C,?<%^FXOC;A'I\_G4#70&6-.NR+1M=@J:.!-T$RZ?C>C;$RN
MLPKK1&V@T*-XS20Z\?WO(^13%L5N"QUFE-_=U.9?>)Y$=B,9$9*X@[<M9NMC
MH4UCP0AG^T+GPV7X+S,@)+\*=DM@H@0/E;)&*3L:NQ:'JC-14CP"G=TI4\7.
M];J#$8RX:P78<Q#CLL[5%-MOU!9]F_I*\9W\$0)<+?$]PE"CT:O:*'T<A(#L
ML8+VMN,28<>JB[(&"T@;2ZC[Y%Y+E7X&+6>0CH6\PT _631.8JFSK4>%?&?N
MNT2$UUI4DS*ZF/\<]"U<U;]2]]9/^I?V TJ7NX*E#U2=W:.;KH:21.;:'5O-
M^SHKT&YNYE,]+',*(ZT-['=;@^]3D27%2+[>[D2GH2&+7:I7 =5_ZE=Q7Y[#
M\B$>S.P=E0K(?O/ZF9#)V*0]R?:2?]_U]C/ZY"Q-D55OFB4K.?W&YM9T$9@(
M/-UL\U-HWNM"P4]1ZZ!+ NG$BO%7?_Z<I2/MO^(&%YVKK8@F#8VX29CLH4R+
M[*2^_^RF]LS,L*-@!752B>3.?95F?/V>+EYB?34^ZR:0AC/F9NS Z3.99]5^
M <J4C:V4!;S5I)8RG#[ETG8+FB9^7I^;DGR<W)/4\TO C4RDJ/^%'SD/MHWZ
M+-L!*,*ZL\,5,7)]"?2 G1I@M!'0OV=A@3-.?$W?WA37$_-U6??UF\VY$>'F
MEQJV\WUD/BI'H6Q[V?'_[#6[T--K7@Z^ _I"]?^T$-%_=OU_5,#I4]!D:?VZ
M8TP\U3E(P_ ?<M&]CG-0Z]-S$!-2^@VV?67'7[7_B/M?ZS9%30;Q:J9;I9^#
M7L"#L4SL5C+]ISFER*ZN&%+X.>@?^KC*7_<,BH:/Q&6R[8MF#2U11%'A]I]0
M/)A$PY, F!HBQ]NQ$"*+LH2-4<59C6*F/?,_I'?_\O>?YZ#P<-8SFG^J!';:
M3>S>]@&[7MLRTWB#Q%7DG(.RD3VJ@*B_*L9&XQSTX!ST#HDS/0J@S@Q;4F_\
M+U['TU7P@C"^[_W!Y*(3:*@E3EB)ZA>PMB^7Q,($/9( (L]!5Q*T*HKFE?^G
ME@F#@?[E4H*=@Z"IYZ 3'6;OE!]M'/CEU_#RWD.DS:_2S94.G[+//])8)FCO
M[,+')IO<_T4>=_/P)_8%&G_Y;S_/'OIGY[\DIU'U7^Y#_K6QW?//=F%[V<N_
MA,OT_TW>?VWLA8X#G'P5!D62_UW8?V_NQ9-X%KE'JZ+_H<7\UR[\MV'UD\"L
M2%$7Z?E?":4<_J3S?W69NGO7#F7@G*0N3^0VW<@_"KZ%7_:$)W>6GT66%:04
M#B]!]3TL9'W)J!6S/(_(_^']_)>'E'XS*!JB4P@J&62V&5'V)[W[K^2JO&@>
MQ^G_S)WUO[I,(LE YCF(KP1)8)Q"'C51_YL)^C,*_$8G[IASMU9,U!;;GF1E
MGBYE4&C/L5;P6-0_6@SGB"[AM#+9M#<NX;XG<N188#*F6N](?/\1N6LW@3QJ
MXSCAJ*X]N.:L<JN216$VS;%X@8K!QA7IEMRWR7]5:[$C;K#CNG_H)>8>;X@<
M(-233A&"=)6((^N=FVT2+RC97I1!AWE_&ZXH[7WKTRNDS=W/9C83([SCM\4%
M%XH6+ZDMCU#E\#ZX=L6=? ?%Y.7G51SSNFYQ4Z.A5O>3[>[S?(HM+DDNK_(V
MH@WNH MUO113C]>/\$(R=-*X18O9=HG4JN_D:/!"\O7]UE'7=CCHVJ*\OVRG
M*8@U:^*VI\S0!'S-*XZ[E2F+U!7D+SSN\V7VVF%1\8O&Y:4N:W4I69&TQQQO
MLR"X(<K23G%\B53-ETL#PS; _EV1@K,"E1L(1?S6[@J&CA5#RO[JXC^;_\UI
M"$,G]SB%9V?5=-_FU;=;8O3Q]'R5\DN?>6K_]*(BO4H53:>]87IW1Y>>3[_5
M#0BD:Q(X?L#[\($)F>=;VDY?QN GDNGH<1(3(-1U<G2R&;>^1Z8SNR_GMY@2
MGT8N=]>Q;)M9G>MX(&>C$G_<1\,N#4U8%0(,F1Y+GX-B3K)"BM#\T!3^"$TK
M@T!S$>T+3U"6190B.%8WSI'DG2!T9;QV7Q%,:98.?I=$1--8]5E0G_&'2](E
M;2CS4X?C+O^;^>7;33\VXPI68/XN_:D*'V8+CV6+^?;>:]S@?']G?8^?/TPS
M V/%JC$K8V6A/[$KZJUGENOZX&1QAC\+A\ZWDU((GF0F#VGX?/FUEFQH)8YZ
M.W5QKE.?=GON0KV9:WL@L:UP]/.-P$?/[?G'0S4"*?"CJU  IAI\8,LBINDJ
MTDLOT 'JB;%X$YRU+L5P:?WE7'U!=SFUEC/=-\!.T\+4&[('S[92X4U<NRHN
MGN*SKM>0^IMB)/GS9HV$DF*^BP(ZL]AJ.]57H2Q=T$)DNW1BJY8A6)#^'N=[
M^>=T-;'!4I\-7\\#%EUMJH OYAP$W%QMQ[1Z&DZY>C=;L3Z=\A9CP+[4/=@+
MG<28RP[];?/IHU7KN-1$?4JS#B4F2D2N$22<+[RE'C?B%'NP@,*B8O?^E$*>
M06@.!&>^H/0:@9B;L1- U*X];2RM84^EWU=9D93W$O>6H,\ WP>UN/;(HQ&.
M7K-7-;],2]:-[_')C_.%!GI<H=7^*T((P*<%$^EQ0QLWP_'\AE/29[9@AE]/
M@9RA9YG\68?W/G\(+%'7KGKP[ ;[RCB/2UHGD@$NTJ5:D_\UV\]1(DR:&X8A
MI$%"-_ B?_7I/KMM6MC[<0>_;KIYJZ7N#FRG_3I1# >-J2VVLK/"1825NLPV
MG"I?#%@U)=SZ]U>)TU7K)QR-V+7+@'O?HK\I'-6]:/)NU["^M*[4GGG:IO5!
M?Y[C:DQX0G#071<.WRBE2Z<.0%BW&/=8V %$/725,!X&\T32&_KCWWOT>6HT
M1M+Z;94&7CE5 WP?5P.]IW>=\68/ZGP4SH:-)UZQ1=E5VH8$WK%[H#SM;]*J
MMPZAM83KM4A(1!Q]4KK;SZ\@,M_S:C"4[5:DV_#E2VB%Z.8BN*?.K$3-KU]G
MXJ,GQWJ)7RL;&^MU!&H3/Q0K/583[M4A+Z.B8++T4;D#M/)KX1,(95%/YK\#
M^JW32$8:BV"JD\L:]@CMB^YM,3P% 2)=6>!IZ:$U)JC%SUF.J\DVMSG[:^U3
MN7LTKWWW?GW+1Z7T\_[6+]48*/4KHONZQ#MC?Y6,?#.@NF>5NWGB:KDT#5?"
MIIK :]&IVVF2Q?+R?RND0AX#%CB+[JQ+$PA%3Z&((R9\7'PRS,:OS&Q>4_PF
M?-UT^>\I>6R!\Z]X1:.&$D0UOEYGMG;$DS!9A2,:Z1<-8=;H]B*6&042:0+"
M[@;?$^@18./ZO-'JN2K7X,Z*$ 8\\^O[ L$]"M:Y1<ZZF#W&KE7:L--'MS82
M:2V8H&&L'RY=>R(;UQ'[V63-)XA[LF;/SG"F5'I(T=7D*;W8WI'LS^05RA!Z
M*DNZT>M25Y:?7))'PS@U </UA&M M/MU9Y5K.-*G<KWFX1G1HX8;38'+LMO/
MR2[LRV;\B\K?XK5%9DL(F[.*5YM-H2)#Y93;#C2^[ZD$J;Y:I]W.^U%!.:KP
MTN0>KL]X4@F"YR?8SRG92,MR7.GK@@4J:DY+S O6*&3'+RR[VS)S?UG.%=H<
MO1(858R0PZ6VEL6Y&^':8@I_J3H$J.YQMJJPNRE%&IO$#-N+5:8L/-HBER1_
MXV*EVZ'"-JLD01%1"[[F++?*51\M;S.Q_\HV:5)^PB='5/#1%0,0B!9TYY:E
M*,(=KVXRJ03%2Q'29UMNB,J=,-=W6<0IFD^+LLG4-'W1_:HA7@#KK[#1@?B2
M<QEOH5UYQG3.WI)8EA8MM&A]DN#/UQ>_,'G*U%E"#KA'4G=\(4908^>V2SAT
M L:/*%, >.I4XG[T/%6737"U8_))TOQ5.Y%-?;WXLAKYB[ P(RB@>'_&2]&5
MY5A]RET:YB[2/U4FQA\ ;\FAM;#C=]F]G>^A8DEK=S%,A8E/JJ>])2+:1&LF
M>B*-4=K-T6.#\LA[V:]YIN;W^=H4(?1MK.5$QI< ?'7;E@@W.N7Z*6JRAUK*
M>C+2[CAZ#I+;0[9LH[#;4&\3D7,0=4&G*BX5V?7/*JU/R#F(2G;O'+0$7? (
MK/8MSZP/"ORM<T<%";@[%FZ?@VKK@TN]PQ.]X2JT>28QDD-1J:1I;;9CQ9"1
M %_T06PZ:X=[) <J5NG^RP#=^Y6]L*M*2T7+6'D#"-8. %$ID5F9X?8_K/):
MP;=3'2TMC&R;_MG-Y5MN\*1,XVRI6I==WN#E<O@&-'>0N("0_*\9V 3P=I#
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MX$I[M("X;1&>!*N6CD8P*REZH+<1Z9!ZI7VD. IOI";^ZJ;I=[K+PGR6$#V
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MG74[HO&WY>16'- /Q6W;F'UG^^]6^3G.OH9[SC7(: 2W@>=.\;;',^P5M<;
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M^]GHH'XCNEAM3BCSHY-+4:4I2*W)P.6L]\:HNN\5#'RVK":CB4LB*EJ0WG,
M0P=P[F+<05<)/XJP3W!:'GU IOILIRF5_(J4^X]M8CRLLO^@H@"B=?DR.L#
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M,,A+@I,J"< ("F>"?EW#9)4\RJ^@Y]CR-*JR7Q[6F^Q;S"[X()4.%#/#1;4
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MULZWUJ"LNDR;&?_!M.TI8+O5WF V&7DV1N#QL$MY]&9. E<^C_6-35;!ZY=
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MADLW="^.0A;>XS!Y^0"L%:D)3);"9Q96(G]V=KU;>/?L[94'GS3D]?V>)SC
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M?_ "5?W75N'GJF)7)BZC*G-4Z7"WSL;,_#\=X94,7$^O5:KI?3"/FV=1AB1
MV7833\##!A/:;UO(^+E*I_MX**K#"Z*/3C,\;@WV% DU"#BZ@0;IW <9VG?\
MB%NL )H0V,F:^*H?KR39P!O^7%G3B?.!IK++^H+AULIWSE=LVY>2C6^;!6/R
M"NP\A/S'(Q9E?%S]N?64KPP/O[2\MZDG7GP$0\ZM0LCFF?8<U'L4YE8*L;%P
MU\ST7IA%6&=_ 2EKQ,[/NV;F,;??4J>'B".[>H_ F@.: )M.Z+8$7,F)K<]=
MR@Z2"F@Z$U5FMBRZ/<N9U:.O.J[#["-O^O[QY+HEU%P3 R*7!%,M1JL38\0T
M*:>%9FO$!"G44!PD!J'"AN&C/HP7L2J_)2+@8CV5_<=:C3E4Z<%$^KXX4'!;
MC&T8X4?QWNAR.$&./RC-R7>;GWHZ_</L2F%_&>[G^-1W;D:MNSK GTJHV?_9
M@<D7Q8U=M$BDMSV'T=/U[)W_9@N@B/KC2!<5;)2<H7_JSB&(E(J?@?#!U5HS
M[@%A-X9V"R@6;W JM:^N2-:-JMB-V=RP^7&)<;_V>"*D(W8.\Z+4KWN>G:9&
M,6U7$P-3'!*]2E9W4EUJZIDC[Z7Z/]278/^>R[EA+826AY\BB*H1RF*;)(C8
M"%TQ<D'"+NQDSW-_N=,_,N/E[E>&WCVQ[\O?YY_4)3I6SB@<.<Z[0@=5E(_H
MLM"[)GUF6EUDM<UA*]^3PG><@X-3S;XS7X8S:F?L,^,'6R ,".F4NYGM#F!3
MNQ(3)JOT]'0EAUES@35A,ZW&-T>%/F#^25?MP1LDKRW >IM\%[BAH2T7\DP.
M:I:UO7P_YJ&\&-<(7QCH_<F8ERD)^5\(Y8OSPOY];U$>L6Y5@DWSG%,T^8G2
MLZ'@C.NI>?K,C/5.ZF+C2PZJ0#!YE"X:Y4$0N*Q<,S9SM1JK.76='_;EVQW7
M[U-S R-52?*22[X%,7L;+:A*JW94)%*REL(125.M$5I4W<;%ZVUY2V<8+UYX
M8#QBW'5OOXH![<-PE8E=)FL2^Q@5FB75-.:MPG',SI3Z.\BU-F%[6<9'XF#M
M+L\;(Y&H_=4O<[_LCR<P$@SK7<FLA)5V=,QDL5>32BG<%\:VL>-Z,O'TB>V!
M:TJAW7U9VM33QY]#-I/PPEL<-.'*"?_/-QVD*"%C](OC81QOS0/F'F=O;1LL
M&86-NGJ',5+C %<"-&X4'HQ'B+%70=@=EGL/0?<I!A,Y@O*=,-GEJH391.7>
M]1B,JTR-8<^ SR]Q\:Z85]EW#(]];F$<2=?+'KMC8-SV+R@J_C^K+/Z##(LO
M\@@$)VUU@;=L4:L9&S*?L!W-$G\DA*"LNZC,4Q<^U??_NW3CI=+"+S9NS^V7
M\PH=[-;V_-_+^?@%^5_J/,TIGA8D.O7BRQ<6R?<@%F6&)S'9'S?V7&.>!9O9
M&8QYJ81<VE:X4KT;OJ'-G;WZ;?W&U]\GOGIC9.%\?1VVD2]]B.8<>J5K5%)@
M4%[?EY9:RZ$+Q_.2Q?>30&?3'H*8;C/;_5L-YLWT(GB)[3@T#U_9M1/<+1+(
MR=HP2\ +$>8TE)::DL+J+6IJ6$"B!:(7&&_$R,A.=FI>H99_65/%-4=T%>7F
MWGW"I_ @Q]REHDC93)&Q01YO7?A0[;BD*P]#H<'CH]+EA9^O<E,]@I0X*$[E
ME[OR*\RT&,G $J*2,>O]_:/13O*[MIW1#-R1&[YC**J)^1O/7>*#ODSA/(0^
M?9\00OR^D,[O<8;M8HQBH/K57CLW+?W31)6"_VC1QF/IG4+P D,;QDJJ^BV[
M[]2-RNKVA+#EM=V@IGBQ+=W@24ZL?D/R%)'763V:_G\.5XEKH>T3!]2T;';#
MOG8)T]S-E[1Z_BV)A^1VB;/;2I9'G+U2&<+M1I>R6Q[>M1.U\?1>^MKH(?SF
MK=ULEX\DEY>TYRNXD_K979ZO0*91'>5X5QA?D:-4/<P[W<\]^FGD\@7[F-P2
MOD"FQ\6,G*'W$\88\OY[KOZW.085VKICC' _LZOWKQ<QZ3Y[J=TC_//3XG8W
M,\C7QZ)JD-MM;R*[<,H=5Q)_0$V_U(KR\'B:;.HN<<'?Q,+D0J?Q0V&F4(X;
MH)%_?\?P?91FEK...PK;U'J-6D9I\G!IMB/,-]G<9>0LO.,;^VK?N=.-+[YI
MB-P^\>$_]\'[:_#:5,L8C-TS5[L=^SNZP.[>V1U;E7,V;2OG]9R9?O5QV%8>
M'6;A!;E;-5YBT!\_IE;3^8YI8IOE3$6YI2"SX.GBW("S1SYPB;F47U)DO:II
ML5Q0.&>WAO-Z(^?G'Q3X#\E^^1:(*0-4:V UNLMJ;]N&V^M:%IZ1^9SF)NNU
MR&5TV9/!RE)$\;4>TU.](A[07W+U=PQ<-N:DAFE7/(X/5'^96N/;F35RYYG\
MS7+,1#F.3_U-.:A1@>&^KTG+1[9+_Z0N^J6_<+J[T*"@>I;ULRGWK-$3ISLR
M77%??G)K7,H;XHX[MJX5 ZK\5R]0<@ETH;C?KP,'B;3LK(ZW[#:QVZ@KOB*T
MMW2.GU]1Q(@I^-4/B2S>$R8ZQ]V'CO!O7.O]Y*?,DAD@6QE>FA=^:G$X:??@
M"M0V(-'4LBE.F&HAV\?<OS_":WJF?H$;5_/Y?_;+(N?]&Z5;+[-D!24.>,W!
MN\,RM8ST75/:'=IP7\PA*+!P]0B:#SW[Q_=#2B9DBS[W %<Z5XF_WRD1ED<M
M?XP.%(N@Y/#9HP,FRU#S4Q!@W/7"M:UYFJ#/F^+F^6_K;J5V]#.9Z#VAW:W]
M?>9#D%#./YJ%BU$[]-.E[BBY17]EJRN'H)-F@P=LSW\?'(0=X?0[?[=[.%9H
M GZF?U 2A9_J8< U;]2JQR1V:Q-,>Y+X#U:",0JRT)X![?LC:L;;AVKC]CL$
MZ3LT'X)0#X^\>?^??O#5_W,(.B$R0H?^UW/.208/ O++Z=MTHWL&OO/_N'SP
M/YHBK^FHUBAE;/JV9H9,VB$H7&J%'MD<3*>W'H*Z/O_=_C=G:.31L$ECPP]J
M:>?4(+]4-N9_4SGH*D;_:$E"T.1'_7)+M(3\F"4LGJ7^$)1=YG (PGY%4;Y
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MIT[GNSC7Q6$X/UR'2ZM+Q&3G(#R.ZJ0^P:@3S08(FY#/1Z(72CSV==GN=;#
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M9SO$S1.X"Q!2).%D;,H[>$2OO=QX0>KF3!>:N\:F?+!6],P>N&U$'<>BLQG
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MRPH'9G';"V$C82)EM.Y>B+@VJ76]L()'XVVB@"&__JIX#>\-9]-+[Q?442*
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MS$>/?POO?7-X&3XWB-U,(^(@4UW8R,8X642.*BQN4E7#>/;-3.\UCU$W"?V
M3W[VIJ-N_C(V'X^8WX5J27=@SOS>8J-.V$N2K$8SH*=-%MJ4].K0!I&Z/Z_[
M:&HY<(F^I/>#/I%7%[JL)?:+[#2.YH9C<"RJ-% M*D);?75.=,*K?D  -LZ6
MQ3T>89NSY1% +IH;-A!UJ.3SK:].(&IOO O5AGI/87"\7?.,B+-_XDX:B,T#
M>58;,H \7X@].C\WKS>*(ORF[_FIVJF>H;ZH4_W8_SZ+:3SD=40E$=.%Y-6R
M.70R(D%[T73Q'<*<L!,#V$,!)"'>8_W%V[6S)K&4]^HN]Y^J>EW[0.?9Q_WG
M!/D=%*& 6-(#XVI56ZC.7S$%9@R&?Z_4L_IV/%UC=FB>_6!@RI<>HUL]!>M_
M^>*Q[Y!%#D4>@."%-,FY1-Y$ IH-'H2%A<GX!=^]'2QU(_?SSQECL>[^J_,I
M]9!OTM4W],U:3CNHD<C/CBEM;60N8/@I"K 885Z20>3,[=&9[H.,^O<>P[ .
M+?X$M0#Y2V6]E<N]GYD8O]U?)&67X[U?S$F/TT!N6^> AM%;.PCH!X2TMD!#
MZ^$-HV5WB.>GS"\_8$_V)71;0]_B_:]S[SIQT6WS)J)/PM<M::!PMQG$I;HA
MRKQP2>3NT96ZO/KV3Y]BL8I2V;"O"^*^&$9!3CLPH9[HVT?5&D4HX+Q?$#OG
MM$8&-E_VVKP(%=*@3BWD]%\!O<[[DG4OM_KM"3CT3Q>2IH0<I4[>!X*)2?,=
M<T+#6M;'M;73C08B*M9,R:EB2L#'6YG-SHK'K"RI1N.ET-/GB_< 6:)--P?E
M05I/"D* Z-T. Z]._S&1X9_![YSVK-S>_AOH4-?D\0L]+H]/3!/7;!N_,2T$
MN^B!0IX#7607X U)TVAD-P>&98QNA9(<I@_FK-#JKLTYQ=EI@FM;\(_7. *R
M\"QHFUY.7\Y/( 6"_7G %S^K1GX%I%>X43D\/3KGU(D)_&8>/ >)=;HFGQJC
MMD[+*&JT!"9>NG#A'.N4!,CG-P,7W;&31U// >L+A+R-U4HW?OO,"LH-XF#$
M$I%<3:2N6S?4M[75/0KMERRJ6%:%2]Z0_=[+FMC_TCTI#-*]E0"M,R#0N?EZ
M>R] >.P05VI'=C_)_F8//)\TTC8<YG4^><G**B&5NB5Z?RR\^]&1&^GN C)<
M6]5J=8*J.)1FKO&X4B7Q6P"G]<_I%A:%.+B=A'$[R/_C]U//SV1BO3N2&2C<
M(UZ[6Z=<[ZP,V=_V\EK:>92+6[M+\3615DY5:ZGN 2%X<7E3WGT'>^U,K:+8
MO*G&+GMFDDI^==I]$LMT0Y[OAW56;RTS]?JW'(?%KI3.20Z#L/0.V91=[^ZM
M%VBY"1K(/3XG!,QJ5 X(]"#!;SHT,HH]D-Y<TT;U8]MU@UP)_'I3E_^IVU,P
MK^3"<5[ 8%F/"@PV5I NPPM"DM%D*$5,%\<WD7^<+;YMHP=_':51M;6VQ)>F
M&@70GC]P;4;M>?3UF),A8Q/\2VUOT^#2QH#=0ZQFL+G5NWG),=X1:(8C*T;;
M5'^VT5N=4<MB:/<.(RNI'YL X]<&P[O:1^T$V%%N:5:20WS;CYPT!9,65$<,
MGC"A7E%E5V!UT3VHR! >(L-69X[&UV"I^R->*CDA$';K8Z?R;U10\% WM+#=
MX+B<^9#.ZMX5,?32<9AQ0 .Z)%5H7%X=N@T;Z-FJ%H0;@.A$=$XO_4KQ8?XY
M8_.SH@"K^?6#&[MAJM;9?;IJ^P L=&JK1U@,F"<>]DQ Z/V2P_B3(H+)@V>!
M"/UQ0O95!\C%":.;GI4FWU,_WX__]J%=WK<GN$L/A$ NH)@IOD=O6\5Q\E$A
M3$36S/BZ4A6!]3QFH+J^/\@C6%6ZJ>BU+*$5T^;(DEJM;?;)YVC4;C LA M8
M-S@J>TQQQ%WDM:DVB5+5%FXC<01>KIPKR]P>N&SS3/0E]Q/\Z;I3)Z^<0D<?
M<R4P@70.-L%F=J-BU89"!D/8@:TBH-'R$XGG39F[BW'<H7'3IRYCCR=>H[*@
M3-_2A.H[W9X2I"9<\M0DCBWZ4)5R>=1O"PP@K4AY45J>[X$NTR&$O+?;NZFO
M'W_6U=C,@*I[TLWOSP&R==571"RFN.XP]N:>/\I"N)&BJ?SNLB8FVJS0LYQ=
MF=.L/0/?>.GD-BKRGZ8R91%+?9D28\^)\-AU\8V2T!&D%O*K4<K%A3P>A$8-
M$/3.VIVLD1=3OU-E,R^)F_Y:R[3A$)-%EWIS;/.U7(]Z%_\!+@Y$D@_#L"%T
MCQ%W DQ(90!F<G@^$V?W_/O>K;SOB=31,Y9=G WC#E^B]<\] ?/U7BDD0P%?
M'"02P_AHB&)2<ES NT?;CV_=$/9[2ET.6BV.;=3_AE'4>.LBKBXB+#WC^C_W
M3OM_FI<:ENX.TT"+[(XTD.TQ:+G._;1)DJ3T3E/D7=RE6_^F\%\(@5 NFD3;
M*Y.^E[Y?,S@$]_!6KPV\>WU95O[KXZ8LB=FO S52%QNC.53QRP^#UOZU]R$,
MN$M\)Q^U#2\Q;1J#-K0:X(*M[2SNC?-#I 8DF!9B[_IZ)ITS4Q_S@OHUFHNU
MK/WSA64G9EL=/DG%R!Z+(_72G^,3_Z&'8@5%DK])O=F;V7D$6^Z,NU#E^^!O
M>RZ@W=:*\.2N@]PTR=FE%P'DFNGZB9PG$WN7HW6*<>DAKHM\7S\NGF5:A5TU
M/I0&UGMY#LY'D#CQ*I.)6JS%<S;V#4G-]#P!UO$VGVMT,C,=]!4_^.G,F#*S
MI_H.!$O_?TU]E*.!4LK;Y\F<;VB@FU['@.@?[U[;3**$\\H52D@FD[O7];C,
M3_6]I#@ O.5_O@$5'56(=]N@"EGV>P>4PE6%-,14;&*D=@K<Y&+GJK<L&V_0
ML2XEZ1L___TW+^K8>QX:_+F9*2H,D,*AHO]<]?,#.O-2 CH-=3XT26FXEZ9M
MOSN;\_JPJ_*Y\;\8$-V@NS!3];B6=R'P;MFC5-[OC4V\C1%2C6?%^>+RK3ML
MCV;.W3%L9_D!45 9&OZW?')_H=P^9M0<>GAZ%7-@QW", __^"[^'-% B^/[^
MZPFJ8!O?A*D>]_?'_UM&:_[X#R7]__?#_8^]3;^?;R=/;5&U6H^#AF/2<7 J
MJ PX]EO_<AK(B_H87TIYCE0:7WD7MZ#Y]U$&3XZK;T(#TKCR(".W+3F)AOLW
M/?&*FA %C0N+^%+RJ3;AN.E$$T=S%<\0\[R?3N;"$V\+9E7V<@U*0H;XG=!Y
M'IR 1:]F8>P]O,[KA%"&XQHQ*FH$LW*?E$EE<D;=>]=L]U@I@'Q\Q!,T4.B#
MTDGK(),NZNDE)'%HVN+H#%J1!NI@&4-VZ;K!=B\!_300O9)%F:E!?1=R\)B'
M,&0[I!9% T&A8$ JG0;ZVY^9TD"LK,7(H7*\/.7L@'VIGO D*PVDG4=EH(%
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M/:+NF'8N4G_N37*$#&ID1LDXN=9#^-TUD"\(Y& \>>8#-M-U$Y&F0)%.)M%
M$9Y%Q[F*$Z%--(ZL2F<\CBM,:U2Q^L8P'G5LJFMOWJ-6NCH>CPSHW,6TD="K
M)^V/&M",<!=<)D6ZT@0GE^6!&WXB,S?4IZ3+M9BR9/CT;)= N&JZ"[TP&Y@[
M$Y<\P]QY "$X85%AI%D=%8]^M_.8U)MR0OB<0H.&^F1W3Y85PL64-^X50;?Y
MHK2O#U$OP2$]>=5MC1OC"UMGUIYC>BN?SEU5LB<.+,?[<&6'%(V@IG\;[1<9
MA^J)G:9_DQ41*!()>G60MC ?O\NJ2QX%>K#K\5^62%Z)!:[-3L6M$[5@(%.7
M-T>B4Z?EU/X6F3";MK0)2L@&K2(]MJ9K=8[2$<PE[M8)$^L5ZVJQ3N^[ K@&
MF?:'3+3")67,SOW\?.?L8-VEE[?UDF/G&^8[Y","K%5*XBF!'D5S[A.QP1[N
M#0%JG(%LW"F+-]\YO[C\P. U5Z[/$#[[Z(/6LWQ7J##4Y2JX>_*NU6ICKE@S
MNO%1?;93+E73NW:J$U'WF%-RD_*6;FGQY144.Q%%X%Z0GYKO@0CZ@07A0??&
M0Y2 -ST:+R:FZ9\+]<P.QE8\<LA^?.>F^*,@Y(7]AWQ1"G)<:3N@X)VBM0D-
M<KI+Z6IFQD'2FZ SMM-SUK=JNK1N%Z3>>":A6/-2]V0XDUBK2P^LX=>?,Y@0
M=VB@R*!*BL[HAI:EG'A]D'ZX?QP?[)RA'(\2BTM*SJ;J<=J3=B3?!P+*$>>/
MWJ A<!.K6(>)W0$QB>;&'349I<MRPUY\GW5F%)7VX .(Z]ZDOB[K7_'O1K1$
M/:NL* :DS%B<L-I1+L7H74-E\1^#%Y.V'94;UD3$M.RR4DUD]EWMKQ8TA 97
MDQK)S8#>H8;[\Y W).;>AF:VXF#V7&:)QMQ-I(R@-WPA<8KK;:0+2,'\I*8-
M;X@$=0QV!LT.\.J3DN-:/4O<J (3X0U906R'J(;R"P^&BBYMB2V$6]T+2TE5
ME%[V/D,=RCUQ]):J@?"N!J)+/,P0IB1(S(WL\YDEKDIS=NO/=6;TA%[P>/(_
M?O@J7;7VP_PGSI<^7Z@C\QP"V(#>0=:5AESIZJ.LW0'-+O-?75 GP,<;QUR^
M*O?(]YD3YPUA35].F5N.D0TMAJG?5,_2[6XETT >8-8OAS+ &]Q>EYV%"<FI
MK;A6[WV6^"L#R9V;'[OHJX52+RI^.??#OYI%(;%]?#X6V:#6"0O3Z$W!8F*%
M-4;]3+CM.@3ZG1A:=_8?=SS]+F:EE2ZQA.CE$UP,-49$$IVV6I\1\[#DS \_
MU]2:4=V81 OKN??-=0K3<X;>)4H#%SY%7>:XHE!RC4^<[EY:@@5=.;RP!\IV
M'#$<A^1#5-;FF$B_8BG&B%_M#9 SV,DMQ'7W;_W.GIM%G?V<[3I%7BNEAQUA
MJ3<9UX72">AB%X;9(I*=M:W^L2G)"4GH\YF;"YZ]3L\^J1)+XNSAA$NU-V_%
MB"2;O%SU3[6'DBO7K::+?!)'M&IES&HNY3M+Z/<MK=HRMG,64BX246%4YI_K
M:KSHR\-:%[WAY$G5J"LAGQ-$V);X+>]%[ZO*H/9NCWQ5LN^Z!A&_?N@$?P^9
M*L&Y= O9=/'[Q^/ S#=$ZT<V$W"+<\9UTWH!CW3J=&XTU3IM_TK[QJ%V\%[@
ME$4B]7+(..8D0I8&.CW9;:RT0#@.:W[K\7KCCQ&:<A^RT_14NI\X\+Q^W1CU
M2E#P%SU+*MT:#>3E*4BY WMQ'.]$Q^3]OB#<<!^6FIM'G;8W'U97QVZ6I)X7
MB7SF%.UQ]IJ$H/"E^4C, \R9U1#IX=\8;L1U()UDK!R4CA[=S1.&OUI3Y=GS
MH%8MZHA?>V3ZB;4[0>&SUH.3%4#UH1N"&X#@;[9*XKV%IU;F1/V2]&ML/.(C
MF!"/=[+/S3I\%JT6O5L7M7*]*@UG0A @SF!9,_("<5L\4VX\SR-?'!07=UB=
M3_)PO1&T:)YH*9A5<$;C\\BE? <?V.MY7J@KDL-Z99Y/_-BEBWVQ)KRPP7*#
M2H04<:O+%;&8H)SQ1>5[!2EGY>'VH\!XGC.'=[W[DVM#SB'41^I1TQ'7:YKK
MXJB36-ZN 2GC4<I\S@-TJ^+)2YN_X.'#7!##VX&](#E BGJ&@;B#D^HE^'9J
MR%4RNVJ81+VQ#M;!=9(O5DG><4KWKQ/_>O/AG8%6'O\LG5#3"+])6/VO</19
M"H3(&QNB")^\-J+BS?&C)P!"EDS?T?-=EGHM+."LWV09GLY0K-<AHCJB,_E=
M6Q'(*X*78#$$EV(WM1$:J!.)@_!=Q_)M+-?G*M&KL9Y*<R_(.H%>P36]<:]6
MEQ)YY%+6"M03]\@6Q_6>Z!S",)P&NO4)/5SG*=ZNU%=D$DBNU!! &+NX#_7.
MV,YR-EE^D.@9  6?+D<@1EJ-"BBRXR$0(//:V.-6GXHN;Q??((:Q_D#G4HE&
M-Z9(7Z'./I8(S@W+*4OHMQ8VISY"#U%QLN? )?(7$/V0K:D49EQB,V/H_21_
MD(O@M;;I.'5NQS3=ZFNYXZ6;RZWE]TC"4=I:@))- S$>+F! 5 O]/0B96\E4
M];&QM;&=J^GFAQ<XZV45)A&2O]G\"O[Y2YAA@08Z![_;BZP)R3E4@]M<PZ"!
M<=SJPQ:2<-ZS(B.^4>=/V9JQ]?%9L_2/XWE?#=^LVKC>>+(!I$T 9@_-$1>/
MWCJ//@!B\<S>8#OW2X.>[K*_FG.&!'D5VI.^9M&?>D G$OJ4U=T=4V?0%0S&
M]D;C#[=X5R>HS!,EC8W5DWRO9S2_SSBRM8=L>'UV#GYWM;*U:C0YBGH5\7RR
M5?SP-D)''\B#=F+8IU[+U.4QKT!8"R;JO3E75T_<2C5 BEUF6'1+,4W.Y/LC
M)6=Q'<%'M,M+;F4^%*:H3SC$VXPL-XQ1Q=;]:R^D2#YLOLD2U\5@_<M4(H%]
MFSW!(53[[3#22SX<?0E XJ'G5K15&\?K8$R]J'(M\\S3$II)/T@"O4+C,TLL
M^:57 94O )AZYC01[3VUU8GA1 3A$J&=I/5&)>MX=5FO9=?-LQFN[/3.AH@B
MU_'E^]O]@HDMXQY?M*_ 4R_6869.]FW)9$S;^A^X='U >>("+O>R\QPXG.7P
M5WTWUZJ7!)330'6,O8.1_- 8JJ"]1_9D+)IS94)8,/X^D;'[B&,DL+ E"7<Y
M]8>1ZT3JQ3NQGM(&EQXE8M9V=D*#XXE]N,S(8Q-6[>L)89ZH_'UT8D_;>.F3
MTZ*@8LUEE@3P_0=,F]*OQM&*NOF4VZ2<'&IMX0P [9CC3;:9Y-UH]/Q@]7E+
MJ:("BT@#IWA?_/&F6*8D%#2;<BCD/HV*#:%?U1:=I%QQPQ("K)N:,&VI,[?L
M%'Z;*];T?1CP4JJQB4F]*""Q_5/HT\EE:$PF!W ,$(4W"2X*,(H9D/60N-8)
M?VHY-5/?EA!Y^ISXXP#"T7#&XUS7DVO@:%B#10<R'G8VLYUZED3.JP*R".A)
MH9S6N_09"OR?;_@J,LV.V\C$'1>4BZS)27UX@YX!@07OKF";7HTU6UMKRS()
M<W/3_4RUM,\X]0>1T#@#__LGYZ5 G/9J97#'FWGD#D!O8?;D[8:1.I,H*M?8
ML[&&V@2))P*5&3S#( W6\-7J>2\3$?-!0FGQNC%QK]->:KA.>HL+? K>8D12
MV8Q_;[!L9V\]TW*:1X*J9KPN MGMKUX$/=F;Y\)XM(%OIO591W>!Z7["K<_*
M_2*>SPP.],5%-GYG<;L <<YX=A?CCOK&55:US?!\JV=PNA]KT6ZG=J,5B, 5
M$5O6V64F,M14,SGFN*7?MK6:ML8PBF3<.<G:-,C]B]^$PB7>#N&JDE6&1:@^
M+^F!G9LUXD<ZV?RP<R-/L"OL5WE[+4<\NERB\U7"H>?^O5_BH6/HJ_"3Y$='
M%=I*ZWG<V+$*A$G5^1S>%RC'$2]YMN+WDN^\:FO\])GFW5F7I<^-%[E^D6V\
M1'><H_@P;L%J74C0+B;&_N38KIV_;)#IJ-^1,'G3[/$CCS>?L/XOHW30UGQ&
M)ZZ;)T3U"@B!.VB@Z6BL=U_]Y$Q[R.6ZR<SK#U0XQ#)^7F/;@&Z9JHG^F-=8
M@J_#1 %YK.W<^>0%QB[,.;CY5?ZN[A!9$F/W@&XG[YW$[&=%(1Y3TT9\YT J
M&W0%#_N^5="92=O@,Y(K$'_ IO$PXFPD^?W$2]<0MK-N[M9!Y4&.0A.E7.ZM
MM:^]%A-8%O&"SJ':"8#WH3N% V@CL7F?A!O@3N55P'.AFD[ONK0,?98$U</=
MQ"U_J??3<:HNF?NDF^FV^ARZ(/@ [W)W#5@,PI,UH[!D=M#1UTTH<6R[Z..,
M[+>NQSX*EU(TJGW2Z0G?-Z7;-ZCR"(VCLM9 XMU.R,G=V&?R8+B 3>-D_=6G
MK&(>TK(G1I@#,S0O/[IQM/C-](2(2)G"XD5I7VSQ+"J,!G+82H0(U!V>G9,B
M=:Y3I5+75&3%;S@U&='_U/:^I.Y_68@7$9V0]E\(._-X*+_P[X^(K&/)ODRA
ME#5[V28[252VB"%9IZ&2C!I&]ET(I1@E6Y;),@B-?2A)]LS89@9%EIG2N&.,
MG^_O>5[/O\__]Q_GW.<ZG^O]N<^YK^NB++8'#9S1[W400W'B@0K*@N!WP,.Z
M9>K'F!Q8?L56/FJ)U,=5T!;ISBXSO'R61^*'M$36'<"0/M35"6&>1MDN@H4\
M@"SK&X5$VS>9-L5GQ=_9'D^M2^(0E+0RY;@M"*<N)'>*L 2!4#)7EZ%]\%Y?
ML03@%U#6'4[.2I.335TYV[1_951,M"60OQJSG7RTVR3X7+8Y,]YO>O9P"E#1
M8*@@7N872V6R!K$9$LX?$JAFY-TF%:1OHC).MADC72L49#OZY,'-)[\);Y7C
M8MA(*-3^ZPYC&F_/=&'FZ]#'=7"A&?LH1,GJ8:!<-Q>4N[T58R%&WX1I43SK
M2Q243CEM0SA15VL!$EDCCFE-,?3PD US&ZO%2;?;G>@Y(Q<XY: :X@\]X_UV
M:2D6_@4=\O)3^7YQN ;OS.#UJ_3RL@K@&BE4-7HF7.8:0G8P_C.:9V?(P^T.
MPJ>Y)>-6['$W:H;5D4H)T&/0&?9!$[WH[U"N U  (GC !HBC>B!XG3_&SUKZ
MR=;VS_:<N_=Q[-@L@?OK&#"'JR^JD 6G0P-AB2P0+2L)Y4P!2ZP^"DU$F1L]
MW/6O^YV/:XU(63$[Y>CL]#8DHIZW2_(3B/6(&;C_FFE)AJ9C),NR*,\.0 )&
MOF*O=3O_*X,/1ND=XL&U:1W2>?1H'<8I1X_-BX0BO54T2_A<Q1[T=R$>#7YP
M #J.K&8X >A*4F]54#$W@#Z$2=QR3:IB M;?[03N(1\TT:KMP=;S/P0B:/<0
MMC9L:=546-S?$5&D.2%?G 7Y5E3@A&^_H>HRR/&'][.ZF)X-8^E?/,+0XU6U
M[U#= 2@4PHXRQW07HKNWA%=-5"?#L\2__Q1OWGG8HFF,JW[;>/-*O8U\6/+K
M*.SG$!;C&/88T"K>AY<!9NCJ!R#[#Q-,WL=T:^MQE#7<-\1_SSII^[J,OM9Q
M+R]MK<]N6>3K7[]ISB*AE($GZ. 14A@YI&+17FOE5R^>@X:OK2(!F0@]^!F-
MR\/\A?W'\H2*Y-7.+%\$=X;.*<9$W:!7#Q '>J&);9W)1L9D8^L!J>TCYVMT
M9-4DR]H*;<5T/X'6,^RV(HR45>0FEV#'6.=0 :,LK2", $OWIXF '58P2%RJ
M.>,=( ?/Y?"?H=[8V%1H/=5RZ[;WVD/&OX9+VYVX@0W3TN@A"/\&;NXBJ;GB
MW8)UV6KVO*1EVY=_:D:L:T;%ER_Q=N:G_V!S\DNX"ZL?Z ,GP,0Z;E"RCB/1
M%+61?G1*IU^JFJ]GVUA=C7Q]T\/]N:)GPH2JT%"\?+]@8SO_[_;F8Z!=,$6\
M7X.'>79\>^\ ) YWV>7/V*=\-PT/;[7\(;%4P-<EF*J0ZAJ 4GZG>0LT'.GU
M82\2=8RV$(,RIAH[#-!N .@^L/+J_4\57I$[9OJW(SSN@5\I"*3C?2Y^  4H
M!AA2IY-T%E+_Z]'<[< 1W)R]YNZ2)5=!M2-=>*9SAS'$CZOR,Q(\U>Z_6R++
MC<U'!V:)PM'<Z#LCR7B%J6C=693HA\GM?;V1W@@H#5O0AR8V<Q_3ZD9<<#F7
M]V'^=M8RWXB(\'?/$LCC8!C$1"[P,/ZN4\(7TAY\1W&=JFS/<O_#G6IA+.K$
M/WSR!#;_.)[<$K*I(DV&;=R@%5!=X_\>@(0!ZP$#!"NE1$\77MVIU>=6-TRQ
M=2'[WDZ/^?XT(\DWQM:*G:JQ?CX:!+@R(NFN_>73(7@Y4PI_6+_!'*&>_*PI
M2MNI_>KI5SLN8@TWCVDJ%AQU!F_.6QR]^N3J1/34O/IH9R!VIO<:?2!61];.
MC#:$C+MD'T:8+A;-C)AHLHOD*U]5NYE25WOB6?])VVRG^%Q0S,2A-^X&$W^1
M(1NR[]8>!?2.2))^[>87\<S.WL#5]K_MD2>A^FVI9FO2;"_8>#S9?1\MF\@R
M4>,H2RJ_M<6D[H9<$ XBN%;HD(C8'C*<B"P=IZ9[OOU]Z0G?)XVBS]$;>5:$
M^](01=97EO)'^@&HWX9U=I9Y9Q*O 1B2"7&5PZ>;.\%J3,.ROC'3O2&A>RN*
M(_)O+#5->0G5[_.O=;G$3YLO0M8K]G11UZ9*"NT^*KB'"@9GD_HV=(:KB5X=
M*9D>]W(V=7Z<7_WFR#7S:&3 X0@RXCK=+[.*8AAE N,FFCZNLP^320GUD>G5
MY%926=ZZ-YBN>9^GJ//<5_W#:>>20S=DVC!,%:RX!Y!JKQ]*7-PS8HQ;26^V
M%&@IB!KK@ZR07^%4+-&.#$E%2>_I  JN=/7WQ*.,6JH-TY,N DLS]PPV-@BZ
M];1O;*;98FIJ@X%\*!.C8-Y$%;U.CL)FF6BA>X:! C(FS7V'P&]N1Q.H+@ET
M_PUP@L$>GIY7WEBVM#RU:1A1O-]3 3>[>B/I*W<W:%>:,L(\+D+6B'_@D+P;
MD8A"E,*]3&CX[(C' KGRPXS(3073YE//E0<T!7Y*RC]M9=N]<ZO3='5WF/!B
M\27"HV\KU"\\M$)MJI*NH'JNK4_JUCL[P9+$+L57 N6=^G\UTB'<T=HH68"+
M)DV>3@H-&6 J$D_5U<NT63!&D9$47^.Q(942E_9GIQ9FU5IY\P,D_N&']YL[
M;,/)F!D/BO;J+\7"XK+R(N'/YUNS-S4\$0K.2]Z;K\)(V&!0;E=G<U)W:(J7
MT3A*DMPI=R/8Y-1$36EG4_V>$5WR#3+?CVTIX_J7W]\UTPP'+ER-RX!CB5GD
M*$S?,2.P4BHE5,RANCE!+D^TK"\'1^F5^8)1O8UP6TYO>O&]_;V;X,5_N3U>
M>C3Q 0W!0[#QH 58=.0Z $'5)+C<R0GUIL@:U]Y5!%\5P_9R_>L]Y[Z^ZJ-?
M-W)%7FFZ(GV[VBI2T#[HC&(CFE>1VD!6]!D\KDXGWV8D(NS.M'8MKL,"M7ZT
M<G_6MVCL/;OJ?;:M>>[]9A87R@IXBN(B=R:W^5=3[F\==Z%;GTLD%[SKO3MX
M\GEQCSZB2UB+K8)Y91]GPL.4GL)N9TD :R2K2=40:GUKDUZ$MDU.A\IYD+5(
MR)$+"JJ]RF43FD=CH.?!:1@^:% 9H$EK7W1)"*]R0\+Z'KE\K)RKRU)[*R>&
M:T3K5'^2/R,NG(<L\/'N^VPGIQ\6S;O_%@\!O$:H\=/1TA,H<[H#)30Y/!!E
M6'( \K4W!'(=K/3T G,Y-'G#->T_>OYN]S]I<T:"?0V;M="T4D +.0"1GRT0
MVU1-9.BR<\/SI;4PF]NQ:LKS7VV7\MFE^3<WISX_![<.'E<1=Y^G96TXT[ #
M:+!:1U@)T*QFW3,MU6$@O& ==+<LM"S_?&D"-; O.V>L?ZA2(OS6PU?3,<SC
M@$T<(Q;P)6L(=2.J'6AAY*)4;8.:%$YLY FSU>ROW]=)\'OIL1?J0JAV:-'H
M/J@<2WZ5%E+@1;>JHD9=:,R:"]K)?AG)Q2YI?UY_SS1E20JTI]$/%3-26UP0
M/E1^YPEFAO_6E8[)-[A,;D7YL8FSQ4&23C4V^I6<9J]3>I:67-.!",8XK>*0
M+@.RDJ""T7IPHFOL7P<)=]ZAQ](J\)2TMS&?)#./__$[(Z\9\C2CO>B^ZZ/:
M2/V,+5Q4!,,/Z*0W[,Y[P(XS[1O3>HO%<*W>N6Z!+=J\]H?V#GYI^IHG_H+<
MW2V(3, &F"YV^#*A&YQX"1R0WWFT_!M*O_SGO'#^"/DS,O<:7;?]M<9Q[89<
MN9G16T(ASOY$!Z,8,*X)0S0GXS\N=O( +5?H%N)X:;K):[&\\F#';FV+G6LY
M];VG1<YI^K3LM)_K.]LKR+>[,Q#*M:KO93B>ZYZ^5LPWYN$R->1^TQ918;FL
M4_WC<G8>WU6[?Y<N)T1[Q[OV=H)15\53.V^1'-AF!O13\,I,WZF_45:$SYO.
MB2N?K2?*E5S;?_<DBWWO:O0[SJX:7/GQX?8?W5?0]XB=V U?/8R@D3.E$B5+
MZ=495ALF=(9''3>(_]T*JL]1&ZO8UPR,^7>Q!(RD<VV\IOU:S(I#\45K O^U
MC+E!X9=3L]_8]C1A!=[4JKMM@VHI/),F+/CE>/. Q.?SL'#:0HH.5B)0*OK#
MZS6QW;KL2K,6L9;F!J[4P.]^-]S".5R[84VNA ,0%_,\,$IY<6J*>95VG;*2
M5#[P%HEX,&Q@[^% +\?@_)M<F_4V1&[Y%Q\ETANTWVL5M?ON:2\6E0UCNM%<
MI<#U*S3UTM/9''^ 4(=FC\>>!BLVO4,\A [Y%,G67],7=-CZ@%^,64"6-D[1
M0HKT=0H]&-;H(]A0<F:H+\@M$>=YC7M>)PH;8#2G T\TLW%VC#":]G%U>%'F
M-5I$3U926T%"+D4.A\R>0_?  BIM?8-DWAUM$ E^F9YKLW8\H_MA$=F<$V("
M0*E*<=L+,X9>^Y@[J+/O?G4V05-R]JY,&ZGHI4&)_I,AGGV%&<.]2OF^%Z_Y
MJ#/?J08L\^;MIBVNQ.S <!$IOH7.;0Y))IRC'8JYN3D[^M)U%7>UNS4'X*]B
M[KK$&+M2 PAGHMF9BA_I(5C?T[BJB^])[JL&@2?_2O][X9LXKQIK]<^-CYQ\
M\Y6,]S_]]4DZB3+0QW]MSY'>@SHW:22@>KLUUPUXC-UO^NEZ1FBXB+4JZ64N
MG=LF\^YYBF+2=:?.Q=?%D+&_T*.H"Y,HCS+8+RC_MH:XQYJ<2LLX-<<E=6!]
M6NC?;WG4,(]AQ8L6);@,NY=&"3+4 NC6'^@4B_[J)<KJH<F]IE'0_#,C9:M)
M=C@Z9QUJ8 $><M4D\&F3G(_EJ26%\]+)7*]O1D_#)"&F.&! /!:EYK<'M:OL
M/F*.#KMO9'?/1V<U5*XD)GI9M-#BJ477!T>K2##,!\CJDT+'=QB_@Q?B!AO'
MFH9NA(9L2MZ(=R0DS-%*<A.NW64S<NW5ZY1"&>ZY =?)!=T:"<U2-<UB(JLB
M2*+M]DRM/&TC+\WZ;$/>6\?RR%,M@N]>A_^367I2N(,EY3."H '&\-Z']W4>
M9:5K-!V >-PWO,L*=S=5(D"O#D!#2D^WC:%2(+7.4(<8?7="11FV;UA994[_
M"FN\S2.Y(D$A7EG3<TOB^KGY=]X<GZ7O'^>KX8+1J(SG@ \]@+Q20<7R(0D]
M?WH>W<RQ1K_SY&K,',TVUR]4<KK-YB;S'A37CV24T09Z"@<V0FDON]HBDK8!
MIBZMHJ?%Y$1+D]C/48^YFR.R'S$2A+][1G_8IY&N>]TV=+"DI5\=DW\:?WIM
M%S&%I>WT021?WJ3KG",U46#@&X.,[,:^N!_QMD$<=>>0:COOM=C^)O4<@$C7
M%UL(&=>O'&9H:K)NK9WCQ\>\CW7KVU+]7R"66B_8RKLX_7Z3'9]^1#C]=1J?
M:QG3#$@A8Q-,P!-,9\J&_[3I-YV?Z2WZ+8@$1P/E)_D1OCUO8K_T*<?:B/X.
MZ-E*]>+=KX*&&(OW1_..URE],Y)<3,MJ!#*I#OE?@K4\;[Z]6J.BK-*D&=]^
M\0OHC]&W4E#]&AI1"[>@A6:8< /M XRP.902C86+C*B[U'S-RV-F7CI4XTIK
ML:*+H8OU4\[NWC:05B#[5#0_:P+&BP[D5W";Z#A*Y?5\.&T-75WS*21ZA)-:
M#2VU%-85SD>UV[J EFTD'X$W\F@!?=^"&U=9!HTYI$NC/O2C^WW-.X+]<#_U
MA;-O(]*5#;<\W^>NR/9R#Z-:J-BT<\QK!Z"$&3JIJ]!R24XPB[R'U+"@\T^6
M$M$]II4W/9\)]\BH-)@K*)H^![]J7;^X#@T>%AM@!.R_-)% 2INWCJ-$%Q][
M7ID?<:9'32>*P+)L BF1OA_@IZ\UV.I^KM32*JH]Z?,G[P3[3XU8".Y08X@&
M/ZXW Q%47K2@YVIE@Z?[RZ -?PO?&,H%JI7?5S8_CB,7%86U-=9'Z*XNP RM
M?(%06/:QJ,F@N!2]7]A\9JW61W:VWL.&5)2F/2#UP2<FXO8945I$+RQ#"C>=
MC#_/=)R(EE];$/;H@?(2QZWIZF7D[TR3@L3-2+^,C=H\T]^H(63N%U1]. K5
M*KHK0G/HOH<Z!4 6,7SV>T]*?KKD%_ -0(WNGLG.FHP3^5LBH$" M8"[%I)8
M\@;BR=$GOJ\^>K?6\'/,5!?7_;NN5"@RUDHHST+N/E@W.>LD89U ?H1.Q32U
M]$)CPR*]].B>S7%*C+#@$EN^L9#F&]?4AI9+0TXM.0JBAC^!$FZ9\- @ARF!
M<^T U(A)9\FM>DE.Z&(R%R0V<<:F#R2W([.(XU>+_9OP\$0'E?5O)*/[8EH0
MU0&EN5ZA[9%N6%*S5.?&#<IPP#6;OW9;B<7BHRC1<B\;_6,KCQ^VM>=I[]R^
M7<@Q?X'XY4.WST79BHP#4(C&$PP_$U9QB&&=@C4/BA[N&D:Z3,'A<4NJWS7W
MRZ:TFOL27>1O)3C'G>,QK6ND6F_(TDB,R-$'^ZX4\30U(\.@RD'?1A=;I<*E
MRJ/I]RRP"LJ;GE_$@[=N9K<&_ ';3AI=+_U$/0 EZF.D_F:(4_13_LY=4@LE
M/WQYN(Y.G1-+K2]V;#3\ ZF%2BWWSF4O6[I]N-YT%FKM 1R >F -L(VS?&BQ
MI<F0.C)-+.F_JXAPWE*'!]/#1P8+OIF=%$:TYOO'Y,TB_8[27.]R-2-AC$X:
MHY8"3MW=V,2]M:;E=N<_,GH*I'Z]$!"TTAX_?/960L.[!H\SSI=C-W()7'XT
M+*,.L*.W$!Y-)QB!J8_!0K^(!DT%+E-59ZZE[DG9O+W-;<!Y(C2E*-KO0B\?
MTW;16*"7DM2-%@C\58+/\J7W4D^MU$>5?'XIJU-M6]::?_I*',3[8M>]@EN&
M/'^W,J+5<#0L02.-I3Y.COW:2X;V-):[6_(DE]KM,2)?)R/8V7R;6QQ+$_Z$
M95J"'B$Z-[(70]F8I\:8D71# I&SZ"T0YX1/,FL=70\=(2(4BBV3_X$EBXJN
MNGYY:J4PV\L%/QFRML!X"7B$T\)9R@-4>WV6X/&,(ERB>HG@7=_?G_\5AR"%
M$/.VH+.*//_ %),/B]"9WP.+!Z X_,FU8D4 6HDT['DX0L:D/.(3GK..>$@_
MAEWW;Q8;M^I%W;L\.BB 7#%B_MMAZ;2,,97VC%%.0"?YV'8H>W\MW'T@>0MA
M9/#-W.3M6GV0^_#&*],9Q1?.F'M\%CFGSZO$@!NCN5EC"WP'H,!:E>L3)G+(
MAND^O=W;;U0F?I<U%QYQO=]XJ%3Q_ZM4KJ"<&BZEPV&1&A>A64P_\@)/($2H
M:=_.B\[AL[WGU-)Z]>3)P8REP![+L]\OIEJY*E:2\AVC[](Q_0#S,7@ G<4Z
M-A:J:J2(/YK63>1LC_ _C %9,WB5X$VS3/8&:\7W/36?N6^Y&@GB\RBA"0;0
M6-W0&=AB8H+OT=KBW'<M*5BI8Y-N&5JC:9?WK.?SUU;DAR=30NYE7Y2KH"LQ
MQ@ E6A*%0XZ;'M$G:VA-URD_,84X/E;[X2F9XS<A0T9&<&#8K^?I (\I-NA/
MZ6_4W*]EQ%PG5%WSU8^Q3LB#HNO]!D;%4, WDHYU&XU60&(\)]Y,L<2#.GD0
M?^WVK]BE8![$,OPS+[QY'"'"+>?DG)9G:):[6[^(D(V6^"\?Y%4N?*0 $18M
MN _X(C.=-_-'7;,35WBN]/2%W G8DFMB^YW4LP6<L<3V8S.B=3!V=/U8G84G
M+&'<GO-FV3M2L-YN!UTBVX6B]\!-E/]+FD1&YR/2E>/YG/A$X+\RB2K[I9EO
M,0),&((BN;U1OD9:_T,<D2K.6KZ2O*Q-6.3YD;Z"URF6MN=E! %"=*Z!W9L[
M"^"_,*DY@$I(.UI3D$W0R)AEA,WV/4GKE1X.D3X1:T:S/=+F((9Z,(8_@QRG
M* UL'0DJL%_,XF#J3#2E.8A[WK#SUQTV"Q)S6TSZXIS]^@G53_4B23'K2;HV
M*.HJ[0?C+>!)#^M_#P1TLU32O*85QPY S?@A1-!=HW;S$Z:*Z:,)Z?7*SC*)
M?@_N\K35'ZI"\!;Q\77 L#+02XB&BI8VT9XZ"5_5A4JL06Z-ZAARY)\OW&1<
M_$SRLA56=#[1V,+Q5&A?A'$?L"Y'\0%*9 CG:O[5F0RH0[SGQL5:W=&+ 7GT
MR1<[PM%Q):*_DS:$HFA)Y*2-E#KD "/^F[@CK;F,#)>&\2X$%QH5EK_XT:]X
M.( 6S7<&*:P'X;.M/#<W/7M/0)RBO[+4Z0>@=#Q$;:?/4[^W>7> *$%<*Q;"
M[[EDU]QHJWGJY9[S92T=VR)P_[(?072"IU,<"@?'8XZ@'$J1$0/1Y\>9T-K@
M69+[I89+G\MB4TYKEAY3.-4:>>DL<4E&P3=_/X$I68746%2VC'P]CW1PF,#5
M7G<9[="./H:Q'J]37\HASDPKP3F\^\.>WCY!;E#Y4;9?9L2[9P20&%F-],TG
M5<$8,=V/_HS?([:>4D%+TSIN&\YW)OV=SJB5QE[@S?<6=;G^2:($''7HB-'D
M.2@9G8Y70-E,;:/Y (.A_MW$N#<P4YF:4+62@D\IL6<C"ET#?Z"L2H]](![1
M=O4@PX@DLE*FB7CP@I .5-)CS41PS$]P37R4.,NMYM90*7S15[C.3IW[LF#8
M-Q$8%UQJ<GK] $1#,X)HFZ54#V@L\51+_-+T1D=HQ"*.KCI4?;/MDVYZX"!A
MCG'39GGBR$655W<?8Y_(02;QYZ._HG'%V-K@0FR*D2GVT[TW:?NAE^W5-U<\
MU.0A\E9-Z1Q/[#[75$V'Z O/*+)O:0BAS&B'A(.R(W>"UR)69.%]]X<%"@)D
MA"_M<)YA?G(8K+@EOUB .O,Y]GX7Y!P-O/&19DA)ZGM(4TI@G5S=;4EA?O+)
MG#JO9%,GI65^+ #9I_W@%*H%T15R,Q/^R80/:.P[  DRN2@C1/>M'O%HM0G7
MWH698C"M43/S\<MC@KJSJ4<N_%'?O&96ZN.?>0;$%6$2N:?+O$333V&IH0QI
M^CUJ<&?@)8TRNAENN,4/-)H%'7KN(WD*V1M^N,["X^'*FXALR?*3$1336?:M
M4"GDN#D00?9TZ,.?FMC81O!>CI_U7/#4FTCA6K,]SV9EJPCB/N&:BX0PY@$%
MND)/L3(=DH2*1*#+D%X3"\'K4ZZ.PPB0I%:DED6# >.SROV+:Q??H9L'4CN@
MY(6X*C@U5"#XT4#O/LPQ=J!/JBY;-<WD">?E^F!37VM_(8?C2IGQ5?_POU"?
MRICWHR(.-7P#3/G([M(&8,A%7#WFEV@+??N^O0L^DP4C5C>V=XI\,NI\$_JT
M&Y._)=Z"10Q.L&W!N-&AV"0OY?V7TY2M]+][8.Y57^>7EUM;?H?(UO[XHV]^
M)^W]QR]ON$]&!#H7[/N0KS;OPF(/MYQ# D80+_H+(\0TINQYVG439:X/5\'>
MBB@0:VP\=[H&3W$%#GJ^\+;Z=E^%BB&*4,52R-HT32-#NOP(&=H+AW!'51]Z
M L&ZCB/$]6EM4#YA2J(L_6/5WGEK55$[E<57=R,[C\P%'X"$.@,ZTX9KX5($
M+ 6:@A;6R6(?J0K>?114,-:7XLO78%SCK<@U^&<P*Z>Z2?.6P$63>&#N '14
M';"D$6=4FQQ$B+^DMABXYI=W%>L_ZDU=;3SYH:CH9%_YL84P<^G0N?@3^J)K
MT[ FL8(W0#5%EH7%_F3,@V@A&3Z1E3;Y^@..N&*RUZTQC,90X!<36Z=DHYC&
M$%(>UTBT%ER.'PC;,V-]P1_]\.0!!$P:JAQ^,T.<N?1-=_TA_0;1HR3CF&-U
MI';^'8[O9<ES7BJUQ &Z*WFJ_?8!J#..ZDJ(*]?NL<GQ%'=X;K7LL8=W*3A]
MK^N/S8\R4!2<-L!H BSI+P?<"^(Z1*E%T#Z3D^.4H)5FG.U#'>^8X>,UL1=B
M5+5\_0GPX@GHH3=\!$O%'8#X1^@*#@A?\T1;K'?L/,6OSUM2[*RP5FY;W)=[
MVJU$)BHC2P,8)\\Y$"#2'0&E*&BCG>%($II;HZ8I6>=['S1@(OS$)SB?#Z?X
M'3V8_),8SWOIKNE#]%"R$D$C$=HXW85.8LGBBQ;I5D\+F\2E=*;J?PI[^%/H
MBOD6W>W/>)^B&F:&>[6SJ*!]S0BWT:+ORI6?_,^#'DTG 5R'X2]+-Z<8(D7^
M6_7M?8\^UNWW W 9D;>N_)(GX[4[;DFV">,]FA?UU:UUZP^==*D[+72=2F=W
MH[%RY7!5I-60HV^G%H(<3@W:+@5V+I=DGLXQ2TJ<B>O&QIGP(==@J1 (G@.
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MY\)@HRCMQU0U+\+LIZ"2U74Q^(PM3WWBB0W)$_G=/;%W[\71"];+Z-(]T3K
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M#N9= *%/T(B/5J59&'SXYM$GA2H,6SNRL,$IL21]\]_C@H=.[_=ZZ^#8\0>
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M0NIS7&UQEUV[Z5"QYFY,YXPRV9UW2:3,#9)3;=+9!4JYV,_+N=*E&97TC/^
ME ^E!.A7,6^$\C7T4F1M=9-U7GH8)F;<]D!Z^84V?19J,5":G9-8:@%!;*YZ
MZ;YAC4M9I^(TXA!O5AMO_L0(UVZ=PN$_/#-7>_;4?;_T4\Z)&LG!&WGO%\\F
M4^_J#B,;&?V-M*5Y?;@&]P(R=<%Z^B0M/['P)GD395ZG\_A'4Z)6C+6,3,KI
M@!.183ZV%R78?[Y3Z8T^QOIVN/VG,W4A[$Q+(""<UDAXNMK[/W2=]S];WQ_'
M8]6FM7<HJC5KMT9"U:I:'3:IJEU2M=(*L?=6M!2U-[574&)64;NU$]1,)=IR
M6Q%?GS_@^\/]\3S.?=QSWJ_7\W7O.>?:-,VL6458A/_#C%]&5_K0,0B*2];R
M\E)L/,>V+P-_B>M(OI:O2F<2&,O56\3A.&^'22W"4('DG9/TJ_#,S7=D*\>D
M%PYZ(_:8Q&>AK!9%/6)-9Q7HAY4D-Z)L$VZ2:=^!,@$;B%DZ<QV L&98&-:6
M]V3IIJ]8N*5D^^0BK$IR3>8SWX#ZJJMA2T$#9H#>L!T:4*W1(HL9J:.H=WWV
M? R#<+:CCN[BC"R?YENGGB][2S#<?YZRE7@  EN9P]1(JF<URE[W-H;Y5 ?6
MHD\*&)$P;# OVN"?W6(-7V;WZEO.7I3@K):L3G'U#;#<YT V*PE%PCGH>(FH
M&B_7P[>G=N$GP4[]^2#BVG<9I0MA-:["W++=CSW19[>EMKXKO5YD@M79LK;T
MK!3^KS])H/YX@AC<.W#(ZW8QY<6K2-J$D_!ZQR8B5VG9_GR:1\#6&W4E/ELJ
MI0U'B#7-W9KD#TDE*<5(ZWK8#IEN[D\>MX%7X,/6F:VNQFGG=EOV0,DAFULV
MAEJ7?PK?< 7+&HHFFEW"<_YM.54GA0 1'ZS'B.J#-N 4#<L-T[B3C,%U&.@<
MU&_)/)0=_'R:-\?-B_11^FIKXMT4C4A2G:U'-=\_TWY4*PV1T#;(#400?IYB
MUQ+)X)UMAQX"?JB<^<#2PHLI_0[!?J@+[!.7&MHKY3,Z @(;FCOHG$))+D38
M4#5O2ZTIMGLA'"VCG)0WGU&YMN<S)ELV7:B ;Z43BU=R/$)W\>GZ>26D<W^&
M/M]_-/6'$<5Q,9NP.'AD ;W7D^C/G\$4XYJMY8'5!M--O%O)O$9WKR;2:,GG
M#60NJH*"/741%^6;5(68L3U[3[J"(E+\=";*C!??^P6[*CX[/V2ITF@2;V"8
MLS;J:I?.T_IJ1 A.E#K>:0/@!.B@T.UVPO/LSM4T7*U.__RJ0(SYWWJQIBQ3
M-?BM.\AF+L+8[;]T%%J3(A54>_%2 ^C TX=N(11$5/R!]X%8.^$P$JW)TE;G
M>=.H8SWGQX,L"_F^-@7CFQ9/&&45P?8DWS5FE(<I[S[T\G]++R\R^R5_TZAY
MB*1">?0?HVZ7U5/\RV%V$\?V^)M\TP\9FJB1Z9_'9LUHIV8M1Q>W\8/U_8MM
M\6@HP=.&R-WGQ86S4H:"ZRKAW@%:6[+>,C5VK]INBM">Q&NIP\HPECT:R( &
M @K/3%B11>N_*D<\U"<<%^."319,LN[X6[PK;)K!#QAHY^4;.LL/1DOOT(%%
ME"C^"'+^DDB!>K(*D*"$MG":PWYJ%!BQ2+8-9N_WPN4&/1$QF#H'37MOQXG&
M;QY^:C-5%'MR^S;5? @=Z=Y"CP3"!/=K4(AJKD<0$3]T9,2/YW[HJ$!K5B/6
MUF'&AN.RX$F[I'H)C$FGV'ED.=[+V^O1RXV ;E#W,I,%2!(9.'CL07/DO#_=
MQ6B5)3JUI7TW^Y1Q*2B1X\D6-YTUQ2B210<'Q],3=090_!#J'2$ZX%6M;N%^
M@.O XDI6:85.R9HTW>K]UA-Y \8!F54W\2>*V\_T.OXF@8(C=)'U1)WC$6(;
MIFO<UR%E7:\[B%"@W7[4 N6%>1PO^I%M;EF[MLW\H+3>V.19>AFG?OEV70:N
M%V]<B]#'C0+P=7CT0B\;^K%$S%,BM<IQSGL+^:B@Z(3GTY_S[2395+V^+"4H
M&50$9FFQ%DI-]B@@)<#<-4@I)]G*LSS78D2&Z<)/D=.;;QUJ2_(]EMY__,:G
MS2OSZT6DT_N4=.ESD'M]_ /W@N:V!+3S^HJ^/B$_JX"0[+9M2+S/7PO'/FLY
M5:ZT,F0?4UXR/"Z*81)-C#X*A5D37?'BN/J8WBO@]9/0$*Y]%!=:_P/@:=J3
M\\\XA-^/Z>?4&W17NQEU]*V!,+)+YKL>75 +*!BJBQR >HVT%$3"6/S/08P(
MQD=$U0%6P9JQ4H"+L;TH3:S-Q6@X9W=H9#WN:WW.6-8*>$1A20T:"FX>:B!F
MX&CC2;RU)/5N@FPW5A,RX?5R]<0L>?O@))!5-9O:B\\K2Y')\/H[6^8?3FY+
MZ10_LQO&E=\3E^[+U/&I6/VX@=8;>+$4M/XK^<\@DA&PI.T#1PIQ$&2ZB;,+
M.@U&ECTW_U[[86)C>,_;J^M]DY//T.O\EBCB\ 5C)(0(&9:ZAU !L&JD&5'V
M@Q"LT=9^N-QJL?_M\LSJ%R:?)O8C_3'(_&X\H3>^M^4<E-P"_VXZV"-,R ZK
MTX 2Y4R)EPFZY(QKU9ZWI_[PWG=+'Y1EL'>LD_G$0#LN(L'(SP<Z54#''(<"
M_#4D1(KNUZ5ARQ!^PA57&!L0TC^DD@V+1-]/Y2_JP\_(-WY,#"&*^VM8>A(:
M-^P[ !]L&U$E137FSSGHXT!;I]=046=DUA$-J'JY8J!VR"BY)+_EZ")_AZNM
MX9W+@6I<="&Q"3<<I73F.? ZQTW--9)D-A]PQ?VKR3SA9FSQRR&)IX]"7][:
M,Z!=MC@FVO0)7-9+Q?!%&FR8555= H'\0 &54EN346 PVK.0/-DY-]11M ?E
M( L#\(%_,1%7$[1:K')MNMHZW!SS[9QEG"0Y2S-[K/J[GKR_,4V0PUOB5DS@
M0FX.MP!C:)A&(+:7I2T.WPP&#&1:KOLSFJY6H4H^M<<M6EFKO!&CY'^/"X6D
M%:&?_CI.CO=B7-]<O!:MG 3'6;6U-TZ3OV\QVEYKM<VM;LL8>UXBW\C:J:J1
M5C_6)3I+,JYRV.D!]_;,^ 457(8M]4]>RG:5EC=ZN5$D]667;_/$!13RAJ)2
M%[ET>A.X")S)9'FDYRS)O\(FP8O[03/A9U[Q3AO;6)DU#_;T;A^?KH[2M\Y(
MC7$^-DN*.S14<F0&>J(43B(BA'='B!_P+5QS\(2HS!422#8][VH&R^V_??Y9
MU]!OY_HE1ZG=7/A3[(T #0;0OYQX(/=3;[/< &M,/E?*IXLXS@',;+A48AE]
MSD'TT0TX.1[;4<WH0LFS(B-J-**APHCV[50:F^S7!B:VN66@>N,IR6,.ZN)"
M4*FN=+>Q3/SCKJ'OV^KDI;A[;/'24*9F+^G7C7R#*[-<=[1XG6\+@\W,81RD
MVV>5RI-,)"AY>N:WO2>N+9DLAFBSG=6X@;5JN1PN*,M?3)G=_J8YH'5JF"W5
MIQE=S/A+G65BX7AV]H L !P^(*IBI-88$=M]W(OV/1U8]5J+V^GJ0?N1R?QO
MX:)WTLN& F^9?S'IV)G]3[BQXZ</=XU.C3T*Z)/?-8[=(Y 6+S VKK3S.S7[
MX"8ZJTOE26;X#WKKDZ0B7?Z@!4$)?%Z=IQ [P1/0P>J5XM8$$?W3P9Z&A!J^
MDH QH<1&KWCRSY^/KBS1FQ5+7O[N2M_^W\%MDK]@R05,2'.B(N;?\Q F(*$*
MJ4@4RGTMBV_QY/=#AVLWI.':6P+HU3A?:CD==1:SO(4$.Y^ZN.>X]D.O((J'
M()?G-91QDRQ[#0#*G&#<=*T0N?B^2*6MK15!:!/R&.?5MZ.D_UVOWGY!A8HX
MB6&YB%X6].-U9L_U'UTJ;9#>($_/>MT*FSV^QRUO-J7LECB9.]>KT$RW**^I
M1SAJ:?:NLWZR/0=%MD'$B+3Q2-=71&X<;9P#& ^_LF(]_"R%@V$43JTRE9XZ
M%']@0/TS,$!32Z@/IDE>"8',(FE/H?;7$EY56WGF'->7[5@\W%$GK_+A?LH+
MMQV-P)7ZKS$V1[0G/H9="IG+OS9;WR.R(R0/F >MP_@ 5^V,@2P^F:$FFH/7
M+;%LD@K+6J5.3F)!O%K!76%C+Z]3[>Q)#<E!W7;*OO:P&!>Y.5G-D\43@A)D
MY/#Y9BV-GLX=G5VO-%H_Z_ +GQ;[CO*1NAK5Z^/S-7.Q;>'PEBY3EKU5F5G1
M&YQE"46V[^J\?P0PQ*M?W=PJ@6=R* J]_<#2^A$BC/#>'G*@(DK$'+2 #X+&
M;>]W?(PQ/T(>-J(;%*1['+;6FC]Z=47[)":W;$*I+UR'E1NQA/,_Q/S'(0S;
M@#VNH3CO]="RYW'G@*6%IUJ?Z#MAJC%'L5C*U$#F85&!DS4!M.(&*R]2'3V%
MO()#(/FK'<:I+?DV"MV]GG]).,Z*".>"2R'T-"CU)5]\IN@B;/<%7!@[&'#M
M#Y#[8;WSVKGU'5,N)=SJJ17FLAI[&S3)[S'1\D 1]X<H-W#(@UEGC>M1!MH(
MK]>,0GNZ-BHW<WXPNXT$:L/%IH9%4D86OW115GL)Y_WY73YP#HK'$Y8&UEB:
MAZ8A:UXX?- I?1UY9BLX:;SF5S'^&W)\5=N^PZ%C=(B.]L,43'$7U<85$0)1
M=Q@M'&>)(@PZG4(^M-$DHP].;CX/N_]$UKOV6=L=7DPKJ^ -C8>GCY%:%S,H
M3$-J'1RN6G 9Z5CZS68%434/OF*[>\PG/D"43G"1DTADC M/'9"4Y4P]$='Z
M[SU?P'SO\R3(!A85IGP.H@'4K8G9">@7,Y@BQ&UK&5GD4H 40M896=JIM?$L
M^245YP9U6A#V'(37#JH!3''2^>H$XV$,G =@-U4KJ_^PLB</&VA-8LK0T0@T
M!Z6+2BM0A1TU*N2_H3CTLQSM;8P9*N#8SV<"@M9/^1E[P9YFNPT>$!6B24.U
MH8#:W9.[=L&I!DYOENVJOOAX,\1.B5KXC5!]..OJ$4=J$<#]*_SW 'C1LH?#
M56) BQ<6J*OY<[VFO/67K8]5CC9F)$[LJ7:*U+7[2>&AD/2B'A\@[%0?:?GU
ML' &*7(*\>B1FY7V6PJ:O#SFCV/TDL28YKM%%KBT=>:IK#8Z8M Z'LAW6X2K
M1%9\J2LX,H3%\\+B'2IQ2VMQ_4ZE.PTFJ?;#6TM*Y0$ZUZ@B]5Y^CJV95O1R
MT()D%/4\)_3B\P3KPY"H*N0]@E#M.BL'((F;7S,GM'0/O*XYD0E,:9 I28NR
M7G11YV "?0I_0<\-80^9$5(FL@[82_6=@]C)K##D#?0"OJR#\.=+SE9/->??
M,)U)IOP'E>&/DS+[/ZJ'CWXM%P;K3,$T2."+#*E/;!I6Y1(2 IS\D+SE^VIE
M&96(_@V+9'6$<7-RZEM'^9AV]WN4?1 #3-TSE^7JW\H@#LL+46V%)Z$=B5(6
M1%0HA!_(>$S81T()W6L)&OJ5.]R-2_;\K2UO=SO=TJ_R6H\H-F9$W]5>[8G)
MV/#^;W_S]Y]+N-:N0 $U/N"U8(![L2A+/>5(57[-5GC%3RN*^5#-:_' Y+']
M D1TM[?Y>@I.J*MR7'4 3-.6L/%53DX\?48OSY\+[-2:-#%[A*_S,N^O$"]^
MZCO?;81=B_\C*''\$1C'VL.L.]MGQ*=_PZ_LJBQDWR=:]T^->;ULJ!;0RW?N
M[&"0[]23J 4%S;T*'#Z,7!6_:%$-9=GIO2RG05N\;/+0@3SQ,3XH[]Y@]'>9
MXG<37N_";F7J7$GKXZ5-.\OUQ\,W).(U;(D!AP]FG0C1E2)3))'BL[*[S5XJ
MJWK,%<H] >^\K_UBZ)+%,@Q18'P/+2W-O]N,^]QPY+@^??NQ=$!81BB%V"E%
M#J@2>T9K2JB+*-O)T2T)X#/)]>+,RRL1I6>2_V PI5]4%0K)+(3)6)._A:@V
M$;.CH5@I@+T.H8I=BVNI#F8T(JI4UBS6$ML[? 7;\LJ>&+.<G/:]?2.0^MHB
M)>D<Y+GB:4P<COU]2$6Z/A\B@K#L:WJK <-Y:MYAM/J]_8AMG+-& ;G0I']%
M>DI/F[KHCX\6^)XY[ I)\*Q2P[R4!"84[PIQ+_3(D,R F* :1($)8</#TSO+
MQG*IY-LO^R\VZE9LHFQZ[0SV6<J@G#]TO<]9#];"P&Q(3QR*9AEA.;C&.F_0
MTDN[ZG%EY,'F0/I2D;U>J</M+*O6$6X@Y;//".W4&\MQ,.O%C4Y>V>_ET%#%
M3O(CK\[U\+E!;DS_;-&DM9GW]W07?VNKPS%3.UZ%G,]]< >%6&KG-?_U?.L<
MA.UNF6$24@'3^&\"S,J; ;M$!J][=-LWN^BR#D]OUN=M\EHYCOGRLB:2?X9"
M>HOB_UKB+/'O-DQC FTF8YTOGN,H(4&W\TB9E>\B_\QS"]F,B+Y:GRFE='=:
MQCA^_AL:+I\#^B>!8XW<)*Z%*_>RZM;LA0CF/FA)7]6TU6OW#!K3<SP:XXC(
M=+X%C98:@G"&? E1G"*+N4-4@%IBR ENJ!H+7(O!?$4Y+KD=+P9-1*O'Y8FX
M_"IQ(\1_T9MSO_7T4W6(:LBL@Q1!=8B1-1K%0N9J&^CEA"0KCW6](AFY%TE;
MC$L-\L9,TM2Q[)2L-8,B7,4:&$UQ^OB(:L 5<PYBXL:@&/XDN0Z1-:U7Q_KS
M169%"+_G5^_4YPDTVB6^ZBO1:H@27_"E!/&'0K(N1&RNUW/L',1,DIGQ-X9C
MX7%*:W&ORVKE8GX?QM0\+N^>O6+$SCRQ)H.G) T=4(9IWQ)[D@\ZJZ\+1&R8
M KWK_).10B*$LI0+5!0??+/XQJ:&F\]2=#(: 6+!W?63CY)0OVG5\!CT3RW^
M;R\6A=<D@H=6%;YB%\Y!KH=L"/U/^5==^4SCUAZ$'SL_*#,0^O=9?,VEGN]]
MM@O=087A!#9S_1R4PC=8CUEC!R;[0YB(@0-)L(%5Q=D:/QG64\N)MJ/:$I4B
M\Q=$,0NN9XM-V#:<H<'R5H\9:Z5;_9NRLP:T/7<_+''A7V__J,8-HBAVHN!2
MX2OLNY93VW;C[@%OHDF;FPH;VXWW@VT^WZH4[!B&"=SX&T1H'Y2^1PAX^!BP
MKT%L;)35.\H6RH:==3POK+TR='9GCU"?Z9&NF"9@=4O]*<^G#ZS/"*:?O!X:
M 3-U)$-B2I*WAE=EHYT5PONS,41='<ZZ.W-?W$WTD=./SP%#M2^^!5A]6O=Q
MP,#4K$.^Y[B\(Z0,.%PGID0JIS CFC"=-2'@623[\]$*F$KY]:1:/#Y?0V8X
MITG/? $4'BPU\1,"0=X'XHACZX>8>DX$E0UPNVZ\=K)^=7%Q?\J#JS,ZT\OY
M-L."RJ".=[MD/14+*"YY_9L9:]-./10H)%J1%(FTF"5>OXQ@9UQWL!\MVC9%
M^KO!\<PX^\%B8+2;BI-4TJ?-WQ!W8L3Q!U/F;TBWZ#'=G/T[!*%0YN,.S\JS
M'->Y\ON#CMX:V13]&O==1K]-#_78^H:R%NW49U\[*](P7X=RVR(%"3!,K2L.
M'O\;S.RN&JAJDQW[0(7Y!F++<VGTZ="6P=S8^JB4450LC8M@:2]>W5," TL,
M4<V]>Z0$B_D775Z.$4&/SME\YG3G106>?G21HSLE%6H2M836=)&C1/!Q,[$\
M!NF,A5(CU+%4B(7AG/H81Z)08?$X+L'XAG11ZILC;!96N_.97RIDUOZ#"!01
M]0?*1#(E@A,U%-<U/4V!H&IK_;J)A]9-"^+VD'WM.*<,WU&F"+_R<5W=1^";
MJ9 [?T"_XR49EY:"52:"NCIP+<UM2:4YK]Y?U8M7^/(% 0(92I1)87NC>SE(
M7AO@17YLP:#12J!%(Q!(Y'\\[Z?)CWFY<C_+9Y=@G?VQ,YWR3D+<9FO^_523
M[V\N"3.!@A=TD?:G)DA3HD7VJ1-)8D8)?ME#S36JF<(1TNWLZB\6<))4Y6'H
M2&DGF5K'[=3.PK*\&8SS6,.O$.$.G1GW@,?K7D&/",<-%:ONU57[?!SCS"N5
M75U6TK5.[PSD1Z5J9E3O.#:_\4LUH_TV:SD"NX+FK@F9!K=8=*_GRL5!U G@
M* UZ;"X[ LE9UQVYP)>YV:A&_[8ZAG)5^!5_X_=)"4VY@W,0:WS(9=)KHF7?
MN-/0OX4!.59=[*DI^TYG>5RY;9[%G'-[#GWM]GN0RR6#D^++*A'-SRZBY%-T
M$*[MHA)P)P,I3&O[$.5VTQ@^]:6U\74#/V#@=7(Q=;VTXJ1_5]#=DH&0R39'
MMT?O?]<[UN= ;I+G'*  JA;(1S&3Z.?1ENNF#$-'^R'2W?->OQ%S3U/&VX,,
M).Q/S(>%]-^V,^WL=8#D0?\<XO]NX"3PSH&NK[!>C%@X!J^/JT]LP0M!KZ"<
M!E$L[SBC<X6%[!94%;9$ R7HA>B]4M(A]LOGH)ASD/>^L>TGB Q1< %S]G+B
M'&1(Y!!BG4'?YJ]93*ZL56Y^:>Q2V2S)D[?YX/0M1UR)X!TSVMG?EE$DSK-"
M],,-F* ] ,;I8QCKHT)NDB?4A@I<_HWWU,)1SQJE'ZB9TC'4I:M=2DP,W5EA
M%73%<Q*+%HZ# %6<G-#*MR1CI9(8Y[CWF.U1Z5&&:X1D_7'AG<07+!0?6 WJ
M;'&H&)(IKIYR+P<6@;;28,89A?$T+TSD"A4?WS>HV3XXNIS2054ND?1WFZ>>
M8:'7LX#?G=ZK%$-0M>D@#G7[2R$L^^MK;/5]@LL&&I3:3J:?E+T/O<>A+^*J
MX$@GD&8[4-#B7?OJ5(GD/*]<S[!*4@4RUL<A09YKK&,HP25;N\E+^[R%'0F,
MDH8_]'1 =/[^?8N\H1?9L;??2W&] -.MWM_I-3Y1Y.CN#5<VVE[SK[ ?%S72
M_#(^EV\H^/8?)6B=X:?4CVY77/F@:10?-))$NSX9^?H<-&1Z>9>/\^V"\KB.
M78I1RR_TQQCN;.V>.76%IO8' 3%W#&7"ME'\4$]60<0^%MQG;XFEC8#7_^P1
MWK]&C\^P;FWLC+6YG?YC4.QYV(_:[NFSPA=7G%;F9LUHESBW%[?['>M)/H3R
M :F\A_((7_U9I25CJ8-/Y'\_C5Z>"'G_O)EUJH+?#@AD>O*7->$_JN"3B&U9
M@L;T4K? 8SNA4<]45J_-/YFOK7%L[KS+JME=];FK7BS6FXD=_H7R''19N6FC
M8''OU@4N+2%E"0Z%Q(>#JPK3W -J+E%>@5SY:>[M=Q94+=FVA'E?A-X4+_E[
M2\R,]NNLY=A:D]Q@RA4D_"*N&UG-/?>O9[1&>)I,DVY+1,%_DD9DE&]ZB_<X
MTZW:17+%<?F#T5HEE]LYITC.9Q7*\)A>GN:U: @;$!A,9!]<3(DI7RAL:I@5
M;;Y2=?^JME*Z7#:3<1P*>0!Z]H@!?S4>=%S/X2:%2V%=VV5S6-DE.MQU3,?U
M:POTL3)QQJH;R5J^^!O]LM2*4M;]7W!KAJ.7DRMU0&O E/3-/C:\P9060Y4Z
M",1S7)\D<PY:+\P7ZR0XY&W0D:GW&X '8P]3](DNU3XU2T,YNC,.I<7Z'E&!
M:_A L *U76I)RMOZ!M(S8(O(V@^1-64AJ0!2U4C3KO 5;W_&77\K)7O(\FT1
MT60<]MZD[*4?=T_#,B1D0BD62+2 "82>)#]#NKY8?KPUJ\H=F&WSKI7KQUY0
M[CMOL9=AN?#Q&R!O#8KQU\S([X&G'E9[4'J($)#1[\ XA[3>D!-2(K@Y,(?C
MKCNGVP8X=[E[&\H/4]]O5WP)>7:K3QPFAX?A4(PD;N)) CJ(D&!%T(]#2FQ6
M$,[&_]DM[L%??,X:\T3Q\6Q)_XQ=>O3V>ZCP!='=B?]5P(:TS<;T<EPXOT@S
M8AM-5"XK1 7=0G^:$6Z.5YA,D?X;5IIS?>A>,&YYPPL![C=-7M68#J'<(4M,
MD7AQT(0>.2"L?N]?75I)PN&U^<\8O(*2D?+!4F%SE-<\5(:%2CWR\>A3$*2_
MJ.=)S/%L@2$ )IH.060)U&0.(AQ3R;5F0:CI'. V;YX6@S]/6[U;RF/0I$?_
M/?.I'LNE8/CZX8 I)]*@:4Y9$/6)V^'2-'(D5R_X#OFV=PM_8*)JGGAGA:>#
M@9!=S)?]#K-$,RHR.U("S 1'OPJ^5GE6_PHWR6;G^>N^5^0U3@0N7LKGEPI6
MX,6'E2%#":I;]=KU;Y'6IZY[.?!XM*E$-(3#,T0>\%S??^>E8;X19'L:Y->4
MQ;GR4J;VV=G6(F;D9=2+QY^H0;:1 /3T/F(!@Z(F\[G]TX_XTYO8RT6R+C/%
M[2>I&-O+.#7._)0M39?(/]IX.1!FI<M&$;&92KE.27$\SOGK/;0U(+N<)-1#
M-(W5$*]V%U+XN* ?N4V0ELVVG/9\SC'L2IT0^5:M<Z0QF>G5DUN#+@C1XWZB
M]$64E48S7I"<\@)&QFTW>_$/J4UM4RVJM/4=Y0W;R!R.)1$%;KV4K>N<MC)=
M(*K=?U);IJSDQ57QV1896H>Y'D;/?$% '<>X'R2H.&RY6-K[?@BGS=D\X_[I
MU4>,6.*'VT]5.E7U..N)_,<?B2XIQ(3! N8>01)XMD?"<U5PYGD+?R7>/U;I
MU !Y-#"HU"3[;?/;E2G+( -&[",]8U#P#5WDN/^I![,G%H4)=OK4R_H'QH_8
M'YZ70Y4B((SM>/3;PNNRI1U=+YRBKX]Y63J>#EW_P-1@77C64#8=0D<R)L(3
M-6C]+Z"7CP1)/ <]1ZCM/XQ_X7#76H;),JU2/]G9C[_?V4H-[_7A(^VTG^6$
M GD&=F6MO\FC%09":P<%52[WL4;]'IPM,O2_GB,JUF:9.-IF'/6"X]7V%Q=_
MFLN;+'"+LT:TO1?!<D.EL@)Y,Z._EXTLN*CM$WP!Q?NV[0^D(M<X^U<^?%MZ
MRG;OZ5+[ 9V"G1GM_"/+80@-4(BK%I185XDBV@CZ]N=+M'V<TS#&2441%13X
M@_B#:WV05V-K4N^?7-6&=U/K/F);=9A!&9YU:NCZ0V-(YE5(MH7?IN&KPKUM
M#3/H0/_*ONW,]E1=N(]L7HK*=;'4.H$&&D$>[]4J+4A;48\GD'1JA6C2!P9Q
MD]%K+&36/1A[RR'+;JM-TNQQYP!?< GDU=.G.=;9SU\^I]NI[BZA(52)7NNJ
MCRX04 8GK+&$\"(F^\FL^?N&1!>QV9P-LWCV(LR6@<T=NB_GH&[=1$F00?"P
M&[49;:VY@]>I(7!&Y@J9_._H&FN.6N;YS$+[28^])8/VH[<Z$=_^1MTF^__M
M6N^-6[T\JW0.HM(AS!R7 4T;<DD+;39V9H"OW5S=VMV<W<T$O*&DW=)0$AWL
M%NB9RVD["T(87.MG^07&68_V)9YN!%03<OO(<CU T,4(,UG9K"*:!M1DY^:\
M73J7OUHMWOOT%]RI(WJ/PK'CTDT3_&'$.8@"&4S0QZDQ0N,=A($(PBIYR+3M
M.W#ZP//,8H)T\ZBTY?U=BK@,R2F5KR7>- F.6IKD^+\1Z_"A]A!^$C-078DX
M<>B:%05\<7DO^W^>@\S:/1/>"1M%:#8>OK2.2\;Q? 4?/WI!H^MT83.HIMZ#
MT1KD72!"_+B!*#JPX'*\T'_"_=)0L/ML*:IA6L9)[,"@+\E*0JRFSG<^%%)2
MU&-YEGR56!Y&%D$^!/PW)KGW0N3GE=J;C1WA+48=$N)U!R,=5JH%65=\J9<>
M:SUFND03;*Y%PWE$.YB2#+O<#%W<MYH. 2,4[8 LC=OK[7P;&(N<*O=61E__
M /LZB9P'3@K2-_4:RN8#?CDOWJS3MZ\(6>3*R>[OC5D\!X5KL%<#,T,.ZH8F
M2>L[I<GSSC<%V[Q\U4FINHQ)22*TTB.@/G&M_S[24/5!6YYE"U$!F55(+<*U
MRG4H!TF]42VK%_NVKG!V\U1*Z^3R&%S#V>FM05K[Y&?.J;G819N/9%;R'/0*
M641,8;^7$HZ&.E:[G?"5Q_SQDAIHS9G(JU RC[D\[LL0V:S@;99T R.( 2ZJ
M7U47N7!*1S($$HB>6.]*W%HL'\<_LP5EPQ;-JWOV#Z1*VAO?%-RX&J\L=-?G
MZE70J]3HU,0.B=U[H.M%\?_W.F*-$Z*8)SF?:B'%YB[E7R-D1\T\GI/]F6]U
M7'OZ*>NX>BMKV<"PSNHF-65QX2"RX_0Q>40M)J[7S0LU#"<(+6W\S,1)J2O'
MRP'&8,P"G]@\,3:/=:):Z65%4ABO2.:O4+W#KY+7J7 \O<XP/B0U@;5?T!>[
M'8Z6QX$Y 2F+GMD_4%IWOKSQO*3]-=O@'+V6CMXL%\NX.Y>?/>&12JTRT)E&
M/@$LB3'')6>Y)*-R8+M_E9]P7"M;ZEJY*W0IQCS=)9W1G7.SI6=6]$7B+^S<
M?<GPFV;98GD%]N9:8"KR%U3C%0)\  Y8H0@3KU7[U>M9K9<%%4W@O"O[G7EG
M&P,C->F,:9X<NH*I<5?>9A2\<:RNFX70(/4)L -?0JXIX3#FX0"84P-<;8W(
M,;[J=8<./?97[-WAXW+7*ZBQK4]B\K1Y'1M0YXO.^)'/SQ(._>N_J_8[7/K8
MT$I<[<:>>8,Y]M7\\;^^U<?#^2<\?WMF2DXIC?M*B;)'2O%(N-7)K7,?J*@B
MEJP*UH=B"))>.ICL'O T_N&@:B>Y3*(CJCA]=YO[TO<G=-B[3Z^E?G19_@!:
M"YGSM#>9^/?C:'7U)V-"PFUJ2WG=JTV?MCC[VVDE[ZFIL+K0%G)0$"+S+YV5
M0L00W-B4_H(K2+FO)(GU N9]-?&V6']/U.6EE=:F\N_WDL7:0I]@>$X5%*4R
M1!1T6UZ(4>U,+AD-< N!S[)#A!.N2:&JOC$S++@$OEJ8+LWQ&KY]Z86>IM22
M5 I0^0%0M"&@ QTT@FXAH46K2Y[&OA6K_+:>KVI+K1VS]%>K6^P?82=F$B_K
M<U#\@L>0!4@N0%X-29T 322Q%Y,@ )SP\]_$OV CTWG1'HA$UL#U1JZODM4V
M2W_3XJS%:1JV*J!2KF6$PX-?.%/VD#$4)UJ\MB1$D%@PP'\AIK!E7G%#"U[9
M\DPOY'#L1^?+XA_57]Y):A\9#%9*;KS:>=/9,?7S2[H_Y6:T0ZT.O/_M%S^&
M4R)4<;28;C 6%896K/BV]_I'X:4NKE*)6+[Q=(,G+=$BN8@<M\QO]P)II*(_
MIRZC,&!.9%!7 Y!2B[P)H(H0T9,X_01_VUPPCP??HO4YR%%:$>5Z]X3K9[11
M[+SZXTQDD8GUT&I8S^Y7DF$)D+.*"P8_:IPK;&O/FG"7]F9SCD=\JTF3?_!B
MYU/UC<TKX5)0[#DHU \<U<,R39+"!FNXOV9YQQL___7>T<&#P63[[^_B7,2R
MQ-)-E2C6>^G/02XK1MCZ(7@,D4[HM"^$DL"XLQC0\((([YR3]7ZT8KCE+1LS
M%F;B$['-N1R0LZVA35@]P?0VHO R%<@[7&3>'F+46JQ_H*JBKG!+6-&I9JAK
M4GS#T8<V$>U1UR$J <N%N3[2?8!['9:8DQT-1[MB=_S_HE41\-^#'3GF'(J"
MO8IZ-6RPSE[IL!C!VTH4OQQ2"##<M:Y3?J1V3]8P?HV;+/E-]ZS0V_ZJ2D"3
M6,#4X@]]\];5J;Q8,;8?=L\^TKX[JX(ZPR\#&-R/W)<A3(/$X4^$'977)@FN
M/AOZ7T4)RPV*-1-3Q7+O&RNCXLQL+V\DRH9LM1"O9037P=Q:_Y5F#C4X"3RT
MWR7:B=K9#E\[E-E,%!RI;VA-!ZF;J/%-?6"-(K-=X'_O.NK[YP6L8$'4<Y)H
M!0+C,/>,J!^KM-3E^O'K[]W25-5ON%_WZX[Z&X89#KQR^U(+'=2,)D-#-#^>
MI?G7AUFH\4]ZP6LQA=\\&E86^V5)4/'?OH8OUV])7;55:E#+9/E9^D;E9\A
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MTD4<ISH3@2-;%C<9\TO.2J!/6V8AETB2A(5H] W6@3$YT(I26S[[K'+@=,&
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MJ%MLSH^HT@1-1?-H*QD-*'4:+^'@L^WS!RNB$2UY&(4ZANWO4'<X%7"\,%3
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MPZUH>:BA$N20<$ABI]P[-KVO]C;#5YNG!J\JO8OU?H;T7HF"3?/]ZKT2,E5
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MJ(E'5J,C'>NFFY"O^Y=NCJO8_5R\4V6?9/FL\FYV=-<FR_9E27^*1:?HXE.
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M((Z+-A>MK0K(+^]]]+>^/*C!D5]XO7PP^#?U1SWU.D:*LE,1^BZ@0P#/]R[
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MG4W8=/;2MA$_?=6V4?JW:,MN(^8T51^D_S!Z_(ND,, 123I3&_4._M99JZ6
M,_VNEWBYR8O9R_UZ:TR9LEFZXA#]:>VB^J6DUZ )Y=>5%K CU!O@(E(-L5"@
MN35^.UMY6_0<0U,D;Y]L^I?;\)=_!,T>WCC[G$L(A%(CM9-+:?:B1;V_<.F/
MP^,PNH967K4FQ#+*0>>K;U+T'YFGHIU=S%LO7*R0^9X5K'NS@19.J=T^?7+3
MM4\?<270#4?P]F68FX!#UIM-8\'Q)J>M@?BN#T(/DY&Q#_^H*87MF=-]7,4L
M%3*QL?5'V2B,*26K?Y$/? EH].*X#XJ$KYR;T'JI/=,5($-B]/)\UA78&* A
MP/1EN9'O>>4@*'.H!S3!!(RAX!H)/B!QB^2]]/3>)VU]S#]90<&4ACEAVR3S
ME9?9+U]][WM9]S2UM(ZY'#M9J (H]!Q#9J<'"L]3LM?'#XZX;@3>8"7P_Q<8
MFV/%71GSP6]RXM6]H"]=D&EE4GJJ?DXSD*&YQ+DY='>YX_0Z!PDE[#[ KQ+$
M/BK86+<@W9IS'2F[X\C1=)61H_]S[H"'0/R !PO %5=S;Z_ZH$"??"/3IJVE
M:E3S'EE&EV-<BR0I>I3A0YG>ZB%SQ5:0+=H :+)RS9U)FE?PNW1UXL^4RTYS
MB9<9 B>E[7]?.O6TL(F!'$Y7!@>+Z=]AI[7@'$N#1!;,S2PD5AEPC,.(H*K<
M_-^M1[T7U+]_,<D+IT6;==!^X&7W\$?O04Z'2+NT0B<LWG.:)!]-AG.#<_UA
M^BKQ9!27L_11H[7ZWVF^8:2LCZZ*H+ *.?.2L/EE$:[G!NF)10VU"0=<HOY8
M%= 6N/&;:-R!*NXA#O:+*K=7(R.\V7*?",M?K) 61"UR$74A]]:8'8\2FHU@
MG5 NS5U&FMV$H3(9QK(Y31@%W.E99\I1-;5>V2C92/^S_6]3AEHS>1Y>^A[^
MA+.R_Q@BVJS*07L$1+4>3A:DQ]#XEA';!2X&I Q7[>(0PY@1:UC.F!2/RU"W
MKW% 0=5E@;W=D]8TQ]?7K@P.+>LJ80TWB@0=>S]]V_@W\/31TBGXVQF_>FNF
MW[FM$_)7<TQXGKQ7>AG!K7'I6Q;BBA.]5WL,8PAV$(=P X\'$K5@";G/$6[H
MI#TYH9RQ+G&$KP)'\Y2>YR+/%:DK,O;V-_T-!:CR(!V:3&<!8P$Q<NR?WE33
M[@:/HWQX5L\4(;#PZW8>M\-Y!-O%7!_U@K[<@"<?OD)FCW)OT7E1"462>#0U
M<1+C29!HY(E%!JHO&MQTG/M!A1L!A0<K1<U%VS8*\5A-LV4.U<.8T78NHX(F
M)<H,VIS<^Z]Z>V)@-<FR5YF=K:G8GMW;<U9*405;"#)37F!X_C?$QJI9K7IA
M;B@T-/Q]U*O.H!T5%=E"Y[-"#S_ZPT_G/]&KA0*U6]%DFUL#'EKM%-0 AU>G
M)"?PMNOS] F%K+>,SUL]&)'EM3K]NTB=8U <]XBW5%S2'**;SDP?P_'3-3!R
MH"IQF"U /R@5$!MH(:0N[";M:!)E];$OO0VNH*9&"JHUESL=M T8+3N?7+*
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M8MWKQ+[&>HG<X7+'%SY>RZ/ V.F].J*P9Z&I7/9@<A0I9PH?>I>L[&@[V72
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MJ*GW=6IE#M;R%!Y^"^#JHR)8Z:,P<9H .5"C2U^B-5G5MYFC1+XLF&1YW\Y
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M,[V8='J\?:.C(,_>R7 Q1G O?G@N#!;WQ/@N6$S%(%N,!4 SXF=7DF0N!8D
MH,\",?!:]"<4YU"5H;QMPIV6QJN/%BXX^*AS"W QAS'LTKFPXQT\QB?.Z^#?
MQ;!5$3 W@=9GNQV-^[5\SNO]7S8IZJ8R;LFLVIXDW95\;DH-Y;4(QW ES?8H
M%V/R'FRU A#=Z8FY,%9#,V2)&7'N8\EH]0$2.<?BAF<9N7ZE*N'[S/.0YJ3]
MDKZEAL"E!+H &'XEGA2>2 :6X@^B2<JP 9>4&#I1BUV_'AG!E7OXL$&?S9L0
M_4#O;S(D&-&PF]Y^ 9V("1%?XM=<2@[QS_/5=_A,S*&TMY4$K.IT^8?<XV=
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M**M4>.,BJ#EYNU*EE4PO;7DO;B6*)*L]]#IZ=PQ!_IJ#I4A>I+3'4BW]3D@
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MQO5%/HI.ZD'@+?LI#.XD0L\T5V_J>[K;X+QDBVNE/Q7\N7CMCAG4KW]#]J;
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M&,=R@98G$,;5_C$8>M?>=&<2+&13FY!%-FP?<?.F?CK#L!2\FX9":ED*O=B
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M>PV=7OT332;Z&P$'!VE+*O'%IJPFTK]Z-*1>7^5WS8>.__NU%X=L9$^EE!D
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MX"CQ,_YFA6[QW))7+H^QH2A)]U?-1LL&Y)KPF5M%PGZ/3J'C6-86=UR,O;H
M;@P8 P\'L")U$[]_X)W9JH+N]WI=S;2<I'WF^$5,E4H)Y1BQTPY9L.29PXX]
MK1U4%/%"BJB*'[S7*&[YBF?C^I6Y\.C9D^P_EHU9_OH;0=>^#3(RG/U&AY7#
M+HFR@99D>>?>.")2&#UC?UXEJT\PYI6*1+AK0:7,6UJ6PA_&VXZM ]N7-+Y=
M<""6H@=OSVC#4*1V^P?S>/5 Q^QBF^)DB1<+C4YZ;QJ</9^(U_N]G.E4QWBK
MIZCN12 $L-I@."DWCS+6E2LVY9N]UW40Y(?_]^8EH>=VUD2FE_%B5(R'U4/(
MFY05R>2M@WBP49LKK!3D>@1> P1H#&CUFTV$[,G>-M8LS:!"8+$J=1%I9_BI
MTO5)?DAEYKZ(83IS8@W=G[VNSF2"T*F5\?F1.IFD]CUDRY<V#PZ#/U8AGW 0
M>K7O\./^&]S=8Z8^JW2(0U[&#N2R36"O8 <(%[YJ/R:*^)O&*5C0#B8=(FP9
M.O!\QF$'Q2S2F^*H.<T&#IB[;++L"ES=I-H6PP=05X185RZF]/Z+W"RXUK+,
M@F*]/AAVY$$_B'<]"D4KW@3<:O/1MMV=''#9T<+/WSQG.Z%4^$)&R2NR1K1U
M0N$>A#-HES[U701#Z8\32"/B)=Z( C\BS<15AGN!RF,FK5/?6IM-ZI^\%"@Q
M26FLBGPL9"M,GE7]1!L2/.S-8\%^AI^;PJM7HC2#(WX?LPLHU"Z0KN='.+ZL
ML2%^II/<OQMM,M?+E?U7JS\[N8"L.*].2AI\59UU-X:<U_?G(^4_=;_/9^P6
MEXU\N98,WRP+?I'W*7'^?]5=^3=4__\?NY"),#2V,I:LV0L9*B%)I;(OD=T8
MLF?LV;>,&EE"ULJ677;&FBU+]FVL*<L=Q)4QOO/^_A>?>\[KMWON.:_S?*RO
M<\^]=:K&=:\@1]=;E_*">,.ZQYY-J+-B[(#)B+5K30O"/TE":YNU;W2^TW56
ME@R>Y'#+BG,G']WFI1DG!9S65EM-;QB-YTRJ\Y#T)KPLU!G+1(GJ$3F(?RHE
M(1?4Q_>OK'(Q!5![9$Y"2S&<IX5D14=9D'G9(%H=!AH1FA=3N<K/((Q\+1]%
M"KSM7[M5Q\]CDDMBE=(8!IHN<-L9V)TXSHK4$ PBD:Q2*P/JTL3:Y"(#M\^-
MITPSMP-D-RI+OY!M%T(D'<\@M64IWDO!<+\J"]""J-K6@(Q0V-V&IZF9$0[&
M!I=70SEK-RL0:3VTGU8]![W.(-S!SDD,&,ZQ XZ?*,52ARZ5 SWIE*5AJ#%\
MV_G W>H%X^S=+LF! 8('/$)2@^'M:7T4"1%$!RCC_QH*$GL2O *O+"MJ]&Q5
M#$GOP+,Z5 VSS5>:'X.7/?(7R-/9U<Q_V&^?0<[]K!_=]OHEBEX4B90DN%LS
MD$T4\;TOQ#R:/KGRY8:HHD.S:Y0C@U1<3%NC"#^:'BT%PYP\I,;)/,3"MU[;
M&C.R5&[8FP.7KJP6WG[!N0KY;E8(KA'S[H)TP.%&U\Q\Y.=BLQY/E!UKQL?9
MDJ-)SV&Y+E[W[H&/4ZE#RC01U_O:I$?5+("CKD6N&@ME_4!E(^)&9 E.XD]Q
M %()I<0SE^QVI,G4/33B=@W-<BM2(OX24#X;I3T9) K.+J$[SB L?G%D-@M*
MP^<@7[&PGBK8FRY+<]V7:&Y\4PE5TM%@\=GI]M2 6W*?UB7%JNGF_^H':%9P
MN)F$.:6PDR> >]C$XH![UHM1'B"Y[.7 *XB!\]_AR#,(CP(ZYM49)$$!KJ=W
M*FH)).8J;!O>_\FND*;<C0CSGMIAD?LXE_!&AT&0+79)G0/#!ZX0!'A-G+.4
M3C\F)9%4F71$?VB'E2@LWDQC^BC?V37I<F&*SV<)T,<4GSSS2\<O)W4E&'6U
MP% ^PP219+[6\" QL/Q. YOF%Y,^G\;27(O7O5+]; HCF=&%6&1#CSO#>/CA
MP ]O-#,8U[EP$8 E!0GZN>B,WTUE+27H7Y&8^FL2VEGZ(LL=:YSG6JQ?82O\
M8,)Y!2-\!J%C&U5#E>H7.B%IR(KF^JB@!KNM.,+U 1\8@]OCI;CP-4[6DO:O
M&H+++1D_%$IA[0N<%?_]UM!"'O\/E=OC0I<;$0GWLGHKQHMB4C6*)+?[[%EA
MJ/AEOR7DMA GFHO]RKQ?,'EX^U^.)E\K$9WB]<F!YA8/J*%.[H#:A#-(MP$-
M2?YGUJ;:[66P3/@K3N$V"O:6GLM>DN=^E/C[Q\PLO"\<R@"'$"^9J(F&#RWA
M+UQSQ_]*?+#<]=J[;]?PH7_PLA-/]%Q/SG4^"$WLL6I/-K/5X7OP+Y',[%)8
M\1-S-<?Q%2S*6V%&/ZNP[-^7@2CPWG<4S:N$[P_HQ6@VASDPIJ-J5XGR[?QT
MWVJ;ZR<PQJFC)LV5W39AJCHX74N;(9XGNUH67Z;M>=KZ^!^M[,YFM"]<)-96
M$ S.@]H]V9Q_$UBMJO[H 4<:J,=2XIZC/*L+L;R$[I]2-7G>J))\J 2%PWK/
M3O/495WXU4>]CJ7^9C.2I$^@AZ8)R\-6C?5OYVXU'PE-,?:\5%FYTNQP*/!3
M#98?U*-.\[,:96B@+R?%*5,SK[7#(>F[+BM,2I63)> ,+]MLA#!<IPY108+.
M:);?K33;+6*@P2VB=M)!S!K7B@[0@ITT_:+7U(- NYK<JW9EW<J$R,DQBO:3
MY"G#YJ!PJ<1\,]VJ;3@AU4C)-^YYX!IX3XE+_DW1BU5S ;$(;QLX+37TWM%_
M7\C8#27I$VXTZ2_I2.;^\,[HCSM&EQSLVZ?NXV:E1N:B[:0-3WT8W:E8\/1-
M48>\.+/A$)6>)/(@HBY(F<A:M3PL9-^3;/?-*\2:.LCQ>13? T:^3]3!L0)U
MOB'J,+_99\!!NDP<Z1%7V$AY]-]AEE])%+,,#H+^<VV/'"S&68?V,N'AH:9'
M**.N&>DH@EGV1>=+!:794=O;YP]FWH[210@R-_6:%<XWK;=P Y.)U6CZ,TB[
M; 0)]FRF+BY(Q&31#,_"6JI46O8;VP_OSE$R&5D5O_LREYI5UGQQFXT8;@SZ
MC(&WNZQ86JY8D51!EX]FV@46O_[Q8AW3AXHYO_@;I4>,55*YH,7TDS]9F_,(
M"+-!&*;X+YT6MPB X8=!Z 2849VE  #=G49[^]UYJ:+E?DC *4CW#"2K:YUL
M?PMZ^$"\J"U[!H\_@_"1- -S\ 0D#PBWJ*O0?RREW)V./,1,XEQ/U$?H^?#=
MO%]2DOM9'#(Q[P()C;M\&-AIHCJL_'"R8U!IY?'S3ZW17ITU32?VV<Y=]_!7
M[<ZK%1I%#0SIW3V!.QK.@0[+R@EG$ >^VRN+D4U7B_T:#R.K@83$=]X%IK\K
MU8N_M'^>;^R2RD^YDU%PYZGN]*V$:,8EK [#6);*Z4?2Y26!.'4&T"7@9M=N
M?)/Y'EQ*J>O1 B,;PN=;MJ=T;ZO7;ZADEYGSAQ*C!+#FQ,;)BEG]R@(H-T:H
MZTR*-BU-*&A>VVIA^ %['/GCOM5W7;/!QXEW7-O8PAC;U5;6H-.[/>Y_**8F
M$,IU1!CNNJKV"%7H#%NX3(3&-EV7DBX8WVWZE-?P@;:D=D*V':UV30PAJ,HA
M*[U1!*8!)W>: (:N\AFA6Z=Y)$/">OVXVU\)F:VK]*DV=4HC/2YHVP#T%?_)
M!Y>FA1C7-/?5C8$M<YI-@^C%FN%(,@_HT&[4D!2A9O?)+Z-KHF-7'U!ZEW=:
M9+77::.+Z;<&XSOST71[K-JJ9GQ%[0()"W#P>*F6*!!)GG7#';W<G/SG]MD5
M5>XUVUNQ/C-W1W=:W,T\/KFW77&];I&S3+*D10!N0&T*%AV&3Y"4G7=M5PL:
MG9Z-?E'LG*RSTS,S*?F.MYX;;4 E\!9S;+;PDH<.TY'X88Y?6?(M9Y#7J4^(
M69^EZY:=MN[7<ATIL_L[6\?8NO]Q%8J\WE3KLW_A>HI[<CMD4UT XPX4=<FP
M@\,ZP,\59UV":G1)#=\#J<*!N<HJ-=E>^+IC&QSL2*5!1#*OME#J15@H1IFH
MG* P?V51AXCAA__T1FZA9'KJ3(5$HQ29.[JXN-V.[.)4&J@?LN1YAJ9''5X>
M4U,M))TG!L?95HUY(9G]LCMG)FIX^<W=3<V</LN;MA6XLUTQ"WBR0J71MR*2
M5@#Z_#E,JP(^X*(()\'40</_I/[6?K;EJ>2:;+ER(IFKIXE&A4B68#I-E%6.
MJ\3+?B8(!$ "M;0X'E+]CRZ&+)+C:399(.C' G_MB/IE/^?%SE>!)8N.=2;"
MN'//,=9O<2)&YHDY2JSTGK'?@=2M4B"[K869*/.Z6H9V\U]P)$F72;/8J7=4
MP??>FQ*)#P,ZJ-AS=H(XX3[IKJ3B$0U^.%!U* 0* T:=K^Q;EUJIS7XU+&1(
M[IO^IC[\[?1F$)HB*"598G+O!:WK%ZR)AHWN[VJKD 5&0#J;()3CAWJ==2[V
M;Q,2?7@\C#T2[\"D(:[<3?$\O[<C%'#AKOXK+0ZJ_;JM(Z"_*WVR<Y<3XPQ^
M(.@),/@MFE1'W1YK0J("^$XV7[DB*O:E;:D0."==S[J0F M_ZJ%:8"!0"&7$
MW 435K0C%\X;=L-\2E5F]1$?/]:$]X7.M>HRI;S38+O[0_G"$#E&"_(2R='"
M#B)7'%Y+J\FL)$%G_))NI[V.G/AUX5&;H"[\,Q0>,D#SD86&+4O?0X NV+8U
M/+MJJ,J_&&1HFW@E4NH5=W%1S^/FZJ]PWW[>5':=$9KZ'48C'YB/3]E-7"SD
MV .Y]'ZQZM:BU I&\:+Y.;7ER4OK!6(^0R_;RW1<LSZ&,C0'2N7^2O>-K(Z[
M*:'SM6:TNO$ZCMD%+O:,6S#A+B<;!]U3FA!(6W'U0WI8HAHS83?&$M8*+,96
MN]P,OM6BG\H% V*NN#,*+AU8:UCCZ71H+V@HK@M0_,1F-ZP5@KDMTKQD167B
M=&E,NFM<M+Z^.8NMYNVQ@0<B4NK[%MQ^OFUIU:CVD08_BEA^Z &B3K2<?$R#
M.PW.S?AAX3PLN,K>/4TUVA5WW=P7R4^_*HNA2FM>LH[$"="W.IQ!HEJKUL.5
MDH"CCEK+2U7UUD?GZ8\=Z@4KK)3\>?)3W YGFQ-_=+*P2OQPS&%UGB0,1[D&
M"?[FOQ[UH"<6?0!Z-29H%B;'F79N;5ZX-<M![X,4#]-=S61J'U'G[+(C]G<N
MLCF$+<#[3T7&[M1=&T1@]6CO[U5C(ZEL55=G/H40^0]]Y%R3?OS*855=[FD_
M@]"37@)>9$[B1"AJ68K)B<L6Y6["I/-M%O'R,F6$.G/QK#R1[CKJG"L&4QMX
M?F8P@("FQH@!6H6IA.W;W0T/"I9=S7=]*FK?SJGV">.KL0G$NV'7C),4EJ@:
M6@IS0]2RE\X@6\5 ]I) M&*I9YLZ4P6P4UI"G>KKH5;9BK/R3T3*SO;%UYY+
MO/G%1T2[M[ZG[C0FB&&&9(ID7P%]"Y-XX%7!A]U8^]?FR>1Z,]@>;=HQGG%/
M8(/!=]"2H 7Q.^J6F882&'IVV9U:!(F[82C%4P>#I.]AQ#+1.D]N5#MB+U]3
M/#Q3,B-D;NJD1]7RRNF'(%Z_XJX@1J)('D%/^2>)O5'MIE1C'YH_*\]MW#C/
M+N&=C_1/N\L>>Z&6212<OV+HR#X'.A!.>\(D%8RU(Z39=VX<-$8%1*^;?49@
M">:] \8Z8SHZB-,]%0]+*V#E$ JR :E68S7#3!ADW>C?#RI;EC.+&2??UF,?
MP7OP??)\!2]<B^9%:<.>ZAQ]%Z/) F1"O 0B&^"_R+P52I<"YN>L%%!J*?(&
M:L,*0Y9W[87S?=P>T+M?@W"VD1Z=)@=!2<[$[G?+9Q"X'\Q@DG2[\-@&_GGA
MB0DGMUS^2-[K#YK<L^(-2^^ZSW'^.7C(@'59K/3M0'-@!$9;8,XM+-7-@-+;
M)U-.E09*)\^>237<P!]_[ZRR"U\+OX:(%&S$MU:F=B2=(XFV@$YY?BJ3^H#=
M28R,)&I'U$3Z_3UA>I<$LE?4RT_'F:0<T3FXRP0%HC[[A,/03W[[^L0/75$9
MR_I*W8%*H\3"E NS [_V/B7Y#%3$J*,:O]8/G>,<7L!  /J"I59NOWO[^#?S
M8$#7T:0*KLZ!@H7 LG6?9UB+M7XANPME'8U*TH.-=V\RQ4*(T$B!"H-V=+A*
M_J7L<#4H:\1G/.< <P#GW_&4]SN<7$^=^)_9<R?X1(H^ES1TLA?]"FRT!5/[
MW3.@54_)*?T(/'W[SR=$_:=JZ=N+XI(Y]"_YTFP?6API6_K?V*5PP!=O!:V&
M,KID"4\H9$ K?P<A&O6VGQ$*L7>_I5W1>=3B<UDC4>%A<03W)M;S.\GM-)U\
M*6ADQBW#E@CKP"T(Q>FG%58G%^(6_$Q26;@<+1",<W;**)M/.L)/DN[GAJA[
M@%$G\IO)3E;T9'Y0M'TF, D?".OL^_+'IWC-_\K"PFBPE)W)N8!PR6U&>]7I
MZ/[,%Y.> /K0!'QZ@IS]<P%D;L>97OI-LE+5E1I/*9-=2TV;?QV\10U#4&[\
M0K$2;>#/X0/0$,B"LMXF&#!)OX-%H<MJ;LH&+7I?"_N]S$8[FBWW;*%;D ,]
M7QTX]U3*\U 6E%@VB),@RAB"P84+?KWWZT3^:6=\QUI?0P0$DO5: P=>K](/
M:2AN*SQDB"/=/TT(8B'9@#$.*^4\?JP]%L2;7SIR?SMM&*\;OZ^V<637Y%AR
M<-I_5"?&./T0LMDD -"T65*A&3XPWU*R J*GYC8;N)7KV.-4 R+O?M#P9UWN
M5CC.]CQ?3\MT("Y&DPE& ;OX8"XU^!<_PZX9K99&PO8]&?'?W:M\97*,ET-9
M2O+IC1[S_+\V]Y)$3]\'<6&@0&T589@.E'@P6AWHR#F^E!$X:W7YF96TPX</
MJ_$2]8R=GQ9 &D^'<<<<* R\?7*)Q U"E^.RV4!XFX^I]#>5MR>>PS?'DZ\.
M$=C2M?<T633W#E?=_;C+L.CIHS9YDLQX"U]?SB[@4^"A^',]'2V-#$;4B:S?
M&O7/>G[^JJ21SS6?%33GK[</&=YAT*<X,A=YI+\PN*,+2&B-?C'F&X@-KC9
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MWWMO9M9;:_Z8F9.[\D?N.3?G.V?O;^_OK+L?%A\V ,]5%)05 !@8&(#/CQ_
MPS+@/0 +$_._Z[%A/UY/GCYY@HW]!!\7%^<I(3XA(0$^ <$S(M+GSXA(B @(
MGE,\)WE!1DY.3DA,245!1D5*1D[VWT,PL!['8#_!>_($C^P9P3.R_\_MH1M
M\A1S\0DV%L9K "8)!A8)QD,_@ $ P'B"\3\:X'\U#,S'.>+@/L7#)WCLT/@<
M@(F!A86)C?7?K!_O!C[>!V"3/"%]Q2>+\T+S"^YK5S+^X*3\ITQRM3WD6E,P
M9@$+MQ \? I**NJ7+*QOV-@Y!(6$143%Q-]_D%=05%)6T=;1U=,W,#2RM+*V
ML;6S_^KNX>GE[>/K%_HC+#PB,BHZ.24U[6?ZKXS,WP6%1<4E?TK+ZNH;&IN:
M6UK;>OOZ!P:'AD?^3L_,SLTO+"Y!-J%;VSN[>_L'A_#SB\LKQ#7RYO8_7!@
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MUKM*-K7\N<+3C5#3MWIM;JWG/@>#96%*DPAO4UY[W_('0)94UD;U"?T# ">
ML^Q >(T^X5-;5TX)Y>#17[: 1AT:+^&-0HI#@99X\86FH,$N+GA)C U<N@#Z
M3.].>PIGG<?A0+5LQ9:+Z<WI]T)K!< PM(,&X8LD=X6G]VL)C7961U3@9XV&
M4=GC;7^(N.LGTOAR18UPB3?CAD<?D")Q-_>^7YW(] G#LY3//D_;,MAI]BC5
M@+]=I$MV:3@;)_^.S?KA[0_23-,9T"P@M/:5L27X(\\;!5;/=6R]>[,.^0JB
M[.)<6^3OC!M;REQ-.?T%@5H4^G^.WI6TA:TC0CK@X>VNA:M'1T6C0 G(TXX/
M27D_A@>$JW.%XUJZNX>*3.[#'$\%'P!D/FOSAWC<57G13XM"K-C@;1W!::GG
M3QE#B#_JRE"CE.[S*E!?JI8/A#/O[%W-QW^&\Q(51GXA?:M6N4W7Y_S6S?WH
MT]D) W>;LV>O3DF:YL]7.O/::+KVSE/?-P-C!%#;<,L9IR!&LZ_) ]_,C)6J
MKS1]6DUP/F/'D\5MN,<W7E)V3\3F$DXY2Y)L@/'LRN_+2Y>[A7)4__(EB,H9
MR:9<*"WW$9_&PG/3+AX  Y4.4&#4R>7=.L/BX=0RI/Z]@Q0B!2%(N$&:%SE)
M^L&W9^1&HU/U3N !,.(!2[\/D$%'^\UK[D9T(NGI7U# 6I,-_"'J'!>JF0OZ
MEUU@IL;[Y@? =HTA<)&>X9Y&R+^D9_UQ+O.2K@S!*(S?E;D1SRJ:M<QN%%YQ
M\G0+E]XDK.V <L6]JPG^]V&R=V2/_V<#O,/1> #D*QJVE&JJ72J6JU)J$^?.
M%A'X7RBW.SB/7(+-D_X%S8+/S3KT'P"FC ^ :9\RXB406K7D!_AH\P%PJ3W[
M &CD1:57DS\ %I1D+G,Y0A&V#X#D@TW>VT=>([MJ1K7=T&,]AN>9!T U^,[W
MTON$>@,<T_4*OM,Y$<PC9-=@71-'Y^B9UJ A*AG6]9YC>Z-:]'(O^D0:YP#-
M#Q/IN]<"1D&J,W8$U(MO#YSIUP 9+OPFB;X3-/%2O@.^>R?4=^]\ZC=Y!\:$
M)U1:PYUHCI^OJ)5HX).GQ2;CW, [E?'%:8E5]J4%D(Y!D^LX)RCE32F%JR(#
MZ>FVKRLUX1OLHP/,GT\N=$)#XPOHGC+%F!F4.DZ 8_<5*2,KP]W3[,Q77!3W
MVZJ/:B_,>\Q#^%'.<(7BR7^/5+($SI :%.'G)-5BGGA20_SF.XZZ#^Z,X-E2
MWZ9&PC9X.H!DZVBT^KE1OD4S"W-4S3MFC)?.)HDB3&^IZ1PJ[B-X*XN0WM 8
M,I(5LR'@;F?]<P*FWGR!8Q51U+///D!$<//4U=' 9!?&>]N*@XW*"81%V80S
M,3:?JLD?:=3+>:VL%-7\C<UOK8&T+/@MJ:"&SM/"]4)?#[T+R9C-A..[2N0%
M5+U@T[C.HVB:+KS([5/S3RPG#%R:&(;VQ=A<U]#C6^)N<%B;S, S!G78 R#>
MV1IND_)G>54J;*LPZDT:FW<D>9P"BBD@/XIJ6__]'1_J?2@4=\ \RJ^BS6>J
MNI&L-M7^C/?7_BO%:'654AD^+1^JE2<^,C\"GD!=D/;^JL0UIBQ756V\;]*2
M:FHJ[B!:_8'3>1N7CL%K66XI]NV&U--]F]\:[&8+5"%WRHW>_H5%UDX5D 7M
M&:"C$P^W.W3AN\?2TC3!\/2:0NSW'K,-=B;&V(U;_=R@&7.L2]Z0:WKZA _M
ML\[AO^L;P!!2A3LO*GBS!8_TS;@[I%, 49?V"KD,@RA3,=M-U@O0 IX,CPB"
MFX-2_'W?A/(P-F;ZD*WT6L41 (XM(!W>HJ)T,'OM%)/(=<&^F3^U5R8NHG\I
M JL=LD6B96S!1/N@^IR2A+S..0:#3,B\38BRI?!=81+Y=TTJQR_QTB[C90'D
M]]E< ?8;=R!J)-C(B: 7'G&^1EK.'$SC(&:#S1&"'QRB/*$N<&Q.UK!<R8#@
MKJ_K##YQWJR=F5>RHK)R$>=Y>AQ81G!G&&!_1[)LO/]6:GO*L+O:!1^UD]]B
M+K)SJC#H$N":R^&[,PK6*OJY61#97A)D)(GJW*FZUY"!,QP?;= Y;,Y=1P<Q
M(*=5^^M7#(5\+>.8.5KMSK4$:#9"1 AIX[]ONP.QP+:_I%_;B:#9X3P5C\'2
M<90]QZM\M,%Z4>!96?F0J)@877DP;**7@0K9)YME--4AX_G'OE9,(9>Q(VGA
M:\K/H3O&A05S3$]5S_M4"Y\&@P M!-^:[ZT$H'?SQ]F;G[)Z(Y"_[R#N0^1:
MSGQUWJ+?J *D94A+]"*8=6@KS]Q&RK_^1"Q8+>W,!(U)XR*#-^,4'@";WC%5
MC3ERW<[)?U$\5J*.K)(M2P1.$@8A1,2S[@Q80-L8C4@SAKD.36B<GA-Q7Z:[
M,LTO':X*S?=*_36O=&7IXM45J?8F46_N/BH60-;6D;8;?DO&I>>G50T_2?*8
MF+GBZ*I$]T)UI'%02LC@WTO(=./I#@+AYHTQN=LMS;>%F_0K/T<C?R6L 7#P
MP[:KJ<2*?!]UP0;-8+R^5B<[2R #?ZSMZ/;Q5;,_/XWYTL*F=P)*I,S,AWC(
M6VO-D,?@<$"/Q3(Y?W: AJ/IZ>HPE91K]$V\P3_^#D>=NN3"<AQ:/Y(>>F@7
M!+:6 BM!Y$;HJ@+QS.R,<O[\6TA:YJXO;Z8FIF8[EJ*UC4^##\4(RB#E4;H5
M^[VN[O<Y_D(EV068&CP*:HLGV;;P\A+.IHQ=6RH[[1*53K:AG_KZ,5Y Q-'R
MF6T3NE_F7/\,>$PB@HX+;P?&K!.CQ;ZNDPJ-@@E6'>SS1CFRY!L7?C[M/?[D
M-6ACVK%74\6$>/7(SF#_!\#G*/"EHU )? @1C0S;> !$K[V>:DAX'IBBUI"A
M114TX'PG&Z=,D\FOP7PEE%U](B@E*?112C*3F'0W70+)[;\\D;^;RU,#WXW8
M.B,Z")+JF'7FW<JDWHCY-!NT5$O_#D^++F1[:'@\2#-W[@34/(0:!B,>  ^
MIJN+D^N$QK-(M/24IP:)^0/ ;KUP\EW=#=_ #U(KPM=_#H>R;3-O"1#(!T &
M)7K] 8!8RT(6N/],S9=LIN-P:EFCV%V''GY[U,/-W<3$ 313EZJ=%!?:;<FW
MOJ\3S4=IOI/+4BV_O)@(F"I$ 6!7U\>/XN-Y8<?L8$.-&ENP=<+QC6IX9$"7
MV;&3)LH4R'$ELYP["+WHR7W9WARVVQ0.[T\>;-5="W4.%(C.77_?!3L[EI>*
M+W)BR8$>7*A,_GW[M\Y4,"9I\<1:5$I J_#&LEI[NCS]R]8OB[S2NZ1BR''.
M3W &%(SY +"U"V+:UU]C@].702C#CD=#^9WT4SZ/-NW2Z%*V?SY_>F+JM'>\
M"=L:6".:O0("D%#[W5IF&41'9"T%(*?BHVOJN*@CR575Q.9 1R[+?73UY>HK
MM?E\\L9M+5D<P]&H-;5?M#_91H/7F>:[S&&@7@TJG]W!\XOWDSQ7! X*>%R1
MF)OQ09HM<?V6B:U,L5NORT[5VB%#(*TX0NZ79)OAB*I"L:SYZ\#*Y<G;<L3K
M6M@*/?&<L^"8''2K7^#&'()(9B<Q=DIVQ>FKL76S F6T7AZ8V3K TC?!_<3Q
M%&B&2<\3,W3O+DUYG)PZ4S)-F(77*Y]WRTB&2D]0C94&=I=4_ >[[?<6%;%O
M=1(:,)\>.T3?9Z8NH:=/><AZ;1PN8Y6$SYB"WDV8.+D,SSJQ"XXC5<AK? ,Y
M4N>*6'/O69P?  [5FY8AR"+8GAI,9C &_'11PY,GBQ!1R]5,5"G,$OW&,3'/
MEL=UJ,3H"&R?$)Q)V?,3-CGUB+WZ1*;AYC$J#"X'@#F=5_^T/  ,W+,OZ3@5
MMX;"A.+>(\JLFF:J6)WDH(/&+CS\'R)KY2KZZ%++K1!#0OO IN)8---C"L_-
M*D9!S7M:5:FG0(UO>I+ZXEA _]\9G3KUAGV9Z&[I$741 ^??>7-.V@90/;CW
M 8"%]%9L@R_$5^5WSBJ0-#0K_&C&#NMW(RU/),@F4OP(K9$6"1KWD^G-D)0H
M7W;0IY2FF.5E:FQ-_ESL\SY@8+9L,_C=T.DV.2TM?!_-@_2&M2. IA0TZSB'
MN0)SU7W,_$W6BDFN:58KSU_D A1$<>$S]_7 [4BD^_US V#__/(]F>7S!T"!
MQKGK$)T,_ICRJD/K/I0?)?FM\:940: XI<[-"1C5_@;(5 M72-J@!ML:J](I
M&H-#NW]#9A5+!W^L4/5'6C+[?MANF@Q2OR_O"2)&3] 3(3,VP10.N-IS8TTY
MI2;&B\HNS'8LP21F(M^F7K2$[YW>/_$C3F"RE[%0$](TG%@41)/9HHT5%8_=
M:?I@+@/#A\-'?]0K*M[*4L"W2;2JJ9I VDT-[)9\E^RZQ9D([Z.E@Z[1_ T0
MIC3F>H#M+$^A _BXD[3_3VO'4FM&@K01$<ZQF_*FFZ@8X#8\ZTX"]1I>7.";
MAS0?NIY!AF,S<U72)O%AE06_Q .<U8YS%MW_!$*!=Y)(\(=I.J>K0?_A8.+P
M"Y9F3'8B,2Q)+'1/]8O['$F::I$A;@J6F:J3G>G3@.4S?F&-^CSMQ!M:9UJ
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MT<)CQM1>Z<IF:%YNX'R\" /.LG?U\NM+M^8B$WZ@)#+*OZG==/X2.ZCOK99
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M%ZA,6DE-:27U:9S&_>\)9I&PD[>"&"][:DBZAHGW%4^.;&2G3N6VGC0U88Q
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M:_Z1$2+:)RF<$1(/=,%Z(*"__?W2O78*>&-Y&?A>'6ADGQT^3>0UT/$R'#X
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M,OT[,BBL8'_DHB9^YQ>IHEXO*?E_NM9D8'0IERP*!<J'SPFXC;]=%?EA>E.
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M15XV\5R!9\#QA0@V $)0P"$$)#$1BC,B2E "N6D/[05J"*FT[?L'H+<LU7X
M*K4%7X4&/X"^YA*\]3Z=/!N%_L%O3?"9/A*+JSCY;,M/32)I/RY@WML=@.2A
MBDO=\'1 #QGHM*[' _70\R^ 'CC1B =8'NF:-P!>'T/)6E;?O2/7,C#O"Y#R
M4"7;81(0*70M39A-$1LD40Q0&0R0&AF 6=3_#$2/*1#?S'>_F_R46 8DE(WB
M,2I(W#VB B50"?B2YCU@.^#L4KS'/ITW^)>=]M!5^;3>$$IK/GF1O)]ML@^D
MC$!+@'X2RR:4S 98TMH/:.T#^-\4!=1>.E1;-'4#MML/_X*&IH#3YHKE&RF
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M"9)IFI*5#;LIF;EFVB;G8B%"@D4)B;X.9:/P&^,VJ+.1VZ^E*9R$L%I4D.
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M__9A^"&6LXX4.THOOHND"+03/"FAL^>0<XQ_';*M_R\%&7LR]>PPXQ#2OD?
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M#SRXBXC<*Y?PB<H4'Z$"_MVL*'MO6W$L>\,H!.;FKQ0DHLT8H55P$;;4I[P
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M6U>6AKVN4-3>KR*'&RFIR*JS^MC)]<C(P%CWY-!?X\U_\#F&839(BCX^(.I
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MO@*F:OZ+0/F1V/0 4J]2_@HU$\6C3@5,^14?H;\W- MYQ6?(C%,!775J)U1
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MGD@M-*S)M^F?:KD+TO^"NX%8K%Q4+C?AI8I+7+[-<NOO;+/4V=[]YLJW*A1
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MHSG*3:_(MM<S7EOIXH\+NR"5E7B;K,_E@Y]T;3/7>J5C.<\"D@8',;S;MWA
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M0;N()E_1^+MLZXHT12^/ KR(]Z)$( 7@BQ?3J0"1D7]34 [J/TP.%O(/:53
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MGB3YKS:#]CCA +.@"-3)G-Z'(8=4;>V'RDOUHH56NY+!BSN]\-A981@#,8)
MTPG'OVTP'?>4XZ,3&J]12@T/].$\)]3WA Y1Z\/\Z,0N=CLOH>3^;9G:Q(UU
M58V-4_Z)._BOVY2@G0WH$99YIM $SQPO"77 W]W["Z_P36+*$#6R(Q$S)L_]
M=-OD6KRGY3D:*92,0/N07RLOB8OP&L7&AS7L!EU=/X-$<?;5'J#'E2,Y+B_E
M?O"OD%K0LE6."8-#JMDRN''3 :#=D^64IIJ*%X.>4VC*I4]TSXJ*?$76/--W
M[#_'B@^I_*]>1<_\">ZB9PFC)SW!HWO(RL#36_XN=M)AUPQ.>?@OES\4P$)]
MQ\/R<N3W_5JZS)_HJ+$*__J1._IP^FYETCM- 4V!36"OE6=<"5':KHK JWUR
M85)6DOC^Q5]\3+NPN)2D']W0U%,52-QAC%<XKVGO6Z@B!LT"435@?9 WB.4K
MDCS0-^YS?!%G;[:[-)LCAHY_(Y-=.)L@FM!Y2^%]SK'G?(H!SNVD#&;V!Z%A
M<M)B5N8G^7IRN )]?()TF61.: [$[$3Q,LQ.Q1S$Z;/I1>W8V/Y@9YMYZN>D
MGJHI^JTB^S5J=JT+Q2,W_7KX;2N@I9$@<TG28 _\D]<IYLX/QV3-GT.73XO/
M70O?R"O&@[=*G#50M'&P6^XF4'U"/%S.\.LU6Y5.88':293?/5"7CA(MO;MH
MN$4 U&&%LC%IN*\W2$J1.^DL(5V$:R#Q,'!H&)H#)DH9T3^$1\Q:$]G:C?$4
M10(CZD2_@S]LTK^PHJJAG0IPC-T'O455P=_"V!;T2SL%>J.A8+^T9H)&G>BL
MU]KS.]/^IV].I)1Z="M,:6@ ]D:63WMTNT<_-UR?\3QCV[M;<0D7D.HZ@](#
M(Z])I#,J7*&VKH;$%F[U+<)CITI*;&;T<XA?A!K171D,7X8HHNV=@7%'9Z9S
M56.Z_/(FDK_UW+*[PA5"8?MW^,\'>O'6FVF$>#)18XO(#93^&2@<>V(6NU,8
MG_F\:.*1]]9)D/I4W]R/U31!R3W-W=;- VO9(0H[Y9?@)>(@#170(5_6+97+
MI-63\IJ!JW:+B5M-,G+Q#$0H;=K%V($)YH<>>.GN]3/68#8&-"0P*"E0KH\L
M*V2\95!AN4W>\F?B9GZ$YT-%44 $Q5Y]MD7G! U1] :%+D4W':Q8^T?"3YR8
M_(!WIN_VVL_;;<KJC\(,E7KUU13X6'\7&:;UX^3]DQ<&O?96[J:Z5;\LY$/_
M-;49@F+;VA!?EHX#,HN0$Z"VBR'FF'.-374$C4)RA/=BB(YILIY[D9V"C#[?
M0UV$ _/'@:N*%??T_=#X? UQDBUYK1L8[8$A"QH81I"N?'*\#8^TKKNDLP3X
MNE1^N4""4:E'/J3X2;!M\'S&BCD)MWJ%1>&WLOK*4<@)')DT#WU,+H0)D,2;
M*4,3\MWC\H<>27^LU)QVC]&GV5;.KIM'_5/T4#!A9^FF2:<=?Q51,T>W;:+Y
M\<6%KP/DY6J@A,?P?,I865!%)RATX0(1Y'0-GQ[Y\O5'>EQPC>'=5?#1ZLNF
M$+I>^7DS&)I9AWAG-63E1,<+]0'E;%9($'DQ \^F OP0M'C45L B41YR%HX6
MW,#L:H^;R:ANMH^8^#6E1#39JH)FY?KWQ)IM_]IOTW.]7EX,_GCM7%:Q][>+
M$]^<:^.0Y.BS9C&_NF-F7O>[A7-@V</@_2T2?;L6N[GRUW_U[__???[WF<45
M7^&]$<-D'Z]EMV[S<=!2QQJE07%7WHCXKJ!**8.(7D*]?2W-#V_7A#&["@J-
MO#ZS5E=CHH.QJX2?GL6VO<]GX_R>Q:)K;W3X6<".YM%03W)*M72BH,HOTC/?
M)68>" @\4KK\O:89GU8H$!^F^-Q:ZKE37Q__59D>\=]%7"*YJ]TS&Q"=!#D$
M,VP072<:Z8072$O",,I:XYV* K",*OQ6KJ&2S](L/$42Y6]PH*]>TK*+G;Z0
M-K]&!3# W;SB>9$]PU&\6N@N\6%VB%<OJ\U<2 /T:J-3$AMW'^.7^<<Q\B,1
M0\R?>$.KSP/]=29::<AQ)-I%(M3R9@D<"P*Z"XJ-Y8\<2/IVGY38@6OBHUG*
MDDWIOBL-W9O/A$[3TRHOHHBB5$ 8E*L,(FUFR$W<LT3A0[ V?W9*W75]!4IO
MY_#]%=TE])"/YCJ'=6@DX/FWY:S]7U,9ZH8BW\G%&C<AX1B=2 W!N4WO&2BD
MD? SFW&\1KZRSNN&DO#=X:#:K6Q+S7/Q_#>9?VHSB4_ %_,;RRA1I[R0J2US
M$QWAGO[)P/1(E^P-D5</ 8#.%:7%2*$6>]@P"J!F6@J;@,D1-PDT;0IPYIWR
MTKSO8W(6!RY^BGOQKOQ3V8[W;J<]/&1B1]Y]C,""#$GW\9<B"'KM0741:OK/
M&],BBA\LVUK+<OQN8+ALKVG&0'->^0*-.7?_$]<3UEEC,XW'>$38:^:WH+K"
MT&HO&I?#(*:4$I+:NPVSH)?N#":!OHKI:K$YEWQ,M??Z#C;!;N:Q4$9R"O06
M7KQ+,?M:]21)'[MS==A!,)VS!#OXT.ZWU4SN!>O[]Z\]W#TWE]C)S6]>,_D>
MBZVY8;!U%OG'_U>]/6DP5,#LJ2$7LII?&& !<>O<>0VP!6=.);FAG/'[OP(?
MUS6^S7MN7<0CX=T+1)X=S2-<UE=&Z:4[[^XDZD(57_#6\YR1\$?-RC0-?P#;
MAI/UPV\I@F/E!V?\NSHW."XF[WE7"<=;)O\2AV1#B<ZBP[:*3[U3B9SRXL,N
M7] _]HM(8A4.BZ=]DHLAAD]B1^6/)]&&[R_-CU>U*GL].YXLRWRU[A]?>>]F
M1(-KU6DO:,$GT/-S(_BJ:Z/5O'KJ^V>K+]<"5;D0$XW\3+^SQ3/ 5V:&>2(&
M#MJD F1Z<]9/S'_JQ-QANFUB;+YK7A=RJ%9JX/K@BI3N%W0JZF?GNW5TRQW;
M?,.FE<2[RLK;J+4RS1L#]-'S%][X-LKT^IZQK)/_A[WWCFMJZ]9&EZ(BTD1
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M4]S<E?/&G4E?LY<YB'J9?&891G]__7C3I<]:%+W7^UV%K)VU"R$XN:LIOO!
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M:Y0RQ1\4#57YL/(94[=]+>)!I%?.;>-5V:]'W QM:;O4K>QM,[LRB#CGZN-
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M*"?<]"1,AA2'433Q&- C#*' #L7OT>C'6TL2X["W+D,_M26T^&?F(X;KP6W
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MIE(N?=O0Z<B8.U2NF F0_06"%P7 <!?W&.$@@XLA"KQ&:9X-X-L%UE.KV #
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MM'*"NT/!"YPXM0]$;D@^M+M+!#/@QZ.::@*1X%90S_VH<E5EKT"_94.#-X/
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M!3:W$X?7+[0:;KS-S[_M+[_Q?^5.E/X?J:IC0_Q9>)7J1@&4#Z"'2+6EWPL
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M2+7F]J7<)LB<OI()RR*@OD-/,*K8W= SJU!RI!).OA5_Z_2>J#['J\'97.N
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M/I;/$IHL*ZCZAP'(0O07['_6)L8*!.M6SM^CQJ:+TSY.Z29RA>,Z;R;D+3(
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M&DKHCVU03J?4?I;TV9>ZGK]/RE49VO6"?&'R09Z'V+! +KD#ZRQLRG4_0$Q
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M9$C5MXBJ38%][[V"\G<F. ]#5Z50XG/AA#2.[N]&C1=> (2)6M.A6';$56H
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M5@TL]"N15='H\[HA"&UO>N?,C]IU^KRE.Q-\LQ&7A%ZOP[=2 E1EF$1C@V4
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M)W')OH+ZA>6.YZ!W=;9T7M2Z!-=O2A]^ G6PCC<;8  T7+9)_()/5F[G]]F
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M$XK]<<(/B:DQ.SJ/QS74B@NM8CSQ5R^B\'%1]P"^^\?W@,0*ZH6C11-(%6<
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MZQD ;JH&L2Q.3G:%Q!KI$^P7A-A5>&'*9:T(7UF2*Q!)&IUH."V5>U5[3F[
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M!"YHVEF36/]0;-;I;!$[6I^-;.IB@N=B]GYN@KX=B#M]$#A-!;QD#=PVFF0
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MD:)5,8CXO2U>3?HMJ]UNF>X$Z#BLHANW8&$A5R)TG4,.=;&>-=/>GFN-C#'
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M\$PG-/86T(O>67L""W=<7#Q"B_Y#+FOK!%:ZUD-$*WI'''(:T0;VE2=PX4=
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MP !,[D.V"2HTBB+":18Q5#6_OXYIF;'_,KDLYU"^/=\V/XFT)#HA-;3PR-=
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M_70IVI$K[" BH["H6 ^Z""RC5;G"W"5]H2+FX39AB?4[_]F6SH39M'F-*R[
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M7Y=E)2V1 7"%<NZ"^-X&^\;),P!(S#KF;V8#_C7#*.4B%2H+":MF-^[/%&^
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M6NHYX:4^JOC\D 0L-=9/C7))SE5EUVNJZ-#M[X76^?MN0QQ5J.=.)6=R_A'
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MKU)E0[1J$3GE116-XMKN'>,U#8<\4.>>3J[D/O;5F.-<'LT/]XR>D\Z%Q"U
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M=P5E[E_#_\$(QB&=KP"4%F!0#_@N=*S7U,AGZL4O>F*69\05H$B,A7*3=GG
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M'[O,?HGGN;F^C_U*_?&^\;EQM7=!T;B!,.0ZKS)?;2#[[B'\L:NV9C7,!,.
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MEP1=9)G-:D95N!IY^W'E7P)\5^]-95B^6]:]AK94,.@L7MRC 3LJEX:W5;8
MS(WOTSVM;*"HGS.[ WAPB_%EW%=TXZ)N<( 4=U'V4-DF3"V\9#NDNQE;\:,]
MWTF(CJR$\VW7:LVR*[_&^;FVW6B3&VQ_O;J4!>AI[QG(EGUP-@8M#Z!&@Q?9
M(E(-3>DP"QRUJ)OQ P*0UTBR)WR<S@(EI[.UA5N9DST!JI5(KRSP+4@(9=V8
M,F>YY2WKG^VV=X135[T0!XVS"Q4)-W\8A!!:]+FU*O@Y[K<4<#;S#4PU#[0I
M$3<1+H,HZ\*Z9)O2JF3]Y^%.?"[LXZ_-R3_$YS[0(?*3)%&5-PJ]!-!9WS7L
MF.CLN9^<EC+E?4NS*JG8^/YG,MU\@RTF9DI3MS']TE<#CU)+%1RC=$U[5,/]
MQJ<^51V5R; \CO=_%F7PJ*#2;?U%CS_;EM&=<6^SSUWWM4BV1$)JJ+I<+<VW
MU)[?"I20R]9\\JWYNTI1OYG4_&LV6Z5E7>!U.K?RP87ZB!"W<QV7N%V[A:&/
MXU,IC%P9X;&2'V,;GWUYME4P#QZI@I^TE]CD.C+^C''<@B4.>.IK_H"]\?D=
MR(<JEN,O%.A]"^B3Z+SO$&<:[S=>4%%7:<MP0PO/Y4$\Z?I!/L1T*6,J>B[>
M\;![0Q<'.*<#6BJ;5K6)17\^O9U3-*!=(.A[@&_0*3OK ^I*TRF+OYZEVQBZ
M8\V#-^C"2'X\?.^W$HO/O?96IA9.GNAL=-C7#46VR<?Z<%/X? ES2",[@<\8
M-R//"N,KUQ1I<L#\04U4?EEYL:EQ]6I9IA"G<<NDW^!'M<28X38:AHGER$.^
M5OLL!F64*AO>I]+84@'V59?XN5E?.8T#J>TYVCMEFA>(.,W3P=<OAPM&<'(U
M#]U5F"/_?LZC.^/>7IW?>#A]:/4A90&O<CS %UB 3NC?M&V..N>&=Z?N3SN>
M/,VQT1#G;;=OG]^ODX'EEOB'W\)U,7<=*C 6R)[2;^CE3I@'C8_G=D#?"]KI
M1A#QSV2"R%]\_3\$5"5?K'\,>H@BBI57*K-T;'6NGM N*24SG[DO3JG<SCOX
M77U8U?5]='0T<[:E[1,"?HT)=Y>MP]JC[-^/I(O"\@OY-=Q:8@Z]+P%O \'?
M?;;:,HDF%6\Y&3@Q6QV'Y&'BP"\1S@^!0_PD"TP<CCEANRH'#2T33^=:X?)I
M8*8F=^N7BR!&4]@6F&H7,051<G^)V.).65L-:%MR7-7PRBT>L,FYUOE^A(U'
M4-#M0I4Z(?6^UR5 +N3)<<G&,&E&4J.5ML"%S@B"]+>^SX&NU8TMYKBP[4_Q
MMXORG]Q-63 /*+$".ILCU5GM90#,)Y"(!:&:],61<'$XD\]L9XO<% RE]"-W
M%)-?%WZMWGZ_[?I^,6VOFU3- S:^4C_=CKBW6$YT)[#0_/?8-,S,N.'QV":-
MO--N6T91-0LGX/Z70,26*GL2:[))?Y_QV@#*<U+F):_!6E+BWJ2GF>-X^2%K
MD"*R25$:=YOK"]#+N8B$:S-;3#;,A]75I!BS4+"#KQ'AF:2S:# M<]KXV&UU
M7 +(FCA0-^9\6I6A+D=DTZ"OE>,0FD<"9**>>E_P[Y[N1S4ZP#0Z29%4  P7
MM.6N3\-Y9XJ27<7$ZU<I9HG@NS'LQM,<N_PE;DQO%X.2I:*#J+9N4R#7,9RT
M5HZF*9'0@9>$NY\]UWM=[\;,5=E0-32::$C+-5R3*>-YF);*HP0:_GW,\>E5
M'K'5M .DK$&.\Q+ L7'!88H<#PA,7+J#CLN^1?MT/&6!A0G48?[XB=9Y@:KT
MXWZ&T_#3GRQN[N8G;2/4#BUWD(([QTT!*.2)?M:S6OYWM>T";DG:O:V?ZT/E
MO@4"5SRW+#S7NT%T<#0[&XENB?H"ZX>R ;I("49R8Z(WV9^(9-HY;:B40P2$
M4G1KYZ(=US,O >((Y_F4HEKGO0IM<Z7*W:"[VDM9-)9;IMHA<T^@8[-P\T]Y
M#?9"W2\>4NZ3+C,QSK54@Q?!L:58%LS348G9>?C+D 6Y. &;\!75A].;7KL4
M[_IF(XN0)XB@8M2]<^MS,7]II8H=TUUPC5S94T^R:C.>K7=[YH$>$DQ\#]??
MCQ@F%2TEO=[S.*^Z!.3Z#_5VL.$OH-,-H=5L$7[\/CJV*<<D)2[X3FJ#ISDQ
M7^\E\YO%#]RJ@^4FU'JP#%$M,6Q? H"+Q4IT&PLLDQ[-VKN<%FZNCK<.!8:?
M1U&TQ3<%M(H2*6GGM_A95FVN)3-PE=3(<7Q^^.4T6X6+<WQRR]]S \AF4]M#
M1:&U!+E)ID0]VW3F_>$24,DQ99_Q$CB;*^1.;7WPY4MP?1\/$R-/,)(MILI9
M:K$V6%!8(DI]MR3 VME;L'A..)VN8: ^=R:CG9A'NE?B(,JSP-#**-(LPVHV
M.4\HZ'FEA5_UJ?$Y?I?EW5^'GULD-B6Q(K]<6A'LX]G^!!43.8[&)?H]?6]]
MP;8\H;>KU^!4GA8L/6R (Q >N.-1/MK*'#O*<'ZD$4T/=<5GHQ*:LV%]Z<LS
M8!!M _F@I[?]NA8;_^4@,K%H:/NP4MMBA\<;\FB'@GC).T0 XYOM2+4$O#?U
M"R.H$#)5+]&1*V50.8O05P5]P>[$$1QMOG$]X&F'W'3$DJ$S$#OVS_5A@:4]
M=LZ-D7SZC:A@G?GVNO75Y;1BY#JBK!+UR"Q1>W2*8/^5XWI#8^) ,$DO2NX%
MZ@LY0+<&CZ,D_1B$D@_B1.XF4ZPE@HF:*@*C#"OJ'5]_CC?YK/7AI[35[D?W
M=NG7]@,DEH)I$UW6H@O#37P;3(ZSW[20FNO?M4L=V*B.XB*"^)I0PZE+4<*T
M9D.$*7'V;O9I=HGN[,,Y<O02@R\RKY6SLO(M!LFAPYY,*;)BN*O+)YR%75Y[
MI$2NL?B.J=6"A>:</U[3S*0BOD5AN\E6N0VSGE-Q7=Z[EM?=**;AXIG 29Z[
MZO7IH)&#46&+"@%ISZ()>*9U6A7^*KB_7](7 B++97E+/$#^?2: =9F5LN[G
M8(^HY=&Q9!>TYYDNV7;ID#_G[DFC?V8VTFI)-6-1Z9U?4LSWV?;O[4M:_GGE
M!Q]U!0"SUR5[,[HUPPC>;6U89@6BY#H,X33K8X?S]IKO']0@%[+9YP177C$T
M-M1KW,*W)\2:+\N<QK$:#;"18VG144O#/XZ9;S40Q&AI^[K7.R,6/][JR#2.
M)@0D0AD)8E67YDM=N$+"!5EN<OG9L.HG2_<U>]()S-*%9).-GWCI-M=BH'.!
MB<C*+DO27]L8XL*""'G9T?8"$H@MU).):\(Y7W2;>E9UUW!&S%B4D? !:[2$
M:T--T3>,.AKTW4>_LQNF%%:M+=4%E1KB+O"[4]L4L?HY?OFCC?1I.^/('/%;
M9<AGWIP9H'^B_+%^</Y&F9GXCJ?_[.[T&;#MK":$%4X7P.>-8KYEM_5\_&5-
M#;2Z5J1=/)S;4(^C<?79SZ^L^U)T!.29!XB1<'F^16UB1$V$<(PXRXQX8^.X
MMSO%X2L)^]C%HU>4\\,W10%2!)YT*.V;>9H7&MD9#9).:0VS1M6GI9 L@\VL
ML ;HAY( CMO?SHXC%+,=(2/>WO9+<ALVH; YS=[!JFJ#ZC6^4#52G?67C3^:
MER"L#O>^8WS39JW&33P#%=L%F%FFTW>,:SWBK3L#NFR*\..S7*VXA#7Y_!5
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MG5^;E8:&,%G4U>RMC%6<&FOR?BLY"([DS6VGM$S24U''_?GUQ[=(?@#OMTB
MV]B8H"!YX+5(WJ(;>BHWZ6\6:^B8/B'$?:U)ROLM$9#M-ZI9?4=0\;-NR8H^
M:U55E)9QI?)$L89F=5+,C3\MB7'%KZI-9]D?MMF&&>I5JUO&/\LG<.-RNW"W
M/_^)VC#^.4IE.<DO:DC 2JT',?6#LAY+1;C(]9"%Z?'(#-!:$"C=D%<&61^K
M>UYHLKQVOB'8N=U;8+HZE6>ZN+KB_;XV>Y:T,G9P87S[Q2=E]XO"&B@@@CRZ
M]\WKX[UXJ$R1:<^PUBC70JY+$W)XC*^3Z.=JQ @/]P^&:O7J$1FAGM&$FIZ]
MXUOQ+RL-PX"WI?@8;Q\YG6OC;__0+8[X%I%&0)' CL^YG/F9XZ#,V4EEQSPA
M;1O$)-3[R-Z9M%>P&*AHD?B3:=D\)$"8(NZI<=QPF8D:Z%LMK$3B\XM&Y0RD
MQ@_(P!9\;417S[SB8M,/RE&8JCOX.WKG%VPRP*1D:[3$+Z7(UR]JU.[S)ZJV
MM"$K1+Z@>C-PN(A/8T%GN[%>KD;!#]?@959W<MCX@S B#*'@W[:3K7N?6M%I
M2HBW&-%+P",AR"4@H/L2T 6=F%5A 9YIG=N+^$^"W^V!7]AF':P&\0PH(=M:
M&"\!V:E&EX"65Y> )4<XL@U[]2;QWS? 34W1IP>O@0O%&*6?2C_<X*>'K;2K
MY>?X:!OP8%\Q&$X-1HFW(ML5F:[L&.)6L?]9):"/TKLHBO*? +\%OUAM/=@(
M4EH+:+P$D-,BLLZ8)$#G:\)8[CCTBU;R2\"O*SNB8)3$$15"#:%_P*JU /Z(
M WFUBF?@$H!LS[RRGFCX%Y/#)2"4'#ER09Y6>W' @.L"K)XN+T3[3X$MN\#2
M_[5;*VXW%@3DC,D3=+Z$VRT1RRC5:74HYM1Z,@C&: <^BO,3W=/:2KX$?/J/
M8[C:?(%;=H7I^R7@"I0XN),8;8\-U3;"GD9= B(@A;QY1PWP0;9I&6_,F57<
M:9;(WQD*1ECTU8P<+*-2I]*AZ&;K29<5;A\E%>%2(^P+;/L >'T,HYMZ"4"\
MQTC@$L1=C$M0+RY!8Y< G D@;A,S[&G<U28%O_..OL,'E;99:[$!D*[3]UA&
M-1SV*YN#.)O"&)$X7,:M)\%_,G[F%VEE4HIIOWB?<@D8249GB?PQ>(7)[!_4
M.5?KE?ZS/E A4E1MBO\2(/(G7#@N#%HAV[',N"C'/?]O4:9"0B_(_2!_HZPS
M:K"SZ4WU+Z:HOYB<_K')ANP(8L49B/K7 ' F2"#@42JB('3GR'C[9?,!Z&65
MK[!03&EIQ4_U _MTZU/7]^\:'5>3O,NTM"ZR=?** N1_)'8T)&?T1HX'5%@0
MQ;*PL\<?%R?==N6^__9K0$G)K#=_9N$C6GU6I)'I\>\RW.TC-M\L<3RK,D,\
M,^.LD2,4!YD6N:Z$TG/*^I^8GOV+:5R1'^, ^N ]9:_W:ZUQ3+@TWTQKUD1+
M/G633,UA],/IDZ\WXNI6WQ&JF39^#7 8E;C7/>9YG2(K?"EB:#*DZOY<5Z(:
M39\ M0[[=?G",K'XU09,$W/F$UWV-.V",]"))]7V7(;V^!N-LA.S3&T<D7@0
MK6>,1U8X_B'S_@'W)YZHJWA:XMY0$"Z"YXLF0-V#J:4%I?&C$!4HC$!+J),X
M<8TJ_OTU(^(OM.]-E6XHWC5'&^G_$@^\IVEA;P'E2;BGY5O6,G"MQ'%-@S/A
MM=LUB*TJYQ?K9B%S[0E3IXM#3#]VL._4/(E]K&:H^=#L?@^.<Q\P,CC.W;[B
MG,I?SEU'@_[0]@]%RJ"Z%]_N6M'..L@N)-Z.]R<X03I5!-8&2#Z$$=31<+PV
M$ "Q1KH]I'Z?O%2-84-U=/8R0Z*<#QM90BM^O78&I:RM<M7XQXL-MOGJ]Y2\
M)5%E^=C>SNHY]LQ5S\C5JWIO93YUR9:54DLRZ479?&GI;C)\T;< (Y(5VHJC
M\3_"Y7 1$G!5%[=+_PK71,NMBTIV%($ED3J&=]02':5_3C?4>ARZ]^-N IV&
MEJ]5TYP0=3#"_V"AF<SHXJOX/:]003&R@=GR8D>8[63I46E/%E==8U(O:Z-]
MA!95<CC@Q<XF_^9+UZ2TZ*5+0(%+IIT'LOZ6<2U)<<"Y;Z8G+E_WKO)5;?57
MG5Y:48!_]?X5 HD=2SIT*2*.>3/5U"NFL'IROJ+QX_'XXX1O/ZWM0^:O#;Z;
M*/(9$'(=82^?/0Y'^WV?00$$:NPPW<<:F!%.W6,WK]?SC4.GDM;> =9IZWI=
M]=*%C1">B4U<IB:>?;&V7Y]=\_7&B$!P)/Y/1)00_RLB4*.2H'&85Z)L6X/9
M)JV\7]6[$NRO7\+3$83,JK7F]ZE#V^ZQZ0\RD7FU4K4(.L"I#WW+/!!O4J=J
M?IE;&FN !-Q4UGHLKIV&9[ZJ80%"^J=_2KCG1!;<]E7!<9$(_OF+&":MY/3N
M37CQ3M!%W&VE'Y!0=&]XM<$E .^*(E<4ID/"+\A-_PJO!;0= B.=7>HI]<ZO
M#FD.F9/4VR2[58UN<%BV]Q#5D;P;ZLE/IG9@_>8TQLV/:L>K 1)Z-/1PO:/4
MOG"VVYD[M2"PU7<"<QY:^P"R2I&K&:)+$:MK;7IAP."KEFH,.RMKQ.4D5.PL
M7V. R:U8\QB>OTJ%?@FBP+W]$&?(,?/GR +C8B2%BQ%]\;\QL@>A.HW',<^7
M@%0TOYE5(_)\G!86]IY/9$_9U_/='+@;UQ]MRA=?>9MT-0C9LYL\O06GK;K@
M04P5+$WK&V]O?W,DF=QQ*5'<:%\HQ=?,F7L\LTWQDM\G7$.E= <(;"D&<5=)
MAIHE/=/13!L[:9Z"*5Q0X80SE/Y/8 HN#MAP@='!O6#X^P+%AC:"F&"<D"$G
MD;@Z9 U[]G$3[APH!32>$U!R5,?TA WS<L!_T!#M^MO5@\+9JBQ2WWGNT3C>
MR[%<,'?XZ'B@=5>#AD]QTNTCPERU<Y62!3+XB'?5.(Q4.BWA:;3%?)9+D=7>
M2_E6G@^^JXPS<BXGU3NMUA%_ *S_!8!#I(5CM_ ?=NN>+RDA(7IUZ//%*&=V
M!55MPZT^W_6:?88G#<"D!+IY$1\"RU<$K.6V@&MBOC<O 5%6C()81C05E@88
M*+G>I:=.EVW&>LI%21*_!OC.3=+)NLM)2"S!GW*W7V35&Z15UBJV8);$6[^?
MG]!8Z2?<M ]!OP13X$[4[N_V%S];.^*NAH>X#/X198X_HNR9%=D "</>=5A@
M:T;"U/*!#*TORYLM5&YON@G"'+G-;!^%?RR;LGNCJCP;?.\C"KJCGDF"JHUN
MDA,.(]_+GE%S!TK-/KQH,3J7WG]X:O^2:%/1;8[&U=2@\Q500Y5TIWBWIKGU
M/O,G^;0D\P)MSHS,.'^K?1$<<?Y((GW1WV-X]-\0>>K^$8#&/2+LZ (]2C+N
MZPA8SI$YLP@$O <K,3!_Y 0E"+=.0%A3YRA2_EK5^'G'3<S)JFHD^"MR%Z<]
MJ5)IC1MG 0V1L[T%<]W'X3FN+.(NJ!!;&K%BL03:A.GV7"0Z3\B(V'_V50HQ
M5Y)O0DQIX"5 ZPL#1F0D]!S]G\/JZ@1F^I=5?\IM)%3)89[,%*72$Q$(],SY
M:5L1/.Q8NDLZPM7=,%BXTD4@F,)/\($>IGY8MMP!IQ978M(.I(\3G!R#:7""
MWDQ)4<\V<L:PA*][4/>%&;)Q2&D.YPFH"/*KE&;!R_/D&WF+D2H*4WOYZV'@
M3G*T.S94T."??N2J\!G_I?,5$E-9W1UG>\4?[!,>0XJS.EKIOUW2>@V!C5N\
MI1]"=GFJC?'4?X9_">598R1JM+WX*L\/-1(;\!&L^E0U[4E75U?3&+FF++!'
M[O_"AVC53N]'\7U1>6Z17A.$ZU.O)+8!*Z%0D?:59+JEU*'J\<$#'&/B_B'0
MGS91/ O9J7AUJH==!<KZBD"3.XJR/F)G)YJ5[Y\VIIWKISC<J;(0VQ[FC$BV
M,;'>KWWXK")QC;#C(]P[+<\?=="9IALMKY6]J>'[2ERZE&DW;=C;+,+>[GGD
MG?*$G1/)=RF!(]7J,3%VA5"7N;+SG770R"/[5)L-G@$6Y];D\V-Y.);1OK/U
M4&3SWRZC,^C6_\ SWO0<E:,YBF78S!0?779V6NAY_FZ'$P[D[UL7T&6-8@?%
M3-1H5N#WZK@_Q/[*Q$^36[Y=LZ]ELT'1W6 \QY23O.Y 0\L8YYTVQA$2QS)-
MT:Z)F53L:<H9_ 9KKMG*SXID&=@/'TCNX8.='T(M,''W<>FY=57LLG^)@KMC
MDLLAX/]A<G.G%OK=URU+IGH48<;R0+ZI+]Q!R3[9+N2; )?:A\)X"\V/3\OV
M7(!$R\NMP7<ZRLH%!V,%(]7LK5U=.5L=8O(^J,;W#*[FJ ;P<JF267/(]"2;
M2 W0P^#:42EF2=T\O-T\-8U8GD_@3BJT-S:4XHHU&%X<*#;DR04Y\Y4FHHV*
M>E'C[;3P#:^/6Z_6+#0$%Q:T_$URPR[N_'BKP9^M#GM80F=CRQF;#"]CB=>3
M=2] %5LUB!<DVR8KDO"X#)XV8AG#<#$7O>KLP @UC"A5&/CWRXE+P-ZG2T!'
M2^*L*FPDF05L_4+IJLE.!R/",7*XXB;Z4]S8FZW(KI:K'+TW^"='I&=J#CD.
M1:MQ+["];;BF.0^=)07NI/D#7_<*/A\8$=&D@+- 6?#' MUAR,WF+W)T%W'O
M+@%90)3B&YQ_/'_\R[KR3Q_73]U$@[&AM_XLO_=[OLHY;SM[6JE"1.GJ'C,,
M1G8'W;Y"H/\7@3=&%!36^ENI",?J2T!(((.*L+7NCTM Q1NK@QW< CBRNX'X
M@OA(^'Q-"9G'5A[T5FE-X=_)5"KV1TX*D=C^=O!(5< !+M_67\&__/7^D=0K
MVV7!_VWZ=;5E@R-9MGZE[4$VS+G:2,ZQ]"\U3*\GVU_;4[C)<H57C<[5;'R5
M1VV(!=2]<ZGKEP#%49QUC.ANR"5 >>C1G]# D;UG#!?$$E3]N(,DJ"]'@FT&
M;72LA%MKCVC]B!1&VPA28=^GQ:W^$Q;VW\!+@&CSHWU<6.#N:K>KV68^J5T"
MA'YALT.Q!NU@1/RATAFE$UL2&*'#5F$9JK0F5?@'-TIBC_$8ER6<ETJG7JUL
M!_<VI<$K\AQ8)JG'EX"O4]G_[?[$\SOKD'E""<<Z=-J))>]2P3D;/@X\=!EK
M?99!M7I+Y:91A5=T'H0#?72NXR-U[!JGDMB]_I2L^'/*[+;D DB4 -ZXAKOZ
M&M=A@#]U,73XB^58X1O@Q2HPRG->#2\20JB?++ETENNN2Z?ZI=Z>\_,1_*:K
M%>ZRV_FKA0SLW\6&%F3#6+ A#X6#X0LH8BP9SD,&,["M=>OZ1,NR4AFB-8/-
MPE6-;E\8HT"V6'O2I'P)",:=.-VX7ZJ':,&+O7\V\_BS9+!E\6R7Y73T"/I_
MOXG:L:$<-F!@E^K_WWM\,?H)_U]&_[>%B^187&V)G;_?J@.MJT'E1[.<3E=;
M771#.Z39O$H,'5[5Z1Z*GMBH>&*%ZE[B-(YB%#F+_09'$RFAOV_%4:V-:^IU
M:A>L#'NG+;[:WH0TG7&DR4 R<#U7/98%/&%V"0#T_ME62JD3=!8%7L2E>VFS
M=7(.CGU7<"(*!KX KV^>CWR3.<S)TCR%8UFR$+47*JU(\BMO.MTQDI> PEHL
M7AQ6*.[(&S?XZG@QJ%3]0^G@6,EW*U,120&)*_% NPB#Q+=B%(\5'@[O=_6N
M/1(C(FU3CXT6V1;I5U.LDXC)QU#_\DBW(G@$4D#J7M?@G/)-UOB\$A,/,X?(
M+ R%P/#D =(0>9RXK*.=MXK_ 8FKS-#?_S4L]EGY/,<QP"J_\_L24)I^/NQH
M[=:?L)ZL7KLU,W<X>PEXW\)8-^XQKSB@'?:PLGSRZY0^!3MC:8)6^"<ZH6P1
MY3;B[#N4*N[NV"%%QL0NV'$M1?=DQL(/(=P=(G1"@R!19;6/4XH(WY5)QJXM
MU<6DQ2*WU V.G,,%'+PI> EXBU.OR+P_D'"%K0?&X+-AGDO;U*\JA7XXVK<9
M84A^ABZX)3^T1Q@T$,2 5"TO</*2@B6ETAO!0>HSSM\^]!V[$_/=Y/WZ6N;T
MP0#Y>F)FNA6:!U%J>B9HH/T>2QWH)]?38F']*)31Q=2.G%.,/B9%&_%))-Y,
M1N$4(OM/9.)._^;O]Y\Q< O7_?\9?U]/LI_D&I&E8YFUKWUU-[S?L3>!-M)L
M#UH_5;N-0!2G&#4W3%23?0974>P,=?6M64FL/&0RU2X$=#E]CV)4>4I,5["8
M%7RL2!;HI[M3:F6495Q1.[Z>_M3'F_-I202C,JLZ'AD?P4?WM[HR/",X:C4H
M_A>UZ/XGM3;DTQ425CUX0,B6$TQ_[#W^Z/JDI;2#_=H51\?6<ER6/-('_.N$
M)3[4UV)'^-CG5$O3)<B8?D:_^/%L3E7L*75-'G)D.QT!(AOFCC*87/]H86QQ
M7^/81DS#D2^!&RQ$N#"H<RO6I"%E?L@&5[T> ?_A)W\<VB4NM/4(UPJTX62T
MVW!L0#I4<SA&.^#S!_M$E?R\6_+G&?!.J[<MK&BC$JM-9I%7T(>/C5>KJBAH
MY#-?*HL]K)1]_Y8@08FTN4TB%%[1^MZL6\T*7DC662)4N7K]H]H:$7QE9P9;
M,'BQ-KCN+;-CCCLAI*0ZK<ZBUK%-5X%X<($K.;]-G!A?U6:?+=-^4FZASIY:
MS@1TB^E)#J.,ZN@DL'S2 CMT1M'=I)=?6CQ[,_&9ET/F-0O03RGJC%'JVCO.
M;>2B$U"M17!(@]7;(PNUI^5U32G +1:6Z_2(T20UISA6VS<Y:W>'MQ.N]P @
M(O^4"(Z/H#]\9$/.LU$T>_Y#SB<5YL>./<:^U;_/X0<3A:\JOKOI1_^3"C^C
M=UB::32/8>,DB]'DT8XJT*9":\@.89?"XN'E&6',GB EPY7E?ENLE^Y=#G;(
MDG;,DXK(,@>NJQ32=.!DERPJ]9E#77[QALOTMHEH+7$9,.D?@O9B0OXHQ[/_
MH1S\(8GV$36%NA:'@:6GDFRF_6E&7SQFK<1Q?<8X1/'F!M0/$NU)U]P8N]Q-
MGW)L]"*7IB>^HX*7C+6\(6/@'A$-,?$O0Z'T<T4T6!=M5NI#(]>(R-L<$4B]
M?R>4[WGNG=J4\J[RKRRJ=-8 /R-<]BE&D+-*!_1_::#WCV+R8!_^(YE:7"/T
MT[Z'8+*-VCFIZ/Z%LER_TO--[$%CW*)BR.T?:0GSN'L4.J))*P:UO",(^% P
M-Y):K=SC;8]NU%L6?F>J%E-]H?6L;J):3G+B967P[M0D@EKKV.R=O/!!SR"C
M",SK!Z&_?1I"Z6^-*!VMX3;],_+;G+D$0*XP&9A(^J0Y?=BMFCG#^D4L510P
M,$C/;+4.[,NRW0@:6*!#T?9Q=7<OUCD;;AG1:%"4]I>DDD8)O))93!#+:GPH
M=?>%46@9M!M,X3'"&*"0WIXJ+)&?S-5D^'6&9,E#O3^9Y-IKJP9ILK?2 *,D
MJ9T1)/S?X\(*[0(.A1_]&YJG^^8H&-IWHR9.N9<NN?>SJNM)<F9CQJ$2D3,"
M7>2Z7(6B_^$I%YY3"W0D+/G(U>!V1QO)Q![]I9QDTSA!@[M2WN)< FW6LR"6
MV-40TI-S\17Z"QX2:]SEA'I8SO_V:48NNVC?\"K!#>DR RQ+#J+U[[&"(P>N
M;/<N2O^*:@%YED+^Q/)#1QB,I_:5;42_/</U84&I0"O+=95<[, "\^C+JJK:
M28GX?/:90(B.8[8(O#E[D$IJM];FI1B'C>$^E-]W8.<28,=&]BBWNX!ER%"=
M?73/X[F@O'^TE/YGSE>/K=<I3G2?4"J7 ;$LZ0A(&>3OSCE_AA<JEX K7,]!
M_".KQ3D&NT%9*1_X9V0-]>.<L?8O0>?ROXO<:N]OPJI7QS9E@_+MDA<)5RNC
M.1]\B% =^^H"N.9/;6IY RV8ZZ/4FU8;]:*QOG[2DW>!R=L,UI9NJ<Q!<R?T
M/H<+_OK'1NM6'D7_?T_PZ;]D^$M0J.&_N@7B&N'R0!Y =4.V'5D-C>C3BE@*
M L\R4ZV181KCV-O ((K8M:/#>7/+B'7[1[*!15_Z?FS#1-<DYXIZB-R-8>O;
M)X@+SQ0-B*>T7=R3RO&[*7S6%"0UGX;(!Y*4FBGG$I/O6#N[MOYWI?@C&ZW_
M.>6^R0CY,KGSTS;O5<ZY==OJQPD4L' YG]V"ABH2.+0PHE2SEK@F).1V[.;W
MN-(V-]4/O 5[4VZM/(MY=J-<]?L-]K<YP;ZY**NV&+9N2\Y)B7H);?W^W4O
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MR:X4]H&C.\5CM)71V'PK_B6:MZ<E?M$":X8'P>(37("6MD/XEMY:!<G//VF
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M30*6V3]+D8YM:=(AAS-81,,Z5-814H>^+Q<.@:33AMNRVV]Y>WN-I^VV]\0
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M[JS6\($&BVK;F8/KP'PB^<XO' ]2K)A1*9MKF9NK$DPADUHS6XU<;B.C[F&
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M>K$[C;V/:=RFX.]R6V<=6O5#T@[D7C,&4=QQ9/_Z+8!KH5S?M.U-=GO&WBV
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MK6L^D\8>R_]]VVOA0I4+ T]'\@<HKF#748+BM4.AH57=E^)1L."7AS=^LXL
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M2#1A?MQSTDO7^,U;T\ZSE^79%4E,*H]^3=TH<W(J88-GW"U+)90T".L2$ W
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MU(\0LS24)  B@3"T#4Y'"2):G:3:6:TD%=EC--=KW^<D)U1D2BX'7?$Y1(P
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M7&Y=TQO0-.<7E+]7 70?YU[OPG%WL""M\OJJ2-TI%B$7 6'3!G0\Y^BN[[<
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MP_!T\!5)>+5M>S15X"Q.TH4H8P)#M\!NKM6J6V.#LYJZ\3\46Z1( ";S9!*
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MF%X$:A]O#[>MQ/#F7O*<,G<8V##.>G:YD(7;DQ>06LV^(7YA@Y$$J#IY[](
M_ [Y/M:FR%>+)J9:Y\W/;;$YOHZ0;-J7_VR44_>\Z-*I-]N-S.B>!#9-7U@0
MWL#N#^Y7O/7C@N,1OU5MN'([$[,^2]>72_%/2 ##^4_'O+7G6NX_H$B%C@WU
M$"1[^*-Q^)"@[!2_7#%O?X9:*J(LO*'Y_K,F)\/%]!@IJM!N;L[JEO,1[GL
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MGID4@K#5GYR@*)@L,5V>[P1.K(W= /=;(_!^CV HX" R'T1!.(^V2BQ/I_1
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M59N1F^,>]XKN.<BY+K*P&SCE0 RD@2S^'76RLWUKO^IV ^_$T[YIJ0W'[)
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M+]\<F +'&47F>R]Y;S?+Q[9^K:[":!H-B6'#3$-7'EUZ,R7J:"Z[E!"(_=F
MW($R&1?N*;?>SV\>.U1,_0_>ZF G&_ADO,/2T <DNNS0;$I_X?X4H.<GASE,
ML&O,"ZAC8LZ&F0KG)402!1UB5[3,S9Q[>T^+CRB$UQU2;0TO<)JF5M\FCZO
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MN.*;<4$H!EVO;6VL-%(>>*OO[:JC+TVC&_ 'S$8(Z%;4_8%PBT),?.J(W-=
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M,]Y"JQBIO*]B2.)I<(D_,%RH9_H3(K"7/A]=H1I\B_&8[W'>P_CBY(>'-#^
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M'!EVE*N:)(U46)&S6"E^06-(ES965P^;!7?&P."-8^F?;_!:6;;(U>B?"3<
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MW/6R!H]U^BX!=^3N$+9U"=]+MO1A@=FIB^N;80P/\?-\"I[^(B1R/W2F_LL
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M576!3[R/><28HHR(;>J[H'XN')2U^@'7_KTLV69S(P7IOZ5V1"L3^L[P ?V
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M*EW7?X 6_7VW^X] [^LF YUWS@I-5*%1?9='F/8]%3/,B^IU+MW8(@4!@\,
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M)S10N2@GG_#A /V#$Q8MU&,D'KX9Q;3%O'QM.6E9)&\=?VHHE]-Y_6X"'ON
MBQ%":"&&6!;;,H)[6;$N7I-%FFX6/3G4M?N6\L*V,%F;@=H&%\43 &YA:4>>
MNK$A36 ] GFJ!FU!6ZB,"#V.+IUX1XS)3.A7;27D<VNO?"KM/B,#!<!6!SYY
MJ!6'WW!A'9U[\)C*L4-3;%K'#_M+8"Q.$G1-+;"D085'SZ6]OU9Y!BW3M^#
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M#>ZUBZ<H>#Q?FY+2INC%_+8J<]Z?WPLAL8*KC8JC>, J"#&8LS%B'*SGX!!
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M,Y#RB<";#T(1+LF% 76YA1=?1CB=CNQW[(K%F]7Z["VO0CV7%PND,+/Y]+#
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M]. <."QE7PD4DSMH-7RC_*TQQ;1VL1F<>TG[YO9)?8S_&I9D]PXCTJ&Z)$&
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MCD?#H$V&T_YLWBG\5\3BC3D7S)(K;J"^G73^2BP0!7*?@'L\2?!UZ-G_NED
M&[[P>= $QS-:(K!H5W)=.2=6N9?9V$;Q7,!%>'B=!!' 09U$!("U(:M6#?/H
M%9)QDIJ1AQM$0)D ?Q5^!I&[VD9:2NWH 9Z9\96_2JZ_ _J9^CPGS/[-!'@2
M.ON.=6&PC";O !Z-\YC%(LZ@"X@ A3IF/Z\3SM9S<1GZ;4/6A_3C@7T(.FB0
MS-.WYEUE2D.1/URK<:65@2J@LR\"(@[@SOA<.18HO;>Y!Y:IRL'$Y!W7S^Y*
MO)'?%K9ITD/=!:W3Z*>/:H* -B!U-;#=S-?ZAFU4I.*N;>=V8#MPCVL#<D@
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M_(HRM,CA&%/6EAX3X+9/3XH_W/0IN;=RQ<-K#>]]UW<KV8T8BE_?KG<B LZ
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ME-2+R!#BC-A_MQ>L07-AG6_.SR_"R3;6F]/[64S(Y[A2 X,+UX/O7?8;?1"
MXFO!9*>:6'@7FM96V$ST:^9UKRIEZHRU2%SHZ4[N".W)DP?L2J:8=1Z;3&)(
M8 4?32K5HA2( / Q$"O@OY+CKP"D( (<!"]ON)]WI-GJPOJU6#2H]<Y!-3S3
MQ*6WVGSWU1GG+T3*2#SE/X#1.6#,/UK-SW1BC*RG?-,+OC\=$5M:Q(1.'1OJ
M=KA[2)=_[1%)\F&+-3X%*BJ<F$&MX:JAR),V.2"5QGLG7H/1?CP%NG@WI E6
MKAE>7KL18-J1>-7VZS _2OBJOXVQFP3UF?6+''!ML[!T+"=.:A?\>ML6I3]5
M$])(6>90IC&2SQ(DJ6?P'6C>Q@U_ &:Q"R2%U;LEHDXNV@/RZ=W\SHOAKJW"
MGG$I@=\6J"#-[5%%CKZ)17E>O$CSCKNZT4^=N=/TW%3L Z@QR3/GR]-]J_76
M*X;7CB'?$<GUV:>U8N/\(&2.G9'L$4OWV<&MYRSRP+1JSEF/C>BG9\]T+#<,
MX(LABR$;1,#AP.E-)ASPOB[2QMRYF7')@GG>$M5QC?[IKP]0+]0[KR-I90SG
M*2[Q>VA>V;B7\/XU8V4M(M%H\AQMPK/KLT$0<K>8B0"H!%F*/%58L_9[L?R
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MUI[8Q.P^8#:PHKYX8?TW]P.HK62/@;VD9&LG'PHR %(E4* +"5<T0QM8AE/
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M\PZ)M5@+AXG6J #+#&!9I6.>!5"ZSW:\^K+&79$?<%A2\;T<HRF%XIX3%B+
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M_HW_+1W1R/)[Q'5!2X!19BBE$:B88=GH"@0VS.^W@+5%_J?UX\#\]/^$.K%
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MD)_\@SS<[T]RQ.RM?2CCP_;*D?O0/!'#H4A6\$,(  <PZ=1?89_X;6:+@\!
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M(!0&9=N],*<E]. !:VD9=:X)IRJ*?K=?KNKU(%@GO_OXD6 $UA3QB YZ.E6
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MG13P^31:CRU*Z:I%ZR#[/767Y#\?^,/8"'ES,(HH'102($1 $3V)&.)5]'A
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M@;8']DS+F5K9RI=Y^B_G]:#&3_VO U+.5?SUKM#_?,#3]K^%""I!/"0%ZP]
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MX_WI>O:D;BZ0XNT]+JI/V5NOG#@2?ON,5ILJ$:U*&*&PY\UY#"JDG<=+-OR
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MA,S<$\/O3?E,"I/$M'W"G$X6#P]-!6S]'?J:;5C76[5EQLVO]8C.=$:83#L
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M/Z+5I,+B(-"2K_L^X S@\YQHGP60!KQF#;IL==ZB"JGBY#%D!\A'.SD)SDL
M<IR#;RU,9--DO+(]Q9/7X>Z]\]VYSV^A\OK&'GK"5.[/&:!5]FG,)C5UO[E=
MQ&$?CJC;"_!7C"[F/S:!1=C-Q'A"N'QP :\BJ_QV?:ST>5#0@)U?.DA%V88J
M>9>$3GY"1]3Y7:%4,3(XF<I,=C DQR3M89FO?U"H(YQ.3:PT1[+W:>N(9AEN
M!0IK>SHL<CG0@?I#2;DW4K5-*A'3YXZFW-UOM^ST)1<YB*6EJIR4@A^> =($
M7B]<(9D?I-P9G/8/AI:/QE0NWL(H:RD]>/&;=D2.]=:V$[8IHA.%DR/HKN:0
MV?J+>2;#ZB!.5UPJ<DH<38*E7EV\==>/W%NW(L<O%&ORN#;O]\R6&O?6P/.-
MFAIL U+W_:(]5C]NY5Y0Z.&BHL'/0\CR0&*',OP.A6WIBPO>OK4&9N/6.E'Z
M5+_G8U5#&RK4Y.6\6'*FXZPQSC0A9XP6K.4#;HH@(I?&V&[A(_4$-@I'I]H5
MVJ$:IX*8]K;EV%%EC;RU3+<$[VKI.D3A#_<PEG'5ZF/9E^)JT;5UB--*N[N"
MK]N6K?H.'__W%L*+QR=(^ /28G\$]@H\VB_495VAK.7#N&MUP2M&1=4X"_;[
MW$PSJQ)Q<2A%RBM2R$!A/I7+=*8W" ;L=7 7/#?D'I,V?V==L8C&'2OBP: 7
M4^/#Q,<M03="QK'6/G4>Q0Y'?7?O$HI>1OK_4!03<;.<-7SIEAVQY]V%)5EC
M9V/LR;^CI'O!='_RVP>>*Z2N'^7FY0?LCJF""AXY?N>1%)0U'NI!>ZK]$0 F
M4&\=WT<,6.(M@3ZXUD1XX.,T!IS:)E/=*[0HH"\L^9Z3ITVR*/"+J% <Q,G*
M=1&7BT";9C17;/.'N;LG+=HD-[\Q6Y=\A!R&)$5@FR%;,:S5>%U>_-[^EW)S
M%=.L^AR]:JC0L_LC+'E;2I\ X0T#0E5::/A)!E7PV&3C%%34!^&DFM?YBO N
MR@_H3_$+F U!-.U2SMFLO#&N]6]LJ1"RM:K^M>$3,GOA_@WKO)T6;&:_ZH=+
M+TM.R@I=Y%"TYTYT$^P1PP4[[IM>Y-(3GANJ@IH)6?DY>S7ZMSU*NR#W/"K@
M_CO;*JU#KMC( 90KK'7_R\D[^)5%-C4PD]L?@;L_(@6*6Z-+1Q[H?@5<Z#9\
MD3'7,-P=VV+\^\I_"<<VI.;EG^Y<T^"BY&[<%-W=#N5JF?X T%SY)'7M7"00
MN#RYLN<,\%Q/M8UL]$QM^_+<+]]@(Q9<QRO=&N-NUUP;L5@+K<XZ[Y-W'5K_
MZ9(N.5[MC?Z]"0Q#-2P3"F5V&;W"Z/'YH\-]4'4A^]^W_H=32*LQM2,Z=^:*
MTV^XU=9C$Q.R6?^I9()3RX\\EYA+?Z;S3EW#E8P9%67 47=U6'9SFGX_L T\
MJ33C=F\1YV0\_O'1TLW?RU_CA/&H[,]$I6EZ,7+"HE5WH^-<@O&I,",W<NO6
M8D@%+,)@,NS$I-G,B:XXWU?R:]^MQRV]%Y<B--&5/FA:9C<\M+O=(3A"5W9R
MRN])Q1%**:9+FRI>3Y'>#VR9 !F4;&C3E[673R:-V39EX^Z7U0MZQ 9%"SD\
MB^G2/P-XH8 P%"$LN7>,UK<5(6K8DL1<9*[&DA_>>-MBB)OAZX;A8CL3G454
MZ@E7R1<!K3IGS5F/^[DKT?6%_[2\$Q+O:O<,_6D_ A:X*P?B!O;1E(BG^&T.
MF!5&#7^B/;4=\ SGVL*Y\;&[PIBP\RL_:W;2W];.?,ZDGR[JOS^['_3H72.=
ME[7_6UAEM_-!DO=YJ*S[/:W:1K0.\]F_89AU4_*NASCZFQQQ0\[OL*<NJ9A'
MM92OI?@-^-MJ*$GOVWNH5LM,R,[R/AM%=WF1X72:P6$&PT'0Y30YUCTZP5J-
M!R@LC= V16;&11+'U+9C2#:+-)2B@3, ,US2%X]DW5B0:$]P4AZAS_)0F.@O
MOI,0(N]GS"_J>30S^]+*0;/:09 %&H^QJSLX Q3HT_ ]6$E>_8%21(PL,CPB
M2V_)E5)UR,6Y,27F54X;]OGV^=-C=*,-V?OXTA#!6'V6LK2LL>$H <IN%X+F
MI!S[$/Q<H*_U&4@RDE"G3JG1<5IO]!-XNE.MY_KLCGYOIY)0KKC$DQO0O>SS
M.DY]N>92>.E>U5QPM-OGS IZE70%J7(ZSQ^4M6,#N-!)J9Z,G[,E$N2/O^QM
M-Z7V0 TCX(ZL& D*G8.%<]EGBIZ:-IH>Z[_I+<W9A+SM )V\F5B>V4+BD1<V
M$O_Y/YHSFEAKRMN0NNP=S=U>=>7J[Z Q019/^@!"1W))L;1VG;OJRX=OUS_7
M(@3HY"_*M+5I7/?_B["G:GTZJ<5Z?'YJU%T(CJW'F)2:J)AP^5:,UN#Z?X=(
M* 9TUO]EG5[6M16:,2)!]O4IU<>WX7YI!._^8]^F46V=YW^+OQW::VV#/H(^
MA\6&L.@#A#NOJ,2:\0#+_]E/J6QD6^=J6V68R&E)5K]^\E-.QOQ37<[/_]'M
M6^JY;GO9GNLQMY&PY[*]XC*W_F1 %6?X2G?<L-\UT4/@!:M6%[IF;YMM(P?1
MYYR9+%($.YJ#ZV4/A4[%C0Y]TO:]Q8@4;/U[&+ZLM<R/]B_Y)/W*(O3:]^#Q
MHO;=Z;6[00T9IKF*9%0QEF2&2A)1IL00 H$C!!03M%@@=?7;C_M/(>:%4UY7
M?TO(9!D2E%60SDO80+:$!5UR,O&^VE.&+A'QZ7^HQI^*<_^(4@0"2Y5@<L%S
MATPJ&5+US\$SI#UKP%)X$"T)?;KX.P33H<@F!%9/^74H>'H)NH3DH!POZ254
M4KQO3H&,8H I_FO1;E+?S*KME:"AY</]98ET+[WY1MB<=]R@MRFU>#!%"AT/
ME\-C66"9P"N+&Q'JYR#B7VXQ0W8R"7DJ%_#\.F6JI9N98W@(24#_T)8K3O*5
M597Y'F1^VQ6WMT@=];L_99I3_74BN^$<X7GU*8O'NI1V2TX?%&W84V_'G73U
MW<UBWDFOXVM:+#\8AQ\4"%UY$OQ"*0?5H$=W.HEJ0F;JR<-";I/SN\$4(ZI2
MM([D?OD9@'&ZW/^W:$8!4-G)5/$KEU=RU/$Y9?:MW>L/,:T7N6[N?!#%]WUD
M)?ECHD, #E@ X<=Z0=(@C?D#1:@4,/V_D0P/D[P-L\\^H3\[?BA4Y4B9^8H>
MCP'E:>XA7#V3N+7(WL17Q[=A<\;'ZCFU5(WXGWROEAM1)@WW@IR=[)\XVW1V
M'C9\^ZX,_8=+Y8G6,M2;3O?6K)51BPC4PY^\X5J4^/5P?NM\G8G'VF/DGOU(
M$9JIYM4.\F4,^V@@VJVWMN-(LC-WBIX;<KW29]!!<TB(*DY*OG=2&^/E40V3
MNT6)KO([@N\V#@CWYZCMO5868?DPQDG'WZGY:*Y3,E+KQ+6D[<:K]Z1_Y;?+
MN);FMX[ <H+V78;OIXR'^LW,Z@>6(>E@;U1F-CSP.]6 < :X!#TZ;:YUPVVT
M9^RC*LU"+K?Y-JQ@LJYFF(HI#E<REK$J02).%\%7$')419)Z0BW\NK\A3V9T
MBEITD;"4SN_X6;'Y#C>R9@8]DWR0II;:GD*D-%&:U-IW!N '<?(F@E0(13&7
MUMM?]B^Z%9MYJ([/*K]8YRWEC+TE?A7Y55MDID@^0"RA][;L#:QE^-B(6[LX
M7?S1%]G4ET5/CD_)V(^0S+W%%%0C-@%D3H N$H5#[K7FF16AI30QW=)9MWZF
MUNC9674*R\U 4928I:<J>'1\J"6SS^"/]4+SLO 7@5H/:Y3:D.'2$BAKZ%MT
M<:\IMYQ%Z%3)W,>=CN1*4^4,S7X+H@0"^$>/EQR8CH42(>8D28(C# ,]*E\H
MTAED9[JO,M8:S'?XS  1F+^ZEC[30KT_<P: 6N(L+5LHT?54G8X)>7O8Z%#C
MN&=3R^<LR^'Q7X.KRF_?+,K1#3+PTPK/;)T!CB6I]B1+8B,OLAE]Z22M&UKK
M-R-][_1'4\Y!B/Z3!HV\[/S#].=*K>*@97JL(?1OHSSAS:5_;Z[=+B]Y?] X
M4W/H __+2:O]<K5B1;"U8L89*/$'VW#G%'B2&K;]K&5F^@Q >@DU;4]<^6N<
MN)WG6'Z'@7]G($LH<N"F"ZTF.J>#;@$Q>09H%)W&"..12>VY4QWO@KR\.GZL
MM#4G/7W'\L,B77S(UBK[:]DU M;I#[JX](W=,[_;3=P&&E^W?_W;N']5FM\F
M)RVUY0UR,!H2>P80T.,[G71G(\>D8630L(_D9JANB/UDDYMV])^<T*YR?0EC
MFRC D]K.9:'[,ZTQ758=?+ 1 D,*AD8Q$2-9#\N3@^HTO_F7H0XM?YZ?'MNO
MIF/2U?]4[I]LZOS:E-?S\I30&55.=XLS0&[ZM N=:>C+-V5_@\\ #(\#0K'/
M$ R-F-:\\9U%_88D:.3WLBSMN;=>7J!X1M&$03&L&D(.,885P#XZ ^"@]RAQ
MI-V>]OP4A4>3 6K">KMW&Z)7=M84.Y@(Z3Q\K,,6 )#RBRA$G94[@EFY^%+9
M:DE99:FE1RW'LTPQCC1_S:T?AVKGEJ%W4A'CLWAICK+6C^!H:VV9D.)ICTG\
M]T4/TD2CJ'RWI0<>"Z_B?[U604^#KL)POZ/D6)][1."&G@"J&[>2G$)L8A[5
M..;9-"_4:9-@/5:_,]+6*F-]0VM(N'9+6ZZF)41V<GU\WT_VBK7]1 "*=-=W
MB5MK&$YLD]-!,9_SJ<*I, R-WT\FLX*Y*!Y.I(EYUUFU]DT!>$O2_5IU0KR!
M8$/6Z]!!M I%FH0<T+:D<B&MR&H'\51];WP+6?&YM-O#9=,W\E^?&,'$@Y7,
MBUS;B5I=OY0F'=;+N<I?3^:Z&K@;'/_<P2K(,]-P7[JW2CD/[((H%+;5:"ML
M63>:X(7M0R=.HR-K$:O033FM"_-&(:P7(VXD9/R2]3(:?3G(("W$\!RAB)C%
M\JJ>Z/3<@&FXD_IZ561R;"?^16=<=TGB!WXI-N1(').0FM+\8X!X^\/!2/NU
MS.TWSE;_0\67*B#\%M;/?D6V&I-1M##% 83@2=&>+G! 3[2H7T\%9?99Y6Y6
M+7=$2KS+0/.MG$#:X(N-G', >-%Y3.J@."U;)I\!V.&^(00D(W1!L/73."&3
MO_FI<K1MUK,VV0H#P.N0.$@IEP.7BDQWAA^H]J %:^;R42/OBG*U101BR2$;
M,8F]4')2HG=Y8^'*;FG39*OD:E'(]7"#,)%PGDZPW(5!8WZ:(>[-L%5P4TP7
MD@*!,.U97C*H'BK98"7/.VYPK!UH<+Q^]Y@]O-AV^86@^ NY-&:PMSOGZDJC
M\W:@3IBVG%'AZU+HO/\OZ@Y%I1HQM?CQ:,.=@70&Z*G3M_W8]B8=&EDV$ND;
MJ+0T<KGW;A5-)UB%:UGS]]J GC1,IQ_!<U*IFA8HLBA5N?Q4_]X'[.2SBR8K
MHZK/1]CENJY>8E$<UF:)93J2ZT$QQ/@O)B0MWR6UU*K7WA_M1>%:-%Z08UF@
M41&BXC\<*M7&J8"39Z>2T/]>%XV0HD(G'T37ZGS:'LWY53XU^HL<M\+@^=57
M(%<_UN(VL5-H9MU,4)]-MN#5M[QJ*I +5;A^XGH(KIVL*355*D;6#R$J+?\[
M;40)(V"?:P-[!JD*^ SO7C0T)&J&N71]9[Y 7U['[/DD\1NKR@Q]1_Y)?FCT
M&8#M]-OY177>NG_-?-(_% JKE]\6\ZE([-ZI3Z>QUF5$6Y5@]:HS<^\*@P0S
M7_@OGG>VU:>J-X:Y5]R/!BE&^\235+@Y6;S?"FY!";AX*N9($$@JS&%\E(L'
M& 0S9],$U=0XB%+36J53=T:CES6(R.5%1I,E)CA-K=-0"$UCVW3)=^F63V\8
M<5WU0H=RGSQY[E7FQ,OMT:=NE[ZQ>'/-NLY434N/9[IJK3HVO5*F^SRIS57O
M5&Y)'U]U/?TF IP,0U_!J,#&G#/$"J\)1CEV5@8]T\07O.813Z^)>^U)[3HV
M/QT%\W1P(B9X45P(X3^\"Z)-GZ<LFKV#2W&"U:*?PN?EGW3&MC#SK DZN51I
MT>[)IJ9J38L52\%>E4NK/2J>WK*[2R=CE<&W/E+CO:(QD"&W_^ZD$G0A#,E+
MD=HT_:%J(I8]T7,4D*L:P1O!>N?1K0"SKZ:E2O(_[2[&GENOQI8*7CBB"_Q1
MI+0"EF8P&7K9Q'O24SVJO"QO@DZFYW$0*YM'ZM&W1HP15.$,D-QLYL,)WW4>
M$8*^4.YCI)7^-34SNB 6WUT3_,PVQW[])$*JF,ZZ9E.K3<?%ALR[;_&]0V(#
MPGF]V3)1V>@,P.2=_&\VS*XY*_;85<RX))M=<,6_^\%.MC)-UWSJ_E@*SHAH
M<OP(B@,G4TV67-"LZRV</+8YYD7F$\LO,NITAI0\KC*_]E?HTG%879LZ RP5
M+WYL[0/&+0JHU47T+_">]HW7@\!JZ0Y '$^K8 6TR)NY1<8I>43P=5:F]H[<
M/[&.!-5O[_3Y1V^S%YF9! 86>K]*&%FQ3JPQM?H\Y1^21!$G5?0LY7=C62F*
M%CECR6:MLY)=;A61!?EY=\-_;0T(Q]$V1ZA:06BMRVI&OP40-\;*TVW%2H6S
M#C..>>!BY)G$F,=?C%RF_WM. #0,).JV9YSF@GC6HM6_&O_A73T/;T<A!MR+
M!1[E!79V7H).D@="/UVUN[NZ=#:#T",Q25@&3+3'N4*X,&3)L7B042!^FIQ9
M%ZH6&5J4V'0#DT\GL9OZ^&=7_N770NEAZ,E4F:6&G7-*\Q#<K8UBYDAR3*:?
M;W,;*\ NE11SS,#]CS5^K1<+_P@3CK'VMYZ^Y5V.,PE1NN>BT$"C*?Q-;@3K
M=0:8/>Y=D#]Y1@TD;;M,*%(EZS9PB1,N!N]G1QYWQ<]A[@YN"'J 8/(TRYK?
MSI'.RMGZZX95]WM5GO%5;*$4S/A;8YUT>S-RR#*>^=CJ=/@HZ3,^AH6J-AE8
M.EDN\G#>9V<>)]')S6D4S,FXF_[$M;K[M[U]&PFXG'P.!#YH!LIV7P?G#,BE
M9J3:D9)OU?[]WSJZ-"5O+>0V\1(W:RW[(6_LI>5T@9/8DB^!>ZGPG:JJ/BTY
MD\V(74WLQ^7A4J)PWH+1(+!E,18!WIBQ=Q>EF!#>./Y9#ZB.P)\HAS5_RNB2
M'KVMWA07QV_=%R=T@94AEM*X/$,,(PMV'B%C]]@2-5)$JJ%2;R*J%1/K2PH=
M?ULC7PEC<@<]=NGX-I0@E4T.]$!U6]_^UW]NNWY6;SZ<"RFI9YK,>>EG @F%
MIQQ?/!W2KNS$7H0E'?<WW%%;Y#(24EF_]2P-^CAN(&^KK%;G\-D'?@ =_S?H
M:H;W?LAY[.6'>WXA@[OK!+9[<2P+GO9C'H]G%OQK;P2*K=*=K-HF'B9?K+K:
M'G=4;J =.2VFMF%?]3+7,E4Q4/&39/YX*)ZQY77X4\M1R&5WQ$]L$[!W4^$V
MA(A,/').3'T$=5(]%H0E>!6X?#4SEY;F_V4!&*1%CIMI>K8VQ<MX1U=[&#@4
MWWQ7)GJ_X1+@XMX2S=B%BI)/#9\6ZS6K)M*YPDT0@=4_DGN.F1<LS ] G_>+
MR XI5"!)H\_AE'E\3P'29QZ@T'3\5';J[W4>$U>CU1JQG./F1PA4#R0+RX80
M.?T.9@:Y 5-!:J3M?O4HZJW>B%81SCSBB]:%^U)QG1YC7^DC03O0 ];4OR.-
M,5M'-F75,B&!B/DOX*]K??<1S9JCH[7^'CMCW5CA&']!-)</:<,Y,#W?(GN'
MJTT9)B9AQ1$$5-B_U>0_IL6'GAR^5B\?KLXWP'M)J3)PQ1Y;W2'()LNT:SY\
M,L9Y\A[$03;J1[%^ATN3[RP R9?+*HR:4\:!K?V&+ _M^3.ZNFQ>L(D6/X-[
MXV-PS/L#%.@[Q:0 A-#&@F0ANY6:FTW/0?X,K7S4&.<6W+LV8.G2B69)2_>J
M5<_XOMJU?K^#*>A!ELNE#4O<[=*TG9_4G9,DL"<$Z OFJZ!\)O,,-3$7X%:C
MS?6\[(H)!+R;9U:6Y=\7\LA$T2O&2S3?8JA<C?M0\D#&J:3/J3H)F;3'=L71
MI'S@001K/K.K)=>/(7%ZI7K'6O&JP8L7DG4-$)D_W#C&E)@%&NKDRJ&AK8&3
M0RO_.NI)!^%?MJ?7!A?IPQ338IIYNQ93.O@IK?@D$G31]\?ZD6VCK_5L<D3F
MO0FNK+0K]0U*G;19K7._(0GG : ">]YC!* M(OR4L"J_<^C5N=\&V:K>_G>X
MS[.SXO1 ]()&BW+/]H/D!T=K!EPA2 ^B:%7?Q)LO"ZE=(#:PQ.M%U:@],-^Y
M@!5C(4UL:: '@00L'\S(E<R*1;NDM7G\")T-&.^CY<JDOU$K=L..X9$)('W'
M'(%$X("-+J?CV$OY9A,523.][;9G /\)J==9@BWC:&:1X66AY20[8N'!ALQ#
ME9J]<L/@U+3R:!=___+/OO?+\R<J:@Q:)@_:#EU(R?VHYK'.,=8ATJ8^);)Z
M'G?G6UZ.GX!\/M-#Q]^'&I>ZKWQ.>8!I_UT\-4K5.GE]J@C3V>\F)9X!4C%*
M:+_QBB\>U7[%HO'=D5LC(RNC<FJ#EO);WEZ/&'R\ F#H&3\Y],G][)"@4J[5
MPO#YULF!8R4].]F,G2^L1H3%GCE(ZB(+U0S/W,TC_+#?S$H\9D1#7 E+I>MN
MQ4-248W;W8+;J2@@2(5T1/:$>DWQ;;#7KH@G*1;^S@QB,FY9:YN;.4?+Q1;I
M<P+U?>/11W*!"WTN.N5@GE<0ZTA=6.UG\FB_8H)YG\.=2X,<7A&LTI5%;0&/
M>390C7O?J@G; KIEQ?+8A*V\Z;RQU;J7= E:WOTLF7:(;8"BS:>XV3Q":>[*
MGI]VPY/"@X=O<-%N^V> V =I)>2" J.L<N&Y6;3XEN.R8ZFM 6/JC9I2 ,U/
MFZJ2#J$C]O_/)Y+_=_SO^'^CP_GD(\:_CF)$2-Y:IL]'^PDH))4OPXC-FEO;
M(HSU=?N> S?L:2;:[ ??RVVGB,B<-&-B0O#HQ 7Q#A*J:XQUX5!$E#R=$?)[
M89/7F%900<] )UNIS<Q">VU%P@/&\-/6X075G'*(MXR-$.$EI>=UB)(A*7O&
M=Z,<DIL<4=93UTN> \8_FRZO"*_DW<K)-NGJ4V#;_T"J_[(4(PQM\%F0:)X&
M<3Z><=Y.V);G$?:;NOCHWAT%42.6N-2/;89=/0* _7:Y$:K)L0'%J ?<N$V]
M;K*PL=9]N?Q6[9V6'Z6NPSD7=TILY7E''V5Q^C[8%7KT!6B.\=>W:&Z/]GU?
M#,NV\7_"9<9QGW7@DO$OE81X0R.;FSP^Z)=4X/$].)AB1D+VBZA@IZ@1=3#$
MW,!!%/?*6(IDZ@[AV\J:X^R#GHP6JYR7[J[7$=:P^G.+:^%-VML&4J*[H[#/
M0/Y+:>@K@0+<!ZFAP;[0ZH_U.UD?LEX! W4D;0-N]EM<HUWP07.1#XA.^&T&
MRNX]DGL&'LD#OT.^GL\2(=",3&B:_'SZU82K"1&-R2IIO#:8?N7W?>(J9IL
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M?0M*I-D6#>>8Y-!/?S7ZU-HMI)P$O P,G#@L"P?-A$2C  <;<F.G3/! TLS
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MU4LOP>00T$0%_%CBZ?4)ZE76+#1EKK^UI7\/I('7D6S'9/Z\80/Z/"^>JCL
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MJ810O(\C-D_9IIN_6%J34+WF=&HHUJX8V*[^@VCOE^W-K8;2]WWFOET-TD8
M@)8_(*JG$R(R,Q@K<N/23#>8&>J<F1)<O6%)@+#/KVM8!LKZ\G@4./U(N%AL
M[TC9;,I\#2P-$[X]9SSQ%XWV-H/J.!9&KKW >V3<>O0P&D #3@0XE70\;CGY
M3!66S'M5[P;3&2CTC@O3*:BK _E'EEP<]]IUE;#V-'WD./_\$I&=07S2(9#L
ML5] FNG&\JTC6,WEW,GY&<URCSJ2>Q#<'UUJ^YIMFL:D#HP)R/";WL'9C.<A
MW;4$,X9'$R\OG0%2BGG)](V!P6%O-9)F)R 3<'V:CYAQ?LZO@4W] [\%:>XO
MY8I>X5N:>;..;8V(0XN/-YMA+\,F#$AZ=6'"Q:CE#!N#G=#HY*R6WKF#5]8:
M(/GL.S5/S[5QU0"&[07B2GLZF,E[8_&J2%98*0&8)N\_OFT]3@56ED^L-VA^
M?83_G:WY_<.*3?"3&^%+J;7!QP\I-'HT%"1AZL,4.A3,.CB-:WF9%Z]@/;SB
M:;RPX"CI.2O[BBOWD9!0/&R0H>T<S&9/YXI9\WO=!9JPI($,52 ;I?!0E<C9
MAVO)^.VKL6L<S&BD'%DEL9$AX<<7\CK$3;IW#!?=<VX\U$BV^,<874*,, R#
MNWQ[V8B4][KUR>S<E=NC.CHEAF7Q (5/Y-@GRC1;M@X#BXV*1 9?0DP*JFDF
MM3F&RT^\$\>]^B;X M3Z;DK9[9:[ 1[L)E]9ZC.%+R2T65Z<@; 19_#7MOYE
M>-N1+)$8G:4,>Y^'3>3BNI(R9QNF GEEI2NO/#)&KL_ 7@HE?$^X"32Q<N<E
MB^^WD[9[T*D35 UD-^(&.3#=QBS-$6E!FBX2'BJ<G_]1H&(:%\YUF)8+U*:3
M'^">ABM2B"5P6[)W!ES)MV(#)X7%\Q/?33:=/.0CO%3H%?/QNIFM9Y6O*<T@
M>X[ZQB6?+!.Q?$V!:1.P)I_PPF?A'8+3?U69MJ\OWTG:(%PNL8^M;0BU]__\
MW/U6Y[+:$@2(]0GDIK#M]U-,\,(:/:?R4R"MX ?5K@OK1PI?/E^OE<XN4;^]
M\\XK(40E299^Z>83>H#>IQ*,Y0"J.289+KD\JM]5*)T$=R+S]A:ZRNC5>2W-
M:UT_ S1R=%V3CLA6=;BO+'ZQ38A8/X=GZU=D@0>3GL!RNEN?C#UJO>+T:V[^
M]G?7V5_]P9(8\HUYH53C8=0]PUL78\,G';*I3TXJSAD3O"G"/@$W\:IS=X55
M0(O\M4*C%9L;S5EN]1IPM^:_^-@?Q_WQJTJ35R(D$=M,'T=6(5P^I_?K& T"
MDA;6/]WKYUM*^=BE4-[>](M]E-E(XOD&7R)8_=:8D! @6I*;S$9\M<R6(J).
M*0_#0Q)%KDZINF"31?AS^@O1^VXC_:T'AG;J[?#A9Y%QA*3PG;'AA8=K%7*+
M:LC4\TQS!>SYQ9O FU1?T8BT(3V=KO565>8JQ.G[$&.'GZ %XY796##W&!JL
M(%?. %TW$#*PS[WN-#,@\>5M]@T]2?+E=.>8YX^;%9Q7S5+6)IJ9[?*45HW-
M-#-M7S&-,632RQ60D_O0 K#*TTL*2P_*8;6VC91@W[I?E%M-T3J'UF/W,"T3
M"ZM_31[:,ZY(M*4J%H@\T%7_SO#G,O>YYSX[Y=]  ;%^BCC6$0=*)5FNYR@P
MJ=E<>=%\@JI"J$UC]LEV$?U[T<\T_>-:K);T=#NSX#8_8@C;Y-"SS;#AKCUS
M3A8W*,\.!,+>%\M_<JDS,IHL1<+ONR9>EG^2+NKPF^/U;^%.X'VKNWF>\=)Y
M#H[+-YW>9%Z(&Y+8Y]X%=YX!TENUU[I1*> FH^=_FUV0EUPE]TXSWLT-FL[Y
MM >]E!N@5:[$22N-RGC$Z_>7M[Q5I?DWSXT7H3MI^#^<O6=0DV\4+QA$06FA
M(S5*$96F]%Y$FHBA=X@*"(@004J 0!"DEP@(_ 4A($VZ" &D!0A5I",EU 1%
M.@DE1@AP\>[<G;T[LS.[^R')ETS>-^]SSJ\\Y\QSU,56H)<WPN]F:9/ ,>KT
M+L4(KS- EQV!646J_CCNM:FYL*BG8.=3P&PL+I#[DE$9'CQGT:5Y_0=<C:44
MC^"ER!F2)->]"F"QW3AM] 3ZU@<.3L]KJ=F*;YGR,UR6J"KYP/Q/-=<I!<</
M80A\3;*4.J]G 0S9YRS7A#X.]1#BJ#6NR EUFKN_+Y]F(&#H\/IKIWB^ AA\
M\CF<=P%^?3I<Q/GY--^-Y/SY=E2%W?-,)/-)\L;;DG'C<(=AL7>7'*/R6&2U
MZ=%FSM>7(;@1[*(D*0:)SW7O:K]#"2WWBAOY>/YG7(JE/MB7_)@?8"Q*N?@Z
M'"IM@HS4M%^1UO*HH:>*D'BV:0G&+:@XYVNQ7=DI[[)74;ZB2M8A+[/%K,(4
M07<?W*.-?2?DQPC0S@=^^E2C3NDD#6*7Z-0%BRF)%C%_K&.M)RL/<A5'#&U_
M-K5]_?JR5O3) N=/MQ1;>#E80R+C_T_5ZYOWN6.-Y8%<"@ F(&L8P9<]/^JU
M9V_0IQ#&75\BH:*B4+NHM^W.LL;2<F_!0ZCZK&W/ ((4#SXC);4(KDUY4OX\
M7&4,'E5MU_Y?@!?=?Y7?D)Q)#&\'FGD?M%]E_V\8H+G^,>%OG]G)5_7;#4=3
M904PD;YV66)>LOHH!%:!/9(U*>D=_?#PVXBLT>T;+,[R;G^-!BY$:*9\K*6"
M"-OB?8N<X^I&^8LW"C]N3-4NSB[H7V;O$8ZQ[@1$12I?8X5=X]M#Q*'0C3'A
M0E1K%+Z1*A(N09))RGH8:]4X =<J%1MTTA7I+WTB>],ISTYR_(7.5^VGM@R
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M/@&Q>!)-XTV3#OUH:[31-DKP 0SJ1J5\B=)Y0JQHJ?Q^ZD_-NPP(=XL@M!G
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MJMVE_7R3KGUB7'<65!VTQ6A@^2SR*:F*;86E.E\IM5MRCX6BCQ0BF:;F/5Q
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MV1F.\W9<OF92E)'%7Q?C8S;Q4<*3];K4>>5!_^)F\#",RXAR"P'?Q,8@K<J
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M?G21&[YQ'>V GD+'H_CJ:2S4F\<5:@0FW'H[J7'F!#2PF#\.=^1MYN,8UFX
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ML]SF_S,LYJ!S:,K&I_GJFBK4.]@A]DT)V^Y_$6<MZAPP?I/T)2V_+:YE4F-
M\V&G?MNRQ6J(&>_#.#-25CM3M.H@R-O<OBVQ6PXAU:O9TIJ#5^+W$#S_+D#(
MY&QNY;M>'[6&E)UYD1B5%.$,Y=Z:UDA-XGJY?ZG=,B+F;D>Q;;/&D8O9^@ A
MPIO'>A+$_DJ"[M.!?8K*KY$2]C$YK5NDRYGX.NT-C_SRW :G2UG@YL_VDJ2_
M"8,B&A<EGKZ7-3"[Q=CL 7J;)/W_A'=C&2<F2W-8\,S$_A/N\V5%?5$B>KKN
MH7[O;'I#/+5#+)N&&ONU%44D]04L+84Y;C%P+EZ]"N(VU_O?#'LF AV)WAQX
M2#08UE&>>=SR8>[W#?&O9JU)?VS>A$JD-,:?&QM\>KV?_N#?0\+_=N**5\#D
M*1)3?[)I KF8$2-4@Q AI)4LJLOWA?ID%.Z(4\+O"IW;^#F:+K ,)T"7OF[1
M8BAWD$(S.F+?[P:N:%6M.MJN&;(T%*G<F6XB,C]0$:*7M7BO&D7W_;=5;W'C
M!I5;=P K!/5  W>0>B7?;4VCD7>N,A'CROW\U*SXG%CLG,:FY.2X+AAU>E5^
M+*'[*#>/A4\M&P^=@!I/0(E(5CQL/U7N$: 7@<A')?S0JSVH^OYQPE]6<XSK
M\?VHH4B/L1\3R5'@2@]T;K=:Y+SCY1CR<R" &(,3J4A$[]ENZSY:^'-#7\;7
M)Y"@%C4N^]+UIG5)B("W\ #CO5*(Z;JCW??6@+6U*9&Z6L[F)E/5YX;3^C:O
MTD$@%LG?@R 3/:359CH@'5$Y!%[1O058;/(''C_LR;9;8YV,]'#E6K77\Y/'
M?AM&G!$SMPJXN/:+9PL.J3O0#L<5:@PNB/)TDGBSX?C4VY>+IN[D'TEVM:?J
MYB(V%;KFF+<EHVY^7H^+TOC_K+7\/QWH_&[-R)DB*0!*>8 4(BHWS,!Z:)J>
M/I<Q1>L/$7E>*Q;._M(W.\M;1Z1-)U9_*N] >:";;VP/HTY /G6JN!L5F64F
MF]9_%+0,YH,\2U[5.[5WW-R0CS87C%7$J'!1VJ$@<,<W] MM?XHE8MCTN 9C
M19SJ[PA.]L=ML"(4MP;""B=WFB<#V^18$%OG&ZL9+MMY1S_/@#$\,8BERAW7
M0WU0J46L322_:!HG@M6&>+PR*JQ1Y)?95?HT3=WXG1R;2N8(81 4F3D-XZ)]
M@K2$G!;&T@'9E.B7BC'!0=@\B[E:3#E3)<RFRZV*QJ1M?-?5366_47?^>?YU
M\O$O#?I6QP)2"/EOMEF+\52T(T/29+FY6F(X[\Z]U '4P*>?C.&"($ICTM\:
MV'$%YM8;VJJF>^]?GV8/I @T#F+_8<[=B/?'=>Y[I@?:O?PIS+W7[_WY\E[G
M/&V^2.NX(E('SEO,'N@CJ/1L723#UDM'89[@'IYZ=]NE.=C.]8[ 6>5V.R<G
M@R^&6V(06W/[X8$#?@<D%(C @SD_?].,3_)K7KFNJ/#;0?%RUA>RF8YAAFP3
M<C+*\.&S[)@4J^$V2,L):!C]?)1X,(CEP[#C%%1['%7GMF;Y3&8B5\ZWES4O
M>73/9!?&YO D6IC=7Q6)3P)1*I+^&N,/"<HD+4L 5T^5!41P4^>]E@]B?Y?/
M!Q&,!TVOMS[X)BAG_8#14N5]H%AV2A8SOX)C)3%]2Z>TFGIVFAI*@AO$X*[^
M?8[RLMO+,X*?[11@\+SH:<V?>]LL8:?_W9/X8/HK3'7F%LUK=V=M9^N"V'5V
MA?98/V2%A]=X,F2:"('&OHT9NHI%,V_&6/ZO,/A_,+I#CCNZ=1#C9"] LN@:
MT;>@;#=[Q2N7O/AIC\-8$NXC%K3:;=^0L>[^0L4(HHS'=)+WCS&86Q3-SU0=
M6'R^97;]!I _%F$+(R2'5EC73G-F]NG)<ABZ2V;=Y"RN E'<DOY"M^()*#3"
M!^I>@XI?T+Q?6H5\A&F3O6IXZ9584U 4)GEG[*4KY7;QR\Q8WVMHJ7FL-V0Y
M?0@K$BF-D,(I]:// I6F1+>JA0=&8;8L6>(_Y?66C;_EO/SK5QC3=BOS)N0-
MM]5H)!B8IQ@B_#;10Q ^ZC__KJ&7>H> Z_D8]S=X_F3!83(O?@B]@]<:O3\O
MPP1Z<W&%@4S"QJ-:I C]).?>,%BRMAPQO,<6'?]'S5-!2?M/_(39_O/][(>6
M$)7WV^=?T!TIZR%1)"RY%&@B:N!,>PN-8<2-^, 3D!"BQB'>:/'WT@.C.@)]
M[E2&TP>)X#.O\_PG'4^OR![1NK>UD$J$;5JFEP*50_X-Q0/Y%2W",]\[%#[0
MB^NROEG7.#,<3"?#?_[@.>AH+"ENTE>BZ9GO3EIX>>J=&5V!5!'2+Y[;$X^X
M7I\9%JVL0P9 ".R4FU1[X"\)UGL"8J[5$:R,H[*'^_USN*YH<M-8?DK@@EAX
MB.Q$HYZZ_N"R>DSV*(BBDO07NP49G$H396\"_'!*S A68Y+4 )13O]1Z<;)E
M#^%LD'D[M/9'S 3SP&A; ".= 9NA;1WE*FUF79F4-XA.@#+39+XMB^9M;3 -
MLN_GK0OD6L[ZUI7?>?+HGO$;BUR)T:^AN.",FSJOWKZG0K;0[-3;,_=K<#".
M[XZ79QE26;JF#YPZGQN"+FD,#8: ]/4#1NK&_AMXVWT/^',".BL/.%.TD _F
M,6?Q)JR#;1U#^1F86<_@X$:[][F2.<%-JZ60G)[KYA_#_I2 :[^A<W6$3T"]
M^CI"R/N #0D\O.R8B*]20]$/^JF7GMTI;UR]>UF1:]3B@ZN3NO /5\)"APD3
M>9FHW[XU%2?*HPE-:*:D)^3?A@M>.MYI/C/K+/$^[I3#<F%KFU66 H%?F=3H
M?HOP;!>+0CW366E3>;1SLRWC(G96\]3'[U+EC&8#K9VR0ETO\?E?,.)?%C1\
MD6$TD3R(J!S< &3=^XJC3T 73H&( 1X)(>4LU+Q=C<C'^^B,36^Z+9\WZQIK
MX)>H/L4=P:2_AV2[XU8DF&('0\3-]@E:):@MJ5W;S-W>"R;>$;YKKS@EZZEB
MD!OP.D@$'KZU03#!F2YA;8FQZ)1F@IN(W$!;]) 2AYTNJR?YP0^SR!F";/,_
M<GPCEF,UF85E(+#+6\PIKQ]7:4M1KBG%OEGT_N/@9TU2+^GPS7O[35E/86<@
MGOZ)C61J,*/'I\*E-5G_N73Y_WH2TH G19-JU$6$)E*A^+U"IX_,4CF_QXUM
M+IZQ7M"C*]HQ$KO"E.(BS+40I=/XMMOM^!5JLP0"AGI-B<( XSY;C<1F@OZ4
M2;9%EH/7PKKT/2-Y<Q[&Z]M:;?<PSOQ,15'?:9]@;=!^U%(E7BH>*83?GB^;
M:WE9^H&B7\RF=/:%DDR"T1/'1Z[V-<4Y=K%2RU$Z<6_;BQ.+.=1.0+%0,%)O
M2\16J"955;<ASZP]:=2B K'U8()#53:W9TN>J0OY^ 0$S@=D3D"WL>DH(LSU
M!#3Z@NZPCF>">A7(Q!TD=S/.:,-P)GI!,/!N@X"/;XY-"&A0X.[[LS8V-H82
M8N]X9LWH]+C-Z.R"$NT"0>9ZW/\5_^]TDVUU1_Q1S@DH_$@0]/$46^D'H-[8
M!*MU.H"I;O#M%5$9DGP&X*Q[#Y=/_D-](>L_;U%D2G%WA%/4 :=%LL/Q&VU=
MHN7GOXY\B[^UH!<0(1+G?,5B%91F;VP'<#_D7#R;*'5U@1H \*$H-Y&1Q%.&
M0MX0?4-,[@^+^%(90GZWI>PE^+IT-(Z+ Z5Z:&AK,GA[>TNJ_"F$]P3D7">%
MZWZSB8)0F8@\<<5;,#;X)P=[:\]9 Z_EW$(QC_K-#;GJ,\Y/;[D),PIGG06%
MQE7BL *[J&8-@EW5'HP8#[/[WLW;QJ>2JA+<F;1NH@XL*Y2ERG!>DRWR%XM?
M^?D<;09P;4'W]Z:63/MAGVT5%LEY_4K-)R!O^Z6#.05DC19DK5<]\D[$"4AS
M\\=RE[+#I<-3\.(S(?&1W\YS&4ZFIVI?K?A^Q(;UC#]60=0JXC.5L<JXG12W
MFR4_1B3/Z('CBL\BW7$G(,'(R9##(XU,SW_?K<]ZA*T6>\5VCR(6%CS$>Y["
MOL3=:M=0&E_,S !+'^=C'$C#MP$1O,_#GG5A8N%&O!J$ YZM4-1TM1>[T!"A
MUI@<G/(\1D"YGDAY=?]V"M>>H^SQ^PH23W&_B!:NST/]Z 24%NB,IPO%4TK9
MT[)=WN@*1*M@&E_Q#U4]/V,^^@\C/ EX6$+[M'$NDAO([@F&L:GMC=?9/9JO
MG D:;:$\:ILM;6_/R3D0/UO8@!EYR[%=<_:?YX+9@QL-Y5//W@ &-1[=[)^Z
MKPQO'IPO9O-:%R"=LZOJCDT:4:RSQ=E*?S$*>:VCDF;U9#OC?,4P&4W2R<9M
MI-BJ8\&Q:$S(9OHY>T2EZ9PV5#O[NV9=1[^ROG+>+PD9^5N2*2.FDSF^ >:V
MD3/%W!@)XN5AO'MJH!*;PR@>'J&BQ(: Z5+N:#QU7,_A& Q0^SA"=UXXUNP1
MHWV#P+4.I?T3$'[-^'2@A^W&4;'=7("[4B)2*K0$$=![Q%Y4(+*EM7*7+<_J
MO>P[E9'IJ*+'J6>V?_V"W 02B5(#W>K'>=2SN,FKA&:L*&"D9F+;J^0RP5IE
M7>NS8TCZNJ/EH*%X4U+T9@E+LVGB!G\D!#$V-H5OC<&MG(#.P3S;0F80Z;VY
MATXB@L8(ZF(:\=[4B\ 1HUOVC5M^VJ%/:9]/0)Q?@ "IP9%:&@35Q]R@7M8-
M]KEO"ABNW&<HUI@\_YAK__AK]GO2T/&J5?G0AH".QIZ9Q_IE8AA5CLCEN9C;
M\5ME-S<L9Z%^MF=:,OB+V/H]CPG[3I[@OM32?**)$OD?$CH^4F@9J=YR7!0I
MN($HFK<RB<>W[!3EW"BUBWD6KE#;4!#_X6?/F,I[][_)'(8E8%=2/('EE$AA
MS;RIQ$.<[RM<P:24%=&B+9G+87%FRS5_/$ ^?,WIB:OEHP1Y9\_5_4'BAWIC
MO/L0&$*]>?P:Y8%FA%N*0C[1Q  Y@XYX^RNUOZP=OS=]-I&=\F"5*QV],,)]
M_9\TK/J/1WKX&C0_]?IQASQ7#XVGE93O>3IFWK4':@C??V8O(?@>?+ (C^A]
M_*"VAM)H'IP=S7RFHU!JTR!=VVX3MBPQ('JI\?VTMC_)U##;N/&3$X:KOV)E
M\+%"2]G3CS5Q&<TSJHT_S#_\0XJBVT4U3D2*IY,CB/PDM2.'P>_3M1/L9;V2
MYLE^XE 9:\/]>\_\/T33:4<Q\>RV?(4T82(EFH"K. ?5P4C^@KZPA>S*WHIQ
MYZO;?'J8EUG0JXY\KLN#1O3717K0!O_[7_!CX.2)$U"V*=!V G*:/Z0E>I%M
MATC%,;_3$QRYYJFJZ.4([)WYNK*FKI9?CE!UJ;,V(1?9VIFJ,R*^T6_#EIC(
M;P%C(I:L1E0!DO%*<;4M[!(&6<9U4A1+1NR#1L-UZU;P%SX)?K/VZSR_8/U@
MB!?TS EH\T6D_)R@>N.<=E"]H^>1I$+&),]8V07^84>)N)T74==!:?-DBW0J
MEP'9>_; Y\=;P)-KG"%95OYHZ(V\RSL&1H,/LEMI%L\8GMSBV:7I'!?21*CW
MT_LX@.1^<X=EQ-W #]/RA!^76]J: C]S<?1]2ZF6,.-Y406*NF(H!LD4O4;:
M&(#2(Z4 E>G(*4=%XMG%/N.1@^'D(%9X65N[DBP&[PI_9+W@28;DZ]/[WP^Q
MVNMN?P,8D\N!\PM6#:FZ?8[*,^*%ID(YDGI9,GPS=WQ2;@@PE0<5724Z)I/X
M^FS;XK3UG#J*XFOL;I3OE':*Y:KS2SS-&(L0,!3;C&9_!/@3O_:?@%B0/.6G
MO-UJ6@&@[NFGS<P8O_)EN_OQH]5$SM+(ZC"HH:>''P2B(RY2.?M[.JRHLF!N
M@&R]W4'2(U<'&G1]>$H0*<1PJ)E?CMS]<M_@269:DMP!P=VPF<28'E&^,?CU
M\\:M2RT#=DD'J7,UBK<87"ZH,%\=H0H#D,WB*%&>@O[(,].H]X$V]>M_"9&+
M-SZZN>JYK:EV/I6XE;*55@CO* %/37$B-&X#X:?:Y!$ P1VP?><-XXUWWC1^
MWOK^?:Q3DMC]VLE8D7%5Y1M&3O>-+G?7D#1.G?$&;5J4DW2YS;\,/<0JHF,=
M*.VV("BWT"+S1%)Y.;3D;J?C5WEG[\=I^NL:+:;/:"P+W4H>)R!NOT"8UK#M
MC63/5DWT\E>8[!KF?]#VGE%--N_7:! 0D2:]$Q44I:HT:0E%!$2*A28E*KV+
MM "!4*1W$!!X(%11:5("TA(@%*6(%$% 2A)Z32@AFA!>GM]_O>7#6>N<L];_
M_3#?DLG<,]>^]MYWKIGY7?E6Y/[BULI*.J*@COY\(P'<#;I,;BF&F4PJ0IJ@
M>)VF4%'UIQ3;K66=+:F&/]J]7AD:'0U9!P%+S^G;_J^XN?_=Z'%PLE1.EF\%
M59P [@UE? )?@O#.;&JE,^_/U$>> KPLV*57#LDN8<0L$I",)0[:6+80Y9!X
M7=S\'>-%#8NIS(97F,J<%OYB=L1E*O@IZAI,B;#8M\>P&7Z)&/ZN;2 NX)I>
M6X.;8[P!EUX&"#IC;>!OP7#IM51<'(V5K-"S>-$48Z>@FSK7?;X_3'$#Y%];
MXZ-\"E!B:>17[QCX)HMX=Z %9*3UMR&G^W<D29_(:W#/J1T<BZ%_U3WO^FKE
MA]\KFP.56NC?<]A+=Z.=X+$(0B:,=US^%(!%PK$/_V39<I!U3P'-X2,DVX>8
M\-&="[ZK#O"_]87S?Z<WCS%I,\=G+-8#C@N)BX1=PQZ-:\A^4-P)>-GR9-!)
MX;(A<Z:^VYVG=,=?  Z\RT#"-F2FC)901[,, -,,BSD*T$LE1B[ ;6Y"0_\H
M3A'(U8=(\I*]1DSF]_ CS?"-DQ53+N>8OA-K3<](13IT ]F\-&3QQO3/)L%+
MI69;4T+>)3[!OA6VY/1@R_J!J^U:%.1]8=MSE5(8MA^'=75''+]:EJ8^$K*,
MR0X!2WLJ77^]2P-L[.0ICP^#@^X9O#=5-%X5NY:U(F.YNM$UP'T*8.\[R0>O
MYY\"5H*>G *6\P%_TDAH\LU0B@Z\VU!#=2DT+!S.;NTNQOUFTS*P=DAZINJW
MXM@-$:XE+PRL8SDZ&7C_))8*^1 ^LBC4\8(B"^U9?R>S>_VGAF#8*RV5G-2'
ML;<CZ)QUG+K6A]36(J2W*&E18A?;R9T>1!T[?GAJC:=) 7L5Z6/_G%_[\G[+
M'Y>]EFL*H\_*B/2D '(P47>@2)!8F:"A(0\SQS9;CA\9^,C)OH_VC-)CP%QE
MHMO7^?)<106HX$C?1#1-5$0SD'V>$L^WAHH5EFT$CMO;VPT5UM]+M/X5P7P7
M0*"31(;[4U61Q#@J3PN>E$ODL&UJ):QUF3)L@KR3*FP!$C_EQ)]CA@'IP[WR
M[^Z;\Q\;&/%GHK7#Q:FJA..^.D;W(BZB7>1/#?#'THKY=T56&GV6EO2PA[4@
MIR?=@OT<#(D$#S#Y>MSVW(L@QF$@NT8K-B!3F?9[,E5 )#K:+[4T @1)6^*(
M"I>%=^N!U,DNN)(O2?H%#].LZQO4WN0\LN5DO6QWWL)L52+X=J;6]8?1R/KU
MQ7K[LA*8XRD@*GS1#2ZJ=-='@]'M$RI?213^.%2@O#'656PN8/1=\J?&#"$J
M?E?*'X<J)?^D2%.E3DIV_2F(>! '<GI/YM* 3Z!D_E1 <F:@X M_9RW#*U;I
M+%SG#6O@G#!Z E,BBA/=0SD%L,ZFT2D^TO$W4LD<OUP_V'B9C46:8^%J_96&
M =7O)EIJ$ :WOV)92YWG!C"R+&3O.=.6.",/MV&BL'G*O6L2,G/3SVV53?15
M54>\+'QBJ>J59%U,FT5,N<U)UH/QG:OU32T+HRNZ0@QZOWOK>SX(2F2E&M9(
M_5]YDTH<G>/ODL0%;;<3Y3%?DV0.7"=LNY*91A0%BJZ,4GSE-:L.%DG7"=3%
MYMQDY+<.;4]X_9F612UV!8X_"#&6\1(:OOUCAU]4E5*.OULWE??2$ ]=ULM4
M8;06<+REJ2W:%SS=#9E9Q.YM[Y5OJOE@%MGKXK:/!*=P&Z!IW]=. 7;%.?GZ
MSP';[*H:?O]>[OE9K*(&YG%2@>)Q#9FO_C% ",(\2WY271G[S^\1+OI180L<
M(_U'Y>5]J<*Z:#A6[J0.[GKF]&+3SEH(!1PO\ <]"W:D3<W+G +DJ6%SN_OU
MM"F-A9FU0PIV=!M/V,+*IW0\PNTQD]TUQ7M!U[-7?_KP;0;#2,'/+'H,MC.B
MMDTNW5B_'?%OY:<0O%N3!H#I$IUK<#Z7H$P479N?M?:[^UL4%[.DD>SOULT5
M7>;?MHLO H@U0/U&0MVV"_$4H ^9%>*893+SX5B<[UR?G-JU RDW^EM]I3Q=
M,4^\+?)!4L,7<BO\^R(+O"6<A6Q_"J )E]%X70KI$>1[X!:-M.W?#_#.HSLW
MFM>$:;B34T O+8W,1)(A*Q$PF 79'U2%I;WM$?F^',C,[ B:5+&-=F^9W6KT
MSU*0Y +?>'HP'6EK257G)YWQ9*G'*2![WO04D.E*OP8AWZ@HVX(T0K:/WD-#
M!RZ1OQ]Z6.0[H9-K]C3ZT&VIO[N\A[_NB_:;R_0J?/;<-_@DQDTH/ 50N8Y)
M:82RS=F3_G;"$$[IK840J04>8Z5D\/U9X&4G\V>/ASJR5D:4C02.+>=:P WZ
M/:&CYZ#@[D;H$W@L53STI*QT!NXZG]9@Z^.RV&'427-QB',6.:PMPQUW0QAA
M(81XPFB:XHT.[5+9'KN*CLQO+!)?+U@:BCL%W'469+TC&+F4H27:&?X"=N\$
M 7>&\\$$R =$TVZ:]%3 *4!D?3HWY)]94F6H9O94WJ?<@\<\\0/GLC-]TA7$
M,ZVC4"M_X ^H*M@M(#,T].&8XM?E).,)K[*FYE2WY<(I";,/K)D*ZI< *PF2
MK4KX(H636!HC3)MX0)Z D ,J(=!8PZE-MRDW;"S.;.YXA.&US.,<;YL0T3_J
M+69,<>[ ENN5!'W25?(+7!KG+#H>)0VM,[+R#U-VDO%Q DK9?>>)=?SU(O"B
MKOJ#3\J[,IV6V]<HM\D%V)P"7%T"G'=O91(E2=YF1MY^;1F0@C(*OE<+</XJ
M4Q6CE5$:^7EM*OQV^%?P!1IH,]^^!(^^4(OT>__L)'%XX(/=K,2M7=G/$ERE
M1Z"\=36ZAV1UBBCU"IF^=G$+1$]((_%5P)UGPX879RUSA9><+6\VN_W#D<>S
M#(!N:0G!&^'19U82B,5O+)ZO5:Q"7!"><7(9.PJ<Q%(,GW)QJ%:D[W8]K-V]
MB\\_4L/2.*@\!)<N4^:66!AS&?R%:\KK8^?IG2>VX4<]L5X3ZBU7+)/QB;O_
M[R*H;@@13Y,@8[!P\LV]/O6ZJ'#><0T(KI+PL]Q266VR2N2F\XN)H:\LMEHJ
MS SB>V("U,H/)_?K+IXAZDS[7AC="<8#4R&$S)-*&I<HNZ8PA6E;&#3:](QV
M,'I@LGV2N_O'8>\(G\[!1_Z&,TT&W?B7 F OV\@S6#OQ'C$I/6A-M;^UA8']
ML/#+3*X6[I1^W5L43 SPQB8L"'\<O7=X"O@%)+TB=Q??C^X%LE\>#V!\&XVX
MJGWI,O[#0<YBFL["G[.$3XH@GT&)96)I,1'&=%)UDG#2ZD'RV>%H/"G[^N=G
M2W#H1-!\OPH[,J6"-AIXB39$@ E.'LGO2/,2UJCBX^XZO^Z/4! R)O4Y7M7L
M FP##.RN]"N(B] DTY-Z\%))/D=\TS'%)9(F1'9>?-(,#E&5K\5;BTN.Q?U3
MF4HJW!IL0O#! @EU.R,4W6\$E>X08'+=:D=DP%UD:Z92U"UPX+>V5=9,(Y><
MC1^6,^AZG^W0%Q0@5-Y^##<]D!@@^Y)J]]L=\9PBN#]^JQ[3.)QUQ3"CL9WV
M3$SZ&T@<WJW:X8"#I( 4R3%8CEEZ6W* 2L+NO6.^D.L(Q8<\ %XQJSWQ \#E
MC&S1$#.F-MH02IJ\@:L!VF7ATZ(5P><W;_V^W^:I)O'MZBCGDTZ$US#YRF>U
M.OO8-LBL]%)L!D4/)DKDCU1*J;]>QN[EH[SK852N7I(72JT]KR7^.L<6FQ)\
M"MA&4Q2@!TN@UEH(%(V'G\%I;I./B&%\W]SXILGIY<.$5;N'=[0' /Y;D'L_
MF%9SJ=R57:"KY#FBVC&.O_?$24,[C-#,2_".=N]MZY-Y@?FM>MG[>4V,7\[+
MOM2+-U7A_!IZ1#\,D/"D3F2>RD]HSL+M\:G$[)3E8ZRS'6*\'@96+#-6OO%F
M%P?"" /1DV&%%-GP83AA1'E!-8[&94HV.%.[DM-.4RUAT=MHYX7;*_#J,#+M
M>.BP[CKY+.DSG *(*GT^:6T#??(785X_44+NS[+_X9,52ZD<O,XY('3SB4:0
M+Y_%[2JO_CM,MLX1FD"2';%R1Q!78PE)P^=&P#27YBZ\2&CZYF\X?K](9V15
M>J<= 0!\P88<*?W!$+EQQSWRJ?8:)Y4P/?PH7VUNU69.4AE43%#&VYO.R))#
M."Y1TBI'OSE:53RA?&MQ5SX66 _I@P-&<&Y*X%F?/C%YVL\?M8=)KL@DF[S2
M^J+G)=X_)5 !+LGT3<]?S_NFAP(C(9\A/8@W<);#-):MHDN$EC1DDJE2+4RW
M&AHXLRLWL^(BR,5\,<;B*<L70O3D#Z8,*!AO2I67)U]S25+R2$IK\A""Q/@T
M&1LG.:'&?,[_&(9W$ 7*P4?CJ&>$Q9W;%!VJ]$FV!B]V1+='C'TLG N:.6A'
M;TH,K_'2'"]_$IPX;G*Y2.?-^?2('[!N=DZ"7AAZ:?'7=3" [(*OC&DR%:JI
M?(.Z)G$*<!SGUZ=3Y$\W4!#DII.*29?[+<E9J>&W#@*>O&T2@#NI@R,7)#K$
MQ,=+)H1-O8RV2YD6.PLE[\E01 6JY(>#'QT6LW-@?;9S:\@^I"OCX3QD/YP_
M2F1Z-T=3BSR*,9:(K[O6\UME)D\B(?^ZZ7SL[_:WN^*%R,.!-_ZA=>QD4[UQ
MGX";R((YX1M>+I.U"JMV7S,^-=7D.+1^E7G=NWRDZ;'F<Y'V#:1*0&Q7^A)>
M3^!-2MS@K&<!XDAN-YYP;.J8V,EQ?#N'E6NYB[O'-&PK'M-]D3&,&RLJMH5!
M<8_Y%\P_\'(F]0\*6Q]))__)?2WA7B/M]&[W-8M(O:JFZ3/ U+_IM*:MMZ;M
M?^DWJ=H26@5\@19;\W_46[K\SY?BEK+E5'."14<;O5O1K1]*O$2Z?UQ7)YY$
M/?HHH+"6%%8-VY-G"A_>Z?XN_;%N!!@CQ'B$IG)+8_E[P]CI5>)1PN[3X3=:
M[G6YU93^E)O:/Q<JW37.O?79C&F#K[YZ@R8Z[GUD;/%W[N&$#,YMU\?GNM6+
M*"5!EZ"7YS[02V1%VE[_2'D NSHFS_:^[(RT+?BUN709I^,]\:]J(\>:FR*P
MV=F1NP*<W752)]7(KR Y*!C;@M$\OVZK331ZVJPPPO+\%/!2IRHX2"IC2ZB_
M*&ZD/_A]^#R0!2;(L=U*U'V6UJ/&M75K?=AA\GX!QZQ9;=_C:W-?+A4#_+K.
M16@V=L.%4&(P_9_7)C2NX4=9R66/$KE]KQ4E5=LL/,PX;WZ')^57#.NFBH/@
M<_7$#:41^$,"*MOWXY9:RONL]W.U&W7RE58OXD,:ZP$<'VLAV#J,SP6ROM$$
MDHVE9U8N":[TQM<PH-+MQ]S@NKE5E=H-":Y/KTS-.-RC<7'=8#;JRTFJI"\N
MIHB&P;3L?-0K:TW9]KE^6]'5^Z6_SZWKN$$Z@>?,7W$1:AQ,T%, !LBI.#VI
M<1-W)DFG+M!L[%R/Q^QZ:T[&B?4 BG-+U3(P;J]D<[&9/[7#DH V:6PB5,;!
MI*^GX&1U39+U'3YLG7/*O*'S@46\6^BS&W_&*L/U5B\54A=YQ8>B0H;CF^NP
MX//@-Q*9,_*'TLIM=B:XF]X6<Z.1,\.^NQG3G@^!*Y=SMP&@7DA<.- TO@&Z
M[48F/LU_O)[R(7C<S[E1<8@_M]V%2UUYI[VUW[?//^ @-8Y8AHM[$PZ"\G<A
MN)H6+]3DIE8CF9O>$^9^YU5[R^ -*V)=WNZ\\PP7Y=-(#S>3/C=$BB$/X/?8
MH&4X_<@.)>Q-FK#K,7_]KXV_Y=/TYE,E3<'B1:X5]_=+AGHIG-F-+8RY>V9,
M/YLLZ2A@JM9DN#2,DZ"2'.#JY76DZ6?0/"GWLL'"ZK&A.&LWO<(MVZ([O91I
MN!8CK(6B#^^^AQ()'P9S@K&L1),$7,')DVU?^S^SFA5-Z9[IGQ_ER7$V[O]#
M_;(Q$F8(R4,TO>\D&F'@A,=;H:/1-.%QJCG^RA)Y3/'$7B^5GOE.<$I.$6=&
M/PC>]8-I?+'QS RK8RUW5/"&,$GL\K2B,?R;PNRLQU2]'JG/;.1R0FF.U@.I
MW2N)_X@D8^MG:1.G &1:--AQD6U]=B!9%FES^+-V=GQV^G[B39=K9NVJUM>2
M/8%G@?-Z:T")B-Y&A.*!<^*D+_7D2B(7I8<F1&3"&%D?YE&!%<]LY]R-Y#8R
M'FXH[Z4K'IR[5X,L,[_]\?4 F%1,'B,T]@,)9@QCX=); P_)P4MP=CNW$<'&
MHA4Y),N7P,&2%RF_+F5]_*U%5Z.O$:$%-NA@Q'O)XTRC_(&\ZYE-L_>1#NPE
M[M\!<+E[["41DJQTW:+QXLA@R^U1B@.4@_3)AU,7>^/(&$31R>;:''B6>..]
MHV=,-L/KNXZ##6NJ#*R1&0C&,\5E1+5'$E5ZP%S4NT*?-O>ATD\S/.7/:;Q<
M,RV<+\TP[WJNT5<0=:<D_9(TSF<F 'D*F-G2;CRI.+1LZ_QQB!:P@UKVA3A:
M8=P:]-PW\>]-\VYN^G9>/B[FF*R[2)L58R8&18*DH VC1M/X"93([[,)&3/U
M >0'QEBUMIQ[*7"I4G@PG!>; R=8FT:IJ+S"2,91_=Q$4C],<[M-Q8@S+#4R
MMLE&3BYQ#P"FDVFC(17O6RG7:;//LM]L^3D$PS_9VGQ'!!HL" I:A5[2IGIL
M+?YJT1[K>$2Y0&8R)/)6U)!B@DL,V8XZE\[SO_EVG?!G_791:$ QAW,<'AA5
M27X&DI",WTZ+'$DCI9&F<%?W;W\3%XYV69E)F4/9>N-03\X>-PI-O?"%J$]Z
MF@YMF,+LR#*1EMMLG4>?2S W5_>'O6&-7/'I%C1[+8U33W%X"B0\9./KWMW%
M$7H1W+/?@QV^@5]0U!_0"8#E"W,VCB=]B] U*"4RG+ "=ZEQP?"W6:1Q8 S\
M#5F>?>J7P2$-ADO-P0&!.US,"NF#0%7!8E9@&@(Y$ EW68Q1X^^U>PHA9V'4
MYI>5 U7$A*V\6=];.>5),*[HW;#@6[ZM*I[ZI=&!\I0L;W:2;X-/-OK P23[
M)K?_?"*X&9;9=%^VR'E48?CQN\7DX[K!.C&(.S^"8)@69P@;5^0[!7!*)(["
MJ42*YL'ST. 4R2W[3[/1&RHAE=OO)*[MA<O-?"5!N^W./6ZI!BR)I@C5#XB0
M&,R8INV%SR8HF:I,U.^"\U&?(<<TS(%Q&@IAYQ'!'DH5G]LS#?.5G@@E1<5H
M9_OE,D5W[Z)%P$NEIP V%-TIH =X"F ^GX"K&B4_4#0(V )OSQFY["_EJEL8
M'S/'X=/;XUKK1L%Q@0[&9S_B$?Z#% &0I=I5]BIGZ@_YNJN?2._!$Q#(P$+*
M;=HW--OL=]XI&+R&[&?:1%B-%LH3PRW-]I;JZ_U)=AUNI6=,N'!!-ITNB 0_
MZRL+IG!2AI)THS$2IN)P0Z+VI)OO4[TLQJ?N A+O[.2D8N?N/DF^N3;>AIAE
M(:V1?2B*U'N$O6B8;7Y3?DXC3Q#0=0(;L]00LW*;68YE,+DJVV^_ZE4YQ5*=
MPDT;?);;8V1LBE/I+2BK@SD37U%,:L)>6=S_K(\)RQ;PS=C?N[F_8FXIE6C:
MA> $R<.NDE?PH[-!O?8:1/>-$-1'US:52&QF_^H2#_(5\0NT-"#!,=15(?-N
MODEG%]@>=1.F-Q'.254G<B0?Q<O5^G>R?S>:>^?YR#[HGN 5^CL?P1;T"RB%
M4T#<"(SG%% "&4"3Y1M. <N#I,5?'/]1?C,^/6K(OH%9I10Y^>W_TGW>O+JW
M:0>]+]-/ =,/B'LB\$'[<#'XKS3Y?50QQU/R$TH8#$3NQJ?%T7C'FN!<<^YB
MRN.UR# UHRT;_\0;SXOV^:T3O_?9(I-[&5EO?<N\HS-Y4H)>*@->0+L ^>$]
MLM4C5>2X7D[XP$I:G%?9NU^$BGNC,AG%SFS'YGFQH.>M@@>01/A^+B(:31(?
MI2*?C9RMD<E&B'--&=6.Z%W#JD U:B6>B?.J8+78=@-!A[<W)5?-@X>7#PX4
M'51G;]$=#FPO4I[!U$\^-JDG[3&Z*\@>(53:Y"HNQ9)^\%VQ_J$@+>UP)2,O
M&) ^<RYMFTAY2>8@Y1#YDQ2!K .?W/X.Q*[,!+A4Z_*82ODXWNEKT/\=F<OP
M#V?K:] +B.;F,^\LK ]9NC(61TCI4,YT7^#Z@NCC_/4IQBW/6T2Q)$1=8,=J
MK?916[,'/BVJ&25.%@^K#1]'"7L4;(%9R/MKND3E+#'ED8K1E4Q\QO=CZ6^7
MU;5^]2AK@:U1S+1Q>T$R$6<*7&]C3*UQ"5BJ,6]*T3NZ\?)>SO/]*ZX/#%:R
M;JO(\.S?/3P*(0O3F.%U5N2J@5- $PI9\5VN:<2H;]$36:A]SJ \9V<L-LP\
MDNJQE_\?=2G=?PIPVTO.G^Z&L$,5S'[L>,J]G^JP>^^JPO+A_FX5XW!RPQW/
M $S$74GQ22'2@S]P$NT4D '$^IR\+:0_!>AK H). :RT6Q[/U@9\$LX 2S7V
MJIR==P4Z3#89>N+]5=J<>H"%Q^K>T!6+E#R=Y(S(IQJA1+]^2S!0%B0(/2_*
MMEM,Z-SM_+3H838B$[A?O^^_?L"3U*38G=?-VJ^D'ECD47126C.-10Q WH#Y
MQ>?8$'/ [A#J;SJ2-+[ )7"[?KX:?GQX<N\44']2!1V#P8FI&QP(_(G;\H1U
MY. &7UYS@X F/4,F1'=U;2'BKF80+F[G43'5GE"'V7 B@Z]7X-A QV91&XHG
MEM]29)-?_&ST_0>AZ$!?7U=)$ZY+X>Y1+AO87U> (F (5SC;@&*@7I!H 9^S
MR_??+I*UOGW0Q5Z?/R#3: A)9NL4\)>W(HQ?2TP4NYAV_#C\!X(?!L0)^H<!
M>T 7QP]'[FL^#KREQA)?N.J18&\J<W5G:<>6=3G_2'T12(88CQW6/-OKS=>K
MS:XR8A4*.)P>D^#/?*AP46>E^>MWT/ICH\ 1V!:A9V'J@+1Z4G89E7K3L^*'
M/T.1:M?M)N<%L^Y(/(.+:AW3R=OI>ZTGY8JRDH\[?\J'\[DUN.\1H)LOP@?\
M-Y3E9@0*QQ4?6#^7'=<<OJ55S-%Y!IPGW1".O>IMZB,\&Q,F*!=-W/*IVGSU
M[!OX[A^^^XRM^-2CB3XI4R%#X>J,+ZRUE5<BU[5WI9<1,Y5=M$ODE'^OS!1^
M2FQ.>T^.ZP,3_G%7,][R"/RF^-GMT2?9MUIW_URY1<6(J&A0._P0C?!>G_@%
MEI-__.-1@C"E7-Q""E,\L@9L<@>:R7;+QBU]OFWV;0[6YKN.RHT!K0C_/D!8
M%D="4VC:I=^NM]VG[G@TD[8"E-_EWO!^&9-@GE'Z?>E-%#UGE/:'4F)L-*BD
MQDJ_9F,<XIHDO)DS%"28V6W'&N]BNWKY*\NY7U\%12R'$=PP[8]4$#F+8(./
M2SS4(]S+'3-:VN/?Z#^29TQ6L<Z9]B=&)-?_[K^#3UNTC*$:U!-Y![;+2J"#
M!EXE!;B]WB%1#TB<=8Z!Y[3!ER"^P.D[_17XEML8QVHM3V;A6E?Z0Z;N1>X.
M(/'2?-I%:*,N\7:C5R[XU]]DE7#=$'#.@!M)B:^=Z- MQD^\5AF'1 B0X0;3
M>\HG!0]0/R_';GH-L#1<?S62-4&?_T?*]!RYO0?=--!M,V]C3'Y".##GGI_1
M=EG:*EAM_[D-&EX(J(^WEG"^2\B\F9%M5L? ;7)2&"Y(52,7G+'0PRG0]0T2
MO]K"Q^JM1<*[S>EZ\06K;[R]G\Y][<Z7O\Z;D XX]\\E32W0?&DK/*9%S7P-
M [EH7.*>F[^:<#W;?4JMJ*1]A_]5L-'*R/65Q];3K(9FAJI] 3S_JQ;KOZM9
M)M/&%P61Z&@XX1.ZWLM3#HV5(NYF8ST66_KW5F;G@U$.?<AI+@X9+]G6^R9/
MIQLMAQ M<=0Y]$F.//LI8*</$(J(1]V!,O5P;=[V0-TE+"3(%<B8+;POJ[*9
M*["6,"9*E/SV=-$1U'V>_OJ.=.S)>[B;IO@2N%L]37AF<;TMY2=F3J]\;AY2
MJ@=S*KHQ@[^\^DCDM6*Y)*$_F'Y5S(6 P*;%4.THGN'CLU.=)6Y_YW?*BX!-
M2*_[,Y)\ZW^?.MM%1G:'?1 XOL!4 PU'EVS\>ZV1"3K^[VMK;9(L!XZ!],Q1
M5N"%"X H<E$\#>SOY2P2>#T"]'<R7!8*U"?4(!+VJ"Y8BCR;/< +69#R^,+V
M&E.)8=*VY]*ATFL\CB.F!G899@U.\(^'R8ASB[XV(N<,O? JZ=B?4\ZY['+W
M6Q\L@ C$T&Y,H[W=#NV8,/:,4PX_8((^OL6N-,7\T% K\4SLU"IN_&YQ]L."
MGK+F'SH[ +S2"N)2D^@3#+ 1L1-9:6='OC\^XNW_T08#8LG9M9$5^Y.LLWX^
M?T%B./+YZ_J<V;GNN:YBCE:8(3$1\Z3CQV4".(5*'XCOG?I['RE6427]5=SQ
M;6?-Y[/DCR>_910/OUB>)V)!:R%68==BRXLT(0-%@N/E+>T4AJ&P:IL>A]:+
M-<N?702R/&[^"L;0IWITP]W  &@0=A+<V)R+'1$:T&^*PX4GL<^I^\>W553@
M/H85>]_=#3-^#A,E&V$Y^&$Z)Y^.4H(P;8'(,'"\\P1K+NG;;1M?!^ZW=ET[
MC.42>,'9UO5;=$<RBSQG$X%+,F4SPNU<!'/:7_WF50ZJN-!>:.5M81#D\US_
M<N1X6PAU>)+*@=V[> KHOD,3(3>:CLE<)6H$S<J]5XIML6BG:$^*VZUZ^F!!
MVJ,7SJ4">/]:?G17GKV/"("'WK&QGNV=&%&,8Q&Z(3,<%L'P@VD8+HKVJ''
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M_W@!4SGB'?\B?G:N($%CW/86(T_,;$W6-'W^'Y>EZ;.%%(1!V\D3'S;1 K"
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M6I&#\TDX72>&]00IV#[P%F\*X$"%EV4?US&''<7 >:%SI*R?(%GR7K<%B*W
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M3:%:)*L%26B^[HU#8]8#TW],'HFW_IG_^5::3\S:-L*OO^]XNVY)>'3F%U7
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M,K3A>_?AR(V^BO<%#N^[KYQ_PG-Q'ZA$BACGEQ0!G+^]<Y9_OD,(7X'$F%,
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M7,2OH,^<$OWIEKN]N"I"-%_>%33+ Q-S'PE4VUQG FW#=(\=0QY=UC35(B8
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M"5OIR,4[%WBX6A!@)W4<%)V&<'U'R0VA9#V/?=\B:=0$5-UP^*#*=Z7D:()
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M7H$_?6@;\\CEY]H^<XFS1;[FPVM*S]-_>FV;.UNV:([3+*C^*>?!KS35!2;
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M7[!4 3OI0+T./JI''D>33XXQ@60K=-,Q^GG6(.O"\H\"6667P/9448RC.YA
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M9]H8@;T(3ICS5"518YD,B)EIE.>N"'C$K>RA'R6I\@1SQHW:-I*'5?N-C_B
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M8DVQ4?%T1K<C7\%QG^1*NX<66H_$;7?20(NWO.UV\)=VMNSDIJOC5'AP0F2
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M= %(U6;EB\[':^R[^<V[2L#,Y-,S,.N^FOZ**9H4Q!K6&[?75"DBB%>>JKW
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M5<'1.CWY#$1;C&$Y"LCN1@8@._BF!2RK)8A'E_?,[&SIL35-1VE&E'Y5Z;&
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M3)X\;;I@U4,/7E6=$,FB481K]0OX0P2?5D7H6'Z=:@49<!%FA;XIF_# *=4
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MJ-)JX9LI(2WI,P(O4C*0%$4&L!%Y,"E#75FD[.H%>B^>DY8G%5&?O@XT#F5
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MMY!+$)D2GW=65#0=P"KU4\T8?!=V^_XBQB(ILI W M4<(T!J.^ FV%CC/5%
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M==9YZG5EDMB]</%0)-929DR1 5?*TI2Q<&.;TMJ-LRK)8=IX^7.*&].5(>
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M86OR7Z\4[#U\?; \N%=(S?J&,:\?1PJ\VO&:D2G"/-ER3(GY-D:NY9.<86\
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M5-'0OS\S_R/_=5$*"KB18>OFXTJT:&EV%HRKK:=7XEYT]V4KZZ= *:";#TB
MJ\YP BZ#!(BLW.[AV+^_#3E:!A)C'/'YT))>]W29CV^V>BO-G%W@7.L'SSHJ
M+S_7'_9I7=^\C9<X[J0^97&&[W4MX%4XT",+UX$;SO4D /P6!$-_TJ02)'(*
M?4_T"^98\87,X')6$Y:)=O]"-8ZMUELGJSC(!PAX"9(*3#C)R;?ZCUITD$Z=
M0%$2X&O]#!&O10)T&:VAZ""E.)WU-"11B0"/(AH3@6O!B?^LIDL"4"F@.XGA
M,^ SC!0)0&.54:M++$,"LZTB3BBP1-X3:QP)\/E4Y9_UU/YCIX-=AM3^ 8WC
M#[(_R/X@^X/L#[(_R/X@^X/L_SQDE&?/\2+N;;[5U!\7UZ;=3FQEH"^@/WX2
M/*"?!O8;9< U6#UP^ME,01//['%U<T>A7,XT]W=G6!8)\.-^;O1)Z/RU_1Y"
M<?#MLM(<!J74S1B''WCM 2#SD2P^%EK4*]XHDU:+K0:ESIA5G!5-HCV>=112
M)$_EGT#A*?!?A+LD0'@V[A4)\-@9]O<L-(_('(",(%#5+QPO@8EWX5+VT"(2
MP "=,RC2B4^@.(/<PE?A(?]:S3R"40=$'DZ]3XW"Z^PC,"3 @\.8_ZB5@'/8
M"^<X?#@#68B"XZ+Q<[D)1U97\?MXX \@# /LXT#@!X=%_J,2$%G4R@CY/>-,
M @3?(P&6! Z\HX%C@;P'?6@2@).XT$4""$(X#H!/X?^D>/__UV=H__3]_X8N
M] ^X/^#^@/L#[@^X/^#^@/L#[@^X?P\X^V$O30L/C>K1<MN#'>@=S4B>::-
MEZ\IWQYQ<<9?Z3>KU$&*X).@ER&3#'TDP!,>KY23.N-B_8]&JH,-1;SW^12+
MSS/C'[__1]LB$9@(?+3L L%WD 3(G8;S"1R!_VGE=4C::+%B"_YB"1>Q5'1
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M=S*.SF24.:R#X^WI7D^4U]-#S1;9T<V.AVEGRNJWO F3,U4L0-=U:925&EX
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M $#4.U6&$^!('9E3#8TCLN#<G5W0#J=98:W,BYLU<K4"(QX"=Y,N]&BLL^D
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MQ(80#UG2\?,K=@#1YYK-+H3<2[ST$V"VOSQ#[_X+0]/5SL>G_&)U6+B/.!\
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M..]P!O0(';Z.X>(BND,?C=W>8TWK4K_PN_FL+*8;<RG3.U.[.>@6"0[<>:3
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MP%J5:7<A*E$*JL"F_<#2!+.\/';<XZPQSEU/[/OMI'XF%+^3U/7RQXJK&2M
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M4KU/SI+8':N<.]R7$UBCQ]#H9HP$\#CKN!**%*7MK9B%Y>7N13D43\?)V)E
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MH9;?=?F2)^+E:TX*(?N#?UZ^=**XLS-F<-8[-[NDK2U:Q.+AZ\AB>6&E?B+
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M>0H)JQ"V8PBM<AGRA;SYP9K[[45'*N!QMMXK[#6ZJ?SV(X'4[[<7C3+Z0.D
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M\W+O"BV\E\E>NIH '.4G_$VD"E8,I";\9W.G!UXU6L3CI:_F,M.P1%X-(G'
M.U!))R?M\F]G9V/&:H7RQY-Z8KQ]^>6[L:A'F-/>R\S()[7.2'WT#%H.H7<S
M WN4&J49+^*O3G'A=SVGO;;0^+$Q-!IAL_CD(\LDG\-0OC2E$GT6*43*>J&,
MEEHFGY_37.;U?MK)/YB&U\N-^^.B;1D5G<7SB8"8B.,TDEJ[&SAXT'-\A6Q$
M:MMF7D7%P$_Y(5GPQP6L9<6C-("MZ<Y(<-6(OJO_D>;Y86''?_CM?H0.0U58
M"R'O/.MSJ9(1DTO:X VB<1^N(L$ VNM/<NO/Z7<5FT(J>K^3F6U:OKHCG3%^
M9_ME<6BL?IU1!MF>#RJ*/H>4!J-7PB&K$GEXQ63(8!O6;.H/AI52+OM^.IMC
MP/N).%8MS1VWT5@$5?_]// RU,)2W9!W1+'F2:'2V!##Y;7T9^SCQ.7X9I2P
M9V;GV(NJ^<V<2[C,MFG-A7_:V[(-%:Z:OZ1GM0N7#-]I':<V_M3]9^E.8.C3
M25B6PHYI7T:,>.\N_#0(.Z@AE<<?7Z*.'D:P$:%1M7^@<8*'MYV^*/FN334O
MF)Y$*1>Q;J\5!CM$B*5A&&7N,N[@%+_OGB1[@P5X&$[4$'0AV0WU97D3DE4V
M;2>T"MC*/BLT.OMJ.(_R[?S0<W[\ZCS+BZ2,U&N48K3T-[(4R+VZ+/Q5X1(U
ML<3%!:>4X,2Y*?R[[=1F=UUXTV61_//@\ HD-N3+5T3UD($H<71M7FUA4Z2G
MIS0U/_>6&1.5?_K7471=K1OS>O)GG<S PG3%Q%#&H3-T)X6-A%36OZ4![G36
MG.K3]>^%01!1_9UG"PC+(F#7]5@GTBE,[8)9:'#XDT"1CQ\GS4O_/H+>+^Q[
MWJ-NH4OEH.2HHCE !\)2!G&OO_$7SC^^)'\3>UO4I'$!FY7NW-GP(HIWO?FS
M#.[$RP] L SC1# J!<5%AA'4\)0;!$ATT"(2DZE9/?H(IUB\O/@[&^NQP%^]
M"H]WY09]RQ<V)%1(UQ/QWASQ^F_\6FI-12^493"W*II_XKC+^SSPN?=>$UXU
MA6[FQZ-H $?0> P&2N4878'QFIUNG/F3RH-P7S*L^E: "13?]]Q96/C.R<KV
MBO]]X=Q<05-J+X;5^/@2 HYUT*5FD'+[6E4U.U5J*YV, T46-%/NQ_EY,:@I
M"K6YBZF<;\<!NG#0&QH)W7<R@-( O*T;#1CRGM1T";Q.4DGSJ/HE>-!9EQ7*
M,^X;_D!]E(GT_E.G;GI-:0#K!2U2Q0?K*"KC-,K7'U=BV46TCO5K'M6C<L,;
MG$9+%[JUT0]SI2W6I:Z=_0[D%;HGY1SK64YN-5L9+&&O-T?V#7YELKF-ZV\8
MX&%X7E4%V%QB!FX7HQ^05 <*DFD  ]FP<IRPS*@Z8!W;Z#(LV]JQ@O@XL[_Y
M-,!6Q4>4\L3F"5K@9X?TV9Y$/'2P_B0RF-CE366;DYIM!M>U]Z)-4[R]GC,7
M9^HPE#QF_>MXJIG!?P@JV,U&''2^T.VV"C\%7K?\,.J3\[V:.>VM"B,?3^<.
MX^,Q7?>P68]HC*=U=/Z%N=H@:RZR)1$5IU5=NV2:5[8YVZ;#ZVNWW:CYJNF>
M_9N5QWSYD:WD!RO6+&"C3!<)'AODXJ7D]M2B)5'(CXEMYJ/Z.9R!S?5+BNO0
M^28\.HKD0(#%8SRCB8.YA;\<;E@5@X+6#>]39I3W/V:7I.\75U$/\&W)_7[V
MG(7;=^49?T%X(B90[/KBM8N>.!K03P-._@SK*6%JG_JC3 \M! ')TQ(ZK]3?
MG@X59ZT;OTPZF46H%9ERF-!2O.1FT6VHW')0H&O-]#%,G3[A(8^]5Z#1^5 2
M.I,&\'?#ZR,^<X-__O@+/\IISHJ0R9^<LSD^'6Q>W-3:'KUTQ;R84T?SWHAX
M;GM]$Y41:4Q$#<!?1HB0S)X7QRST91W\;6J)6?0=:)V5)[Z9>^D>_$#RR:O'
MYKV%IZ@))&O0)>P'63N6K*#:^(L&$.D=V8>AV^_Z;=<[!3['#@>I7Y_Z+3=]
M^CJF[;=(=B0T^L(\H=QWD(_IC#O;.'4R>\7W!-9^ZB&WQ0]+I8/?GS;5]K0;
M8PR?5U4(#U_R9/PIHHB_0 .\=U.U,4TJ&:0#>O%H9OC)(7_?P,J?:CWSTW5W
MO6X)>T0:2Z5(NB0J^<GHZ3;X9_8PWJ04&:B2+]*I8]MZ" =YJ4SF7J4\7< 2
MY[W4O[6^*_VV*-U2F?G07P'5;KQU!=B7N?L*4JWXI@4L6EG8%;;&<_@+_'20
M4'IA.5(X\,YH;J(22/]R<@E@$DO[=@L3)W@SPW ZRSA]3-RWMDQ _1%W=^;P
MD_=_']J;WG+G:GM\BREI)6HTXC%9E!22BO&@QZ*NU8J!A@J0PW:Z>9GGT6^9
MY:^")W9\+V]8<([*H".L.NR.3Y_&<F3ZB#V/R+*%JR%R#UZ"6<1G>!_T>1(U
M'M]C>8/$OQB3NT(#V!%>%999F"[5==R=;Y\'A%Z\S^;F0S;>B]BY.T='E@>@
M8#7"S!9L*P55;8@><5K.X2+?]_I@WBFK)NWMLO>\KFR-Z#N_K]E\G[2F>OGR
M?]#)/G>U?A E'C$)%: *@BR61)>RK,C!+(5-])F4[;[:F9QK9Q#%KX1=W@['
MG#R?")4:KH-_H '-0]L,)&]\:H*^+7Z9'<%KW$%T&=C)K5G8F%J\4_?NF:?C
M6&:$LUR&Q)<7KG9_'TH+N?0S;BO@D?=(/_ %V,4'S:E\Y"O$@IB6!R;_S&^*
M++:4XD5WVK*D8WJWGHQ:$"T)05!A*C=H/*0]6^LFT5..1?HZ'?X]M<$QU,7X
M=/:;QHNW'B?09\&\U=UH.(0&K)2XZG2##=X>P26C*]5"M0)[1KFW;&$Y%6<N
MX/]YAQ/]+GGJZ_?G!MM$>#^*C6S1D'/89R _@;SAP;&5OFHR+=6=+'I<,]$$
M(/1%6HI K"'ITO=JKY+-,+_:X-)OHE9&'*+MWY]=C'4LMY>A&\>M5B[D)2)L
M ,6)EHM8G-5M^_#3)X@+8D%L^>QZSM);=2NM2C\%\]"D,3C%S'-\;/(O@O&N
MW.MQU#&]IL-W*>\P6X56-*!0!#C:2%#\00/BET6[GU0B_1+Q<GVU&D99_=J=
M5S=S9KL(J(M;09LAKX;X+/F4ZI7&#"]\*U0Y92T)A#.8(#NJJ3,1VJ E<7=P
M#L9#A:81MEEN-D_L/RG*YK4B73F\&_X&9W'^4]);\]*.5*_UU!$;1,EJQ2#F
M>0,8V(\1"((S+8&B-Z9]]Q>MR/)SMDN>UH_Q9](^?QY^(M*ET&$3^_9YF W+
MS,VO,N9N7C(/KM@X9:< C._.HEUFT!?)]T@.VQHD"-[Z^7X]2^\#_(BR.D5K
M][3L5-PMA%.^3L(YANRO!ULX-];*XT2>XG:4&-(/3"6Y'5A1"O>]CU6YP&=#
M$:Q1]I/Z)FNU P/),V_>IYMF?HYU2#$S_:O?UWMU_<48P#(=)C>$BD&?12>,
MF(&Q>*M;O[WKWP_YN]4N6$E_.SVZ%NT@,QSMUAP8K?_$910))2X=VX.6>.A7
M;XM9?5GB#YO<?EQ93T_M3D%A=Z#C;=1#Q2$%O4_]KAZ?(>?Q4<22]'#57IAH
MA";R)H@G0?N6Q*?(O.6@<Z^!5*)U^W2P8]U:1U=;4/+G)Z4!T3Q5?VN_ZWP*
M,>VZ\/!_&;[$;KECBX@O4#[]<R3%?E?^+_J,'N4(Z3LSS5.4.E7.SD:<'E1%
MUN)R='?M\T];G\:&UFP4ZFJ/[R+=H@XBWE,*I8BQ+VL-Q%BWZ^JZ=2Z-]G=^
MSJP_8RPS<>>DX\W=^Y^27OX#I MM U#?";@^V9Y2J.\,&[1BP>OTA2N:32-O
M/"N!<C_2'8I+6OYZY)KO_GO53<S$U4G\]XF3=QY;,Z7!>^DS]* :[_*,(/C2
MX+RC5YA9 E*XL("OYS!VR;1A)NB5:'#_N7-[TNY!:LT^SM^E.;\60@J#:P.O
M$V?30JLV#@\Z;V5Y\%H'AC]3QS)Q5X[H=9VN*@RPN,"O4E!Y>V-68&Y6Y_S2
M5Y<K38:!_I+I%]WNLG>^Q_\3R2H=R86$DK"$K"'K.&A#?3(YL!JT[GL:P4R"
MQM2=C35JRE_;O*4=.'!<G?W _]O'RP]"DLZ\>OEJ( 9WM'F HE,?A+A,':C5
MH9.;6^&IDNNDA[$UWCAT_+V:7X>=LZET5/+RFCVTD!W(RBDC[)6P!#V;%G#Y
MX,<H?::E&@]E^X:TA[9E;5_R($X.89]P%.&S55OJ^=C66UM_[S>L][_J^SBI
MG^\FMFL3J7X]@#F(*D-IZO8OI,?IK#@5I'+I/&((7Q]?J[DLZODW<T-8<RYX
M,?C^IY]89(!2G#N+I]FG5H9"2,//>D$00VJR)^ZFH+D1QKUIOSHSJU=];4OS
M+>?7,B\$(:34%^^<';IC(")K-.0'+PFJ:UMMW/0E>@Q&89L<%S:A7QU."FO)
MYYL#\R$[-Q_<?^HW".&*#+A0R+5M.90O/!'D'.YF0Q+(<"N]<RWSRX:@SH09
M4V.3C^.LZ=VR1&21X;!^<"V.W#1SEI2930.8L."#D'=#I9NGAVH]U7]JB]P)
M<!XC*<]>N=&=\LG=0^A;T4W&270UFC[&4_$Z_;NQ(A[]%,5>!P,ATEBIIKD[
ML<LEL5;A;XE'LHS7F]H^-;NNUVZ#;-*%DE";";C&'6006$9R(\REZ,L1HRR)
MM?F)*]E3UM-D8P(I4-UE@SFDI:7;1I>?E95+FG<8;RV\#_DZM4K'=Q%]6#VV
MYA<'?E<(A#L4&,XU5WY7'^"?=C1P5[FLRI?PZ5/_J=+ I%<0AQ#'B;QYA<KA
MAQ> L#G^8G( ^(0 YRZ _(*>UE>NVNQ-R%,9N=V:LRE=^?OUB >QGHG2%,R!
M@9(=02A1S7_'1Q^V.FI*W>R'N:<5I6_T#7Z[/AMC^-$BE*LY*II14B)<CN"Q
M%4L<(LCU'6-..H.6)D0<*_NOL)2,\@'.(_L/+)_:7[PZ=\L4^]ATQW E!]B'
MBB'MB'"LD*\L*36Q&<HV@/C<.NF=\U;;4D^>.5+8*80[[6W0QQH8)&*B@(WL
M4FU8]A/.2Q:M?128U^#D195LSO>"%!>;.U)/H%TH-;)3:$&D*25#D'"R&I90
M$_2LYRJ7]<T"R_0=Y^_.3-9:VT5.PMFYG$;5=]/#..?TCBV1UJ#4L2%2BR2(
MA4=3V=M)J0.BE3:_GNKZO_1KWLS3OO_3;L?B1UN<H<@/V43 [!/B$4!ASG2/
ME,MT<%R][)27<N+%L,P!_R "M1J++1  7S0K0X:H@K/! S+:N16;VE/?(G6C
M>"[Z&;S>4QW:= D9@I_&>/A_W>N_W3SII;O^\B@U66+6([GE9F.K\9J@T-F+
M#R'=G#QJ4V+'<@/U7R'XH?[QF! )OD;B4AI>L?+^6'+-S\Z@6X<BES[=Q>J?
M/)]4)G1.03@$,#4-O"SQU2E"AG0K<651Q<H:/K.E>4E;([9[NLYNB5^N4&6-
M86HVE?U7"$XN)BA/SVX&ZCSMJWRFK6-Z/<GT,$"!V2O;4,KRM..+#V<Q%Y%6
MQ"78P@B5G7L5PPH>VJ!I0'0@<7;LPG:0WL7/9P@/?V,%)$D].49C[;[O1-:>
M A0FHO4 B@EIN4<GG-.DE!>$>NEL5(.6N:H^YK"[S2=8//P1O:/O$R%8T6IG
M?R%P%1O!V]YI+-NM^[W6WWU/_H)2I(/=!PEUQ3W_@RW*:Z3J,?=/-#<X1]3:
MU>>M]0K[K'UC/O'7SMT\&0LAL4];:[P2LT8+3G>(:F,Z9+ZI0?3I.;1JQ"A5
MF52>$5P%GJ4!)E:6-Z:4'&OV;@_+!.A[A@P:\_M \B**G\,LNU7I':Y,&JP5
M>(T?CS<X/??' C7SU2MLN_;S^/Z55PWD:DQ]'RKN%H81K:\32Y]AEBN'J4&P
M>+6-)W>TB[2FZ\5.<Y+7*'4H5>\M?XTUCN:\Q>I#59.VKN:)+4E,GE]]2:1F
M>YXI4SHSPYM3']X6##Y7F3#A VS_]Q?#_]@_UP%[B?E]M5N8!MS]K^4FM\#4
M5>L9ZD--5#3T"I^MR5T?^@_P_^D*@ K!UM(1"]0/(<M'U__H]&'^RE+ICNC]
MI0)JW-78519RNK4H:O[4,3WX+Y6##C1 !D//8P<L3?_K(W<T8(_E/]_]B)4C
MT^%H ?.NH^;G@:O49%WSXE6<W@A'Y><;AO*?.O-+:$ ]KJ&;@[B A7/Y^"GK
MZY29E1L_)E@\[?HXABUWFF\8O'[RL;IW>7&[W[:;Q]6WY57M=0^:6C$(AP_P
M1ITAWQL'X> Y2)2^&=%AE?E[@\>[#0?F9@SSMQ'.1.5OC>5#OH7KC@&/+QW/
M+3?;:1E< V%$&C"(X8Y0)5\!-U?].5T01K[&V)(^JB!Q9J\FZXOC.?5AF8V7
M+],M.E@OVCB*$:VS$=+X@B1EF!OT*_Q*05_.FNYL,HGQ2L_T_B_-7YF$P:5+
MIB'I3JN*G9KV4HGG@1-L%^J_L,LS_G"&GMS4@;?Z][M8-8]\U'0Q_J ;4>!?
M->Q#F/DAJ&-2XJ36DF?\3N'49>G9;D8L]0R8B,?,I]X"N>3H[2@T2N*9PW;&
MQLID:P[JZO4-*X27ZWVY:OD&KA"?Y76^Z'$@O$C3AN6'?T*W"4$U:ND,)5+&
MFF4#M]1T#\]U=8P&8#/?Q_WAMY]48NZKL>.G;!F*=S=%#JKGF==[$,OJXV">
M,%Q3'X9G/(ILN#+.C(":H!N;<P<$E.\]JW)=?&W&X4,#NAW=DC5Z(M?C/M!!
MGDX=S$$P,:0C&$QBIV[:Q-XFJAZD'O@(_#ZS,'HP+\"&7)=W>E_%OOV@=[/]
MB>N+R]"S$:,8YC\H/E3OQ:""&%?)QAXBNJD*X6\S619ULR6=;6LMQZ)/,^T\
MIUJ',U. 0<M*A"!HBX>SDU4:B:D), _5A*/E_D0._LGO4_MY_HXB$F4*JIDR
MENM=QYKGS4\26$49)*4^C/\*YV,@H7N("TZ4MU1EI"I8@<?$'J64X7.A3/4O
MM,8YP$=.6LZC$@SJW[ R#+'93^,E/>>3#  ?L5>\>(..56C\,M%&D0:(P9%Z
M)-A+)#\4ZZ69ITX#7*<DYK]A#MZJ0S6D#^W4]M0X7AU+G[KI5]_H60A)ACV
M,H"Y6 SQ&H*L7(T(N35)MJ8!K#0@[AYUH+LA4W19W3)Q2B14J>CP0I""6KKP
MDVF'UX^@',''J)/4D=]D8WK>3!5%JGPAGVW%C;]L'M7V3DQ4=OYDG^!=S=^?
M7E7GP'R]3RAM#/*+F8^!V-:+8H([4Q=P@@E!T"@=% =:I"U*5;/G@DI2ZT.G
MZ'X[S3;;OB[?I6NO$L_QG(]+9[@@AHXF0@=@/)@'\"3,"56D6JUGA&IBO\[1
M;,&SJGE+@=>5J6VU_1Q<RZP$$Y=83O:=84;^(VD3(")P$:D!HE:5V;%8$O4S
M7$!+E7_9@JN'FDR <&\^S=%J^(;V'J[LF<+*6(R<,WGJH_H)8CVAJ.>Y5;/2
M%J_?7F22?)KGZ?/S)ZW/EM.CY04MU?BPMH'QE,ZL^ @UL@38407J874S5*.Z
M1<L19W>\3\H_UA)M-/H[I:-G$QG'MOFVX#&E".,U+H'"7EKP+N"($ $/H'R;
M.2\F5Q-H0%\6Y%FID<;WI9Y"IK>0/\_0M^ZS?62"5O\LA"31@ <P480QWB<S
M7VB"RHMTMSZ-2/D#=285)""A@;S+BQU_Z_QVQ%,SGV=>.*YDV[& N2TZFX3Z
M*W>3:KY<C;DH_>3U VDF[I\FEO16>$(=IP%-D*1NZR<D_P_Y6E]:1+E8^B)X
MIPV@"&O;Z;M!J;:1.T<;>#^\!X-CL6R.GRM@+V[I$'XL#$*'<K(^8!)<]<!H
M_/8-"Q(-2%2Z<<U%FSKIZ(<><:M0KH%V!)\JM] _7$@)B1H+A/O;7H;F+G,8
M &#N@0^H3'1>A3[OAE0;KXJK#/L@0U:.G<^9%M4ZWKEV+>FN]+,[?>LNAL"V
MT'$E<UCL-EL) C6$X=9RAB=! 2U5<83ZQJ=9:PZPHN\V\\S8.Y%F]W'?T+7W
M[2]>CSE$7^-]JVT27F("(->/V4'%030+:%V#0[1>>H2]WCZWJZ*O40*F;&[K
MIN26Y$4NL2W+<?WN\AG&"7$>B*":?PR*HDYY'BT_+R.J]EN?UL8464,.,"^1
MBMJUWCYR3O>PZNJI:D_:AUX]'OFXZ/J'?I/18RFR36L#$145P3^P H\/\_;4
MU7R*6E@Z1T3B3-XN&2FL-74Q/=S*39TMIP&1*73:SB#?H.<#(=A^E<C1]?;4
M9!3K/BH5RM%" Q@V#W5FPPQ:>(R?:.>>D>VK^MC(E?1SXY1-\(U!3\9U5/*2
M JE@.Y'X='R%TM8W+@@Z.)+XCE!DF1QTTWVIR?UJA)]4>XZCRJ'03KP:@U#J
M4V/W:&G^+2B$K%'C1,5!!;6ZDA6.N 2.L9U\ IW_9(ZU'O*8^G7WIQAI-ZFL
M?V1*:_>H?88N>)CCF]Q2:I*CAYB559Z.!CB/2;?D&??&[2GYY$O$K%6/ <5Z
M";(:O=.3R##":( _CR=5BLC_O5IEL!UK[17H_4"7SSWCB1/[JT\T '%7?J&3
MDN-'MCV^L!F6^MR #XZ\2%+&)"J1G<L\7:5)3(=SN"DGW3>XM<^[!UXRJ9]M
M)0YZ.=KWT@Z3Z4$!M2U-<ALL@#8O1W?JQ*"YD(93DLVDNN1*,/+'[2_N+WQN
MG>N5S[M6):HT):E65:&\E_!G-UJ";W9_=R%J%=T34K(AT"E15NK)[?0H\':G
MLXO^XX\RCF72WJ]E3K)?UQ@-EZ7W(<LJ/"9?M1/T/O:]W8MW\?,N./VHV$I"
M:/]7]A_98TWCX,[HSUC)I/+0DYW+B4?,Z,)\CHD(!3)[ <$,BP)-E=U:9S3%
M!;RW_2VFC2ISV.RT><UXY6]TGC^/Y9J2WCJB-UTN%M5( _I5>9',X+L2T.WZ
M'!*&KT0:EV^B3B'E5KW+O2LS1S,M2L*W;@M]OVMDNL8O*3!H"34!]U93A2/F
MH.S.>+E8-#^XT"?2%B_7$@6?05J54=*QIJTIB+5V]_; QE^IF?9,SFTGQS\]
M5MR^*L_XO3XV@F.F&;500KA>%^1\#.<:7:&<^31NEXXS]%9*Z]I)EI7V5D]R
M/V$^KK66KT3)[;8BY6P>C!/?3?GMOR",](CXLM, F[9T4>>OOK63]K_7I$_E
M^UQ-&LGK^#&))OXGZJ'PMT%!./%U:FP9Y4V$TB,#G0['6M4@9>O^VS.M\:)K
M;$XM<IT(3NET]ABY%\V!J1/B@E:QIA-;FL>(6[BE6=:5%/ZT4NZJ2INBW$R
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M2MS-)O"CE$EA^JK:"J8]"$^C";5KYQMX?R?.Q@S)3%M(,"QRW^= R^$\CM0
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MP>2 "6HY$NY('=HM/RP*$!8E!*4VF#-X"*05^R$^ O$W<KY\W+;3NMSP5&-
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M@6(,5+70(5I*GW%,(*)OT:#CO@ B"N%1)+#:J0C$4I:)BMG%<W ]RE8\KD\
MNAF_S*YM/7'DRIWPSD7*3?I>6MF(;/1/"EA05VH-PHK %^MR3SU%7?H(:QOW
MC==0QZ;61#.W=$3]6#MS!'_FJCKG:AQY<PCZ1$RXI6I!E-*<I*L,?P+D4DN6
M>[1P,7]\ 9MM0$YO?*?*BK&T8LFF-8= ;H6A@QNY'-A.(#)""K [L(+?R=\-
M PL?27L><8UWBKZ/V$\8?V&\Z7 _+^!R1OJVL?/]'+.Y>U'W58/]?SL[VNS&
M >LG,5\=WU<K>J*X6?!\#J'55IA]^5RS:D]>?ZV*EU\7^[0-A4U+2ES>:#",
MHNMW6ZFA1RRE)33Y0JPC9^^,+M<$T=3,4K89YJM JRQ-<GO$#P[FKG)U=:7X
M)5'1@'7GZ1F:M MA%?%$-%D F;II+6<ZSVI%Y6V$EAC^/64--=DLI&=>C"I.
MQ$.%\/2K$!%X$'4@2?>J$64 ?XB,]U':^.,10';O+92Y:NKBSC9\"Z6,H9<;
ME(_@^S5UX_?(;:IY3*<.-3SRP"A\6E>2RIM<OEIX910N6S8BW8A"7H_9[G;7
M'I!_&G@M2>_#W%W^(!Y9N;RM@ ).^W^^K'J:&0U,Z[+,Z#S *_$"(1B3#F1/
MTV<OF[SK\^F7.![1#^?PI48LO$WOVJ2O)* $.9'ADG"3PRJ4Q0>:%E4V]B-<
M'S_GK<2)70L)_;B7D)-K_$$]2N")/$L"]^#2Y8P,/0$(91+=P%Z[07I'"VJG
MH"/0A+..6C-6:,J?YXXU9=?KSD@7\B>_*AGB7CTG'R,.:M?@67,2!QJALF1'
MRM"=YA,V%>K^$0#?FY:<453=WN] >;D\9E/9_,N%<<MBDN+PCII!,1$]T?@<
M9=A=,,?:"+$8[^!]M;@ZY?W!"-=;Y6#!H"T&T5Q^8H-5M^XE"#89'UCM6PPI
M*RR@K.U^)=TK_&KE[?EBB./+^V<@0RG1]/0!IO-TV13T;AY HLYUN1!E,?.R
MA,[6=R;/CB"1]D<O9KA/OQIH\BX5B[O4E'I@K] BF94N-WXD P^@-F[ULVL3
MP#WD<\99?:7&CD'V4Z@[XVIQ2*^1SZJ7Z!GSW!\]^[ & BVF9&PC>K?BIA%G
M=10JO_D?: +MW;B&MM?6,XX4GI1=+0NTXLT@[_!,9C8C\9]?X".HJT5Y'4WF
MG#2]P\+P:QZX<P%%G%XXKC_?0KOS$/$H"W LV6S^L+ <&N5C/1ON^3B]WOV1
M?+FL$*A+N"@:[('F7^U4H.YAD EYNLEN5%9,IQ#BO.=,GN!MK$_UXQS]RP/B
MOR7D+L>XRH=0?KK^#<\XL P?;2O:F'"GSAQQ(>.I@-.<F4#!9L063(UU"-8O
MF\<?] H_R#$H*!__B-]Y@*?C'>#>5R2HJP+LD=CW8M1JS\ "1[J"=+DI"UDU
M#L$".<7R:1-FSZ>[<E-<Y;V0@PS";Y=*1N%,1 \$/D<%N&O.L39(+,4[Y"L7
M-Z:4'(PHMW#]\]ZDD+G\2Q':Z$31AH6.8*)27"$K\*#$UFOA"K4_^[ S5^O@
M2X[6W5=<MC_OUA'F$Q]]2#(TOB:9L@97!&9)@KXI,Q"6\$N>;0K-2>_&$<TO
M4ETP3]PF=K0?9 UEZ[0FZU@9]CW/?\-SC2'H[QS1?6-5:QU"?R2]OG"**IOR
M1XZ3#@NSZ=62C??9W-A)5<O@M:WAOBB=9!?8/B38RV&HC^UE"P%OS%!(W?5P
MC]S>(UY C@1F^;&:YYI# =H'0KZ7"0]G&G==1PF$_?RL;%8J8SW[I8M)+)TS
MX+!85\TV? 1W1@W)C[,=J;I>F;0P<J=1,V=WS8Y7\['5G/^GP>XN!CR)A[B@
M NQ0T7C.^#]H89KM*)P+'.':UMP\74V[*CV.6[FDDRQP>_OV-^&OI6UR&_<7
M::U"2+W#S^%<ZSC^SM-K N:Q\$0=\W*(W;J]6\?$TZ2E4+MI"U8-*,%.7Y-?
M4HHMCXI&ZFI2<\E^E+).;E@H 9**$J^"98;:JAW:]&(AL_*JWA[+::9QIO':
MBJ_^NMV[U?[L*:W\5(0VF _N _35A$\47@(L*+_O4IZJM^DFNGT\!CV%96J7
M;]/&U\94#,14^*#YQMBS<EFH;!Y$?Q%ON(HC;*+7'A+_44<0#^: A3V.1)E3
M&;4S&.N?C<5G;?@-R-O&LIQQ=7]:"-(A[F$@S%XA2N14*L0**K(_@]D3$1B%
MROLN-J<[#(\)IE,'+@DZIJLLGC+^>74:Q0SCG3 X?'LD[X7@#V<"<HF[[97>
M,@CFM28LWV[G*]7JTHWII._P?!N#]"7'B,R[?H.@H'Y1++<O]NJ_VB1D'W0V
M3%0WIC+UY9R@(,2P34.=[]S<VB[32-/+[=$VXY3RP@YS^X,CM*HJ)*;HK/PQ
MR'D$RX=IB\?,FQI1[U93M12>S&':G(KD*W>#E1I:S6?596:+4XPNSE^XS' '
M=@IMND*/!P.7W#%@_G41UBF:2S6 O45YDE6ULOH69G0G_FOJNV!\FG?R+,>=
MVM9?S,FQ%I^6M6-#1LC+?HK-)31I"ENF:HAL*BKTO:? >.E9'WG#OV[149KI
M_1%O_HPPJ94>@TXS4]XWD\QGBRS':==+UP1VW^]W9E^>]<RI]5.^V1E;$"4F
M>^9MIE\70][$X6== 0#97\A.B4^$BY8CH+#2KG#9SU2SFDQIKJ92H=,YWFZR
M$2."3=J_](2?Z6ER8JVZCT0 _A.V!*/BHO^8@3$:,TY7FBBWUE9Y*Y\V6VN,
M&9?P<YV7*U&]/5348G@KC)^:ZT05C0T_!Z =**F-!5N)#=\4B7OFC9,2P>*%
MMB1%23=#:^TF\H7'@SR_:Q/4S,^&3^/X=+G[O"G'H+X%3@HDJC&26 VY1XW+
MP?J;A)Z_T]0T3;TV+\>4D6S,V,>*X?:#.&K))WQ9X[=]5,46=?TB/0ER(HV:
M ZLH)#RD&RT,LS*<V G=$C#BK42X^Y_/5&C*YZG(.TR7K.3D?W'/]I-0BK)$
M^S$H!<%_<BHI"ZY.^:,5,!T'/_T!ENO4D:,1[)+X$O,DO:WE@>*1B_#7V0<D
M8>_ED=F]73>J81WU'-$&L\6WPH=%1.@($LCN/4X\G9U-&>*H:.N.'(0N_X7'
MP\\^^A7$;'QA$E74 O\H)RSWRM5&H\^C7*B"F+::#)*CC6$SI:,PO\+!.%=F
MY.Y$#%>;Y$5?W)WMUGX##4G)\W0%![)'H_M+Y11?/+H'$I,3XM-,/("*3&_U
M[M=4"F6N+HC4R2.F$Q8-,Y?TCVK.8J82A&9J@/;=!.I6(MJC]CQ<!@CSQ_MR
M>HGPU]<5$I?[<1Z9CM:FKU(BG^+CC =O.A;C_!^_8N]87SZAE44@N-F!.IP7
M4* BNYR8IHJI:;FN3;K:E+#JEZ7WIC\JRL@87N'JJ'G\O.9M1&!*V.2I#H/=
MF#$4F(1+R*NN[>>,$,A-0_$'N'G+QM*L" JGUI;OI]JKN#>AMFT?ZGU=ENMY
MS_)=4")"]PV@7P.;ZQ5A:FH%8@GYD#.P2ND<P7PYUJGVIG2Y]*R;^$7)F@MR
M\*$W F3O9:4?-MU.:A1P3]B3B;ZZ=6N!@'YTL!^A0+0W".(Y^6)>:(.7<O>O
MIF_VW).[HUWNG_;5_Y?J7O!5M(?Y7X5"Y6-0[=Y1]K[+_V8[:\/(,6C^4Q$!
M\=(\9_ 8A$S<@;R)2KI8FZS[3NYW_:[),2CSD%"TYX/^DV-_>.Z_-?NN;T/V
MY'T!A(FH6AZBXS&B;[_WY-3_PZCPD%O/G:X!Y@1PHHK=$-%,0.&N@\Y?%56D
MX$4I;A9#AI2T>(G.VSK->TW7W]CWWDZVM7ZY#W$I'=^1"W._TS"I(#K<V!8K
M&TLQ7'1C*V<J9[ 91% LS?_RZC(<@V;M1Q%_6#_L+_V?.H7-_^D4]@C9K<*+
MQO)A.>,"1G@ZXZF")M-*\JCKY:9ASYL^]3UWS1I*.1>9S:_)[\:_]&X]=:.U
M6;>Q-O</,@U\0?<:$-U_CB8VCA(LAVE@[-_L7_8J5.:S'/JXH*>7_\4A"")S
M%G<QHWFYPHE9F"D.\53._!PLRV1LAL#4SZ[<R-I2?7JS'%^5H  =3CLWG'?C
M64;-\V$8Z!P6-4<034"9'HB:D)#TWL<@=IH;<5Z$U,N'Q<6KC3!Y*E3>"CX]
M7/BH^8WX8>^7WDH5J,&,&%NZ6[7_+J6E_K"(K&-=*%0_1O."/T%S-EX'VZ+D
MWJ^T53S_/.2OE7)8<-Y7'J3IQB_L/=EY'E9$>C"04EVMXUD.4^HM9._\%/I*
MQP[?NABE*6L-,I!&;7\99^*7,/X1F7)6#J.C01D@@B..3L-J>[6V,,)R UKE
M2)T C42:%5Y[,FW;&RH3^&!;H9]P/E=9RN\3TS7Y8/F2NDXFFG2TV6&YCEPM
MC8O"E*9['L:BX%M&31&YV-3V:6)K$19HW\>>C=D,YC5_]1GZ@#[Z1T1 $3O"
M<RNU2%1'M *V1:C)I6Q9C./;"C7A+!6./XUJ&RSNCCD'T[IY4#5\(57]]QD?
M-JOM*A;IS%BK3SQT4"OHS:@:]/E>X^Q,=]'.A"&ZWTC(9FFKCS,^4%>7<M1T
M)'F83WM . 9AU67:>$7$@8#R$<_WYC"[O@[B&HML]J>HE"5_%/RG.\_>,:@'
MJM0;(MJ#8_9<4.IT-.\+;+OU4:"16-#CW1A[<Z3P[[,!'?<:1C\]$1F<D.XE
MVB,@@P2EQV_F$[05Z+N#EHTF4?HD.G^5A;7;Q65-S4GSHQ7(YXP9@[]:K)S
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M#L3#IR>.)L9@>0O+/<\]9D1$L\6R;"8VS3:1%76*+(VM%_/KZJ7]NAX/UCH
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MYP"][?AFHS'YYUR?U(PZD%I&[]5ZK_?2-7$3X8OT&10(F8LZ07*/"E!*Q''
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M7V%@\^L6@5*-\+Y(VFE/BB21+_JMKCJU''-=^86CN\GO:7ZU.7Z%TCA\_]9
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MV)ECV63+B\\.''L==?O#;CO=O @][\ P$T]U!?PA,.1.)2I%A3./ZXI@'7\
M6B,0U%2M_":QKKF@#%;#*P<K^_EE&_JC/5*_I?Y:U_5F,I10X-*;A^S*&5?-
M)UN\P"6V.1ZNVSGH]$S/*FQB1A1' PW+7O(]!=GZ?RFCS,0%)"/FL@8$_K0]
M^!,B/!"E.F0<H-'D!Y4?#'H^PCV46C:IDOEVD9&I ^0*@?L Y=1SQ/($%!VE
M_2[EW568.JO'B=<CSAGY*V1TYBE=L<?JLR60(X>TP4.C47[M&51S<C'Q&,0*
M9P5F@RMA_D;C1PHTA<QI82,SG,)T[K-F!?[FUI2X-'-%X]D?E\0CG<(N;Q;Y
M$<&S[KL10'D5#A#M[52FR")KR#OY"E8]6MYK-KP:GLQ)WJ')L&,0C*<ISNX\
MSPJG5?.@KCQ<$HBF\N%KR4;4RWO=(?U%-7#]^-N?*2<)Z59KT?VD_D'2 T_Q
M>#]N8]-KR*6+YW\G@?Z@$XH:F@<0,=YXI;/>"ZP4G\JWP+)U](T)./C]PL-;
ME;8X1T.RN]">XAW+4S;<*H;%S_S:HT*1S#0/H(@ P4KJ 6Y4PY$>FRM E4G[
MY NH:4^R/U^60IV5 FI0N^D8E+$MY=@Z,+^<@L#.=?_3S:VC?:#1]\XC)*=2
M)HL*QH3$O<VQSKSSE%QB$E,_?%Y44?7+3W)$*[]$8[@<8.4PB?#AC!38>8^L
M</0(\<FH[0NMQ'AM0;VV#2ZDNKUDK["-.J_,/W">;N%H&KSM#>8';]R91OR)
M\P*0^&4RW8$D@-BUH>3DDQ"<JUI-S=Z$(5B K6"W!O>0*E%,*.S='(.\P[O"
M)U>_^.SL:9#5WN&\<?6^?6%7[WQNF0R0P[%X34\W!6:HUIO+S7ZM%)"(LGN=
M0*<W*$4'T0@?033\&L'\TU?35<@ZU<D(=T---X1QSYFUQG$RC"P.7C;DBLB\
M4=501'S*%O"6DP]H+_76XJ1QE9LU3N]<#+@V9/?-A[)01NSSVD^'B?].S_87
M<CN7QCB/QD JLO]FD;9F<43%?\88S '1;]'1.UQ$<VX !<0-=.?=9-P-NSSM
M\(4?FBW.),ZK_OS\(]]K](R=%8V'C1\W:XHCX+S %%?&E,X@G/5Y1:OFD!"%
MR5]/9(HJ.]#FVX.+/Y*DQGVR]0P1CL'&=J6XS4K>Z+L?Y))"MW8+KG]@2KL)
M;!%Q/]#]X8I4<"Q<VA._Q>7A;%&RZO^PP.5V<]'C.,]WB/D[AK]^<UFJO,UD
MN7S_,/9 'ZZ,2#EY6!04#_.Q_DIZ.%Y>'T74NVTD=VE[MN[[*,&?G/>7B:34
M5YOH=/DP3:TV=OKD-#PP7%(QH4WF7=TJNTP>K]K]/.+"K^?-=&,F-Y'^O[H&
M^-]RAE' ?=4N9D UI9S08#VM4+Q6"()Z><>G'HW7WX"6WK+&-8AS-^E;/F>2
MJ)X/'\W=!Y/UB5MT7G6>NPL<HSJ<HDF+:"Z3W3)$@Y8Q?S-9.<;RV;EK6UC4
M7'].^"7 ANJ"S^VMPW<@>A<$/U&>+@A.5_]A94)-RDMG/,K44!\ZZ'<<@T+?
MDKN_K!;ZWZ3X)AV!PR=P/#OL_MU:>U$HT9/0CATAS&L=V'R&_7R7A3);IML>
M4+<W.INS(+G]([(]@B-9_[!4]SHP0K@^T _EZW;B2NXZQ=)H"F:%F/L?MH>^
M'VCY6_)"YGSVF.G'<(=35S1<9R9.^']H&=R2PAF/@A1_&?<4^)6BL=NO'\\B
MP7@&4\^&3^L5H%$IYCVB;#!Z0FIY-,K]X#K->B9<TC,0/5O+%]]8X-9@YG13
MD-NU/6T5BD_2H[_BYOA:3+R+:>L8%!U^MHG"V8-FA85/8*C 7596YA(!(8VM
M\!Q9_BO)\7_+L":"(P_O,0V),$$2E(]!W2:Z,B:'I807XRZ4HS=[)0[:2(T#
MC>&7/2?IM]&=27H^TF#V5H N.T"E#I%FXGR/Q.#RE*UH!3C]LKE(HCLQI^UH
M?,8E=E; #?;*Z*EP1A23S34AO-!DEJ=6<PS"9^3\FE91+,H@E% D"%AC3.IG
M5 NT3*M,@TLS]24>?HU(T'QD !Y*VQF",U&74\&N(S%^<$DJ4P^2'ZAWHDS\
M=%C)*X]M:&J?"*@0<<]D$< +-PWLO0IX&57\7.4N%K1OL!L*C/TST9 9#B95
M:WV'JJE=G'?_U'(M<YIX2>!2B2R]MJLA"._Z"/\$53J $PZ7FP^?;$-VG^B6
M?:-8.PG*MR;T82.1R^_SL.KV+9D_B=WYFBD2BL-N@W V&\B!($U\1O<,C6E<
MU9SG H(@AVIKG]IYT?QH;,#?7_OK6"5#]">58KGNR\;X&;5BF)5#_-&9<\0B
MKL'2-1;":J<(UNY6E5I5LE$+WW _3ZX@:^QBQ;4!S;=GG.@.J]6@G"8 SHWJ
M?F?B*<J$DBW>.B5#&<NH5B+7*&")LW@[$]>@!W)UK_ 96:N1 ?\4UE&0/:'F
M*9V7*+XQ?%WL#/8%>W&JLS5I[2[EQO?_+O@7R9AP7="^5:?)X,/@W%K+'3ZB
M*P&T4HUVL:-2$[ZJR> +JPO\\093M=7ODKYOPU3WP.VY%P),LGF^^LP5&L)J
MK]<#[OAV9/RND] D^(EYLGUM+V-S6L]O_?Q>@6$MJ<P(;D.MQ'9O/Y]GQF+*
MW?3N#T%AC_%H+,=OZ\.W*#?\-\>&!@HJG&^"!B%4WYZ^QFVW(?4S5^GJU<^=
MLZ>@%ZMB'[\I]/ZBRW2TT(9.0[N;IX#/TAQ*5K&*U?C1O6F!%RQ2WM=?[E;J
MOAEGS$CT-'6YW"640F>':#;O00@ " R"8Z<HYH@'U3GE/.;;*>JXVG;[6^ T
M-HS\-NV:@%X9K3U8PFKIRI'\FW-YRT?7CH:/I.H/WW:*P,[UA)S>F>G!\7K:
M\^82\[\H"%>_C;Y94);Z)/V2,>U+C%^%_^ %_E4]D6ZJMB65KX\=O!M $4V"
M;I!1)L0PP[G>3JGZ.D,'C\<3Q0Z#SLP;W^K)AN.ZMLNR,RFUP%/1"[9'@TZ*
MU+*%U'>.<.M1G5M^!/H2K/Z5^J+[?$.^9^2AE[(8KSD_UQDN?&9X*P02"P=7
M ?F[;51T<H""RO:0(047OT'3*#'WIQ_@^9G5VMZ1)]'%1,];E_,PI1]3H88O
ME &42** K]QUWCG,WC;MTK3:G&C"7@@J<&37%&KX_2N14_P=_9._L@Z>@9F<
M=)]@74RE#N'3>7M)NB<.$#(0M_'B-<V!JF%5_[FM,>^:R,*T5"K.*D>-F_%P
MYB5!WR7*<&-RWVA -$54B*9/8CDZZ^G$/H$2)%3?#>-1,[^07.DV[2LF9K:H
MT%Z;Q>S[TGCN]Z02 Z?R86XX"PQS\[ :;@6M7;&9%N4\$OKV$1R]60-UTE04
MM&D[5Q<Y&_A%,L%$\*GLZ7Z_-S:F%&2OD_0A\AUU(++Q&!1WI$+U0?H16<F^
MF+SEZ(:<R1)4U)+Y%8?O9X^(KL[W7ZL7KZ<S&C,4_G_NVHVNIH)/F%4CQ?P.
M)3"9.'TBRU-T/*O5B\J]7K<WCJFV6-))YK_/&!H4?UIR6CD>3T,E_69%1H;K
M3H3_#_;>.ZJI[EL7#H("TI3>0Q6E2U<P 94F(H+22U1 FA 1@0 A2)<N\ ("
M2B\B37HGTJ5+%Q!"@J+TA!*W)(2;]YSO?N.[YYP[SOG=>[YQSQC7/V;RSW[&
M7'OON>9Z9K+6,^DA=96 UQ8PW)_+<W "XL/\S'HFT*)2;M$1_<2,-Y1.ES/H
M[1'+@%3L$0^QEO^O+/4HL1; WHW@@MW'&&B9%LJ]Z)C.BQL28\K6B'LQD@)^
M#1JO)S=_>\&$84,&$$RNMQ!D<[GJT4R#6'MU(\IL R$CXL?SADQ+[W2>AG1#
M24MS^\4>3O'\<=JAY^ %Y55,/(7C*_+Q!)(+R]L.$LF^7X=O./@%76QJ?1*4
ME"5U_:&A/6?KP/</XK1^Q@&[79CY$0_,N?:0(O(5?%,"A(=\GL 3#J_W-+I-
M>-#2%/O#K&6(T?-)%>]0MKA<)BO-=TO0MST((W #FP1"7J['^_^M4(2.7=CM
M]92?(ZGB\,2ZBL:8\D_ACVYG>"_)M9\W #UF+J^3H-, O0AF)*@3&PFZ R_1
M+B2%B 6UN.I%LN6'Z:K*L?:]+B+\PO*RDQ]B<.%=[9"3??S \$*QB>HD4@Z8
M)[ /$"/:@1N$6P,]/NX9_/1DB4"]%NS]' $WK'6$4H^LLE9BRIDG80)NM-.X
M9B$3K' I-C<II*;"1B&TZ@#,AGC4TYOLKI:N-%ZVX/K84TTUD0_.%S"2G6S_
M:5FGWZ-A#GFI<O3OPA[?]')UXI >?P!E\]HJGDF?&2VP$_C^D,DH(71HC_/-
MZIN[]*\ %V(M 1P6X@2E0V"Z*73XMR6%Y0 >""!K%LZK)OR5?.V 4!-S,[<M
MD_P!V?^U[4W-O<F..] $-"^$%^D$!&!S8VU<PA6HRT[9VM2V@I84\=W:%-Q,
M7'K@XMOL,3U:5]_[/R1"7["-0\# O577$$=8A(U$#NO<ZNP3E&Q7F;W;:/&8
MO-RV7NG3-9P!<<<J3*EQ[]1*^!O^(Q-B ;ZJ"<<6GUOW=B>C$+-A$6@9Y]PR
M+2^[[6"UA5.K*C"TUCE?92"037OAA;)*2&((+T45$=Z?@6%\#CO3MU+-[-[$
M+V$I?"FHT*?*WG;%Y!NO@8'8UUNR\1*#?!^_L8X3H<!Z->4SAK$*:8DS%E[4
MGK:T14^=@.HJPY/$-!Y?C!%]_.03/;,>C<@K$*X]=>4$]++]'DD<G4BF*4<J
M$3+BMN6U;H14(ERL\(WI<#GX]LZ;6Q],1)[8#E596PTW>'_2X+O&1N;P.@'=
MFZ&&U>@]LUDYB_'[G02O!A^?4XI.AC;;\;$5&@_ 3S^MQH+&CS^<@+[]0#OM
MDOBJ3T '.5>Q7IWBR"M $"D(^2P5QU5H?\.WR)7I,4_/G$WCK*T_IO><T7>\
M97I_D O7!K3!,OQP]SQJ E9WH;C8-2N]M-1-6+0SU[2]KC[%ZDFAJ_C9_:MA
MXF8ZH!H0KA[%25VDI]!>;(E'A\M)[VQ^!J8GY^DZEXVZKWL^)_2()#_Z*Z'J
M_BO>2QKC*C2X20]AQN-BJ.MX^+(40(,MBQ#FF5G+[LU1JY^0G*Q('Q[J^=)F
MR/DX0/ -7=>E% 2SP5HU1!PI# 118Y#^N- ):'%S](7[PK&'4Y$_HDMFPFK7
M)P)>G]=1R.BZ<T=Y-Y8(CG-@("AL;9),7*$\[31Y&PN[$4AGI75A+3PETD5N
MJB("+'7/2MSLV6O-+ZSA0DX7&B$,"'789 B<;>%>+\^"<+%+WL9LI["]YOWF
M^A1-VQZAV(HP/H-%4;W?MFX:6OR@ ^C\:A_Z#$K4=J-UKMM3QJB!>ZS1/\,"
M)9AJF/I*4'3_0<Q;!'U\?)+-Q'$AY8HNG@G[+?!KX.U.T3G?:]<Q-S\?6#F=
M5Z7D/^U[&!V O?^JM^E!*2A'9GKS'U68=*5]_8]W+;1""T*4$?O$+* </_Z1
M*,Q8.]%^;N%V=?DF?FE0?,#_<6J @YW9.Q>YM5>_[[Y_P?5L7G"\/X0=D4'L
MFT0JX#$W .=5D[/K_OQ+B?FX8%C?@I%;(]'";XK1*?:"3^9W%UWSO=J.7S0I
MU]17DJ)\$Z2()<=%OA[;%X[&;\U4JYR9VJV2R]%0X+XFQWZ#*;E1N^ILX^13
M/385FIV%"G5U?OMO%O?D&KZ]:NU2EK_YC$O4*G%%D)\\"6BNLH7GUHV'FH2&
MN('#FZ[RQ+.,#%8@>GJ%!2ES=;/?4BRAKK8KB3L,URY';OF\024CJH;O3[<K
M5-BX!L;^/)KI>S-AM<'"/B3GQ<>0:!;/\*#"O/&53C\+L@D+74C%T8<AQ>DC
M40ID-B &!^:S[B(:C=[K#F0.K,JHJ"5W!AJ>OY\T^O%1_#L>/VJNIND!JKN6
MP7A],H<E;B8IO#V()XE\7H4_$A.](\K'[QF?(J[_L/G3]Q%]A.RBR6A87+S%
M6#3)%#7"K]Z#9EH/7$X5FCE>SO5TRD)V@CI=T&]ZWS],"GYM;9W$2Q>>&_C]
M(<"T*L1!5#\NDC2ALT,\^S60T138F+ B) ^M'W_(Q# COI=/QPCS6A5\$,DK
MZ$B[D70>R3-!44&-$G/9R+8N$GY-1T(-[=F%B]?>;)[=2KO!EF[P]0S?3K.6
MTUWZOH4?/>/LR"LGH# 'LF?C7+T'=4@+Z76^[ZF$,"OT!&0P^;RL6BZ>>U(!
MKRBF)QT@\+OKDW <?I<8<?S*MAO%-[53'\QJ;+EE\<$(C3U<3<\>-G^"_O(!
M]80\/X"<NX)S)/CTPSXH](U'HI3Q&3&J\)<Y7.=_$ELC;)Q[AW%&]UM?=OD\
M(;'E+)Z+6FSIO#LZ? ZR!L ]5).HSV;1KD>RH_>J><6S'NFTYP_/AE6PB80I
MZN2Q=$!-&B:?R%4\\<ROK6V(>1BVL'Q9T%LO[[2N:?<[$(@>=)8\3U#O09R
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MEWH#2;J<V]Q2N2/G;8>P_N_;G;6=AWT<YOP)<0Y-Q\5:8/R>L=K8W*U9+:F
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MY%^.FH5Q0-00==KI.NK=;;PJT#.CY^F$_!9<#YF:[K!*L BJ#<PGW6G8@O)
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M<(4[\;+;LPA1.NXF'P.OHB=I&G?S!'>T0C=AM6Q1JFCF]1#>>U0JK1( [[R
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MZ.UVV30VE ,T*:L6^*<YP0IFS?5IUE(&K[6>2:R_7+)\EKZ@%]!U?)XZ:00
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M5("CB29L+Y\+"%SP-%N0J53?&MET7[1?4+IS]]37I+_V8?X3VF#.P1,0H_Y
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M.W8K?!S)>5S1KDPH[+/LY(2S(MH^"BLTUO/'(OP'^*],P;V>_'I"NFW4$CZ
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M0.U3T#7AV.*"#>,*5R+/MHMOJ>I,NT^VYC2CEL!?ZAEB8=J^8PQT+W2^S2R
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MLB06S=0EBQ=Y,6TS%5#;\#,H1P03O5ZPQ]DS"F5PB6>OVD2X.&"$Q@4<PI+
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M[,]96;L\C?U7:&U<>M*@%?<]8SW-/&-FT9J_?3DAVO/U^8F;)%U(=LL_"*Z
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M\C$["K"\EIL-@*44@+4-B$547J>8A( %;48Q37#U)_%X_J\BQ5=]!80U^!Q
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M/B[B1A4C\;P[3S"V?93E,*BQ69CQVD!1D_6O)\X_/T:D%G<0;\\-J*\O'?
MTS:M$VHL\B%S632Y:;X59>\;ZW5X;LC4U?*FZ$__&5_RP%Z'ICMX/2U$JA#E
MH^5"^2TN57_\*F/XM-7\_KG"I85KS.=!3D,O*LG^B.E^J!!Q*[+I(+9%\"AW
MW7CGN*V-=!Q3FJV(E$.#+!OR+"X5>TUI79=S8-:EMPT&"1[#6[/Z.FO#196
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MVT]I])P(0LC T77814=>U1XHQ:U?O6S>5B,WN$P3ZBZ2=X!MUF[E:/[6HP)
M\RYY3\8@WB6Q [8SOU'N=>3?Y?Z8MAWC6]< "3%6G:F1=^!.M$!Y8O[O,1'K
MFSH2LRY*:B(3I2)[( R!Y W;+='":V*I/N/\LY6>*]OR+OV:Q_[9IQ/%]=1R
MBNVG,\OSNO*4PG$2*C)?2D7P1E@YSAXH>3@-+L!6)\A\_*SG:0MS^,>1 >5O
MMLK9+B-+1$&UUTJ9Q,,X\1V+E0X,:7H+PR.1\&<8W,\LK0Q6?-U7104#XJ(G
M47WI5_K=U=-FH_!?+>E&=N&[<ZM_TZ!]E)HQH'4L5,7RCK##FSC7_ ;3.- P
MY=:I;SZBYJS)B9,M9.=++WS)KH%DRSR(?X[A@SIUFH2OX'R/.GY$4:I')".:
M4PJ> [!>J/E%R\!TM\.'7^:?#BNGFCQ)<\%O-M<^OFG8H$(OI;KU-I*BL+>U
M97!FK>.JTW6L"8W'.4.?JF0W:EL<+V?(A$8,K5@727-4F^@VW.5BGM[62L]$
MJ[C->CF 89DX/]^\K]M'J!G6@]5*64M[U!*-1:_&SU'2]#%'L?LJ;0"3>5MH
MG=[MV7<"SD.D-18!LC26E_'N^CU-U,.PW[HG'J!N8 \Y9S$A"*R.KBUH5Q6H
MW_D%9PRH+#%\(,#T0+[Q^22LO<>U ]/"G[%"N =LB8U,Z=F+2MIO(HP:KG*V
MJ$ L&YGB#>/=2H+[5:WH?)27#UE/B$7'A2UMCODT0]NL_%7>I$QR,J%.P1*U
M,Y!-E_K%E#V07V.6HF@@T!WYE/ *48XS2C+GTKNC*R]%Y'=4E[#7M+7FY^/=
MM 523*TBFZ 62_SYQM3*)J",2^W?WNI1+*0Y\$. R= ;,<]>XY[EC:_>)'LF
MP>P,[^^25ZN@*C%U511'@2V1S#U0*(:$.!@#:.#/ L-71KJ0P54S"RL1<^[,
M?WFK$WL+H3.P[,N6!%CZ/50OZ%%XX4XX3G(*'L]Z*>R.NSBNC=M?FWT+K[12
MR<%@!]VUM!/V)5Z..G25[+P? 0I1C%(YDM<8'!&_@_HQ(M<6MVU<0M$?3H6E
MK1UH3U<75ZO 5AC^[NI)CZ#!\Z#'Q-#5?;L&K&72SBF<;-LXJ[F+Y(J$?#:U
MM*OZ,%[G@7J2F_F^89D*A>^.%HF!MA$9BFW6?:5W%W1:N-2LKGB_\M#MD^ZH
M>+VWH\+T\7-IT.L'=91>NY%O1U]#]#=2%J7PDI\ZSE=PM"$S0<9QS]^VR14(
M/1(=>C5^S.9QS=!9]1P#<&W[37N"WAK?FETJB/L%:&5=6LRZ34WB$]BEX!!A
M#NL;Z=4+?08S2O1X_@SMUAE9=V]A!0@3(LQ+-$(XX"X 2(S!JA WM%=^%(T?
M7EJGS31.KON:-SN^R#&Y$Y>CLZ'<%>EAPVB=/]GGN@066.L1WU=!1W!F@$\]
MWW*$C_:+7F)"BF./VP6]I^ZHJXF$#OY=([&8T8)FR I$73%9(JTZ<!NWR+E.
M&:S%C%6^1>23E-!GA&9D*"QD7F3C0Q:T !YN;V9X<+D'.=F%9,V:2O-1O,4L
MN,'34$5)O#+?JF30:0J&\K>-N:#+0%<UU,B>BL-H+?<;J90%[,R\8VY_H? R
M;'BDC*Y;; ,>'&\"$![/HH([5 <P1X-&@ST249[;W[T*KAQ%!%W,5DJ8DUXO
M6%Y '08EY/Z)_W__+_"^$,A5<)XP1=CR% =ZSK_@F18_.97!0DH0 @?1Z#)X
M4UWTFVNVH0]1SK6=G!L,)=":0D+JO]NWU2G[\T6! (.]U.]((C]@#W1(Y%Y@
M$#\+%YP=<H9I\31"*9O8%" 4A51X;G2@4TQ-, LPYU)M 6WNN@V7G'5ZX+=Z
MXKG\K2VD[O+&K1N;7I?W0 .G<O0Z%5TYF6)?:LH3Q=1^#GR')?4JDMN&5!@^
M\W2W,9Y- 2]@4X-_O#FYD3P'5CO73CW$3H<QLSL/LJ+3O\JK_<?MI_\=*5-
ME%N$DP:<R@'#E=*Y EETI/[;ZJWKX>'5)?&J^4@-/31C:#X<[O?HOZ7=#W_(
M?8"SXP72BATYSCN:I&3]MFE/Y(Y.[FJS.&J)]$$#WIUEA%L-XQP+5!D)^DGU
M<AR#7DKZ"5U>9<<>B-9(_DZEV6 T*EIZQ@)&?:?0QRLTG[N# WV:VR4M[K_G
M)N^^^]J83!"/P1!?2L8@A8"$ALJQKS4/P7<^X>;2F,S*_& ?$(RBTMD$DFCJ
M%4S_\N>UZR_^XF=([<W^ 5!+ P04    " !#@7)8XN,=W?Z- @ M0 , %
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MFMS]DA@\8X-;,B^S_8_W8:$,M];JH;;+Y[??Z5U"+(F881J>@K\'$495Y:-
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M>]"/>-BZ57%Q#LNU<V.4B.8RE][D65D+ '1P @KZX!K[9ET>T<@FN'+-7P)
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M>GHWGO1+DXMM&3R\Y%C]J9/F 6SA)=S<UX=;MVQI:1E_;J[>,&G'YFIA2P
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M(S*PQ6#PD=*>(R[^&W05FB*?,)^"UV;.N Q9)0!CM293W/<(0(K[-&C/,)L
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M]RX\T(K!0F*HW/:8FFWWNFY&RV%0Q2'FY%@X>!%VI'&2@*5_0@"*SIB1WW;
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M8-<2KW*YB96.2QA^@6?>@S;&5;@7!#S>"/O3[^G)D8.J3[M*1#D4 8B]0@+
MC^U:1I\2@*):D\;@Q>4C$8P)'B'PK_\%(BJ>EJ5-*0IQ##VBA./X>A,Z$FCK
M&W\,%:C?2=O[(]ISZ7\#G"TY>#QXI+'/%Z\M53WPZBU?WI_VE<O$8!'3@)@.
M9( :>M/0?+R;3U^K^P'+1G)QD-^6,]=[RN\J0=CK&',H2WO)9;6_>WY=A.-X
MN@S;EH*Q):YL_J9WPMJA(;N0YC%W!(C21+YSU>7EWJ117D-#S%'UKKG.:5\9
MDF4$C9K3;DV@XYM0\'5T?6X*Z\G"C<,GK?R.!K&K(^7*V7S>IK*9<J$:NOJ)
M:AW,2OV<'+B6KX63&VO%0Z>^@=NGA]],O)&1J_\76^\=UU3S[0M'45%!$*1+
M4>E=I",0RP.A"$CO1*E"!*1)J%$1D!H! >G2.Y$2D!KI(DUZ[[V'%D+JC<\Y
MY[V_]][[Q^9#)K.S9\^L\EUK9JTE@3@,Z*0I<&[_A?Q$W=3B\:4N.K-E]\V;
MYL%OEV*Y&/(<C WZNB\8V2=L@0O 5TBW+0+%T=P9N4\Y@JI?I&(<.'L?7FC:
M^,'C'7#!U,"JZ-!3N=S1> '8R@7.<CA6##*T1.OM%J(Q-$*&#[X+W#:^,P?N
M_^G,1C)WB[P/V*0 HT^9P+%@ 6C)@<W8Z@T/.>9[SW;#I,[L]"?I1^/]$\ 0
M[ CF.7H"3@#YEN\HG7W:EW2S%"0*W(A#V#]>1>=^XYE(1?^-FL%XHB?:>"Z9
M[2C)8DJ]?%1SDJ*3ASLV&7(2>R[8&:9_.]@Q:^TB.0TY?;4*TM(=>IZM9Y]%
M,>+*Z;^A'"3/[P2S4.0?@BB2VF)[&+ZG<BBM??BVS@&R#!:9GL9!;>&[+-TN
M8M%,]IT)/[D@6PM3VB0-GE#4OS[. H3,(?4ND-B(<+%()@AD@F8D''X<H:KJ
M7L^OU6X,L'?Y+\=[& 1V!TN$J;98AYJQ[.<@G#V)B>MPRC/#RK&%9,!3/9+A
M'@P[YN>8#5,MAGD%>)-<^_O*9:I>W!CH2%+@I-/< IN0 >V7R8#18S+@"YRT
M8$-U&+6$((C ;NLM'>SQ[(%%V-;P>G&K&] !N7VW+(MQ": ]=K:=.M6@H,2N
M8B5(DE\\&..5R4H&Q*5I_)<C00H<1!I#'3TB_!< ,;X1>&T)=LY> \<1PBEC
M8CY;V+/\ZT3I!&(H[YG_?'1P.6+7'G8DT44&4#JXQIVOV"#QPK">0'0=L1FV
M)3:VBMP!5R43D@=I8#,3I/A^8_&48W8G_![]8?<QJ)8TE_4?W!7H ;;[/UH&
MT5&MF&!5+#P;"WN>!'U]D&\?K^UH_!D0O2#\ O1<*42?_B.F&N=9GJ:5[AM8
M>J"Q*H3( ;XB Z8FVF'4!)Y"EP;9_6(O#X_@VHJZX:Y-IJZ]SRRRBK]C2<CC
M9@M?4U!(=.O8SS%O2.#C)Z<YB<[I3X;4F+[^,=SZ@@N38=)7>RK^;RZ*(KN_
M^2?X:VH#>HN^13NLOLAI?C(P_O"V6?DRFT:7:F$] 1*+EOV:]CQI,?:N+G!>
M&28VX0HN>E-[PS!;S"BI:LA?$@N,P]1+<*DGE)W!/INH-B\KG/@<Y5ZTK%+=
MVLS<((@$!9ARJ$1\?C% !HBY! 7!KA_M0<QT5*])5+#U\')?4*XV-?%(-<XW
M4*"]WNQ,8B7"^(M;@.P*FB_1N'[2Y69+LUF+;=P*Z=+&"17N^IIDT]M/6M./
M4<1Z>I[/%78&8X)C$K35JD&LW[D_9.1OGG$TS5N)_L0/^$N.-]X/%/S0.@QM
MF@\\FIN;%MUH) :P@H2RU>EJ'Y@&^8R0KF4+QL@**BL)5GTC(?E494?M7C:!
M[I !SAZ$2NLK&8MX4=DK#OAG&;U!"[T$B.-#C;M6?%+?3HPO-G$Z^K6?S!2&
MMPI78/3Q->Y'"J)V1YOXFDUAR4;2M9!"Z/#T8FA]3/D,?L$/AAL;=_;/&]>M
MGNYOAWFOF07@QKVG@\K;EBVAZ;":#]G(X; L@1V0?02\GXH3,>K/@=U5"VS)
MQ4SRB]RR%)T'"C; _(]!<08%W'J9']XDET\L-*AHJTW<&[^W<N9[_<'0QBGW
MV""T78=E(LJ'8UF1A'DH#QOXOE=A7YTA$!&I$7XG<O? $=[!S9%D#U"*68,U
M](X&FR."V=:R',;NCU$@XN6^K(#@9I[R05U9,J#F_G"^X4ILZ4 WPU_"@1R'
M;*A5'+=E436YKKC>\ GB^2=^1\^SE?]!5QHFG2O[ZZU!YM:)3>#N((5]0.W
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M:"]:F C]#G;"M]Q:MB7-YSY0M3UD'TI"KG6L)EAQ\CS=^9JN[FQL8UIUU()
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M6''[*<7&.B+N;?BN2EDOM%,4Q?1@>T!4BDP[;:75^_6966%[6^FPQ0]7>P[
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M#B[#U1ZV51=D#"6]Y( V%2A^W!(RBK(4!5L&S>D])@-"\_%R_V8@!J*__LU
MK$=I\D#/X%GQEJ2;% SO1,S:L_'%* .W:_?G8E*V!J12";\0(P?GN3QGDF3
M'M+!)JL*F39Z\.N8-24 [*I%DVAMH=H\HUQ(8DG>G2$#5&TXR8 VBF5PSEU/
M!DSIM:DR'.:UJ#36_Y')L.CW\7R=NM^F>.E-[5$V5861'>>+(-$5?[P\AH8,
MB+/[[PP%$(L:8J+<B%-"XKI!OS3'\W*M:Q*NR<F6M5#$WLMLYQ9.;*>?0][6
M>(-UZO3/MOF!RV'WM8[>%E$)-"*F)C &(5VIQJ@(P@L!'1&/ED&=F&C7-UG'
M0Y.>10$7/D 5NZT&IRV?ZMT*'K4(AO,^*/B&"\I]D'Z33^0C/!BRA9J^U3%,
M4,$*5LPY@S>K\QBF+-DBGK)@S([RO$7RXO8O/RO1?'(S=G?B1O+21DR7[2%#
MD[!\(:B1(%[Y>WL:L7N^:/W8&[(#I.&?EH\?RI"QKGE-=S6NP[TF9,*#ZW@X
MYS!YMQM]L%P8KIZ_]-@YS_I92NVH3-(-5P'I=O5"9_9?_&] 2Y%8@6;1):>]
M"\N(CTH.I*R<VXKE[GSFT;Z5-1\$ 1]ZPMC$I-(W]B/=HG/+^(N[M57;EOFV
M[-X<&BT<E9N>KMF%'M*%!"VY>N(U1K]! O#"J==RW?H*.?U#1KD70XQ8R]V@
M,UVIA1WTC-:0AKXX[:+9O6-NMJ3[;XOTV^"/KN@IFW!,F-2.8DN:TH\PX!LG
M+9@MCU%]-=[_K%SY]_KK)LZ/_H_ZEO]S/7OUUZGLHMY)Z<3W?]2]%'E$:7CT
M?Q79Q#FHOO^6$RDL]9WRA_$_OKK\M[YG6Z30MXM_KW0E0^<QL<N4/C?^L_T9
MY3?C0IGT-?[ME.@LW#O\MZ!G7K9)AD8-$O"WEJB8CSB3$2VEWY78ZI^^"@&-
MGL%H1B'<&UB&=VJM;H(_-9@?E>B'B2CBDC8(6\%>:(<;*W.<%*C]B/A\L^?>
M37K;JSNXB6VKAY_,RAJ@$/Q0P[D*RG#/LR1SAD9$Q9@,N-6IK)M?\[#,IXUB
MX3YIFFZV,ZIV+J\H-WOYNRH82&HX2F'JVLU[$1)M6OP3:3H&>0YC<H U\^.X
M.('\NTYZ);[X"0(5"FU&I6X%"]PX*<>M!5)[<XPOSV:E6$*Y.^QPP<@QT_4F
MD)91]>LGR>;@U5-0W[K^FRXC/=1Z0/=/E"2)X79Y%FS/%44ZMPI.W$0>4YC0
MG5-MR=K TG)BJG#^A4QXGJZ2%&;C2C-)D<5L7&/*1H[=U/ SJ$AVRP&9:TC/
M5CX>C5<N:!)9LF,[X&)##A(>,611[02[R1&_K@#G?W7O6-,+YOO1=^EQ6<Y:
MD@$O)K6JN98J\IXFLFV^.]M(.&%ND:MY]2<AV=BNE,>&Z?ZQUW8J*$Y?C?E\
M!/C@NG%>H:36LV^(/["I+)(&/ RVDX["*>X<+Z,H,LGQ;T  .T7*>E(F;Z-<
M.! T@1[$SU+>@ R0"50YE"=I 2-AN\+_IL6I1VY9"W8LG N1A,F [_F#I!B7
MC<M>S8,IY01S_^_E9$#XPI$J%D)J>[N DX5<+-NJ&RQPD:N+(P/*ZA+YP26?
M04=% NGUCGDXZ0.*)"!I)$>@9J/^1@D&!YMNT4=XX]TCR0 :=_$]?K"@^<C9
M3$_ZN[[LSUFY=D MPM9836,SO4']R,&W $BO,ZU!^YUV4:H/HH'J6UG@CL]N
M2*7>)9>_!U\-RH.H_B\?]0]B-('*I\"YH3 2<?>5R;G)=-_]5FAK[P^,&!/]
MF<Y+-7D9/W-Q1:-NPS5+ES[8#)0,Z.AM>XI*H+QX-@BL!+4CJ>L(DEJ6_KI=
M H![$<NOD/ (EE1["2[OQD?Q+S88%6=!Q..J)KMVGJ,'_QV^(%1RH)^<JJ,G
ME68]L60?=(I_!.NY?0@F^L-V>\&7H:8=R2WTAU>RRK:._'R3/,N* CA]#'?5
M'V-DSQ![%!N!SYTBE"GF8K5XL/_8<DVJ4VF'@4>GX1>;XN RXG44<H@$)/"W
MW6>9SO@!S2JUU&V6WB^[JIJKBFP+_H6370B7 ;(XRQ^RN9>=&C)59G:HYQXI
M+#?U8K2Q^63 U8U/"VT-'V>\]_3/+%F401ZQF:T_NT<ERX-\G7*FS5Q,S]!J
M:[-@/\>E<)"07"E/X(O@BPW"T_DE/J _+QQH6X>[$+'R!GA40;->.,K%_5P\
M=8'H54<&#%VS,7=RYU_K>_Y/8W[B&$.0IL+%9KW_PX.=AE>!NI,8X5'^EVC3
MEFJ_S&O'=?'>#H,M/@:MV!AK')MX[ ]&=(SX5%\;L7:<6 [JS<9Z;P;35/_9
MX\<_G#$K+_,2V8!<FD%QG:^WP,B ,*&/\7I1]GRGP)<\!,]&^'3 LEPNF@QH
MK>69G(BQ*[&9^ZCY7/@E1[%D*W6]/G:B+PK_-/ ?RKKF;)"(:I2%GG"[E\\T
M*GA[$M?7>^M=J-I3!IV>3N\M6*I**L]DPT._W"0@JU:\>FMB2YO"G54>E,WQ
MBCL=K,UP,0BL_N6\RGJJZ6YE=$_=&O!L_$;@4S+@QHW#6Z2PJ"S\*2M%/($-
M2?U9-]U;[@0"_9"6U7XEYG/*M[1^7GGQYK<&@"X&CKTAIJ+UP"V=%Y*8M'Q?
M5E"$#:IP+.X^<1@T&,9NP<YNQNRCP/OC'K+,K<*=.6J[X(KAF;W=8+,W\#9!
MGK*0B$Z]FU,BNZ$5.AW@?<UC>.];X/6E\18P<[AA$_=.#[ /.]$?7BRD&MO]
MN':%%*))!@2E>D:]'\0,PQ8<B]M]"A\405@?V&7$>F2Y?-&D@(='6ZB#7+"B
MD);$  5U7 @_SRC1W"4#V+G<6_68NA=A41PZ:QV;X_$:KH5?>9)?A[@=?..[
M=8+0)2*::&24:K.6&Z&]T_UL-0T./!X3_&S$Q[RDBRJ0C9G62R4HIYI45NJ,
MV0^B6Z@/"QPR,$ZH/52PJYPA(Q<O8VC-"?+E43-Q&Z:['[#(T!_D>+$,\@?J
MGRJ/W$/UUF\N\>N6"R^6/+2>E\S'\T@Y3X=,-KYPCVDYVCCE/BTF-KK7W>43
MQ#?1CS>'+U/O)I=O)7O.0BV,QLK8XFNK-7@S@:_31>D#0_9L8/0_P3R]]S]!
M;=%R'DE"I9098>GT,RO+S<S?T%GH+1[<E?KJNWO.,^<5U=@8T..+HF*[KG0!
M;$+J5^72 Q#DQPCFI?!J_FWB-];%*.AH(A!]SPQNHP+)PGKAQ;CD',8('C[N
MS/FH ]TLSG?%W<#FA&_@YTJX<<$]JL/?,YW/X;10U\.<)X\REZ60;M>)H_K$
M5GC'^TFOG:4BL0;NZ9QJ[3E0,'?:S\+(CBW)JH;9Q4#6,NUE^A@EN4)YW$R_
MFV@8=V@!-4^Y_^!>"AG D\E,$=^^P &E0U@H[,A0690,>$EA,S;D'KC6@@S(
MAS[?R$CF/8VL*IC]+INVCY)Q4JMW./W[3^"<EM*P <(";;YR=_2ZL&FY?2\(
MC(:3M,)#4;N\% $F.D8&O)8\9U/^_QS(3;E+/(1$>AK8I#H/D=:T+'@2?'0?
MZD5JSO]7,#+!5BTMQX+#ZT#$-D0)D3Z+\J/\(A.#TCV@L04>U.J'S:R#OS4A
M*?2%I>X HR.PO>IC V\M9DM[8O.EP_^F=3QQ^D\'\^_FTID!@:WE)87]>)6F
M-EW9%?X&#5P IA"= +'@3E@NO8#Y5&[Z.V5EU4_B,0AW48]X(KJNA;NUJ-<5
M \3?@0([W7DFIY[)U<ES=CT_7-/,#/F3*=6=#SJDQE@UQZYK+USMYUI+SU*H
M3'U4D;)Q=2.,QX!^O/1VF%\D;IW!A@Q@W$ZIN <?I]C\0I"@":-! (GC3<4,
MB0D>&SA(4?R-S5/=Z)7C =$_331X\6U3P_R)R$(=I4Y51V38H^$?7%'TB: 6
M39QIE)Y$YT2RF#,JM8J@JP2U&./Z8KZD^@6YL\!]2@906\EEY&!MNB95T[5Z
M US>W;6RZZ55)0.4DX I/8B[%6+&S.$E6\+"EB63J5_&A'\(!ORMQ"U4027=
MSIHO?B<?<5 ;_ \37<WS9@@+GU*D4)E96WK-M.=)V5<:<$%6=7DZA^E/X+7R
MS[=ULS;2.==!8@<4D_(6H?18HF68&!VL^#?Q,>%_$A_7_F?BX\J?^VQVV8BD
MP:*!"G:MZX2*7;P-4\=P=HQ'T5Y?65;&2%T?=IB$6S%JJ6]N3*R0J.!S+D@9
M,)^+$.N>C=<)_D3J3HU9ST8+@O"6RA^N;7Q@C:N[Q?9Y,>B*UOM)<<\6.6)X
MH.(RG%6G= LW-Q[A\#<O7&'WQ5^-<,'?MNTO!G2OOI#NNG+Y+<_-ECM02XP=
M%GPEKD!&.^AR?;CVB">'N;VBZNMW=FNSVM*<]AN<GT5_]4G55',\SPXW30BP
MM)OM.>I3U_Y4&M75(\0W=M!22FC8\6JE8)X L]<PEP/F&4N1_"9!@UA^F_=J
M/P'TKTT6"$S7MU\*?G#]6"8^::-A2[TFIOR9+7;UHL=6PC8DC!@IP=^$W?!0
M/I*IUBZ8;?RU(=9G?8T/EV!=2&"B(0&;**:KU0$P7;9LI3=U1"\/IN[19C6K
M:/-?F8\_'6 %=^&8+$[0CUUAQYF@8Z#L3]+,&S'@;?.)L@;7QKH)"=2OZP?
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MM>J815"C8N546_)#?X_X5A8]ZB0I^H1U7-B%1UIMI)M"?F8G?.:K\M_:Z$A
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MG/.><3M=5<IG5N6-J]D0SJ,#[Z.)X 9[&B5#!Q@0=" 2^NXI*:@=+C9?L?C
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M/S?TF\[.B1 O]6[9TV\+T\ =?[FGPSL\GU(%G[C=L)Y-0,0>;.K8L.=S_#P
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M(6]=$-BZ4O"KU;<Y&RJ:_;-Q!TQSTE.W&GL3C0<A>I:BV6([Q=<RLRSO-_S
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M%=!=CVBHJ5_N.M;^314=^*4+C'PZ (;^-,V8#I #C7KQ(RU$R#+;FILB'4!
M-A5 '*RAI)4_A_'_KOBKVAW^31PC31,,^Q78S["/GD&C0>> 4?^#9Y!4UBT9
M.>  < 50JQ)[P76QI8R?5)(,+H#OBRQ$*]#WGR.CB-[@/S\<L0:QK:$#2O_5
M869?#=2=09]=YB>ET8'OT""C=R&_;,TDE,*G*(<A?T24:'I5.1T(!J,Q9^F7
MNM]$S-K*A:P$L:!_)^1 *&F)QL5(0^)^!N%=^*S_3^^M-?&W$&7_("-&%%T
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MU['E]N17F"Z\A@?>-?(=R19?8"UH"J>90LA>UY;#W2ADT)1XZO.P[\ <-*K
ME!RL!"+!?4<";KS3M%=+WTP/B?OA0/3\('3+HM;G/:DPG:B^.?X5)?BDT@_3
MCX"F#X$*1[;H?<[_PQ,.<,<KN&^&C*F8H"U)(*<;M%<CE%=;+H&,1L%G74 N
M0'2NV;X_HU<N 1;Z'5CL!E)&CR0;U- 'IC*PAA3#;4$[S/!30G_+Q+,0T!C[
M+3UC\,0M/=.@XV5HAQE_C6&<?P :[T@SA9-=KBVK-?Q00GOYA ;;4H+B6(51
MY/BI!HA-,- 6,!?AEZ<@WW:&J%DNQ"3(%$*K78N#-+I6_8\_1/S_Q_]'#ULQ
MLB;E1BD1OH/[9.AL67=7D/VGTVY%#;'; #JP_^BX.D""8GMK(1AL30LAT5KG
M9KZ^ZV-UQA@>^Q5[6YK^(V1H77]ZF=XZ.7'6^TN.-LI*WR%G.OE52;9SHH%'
M]H@US'#H:FE\:M28@4EZ*/6,$,?5J.R!R^FA8O]V=X+_VP^Q]@_M*F7R CD?
M'$X=[;S^@LV&> 8L;"SPYB@WQWQ;@YSK!U[K'AIMKBQM'3GK^VZQ<O?7!RV!
M"-XPR1LSU>W!9D\G]OGM<UXQQ)VMXF[J#%#!8R+K4E?SS*^)",8Q3?16>[ >
MBA=A:C-WT_8Y'"%:WQDZ^!542ZRI__&MV#\/(O-Z,16U-K#$<<-V+_Y:EG!\
MIM,RCW,S66E L2LCQ"SZ5C8K=+):D,^C+I ,>P)-C)WEC!LRK)M.TT[05O\<
MJ4MI"8JJ]O5BN78<Y4>86K_SQM]F!!8?>?ZO01/];!M;HT#Y%D^UQ(/*@QUZ
MD\^>S.JJW^ 610\4M_-=_[>_^?T_<9BG/1B+L']?\L0[XT9)LEG':SO%E(6#
M5V]/GLMO$G?@:KG5:+.-I$SF#>KL17!*+:I)C7GK$!0?\MU6"CU)+=YWMM"N
M\Z.)ML?&O4^GA*L0Z&:WOF3OL/4$?&P&QR5S B]#1,U\'"^_[6G(HZ#,WI6-
M0Y=%)S>CI'9>;Q(WGRGH[UQ\.]L6]U019+M*8>;??*",>**A 3811!$S@G!6
M0LF;L%NUF;L2SKH_EA\L9%A;@($[R<$J%9^:L6*D>GUAGF'">:/X5U;G&ET.
M3-_=QPMF2Z<W1JC $'* C;X;'F88>;*_:,Y=Y^B:,<M"5(O.) P13]TSNF@:
M3(K[*+)C5EGA^4RB:Z]_T3)-M+Z']/Y]7;^8S6;)H(GNQ+*3:#K.3F/?_QO+
M8.N0R,,KU1EQ!)SJ.E;>IEA>SB]U[^28R>5H1U5;N3NO2:&3HOG.QEF/'R M
MQ8T#N<L4D":W,Y&,U\KY<_FW!<GV4V[@6;C[_THH"Y=V02_LBSV>!.A:KV#O
ML6B4-A[MS8#6@P6 X>?4EX15K2<1EM7WI^^>*]TQ3ML.$2<?Q\64)LIDQ4]U
MXY]J[,:Z"7;$5T$+R<&FH6GR#(98HR=+RRY!][38H1_32O^GV(+6X#!1E(2H
M_? !'"U."^;QSP_,:A!+M^@ ,Z5]=A)7%X3(5?L4*HINC\KXU]7X\ZC,F%%!
M/':U'-#K+,"J/M(4T'1DT!L] Q0R[:D_=WB#0[NR8?TL'8B-SX'W'8=1C^SU
M&)>H4-S3H[>NK9BK<GNP5[,F5]_?UTWZ^/W=:;Z3EV,:N!,<K[@###DB6!T;
MQIJ13?X*^:V?7+M1N;&=)M;1M^:=1*Y^?I9WO2SR@=>ZC>'[.<.W_?R-Y8_2
M Y$O:P"/ZNR;-UV])$I1-Q<FR]_&%S>P[+89).WDC;/%D2W@C:9&9$:P2GJI
M#I:L.R$3>408#6=*ZN60-,UY:)& G:RLTCZ1.ZG3;Y7UR79.LRO?"S;?G*HQ
M.V(RF+.N;.?PW/-R=I_VK5NR)SYI<5>%Y/@$?77!&FC,&90ZL!ZK>)1^*S.:
MAV5;_9GI_DK_,6]*JAI\_6 G?-6: ZSY>=5X' A0@ZY5JAH;4>_VSDMC44</
MVWL-E<ST'?63B[R[4BW9^;E,C;#AR#ZPX!_$Z:A:=ZO44TH0/1/@;6_OF6-3
MY^SH)C7T$55\ZO+9Q>DVT8GDH*RLX>N];R[-'HKK&VJ(6-\X@;DE?5I _-W^
MZ#,D[KD@9@F1.C1+WO;\DMS= CN\4+!^'9J^SF/< EC1Z::C=>;8YO397)1]
MT2N%G0O\V/4@*,4(TG';1=.VG"S]S-XS>W!!:J+_;$<5HRGVS*GL)0P9);UL
MI3_@A)).5[UZWZ=)A?\L,L9V%*]QX@M;\+ T\9Y<[N#CJAKDLWW1UC&MMF<\
MP4+VKI*BZ7I2V\(2&B/#XY27"K'%:-]ATA9BVBW2]O2H/?6!=7O#RI4A9O\R
ML _T%>PGA_<<7PM,Q?33')\8:_F+S"^]^-I6\ICBD&=)+>BM*:X*D'USG^^F
M_';Y^B\'H^XPOBZ8-_ *R9S%^M]>''X2.-4M+NYQRS%%Z2[E?+$PH4(UCUFV
MO*6Z,+&9.7SZSJ ]1X2;F]1D[84S!UO5\@^<&C?Y.&\( %Z"Z^C;G4%R 1=M
M;O#OLW'J?SK,)[?'H23J/,1Q6?51(&YHXN1B:2M'TPV^HVT5IH1F[>X*B*.'
MO8-73O\Y_.#Q8P<V\RKN9MYELZW4+5#Q2=Z(S>-(K^PLPSE.V7/'*T[INT;A
ME:.(YAI@$GQI9$T'JF^.4 SX\?D!8&MV-NTM';C_&4=,7E_JYQ]K#5/C)&R[
M3>6T\.>1=^2M,JGAH=2^%I',7.>8@N#;Z, ^.C!C#[:_VU[2@3$);@Y"7ZAQ
M'M?[5IN1S?V&67XQIKK.<S2=M-8="46Z+.T84^TZ/F7V/ F&^[O5=RNJ1\8%
MYDHU7_H\:(/"&*A-[7Y6:QQ9T,<O'CE!L-(XV"8=)$#L'S!,6%=U3M5V$DQ8
M=-B\.)K:=R]*LX'_4>"1T6:C7=<A>VG'KFMPE-*ZWA:U3P5J7GQWW/NZ U/N
MT/L%-=9=?K&ZJ,*DI=PL#IYFH[^>8P<H$1+0=7/S<@T#E(O >Y6EQ\><,)6<
M%[K23;&91=A8,\:V^%UQ[Y-Y?)[7]AO&/GHZ8J/C>DE;+_@R<Q 01X264*X3
MB_("( 0%V_WXP/<SR==B=EQO9M&[-/142>C>E^TXTW)EE =7:$P>-_N5E&0W
MFUBMBSE"0KNE+GV!)D"YO;H2>MWUG3T.U]3(L7MI/.33.F-+!PC'KQ+!I&Y
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M5.*S.E[)$V9O95N']!::FIKS_-+X<V:X7X7M?5H6_-S;CF/^^%B/?C:W8II
M>]MKGJ>D2/%'@09D__.)&J)XZ_;ZXY$&@F7U*J(RT1"F*8V]%$F\=-P7,N0Q
M'=B/[8._"?B\$QDR9MWB0R@>27*4+ \98CC"+'N8HRZX]:5:08*][5[EF0SV
MB8%R##0M[=P,*J'I5..H4Z.E:DFZO@%LV"<(^>)&LN1)DUENEZ&'T-=A89>D
M7USO\8G2.?O.U73V5"['FM+"@IPU,:/:4X<K5%DA=HYKYD75:8K$9/+JFYL!
M1>=WJET=;YH.5+W1.W/+'M_,^"1U=WGVVN9.=F/;QND_;I_PCX/? >S.5>C
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MI"**^)E2QZS%3T\F$<=('L2L9@7,.?CKC)B&<V>BP]U?^I=.P;W+R$5\KWS
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M4"$[)G8E+]_8<!G'WQR@GJ5V;'DGZ0::X%4;A]AC1+R?/3CTQ$,E^ G_.MT
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M@9WSM_^3L*".(U&YQ:AGL4SP'T!RO-!#^%1&R"*_0L\.=$&5*=">/05_;-)
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MU#@N%XX'E]H&QTD8!RFJ;Y4I*:XZ$AQ1;ER#]V"ESR@ B9<AZM% 3'XT$(-
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MX7<1TOVY*VK+/:54++S8$S7]"=R@=@87G'GQX^3Y8FI?Y<_4F(Z8M5S/YC#
M;3@WQ36861FG$A=AAEG4YEI.O$=6R,"U).OR<H;P/#K]FIHRDR<_6FHDM9ZH
MO>7^NMGT %ZOI<;3EDJ,J4NY6/S]/5F)/9XOO)B]T?I.U#*W]!R[UHFCVUM@
M[4KP_98GIARAF6I^.I/9G"TI[?B1JA+JM?WTDV:4%B7\V2GX*S4VL@H-] 8-
M)'#>9R60M^;V43,SRA(OAI.^C*>^8>#V>14O5"%1SORZMH_R+D 6"G,E2CS,
M=V@"FQ>7Q]RMC;[,9AMW.1=\)/6QNZ![FV)=$VP^=QE=$!4YI2-UEE=4>=M=
MH!EADS.I]57@B@+=F_'(I!<O3%_5UPN#*,HD:5.R<AD1RKOX@R*Z>AM7F^DE
MU!NUO<Z=D<3 72XK>P;BF;/UJ<(PR@T*0<X8"TA0*%?S'7SO/H]PFE30<\[1
M:QV*+MYQG/,=9-6'?OST1Z\-_CKH6J$EF^0/>0K4^M/PI>6< <ACJ?V+E?&4
MH'D:J.\R)H&*06\9%&-)1]5IH/0OJ#N4=^BYQ!4H@0-@0[<:H*Z D=Y+0-YO
M +7M"T3KWKE_3JK09]!/I?:EH&?@:[8_T3O?M"DEJ$84P)]T, !_XO*0HHA&
MH\UQVY05--%DX?E,+6M 54 />NMZ #=\N.3+KP]'>& QATAJ )TZ1@0\]=%0
M$N!+!1@X-,$&/OF-!@JEVCT.8/VU58?U#_>R_Y$COL^A@=JE;6B@[RK@ _-8
MU)]?<A!UA*JN!*>\D>J<B<<++_F UT)(RI/4/C23!Z?*]9DN&VW<DQ@_H9(O
M\9E7+W2YMQ9J"2:]HCLTPRFJ10>*VH/8=/E!B3=)Y@X0^J@2M?14U2YJ"JX(
M+)0R(?C^XGWA$XWJ@8C-T]V'4'9 ;K&!MQW#H-=LRP$&9V&.HX&"(%LQ8ILD
MYE7H@:Z']2[,Z(ZUP)4?QD59)[0R;=.U]W9KRS8>IZ5EMSE;4=+A\Q>L 6+V
MO300L%Y:_BR5_A!^UFH 9I8*NXS;*(1!F';T>[ZM,"C$;'6<OQ69,94&RAP.
M;'V8<H@NY/=? PK&Z;,<!;.0O7&;X;MBEURJ9;^-C;4\/RO*E?I"*.2YREF^
M?N;K<[-?'+Z[/S5NG ^KK/E:QC:I)>:R[=C%K)NI["5-%8,)X/3JL'1CQ(YI
MKV:2OT73T-E;SNOK'DG&<8MNZU*LKE<V& [KEY&K0A6/UWY((I37@@O"R'=.
MGL ;H@@/U!'2$GL?;;:O+'*.JHSS7:7?UF.WAQ>$!,%DOZS>O(,PLYA)%7?_
M9+WE6/[J:(RXQAQG78OR=_]#^46S= UZC-Y%!/Y*0(4Z&59F3QFNKGXW[2XJ
M[O^F=.;[F2+(Q+$0P5/5'BAE-A.62%/3V>R?+J.9/0:GHSX]&/6#=FR)7FI)
MBLVKY+/#"1!N( DI1#=((X3'N\?2R<XH$;ZVS*[^WL3F@XQ6]1F-W8<%G@]$
MZG<(4B/Q4ZBF/'"]FC1.N(F[ALHR6+R<ZV3FP59>72)S*;)1D_%;$._'X]U#
M^EM;@X&D4P']*8=QF#IN/69B3&,B/&27Z;!%9!]4^X)]6K3=1Q4?&LC434!R
ML&W?UTLMB:1$Q0Q!BS7#2ORY]7!?4K^T9#4.?+J>I?7@4K7H\6GMHB/ORE59
MOCB&*#7:W35MOQN_<:E#H]\R%.)1OUQ9BB%[?'- 5F[FJ+$3X205HEL3O*0Y
M&U>ZL7<?T4 H*R.TN3$6A!=^%XQX4Q"1KW4=&8/A1 %1X'4$\1&F7@R7U% J
MHRL1]SZU%GDT_JA<)(_U?0?3EX<>L=J!& ELT+J B_TP%L"=6/'LF3.\&F.W
M!C F@VSYFYFG;R7-?KBX^.P8W?,Y?&L>A'@IN.3AC*K%=&EVYD0#/,O:/O[L
MV'A=??0MNXC@HYY-_C#'&8?%\F-7QGG%]MT4VS>'FMFU/U2-$]"C%K/4+)P"
MP0EWQQH<LT:]@,F56,_+#PLD/(V;8"R4A$<X7U/D=^YYB%0DVI*.E#5)!0^I
M2>,1D26-^*B29_&$Z-QP40NQ2/Q^YM:6M$'&=,S1V60CY%CZ]$;FC-X(9AH>
MNN:4N,#",J(1GW3HHDC6ZT,+IRF]??S"I=.;U@4X#D(YT4ZXKN:PDTW3N8"0
MKT\K'[-[57J,USLK-''>:0)/?K@RT?#@F7/]W+E]$3VVP+9IZ"5H=:S6I?*<
M#HU]$ZMS93N[6*W[Q832D(_4)CA/-32-;#H4P$!<O9=DDM*4SU]0F7)3_%V'
M\VWOLIBXB+0B2;?(S\PL?+P7(V? K-1QJAAN,[@DH1KRU?'J1JKMQ<QG$+]C
M%78^(TI@A;C(7L37_&V"<I]+K4P )D6(F.ED(_3EE9V7/TPP1O&,9:A %,^.
M5*&&S;#3'E</T9 &NB13"WC[1@D0]3!&.\YRWS^..VGK:SNR= &D2M5BP+FS
MQ4SCTIXTW 'U2I;:IG8>%Q^JPC5#L=\HN1COW_6SSC*C[YE0V>=[K6/4U2,1
M#^+H$/W@X%JA^&8D,TQLYN2@L9.%=@GZ_?T'Q^-87X .2F! @#T&,.AW4@VH
M R(P>>\#5 [<#KO/CV9"KYD/P'?BKA([-XKQ%>P,7&]A@]R)+CE:50&:ZO(=
MQOH6=.O':"!!CAD]2KAY/#6Z#9J(+L2N R["B$E;K823+\!Q[VD@!TM-2 (E
MDP 5>Q3;K)+5[;8.S806<Y#?04,A! D'Z(&.$ S]ZQLM0"*3:H$33@%_]#F9
MSWE\WY'AL;IC)&7/[&VMTJTP]@US[6M2#AN'S3<*D@9R@1*MD:SN/73P'TR4
M4,+P0LPZ&BA0GH[,-_9$IMRP4W;=*^_RAI!9P[8V]2@9*I<\'JSS[IP[EE&Z
M\?E,H<1\GX%L\XMC 7&8118R*Z,=(0]W2D" =+&!!M+)=W0^U_A0;-'ARYF0
MPM=O:B;MQ&KW_ G?<RZ)>L;49F60Q2EQ&VC;S$$U:>^BIG['Q)3X="NK<?O+
M/]KSGMM Q.X^OFB=6_UY_R/?.!'Z8P)\@Y+C@3Q-1,[J-7V%J<[?$2@<L/VY
MOG[73*O37EJT0+C]<D[WW=LJR%XTPIJ^@AB*LVM6XRU<."#IQDK$D[9>57#@
M;8_@4=VH$98&]%'Y@1E>CMEC>351%4?KUR7EK33\3KP&W7I_IO!""*-L\-SB
MD2]B_>VR]!_7V,6D49>NXETCISDK-, 3YF+6>WXC/J<-1&4BV%O2J1T0#GG(
M&W1Q4,L/3_P;-7F<[L[ZL>!4MO;QQOQ'V^>]/YF]'+\<\?(=YT'@??131%@\
MDA=MGZ#&94WLAAPF'M&I\%.NR@G/+ N:"^7*C+[1R?;QNW1:0<N$8IO\$O;(
M0TI\24\$(='N9;54ME28W%CHQ<*?*JLC$A\;3\IDR\JLS09>>/E"5=V;HQ%Q
ME&A3!RF=1-$U25S1(K/EKGAQ; HGB-^VJ9A<%GDZ+'T_%C<,J9MP#5QZ.,1>
M:V^ +D@6;8[$R%W(F"?C(T=?E$X^UEXY"=6)J[W )$50QX>$P-1QCC.QZ+#B
ML==M?IF2V<>P8L6Q"0_/FRL<G8H]IHUS"X1^43N+9T.'D\72'4M?YN5GVS+M
M\">_B[Y0N;WS$,I$'&TA2./N%F4MMV@X^>0/^)3W>NATM#[@>7"[PVTO*F E
M6(".WQ59H2*<:7_ $>3NI'"[)+I#NZ@P>+)[Z,'T=- I40&7_2U6D!=LW*T+
MYG4&$RS $I*<_=-(?F^1C4-HRYE KKD;)MJ5D^-SKEA?/2#@GW8CYOD'/WL/
M*=HDQZ."L0299?2!$2_ TWJA $\3!#A3239\63QV_^Q_T33?7S3-1A*@:9GZ
MF+5?[\)>J+;;)9@MSJ@I(DM_37O9]P]9Z2RV!;(O@3P%7WOX$[+S19MRY]>S
M($&]Z3U*^"B<&J,)C8/ST$!SI;#K-%!!R#V '"6([<I.V9'?0T*P!"F@3#S0
MY0T@S7"00[^#I2CGP;$X)#E"&HH950X324,?AMS_PR:2$D!Z2X6W2>/@E%_?
ME+]5\QCV@ ;Z\,S;A%KCCJ5PBD&I]$& ("WU-!"!TX5R9O<]/I"J7S -/=@%
MHM4#U-!6SS[[/'R7!MJU.TI5.N"Q6ZLBR4X&]$..GX]O4I,9DJ.!F.P-+4V?
MCFHDMA:DQ\FTR;UZQ90@I/) FB&RSN8,M2[@*I[EC9JR(Y)Q8]=LEXE1T^N,
M155!V*6IYRJM/Y'O9'(.TUGF^]+ON1"%I<A), B!': T(V(+/2,L5+UX"QH(
M%0FE@6[X;J)"LR.HF ;CHB"Y<:.X2 54CF_98'1:^MKH1"+V%&1>. Y-8!^
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M!NKFKYZ$Z501ZM/Y)AJHZN>OCY(C.B"OD%L6:F#X<$,6#;1\QX-T$HJ 'X$
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MU?%!U0'I8*8U((N2%I;6&+O=# I"7BW'@<+<TY5?#2\/GYH0WF;->/2,)Z;
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MT6B3&EZ;0,T1+FC/_8S/,>^J-*.B:5AP@3:XZC'M=]CO9X7[NGYC?345*\<
M%IA=*D+[AQ V9*[T\T/Q3MGVS=?OH[ZA*ZSXRH3^.!J$M4']M2SD_=UGZ?=F
M"8:7"M.5M)= D[76GOV2O9V;J(Y%QWZV,DG&!"L75MOW+:I\\FX_-T5LO)ZF
MH RX'*>3V'(.<U<IKXF3X?U8?(,])H9A->5GQI+FI4>C0CU>W&>R8VD*2:&(
M"Z0?.BY.$J;95?Q9X1__UQJZ_V^W5AK[\=07BTO(HX;]6Z)D+FE?VXV31L<Q
M:LKTM1%U=)N=&&E$"K,GQ;B6$3]!U>H&_CFW^1\9S03B/5BW+R'^I/<SEQK
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MM-_5-/-G'-V:IJU82(R Q1XL-C4:)N):3MO3B1<\C):^4/#E.8#V+JU#'#*
M<(IH/NG_"A>=/T>V;:V=.8OS^/3(.L^!B>5.T2-TXN,)\[-Z564/,CJ1[\IZ
M7#XK/?JCK+R]*]%LSU>EL#A_1]&:E]>=&O+>?/K;^/<&^.?31="'E'X4-?)Q
MP,9[3DZQZGL<;9X$R#,G =)JE!H@<RJ,%K0WB"=U&'0M.;+>F9*@!J[$:I/"
M<?"Q"5MX* $#G:0&7$++RC^]4BGFOSD+8?(_5'^"2O4[N:A47^-EV7!_()S*
M](&P\::3]CPI#^)V*'CG=K,_:N\]U*@5MB/6 0/;;5%A@G2._.S_1@PA#)#
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M^3*#>97L5T&(_1S +?+B#=QX7OK&@H*7,:.C$DL7)T(5^!^^^GY)]-@XL.F
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M/\H<=Z:U^,($V,*@]C@^%%G'YJ7.)8=I/OI^(;A#T/D6,"97I"IW:<.'\,.
M2\3LOQOS4YF"0UI.)W* T',0SC=E[X6#IW'EA#X.H XO6I4UAB#0F<R1RE9Z
MX^CJ1(Y06%[DF]<=R(0![-$S;WI")'029>+UHU\1C^!(E+%E$^("9/[F3R/^
MZQ<ZL6>VC1V(FX28N48;N[L6AQB'4#U+ZE_>A?@_-QWX_WI/%9)NL1Z6?ZTO
MXZ:_;YW.L+?ABWZ^<TUW9G@-KLR&2FI3%B8:,;-.L+J4Q:929)AM])FCQJ??
ME"1-99AGNC68"TZ'[+"\*/4G['1G6STJW%$<-"7ICFT'B78E[;?M#$<4>H;F
M-M*M91S:CKWA4PK:BL;/^C"L4>SN!8Q1MT*'7/N2@XB-J8PBG]SMR@ ?X4LK
MDE>TBU;?ON#9PML2W310Y4[%UZ*V44ITB3NNB]DN52C4.;C.X&#/=XILBR8)
M?;'C#C9HLHQ8[:)#;"W^(^,L1$Y9VNR@ZUPKT<3KQ A'?;"-[!7* ;CT$*2
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MTGM&U_>_%1R/AF8#S0$^DT!N-AFVYO4!GY('<0RE6&8:+ @QOYL#9#.>+?K
M5R#".IX\V5JEQ&A T.!?6=F0":$Z+07],4!O18$J*\Q.%",2-Y>(C49.P9FB
M#+8KG-5 I'\AQ(81)UU,V:.0[['Y=BU]/F$5>YWY'7H&_?[XWU57J%<(E*=
M/7Y(G'7[L.ZE=!CFO]R9.=2#"C 2\F?I+/EBR)]19V?81J(?+3H.P.9+6-#-
M^!V4/S[S'$$+J_D((VO/J4Z8.8VW->I20B Z65+I?EC/P<4K4V#&[LED[*$%
M$R_]3Y.!$?J^U_@/37(->/*2>.NVO>  -2;78F B;FE'>DL0FTQ\R/CM;C%9
MF82TLW''Y(YM%[UXYJJ38Y#V2ZTE5*-%/P>HA4E@/+PF-/OTK,<1DDTW]H_5
MR_+WQ*3ZZW%GWCK4N^4H+070".+QA7%Q )?T3>PVG:WT5)*NZ7WO7 MZ@>F%
M[AQM[<$'P^P%U]C]_C<V! FH V)'@*6*U4IZ-BL9NPL30!.+? TB)MK"V=L'
M+PZ65JW=>9@@49CRX?)>=?M:OTMSJ^5;-D1734U+*7,OW*_&\>A94V&_%ER/
MT?SJYYS(A"P?$F/HQW+!C=.*H8HE/<)VL0?]8]H[*EGC&KLG<A%Y_Y(FH\1P
M-1>)DR,8"&,Y69>SXQV1@[XT%Z9H) 0TZXAT+3O<M,*W !LX,TIY+0U[F3US
MOIV9#LW\BLAB]=_]W)H&=&&UG77F3S$8$W)GP6$X2*XABDSB &M>97^3;&4_
M2+)C.< \;%VTW5:_$/V;<</7<<&(>(1V P>HLN( (LQ:2&).3?Z2AM\U9-#M
M5^N_7<R(1(R]9/.L?F*<26:-HL@L84M#49H+X4_BBQ@O[1I51!,*IK\'G3 .
M;VRFA!(.E%=&=#4.GM'9]U,LWC[QRCL)M3LOXH*\1M66/]VXE-0FQ]B/T2ZE
M4I@[Y,A9K4\+?SJJ>0C5WG3%[J8)YL*?:WW/\_'>,1G_8H]'C-!^HPS^/4,]
M9@'$AMC^\AKB#DR@]X0[0A@DDB@1E-UV@2>LJ/IO;T_[;N[VL$Z?O-0/; GB
MX]^@Q%4)]32=BPEC(,!CH%]-A8_-X&<-!P?[X5/7/E2E$I:*3P]7RJ90(<.H
MS-VN\ITR^+QZK*0O@FGXJH4*)\-#]:0S#-T^O[:=N1,I_ZZMZM'/.7?OQ*%[
M0>(;119=OJT905/U@@H+Q1X$D>LR=ZUK(BQ2$R<!%C$1 :H%]/#M35ON&'59
M\4D*> '#\C;/=86VZ#NU8_%]U3!)Q+>#*"[<[!G(%G3HM$#TYA\/9_UGS%'U
M_:/T7\&E)3%I4'@)%;<:C2*;]D XTT'1X)?D?DPO]H+,36T;0_0VGB4?\3<#
M^QM<JO'VHNZ]2_RT=B8!3%@Z*@O)SE<+_!^OGC"W_Q8!8@S]!I@(*P^(L<@.
MK$O+%*XN+'=*T](0FX()^KLO8 PP#JT;029D#HN0IR'C>"JO8^9W+H_3)^-B
M$<C5]!Q+]L[ =0']ZO9G\6\&S>X$JX IP#B+,:2YU(R%W949"]4[5G:SI!R9
M= _^53C$+LQ$K:/7\L/$I\W\;[Z92.?-C,6."3'/TW1),1DDRB;PRT2U#JO^
M;97.W)MB$_[,B-87*GM7'XO.C!(L.$"H-#0,/^:T*$S>]QQ@,@*8P[E82&'[
M;?L:''3ZR"M!F*,O0,E7*2-CKHN#59]W14<=VSP_>4-\4' '6Y3.@WE)Y:;;
M@UW4.O*==+*0)+M="A];(H#.-BG1?7WMXG>7Z$2)I*=A7^JUS7N6 _]>7& W
M38/>#\I1 QK"ZF15P7N7LV?>U"@41_#-/]MTN/IQG?3#F,V';QT^,GU,=LSP
M*NC2(&4<K8=P*KRNDUA8E#%FI%A&>/?8=,>G@#Q!H2.R]=ML'_\O'___(1]/
MTS^([94*NZ^_UY#:1)JJ2S4EY\3V?O95:='O75/5[VT<B=G1XJ.\+PJ]:UOL
M4_]F_@%6&LYUQBMZD!A>!<]'VYVC"M4+;=%T0E)[7\^H&,5OR2PZ_6)_43H%
MT,EME#0!Z#__)PP.'XD8SX?FG""SWG^(QYC 57[UG[]AO?^D,894 42^%C[F
M)[.-=@1:( YP -_<'U@+B'TQPE?'_Z[\+$GH O,'-OM/5[.P^]>K2! GJ4P<
M![@)\7'M(62K]9(7<X<NVT*HB0.L"'& KL!2S#=4U3?BO":B!O89]IS, 4;W
MX<+9ER'JGWGKEXDU@MK1PT'M;.  WD(L[>&^.:U?C?]VT;(AG0)1>B[F9&"V
M*9L"IV$?0G,#%H_]D8U4J2&H8P>P N")B2SJR;OPB"K_"<-R<9\?LOR=@B]]
MW?F < 7I1"MA@T83(/C81I%^C #KI9XTXR3:DX*D)H[4! C<=WD]71%2:3=Z
MT5RG0=-LQ<+1 ") MS8#L@GKVO=7[@0%8)PYP.//&#YH?@Y"\GER1FN%]8\C
MR?<[UU[R@I367 52VFA;/#NQV=$'U7[1:_Q$!];XNQ8N''X!NO'VTU]NZC>>
M_4OG!\HAG2>Y0#J/9,<;HG@:B-59$)V5FSYH0;9H7[JK_(JHKO_'XJ_R5T2;
MXO'[FS-&M[./H@Q7T[53(5(FFY,"2=6:]\)_&BB*RU]P[</_%-7_L<QDA+/U
M6*COV%1CT'MI/;5(_?6?1(BF$"6\36:\=&\0]1JDU)<]BZ;'.>U7-Q5,W''+
M7F1_I-2<C8RXY.64MQ.][WSA@PG5.FI9U&:S;HJ7)LN4++_-XL6@R?7Y3O_@
M@V)&9E\>^+\6M).Y:>9OS!3=\V7B+"N*:<>3OWWX:]\SK%R(0%'#L#-599'1
MA"NMIGG%$%UD[L+"1O<$PT+>&HC.'C1,^J@>>?/,2:%D?1/&*&2I/)3QCX@N
M7J!RTE/&<8Q55Y6(.W6J/DWFV<+>+*G0K/+/%FJ',#L%<SQY>PD?_\-&:NES
M,^^"#@S83PCB\]&*2!8['='!BY85W7)OV1U2W_)K;.55A0,?D-H2U=H)+GH)
MJ(RT7:'T"8/N5UW.%WW%R^(\,CTC]YX33L^X0MC"NH>%8^3!$U3X.8BA.[@;
M4E'UE3)&JQ@[=_)3I[*JJB>ML_F-YY\V/7:RYQK.G4AY) 1!V6 W-/(\E3)+
M"0CPO?'L3C0>C&#8MM]^/R_F]=:UV!][1CYWU\[\Z'(]KRG>78$.*"E<S>&)
M4!KVX Q!K.A])WO'C.S^^*G:I'?U[?5G]]I\"SVH?_')PVJ932WO>4[AW_W@
M#J6%->%"TX6T[F>">618B)[&FXTV6V.*"H9L+=XN><0?OB';)$KS8XK +Q3U
M$=?3!\YWP56790ZM-!39#X[:GGY7IV?A_^;@J9C,T OG-E^Z:; 1V8F"G,CE
M]'L<0$;/U9L\)@V*'76JU]YFO*4O-]?1]JFHN)OGQ6N&\LK<WI+5W'K\JY%L
M/G>2![R: \!P[KBM/Y*(5SINXT3LINF'1IT^3]:(]N;N=/WP^5KM:\DK)DWR
MSP"6Z'^-HK4B7.$03(K T??])*Z9J&+Y^B@NZXM#BC,T"TC6D9"L*^!K=%BZ
M#XCWD#U8XT]3N/JP]27YE9R67WK\%R')([\G)WS_CIJ'$$$-_',JVF(E D=&
M/6680?HQWC3]QWMX_LG1LJ3^D5@'PH1PGUJ361\A9%K\I04QHK3 [%AM@1XR
MQUO]]R5:6#[L]WP#C,U?92:0!OJ842IWTU]=0HRXKD$W.^X=_5,O@^&;\!)S
M'Q/">7E)S" V,K64&O#;?@X>+2!&,8]\+XC2<6^24JV,7!5*BNEXA9W-N^W)
M5.N;O8]WDSW(*F"K@+%DPZJT+6"13[;=X(EQE\B]'EERB@.=D]O+CW@$O1OG
MLI#8M?\S;PS1B3@(&=N(#-"+# ]/%R+L=ACZ&>D_SO#VSW5=4=ZI=]!.;$OS
M4^DMFP&>*=V@85 ;XH,R&!]6/H*$1B?4Z(35Q?+_&)7QX#[9N=QS<=GT>_P)
MN6;-8PG;"U>D+0+?M[4<@Z'Z8C">+#QA&[;U;F]Z)N8$[0$6UDV98_=YN>WW
M+$Q]-8ST%S[),+AZ2=M)UUP'6=2W>R+V/IL+3/5V1T1AMI':Q"RNYR<MN#\S
M^SAS/-_@4JC5E1>/#O)F 5B_.MI,=7H)9*8RQM/#]65GB-1'U\L(DI5=WS\P
M=M*'7.P\+AB9%1M%W7S7>&N3ON<'7EC.\FH-Y(S#"**@^WI6"BB3C3:NTT&$
MW!ZH4O#U44@+ORR: M]['WE^]ZD>@RNO[]_1".%^B^_X/YN857X/^/]'*.4?
M5P;<(26("X&=;_N*&'&["TM8@E@'&?N?AQ?AC&Y;&N)T8+G_[>+_WR4O$O%[
MO']=>?YB:8!RQ(L1+40U7C#^#A)7(M+)N">0QDWO7%^#X/U-MQAF?YGT^MC;
MA;&$J"8>@;E"/K"RF8E:#P<3]J_4_DD"8%L#6" T2V1X,QW=CPK8@N_U/#R<
M<+Y7QR.-NDL#^<:C'Y_0TU,V7C2 '=Y]05\EGW5O^0E!&7,)I-&LT_H,/M+4
M7KIX*-T7V(;+5BWQDOKL)\GM]'E1-NP1LT^%BB>713*V8IS!CBRF4VEWR5%$
M UOQ>;V.<527^;/Y3O;HN8;+?B&22:<65V[>=*C8(C:+NR:=1XQ.+X.P:(R4
M>-@R3(BI6T&=E(455W07/.M9'KJW_Y9T:=1XXLFH1HF8J*K['X[Q#HI^0D],
M" 41).WM#":$I$&?6I^1O6BY/BWW@$.)!C7*"K[#&^95\/B=X AC%W,/*\.W
M0!<)AHV#3(/<:?KWSM$?* ?;BOJ+9;67$K6!AH<C*9Z'&\T 3!@D@0\=1<'$
MOTE@+FA<7X&(*.G'*/AZ*'P/QXE.[E6^CW221 \$72H,\_0)Y7T/22"S.FP<
M?@\!>5(5XQK$5N;1=B()UN%9I>'WVLR#_F'>S[QW,/\&(SNN_^J5J$L[,1\/
MFN,L_G?-X__BF@?O1%_C5O@XK!8F JX@PPOW+[FCM#PZRDH6BC>3'\H.3=ZV
MI[<&(!M1H@@OBTA;H=E8ZAC9,YWDH&1 0T243N\7:UP33QIU-[))&[UX[]&!
MX3S8UZ9XB2#1D$!>2#2X0%0^TY&5@/%^@;X[:CIRU2F8/=JI,+RX*I)9&*%;
M=/+&ANYQ/WP:6XS=C2N&-1('QJIE9<$/ 3G3S\KOSWE<23;JZ26+\/24[($=
M@L,I><"ILR;2;XT, ;^Q=["YJS3=1IATE375;R(V=%9/8^*YP([NV62+LWOB
M]^^^K> <9S\7M_.@NH2@('_?0,]J#T,?_08Q.,3F5\IG7J9F17?CA#!*+U/W
M;'4D;WJ(,O_T:9.$L_IBUB7!S2>/UYAN0+TJ^=N.-1B9<A^[ ;R7>^(UF%'-
MEJ8IOMS,I?(1=:J\(NF #H^_<!PH-:O\8G.!QZ6BLHC108FY.?+9N(;M(2<M
MVX'#7%GK8O<7$7T4KN_W<$&0/@?X7WCR?QV>_"=,^??2OOXWGOU_<7#77?M?
MY&4=P1O]198<BR>4O?&H^"36"0G&+Z]')4P>_5+6OR"JD';\<_X9U=Z.R>^(
M7]!/D&?+LX2,H1E9%)GY$USP-WJW$6(SJX?QD%IJN1'7D*I8>M__P]Y[1S7Y
M;NNB44!4JA21&J6(4@3I"B2" @(B(E*D104$C'00D) @2&\" H)"5'H' >F$
MCG3I$GKH/:&$ $FXX;?W7F>OI6>?->Z]9]RU[SA_Y)]OC'S)][WSG?.9\WGF
M?/_PUVMG)&:'=B")VUY3V)D5KVXV/4@F\.+?R@?_&'-V7F]'_7WZ;Q$%Z:U
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M<YU!A@\O8X-:;F:&*/FX0Y5>(='#(Y_;F'7ZUR0<V5Z\RI[;]KNU&DJB*0Q
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MX^I0;)%"4K1_LN8DVZYV395/+T24ATVD7:U26>#;]M+3%^3+./7$65&F@",
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M6@XVF88#CP --^%"A)A#(UWV%3R9J?09TT?N_.7:9YH]/^8>L/%MJ"SZ0E>
MHQ"\8Q4!>@AZ4<<]DICG/L7:IKC"0&6]?J?82_/"1=*<A2?YLA(N:9^C'LP&
M$H WUH%PEQ,Q8$:=_%\OJ$5).4:AHJF<SFS8'KUOC L_V@3\_1164\.;9Z_O
MAV^]+L;'.'^SDQ=BA[:4=TZY'=A7?'ID2:-GZT99$(\(HLVA+'S@]LRIVARY
MS*]FDT)OX\F62M?;!5_\U#WM6%DAXP517WPG^HLL"F^K4P:?5U*;A0182!5C
MMPGQ9RX.B;LSK#9_V%:5:KM\FYWA!S6+$[03_#PJ""Y-^@JVNP&2(N1JQ=[M
MR]]06ZF^TY>VE?9,@3_(J5.$1M64%&YS&:4J:V\XH-I?Z"ZZ/SS<V,-149%,
M7G/^&O\<5'\2<1;GNM:1027YMFB\H#2[Q4!3F.-:SIB\-_S4^\_IM#Z%7_;W
M<=(S$[T-D, 4#E(*3#SK6NXLF&=%VRO/O+F:_6G'U\*LJ.O^[<ML;]]4LR]5
MC:S;?2'W;$LT'@%.>G+HX?(+_?/>FB3/YRVPE5\_ A1$^X;>FXDTCQRB;[:I
ME5CS3YL@0@E-LU&1Z"[&^('[!\_]Z<<_I )."9!^X2_?:I 0=K:0G9GBLT.4
MC+1&H5GOX1JJ K=-O]?I@&S*/:#?XS7Y0+[3=[^).H E:"_70JSI[;4^*-WS
M*=/2O.^L4_ BUDY[9OF^G-;D<P]G+>T[1P )@O DDH8L88OB43IAB<FGUV:O
MF?^:A(9YQ6]+,'%;^D>>%LBZN-?B(;M53F3U:-H[$%[;=7;VIFHXGYD_;H'>
MI'8,Z@@4;_I5JKMO-"2['^\8F.[?)?IT2;%5R@YA8<K[?FZ>[9>>&OO<;R>M
M_.MT@?6&@FUUT5]GZU%\ EA@%)%U9MVH7EM&NFP(G[+GT@[E1^1'F'_?,.SX
M='5!CBJKS8_</RF#W5P_AY-N@)\FJ*4U5@G%'WK?*2XZY'DX?K]]X69+F=;7
M/.?Y#TQ5$X'0'5<,I %!37Q2ZC?5RL=7-AP_!;H7<S[2N&10+-A@D$_J1-O)
M;*(LX01V;YK8WST#I!M=EG]8,%PUOMU;?OA5D_,#TQ,GSYW"/B<>E?CYG>SA
M3'6M&OZAPL/OZ'+IX;U]+Z]/,>DWY#[VD19[P*6+:T:SD##0%6Q<V]O=6JY.
MS9\R=/:7K^PJ)F+>:;+^N!=:W#QM?0^V> /R%")%'D2>HN2S$GUNHE'!Y!M'
M@+??^S<P=]?YR2/5M5MF5\1^);-=4Z$22"+9%0 Q"0VZIV!VWXI*<2D1I!)'
M2P%M!^2+)(;P^I.NK-E*)T9DX_5:?H7S:DFV"(D\J.LS0T\]1Z]6K#QXJ)O@
MV@!^ @F"*V/;_ <L<,?SOLIJ)/+LXC=3[9!H#E:?$)5G&N]76$"G@9>41<?
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MM<Z8RU[1TC+KCWV53>8[ @1->K6M*\^0=&<=UWTDWLK834.'_.A."U9$UWS
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MP>QQ5/A G,?ZB=E-!NUI_RR[ZP2/IA2N6FOO'V)QPQI)TTR5 C>=:IAY&RX
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M="M O: TN)?5?& -&XHJWS&1G;4]9"O#ZNS,F41R>\(V83V(()TN03;!MAX
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M%15N>_>;SPLLN\6OO\2OB#*^2'\ LI76$M2+[^2%%9V6E"NT7PPZK.?YXOT
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MWER$W!Z(W.$=P.>?4/DU:S!W!^YK&CJ'\5+TSLITFQDME>X!N#".'K^"VV$
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M6VXN>2+82[MAS4\>YSYU*7F6SV?EEZ:JC8,&Q@\A+SS!LR$]Q"ZX8+=CYQ3
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ME:S'! .T)^!#&R7/1\!A3-!KW2FH#ZJO8 _T8%^I^< ;"=];%>9S_.,/O[K
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M<B 31(.Y810\4^H<!T+S7U-;NWN7 \'1&&GOEO/[6'=RB=(<R.]_[0:V81$
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M=A1N*[R_C*H_Q^H[,'X6%P0CW<<T&\%FGS$!8M@TB]E$F/Q%J'+_DU;_PW-
M57]Y'14^8D1*7VQ@7,*T .'"9]N,$P1BYP?&@Z%+@Q9Z L1;_S,1_^6[PE>#
MI/;CW]<7%]PD"I &WJ?6T6*8MA-WR7F?&V6ODNJJIK$Q'KB; ''<P2J"S2:-
M8"96@40Z!?#[(#P"O*7X*)UNT(_?/(8W^:\1";W"D!<;?C*#M78F_#D"'V+^
M$0[F=>!CK&96?.1"XVI'WM_Y*NQZJOH2>X+=V?8('@!0T;]XFBD95D8$IM@'
M-XQK]F^4I/0T^_(1[9SFP/D&KRMS$0J9YV/U.GE.F_'\/%?O>E(IW<KJ/UA;
MM-LKVS!5\<L5I[/7H'7\EE<]SK^I,AUC96.FRI%1VR5?UUZKK)Z:1GF3X*/I
M'6E*#4-^X&"V6-C2\NVURH&C-L<KQ'BXO136K(G%P-!:WK,J 388LUW FJ<2
MP_R *VV909[2>_QP:JS/W*=S:\1N3B-7HC%"-M0X8/DO I9T!3V*63O/U 6
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MFZLL70K)F'^S]UXPWSR;%X6BA"_RD:Y7]/ Y7YQ'Z-O#?V]\>ZFN=DQ\V=C
M).DF/>0K7S,N'7_#4XYJVXH=<6CWY\/;-%+7!U_-?.J*<KCY7+XGLY",-9P]
M0A0HD:?T,$7)DX.AN6VT0 M,<[+]KRF/N]@' A]:(+[YUU.5OK\8#X*V9D9.
M&=RCAC?!!4J.OJ.&QS!/DDXN)=8+S[^N:$B]\&XB<5_M$FA#E(N*^=.]DVEX
M&S:&*%2A3E?E;<:*VR,9+1O.(A\H26T5TPU"97=H.GTO*V[()]QE"$<DPQ+C
M,$C\N!B@6)G:V&;PEMIV5J'DE6[O2>.:*[=-PA#LF$!P9G[Z8_+W1$'^V!OW
MO^E2>L]?5-O#L=X9N+Y#P&6A"EY2Z)KW@+ZAIUQ.&Y\;63HI]UJG-CZI-S'N
ML^%.X6:>:LCBHA8[6"=]@X5IQS\F3"H7:%@BW 8>P70*+^26I]1N/.%?NP;^
M=Q=A_]W?M= RH\VA\6A6DM4OS#UT9 :KX3WFV_E^(!'CZ+W_TS_KKR%?&]=D
M/^>NX*OQ?][4S06K*N_9VCV"(:YS0%(L' M(^I[+(8_5FS!A6^@,*J)I4)>6
M)M5_H[JBAJKXYCY!;J2]*+986:4I>+=!L"JINJ#X5**GLMEIYY[.K0.O]\68
MK:IZ/%&"QVAOA7! @JX4(W;4-AXP5=0P]$6T)::EDY+"$I129PL<XH F"V>9
M.JW6&>MXA+;TBD\?&SV3U)8X<^7'?6-\E"_CX6Q>B3][O\DS_*Q'+X9R$YA_
M,1.F&I8/\ZTW$P#_%@A;!8_88HNP,0"CVP&?1C]9!V"WDSW]\*HM(++YY5O@
M:R<\\'0-()8CL_ZQIR%*^NH6C X K<96!68*\^"4BBJ@B$/C2>I;4B?@3 E
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MK!P\D+3$46@Z@)RR #KO)U/*T5(1F-*U0*R <4$S FH6&%-F*1\@L7CR^%3
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MD8V8 #^'2E</,FTG!8TZ[N8TUDP6/[CBT.""C..2XGM]^MW! ZAG:5IO"X/
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MY8PI=M?7V67=B>>S(:@>:9[(ES%&A4Q"Z,IK6U='-B(6T/OF1M*;BWF= 2C
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M4KF];(/;[7<?B< 4WFZM>O3+1,U9+28K63I.H%J.N#!$W=,SV1."\?*5_.'
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M]KM +>IQH^0'@8_!!]3CZKAZ3HY69M#C&3),:7H#E:>_G:U.D4TOIB<3/W%
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M@2M_:@U(.,/LH7Y"-TPO#THJ*%V6%S=8E/BCM X\W34</<T\L0\EX*?"+.L
MY0JD%(!_=-[^9YZAWCA2IF+>=,;J[@MHU07X9IVCSW?Y^OZ=Z2\#+PO5@ J*
MW9+F(KR>80H4?W U:GYH_95G4T]'9C"R?$=UB/_QW[\0X"P\/0#BEF3([^IG
M*'H BAU9Z,10,J=A)D$/'UQ]GBMB]W0FB>V!VD,9F=/ANQLXCP,0.X-J7+P(
MGH9?'0X!\Q-"*/545<W\ !7YZZ\*G<*WC.JG;NV/7/\.Y\+DO3<%ZT2:+6-J
M13==W,B#Q/6NEL/_7H',$&(( ?XD'1%B#Z"^>7%AS:[3LL9,2>!KVY'5/Z9L
MW,^_5U66T:#[Y;\7DF$UV*XTL#. ]WD["YS]I>_$G^SX/G]%9'1+-E-Y%7&R
M2%D]7(UC+KX_<\OV[K7'@QVJTW;DO&B\][8 TAT0(D.XI]9<%:J=+(((S(OQ
MB]/F9^(.!R,.^2^<J;]P8:;Q]-?4 Y @JKU0@Y78Q@LR/*%0 ZCZ )1U?]DJ
MDO[T=^*#P:2(5HTQ*8LHEE\C)39K:'G,2?_AQRBVI3DG6LJ8H0C#'##[B+P
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MO!JZ4,W?M?#$4 M(T&Z%B@&&?>VNNHU^,R]41:X$T5Z="9W[8FX<=Z-*<B:
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M THC3Q^ WI@<@,[;81B/FR ),$[D:0J&?HTIZ")#5Z1?ZZ-#_]X<#7^A_>
M9+^9"@]XON[R2EAXYT&WL,4P-O'EV[U;@3Z_IYL"; R.B:0^^SF2ZKCV-IL1
MG:R E=W\[SJD_:_&,D.>TM"&8AO3_ <]X-H5RB;S=2=6I?:5FJ1#@)E^4F:1
MI?,JYH7!Y'^ G>5_% _G+P*;E$G2?-5^-AF?B!*F?"M;+E]PF]!L\C.C:86V
M]$IIC<;$I$I)K->^<NQV'2G_?4GMUX+5*-S-_(53GYFMO5?2F)II^KMX6^NC
M=Q]>8;=[POQZ *+:(U:7$CI"_^2Y4-V]Z]5"(Y15Y&JOE@P-_'-/?^+5' Z.
M9<K,,B!55$P"4KE2-7[7WX^,*H87O5(U^3R.O3?J%LTYEI[GX0_7N=?@&3)/
M?>[N(]5"MI)BV]+#EJR)?*F+J_N=UJ]=;V>E-.0\TR.;;C]UN+)<Q^-4]-'%
M&-@AQC4 3\:#&6!@>[$/(@8DW*Y.L1TV4"[RDUB)D<XI<S;_D/CF2TVA2-T3
M&]%OLU)73KR06L3D#+Y'8+KS#+DF51C\<"JTLP >SQ N(L!5WI @G"?AUA'5
MQ;2%7I$<Y1S<H\NG9XXK!0ITOBR=^<RVGJS8B_9:2"XH2<-[HH\RKE(?FQQ[
M$_Y&I0SI[Z90WL2S?:>W[?ZA3\?49A\Y:Q.T@3[JM39#3J#8:RG"_Q+CRB.O
M\K[%B!1]^ 9BUR$:(^?E%-I$MWO:I_K<8\KSZX8]T_+0[BN[R*L3^L #UQ7A
MY@+Y D7/IUS2&@HGQQ_GW):]F]FJTKBFN/P"DS%_ 3[=0.[N,+<P\\"W3&[O
MP@^W^Y-X1%3L+*J)W,S=YJ^U)?USA*6MU-M,=@#B2K7;/$G-ZVQ@ZDU@8<8B
MKMSQ]^L_F<Z]K7'*_V38;_IKM5GE\RD1>40(\37;VI<5%90"0JNOJYYY[#,U
M((XSI?)V?\SE;.LX^+)+<8-R(_QB_+AGCVLRU!>>'-*(DF2HCO^.2'F1%AC)
M:5RP9?ZB+LT3YWU*R:7#-U'\Z_T-&^?LJ"(0,H$,/=9+PD_=;OW48TLG@]-_
M'X#XUP90E]7G_,+R:)/0BTBOX$=%I6Y[[D_NN-E%\5?BKE#=VZ2%J+8O2&GP
M+E?P,,[L0SC:;?@WG_51515<+^^C/Y9-"9'?BD6]=>]>_LXJDUYVJ%)E55=4
MC;X4!UN6V8;B]^WT>3!EKA/?L1WK"AJQZP0+&2IL-4ZT3#&#)9349KH#&AJ"
M!&Y>[,A,B)9V[LU0OBR++4*-SI_Z#%C090 BHO([;FS3P""XR3S_R/W"K?M.
M]I+BRP4.MU,+H8]!O_?Y74<-K(J(OD2M(I\R'[O,I ILN9?#ZU?\)B;6-L_^
MQB3C8>+SB%ZF!%$^*O@ E"A]BI(0UR*-\.V[&4KAC_6:W.+[Y13_?&%6ZU60
M/[>L'Y?]>*ZQFNDOM>AH+&"R9-*IFFK%''QLG%/A@+CM0#6)VT+:D9M*@\<^
M\W@L&YTX>_1[CYFT4TZF6-;'X>B^\T>26@VKQ^O\3G+>P(W]UN^+U+>HCML*
MP*HLV[^)EK4>E&D2$+:Y(I?4"LIV<.4"XDBP),<[7S"Q2/,BH,PBWMU?;B4)
M+?S]G(*-NSAB.NIN94) 4#SG9^Q+ADPI2_8<;Q%E&*%3#14BW5OGN:BSF'N3
MO^$U1,G/&C]/H7>+HW5(.1PC ](+2IQ'#5VF-%=APII0D?6_\ Y(,O'DJX4G
M2LS3A-<,".5//E_]FT>\DP-":Z,E?#S/FH(3PK8/G[G(U?J:OQJGS8)-B]JD
MIH4H@:D\5#?G?B,TPW)T=^Z&9$J*%J]E^7"12&H\A^E=7?;;&H/)S*,3.+<P
MDK)^EQX'2Z64[TF^.C9Y)]K\A]92*"#<5ZFFGMEEA$C(,- N1J!I*?LO<4(D
M)X7=OD@1@DN!_8,3QOX:5??J28%%YRL>R7W8X+G.;R/\E0C "847)PVED1<!
M"\^8-C07\LJ1,BQB).A%1$0B>X9<K- C6DICX=5)E9+[?C()^M^Y+H,=UN=/
MC3"4BZ$?_1QS"C/?7VD8P.%?G8J_U"\<IB]PQ#Y*+5R6>P@[@$_#UW+&X'V@
M)Y&ZN? DZ9-5%"57_:H8Z)"=8X-9Y:D&'_G/XZI+*KRF*X?8!4T/==![E'Y\
M^&OV'^#=W_\?_S4TQZHO\%IF1O6E9J!\QBPY8Y&0_1P/P(>DJ,KMC1<U/&5$
MBO#,T_,,?J967HVK80N2+FS@=GGW-/^XS5,1.1=3]H!U3 TL046TC9\4:6X#
MA$<LSOBEG#RS0T![*I\L7XOV=E%Y4Z@KG&K5Z'F5GO?P08W71.EK?LPFVAW,
M_9,IS6+RD!.(2I[U;6$G8*"N465S2_7V[7B=X?M'O*6UK-WGK8:C//5#HSY^
M<3V__VP7?L(5,2:?BG1ZZ]VB8>B5J''I[,J$HM^?FSQLIO?]0@O5AKO%/)+O
M&,]$OQ/AVV3-1YO$#_KIR@>$O$6<G9;>OC926ZKAG;OCIU%/O?KIR=FA$UD?
MU:,XY9^,X.AMF.J%!)Q,) E>BXCI<)4;1I[I9%Q\[1=VP<S][:MXG?ZK.M9F
M!0K/NR5G<0,2V;7Q<AG5PY?!$&]855Z"ACGDR$__);"8KZ$D!55UK.X-@%I;
M&W*8,1?JH7;-NU3WZBE^ONL9]M#=6LIC+[1%" "#GQ13L[U=+U!%"@O/3J0W
M*UUY<%\DC/_LGPZ.38?Z&R#CX_G<'S.4NL*Q-]]&*?HZ^M=7E;C8N[;F:859
M&0@13GWME3Q<_NZQ@"G#[RN.GZ[AC>*;P%V*#"*#!1$?%PB"!H:2HW7KB7(-
MPU9Y7EO(SU;+;M(R#BK2#L)J;'S?G"99RW 4"**?P[<WI1E#^9%VU Z>C[Z!
MOL2LP2-)Z@NS^EM!&H/O\V&0L.UENT,WHB[J[F<QM.435>3S.E!R&(*HM!Q<
MU&)QLG"&KN)BVKL:7ME^*+"7E@K]GM\?,>9Q(RUGBZ5X$Q!--(MA P?Y](KL
M+FGE(8;^4K@L!D:A98?X"U=\'SQ\^5=X6L"D8*YIT>P'M:('A'.V'@%%I.U6
M%S82/HD\&4P?N/%KBY_O)U.X/IUF6J ?H7AI^3![FJF7E]+W+"Z;5LN+KME&
M(.2?<E0G4V+<@&<1S6-$WCXQY0! ;W^>>%V@[J:_ +-0_!J@LE0X8NH1$G[?
MH\/W1*-.C[6^R^U%7T1-JV-#'-)E"7(<T2+9^Z:Q80S;0O ++X'RE#_M"Z"%
M?CJ/"WQKRE/VZ[.N]9V_(2<.?5>D:_VL^8E28PY1X<F:T!.LGB-Q:37U;"%1
MV7J^]]J#Z"E"P-/69%?C/V?8:W+O]1\ZSC@-<&BWO3@I9#;2<AHHI!,DKA\A
MSA :<AT-;".TGFI+1AJ>,V/?GI7E>)$[EXUQ>!NERR^ O#C"L*!*MANJ-7_&
MZ27$D9O3V\=/<M2O/S/]GC-6228)?'S:>DCFNQ1U<OC_/CW_?RW0!]/_"5!+
M P04    " !#@7)8T^6/V B[ P R5@0 %    &%D=FTM,C R,S$R,S%?9S8N
M:G!GG+L'5!-=N/<[" A2!4$Z2),F(DVJQ/(" @("4J08E0[2>XV @-*+@((0
MZ5)#"TT@TGLOH7>EEU!"@)0;W_.=<[[SK;ONNO=.,BMK[=GMOV?OY_D]>S*$
M:<(R<%U334,-("$A 5X3/P!A#G@"D%ZY\O=+/,B(7W)*<G(R,G(J"HJKE#14
M-#345-34M'2,UVGI&.BHJ:_?O,YP@XF9F9F&GH7U)A,K(Q,ST]]*2$B)9<C(
MKY&37V.BI:9E^O]\$'X!#)2DLU>_DY+P 5<82$@92 @=  \ D)"3_'L _^L@
MN4+LXU4*RFM4U,0,\.O %1)2TBMDI'][3;P:1+P.D#&0,_)*/KIZ0^\-!9\;
MDU1(8C8E_^/*5F;]T4,!Z;?NH=>H;K*PLK$+WA82%A&5D;TO)Z^@^.0?537U
MIQJ:!B\,C8Q-7II:6EG;V-K9.WAX>GG[^/KYAWT(CXC\^"DJ*?ES2FK:EZ_I
M.;EY^06%/XJ*JZIKX+5U]0V-;>T=G5W=/;U]8^,3DU/(Z9G9E=6U]=]_-C:W
MME%'QR>GZ#/,^<5?720 *<E_'O^WNAB(NJZ0D9&24?S517+%YV\&!C)R7LFK
MC(_T*-ZXW>"3"J%D>IR87=EZC5]:_Y#YK?LHU4T!F15!U%]I_RK[?R<L]/^7
MLO\2]M^Z9@$:4A+BS2-E $# FG!.*L+=]OC6MG!.I265X8Z&)CSZ^K:FJ69G
M_/>:POTQ?;A5'V.F-I?]Y.?WPCE170\5[.UOIE8FD#/IO;Q')9R39V=8:&"4
MJ=\:SJ2GW\&DIZKQE)@MX9$JTXO*<-$Q@[1\7DGV%'\#LS)YSR)&8H'OWW.B
MA(&<*%& F.\9Q:@J\YTKZ0OV$^-3>62%XO>_P>^0$R^:$.O7)R%64D$LDO]>
M3Y7IO>N6EH;6<V+:_SAEB$W>OI<3)0(0\_P?)S-Y'+&M6\1VKH9&"?]GPR+_
M=OL*,>%_G"GV(OT/.XE96(D%!8AJ'I+_Q_GHKZ"KQ&: ?\^2J:04>X X7'G7
MB:TP_5>ZGJK67WD);?]1X:N:OWF2V:E\"PRV68F)/ZRSC3*U3;VT6/^*$9D8
MU2FR)M;^O.^1SJO/L[X_+/\5JE\F*#I1U4WL LV_E41Q$<< T(>9:AH6W?$B
M9B?1)=:GR9B:E)H=8[BE]7!+E2_T;]>?_S(5SLE.C=0?\\DOG7GJQ:0_I9H]
MH:=JU<>EI<J<+$.L)Z?*FB[?5--]2NVC*5A3$[Q:^O5):N;3&GBR.-VKSS6A
MJ57"AOEYIJ:#Z;S]8ZD)GOFE+Y^DIB;ZZT\]JQ$=&VD6+IVQ<S\II*OY7#)5
M99UMWZ]=&)>2+$*MA7T15B:\[7C;3L%>E6]LZEF>;XIP7OXK.*YON%>=*"4F
MXN6X9_^@S06'N,I8P$YOQCLC]&A-TM/%J.^,NF.UI_$1>/'#/U!!=-F*DZ-6
MU6-2\T7[XR?L2:XD-L^OZC(G9^^P<'-/U>",!HH7IN?5O:Z]2>!BE=I 74%H
M-]GFSP8Z8,2":+-FWB!E*MULS#T3?B3Q!=U;@8@>>M!X5A@4^BY*+:!5TH3[
M[/]\+C%UTJ':\EDZQ0[W;X\?$H#P4RBSN89+CCW+;&>'_1]EHYO#2L7KM!VW
M!&@2I ]>5O&K#93FO]2AJFBE&&M9P7T(9,&E+5M8=B2KUSH9;3ZBYC[LH.PY
MZ:^.QP!EDAA8L9Z7D\_(6I_[V=?5W,CFU+*67DAKE0JH$>.QVL^E.:S3<-A2
M[?+CU?ZE>%YC8/^=2S6SM\S]K]U=Y7\T/5H&,V*,%L5B7=IGR^/)8BL%$56I
MY#9=WJ';)/(446>0&! 7 :@D  XF38]HZ]#P^/ SDR<.U5]2U8X6K)5J:RF3
MU-A:>QZ9;W0/SUKB62"1)WL2> ;$+KAR(:AP\-('BEBWGHL7=T,J#+J/EWW*
M*%B0[1?T/J@[S1X'7TL;C;4K'LZB_5'BXN@88!:0Q=EL/VFK-0;S*NFH&=_=
ME]B'[K<ZW7BZ=V)(AE07:@-QMC.DZI)C(N11F7OY.E=5?HJ5>\189%2N/H[5
MC#J,=AQ9WRS4X&CG5^>K4DPJ+;WWB.L1T^PGMK]3+2Q?W.J7<$XC+<_*0523
MJD.=J7&$5ZS.3*.V[9L[/6[[Q:IO1(1+:LUY%>-&C(/5048R>_</3%HB^MJF
M'.=Z,ZR,T*BO HG-S ][09J(<@SHU6%+>^EF>ER"@+QNG:D&W=JF'$GZ#L06
M>BZ^2$L *D(AIGT&O\/2I[I5V>F\5M3\+?+/JM.1RJ2K$*J9_$7XRJ#94[@?
MF=8#7$P%OP)9.$T?B3S9VO045Q#RTAO2RS\&VE6@QR?/&[>E#(:7HYC.9RLW
M;5DI?]<71GXH+X4N,NF9F?*$!JJN?IS5YG@T*6LWL6=;69WTFCY;M#!]*UG+
MR!?UH>#\;?F J9B'V2'/IT!IEXT=;J[)FA]2+(,ME:G,O9M2?>1O)@K2&SFS
M19W'C=ZH,H_:$P!:K%F)B?AI?/AIR=QMBWX/E\)! 2O_".J8%PK"^]TZW[;M
MR2%/,G.@,E)F@P+Z7:-:',R^\]?[?BV'TC_1H-%U$U5EE$E2(G_Q**GC$. :
MY N,0.I9'B*Z3%.AM'O0#_"YGR+) W&KM/=M8R>.Z^^9,^R+<CU9041[9EQM
M:3EL@5M;E324.\N<Y\;0ZW>Z1>$8,$($0$"L#8JFB"< #\LY=82F.S45YR_,
M<X7PHR6*AAGA*>CC8Y"TR,2LEQ?T7FCC;\RCM>[G_<M0!JG$!+5D%7J\@BD4
M"*0G -34JUTA^;T,J;U"EX;3<RE'EN?3<M776?!D8B<NSU$VT'Q,AOI(X9?;
MV<7=RJFC&P>4H6DX#E (3(XARM,JE]D[*$([L5TJ5_2TL)]I[)7+A1VV;%(F
M8X\.[\BE.;2FV_PA1! ^H<WT\2F9LQ$01ZE\,:EYX8+^?7AO#&N=A\E9%*_8
MK@C*6DGQ/<[Y10;5#W]( ,IM6JS*TPT?E,G*3A"-!\>OMX61$&L\%XCH-C9E
MH)$MHLA=U?VO*YF6>M4*G9WY'ZJZN\%?7\1-.N4W=%+JY-8P+R4.CTVD&55/
MSVNX>-"D'G=Y-^D7&1EL/EIG?\J;],=N->I^ZDM64;7WJ39" *"8SMWQ<K%-
MS\(4*XAJ[_P#"U-^.+JFU)6F GJ0,KAD?V9J,9]:5SMN:O&/FX!TE][(::M!
M3^EY\DSZ4(JFPW'TJQ^A&:\.+D4"V4;P=W8NFF;/TQW%!7G=;#F87LX^7OOS
MIH?4]E',!LR29R\V?V83>E/\G>>ER;O2[V-.8V(!GI0?L_.627Z5/BA&9PTZ
M^^O>*>&D0*XCQ;RU2I;VIP\;W4\*D :V?^=+>+J%*4;+HJ'6>K[Z2<' IKHY
M<1(:)=D[^R44*J8_%K_@'&1^<!H[E.$E6/:[J;9.\INR=+;Z7]DOF&\[R>RV
M1546;IWYP]>-4N]7O[+0=..\B?K*-23]_KL5RM1_(P2KOA+M"7UYB"_*^[7A
MT!MD+2#:/7)3+[E3>ZJSV..S>9*WFB!SV7>,N@5*(\&N\6YNR1<\ 9@6%X Z
M!WF'1<%*[?S3(F&T!26%"_9I9CY^+ DUNO$6I23=%$?Y7@$4U>GQ2CH+O34\
M5#NO1---/"WX"(!)NN"2@#?1VO-ML/&2_!J4MCA<A*T$=,"G/'\N\&V-:%:
MS9KH>C1(0BO(8D*E=QT1&'I4-9XI%5ZTS3.]- =VJC-11L#]..[-56?&II>@
MQE?/L'=A+*:.D!G0]))MI98$_YY*\%[5T\NZ=^:0TB[).9AL^.]A1SN?1A/=
M8M&H7'0=YMV>BYD92OE/5%97UX9^8]S4T*)9R5<Z1M;K/RM/ '?'[XT8LS4E
M#@\WCQ4N[\4%M;4[C>_ZWGL-::XQ^VAY1,@4:[^2=/+G7"#"D@VS;&9F5[87
M%[R4T7S^J7?>O6P?RTU@?2HM#"L&68N_L=5(]R7D %; H%Z_8MQ@N?N=,2@$
M-@*FP^BV@JI![ZU;,OI#>&-5%PL%7L];//47[A82. P+.4_ORC?4U9XY83/2
M4^Y/S\OOU5'J)0#@P^Y6Q&%1H-OO<^AAA&]8/_X,;8[!HHUE_6S="A<TG+S(
M4I$,F3":'KV)B^M^S&B.X$5_=71%;*"@O^<  >AN_?E(#G<Q5T< >&!Z$S7T
M)/@);M(X'*/2YT13>9>4*PLS6B$I#UHY&0M%U>CYKU:CQ^*[N>A-%;CI6?,Y
M$3<&94=+P!<'1>?]JLZ8G=:S)7JL1;%O@-X<^B=;8*WUYO9#:[?=/D,$>UMY
MV:EZEPYCH="U$ME<(F.%/M<#_X/OA9 %@E!2V@8O44#2$>U]N[5X78IW[I)D
MOWO6XRCZ[CUPER^70.=5U8T'*_HF38U1[CF]T?HGBO4Y'U_TTX< '<"=DE:C
M$_@1+6H-MW]M&9=A7N6M!;. D/;]*%2],?R?AE?O/PRO)P$X+ YT6O<C_D;N
MX'6D_T!L=.N.YPP]ZY2G#3)U0XD+",ZTQ>]K9;=NI*YOF!)!R?^#+^/9@'!Y
M^O!*9 R<VK 1?IC:X/&NO\$F4OOK2(PM;^@:\_"2R?Q6G;[IHEF_HP=;>[LB
MDY?*!VY5L5P-@R*R;SEC)[PY_P_K[MG@[87$5U%S2&7Z51"-6=Y%=^2I]FT*
M)2.M'1%>(Y7W53%9HN(4;8H'431AJJ->7.;=9_A6>X%+CYT:3OU&^&!0BHZS
MCG'PU$3O=Z^2QJ[((E__PUF'QJ"IKUZQBZKKXC?6D(Z 6RNV./VTZ+9&YTR)
MI%UYI!;&9[79O==%9HG&43$\EZ:LLQQZIS)QMR_/NS1(7;MI]$"@!E&3U;<-
M0I!W.'' @E_$1!D_25'H$M6/UDCYD=/HR!.A(CDI/K8ZW.;_>YZ.]$Z%?;5B
M@O_UQZO1TR+CF>IVMW%T-E$C4X%*Q1AOKS"C<0F9AB_6EDUUOB;QSUFIA@L8
MHZ-K4KX8/\G%*J' 'TOUSS0/ARJ+9A1XG>_L"J;>O[7\OB_/U3$+]KV%'C_%
M<UBL3&V_,HQ11<"5/PDD[X%F573V]LTX @NZI'?TA 2:)WQ>VZ\X3+IU3JS'
MUFE>8,M]F2=+I^0,S,S;!9L[[EHFL;THR24-+:6_%2H9IF=4&"4+PV@H:Y=L
MXW5G$#42MW\>^3@?8;O%Z^39NMR^4?47N/8*WL[9#XW:4F_798$G-'$S30T6
M+"S9X8<R^KO+]^H[/5Y$I2B,URDZK!C+9'(3@%<3?!7C=\IE.;8\?L^9_C/6
MAR&/8WXD!-PXN5J$+ \F+M8C<),X 7 !7VC(BBC='JRH,>)GT(GVUK</VN^&
M.BY2H'C"R]:@IG^M[R/^=QH2NWDA+RN_7>F3<E4T$@R"77H1@)ZPE8/+:U <
MTRE*]9G@0+F/S33K;TQA9$QY"N)Z>2Z>V24&WXT>QOSC=5#E%^PR"ZJV.4);
M*M4Y=4D.^;]M\,<I$H!T:0+@2H^K*RI2T>+R4S&FZ9\][BTW#%*Q_2/N9*="
MC:*/RDG59GDT<?IQA=<J@%I!B%+W%F.Q:S \&FR-;R7JN(.!X1&\!&"$]L7O
M?HYO?D94"A&B\GY*0I!6\W-2H]&#$Z['9K0Z?6LZ+='<UO!Y;::B!%9KDRM2
ME*#'8NY(XDHJW^5K#FLS79_2[[H=M_K@ODWL&C]O.WFKOL+P,V/[2Q-(;S!*
M%]=( +8$9,^$VNC/!5JN$0%2,![_4?/3"[>HH&&P1*_]FF3*X5B&9H8#;G<W
M^(U12\@*;4#G*PCZ]J<?.SRV<QL0VUD-4-I/)9]W%&RS;EGU*BG;4#BHC0=C
MA%=T4M<-ZQ_QBK!?GD;<D=J04MV5\J&W##G3]C?>O4$ I)&X>@*PU_FB<-^#
M/YH^1;/@;=7%_K!%T W' Q7#R9H ',7SU':#JOIQ6$[W5R>?&ZI\5E?9C("8
M4/J1J*)7=9?&_RWACFQ/H,BA8^!#S*?OF[QRG3Z>+;Z]/ W@=(/$D5TCK)VN
M5I;3.[&(NR:F_G AYHVRB#FL" J^T.31NKP7;&?U?$O WWRW/,_J^F-WR@,3
MTZ[H'YC@\UVX%G79_5- PL6/FAA[2ETCMAWG>$IOA+H/75DP>#A6X'(WR-0'
M#H\->/=I76CK ^EV6XLYKE'YQOJ2'?>=\'O5(N/E9LK.YDWF_HE_($M\5;$Z
MMC;Q10/UWEGTM(HGQ0KRICL7I[HCYYI1PF7#D503H\IB99BOW^PN'N"+GZ^$
MQY8,UJG\?-3I7[@[?"BK(HZ)"A@T]L?X/!.U->R1D^(VNA5 0U/)&1*"?<FC
M&ZB#0:W0OW\^NWDSW656(NGZJ+VI?ZE>&[3-HC)\2!'0#727_EQHVY<R<\K*
MF25;00#,.R?0GA<^MFT7W>T$@,DW>++<"TR[?>'4>)I^U&62X+W=1_X:N0BB
M(@".+O2!FE/?1^!<4MJDSYMNR]]\^>%0LSO'9;;><IJY5=E6P+8?XH@(\?<)
M?U.'BHPLG>H;\FN*OGRJQJ_^[G.B,>91*QF==%V<MJ!<\$M^<R-MK>UAMI"2
M/5ZNDVHPLN<\-$HL9UR%$U-M6JU5IM1V,8DKB>U_4 Z5^=@^(55T%:[REFE#
M;Y8*'ZFD:CI14[)P$[4G2ZT439UW.6+>,=J(,WPO:_157/[GO7Q39JU[@%46
MP#RF?3C7.95Z&PVA=GP^$U(_KU'XK#)DI[Y<4B.%W2/SW,!;8?9GGEUZ_$<)
ME?[\:0L'8R)-W72M@84L.82Z]6"W4X)V+KE\_=N?893LBQXY?PHJTI6>'X[/
M1#_MR55Y+T%:H/%@T%K$O22KQ2"- -BO!L7+B6H>7)Q#F1P( #U6;^72J&%2
M6:YDJ[;_K*"I(E6 39[MSG>O(KA$1);$Z*Y-,^*PH,[2EG)!L',H4\;M^ZF-
M*,!C>N82!X:_>"5S>/ ID,LV>] J2>>6]I,]O[N5?=36]VFS0RTYXBF(#,:!
M[B  'PA JR(B$K'"<$F!_J!B/ NI:1J62/"HZV7;VA9Y91'75_^LBK&(^:-S
MOZ[7]FGC7*_CG\ E5>;<;(R+$4IVW,SNPF*_S+6D.;NRSN^;1!'5M4Z[P-VW
MZWO,WK9Z1E[B=\_4FI+&G]=D=>T3O=2 -F?T4LHM!@VBHS4M6_=.-1K_7XXV
MS4=^Z$J<+M.USJ74V93-LC*/5A6^P\%&W5([]H)DZLP2P=-O"24\#U^JZ3+?
MC%SA\NGD?CU:8_'$2!)'-#FSO?>7RD?<],%518.]?0>SLU]?&"Z GTP$@GR=
M9+55=K0;NP[XCFY^0NW W\LOXPTU$XEW6O:'GBH3(U.)AF8-4*.GJL5^,U.;
M:3OU[R;9$W$Z4U/5+:WG77^WJT+\QXMNUIQ8W+2P67/ )DI(\'+2NY39J\4^
M4U753&KZ"E=T+Y&E%*M]45V5A7_#W*0MEM4'RO12A(3R/V='O]TC ,JKRL%"
M6+'LRO'E<:>.^UN5 5F[01I%.R=81(3K"6.6V%*:<S06#W%#FYCG9,H.FBU"
M0O27U"NKNU/L&1.QSW[&_W&8)O$%2'8E5>^.(SF-D>.Y.E&_"YG2DBKWU;Z)
ME#PRL>SD?!\9RPFI^3[EM11QLE/AX<SK<O#8&Y\IINM. /P\\(?YLV[?W'9>
M&K6MH,122YF:]:UT4D0;=42^Z10N7V:H2IG)S5IR)ESE#.8B %2MK>:A]QPG
MQ7C,#W=-<VH2WXK!#CSI=R%=+=2R*W9'C?6T!" -"]T<AG;^%AWRA?S$QC%&
M!8XT-\$XH_0FEHNV15+.8Y*CJ^?/;;URJ0SS\DU#PW.B1-68?A>,I^9EV^5$
MO2?1+8"9>CUZK#^F/Q'CQ:3W]/O?/<UF459JS69[$:/L5''A'0V=5_!D85.]
MJ:04_RFUL!\YQ)]W>8I1PER.M^TB_]WK*_TRLDV,OL;3X%:#UW,RL88RWM*]
M/3%K2_$;1FE/&I23*2_Z$&OF!AUZ<7&.!_=C%9H35>T=+C9]>!8C\?BH..V[
MJRK%A3@DQ<44S\M<\8+8!Y^1CYN9-F)SY:W%3IEF1V5._YG3ZQ^+HM 4NV_*
MH\ID]"Q/7G]4E=C:REB4B.-M?2[-FL\E+Z5&MKWN9[YD"G]54_)4::S,9I""
M_J=.WIZ6257BJDR)AHXI_K?M>LZH*G,RJ_$2M%(B+O*3"G-O]N#MG4&JY<X(
M]X'7"6DQQR.V \\?7#?^Y74 J8R/'0X/OO>HH)_7[('[U6IK ?)C]6$.GL B
M/0)@(=8ZN!D0*%#6Y'6)6.;1:J]'%-O<^SGV:N=\#S.] ;&7(.E? <6Q_\ET
M=.YZH.G57!VK</>V J\ZSO/N]P#C^3M34""8-+3KG@R7&%>*37WWL9_9L?.I
M[BJXM5[9#:7[B_NVU1/N6)F(78;^XC !SHL[N=EK&Z#X5/P"7DG1)_P$?&VN
M_Y.72.Q"7Q'/MN4*"7?,!C^^ 3G05X>.GSS$M4BD8<DQ4!=.T=Z;<ESPD\AA
M\&#^D?(-]*O&]$MTU&'G8$>L;,?X?*] C/O+&,8DW8;;+6&X9@*PGH7QP+=%
M$@#5!X'$>)T ]$(.TW">4 *@\1N6 W*!G NU<!(7?38!&-6UF$:<LXV>$%F@
MH_]T!6L &23R5R9T=W!Y4/H7B*P&9].N*]=8GFOELI]%!JXQKZ46$-7@NLIT
MY6&O4$SZ.G%M.D5;*'5>*_#-;34MC!#G0J$SOK+EJPIQ+-Y@_^:_=\=WF?V8
M?N9L[2Q&A1UCO,N"9YQ4?K(B]GJ\V\_)>:5T]??\P:QA<HF[FE3PN]?TOH=G
M>QJ'=:L2,R=S<V'VLC-'4\.FU7W2W/=3.7+9SAR.=E8VJ"8%C:"*+IYH?-.P
MS[7X? /:QUDLUW_TB;R2BJH.+I\[T[DX4_' %>/Y A4P*2J91;XO!N^VE.MO
M;SD]DQRDHY/;;V<AH^'T%!)Z+S8'>DT S@44$;A(&P(P%N#_&^*H.[/1AN<^
M-,??.]S[["\^F#=:-EA6/T?6LWN=6>?CKY3+>C);?F6DX24%<6AY)PG KI(<
M/GEN"KZAXP?9AUE=[+LM_U@5<2.]Z(N7C@[>'QX^G#@'HR,(0-+"FL0E)>@$
M]A-DLW3.VT)/ & @7&;)BNXLKR;6&95P*PSW?0/Z'=8$L0UX>0=/B;FOH,96
M<Y( :>RHP%'F?R$ C6/GP6KFBH@5,R8"T$D \GG(L%3C6)$@E-@S%>F6NJJ1
MLC-=O@41R:&=,_ZW\D!R<A:EOA(2"68".1Y0!2HX4DO0FYEA*M>C_?##34_W
MEI^E4%D8XIU5]N593YF/D+M[AR:!]JB8*6,?QI>;Z'OG9QY/XN^MKUB:GXCW
M#E&2Z,*#F-<T@J\&#]6-V/N\8K0P-K:;6O['*7P]1..6@M^<W6]=*M^3/S#6
MHA?EN0+K8S/OW-;'.E<.;Y3H/,^_BE=PQB9-@C >R":.56UJ]'L,F.NT*U4G
MI2@O0=?2EY39^FUAXKX4Z^L397:,V?)B"B[L4MU.T0XB\W)'VP5Q.<>6!LH/
MVCB,[)X",S;1.Y9OS3K:&TEK"+C.M<R'JXM]DR 5X"8/5#@\P^LT#N.[-! G
MCLB[="CT(3RE=J]A>\,<SGT%?I[AN B'U>EV7(BA=XEW13T/,NW.@Q.JAX6+
M[2/FJO$:W(D$X$T/Y"1KM86I?+<.M^!?_:>^!*^F.\J!!\9/G(R[TA_ /KJD
M:8\*U(-KS2O>WI3LY9'@][Z_4;N+AM4'^ESJ8.A7="-D>I3OW@E\\E/2;&M6
MNT^=D_*[^_K5:056#G>_$UD4K!41X8$U19U&1N9\F6V]95_N#)!U4L54 J<"
M*^H_Z69@)8$6*Z!04'50[,>I0,793MQL,J.Y*KK79N;]P)-$]J/VRX9=^=+*
MK"$O2S:+EIZ=GJR[<8QE#G>9UH)LQ9%)IDO8)8,Q/"WVY;C* ]_[Z),M6IO$
MOG?[N\Y1@QS6I*ZNI"*T<0\W?6$1@4$K9F R;&#+Z#NU.3&+MR!>Q=W83 OC
M0QJ*%;!'(#4F/S=0_Q"'FPK)4?E48#(?_2(\Y8;;=%E"4=N:Z[[C&C@.=.0Q
M6X<+=T*<L):D4?A.%9&5EE5N;PP:]1].?IOX/9 F9=2"4U%?0#",MX]B-/?/
M.B4%+FYGUE[8K5ML=TDW/ *OGE>&[[N*]04S!2/9)3J&N=17/H_LUT!KG&_*
M,3ZKNG:_Z"W70PXZIC7R2"Y'"+J& "0'H8QQC9 M<UE4X6XW 1"<:P.='A&
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MH6DU+\7;E?5;9V2?>5[(=F)],;VWH9<Z]A>9I:7H8)9T,8O*A-9?"O6 MU
MT=MX&D\M46*9$/0J')OL=),ORYS2]CC\V3+^)!" I7=+$6)]I[K3&:V*7?D^
M$*]23)Q625&6'WCO/M$Y5=^TQ.=.I)]O(@MV=+SNS_"4&_6A$OKMWKA^$KF=
M+^Y43@"@ZUZ@FKHP2\RG0[#AI6AT=(8\\D6U%7DT$UGF=R]Q-M<'/; A1=SK
MP^&(/:S$2J;2XPC[_;T[3DE3"G?[:F+9RT?KWY,LDXP8_X%T#I-!(R&,LCA
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M?#H!<(!%&=^$<M;H%;8<8%0#BPS]@*&!JOKA;#UV:#8L%R^."5Y:W6BUT'P
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MJMX93QY(/6G3..&T;SUYBC3[E%OQR>KK),-;8Z>![\*4 -O.3](RW^%=#@+
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MXXL J8<DX/YP8ZIY"3V-0D8T&2\[75GZ!T674JK+G=^\.G[P-C,EL)#CHYH
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M&.W!_4JVN[V)<,7$P][>@)@GVM,/ PT[C4=/-(4/MR?VA'?+$][]L6;X))9
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MK%=[NEIQ&"_NOH2\-)22,M)]:A/HV"2TN])#DZPB]42:U9?=HT>@'V8#NNO
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M<XGM>/D[\X!S]5)B@IJ@7YLD.K:LV-S)-&\]QYMH.SZ+<A>_%-U4:2=]D6C
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MD-V5R[YL;YVA(1\_,+,NW)/F2EW>UG.:>=YW(O]RU?C56UM"1OA&NK^D$PD
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MIW2O+=6M*@B[9[-_L@:B@8!!'R&NV=A@ZNY284-#@QY+A5@XFD<0Q(*K/HW
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M/NL X@0&X,?3P%^?WU5@U-+ZN2?X\\H?>:5N[*$& OI@_&-O\.@*\./J?_8
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ML3NY[X?EP00$HV3[F%^Y&@^6WY4Q#HO)\&+GM*6NF:B/FN>YO,OTB3#:>'8
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M6ZFEE7<OA#S*HR? 1]OP=NZZJ/M$Y[;*XH.7&4SG;9RO-V8<ALO=?8W3)##
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MV:XDQ/RW+L/?NMS>?^I"_F_H@O]!"R>AY?\;[<W?:&-N<[:E;(G5L*:C0W
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M><95FDA:1^-RI/#N]Z$4O+I+74O$XX2\YD3']JV9^H=)EJ])[\R8C/0"DSO
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M&M:\?(Y[1B<$570Z(CZ')50Z>.01:SQ1+ @O#NC&,0C0+4>X/)I"* Y2;GF
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MY1AJ]8!7+.DZ?<U#JN QZ'58Z B$?)JX3(O):"G"\!+!;2&(=FP-4Q<LYB#
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MRFTXA#T/-PZC1UT\2O KI@I!8H>^R>Y][^\.>*,(BO#R-M$VCVR3J(=%HRO
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MB$H%I#?$NB 8>]\N>FB_!Y,\C>!$XSWN5Z&E-Z*<;^5XC.:]3="Z5> :_-$
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M@0\^(R%W!8J1,_B3-<H2'"I)7=>8)[4/60C"P[9P>]M_->F^*/-:LMG"S/?
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M7SE9,^(Y&O0P\'LJK)2\M92I-*%JHUR.S2=6&B^5S:X +4S7',*\D3' J@O
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MELG%:XN=?DN?^EGHS)J<F^0@/'<T)FV22#.BY\$53Q^8PGNUB1;2D+%BT8B
MV@6(#Z@$!- BG93&^PMO--P:Z1.*HHK)?A2]#6#H)D*69$)A4*Q"/,4S/$=6
M7D%SI'KD;.D-94 RS 7V-G@$VD:6@RD3AXO\^TQPD# 84)%5F_>3E%Y9*M.M
M=9DG:1< [[#/2FKR:WG5'WH\9!OTQC?-DU,EO& IB&!X]X$'2X2 9&.1TOF[
MVN"=($=8%SX6^PSVE%CC$T3'#.W+#J[0<9 :D957L[Q*Z'[,^_[CDEN*)N#U
M:]9S6J+\L$P;D/:KHC9OW,,SOFN67V6#FG2MPLJ?O,.IW%5FECI!844_D"5P
MB#A)" U47L%I.J%<T9>@QUVH+%$OL*CQ*[_%9RXL,3$K&VP >W">'B)"DL-3
M1.7IL<V8KS,>J$NM)C'LM'7]J=K@ID_>'_14\Y3C09B?>\7\8;&RK*;3BA01
MT]?I)#AK0HJ,]^ IQZ8@"=[.I:9*$V/'6B^I@>&\:@CW5HQ@)]K1Q0O;&5FG
MB*2IZ):B]EH-KC]VXBEH<VUF^'BB,=?=<^J!%,:Y[0#Q!>![&X%Z'\FL.I(R
M]W[I"9G;#31D:-L@/1[)4B@!EI+FT4*M. (O6\3I.-67>?*>_$N3W:R%@*/Q
M<BW9P/G.7W9;O3NHM*-&&!Y_1C :)\L3/\UKXAF/-8:?==K^G1[>%<Y.9D@=
MH%XKB'R 4/#J64O?!<F08,---Z8WQ#?K@@G?IY.Z2X732^YSO>Q(^PAL?Z)P
ML&$)B;H N(I&3J^,-]S+--4(^*;>=#KNR\_+(I3PC_,HP!J2:1#:[WDJ[C0_
M8O!R:BL;;=P8+VC/+.##035^]_/Z'$*/J+YH!<$LA&4/'Z$9K(F])_:?#0L@
M47?+2C&@ /9%>*-5SELBHB-=-&Q[J7[2!RK,.:%Y75/JJ+4U;OGN?4;N;U?A
MUW2&&VR_^\?QC_@,R!C1C&[[>0P@SY;3<0)==SZNM@\*YQ[YEJ%[7NVMA4/*
MZ]#0S7>7!+G3^?_V EL"5EKG+P4K8"*S@>'>0<(O.[&#N\*N%M54$U7V-Q=X
M A+%FUT7;VX<ZP0I>2!9T<OQQ -RL\P%X%3O46":E:H>AYJN@/7^\ ZZ>[4#
M^BP$L:]H2P".*[IY++)!.0S5RZIPS^E[I]5R[H4IM4>NJO!YK-X%O%F$Q?[U
M#$3F%G;";8=.9,"W+@ S"^04'>L!JUE5 Z-!,1U505VH'K\4W+3^0*YLX(DD
MN W8<PE#$/E Y?]]9N85)PC/<1P.XRB$LKK&>V#9MF1?_-GPK6^82>D^87(N
M'1K6TUKX67(WSC[GD7>=W_XU+&0JM7U> 3?4B6"R=(90D51M;9>*+:UT GQ<
M% V<8E<M-0\D5** 39V:>O5[73-&!M99#@D)MI"9 F?:'@7I/3L[]&>-P3O+
M)C67G;B<_O^VW@%FHEE)YJ=1[0BJ[I!;U9$A+84:K?U3VQ> \-1[JF<-P9E^
M:Z[RFF1TGN+Y**Z)M(FD.U0HQV0O'@C7N&US U,)(GJ[A.T7\ 5NE!:>;KJ0
MK,W;##ZC Y[SE:%R!?>\MM]ZL)A<_5LYMM#!6[%<5[T5/-&GTMQL&"=64RA2
MNG$^=CF<L#M[$?_O-DF%S$)H8&*_+X4$1>S:</%0=,51I7:PIOCG".C7[ =5
MG]A=[ %/9(>84<^(=(L(.F6<2G-O.N.W&YVQ#E[2+OHGGWNN2M2_]>R(YDG?
MOQRB/FQ3(N8"$.G7=*.FNC$8 HEDV;&/IF^.91C3;?E7\UI#)8Y_9Z0>/B5Z
M^2*>%P-*LLFUF&^1B=P6.BRLJG]N'/#RQLOA'=_>%3U>BNFFP1Q%!\(-^<]H
M@=_3DXY3C_97T8-K\BN$X@#.L !<:O-I9,CXXA#=[!HJ,Z?Y C @>/> X$F$
MP#23FLVIULC^_WY!3F\QK(^9]JNS1$>UF6BO#M2:VG:AP&_!X4Q3!XKWG&LO
M %DR]SHN -^[E:"7I=F(RMYZR=^MS)9MZ3<-OP61=L?WOIA:>L$Z@;0/X<1[
M%P#QX&\*0$EK> N(S&2YUI=A73%$PC>J(,XVI8NTAXB\O!\6P'9XT8\/#@_2
M*<%?H! S RL/+/L$VYM')^0WA"?;,+M+R+H^-?)V:$K1*X"./6#:4Y/TR[R]
M_I)^0Q<>7 !4\4<-;>0,)QW@?G+A;HQ@B:+I-W4R!$*>0YS<V^8G@,$BZ,5O
M(+$7YQD=\NSHHW%[Q FWZ5?2@_.OB@%X[;8#8E3K9'IP@_2QV]MYEYDVD:/G
MGFKWF-MC%R9CSO5YV;-NP(;/ !> 'K8)^+:2##EI9G+L-3'U27[*FU)C5L^P
MW)3TH-G)QL8[*Q-:S'62)B,OW5:@(0[O+P!M(N1A<QF2_Z9??!CR$'SG/MFU
M HTK03OOW%JV(N8JSW!R)2R'6'L%FJX7,US.@^)_^?"[$7*!E_V;MA%LK<0&
MED=7@9W/Z<AFQ (=].$&QZ0>D=HA[V0 B&M$.W/<NWFL-SE%T0L:Q_CHP^\
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M7C=#'EZ@+KGZ!;\;*N-](&H 3F,N5H#'P^E$_@EQ*N+ZB\_')H1[2-63_:E
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M=@'X7>1.SGJ=3;Z_L&/\VTOX A"=#-_(B_E$9XUT_#_/S%H(=BVVO800MBX
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M^H!WV$9> &ZA(Z6L;,EWD17GD1/:2-XSL/UYC(7KGN22[%:8M1/.D*R%CK@
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ML=[46SVVKW"?[YC?('TF/8OA0SGN_._-3!#V?Z1\'H#_9U)HE\?"G@^\0W0
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M.<F*VJL,H=Q"(E"__LM'(?^6?RET>V7_PA6WX4FZ6T].';I.[?X%WO^RBK1
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M3NY[Z!NFIIH6W4!E6M;O'7'^+!FA 1A9#=6#[D7]GR;Z./V$[53%?R/)4Q?
M^W4!Q&,"T]_-_QZC%PW +V9 6CO](#-=A)?\ZQKBN^Q_>=_43[#.^&3+,0E4
M#[>&BCK?^Q;Q\:Y_!U!<6^!,:EL?GVF%DU^U&D@$CZS*9SB9N[O![FW)0+G_
M.G1U)H!MSSY1Z^YF5G_G^S]DSQ ,0@]&XN%5!EOC2U<UNZB<^(C#$)BDT[D
MXKLO(UYWZJ'7OZML1N3X3J\XN3+4N#70*22^F;/]<*(RIXE-F&$B?D +1;5V
MYY#YCVUBOS%E*,O8/\.D R)\O6_Q[")3$LNH(W >)#],99S*0MKIIEYO)@6$
M<ME8=07X-5/G)\66G)S>X;Q6'@J$L#F^UUI>?J\H-^U7OXCJ@IPCVZ.#^<A\
M+7@D3*_(TGPS@"DZKLMTU<K$L;[IK1;;1^F>]LMLG>>!4C@ )^0KN<)!J->
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M[;=B3^AO-A,Q>,3<?NZ$9V[V9E YVNR)IKO[9=FD(9GS6C^NI-K[ 0#:=]Z
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M-Z'@]$WKHN>X]D!,%>*2G0'(1E>X3Y&K65-$17BPS^QDW<YMJSN7YOCOWKK
MUJC #=090I2WJ!<5M>],%>F_G7T^H>*J(CT[_.DZ=[037?:\L=M'X(+#++HY
MXYGDV5_C1;RN$QG1D!BX0,YP;U981[EF37)6_L4Z&D!]S[FOQM!V\T2,+/B-
M\+HQ$,=TW?\%2;Z3?UO> #R;8<*5*K-1>F$5^#N69P+]T:'$J<$56^;.FV7U
M*RTS@/^*!*]?Z6C^U86E.92 /WOK(@7>485!UN=N6"K9O(6^1M4DG9&ZT?=@
MT:-G91C<H@KE17X_U5"16G<BEV9CWE?6;\F@<ZK-!L",9&D59]P.XZ]'W+W%
M&]>LM!PVBL< VR1A(3Q"4G!HWBGEH32"UZKD?IJ^*7HY?C"8?N/CM)UP,V;R
MJ( &,&R2[%Q@\TOMFE_GO3DI9R4GP!4C>NE9K -BL%23+4)6VFJ0H!/'7=QM
MPWVM7_,<\Q3ZUUI7Q1-L0@3,YK,KY I,Z#PZ7#;0!;,[;7F1Q2L5Z*SQ/K39
MT#@T7='NTS[X.O4'2"*M9^%Z+8_.7D=OA]*7B;>'!JX,5>DO57KZ$8*O][EQ
M*JLM@S'@+F<VGZ+S%QK3Q,:3?4;UE<LJ7OW8&OS6;W[#55A1R-U^+.C(%L/K
M9;9O0_^$<">7YVUBD<U&VMA9H\G^"QFF ,?WI9<4 !FY$,/@-A"74F17G*_E
M\QO[<\I]=#P"*3V,\+FX7IPMT>LCW,GIH*H.=7O4-U"R._L9'</![".IPWH9
M&B!211JWN)-0\33)M849JV 7I]N2Y"I_N?2S8Y+."T#E ^0LJ0]ZHN'GJ8:N
M]<;R*!UVQJUQ/I<]\1/(P$S4OYBI^/F^](5.-2_U"Y*_4B5&NBS#,,4MZ<L8
M#9#S\F6]CVCALU?/S+6>;MQ5TX:_$SRTJ';HI#*BR=9CE1&G/_KXP[#;Z\0D
M_2>J,E^Y7ZFZU?:$E4QO J=EUM$OW)#VW41./J><0 >W+?[7^AH7I%^*;HVP
MDXJ,*)E@IX6S\N'8R$>3<L_J,W:Q+NR:"P)W+*2Y0J<QG\(B;MQHX^<@UAL3
M(.T+;U$LL0Q.".L8OY6,J6W^H3># -47E;%FXUX(#H:NVJH;Q>IC.G':_==2
M#E833"N@RJ[/ MB^9;PJ[MNK-V*.+:@HS'&> PINWKR3OS3WP.JJ:<?F(V0,
MKU/%LCAKR?N+_5_/.5Z#WRR$F%$GCU5L[Y.L\'O8<*^+"$2%70WRHDP2@9-#
MB))JP:%Z>/GH 3)-:!!>*Y78I:/RK=G(II#C&6K@^^Z]*4@)^M6'IM&B.;E7
MK(;J@9K9_XA3^!C<F[/K$<Q, ]2C*&(9K1DMSO_TL)KLF0/_/L-! T"$_O)5
M'9;74WHB2?Q'?R6)ZU"]]E_YZ2OE<1R=]:1:?&=7,*.>QV%GF&4-5%%.',P+
M,ZPZT[&6D.XK3'2P23GE\PE=.],)V+IW!(;%^UD%9!,";T7ANF5A%_OA9/#U
M<78@8U<=RVV=/TT[I,H!4?Z?$8/W]NQ;4=TH;A5_? S6H]X!"P= YR7QW$33
ML5\W1T)E725_AV^$6W?ZLRB*#)(<?4P27 &?EM&HT3]XZ4YN^3%T@;A'R7#L
MR/5?:YU*:0DJ3WRP"ON7[A\U!347>'5]<!?P'ZS:@?$R+.Y>#<RN*,1L9IC\
MS@SBR''R9Y@98<<VXWQ$.OE"I2\M<T\TW:7;-:->#CGA)/-0LI!G7'@%2(&+
MITA4\Z ,<=UJ?<^:!G"=M_X=4N&Q[#@C.YPOSNK,Y[RR&>I]//%OG]#_.I\0
MTS:%!A#\H/%7N#OXV- +(H,>!]8?DE/UN*AM4J?;6;T;-@)!6Y_2BMN/)$D&
MG=6(HQNF!W^]V"XG/#A%.MB*)^T@ONK)?2M$E5OJ<]M+Y)H/=GPERN9L*M=_
MFNJQ70]W4^]P6_\U/ETY6-S77J(^G?\7TJF9+"J%G2*=(BSDIFL)3A3R%](1
M[*L-]8[Q<2$^8+T$]K,""O?ALE/:@T? P!9=G &&KM/(;\#<YN%@?<-XQ8K+
MK3<:CH\78=&-LX3/:RJ)$*GQ_,2E1,>X= $C3@O]B_RY%Y#RE"<#N"O&=A>+
M+(FPLMD6=Y>9(BN70!I@QCQ-1,+(_0%ZXF32]^=)S"F.HR<;.)U -WCO9#[*
M5CTKU(#44\\'/<JS>AU[NUZO_=-* +D =\XL&J:/EXQ"@F'^A.V1T%>CY;W.
MKZKZ![Q8^<X97GOJZ//]SOWU',M5#Y0;,-HL@\M5FM2!Q\@&&SI%"WZLO$=M
MX/N@L-,L-T16)M5B41'R'-5^5B;4@52"B9!G=?=]?$$*L$6C]\E8PPL+D&=$
M<I6'\9S+>-Q=F'5+R5RC2]9"XFA4[R)44$WX1%Y>T3VPUC%--R [Z^0>=6@7
M9DQ0WUY%QC%%REJ0,QM&D8'IO2"=E"VE*N[%-TK+KT_16V2<BC?NZAV#BR2S
MI<,H60/ ^I)Q'R5.Y<$2_S++_3/<#SD9T&_TE9A8\?!M-@)#FY)/=WP8HC('
MZN4M.%LLYIX#0\0-ZFH8*/ 0NJ$0ZB2*[4"9*T8YA\T_%<U<(UU$]/D\6WZ1
M_[98/).;WZ<B^:YG,3R&3S[=\M!JU+M[F)+\?&5U/N>%8<^BZU,J@M&O'W)=
M1^G(]H17#>) G91_O &I-NO8'- B6FJ)<W( GE\8?-_ ??9>;*!9+]M^?!JN
M%8B5W$HI(6F:33P_!4Y+_I.;>O''*P[0XA![=M6IV?:;QI<;580J BP.+E&<
MZ6*CW9^45#0)5UH="T$_I;MKG8BI7]A:XU%UJ$"ZK>Z$@%V80C <H?OBRI8D
M3TIN&6;ZX=6Y!2);+/)5Z1OE'5>Z^UI" HYH*SA!=%$R&GG=G 0R8-O@91T7
M]&EMKAK;>A8W6*[;X@%[Q_IF>U0?I [8/HL4R/M:T6&N4ZM:#C6.;6RL23F8
MQ&C+%>[+%F6AP_UY%.2@[N/+HX>([>8O?M*;[3?%CN<1_LZ55E:S61<PK'>4
MZT":'P5 5@Z .])]/P^V]VQ#_KK=SSFCXK\(8255Z]KPZP3ITUN];7C[=/3M
MDUM='EVP\&QU+QK@6K"D7SVV(,#-+]^4^M-&5DM<<SHW<H"IWO>XQGK-_F#$
MH$(;AXC-EB*E?5D_AK^32]@6U5-9Q8"K'W*DOH[8B"K TUM/<H*T/SHU7+:
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M\F$II7.>7;'Q!D5RRGR3=DW.3BQ^(EN9;2I]Z0HFJ7\&Q<64XOA-=Z2TNH
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MS6M<ISAAT?(4*[P-<]/^6C ?2?B3XVA56GUIZKE/1+Y&P?5QJV,OE-0_,RV
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MZ_O\-'_P#)!1MJV^M/*O<L!_[@#C<8<J$$>/@_^B!3:$_-7-O[KY/]3-I3/
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MXCH6Q2)PGDW?,T*DQ"_..EBQB7I=$?E5(O7,9\?ZHL;2GDT-7>:5)TAFI$'
M]6U.VM!2,1@I;#"= C<?O5P3H8;"MII:9A<?B2NXK5.2ST3:4&G:L%P/[/\I
MVQP':LQ"ELJ-"2H_R5,;W>*=D)JOCX.6Y'4GE,;_G'C=JYC2,#UZU',@/NB:
MI((KBR@MX2^OQ#VN%3UY)W/%('DFKD= ,:575O%@)9/QEPN#45!TF\+K&Y#@
M$EA:G*'5&ZE('X/?B5'T__Z7'6T4W%EGZN(+G =1\.NX4?-WVR*6B?U)GCA#
MXZ5[IP^+GU4-OV-J[-FF>%B*F0+QQJ!)$03^.<=TYM.I<:A4ICG_B=:#KS8^
M+I"B^MG.^".SCKZ]]VZ,G1:?+Z+,AZQTJ3 )0I(W=7,P:P@!1^&'%F;FU2C5
MDKC57O\4EZI#$#>>+'<>JG:2)SG 8H(O>H+;3LI:T^9<"=V1;'G.G#JDX.@<
M>US86:SSU#O]2,E55]5G,OW9'EMYAKA0I/[3$3M8MW#9@Z38)S$WOI[SPR6V
M?\]%X'+%]6#&SK<JBF9R8Q!O":=;@SO0K=^>GO%QL:$[ R2VO99>WC@9I)'[
MB?3%PW.GB-KX/ASI#MJE[,"[)4J]Q6/-6V_:5#$M:FSC_L7+40GJ'[\\.AF\
M-^<9!H)7.)1YDG]2(;O_)$]K/@ZQO3DV8A3CY<(&'JJXJ=PUVT#;O^9U@//>
MW$/# ZN^>^T2U:LFV.86'_H9Z5%9F^3<N4-7*4A/M==.R2$N=<P*?EGU^FOC
MNP]AC S5YA>BG4P%>RND8KZ]DS-8%BC9N3EUPIB8+.HR^XZ[Y_<NQ/;=__O$
M4:$8UHVF9(+WM4[N:-_MSP2[\ XZ8JP$9[X7W+@U;7:Y/+!I*1Q?@6%N[1-?
M'"]9$,"JAXA)ND9*;-S0UGX6.+SQ^(WHT'<=]^7/7H20U"U  2".=N:7$2+)
M9FV!/26W#Q3SJ33*5,N ;WQ*4:8JV#,B,0ET=QQJ8$.0.QW,8-@79XQ(L1!H
MNVL_]<IOH$)>W?MVX7:@B?*%MW*L"@"&.!FJX[)-\(*_3F/&1<D4"\LI,^&-
MKI\-8)/W.;'"55=O*;PQ4'GV:]82K>H2WH>L"-:7$Q7HZ=U!W7"/2J@<VBBJ
MVQ0<64[8/D=!Z%'^?X03FH&5S!U1PIB)MC DUP9(P)4,*CFT;>)EEO\\T6=?
M,\N-38J.9X&4Y=Z\X)2M2R^/\J$_XZ8=9-W$W\CTU5&NJ]>LF-&LY6TC"['*
MF7YW#\-'1W<6O0Y;_-71.BU6=)#7A\:#K[3%"#V#4-VLM1=^_L*V1>PI'^UN
M<M^W4;SPPF%OSQX\<1(#E8$70\UQ_Y90BG!54,Z:>U#U^GA_ZU/EW9S<L=Q$
M65R0JD,H)9'[@Q<9T&+(8G[ZL:P<FIMYQ\*B<NJQ^3A>#^7O4K=<)S!)Z#YW
M&HUZ4_XTK\;-B@,F9$9DQ8,+\>D.JJ/8R^'C8V$7'5/1#.DM14 [Q8V&K*IL
MP?O%=H8*0SH&?A:O45IA<U- JM.>=%FL42B2OV-1AP/?0;#"P! 2B)'*Y6^U
MNYLJRQ=#=HE?'\9])ITJU.$M[[BPV F5\_+"69TRN93FH)A+I2ZS4>3H!?(^
M>Q?21;Y[&WVO9T60^;EH\@E?%K)9097%VBXTZ*9P?M'-7#MF+Q;$90?%5)<R
MSXP?A*K:+J) +8YZI46'J@]3DPRD4WRG=F1Q'_6ITO8K)PM68Y$DG>SAAF 6
M\F[Q2:[FX_&ZESUV2]%!6;\W\?OF/_$S:*.5G.%3%!"H+K"Y0<9(A\K$G!<^
M_7TQ)T[27:.N/M>X"<IPO8K4S,V2=/, 1HW/10.#YBOVYJ"\PU]PITGHHW%%
M;1OZR7ZM-\,S57@M.9*"ZV*,?D&/01^RD+$_(?9!N4$'-$..B+Z<><,M1N%I
MU1T_Y N%F$_=*YU*U/LES!B9+9-L?!+:,H,O(^CZL"T7;RVB$BSO\R763C!.
M#."CT![ZJTM(@U<,O+$N6"9_JUW$>6&1RX EOZBN0;SN6]W$M^'.FHZ$WW'A
MY\__Q+:3ZD0H:-LLH*B<OA_D;":RN10G>7YHLL[/#7VBT</QC&I7@Q%K%7!Z
M&R*#0;7%X'5.Q?%9\@PC_-.9$$-AK4^8D/>&ZK:1!8"%_9ZO/2X&!DJ9^D9U
M22\8W"37U?2G/_SZ^537T>LA+O'$\N!'MYL'6&^QQ+[-4*DB8XL<I_,49UR+
M&(;J??'/4Z\GW*GT]A0J767\<)7E3FQ\XP5-'K>!PM-V)-DHD1S+HXD8V\K]
MAJQ/!X\C/E%HTM<]OW2IDT]?FE9[;)O! %/A6HQ.H-'2W-V3W^E,M;%SD?1=
MWR:0..YV'_Z^5@HZ^E\]H?+O19BVPVJ7%Q)RVC0!/+Y9Y!%>HQ7WT"+@R/O@
MT01"B0K6N6(X]$M303U_<L!;TM3\Z9&.>QC,SG!J7GKF_<4X#8 '.'@,=-W1
MBA,I A49 [&M?EN#R09CYR#)9GXO@K:XN4Q[.'L)# _K##Y<2WW##$!.$5Z&
M'VNL,"R&EH0?@(@SR8=I<7%.PX:5B=6$NSM?@D%]DVJ$\[FSNN7\9X&(O\K_
MSXOARX8"K=S)G'*A"LE F)M&._G^0;$X7JM,:245>-AU!F";DLR5>F4O%!M1
M<?=8^/T9X-WWO5.?IC, - .7?4J_,7"T0G:R"V\O6]\3F&K=6"U5^8<O8_ZQ
M(E#9K8/R/ZTCIJA7L?@Q,GQ)"2U6?P9(=X//"Q =_EE\?8\6?*TLJY;V'ZO^
M)_GC^I:_%/E+D;\4^4N1OQ3Y2Y&_%/E+D;\4^4N1OQ3Y2Y'_38J LX==N<X
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MS<**:\E>T?.& H1H*(L\16PX.(Y#.LJFC%I!=.?P&H(>"!!]Y6^FC_O0_O/
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M^Y+&5UKNZ15\@5M9>LS\@YQ@RY69Y0^T6:M?,NVS^;H)&7$H*OCS##I(Q<)
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M[H67M'( GI&3D?0,,;)4D<@)BF8#](9F[(L/8IKZ_UGB3?Z[.J+\TIG_FM1
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M ^M9"[.4Z[O^L:F>^=:&P6C(",(3P;-$*)E$F3B%&M8<K](^7R?)2+X,I)Q
M7/J310J+=3.Q(1F)QDG*U/RQ8/9L.M-3A]30A]KNR-3U$(/T2I-Q-\]>A"<D
M<  X#PY@&,4!O *SAVS'V1.B4R[&XOCGOY,E'E=0B+OI/$97=J\&TKK0/AQ
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M%!<:9I]3^];JG=WY*9^C$6-B2EY';B"???]Z\*8^^ATSA(PFZ)'KGJTW2I3
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M]UR/@8O3HUAH5A,K@1?'*J)!JR,8Q1%:\^M1WXC(QJ>W^'X *;9)IZ@2B1R
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MXXUFU$D'2F>9</'GZ6EZ2$U*%*]57?;H70<);R$5S4O=!A;*K]O$A=X=!ZS
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MK,DN"YR;=B+OQ,'Y'/^*<@ /ESB PP''1T 39U+U"//^E=\WQ4(VIG'1BN<
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M$ERI(L=#=6M53L:X:#QJU/;4\(7K;:N4*>UW,9J6L@WPU,)HT(U?B <#*U%
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M>]F@81VDL"]8N-F CB2-%G_\>_ZO1"C4H[XV([2RP$9SW%H^_6SZP?N><9*
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MR/%>MJ<(@VL["=M;33#U1PGQ$A*7M&EVS"Q#5:N+@Y])LCF[W(QS>=C#12K
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MID%&/Y?5\(>/?9IJ/%KYS/TAO_?AKJY,6$^+G&1JG%+4]K]H$^!Q)HS>3>$
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MH;1[[..I[R^'N*P,CC3C=UPQ?_@B^Q&,I()0GOYSG9VS"<)GQ3>E#JRIV13
MRV;2;K?U75N$W<J O."E/JLS/$*1 +W(?YW#Y[[^%("6*M<$0Y)]GKJ7\TO\
MM;;/ ;X6P/L*>(S98/,\ "1]+(L7#[D39$"O[VW&JVOE&5AWY&S]NGY/R,S'
M!Z:GNGP!+^M7_]L5M'\O\WMKP!@[#NR5Z79$>RGI ^3C_2=(QS2]BY <N->G
M6@_I0#+) (%S-C9.\A2 ^Z>%[G>-*8)!%K'O#TM&^5);OUL:XZL8T]MS$(<&
MCJIV$"4_1:Z[>3\>_'\JZ1G%)U$ R9*KDN=^%,!$1OD*^OSS_W&+Q!T)6A B
M"Y\*;!XLK8# XQ<#!#8)_/[O-H#"8&U"/P5P_>2C-_U5%1YG#V>U1PY--Z[+
M]3*]])68ISM1@4BN +MA!%.$<+H%>80\>2AN-]=_2,QV<W"=:V@\";1O]Y0Q
MY^I\'L<>:7@"U@LDWU'MI6'(J7/,]S=>,\O_U\-8H:+?5C)_FZX2REPS2'YL
M4O[+AOYGR%_A3WUPGIF3.*333@*SO\OADW%E$&2E7'>U%_,M4>DI]_Z1!J#1
MZX,^I'>SXF]8U].\\KLNE4M%B\C[=GPIR2E6W^#?ZBK50F^%#IZE9534;(=R
M)SXS_35_VTR,)^@:6@.XQW6*ASL'[A7F!6SH3TE4T&W]'<1;9H*DH2USVK_P
MLOX5H!F6 -ML*\A?LI./\_F3RA:_NZCB8''"1@AV0[=U0D)FTV?AQG*:G#EC
MH[, _0=U^@(?(^DEE*J]AJM5A/(3E1Q3;YNMWKR_R2TJZJOF?9 E/J>T,]9/
MZ>XK"U?%FZL;7LPU9)<(BH3E?V"Y].OL%07P'NH40)1?<6H#56ZR(>Y.5@YD
M^31[%$DQF/#D4X5/QB8,\JEI>"DCZ;9$E'.W_7:00?O0K[#IK7<'UNIC1$]<
MEB%N*;8NSN5@0D'<N]D04W';*XSJT]MJW@M;U?>R!TQXCT,?]O))C;5I%6]1
M +\;,Y^N2KDI8S=\ T[-/UR_['<9E39N\D/!_P -I'$.5"%3 -)E+-,5#2KD
M0WS-U_S,]=%..;;,W1]1UD;.C=D,X=Q43-<%[[TU!<[F]Z3,$G;LD$@G/M'/
MCLU3DE55:9+WU/><I1.RT_A?V'->,)]BS$::9:2)HV9V0$#C AF)I5MD@PE^
M9X5DJ@I."4RW:939=5Z+6=^V3/&SK?@32[Y:6Y+7KMVC(=C"JV-I<>0>"V.G
M %9<;;>\*(#7%(!#2+2@'M+YL'&/?V-/0CHA$(V5QS![KB!IBB-]AO]!]7"]
M5F#2\N&WC6%XG)U_%;#&XWEJW[=9)1S6I2C];6VOLCXP>!_:W?7;^(\))D]%
M8%6^%V.P>J>ZR$"EP%?Q38[(X%48;;+\/_<MJ_O7 &MA@3Y#%  +0L&&J(Z2
M$3<;U5?D74S6[=SQ$%8Z$;WZEYU#=#_SD.9>'U5D>'BL*O?<!K*2V%MB'/?O
MZP.A>\'BDH+84)APE!DCOTNNF\).7*N\ZZB2'TH6*Z&TSTOTJ)]VAV%N]!ZZ
MF!M);X5Y:/WP?43]\@@N5'[VIKUTL]Q#!J.Y]]-&.%VJ/B?_D/V\LBXV/I"K
MX^]1Z40IG>+?=V:(BM%M;.SKTG(Y[R5.96M@7*@@Q.H+X[I5 $*C]9]KTM]H
M.(+D:*$_RV/R8H[N&<=Q>1;S)E=/<I1H:'A?R$7]W?^?G-@#9;VB>8@=]W3=
MN75"C:TM6N^R.0\9,TM3[KFI#8H(?0OM4  YC7X"UTIVP5@NYE-. &-7 G!+
M$=.U35O^Y)=$Q[6RX)\%#G(8M($ 73.=YQFXO#^(+27PS-MSN$2,P34_8X7/
MMOB%_>^;L:B-R!YW=/[/F;-L0_(4L":WM B2UM7/-11H6E7M-*#4Y[MH9UR*
MKB"<R%S*"L%1=\'JTXDL?2NAS=@,57@A05(_]?AB4-6H^JB*9AOZFL(LWAB(
MW3R)C8LM2P$7IIX>8C?(-.)8=[7)A$_DRT1&7&BU<L(ZU('@V#5FU3G!]^!6
M]&RC]VD,GQ(.[!#,@M.*:W-<%G6U[R,S1?YL(0W52(VM(JQ[&R-!K4LB8;1)
M_0 Z1PYJF4N+_T$/8*5@7ZQ^?JE_JQ$.E! JL1@L2U O=![3<F1X7]60H)P^
MA%G7]?&,$/3BTN)JI@NL\G=GGB$K$.;T+FR&#V&T.S A1O;N,:>L91V(EM![
M*"??B/9NW')W+E&2Z.+FL(5!!Y[V<B>_>Z1ZDH=0)66Y(EA<8&POP->)@83O
M:T"FK>?]'L%*J_M,2UF0)DLN <G9O5>Q-OQ+38INSSNX543<Z3<1MTD5J@+!
MME-"A)15.+43'R/N\N*-L8I@H=*0:/OFQD_"32U-<[ Z^:]W+PF> HQH-NZ$
MJ;;FM3GBU0FE%<%@ F,>1%4@C3OAYNRH3_[VI'78#4B6=32_\R/ E</+D#M2
MTDB />ONU*73+=R)6=U%=B:R[B]7E98\$Z\[!UV>UU'I^L=,5GJ'YOK/O:$R
M%=U+4ZAZ\H!B1!V,357:)GJ-><<J;W%K)>-J4^1(RZN!XMS+4=H" A[#_OL8
MUY!"]7-'6F>TS(PPEB_;5=[>ZTG+I_SU".*S)PEO\17[EPG1;<*K&* %_>W*
MG"DOG3^D]5BIQ?RD["K-^P\RSX?*J4=34;%"E:_3B\6^I"^BYD=^_37!N>0*
M]1^J-;2Z9$Z=%Z\Z=H5PKS9^="."*COMT.Z9#_-_)E^G7DAB? -,NAR>J UG
M)*4%,^* *_*QRFHK].]FJY2Y:63PZ7\C4]?3N9\I_Z&V[4DA:%-_"'7_%BRZ
M2A+H13\+C(\+XOU;Z^$+RY0C[\!-57N+<>*I^,*5!;/)9VWDT:GB^C11ZS;'
M_M3$C\%!TM18."/]UU6IWU;-MD]R'M87I)P(0:-]#)I77DE)I=U6J#19F2O;
M'18I+W/&;:,=%F*'!EFG)&EKF#A$[UV./>F IX1>"AWCNXTUB-\C<P<;-S?)
M+SD=5,J*HN;[[VW&;^QKGEX!SC-\=#T[J!V^WZ:I%V6R+3/YU# 9K9O_3,I_
MP.),WV.\DBNH>!9VC<"-=\=.DJ?Y;F$-$=/(FCK:NSY*EFV;;2=?:,V[8)+.
M-D/S5ZC?C]J0%L /"(QD@ZY5>5+81>H;$Q/=BL$3RCFC>DR[@@*:0[>S4&UY
MV;#AW%"]QZD<9GC/1J30@=[<WH7"(/C/F/)B<$'[<P++Y*P03T>O50I 8G51
M,\:$/-2F9*ES^;5Z^"^,K7_P'0$6=-?D%TQ[BN]Y]#O#A=QQ#0=_ZPORC%,&
MV5<YH4!O)_;S#UWWE!L2 B_(\Z?4UCS-=)6SYO.4V-3,NW?S8A+_I["=YN,'
M<;V5C%W(&_ZNP9(!=U)E?.//L))_-$/'N5U!K7/9)6#D=.0$(AW^!?J6Q+AJ
M3_ #3V':-(KZL..WZJUS.//!]<JY[P#J 8)K0]*-9QT_E7U!QEU,'P^#04I6
M3\5MZ^'WT7.(_JWYPT/.N\N0!?!\^I]C%7N\,T[C@I)"63:E[#;-%94#0[,<
M7=UE>W?M-/F?"SW+(Q8#<$FC5L<NN(198UT<(@?;I9_2@^Y)*[7W='26B&;-
MNP*Q?O#/;OPSS:\OY YTO<][VW/;YA>E/[VT?#RS'F0+[P,3A#7YGIJ\F&CX
M?'#1V;;P;Q==!_R_5]LH_E/M!9K2KT?YSYS\I,9( S%9UXJ23?\0,Z)3?RS9
MF!$"G]9;3+JA?-NSB&SP/VSNVN6UDW?A4<B7"T$VN/1HH!D*<6<G,V=>S_-M
M+B<R;7WUWG,M[NO$F<1O_+7TA5X'&\JHN?JE3(=]L>ZV!^D/;-^B-I!E8QF-
M=TME(1<NPDY'[7\85\-13]Z*&WHRG^FD2_V2-6G*OKU.-GAT1<?$YW?RFOK4
MJ[19N$!0 &OEET2'*]IWK_VY.1D?4!:C5_#SU/HGC"E8#-G0&.\3OFK+[\R.
M5I:;2;\@[L^_FM)=$P_64GQGWN;'?4LY@*F#K5$;!N^)P&\P-!<%H >B/;XZ
M67G[4Q"4,:1F?WBR8+CY7!VAW&M3*P?\2]H\8CT3!WOU?'$V+(_ ^Y%9V!IF
M-:S?'.]/UCK&I?9Z1KBYGYZ"2/\&$T%]]G_#\_0>4+U[Y^@5PH=S]9E@0[R*
M4:^!R"KC[GFIG-R#N$%F8U2U[":"#:?Y=<V \?=.INSHG$SK)G$N*$$\?[&Y
MU_<'G:+?/PA!4D4=O6&H(N%*5D<F':0$\K;!K6'<T5+5]<><WR%Q35!RM#'2
MW1CLY']U8$,/ZY;B&E PZV0NW<FFIZ0?9[0X_X=84J9-M:D7(F<?UOGRAT6P
M!MMIF6CK@+BS]VZR@<^27FY!H6AK??&IS>9%)TZ3/_SG2KSKI%IEE4*[8%H<
M6Z5GD>5HV6QEC358QRU.F0;E\>G:'[?G:OS+ARFV[C^!US:M@)T4P#471=_/
MQ<YG$?B(5R?FO@U)?>)=',S125/_="<;"!YX68 ;@,0LV&<D9I("T+U5-;H,
M)R8A+UW@ZM4N"D!G#?XCQP6V_5?A4"G(6?SLG=K<Q%DNRTM&C*429!=%3A6H
MO3!F:Z/>_S.""]Y<*\R(,)Q*>6\IGRLUYDT!$,YFCG;<SS!^7- 'IAP#8)JF
M"?=7R(0V=GO<S0YTXZ?Z>V[\U5/?I?2$RD4&RK0?&@T\4O:[BI DI83^0PC=
M6(,GK$.&M>7#CNO#G_UC@;M_VBB]#DU95X@(W5O4(:I^(/2?JUOX.ZK'2-*X
MF"GFEK_[J[SYVC)YX='?^/O7'W*,\H:(=H7^0S1H)'CAJ&VFZCFFY@AY?QVG
MJ[ ]:;834E_N+M-/():IU?N> 9L'5N*_I[UZ25OE7=&RUXP@+ 1DD1Y7FI05
M-BZ&(#4\F(,#L72_YU8AAK!]P<_$F<H>7/[/R9 E%N=\TM8'"D"1</*Q6WQK
M<.]U$-?G7603YFZ5F61,+EV&0[!Y7L()?!6\/OU.$NC_)M0>QY<B?-XX#B1E
MUGJ+5"Z3UPUJ,Q>XI\Q>V]T=+Z8 S,LM^LF8 >".V>J4N./%9R\ZV-XO^M=K
M0BUWAMDNWG32E>"5LM"%Q4L3/J*MG'4)-V0:)I4E^EW=3&JJ+\>.3MY&),"_
M$@,H .&5"ZCZ>4&:F^S'QY97@5>B<_S7[C67=!J;I4O^S&H8#6EK&^5^4!Y5
MR.7V<<I=B-T'&CW7,H=3C9\XOG;L>G_BC-4A9IOE*^M/.M8O3 Q*R]-E=^%I
MJ56[033XJ8N&J/\OS>;&3Q!PWYSVJ=\7U4YEF34T13X/R(]Y<"FVYW88!P(S
M^Y*HL#,<X@46HP Z-)!_HC=A>*D."J  )7L4K,)E/+3UN,(MJV9F)H1(NKS]
M-&'_5HO*X JP)T1@33X\'R<1[1X$L1><>"2 ?*+C=ZM#0>ME0F_KT[OPJW7?
M19)3[Q[TY;5C#B>6X:Z/8^Y6?&(QU'.TF*J5,MS6OWMIRDP/]5E&"4@XG?$^
MAY[M^%PHS0,+%)2=>-,!]J!'T;"/>-!L"3JZ 7$:+P=]HB=^?I[=H 6V"\"E
MK'V*P*KK3<+KY_0T]T2W,CE0!O'R+SK>Z;K[K/%]+7%#.L$C&[Z.1IFI;['6
MC9Y][/%8NHET&J7V_[Q" 437Z:E:]^\=B]_?'F$[ES9A%'P68Y%\C5- F0M_
MGWA%YY4SZ<W''*6=-N_C1KTA'$>P2<G@;XU2[PD*X%.D)=8=GXA%]9(,#*O'
M*GP@.F]?6A:X/N9(>IKVD[9&<T.U"6X&3U*]%CIF!>Y$?CP#?I*4:6V=.P>"
MAI+9U)B7E)/I;GB-_U3VN=H"&9V[]Y -P6J_.0FV/V*F *R.'HAENG,;*="(
M&^D5!@A[U[4O-"XNR/%14\>G\3$RM>.K\&9(O;.W(:(:P?E^YR]W1BD /C1#
M#B/)-T"0K.'RGE2D*N""Q&V\=&JF &#6U-#U81O(K5Y207JY"FM8Y<S@>DB0
M1O!'U5M$CYDP)FN7[<C8KORRA/.=07(=O? :HGZ$]$Z9 IB<F(/N#AJ<LQF2
MA9PD,\@%J!X9A".JG@?%;%VU]5H[_7SDYT5DD5E@/20P&>3NIAE(*C=?(GXM
MTX:^1G+:R>VTFS]-6"A.G:, 'I'KH&]>"N!6\P_,2>K;4^D]ID #6\)25P/G
MN3ZRR)H"0%G_0IW6>X!N@ISHJ3K)G$U9CZ?%9.-L,S0N2PT(F@J7-TR.,8;J
M7PFHA.^ZEX"(P81,]$T*X%FEE<'ZH!4,VXO_@%:C *X_&?9,2$+T_A.^)[]Q
M7'EOY:#,6-]GOG)B9"G)L/CC9WUCY"_<Z"6B4?/%\"G!@2[2XN3"LD<-5K%-
M:#O&!<8D<QK.)_?B'_:I>($A6W9R6'QSX[F2S21<E^?*ARW>VJTPKTQ"5\?2
M=?UVW*0- 0(M^0Q9X.L&S]O.]:UK;C\1,I5G?=B]E1TO%8C*=X%5CQ3RK141
MDF>6H30+UG7@]R+6ASU!G)4\5P(3344.=%.M-5'B[4NI#0<RY3R\YGLZ6N-.
M(3H:P>\I !KAU;Z/ >-[!0Z//4E?2S,BESF*P874O4!N(N_PD%5;(GQ1GDWT
M'>PS1H&XTT7NBS-8?G5+,@<YU+?M NXJ^7I,8CW02\! 5C%R!L+&$]X[R=E2
MTOUTL(0A+;*2K5O*N;USC2L7+%*B$MDVDTXKOTIUA5AK:=(O/3;]F!S'+$;O
M?]1\I,?Z!VV.45L6UW7*Q._HO>EC-ZN<P@O),V[9?DK'Z79RS5R!17OW\[9H
MHD3BH<MB:B31X=+P[@G"5OV!HTS)5$(/FX^,\:U,I:@9[1R'N!9%)C6B\W'O
MJ^!4W%H/!<!UX0ATGTP<P3F<9UK,8XYO.N<_$K_EY2;?#4.(NVES?@VX,G()
M#R]29G2&6_CKZC;B-':Y$J($/M(.EIO^\U"P_^\CTS4.,K/=]7-3:/]K C4%
M\'*- BAD,SWJ"<EU-[LY@&60^<XN=&?^54IPC:<YQ#P/U3J%E9+ZXIGQ9>-.
MBIE>0^I$4"#Y@JG,>_D(_WDU^R^PKC?AI1>VV&KJ3G5#&OGWHQ^VRB(.4=Q1
M'31_'-0N;U"W>R.OU0712ZZ@(@5KJAMJDW?TZC-7,"LF#[1?VK0FJKYYJ)P+
M&4%"P#&Y[-B$KO,EAFUT\:QLG)%"85W#N3)\O<Q&TV+/5$2*Y5B@T =<N]&-
MI"<^(?@4:JU@=,_5CK)$K47'_^BRITI%O$,JQBTPBB;M@]5$.%)3-?,_-C]<
M;/"M3[>MA'9OXI/P-#SH)?=D%;F8NW#8P\[_Q"4,H-7B3I+HZLG' BR^UC/
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MW9T=@VE!I8]CRT_,[MDK>51T-P6'*8Q^(-YJS5J!=X"B5._7$TQ]5J$?410
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M65:LZ0TUI6/L\#,Q-7Z-KD/WUC9[[4:,;%#H[9,CD&$)?&C!&I]!^D:D+9&
M56ZCT#XS'?P-4T=9KWV-M.D/GW#$EFXH+$^W N?"UWC>B9RB?0Y3PN**2X7G
MKJG!,R@ P\.'ZFCC+T)\6ZW0K3OP^YV]H2/&3VVKX"<V)#[$I-BQ-K%U4%MB
M[8]KKJSGJ-VU*ET3PKUE6WO/)FS/![9MU\2?T -.*T+N))X"(!2Z"Z=[???W
M?8STUW56OE"!_,B#RE8HX6[DYQ4CE!W#Q!W ZU/Y&\*'XH8,3*.E$B[2DP-@
M; \% 'E9,CK;4G8?$_1@<]@:_QQKBE]S0<=G+CSZM*R8T#$=#^+Z(^O^>R'
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MK3,)/=Q17DQ\(=[&4"7"  KT7MKP;!H_.YNW/+ZR7@O2"H,\?\O %Y&^)%P
ML63,^+Y8 [Y'%/Z;4J",$(.S Q/@GNXG;;^^LQU+6TY_TTG.*@[5%=HTK Y
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M#U[\AG-!F-KA%W>^5>)\W_I_UY?9B=9EX5C&FQN9?)RE^SB/!&]UP%Z!CA5
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MWD?G34^4+!7 ,SVW4)!TN?[$58,G;OWEM5)PR0C8=TC7T]TSD.A!2@4M\[7
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M%<"@JO(SN(^/D9"YQ"M7L6%W>L0V8B#Q[M[N7OU2PXS'+OL.@B,%PH'($L,
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M2;^MME!6&]_6295245P1,0V9[_*+I'>R],K$OKX%Y<35ML*9J!,TP-F$-][
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M?=!X% TP^(&R<71 Y083?&B 7(0HE3W CP;@R?M+#^+='T=D.V&_VHIF6&D
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MX(G9$Q-E+?)/#CF-(*'N%U1YG<;7N2[>OZVO!I@'[&:KX <O)Z_TYZV@RVF
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M 260QR]!!4@&X<;C?&3#\?)0W9+VRW'>8[\<:EAVG[U-^8"@$T7S&=, KX%
M$.9^/P(,C)P?WY*YFQ<EH)-W]HW(#N3L5(AX/3?0#YWP8*(*QD1^0?G@ ^-7
MQ5AQMEE?Q5$.)F>J'#6J.,]_\&1(,/Y@*Y35U]I^08<[MAOC)7-CRZ!=7NW6
M(L'7,Y4\H>?;G!IGX:VDS"CCPE^<ORXLLMV?:_5UU-W5I[Y?:F,$T\^&049
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M:?B.][R2V5JF]SVL>I^L-SY4F.D]W-OW8[GHP_/K4ZE6$A4!UD<SS@C3XNT
MT.:S "1WF<H5YUF!2+,Z'9'RD8WG]3L7>\X[W.CD2VU]!>;>Y?WTG0E?U#T8
MV:(RMET=Y( 12DOO_'58MH WGNCU"&][PP"89P!PS(TU%A&!%F-0T2_$]/&.
MGIQ53RV.F<E$=LV=FX_U\R.>:P.]^1Q$.7J4$L1R[DY4%@[KZ^J]&C[2TI9
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M$Z8[Y7OA"9M6F 6B:2'DO#[QU0%*HK3I56^Y\XXY)2<MU7<GEW[)I=PR,7G
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M/O0O0[N3%!A40) 2'7QM%\O%]0")B2GOQIZA.7@?Y""$Y[KBDS-\8:.FHS2
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MR&N-.E;\^_5<X>HL7'I%-SQ#P:F]Y)&#]!KJVLMU<.*&#6Z@Y3A&OEFG<M
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M!?K65S*<P/>'X-_#DA[C><W+Z7<-H;;4@7-"TO!IED/Z/34?!\Z'9L.QQ::
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M*=SUL)+JDID.O95NH*JX.)RP/,TEE/^($_9Q*6077IV.P4O=-2YG-G\0LQQ
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M9;+_KTQL$J$ZO1 ;F^/D*)+EV#VIV7.2W](8-3\-O!>(; Q+[Q&-8;P T"M
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MC*#_]V\C.'?;^\+]0 3UYF9P] %TH]Z;L4GY1^DS]0-?>G1X]@B4",;UXY2
M21:E^5Z3J'T6Y0X^%KV*-29.PDO2[N"2GY"'P3U-+H7+!Z\H?7K[ZKSR,]S6
M9O).+$X $[69"5CG.0!G.DN924&VXR3+D(;\1=FLVXK>!> ,MM1+!L;4[7!H
MBZ)'LZ%OCSN +%Z 5NM 1?P]R_TA\V01M(!EE;V*[^N&M-_(@+,GKL<7G&,8
M1:MP)KO$>.@H(2X(@- %&UEGZ?SMI;S;O&9L2$I7?+6 4<#%B=</IZP-TD)G
MNF]^HY9-,P?=DQWHT"<-B.7A8@RA:Q<D458-%<(HR'MLF[$*(VDCGE7#RRY5
M[TJY,^IMW:O!REV(8[&WGA._ZMW?>NQ UR26X49P"D#,HXM1&$\C5M-LAANZ
MJ8^Z(*DO7%6Q//79].@SNZ.U(K\B0&H]HC3BLC +V>&L5 YH,* QF841P8]-
M'[O.6;"7]'O@*; U4FJKWQ@)=FRB3BM20#A9X!Q_R7\? )5_4)4D9^7!/UK"
M*&= <.&G02FDO?;'KPL2M^+H\0P+Z6Q)=,E'PXE';\L#?5.!1G8J(XW(OL:D
M$UO!D';)ALT4-[XB!CB\,\@1K$U1U3ZH(:ZQ"PH;%]FO[;GR24LQO?>?52LQ
M)FRU?0X\W<4@R/C 86S-#X'CZ?]*::=;I"(D#'Q=*!H,&]#]:X5!(DB[Y\ V
MC=#9Q,],B<?>9<50X)#AAP39/7-'5(N_7Z96/YQ?F]*-S#J6\.-UAQG<,4_U
M.^C[&47>UC]S4CYX(9@DN[$#I\)*^N0[)T16])H#J["6OZ_W^.5,.%!G%-,D
MXXUETLGN+HO=*A':$#"[>>_5BV-OL E,+<I4J3Z];R.]]5U-)N_LM,^WTI3G
M.9O*_F*:<<>ZXS%C5CJA.)].L?W["84X,5P/7).%CX8?^,U5&JLJO0>8=<@0
MX[&6(957AWQD$A>#-[V5P%+@ZK(XC\=Y]Z7X RBEQIMV[&N5+#4*5X#4_&W*
MEDU,OL>&Q*HZQ%W5NJN:*T<\K)]:3UAZ;B(X]"'PX$QM)N@O@8Z(#1Z8(+;_
M0[7/Z.Y1I"]3,N%4+ENPF6$E!:2MS5U!ZO9.[10.I']]N6;FF]3C)RZYBC[9
MO16.F@IWSMIT8\<DY%2P9AO9O.TXQ6I65SH]/'JDZK'M0FAIVOF2R7NV#[U6
M H7SCLCHV2I5([S])Q$4^#F@@2 ,@^1PM-A..RNO)5(__MX[HZI0K5(EH>Y5
M<4JE:<G\41%M;58>*%31#=6.KW#.IS<+8K6&E.M8;04IC VV9QS4[!OZCY>?
M2O*L>VW\["Q5J*2\EX4=>OG]LE3]N3N@3>A3?91(-5CM5B.0[D9O4MH,'TN]
M.@PST!GG&_N:\RKYIS=(Y)I40WG2)>S[Q%\I&;J[H)2]G/YO)BP#\10&S?=Q
MUAW'*5,QLI=K0MY=J]^TBQX7D<CR^4Q9RS45YFM9*EWW7+9 EEQSM0D]'5*L
M-VCE<DV0GPS&-K(6]^[!+/K/0$2-3.>'W&D*K0]IPY:,I5+MW\PNI)] O!KD
M3_EE\G+%X]2/VP<,>7I:^,9;"8E0B95F+W XO99B*=FZ638+M1+UML:8_OSI
M7S%5/36UDSU?R(LM!,68F,"M:7)T+>X$2IYDS5)KQ4&;6-4%40<ZRXLI!98,
MJ$36BYS?"[37:4M312]L)DX9K7TL53S5(AB&!W%.CE8AD@FB''S)M'U_MF**
MY? ?#'IF%ND@>]LAL*?^%E_HSPQ6?K1>T-LQ_B[_?1ROK"X9:").$"@VC%P0
MD'[89-P.U_&MS',T[5=QR'<(>EUGZI0QU5LO&R%[F[>#?(9C ZPSM"9%;^V,
M1^GL@B07,T=38OZLBF"0MIF/]>TJFU\<369>>^B1=L+6X@4D,R#V>W"_C>\$
M5Q38!76FH<2KM)[^HQ"BQ[G">WK66H2)9!HGTUK%E](53$J;RE^LE8=>[^\*
M2SMW[>WX&WM<]RY(C"/+"FK+]']6W;R?($W%L(!9;N=:/V.N?7.)?:7Y7E6\
MW+EHM8</K:LJ-1FW6(\X 2PM)J6Y<S4N^R@0S)CC\\+)LT??95I]7 @9O[EX
M(8@Z677#Y#[H]%-O ?TW]/C0E5:I]W:@I]PQY_-L_IBE^U@HO4_6D4U,A%F7
M>N.$XG_DUY9'7?F<D?/8=">J4OO$)?,4;_P9<=,EO_6$U5BHY I<'VBT9>-C
M2'JP1ZP$>D%1T1UYZ3)-G2333?;+V\XJ@97J;TJ=)6Q=*-]B#<R)ET;P[O@X
M. ^+T HVHSLWT3'8T#WL-TXW)M>P=:S)KS^9!8BAO /9D/.WK81>/. Y_S<6
M5&Q)0_#-X/HO^'=:Q:*J$!T(P0%$4GZM1;6 I^_MF[.RY_=-&HF]37/:$I#S
M;OIN<R1PJ044)K<+4M!%B.Z!-"(:*ROX+C2<X70!(;I8*RE,*I__IY5V>D%\
M7,3J[*F LQ*HES=M:A@-T&24:+7_LS4.C&!56U'W>1SF=)>^8[7L\X,9^=M"
M!F9R&\3P5\2V1$K7]8-#41S1*5H_D?6+YI'"@$KJ#&.&.\+0$6\<"[HJADM+
MQ^3A@UJL^Q'\[K XU?3SL/&/N&'HD8VY!.C!U8>HPP,%=X!/L[L@J]&'64DN
MW1IN]56DZ!]7HW4]#U^^6NC5+UM[![0VEP2M2JLNG&^6UWSH9'"UF>4?\4>Y
M$*G[]2PI,R56+>6D5XI846R./;HC ORCD,?^2JHCJF,@"25$Y@6*6Q!\9"B5
M<X8EGE\8K7%G:)VAT<?1N_"JN$;4\^ZI^T8OE40#OYPTYX8I/+!ODM@%;=J.
M,'<() AK;/A&>1.&8U;HFWUZA#AK@K9_R4*ANANOIX5ZWJA&\=QZ0GC.V\=Q
M!_C9VQV9A2D<?3I>'("B@+O,F/4R#<YC_]!0_ >=%R6!^2]/>#F)?K'/M6N+
M.R1K*E#'UY4,<V) Y8%U&BJF>F"_=YA=0E)V$5.@3]^6]))Q46)M:+R[-D"W
M*D??^N)/?>UN/8FV8EIL,RU[#6L^#A=9()\%G@7DS/PW@["HAX$\5#56[YMF
M$0<EKR>+2YRCF=_ ?3>/#W-!5>Z\@5GF+?S[OHE3K'I%Q6K6 GAZTQ7VC_#\
M=[;6NC.]ST#^ ?>O=;K.HNX?^1>SM$I'2& @M-JG)%TF:HF'Z+5I4:@-N%P]
M97L0_PADK"='..$V;<X;</\(CZ&"$6,UB2"'.X99I_Q#M. AP-$J!-^L7FK1
MHO.Y[-]EN1\/CGZOK4*Z'OYK$-EXQ? 4[0A:I;#+G^K @$0^'."=I[K7MN.C
MR2?'=%:7->RYZIBR@R4/-V5M2NBW542FNYVRMKKW^Y0GKBL*V$*?(* D7J:_
MU#P>S/&G]2G3YQ)TMXE"?9]\J ^W9%92+P[_33^$AG+"KS2VJGOTZS\WZSV;
MP&[<-&:OQI//+CB?9"T3V^:DY_^MO"N<<)[&WAJ<NMDTE#GIK)=&44XTR=B?
M[::,OKEP;E^$!N"P.<+6C\7QSV^-P>4'.59L,QNVY5ZI"W?B^]L?5S336M>#
M%^O7WXES,WN>;3$A^6"F+L!9$?C YK^RDP,3AW8YG6VOX:471F\,0)T7X()I
MH0^WOX0\O6,H8A A[W%I/:D$Y^'5^^*MG44.MZM9# 9A>=*?L,;C.*?GI+ 0
M!MC.8=NO\$A?GD^S7^8/#_M+BB^UT;]0=23MUU+=S[V\\!62'8C8=()4,#21
MJ_5-5\.J"R==S=I(!3QF[\68)ET=LI#SUA0PK;QP(0T]L)XV]?8ZOSP-,L7L
MO%"8B(5^!.)W0?3]9##;N=@WOYV><@3(79X],90T_#32X;6@ZVN;^#@)W2,Y
MA@_T/I=M=:&J)#MW04+86T Q'?],09YUN0'ZA%%Y%DBAC$O>,*RLKL]F3-U3
MR4#Y=ACCEMW6IL^X+M9":(0E?Z:\5E>88"%S%8R%?-,A0BY8^7%Y6/>4KX^J
M&FW7UF7^A/P)+"E61;>5NQJZ@^Q"(4OKS 3HY!P3^JQDXZ(,5!YK-%I=:D2$
M_27W^-4.20V&9MMEO%F^[ ._)@WB!^F"@CYS1^>$<>H8/+TFAE7<ELG/.>4O
M!CAK2?C<Q&3_=!_20>H=O=7S Z)GFF;Y189X3C;YUIDC0,*V'<<44&9UF94#
MS^AS?+]1XAM]'FA)BSJ"$](?W"=CJH*^:>$><,KV6S1/3N Q#QX[/I/.YJ1F
MS]5X% 2GZ W7!(0_8?1.\$=KP$[@<S$,64+%X^QO&:4%SY;)#V@&'ZS7:+]2
M$STY_CNII"#VR3:$X 8R"=^&$B:K8$P=NH*!)^\[J1+Y\M2</M&IEHQ$LQ\=
MWSX?^9MRI"M D==MTWJGH'H7%$\^S=:*A+E]PL+WN$+GRW%=W\>^].1/6]1;
M8T,&IJZ/EP;DV W[C!#:O7D\B;7#-C141=?2>A$6&N,X#K.Z2[,TH%P85M(C
M[ E+>\@_CZR"EJA]Q_.%-;YN]ZMXO(L%/S.YGE=+'N3YOW-N_S?^O\5MLOI_
M/1W!OIYHAB4OD@UN>C>$<C#^--D5^-Q1\:BJX<*E[@]O^.22NO@SJ?_OQNO_
M"8'8G?P_4$L#!!0    ( $.!<EB=R,K85E<$ ,+8!  4    861V;2TR,#(S
M,3(S,5]G-RYJ<&><N0=0D\'7+QP%18H@*%V(2I4JO1-!Z=)[C8#4B(#T&@4I
M4@4$I$L3D!+I(+T+"$B'4$)'.J&$0-J-__>]W[UWYIOYRN;99Y+=S6E[]IS?
MF27,$58 =S15-50!UZY= [PD?@"$!< S ,GUZ_\>8B,E/C=NW;A!2GJ#@HSL
MYBTJ"BHJ2@I*RMO4='=N4]-24U+>8;A#>_<>/3T]%0TC$\,])KI[]/?^$;E&
M0OP/Z0WR&S?([]VFO'WO_W,C= )H;Y%4W_Q$<NT1X#KM-1+::X1> !  N';C
MVG\:X+_;M>M$&6^2W2*GH"0NJ+\#N'Z-A.0Z*<D_J8FS(<1Y "GM#;J'(DHW
M[^K;DCWRO"?Z/BG_%H=R=1>]P?@QIYC=VS!R"@9&)F86+FX>WL=\XA*24M(R
MLL^>JZBJJ6MH&AH9FYB:F5O8OW)P=')V<?7R]O'U\P\(#/\0$1D5_3$F.>5S
M:EKZEXS,@L*BXF\EI67?:VKKZAL:FYI_=O?T]O4/_!H<FIB<FIZ9G9N'KZZM
M;VQN;?_=V46>G)Z=HR[0EU?_]+H&(+GV/]O_K5ZT1+VNDY*2D)+]T^O:=;]_
M"VA);SP4N4FGI$]FZWGWD>C[6_>4D_*KN\@YQ R.Z>W>CE,P<(JO<B'_J?8?
MS?[?*1;V_TNS_TNQ_Z47'$!%<HVX>22T !!@/4K3@A>VP(P=NJ>O*3LC\*Q,
M;F+"Y$7(C6*@;W(Z&L(@SB6;I5-1]*0@AO\QH'PF1]O"Q_X!!6]!S<M[^BI/
M.PUWB&,&71'W] UZB0/J?_15Z#F45.X954?P31A4/GSBRA"9[VKVJ4Y?18DX
MK'>-. 705[D'V-S14I<UF'I"H5K\K5Z=7+/-Y;%)RK4I?95G@((8OJ>\!3$O
MKL?PEO[C\N!^75WL1%H1\7?1M?^B\9]^Z]^BKP4QC_]#\/_L]#<2V(C3MXB2
MOB<*]S]Y&_RCIW[CGO[3_Z/S[FEHMCG_XW[CGR9/_S=:]\)B>+_:_B^NA94
M6:)<1"%Y>8D, /_=7Z@37TD1_TV0FBB42(2,2]WFCM[ E 5O07':N_]82J__
MGSX4/I(Y!D,4O"5JK+]7:<WGSHR9)23=YN_5!]XN$7P-1X/TFZYE2C2"KUSG
M0*G.)>_!0(G=</SO5P2 ODV?0(I(%8Q":-D7G).HRD1EK.+?A0=G#.M;ZQ\_
MQK-.CV'T[:^F^?-N(GI2@.D>H+G7P%_CEH]^EY8/Q5Z:X[43 D+Y,EO"L00
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MK\X8FWJ/_;[H4></G,.TS557L7PIA46!LZ&_E\6S$"?0C5>"L@W7.W#79@D
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MM)U/^8[X2HCPI+2%1?)O"CWE=$KJAU3B:EJ)J9A<M]MWVC9Z,"#_MU#D]'"
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M+!?"QOE]U*.&6?(\8KYBMKYE^3C]OF+9JLM/WISH-@R<3H&B=J&;#J=." (
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MW @N7/>='8LY?[B6X@N_&FS87TYV6 20<*+@-T7Z11)$P,'!-^K1E>[N(00
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MJE%6;%]1F-XDX@7=&P:3S;^82Q<WW9)0/L'T7O?Y!;,I[FBF-]Z@ W\U#HB
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MC3$U^[-G*'TB,"=9=<<$$@ 39>6;T'<=)UY78-P'8="9T?2YVGXA <!)UHU
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M-=.?E]=R(NO)MR0P,:3Z1T$%MOT9QQ"&,=7[I1?"KMR, =50&6AM59>XCIK
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MW"EF[%B,G8PB2^/2(O<.M4MUV"8F3FGJONZXYM'K17*<'WG(8U\7B#VE!L/
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MAHEBHLK#3_QWVU4D$C.#;-#-RC&%K"*#IAR-!-L[ZFY"9B<1+'K/EY7?C5
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MML'X0FL2CWQ%CF^"A$+TI^N8YUR+Y'X$/EU[;"T!;+53G5:THY+W%_KV,-:
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MB_$W"/:=Z-9/=D25T;V[U9*7II']GDV5R7%+L@-VX&%0#>TVE7'H5J\.<5(
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M&[,0?QE,S\H#3WG4^2RB&%YY(<'N4!/M,>L5TZSW_7D;'R78?@R;B;34H,;
M.NMM0F4_)%9_LALA"W$[25;CZY=ZU>'RD\^\EIN3M%-R3HZ?]EUJ?=C(Y4)G
M@DN:(X?8C\BG//61\_D)=35U>YE5?;>Q&=?:)(#,"J)#7!*%%C;RQ-=!8DD\
MTIW<OM*>9FY.O<6E_XG7%Q"*<4POPW\ND[8T:_CC-86%=(^W;+'G+U[6"V>X
M4(YO)?7"SX>X4_?%<E D_^G05^>MIP^-L/=7M&/O^UNP5HC^P@->&4SN%,PT
MNV@7R?.KS_;B 7Q&Q\ 9R50QKZ ..0N-I$U?G!J.FW@%-!VW2M^TVA=-1\6P
M36VON)Q7$R-&]MWA;[6N*':(],Z=A32]>J@[P31=<[(3-6HX%)6XS+_,DUM%
MO ZB>97AN"[+ZJC1%X8"T4$I,(=.JTS[HB#&708?VDJA&F1<N\C#;\+*FH^3
M%FO);U89%EW;8F16%X--;XU5.<BOX/**MAMD0S_"GY7E7*GC ?'M#/V?IF^A
MO#I=O\09]?".YOF4U\_TH49/93&]^BJ2/\QM[+C[U[D<,HJN+HO307MD>,!C
M9#AH]X@="YA,])\VE1QWUXC0JV<Q4:/_D=-UXX]C+'70 E=\3_2A_S'3B:9I
MP=4- HO _Z=7C=AR9E7-=1IW&!ZP/XH'*#\J"]/4ZB\RR\8#.'H[!]\N]TN'
M5ZW;X %QH+]7<<O/&IQA**<VYM(3N*N+6XA5JAUC97>K4")W(3<3]T+S/8P5
MFJ7=<'*?:#G=Y5"[-N[MF)BOK_=BO^3S/N'BUT2R3Q@_-Q&S)9Q-M@I>2,#_
M==@@@9T8P#\#":L])B@0-I@?=I+%]X/X+@X/T-A]5RE;JLE_0\MG^AH[KU&)
M!SC\LDA:RK)1L([6JK'D]!L-9F+_PH$NRBPG#MH_R0QB8&[1ED@MW0M:(SOV
M=KX.^7IYDX!*+3OG^P2BY%0TN[IK]&]&3J]_*QY +0"7%2C$O%I9HG@UN P7
MR+:(1$F^_>/G4<N)!TR^-';6\B)VW"S6TEYN=]Z<;],P@:EF G%_%VG$AIBA
M6I,<#<WI_&X-%PX?2^^_XOCZ>N]+"WOG)V7'QE5)@-XXJ!S>+O>NBYW2R<$]
MO$ZP#/$#_E@F-!D12<9C1=Y52/QIZ"?=NADKTA)$9V\*'!/+))&_4U!@7R/@
M@FIJ5>!"1*DJIZ_=46N/"<QPCA+VFUT"M3$V ZZ%&TQ<<$0N!Y??<CZQGS__
M_-/AUI?6HB,-%]\/]4(ZMAIDC&U^_-$R3ULW:%WM$\I)?EU-.MG,FNUT#<Y(
M!#M ^:X<NPH,'D:-NTND<&A^SK"J^_[K['8W6VM3VUDGNAF^A Q*7 77QW;Z
M*6(%N&J#PKK++QS7GK(&J!!EOHDZ/4:V93)%AYA5K0>'Z) J^!6J_"TFOT<=
M-"%[M:<SU.2KM[](.,M=!*+YW0K;"K4M9#A-%<JTM DJ2M2)*GPY[=H[L;=_
MR0:Y(L=DOB,XSM#BK2%OT52'SG2N4:.&V&RKQ.>L-_\N3[$;'__50<[.](-7
M#DGGS3U5+?A?KV8FOCGR [I>3A#O21 H,NP<UW(,VYJ"%&&;;CFL"-X.-8CE
MN-UYID#^Q[,KEHB#>Y9CUU!.:&<>*1]%,?2MH/_0#K;??8XDWDVEZH)]%3+2
MW_&D+Y^; 3NXB5Y%\^X,ZI#5N8Y1@YV_$=>*K8LC*_3"<&SV<3M(*JC_F=Z;
M7'X&E+G9PX 'W]8=&VG8B3-RQ(PTL%$(#)17#'D+,ZN%FTN=MAX]S$DQ#W@Q
M)1O/\MFJN]N1A#CM0W4S^58FNULF@^$LINA,2E:$A$_&GN;/IZ-?@^0?O_8T
M?#GO9CT>^#3_3LO-GL\#-E'P5W+H'J]0UW+>D)7=GZW&@]0:_X(!=M8<3%(N
M)G50,(3!,\ZTE6G/D?QSJZ*BX?WDMRX,DD3-!R]6FGNQ\54#JNUFMT\:]HW>
MUH\=FJXLB0VL#8A&W"H!\+?'?3'UO/+>H>=;6J280L002+#I2HT5UK5^=TKJ
MC"4%B QRSRQW6*K'<#A1NUDXP)SOD7H;?\< \0"@_U?=A,W]3S'II84]B7\O
M,WQU WZMI3D5-VPC4X% S, JB!IB*H463_JU6Y^ 2W$HF6?D/RA;BV6L[MUI
MT PE"^(DIR1ZC'SUT;T=-=0JX_?A9?()EL)QRB=DORUSW8SL&H817(F^M5N/
M!X2)&>F;#Y]2.%I6)7#KV4%'.8L\HE[,%,C\=I'VA%="=?" )XLEL*D""5Q,
MJE>9<FMLU"*JW=*^B5Q1:%Q-F8^@'V<G0*!K-32D$RABM'4:?=]>KSHI@MF(
MNPY6B?KS[?'@<$ .XX/B67]*S-6J9Z@L'5O@LMR3"3]F1HH(Z5P4/[N-,5VO
M<IV\\.E6%\=WR(8.?(Q"0C4!2#$SA7FRLM#KFI-MI\?NPV5!?327QGKTLH=8
MJF? W8*+63-"6Q?I(LL?$ EU]ZFR,E1-@-@<RIQ,7M:MP&Z"K-F9,<1=B0O<
M$U!5)[8)Z]HJ1*)!ZI[P;SZ.YYICF^ES$:>%>( 3'3OJ,\;YMP3%F\_.0Y<$
M9TFD Z2\?H!!+-[GKR+(*(BG:H'=L2S2NG8L<FB&Q8Y4DRZL:+UR\&Z72L.5
MUU-"6/DM;_R9$7M#,XM]-TDLDOB$H@<DO[6I(EJA@@YZ^LXD]]07L@;!=?@_
M'F]41BWJ_= ;.Q13-A]G9EQKJO5.H9:_1YH7VM(C2RD%3P?9'3)Y!3B%L_'_
M79L4XQ[677DN.M'P?99<,0+DF8[TS4CWAKMA P]N0N70Y"Q)3XN<9N<<0^_X
M9PIN00B$:R\8R,93A4X*;W02*'FZ/"I*F<3FD^BWS-'RPM-2POBSG(CAR'H4
MKQT>8,3*N&Y:+1^<(-/@!-FW,\6!ITP?HP;S[% 3FVTXZM1%M3&.<B,^DGQK
MI>76KQ0)Y"_)8I]32<*),5)7TM?J& <TZ:1Q _I9BG-!WR/I^'L+<TJ3/"]O
M?1\&]%/>Y3Q] )G2TW2*S+QS>S+XU!OQ8T"WQY!LUB#UJ4 9;8!V!6N$=,)'
M=Z8="NC%<N87&)N8FH^JFD47<V=P?E?:#ONLRYQW&JNW<TE6M.35["=*[TZ^
MJ(0Q*R;E9^? P.<1]GI9A@E, YQIQB:QI_L[)]7!:E=>MN+'7MQMJ<,:)PU^
M+Z:+-S&<D6F!N_WRVT.ET'_ERL!>[!TPRDG5T6MY-.ENQ^]Y&0VZA/'^@^%]
MEM=Y#U+ "U;$4FNKS;+ )BB_MQUG^M"@Z\Y@-= U7HHK;R*Z("EF!P^H0%XG
M#9$0R$H9#SC),+R4.-LC.'*++ *KFH-.WE0=)_U+)G$=M\).1V!8[L3F2&P#
M:"UY"W;&J(&E$7#1Q0-\@D_GSBL6+[C1IO"CT&50Q6&G-Y#1:]AM=_M!HUQQ
M=[GQ,V5JU6&NF^@VBU^G,[?]MF:>)17L3#8_%"_O^J7\\?>0!VW2\TZ# /26
M_LD:>HMO=6CJ<"D$35\BZU1B=##ZD;,SDS:\?32JPG7LT39N\JKJY#2Z4Y!R
MAYU6L)&$;NA:7<!APJ$],A;$M?)N?MRCG.TK'N V^>S9R*\+:4??:ZE]GO?F
MIX6<>8(N5[LXGUD<"4JO*SH\R8Q1UED\VU,AS\@Q4*.&\SK&YC &N[$#(QKD
MVP5-U;1YS&C\Z3Z5_.M7K-N0:I#;):DH5+3YUX$;=PO2"H-$!X!07S!QN/M^
MCRGJ*4N?'EN\/)HU9E-9K:CAE[MKWM+A,[0GC[XQ^@XEM_AU(YU!:]3&-\2<
MF_SLX"6_W*?URJ@?21/5I7;FHP7E*^M"A<%#-JR0\QD/OX54>,+^.;LXU V3
M4(:97;&NY-H_:5W4:$XDX[.=*_'894G0RI&58!(8BSNYN0N?IEFY4[ Z](WF
M2>6G\YI4JUF#\)1D1"RXW, S;BRRPW7K#J2S60C7#>2O1Z_C"I;UL\;=FM37
MRTA[/L4HVP]V)(NO"/^,"ZB3W(^).\0#[OBS&^*&D*0''!/PY?M\RK]V]%2Z
M>A5G[HQWW_I<E).O/%3&)SU:P*L,=H5SMZYN62?8K]!H3NSO74$F3\!=II(8
M4!&$G?5:9]F,1)]LV[PV=H//*E;RU6N/9B(/S: %!KC]#QR3Q$H-EA3YWUUA
MU(=6-^ _H>\GH=YYAC-][K]D>[_OW.TO)'L^<Q=LELS[:S>*PM,,-0^4PP-^
M@H-!__T<O_Q9;^]3=A%U*3%E[8S'KFH]LXD352=;7?Y]]8-YJ/!5O\7 4XQ_
MV[/\[$&O-R$K,D$L*USQWUV8D@*\O^N>[]>A-IPP*FY4][?/]OGL/]M5\K^'
MCL*%_ SB":3VL0-ZNA(=8@@/:_0&A:\??:P*=>2HOS.LI+3VHD'E&[_7#!7G
MY!8RN P!BUBXA9JH$Q4:(&MJ+F"^P=)3%UJAZ*?3]O22N;/8K8"YZ5RNL4RT
M\LT#:(6@4K.M1!,<:W8-EBK6(-X[O))-^%HPXU8J*\_"BQ:82W/L]&$R+M_,
MA[3C >_GQ5GF73M]&E<'F@-8;+7TUJM[1RJ/#SX8>NZ/KXZ*X4*7KCPO'IKM
MLS3"_"IB!,<H-G%WJJ*O*+QZAQ30^34_C6O#3#[<79A/7A+]GB1#7&? 2!"Q
M:I;9V*]YX^D)SFX9OL%M H]4YTW+!$\K3L$%N+^9-YH?08W1QJ[;/@<I-LM7
MMCE&OGSAA:O ]^NY5OK3GI9+K"<W\WS@K8+D7G%M[%3[HF8,._27@WE$7@/M
M6K)9R]SKNC8ZG)^=N[=N>X/V25#(E?S2%?@^G,@K6$=<XE[V0-XLA JRKI1C
M9ZFU\T,)D$;M&A<%N<\^?;B" +(P7$9W8%75FY1FE/<7W];9FM_D3FD<]']+
M<O%):C<B#1%_WP6<GX::VAFW6RYX*K<HO [IO836@"FN)#%/.B?/<B8(PTGP
MN9>_ZO''$N4_469<KKN?+RX_0VJP==?F1=O5S:Q_2P[6JWXW&6S4*QG#TVOL
MBZJE?Y'/N4FQ!31"SIPQ0>R!_E)&]LP$BISY.;9@Q%>JJ.>Q,%+]NJ1?@K6;
M-G9*DC/UTN+L%X:]&&HX<O(##Z!*7A\7'1+R[^'_<@O=/!IDT?)>VX+S9NUQ
MAP/( V%<+<M/:Q7:(T2+"E_<F':"P$</@>X8L2LM"(BD4<8]IZ^ 0-8SB+"S
M@)7]N+V<6\+1"14%ZP_)WP=.RGK#VS685=$TG89)(045-;\S+L87R!QFB4@9
M9&-=G.,.U/Q J'=GTC4FW&]K,9$%Q?.#W0(.#QO>3^R(U*7D..16@UE7G9J@
M^^CB5ZC%(!S'3CTXR#+#Y%G/5_[C7L[^G_ZHIX!/5'V#ZB\W$%]_;EQXRO)[
ML OG?,X[K?--&A%<,3K,PP,>4#*'\90%K@_5(<VC+SCK:[#!3_" $5^?B\RS
M9 )/;*\L_E=-X).N/2&";D\BT,'OM<5+#2<S$=PH^Y&)+,$KF1'H)3NV=AL/
M8 8O6F<>/6J]A/<J'$[+X-1O_E>=[=PXO6%8=4U$E1F%%Y5R^>BS]0H3]?W8
M#2768H1]RG1,]ZV8-/?9J*^3@__7%"$G;"-RS0!5@/57(X"# )U8*75? 2]4
M+C3>)).@\!^:^[=*GUZGUH2*>M8EJDD)Y-1&S:?%1YY_5XD*E*GK,B;MQI8A
MM"= MH(4=D?E87*O>@?I8Y]+ ";O9X',4'2@/7:"A<T,1>ZQ95X^UW&:!;U+
M4L"L+C<I O(A:KPSRS?=^)-$?@]5*[ ?8:>:+3$>/PJ+M*ZE4DYMVC,I=^MK
MVOJP#'_./2Z!A?S*3D[.?(UVY-Y$U15/>3UN$-T, *M7K> !-Y $9QR"!Y!>
MN[/E^:T\$-Y\77L,0@@\;,B0E[*2]"NEUEIN36_?9-I,8]=#6WJ"&)KORRY0
M35J/.)ZR>!U\%"/SSKA?<M<AHN>81Y)GOE.#F!&>>?T();B:6%EH+%^&V35$
M[<<;!<P1<*W/S4JN.EM%$ECRDBUA@"HH?\\/:$[';\(\MC7H\*]O%7NF!M+-
M%-LH*T%2@:IN#BO^5*%JP6&1I'7S)_=?:CS@?!CNAF%X&+U4$SA?JS.RS(V[
M@(<C;:-),#DMTHGI.5[!79YLSV@>U2EQUZ<J!K+S6(,_,'CV$Q%CC-!7(DOP
MZ^^+I 1I\1B$O5&47259G.9M8F,DV3[0%G-47,I6[P&D0M=TX@%,7K/:X_EU
M:,H\^DS_P0*UJ.W$>?,/SNR)=[4 +8/"S@,^['M7:):5\>9H;."2'_VDP:A#
M>O*/XO?E[?V>U".'+S-< Y2[U&]#":,O!P^HC$Q/@+<@R2-9VS,<<I2.GLX!
M_QHTMB[D A5E+!X49Q>_C>KJ7=/>W9"<5M')HX]S*"@>MR, WTUL(HY#?G57
M@Q[2_+2ZLDDUOBY5B3O6;J/MF^ULD$DNN07G^U5&^!OL[WB)EB;M[R1&/SY(
M;E_]Y>N_!J',5LU"FA\9SGDUM(OD1T.\:8]5L3G-9%]UR74EJ3^+1$![FUR'
M5$X69XE4H23CW4PW5J9B9?Q/(>D-@])SEZG:%JK\'2Y:\30:JSY-;-7;EVG1
M>UQXP&.J$-@>-QZ B&VT.*M"GY670?7'W0P$N=0X5&U7:A#@1Q+>]OU[(@&S
MR<=3 +YI/,!<\((:2O#3YB!L;D+DE;)_'^XQ.CBR  T.X@A_*[$,'+?B[*/I
M>ER4O\[_*N'A#4472I_-2)H("- BH(E<G>-A%JNP4[U1%7RQ-&KQ3 )=7;QR
M^,WST\ZDEIEJ_D(50J2_8TTH7I>TWUN2Z_-9R[ZQ31L[\?:$6;5G1(Z2GE4D
M8N8KJ3<)?[/ZBAQH$CDJMI-9.=1:UTQZ+5=;/?$L2V*2IFE_M?,BC)H6D!7"
M>MLX;D?#'D7U%<DH>H6<01I,;,98C%Z_&-FN/BYO(:N3C74=]8P-G&JR:?@1
MU>4.WN.Q.D'#F&,7_3(OVL\R9V26!:.  C#K*8RO_N]1A)*%A:N3NZNHHC?)
MZB>E*>'/=X1]XCJ<<$.XFVA86R:I\1:.;[S4_7V<8P7$>RVI-^+7;1*W=Y\5
M7VPRB0WY#R]2^C_$9*N!=%#TR%\&&K<4R=*%)]_%#ENS5)35OO]1]][S7DQ-
M!E\0:G'O'!VH];=C HZ6UQMVIY?5QP-LYXQO&U,U/>X%2'6WD$NRIBVI3- [
M/$B0VMH0+M6@DE*9G7>I<I(#F@P)HSV"G):'9IDG>L=E:S5"1:\^_T21P\E+
MHS_6K5;YW;ZR@?70)>%:Z?& *S%H0MZB6LZUUXBC>ZD7I$(?4IV]J1?K&6.E
MG__"")HI1*3')/O>.2;0[)/_WT7*4_8P=G*XJ,.C;.;/J3(A6M8S%72R90?M
M <ZSDH/2$W'G5F093PPSN(FC(WEVG^PU.5E"DZY8\8 >QW(\ "X3C?V7JSU.
M6$IJT5+<9PUQ2C%1)XTY<[DK%VGOWX>LS P%LF'RG6B\,B3Y.8UL:FK*#70-
M)(28/*RX7K0LW5">'Q0*C+N"POK#__,LPI631HI*1?F]-MU6U+[^1'BX@XP<
MCB>CYHIO-S4ZI)G"+JF^%#M1X',\=Z>V,24OYG/,Y]O)<2WP<*"P5Y_91*/S
MBHG(VTDQ/JSXK'[=<X.Y^1Y.(8>$<8^<^PRD2HRL-\,N#\]$&AG,;C^,D!:J
M0=:&!,F6*4'989F@5WP;&M&9=QHUEII<3=' 8@=R:<6LTO[$BMR=?<%4RP3U
MX6X6[4U)*?9(VKTBE>4?O.,N$:++'K'GS>MU9Z PV-K<*>R*[A_YB9C>O"*V
M/3MGW@RO D<:;DR0^7K-G>K$Y I$P^.K#A<(]CG.=1P/V-,F" 2E >CHU3W,
MS.A+=&=IEDGW8P?[N[C!_D_,^N'4F5IE:["&J-,TI[UUB_%.E7L#G]3S)V!^
MB.N/\E=VF#;M1DQL/5%#BFBXC%*Z UUWY-K'<H\'0R^'U!K=18>(_*>E-P.N
MF>RRY[;)RDQF#K3'! 59G-^LZR0YJB^DS/\E/3&;B3YS1;.W4]$989):41V_
M5+GJ9^>F17MH G+WW9^]B@D,$+X[([T9;D8)LUBDV,;=GE\MAHD86WOG9\R@
MAP5R6EHMJ0L ])R!??=B 44;P8_KUL?^;!#4D?OF-T<)9.-9C8*O& [<F5J*
M&A=3[?OC1/&S-F6#_FPI9'6N??^M<FO$DB]IH6$&C]HST'W[T"S$4$Y>?[CU
M.47=S,-V/IHO/8QRD@-6DYH7)P>YHYX@9>3_NU%2<= 8R"'SYO;DI'BLG>E#
MNX<QV1^J4>\3.%G]KPKHYOW_/S/1NGW.]RK1K\Y-QAP?H3HQUG6QKYWVR303
M^)4DA2_U:"V8E(_92RR$]*^?D9&CGKLTZNS37_*QFT*E,-O+@A%F=K^'!<L<
MJFX']_L:A5P7CE/=CE\K_/.0E28B##-[]ATCXHQ*ZHA1J1G=2;4NW="X/3[J
MF.G%T6_ @OG!3WEPU5RUSUY)M;>Y @=@_F+BVF/:\DMT1^3I4M4KNONGF#Y\
M_65\PV<SQ@!9XQ2Z_R2IC8T]=$)U"CK;$R\A5 SX=1</@)##EH"GF@@;VSWO
MB]C"B)X%#G9*PQ@?M_FR#%C>4+:H&<7\EMG=O1,-B@&*YIP[WZO/]!@X[CXY
M^LT)O7D-=FZ1/8/?PKA>B5]KHS3:6=CO]:RD/_LXUSD3?>G>'^U)^6GG3W9;
M>NZJ\]+2FH787@;19%?'80!]A5W]C^WS<Q^[RMB#X11.1#U)><B?6^9UK!$1
MKH.0/VZ@+XML@HV*']T%F7=FK).#-\9IC!,MS:,*&;]+ ?OILZ5-Q'V2MUKA
MXT7O<J1RD_C"*TR;F@RV0-5=P8_&@;2S.T':QMN>PQ4]41Y*I,*!6\H$'B*B
MJ[PBR*H>\A'8[LHF'J!8!3V\>NU%W FB0/@RN@^%G&=P5XYQ\=;[#<Q=_7 :
MV&"<GE8)K$E#Z>L-LQ- Z?K[ #>N^1GL!/(NMDIN$/K QD@N+4\CUC@U?W2G
MP5O_@GTUN%T.U@ZC%YLN$^/[RNR8(]84[ZS26[W+$J_UF8V%+!;,&6?F@O$Y
M6NUDO['GZ#2GYE[HY??F2(F(\M#I^+Y<#S?;Z<4^6AZGXA2.W!/TQ@-R,I O
M@4RPGMNH36PX"@_8^J*CI]1^C/'/W5E!JSB>(S<(2N.*>%O\>)=-<&SAN6/I
M^^J:R.YU7<689*K"4!CO <R6_0N2&BC@521UTN2J5OE78$6AIK*V/D-D@])0
M42<RR4.=:.B%M%XRK@TGA!ANM"K=DGCV.$D_0*+&6I*"DVOPSX&N(@A%8YIT
M]1(JA,DK]LJYLFGQ?SA.D=!N6VGG,=,P<Z'%,V- 6Y\_ N FENKI$E79R:JF
M%-VU_!3-66!]D'TZC\6*RADM<W^#@I<S 3.V"\^0-1-BC&2=CH]CUJGN@7BL
MW;64B%FC/NNUX>@:QQJ)T%M;TL\*_?*W5]L++43I:]3#99WG:76^WSR.N _\
MB%W=-5VF(L@P+4%*,BQXY2"OP#37@?/L\)<QXOF7N/YF&Q#/K>M&UTDFD)C7
MG14(,GR!-6-EOXID?=(A0[7:VD*&)8BKYSUCHNQZW6;J)Z.=3QM389E[B'45
M[3G32,0\PD3LM.X,OF\#M_=GP8 %-N)^S6][?CB[Q4#_#B'L(%,A\93X3F/@
M&?<XO&HHQ)2O>0S^3(QLNH1#V'A>9:0;\^F.02CW9V)@P@Y[M<UUC!UL%[>(
M!UC#N;!?\8 U%[0$UHL;%T%W#\<B)VN9A_O]-O*D>O$I+1[@H*9XJ(P9R%K0
MGU>S\J2,).MP=GH4]=H)N)KPWH5JI#D+ RXTV3$CEI7P]707&U^;,791=A8-
M6O-X>AY.$^NWN^XT&X=3&8PCF'@EV(E?AY_(%6@.9@\E0Q6"%9^T=9,7/*3C
M3P:N.E+5BJHNA989<&,KPX/P@.*<XTDSM'_3"ISCRLEHS#VZ\N (AGBVEMDW
M'SGK&1>QS]1E3*7273:Y(O$'#Z"!/E63:@1#* J1=HFWH]SC8YB,RV?4B19R
M/4]OU!;MZ%8';^@LZZ:#F;<+W9OQ@/& ,)[\]_\]IPY >VF[JU[X[^.CG]EA
M//^JTP ("TD0K>;;YX0-@']+P3N[,<)6.HXM*1^M$<KXJMNW>7:559KLR1XH
MT&I__E?1ADJ7+X#R[K9IZ#+6W-WWH7$T0E&\MYGP=Y'>XP:CIR2(V=R,.S.[
ML^5LP3--)9DBB09F*;LDMI.[.]$:1!%>TDDPLKDDDU%8Y2G)?G>_Y;J+=.&V
MJ2K<3BUWL=$+.POM7LANNL0889#J]XW,G9:9CI37HE;G?/2(2FS1.]7[Y&V6
M8?ZZ7;R0[:-KJ"3LN?OCB]_C]?!=K[V)LV.Y". CJ]H,JU("(YM]Z?*2US>1
M/NG@<_CF2")'M ?Y"^D3$WBRJIQIV0T^UW<#R1OA'J _?:&?.8D-#$HJ9.ML
MRN#N1B)&!H0/_:J*#.?=( U;DSL>&\E4I5SA;1"__<F!!T7EBN2YQ3>_@V_I
M.>5"/Z#9$FZT'BM PYY3C#B^!RW<HL%,DI /SRERADZ\EF-25P B'T6JU'J+
MT:\,Q><9EK%I3/=TI)=5H5W;#<<$B&<X*D*_,1KFMX+S#ZHZ8Y5[UD9UTPW&
M2[4JFY2->2<*#8ZUX\P5:/6D0MX5(G82W^IM.[4Y/3M<3OJF+;ZUJ%)CT@O;
MC@TT2]4IMEDI==*H4?4UL7A;_06X]W9>FA<+D*333'I6T!2_H?HL;9WGV)5C
MKQ,;>7VG7_F'WB8N@S!<0W)PC(LML.-9/3R@)???I*G5F-7H>WC 7Y@V8<LT
M"%/D>?T$]YA@M7&%>,"76!A:^V+YNB '6Y $^\N+:P:/P!B05H<D7H++"^5E
M=DF&$9Z)0B4ASY[H*5Y\GE$<G@16'278F7G]T!\7Z&>H+SV=N[79E[$^[R+-
M2F-0]74FL;<K-!(N?T]3)0BHX!!=!;.!S3!HH'7#;98/J4W!-G"CA]^>%KPO
M]OIIKL0=B5F*PH(_B4*]K[@QX$[I^/J@^!IFBK%^4P4$Z=]*M@+S;0RU7/%R
MN8EU*-JBTY0UZ/UHHVJAT8L<,H89IN^^MZ5NE.JH&=IOUJE*Y6F%947E#28.
MP4\W77<R27%=0)IAP=7ZL4,GL3\LCD;>KSH(I\%+D'L[=0LG!'4>!M+8NMA=
M0A//F<\3U@VW4>]+6-^+?&G]M=>D,1J#7BA$YW09]@O0+8952436\K%N/(<=
MINFQC8A&#.Z93*U5LL:!JS5U \I=!FW-M^N]2(TC3WT)@U38J*^NBJRNK(S3
MKNR)1ZPR2[&0%"=6N6QV2?4VYL^R<#O/E0NEQD2MM)N+J&-9A.;8FG :M9^"
MR\* R$:A]IF[A>:N=<HY\;XW+Q@5E)!\QQ=S(W#NNNOBIAFUSH"\R5A5D )R
M[!E<AU+;6'WD]J4E6GNK&&3'E_'-(E+_$C>M.*,_C?(,@T-I5AQ 1J.+#N-I
M62U#E$U,&N5,Q+MF.01SKA,<V2AA46I702+@N$IYQT6S(<>'F@"*2!$(6&.R
M2NZ)>%B79D-E9)2!P*;M'^ 2LUNQM-Z>^WI*;@7.MFJ 8;1_"RBH5 '51D,X
M[KPK,C:/7V-?$/.CNZ+'^ E<2\ A:H@>5Y?JXATZ!N?K/ES"D8R0-6=:7,\3
MA.B^I]8(AUOYV+.2A$$#ATW;-O9W@0/FI$7IZAX1SY.[E]$P@WBGYHR" MQ8
M\Q.VAY@:/W(7[^]VY6#K6BF6SW-X .;X'D8OEC)>!A$UN&>03+@*L7YVD-3<
MM+6UR[2IL*%[NCIF>I_@97B A1D-V1#)SB5K+)5X[YJQ8LIFW_?W.*)X/&!1
MYXC+Z/>8XTE=XZY,8>F33MEN3IZIDVY1S=(]ZWSW]T(:Q"8Z54.:V%]08"I#
MQ[[":HO:*Y[#5U$=7W2OITFN(;T,>:J^?JZ%QJ+GGO?GU>>8GKCLP6@T*1,&
M=%5<750FA>&:NL6\,;IJ<[$D"PLO'UM\.@5$]R+TC--#V-1^#V&%;U04GF[J
M9*D7-ZYZ4!?RV*8T5MAKE>GV$K^;M] "I8NH!1L.G]Z%N^$!"/WY]MF<Q/G>
M"O8/E! VJ0=>Y"V^S#[]%^N+; /&FEFZ@8YQ81<@G-+V64P"'(;$$1T V;$E
MLN8_VZLOFQ+*X)71PI;/^S )JWC @])9^*S(6Z^0:E0'0NO,SG&Z:XT6)GUQ
M(%Z5=,.NC!96SW(YNE93R7?U(W]^F],2QC^9Q3I*<[OO*:B>()_D[JZBG74C
MU63W8>U[C9[HAHY,ZAR(WRN"2SJCF.@=@-9&7\VM(Y=>3]Y%1(B7,PW5EHW@
M :^C)G;P (7RT;V#)U75QY8-M2E?!W5!0@M"C<\ /3>)ORQ4QJ5[K'.[1M8G
M?]N4\/B D>_P7"!!TR56Y<<S)):HA#+PM@3DWMMZ^;C,Z[RK/K,==@\(+[I0
ME8K\H+2D]2M$Y+.P\H[RVGDIG]DWEP%W*P>!S>G\5".OM6-J!\WGC$^/K<+6
M+-_[)ZAW_0'-.!O.39O(GE6 9;H[J<N^"31\-IG;]+&(.:_K?%H[\?;,3X;Y
MEQ[A3="7M4D*DD5_#^/4GHA2N]U<0-O'=&\NL 7*GLR!:HN)2-T2<P IUN(!
M7Y-5'2AC[F06R=O1)CJ+1E>ZM\B*'/GK#'$<3$J4.U[N\ P37J)!>89[#,M-
MO<K.M.=D+%QC9S'=@*,^A8C*<O,JY8>45-!Q&U0$]9S!:\>R)W8EJXT_NJMO
MO2HK>L&51K6RAI+V6;+<TE;5!EEH.H8UDZ'=S[] E6U*[18,ZJNYR7BX&*EU
MXI=.'J9F=OE+(C'!*\JGZ0H?HKSI+/27M.[1@0&6<1>7X].R)!01VTZP0F^:
MGD*-_%]15$+R7>O7:P?L3X4I4X"=1688.<2LP8%5'7;,8^>"9,))M'/8?8>T
MVW6KCB!$Q5;51F&49Q+K)5E[ETX6Z86E^;X&.:DBU4I3TC59Q(_K54&D"GZY
M,\9-K;."4\\$31*%^V>YGB*NISC/.N6P]CS0QT_0BDEY7(L'8O?(.ER&E[Y^
MOT'V3(/CNZ*O'E^.ID%>$_*^CE2QB,6*6<>^V<I7GX\^$?1GZ&D^!R-W#M]J
M":$>8&#8"E_^R/4C^BQ8U@_OA8W!2P/Z5\,7'S-TF4V%7<2I7P[YCS=F,(U:
MH!5&3?5+\]/="P3ZWR(BPZUC1O@#T])C1=[?=V%('<F3QJ1()["5]1Z.7I>X
M]=)!@-Y-L"76VZ7]$YXD<HWP6\._+6/%>7O!K^YN02:A0E<:F$KYH(?-1@[V
M7(Q4+GE6>$!S$GPL '+S!2HR:?JDP>A*![(Y7CJRQO"^E8F\>!T%VT[<.[T(
M>N_MD3H16#@?SECB^#'B(]Q1GS-L )%%KB'WAW'92"H[KMV<0>SI4<WHJ)F\
MBF/I;2^52;E8IYFSTYQV4Z8OG+CC^4JJOO<X]Q:OH=6N<%D'LID!CWJ_<-3$
MQ,-.1A\1RW*VZ:XJ[TGTN\3RTE0+/G"B^X/FP^["5;XQW?B@O-P\NE61=+:G
M!+EQ=@7BI/.9+(9R8',:55%FX*91-]4'O#MD#=$(&7OJWCT66V.*6)Y.P+ZI
M%F)GM52%+J='T^0!(U3!6$!!-Z+.:NX2A&/IZ\(#3NZB%G$WC6'HRQXTPWXQ
MFL.XPM?76W2 MN:.@_381?+)O^+*8.#I$J**8 QMEA\?%.:,)KHG#TC6'UWU
M'#H1]'VA8UE![,:&C;"JZ*#)?&B/M44/Y[E8P1(>P+3K?V/R\?@)A:*#R-L(
M.AJ%P 0YG?@ )B]6:O#-D?+4[^YEA0K*+E59:YTN7^-7]B9-"X:_X^9!U!]J
M[E5G+E]D,AZ;3CAT+8:^P/+U KF@IFAP1^0K&3CU#IN/?.;C";I[?RA]]C47
MY]:N)ID4/LF3O8JHR[J5LJ77CZ[]UX+"*!J2D84*/ON*9O\#H5 <?5TQ<I#3
MG&#U?>>>TAK=+8H&3E.IP]1UX"/,\5M,RJJ ?'M]KOA?,S-O?TL/^S[J:>;.
MYTS))R_',ER-QZ7L?)F=?_Q*:KQ,.^Z8+%24M%.K!6O7"^[LG0M2^D\N"*&Z
M C\VBD'RMUST9PS)1&-MGPC'D]5PAKX8E$.2'E%10";9Z EJM-20T\7$KL;9
M]'7<#<T,"<JLSP]COHL$ *M^*%@PBR[[ZT .=(P='R.Y$3^@/[QANG*!*\'[
M"BOP<%-Z!V*]T1-?B'@*MZ 5>?&3]<$[AKJ,FR.-Q<KCAX@'*HMO1QTWRIMK
M'-#&1G5@^9V[:SHJO(]4:"?YZ6+$T.YH,3K#44?5PL-+P?TZ-(-J>=2"UXF?
MP9C%/D-U%*<3/.FQX+8QN!TY0]P)HW]$7S_X\_OVSV^XH7(-WALM:_1,7 0N
M^!+%-["M6Q'%',$N^J',76= J*K0ES?!<G4&#\AT_8D2C(#[LWM5JJ,IT^D:
M)ZN?68;)Y%E'Q.;YO\]E^WKRN $6;H: A?H+VXJGJE=9Y!G.&AF'YT+N6H'Y
MZ9)N(2*$OLDU\?7^*DK@45%QL(^R]^H]^=5'15)%XMB0GM2:&99:0W!9]U5+
MMR;./"5<C,0*5=<\U4IZVY<-U%T"D:5FF"9TC3%FV#U_#N*1ZE<\Q=%%/;H:
M0T3^4J:F >;FUN%]2@?L9<6-S 1TZFFS,:D= =.IE# V5R\QH\MJA97#I[<R
MW_28%RR"-UI+U)5-Y06EEI6(.6-2#P^0CDXA$M3QJA0WID/P  .ZDKQ@[.E3
M]CPH6L%*5NYILYV"\4Y>ZNIOE/:VKKU<V4>ORD[FR:BJ0G<'7\T?[\8XB=Z,
MWFN-"OL)H'7Q E"JN9N1 F6\BI?VDE2S!IS$TH>I!")/K)4,.@&?B&Z)2RY%
M1-6U=&4,Z_$ZQWLS_UTO""U5@==\G<GTW?$9ZA"<L>C(9) %UHO#G?)FID@2
M7:J?2\?VI;D<=-5M&S$'[_NM/E#](P%D2%+[.ZE1._I#S>X^2>,PRVL+3G8)
MEM\^JTS[I@\4S$]]=%63+.!7[UB&GE[I>?.!Q*9TX/H8R)6ZU^RR8ZQH*1"B
M!E:33RYUYTE5");]'F2@3_5Q=:8QR^>=AN%(+H>FH<HF!;G:1WYL'HDDDF/J
MVNI*U^NJ,]; >])CQJH*L>U\9B+^)$K*A%'XD"LEV9(JR4.N$,CM/]K,A:E:
M]OA;5<HMK^HDQ:U<^C[%*G12DM=0]^;#B@QI(3@[K2Y;9YJ#[9Y'GTCGV+MW
M13.)YSL>2#*<H%?T,F6IW-D7Y_OA"23.$%<VC/5-&4_RP._*?VZQ:7Q0<,<#
M"*; 'LX(54>5+@97\:D]GM2HY[&ZHFL,VR\?[Q+DL-C0'&ET#'O HV*\;V^C
MP1Z6I["\K/E+9GO49'!S.;,SFN[Z26T"@D*^KRJE9L#B4X 2UT<++@WYT82'
M*"+)E2;AW;,53*#SQV&PU<^9.D8:!<A3YP,)%448Z<5.6,IP@80W^)V*5(8$
M%97-?YH%O&MOYAF'6I0:V\^,G]1'97URY3QFT_@)^ 38NP,HJ><II4_E&(S/
M$U_G]A@,;F$3;\:XKNR#VGT^ZAXO3%4BG.?Y1&U<A%F#K.08"?'C%,Z.\ SU
M%_K?^)G]_XF?IZ?QA9U:&Q!MM]%.O0)%?2^U7ZKN<^>E#&>]Z.!@418U]C?#
MLE)6%G: @%M1,]#L+Y^]D]?.>P8U#-&EH [FLI05_<:73KZ\D'MSV!*3N"3A
M@SG]S3)UUXPZJ9(B7@[U>TC>N?JI/76.!)T?T 9O'[;UE7]=GSK\)5'SN*#B
M+5.6VM%#CJ,ULTJ-6D_R@L'E+X# J2^F0MF[J<'?3E7]P*J-/S2:O]0H.#NN
M/] 8@ST[51K19'8.0+PM9YQ3Y+7/LZOAJMSQ(\KUGS6C/MFE#?!".*@K,$HP
M>!!@RG6]._Q2CQ@MN(J, /+Q!!N.Z8B>/DK2J-3@)8]:LTP$'=)$3<'E# T'
MM H8W"*+-I)G3K )AA7.^["A6DT%.G RW6XF&=)NB/[Z"6KX+Z+!3_BL:\AN
M].K54Y,<_CLZ*MT_GRDZ1^5>3L8,O^,IY%-^( E5^\CY7V/<M1,G- 9\Z 77
M1-\I7,?67VH(*P2I9"_=UGFK+ D ""NOEEH:SJM9N=)U-%:\="8+Y4A\PKO5
MLO:<X_O+S<?9V?D3NHK":0424C(UI==#7G]!#NPAJ<\R'R#P@&G#OH<MM6,"
M/_J!*4+U-[?3;":?U,%#08B"2!R/76G^CL0G_>UH7/606DA[['%,8VP_N-IY
MW]1 P;+PCTRNCYC(&W<5_U[WW-4=NKV,F]AB6;\EN2<"XGS%)A\&Z<A([8=%
M2^\3@J>D!%S.S=C2X34OG9:=EP-^QDYG1O+,A\;9'USMA3QKP@2MS L;T=56
M##^.IXLY^67 :?4P0*)!R+1)._#0]*D"G5!85+=7A G4.+YXH*=L68%6AS6X
M&/H4FRNKAH*UU3"+1UKDSLT,N4U&G/_M/7@00_U95X&QE7)^X-."%#KRL)V*
MWA[X<.Q# ,OLYGWE!T45G7??(GD^:+R0CM/7UOZ5>Q$[MEL8 =>-L%5W:)5Y
MUJ6 .N_2PP,HH.8%F+@WWQ9\=P5%^J+V#;)E5FT'7U5D1/F>=KB;T2-MJ:BO
MK<I']\6*Y80G9)B8]0>^:CWB^DPLL^8HN1]V+,VSKG9L]/;;LR9IX;9.AU>&
M5</[.*4#W/UKBXEFBAW/R1F!TJ"QR>\AG$:8^3$>AVD6$^\!/4PIVD@/\V>%
MS\_&H*:BNCY@_.,XO^8P*5]#@+P(Z_J0?VMM+\^ZWD9UGI\C\O=EC<S:PCS5
M"XP->K(##R 97QX6'"_A=#@LF"_X0>3T5I@T\UQI4&K YT[6E2/T95.5EWGU
M,#_A_&HX01ZYG[.L60V-Z0V=Z#JF&36 U5B'6((+]@K_-3ZX\!"$I*[C :%B
MD%(-[8;$J[?U,&%(Z _^S6NAS\0O #>:HEOQ@*K#""CWLAJH[<S',9@K/:%B
MIHL3]<:2]PX1I\H=_\]ZP9IJ':J*$3P60HQVO7E,B(7#6KWL:P',Q<KB5^<!
MIQSC-F FGQ.$9:O_^S<<"A!0L*7H.YFNJ9;'96VAV&0L.ZXB[!R[$VV%'MJW
M6CUDW;YO!Y?+B(0\GY4XT]9@Z2XH2K*QOHD=$3DIE-6\TL-4=IJ2-: Z"_-L
M]>@9Q'<=C[ 93A+KG=-$Q\Z-U(RL%AQY7E5TP$&YJ&WKY&DI*1VG%(-+#^ 4
M]BMR[26:ZM_]X+-8O7MHO;-OZ.A66.3"L_(1Q_>-H^2_*Z9V[HXHL# ^YLQG
M,G =?"&YEF:3NM)\"S<"0^5>@WYM9Z*B\("/V++=?:#3;&-DYD.3VJ-9.>F-
MQO.5I"CDLA7F7!<M. 6K;%X8KIF&+DI83XT#S\8'/39_[NH7.8PYJLIO\5G_
M+4AXF_/MU[A^DX-[0=/$A&].*2;F2@VSN&*=.&.U/U"=DM\M)%:6Q/*ZD@K,
MW]_N:T,L&]CAK4"K>UW$VWUA.)4Z57BE<N3B;U.% 9TU8H*6'PC+T-=63#X.
MN1UYJF^H3/>BA65XK&8\%'A*%06S/V3#["HGJ<5N#"E5IJB\J3<68%$J*$JT
MMKY)N QH4S'U7V?.37ON?:)=TOX]$TF"O_2J,!)G#>CSP!,OMT7A-H, .A*:
MG>\-W6$ (D^.0L=T(^Z%1JTP1UZCM&2H"90S[9=:1W,7PIZ]JB:Z2O"^72IB
MU. NXMR.8]0B*'9\*N>9,?'"%+G2[=]W[]0-A2-9JPXCV:=!LQZI[O SI_0U
M@O+O>NQX+.XXWS0+VND4BLIOW E3N:>^_4!,A-7$5B5=);+0R1\Y'OT2HX?N
MZV G7JLWN0_Q+CE0LOOH9"'\RO@],8!:WB+J;O=N&CD$^A:;)ZN'MGAIPJ);
M,[+_\76QD!'C V6K02E/IW<CC=EA4A:^LUH6T1V*T>/CX)[9K/V9X'WG50KP
M'T\@8YS:WXE6/SG$1,S['P/W$-;"+X^=&XC+A#+&5WYK<)4,#Y!'T@[_=OOG
M]UK6J,&O*, *8G0/(M",]9@"!D-'W:ES#0K<-(BZ$53092>R73^9*!YZRN=I
MI[2?"'Z#U0!6!:)ISI+17>VEXFKBET>+ZJ-6C*FC!-2MB%;\8!!R-DCU"=)K
M6W+!X3NUG6$76:@QK8)(\WL5QE,L6SG;2'=E[-76DD$WBB"CD)!/'>P$\7+7
M!5A_CX@[OL?#M/F;KH8 9@/_V]>H  ]8/3VNHF,;E(O^P-0)3-/F,,A%R)UK
M8ZMPC^SI*Q3(I<73#AI>3U27F<AUI7"08U_"J2:JB@DRQSY).K' 4^P4VW>8
MN.+!?^#CXI\,\ "0YOT[W)B^D*X/SAXZ.U)&=5-0:4SY"BPH:<08XZLIWB/$
MYE<2QOGMH]M< ;+VSSE<^\?9$OKD.^-$V\O0\F@Q :OYTPTMD,K%01BKA8"A
M:%:*Q?._9V[VB ;C&;1G1%4F&R1VY_+T.C7R^O/3V#> (FG>7RTZK"@ :Z;A
M2?0W A"QA^$8,%J+;9>ZF3ES!B\.'_=XDY<^>M81I=*;4W@"?Y#](\R^OS-*
MY-ZKXE)U!^6#RU3FC7*)D*IY5=TZ_9&5RPW50OJ'K^YX\+\*4.[48'K2%/X*
M6]9HL8P'W)WV\EA4^[O0.S+P,5;Y?7*WYCO;_QBL\GU3-@0B[=U<$6._(K-6
M.A-B'9G"534VX7G/V*@79?QJ16D],JSBN13YW35JW\DZ6U"U4[L ?:N,'1Y0
M<?KM933";%8BV4_8PHUX5/)R;?+KL(JFUIP^U)KC[FR6!,N9''@%O/]HU2QT
MQM5N)G*.7MH"#RBI',T1XFQ<<^2LO+>?YJN7L27=OO!@4G1?=]K"-YPE^2#'
MX"6/ >-S<B)BI@<A1;1:R@+WZ,IUBL?.JJSG&BHG@4_\1TUY,*7_I#"$XO'"
M<+YR^+0\;T^=ZY?$F&]2)V6>RZ!. 9NE@P(_O^R9J7E5[[O?%)"1\Z^^#2I.
MFKH:"]"Z%.M/Z%^_^4_3C(FAPNEK74QI,?0]FJZYLF1VVLCDI7UU6"+/5A#=
M_)]'*5$NFTASHT4R/,#VD.&:>V3QS<C"X)7:,TM5$\4G,8\MSL/HK,SC>I@Z
MO;NX@28*K$43M$*UR7I>(0.%S079U_J8_150A*9^1VF'^2UQQR%:C^<5%/T
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M69;^T76^DO/_\ =T!*P9\5='=&^W(3#^IW+_C?^K0#XN1[X3ZY56_00@5I"
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MH=<0A'>M,R34)K%]*_B[S9>!;9N ?]A ^1#_,>F<(0&$M6T%BV_R3W%AK<:
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M&-[Q\5J9N%3@7&K9'KD%2)'74M44QRZ*23Y) X^JDR'AIBZVI#IR%K*8^PA
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M: &ZPY'*O%*[NRG%6C!$'%T<T((HN9^T=$2]&%OE< '!1**#SN_&.*Z6'QJ
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M?W8C%E[;PA@VWHL&]M^.=%!1PDI3RWTI]\KKGD)G7L;5N6K.[V9D.HS9T P
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M Z5/.9)&N3KT&H\)1ME61=[G?:DEIB29;:G#CSRXC(A.+E/>$7S*LCL8,9D
M;!+@JK#W&=FHK]>@9IUNW$U9?H+%R*=!:L/G+[Z?/;F8'0/=O2M*<E"-D2SF
MS5$+V;4<<& \EPX*APNJ]>H1_0.T)[0W/MS=CXTZ4W;'0F;SH<W:O5U,?0G+
M9 %E25,P:#R@"\U)8X!+EI-2\2ZX;]7O\:N] ]\8]D]TVE2!Q@L7NZO%XTJ:
M1\?*QH#]A<$C-'\1;#2+*#RTHJX"-9OW-4HR=/P8]:%1ZH#G!:[HSYI,$F+L
MK0_VL#3=*9M*H@E+XPW(CE#_TL; ,: @%S%+Q^"!D(I4T8YF"H?ZM_7QU%KI
M73<HDF"V*?Q --Y@I+KEGJ>AC6W7E(ZXNS]&D;(\ON:@]HGYKM7#XT<#G+]@
M"KJ1ZD(42+^Z*&47]=72-_"ND>8S7Q_Y*3Z+$9EL(0A_4IUQ)]<\F!1BEZS\
M5*U(VB#F 6WM#C=W<V+#/%G7BN+M=[/>3RV8X"TMCR_(VT,0:*UPW,7@/3WT
M#HJH/1JPU_+K'J)D-_>(^>UQ:O*>S/V/^,GEWF:7$35K*]!K<"62.1;Q.("Y
M$)\:)/_D7B[SP VI@IF-1'+'XLC)SL_Y8M1CD<J^!^,_K1E0.#F:4P30U/A[
MD2)C5XK"C7N6I?>\O]T;%'MFX\"EV ^0.IM[@A_A&0X'AT)HG5[1<#T@T5?>
M=%!C-4?,[4HI%^&QSU9C:[MKFJ)M929#GO(RD@)C927'*<!LM;N<)(I#[>M\
M?PZ62S)]$]<1VWVN,DKU5G/>]K+.D<:]ZP/W"H0A8"=)DNB/S^Y1X\XX^<)%
M=+.4LV56-SS[5.1JBX_-O KKRQUZY_5;USGC[[MDXTTH!\(-2_!*C<AP&@M!
MN,$SY>2SI9A#Y3<++A%[/V?6Y?F(WWNK+?32H=A_+BN@!\/V#19J N%8 G:\
M>CA!KU6,SH']AQ#2'1*/(_-J[VH;:M<R[MYOY4#X2MQ%,B"?(\4:[/MJ_#PJ
M%-4!*N^7%WS\</F.#&O8_'SGP\@QK_T1*0S.M&YTOG0=L,6I,/*'UBOR)HVN
M7;06J,Z_(YZ\CSIS]MW;9\O7SYV1BY)XS5\_/G_\=/NU&8Y R&HB[ ET&8J8
M?_L^[Q/""1J** 9.KSB.X!1.0BZR+I65=&?\>'E4G635^4VWV?W*UTX:'="!
M)0D:(7B/5D?@2Q>WOVC.1.L9[6[2/:-K$=>P]39>STD-_^+(&O?UDE=/3F,U
M9>>JW*'_PY'^:JM\T;*Z(^;:-'*D9&*PF<8<ZN?B,M6.$FSF&+-6^;;>?F+H
MKE3H@0-M.Y-S^#7W@,XR7EI4/]V2#VR73=5%>.W.E=3>;19Z.@,*$'L(O>P-
M(8)(EOB5*500Q0^K.%BIG.T=L)^5Q]/KE$)QD^%%KQ<=H1F>]Q,2GK@WG8HP
M#ED2)+-3E*A9"F1AKX;.]U^>#^26%9,]PSV$#$Z<>Y8@I".87>M96Z.&.PVZ
MNCC3#E-%)EO1M)K0^&OCZC/;?S-XO%7H'0AC=4PR\\\M4A<ML8<M;MY"Q_]?
M[+UG5%/?NRX:Z56D2PU21*D"TA0(J#01:=*;HD@'Z4$"$9#>!!04E B"H#3I
M17IO@A0)'1) NB24L"3MYK?O_;#W'N?<?;[<>\X9Y_]A9HQDO&-ESG>^S_L^
MSUISS?GC69YM)#3;!K'A"KFR_LRK!GM*X"2#[+ A>47;[2K$2OF3,N8YW;$/
M;E7]1WT:408<MS)W:)1H0P1>N[&$\Y\A'8@9[0) R6IE(J;#?G+S%^QF83^G
M23XZ0%[VK=OYFM*+OOY3- \O> W"P)0@_P)<0OD$:.IM09-[J_O1NM4S\FLJ
M?^E%V%G,:L^_YQ%9R_\KI++@XT1Z^+G""Z$6N;3,BE@=[X7,%1H'G-0C6('
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M%+6RKT-$0))]#BJ4[6FN+>S,W]ME'>ZU#\TV$BN3,Q11?,\QVW\?EG]$8K3
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M2,.A77)B]9=R6P!'_^2N8[-A^T!&M,N#5%ZU\='.;T-=W.\?7]7M\PE8,/-
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MZR"#\IT!2EU-A?B<1^,"]ES-[#HP*2MDT+@\(0S>G_[O^]P0_^S_-XMG)$7
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MH5O_\W<2_B[29W.LP <N&*?;NJS'?UM,214DU M2Z_.+=:Z5^X[R$QY:.TB
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M!NE]9A_A[C'<SN'R\#+S]P;KIJ8T"=O+#PMT0JAE;KU0WP.5IR?R;R#CM(2
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M[7KT2$9IWO@*M7A_;7_<O?/W1U<#'?_!;CJ<K?W<UC?/? C6,CZN0NYB.7/
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M %RW?N8/+/6F4;V1%S3TSMB"F#9WP.CH,W49$PMML-D":1E"31*>!=QZ(N6
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MNN4.9[XKGSR@>'DJ56RH-_(_>XCZWW?W#],KOD*HN:/1J/4/ JD!M"1IM-F
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MEU:>.!U<19@SXFBT61/ !(XZT_?-@=;HWBM/]3.?=/,05F<4&+7&W0^!=Q\
M]SLZK43K5IS+IG@X0Q%X (MVAIHZ8:]K-HGL R63?/%7>XNXWVK$[=_S.R2,
MX$TU(MOP.4/A/^U0B1>A.UG<(Y2)1_VNS^(Y-?B.H16]K/ 56R3Y(C4Y90N^
M2<?-N;A;LA/#>IH?A@:SQQ9LD8Y,PQC]0(\J/,>],R?>T86'V!<9_]6&N_LS
M[=N:OL!K3E=OUTV/D@Z=%:1SKZIS)_J$$W;<-;[F2'=QWXA?SB YNCS!!SWI
MCA_\Q:G*G^0P2Q9=NAP"<G&_@=T^)K2Y)BF'M;F#9W;9+MLET&$:>] 9=K+
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M/ @,26J[7K^.H4; ,CIKFO@!H&WXOT&6!EUB *&IV&J9C]%&R L6I-43:TZ
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MV(U0X*(-8T>F8^K$BN.8#?;&=\EPE>5CSDW 75*?VT5..A=%/576JOQEQC.
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MR!/+-O-5IGQ&/U+ >/C<KKNDM("]<83]- [#5NHFSS/WN(!T6W\$U#JRCD7
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MAU($/T=4:>\-43G/5G]?']%ZK?X 'ZQQZ9\A8I,,%+J1-9Z1,R*7*C)8;;-
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M?;Y-9=N=X-+VUI,3:M&53U(3F-7A"8RC[0FYLB#[&7CW"G;;APH9Q47M  O
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M]=T5*^WC\Y 3>F?OFQ*D3^7F8MLVGZ(KIU$@1\&5;[]R22,R5$7!R>0[:UU
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M.*2BJVD2]95 ,!:7QN^Q+;WYF?9 Y7*_?]I!76^:KN=-D*:>S'-M]['GYY5
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MO4(MPK;U'3YCS8F]SL:L$?=A53AOL4X)8-1"CM8-A%]SV6/%A?SGIA,/M:S
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M>/:C)_B-E@UUS5R\+_KS5MI4:?%8).T8V^4!::X'TKOH?/,P_1=Z/*0PH*Z
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MWS\IJFFC*+1"FG9F=>'TQEO%[?QO7;[KU._6(8N?<=OJ0B/9+>\<KSC@L60
M>E'7U+1OYEU$1^X_]<+26&;^!1YC-UVU)$]W)JB4=I)"LQ26,A36$(I0LQE$
M@FVQ<G?'T,B(EZ3OL^>2WZS[A&)K!'O<AKPY,[/1BR0?O%#989I]3*.%Z.7
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MZZ20/;[HED;^Q]7Y?;*3#]G$O21SK]UQ>:$_9%2T]>]6<.P&A>PUU<%&-"1
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M!6B/(:+(YC.E$Q5!(1?[)*[![ZE</^?PW&,-0CQYZZD6?1'T@(^8LZ*72#<
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MDKL$,(T7^M>^@P%:F=J:=&ZE?2Y&?O>PI0K"5F,9H+F/&G])8"H',G<%2AQ
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MMSG=)D+?.U2/XC:OFT]X-0HC.^0=1U=@;/0Q7&/=MBK%)\ZWGEB8M:?&U<T
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M$;=%?T^Y(A6)4GE/EZ?R&]RUJCV0/\D\F"U')G$<'U+]93NG1PA++21?(S)
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M_<ENF<^>57I.VQ2EV1R$L*'CW)9*2?-]#%!CSM8F81.E[CZL!K7#1)T_T:-
MJKYFJ&YQ6&G>^\CGMH\8#MY.YW$FV7H0Q7 IH9A F"@\PR)[SAXLN*$;H]1_
M_8@ O[DT+==!4TEP7 +TL ^1STP>%(YH@<K,AZ/PM9^)$TZY$VY$&PIWS>I@
M5-/+YPGX ZN".P_8CJVD;S'=]1[26(LA;9(?-+41RS.+ZE*--)"TLK8XOK:@
MX@@9A2%I!D@DLS1)2N$X2-BTKK'R%;@_!RM"+D#3.M B<?J ,AZ6C#B6.-#F
M61X4_JZ?_$LMY(K3^/SCZ@H5\=L+;N:F#[G<R*/S \O1];&OJ":T'+3LE;:=
MS.;[[@)0]X_74:<DQW3E(02UGW]';!>S-"]!Y/=JF;2IEI9#]6"RU"X3!BA0
MP)T,!Q+O-<*A?1)G%W_=&\L93JKU83GQ[&YT=1?[:1Y#GZS[H=[DBNUM!D@I
M@N1'[\QC@'Y9>U+,07$1S+PE$9ODSC'+22A@VQ-CTS#O,M'\V<2I_TX>;JG_
MJDEFT HD$=94D8KQ0B4R@Q<- M8(]':-K)W:,"@!DC?"<3_@1PE'BF(:QPJ'
M6?I8BEI[V/ TYC8S:_.0^&=(EN:Z>%PC1WEK6O#M":/SRP*70D)7^U>-\]VJ
MRL+-C\9G)L_Q?KK^Y3FW_CFQ_>;__LNT$D85G>A"*P 2%"MXH@,QSE;N)2GG
M@G3(5[MW2E:]1+[47 O2N736B!=_?QO.S"\9TA[77J?SS,42#4U=1EHYD_A.
M7A +;>9^:SW$>0^L&>F5/P%?13?5WE^62 J-"\-G!9UOF-$!\R_!L!UG@J1O
M%*L'_Y#_^11<J:__6]/P.]?/G"T*Y6[@$@OM>2@=I-%=)X*+<QB/I&SK\D6U
M"LU;R#1E3GB$>2F8N U:LY9?'>UXOC)(YP.6D3S(KC-HU?4"]^R*Y3H9MU_B
MJ:A[E_)D8F5%8Y3TRV" V(.49=NY8O+/:>UV'#\$"^X^0(NW)]4H?2SZ?OX>
M4?=BW)#/C;-<E<70;><)9#T#M#50@1C"<(9TB-U^9U(?JS995%!>J1D;9#R9
MGMHGHAR8E*T#RD/<*&EBV4WY]^'7<B;.AB(!%^E!<$_X3.M 4]+\H8U;WSMF
M=,>PSQ3/OOJ).PXYV@B:'=*''@>@3# O3$M),3*LH']!:,]0[ZM:A%4%1-^;
M H1,%@PO9KSY';/R,S(3%.N5C0QEKF@Z,@PYUWZ%%+8E0\LG+ IZB%&YO,.J
M ]QN3$B5-R4OJ36Z-Q4O?'*1ABT'-P4-;7KJ,>.KM7[F7_?0+$\3VBNJ'ST?
M&>0=0&B7NGM9:GI)\>6DR)_<H^$^R(F>!T'KL/GK^)R!G&SQ%C>N;ERJ-/21
MT?%*EV'O954U,\WAR-K9KZ$%?_1E^%3LUMOUSW%^UB.[TU"1HW,Y^-I$O)K!
M&N6"]9E=SPU.Z.G%1<OYLOS0JYQWWFM:.MI9R3-!*HOB2)4ESG3:SGOW(<X!
M?<1A9Q(SAT;%=CH2=JP^EH@$16@4?)U?R3N[>CKCU%_;$PEYG$?CN=H0G?=L
M.U&I2,FW)-L>R-Q:GQQOQ@4KGXDXOW<;!_;S!D,B9H-C0W>&5C6'CLVB0[F^
M7B;EC&%/LJ4#BP05Z@,B;&!)LH4_-*H.O"$=?/ZJX'I-6:9WXHC[.!K*3#O-
MS2,>].%[JT5ZBJLOES/*BG0EY>/$MRK6)Q\XS"PU[UHP0U%]$].XLRU$<O<<
MVVF: ;Q7O.4JQ O7+FN<CCJR-2(.U?![LA3<D<+.(KU]S#?>Q)4Y[%GDX"+%
M##E#+F2 2G6D?S)1!L+* '5_!W8IOG"];<P<BICKMH&UF(^KTV.6.O^V3QE?
MYS[%A.!>MB>'9V8W'PXSJ[$C ]23B=QH0?Y\QP M-N\[;YVE\"-[Q)D#A3!%
M8"M5"4K,HZ70O:!>%+TY^A@#9/,3U[XM-SN/,WK@R!P@&-EEB_FQCKD=1A'(
MH:DWU-UBSJT8,6U0L35,#.T>Z/Z3$28);W&MKJ[3C''MDE8I8;*4MQFKEZI^
M^2R.+$#J_5^!^U"S=63T/\R[_5*VN<:]Q\3@?['WGE%-=5W;:!"D%^F=($50
MFB)%:D"ER8W8Z42E@X T"1 2I'<$% 2D257 2&^1T(L(2!$DU"0H'1)*V$@(
MA_L;XXSW>9[WC#/.-\8WQG?.&?>/^6?_V'/OO=:\KFNNO=:<)/4>-@.F"<KU
M/Z'OPB5FZ]1ZMCJ8WOWJ9U_.:.]$C2\0+4:$K-;!-4H1CR8UK*&<'F0+OHPM
M4.;@D?R88_FP\6R\GHY-%2+2XML)"(QQ.D:2PXZ+VD[9P[)MC  X+?I=*,5Z
MYYS_\F7"M$+<<8>"D0VZLV.;IMW1R)8-(J=$(+B0(,IY(B1:VJ[&M84W.7MP
MY4FC<?\)J,_C\_^".B7_RZKS_V/_[S"+/(H;,.!&].Z:S/1\OT:],*EZD=I3
MXMJB4&2N\VO@7H<R_<\I4-J6'HA[Y-;>)<.CLE4]L?-'(G!K$J1W)/PY++_W
MG W68\P].ZIRLN'C&9O83_97^/3/QT?-M +5>?M;O+LN%.X#JC%;WW'BGV7J
MNPNHXA5:K6[HSAG,Z011H'RT U/U^2#['9 ]SGM0ZX3UBYL_-[D*__KC^.BF
MD&&U-ZN/486X\81$A%=9V!6+HD<R'S &3Y$N'L@]_I03$$U&RL:F-S6<]'=#
MM[&:+?X=M95*\_^Z-'J<>ZI&OMM#*/36\JU1E*06.>XCK5-)78!& JQU_W*?
M!$4<4M(KOILZ/'DJ0I3 5%H%\#1VX?@LX>^.8>\'FZ#],^^K(;7UF#\L?2>@
ML$$C\HO&$Y ^[#1W$73]Q_,_GO_Q_(_G?SS_X_D?S_]X_L?S/Y[_[SW7EY1U
M^;$*>WTZ^ZUYF/@2MM=>XGUEMM: YY[ _X1^IXE97*!=@7#4O1A#:Y1T%+L-
M^2B,-C;27<RP4)+<G<N*@UC/_IVZH6B!<5)K'Q^21P45M<#D+\IM3:K[X[=N
M'740Y^448S8NWQ7[?> 7K20ZV9CY"VB8<4 86IO?^\4%_P85MP<16+D,N/3-
M<V&$7M268?]RKO?MEXK'SXU\>YK*;HA[I2]"4*'9>/#?"CA"E>'^QW5[F!@,
M)UIUT9S9"MEIBIJ#1?<93V[1*:OFI8ALT4\[V<KFOCSDEIE(#@L+53> 3?5A
M$G7EB/:-.&]ZN [Q!RJ6XH=WT+)1JU)YY=; 1RQ7GK4UCK<,L](S.'R;I_D(
MW %-SM-L ZHKX)> :MPFOQ$IM^%M]H_D0EQ.EO-X ,N-\TD-007&R4D=K!KK
M?8*@/_3_;5\U22D9*H#VP"T(P?QP!UU*K#\]YE4G-TLGA';MLRU5OBB/27QT
MRB7<&[;Z*7OSL'7O(Y0&H0GKZU[@U+Y/',0'QM1]X>C+9JL4>M5$/.Y.=VM)
M>E?\<9#I%1-/!5MEI5;$!DAG+?ZPD9"YZ9_/1M6!JP V!6[$=:%23 5VQB-0
MF<%UK]7M@/'E)3UND^KI&TA6Q\4EB[$'_S':3K R6V]6P/O!CTQS] _[KUC3
MJ.IQW.GGX+UWTZ=@J98S3&>%]E'\X46,ZT(RF'V)V!>/D*% B+WIQ!-0M_6;
M3V_E]Y*N!ZE^$=UZ)T6_ZJC/\_;IQT'!?AELRW8\5(1Z?@W)MX40H @1R2\K
M@ B3FH0[4_4H7MLAOIS2RN:=QQ*\RMK#-(\9##IT?$&Z,>_1?8M*W1Q"L.4N
M[#O(.;B@3(3VPV+[^C??GM>:. 07G&E42TO=[6[?6_H@H#U5]A][XWE__]UO
MKG=(:9&C2]2\)SC1/#1 @.^/5R;H@N=U$A ]KRJ2-C0E"G+ ANE(Q!\V])%K
MF\=.0$_GP 3[YO<& 9705:*I6%+952.1*;^_SD=+N\@_-*U9>K?HN#OV 29#
MF.K99J!8$ETB=%5A%ITM_O9JIE&C]6 F^Z'+#<W12JI5G^[='>09%F6R3?1[
M%\91MO*?JQTHI>/"-C6E]H4S71^PJUQ >G=PR8;F[9A"??&D[6VG:\8'(IMW
M:*^J77MXH0D5 ^&D:J]".55"&?!E86C(A;@J TE]%$PL).>M__2;0$84W\.O
M6R),_$O]O4$%'(6NJ'35$:PI02:I'BJT#F%$L^%R ]OMV=IRS)IS;#%YPL?N
M(<_9OD[+N]^]GO9 )8O52/"H:"4E"L*E@DE88*-H$70$C+.]&EU$E^Y^ Z7I
M=/U.:K_&6O5&=_$[@\6_GT&8FJMN<'AQ;6Y<!;0F1X F001.0.Z0EU2&'Q2[
M3]9P 4V#'+KP>99<JZVMI1<S/)P7VH4LI$#*],&O:%2G/?)%=2]/KT+8*:)E
M,)GKS4 ?WD[9[/X]TP_+,3='GURG<;.E3TVVXWZ:%NBU1N]*NQHOUZ%+"_<G
M9<;I2L**<"G=)R .MV!P\IZ6<8!*\_\9')4/'6/[Z>(?1D\^$NT@HT+^(QSE
M.O_'NNR\(A&:@.8G'N$:(DK6\R D*-:E,308AQO?J/+LS"I]VZO>J%AP:7=
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M-9OY=6U5>PA]M-/ZS9NZ@W%)++VUX9W5DGQEG[Z6.-CUYZ ;S Z;)$^::-_
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M7XC<80C]GUR!_O^6\>YF4GB4.BVH\L>I\-#C-WX^;A]6'U54Z"O450FGG(_
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MAOJ[;/JE0=UT_'82]HRMR85\+S)K:K^O>F6F2:LHC:1@GRV'OLG?5?A/0.G
M\7O(_,0):&^MCN: MV^SFGAKI%=7@5B_G%*Y=^S=F6JJ6,NV7]^#?C$H\H'[
MI7QJ[)*W\H,[Y=\L&T&[]RG@XQHJ*SR8Q)/-\1(=XE#I<4LPTSQ-<//":UGI
M1%-M5Z=VNMR<SS0R\91Y $+TZ%P01BY6+/#4H03<7JU;J^64NV,+Q[TL_/FY
MI+[&UBB19)6WL#!I/?'$>,S17?@UXG([!KADU-ZD?;;8"K@W^*CE^Z?EVK%"
M2W$.M1*%ND+).[PWNL/.%;";5X%"38]NN[<8H#8+B7G8;7(RB:$KYQ!2 \^/
MT43DE@^YH%SNOE;*D5>69UI^US[_])W\XP:+,VUA0-;1/;@2H$%8X(!=[;6_
ME'*=!([51FVL6U5NB4ISF?XZ[W;OJH@#3#S3B5;PFLA4.[AQBE*B3O8] 37[
MG8#,,WFS3D!G;8E#94F09R/ANF(81?D #U,ME@C!KB#?-<6DB)^X)%#H%"YE
M9G"1/Q$=R!%1AXS+?OC[BW;GO "E.8VI6(9&LLFU6]%$'/3)UURP>!+B;1ZF
MR9'B2/0\ 75O2BS8QWO7?BVYH#9J+.QFU,SXY!ZC^*_>*\-RBV! ;J$="H(+
M?Z=RVP/\G=G0R)+4[<IE:G^#)5OG^_;1NA)#NXF,PY\96LDF!%%U"H\#V0IP
M(2+)<D2U$AR4V0UKV%RVIJ8VYL%'O#0W7YPQEJ5]J+N7\TZ.TKWXB9]6(@QB
MHBMW*I8S.\"T<T!7;TLC63U&04PE>\]FT*>N'\>]%">:;!6V&%@&NXH?B=(5
MIZ@VD*@O/QYC.BW4QN8-RD/S+ ]N"#[>_-7"1,^L?M;7IQT5B73;O+=N?3I)
M=8!'.V3GII;T&\25($>IVE3IEJ7TB5<:,A]0#L=)D%_"ND(GH&J7TW@?S52A
MV5A@0KIS1$-%M>50L/1VZ@7JS*B_LF&A'YFE BG)F<4Q*&\\M!..N(/4Q#TY
MO7L\8KA1C#.]>Y"DUJ/R=BM[1/GG7-_SG4B+\PI83KDP4=^O489ZPS!4RBGT
MIV%V/""B)Z#U8LR?ZS^&3\%5'.D"B4'RPI5(+-UY*L32+/S@8$B3_XQK0,*#
MYNCYJX*!CD9G;U3+[1+$E>@<EVCW^, SIHN))R!6,)X+;C@&P7&;]%38<XN_
MOFWQ/&;C%WS[JO=0K?,&*X'W.YSWN+A-"#'*I]Z(Y-"V<<'?K+FD6)@D%0Y3
M=W&#.3U,U>_HXNWHZ,!CY#&+6?FUF)?PT*/;\+O5I-M1;G@[R<XXE6!$5L5-
M187&G(Q8$RGO-[[ED6SM*3DZ>I(-QZ^TU9\0451F#$FN,T\PS T!M@F]15<=
MF2IT\Z^KC.TC<X]Z&1Z?!2&J+=Y07(\_Z/(B1LP\P-U@(4M8\.]?VOW/IAV;
MFOT'A+LO5PPTBB?-^+PRA*$>H$:0V+L89YVKY,:4NY-H23PT 2/@&'4/2;_R
M H.=_ 8/2STD_@6OGQ%@J[[-([KQ+EQ/MPI0.K*"2QT7>BO*4\$ =A"*:4P<
MDDYYHUK?GWB.);;TIF_!*Q::EZEK<GX$_KZ1F 60OVP ,E;L8@UQ[O6W>S0^
M+29EDH*<70)N4KV&+S[T&GKL). \/[J>@(B/4IB$.6*\B?$L68D5N( T<<_1
MO0'E%UT[AE*_$CW:Y^(W=>4 WW%RQM\EXV=@X-Y5\@*SZP>1RZN![!U.\:):
MFPC[J_U!;ZMI!:^[TFXFI "RC1NKGCAC;<,%;OF%6]G+&V%=3X*D5B^,M6NS
M,&5<UGMVM9S!#93&%LS1:XZ%XAHW3D"X8[ -Z2#V!/39_XN]^:6OR,^SLX=5
MM0BU+N$:"IK2;O';B,+'00XB,G1:445A,1WVPN/PB[J5WO+;S^IR'!L:7]\\
M[[K$*<Y<J?Y9BB-'4CLY5(G*(GT"NG#ZAD@J9H2:Q@PZ9B7E]^0SPW4!#S_"
M,?+A$4-D5=5[=.:=(^T:S^CKA<*#-Y5%,NW/++FDF@'W28&=4&$TAQN!XZS[
MPHRN2&L0E_"XMT(;0?@U,NV!H8"39"JV[<5QS0GH-+RD_PXOL]/PROBQXQ5!
MV+3!G8 HG,_,BFY/9EJ7%OF4Z'1[QA@[3SARO:3NT)L798..$AZ=?M#H4_8%
M)PAW94)/H7Q3.OVK2[AP7-7#&B-U$\%(=LWM=A1RK-Y#--"L8<)_9C#4R+PE
MR2E\:_)AQL4[B=%&]VZ<T3SG XU=8-IGS"%[1'1^IG9K'B1_4M42- 9>GJW_
MEJG.-=#JV<VM$,'S0/K%>Y-&IF%?D[WMR#9UH/4(@NQ0IEYVRR9'X<T9UX)?
M%+'E)?Z9S_5QDOY2M9=J="6R/Z'=^6UXV:6=Y61EFH.R%(CW]O01KBRNA$C%
MD*Z:)3R,OL'S?=IFUKY2D5W0;C%I5$",\2ECQ\@-^ZY%2*R]$%"(RX&> TQM
MJTGL<7ZIO.3\RQG*1JS%R8D<9V\SZAC -4ZY\]=Q$I43B"&;$[?CT.:+5?P]
MV.6XGF\'@=GU'VWK+M4.<!DQ/89750@,_*6&G]WKRT*TSR/;H8"L>0\FPOKL
M["X@I@\C6?7_UF>YOO)=0P;(T!"26.CI#68%A1X11\CO 0=21-^\!-$B$FYV
MC,)[<P@:ECF06<H1([\&ES C4K>28JX=6BZ7$[)53T#8"%QF%%79+9\Y ,(=
MFM.'?96(704_;D%>A<GG?[%,O''>W$)4;E$)N)!"R>_;Y*22RTY 90_+*"$G
MH-<#\-,[? I&4N.RPR!ZNE<1XQ"6$Y!+DR<4SY'X#*XA/989/JDO-:5<?DWQ
M<W?5>=M$KYE$4O80</7(#BY^7%!_T7\!!.#[["8(2:4>]/$>-A$"XE<92V\Z
M@U+3:'H-$*'4>2BCKA2,@3R42; $H/P])R#0D*=GHQFZ.N3H&I^64[1Q69SR
M??:J2ZT7_^K7)?57HJ83"&4;/21A\GMB R:4.'X/@! (VFK!3@T)P1\*$X:^
M);R.DW ,4H^\9#$H_J0EK1V,4CVL/V5B%:":X VBCH%I_1?88(-0XN^L<LW0
MAI%;/V3JHY=":U1UW0UQT%]2\':B,6K,FI)[.IV[7:\ %>0P0.;]H)P^7XG7
MI/<ED!6?:=/WSR-_=UM.)I"!X_PJ[8 3$&,DAD?%I^IP7K_SV^3[OPAN+4Q+
MM'D::5^X3_$+3$>A(0;#ROJR%\A\X0=7L H_Z_.6E9N>5C3PO%B2\TOTF6P#
MG;HK0PS^W16+FSJ( /_0%EZLDNFRSLNIPDY+;^6ZIYIK*[%V9 2!YA1O57CY
MWC:RO^V&F,:63%:?SKH<0",H1&MVSCB;[[!8PZ7G79'4P361]($"CM$0[X0\
M;C1P&R'=\W&;:#P&M=,LFRX%KYAROBG9B0]Z)R[C-3=7G2>73>38-"%VX6,Z
M,9P4(V)?'*:.(HA;J#L!N;LC'[<DG**:RTN7G(-[-VO4?N;:_+K_;M&19*^
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MBU1'D,.GJ#MRS,+[E3J&8=V#)$*)%DDRG6+2<9]4%&[^#/UTUC?/U^BQ],Z
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MWY$S\PMYD6.K<3N2M4\;? N-_52[E;W:\W3ZO[QX'2?O\>+7(\R+?S,"##T
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M-C4S =W(U"3]J+M4N#-/N<^ YJ$\T=F6=^>/!&V_&[TR*K9#X;25R12#T;V
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MI/2(GS7?I3Q3UN9&Z$U%>)=Q?660L7!)ZZT[R]KT15&NW4PJH1/;G+>Y2@P
M[J($J3M/F::D#4V%B(#D'^VQYO7FG@&+O!7I*;&6? K@-.)C$,35!WV(&4!+
MI7M,MW/1?M\=_VL=Y-J,\/<WT'WTP.KF=L-YOD"%NH%8ZZZ[3T!=W$&1*YQF
MTJDS)#"EE2'GK8L!HZ1_HL2 &.)RX/E\5&EXH+#424JNNZ57_+-L*]%3=_F=
M) :5%O9 ]Z&S&"> IQI12H;U%'JJ"3+OTFY;T@>KYY&V=8,G<XT@W@2%#+$7
MT:)^-NWNF+JWQ> OEX/HUJPRJ"<:/]F[/X(.KOU32PO.%+,.4<C%ER_<+!-:
MN%[??MM<8:QN[N2NHX[2P[1MB_=%8JP,#EXW:N=+.S'B'2=]_H6V2N<)KDM.
MEY8M.?7[OB$II/N5)G\7;DD_KGKWB&*F2FS_7UD.GY;27P*!#(<UM&0);:>K
M]H034(D[TPKC7L\Q]>._[C:[-G3=1T/D=X(/]SL]2L[W?/AF/,,(-85I"'O:
M(<]$CC$UB0+*N "^0J@QHBBRB[_H@?F+E1?/OH#.;S,K"ROA;^[8<,$/H+NN
M[($\]D#)6&E#0Z8,32D6J<EJ? U$C:W;00,:F[<OA$@GKN3>]=R]@_E/MJAQ
MA_-CMSD45T],3$=[@^>^0O@ /E/VTHR=<V.[#O9A[/R.17:"W^]+:H=FTE:+
MGB<N[X%F.6,<?0)*+.H0!"PC[HT9!);Z7$)FF8><&^0/:Z)%C^OWV?O=<]$]
M>X^/^ZLZ:NAU-%2E79-J3L=/[X&\AK$Q;6\X#"^ T)B\D3\8$JY:C+'YW&33
MJR)_X>L -]&,K\Q=^0GN\&=EN@DKEZW$5&/%H+21>C3=!'2]@1=9C8+=_*Q)
MH7]DE5(D[ZB;,&97O&>"WP[_5N_3>'RQ%KM6#-[?J)"W!^)"AC'TD0=FF+HT
M/N,]T%.T8QM-NZ]$H!E/;%WD=L2;U;9)R)@YGCW,.SH\>="+0[RQM]C#:(XU
M\L0"CE!J'5-S#W1DE3Y#A\]")RG^[5M*E** ?\EP?X-9-EWS4QIQ>>L?AR3!
M<V"Z$X"A8NG_@"D:I&=)@OV%ZI6$;=H#??P+;<8/TS,;'GX8!?\J?5[F,BZO
M^Z7T1%<7N1ZE@NJ#2J".L"<<1_M&YYI6K;Z=GDG;7N\0G_*PCVNO4GA^F'X'
M462D +FDH0-2"&8)<0*I&XSFA']YAA)$J\>Y7F2]D1_G9#R,0!,#QKNVW7\F
M[UB-&Y?"\[L*YS[-E7F=*S&2%OO)B48QIRO[S)P!@:". 3E=AA)L_#C2<"U$
M&=.,G]\]T99ALCU\KA[Y'C8$ACDR?J6 E$>@/K"G&L@(0'Q9#81[*W!NV:E.
MW00QY.#VW,%%E^OKQ$!)W5?>?NV?P38\*YE=V+D9^B@5TUUH3E2PE16GUN(8
M@ZHG"WISG'L# V4:ON]N@#)N?5?WDD=>(^@2;ESX!:5:8:+1(E O"#>PRK%8
M0@8JK%A5;?N_?'P-V,96J^+Q\"=<WX>^M&P_8Y*"L+,Q]/WD+<X4@=)=@$*&
M(=,(:'R'8."@LSJ.&TZ%E^#-^(5=AD>+)UG"N>9@\D[TQM_2KOT]:CT4-?;1
MS!JF2QMU]#EU>\53R!<2T*C?[+-QA#60-P)I/Q0.0[V:(338\'1"J/_[_Z1-
M.+4539+8 Z7Z[8&NU#;C]T!C?)O8=21!GQ4VN'.9O:6-0WV#UV7V!R3#FY]B
MA TA>),2GU"JD_//I3,MGYNW7[<UU0_)XWZ$S[O>L4_>'L!E7['Q_4-. 3$_
M UD,3?8TIJD_W4"SA.DSR;Q,A'&MV1D&-TNJ?+G1?''7U7[9X4WH?V_EPC;O
M+B'6P9]0B_ /U5O]HSS J1W29Q8VL=V+Z&ZO]3S?+.6LWW]R%D]3>-/'2VW-
M^C3LI=W%&!J<5MAC(:/ &7A*HS7D>@=U#Q2#E/#U.I5:^'"E^H?3%"C6PV+U
M92MC-EU^5>:PJ1^ZZP;4DY ":3#OQB2VF<?^L6^WJ_D91C$L&W-VFC7_(G4]
MI?Z+>OGO>/X>[F]_:UO7BH_=QA6)6&7&Y\,30N9-$02SU!O8AE#^(^I'OAM?
MZ8(@'OO^KN_$UD,I<(8 4- K&=!)@>+V0,)(@6KG<"JNRME4I--(SF5\->Y1
MR>.R4HVF*85C<7_^I8!V(71MP)QALM;6GX(TI2WW0_&A^4-#*DPYZ9\AASX-
M, I3_4YIW_S/HO1!\851(^75+3[VT!ZH86=3GR;5>QL)FFR )+D>IAWLOCK1
MF%IFUG3W_(/?MI9$%OGPV8Z+1P)C.Q^+__G!::>?#FM@E9?EV7Y#Z:_+2J1\
M?=S7;S91/55#?$)D3O0LV:?;G1/?20O*QD%T?S1OSI,P*?_R*(VT6A= ]YV/
M+5MMK/:O4\)D2"/4?4J%8'.&_JLSO?V_P($5GB^??>E+'7:L?.A]+."%SL0(
M[6\@V;_OF9>'J=BW]C^&]H@JV"P*&6O9 SFM=C#= A:=_RZ7@Q!*''$.7L92
M>!FWO/=OP/&>MU;"Y19)(=PY.*EP-E7WC/_RK"]5.OM]C^)I,S5Y34C>":C:
MS?TEE*P<U%FF(_"..D]&=U<;#O=(8N.GM7*NM;6E+&RE?(?Q1P^M597E\NN^
MZT[S,HC:,=T_E)?Q'GE]NN/$K"O2>?S/(D^_\,B%MLD_B6 __LC1_T23%=@"
MK;OSKWX[*U$6J6!G5AG6DQ+9U2&9OW0YJJ+Y<WW&3[JI9N])-RE=ZDK8O3]?
M-6.R#>,X/&6 $D JL]Y\9V6C3C+E:#,Q#5&JW3/=XI+0!/GZCB;?RHU$@1BM
MU">TF(1.I6'IH U7SE@]. G(+</G]D#TH()N]N5Q](>0Z1G5VD.U^.)6UF39
M%2>DZL:@V?+%Y?*H?3_*RWD#8.6Q3S/! (.6VL,Q@J-TU50R3]";!=;_Q.^W
M;'#N68>\E7NH>Y?^3:+O$^;"R&&<AO ;R[KI2!<29C.3'XBOS7@916<X=(S_
M@"?G?,^P#1GB9PY=&/O=&\7@M,(1IH<.LU(;,_&1EM3^)*;0>UPITIA:5:V8
MEB>L=7.A[UK'Z(4K9T^U*<N[29P_IG%T]U=<#;K+F'GWO?<_CYU$)A]QV.FB
MJ/.&G4J QM+;@R+GS U&1I=Z?"!Z:QK*?PYSD)A)[P:L:!MD\6BD 0<CA@H<
ML%PDNVA#R5X>H.,V#ZOC]9=SCM$$AV;37[T#QRYX=-P%L-0P^C?6AW9H&<!#
MUHUE"I%4#D_35-UI!X.,)EJ=:[86%Z[C8F\(R8^"GNG5?GO(R5-[H/DX^D6:
M5S+4#9RPWX[83PW$^YWN?XTYZOF_EJ:^QRKKORT*U;1(SE%X'QJ'P<1$!VY>
MFNF&'G=%=QFZ 3['GV/[<*25CJ?!V(8>Z*1MURGO]@DV_-B1Q4\!R.7\?X8<
MF5- /\?*^DOAH2O3[+K54B-$UH(V9G:Z?;U_$5N"$^Q?"WW)%&D[;&N-4XJ-
MDQ=;WC^GDY>-1]>]P;Q'0$@)&!(ZB<U7M/*CK@U;=&:D!.DQI5ATW/@Q[_6!
MEX,<K;<_<H%^NA0KF6E)#>@S/ TTTIP<$N% -3E RYH>]ENN/L-.V/+WO<-9
M+^\@B\^=HSC'.8=M)O[/7<(Y[O(AD$D.X+A+3X1F#WP>/1?!<9<>#'.\MKU7
MXL[-H0G5M:R"'S?3[A%I<#3'9N1W:.W;#(XRRJ2_H*EQW.W<4+\%S2R9')9K
MA06OVPE=K0O/4$!\=_!(TN#5&!@?D+@RG^;>+%Z-ZH<T[($RL+Z9\6AQ9/@;
MG[:%\8T(UY+*]%-TO++?L>DEFM3 G6R;;;]TA]%<B&+FETUK5.W^F<M<',0Y
M[DL?]@2&6HDE.2.\V,+033@%UKP'JL#C=PW#9IFU?[??;.[>BEI8#M ;&"7\
ML>%)0LW"ZX^]9#@@)3]1_5:VZ+;E_#_1Y0^==%,CRVQM'")+E=L^_'F4852;
MT0#A81,Z#@%! =14JXEVM;"2+E]6GM_R!3172T,3Z/53SY?PHR^.]BVT2 4.
M+/^9X&"4FQ[&2BJ@/V3]QXPB,B26:3R9R+MEBZR.'\+R*4X)3=EZ?F2U-+/X
M ?[O[I_J\,<.HYG"J_1(((9QD0FAN2;3P$8<"19YIV/&FM(.>=3<2@#/D:WG
M2[*^(0=P!^/ZKS$XZ%$F<3#*01"MEA/HY"518(0:>:=Q$J6 0%Q-]PTE*WP2
MNH@H=([]U$<NAZ^$G!2^D,"(Y22['V@^% $BT^Y&:J0)3*=38>:3[J?)6R:?
MDWN[7_E[)2NU_'X!"BWUNYXS6?V(34!_[.\%I^V!I#OX?)<$QB ]^;"$'K<[
MWQ0Z&IK=YX.D<L\J)-D_OT4XE34;8;=VZ'^R0Q3W/]EQ!6D$6+U#\."@\]..
M(LXR9AS9,1\N5=[L0?:Q:;H:L'/EYY\W'/MKB_7 )G.R4@7SW!9@)\M1$D\S
M&>*,VY0]T$]Z4P>LD Y59B'??3*\@PG3F_^JH;D_#?([D2D*(4%2#?50PRA%
M:F)L<"VE5LC5><[R$ ;_H'FI;J'O5]C0>MS1LNW(0-<K9/ <AFS-\?0?U>+&
M@ !TCT=#4](:UK\)HO%P?$']=UJ1G=#9 .R\#*+V$\?P9'"DYH C)@E*+(R
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M'61$RSRMMJ3G9<S]C.?+DV/*;UGOV,?6X3(=? ^71,=__6'XW?WU:(OB-OW
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M&NPKU9/T?;X%]9COK*ER+)>L<CA#B^D%Q)<AK]!@/6!1X,8RV;.:Y%M[%!$
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MM9*38;)XM^'H1*SIUS-U\[J%'"T*WS3FPB/^'(#B*7Q_I"5;FU0(=$2"05M
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MNFE,'7H+_6YR:D7G6)GJ4=7T%>WRT9>%.5K/Y:QCW=_=>TSP:6.L6@\P+S+
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M<205]HF9_E->J/-JJJ)[%Y)  W$OM'Q5!&L>6N?A) Y 5">LS7YYDQH%:P9
M&"IS"ID%!Z!'0(@9KD4"-=K^+:F-W3(PHXN#9!*<07T<%WAD*>4G_AV6;^\\
MTYNA& \]7HQ%,L*?!4".8([L2)M;U-&_%3*<5VUM5FX.>1V -+W3>F@(=:E/
M?C\"2_B##AVI%4%>HDIW)E'IAQ#!X5,*O4BS,B$]Z2NS+.EZ,C1M^356ZYT2
MVR4ET&/13V_Y)W=N &ZS.':L!L,\GL6+E1EK$O=JJ-I__>LPGL@3*G,7K[ '
M(Q1VZS'4WOZH:+7H3A-[2%713D4!L+F3 :3/$4^"3];&A35H[+P(;/U!GB&W
MCDQ;\7UK^@O]F+[Q*CCHD9+]RPK/?Y)4)2 **HPZ /%<(&AC[S[,[)<1<HR\
M)S>%_4)TA]U'?>TR%(?Z=\VR!%C]N\X0@(MVJ!Z[5\A+-@S7'S5!Y5/+VD9F
M_1\11O#LC412Z9-W&ZX_;(<B8)>!:/HE\<,LHG(8"M$=$OGE!R!I/ J%-7WO
M=6/%CZ2+A-'D7(L=+XF9G9Y4)MT93? HG!?2WU]GN-$"XEIP,0T'H)2 GS,A
M3C*]4Q9HC]V-,]2;8EM,A)RR>L@7_&OLB3T-IBM#>#P2JL/PZG 6'H&)8XZL
MS&Q>JZ2WEY$,<K>SOSHJC&#[TT4N?))-5/O>U^9#+KU V4D#S TZD5$L>?J=
M\I+]A-"/JB?L5SAE3[?X<I""!*K.KC0]/)N^_-]+C;FXI"88T-G6)$!'M,.Y
M,)97Z$ND_A/+(B*/ 9_?-,=U!;W&U U'Q\/5#GY2$:7(>27L;NML^;AD""ID
M)P=@S*G!210!E@A&HZ4.?HQP3JU;@RF?$W2V!!.K8B'EA'CX8']$:<:Q,,Q=
M\>S7Z,8'JQC$K%LG10+[&$#-$9-A2O1K9-OHOCUSZN8QT\#GU;\=C[UKT-#L
MS<#IW^L.+'T@KR36O1><%#YA/C<=]TP#QN/!ND /RZ+KTQQ?PFO52C<0"</7
M7^7;5G-3?OU5,(OK50QL1>*[C"6)$+A7ORCF*20&-7M_%G]\><9P"%[KPC!O
M/U[^=DA.X4R6ZK7:.>\@WN0?O.6?+[N:V;^XU:04-CZC!SC1MYHES(B%&(U6
MHACT]JYF-@,<_R"N+3#=\3G$VJ-M4[-;0B&5-^$PB&5KO2&'GS@$=_1 P+HS
M^-G3I2B]<+;5W M-Z0%4<,+98%_78GF!4)Q(@LC"656WW?B5DUE=?%_G4ADY
M:Y)XCS .X ;X63'=/)5@.?M&(50H!)'PS\3)0W1GR_#%]XJW@3&T -)]OV>H
MHB^P>_SXV9QU7QI:'&- *Y7(QU$/\]TYNL+KAD)+.O&6U[3.78O[N5?NU_DU
M7<[#:IR0Y9UH4ZZ=Y456PM?!#+<YLR*7$'Q=&T0,8V!=Y8&T 0(^3JEUQ!E:
M#[:%HP)G[GE<O%<@JNR"FA+PF)'<S\"Z47%1,Z?J!@@7J4@V[)V1S;( =Q\F
M^*UIX;)(/_I4AA&GP&F$GR>%8.8Q,2F4^27B1BV+"RL %($[U1"TSO;_&K.0
M@2BK$WM'I(V:1<:/HP,$L\YL;11]W9_/4&\W=;YC^T'["1MX_0!4[FQ*Q[4V
M"0_[-Z:$6#."DG53SOCG662(^\Q9M$]]E(X_5J1V-5M>B6]+ZA&.7C773]J#
M2##OT(GM*,E6C8\8<],Z!E_U#%_C*Q1YYL;CRR<L,#=L[CHNA01[1&=&]CV%
MI#4)>\[H NOTNO8/M"[LN5G@C^4KU)NINY8AOD<F6[L;K[ZP(\^=NW?1M?D"
MH9\FNE9,0\;/B.^_I1'&JE<O>'7NCFD4GJ_.F&QWNR_%.<;SW/K^PRP%H<]Q
MD@K>(O*)H*W#G$>LS2&I>=&6(K?3!%?".?^LG^@PZ'/ECYX%"W9]6LT]Z_[P
MC<1Z5JZXB)9XJED:MWWTV<F6*8;H^@U&VJTAIB/#Y+^]$67CS8<X4O/[VK^:
M^=4R+U\'W23?$->%M#.R')*>EEN&,:FVF.-Y=/2.,9#V%NM/AZ=!;Q5A9>D?
MLMY^6\9=!-S>6Q9WZJ9YTEN>;#!B<R\N]39*Q:2$/>PQ<N%"[J>%NW^"@;UP
M1ZOA\3+'O@!V#]-U]W9J&IQ\:$...*VUC6.WA!0FSOP=T-%*.4E]B'H+,6-U
MP$[DM> JB6W2L%^:W_),XVXT;''U+TT_6G&:"EW?T@_=&OOVKJ"R*@Y1%35&
MUA(F");>Z#BO_+$9$B&L!SIYP_3_/VP7;#O3TAPZ$PH9_:10T79(M7++@UT=
MP-:._N.52/KLP[HX^".=ZDK-1IMT1VQ9M/Z?%!>Q._!K7F1(*MP3G$Q>BL3#
M3F/RJ,18 E?A,OHS^*@S']QZI";DJ\2#CKG[*F@IC(R-9N\$W!\%^K>3"+"W
M(@6@(33$1'0;8QJS93T&13!T:+>?*N!H:MHK5Z0\Z'?CB_-_JF0>17/F^<K>
MEO5[3'+!X"T.P0;J&0X.4\5LDB2<%MIGLNB=U.W<E)E,Z=ZHH3D;XE>>ASE:
M):!)N9K ^8>J?V\JL:]ZJFQ!J."T,&4/XHDFB.<@F34L04SX@WKR8[C]!F:I
M+0K,'9I*,\ZY:>+S+ FN5/D]U?"&)'O-W;GA!3HE.=P#?(QY$>CYA/5BH-LN
M2)K7CSZ@_\BB)OVI&BXMV_Y[)FE=(E$8[DF1YY,K$6Y=,+D7\1;B/XB48QH
MGPX)+(D%V\]3W0R0+(,M,T\8I$)OH5SE)MLQKE&27J[I)R.L>Z"5\?WB\5+8
MFIPR3$D'10BJPOB]V^)L*/'H&QZ3R1+$<]I->:F@=^*W@=../[<7,Y^80MO1
M$>DGJ5EW9Q460'O:B7\-=G0J#JE. NB\W,B@D/)ZOND/37DV<0.?5!U2"US]
M9%VD%\H+3H@MU 18R'%'1 UFG['@OK__%::$\"K%N#1+V'QB7#Q3'VOEZ##,
M KL3O<:M7L*<JO8_-B1=25[Y*^M4^+L;^S;#&%;5T!#;,>:5]^I]75V,A,6C
MK*AW2N*J)#J(73Z7@8\Y -6ZM5"2Q__=R8DF. ?DE=W<0<%^:!7-M+KF*_&1
MDO:^V[(]D$R2TCCE)L_.B,;DM<NH[R>%G?= T3;CZ?;+3?)5 X3S,ZHC-[!F
MC[Y:&N\8#)%*[:^-OW2O^F;]<M)GB.O#)/"@;2< >%TK"$0[,,P2Z([4P**R
MMG":T: ?-,@V(RM1-D;L3E3'Y<OL"[:FXDNG('>6PR%0KC('P(?6X[15P)#!
M!Q0L6^T81>Z4]/AIYNMQ:EXJJ'TISG]BGIIJ%LK9Q%$)>- H2?GJ^S@L^T?,
MGM-@0!H?U@A'RC_%X*CIRK37098&?HU:1*UES#MIY%Y4SF/$*MF^'#T N2/B
MX3RL8T!.\S_%>*;]7-F=,$5GC)P9X\*;B-$_FVL_WUKFQ5Y6?;>XJ-HC\,38
M4![U$P3:EWW7='0_AZ6(>=\<+D P4U=M@EK1?U!:=W,["D(8K<VEM3G9?9**
M$^7-<BZMKM."G4IB;NGV9'X<([H%PAXF@JF[ 131+-,2#F'M0R6]*<\KU'=I
M6>(TI=&I9C[[AY]O@)1@7VSZ]YLT/>./$:"PV!O(4QA\<Y/"?GR8)+!+N_Z&
M@3X4KX+;JU:<IC 9QCIEYPO*N*&HD-[W6U>Y? TO$;VH\OM)O'DL4Y0QWLZG
M0QN/T#-$$3U"79Q&:^+5H+:0-.;Y4_2Z"3?ONY9'C]G9__6Y>5FE];,VO=04
M%/9R3",>ZOH.X[!K5C4:(.:]J9=7X5(\6:]@^:FV:LU47)&[E+1M79@!ZL,B
M2C'(]@.01&FX.P0RP_1AQ+5M\F""D"/W!^[36<4[F%.H\Z/W,AR3EP*(>2<@
MLKSWTU[V]CK9.Q4!BG;[Q4WG6/WY9QA<2=@;;ST;X&UY<)&5[%R9MVJRCA/S
MEY/CHR :ZVSXFW>EJGV/L>Y*-T,\@?&.IP9MQ&.K,HH,X97E!I%,KS,+ZY-R
MAHGR-WLGK45<(@<O*KX].I:/"^4O=D$%^_2.[0J6#E;)R2HW"US]<E1*YMD1
ME1:X#^\J\I@N[JCL:80TYOT5^F!;#.Q:G85:\[_0_.-;J;ZY?WEHD(Y^,2SR
MD)5+-E5V4H:K4>RV#8,$-7#+OF!X):C6Y41?D,(!:/N#1Z:"-LCTYMLW\TI<
M*QS"O_7C&"'MN>"$,-"A7#JS44!-"D6W2+0")59-]FHH%%[M;2U!I\N[^=C\
M<;[!A2#EC1L=7M^;SF+=@:QWS'/TF<(SC&WG4\!$V=T5Q>OTHI(5AP^1U*^G
M9)QJ<9Y#QV8;W)VY,@) )18JO[^_!.V+E <U0P3\P8DRHM$D9S$B:V30YTRN
M6#E)^W*E[DV"-HK_\Q6P9,K/EHZ+IZ*1?%@^H'T.'/,/W/%_?)W77Q-=VX6#
MJ(B4T#N$*DB+4J4W:2)2E!H!E0[2I 4)"8+T#@("#[WWWB,U@-([ E*2("@U
M <51 GR\_\!W,&=S,+/GOM>ZUNS?WENI.DXMP6M3!3+ "(2-GN'-WAEJ2ICR
MCD[#OOV";]F)1'\EU7+2J3H+7=P![/$V4*SP )@"@&%X[N4,]M 2OKT!5C4!
M(YP8#,P(LS-\+9RX68*>8FSHN 8:/70P-^%[;DSQ0\CW0I2X';79G<"R:HYV
M\?Q=O3#WZ\R2-Q47G!6;P2>08!5;):;4(U<D)LULK(?M=0P>K$#0$+[/(Y5Z
M@)27HJ.O_<^MIU<W5#K2T_F[KG_?B7.-V>(SD&+0T9]B)<Q918V@>'J@)-U%
M-KF432MP^*\7@_Q?M:D#K3_TH9#Z@C&4D$'/8A47LAZY2U!8S,64'2W"IAJP
MQT#H,D:>SWK:3IXN^(5HOF3Z[/VS1RG 5.,Z%^/GNM7!WE:+@2-FDL*<<F I
MD%6'$*O<G7$)L!AYTJWE$RQ8)!C#[_+^?2:OYVI[>%JHSS%JO[KL8O$N 3F%
MX:&,V_QE#8ZK]R290$B"$U6Y&MG'3A^S$$EKB6POH(1W>;ZVGXCA%PP0-H3%
M>2:"!C>U_T59O2MW)*YUIBCF1JIA^7+#4\JTG>.+F3>%6F_4K^.9R'X;= W'
M'_:;Z1C<[R-?1 ^:7C4.FTOOS7VDZ*ZJ>/L<F@)16"MK,!94Z!Z?<;NQ[_.=
M "6VB%N6$>(W;[K5'WC@RP"/,VF$ 9':Z_L:[(?%?>LVO4N07CKUO5\[J@XQ
M?7NV/E4(LE@\]FA [39<%[-"FTG4PMKFN%?^S/:LO;VV.KKAZ/YJ*:#_?353
M(H11DIW;0'+[ZO.6(.C/JR\8+V8RK2/J!Z?8K8&P/T8:$D-98<&PB/ADY7ZF
M'XF?*8VM-(PMKVGPMRO[$U?[>FD0KE@C2GB2K8T:QE8D\\OL:_,5U^R $X%X
M3Y>9#%[;9\:SS-?_N^;ML\5#25S,K2:Y=F3B(>_\+D'D)"N"6I2D+">*[N>_
MPLXYJ)^N8R)N6T%G^!G#\,[G#LV9F^;FJO8<0#Y.=Z1Z@]/55@FHKR4) Q]E
M80?N.O,D6=Q=97GA4\E\[!E5A^<+NU9IFJ(73EE9QI5!%JD*($A=RS,/'P98
MULHSRVM'4BQDFGB%J3*EI>_RPTE)/ )$FM[8BSL_5 7.B_@[VSOE>5@79#Z)
M2G#V#=,KEG[TR]HX,.F6"IL%S1V9W8=^ T&J6RRNE+$U,A]_%3MPDV=/B+J)
MGF@R[*>[.")++@&&,5]\NYA5A:J%^ES/5\%X46DW\:XN4?<_P69?J+5?81TJ
M;..VG]IUA-4BDA>)4[&W[2385GI@CYAVNV1*,V:/Z;V?#+R_D?)\9$?Y=4DQ
M Q/Y0:S89L4%U&CS$K1LS2VO#>02H4/6Y=&M?UMJ1=?0LN>%^%H%?L[?- HS
M)<9_[D7O3 Q>@JHL_FJ]3LPZX]]#"B_VB %'_2P<.\-LRDKRX1%[6L3$G[3-
MSA4&/H+WQFZ.H^F#7/GZ>5/)R1)JU%6!FBE&>)HAP2ORMP?*J@O&#7G4DO'O
M]&>_&#4]7Q!7*"6O:%J?<.Q?<BQX"$I/0A&2^KRN_?QW6.T1XEID!8\;>3O.
MVJ3K]ZKMSO76H/3VH$P+XT[41T8NTTM0,,5LK]>$Z3_(<B#F'VWRCZZ-..%F
MPJ>PSV?,I9\Z$Z^Q;?X7Y'7'F[*OX-;_#N"^P7">IRH [WY$F PG\E EN#_+
M]:C9O*J06E,KV&%YELRMT,;-:X."H5)ZS ?2"!W"02_&P.Z::O$EB-EF,>M.
M(T]>P^>1?5=1S&QSQ-?BX*K0<4KA4&]WW$9,MM=([9U!;$82L0@268Y]!71K
M-75$]=T\.S-Z.UDT[K3/?/QP#YSU_>)7P8L2AZ4FDL E*';N=!; XJ(X#TCR
M92X7X*;,^?W4T^\^^R<8Z5WP?&C(C7H@W(!0EQ!8O?<V/2^I9+DP8_O,.)<W
MC(G;:NL-LVZG+*Z7JM=SZIT:.]H1'*$L0+P]9;RT8W[/ZIO5FM7?+;K;PR>8
M.(&3Y%@#.DI0J-Z.FAL-V!!((9YMR@]N,(M^@XN9=B[(QM7*!5R"=!>@XH4Q
M![5E6IAHY66A^VU:?^&\H6YJ@(AD?L'0F5Q;+G=Z Q&V:QV2&<;7;F;PL37<
MAV,E[O&;NH+[2C['8N'#VJ!@KZ&D^'5*@!-KI:R+[V6P@KOKF1\ONK<);2.<
M'4PJH&+_6]^02/:@3W:"Q'!>U<.$G$FUTR*<# <@>;L;.0_%296UGB:J)MM!
MTD4*C[L2L(^VWOU'M'4M_*'(BC%:#<:IUN(?U'HY T'%/RFQ.1Y:[EJ.W /Z
M/K[(V&^4RAA+TLQH=&.>SGUE"WP]B.1P7GX)<@8S(A[,OY8]HGL.VU5,GZPM
M.^$'4/MIPZ9[":/Y[O[:B<:W'PFRF6^$@NLKZH('\L"JS&@B3?^2;()C:X)^
M*P1JWG62BF'#Q\-618P%W@<%AQT'*J4^<1]6<U5C0SR=EJU5I6&0N'J+ZZDP
M&BU,#W@:M]0:K?6XZ(7'5C(;G3"I)7;EUV8S<WP!-=E1]G!S.1"HCUZ0A>UY
M2#]NCJB3]/*Z8_DR3);=.? 5\S.0ON FF:T90?<4#6B=Z;BM)&82_@QGK)R6
MO[S]S<CAM)TE+<@AY1,#_*HUO=D*^ SN['L^_[LS"*6]F%J7/$\GZ1"!13P.
M/&CS:-,.R,'D"2\=.G9W=41X_/V4GB48DZ$4;';<R"92(4=W"9*MO_VU=P@2
MQT$QK*(U2"0I $&;-F+&+3.>LA6+DV>F[>ET*O,S7"&IDS(Q\:Z27(>28VQ]
MO!SY=+V;!1#0!0L<_Y2 BB&]E;EBS)]-T9+[Q;/00^7.VY%4/2+L;-@H36_X
M[GT[30%*>DN'F^R<[RB.5<1.CD.H\)G[GPB[T-AP7'VD; C$E,BVT&ITPW7E
MT?/5W4O0BF(DN5;E_9.2S-$\[G?T=+<^@/KUT_8W$NWH^ $S@OOPQ;WTQO.8
M8AL['>FP8\'']AJ'4ZVZG06T@\9S!_[N5#F<>RY>K^N*7)S;.N+UN1H;^%(^
M$$:OJ*;_9@,"3!CL[Z7V.*PE<6,EP />-HI??%BBR@8=FN^Q4>.$C#'7O(UJ
M$4^QJ"@U)B3C_[8C4"VL1S@11V+0*)R$*14-;+#]7UA;LM_OIHZ.+O/VU:P[
M,=?N=J3D9D4>97Y?UL)D1R6A0PC@_TDZTR6(#6V(Y8P3J:]'0+$JDC_YIG&-
M84&OVMO1[6(7:<J8>U(9YC2B'I<@\RJ0ZF^B<YQ,TC7 _AF1I1?%DE7T,V#6
M9MW6,#?E8:S51WQ:WP^R*V)=R 5;MA%IXUY6+0=MV/>T)^Y"6F!?O"1'C,=Z
M[C+;<%YWM-$B[P?%6XPF_^0HQRRK,I.8%_VI/MD;$>IBRH!,'$]IQ2-/FOV9
MJAPE]M)7!NQU# 91:R26*DK^1X0$,Z0H/']3(G.XVBMN77*6I($#<PGVW"24
MYA7H9'\)KA'T[G^;+_W\X4N3-KH!&8W0]^CN4#6#O="9"V4XJRUZ[J#&?TK1
M4 OVB7!0S*D_J]!*I9U2QVO%?NW[0REL<^LI=T3U#N3F5R!_$WQP%R>SJ"H*
M=.-8$IP)I_@A6V$C^G6=U[CN,QU^=R4_XXSH <XF@><1QC>?W/#-]HHZ1$/.
MQ"Y&>]Z&XU2>CORC;99NE_HT1)K[MM:^]*6C8ZHHDOL&* 2KS61,D8-P/2_N
MX;B8_&=3>@G"J+$LPSW%VE8]J.,$EQCQH ]A0J[L.CJ6=ZE24J5$1_KSDS;
MO2Y&X*E:A I1NSQ&7&+KN/S8#)=]\TM?*CNSP^.#!]^*O=G9_W<45+-:Q"\O
M3L0;8(T(L6V+,B:NY^)6DVB6]?UC!&?]5ET$+!E J 7*#'W!5QT;VUP[U_\#
M1QL#2*]5R/ ;E\!V54@&)))U<$1Q_9W4ZI3G)#$D3#?-E2J0RV2<V'UM-S:_
M#U0 ?D.P.) @+.&@0W;T)'G"3DR:&3$_RM1B00:HE;RV&F0J:$HNK</O9"5H
M)EKWQ'=DU&=9/J%%B.@+P,Z>D.-N[:NU?&\T-1AR1_-F//9^E\,72-]M?S Y
M/#)Y"2(\Z0UOA]"H.4^PVO40H3&R$T;#&0WN?P*ZUOYVA,WJ_YGX2%<A,GF'
M1H#!H.&+R@WX2"Q)6CA<-FEE"8]&WB.:8;)?K0%>^G,[\X@Q]M(SIA=B W2>
M>IZ'R_S/L??.]>^$JNX36)-DH#'KX%G24VS.T8$*Q;.XJ6;TL4/THRP!;PNS
M%U)@8Q5W9 \307C CNUB$L6,<I;@0<5<W%F RDJH[HY8$S"9>MDW/D4DYDRE
MN%0/ED2N(6:M<C\V"@0Q;QH1SW!10Q/2)D"NO>N9OA9N+\:YFU"7<T4SM.&;
M7P]FOBX/^K YR;]K/%MN3$-7F-.']4%JF2R&-EIFKS*Q4SUV;$W BC@+6#R<
M53YB@7MA:7L]7N)LH,:I-_($Q!FP.SKQ$3#OL3N6BM7>X(\($V /YT1 #:A%
MJ7(3VS%'T2LWZXNF<#1&PQ :/YKU.Y_FS%&2H^+-VS>?'D]XZ_QQF6?FL0\C
M^Z>AC2@_HP"*AZW3ZQ-_202,X-X ,(.NULS!I4L0RZ\3K]K1-)UMG'!FR6[J
M2"=,P>S#W3ZS^FH1<DP/+W*E]SJ2A:07UX>\"T24_;@0\67X5-,X3H1ET=(9
M*1;&DL??/[$)J*3V+F$\:#U6PWA1 UY#V5Y7+)A/@19RK]A%WNM&>W'"BXAY
M'O(/.SHUYPQEZL;GUA,^OVJ-OCB(E68SICYGK($[_DIZG]G#/0?U+$A=T@I1
M73Q5L/*DJ^U,$*1%1[%1"/QW+$)>7]2K0%([TP3:AUFNZG^X&AS;*@:EAIO/
M#7K#1W_7;5V"8MI**]6K!#J\!\?IAWN"(Z?D[Z?^;SL@.QXD'XRD,NWOH;@S
MXA%(K+;IZFEN(R3DN%F7I6&#7:X-=_DW2]6P,F*FQYW8[NXH'?_H )VS%O6J
M(F^07A!1@]RL>)JAB?;AXDT)X0'IO=.W4<-CU[+?*_ZGD5[8WMD/YHKY3L]^
M5LO)#)%F3"/>-HK=:.[M1T6Q*D8EJ0H [3A4XL&!LEJ@<U'A N>CUD26SLZ,
MX2^K?]I7Z02,Q)H1LUT?^\Q D.+T"80>D(+M?6]+N8"PPYV;J[ .9EN+9P;.
M%G?$2U>)K(0V,XQ7,6L(-H L/J,:O6+1CE[$'%/"KB4B(!][OA@EM-^>S]ER
M+"G1*K(38^91%W5#,&;U/M>+H0YGB<3R4P+@?@FB2AM"D2O3YHD3A:.>M.*L
M,K8W-.95)YM6^CT]2W*7[#TS6-NC1GT'9&J\]=E _]2P49@C&H0C0?(JUU#L
M"EL0MLL$Y3(CUV&H>X()C+FI51V#Q;3/G-G9KW/LNF,-;.2'6%?JAY,XW>P8
M$5ZL@Y"(=N.1\I]O QKV_&LFBG_.M,ZN/=&X<U>0D9+E7J1%@.3(V&-X9EB/
M),)VOAXMC?_5=%[2JA;=OG2:&?CV]3KG?3B+@:N@=L:M@_2/-9IK'\4O0?"F
M&#WS5^H4NT/,?PN)Q7C=6"04X4X\__#E[.$RW& @^[^5FW&0?A4QCVXCAJHU
M@V!_-/NW457+ANLN-VD=7B&QYUD(,]P1!^(FP:D1/Z%Z8DA\?PKS%Y&E8G3T
MGBUN03HDTRF7)?,F5Y!IH#+CC2G*+?))+L#O3>CRSB#+!1\0CKM%4BGY]KSV
M/VE9]!*-X)!56(V/0">6;8>-;;M'IW.:Y$'<P^K&HUQ4=/&!<3W<,*M+D.L:
MW$Z3\/MXY:><7(;TXQ3.'X_R6]%)E('?=+3VSSK,#*9 N_DM?PY8"0*F2PAG
MW"6(QBTCGU8"[5SU\Q]MF0=O2W=*4<QU_8:_AG>S#P05QD98IBTH>"&NNQL,
M)/E"A'P'\>"B^-2+LK\,]5J_0H;ANP>B5WK\>.!OUO+D6G>WO;+YQ?_WEPES
M"7H-I=_MLANTH="8;C6HY801 V-;4+2K=I;?]*\3:MKU3IJ4'>YAZ)_H7T<4
M5F-(5H5 ,3X3<Y1TP=L)=..-HJZ*2YF%;[:PG9!1)"&4<3PY_=S&<+NI_4.%
MDX-C/#3G^-!K[9TZQ&(WCX_@W)\K/]CU+,896\UM;VXH\*AQ;C]V1.)@4)\W
MP3[BEBGFT3[F!IO3*P79KTN#BM#A#?8?ZV  7 W/?#9_>/A++?)?+P;*I$4S
MJ..%BQR5:3.(,)7/<!VCPW/B*:[')]$0+(:FXE;2_T0BD!EV+1GE1)9_%[.'
M1X8Y@T[0:U\\!*.;^KF;FIFC8<TW\H]83.[>'M<#G5O6V 0/6PM'^DLP/IG_
M+>(!_=V=YEQNW7@'5JDI$U]1+'CPT$FX@%PP]B_L@LZ.!?DUGPXIL,L*849X
M$/ #/'1+=<H2A3^1-^=U<L1/^KGLW+NZD\78PQ\%%'%WLTC'L[Y:[N$%.*N!
MH],.P ,2JWH7GGU\"<+NA/,OM*KHZG;:2*UO_UAGPP>T&X_1=28J-:HNCI6X
M%+O%@O[-#:RK3J/=43@Q"19@_1L<9:QH7J(<0_^BBU[W;IRO"*VF ;L0)7F
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MUXNKK.2:[6L!KR^$I]834A*CVIZE\2+)C<ORID^#J- 'I^#HTQYQH!&?M&*
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M77=/D!Y<<1?JC!P,XF<76HFP4;_E$$BNO*2+W6#<4VOR2D)*PMWP.+4854'
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M?!GOA,:J+S=_:S_@C511-P97[&7/( 6NC,%6CBC\WN] ZT"5EX"S_E*U(LY
M]EJ2/@_D($J782;LULAKS^O@7%J?@[)7!O).\+H8]IMX'(I[0]M5!!^2'COB
M2,&=^/+#!7^H2B]F@XZDMGD>/*@H68OT\#=BL/F4D>[9H,_7F<7O:O,F5A,4
M/6X5S>4_(3\,H4>K;').T5J[=T5]K4-H5Y8EE6(:],6>VR@JO1\0\^"T?V/3
M4,R5DI+/2-3,Y[S84*6<RS58!EC[,U<VA4/;+4YJBT*,TJDO0>I&E64D]0X[
M"/);/A5"@:JF 0[1F">9(8JIKR_QO:Y-_\0F]F33?Y-G(%0E<V"#!2V$M^.
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M2'E\M,J-]Y>N6'I<_Q(17<G-?]WE[V//X^@+=ID>/O@S5XR "L9X$$DN>YB
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M8I&\) 6"_;XA95DE0&7K=<?^";-DBEUJ;=T7.3(0/S^KEIT'$$S4PW/%(.B
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M)YL]!RE\[.GKEY;_?2,98,*?_MS]8DMMRI5:0FL>D\SK/;HMA.-QM#0\3X&
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M5&.(&:LJZ_S:&8)1::T^+3UZ(OW75C_C@?F7Z UQ7;4?/H/@GX?]$=S=PK;
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M4"KFVWO(ZR)8CT/8N?I#QQ*6&D>I3];,^P^6DB*I4:"Y[Q[@AL/8/_(Q%ZI
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MW6_']DX5V<,R#>KG90)L4TU'UZRZTZQK%/]ZLWC+B2)]WA,&'V\_7>U,H&!
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M*P13$&^C-0>WQ,I*H'BMWSWC6IPXL7C#P\U:T:U+UQ;IJY#/$+(VZ+.8VUM
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M;^^<W+#[:\_L9&;PJU>N_!EVUJSH)?T! YC_;WCCN[%6_IP:+%/<*@O!-?:
MI%(+L]7Y 5?W%F7>X8W[2$],IQX4I:.KN-_D>^NN@"3YL8IA)MJ!'^ C7((&
M>(,:\:<&^.X:2&+A+AN<K^F[Z,Q+=KN$NEK,\7,6A?.<=:HPE\"_3[]0O#B7
M*$:=B0+>8<F'('<(PYQ2 07@<6;AB:3YE,_RO&6*O2(\V.=]Z>KKN+$REY=9
M?9I*X=:E@)[V-$D)'/]2T1XRA"+T>ID9M#2GJ>O$1-$_%[H6(Y3>RKWQPS46
M<;5)O1T"Q&1,#]4O"'BZ;DQIM:#$_8VM[3*G2<J+5';I32VS-_Z4:B94:"BM
M!M/ZF4_\VI5]:8B?1[^"=%;K8>N8=T.9TEN.</\U9F#-WV'!7;=7)JZ!0NR3
M>B370PYJ&\\T=PL:J="R8=B'$##!=:B'S7ZW'NH>_%R]CD6O2N.HS]/3DX72
MC55#*WD3%"D7Z@<M=A $GJVO45^"G!GH^FT$DQ3?N[3.7F'"R4_',WXSS0]W
MM.OULAKNTO?Y<A_Y>W  >NMNI, KM:X$Y%%C.)G,JT_FF4+>N/\03S3=%K8B
MJOY"3E=P9>QD1VGQ^" 4+OZ :=V''FXX6T.R=L>785;SYG_8Y)Q_Y@FLPM6O
M.JM:4V6_>#Q/Y>?H=Y3R3V*?J7"G19.6!*USLPEOR<3TL,/FK>9.4B&CXDET
M84KO;="B.B"IAL5#$ B"N"O2'=V$GT26[>:4EG@6_USR4*O+/O\4PM @,Y]O
M\Q(YZ:MP8^ZO+M;W+K_9"1/3#H)CND8QE<VH<?HD5Y'%UFH'+\;\(/ISL=NU
M<N*U2(A@V_P%I='90WCP?(^;[2&=<2V V&70U)O1<!%NLPWGD<&VZ34TOP4K
M;:9O.6U*CV2PD_4P#)*4 .LBX+@OH@'YNNL^AGM[MO;/1,2 18Y/@FS6;I@
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M8M^/*LOSF8SY7^%)%U&$UR>SN$^^J:./ YDR/Q&G&92:*D5!"+&1&/[Y15M
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ML#%H <(IB'TK.P8S^Z)H\ZG-B%_F KH_B19JFV>XG@T"U"S(6=M4G_^L)I0
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MD?(!MCY@0%][M'+_B6*ISL?-S_/%JQ>TE.A,Q<6O"7CN0^MWS A9D?LCC/.
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M_W3:9D=T*A1.RN+TSN]X;!/%/S9#"[[BV@(."8^X]$TFXP="P#\P>ASM1<J
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M73(UK1[.O50$/1UC3:)S'%6HA:BPC#K0T@L._L$RL)$U7E&B4W442E]%L:]
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MAIVJH(%[OD6Q (1>QA4<S:F\2BVEK0Z3N,>V74]<I01M)$7GW^@,Q-FW>\U
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M__X$B5ONQ?P+2Z;#HRO6G2ZVC#T;"_Y8^-M4^;%GIV-[7OZ5^=#9D^11_LK
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M+$E.U;M1/1-4@AW!MZG;KSS%^[8;ZI?8/7_[W@=K^"1FU(U=%_,2<1%@>;H
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M2.%4$X0]949XSNHJY*OXA^BX@AXFU$W<DU7+LX5VT\>^>"88!HKF-4: ^\]
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MX729F;+$R;F=>6;RT.<^_(\PC[M7[.BPH[)?^Z_$P(BI5 .KJTP6P7/&HT2
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M_&'L*B<?Y2ZY(P4I*9O,WG:4+%GX;Z9)I/I#3^'5J1%%A63OB[0O)^PU%6I
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M"_CU=YTS2,F0=X-!C1LWO%I5W$TJQ*\E"B)<:YE$7'P7:7YG\.\O'>UF$SY
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M*\ 3V3>7^:=&\PH"/#K\'A0?W9S4S;FYOK2TF.?M?=_LO@4BO_\,A#,:0LD
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M=)[FLV7W,8NIMXR+/1*)-'D@GI_T!^YDJMR)55#43MY2(DE1F)66X61=FC>
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M3+5\Q<%C[J+K7448 D?Q*$;%C/]O @!02P,$%     @ 0X%R6.VG]:9QS ,
MDCD$ !0   !A9'9M+3(P,C,Q,C,Q7V<X+FIP9YR[=US33[,O'@0$J8)T*2J]
M"PC2(RA=0#H&(2J]]UXB*J!4Z=*E&>DB36JD"TCO07KOA!(":3=\SW//><ZY
MOS]^]R[9O/*9W9W=V=W/[,R;6?P,?@EP4UM=2QU 1$0$>$GX ^#G (\!Q->N
M77T(B83P(24G)24A(:4@([M.3D5!145)04E)34-_DYJ&CH:2\B;33;I;#(R,
MC%2TS"Q,#"ST#(P,5TR(B EM2$AOD)+>8*"FI&;XOT[X7P Z<N*QZYG$1/<
MU^B(B.F(\%T +@" B)3HGP3X5R*Z1ACC=3+R&Q24A IU-P'7B(B)KY$07XV:
M4!I** >0T)'2WY50N7[+X!79/4\&R?#$?')NU>IV1L/1(QZIUUYO;U P,;.P
MLO'R\0L("CV0EGDH*R?_^(F:NH:FEK:1L8FIF?ESD+6-K9V]@Z.3MX^OGW]
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MXBPA'E/6TS;QXBBM._I\Y#$7!KK70DK?)-<RT.8&WO&O?(Q<(>RF3H*2?1D
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M:B;:STHK>+R6O-GU+!\J*E:$3JN'0E?<YYI5$G33<72'M#MFS&NOI4H"/9]
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M7IGN;!ZD67PZ]64BY/>!R&93792-E[!W$A^/K4[E(V!P:TB5?K&09TI*[E9
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MV[G+]>0>@*+Q.3=[?+/D0S;>6>QS#"U6:;8.?51L(?A*^$[7';6MC]_]!N*
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M8QZB)OOS120Q-L:AAWK>O1]"[?/-5SK3S-6PZZZI4UVSJ=539:1P3;G-XG4
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MC,.DTA?R!])_A#@091AZ_V7C3)TLV2'<KM.:A0!XUYC@:<BSPCMPJY/4B[<
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M;AK%>ZVCI>J+*','A*B%92\/;;:$R<L3@08_#.JYVIG@1PBI[TKLQ%[BW_3
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M^J*;E.U'DX9\UX;:E,"[JO5G2V9J?X:9[ZI))3%X_GWYXV\7.' JCW$J7/4
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M!Z[X38=-(NP:\CG\R?U) &#3BHGA(2;LJP>^9P3 (1E&C@#H0N&)Z!=- *"
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MJ)8#9Z/3TZ/1DTON=0(%[C=DF U7;UD^Q(\2 )%P8KZ'IJ- AY^\MW%+>-V
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MVJ8LWO(UK5+SC:GUEFJZ[8^A@R=M()Z<;D9+J=G&490[TN&WW%U<G8R+P_I
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M:4;[,"IR6>XFN$+%FWLN<EW67\"E&_)_UZ<IH]^=5T=#W-=R+ZRVV+_CB@D
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M-+#VW0*:@\B8&5JA0'J\7&J[YQE%#X&2#Y38;4O^N(K'AJZ2%,=FL1*S.W+
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M3K)K,:72.[V^0ANB!S=P?@MBL5E&-DF^:<5)XF?5+B(C1(Y=>R3\5FDI!H<
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M!3*G@=LC!L<"X9A]?1B@ NPSHJ5H".)'>&Y&K)% ?P[)_D,'W/;T,@,#$G\
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M.300L*1(I[^I_(F<3NO&_U[_>_WO];_7_U[_O/2;P6A=Q+?<F3TZ$FA2"G1
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MZ;UA^O68F#>!W,:?U/T(8:P: BG<VT\VS2\^G2.!QDZWT:\CWPJ&'4!PX([
MRZ.!S+@E$PPYGEFZ.U^YT/A= 77ANZ@AFAV#M_)4S9Q?O3-HRI81O3#:P(DX
M'!Q;-;#+ASRO"C]9X;=U[9/#1M[MEX%];;WQ%](MJK <7\RD07P[D!;BU2&9
M@+DT2+L4]<SD3L!-B!1JJ<<;W]'-A)J]^ID]X\[Q7KJH%IWR,W2GXGTI,4YG
MB!,SY'BA(KG4@(6>*W715>(?-Y;JHLXXR\=S3T",0-A"/IJ6)@DTL&<+G!6
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MF+?N(H'"D!26H4+G<5G]MVM?>N66CJ>XUG9N\8I:4VTJ2<@]/[(LHG\2W;\
M?T04OMR"]GKJ(%H@,"+SYH+W:T69X\*W"V>MHQ:8YJOP+@LDT&F\Z(#EF+]F
ML=%RG>5#NGYWW%175OYJ[_H1&6;0,C?BN9Q,X!"<6DXHL!]&Z_X=KLZ(_E_6
M!QP= @W%F<.7[^K<;?::?*4GCC^GK%4-=&[68+J93]V+1D:XT%6?')2QG4!:
MD7 SDP1H)X/F+3<"# RQ1P9+[85Y"'B.=U85Y:Y\5:9NW]/;GGRVR9A5V,U<
M$1QL$4R1:XL7)>0V,>&AHRQ_H>&1 AZRBCHUY?$\#J\]R#@+52.,R1(J6.]0
MO!XTZ8]MNNQM/.<9(PJE7TOR98L4:X]?05L^M+;C[I'LLCHVG@*4]55++6QN
M=V+>3W95E?5>1)5X6;LYL =\3KJLA4L![3'S ;S:.L4:Z;= 0JKKWJX^,[8W
M"BDNR'2JCI^7CGR4FOR<_,9GUC+* /LEH8_BV!?#'I*5C5Q=9ORU39C^IZ*)
M]A*;F2EZ:?Z)=\@*&1?NR!]1N2/<?/21W$96C=!3.+L,&=K]ALS]>7MU9L-D
M=\]U=L,)6,.E:$/,5I1V(!/>#P?#/,W3I,"E#QNDD\]<?D-S:K51W.<N;]/4
M7J<DW9&9044%'R_JD.)Q\;/\8NAL%<XH9_H;W5P?C]PXIP4%>B3:\U!"1H,Z
M1FT^I.&:VFO;:EH3#<]XBR<JM\162* CT4H!S[ K^^H'9_"';V^D'<C@ E6^
M;'L(,+*Q;W&]:@5%P4W:+20WW6ZP[RI:>-=W&H$?N;-$V[<;Y5;%YAHO?*BK
M<RX\N4Q1(/OH\_@3_"U"?A.#_UT<!,.GA.Z/$A#:54+W%;P=N_V@VL?%5O"F
M3WX]"30KF4&3LXP(@\TF0;YRX+:(K6(DT#Y/T3()% ZMI&F="?$=QRH_;;AO
M>[\@RJDR@L?1,E96/#RN"M9<=H,]3S'0/'"&760 #\/XS4U7SO7>G308*A7)
M;Z@OTI_*B2RX1N.L[.RL[$O@Q5"$5R!/+N\9597G&]OZ.A0ZI:QNRK/:R'9G
M4#/S=;@[34K/5C667$FT79B\Z+G)H>UR#'W+X!7-=#=SWD(]_09OR_-KSW2B
MGD@Q@XSXNF04#^[YLZ$1X3D#NT)L!EWY71<C%$.97D>SLIX9ZHR*D%]+FF\2
MP^@569?"6O[:^:2@41>ZW[ET=V@Q],OT#<R[,,U'H7JL9VS(=MY&\"T@)B>Q
M634XAZR.61+H..YI1?_Y7EZQC(O5S]3)LY7:15P3/^:D9?.JG?ZX=@-L/@B5
M)78BF1MX%K9"FMC0?2]+FG+G'5A4@E>3OAKWE;"XFUNZ4RYY>5B8YK5KHMSF
M8*UIZA4SYW"M[]NT3)PJ0CAK4V1VII\5)9) CX_<8,]4= %3!XKBP OD#>7>
MD/8DWYEX,K535MDIHK)4M^9,E6OI)P>.*-+=^=_K_^:"@F M>L@OR; I;1+H
MX=K6/HZ,2%E) HG4$^?A!]8WF +!X*IA;PMU9KVM]2!K\(0G"60>]'F=11B>
M*NTR#N^L$9K8:A_ "Q(*B9,8I-KH>*>X]K$@K1%.%@'KYP_/W7[Q[?D3>E-C
MN]/.SI3[%$!Q-IL/1<=Z>ZD.(>>, K+7Q<J,OLU,3GJMWZ@OPUI$+4AT(ZX;
M^'L=> 0.&&G4R4BA-)+!$[,IJR<^3DZ@E!8_5A2#O*13R0HX3]V[0V%- I&S
MXX(]H-%$5G12ML [=%.L WGO:&,!RZ=%5TL/"M";<&Z3])..2NHN,'"38&!_
MN@SN08K^(_R10F]H>Y4F[=LF,09T=L8]3I7/*A,SW :A][J<S6Y<:1S&XG'@
M^:<R+G/]D7(TPY='<X?O,FYM;&3;6D;//>NFZZ#@?[7QT!W5E#-8#&M1%1+=
M$%(=;J!&']Q!8I['\TX;FMVR"O$--0A6_R+)Q<A_GA5M<U0:QFX'.0.9?5FW
M.%8DDZR/%::6W+QBWLO;Y7/FIHHDYT7%[K4J8$.=38,<]6=:F F;OH11CA!A
M =.:EKY&F388O;KD/1M],4:)-SJQAVE_@<.)\4MC.?;Y*%X!$=C>Q#TBHYNM
M,$?P_=)Y4M#](]=U_F.?%"O5[OE/NL3UG5;2N&Z"P)\E@8BW&9 DD(5H%S$>
M=8?B";%/RAT,U&2SF<E-S .C)2(N^78HUY:&5S>>]5ZZXO=HD,N$,#B3TD+(
MDN.Q";Q$*-\J#;PX.6-'/(G>6+-=4BL[\JJ+$ARGFW:<W='X"^NY<9"^)CJ/
M>-<M@ 2Z_\F>!%)Q+,HF9#60S?=/]&/S*G&C&3;::TVL-;4'EL!V>G.>PCM*
MG_;=#6GQXY[Z'$S^'D8@# 2E-M_5*L2J/K>A/Z<9X@$A6]OWGVF*$[CP]ND
M2&M$@<]<\?[>FY/=W1+T.WL;AG*I& XLYT#3!3MFQ:@FKMJRH>Z1SY514^VF
M ^^?7A'G91!JEFA9Z15;(%+2(_ W,4JQ.7@NG%, 0J3V?)R=S:W4F*MGVM?S
ML[_TU'8*M\XN(0E-.?7)6/61="+CQE:*'YG+*4'3LPJ\CKKFQV=/WY!@VJ$[
M B>!CF'0FF')LW)/Y^4S5H+:U=U\:$>)76#4>Y]BL6^37@NL%K)\2W#<%?H*
M<3B#S'TGE[.:QYK WI\C%$^5OO9^?)?F&"VJ*8,$>N(#ZT8L0W>_^9! V:@F
M"^ 5$Q*H^QX&2G@42WRN<(,)C@["N1'9A4F@$^/8X\G KR5L=3(A%LM-[*Y>
M3ZWZ)NUIX27196:_,ZD\Z [4/2M)^XZ)]QU>VXZMO651D]#CSC*KT;D# LM#
M4Y"LB$WBD<!IBJ[IBT-"K]';9ET!I\;*@K#A*1^56J^U\UA)/[ZKS+<LCQC8
M"B%"JG"YL[(<'7J>^KX>I;DL*FPE7\E?@CRA+XXJ2[N-9](=V1['T]G/.^;.
M0I]4I2@EN%S.(5YJ/&!K'SQ;@K6Z^96;X_5"F69A$MLJ9.(Z5A_GXH*F:-M/
MJI\+$&^7*D4^$!)$B)XX5OJXFS?NW(?[^F1\3S0T?$J7L'VX<P&8A5E\BF<$
M&2Y(K=;T9BO#O2Q/RO<8RV?'%\WE94?<CZ5\ZYGMWZ@57R>!T)O]S9 S#=2(
M#H1-_EC5)0D]#BFRYRK'0E07+GIQ/WR4QY[!.M/L]PUFK3F9K8.#97_J(S*,
M.,'5X\>4!1)M/B1]WJ\3UOTT3MYH?QW[""T>N@.=[&]I @_C(;D?E\69DR)9
M4::5S[50[]ZJ,\897;Z3<Y7SC++DE\;S6$V<^ )-!!Q<"8Z1$Q^Z/%",\D'P
M"PAR6-HNQJE>&7THGLS,SAC[(J33IXOO0 7V7K&!&I@:IA0DD'+7#7 F$=@*
M8^?8!&7%;PX]=#>5$GN@)BLU(3!W5T/EQ".0RF>,V>7#1W5UY^&6B%.PG:;I
MID<(^.%S,_[=7K$!^0@4GPE>0''R9J.?&!%:2 *U:(14X[D%6#]0H"!S%Q_=
M\%M:WV-!GK+>P2)>D$ /8).11*;)N:DF!A(HF(]XEN8:T7@&6/SM"*DLH^<=
M^R_O/UQ+)_ NQ3:X8#2Q>(Q&2(ZM'+V4<MAZ[@.]*.G)&] CK]-=0>;G,T#L
M-<=20#LK5'#<9=!,317%]%KL1A_DE'E]+(XK+\0=RA3X(3G%$YG]T3[%!T/>
M'CI\MU(M//)$9MM#9R7E4KY,0I$,E06Z!WMV7(;O=9*?[)5A]4I#QOLYE_9G
MW(,]^2<L-D?5B">S2: K6UX >Y-P CTUR!^H_HY-H/7#&FPQ9!UEWF'RPZ++
M&Q7+N8]%I24VCVE^>5RK4( *Z# A9" 7.<V8 &:VPDB@'3[?1D"PG 2*?[K@
M=$"N"$R[$*W_& ,"!I'_=3AH%GY K@8,B@Z '=R'=9<??MCVQHO8E[@-Q]--
MSFD@Y\G1U5'N:7(+6L,5N"OER ,1J]XW_&R<]X[??%4C,'"FJ3((HX!]WXA;
M.9!=;6)&CS^I+!"],JQ@CRIIY2FOB."7*7U[U-78\?ALGL#CA*A'[G"T!OC;
M!>A9R!H62KALA''"<2%:8*?]#7"QI6;>6:T"4,U!_H4D ;E9QU"5'-?"OD8F
M'3Y\7E3<BMDP  UHAN/),1Q$I!4)-*2+2 /V[)D(YKT6))UW6 >#&7,3!A(Z
M7Q$S:12DSI)7K6P^V%<TQ<=!EGX5']<!\N7:P*#[E7$4&([F="$T?;'9^7KD
M]I>O[J-?LR+\/,.?TE)0Q7$?.T63G,<E-8.^&^V-*VH!C'J\?7*]P,!L^J')
MG/^[=3@99$M?$F/1 33Y>#J6^:70'<1Q[T 22 /=&8]@:FJ2#V=0TA89IK],
MMW'K"-E95;2&LS0-CI<A^7A8#O[BL(-.2<DKYN@&U2[.2P(II9H#E"#LX0ZB
MAG-#][>8G<%43L==WHK<J-@9O3S*5?OBFZO*Z26J$S A2L:0]PG-DOVBZ/%6
M9+39\7K<Z#R8'6\YL(4W<XKL=; Z1FMRJ_QZE$]<]R6>6_*5^G'#,>2!"'])
MQ80Y9"CMB)18@AWEFW<<W69\VSVM O,T.*Z9KFC?-4/T*+%D5EV%LRKL3D7L
MI=LRS1@I26G_CCDCL?LCVWLJH&TX+=X:K9=P<-O;N@MR0B1:K;7.W74R]9/8
M//>L,NQJ<?Y3NJ@L\5@;OKB^S<15$JA:8'2O@P8UW@(]O5GZN7JP^J-!9WC7
MB3WM(YPU*_6GLO-NT:]#3I% #C0L>$=<Y?'$65C8E:46_N7+(Y5BWE9/KL)\
M^.-Y;$86I"U8GG(4]+-"-[;03AU&D'8$#=X2G?@<%;'2.C7-><+2S[#D\PQ=
MAWY:L,.QV#KM>'%*T ;0J"(FW.;ZP@XDUXS"PAJ$[V>LIH.?2$<:3W(_4;L4
MINOQLJM7</'!8K=D2Z\;](TR_N56>^S!B57HOE-UJ?Z"UT:FRX&\/^V8O_CL
M%OF:WO@UU#?4QFZS@KV5$P/G,_Y':1,HB@]GMA^=O%2'^,A!_&MO7ID0["%$
M$ =6JVA8BQ21%F<]'Q;;H.PQ'_U_L?=>44U]4;]H$*0($GJ'@* @58H4*4&1
M+@+^I9>H@#0!$8$ D5"D2D= 40E%BE(B':1WD%X$!*FA0R1!B!L3DIO_=^XW
M[CUWW#O.>3GC?@_G8;YE9.\]UYR_LM=:>RE=])TSJ$LT#6/NY7!XZ_I,K49$
MD(:QBPZQI,Z%$D2H%9,$SUI:-2 OGSR:].&]-_4K>VS^28R]X<U+GU._)BEG
M"2%Z65AEZJC,:4T!#4[B&<BM6.BQALS[,S1R@]BJ30'!;D#)22:@OS#"^$0X
MDY-\PB>2S?=Z9E/B<]?I@^.6..4[[[J>BM'DT.$<8P[4GLI@_!;"UI$]X/B\
MBU/3:^/=S0@9'S=$.HK]+%;3Z@/=,[#8RQ#6$0/L6%_'<_@&9AJZ6N!,C^=Y
MA1^X"43[%YE5 ?IR6,OV6SB#A^EOL9OJ8K1)[].CF[^NSD*Q=D2]<:(1XDIM
M/2XXXB19N2L/TA1G.7/=89#[4NP=%?;>=TQFS6_^#&$V00(@@O=%27,\DL09
M/F<Q>[RO;4TTPV$7[1R='3[6V-=HQ5<*7KO,)UWV;15O"\'=0=$!878XP_C
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M@%-(9Z@%Y(\OIV$4T&Q(N.=O16S+\'B[S+^;2DL$S:GDQ<CJ0D02/BY;AU-
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M7/_B@4R)8>E2W["^=/Q+W];(+'%MW=79,RX:'+565_-T9 $D_K<!WN!MI4<
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M^C$1H1W Y512/%F3 OJ2W$%.]"(F4A]^B4H3=A30T&U\XUE4(04TV=VV0K[
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M)Q9_<8I5WS'P E\D4]&N]2%& =!_[L>A5^8][T*P+<AA\,I^(%32K<L@'F1
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MV_ *W2L,7G]?KWC.!%X4&/NUY9/8[EJCFX2- ;%42X)HG*S^E[T.A<=A/U%
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M^J::K:>PJ6MRJL80:GMDO%0T:C+^>^8N5M=.*Y$/>27Q U+\J&?^P)U8W3;
MZ>C7V"'-X7@\GI;3O6(.]]>*2AI"E7KT9"=8A.CB!-T"DS)!R4BGI PP:9MP
MORTEATLOQ@CF^-,S+"HVD>6O/Z.,!H':^JD)+Q&&L8HA?FPV">2=8&U'9^LS
MM5EO2"X;ONMJP G;U@C[E @.G_('#@6RCHSH#"/\,0'V!F&(7]+>:;Y:4X(+
M]JR_7]$=?JWSS@2]K2$E8@JL^<WALI9F'$3YOL:I'R,'I>\2&#V_.?,)\;%]
M8\0E6G-2;HZAW;'0*!0KPC0'(3M"0>8UE(C46SKYO6>IRLC_R\D];-S%>Y<W
MX@VU&FP-'#)?OME 113(Q4ES;"1@Y_G78\J<'SZ8YF,E[CSX$P[PX(( P!YR
M&*EQ#LJK) VL5#4.]'Y.9*0B8@+5-[IGZ20*TQ/N1[2+%WJ\*%V]=.N?DE(F
MLW2+^D52UCDX,0-7JUL9-*A?O/57LR<K/JN$%]N\#/2) XL$3\%IT@O6S,'E
MC91TQ4[P\3;7:?C8&$*%Q(9="Q33(M)A[:.<Y?L\^FFK1RI.Q!7T59^_] A\
M8]2YK-2S(B;\C=&1(OX?G<*+TVE#<LW/OC#X24IZYJ];M/CN*_ *^N4RH'(@
M&J14\G\I1&ZB>"MB_O@O;,=5D#G=?=VS9H7UN;O?[:0MG@'! ?,D#H_&<E S
MWGZA),0['6Q16UI7^V?<;M3665W'BQ7M+DA3=W/VR\!;#^42FTP0Z"3&.\;
M_,"3@'Y7%B5<ILA933^G3-,_#:5<'&J(E0!A4R+451WPV!)61S#;G6G)"WU2
MKD45R\.9OD+!'.FV,X/?TK-XA$^<#.P/WA*E0]#FOT@)&%#,*T+]NI%O=9W
M=]!7&XG=78!JNAOB+/QZ(;C=9"R0@^)+BG(43<26@.'(>X-;[.WO,G@K?5(=
M_K'TUCTPDJ7G P_D .X-\L3B2B+;*?V*+Q;,,H=T@'&E0<BHF]?GRXV?67]F
MO]&2'T_G=(B,"&0E=(:<LJQ^;'6$96DZ_KA5YO3D0<P=\4':9&LYFJWUMD/Y
M ?CV@2];8!\7\C(%[,ZGI)L\%6!F/*5;KQ_%,\GR+0G\ R?,?-%/G"0I#PJW
M;3%+VXIV%B*+K^$'# >/'C]+W')/)!G2]9RG6.\H9X2BMS,A9:%](OI.3,S7
M; %1HN426MK+9^%C+>T^71#UZY>+]M[ZY#OS,'6V4:1#P=>]#7ZA%R-)$B6;
ML[?MQN>\X_%5'>C8UU0DD^<+C2%G '\#KX,>1AH$GV]EP$3RCX_OK(]KHT,4
M7G4ZO15_K*=TRV^_0R*'Q$J&;* N(?QQ_K,ZYA%MJ6*1-F$9_C]MO=6:NC__
MC/WYES/)PN;?0NS^':H$,A=%E; TT33-Y+=K4#Y6&>!G_K62H;[K_< UT\78
M:U+T'>Q75*[HK2@7NDYNMTSYM**FY'!6G[]/%ZP=N)GUN<)</+C\OB)R-@9K
M+=ZU.ZZ> <"I..(:>G3O# B;DQH2(J1OXMT%4-A+V8ZWOM8=O7E2_=(V#\ E
M9CS>WB03J-L:Z1L$2;W6$_MD5U:D2SLU;^5,.9I2T3Y8/&:YV>S6N40=/ @@
M3L@*ZQHL\DQ@4Z)= B%7GX@_+?KU]U#E-"MONE/AE#[*V'@F7RY#98O?368=
M?)%"301KG7RW)SY?:9UVO0!W??[[G Z'6Y]4I<[F&)H*LV8M7FG681@M'?@+
ML].8W,:"6U!L&R:H2Q1HUJ2#&7IYW1ED'7V?\8H L4R"SS9X< 'P>7EU[12$
M8)B@J.**GG;.J1'9 X6(89O7Q^7+[_,790N57:"%OG2[S>!]RP#P=_[?/28&
MX4_<V6BO0E;YA+XA:&6@D%AY0O>.X!C#)1Y$;Q\Y\HTR0Y+RAK6-R8" )*&A
MW)/L0I*PC-!M2'E035C\8) G4I[FL"BZ?6DXN$+Q+YH-]<5O\"*2I-?H)'W,
M3J$_ Y!OSH#%Z+:3H%0,6@Z'@_]*L;?VE.T\O+_)&W30#UO//VH]D"845V.<
MI3OSBAP.C^_/;.P87)B?0M.^Z(E5V:+V(,??H.X.9*<8-)*@9"8GL_Y/B#_&
MEL8P5=/?H*0=#EZ"?QBC3H/$\![T7ZY!:"OGU+<,H0E!4M(K+K&VZ_O5.E[:
MF\Y;P37*B[&[%HTMC4%3\_$:MNG0YKH,E$\FK.]7GX\]<R[U].]$4U-%B:![
MOQEK.Q$'Q;FM_X&)1$FX,T5.K$7-BS2NI/5E3-0@U?$#TX]WG^)J3J]3">Z&
M]@$>YPDY[0Q@?$J$#BP'I$Y\'=D.B/,<F<LAL9%OPOVQ*<T)S!N!4F/>,>2-
M-#LRN]OL%\P(EKDG1)B:!^<NEB<6OWCRI=#5&_FO&BO,>;!K96TM6ORAE?'-
M8H9VQ?/+^;0ODA>H1B?^!/:I&!R$$L2:IP)SW[CG6C?;5\',:U)OVJK^PWP.
M$CQQH&X]O8BP'X=<(\M1[OUI1*>\:" $X-O3P]HG9TQUM<)>).E=T(;8;WV@
M>T@<8-R8IZ$\S?I92E1L;[@QCG#U_5KL\N-*_I2R,CTG>ZRT0%8\P,V!!P.!
M3.MSUTE0HD]+W>E79*9";3[TP%0:;\5'R>P4CZ#VB+CLH8(KLB#Y$V%8D^9&
MNDFX=!N*GJ*%E3BYKE$ZN:["9^?OB'D2&:J2QQ <C+HK2T5C>-%UT@>[7(U%
MTB >$OKC"@VPYO/,S<(95T>E!X\.6>L>7M.C1GH/*6G,=PI>)@Y<,*?P$^WB
MA*U9(7I8 P9L*$_@2-YZV=\&@PY<11X0!$SI(@0:QO936O9(]5@0%:G@"=$2
MWQ"&98+^#6" DB&/[I2&[[1]L48)%]_G%)16$H[>B6JX!D<9#FI'$.\O<!;@
MK*],AP=7JEK*B%;7M/(7BNAV):R_CZ?8LU,5$*F;4OP.-V&>X-C]7C#7^E41
M=&I<?&GV'&3H45=QJ?)'ZK_B9;(?YX$,3TOHIB4!=Y^0T,(OUW;U[16M/'CT
M^$UO.E_3SU,*GZX]AT@SSTHP8!2;&J_ D0?/B*@P;WWYZG'OT8;Z\N&D@/DW
MLG<+&$6B!/F)(;ZGZH\]+:4W$[!,EH'\DR0=<T)@/:9@ #0MK(U[7@ZWJ9_9
ML>^QHU;":6Q?!O:1D=8[@J2TT^84C>.;!<O60?,[-NH29\!OX^HSX,=222[:
MVU5R)01RGX85LMN;:R'LWI'S]5];$T!G!'4ZPBV4A.[C)0YN$!4B_'\X&?O-
M3-F5\/DYMV='>6P2NU@?O'81B>(&/#-N4*-(0N1;JV#.0$:2IP4QO*C0Z6I8
M>T:O2/AV3PPTBD$8=H4J%G/_BF<2M%9EOOQQA#.Q=<$Z$L*&@_46>4SH3&27
M:SNFB^S8LJ)-$8N4CD>,!(!?QJJ9?&=-<0K4A*)S/$[_W)&.O)@Q6>2"=<B)
MW;8--P9"]TO43F(H$D4D<WWB.LQ,[?3#H0KEX]WJ@Q*J9-DLYOJ@F09<-+"C
M,9F T8AX?9).>8[#.2M2A!/7IBJ_I/4[9UA/_K.U?[20 1LZO515I6&3?@N.
M-!NA*.9]D;ZP?ORMXX8D%W[$U:/Y,?-,D'NSX$'.R3<*N,0!628=?<=9Y\%H
MQ8F5@[<,)\K;4=B'V>H*RZVWU/R=P<%]GOH$9(?5C9/W7M(,DX[5R>K7*FI2
MUP.N;RE49SB,[[S;Z5&B$Y:MH>-IZGQR5\ [_YS6RO=+(AY9$S["/[:?JI!5
M>>0EQ?!7-*843I:D\G,4!93%^!_#ABNL.=<;9,^ D, -G[J^Q=2P3>/RZ8#\
M=Y+"D2F U+)8$BUM ' \?II(O-]1-Q$*#:7P$W2>$7[FN3LY7UTQ"MWT<_XN
M49G-^(P'X!'TAGAO#\#IFC-$JTXB(":8M!)FIZKC30^+=H%TD=@"=X4W.A=9
MBBWX.R]J\H'OWV4Q/?U;9QV%M(=#W+%,]B9HHA/)RRG9!/;.6%5>'RE[*2L6
MN/#^&5V#AX?X?#,JZ*"Q(J*%7ZP=Q8+6+(*II(]ZF/_#HV_R?W*KOUO(QNW(
MH/WWK^>WV-VD@(*'0]Z7SH WYFHBFU(FSZTOYN25.KQX+$J^9"UMI^@ZNX/O
M\&Q_?I+HI:;?:ET^\'YOUAI:-US)'3BQ/&75--@KX+)L4\M]03:;-7$P]*Z
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MTBL0_\;O'T'*TN?@8M@#OU=GBVB=XP_1+4R<LD^RG[\UK*"HBP].%J1JH@8
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M6T5;0G5A;Z*JA;R4.BOA5I]QTGP4=Z(V&L)?/ W7:/:3Q*WU%C"PH^M'75A
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M0W,.MBR^K' /4]I;>!Y]@UK#BG#Z%9LNBM,?OR6YKZ:">=<+\^9.4A18(.^
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M/HOX&2XWX5'*+1MV=[?;IUMX TL:W>:9OF[Q</K!-0.N!SH 8_JA5#HW3RB
M0E.8X*3/C^.K/^:W9O)Y7"5/$.P?A:)=T[AUGJ[H<=5.T8##"SX,O4)],+4L
MDT65UR],-1TK#D<9/?.P@KW2@QT?^Z]-2/US7;3G<R>7)<MG)\YZ?-@ES_,\
M\;0>K<2 QNAM=AK0#C^(<WMM<%@*>H?:T?^T9!,V*0-7'[>6U+^U/QR,O-=
MA1U@Y@=>HUF0/M S2$'"[-I7R7Z#R.Z=V]+N,$1MHYZ@_AG_H5HZ!Q&-B)AF
M:"B&"\9/0+"#/FT-CZ$!V4D$B4<R0QL;BY_#9=2-UP98,\!BG.<RE1F$&Q-1
M@LIFYOTK07=)CIFYHSXDZ,^RN(%6&G!1J5V [>C:8;HR8-@4;4(P471 /6CP
M:R\(PV+51+Y7KJF9";)[VO#-R?A[&S4+FA_BEA[HL#FW"<\B=<EH4EL0E1-Y
MXZ'#6<09$(ZH&G!P<"P0VI _^MREUCV#/7F8Z7DXN^:9N;IOGWS5G8=*T"$T
M@$/],DIQN!1Z6":0HIQN=OM"\UV[LIU31Y#$YPX1?C7BOI5P9(KSPU'=!HGU
M0)7 ZJS"ADD(ZE:?HXQE3;^\7M(/B1R+=_/M*=V5Y_09$F!N*^K9GWR5,&\%
MSV").+_T\D$Y. 1T,4@R3G-0;5*HT_YJ$@P(^EB/'IGC88I4XNI"/2'"@Y^3
M$MZBO/$L_-[&ICTGR#M\IIO!ZK]MK_BV?[\\6A D63DM/*_4L%TEQM@*XZ;W
M&2XD=IH%I47R"8,&3/>7]&<NJJA,Z+HJ=K=DIAE'B5]1-TA/4]GJ('O^9:KO
M@?$-:O\&UFMV!4><5V[#EMXO)TY&.W-B;7\7^5M8FY[9&_K-N9N(DU13OIF:
M?X=_6K%Q'QV6=KBRYW.UM_JJY<UJ_H76VZ4_K2_7J4:F1UVU?U],&FX5@.J;
M".CB(^JP7Z[6/1J4ZW*;8+D9?\8C^4)S,,34 =[C=8$STG^VUF)*/[*P#H)Z
MQ!T_ZHT+@]EZL*YXWDE5VI@:.R\0^.A&KJHFSE%)5'X)6Q+55&M!B&ITT+_:
M,Z<]('C=VL0VY;.[/7_@I6HWUJ@LC6Z5*'UZ^ST"/^*A(6B.FE.9-GN()A,H
ML^V>8X8]6ATCF&FW\?O*)?ZG1Z_9?#GVS.R-ZGU E1R#1+1BCE$O(O/,B86!
ML:TJS*'AQL:G;=%<F2UQH])]]3^NECBRW5%F7L15&FI 11?1Q?,1-1YX2.A0
MG4QQ<:\KEMVNQV[47K+#V6%.Y]A])>$5Z%+W%-LQ)?E\YJ8#E_M\KF_1Q9.^
M)1)-PO9>7^U./C(=$8=L1W!>9K@HFOHQN(U7-/_/-'2N*4_S-R3FJ?(0V%,'
M/.+H&-C6E$3^*%+TW&+@Z7=[EA -#MWS[1Y1XD='4MC&I[QF.1FFU0$B.K2.
MF2)@LW7 !N=#MJZ1;^M06UFVBD/F$S=%.H1YCH>]:9^WW<Y#L+]V$@31!+?4
M:9EC38JA<O'?'%0-B#5)P>4&[H$FP;"FV: IQI3GTJHSGG]2QIZ@G"+DWR,4
ME))$6Q4N+1B7\]DM5+F%L#:.R]?FO+O1)1FVD6 ]SU(_G[1N4J_BA=+3Y^<M
M0)?>TW/@T:I$10G_+#[=^GML1XSW=[C;NIG47]8J"$Q#@K#$>#MGLP/L2O6Y
MDR\VW.=/M"F/PVOWC"VT[S\GK$5Z@I[(#UXJ7Y;W5E[6\8%_]A-?*W?(0=L>
M9'3\WL<*.;[*]%Q3KXM+)!7BK3Y.MQ"IY?@Q\#6.!VFW6+!5'98IPCP.Q/-J
MS%M\\;T^'[HU*O8^)75$"24O*7E&+$]JCYH=V44Z15A^=) &??NN+7=*9G26
MQ%I4S%P]Y4.,(KOYKYOZ1!,AS=23H"NQ2?/(V$-L'\R6K3*WPXJ@]-%_9W;D
M5L#-@"MB4X[*BRW>%[3U!I!MJP+$>7/2YS26P==FTI/-(?B#>ZOEYH)5J><B
M=Q5\U:UW%:79%)TWH1]G79V.4G1(Y2U.@77G*HFNA8$U\OCE#LW^<]CR>.3;
M:/R\]V>1\0 &]F)O@B>A+IK>ISV(44$^PI2300AB>2#J@@,AXCB![-7%?]_[
MCH2SU075FNJW+I5^E[LMSH1OX<Z8A^PK@-^=_'RXPN[U;BUC>9 N)I4#V*)M
M]U"OVU=YGZL_OZ,SR]_:=VQ!]ZPKU,Q00Y 1#V%:<O=1Z'4\#T+I.,*P6/;*
M8^=QQ("1NZ)ED)B4#RXBG#]U!<VFO+,DE@ZY $Y/.;BT"@J#%JZ?'WD7L/(W
MOYN<A">%S-2GSQ)_LGASBX[6VM']<!+H-"4 QZ/]7F-9%N^9CMONO;JB?6%:
MXD9#:LJ:^!>5HH7#KTO^'Q5BA<S0I@%O8YM4ZJ+GO3&KY-C'NV/N'EX]!2O/
MK7F[KTC<"?6RNT;XHMUHH@9)1./#:,"2,PWX@: !CH4NH/T4%C1..]Y? R?C
M5B%%NYA%0>,$+"J<!K@[MRI:%-HM+N2+&KER?<;Q,\8\N3(:678:(YE4MN%I
MLU?^B^@$0<JVP1E<;YOW-ZIP82-07+EF'=Y.66'@RKK<B*D?_=D.X>=;O$PN
M8)LW'A&,X587 F4?#:,4+:9269JXNU#?<#E2L[/]<:U V(QAFQM.;<^XKO>1
M('X.<Q@%S0-UT,$.>8^]W]G52=4.K-  9-3<V/5W;]'O4RO%QL\(*G/-I3$0
M$<TR;ZO:PAQ>U!S.!K-HP/W! ID5"L(Y5XN[4T93I<RJ<5O<=UZ2V:QMT4Z,
M<>;/WODX'Z6^.J[%D< )^!G0HN7>LJ?G^*W 2<.K.IIB;<_:5:R93OH=<3%C
M#I7#A").U8E0% >=:DZD\??(L>JO&CMWY)F,WWI8< (C9/'LC>^1A_$PXSY.
M ^;.,C33N@\_Z-\<OT@,:Z(!ITH<KE)O:^EC*Q0,S49#E.T];C=2VK/7XKH9
M8"YO5J%':A1S0.N&.J,\_#H;^'B/,'<SJ!\F^^)<>3#[H2"AH%@[W^Y+; #C
MH>HO8D!A@H\8TIH #U>75?CXA:*$::$>[FVGMO=QFQ27EZ4].>(HJOL,D8)_
M>.*$=9W/)SIMTH @'Q&2;O"?X_'>)C1<05ZJ-W28]K[#@H.QNY^<]?Y=(> Y
M/YI/5TS]6Q!^)*;E]*9IW4<"9\G-G%G+RV?+=:YMU!OH:*7,I/UJ>5WR7UCK
MY8)FKW&U)BXWG5I6C"]/P)N="\3I^W:I-1<TW)4S'(BQ[X+3A76HH!08^Q6E
M(2A1QO>\RC&#\_3H]?M=,3P=&R,#EF,?A6.[G=^T %[>7)MM@11-DL2T*S8$
M=1N/X#$!$=HEV+0V[?[(!-;&B> [L(X9=*)6F6Z[SH3G=+(BIB1UL&UE\NET
M&/]1X^;1\(Y,S>RR6S=SY++.J\S;B'<?T:MG5%M@G,PI/#0$TZ232%HEGF62
M"UD'Y45ZF0X\ZUV?=KC"KU.49H"J?&9#?,1XZ.C+.\RYTY,V_Z=7<_WW7W7/
MP2X2-T$(I46\I5#EW18 .UTG_ZUW E]PW,QNI2_F^H-%1R,%'CCZY=(59GM2
M4_/CNNSI* :*<J^\?>HQBJY42VM&[L/R!!?6S"HGB5/OW(K3%('K;1]G&$=R
M"H\2*55MC?#(/1G_3-*1(@+\!)BA7Y&$VW=;&,?9NSLJMI^VXD\\#JW29_+?
M_DE,2_[JTS.Z$RE?2;$FR+ M[)GG*X1D/+;A[K+QU3BR''(?,G':BHEYY6C;
M+<";2]O#>F5Z.A]!U[N0^:CF*QY[U*!<TX6$'7XWWLPWOA/&C+;BG='+L9-<
M2Z__SQ_W]+]Y&?M3<="-^W6*-.!7(V9/<KC&"!*$8OD37Q^6%Q#O_!-?KZ_&
MQG;]B:\S?/MYE32B0=<E-."[U$%Y4!W[LHI;AK- _G#0=L15*3WA)^H_C71>
MF?0X='1LJ<=-7UXL5\!^MPZ"Z<)D6(,H(D7+FXYG6NR&I=_@RFZDC5^2WZ(!
M87#KPJ ZQ6'K(7D,F[9+CJG#_K7H\=O'QQU:)^6%7!]=?K/SIF!HN6G4DNRW
M)[SG79*DU4"^]^P90O3'6+G5SR?22FUV  DQ6D>0\FJD'NEY87DS;-6E>>A0
M[[,G+1EWS69YEKXHQ'BB&FN7:FA  YH!=9BX\]@,H4FDN%6]=_[PK"*)8!\8
M 'D0UN5V,O+Z[N4&H8^%&NF'ODG6Z$D-1[E& (UYK)&)%JCB0^ZR^E*C7$(]
M+)9"!],FVTV+T T3F#$->$:.H@&9*JF ^]_W>.<B#J]V[;L@-\F68.EG$-&X
MIQ_DM+5?RR&@-S.XFAUC*(1SY@7:5%@K I"MK_35,:^&9X(H7$W4.UI-:/+%
M,?2BY:RIJ[6@]*L B9:1((I:TS3S 8O/41I0SX^CWLR@"N))_M0 +!-ZBG6>
M!EP8;GYM-)Y#4B\VV8TJA^/7H#SP!1.B+A680&^808D[D'#HEM2?: '@!-^5
MKA/Z%'D?^BB?TC:&^?MW4:!74"MD[S3E) WP5<10$A G>W7%(5^'J!:KN+]_
MI_OW@A4&+V3$,0_9HR_OB^XS^@P+7CK(I0%X%3IO%-[NH;?ZBLPW[^1]OF.?
M)N</,GQHP)5'LE$7G,-=E7$\>P2L GHJ$KYIC%ZC9U!>NG?[X4T=KPI;Y;Z[
ML</4HX;:7*(&_ZWC *%&[8>7#F+KX9Q(+;H[?NM4=Y9RC63QK8^B9N$JD".6
MS3^;V'#2S\6_)"JZ0YP[WJ<+7KH%%:BQ)*PS@/X-.Y-L5"'0&)*+]"2O2@]W
M"D.N7'PG%JWYO&/TB/!5%L8D8$\P=),&1)C+DB;?4"3LT<0=_#!%\K?=S0$_
M!]']5ZRB';YM0G+4%_5Y3^/E?RFK6WE>+(QW70?%%%MDF"CF1/<F#)=/M^AU
MDFBH2(2#Y"K*R3[GSCF9TFR;U=4QNQRVD5?IP9,I$NP,._)<&\RM$%#,#-N(
M#1&4ZGL"NGY!^C<('J\J^DY"A$NM9T3(=11\$[I?+O[XY;'17T_]+D?>QUB
MB:1=%"_I)K[<5TZ-"V5(@/#H"W?G>LSH9ML6B2P6FKUUJCCQY1/J8\?92RV
MYRP2WA85Q4<#&FD ]\CBXP=IR<Y.\J%FLN;:0NK3PJ$:XDN7WPK4VD](T*%B
MC)%ZPSR1!CP)QFZ]'NP/"GV_*C13D<&%8$Y0J?!0^K%\'TK\)7B%!J1;!=
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M1E-&FF"L=L:W"8@H'"DD6V.FS#.G]3F00:V*4':8QS1+CN@03%/MK9N$>'W
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M;$0AZ@$Z>%Y;749ENZ<&P;YKTA+,V+%!Z8;E5^[7^LU'E,ZKGR99@)UT:1!
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M:6L^_+_8>^^HIKKM;70C* )2E%Y#4U!Z5UJP "(BH/06$14! 9$6(! !Z4U
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M#2% '=.W<XG(]@(^)[>=>%703X')QM9(LF!L6W2M/LWQ=Z&);&[>QY:DQB0
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MTL8]D)X_Z8&-F]M_I@T-TN;)ER7:I[5UJ27NB E7]6D=64.)[O4SCM N;&(
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MYNM)$KJT^J#HK9G>&NP)%6#V2X W*2,T".VU44&NQ.6+("JD#-YHD=9Q>5Y
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M[3PIR<RZ8"2:<U,R2OG2U_;S4A$/E$/=MW,(-YH%H*V-TX=LX,'CW2UUE>A
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MCB,7:)CM"=VVFY6I FE@39OZ))JQ^S#*_T_I#*\?;/?8#^1H&W*/ V6+.C6
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MT_59]ED(G<$5>S#ML&1U_QO(25Q$FR+_+5.&3%L]W:J7]0K_QOW_/(\W#HC
M.G\,Y=,HS6R[;_[U!+!P[R_OOD+Y@Z]AE)^P3+D%V>ZC G<KOOW+T*'-OIT)
M&KV#I[>&R1"Y2]I8?<^_C[Q4'Y(G</K9F.E\RWR=-/3,AT1%X%=Z8KI#7RO-
MX/6U!]<](I\+\286M(_P[&CZHP?&F\6.MY6?>!+/<DR:@>X)F])GU$NRXRM3
M'#O3LIUCV?MFW] [.M77?UXZF20\>\?JMK9RA(%U/:[I2K\?E(>L5N7(UKV=
M2WC]W-N=P<@EV/.4XIDY!G,5%6EAI15&=V#OH!AG\S,*MU&%TT]XC 7Q6EVY
MMES(VR54@Z'-T[(K.D]5_*50-<$Z\)T5*E#F8?=T2C3!%GS[DFQR+W/LI:8J
MS^_:\XF%:_<,F$*+@-P4A>D"9QI@R3P#XXB0BR",A@'XT( @B:AB>[AHA(KD
MCHK&9+RD4)4(?%N5;FC R6>F+SG8, %A2V,6O2,I%7!K6(AOH+<+CD6M+N19
M>*NJOF-&Y4]7;9&S9[M&,6X%;+_W,JM8:V-P)B'7!NXHN@=_2RUA6BD7UI,O
M(S5KT75[6K4#P7AN8_T16;3^J[&E;,^O3FX[3\JV=X[GEJ6^__I^+]+Z'GT,
MV$X%Q#-B]A,U>2EYY3+U%7_U*/S7]J#O#RN3&6-D?=K<11Y4LQCS2/RGR,W2
MH$".O@]=QD'WCUJ7C:;?^[,_X3_*O2/B\VY9Q.DM//]:0,^L%F9<=_@&R9OR
MC K0%-R^>Z3=P<HH[1?"B 9& L66/=\,HUY._D2J_/$J:"T56$PYR&HW4M8@
MO>"\=07:O9M=,('<[*29*RJP;+Y?1P6N(FFZC%)S9\!0A?V=.076\YTR005>
M0\&#Y4N[%#QFSX5FZJC 5JE\_+EGH==3UBEW2[:G]Y6H .TV>]^1-$P<@I"1
M5*#<UL^\IW7I*3)K0^T/;1?]X9&Z#]R&%D5DS/,Q4,6<=/?MF: 0):9SDP4X
MF/O*<A\%<N!Y\=[;\=YG\N@_[>7-[//ZXZUJ6J^D%OY;!;V^%0BILK*WPZH-
M6Y,4.MRXIOC2KS6%>(1T,=OW!C,C2IZP>([KK756R$RKX1]VMVK*4<K?7JMM
M"$UD]_%1\;L\8*Q$,W(HW-JXL0%Q(=VU#)X^TQ?KSTXW[GARN"[V5"QEV0.H
M>@/<=*6/4PR^O5G(#OU.X0-Y34!OHO^K(3^2Z0FX3%NZ\>M>Y=-R7HXB4_P<
MY \2K(LUX;/KJ(_:"O"&F&B_G.):>[7\07[]!OGA6&7Z]VR?72%10;5U!%YL
M2H>C]Q7BUFJJ2*F//X/&\9^RWRH=#:OY>F+9!.<_SST$&$5O??*T.!-E!M #
M;-^!:II51:22=):F3_B70SL#PTX,H:&>LDTGF_)WS(B\N6O^#VQN<=G4XBT<
M,4IG#[_GC;14Z^.W 7]=!JW=>&,\$4JRT./7NYT&/&_IQ^ )&V*[>C^9;O[<
M^L;FD[UE";H0Z;&C<6AC7\(J%6@=NA<FVAAZQ5&K32184*:.O@>>?5(K(Y;1
MK4,1V%)#8I\OF#XNNF#*44<^)4$;IX]?>72(52\UU@5%::YT=B\GA[XY!!MW
M/C'=!F%4P$&)BBD=M59?"A.?W;'F%/+OX/:=R ^Q_FB=L$@%CB'\9TU%X!Y.
M8%P0=JN2,!:2(*?12@F1W;G:>&FP^L7EB6$+^K[K'N/_XJ)8F<)Q^$:K+CMF
M8,5_[;B;YLG5J@=RJMV>!GLR00HE)_7BN0..&)Y\ZNF0^WZ+NQ&6,BU(9B1F
M&>Z70N^@^,B>1.$\*A"'-IJ5N5U'V'X*[=^\+-KT7EQ5%"_;X5N?-.WS<.T'
M_=:HU8BL*JOZK/FP@N?FI.YD8*]_X)EV+N.E;VV 3E<9DH%\A9#25GINE2R&
MR^-MMWIR-MEVT\1 \,NLRX!MT5V  %<C*)"Y93H#3(@I,Z;AVK:^_I!6CYS1
MX:UE0;74:7.;>7V;  ,-)5%-:4B[.ORSQ,?]U&*0I2QLR$EV&,%(PV->A"08
MH5H=0<)2&DOTBR:Z[JN'4;14&5S%U:&*$EJUV&=/V#^0'6>]V<C0 9@-\1JF
M&/0P,K09IP+6Z.21PW?/6BI?;GYH>C[?XS$5B*X$Q:B ?CKMQA1N'B@YH!'#
M"Y=JQ7"H6@^0;Q2ZA9T<=!PQ>#^\,ML0_OR:9>+#TPZ1_;/QY!_?=0\C=/;?
M8;P]4 QP[\]- H2UENFH5&\B7;]?0HC$N^G,YKK,RY8V%5NGJS<Y3!-Y&8"P
M9'@"SC62#"EW:]#]A/O$>6EX2R5!D-70/'HJI"KWEO1D)%0;4;AA33;"X=F;
M:\VFX)%V0YM:1B7&-A5J,F_PLT&Y6 FKAW0!VH>%\H=W[4E^;GMR,7@ZXG9?
MIX@0>@2ACYNDUZ\#7<7=UAW//6?PT+37?+O^\XIPSI/+/Z$I'B'KR^_))N#B
M3))69\-P9L$,)KQ!+K,(YVELU9@L> YMJM90)KVNR_6,%Y%3]P ?<:Z0O:'T
MK^0P.#D2QZK0;J=34?YRR2JX(\,O_\ZGK<>+VISR/A^%F:SX&9^$6&<A:,(E
M-7N"@J81E(O!4RD="$H(96'?O&5 'UZ"YYQ=$X1+.8*AD(@7C@8>W:2LIH%Q
M5;DW$Q>]AHR.W3>X?N'-Q%$)>2ZA"/V NCN^&U\M)MW6#?>60ARY9VLQ?*>(
MO&TH-B/LQ[E1LMP[N/*.8T1+^\T3CE>SU.-$1I^\'F613:C)LS@1>#-92X$=
M/FLW4G//4T%7!)Y^ONZ)DL?^A=FK<)?/DD<XG(RD)&\ZLTNZTI]*>%ELX&.-
M?/[#W$F+4->9?Y8(Z3 5_$V1J:P:\%O64;B*'E)-L,W$&?L_7\T8#[KP:+ R
M]H[9L^]GHF0#M4*XF7YF/YT\_1"CT.YPL!QH^'\_*ZYPQ062TV$\R!_B:U3@
MTJ<P680T ;HR5$KF__@=C22RMXWSMMTQ+N))?SVN6CO_5(-&!N>'GZ[N/CS6
M/?INBZOHH7TE*4<_+(A\<O\]VH2D36E%LI.=<?O,.QW*TQXWW'C* \,\?ZG?
MO$+L_E3T$(NHU6?D-\.H'P[IBX=Z],*PWBVD-5Z$$>B*Q+)T)_Q>T3Z'_>%_
MV7MM*T[R0M?3)+W(_<+VYP\,F,;+'E;^W+L6OXOZ#*W9KI1J]Q3$KK6;1EM/
M,V]-<TS$;?)+#CM_+T?%3C>I9ZJ9<T6Z8]F,?FK<_^I-H-$2[]FL=BA7V.@T
M=TZ[$_?S^RZ*$^Z5CF#\SV:L#/QQL>610SVO$I52O,\%?#,JRHCJZ[\B,QN'
MF2D<KWWQTIVB2?C5G!<( W5>325XH'B3KO#)"ZA)?^CE3I#?L91]$!@>OO'L
MR\VF5*++=AMA+1S-.V-BW;)G.9I2@Q%Y-DHSG8\3Z!U7CQI?7F%/*_UD^>%5
M]%E1H-WRF:,(#33@C,W(\?R=3KO.%#\:DC.:@W?*0&6QP+<Y.2^0-S,73J;[
M-"9QT^.U:GV?[CZMY5/(T2!S"=JDMZH@+M: <B@',E_\YG@!GWS)H9_*1];'
M[U3*U!>FGV[LF4B-: XWLXWJ^R"-B@K3!F.N$;WQ722%Y6"=GX%[5D5WU":+
MO]M.R%ZK^-*JO7YT&78;<8$83F"/V/+FD$]Z!T:M.&]P&@_("2RMS\<QOQ5R
M5S:2].T_EOY9U88M/G[7N!5:FQ6_0CD-%VR>YM1EG4:<$U$][)?0,>J,N9L^
MU])]HB.)=]KLHO#2Y<.:N.1*DC\\\Z!N#J<V+Q8::4V1_T[FE#'RT1:8LR(8
MN8E@92L&]=>-"A1N2TNZ'KEP=)W0EQ$UL#7)361!-E_QKFCB&T,8#(4=6PX,
M.U*7+2CG:Y-C%7'<Q:_GW<#G'&.'-S_KG\0V2YX>-Q5II'7#!QC3\A03H2Y<
M6SB(*-A!D7M/&?TP<.M3BNGEL@ >3A/M1^^\QIO/\YT4.E%RSX76T"8K]P8R
M"G._$<:!$ 5S</:8HY/WFI3 @"KY1MK ;)<3BBV[<:?E!:O@R@.(JX7WTZ2R
MJ3M29*Y(NTHP!.L=VY#2;&+7B>TH#11.&FGR?R-<^*Q+O&ONL\2T\ID.'XF@
M*SW,#Q[8S#O[A3;J(W:(W=M5Z5A,&SLS DHPC:AHD@27V]2I@'>,<1W&F.]E
M=2O..F_XD63'#P:Z*,GWNQ<1>)(BV2A984)A.YY8$%_=B&(\F1Q?IUF>7-@M
M,<;'<,'Y(Y,M%]^/4A1;L4WHBOG-CWN"^HCP(LHT#3E="=/Q9&-"EA4!TP([
MX0X=VW--+!F^F6WZ?%(\+43-L?_%C[:\-D#Y]365GPBW_3(%-"/1UQ!TG#$%
M',E&Q$E\$:S/6:18).]P>;V56'X0]U,E9KB6X1EEVXB,N[R&_9O6S<CWKK&G
MB-9X6Y+A4IVFR4*4K[^_UY!;'19!<F.H.I*TG<;$</S)@^"1+#)7%2XK!2T(
M:<6SMV;[?[<[\K94S\O;T__L#*7_V;F._,6D9K[#M^96SC4S<NWZOT<5]]6_
M0>4TB8:-"O1%R&MS8_ET^2>7D7QHX_M>?>$K6W!UFTLL1]Q0 <\^MWQDD&?K
MZ')B^AT&4(8&$#>)T#@T-P[",@DRXC2BOW@:MV9EG?9CN&K0=>LY<$*,E5]2
M&H)VX&%0LG+YN,IEKB]VX,3Z[Q&@[(0DTE,NTHSN: ,5^&WB%/Z7$WI"O7_1
M4\(%K:C=6.0$=#^[4?-/80;_==CS7P-898BWC'^$\8!?3<[6?^<U0'NX0*8V
M+K%7B>RV(V*H ',GMB(/"PD7$:T:4IW RYA]2K@ZZG7RYK+L*,W0*3Y+7_]P
MF2^\8]I]CP57@A>$A&O?87_LQ\[LWJ1!U+H@[UHY=(1G7**_$7^?<_2UHL'E
M+WURA$Q8]#2_M@*N+V8#SN-]]&=YWX2_-^N4S"7B5ZQ>OKBB]:J47OULHH:H
M *0J.O(ER(LS;.\["H:-#ZN6J^]]Q?&_U+L-T^2]6^>F61^7\>B8D>-<\&C3
M*(30B56(HK#_?NCFQ#NDGX0>#!K2TC*2+>_G"9#,90-^0SD=HP#NC1B\<*D[
M@>P':KB^^DU<VLG9XB_#K[XZ[;4C<OU,EQCS99OSRD*W1P>V?D'XFGBGP37*
M<;Q+ZUZN'31!^US :+#G< MO5&3%F/,3M@#-F1/G^ K9KG=VB(C1K%:' LN]
MZ1.J"L<<I]P''"K"<7(\C.S>9PI5]*9\7$V^&/:\.C)S<Z.FH+(\5V.ZZFZD
M7)N'=G9NUN"4:N[NRN@-"9Z]=^&@568,H:\C3!K,> %B<*Q3T46MA)X&I_3"
MW<$+IS(NH->UWS%Y%@%T'73?SG_C3FF!Q.4#'XB,T6C6<G@PE-D]D-/40_U-
M%<NDPC?)+Y6R'A_TF$X&'H\<>:2*=!&,>[V?OWET6N$P>N>)_=>@#7'[Y^JY
MFSJ=0H@:_%8/68T@G-(*.?2[B7<HK[AFZ.9Q)@?G5[>,M5)_5/'<#^CU^T[W
MC\'1UG_UE?^7^E_(M0VV2QM4$Z;[F?5?5RA_B&GXIX/S\.0?8Z,]NJK_Z"?_
MSRHOG1K!S*G09#WL!/*WP5O+20_*10TJL$64HCQVS_BG_GR_:78J,*>BL1]2
M1WE<\[>%H#^=^/>W7<Q#:FYP[^<C'EH\"6M.UID\_PX_R\Z"^:Q24EOWBD>7
MGW2NAN1@VS<6L#)1T,J]&':*\.WYK-R1'?T13RO25;2I?$C 7;/E)SX9HEOT
M+U T?(B&@E J<,&RCG+8 4G\"A23E,!9O4J0<:8T9)K#K7;'_$<4O$+!Q?JJ
MUDT.>XE$Z]IV9=,3QIQEJ?7'*DK$PN<X0N(/2A.X4(%(*K!YTAXY8]E)!810
M]N\K(XTK:ZMJ4K[6UB4YQRL:C<<#YNF_@4*6/RV6_8N;TXB,^"W"3KN3\OXK
MS.T\4SW"M\H*MP:I!+M?%NBA^R?KHUL4:MV2%J[]?G6IT>7)ZJTCQU-<_A:^
MR1,V74"/@%7 25C&#F]Z,,"4WQW*7F-1CR'@,1J\ 2WWYEF/KGX=>/_Y<)5X
M[='K,L]!DYDUP;#^Z;KAE,X<# #F8%$19*T7ZEF',0F>3>VA;ZX-F(BP-AG]
MT.WOS4TE5?^2HE_+EJ9OP[@6I#@I@)V%( USVZ@ 4TU?](Z W(3]V-A2QZV]
M; ;9DRD]=;$SJ<GT;,&C<52@^0R%#RQH1AXE^^ @0B#2@@8#B6A37-R:/&Y$
M]F15/?RQS]-;:=*>KXVD1#=W4SZ%5ND#0:-X)F):ZPSD(*4Z;@]:79OC28EQ
M_;;<6"<F^HBN2T%"=+90<AL5J:N"..X= :7397"'':_>5>M50H= $G1/]8QX
M!A[/GU/I/MESN03A$SDO<E3+)Q)-O^>C#R!"J !#^^":+(4F@<RBOWE"FQLP
M2?XZ%UMJA_3ZWPQ!NH]7F[\_+''2GB7\B\O4IYA9=G+BR/36 F9/</3]:,I_
M*>%&C\\J,,!H6I:W=3]XW-ZOBK _/+=C)*.8.F)O)&;.QWQ>+)<S[6R?4\;$
M@.-$09[!-;;E/J*5ML+%_5Q7VF?I=/1NR\Q^'O-Y_'5"D'N#SJ>>VAT>C2P-
MGO5O(^N&-6D:Z\<*9!^5)4_H,:9<(NRTE/.V:E9K)N6MQ9VJCU6T^*YM_G:J
MY>%1K1?YV%DO=OX;D1&*>FH_S(TS)&QQ9[Y/.<H^V%,(7]N<3@P[3;S]8:(V
M[]VBIO]C)1F-W _G3PZ=<ZZCNYRG%&'*^N1LGX\^5T^QE$;@OOU!))[HYG3$
M] 8_%:B%DJY_TD1WSM21.Y#X%,IWU#64+JJC;^B#]XX $GJ0\MI6I/]@DY1Q
MRJX2-!JVPWFP26HRU!)V$)LI#YUKH_ C?YK2@#'+CV[+\G_AWDZ;L2VJ"0+F
MCX_SR\N?&EPM2N9[6M7(]^RPV3G)?$69N;4?*MLN! Q9Y74&%6"!8-53:4//
M<,(+/0U>T=;@G4!@%%<F?W5BO#1=$_U0U6]*0AD0053@\&DP% 7.8KT?^:VQ
M@![71Z>&VM4'>]U>V1@]= Z_^=Q8V:#$_5AXFM(7[H&P*20CVIHHV*)[C*@1
ML;F&QWLW"\S936^+=U6NO;C*:],7>)@K:LE@YN-]F="+^EI1*3%;EQ$NI)MA
M@Y"C9'U(:PH769N ;/UX^_L:"N%\][Z\O-?M>S_.,UQ*%U\8A^;Z1(<VA^GM
M8MC)O#C84<I(@4@UJV]S_AD!A;;WGGXT%;&8;>_@5CN ]N64'(JF4Y2D!]+X
M;LZ6A\[K\W*G]&*8>HG6V, 5#,YTK 49*2(S3(;Y;/>>:G48\FS+%NIW_.BM
MLV9T-.=27_.,I]D\V\PGC3;3L9*.Z<,('9(&6'5IH (=Z$\80.0AC09B<GS$
MORY+IMR/896V<N,"5))B[M'5[N_KZ]ZL7-^)0001.;??#(7)PF^8@=[O$-H$
MGN*7)L5N G5Q,VF=-S0X[9\BE7]D3CU/%WL:1:=HG"FF&_8>#;Y]3?EZ@]+K
M28"UIX&C.]F:'I43["L\=4$]4T'HR?<<B=;"RKH$J9O[XB\S.EUF>D-FH'%D
M%M+%L*]VGJ]3WRX'PQY7>[]?RI[,R_TPUGJFZ(B"M(-!<56U$B.#]4!!K0#Y
M$G)LNKT5ZSV.P<JMFW7NYU[^M$[_MF#EQZ_>]1T7[[Y1U[X/G_+CK5D@&9H*
MK1 .#XA@$P-\PA2T)EYG6O$/L4'8XI "G3[^H4$/!3@7E'GN&L-OS-O6BF?,
M)+Y A8*\M$G8+F"(/TZR=+>F" ZO5./OF&[?F6]_7-D:2L'L7\QHRS.<E'J#
MJKU7TB-_8T-%'S2:?8:9R:1AX>/IYC Q4Z[N<MFW+VHSSG[R(]UGK3]?%21X
M_ERGGHD3.$]2=RC@1?#1[$B\+C\8@S.-2&_>UA3!8'N93@GD9?28":?,&Q"_
M&#C<O@VX/)@/E(:^JKZQP'9C9NTH O(^9AL&S@;-8,(UIUN9U/!G<)U7A[QK
M9!KQUM;)4#67(-E7/T?6TEL.M=<)G6BT_9B24,"B[?86V:Q$@8!V0RT"6Z-Q
M>"_/[% >8>7 3[%,4I+58H%OZ&+,?P:/_F[G^ACY%/3%=4:AG0FNV\5@*+'H
M&@$:J^V+[4*?S>8I=<9.2/@C7:63""T<YT63T+G29SZ_/^G;#K)CO5/"SI%=
M]XN]U3 ,'OE 9,<4/T^V1<-PT2O[VDOOCSP]%/7UI<K+2FECE"5J(%B:]C[K
MI5C3E0TL9@5S#)1I@WZ )6P5Q+Z%CVA^^_AF:;3!*U;"*G34.$@H2=#Y OG-
M,Z\ E1,O/FW@7D?A^AXA:^>0?+((%IPI! YM$V#<UE^"._5,.XU=C7\4]IOC
MLNXEF J'XEK7&3K2W?AS$9WMT$J#A-D@C!LT15>.Z!U>4W"X%=7KJ?;*+J_J
MG7),%G/:[.U$K@K\XT<FGLAF0VUZ')(7KH%=*,>BV);"I$0@1%7>G5I-M4:'
MR2!1R'-Q)_LGC,+*3)^[($[F^EOU^.*4F#!Q0QR>93N. ,%+O22?(WI]PI;N
MLU8GV;<J+<[[XQ57'Y1Y:ISPK1>B#Z_Y8/TP?2BL-XR1Z)J"<5> D$-&R7)O
M0<%+P]5M_9N>@@ZF$F:9JHK1V?#@SG3/)R4DLA=P;F^=]B;-^EP6B?]]%G#_
MWUFXU46"2)2;@!1>A]AB8FW^X7UJUL7+ NM^B1DD01YFFV25ZMP02QI&8">0
M$V="P*UR)5E7@K2ME]6J$F>/PF>@]H&#J)#_YPJ:CH%4(5N1$'C\FM,H68&M
MJ-1Q9:/""7='H8:;-^K!64OSSW@;*D"@<41&FC*]4DL%/I>F4,[IB92\ A.N
MC**G5WJO]9FO5RZ$IF%/CN7.:AEU/$!*V'%WD+5 Z$&%)<@XA!#W._4W%?!>
MIPS-=TOLYFC<_[9]MF-[<=GQSSS\_XL[-/]AQV97#6KWV#1-R;<5[!U_9QGX
MEZ7.?ZJ6A#5:J<#N,=IE3GC:57+!AVD6_Z^G_OT0;@Q?.5G?GX!I2P6O&-TB
M0L;XR^R.L$@]4WSP:D>40Z<7SHW".^(\D+%.PN^;"+S)8M64SE14M45_6U8@
M[YG/0<3;I:H7GYC22_K K$?CR ^(!E4>LZAC<._/#=?2I5*V/(+B/;*?,D^/
MU4J?3ZV[6<N?,CEWVT\R'G EJT'VKT/CD: )<GM\.U1W@W31M+9A_53M!LX6
MD?-X3#+DD99CB.*WHUO<&]YQ:NS)!0Q^M42OC[A0J4Z*\(<[Z3>&TIKEI))/
MZ 7&I1X)^*5=\'D#9N2VT[^4'5J#K]K-W#DN.X#9R7@D2C%X)'O0E1LB-40)
M)Z)&>X'0(A'A-$01O"<@UUL3]52C-E-9\&VB?4ES >MZ$R/#%MXQ)07AADN)
M*CBV:2R-N,B8B+Z#$[XN+&,\+"\G'J$\E&9U@PMVVN)\[B94/K0O>L^PI4]H
MJ8"CPA,AYGGD+1M*I[:A8>ZT;-\IY4'$"E;<!4-WF='M+/?&:J2XVQ0S(;DB
MRXO"=&!_W<2'*DJ>?&A_G<9PC8D*9#K7S>WE/Z5;78>G=T(8*>)P+1.B:?PL
ML22&;/Y@W#MW[[:Z[]@DON?.)1M60:$(0<G@? K>B9]DX%!1B:,)MC#A&EU_
M\I1<[7"+0:!BQ+#PJ_OLV-:M;93O?YQ=&AWR9TEP>+:/=<)#H$W%1/)K]Z'"
MXT^.:"BMLI=[&(U;N\;E7L^X+_-8HT$[.GX5@SU,FZ?YH]"=02I 5$6VL-!F
MGDX%<JV8"N \JL8O@:8K>_NI+0..HV316LC&^"_*'HQR*@4\?Q_ZJZ9O?Q-#
M-A$9%-LO@'TX:R=SP#IX6BDA#E1@VIBFQ@[J)<C%D+<_4H&F+"H05S1^"5JU
MO&W(HA\((T3\0/9Y%) 6D6 V],]/$7(Y9CLT[,L0*$<%E I(-)%;(S-4F@*&
MO+#_C?%>%S'<0*!W'XOD--QDMUN1B2]"YQC^/N=X[GISRXE)V(:S/I>5ZSON
M=13YQ"SEJBDV:Y^F"C<7 _]'KH0_RP @U/)_H4XJV0OLQ4W'!->&OP EL'?K
MB#*.PU>3IUV?V;B-/'FI=,IC['B1$1,@ZYGT<YVM/>SB# :?44PV()2T]1JV
M.PDU$$Z5$^;G8!R+'R;E?D>9&?<\%$<]\V4HH@L2O5E['J6R7Y6%TT+X$92R
MC,"H"C(7B:'TW6(!JP"L9M+A! GWT>:Y[<L'HM?YG]YW"U"\/YI)Z<54><>M
M:FN0KH/BIH>6(>QRZ!MN]Q%:'N\DT$?CO::DP[X;RT8A?EC&WI60RS]?^J%2
M(U %Z=$WGM .$<;<)NT;S&)/E6-3&-SWGM(;$F6SGVJ(SW;GQ6X4TCEQ?$V*
MWOU>RZ7T16H1(T#Y/HB #(6=@+.T4%@;P!@B2]NX/KJV0?C3DJUDP#*C,OI;
MV9$KND>48N=DOW)Y[=KC>&J(IFW3E?(%!">%\'S-A#9-SHEQ=XU.XX#J>S=S
M5T)N??2(OL6IQ?7F<(Z/@\#6='P8$S&K!98"86A26VQB&D6[%?T [RJP+P<;
M1-YU_2X[\>4)(P>A<]]GZ?]@[SV FFJ[M>$@O4OO!"D"TD00I 9$!$1 4:D"
M*B " B(M8$@HTIN@@H(2E:H($6D"(0%"M=&[E"14:0DB;$D(7WS/_.=_GO>\
MYY_W>>=\W_GGF\-,F-E[5G9VN?>]KFO=:UWK.)>Y\X.F_"B!UP44-:#B(KF,
M*GB/0$-5 .&;[5&U&)&&U!_F+8\5[CD3;?3U!"WOOTUI9+=BT7WIT/J5=?@
M5-NPSEU$^P+A]B+;OO8,KOCVY4Z]?N!CORDO=%/83<O=:VM7Y?C'3S'&='/
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MG)= C::< G"$V617AQ- B%M_E3IAJ"I _LA%=<5$DP>>OG?/:7'/Z_0SH(;
M]XT%&D@:.##WLD,3%UPD\6NO $5891?K>A2B=48=O)CG*Q]H%-PM^CK'C:4*
M:I%Y  IP\^OK,M8?Q$C#E(>-Y6[1F)@-K2HM*G">4K5OQ$HR1:?%RI3XVC@3
MO]WWE'"N#;.;BC!/N@!H1)<N\WM Y0A72T?!AVV@1Z)UED^EMVD;B%FS\PR>
MB?'V8(Z;ISXEH"8:K !'<CRA&68*L!+!Z0[YG6N3V(0P.XZ"^B3^VJR=>[D-
MV3#4T\?.J5K<Z1_32T(VP9)8'P/_K''QU;-#:&DDST\$]QF:8DT_?M3#GO:Y
M4#&RY&+HDOH7 >M=6T8(4PQ[^.GA'6[7G<+ZZOV28N"B_RNUD:J"E\;-*"!A
M$UT[2.!POMRY\'Q^42!G-58]LHOW$8HJ>(RL[1HD_8TJ/ZI&X[CJIVAG)_'<
M5KA (A^B/<X\6_/%OGBSFY6IH2=R=KP"OU%!'L*#NWA3X(J/KY-%.CTC2W%W
M*Q['?9&]%S:Q)J_^83L!PLL"^%#TEFEBI/V\.)@'11EH[L(*S U[U2&ONMEN
MX4XWQCY_?E2WNN>&3?GI.8OX=]X-_$KO.6M^1LT05,KE"MGY;WE=6)&_+>9L
MV2.3^2+SIX)]_W9/J)LPSK;AONO4I&MWD*2*G"7?Q=,),[-:U[B\MJ+RFYUS
M_\C;_F()%*7AGQ?B3H % M,$5 ;DL :&E<J+H:B_9MV@>A _="T;&K#C7R0D
MS39??P""*!J):EEL8)G@;(#C#@) >.+!;./[N>V\,S;!1Z:-YKLW^[1^1G@.
M[\QQ@9A!$;7_7654L#'R)<)8)H8?J"!X8I/0YA7+>?E>$<;@$>TIS3#?TG.Y
M"5Z^->V*^;KU!"C37&H_J6S]4E@P/EK:=3;A ,1?)]&KBO?=5*6>$F>?5^*T
M$N,'7<RTE.%A0_F3"U^6KACSC@6%%4 WMM/\V1=;&G(U9:T/=769>QL>/\;6
M-K>(N4?*?4Y>)6@D;M,OUM==L1\NO3QV0;[))PD_2'QF$1"[H%)S9.IQ-^?X
MMA2(]3U5&Z#3(TX5BC5-&2P$=5QS]Z"F3P:-4_<I!Z 1V)?FP+Z"H;M[8\'N
MET@:!(T4PXN**3 MHJN!OX<(<).@%"1?W9<=(ECN(O9 NB"N07J:U?3[,,@Q
MBS8X8SQ"%<'W<4_>$A]V!X_4?;D[92N>/M IZVH2H3WX[H'0Y!OTTFA+'+J
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MQE?V HJ1D^(E/?P/1']M5<E=2N@-I'*QX&HXD9%CN3#X/C)T=E("-SIY%$5
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M>XL[6XO,.= #4+2\Y6NY0R:FHBKIUPJ5&%>B5.@^WZM/P!V*G---G!_VN5=
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M0&=R(#NN!+$"O#@(;RAV;98#B+ BC3YO1HQOWQ.M//+MWEJ&21_>1%H#11M
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M=G+?>.<K&SY_L+M#L2?VL8E2C+209:OD8=#<!=9WM+XFVV;>#)KL=YHF9O
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M9]H44MPOR6%8Y'*^,K^R=<_4=79^H:L?OVEZMBZ-C2V_X#U*3FH-(:*R:%Q
MTMM5K.\ 5<[[3I-C8N=+MOS[LRKN:,Q-R>2N3CN-!<CQP!$B4@([ASP.<P>R
M">M^?03U,GP6![!0NTO.2@S8!LK$7[\_=DWSFQ9+@TRY(L>$/-)O;RL5A$>'
M^/(@?8M=IKID&Q+$3Q'=4U_(@*)!5>?^ST@*,N;3 ?@/,Z!ZSBBDC:902PE/
M>NM25S*L-SEE=_825;68A;4:M(/*KL4"1Y]/4Z4%2-@,V@G_0AW@$MZZ$SU
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M'9##M_KPH^3+HW%]UA]Z"E7\;TWPS;,6Z6S=B=9G2-UY0[:;V-EUZJ=>(1Z
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M?&$/&0$YBY<J4BSX1%!5'_?AKCE$^=5;LNJ)LEV:_9G_YA+@\2[ &$2XF\-
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M"MAI;R G(%&D7D+R*4##)B(8]ZKN%+ < 9H"L4!_N."0)%9.*/%S&2;V=_7
M"HA(\/ DVH8H*A5\:*N]K]V9=,3SN[KR\ZZA4X"$>.W[D&O!/Y-B0+L*!')F
M?#8NAV1V]R09+TR*;#EW"D#+>)T"^L]M7?I7!&-/+H$#>Z;'1X:@<43%Q.+S
MM$2YIS2RA@&_-JQSR'D5$_%*#E_P\/+O&H:B161LCZ#H^P0L*4J:##1: 7H*
M$)M$DH.=QBG@7%$/:%<93E:@LQ]. 8>0)((QY!JYS_UD  GZAJ> OKV-L3O
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M^;\CR'3CYI#1DK:OX.'W1GV4XRA9U^J]TYT_)6H L]UZU-I MZ;^D5V2;:<
MNQL2)+I^F#*SOOVGA0[/Q*>//&1$E HIV+?9EYHOG&3N,GB93VQO*@PQ$SPE
M/1H'3 V_*5!05_]BCG0P>A[6(12;-FCP;)A&[*<];TX8YL=E"[T!\R/,L!WE
M%[FK7/M?4+<.S(=PI- B@NG-\A'Y+)V?WC.7TND"X+^JF;4 JZE[X-2^TG.
M99((//@.7BFBJ^RE9-:=J#N?6V)5^\POY2M.OIAE<[COV?!<TY.]_,WB1/!^
M"QD MM\ 1*B1 1#?^!L F\%D "[_!N!<0 [)]-L)D@Q !/0W (9D +X<_0L
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M?'Y")EWO$P !3<;CL)9*^8;^@6R'*;2_KP-OS8=K0^YIOSA_HG ]':5HWE,
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ME]?/#E@FOL)$UX./(_'P]IR9"*9,8@ZV_QY871CYZV>D=%;_3FL@NG[5HZ<
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M'C/+0X:LNUE^RLH'91]C 8ND*P@Q%"%-(,F?ILCC'3SI9JV2BDFY<^[\U'?
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M<XFR77YHZ@D#B*QM!:B8BR[V^!N$1/&83:5>=BLS]85&WJQS%*GQJ6^;/HU
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MO-EMH=AP=I5:PLW5O/:J*HF<MT=IB@FFN94U)3*J# .33@'M@X1P6]Q D-
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M],X85VM;5^>;ITE79]R+EU]:F5&(Y,92.R*S-'W'4YW99L]%X.RKL)<(F_<
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M@H9P F;?YTAN^V!1<=W>PK&L/8?Z29W$0/$ )0L]1:P!+W(TA@HA2H+U.ER
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MX$9M^L\O\2I#KW!J:FE 0)K7FB)8N)OP[<=5+="!%A@C-4QE*E7?,!C;I"I
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M6EZA\_*GE<@'/W>_NH1XYH@IY!@L.0:50!8%&-2@?N[EB\#:FDV&8I>1?O*
M2J&=]P+"4 A]@!3WH!R.$WK!:<Y[#'K[69$ :9(E6.&1KR"L"%WBW(#*$,8I
M<H#E=[+S-$*'./<XUWP*D2W1.S&6*4:2," U\,]%&( 6T8&@D\%7?V5QQP0K
M$B5^L.X]676BF5'2%*BN<!PKT6CM;&HM,IAX&N^9' +/YK-IDVR_2OYW9XFP
MGSZTJ?G2609,093IP<O[%B0\;,P_V-EWPGCE^)HOVH>_<4V!;^@_^73'L+>,
M*:GI*4DI,Q!/GTXC;3UH'+2R++,QS8;[;XR=]5^3[QOV1X/$Z!2F J*DM IN
M*E(BHBA="J*$ R5DR-CH#D$!A0_=$J-S4@.& B)=PMB0D-Q QJV,\?!]?G]>
MK^<ON.,ZS^-X'_<5-_?0@W8A8UO%'?8^:U9IYG+)BF5P)*$IHU?)9!D<I@$1
M\""P8LT*$3V4K:=CJ+- E(.>]>A,[[YBAJ'OG?5XL<1O<):/:O]QB;D 2ZBS
M-(/C/)3LG-M[H-EZ@N901-,F=T0R;THL+L[;AOW@8+^@J?;S_A8^A/?0%G3D
M$_?7LPLFWG$5D%L6"4<*43IODU7K*9_M^PHW<E@S=X6;+<D-N]S?[/GM?)BB
M[C,X&B_@<SQ.(1B]S4;"G$':4S)"L$KD?^-='<R3C6YY4]B'FDO!CM^'[ULN
MBF9]8M*_Z!IPQUM34/[C+PV&0WTARG3_"6@^_A&9WKS4R0IH8L'$7%'/-F:H
MS(0F)-9VIG9,(SY04# T+BUP]<W/?)>55Z+EYG?_P;;BCPP(M+>CNA8N&.VH
M':09T<'8[VC;L+MY]="@TRK1-2[(QEC.G;G<W-@\6D:@\>:-?W%_CZB?@;\D
MLP@X<4&B)R,7_.>&G<U^\?6UWEQ>_9+?Z;5]#6E\',)!T<'SAA_8;S]N!84@
M-[O139TQRNCG)Z"$#K7I0C*JZC3E1MFY'7BS+YKXYGG4-W#*MD;^%STG;KW\
M&IMZZUQB%PA<6X9)P,*/3% _<IC((U'^%;L,B/N;#RCIC<7N*'$RO+(9,E>=
M+)CJV/@S89,+W'3N >,F."M6C%;G,&>%5YE+?@R\/QWR'X A,7(DX<^\W0U+
MR;<*FY2"W]1ZC1!]GV+DW]*G?)PK$8Z5"-%S$-<I^$AL0]"-MX-W6B9?/IG"
M%*0&.6B91-C%QRSC/U+Z[Z]:_&P]QWM*TQBMXS2HDF?G62@S$-#O*#.^I;']
M_.].?LX-I?_F!IZVIH.U)'_5&.XU*QL3H^6J$"*]56A2;AS,*YE7CYRA1Z:7
M?D8\ZK9L>YR9$>]5;*IR+W-O<]M<O>B,:ZKQTR@9"_.6[N=7ET*":_61A07T
MJ0Z5EN/4EZ@+A/5%P3I*XF+YZ[S*S*A6J4]Y190%DY?3B9JXJ#W!GMV5R^Y.
M7I.;+:[TD1-0DW9,XRX$*.TY ?'Y8Z)0T@VC-!65>$@O@=/_\J[?D0G"U?I7
MV/*04FS-O1"%X,G? QH,!P=]O98UQKI[,E?ZBQ>-1>4_AZ8:WP!);I1$8]QS
M+HUN:\(E'C9,-E0,]$Y-3ZE7_K@?75A8+O\M^%8?4I(21$T_SM,$SW;V.PF6
MD,TB_<PBQ5?C-:Y;YG@KHXD7FY*V6;X4__IX C)\,J+H$^@9Q7%.3/;^;B-*
M %"%GJ4ID=&1T@_*\]>I;]V8<@^N% 7[^!Z^_?6#S4H?A0*.Z&<8*&P] 6\Q
M<?GMP)5%\/ANA'17!:FS">C?X+L2_4OX.YG#"?HB(VIO(NUEVL7.FV6@2AP)
M+HDTZI"Z7A4S/?>#4)U&_7#TL(F']_N%[[N*.BR$A&>A_V4"(SV=C?A^@B3-
M<;HAF^V4L363XJN^1([@VK<-5O']!L.2%M7O[$6W%^ZJ_62UK^X1D&VMSB %
M;)]7"=5TFC/KIRY*D.?MD5=/'0AL-%5<IQ(8'*B+>MV88_%JV*O^YWRH>-K?
M3+W_WKDQ;7Y6^$5@I_D=YVF,Q.=R_AF)E>(E0Z.)N5(-4S_<KYNN3/R;RM*P
M5/'9UH&>=V6]^"U/1R^T)25]<!+M 4[,4:NE:/<Z1:&XR)'3W2-<]@YX:2".
M2KIAUWME=H"T$20@NI>OMS(0N\;H$Y'3+LBT><.W=PX69=G7F&B)-[;;;*E4
M$O^W<EY$1.VL(7-0S()TCA"K\0T6]^D^D5Q^_]R$S.:M#%C"A=KQ'97\+T!\
ME9YSLN272JTIF7G)5'5M[D"(>:"A[BN%T,X34-@'1.?#<7^5F+>2(ST2WM&6
MZ@.C"#T;BL&(Z(962L>XXFN%OZ^--C.L'4RX^/973$"HN-''#0ZV!,?1+4V=
MV_U35/8=9\4K;ZY'V2?AF:V&KP=L/\4T;^'9XM;&_.8)<=K_5J8C&H89)W3?
M3+]M<S+Q%(]\H7S!(OG[>V7V.^]^O;X),?K_2YI3:4B\*\73,9IDU:\S1;X?
M?YH"^9&:Y/1<#^4&R1NDB<;@VT$!V)Q^-B7%6*^A=T+Q/-W_01;Y['>W,HZ,
MD0[ 2(6[;50+2ACH[#JD)LLNEI*/S'-T.L&FIXG1G].S>9_MH\4[^<OGPO K
MJR'0XB9*1O2NE4U0<(!IMI^-N.3#PO;$R/#/;*ZY;(=WSG/I/0FY]=M.\V\]
M1:(?PM=Q#:D :)Z V$6BZ1  A8Y%Z7R9*JI/GT)P;UK_U.PK'L9_L$.XO0RW
M-T[=_G@[4@P_GRM&>TURBH+4C\33G+QY/OF3JIAPT^*%!J-WJ6:ON5@-)?04
M_CZK<%EE$_V:![[[67SU2PG"R;!]LC';8-QXK')9W9[@=+^FFY&G>J=7ONQ
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MVUC7X"6X9R^4A;P/Q-WP)?:7>3<$S7"9UR3>B_QTT3#FLB5,BWR326R5S@I
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MXB>_BS_R?WC1Q)9W&SLR1%)[BR=;FJ_9W(4H97B4,\D%?!.H/?Y 9R6@1DY
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M<W6Z$J1.,_5IFS1@(J'7QOR<SB)\+>G3;6D-1G[!(KV*Z^;6*HI_#O2MOWW
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MNDDD*M(-.+9<\_B57:[%K+:?H62!W%%]_!=;/AM4$6C#J 53@44JM#U'ONT
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M _O-$!M_808%=FMEWF_BDH8+HPVVCF_Q^B?\W>TD52%38'+.]/?1NY?1V=?
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M9ETZ:\&P&F,:TYUVVZ7EP=?EZ&++"8*#FH7C!.'%N:*1S@"AGQ0'<FFB5*%
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M:C?4 ^6C/,RT'D5?<S[_.4FS[=DD@-RH6(3RH=VIOS?Q/9RSHC129-G6HP6
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MOU,)'3#%5/)UY0_OJO.9\+[I,V/BT7S!U/;,R]ALAZ_$.ZTO.7)7^5<CH4'
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M@KQ<OE#^:4$[FC)#47<&-L\QLUO1-?_V]J_-E+SS3[TDS70VET] )9<9<D!
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M#GQ\KBIU-![/U/ 9X/'ZG.$A>K/A0)U/7^6LU.N';Q]K'_O=W*>1* $F2&O
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M(-<_8^C=O;!?S(YM586;-Z8]5S@!^.T)C+P/0L2NSU43J*5)]DZ@TOMJ<>Q
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M7$E:&GG6F!J\UF]U<6%C%D&,WYPT5GQUFG]813A+,3;#[)B-(?L\E/^@I,.
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MJ^JM#:]UGO/^3=.>^<UI6-.]V-7VB7.YCUS,E3J=XTX)RLUJR%*;\5D^2IP
M%]K.+4^%WB#K-4WYLM^9T[2I,*KUS*A(R)>6YC3S!DO0T'<E!&0-4\8!QO]
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M]\Y<>\_JIUP/9YK[Y,M6]MBRKE*,"3A__)L(JO4OMW?R:%QTN"TC+1K?*Q+
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M*I=Q7KFAQ@8T;XS67.)OQS0^-3M\5H@NB=24)-CL)A61GY#FRI.+2?6IW4)
MEK2F1PA?W/.@_O<?]QI''J>JG1LPLN:,"--L;JDZMJ!43ME14&)V?PZ&X;T#
MP@QPAG,-XH^;,O=$Q9#?$ZU:/83D#R[_N*^1\"H2';KV\3SQOS/Z,<_N=9#L
M^PM@F/:/+ZV)Y_FAY0_L?$T;AV3LA!6[@O>/:&.X-1J:"^B^B0_!7OR5'8;$
M+B]$H71%=_FL*QH.VF=]&+EO&@E4*EH, !J.(BD"CUE??V--1QD[7,!:-/*Z
M4NV]R=Z(RT :"6$Z*X:P_QK2 ^7WUC6)Q=&M@PL<*6_RVS_UN57W3FY2Z">Q
M"U\>TZV(%+Y'"HD.0K9\O$26B]U1>JQF?>/32(_\S2M1-11%8!G YI0'@.%\
M!U)DAX<'(FZ2TI*] G^F*)RZ#"Z/?G'+O>[XP-?5/)J',9[=,R;CL&8XR%?G
M]";@NK AA"5F"=ZW2])=H#Y9:5'*A>S1F:P>*.YA/QT>WDW&[@ .X&>__TI0
M#D0H1(R<LP&#X;@)"RW?02$*$M=S+R^IH .JG8ERI]H<*GZ+TP<\";U#JU&J
M5[AH%,YYHG%C*/Y.($RDD_PSJ.H?J$]7)6%S3K"E=6Y(KN*L(@T > 3V5LXG
MQ:'9I&S\? 81AKO #^FGR\<GI@U(8>7.IT,+"J.*HXP>/"%Z4DYZ._T?@[]0
M'"W$_0,YPZC<86!R*&ZT99T+T5F?*O4/U/1[D@>16X&9WY<^WGV .4FNL#)]
MQ?1F2.$MXS/QQ C:'T)2A3A<1^[?Y<F>Y1?/"G(>(:Y)L9D(=O5RY]*S];+I
M"WLX/?OF[Q1]4;1_DR2/KU\(B"S$LT"JD52>1J8.J?GC9M= =(N'FS;-Y7!<
M"8OO4WXP=(FM[*G:Z<#+)L+!$@WN("6""[#OR6+UC*"=Q8@KA@A!OFB*/YL/
M^>M0F>YT/=[9MA]Z[#>8E"4>P1/VQ'PAJ$N6\<>SV/K*S]*!7Z%KQETY2\:T
M^!1CC8>7[G&P]TQR4.#1-%@7,"6*GT23&#1F8CJP)C:O:?Y>++L&#N19(<:2
M!BQ6WGDH5X>F\EJF:P]X-%\?U2R,06_D7WB>2CA.(V^2$WDR*(G3NK=B,>6-
MTJO/Z_*^J?-I18<B63\]LX$]9OWT%47?/M,OMRB,O0OA@.9'@=C,P/K2L\%7
MZC'%[6ECP;&68'[.G7?5E-$CGVEIKK564([#</F:_"$J@UQSM75*BQ$BFFZ.
M;=AT;_>9.>E,GF3/Y,2*G/OMG0U2/ (N,8#+*0M@@#M(_)6"OD^*2X,*K[I[
MB4Q+:_K7MY9ZO!OA*,I:8XFOPMVC>+CB1[\1B?AQ4?PWL?'K'TPCNT60*P//
MR.<BI.X8%[P7]",NG\8IS$3<^M554V4\Z%U31IOJ0SIM_S&?XPM49/I5'_U?
M"U6UC5JF.I&90$F)7>]W74$>^68N :^MJ!-&54&/WU+,=%9MUF&\C^'QZNB8
MR]&UGWU^_6FY/%_2]#G'AW6.2OZ>X<!GN"0/57K-/5 1L\80N@G^0C.,U-57
MR!$44&%2C_19'VENLOUB:_AI1M%B3&BU:V!FQ&R?PI@]RM^N;9V2K%2-NK>@
MZ5^15&M@/D=6[^8J^/S]RW)M6IY(:GRQ+J6P80C; $MUI-QDT;0V1 XI?DYW
ML@&C!O)TNWVY+K1@  J9DLVVF$;QUP$)^X$F\H'.4XK*ISIG\X8FGU?9NX*-
MZLH'( W_0"\T=8BS0U F;[>!+%9DZ< !_N='Y[Z_JD&T2I?;4_V((\++5;$2
MTSK6-ZK45BG!@261JH4,9%DX Q!G,F<SZ"0Q1YT6MT'\N[B36VKJ?3/A)+S5
M4O@D.ZT/,_Y4>^CRO3!/B8MZUX^E:RYD(M\GH=-*NK"=\Q@3;Q<W?\[Q^"E[
M7<]&VAEJ6OI8^2[E3:\& F7BMI(IXS;?]_V<T$H/:_68M6RYC@_MG6U&CYM?
M5>J*W.UYY5TSUN'G9WA@9S4X3+*_DT<0P3*YM'2_M(_3@;.8!%?$SDCP;?1D
M-/FNB;K:/%1V\91;9:8 _=PO#DNR+4D-E2ZX_<063^\DKT\ILV$C7#$BG*I3
M)[F![?T*WH!'[I&EBR;"PRZMFH;Z5W@VT=7+^HAEO,L*_49?_#6G<\,/M.<X
MQT&QM<8&0'#UM*LH7;G:H7(W0JV^B;'-; M$QM[Y4#O]3OQSFI%MGM4:>Y$"
M_T%D?B&9'8W[VF%RPY<'I8\%GF7F<.,FUA-=T6"J]4T1)VWSJ[=?>D7RTJT6
M9:YN[2Q+7&*0E Q7_LQ@;'BMI;DMQ3F6UNR:?N+-JBK5_^X'?R^Y!>&+Z"ED
MQO@3:A%.7?.H1RXE/Q>J*Q'=#+,MP]&WYF6>,[IVM#)DN3ZYY;<CG^BG-CG3
M,K"&LIV1.I?S*&2*F Q5QH:73-:'-ESC1TH[YZH:I6<S,FA6<=/K]([R%#%S
M$[AWTW"^21%79L@Z'GA9+I0J2:C06;%L7I.R6E &CV!9F9^_Q?JZQ.9/U!Z/
M%FD09G*6CJ(H!;C[US@;'>_P2\L.!*])=G5F_C )J?4TP^9LP2>N-=U]G"[9
MK;SE6;%<ZAWFS4'QK3-NMW?#.^P>4/RHSMX1T8IF]17&S.,Q;V3_MCLG2N#=
MYWBYY.CEOV4QO>SZ\+V;-6*P@!NX3TB1'6PK4"!M#9@@]*/LP[E,!1##9B97
MGYC*N'@]9S4;B11^+,1!D?B7.1&$@RJA>(D'P]BXDP)6TLVNU$\>PNVQ1_?>
M]H:X^?/[)"(?]ZY<4[E07V=:$9L\LO!9 AE"?(F/:1O0(\%2-!\1))JWFX?G
M,(XU_T#N)HH6\AGMKW@D.*KVEI6['LOU"FH=[&EM_.CF^W&N_L'$V';J=WZP
M+-@CZO-7:\18CBQ3[BLC6^9))?C+*"MC$'*RSHQF]&\VF=T-][[-K=(C-SL!
M$U8!N!+,U?.S8WTPVC,>=I83?K,CWK6)7OSD4;,<JI16MRMQ5X=+R3YGKU$:
MI*:!9=^$"\,4)85$8NR?N"Z[DVBBE*+?KTT^AH^?2M6W1 ]NHG#^Z?UJ/YUF
M+\P???F<'G#9@,? ;Q-75606%%KVRZIV;)@"T%5K4,V5KLJ\'+'TE'$DKZI9
M*>@)4'Z,GKZ(TJY^.,<]+-Y$W&%:*N^>LKI3Z;<'.US?EP9"S*G%])B_1S)2
M7 UX2W\DRQ6QO@:>(NO6;:]!B-P#A?'+$3$!HEGE>/!EI'=]\YCQFXY<[K<C
MT8$/JY4I>![JJ-5;PIH-(M\#OKA"P0<(^'*W $GI>UUAJ8-MS^Y"M@K;GYL#
M+)'FR3D6$)^9=\JK?*!#- NZ5S."'X@>R/TX]O-<]0,QM:E"N;P2H#0E,:8C
MGQWC%C63CWM#F&9N='/V4%M*6(' [P//H M&'UH;&EIC/WV:%XUE0" '_ ?Y
M(CDY#>B+0" !T(U!#HJC^@'X8EQ?@3)ILX' Q#"$98%R_[1;$<D=0](,2+\?
MK/R4U"*:*Y]:-A?P*6;455QJ(&]AO0'>_R>";HPX:]))NOS<0[F<N<,?+ZAB
M(6S;_J4T0^34*UNFOM,UD*K! 8RCBUDY>#V&L@!2RE#7@  \C ^1I+&MSIG<
M=B*W7-7\.?[=KO9XE<,OT >JC)$BL# 0<\J%#!ONOCJ-T?$F4>)AT1@=EW<Z
M)5\]U[A)PG:.GO/$(\B*B,20#57'FG*FP\L"N<UU%NQC7S!2M@_"?,Z$--6=
M#_(% 4EXUH66'SZO]XN:&U*OBX>%BEM27_,0;DNY6^/80;WX=F%17>9]YWS:
MHXIW[/;2JZRKM#X@-GU!76_O=RG]JJHBCX.4@B,U93?^@7:?XTQ?1*B_'+J/
M3!L2@I'4[9528LL(*1XM:HI=;FK(VJ=5PDP]4CI>CR]3O%&J!Q[_ ]')[JZH
M]"I^^3U"EO5+SE:/6AU08D@Y@7N\P118]SU^^FG@RA^'Y]%16E688P+!-0TR
MX,N)E&%2L<;.852*=>N=6EYWCJ<(U$JDTGZ!O3EJRQP0&V>QH1'GH.@2C[(V
MA2PABQ#/QHT\WAN]?Q_#N3DAW3:2=AP7"<Y]0M?PX"VU*\_HA"[)%(>.BU!
M,E@30Q)WN]>+=_Q?Y(H^3:VI$13D>5I75]63&J/G < &# ;/V:=_#\VT2-/N
M6&<X_@.Y(EAH9:5#BAX)D&*],V7\QEY&T6HF+A:!"\XA$:,1/(!*W1CAH_%
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M[J3_G)64FE2\%+\VZT#BRI2J^>W^]1V#:%ZVF-79DL@>OZZ8WSV)2^<9I^J
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M^:H;/=?Z.<S>/5F_&LT*U[?A)A+PK:])MXZ&6#R4VZ;%8Y5&,; @_\#XALD
M>OT9GCM=7'KRU*)1^9_Z!<QHV(FZQZ;$PEX(RPY4S-%M8$V#E/_KUASY/L';
M;,<N.;C4@VMZM.76;1ZN'L>!AC$6#ED74L#&>1*I7&_Z5_XS_%]IF,F\5PM6
M[--MG0#1YJC;L8XC*R6NE'X\XI2,-^#L*.L9C"Q)H=?I<L'\WZT') NX"4*T
M2EC76[#&\]#HHHY99M]VK%IR!6T$.):!D.<-IS* [F#$#5)]O.9]:"E^Y1^(
MP\.T6.6XJ6_TO<<!-JCE3:K(X:OL5=LVM1OO&@;O PFG$D@$/BY2\RINSVW
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MK,%3N_^DV_C[-?=F^GM-VL'%Z$F<@,;1/<M)E D)(7%C#<LU4N1E5K&R9/:
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MATV8H@'-WJ7=KA?J"3(-:O(71U.M7[YTB8;_SX-#\P]^RC1]H$PM\O0_7L^
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M=2"-5)/2H0J8K'T"VTTWU/#8 V8.YO*SLY.CAE%F(S?O?LS(,UYHJE=,L8X
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MF3%? 11A2#RT6>A+Y3'([;Q6OP%SQ$=SX LZ;C\>(>2#XX.84\'W@!RJ\!U
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M(MNU+J(?8:R#J[.(_L.EM_\>&%6CN94C=\<ZGSW-($JJ.<Y^M]_)UN)?<3*
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M;\%' /J[\RR>%S5F6S;#!>L$]BW+%TQ 75L01436[[G>%>5)&BO1W+,G^]M
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MJ6(H()!_,.AG=8;9':&05(4?PW6O.V\TJ,VMUAV#/N\ GKCH5NUH;+PFGG<
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M=I[W5;]J0_R(>OQ+R+JEI9'3\)&;'BUN<IU\H$[SZ9B;S'W3 U?6TX'HPU.
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MOZYI.VG=(LRP<V#!OW'$>&V(D,%IB'_" XYL<O" ?UC'#7;J_^RTVB#CA2;
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MY8^TQ -"F#W'*^L^22+WY;A.[E6]7>WVP94&;B.-]TYKC6)'$".+0I^SP\3
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M,SZQQ;\%]$I-R+\]1;X5<%W9+P%<9@A?9SV2L1:']W^.?KRXJ.W%#\G>(+K
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M>5/\([31Z5,MI\XCBY^L\5&PHNFCR6)(3,Z.$6EE_P>2'0.*_K=N;$@Z0FT
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MYYB YO)J \+9L97A;('7ISIB%Z73/'YOI#NH-$G?$6NL=J2]!<:Q[,_'7GU
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M%ZNZXW1RX?71$SZN7I _F_E8][H5?TX)%!1^@@2AI3^)DC6A2:B?J#7K3!8
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M*/OMCT"AM=[<<$E=304.SO5%-3N4;QW-:_+X+=&PG2K,B[O#Y_CTD7']CGA
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M"5'*XI_0),^?GNE^]9- 7_XU"N"/=D/DWRZV1R^D+TN30<G_:$A-D8)CHDF
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M</_%&_B_(I'^NYZER[$ZW?\;YI.8@'RGV$_STWZ.C7^CD$% 5'_@!/Z) \%
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M5J$CZ5/=!&'($*H)[:1E.>#N1FHI$'8:?S@9?-^'Z95Z7<222$>G4WYN_=T
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M=AGU*#R\\W,+;?ZW2B&>U:/>'#NH,MD5A4G' !15%HX,:@RHQ7XMQ92_L/6
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MX H0*1# YN'=133"E8 =9) I<V27:>P;UG8KA9<VK*U7%Z%),?YM8 8T&?3
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M ]F;V ,]+"W+L%+73,+9KUT^?!EM=+%M$L7T.AOS"K<Y: ]%^&-PXL'3Q/=
MW:&#-VA,TR".CRR;'$=DVR562[2>PTRJ\1D;8VM-)7U'\YW#IGGVY,(J X1T
MFG0_[@G+E)KD@MNJDOL+]?GE8[.8NCC=O"5[+H$AOI>+:^V%2+QX%9H!AZ!Q
M38^!AZ<62]K>H?4_PA"JO6YLTAVK)BT=RA%7))<,680XBUJ\K[Y)3O7BF.=
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M8W3^2-N^4;(1:%3'%XW_OUA[SZ FHV__-TIO1GH'%1#I*KU&1;I([R4H(LV
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M*+;TCV&)N7*/_*F M"5NZXN]1^*\:2)UXPNQOZ!$T$B+3\4!>]=/[[GR%T1
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MG'?GZOFR%I/M@HV@4W'B]+9"UD_1!C2]3A-G[^XQ^<PD C/41DW*'NE0,2*
M9L> (&\?X>[.D% N-SW:Y^E)2[T6*40;_=E!-*0=X!7R5&%7DJU%19,VZZF4
M3=,BA." .2DS21-_G&I0#5)5NT9R%1,5*71;9*!F DENTKE[NS?:O7_CKI9R
M,X4.*7&UK.[L>N]3R@?T]Y^JB@T3 2]Q,(T+&_A""MZ<2R;3(\PQL#%BX;-G
M[.+SMQH02CQ@G#=YDV=%V3'VDG-*C0PF/2.5<VJ,\T>K/CH8ME[=>5R;KCX<
M\/*1>^78L9URUQSLC9)91.5')WX:B#-M#]<EZX.KC869Z#N]Y=_>VSH;R<S[
MZZCNQIM?:]&BL"]<8P^NKSI;)]D+3@1DDO*6E^=E-;(0+HXGJ[[\@G *YN[R
M)H^SB-)&-8][?  N+ HU[I%CS<GS@^0"0^Q[UH#_DEH$J>CI-I.26L9NT+_^
MW&)U_]_[\VW.'XH]]LH^^<VIB@5.3W-S6T(J\A*7EE@8^^AU61D?M)N1O06L
M7?UN_V(MLFN\H$)4O^F\*9N..MNZ)J?452Q0 #./=9_P8V#'EN/\"[??#;E_
MM82F3T^[NQ[RL>MT5C/.DS/&GCL2:,W6Z/9CE_F:F3%)CQQEIE\*0C5?>WK,
M/J+DW^U;_X1EJH6']6,0[3[0S]!T W*<%UY3F%W $G)[8?$LGR-U>+;M=?M9
M38ZH)DY_Y<V!!5YPLZ.57TWH"+:_EUK8@1VY2^]Y5.>YF"C]::;& E1HP4YO
M4[3/@<HXS06KAW*^0FN:LJ \2'4(#<3Y B_-D/@Z(N"BLIFJ#\QP O[%C,W%
M^(U-9=FC4'?=O+9IW+$(E$V-C$_?-VV< I/4TI^'^^ :UI_0)C0B#'Y#'R(?
MJR*4!TUQ=Q(ASVS-8IAX7/ [XK[(' U9<:$/&A?'^G,M'H9Q+2I/)T1/5UIH
M]H_:5AL$/PWM/5\VJ:IO1GWTD/ 0L/J2*9WFZT#[32W\NOM1#8$V&3,#GL!#
M5D9BSYW*%K?F@LL#@R>^L-E8W<K>B"G@0-L.#.9\M/7GO&2:.+ZP$S:HJZJJ
MBQP8F!:*I'.'=GOU<+TMC<V/, 0 K@%8=@859.FL()6?$S?FG$0$I6_X^JD^
MI I538 VP&57[HDVFTTW^C\YOJ> *!_WG:\_RZ6%O28"0L.@P%6MW=.*/_#K
M^KH7O3F"X^O?@IEWC=FJK01NH7/TFSC$7SZB91YE8GF12$:@N7!'@N&#N;Q[
M>*D-1*>&N&3Z59ZS2$?7&X8?"/>A8)C%'\HDC&<['Z][5R&4OROP67,"ND$N
M4*-9#>9![1O\55[L*FE1-$,N."U2(8MHY9]?>(A&,+CR<8>BPX;8DI^QE@ZT
M.[ Q?B4/69@I.A*7$)?!_'+3MRMQVZ]I:;D&*C7/=IDJD_WBK@$9Z=__E;2J
MU2$540VM7EO=2& AW(A8"Y:SV9/8]T+=A2;+?=.1=]QP:-NG)V%8#7\\I%F'
M%$^,8[ GY[!,BLB:$C=Y\W1_D:K\V-7AM=V=M_=^^)+Q>-_K@1>Z@:GP%.4[
M;?.!4:$JBL'E?Y<O\WT*YON]FF9^OI#(A4W.174B*=R6;H=U^[<"1Z54U#W&
MFI5J>S^2+?:.K0V*B=BM5%)2JS@\;RIU1HDJ36"]6[2_MP5NN4)8ZQ37,DQC
MPP/2/N_7$8HWM? L*SJ?"9/\0!5U?_*R0JT":_BEQ<U,[MDE#;X"\6@OPFAE
M!H&6XL![<.UT]^(S- .]E.=7#A4V."!/#^SNA\B(UE^EGF/:WBYV84K^'N_A
MQ.L%_FQ_!P..:O9RJ%,3&/4=N6XEYL$V5_C)_U[DR=RVIFNF5 A,%CU$"6'6
MP6#3"O_4>!S)[(C=R:L/;A?S2# 5^0'@27QKP2N^E*;P;+YH82O@S\29YZ\E
M*.> F7%&$Z@9WU^+0V.DM2Z333KYKF.^-N#**EQV"A?[*%.&_+%%#U*?S @]
M-<3OEL8;W(#8>VWG8K0'O^9V@!@ETC6D^[Y:_S@XI1W[;H)[[_EC9@[.0PIO
M!-7BD-]GJ'37N=!D>WF-:Z,MV]^5$_H?;S]=3.8PXNQ61J).V9EQX$XE]LB-
M[X:I.@6NW^90I=<>.'+%OPWB*G\*>53)5<GW26@?]7?QI&W]E^EKLYOFK$Y"
M?\NLQ'A5X2;X.P=4^+L&>Q&K06!>:[L>=((Q=YREWYV5^Y3U <:6'BQ7CD)0
M8A3]%%FA%JSG599+PACG*#SD11W\UBAJ$3ZF<VO9M"9QXZZ!,6L'ZX;#O;'.
MTO>E?9FLK+E:OV?R9F*Z&H>EPU!?_B;%G^SC[@SMQZG)NBQ=QZFBH3#_PB7R
MF.+&Q""K%Q^J%GYH#SPN";5:6]M0I5(!X5GRT:!HF/2!7N<RY[&$Z@F#TI#$
M.*Z/T0NBVERXEF)[C;'#;"&0I:/7O/4"D]N52X-C< +3XQPU,7_>/W]8L'5@
MO<\YHF8=?V1'GEQ>5:T4I<GA].S?X)W*'&<MFN@(6PDQC=O92]5M\+C?\<[A
M)=;O\ZS](8M6D#\PDP,R JT3IO-H92G?*Z\%OR35^@UZ<W0#Y2<WH03YF9*\
M7BVB>&:90O4P<[-M)9L( -0BHQ T,)\U!*.57K$=-+:[XYG[ZP@A&Y=QS?OW
MD]_Q?G!4356E1E:)$VA@2A,G$5,5,#)T$,3,!MH:I5FGTQ6X3].D<NUD5I_>
M_WJS\9=!EEBSL5ZS$(X;B:M% 1&TE@'/,.\73.>\(8M;U=825#P2.E-F[OWR
MK(5I]=OP9X@.001)QAP1.D@Z^ _:"H0Q-#A3':%#S-1E_'NR*+B05/&L5MJB
M3DT62)["!8S\*WE=2V9.\R-%V8_/O\4X)IFDAQFDN_EIFH&KB]X2SK88SZB3
M[.<WROCROKJ^-G@=\M24AI>.GDE[,_8O8;[X,E_%4Z FH>)0"X2%M99^P\\5
M^_P&XL0L\"G\%"0%X4L$;*FD;1,!#(AU?CDP]B8)LPJ2[/=6]Z_@G/NPK^>@
MN5V-!C$2#JE#L0SVO6(%"1C-=2N6MZ^U?YR4F2]QCNWBU1H96E,=*</K-D9=
MD^=OS5-KSST_?#M?0Y[PO9<A  %.FMQZUN 7WE#I=VEU$3#=UET.AR$Z;B V
M*A +PD2 ISM)[83:DL"JY]]@O&^/E\\M6.&)4!"Z/AS.=XDD,(+I7%JY+EZ.
MH(@ QZW1N8!Y^5?+ZU__[T%!<9W+="KL*\&::X:8Y7 9?N#RPLU$]PJI)Z%S
M5J;O>JR2'SY[=XUF6ZR-\9-)A;CI>_Y]4^/#=2U9<?J24I'!E;;AS;XVC#GR
M3%"-CO3K6R2I&R!6_V\@[IVA1B*@BNJ?^ V*/;?I62)IN*1=-.H %.6;RV3=
M(9S%PM42;Z'#O9(P4"T"6$E.WC&QP6D]JL'T8WYS2693124T6?/>5M:>'NUL
MCXP;('O924/A%99JZWXWMF.\RWN'QL?VSWEY2_,.>-5<C8%D!'4BX$?;@3RA
MM1QT3+,SK'8=,6".) )V'69 QRE_V_3P-S$[G;G _,:DSB6.L6:9# UKM&^P
MFMC#>[9[D@)&39P*(T\R*YPQ^1U<B#CN'K;6:YC+^IA,G=M*DTJV-%"[#@O'
MN_IG#C]IAK4=<VIG558_57%D+B2=5JW;6UMN)E+J9G/XP$B F3!<VDIRS]!:
M5PM_$%TS,X*U.<5J;GM<\$@TI2HC[O="D+,KLFD[IR+_%S1,/]=@2AQ2*T87
M,2];L: G;BSI$ZE)SIB\8!'WMB=8CYE> SDX>GQ/!EZE:8ITS^7!4:V1OKKU
M-KP;?AN3&%*BYX?$>:+#O[F]J;;NYXA8F\ADNS+[J/YGMFD.]2E9]/\PR]X0
M,YH_!"9=O"W'I16*5RVTW#:L;=FK2$PCOV?WN#TRT8PDS4(?FO^XD=F !D;9
ML^"">2?A;)C>!'1!H^@,73XIW=#$;KIZ<27\ZN\-?#%3;'(O[R00%VCH:NJZ
M/9WN[RSXNE:U0BDUY=1$:R/J/V=;F8'F:PB";76$M!+\HZJF-LP5B.)JA#HD
MO8-5;3PF]#YL1.$=->CNUCOWXX$CDMR5!;))Q4HV\Z(O<IG%DW_*EJ"^\V&4
M %\[GV<=YIF2?7J;SRNFU<-'3Y)Q";OF@]V!;%G(69$%B1,]A;^.5#/NH=)V
M[X]^F)1HVB:.%?\XF2DJ^WLW'2RBZ9X5X(-H=U[GWVLX2$4[=WLRX#R[EJF.
MJ?-&CW7TI["%Q5NW!Q9D8ID4?MPIMXD<O,NI2O<B\SS*MC:C.Q>CIW!K0L!]
MEKT36VY^W9*PX?*S&5$M ","&MVW$3A3."DQA+O^5[<].*H-S>]O9:-#& C;
MC=\YM>RI<16HZF.M0B_3_FF]/I8_+B/!U_5XW''!N.]IK1Z4V4NHB@N0+Y@"
M_9UJ.3U4HF3J.AYVN=!0Z]]F!P[*,*"051SVMC^LBYU6HR?MK!,>@3&(PE-Y
M8L:) ),4((=;X%YW73K8*3G=U(4Q+"!$%WCRY*ZV8A_OSO&M!@;N%2+@+5ZY
M@@AXM:5&C=G(*/LK<9GG7##?Y94Z>18;4NT==%K9VES>QZS''IT6:.2>9>$?
M#&M.7) 0&2TH&2KVZ%L?Z960M[Q,:/,PQ14'Y2^X\=%/R]+L1TPU@\4D!I06
M-(&TMS7]7Q<DM(N,"//V[25=>$'Y5Y<[SIJO8);TEIG=U02AM[(@X6.7'\G+
M;L:+?942NR_Z-B221G%8^IRFU-7<>B-7-C'?V1/A='=>HG923]";?I.^G%I@
MQW8_$LX$Y>Y0"@/C@CIR^$8]/USW0 V)TKD^#<3_>'L*R@ZL&OIVPBOZ*U9_
MLBA%7UD84EDQ\6,5*EIE4JS[)OYTPBQX%P9QO^#!99!R=&C0,D[<1AY_>T8>
MC$E5R^*@B%\IDKA<[G_PG4 DD8^![ 4[?'Z)#">-T2)<]^0?0GQQ6^+[WL"&
MJ8A/R7J?XOR^5P[9?ZOI^RW]_&+5J#]37H1;./D5?O9M+:,9&!#=XFXH#'*;
M](T+BO'I.VAD_N6_9Z4E&WDK6U?AEZ*F\<;8;/%1:[K$ROI3HQP^<U<;.X^D
M*Y<)1("[ 3=\PO[&3&_^2I.J5.=Y8%6<57V Q7UV/EMNF]?^OW2><SCRJCF(
M_>:/@LO57J8B/#W9['%;DN(R)9ZR'$Z->F^\;WSW$9<.!]2(G $'4T,#UUC/
M>PJWS*WY<AD2LYT]GSE1S[/6ENOQ>,5OTI8"R+8L6R5Q[FA^_C-^S'NHA<:!
M<#*A[ +\-')GD CP_VF2U)G-,P+4K7CQ=2Y;PUVX]*AIF_6NGS.UO/*PY*D+
M/N^?>("/6@/WR-;X&>QQNMQ-20RNAK;6&N6V-BHB 8HO7,WOKO#<^M#X%@Y_
ML 9Z3)+?C]M^#Q X$+\,2()V C(4G%:.Y\4 HX\OE;K,,: H63U>!87JNN9Q
MR$;LI-KBJM"+F_(0V[W>-_''%4!&& A3'R]C8\=MCYE.KMAB*T=ZDC(9HZU-
MYT A2X%'H6G$2\,'*TS*,UK8'NI+*Y.B\8+YI=.&C$DWO;D&'7F91OZ<W.OB
M,/5@(H"\#"./93(00LD_@EA!.H1WGZ_N"+TE, JG&#A0&NBNMU+@H3@@9AGK
MF-E'8(P^ <;5RYW*Z7.,_YRQ8!X8%[\OU"5B^J""8ZZ<^P::YC?A\Y]6KG$5
M^2_J^:Y*9ND9^9T)/-;!:8WJ'K'=Z68)#PQI!-]1^5@&\G?R7X4Z6RK5):T@
MKVTIE2C*3RN97A\VJ#QYL%QQ9Y/%3G&\A,I97M;9?;D ]8N/TLWHTXO*+_FE
M;4/\N0B,C@A%;I*:H.7(!T^U#C=8S)5K<KKH0^ 3-D-XK1:!IHL($$X]$"!T
M<&40/D'<C\&D-VCQK&A5[S7K43S_YS]S0^U^6483QS]N?'^G3/EZ_%:D\H>K
MW@$",JW<_[B)<D=>J34$S4"E/E69G)]#!.A/W*C/,7M)/T#ZI(.56;1PRI4]
M30'%8FO+CW= 2U^1>A3BY"6E>EDKD,M-(WN-"SM$?Q5>GT0"K".$M^XS;CG(
M?T5.KW'"3X\;HO>T,;['RSF :9#^1V!9_E4._D=B&W],34L[\_],7'S<,4U2
MX0G*1TOA!/WQJ41 -#^6^=]3W_7MC4B[E?'OP'25I-[91PCON\!%:HPX!-HS
M"GMZ'0KNLM:*7/GN<*118*GA5OV-@R+<[<H-?UF33C"M"N,*]RQ2Y=[*/A#G
M?>B"_^@ADRU)9\5[_]JTRRC3_2L=:S<L1J>';YKLO F[/)5HKE@XW%IQ CKN
MP]C/%O"S)/_^C.B?@HH1>BZD+B6;D"3'":U"]#?B_ F]99Z7@LW(4I@1"1GX
M%*8<IE2T2#^S<_Z>L?R>O5NF+;NT9FQ/FMDB#4#Z'H#G:O=I&4$<HQ4%"R[6
M*L9E/1C':SWC^>);.U6^UACSXLI[!1(8MDO3KRDX[ICPS#%"M0:( )^@L^5O
MZZ&I9K4X(H!L$Q$&/DR<][Q@VB<"CDVGCOSQ3$NJQIXD3TU2AV1.;&'IGL_V
M2M+[$ZQ&+N;=C^$CG8V26>@Q](4^7^?,P^NUW\;1M8]K&>_>S"<A)BK4^WM'
M?ZD:$ =!\T>UN?]KS.R<DXILG:WY-U325R[GS="\_)F;/&3AUXA^WW25U2=6
M>@U).S<=G0!KB\F)[13L^V)$B VFZDSX@A,WCY;JXN>%=GHFG"ODFB68[#*Y
MS?EFA-*%NZH<0^OJA)X[=MW'&#78'I&49T Q=),D:-$(ME];-2Y*;%6K=/X3
M#@WACY]P'-ZZJ34@ST)&]XY&0)CUO*D2+X"1BI4-*=M1H\/\19:&4K>VCG_.
M]$K,;7XA0<JK>A4P(8Q\C&R0OH4%2:^=Z!L/"23.G9_JAKJB314UM%Z(Y^D(
M J#"L2>%N8;9NFEVBCY/59!+C=:^Y@KYZ9/QCA1"+DU[92?.&\M[-XD D0<8
MY&4\'\^_YW6531$!*Y6@0P,"/XGUGY+ 2T,B.+<$=@>C6;,:W:SW%:K<=;HD
M$*F]D639,+Z2LL>G$O#J]AU;UKDF;44.CBUSO-U_'3!?E]A;.="*1"4Q/?3H
M0<=9?(O=>O[\KFX,RUOMOV*QBMT"-G06R81M.7B@Y9]TRJ?9+CXPC\V?N4?Q
MB(MD!#8MP #/=$K0+NY!GN^VG3\Y.1W!WSP'X@7X,:2*\=QU&9-XQN]$^'$A
MB'AQZ)4DU=\[](' \[P4"D:/A..!CO[.Z!&Z/ZW\-<V*#?7CQSA(_J<U?J4O
M;Q>8%/=LE^<,SVO=>"J/<N6+ZF7/"UHJE#)P9DG#_/\Y=O5?LRN^T*V+T,L
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M%]J( 4,5,2+ D2H*="SF1MK?T'I$ORZ&_S+T-DDD];9IU$I%\%%/PXS88_R
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MY(@I*G&#J2O_U6M-+<=8_\AFL2]0*9TD/0PAZ5F>:W+-?2O7NA)/VG3%YXP
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MLN6_TE-Y*0[BO2H5PN$'(K4[+7+^ZB,'E3FVI)WV>REUT###3+-:_>CY#(N
MJ05BJ>A#UR(Q5S-7J-.2$T_<.Q-?ZZW"_.Z;O3P-=]Z_3+17.B> K4L%Q\"9
M=KXC,]!8EA"7&Z,HCZ4XB&E?3<^3,Y_#CBYXK_)-&!4H4<26Z[54*NNR*^2
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M.*>C[;V1K@+,'.0):G_",\K6R<MHMLW<PV9-Y_>VK$U=U/FWDF(>SI*BQ:>
MX WWD8[1,J6'+!CYM7+)%GF*J@&$?*/)!Y,X7ON6?&9"DG(RU:7:3*[$16R]
M25'QMK6P>14A+[&]>NG[Y7C#E]8R!8I6WRQ7'WZQKP1JOIM \K?PH)V\&A)K
M.Z0OS3I-&/#8V&J6S<C=D4MM^K$-O&1EM\ J6UTQA#+ [%QSI$J-+(Y5_9LN
M<S'2<K1TR7&LS,IB-%_\K%C#0A/Q^<NBY+<"35>%3#YUOO7CBI'R)CC&#_KT
M7KO]O<JW"2[[DV!/^"6<8)Q]M V7\IV>OYVD74W$W$/J$\OE;_6^48XX,EE
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MO?4*%,6-Y(1!1J"9/*"<-*A-S/_&!_7^X;/;'FYG>FLFQUY58*IU6WS/A,J
MP.NWPKF:7F+_J(*S3P&0EDCV]+D/Y&=X'YEO0$ERK0W:U?MMC/B!78=I_(8
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MXXL5JB1:OWU@JJ9+<U'S17WSM_PKDK0^3$IH]]5NG1/V]W/U7789V1C <CA
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M6*I:)Q/U'#&AH:\2RNP%52-VC\0I[-3HP9=P.'2,T&]$?!G^TGD%>2,S'RY
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MVL5SA.[SPL0@5]LH71<P60BP,A4-DM+V,4=@OP\(%JME2'!)%'L#"[I!3;#
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MYBHTOR4V 02GW7M:J!^@FV;;EL&1O31HFI#M-XL^D#XX[N=")P-?@JVZH$!
M:ZC'S &3?.QD@%Q[]*B'9<"K1Q%3M@Q0Q2P#]&83\UV-P(LY5>1+KVGS#'T_
M&- D$]T$04F-I0L"TAMM/VQ?#$KKU-A")0&A]X= C923H>0>NJ#(+RUT(43]
M^XAV56#"@>T)&2#CXJA_+9G5"WFW"\H#"-4,F4,BINRWI6"C'K8'K^HA5M ,
MT/ :XDU%"Y7\4R2L1@7)EW/9DZKB2L^=H9L QDT%)& 3!$0'HFD<ACZ337\S
M UZ=V+8!$$<%N\]WEGQ%A6+PD^#UJX"_E&T/&D+?#]C/"*@#Q1#;J\A-!E81
M14T$4Y_59"@C[?6A'$CRZ9.0:<"/IIQ^"(4$KU[%K%1L]V> ^J[,T.&(R<_;
MFL5>KB"U<RZ+4%72Z;D#=%/(-ST!6\X(\ 0Q)*U=CV;8@9AIH>NRT37/YRLC
M'?6A!X$UMR'F@'FG7('Q<X'Q&X#Q(=_&[T6\\1[XMNC7P(L)'>)*V!+#;YM:
M&E@GD"7C</3I# C14 71K@!H%EB'*^!,1L6HS65 LY>WG:DTQ'515 R/(7N7
MT0P1U$(&:$,.D'""GEM&-T50$J/6-92 K0C>E(5L'B5]7O1M4X-+ 9H$/GSC
M\'V&+$#&3LA<(B#CPVT9@?\HXOXM5FGV,"4KE R8NDX/B#JR@'W%<+1VP.)&
M!Q#MP#[_".PB5WUZS@SBFSD EQ:6=-"KV+#A)$9O/Y;7F@[+IIMB*(G;%@3V
MR!O ">.6Z-/9]!S;?W<1'$6Z+FZ)C3% 9!\%FB&$BMI>"C!\G0&@"=DV8%9@
MEP(ZUNN$_-1QC>K,J)%I'8*XUKF5!=F$ KO!;OL MRO ),#. X(3?3I]N\-7
M\$_!\@T7?>?5X <18V\ ?TRT^MYJ*@M)%DV@&;)1RR&4>.162BKB,^3;'*I%
MP$K:.8F2U/-Z]-P0^DTPK4WCU[__LVW??]O^_ZTMU(+*1 9R#G,Q_FK(A-X"
M9L&) ('0F B"B(2I3F$HPFY&U=+O:[/+D-ST7=X]-G$&QD7/*VZ/H+QJW'WY
M%]HBKNMBSRQ]+62:T&C2(QNI<J/[(>\8('0UI:EDQ:]KDC <22ES<%JTYEFR
ME/P+>+GB'X0[2B/1KZ\NK^NLWNV___<@4XCY!:?@^?^8>CA?_F.B Z"G]^]0
M\3^A1Q]Z!@@_OX[UEUG^@CVZ:O#BOPS&1/H?R:OW_VODU?+KI."AJ%]:?OJ_
MQ&B=_V8T\% "@%(_L,L /(3\]SM]>N%=Y ^$>;+U)G3S"GT$LOX#NPP0#1Z(
M7B!XQSG1NS2VRA)_)/]IIKX2TX]@X@AN7>@GS"'PU9 Y(,E_!#+NO6QZP33F
MQZC^ZQ&<*S!:-: O:87O?"9+'T6N"R&FH-\$*+B+^9< W:&;I^BC7QB@ES]Q
M#$@6+$"6,Y#\WA6R;BO_$RDEH@J^;A_/C:_%?&.N;WP&>)$?HO?I=Y[2V"K^
M%\MI#!B9?D 2<;CU'_1F"-#0SK_#LQH SR#$:Y);VT?'%FV#9S9]_[ZHS6>8
M[^\ #.7]-S\Q2:N^3ZL]#W2(VGJ&6"G^ 1X<0/L?[Q"_XA;0O"&M5@EH7HWX
MY ^(BZ3/ -GGE =D^L)/7 /H:17Q;XE4](J^H@!JQ8^#U_4 D;X-V@^DUJ=
M:@6REPF&DAJU;J[P0S^;1V>>DHPYEU\"+4*!%AO?&@"H L0.(\IW7M.CF71\
M=Q6ZIN+$,$4^E-P(I%IUR%PJH)9O? :L02%J,QNS:?X=,F].;)/0-F,&$82&
M*>JAY!*@AP9F+A7QG9T )5T$.B"_=T#,%0)Y6Q6RO<=6+F[W, @EY]$%?P$R
M@,!#8A!]RL"R<3^6+8/\-]J4 #SD(S:.('L#/("B%B(VSBO0!?6!_O/?> L
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M;B_F+=48[R#T7G]V]'C0Y+O0+7'!#F$M ]W,N+XR_Y7D@S*=VNNH<+[.>K:
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M#.;Z)"4M.^0K1/-1BJO[%^L\C"9IW1I73V/0K+%CJ" &Z##]B!T+WD))@.5
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M1@:4(MED";M@;].:R[CK5[V3V*85!]]:NZYN1#(=&1!729<RRK.R06NIN5K
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M7*UKIG6Q_6M^4HD?V%MG!'/M_ #)AIC2XH^ .3A=J&R-K^^?.]@"5@JY%,4
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M:$82"ZM]7WLE+""PX,$$,1<25.'CJA0RP:,GJI!%S5(@4KI6NO9DW# F>+.
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M_HM=D]YI07RPXQ2S\2[\)HR]OU#ZV7E,^V<-B&CV+C%_8Y,;/YU,^<\P+7@
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M&*C.K>5.;V6 JR]%0>"E0A^5"(X!TX?2<ISQ?=P;_ S860'NODR=LRF/B<
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M261S*9*X1FS/2)HU_8I>S/U@Y0=>7T,!R9<&XLE7?'3/;"P=D'2GE@/U,[6
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MZB>8XO6E!9.>M!QAGT%XM+_%>!X;5Y-\Q''OPPN=(ZQG>%$$B)$%]AC@OUS
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MSEQ67*%N@AO7MKQI[<EUQSBC7IT^7E/Y!5W>WQ8(_L-KIXDV53%ELU"7[^O
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M;C"P@I<CLRI0M1:JP*2]@+Y).[V63,<A1%VHQ#?DX#09(WA05\TI_KB^1"*
M%<*] :S0>7L:0EC_@16 V6@X5R\=3#@=TMDA*YM_LZ_I\.?2XW?"K0Q%CCX*
M;X2!Z/JZJY!L!7'Z4.S>:CXY_!W,+D7M5)LHV:A%,->,KI9\PVZ!AXB<L4R&
M'0E#0WR%JVD?D[Z[1:B7M3EK&RX4]$[R8<>[S%Y$"5_-]O_^6,T;2;Y(B4)
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M<,5_NK/&1[;\;3WY!#L)W=Z5(PU^/8=M3VL_.GQ4<[MGO1<'<(Z#1"903SD
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M69#0TDC@/];XUCH2[S44W?%2VK6I79YV\\BG)7-&BM2,O]P3:4>G*%P?!7W
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M#M> $K!3 +O)&L8T-!F[T[4=MK)-.4#Y41:>?J@CB36*_8!X"XNAI^@$<']
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M1%EFW-AU#G =CS.A6U+?%N4LKQQ@J3:8!\5K)"9GO7(.? CX%^S;YCJ2A.8
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M[GFTZ,7*.:OVK;NZZZ43J:7+^\+(^AC8*[&J-QD(,NN/'&!M>ZLK<U\2O^V
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M4X4P$IX->ZUY>/J>$11CCC6)SH^BPU(,4AK-96"R!.%IW^,=+XR(]HZ**U]
MDANCZB= OS8T)<H-5#0;N$)B#G3_>-'7A_D1#-P1"SQOP-VDKP8/1(E)L5*
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MFFM@&,4R8BUK#8+16>2+019B&#_,@A:3?3?LY>@I'!Y^]Q=#,PM8*S ?[7'
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MA_K1 5XEU"$AU)5IV."C9]N&K"4, V[(C^DG_,)W:;)813<%C+$7QP1V#-&
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MWN;*( XV=O3O'/.Q/A."X&]$,9W-14C4.A)[[U5[B#"_1VJPR $FAG2OB<6
M:!9:&\"$AX-@6/S0#2M*?('&('C?@[K[W\AO89>217]8=&6?X*C4.#=Z_H3
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MNX1"<\@>LPNML-K2\UPLI!.A)\S8"2LF!@[O?M]EW/Y$<7!\/:?#@!C%!GD
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M,LOMJB2!4XY5!D$W2C(2V^5 Q./IZG=ME@QKW3Q ]B*(DS;#B!%DCZO9I/&
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MTCD"5VOJ\%:,]7^J)Y\72R+1*=^0C^YO.-1^?H5L42)B89?^3DW9DX9.;\T
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M$[WR1FR($?,=O ,NU0@S'/'6' 1RA!RPE'2;3XB#GFB$TM_M<#.HO<^6#.K
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MTC=?NJMW]HR_V46?13TW_ 07I[H2+W>"<'7%?ZKP9N^19YG]CYVJQ&P42HU
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M[#5-L"YT@;)OJ3NWXQ_C4]DHH:<1ZOIR:8[*"@+M>R8B7<\5^V_70I:(^'-
MHI8B96E]'O,6B&L[$YZB&GQ<-@^J=/((^)>E^#8!U"J'K;YQNB4N)IUF.'P0
M0PVC ?Q;PJR*3R&</BQ"^;FKW5">/)X;#FN_CAG '/+&RQFB-S$B29&++=#U
M298M;4&J.ZG>FA)+FA[NY:.XDY8&OSIA\&O7I*-W7",=VJ=7G^2$5&M!&N._
MQSR0 %S6NSVRNM+622X@].%\N!&B%YS!P"S'!SC@I?U PD3P_OZ00J:I0[IW
MVVYC!YT)VZ*_\;%8X]_B8-R(CE;/![314<(\VI-4?&1"]FXLHQ36H6'X%8 3
M<E!7)>F:MWNT57G60 NV]ZG-7[UU;^)[E0W^O1VGCTMG,VQ5LR73H4R>_/Z'
M.>6R#<,%*$M&T Y#7%K%#]9^%\N2,%G(W:5^^MFNX3CE/I9AJ%1-M=VO]!7'
M(3?OX\PR,6B\K81%R7,UC<9K'^\^UP',=M=4O82]Z.S,UPB!/RK+\;2]*1:>
M\<D< % TJ8\"!]4@K"GEH.W-#T[F'D6J9.VX/71 VV)Y%?<9J+$]?.*#J:"N
M/43$J5]O9*DL3R_WT8'<4GWB.8 3#22I':5]15L13LSC@L\!T:V,/L"?H9*9
M]UJ;'&IJ?D/=;)UGZ**C+%=$1"/IQMU?]0- GIZ],E]5:IQN;IK/*9_\?FL/
M:ODU[> D$1_$_6755=*$77[N<>?K6[I[]JTD8+PX66'0?-&(H#8DD,J'0S"3
M8@?:U%]3GD_KMT;+6T(?BTZ79!OM*BFK-O-=<F68NE7#GX /93U;_;=:3M;
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M0V&DO9-+Q[C\F,ZZK;/KT^A'A#6VK9Q!D\-1.;<4B*B%>B(\/IZ+DYNM"B>
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MN:F#!:^@C4YPCWB;+/'3?'ET,9A\0ZGQ3Z*P/%QZ"2L$<TJH'@ZF:R_7N45
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M-W+5T[2ME<1DJ5]W-9E$$_'@V25\<Z0.[P)<8PP"+K,!KNQ*F51)YY2:H&Z
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MIVS*RIW"S"KE,6_<W7]!,@E$ 0 RD7%C^4$TL0:_$?5'W@ZG<YVTI9!#&$R
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MA.TAKV5JZC.G+8'MY&N%#+RCM-$I747@^/@NRN"'>DI$(%H(R[LL4/[<^T\
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M"UJ>@T6G L:_F^N6DE!FSPKGS#5^;]/P$MA#?F9G_X4$Y*?/"^%W__(>;9/
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M33>J]/D\T\?XD& @<(@YB0@-*;59S';D1E[/7\U>NUH&40:#+_^#/CS^VYN
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M+CZI#ZOEW0<3PUJ7W]/4%FOC6'J_+/7\SME"UG^H*Q0?UL&..2=293' "<\
MS&@**(H92!0*HPQ&A"=.=SDC\#CR2MYR;,Q=PRFH6&WJ7SI6'AUABNS4Q)6!
M=U,VNYCG0<ON2?QO@@W3P9;KS1^;ZNBC5DD?$5I?U4I'X'#:\J7C07Q4SW1$
M4KZJO<\H@11C%0$2FEH'0FH%C4(.DC1D6B5K"S%,7$S#8Q(CVX??S"L!/Z[Q
M/K3$>^_2[F-&N1R7=!^SCKMGY7&"P)7KMI];NAU/]EMYFW.=5@1<F_.F0^XF
M\4GJ,PC!) $RBV, 56I25B$&/&)1B#&5&7;JC]1%;&0;9Z<^T@YQF_0F=]CL
MUJ<O,-Q6:G\<G)>MC8">%G GJ4F7LHW0AXO:ZIV>RWN5R_G=LM85>K_.Z;+0
MHU85+):B^G51%[0XZJB$529BH8"YTP8PD1C0+,V @BI1*2,RI4[IZKTY&5LQ
MU'P%+6..>J WOI9*8@K4'#7( 6#!+E-5:OLN6Y,<3P:CY$L-]>9C6ATU%*XC
M!39XP"&MI?<S6HOM$DLR$C+)4D!3I,V73$']$T> 99 D)(I,!QGW[M+GR(VL
MI_HWF#Z+C^4YPIO4CF>*TS6VM*TR8J?I2V)Z;39]EM@5^DU?$OQTR^F+;_5;
MUZ]7^>/*U-9ZM3*]Z;E)2-<GGJ9W, V3$)I^\02Q1"]K1@"AIF0Q#2F.HRA,
M:>2RK#NIC;RJ-[0#IHD[+N]NF.Q6MS?AW1;W5FY#-]@2OMQKVGEE6XGH:6%W
MTYIT75N)?;BL[5X:[.335D$5%W^_6NCWB[I$Z];M0!BC0C' C,,/*DH E3 $
M&'+!8_U_F3@M<%O"8^_@6S8J,[G88>1__*O67-F_!;)BJ+>'L!M79[^A-[1Z
M>Q,WI;+&*D7C**Q_AV,WV6NY(:W Z'!.VKWOOU36M]4KV58TFD6*\4@P!!!D
MQGT9:CV"90(2I60,0XBCU"FZQ);P)!<+ZZ68%]ST()0BJ,MC/3:\^"N*M0>G
M_7'!-TCN!P>'PE?3U+4Z)?H$E:SVR+Z8VE6GP'"I5G7R_9[5=YL4_4I;-99S
M%HF,1!B")!,20"@S@$5$0!PSP6F&& N=&DR?H#&RJ;$I"5&GF'[6C]U7!?3T
M4XXE=D_@ Q.-1A9&( SUL0NFF *FT@3@6":8(I02@6=/,F>KB1#:I66/T=?/
MGX=C8:<4!\KGIO\.)M__@:I#&E_EA4]0F+:T\'D1C\H*=SPZH![!:1,^0IE6
M17$"5!0IO?04 82'#(010R*"(5'$+?7P6H>AKV<//[_T*"4PY+QSC1-.3><F
MN"W+?,[6I2EE:LR2S[0*%AFE@\]49YN7<IIQ/[^,=F*Y?:+SA9GC=ZO\*UW(
M-Y*56^?*+>?KA_7"M!+X:[XJBE^7N:0+TY[41,R^DFJ5F^;3,Q0G"M(0 8+-
MMDNX HS'!.A%'X>",YY%;+:4=V8@N]7OA2^K54+J5;++G?5BV=(-#&'72Q _
MX-OIDND [:5V##L[OE:M?UI^@:8-#,<WP0Z70<5F<# !-_KT9%@--*\>*XSY
MA,Y7(3(O/$U;K\PGC$=ES;P./K3?@AF?K^Z6AH(>MRVR]F7;I*LJS+Z][\PR
M*%B"*,BD9$"?8B@@L8! G_<0#N-8(>%6M:DW*V,;5PUC)IQ\ES6S8H.6N;X]
M&9QAMS3#)@'335]:X1@8QH*&LZ:9PSAA+L,A\M[IP9F1*_5^Z O8^6X0O4?T
M6J.NRNPL3I=,RSA.8))($#&H[44:Z;-B E,@91A32#*NU9Z'(G4=+(Q^>>Y:
MI>ZFJ;P]H BW^SPP&O(8"@YB2J")5X" 9:9T?9+2&&75;:>;W3[23 PQTC>4
M)H76X80_VA?7<4OQ6)V@97>G0,'HM0,M0!NW>& 7 R^A>J %0);E VU&ZIE&
MN\G'?:?%>KU:EO/E6M-M;ELTI=I:KY_3NYLLWN@?BG+.9V&<D=!4#X]3:?+6
MD=9F)"0@EOI#E$2Q2*W*#7O@9>3MY=>?OO[DF/LZ %<[53816FXZ;2]I/C K
M)=AR%FQ9:_T&S?,5=S=!RY_';-7A(/G*2AW R;39I\,A.\HR]3#D4!?!8<M'
MO9_.^>U2-*T?#PZJ<1)QS@4$2!)NBJF:Y!=* $:,IU0F),1.<6<]^9C4.4#7
M8FX\?9_SE3G#/M#@W7Q)EWQ.%WJ=*O.)>UN%OA/@ZBD8#=;^;H)3/5XKMJI(
MMH:QB;P$O>#Q[B)PX^)*_H%>4)UW#O0;;N)B@M5_?C,*M[4XHQF+$XXD14"(
ME&KKSMPQH4B!F N4A"%-&77*^/7)W,AZL:*XK?)7K@+9W.S74:C+U1)L/WFJ
M60OJGF#5H?=9TGRRGEZG)L]2?5YI2B8_)U?_! W#_L_'(\!X[:I[IUC[<Y34
MZP#56[V\+AI],R+:3B9?2UJNC?U+YTNMA&-]D,Z,$F89@(H@@'FH0*9ULF+Z
M=RF<NG2=)C.R.MUI?%-3#7ZOZ3I66CB#D9VN&RZYF];J(72/E(4NF;PE*)PD
M,G$Z0I>@Q\D'G4_W341\>,SEO582\Z?FH'JZ0IDB2D8B30')4 1@G$J 9:9
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MW,9\UMIFKLVP5\^_%L85^GZI;46CEFY-BEUU4-XDR- ()IQA#A!D*8 H8X#
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M\Y!2C0[K;)B,;@OMZ![#[TH[+\HHA1>G7VOG!>PNL.AAM=5%ZJHC^FZCEYE
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M@D@Z<'TA42*G./Q3A8%T0.P[SJ.+E'MJ<-OS.HK9MWFYD#-M8ZI0F60C+B"
M69P"@D,)DHAB',5"$+M6L*<&']ETK&B8X.<H_I']I8WCM<S1/PE&M]X;*J*;
MPG*5KE?']T,Q!G5[WPPV>:?W0S%.=7D_>L9#Z2!3:Z.JO%'(_$E^F"_E>WUX
M+&;:F!$\$[QVE$*40D!5%@&&(AA3%66)<.J:9T-T"L_I7IF^IF)-Q47PN^$C
MJ!AQ=-)8 >K@8?4(4P]OZT"$AA7JN2#R&'5XSI&\7IF="R!T5M&Y]&[/"K^T
MN->CFG_>_G,]?Z(+<W)[1^?Y;W2QEF_F!5^L"KW!SR(98TPC#-(LP_IX%$)
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M)!'4YT:,D3Y!:@-%(A0G,(SU&G9R'UG2'7E)USYN?M1.^)<>%8XM0+2S,$:
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M#_CS3$I$)4Y#P+#2FY]2":#8M/C ZO_G[DV7&\F1-=%7";.Y-E-E)O2)!8$
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MID!1SA' JN" YTA4DG*<(K>,ZO.T8IN)AK)9BQUMXV1HJ#M&2%X RT[%!8+
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M"'<AHN;P.3\M\'>YE&NZT,?R6_$P7\Z-16"^H5U>URPK3-AP58%4D1S G$*
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M/_W[66Y,M3;-S=-<2/'FYV^UZ:"X:UQV:Q*UYYNYK&<YS*4B.04L-Y76$8.
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MN> XHP@!+$L)H(!(GSKTT4,I1G@*"119X6) ^#(2>5'K+PUTLPF\$;4S#J;
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MRH\;^5#/2$J50CD!3 JI3V<I!B0KS*T)4U1K%IPC)^_J"+WH3I^V)GE7B7S
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M$NE;OMFNY\O[62J((H(50)5F'R>< @() 2PM4B)(RCDE?4C!=X= QC/T/((
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M$N1 N-'3XFR1U;^W-;9[S2\ ]MF908?%,R@KWFTED!'AN$]$F[5RG-P>@R;
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M.[[$/$J$(ZO_XS+4G*0/WT_C8C8A)S=;GQ)$%2GZD8A I"(HX8632;(DCW,
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M#'BSF*>+VBPNM4^T 8I+Y/:;PB *61^O,R]<\U)*Z\-J%RT]G%M-@--$V!V
MYIIC=HV)E+,O#@UHI<AX4M0(7@<-Y.]SZZ(C\]GZFO!>0L9I-C[$676TF#O
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M_14)=5/77>/3Q6RVD0>1AZOUQ*"TEM->,BHP.J5I0WDC' 2?D'Z$DL?6OM*
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M\HBGK<)%SK.H-2.)*UU;_->9NEI '8P9@@C)A.8][+JKVAZT#.W)-D2_P.G
MKM_L52-D]BXY"[((7Q.FB/A2)&@;)/K$H]"M\XH>WPMHT**U)T/EX8+O #4/
MON;YS(LGG(,NI9XL(4'PTD,L2E@F%0^J=0+1\6^L_UL\B#53RY%/8R_F;1J5
MW?/ EQ+SV3D'!3EME& MN&(=,66=U9P1&ZUSL ]\8N7_6[P^':F"ID!ZFK+&
M9R<?_NWEZ[=_;SJ5YNI#ARQBW$%Z^]K%9V'U^>5L\>=5$^SDO,B69Y#1UB;8
M4H+3M<VYU<PRH9C@V'Q?[J:G@5M4/_/=<O%U2I+[[?L?*\ROYI<=F$_(3_RZ
M":TN)> ,B\[)#&434!&_X$VPX+-U)NLH@AG =WHDE9TDLAV+H'N<J2'5U8''
M==-=Y,%Z9JV"&&IG#47A1B1C#CDK[7SP'EWKZ/0 /WTH& VM[0<]]<>(O@/<
MW,@>J:D?\S2=X0V6/BX>*TW:J$8Z:\ [.O<5YQR\SK5%F4;E.8NV>>_/(?@8
M-U/NB5$\.A ZV S/D59.TW!^QW-R6N]Q_GOSUTDQW!A/QX]BJ9"3+#3$J 44
M[K5CP6 JK9/0'R!G7 ,[/E86PRBN PQ>=%>[F:HWL=XE8U4$(^KLSYJ$%XQ@
M4$J)WLA,1TSSQ(I[*1G7*':'O ;JZ@!T)RDM<:/#:SNG=BU:I<59K?B?YW=+
M/)V>G:Y>S;_BN08FLG;US=P"EYJV5O*,!&<EH$!;C @^Q=9NYF&4CIL-W!UH
MGT#=70PRN)3?ZWH-]KYVYGI;2+1UONCZ.N\7PVZT+E5T'JQ2'FJ'"W V;)*?
MF$G!6LY;'_*/I7'<-.#NH#RHBCNPS!?O\6_G'\(,WQ:2*W&\_EZ3GC:-63;#
M*<GS=TG5S*>PR=4CGP9"X@ILD9HEQH76K=.#]Z-LW)S@[N Z@#J/M;0?VWD1
M=<^].OT2ILO*Q3-RC3[A:L*4]U9K#C+7CM59.8@.27**%:FTT:4T]Q+NI63<
ME-_NL-A 71T8R$WV1AW:19*[.;DN"RN5<QFTJ!VJHB0?7$I'AE\ZCYPQI<,0
M*3KW$3-N^FYWT&NCM"Y\S+N/K9=".R^^NY18+C(X;3B8LNF1+A5XHP)$B9;X
M8TGQUBF[^U,W;HCTQ)>= RFM W-XES.*Y,C$Y^?G])QO- KQ-IMP<PBL)L8G
M(:/CD),@HR]B@D!@ MJ++.@8!4NMGV</H[2WC@AM</-#>#97XJBVL^9%W,/D
M<_RR6$W7%US5\V&3>[G>\D??O^#_/7V3SC&<?MVTT\F9)%LC.1:RJ"-Q! 0;
M/!3!K-(\*!9O)?W<S<QH3%-O71::XG1,_75ZZ)^D[=79N_!]PQ+/5@DC/:12
M&X$)+NO G@*1>^\P8!'-F^__D*C>>B(\D>T\1C5=GNCU^O:,Z)B&.)UMG**)
M<=H1^8)"M<V8=V*'&$' $(5)6814!ICK^T.Z>NM9\'2(.T9!78+NYD7K!6O?
M)XXY8HL+X%(R4++.(Y-6T.82FIM"+DEL74"[-W&]-21X(OBU4%4'&-P_)IQX
M@=X4B@"CEA9J\U[PW 9@I1;8)*<16[^.[T_=N$;PZ9/AAE!:!Q,'=W"V?2"]
M7Y#!BI"Y]1"9*Z"8)"<CF0"EF" Q:E]LZZCZ\51VTACUB5)^6ZFK _M(_NQ%
MUZ_T7V?3)9Y\#=-9=7%?+I;U>>FJOO<YQO6D1*.Y4PZ"M+*^=RJ()3K(W%AM
M110NML[*?"2)7:8--T/,XNG4UT603(),B'GUDB3]>UB?\[*YR=IR?C+/S\)L
MMGI;=K,^D4G*4O/U5"#!*BL-A"0CD$]$YB&+6)H/U6A">)?)PX-A^<E5W:/]
MO?&83QQ?O>>KI'60"J%P5SUOX\$7ENO09B2NLI/-JQ+WIZ[+EY\GL[IME-:%
MP=U?E!/)$XKL.#GV]6F_%G_2!@M@0[:84D39W!?8G[HN Z:A #F0TOH-F%Y.
MYV&>=@E2!L>5 ;3U:K8PXE4J#DE9)[5(P9G6+^2/IW)<>_G4 5,K=75T8)_/
MTZSMN8@U?+98K5=D[:,STCG@*B$H+0,X'@38E$P4WF+ UME"#]'392C4# L[
M#N6C%=-/+N1UC_C^CK"BH"'&"HA:'JIL837;4T'QF@6;N-&Q]9/-#XGJ,F@9
M#'5-5=2#?;O&T,4>HBVUZ?3RQYQT]XJ^,2<9UL21^PN7MIU?620'0S(DST*X
MVON- C'''"!:Y87%K$+K8[@5[5T&,T^!X"=3> = WU_,$R6<\36+E!OR@X@-
M![ZFTQ<I@PXQ*J]:'^O[4]=EH#,46 =26@>!3F6K_G^].O@:9M63N6KQ6G]
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MM#):Q\P#Y,JE0E=?E#D#KFSD4GCC< C0'D/SR!,C!@7ND^ER1&N[*>J[63I
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MK-;34^)E-1%>V^B* I$*@K+>@F?6@HR9(=+)05%F8T#>I&#<]C(#(>L((7<
MD9>+)=)Y\FS3E3%]_[@,\Q5)I,X@.9GGS5]G&PV=;X%K\470PHF(8&J"LZ*
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M+D/40NDDO%?M7ZONIV4_</TL#P]-)=\!@NK66.)GVAVT$[9,W6^LA90A22]
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M+,66U@]930COU X>B*8[K:>>6K4_*9XG*B252^T"GIP'92R'Z*(%&0/WD9>
MKG44>PB=XQK8#M'Z*,5U ,X=_2:17.7:*;Z*C=QE\F_ 2UM'MIDB.$F0L=9A
MQA%M/P?+2QD88 V$WP&$=@KIONMS%ISSFCD(1I$378P%;W2 B'4*-4:90WPJ
M-_'0]X[!<DP&AMM@BNJT%>1[_(IS8NKP!XI;G]#B;>$AHAH]"YPOL9W%/M_<
M[_Y]NO[\[&RU7ISB\MIH15Y,5!ITS@Q4, PBUP@6(XM<!2Z3:KP7]R3M:)=K
MN@J?/BWK*]IFP.3YLMMH*TBO>4VY1LD)V<8K\%$+T%X)+ ZSUJTCU8?H&=?A
M'P(K=_RH5MH8>4S1L]J.%Y<DV/7W-^%T>[$8,X4;Q070P1/]41+]*5 PDJPF
M;DSP92]/Z0?3BNY;>USDM-/JHJ&(QYY9AU_.ENES6.$)B0:WA<8W63J_38PA
M8W*!3FZK"RAM/81<.!A6C!9:%>;V:NCRHXEV^Q(TWNBSXW6^&%H!8V?/OL9O
MN/CX&9?A"YZMIVGU:I[.;Y(Q*)Z-"5"8R628<Z)XTT?@O#BAN+?!F1^Y.3]8
M8\2I>,-H<]%>M!W$83L,\E7LH"@VD+$.!O.,XDIMD&('^LJF%)4KJ+5HW3/E
M1S2->W_4_ @;1!4=0(LBQX285]5-?#U-.%_A2\35=GH YDFQ)!FA'60K+;'#
M-/B<(C!E@I$^1:U;WU;^@*0N?:,#]7\WC&^FC ZP]8,(Y,6W-#O+M;A\M4+Z
M7Z[U5R;R6 Q:LL?;S@<<G!(:;"YDKP,KHGG7G0/([-*XM<'@T$KK]$;I=9W#
MTSP-=H]/;7'S]%CB&]U&G2][<9&@1;&N7F"ZM&FUS0VX&!R4C")E5T'2^M+I
M)@7'VJO7%="X^<SGN$K+Z9=-=XN-SZ"+X89\0W EU(9GR1&;V=!7)D?':$_9
MUK?;#Y S[AEXA-YO6YM6(N_@M-LG5ZTH[K1U#C!:BCLP%(@E<$@4T&B57>:N
M]1;I/J>T&00.2"-]C#YZAMBU7#;A&./!>.#U;5JYE,"16PB,Q.4L,RI[?"J(
M_4QII(^"P@%II(_12P=0^^V,)$INWD5G63+HFBD%+(<ZOSXH""E)BJ +T](F
M$W)KM_PF!9T"Z% %+YI)NP.L_![F9X4\@;/:&NQE2+6-V/=S5E0J043'@9<Z
MMB+KVEE#&. B4<R 2?GF60$/D--I4E,C%+720P>0NM\IN(IPM7=*:R? N3KV
MV\C:7,M2[(DL1Q-C+*)]K/$@2>-":R@GJJ4>QG]JJ;Q<CI#?,+7YX_-BEE^=
M?EDNOF[>(4YFL\6?89YP@L8%%": 9+4BV"A7[S4X:!.%92H7R6]-X-KY O/(
MI7MTR0_4^N+)5-"!W7J/%!1/TQHW!>=O%O/:,),8FI1-%8GUD)0+M1"@!LDD
M-ZD,Y\9$I[!US>XN6GJT5,=AJZGT.T#1?=OD/<[QSS"KG7PGG&5M@BG  R]U
M9CQM"DG;(RHZ_BV+@9G6;4%_0-*XR;Q#8JJE+GH\ 2^*,#9_R>=>8^U!%GQA
MP87:E86QZHEF\"0H""HKY;1)4;&##[]=JXZ;I?NDYUX3P7>/J-6+;U^F%\,8
M4L)9_<WZE%F2R49$LL.:7-%4QQEJGH%Q2R<[<DQ&M4'7#@K&;10W'M):**2#
M(_+5/"VWTMO^]]7\EE=YWL[\^T1+KKB7DCS('&NZ>Z"=I"TPCX5)[[)0K3VO
MO8D;M[O<D,?F,/H9V]S=VE>+>?4SG]%.FF;<[JG[HIE-IWR<\"QT((<3HI!U
M>&<DN^ZT!N:X%Q9+)FKW,GG'4#%NY[G!S-Z3*69L!#YDW\_=THNTC=6$AR2]
M+@JL3A84,QI\W61%A,!\=MDR?_0A>WO5<1O+C7*P'B7XL1'U_GHOM+=EAYD^
MF>?WTT^?Z1?^6-T[-&12$[<M9Q:,$O6FANEZ4Z,@.XR<I:"3VL^\-2)H+QSZ
MGPZ'8ZBK W_O^?FRM-76VWS(>K>]>H/KB0]<1%3$1&"<_D %(3('68<@%9H0
MFC=.VDW-?A>W[&>"76,5= "FFYOF[UAW"N:3K_3=3_@>ZT/<Q0_K'0^?('H?
MDE>@F1$4DFM5BV<]^. 0=0K"ZM83ZQ]+XW[ ^ZF>#)Y$7;W#L19NU\*8]Q2E
MO\-EJM?9KMC"3=80-@4,@DF(B4<@RVVBLIA$:EWN\5@:]X/C3_G*,*BZNH/C
M9II L#ZSF"484>U[L:QV"TCD,<B,2']$V;H*Y"X5^T'JIWQD.%+D'8#F/\)R
M6MV!*P8PHQ(:XW;VGXI%0Y31@Y-<,Z]94+A7&>PC,'.'B/T@\U.])[01> >(
MN8GY=^'[YD9F8K/F)7@/17*21)(1G/&U>W&4$H7CLGG/_/LIV0\[/]4+04/1
MCWUK\>&,L+^Y5TZ+4ZPQ"(LL<=2\'K 1E"H(,9#G)VU R;2)SNZ7K'/GH_=#
MPD]U3=] AET7<ETTZ%R4EV?KLV6]$4XUGV@VN[29%[ _FY/^;NZ(HRN^VBS?
MKC1L '$,4T.FK-+.&/)Z0J;(S9"_'%CRP*5S6@3%E&_M-+2M(;O_/FZ*JPOY
M/C_#2VYIERJ;&4+AM3NL14VVUB5("H6111'_PYYU#],W=A+BP<AX^+QKJ)0.
MW*A[4RHOKH&O\?>&-NS'/W'V%7]?S->?5Q-?,&15)$B=Z;"0R8)W28#5495L
MLT/7NHWNH;2."\3AT+-'JEES5?Y$D/U/#,N/?RXF65K&(NUUD:PBOU08\*58
MPA?Y*N@22MNZI.V1)(Z;4ML=0 ]1W,^&2P(:3I*U$;7R@#9I4(Z<9E<GB"7/
MG2D4=!??^@!_-)'CIN;VB<U'*^\G0^?+Q=ERHA 9J[/9358D3:R9R:;.:X\A
MZ%"T1=/Z7?2Q-(Z;[MLE-A^MNI\-FM.OM/6D("E*!EE%!,5\ F]9 L?112.T
M="*/"4VB<=S\X#ZA^5C5_430/"FTYB63%%CJ(J6 E&O56;82@DT)BA>9!:9"
MBJW?NPXB=-S\X>Y >K@2?R*D3H*(VG!1(">FZ[AD ]%H!<(XZW-![F+[.[+]
M:!LWN[@[/#Y*58=#<+$.L^$A^,<\G^<V8'[Q+=&OGIS6OTU2\5(G7PMS<VU9
MD#F$3'ZTK8E?H@04LG4VRD&$CIN8W <XFRBQX?#KUA?MWR?<*1EYRJ"]*:!\
M\N"BDI"#3"3#$#RVOBPZIKAGL 3D)\-;"T5T<OPN;CU\78CJ)>V9,*N.Q>^A
M=E=9?[^47%*,%U<0,&!-NC"&(K7L0(<0K5'%&6P]<N(P2L>N^F_VF/,$BNH<
MCA\7O^%%3^ [;P&T6W/@ED$1-8G#TJ;V11FPU@;'LN0J#G$:'T+KV.^+P^/H
M$=!MIM2?"+P?_UQ4&:\F5GGRC<GQD+;.OM*L-A.EOR8E2,"9)\:&:&CQ&!K'
MMI_=@O4@)?Y,(*V/!><<)A>EU1)BI,U'QY8$'S@#IJ63C%GZ;AH+II=4CM^*
MI5>@'J;(GPBJ]>U@RV PY$ZA$E"D<;4#?(;(R-_B7KCHF(EHATCN>!21X_=Z
MZ12HAZGQ9\(I_;%EL'!-= 0'1M>VE#PI\)FV)*?H,7'C<U9#I'8\BLCQ.\7T
MBM.#U/@3X;0.C\)0'Q4FT15KN$C '=8:+A)E\%:!B85[56P09HA+]\=1.7X[
MF4Z1>J B?R*H3E3.,>N:^V\*B=&8!#Y:"\$9IJ1CWNJQ+.GX/6<ZA>6CE-;L
M?:AMO<5O858K"3Y\1EP_6YQ^6<PKEU<%!Q=-K\.U?M=O<'U$B<61*[:HJFC)
M=*-"BNLDO<=9?6>YFOE]=?,JA,Y%% Y>Z4B($P0V86NAEXR::>[R[294QS?R
MWXNR8PWEA?#?EMUMUC?ML%'4"J=B(!.SH*2TX"SSD"4COR5DI'W76 +[TC;N
MA>@ "+IM& =14@>G]#X#1JPO5C%GP7AOR4=F!;ST&KS16#@ZCLTG(70_^V<8
M/!PP".@QRND9;]<F2=@0'3>16&*U,;&O6Y2+#-'R.F69IZ!;WZG_;S$(Z%%0
M.& 0T&/TT@'4+EDX'R22.><Y&$%$*U5#?0]!,4'QDV(E*L50M'8@;I'0*80.
M5?&BG;P[@,N];3;/67&.AYQB 6M#;6Q-G@/MK,H9+U)P'M&VSY7824[_LX".
M@5$K/70 J1I@G=''W=X9(@1A&')@$6O3N9J$KGD EI$IE0V7N36<=I R[I/;
MT%!J(?\.8/3R;#F?UN8')**7TV_UJXL-87(FX <)LKJ8BIL",8< 7"@7'-<I
MB]:54KNI&?=9;&@P-=)"!WBJW:77R[-4-?-J3G+[1*Q<\!*%4=YG!Y8'.K6E
MU1",48#%HH^"9]7<2WJ(GG&?L(8W4(TTT0&J=LKJ]66_'YDU%Y%9**J0J(1'
M",))4+1_LN1.!=$ZP^_'5(WK38U[CW"8:GH&V]^6B]5JDH5DV8L(0M0LF;HQ
M0RH2O)4QAA)HZ[2N;G^8HDXCOP/UOR^\'J^,#J!UDM+9Z=GV$AF)B#3=Z(F^
MGN%&8?-\<KI8KJ?_O?G^3N8G3!0F>:KO<+6GF:Y],%FFV 6]LJG0R5!:EV*V
MHKW3"+,-7$=1<!>51SM9J1WTI'52L"B@.!- *?HJ"HJM@S11*<F#+*T'TSY$
M3Z>1Z< 6\[&*^$F?UFD++L]J'=\7G*]P%>;Y[?HS+I]MAUY>*_D:\+']T30\
MQ?/[<8)YV@=YSYP,+*HZDYO.=4>A22R9_M!&H?>>F>;UBD_S('^A!$+9XCOB
M;SC',EVOSI4P"4RC,EJ#=I;X#N2)1Q$\F.QS+38-QK4VE ]3]%,\OC\&+?><
MV*T4,G;WWW-6:AM3^ODTA=FS\__2,4#'0BUL?HY?<;;8G >U/?8EGYGKP+S/
M=1)Z;0M1'6FA,NC(I%/6<&7%CZSBL42,ZQD.B+4GU4X?84YEE9@JQ!3I+\Q>
M(EYRHQU7G"%"8H984H;BM5KL6O-D4(ALG&V=-?PP1>/Z@T]GY%HHI -X?0S?
M-@7[]>[J@H48?1:A1"C9UH%+5H//3D!.&+635@G9^MGK'C+&?:5X B =*_H.
MT+-Q>L\WQ#6G]X(;;U2)21F09C/VLG!PV1A(21$WRN6,S:<(/4C1N*\43X"I
MA@KIQ .["+%.=H98$X,V)>D8:%LTJ$31>.31 1I!=)? ,H;'^%L_7G+<,I@G
M\JX:2[[3*Q"*[D^GZTWR"D7Q=<#J=/X)Y^FX2XT]/K7%-<5CB6]T\7!MV9/;
MRUX"\1*'-NHDF$L@$.OU:QT81, !*Y-AHFCA?.N:]D<1V.00O+;B]AW0RU!T
M2A$"<MH:,B-X%!J2L<9JPR0+K8L [B5DW$N'X9!R[\EWE!9&//!6RS6)JO9,
M6Y)<U]_?A--MJK LN183*G#:TX&=%(*364,,7EKD43AM]D$1+7 -0?2W*_3L
M6GODD0C'JW/14+8C8^,]?CE;IL]AA2>?EHC;.XV;+)UGN:#5RC-M*8 02.&G
MIRVDM *.)*#(I)=RKTO/'P!F;X+&05$;G2^&5L#8+O9K_(:+6KD<ON#9>II6
MK^;I/*D)8\UATA?.H] !G),>BB*W3G-E32E[^=2[UQ@/&@-I<]%>M"/;G=?D
MYG_:J.19%5;=04D:PX7)M&]" !4]!12I1$@\V^PMTU+ME7?X P-S=^61)Z T
M/8^.E&M7J+B>8DG!7_ :H1A5IV)S!HYQ#XD(R*[.Q8Y[]01Z%#;&KOQJH<^=
MT#A0N&,?+._"?W\_^\=__/7W0%8V+UZL3V9_??;7D_^OO2]I;BLYPKS/?\F)
MVI?+1*C5DD,3<DLCJ>V8$R)KDS"F@#8 RBW_^LD"08JD"!)+/;P"[8,=VIHO
MER^S<JG*_)\;#Z@EDUSF #ZH>G.B;NWQCCQ@">3_O(G%JIT.E\>_TPL>#E7B
M?!B)=E W_B&?CZ20R^7:8KRU1@=,P'0LH(IC@$EIR#E)&Z12*)K/OGN CI&W
M&34[9YK)ND.\;*R)<>&#U Q,J.7L& 6$1(Y68B@I>C*UY@^0'Z9DY#FS1VOX
M"<@<(.X.0/,^SU*=C7/#S/4K(.:R$A3)8R(3HG!;URI3!AY9,86"\\Q:M\RW
MD-(7; [1\OW[D@U$W@%R[COAMS>723WGJ3"'P 21KSP=W>ASO2C/$PJ7H\76
M=\6W$C/R:K/F!U4;J7< GP_Y6YY=YM<DLUKQKJ7MOT]77UY>+E?SKWGQZL]X
M<5G-Y,5R63=II$_X)[EK'SR+""B3K%9'[EI) 1P+%TEG)5GK?64'D-E73?A
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MZ-#Z>LM68CKR9<>J?#Z$_#L TH_[C?5--B4QFSIG1.83^MH'"HPD1)X=):=
M5&6E%3E^$8:[!GV'E'%!U$C16Z\D'R[U#L"S?N9]^X)8O;&U826A)=]<$FBG
MR+H$S^"$KB.U$N5%P9+HFH^'V4[.N#6+84#42OH= &FW[#H7KX2,=2!C()Z$
MH8A3%G">+$:P2%Y\T/SE[-L4 \5/AVFH.]1M2BXF<>U"U,"CU*!X".#JC%Y6
M&,N,>:?TH,79?:I=(S<1]M'V+M6N?43? 7RN)RZ\GB_NL#,)K@0F7"+#*K9N
M"&1D9S8 2]H49D/DJ76.MXV6<ZC5'P&C)BHX=I/5IV$<TD90'_-J=9'3WZ>K
M+_/+U4M<?A$3%8**IA20@=?:B\G@D4NPAD*)()FQN?7RX1U).X<B?2NWU4A!
M?<-O0EZ8":X$Z.2)E4PR0RP28HXE&8=>E-97PQ^B8]P9RZ, :R_1=_JFY>JZ
MUB?\,]^:#E9SEOFL^NUY>3M?+G_)9;[(M_[I$8V@XS[8HBO4D.5&+:*;SSSP
M9$MQ5ESU5)07.E"(&GPT$;)WR<J06>&M]_@^0DZ;^^!5P*_)ANLSL>GLDBSJ
MW1]YL=;D X*G7RQ7TSC)CBFELP43.4DB>0L414@HJ$LQ-ADKAYFE<Q"Y/5SW
M/1Y1#]\E'UY_'60/![!*46Z>?IY-E)9&*FV@1!OK.%\#/I.89<K6,&U1-@__
M#J>VA^O"70#U$.V=)TY?_4D")LU.ZUO==6STVYS^=K8BTN@SG]_,B#PRVDF)
MGFOD"8JKF]$L(HF"HIS,4+CB+5.R]<:0 =D9-_?I".F#Z/]P4YBO\&*\ /?F
M'_R29[E,5^\7\V_3Y7&/N8__Z$D"W?U8/T&PZU +*Z6'H)BJ$[08.*2(01&>
M1(K>F] ZEQTPV'UYN:B.X>8+FX<J&V$_9*D_7BIKYY-."KBM%Q6-JONO0P#O
MLL000\JQ]8N/PZGM-]3=!T_W_>J)M-=!!+'A=!/__,3J)%HKI*F[$ OZR@X#
M5$E %"*C,#)IV;KC\@1)(T]<.1$R'@9D$S7U@[HM4IPPQS73I@"/3E+H$3*0
M@#)83]S9)*5J_N;M<8K&S9/&Q5P+)36+#X\:3+7^["%2S"SD8+,'@[:.3A*:
MCA)BNH;G&EU$Z45C/!Y!;K])_3%'\JGTUX%WO&9UX^VW&:".NOB@ [":I9$T
M+:"/ 8*7Q7,"E(VM*TV[43;R9H93 64+0!MJK2,L;F/'%"T"]W5AML[UI0%Q
M(C#6"27"11_KI)+3NL9QW=_8Z&NAIPY.ZZU!!Z%!*3*7)#U9#RI7V[@>LDR1
M(AHC36A]S? 8F(U24#SFE&TA]W,J!M:!P+,XO9BN?_JMJMB&_UHQNZQ#?>GS
MEP39[Z]SJH-(;OX=SM+KZ0SI9^#%S>"3YCWR@<D<K.!X2O&>H$3)F8Z!H83
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MZ03-1,UBDH$;\"I94,CHB(LZ@[=&EF2]T'A&S<2?Q/I;7OTP.>UD*%F"=BR
M<I:1>7@&*:'2P4<596N_]!@]_;;Z]L'$MAM 1VN@@P/N)UXVMZ5FG^M;MY>X
M6'PO\\6_<)&6DV)=%%R3*[=.7"TK<$8Y0*&9\ZQ$W;SAL0=Y?=R%/!X33X&M
MD8)ZQ%XUU<V?_<BEZPR095U'%./B$B^6$Q\CI27!@_.!0@!N"_B4.4A._,54
M9P:V+C<?1FD?]R.'1V1[M74*SJMFSUV;BYXB7&8=<&4D)31) I:LP163M0H4
M[XK6:R%V)&W<#O!)X7>L8CK%VSVK>GEW!_DF)5H^<OLB<^T+JSO@3*ZC+D4
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MBZ=H&A?'W8!G)U ?J,D.D/F*XM#Y]YP_KN;Q'^_^N/78E'&N'!+EMO@"BM)
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M/Z[F@ ZPV!%3)^$5A8>JL ];L$Z!X'?20#0Z^O+.APTK@N[6(/B90'L<WFB
MEX YL3F8JY*FC^8R*FC_7;(WU[(2>H](E53051@6FF(_5SU7:$V5L?B>SB%1
MEPE1T9\%%E]4O?- EPA!C$GLGG1I.&Z;P!T=T*E"5MS9]=I;%7-S1S4H_3G0
M@W!UP<U'F;.G+)$WD)3G"/?D:T^>HB<"?:/V8YV-P_D_WH^Y(T51K9+:+$]1
MVIQ'ZBQE$=8>03^6B.R==1S)K%7:W%5\]P)5IJFT%N S16&HD%-0NY!HGU.R
M@WC&'&PHQ^-?HM35(H0_"XGFNP579*$[<GC]_SW7MZOTO019&K)&B6BCK2YM
MFD,)B(VR6M_M?2; ;ZC\>M;F"K#CF^[@LSH?>A3BRFV*/VA8D=LX'9(;N$MM
M#Z*S9*G8!2&&9++F.8!! F"*% &"L^2<J8[&5AVDO:CZOGF;HAZ6\4ACWJAA
MV,%E.P2..Z<N$5;S55!F8Y6,@4IAQD?E<;LN$R2D>:*F@*V36/F4R!?PBWC[
M*CRA\244#)6U*NWNXX3,X6+_V2+^#F?1)4KV,]=A['^E;![6W/6"RAGK=GRE
M94-<*:#K:&#"<P/=ZLLQ%ID\X=.NS-PPKM/QHMMT86!,Q0I93OEKK8.^;R[O
M$AP=-0Z" [I.8#7^%]7 Y4V#AKMIL&O%<MM>(P@Z#[8&C>:#;9_3VFGL=1[N
M^8^U(L!;[:^N=B]H'+0>;IY7N^NFUT\Q!M'D/'NSM;=5=2B78[>5W[+FXI4'
M6J'WX^A#^.^CV%T\>3M=+/:EZW=>[7^77KW:;F/R<9_W?Y)_T-/E^ 7DYR-C
MOM!GM6B9!EQ5RW%JZ*2257/R/<WR!4_A\^CYQDZOI@K/4A+<A"S=_OBY\>Y>
M77L^V#URDG$FGVD6!W3Y;EU</0$ZS^/=E4823W35\>.S6$+$^K<0%G3:QB[]
M)G2)"WTS6YW&KK0X/>$:UN]<^>-@9&Y+1K_^"DC?==QG!0E<O#J9*^-^,^_Z
MWX3&L'29<I9W''T*9EWX$)-/89>[?.'^9?GI+X/NNDNH?P-02P,$%     @
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MI8Y)ZG\9JZ'*O-=[W8TW/^/]=DSS(Q/I-0QNF&19$AUL;,#[G4'X,*$R-:.
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MGDU1Y<1)3'Z,0F>Q[E:BJ^+A#Z-"1:6%BC)?( K8(<%'M03-H3(%LQ"*J>Z
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M_]@_^>!V67S@F*J;6 -#_\4W/;8>&7!<FB*PF,Q$-;GHA',\N2A;,ETY!N"
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M+3(P,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( $.!<EA$=MYH^PX  +:6   1
M          "  5^E P!A9'9M+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( $.!
M<E@M>?/J^QX  (PK 0 5              "  8FT P!A9'9M+3(P,C,Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " !#@7)8.:"; -D]  "SN ( %0
M    @ &WTP, 861V;2TR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ 0X%R
M6(DUB?<_LP0 )IL% !0              ( !PQ$$ &%D=FTM,C R,S$R,S%?
M9S$N:G!G4$L! A0#%     @ 0X%R6/V@SY*@G ( =/4" !0
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M &%D=FTM,C R,S$R,S%?9S8N:G!G4$L! A0#%     @ 0X%R6)W(RMA65P0
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M,#(S,3(S,7AE>'@R,3$N:'1M4$L! A0#%     @ 0X%R6(([%;Y?!   &B,
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M>#,R,BYH=&U02P$"% ,4    " !#@7)8QG/)U@4;   !K@  &
M    @ &VK", 861V;2TR,#(S,3(S,7AE>'@Y-S$N:'1M4$L%!@     6 !8
*Q@4  /''(P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>advm-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:advm="http://www.adverum.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="advm-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-08</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-26</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">advm:PazyukV.MachadoEtAl.C.A.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandSeventeenInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:IncentiveStockOptionsAndNonQualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-07-06</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">advm:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:TwoDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:TwoDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-02-07</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-09</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>advm:segment</measure>
    </unit>
    <unit id="security">
        <measure>advm:security</measure>
    </unit>
    <unit id="lease">
        <measure>advm:lease</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone">
        <measure>advm:milestone</measure>
    </unit>
    <unit id="employee">
        <measure>advm:employee</measure>
    </unit>
    <unit id="director">
        <measure>advm:director</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-32">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-33">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-34">0001501756</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-28" id="f-260">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-118" decimals="2" id="f-663" unitRef="number">0.10</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-36579</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">100 Cardinal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">656-9323</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.0001&#160;per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-26">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-29" unitRef="usd">151800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">207549152</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="c-1" id="f-35">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-36">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-37">San Francisco, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">75000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-39" unitRef="usd">68431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">21526000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">117158000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">6247000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">5006000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">102773000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">190595000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">52266000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">78934000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">14764000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">34927000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">1976000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">1231000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">1413000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">173010000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">308372000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">1921000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">2238000</us-gaap:AccountsPayableCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">12584000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">16767000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">10409000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">13241000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">24914000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">32246000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">64627000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">93561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">1047000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">89541000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">126854000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-70" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-71" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-72"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-73"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-74" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-75" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-76" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-77" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-78" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-79" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-82"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-83"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-84" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-85" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-86" unitRef="shares">101433000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-87" unitRef="shares">101433000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="-3" id="f-88" unitRef="shares">100117000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-3" id="f-89" unitRef="shares">100117000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">1003709000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">985651000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">-473000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">-1531000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">-919777000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">-802612000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">83469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">181518000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-100" unitRef="usd">173010000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">308372000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">3600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-103" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">77676000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">99277000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">49915000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-107" unitRef="usd">57858000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">127591000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-109" unitRef="usd">157135000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">-123991000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-111" unitRef="usd">-157135000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">5748000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-113" unitRef="usd">2673000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">-118243000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">-154462000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">-1078000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-117" unitRef="usd">74000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">-117165000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">-154536000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">1057000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-6" decimals="-3" id="f-121" unitRef="usd">-788000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">-116107000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">-155353000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-126"
      unitRef="usdPerShare">-1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-127"
      unitRef="usdPerShare">-1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-128"
      unitRef="usdPerShare">-1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-129"
      unitRef="usdPerShare">-1.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-130" unitRef="shares">100824000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-131" unitRef="shares">100824000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-132" unitRef="shares">99251000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-133" unitRef="shares">99251000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="-3" id="f-134" unitRef="shares">98381000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-135" unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-136" unitRef="usd">964965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-137" unitRef="usd">-714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-138" unitRef="usd">-648076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-139" unitRef="usd">316185000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-140" unitRef="usd">20079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-141" unitRef="usd">20079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-13" decimals="-3" id="f-142" unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-12" decimals="-3" id="f-143" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-144" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-13" decimals="-3" id="f-145" unitRef="shares">886000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-12" decimals="-3" id="f-146" unitRef="usd">604000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-6" decimals="-3" id="f-147" unitRef="usd">604000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="-3" id="f-148" unitRef="shares">835000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-14" decimals="-3" id="f-149" unitRef="usd">-788000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-6" decimals="-3" id="f-150" unitRef="usd">-788000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-151" unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-152" unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-153" unitRef="usd">-154536000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-154" unitRef="usd">-154536000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-16" decimals="-3" id="f-155" unitRef="shares">100117000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-156" unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-157" unitRef="usd">985651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-158" unitRef="usd">-1531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-159" unitRef="usd">-802612000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-160" unitRef="usd">181518000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-161" unitRef="usd">17569000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">17569000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-21" decimals="-3" id="f-163" unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-20" decimals="-3" id="f-164" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-21" decimals="-3" id="f-166" unitRef="shares">824000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-20" decimals="-3" id="f-167" unitRef="usd">488000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">488000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-21" decimals="-3" id="f-169" unitRef="shares">491000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-22" decimals="-3" id="f-170" unitRef="usd">1057000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">1057000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-22" decimals="-3" id="f-172" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-174" unitRef="usd">-117165000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">-117165000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-24" decimals="-3" id="f-176" unitRef="shares">101433000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-177" unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-178" unitRef="usd">1003709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-179" unitRef="usd">-473000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-180" unitRef="usd">-919777000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-181" unitRef="usd">83469000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">-117165000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-183" unitRef="usd">-154536000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">5644000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-185" unitRef="usd">6528000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">17569000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-3" id="f-187" unitRef="usd">20079000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">1935000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-6" decimals="-3" id="f-189" unitRef="usd">880000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">13027000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-6" decimals="-3" id="f-191" unitRef="usd">4040000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">-50000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-6" decimals="-3" id="f-193" unitRef="usd">-122000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">224000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-6" decimals="-3" id="f-195" unitRef="usd">2124000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">-1000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-6" decimals="-3" id="f-197" unitRef="usd">1417000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">-298000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-6" decimals="-3" id="f-199" unitRef="usd">-1653000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">-182000</advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable>
    <advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable contextRef="c-6" decimals="-3" id="f-201" unitRef="usd">394000</advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">-369000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-6" decimals="-3" id="f-203" unitRef="usd">845000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">-5206000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-6" decimals="-3" id="f-205" unitRef="usd">138000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">-3222000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-207" unitRef="usd">13607000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">-90902000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-6" decimals="-3" id="f-209" unitRef="usd">-108091000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">36718000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-6" decimals="-3" id="f-211" unitRef="usd">104363000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">134401000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-6" decimals="-3" id="f-213" unitRef="usd">257899000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">808000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-215" unitRef="usd">11816000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">96875000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-6" decimals="-3" id="f-217" unitRef="usd">141720000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">420000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-6" decimals="-3" id="f-219" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">1000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-6" decimals="-3" id="f-221" unitRef="usd">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">488000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-6" decimals="-3" id="f-223" unitRef="usd">604000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">69000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-6" decimals="-3" id="f-225" unitRef="usd">607000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-226" unitRef="usd">6042000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-6" decimals="-3" id="f-227" unitRef="usd">34236000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-228" unitRef="usd">70934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-229" unitRef="usd">36698000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-230" unitRef="usd">76976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-231" unitRef="usd">70934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-232" unitRef="usd">75000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-233" unitRef="usd">68431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-234" unitRef="usd">1976000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-5" decimals="-3" id="f-235" unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-236" unitRef="usd">76976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-237" unitRef="usd">70934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue contextRef="c-4" decimals="-3" id="f-238" unitRef="usd">14903000</advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue>
    <advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue contextRef="c-5" decimals="-3" id="f-239" unitRef="usd">0</advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue>
    <advm:ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">13711000</advm:ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities>
    <advm:ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities contextRef="c-6" decimals="-3" id="f-241" unitRef="usd">2842000</advm:ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">91000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-6" decimals="-3" id="f-243" unitRef="usd">64000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-244">Description of the Business &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nature of the Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Adverum Biotechnologies, Inc. (the &#x201c;Company&#x201d; or &#x201c;Adverum&#x201d;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $919.8 million as of December&#160;31, 2023. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of December&#160;31, 2023, the Company had cash, cash equivalents and short-term investments of $96.5 million, which the Company believes will be sufficient to fund its operations into late 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-245" unitRef="usd">-919800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-4" decimals="-5" id="f-246" unitRef="usd">96500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-247">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement. See Note 5, Leases for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;All short-term investments in debt securities have been classified as &#x201c;available for sale&#x201d; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#x2019; equity until realized. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#x2019;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#x2019;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses available-for-sale debt securities on a quarterly basis to see whether any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flow model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#x2019;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were no credit-related losses recognized for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued Interest Receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Accrued interest receivable related to the Company&#x2019;s available-for-sale debt securities is presented within prepaid expenses and other current assets on the Company&#x2019;s consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#x2019;s investment policy, which limits the Company&#x2019;s investing to securities having specified credit ratings. Management believes that the Company is not exposed to significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#x2019;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#x2019;s ability to attract and retain employees necessary to support growth.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:f-260"&gt;three&lt;/span&gt; to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. If there is an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss The Company recorded within research and development expense in the consolidated statements of operations and comprehensive loss impairment charges of $0.2&#160;million and $2.1&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. See Note&#160;3, Balance Sheet Components for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on the Company's consolidated balance sheets. The Company determines if an arrangement contains a lease and the classification of the lease at inception. An arrangement contains a lease if there is an identified asset and if the Company controls the use of the identified asset throughout the period of use. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that it would pay to borrow equivalent funds on a collateralized basis at the lease commencement date or modification date, as applicable. In order to determine the incremental borrowing rate, the Company determines its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. It bases the ROU asset on the lease liability adjusted for any prepaid or deferred rent. The Company elected to combine lease and non-lease components for all underlying assets groups. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For short term leases, the Company does not recognize a right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. The variable lease payments primarily consist of common area maintenance and other operating costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Research and development expenses are charged to expense as incurred. Research and development expenses include&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with contract research organizations (&#x201c;CROs&#x201d;), the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#x2019;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#x2019;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents approximate their fair values due to their short-term maturities. See Note 3, Fair Value Measurements for the methodologies and assumptions used in valuing financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and employee stock purchase and using intrinsic value, which is the closing price of its common stock on the date of the grant, for restricted stock units (&#x201c;RSUs&#x201d;) and performance stock units (&#x201c;PSUs&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model requires the use of following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term assumption represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Expected volatility is based on the Company&#x2019;s historical stock price volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for income taxes using the asset and liability method. The Company records deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2023 and 2022, the Company has recorded a full valuation allowance on its deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Comprehensive loss comprises net loss and other comprehensive loss. Other comprehensive loss consists of foreign currency translation adjustments and unrealized gain or loss on marketable securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, and employee stock purchase plan (&#x201c;ESPP&#x201d;) are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#x201c;Topic 326&#x201d;) and also issued subsequent amendments to the initial guidance. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted ASU 2016-13 on January 1, 2023, using the modified retrospective approach. The adoption of ASU 2016-13 had no significant impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy contextRef="c-1" id="f-248">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-249">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&#x2014;The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-250">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-251">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-252">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement. See Note 5, Leases for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-253">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;All short-term investments in debt securities have been classified as &#x201c;available for sale&#x201d; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#x2019; equity until realized. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#x2019;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#x2019;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses available-for-sale debt securities on a quarterly basis to see whether any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flow model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#x2019;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were no credit-related losses recognized for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <advm:AccruedInterestReceivablePolicyTextBlock contextRef="c-1" id="f-254">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued Interest Receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Accrued interest receivable related to the Company&#x2019;s available-for-sale debt securities is presented within prepaid expenses and other current assets on the Company&#x2019;s consolidated balance sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</advm:AccruedInterestReceivablePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-255">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-256"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-257"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-258">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#x2019;s investment policy, which limits the Company&#x2019;s investing to securities having specified credit ratings. Management believes that the Company is not exposed to significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#x2019;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#x2019;s ability to attract and retain employees necessary to support growth.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-259">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:f-260"&gt;three&lt;/span&gt; to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-29" id="f-261">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="c-1" id="f-262">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. If there is an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss The Company recorded within research and development expense in the consolidated statements of operations and comprehensive loss impairment charges of $0.2&#160;million and $2.1&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. See Note&#160;3, Balance Sheet Components for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-5" id="f-263" unitRef="usd">200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-6" decimals="-5" id="f-264" unitRef="usd">2100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-265">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on the Company's consolidated balance sheets. The Company determines if an arrangement contains a lease and the classification of the lease at inception. An arrangement contains a lease if there is an identified asset and if the Company controls the use of the identified asset throughout the period of use. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that it would pay to borrow equivalent funds on a collateralized basis at the lease commencement date or modification date, as applicable. In order to determine the incremental borrowing rate, the Company determines its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. It bases the ROU asset on the lease liability adjusted for any prepaid or deferred rent. The Company elected to combine lease and non-lease components for all underlying assets groups. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. For short term leases, the Company does not recognize a right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. The variable lease payments primarily consist of common area maintenance and other operating costs.&lt;/span&gt;&lt;/div&gt;Sublease income for operating leases is classified as a reduction of rent expense in operating expenses. The difference between sublease income recorded and cash received from the subtenant accrues as a deferred rent receivable. During the year ended December&#160;31, 2022, the Company reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. The Company assessed the collectability to be less than probable and recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December&#160;31, 2022.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-266">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-267">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Research and development expenses are charged to expense as incurred. Research and development expenses include&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with contract research organizations (&#x201c;CROs&#x201d;), the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.&lt;/span&gt;&lt;/div&gt;The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#x2019;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#x2019;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual accordingly.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-268">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents approximate their fair values due to their short-term maturities. See Note 3, Fair Value Measurements for the methodologies and assumptions used in valuing financial instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-269">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and employee stock purchase and using intrinsic value, which is the closing price of its common stock on the date of the grant, for restricted stock units (&#x201c;RSUs&#x201d;) and performance stock units (&#x201c;PSUs&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognition of PSU and performance-based options commences when the associated performance-based criteria are determined to be probable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model requires the use of following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term assumption represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Expected volatility is based on the Company&#x2019;s historical stock price volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-270">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for income taxes using the asset and liability method. The Company records deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2023 and 2022, the Company has recorded a full valuation allowance on its deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-271">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&#x2014;Comprehensive loss comprises net loss and other comprehensive loss. Other comprehensive loss consists of foreign currency translation adjustments and unrealized gain or loss on marketable securities.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-272">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, and employee stock purchase plan (&#x201c;ESPP&#x201d;) are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-273">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#x201c;Topic 326&#x201d;) and also issued subsequent amendments to the initial guidance. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. The Company adopted ASU 2016-13 on January 1, 2023, using the modified retrospective approach. The adoption of ASU 2016-13 had no significant impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-274">Fair Value Measurements and Fair Value of Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper and corporate bonds are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company&#x2019;s consolidated balance sheets. As of December&#160;31, 2023, all marketable securities had a remaining maturity of less than one year. The Company held 19 debt securities in an unrealized loss position with an aggregate fair value at December&#160;31, 2023 of $71.3&#160;million. These are highly liquid funds with high credit ratings with final maturity of less than one year from the balance sheet date. There were no individual securities that were in a significant unrealized loss position as of December&#160;31, 2023 and 2022. The Company has not recorded an allowance for credit losses as of December&#160;31, 2023 and 2022 related to these securities. The accrued interest receivable on available-for-sale marketable securities was immaterial at December&#160;31, 2023 or 2022. The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. The Company has not recorded any impairment charges on available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and 2022, the Company performed an impairment test to measure certain laboratory equipment at fair value. The assets are measured at fair value using Level 3 inputs on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The analysis was based on a market price in a secondary market place for similar laboratory equipment. The fair value of the assets was lower than the carrying value and as such impairment charges of $0.2 million and $2.1 million were recognized for the years ended December&#160;31, 2023 and 2022, respectively. The assets indicated as impaired were written down to their estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets was nil and $0.2&#160;million at December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-275">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-30" decimals="-3" id="f-276" unitRef="usd">10204000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-30" decimals="-3" id="f-277" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-30" decimals="-3" id="f-278" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-30" decimals="-3" id="f-279" unitRef="usd">10204000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-31" decimals="-3" id="f-280" unitRef="usd">64693000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-31" decimals="-3" id="f-281" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-31" decimals="-3" id="f-282" unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-31" decimals="-3" id="f-283" unitRef="usd">64658000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-32" decimals="-3" id="f-284" unitRef="usd">17616000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-32" decimals="-3" id="f-285" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-32" decimals="-3" id="f-286" unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-32" decimals="-3" id="f-287" unitRef="usd">17603000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-33" decimals="-3" id="f-288" unitRef="usd">92513000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-33" decimals="-3" id="f-289" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-33" decimals="-3" id="f-290" unitRef="usd">52000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-33" decimals="-3" id="f-291" unitRef="usd">92465000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost contextRef="c-4" decimals="-3" id="f-292" unitRef="usd">70972000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain contextRef="c-4" decimals="-3" id="f-293" unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss contextRef="c-4" decimals="-3" id="f-294" unitRef="usd">33000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-295" unitRef="usd">70939000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-296" unitRef="usd">21541000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-297" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-298" unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-299" unitRef="usd">21526000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-34" decimals="-3" id="f-300" unitRef="usd">10235000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-34" decimals="-3" id="f-301" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-34" decimals="-3" id="f-302" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-34" decimals="-3" id="f-303" unitRef="usd">10235000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-35" decimals="-3" id="f-304" unitRef="usd">59487000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-35" decimals="-3" id="f-305" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-35" decimals="-3" id="f-306" unitRef="usd">824000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-35" decimals="-3" id="f-307" unitRef="usd">58663000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-36" decimals="-3" id="f-308" unitRef="usd">102722000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-36" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-36" decimals="-3" id="f-310" unitRef="usd">246000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-36" decimals="-3" id="f-311" unitRef="usd">102476000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-37" decimals="-3" id="f-312" unitRef="usd">2059000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-37" decimals="-3" id="f-313" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-37" decimals="-3" id="f-314" unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-37" decimals="-3" id="f-315" unitRef="usd">2024000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-38" decimals="-3" id="f-316" unitRef="usd">174503000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-38" decimals="-3" id="f-317" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-38" decimals="-3" id="f-318" unitRef="usd">1105000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-38" decimals="-3" id="f-319" unitRef="usd">173398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost contextRef="c-5" decimals="-3" id="f-320" unitRef="usd">56256000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain contextRef="c-5" decimals="-3" id="f-321" unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss contextRef="c-5" decimals="-3" id="f-322" unitRef="usd">16000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-5" decimals="-3" id="f-323" unitRef="usd">56240000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="-3" id="f-324" unitRef="usd">118247000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-5" decimals="-3" id="f-325" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-5" decimals="-3" id="f-326" unitRef="usd">1089000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="-3" id="f-327" unitRef="usd">117158000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-4"
      decimals="INF"
      id="f-328"
      unitRef="security">19</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-4" decimals="-5" id="f-329" unitRef="usd">71300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AssetImpairmentCharges contextRef="c-39" decimals="-5" id="f-330" unitRef="usd">200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-40" decimals="-5" id="f-331" unitRef="usd">2100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:PropertyPlantAndEquipmentFairValueDisclosure contextRef="c-41" decimals="-5" id="f-332" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentFairValueDisclosure contextRef="c-42" decimals="-5" id="f-333" unitRef="usd">200000</us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-334">Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lexeo&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#x201c;Lexeo&#x201d;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. Upon execution of the agreement, Lexeo paid the Company a one-time, non-creditable and non-refundable upfront payment of $7.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, Lexeo notified the Company that it had achieved the first development milestone; accordingly, the Company received and recognized $3.5&#160;million of license revenue during the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ProceedsFromLicenseFeesReceived contextRef="c-43" decimals="-5" id="f-335" unitRef="usd">7500000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-44" decimals="-5" id="f-336" unitRef="usd">3500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-337">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redwood City&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a lease for a facility in Redwood City, which provided a total of tenant improvement allowances of $6.8&#160;million. Related to this lease, the Company provided the landlord with a letter of credit in the amount of $2.7&#160;million. The Redwood City lease expires in December 2031, with an option to extend for a period of eight years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to September 30, 2023, the Company had two facility leases in Redwood City with the same landlord (the &#x201c;Redwood City Premises&#x201d;). In March 2023, the Company entered into an amendment to accelerate the lease expiration of one of its Redwood City Premises from December 31, 2031 to September 30, 2023. Concurrently, the Company entered into an agreement to increase the tenant improvement allowance towards the second of its Redwood City Premises. The Company accounted for this amendment as a lease modification in accordance with ASC 842-10-25-11(d). As a result of the modification the Company revalued the lease liability based on the new and remaining lease terms, which resulted in a reduction to the lease liability with a corresponding reduction of the right-of-use asset of $8.3&#160;million. The estimated value of non-cash consideration, composed primarily of leasehold improvements and furniture and fixtures, was $14.9&#160;million, which was fully amortized as of September 30, 2023. There was no charge recognized in the consolidated statement of operations. In October 2023, the Company entered into an amendment to the letter of credit which reduced the amount to $1.9&#160;million, which is classified as restricted cash under long-term assets on the Company's consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;North Carolina&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company entered into an operating lease agreement for a building in North Carolina (&#x201c;NC Premises&#x201d;). The lease commenced in April 2021, when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with two options to extend the lease term for a period of five years each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the NC Premises through October 2037, the remainder of the lease term, and concurrently changed the lease payment terms of the head lease. In addition, the remainder of the tenant improvement allowance under the original lease of approximately $22.7&#160;million was transferred to the subtenant. This change in the Company&#x2019;s payment terms with the landlord at the time of the sublease was considered to be a lease modification and the Company remeasured the lease liability and right-of-use asset on the modification date, with no amounts recognized in the consolidated statement of operations. The base annual rental rates, payment schedules and amounts under the sublease agreement are substantially the same as the original payment terms by Adverum to the landlord. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 3, 2023, the Company entered into an amendment of the lease of its NC Premises with the landlord and subtenant. Under this amendment, the parties agreed to substantially reduce the total tenant improvement allowance in exchange for lower monthly rent. The Company accounted for this amendment as a lease modification in accordance with ASC 842-10-25-11(d). The Company remeasured the lease liability, resulting in a reduction to the lease liability with a corresponding reduction of the right-of-use asset of $5.7&#160;million in the quarter ended June 30, 2023. There was no charge recognized in the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, management reassessed the probability of collection of the deferred rent receivable from the subtenant over the remaining term of a sublease. Management assessed the collectability to be less than probable and the Company recognized an adjustment to eliminate the deferred rent receivable as a current period adjustment to sublease income, resulting in an increase in general and administrative expenses during the year ended December 31, 2022. The deferred rent receivable was zero as of December&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the weighted-average remaining lease term was 11.6 years for the Company's leases and the weighted-average Incremental Borrowing Rate (&#x201c;IBR&#x201d;) was 11.7%. As of December 31, 2022, the weighted-average remaining lease term was 10.2 years for the Company's leases and the weighted-average IBR was 9.9%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the undiscounted future non-cancellable lease payments under the lease agreements as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease Payment Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Rent expense for the years ended December&#160;31, 2023, and 2022 was $25.3&#160;million and $17.2&#160;million, respectively. Included in rent expense for the years ended December&#160;31, 2023, and 2022 were variable lease costs for utilities, parking, maintenance, and real estate taxes of $2.4 million and $2.3 million, respectively. Cash paid for amounts included in the measurement of lease liabilities for the twelve months ended December&#160;31, 2023 and 2022 was $12.8&#160;million and $6.0&#160;million, respectively. Sublease income was $5.3&#160;million and $(0.3)&#160;million for the years ended December&#160;31, 2023 and 2022, respectively, which was classified in general and administrative expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <advm:LesseeOperatingLeaseLeaseholdImprovementAllowance contextRef="c-45" decimals="-5" id="f-338" unitRef="usd">6800000</advm:LesseeOperatingLeaseLeaseholdImprovementAllowance>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-46" decimals="-5" id="f-339" unitRef="usd">2700000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-45" id="f-340">P8Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <advm:LesseeOperatingLeaseNumberOfLeasedFacilities contextRef="c-47" decimals="INF" id="f-341" unitRef="lease">2</advm:LesseeOperatingLeaseNumberOfLeasedFacilities>
    <advm:LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated contextRef="c-48" decimals="INF" id="f-342" unitRef="lease">1</advm:LesseeOperatingLeaseNumberOfLeasesExpirationsAccelerated>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-48" decimals="-5" id="f-343" unitRef="usd">8300000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue contextRef="c-49" decimals="-5" id="f-344" unitRef="usd">14900000</advm:OperatingLeaseNonCashConsiderationLeaseholdImprovementsValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-50" decimals="-5" id="f-345" unitRef="usd">1900000</us-gaap:RestrictedCashNoncurrent>
    <advm:LesseeOperatingLeaseNumberOfRenewalContracts
      contextRef="c-51"
      decimals="INF"
      id="f-346"
      unitRef="segment">2</advm:LesseeOperatingLeaseNumberOfRenewalContracts>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-52" id="f-347">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <advm:LesseeOperatingLeaseLeaseholdImprovementAllowance contextRef="c-53" decimals="-5" id="f-348" unitRef="usd">22700000</advm:LesseeOperatingLeaseLeaseholdImprovementAllowance>
    <advm:ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities contextRef="c-54" decimals="-5" id="f-349" unitRef="usd">5700000</advm:ReMeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetsAndLiabilities>
    <us-gaap:DeferredRentReceivablesNet contextRef="c-5" decimals="-5" id="f-350" unitRef="usd">0</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:DeferredRentReceivablesNet contextRef="c-4" decimals="-5" id="f-351" unitRef="usd">0</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-55" id="f-352">P11Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-55" decimals="3" id="f-353" unitRef="number">0.117</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-56" id="f-354">P10Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-56" decimals="3" id="f-355" unitRef="number">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-356">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the undiscounted future non-cancellable lease payments under the lease agreements as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease Payment Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-357" unitRef="usd">11086000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths contextRef="c-4" decimals="-3" id="f-358" unitRef="usd">5248000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-359" unitRef="usd">11448000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">5405000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-361" unitRef="usd">11821000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears contextRef="c-4" decimals="-3" id="f-362" unitRef="usd">5568000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-363" unitRef="usd">12207000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears contextRef="c-4" decimals="-3" id="f-364" unitRef="usd">5735000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-365" unitRef="usd">12606000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears contextRef="c-4" decimals="-3" id="f-366" unitRef="usd">5907000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-367" unitRef="usd">82047000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter contextRef="c-4" decimals="-3" id="f-368" unitRef="usd">60509000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-369" unitRef="usd">141215000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-4" decimals="-3" id="f-370" unitRef="usd">88372000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-371" unitRef="usd">66179000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-372" unitRef="usd">75036000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-373" unitRef="usd">25300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-5" id="f-374" unitRef="usd">17200000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-5" id="f-375" unitRef="usd">2400000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-6" decimals="-5" id="f-376" unitRef="usd">2300000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-377" unitRef="usd">12800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-5" id="f-378" unitRef="usd">6000000</us-gaap:OperatingLeasePayments>
    <advm:SubleaseIncomeNet contextRef="c-1" decimals="-5" id="f-379" unitRef="usd">5300000</advm:SubleaseIncomeNet>
    <advm:SubleaseIncomeNet contextRef="c-6" decimals="-5" id="f-380" unitRef="usd">-300000</advm:SubleaseIncomeNet>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-381">Balance Sheet Components&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical, clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-41" decimals="-3" id="f-383" unitRef="usd">14638000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-42" decimals="-3" id="f-384" unitRef="usd">14382000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-57" decimals="-3" id="f-385" unitRef="usd">13586000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-58" decimals="-3" id="f-386" unitRef="usd">34336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-59" decimals="-3" id="f-387" unitRef="usd">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-60" decimals="-3" id="f-388" unitRef="usd">1325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-61" decimals="-3" id="f-389" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-62" decimals="-3" id="f-390" unitRef="usd">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-63" decimals="-3" id="f-391" unitRef="usd">184000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-64" decimals="-3" id="f-392" unitRef="usd">1010000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-393" unitRef="usd">29276000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-394" unitRef="usd">51921000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-395" unitRef="usd">14512000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-396" unitRef="usd">16994000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-397" unitRef="usd">14764000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-398" unitRef="usd">34927000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-399">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical, clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-4" decimals="-3" id="f-400" unitRef="usd">8040000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-5" decimals="-3" id="f-401" unitRef="usd">8710000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <advm:AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent contextRef="c-4" decimals="-3" id="f-402" unitRef="usd">3367000</advm:AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent>
    <advm:AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent contextRef="c-5" decimals="-3" id="f-403" unitRef="usd">6854000</advm:AccruedNonclinicalClinicalAndProcessDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-404" unitRef="usd">351000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-405" unitRef="usd">532000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-4" decimals="-3" id="f-406" unitRef="usd">101000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-5" decimals="-3" id="f-407" unitRef="usd">254000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-408" unitRef="usd">725000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-409" unitRef="usd">417000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities contextRef="c-4" decimals="-3" id="f-410" unitRef="usd">12584000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities contextRef="c-5" decimals="-3" id="f-411" unitRef="usd">16767000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-412">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to various agreements, principally relating to licensed technology that requires future payments relating to milestones or royalties on future sales of specified products. During the year ended December&#160;31, 2023, the Company recognized $3.5&#160;million of license revenue during the year ended December&#160;31, 2023 for the first development milestone in the Lexeo License Agreement. See Note 4, Revenue, for additional information. No milestones were achieved during the year ended December 31, 2022 related to any of the Company's agreements. Because achievement of these milestones is not fixed and determinable, such amounts have not been included on the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 22, 2022, Lyudmila Pazyuk (&#x201c;Plaintiff&#x201d;) filed a derivative complaint (Pazyuk v. Machado et al. C.A. No.&#160;2022-1062-MTZ) (the &#x201c;Action&#x201d;) in the Delaware Court of Chancery (the &#x201c;Court&#x201d;) on behalf of Adverum against Adverum&#x2019;s nine current directors and four former directors (the &#x201c;Individual Defendants&#x201d;). The Action asserts claims against the Individual Defendants for allegedly awarding the Directors excessive compensation. The Individual Defendants have denied, and continue to deny, any and all allegations of wrongdoing or liability asserted in the Action. Nonetheless, solely to eliminate the uncertainty, distraction, disruption, burden, risk and expense of further litigation, the Individual Defendants entered into a Stipulation and Agreement of Settlement, Compromise and Release (the &#x201c;Stipulation&#x201d;) on January 24, 2024. Pursuant to the terms of the Stipulation, the Defendants have agreed to implement and maintain certain changes to Adverum&#x2019;s director compensation policies and practices. If approved by the Court, Adverum will also be responsible for the payment of the plaintiff&#x2019;s attorneys&#x2019; fees of up to $0.6&#160;million. The proposed settlement, as set forth in the Stipulation, is subject to final approval by the Court. If approved, the proposed settlement will (i) fully resolve the Action by dismissing all asserted claims with prejudice and (ii) release all claims related to the allegations in the Action. On January 31, 2024, the Court entered a &lt;/span&gt;&lt;/div&gt;Scheduling Order With Respect to Notice and Settlement Hearing, which, among other things, set a date of April 9, 2024 to consider the settlement on the terms set forth in the Stipulation.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-44" decimals="-5" id="f-413" unitRef="usd">3500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <advm:LicenseAgreementsMilestonesAchieved
      contextRef="c-65"
      decimals="INF"
      id="f-414"
      unitRef="milestone">0</advm:LicenseAgreementsMilestonesAchieved>
    <us-gaap:LossContingencyDamagesAwardedValue contextRef="c-66" decimals="-5" id="f-415" unitRef="usd">600000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c-1" id="f-416">Stock Plans&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2006, the Company adopted the 2006 Equity Incentive Plan, which was amended by the board of directors on November&#160;15, 2012 (the &#x201c;2006 Plan&#x201d;). The 2006 Plan allowed for the granting of incentive stock options (&#x201c;ISOs&#x201d;) and non-qualified stock options (&#x201c;NSOs&#x201d;) to the employees, members of the board of directors and consultants of the Company. ISOs were granted only to the Company&#x2019;s employees, including officers and directors who are also employees. NSOs were granted to employees and consultants. In July 2014, the Company&#x2019;s board of directors and its stockholders approved the establishment of the 2014 Equity Incentive Award Plan (the &#x201c;2014 Plan&#x201d;). Options may no longer be issued under the 2006 Plan after July&#160;30, 2014. In addition, the 2014 Plan provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with the year ended December 31, 2015, equal to four percent (4%) of the number of shares of the Company&#x2019;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, the Company adopted the 2017 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). The Company reserved 600,000 shares for issuance pursuant to stock options and RSUs under the Inducement Plan. The only persons eligible to receive grants of stock options and RSUs under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance, that is, generally, a person not previously an employee or director of Adverum, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Adverum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2006 Plan, 2014 Plan and Inducement Plan are referred to collectively as the Plans. As of December&#160;31, 2023, a total of 41,905,487 shares of common stock were reserved for issuance and 3,158,755 shares were available for future grants under the Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options under the 2014 Plan and the Inducement Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a 10% stockholder may not be less than 110% of the estimated fair value of the shares on the date of grant. Stock options granted to employees and non-employees generally vest ratably over four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except exercise prices and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining Contract&lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#x2019;s common stock as quoted on a national exchange.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised during the years ended December&#160;31, 2023 and 2022 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted during the year ended December 31, 2022 included 2.5&#160;million shares of performance-based stock options with both performance and service vesting conditions. No performance-based stock options were granted in the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair values of options granted during the years ended December&#160;31, 2023 and 2022 were $0.80 and $0.93, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was $16.1 million of unrecognized stock-based compensation expense related to stock options that was expected to be recognized over a weighted-average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#x2019;s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company&#x2019;s common stock on the grant date. RSUs granted to employees generally vest over a 2&#x2013;4 year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the RSU activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.462%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.558%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except grant date fair value and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted during the year ended December 31, 2022 include 0.4&#160;million shares of PSUs with both performance and service vesting conditions. No PSUs were granted in the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and 2022, total fair value of RSUs vested was $1.5&#160;million and $2.8&#160;million, respectively. The number of RSUs vested includes shares of common stock that the Company withheld on behalf of employees or sold to cover to satisfy the minimum statutory tax withholding requirements. As of December&#160;31, 2023, there was $1.0&#160;million of unrecognized compensation cost related to unvested RSUs that is expected to be recognized over a weighted-average period of 1.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, the Company approved the establishment of the 2014 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The Company reserved 208,833&#160;shares of its common stock for issuance and provided for annual increases in the number of shares available for issuance on the first business day of each fiscal year, beginning in 2015, equal to the lesser of one percent (1%)&#160;of the number of the Company&#x2019;s common stock shares outstanding as of such date or a number of shares as determined by the Company&#x2019;s board of directors. During the year ended December&#160;31, 2023, 824,223 shares were issued under the ESPP. As of December&#160;31, 2023, a total of 6,219,258 shares of common stock were available for future issuance under the ESPP. As of December&#160;31, 2023, there was $0.1&#160;million of unrecognized compensation cost related to the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Recognized in the Consolidated Statements of Operations and Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <advm:ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan
      contextRef="c-67"
      decimals="INF"
      id="f-417"
      unitRef="number">0.04</advm:ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-68"
      decimals="INF"
      id="f-418"
      unitRef="shares">600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-69"
      decimals="INF"
      id="f-419"
      unitRef="shares">41905487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-69"
      decimals="INF"
      id="f-420"
      unitRef="shares">3158755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-70" id="f-421">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum
      contextRef="c-71"
      decimals="INF"
      id="f-422"
      unitRef="number">1</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold
      contextRef="c-72"
      decimals="INF"
      id="f-423"
      unitRef="number">0.10</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum
      contextRef="c-72"
      decimals="INF"
      id="f-424"
      unitRef="number">1.10</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-73" id="f-425">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-426">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except exercise prices and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining Contract&lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#x2019;s common stock as quoted on a national exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="-3" id="f-427" unitRef="shares">19320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-428"
      unitRef="usdPerShare">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-6" id="f-429">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-430" unitRef="usd">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-3" id="f-431" unitRef="shares">6179000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-432"
      unitRef="usdPerShare">1.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="-3" id="f-433" unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-434"
      unitRef="usdPerShare">1.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="-3" id="f-435" unitRef="shares">2470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-436"
      unitRef="usdPerShare">2.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="-3" id="f-437" unitRef="shares">23028000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-438"
      unitRef="usdPerShare">4.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-439">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-440" unitRef="usd">99000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-4" decimals="-3" id="f-441" unitRef="shares">23028000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-442"
      unitRef="usdPerShare">4.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-443">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-4" decimals="-3" id="f-444" unitRef="usd">99000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="-3" id="f-445" unitRef="shares">10352000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-446"
      unitRef="usdPerShare">8.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-447">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-3" id="f-448" unitRef="usd">48000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-449" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-6" decimals="-5" id="f-450" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-74" decimals="-5" id="f-451" unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-75" decimals="-5" id="f-452" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-453">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-71" decimals="2" id="f-454" unitRef="number">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-76" decimals="2" id="f-455" unitRef="number">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-77" decimals="2" id="f-456" unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-78" decimals="2" id="f-457" unitRef="number">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-71" id="f-458">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-76" id="f-459">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-77" id="f-460">P1Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-78" id="f-461">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-71"
      decimals="INF"
      id="f-462"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-76"
      decimals="INF"
      id="f-463"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-77"
      decimals="INF"
      id="f-464"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-78"
      decimals="INF"
      id="f-465"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-71" decimals="3" id="f-466" unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-76" decimals="3" id="f-467" unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-77" decimals="3" id="f-468" unitRef="number">0.050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-78" decimals="3" id="f-469" unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-470"
      unitRef="usdPerShare">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-6"
      decimals="2"
      id="f-471"
      unitRef="usdPerShare">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-4" decimals="-5" id="f-472" unitRef="usd">16100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-473">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-79" id="f-474">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-80" id="f-475">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-476">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the RSU activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.462%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.558%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except grant date fair value and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-81" decimals="-3" id="f-477" unitRef="shares">1693000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-81"
      decimals="2"
      id="f-478"
      unitRef="usdPerShare">2.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-82" id="f-479">P1Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-83" decimals="-3" id="f-480" unitRef="shares">560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-83"
      decimals="2"
      id="f-481"
      unitRef="usdPerShare">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c-83" decimals="-3" id="f-482" unitRef="shares">491000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c-83"
      decimals="2"
      id="f-483"
      unitRef="usdPerShare">3.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-83" decimals="-3" id="f-484" unitRef="shares">219000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-83"
      decimals="2"
      id="f-485"
      unitRef="usdPerShare">2.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-84" decimals="-3" id="f-486" unitRef="shares">1543000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-84"
      decimals="2"
      id="f-487"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-83" id="f-488">P1Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-85" decimals="-5" id="f-489" unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-83" decimals="-5" id="f-490" unitRef="usd">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-82" decimals="-5" id="f-491" unitRef="usd">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-84" decimals="-5" id="f-492" unitRef="usd">1000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-83" id="f-493">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-86"
      decimals="INF"
      id="f-494"
      unitRef="shares">208833</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage
      contextRef="c-86"
      decimals="INF"
      id="f-495"
      unitRef="number">0.01</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-87"
      decimals="INF"
      id="f-496"
      unitRef="shares">824223</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-86"
      decimals="INF"
      id="f-497"
      unitRef="shares">6219258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-86" decimals="-5" id="f-498" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-499">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-88" decimals="-3" id="f-500" unitRef="usd">4969000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-89" decimals="-3" id="f-501" unitRef="usd">7108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-90" decimals="-3" id="f-502" unitRef="usd">12600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-91" decimals="-3" id="f-503" unitRef="usd">12971000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-504" unitRef="usd">17569000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-505" unitRef="usd">20079000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock contextRef="c-1" id="f-506">401(k) Savings Plan&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company established a defined-contribution savings plan under Section 401(k) of the Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. The amount of contributions that the Company made to the 401(k) Plan during the years ended December&#160;31, 2023 and 2022 was $0.9 million and $1.1 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-1" decimals="-5" id="f-507" unitRef="usd">900000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-6" decimals="-5" id="f-508" unitRef="usd">1100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-509">&lt;div style="margin-bottom:6pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10. Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company implemented a restructuring of operations, including reductions in both headcount and expenses, to prioritize its clinical development of ixoberogene soroparvovec (&#x201c;Ixo-vec&#x201d;), formerly referred to as ADVM-022, and focus its pipeline strategy on certain highly prevalent ocular diseases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the restructuring plan, the Company reduced its workforce by 75 employees (approximately 37%) as of July 6, 2022. Below is a summary of restructuring costs during the year ended December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and Benefits Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the year ended December 31, 2022, the Company recorded $4.7&#160;million of restructuring costs, of which $3.7&#160;million was classified as research and development expenses and $1.0&#160;million was classified as general and administrative expenses. The Company completed the restructuring in the fourth quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
      contextRef="c-92"
      decimals="INF"
      id="f-510"
      unitRef="employee">75</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent contextRef="c-92" decimals="2" id="f-511" unitRef="number">0.37</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-512">Below is a summary of restructuring costs during the year ended December 31, 2022:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and Benefits Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-93" decimals="-3" id="f-513" unitRef="usd">4632000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-94" decimals="-3" id="f-514" unitRef="usd">53000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-6" decimals="-3" id="f-515" unitRef="usd">4685000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-93" decimals="-3" id="f-516" unitRef="usd">4632000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-94" decimals="-3" id="f-517" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-6" decimals="-3" id="f-518" unitRef="usd">4632000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-93" decimals="-3" id="f-519" unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-94" decimals="-3" id="f-520" unitRef="usd">53000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-6" decimals="-3" id="f-521" unitRef="usd">53000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve contextRef="c-95" decimals="-3" id="f-522" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-96" decimals="-3" id="f-523" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-5" decimals="-3" id="f-524" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-6" decimals="-5" id="f-525" unitRef="usd">4700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-89" decimals="-5" id="f-526" unitRef="usd">3700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-91" decimals="-5" id="f-527" unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-528">Income Taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents domestic and foreign components of loss before provision for income taxes:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s income tax (benefit) provision were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision for the years ended December&#160;31, 2023 and 2022 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax benefit at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of internal reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company&#x2019;s deferred tax assets and liabilities:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals, reserve and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 R&amp;amp;D capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#x2019;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2023 and 2022. The valuation allowance increased approximately $17.0&#160;million and $39.7&#160;million during the years ended December&#160;31, 2023 and 2022, respectively mainly driven by net operating losses (&#x201c;NOLs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company had U.S. federal NOLs carryforwards of approximately $493.0&#160;million to offset any future federal income. Approximately $57.3&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2023, the Company also had U.S. state NOL carryforwards of approximately $300.8&#160;million to offset any future state income. U.S. state NOLs expire at various years beginning with 2037. At December&#160;31, 2023, the Company also had approximately $49.3&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company had federal research and development tax credit carryforwards of approximately $20.3&#160;million available to reduce future tax liabilities which expire at various years beginning with 2036. As of December&#160;31, 2023, the Company had state credit carryforwards of approximately $17.6&#160;million available to reduce future tax liabilities which do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2022, the Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code Section&#160;174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses. As a result of this provision of the TCJA, deferred tax assets related to capitalized research expenses increased to $29.5&#160;million, net of amortization on research expenses capitalized as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Section 382 and 383 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#x201c;ownership change.&#x201d; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#x2019;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to the ability of the utilization before expiration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S. federal, state, and foreign jurisdictions. The federal, state and foreign income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December&#160;31, 2017 through December&#160;31, 2022. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has total unrecognized tax benefits as of December&#160;31, 2023 and 2022 of approximately $24.6&#160;million and $24.7&#160;million, respectively. If the unrecognized tax benefits for uncertain tax positions as of December 31, 2023, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. A&#160;reconciliation of the unrecognized tax benefits is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase related to tax positions taken during the prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase related to tax position take during the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease related to tax position taken during the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, the Company accrued interest and penalties related to uncertain tax positions of nil and $0.3 million, respectively. There are no ongoing examinations by taxing authorities at this time.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-529">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents domestic and foreign components of loss before provision for income taxes:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-530" unitRef="usd">-118089000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-6" decimals="-3" id="f-531" unitRef="usd">-154002000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-532" unitRef="usd">-154000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-6" decimals="-3" id="f-533" unitRef="usd">-460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-534" unitRef="usd">-118243000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-535" unitRef="usd">-154462000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-536">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s income tax (benefit) provision were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-537" unitRef="usd">-1078000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-538" unitRef="usd">74000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-539" unitRef="usd">-1078000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-540" unitRef="usd">74000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-541" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-542" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-543" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-544" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-545" unitRef="usd">-1078000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-546" unitRef="usd">74000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-547">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision for the years ended December&#160;31, 2023 and 2022 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax benefit at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of internal reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-548" unitRef="usd">-24831000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="-3" id="f-549" unitRef="usd">-32437000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-550" unitRef="usd">6001000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-551" unitRef="usd">3414000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-1" decimals="-3" id="f-552" unitRef="usd">21000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-6" decimals="-3" id="f-553" unitRef="usd">52000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-554" unitRef="usd">1810000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-6" decimals="-3" id="f-555" unitRef="usd">2529000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-556" unitRef="usd">18479000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-557" unitRef="usd">31542000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-558" unitRef="usd">-14000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-6" decimals="-3" id="f-559" unitRef="usd">-46000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges contextRef="c-1" decimals="-3" id="f-560" unitRef="usd">1323000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges contextRef="c-6" decimals="-3" id="f-561" unitRef="usd">103000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <advm:EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition contextRef="c-1" decimals="-3" id="f-562" unitRef="usd">-1078000</advm:EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition>
    <advm:EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition contextRef="c-6" decimals="-3" id="f-563" unitRef="usd">0</advm:EffectiveIncomeTaxRateReconciliationChangeInStateUncertainTaxPosition>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-564" unitRef="usd">831000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-6" decimals="-3" id="f-565" unitRef="usd">-25000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-566" unitRef="usd">-1078000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-567" unitRef="usd">74000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-568">The following table presents significant components of the Company&#x2019;s deferred tax assets and liabilities:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals, reserve and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 R&amp;amp;D capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-569" unitRef="usd">127961000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-570" unitRef="usd">111709000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-4" decimals="-3" id="f-571" unitRef="usd">1760000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-5" decimals="-3" id="f-572" unitRef="usd">2053000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-4" decimals="-3" id="f-573" unitRef="usd">24702000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-574" unitRef="usd">21439000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-575" unitRef="usd">7305000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-576" unitRef="usd">10705000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-577" unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-578" unitRef="usd">279000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-4" decimals="-3" id="f-579" unitRef="usd">11000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-580" unitRef="usd">1562000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <advm:DeferredTaxAssetsLeaseObligation contextRef="c-4" decimals="-3" id="f-581" unitRef="usd">17708000</advm:DeferredTaxAssetsLeaseObligation>
    <advm:DeferredTaxAssetsLeaseObligation contextRef="c-5" decimals="-3" id="f-582" unitRef="usd">26241000</advm:DeferredTaxAssetsLeaseObligation>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-4" decimals="-3" id="f-583" unitRef="usd">9850000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-5" decimals="-3" id="f-584" unitRef="usd">9850000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <advm:DeferredTaxAssetsCapitalizedCosts contextRef="c-4" decimals="-3" id="f-585" unitRef="usd">29455000</advm:DeferredTaxAssetsCapitalizedCosts>
    <advm:DeferredTaxAssetsCapitalizedCosts contextRef="c-5" decimals="-3" id="f-586" unitRef="usd">23697000</advm:DeferredTaxAssetsCapitalizedCosts>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-587" unitRef="usd">218752000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-588" unitRef="usd">207535000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-589" unitRef="usd">205103000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-590" unitRef="usd">188141000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-591" unitRef="usd">13649000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-592" unitRef="usd">19394000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-3" id="f-593" unitRef="usd">12335000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-594" unitRef="usd">19394000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-595" unitRef="usd">1314000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-596" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-597" unitRef="usd">13649000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-598" unitRef="usd">19394000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-599" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-600" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-601" unitRef="usd">17000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-6" decimals="-5" id="f-602" unitRef="usd">39700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-97" decimals="-5" id="f-603" unitRef="usd">493000000</us-gaap:OperatingLossCarryforwards>
    <advm:OperatingLossCarryforwardsSubjectToExpiration contextRef="c-97" decimals="-5" id="f-604" unitRef="usd">57300000</advm:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-98" decimals="-5" id="f-605" unitRef="usd">300800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-99" decimals="-5" id="f-606" unitRef="usd">49300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-100" decimals="-5" id="f-607" unitRef="usd">20300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-101" decimals="-5" id="f-608" unitRef="usd">17600000</us-gaap:TaxCreditCarryforwardAmount>
    <advm:DeferredTaxAssetsCapitalizedCosts contextRef="c-4" decimals="-5" id="f-609" unitRef="usd">29500000</advm:DeferredTaxAssetsCapitalizedCosts>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-5" id="f-610" unitRef="usd">24600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-5" id="f-611" unitRef="usd">24700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-612">A&#160;reconciliation of the unrecognized tax benefits is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase related to tax positions taken during the prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase related to tax position take during the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease related to tax position taken during the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-613" unitRef="usd">24745000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-11" decimals="-3" id="f-614" unitRef="usd">21944000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-615" unitRef="usd">43000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-6" decimals="-3" id="f-616" unitRef="usd">274000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-617" unitRef="usd">3301000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-6" decimals="-3" id="f-618" unitRef="usd">2527000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-619" unitRef="usd">3475000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="c-6" decimals="-3" id="f-620" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-621" unitRef="usd">24614000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-622" unitRef="usd">24745000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-4" decimals="-5" id="f-623" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-5" decimals="-5" id="f-624" unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-625">Net Loss per Share&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-626">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-102"
      decimals="-3"
      id="f-627"
      unitRef="shares">23028000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-103"
      decimals="-3"
      id="f-628"
      unitRef="shares">19320000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-104"
      decimals="-3"
      id="f-629"
      unitRef="shares">1543000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-105"
      decimals="-3"
      id="f-630"
      unitRef="shares">1693000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-106"
      decimals="-3"
      id="f-631"
      unitRef="shares">169000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-107"
      decimals="-3"
      id="f-632"
      unitRef="shares">307000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-633" unitRef="shares">24740000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="-3" id="f-634" unitRef="shares">21320000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-635">Subsequent Events&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 5, 2024, the Company entered into a securities purchase agreement, pursuant to which the Company sold 105,500,057 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase an aggregate of 750,000 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) to certain institutional and accredited investors in a private placement (the &#x201c;Private Placement&#x201d;). The purchase price per share is $1.20, or $1.1999 per Pre-Funded Warrant, which represents the purchase price per share minus the $0.0001 per share exercise price of each Pre-Funded Warrant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the Private Placement, the Company also entered into a securities purchase agreement with two directors of the Company. The Company issued and sold 230,000 shares at $1.35, on otherwise substantially the same terms as those set forth in the Securities Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the close of the Private Placement on February 7, 2024, the Company received total gross proceeds of $127.8&#160;million, before deducting placement agent fees and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 9, 2023 and March 8, 2024, the Company&#x2019;s stockholders and Board of Directors, respectively, approved an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse split of all outstanding shares of the Company's common stock (the &#x201c;Reverse Stock Split&#x201d;). Such amendment will not change the par value per share or the number of authorized shares of common stock. No fractional shares shall be issued as a result of the Reverse Stock Split, and holders of such fractional shares shall be paid a sum in cash equal to such fraction multiplied by the closing sales price of the Company&#x2019;s common stock as reported on the Nasdaq Capital Market on the last business day before the date the certificate of amendment is filed with the Secretary of State of the State of Delaware, such amount rounded to the nearest whole cent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Reverse Stock Split will decrease the number of issued and outstanding shares at the time, in thousands, from approximately 207,549 to approximately 20,755; it will decrease the number of outstanding warrants from 750,000 to 75,000, and will change the exercise price on these warrants from $0.0001 to $0.001. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trading is expected to begin on a split-adjusted basis on March 21, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All shares and per share information presented in these consolidated financial statements does not reflect the upcoming stock split. Adjusting for the Reverse Stock Split, the number of issued and outstanding shares as of December 31, 2023, in thousands, will decrease from approximately 101,433 to approximately 10,143. The following unaudited pro forma financial information presents the Company's basic and diluted net loss per share upon effectiveness of the Reverse Stock Split for the periods indicated (in thousands except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-108"
      decimals="INF"
      id="f-636"
      unitRef="shares">105500057</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-109"
      decimals="INF"
      id="f-637"
      unitRef="shares">750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-110"
      decimals="2"
      id="f-638"
      unitRef="usdPerShare">1.20</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-109"
      decimals="4"
      id="f-639"
      unitRef="usdPerShare">1.1999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-109"
      decimals="4"
      id="f-640"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <advm:SecuritiesPurchaseAgreementNumberOfDirectors
      contextRef="c-111"
      decimals="INF"
      id="f-641"
      unitRef="director">2</advm:SecuritiesPurchaseAgreementNumberOfDirectors>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-112"
      decimals="INF"
      id="f-642"
      unitRef="shares">230000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-111"
      decimals="INF"
      id="f-643"
      unitRef="usdPerShare">1.35</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c-113" decimals="-5" id="f-644" unitRef="usd">127800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-114"
      decimals="-3"
      id="f-645"
      unitRef="shares">207549000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-114"
      decimals="-3"
      id="f-646"
      unitRef="shares">207549000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-115"
      decimals="-3"
      id="f-647"
      unitRef="shares">20755000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-115"
      decimals="-3"
      id="f-648"
      unitRef="shares">20755000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-4" decimals="INF" id="f-649" unitRef="shares">750000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-115"
      decimals="INF"
      id="f-650"
      unitRef="shares">75000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-4"
      decimals="4"
      id="f-651"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-115"
      decimals="3"
      id="f-652"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-653" unitRef="shares">101433000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-654" unitRef="shares">101433000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-116"
      decimals="-3"
      id="f-655"
      unitRef="shares">10143000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-116"
      decimals="-3"
      id="f-656"
      unitRef="shares">10143000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-657">The following unaudited pro forma financial information presents the Company's basic and diluted net loss per share upon effectiveness of the Reverse Stock Split for the periods indicated (in thousands except per share data):&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-117" decimals="-3" id="f-658" unitRef="usd">-117165000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-117"
      decimals="2"
      id="f-659"
      unitRef="usdPerShare">-11.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-117"
      decimals="2"
      id="f-660"
      unitRef="usdPerShare">-11.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-117"
      decimals="-3"
      id="f-661"
      unitRef="shares">10082000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-117"
      decimals="-3"
      id="f-662"
      unitRef="shares">10082000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
